0001628280-25-007732.txt : 20250225 0001628280-25-007732.hdr.sgml : 20250225 20250225161911 ACCESSION NUMBER: 0001628280-25-007732 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 171 CONFORMED PERIOD OF REPORT: 20241231 FILED AS OF DATE: 20250225 DATE AS OF CHANGE: 20250225 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Merck & Co., Inc. CENTRAL INDEX KEY: 0000310158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 221918501 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-06571 FILM NUMBER: 25663539 BUSINESS ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 BUSINESS PHONE: 908-740-4000 MAIL ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 FORMER COMPANY: FORMER CONFORMED NAME: Merck & Co. Inc. DATE OF NAME CHANGE: 20091103 FORMER COMPANY: FORMER CONFORMED NAME: SCHERING PLOUGH CORP DATE OF NAME CHANGE: 19920703 10-K 1 mrk-20241231.htm 10-K FOR THE FISCAL YEAR ENDED DECEMBER 31, 2024 mrk-20241231
FALSE2024FY0000310158P3Mhttp://fasb.org/us-gaap/2024#Revenueshttp://fasb.org/us-gaap/2024#Revenueshttp://fasb.org/us-gaap/2024#Revenueshttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpensehttp://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpensehttp://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpensehttp://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpensehttp://fasb.org/us-gaap/2024#RestructuringChargeshttp://fasb.org/us-gaap/2024#RestructuringChargeshttp://fasb.org/us-gaap/2024#RestructuringChargeshttp://fasb.org/us-gaap/2024#RestructuringChargeshttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2024#RestructuringChargeshttp://fasb.org/us-gaap/2024#RestructuringChargeshttp://fasb.org/us-gaap/2024#RestructuringChargeshttp://fasb.org/us-gaap/2024#RestructuringChargeshttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpensehttp://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpensehttp://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpensehttp://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpensehttp://fasb.org/us-gaap/2024#RestructuringChargeshttp://fasb.org/us-gaap/2024#RestructuringChargeshttp://fasb.org/us-gaap/2024#RestructuringChargeshttp://fasb.org/us-gaap/2024#RestructuringChargeshttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpensehttp://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpensehttp://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpensehttp://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpensehttp://fasb.org/us-gaap/2024#RestructuringChargeshttp://fasb.org/us-gaap/2024#RestructuringChargeshttp://fasb.org/us-gaap/2024#RestructuringChargeshttp://fasb.org/us-gaap/2024#RestructuringChargeshttp://fasb.org/us-gaap/2024#LongTermDebtNoncurrenthttp://fasb.org/us-gaap/2024#LongTermDebtNoncurrenthttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#OtherAssetsCurrenthttp://fasb.org/us-gaap/2024#OtherAssetsCurrenthttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#OtherAssetsCurrenthttp://fasb.org/us-gaap/2024#OtherAssetsCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpensehttp://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpensehttp://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpensehttp://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpensehttp://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpensehttp://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpensehttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent33.3333.33xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesmrk:segmentmrk:aqua_facilityxbrli:puremrk:antibodyDrugConjugatemrk:candidatemrk:jurisdictionmrk:interest_rate_swapiso4217:EURmrk:casemrk:Plaintiffmrk:motionmrk:patent00003101582024-01-012024-12-310000310158us-gaap:CommonStockMember2024-01-012024-12-310000310158mrk:A1.875Notesdue2026Member2024-01-012024-12-310000310158mrk:A3.250NotesDue2032Member2024-01-012024-12-310000310158mrk:A2.500Notesdue2034Member2024-01-012024-12-310000310158mrk:A1.375Notesdue2036Member2024-01-012024-12-310000310158mrk:A3.500NotesDue2037Member2024-01-012024-12-310000310158mrk:A3.700NotesDue2044Member2024-01-012024-12-310000310158mrk:A3.750NotesDue2054Member2024-01-012024-12-3100003101582025-01-3100003101582024-06-2800003101582023-01-012023-12-3100003101582022-01-012022-12-3100003101582024-12-3100003101582023-12-310000310158us-gaap:CommonStockMember2021-12-310000310158us-gaap:AdditionalPaidInCapitalMember2021-12-310000310158us-gaap:RetainedEarningsMember2021-12-310000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000310158us-gaap:TreasuryStockCommonMember2021-12-310000310158us-gaap:NoncontrollingInterestMember2021-12-3100003101582021-12-310000310158us-gaap:RetainedEarningsMember2022-01-012022-12-310000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310000310158us-gaap:NoncontrollingInterestMember2022-01-012022-12-310000310158us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-310000310158us-gaap:TreasuryStockCommonMember2022-01-012022-12-310000310158us-gaap:CommonStockMember2022-12-310000310158us-gaap:AdditionalPaidInCapitalMember2022-12-310000310158us-gaap:RetainedEarningsMember2022-12-310000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000310158us-gaap:TreasuryStockCommonMember2022-12-310000310158us-gaap:NoncontrollingInterestMember2022-12-3100003101582022-12-310000310158us-gaap:RetainedEarningsMember2023-01-012023-12-310000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310000310158us-gaap:TreasuryStockCommonMember2023-01-012023-12-310000310158us-gaap:NoncontrollingInterestMember2023-01-012023-12-310000310158us-gaap:AdditionalPaidInCapitalMember2023-01-012023-12-310000310158us-gaap:CommonStockMember2023-12-310000310158us-gaap:AdditionalPaidInCapitalMember2023-12-310000310158us-gaap:RetainedEarningsMember2023-12-310000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000310158us-gaap:TreasuryStockCommonMember2023-12-310000310158us-gaap:NoncontrollingInterestMember2023-12-310000310158us-gaap:RetainedEarningsMember2024-01-012024-12-310000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-12-310000310158us-gaap:TreasuryStockCommonMember2024-01-012024-12-310000310158us-gaap:NoncontrollingInterestMember2024-01-012024-12-310000310158us-gaap:AdditionalPaidInCapitalMember2024-01-012024-12-310000310158us-gaap:CommonStockMember2024-12-310000310158us-gaap:AdditionalPaidInCapitalMember2024-12-310000310158us-gaap:RetainedEarningsMember2024-12-310000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310000310158us-gaap:TreasuryStockCommonMember2024-12-310000310158us-gaap:NoncontrollingInterestMember2024-12-310000310158srt:MinimumMember2024-01-012024-12-310000310158srt:MaximumMember2024-01-012024-12-310000310158country:USsrt:MinimumMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158country:USsrt:MinimumMembermrk:AnimalHealthsegmentMember2024-01-012024-12-310000310158country:USsrt:MaximumMember2024-01-012024-12-310000310158country:USsrt:MinimumMember2024-01-012024-12-310000310158us-gaap:NonUsMembersrt:MinimumMember2024-01-012024-12-310000310158us-gaap:NonUsMembersrt:MaximumMember2024-01-012024-12-310000310158srt:MinimumMemberus-gaap:BuildingMember2024-12-310000310158srt:MaximumMemberus-gaap:BuildingMember2024-12-310000310158srt:MinimumMemberus-gaap:MachineryAndEquipmentMember2024-12-310000310158srt:MaximumMemberus-gaap:MachineryAndEquipmentMember2024-12-310000310158us-gaap:SoftwareAndSoftwareDevelopmentCostsMembersrt:MinimumMember2024-12-310000310158us-gaap:SoftwareAndSoftwareDevelopmentCostsMembersrt:MaximumMember2024-12-310000310158srt:MinimumMember2024-12-310000310158srt:MaximumMember2024-12-310000310158us-gaap:SubsequentEventMembersrt:ScenarioForecastMember2025-01-012025-03-310000310158mrk:MK2010LM299LaNovaMedicinesLtdMember2024-12-012024-12-310000310158srt:ScenarioForecastMembermrk:MK2010LM299LaNovaMedicinesLtdMember2025-01-012025-12-310000310158mrk:MK2010LM299LaNovaMedicinesLtdMember2024-12-310000310158mrk:MK4082HS10535HansohPharmaMember2024-12-012024-12-310000310158mrk:MK4082HS10535HansohPharmaMember2024-12-310000310158mrk:MK1045CN201CuronBiopharmaceuticalMember2024-09-012024-09-300000310158mrk:MK1045CN201CuronBiopharmaceuticalMember2024-09-300000310158mrk:MK1045CN201CuronBiopharmaceuticalMember2024-01-012024-12-310000310158mrk:ThirdPartyMembermrk:MK1045CN201CuronBiopharmaceuticalMember2024-09-300000310158mrk:ElancoAnimalHealthIncorporatedAquaBusinessMember2024-07-012024-07-310000310158mrk:ElancoAnimalHealthIncorporatedAquaBusinessMember2024-07-090000310158mrk:ElancoAnimalHealthIncorporatedAquaBusinessMembermrk:ProductRightsMember2024-07-090000310158mrk:ElancoAnimalHealthIncorporatedAquaBusinessMembermrk:OtherProductRightsMember2024-07-090000310158mrk:EyebiotechLimitedMember2024-07-012024-07-310000310158mrk:EyebiotechLimitedMember2024-07-310000310158mrk:EyebiotechLimitedMember2024-07-012024-12-310000310158mrk:EyebiotechLimitedMember2024-01-012024-12-310000310158mrk:OrionMember2024-07-310000310158mrk:HarpoonTherapeuticsInc.Member2024-03-012024-03-310000310158mrk:HarpoonTherapeuticsInc.Member2024-01-012024-12-310000310158mrk:DaiichiSankyoMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-10-310000310158mrk:PrometheusBiosciencesIncMember2023-06-012023-06-300000310158mrk:PrometheusBiosciencesIncMember2023-01-012023-12-310000310158mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-02-280000310158mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-10-310000310158mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2024-04-300000310158mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2024-07-310000310158mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-01-310000310158mrk:ImagoBioSciencesIncMember2023-01-012023-01-310000310158mrk:ImagoBioSciencesIncMember2023-01-012023-12-310000310158mrk:RoyaltyPharmaMember2022-10-012022-10-310000310158mrk:OrnaTherapeuticsMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-08-012022-08-310000310158mrk:OrnaTherapeuticsMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-08-310000310158mrk:OrnaTherapeuticsMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-12-310000310158mrk:OrionMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-07-012022-07-310000310158mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-05-012022-05-310000310158mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-01-012023-12-310000310158mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2024-01-012024-12-310000310158mrk:FirstCommercialSaleMilestonesMembermrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-05-310000310158mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-05-310000310158us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMembermrk:OrganonCoMember2024-12-310000310158us-gaap:RelatedPartyMembersrt:MinimumMembermrk:ManufacturingAndSupplyAgreementsMember2021-06-022021-06-020000310158us-gaap:RelatedPartyMembersrt:MaximumMembermrk:ManufacturingAndSupplyAgreementsMember2021-06-022021-06-020000310158us-gaap:RelatedPartyMembermrk:ManufacturingAndSupplyAgreementsMember2024-01-012024-12-310000310158us-gaap:RelatedPartyMembermrk:ManufacturingAndSupplyAgreementsMember2023-01-012023-12-310000310158us-gaap:RelatedPartyMembermrk:ManufacturingAndSupplyAgreementsMember2022-01-012022-12-310000310158us-gaap:RelatedPartyMember2024-12-310000310158us-gaap:RelatedPartyMember2023-12-310000310158mrk:AstraZenecaMembermrk:KoselugoMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2024-01-012024-12-310000310158mrk:AstraZenecaMembermrk:KoselugoMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2024-12-310000310158mrk:AstraZenecaMember2024-01-012024-12-310000310158mrk:AstraZenecaMembermrk:LynparzaMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-01-012022-12-310000310158mrk:AstraZenecaMembermrk:LynparzaMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-12-310000310158mrk:AstraZenecaMember2022-01-012022-12-310000310158mrk:AstraZenecaMembermrk:LynparzaMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2024-12-310000310158mrk:AstraZenecaMembermrk:LynparzaMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2024-01-012024-12-310000310158mrk:AstraZenecaMembermrk:LynparzaMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-01-012023-12-310000310158mrk:LicensesAndOtherMembermrk:LynparzaMember2024-12-310000310158mrk:LicensesAndOtherMembermrk:KoselugoMember2024-12-310000310158mrk:AstraZenecaMembermrk:AlliancerevenueLynparzaMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2024-01-012024-12-310000310158mrk:AstraZenecaMembermrk:AlliancerevenueLynparzaMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-01-012023-12-310000310158mrk:AstraZenecaMembermrk:AlliancerevenueLynparzaMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-01-012022-12-310000310158mrk:AstraZenecaMembermrk:AllianceRevenueKoselugoMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2024-01-012024-12-310000310158mrk:AstraZenecaMembermrk:AllianceRevenueKoselugoMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-01-012023-12-310000310158mrk:AstraZenecaMembermrk:AllianceRevenueKoselugoMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-01-012022-12-310000310158mrk:AstraZenecaMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2024-01-012024-12-310000310158mrk:AstraZenecaMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-01-012023-12-310000310158mrk:AstraZenecaMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-01-012022-12-310000310158mrk:AstraZenecaMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2024-12-310000310158mrk:AstraZenecaMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-12-310000310158mrk:EisaiMembermrk:LenvimaMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2024-01-012024-12-310000310158mrk:EisaiMembermrk:LenvimaMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-01-012023-12-310000310158mrk:EisaiMembermrk:LenvimaMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-01-012022-12-310000310158mrk:EisaiMembermrk:LenvimaMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-12-310000310158mrk:EisaiMember2023-01-012023-12-310000310158mrk:EisaiMembermrk:LenvimaMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2024-12-310000310158mrk:LicensesAndOtherMembermrk:LenvimaMember2024-12-310000310158mrk:EisaiMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2024-01-012024-12-310000310158mrk:EisaiMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-01-012023-12-310000310158mrk:EisaiMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-01-012022-12-310000310158mrk:EisaiMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2024-12-310000310158mrk:EisaiMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-12-310000310158mrk:BayerAGMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-01-012022-12-310000310158mrk:LicensesAndOtherMembermrk:AdempasMember2024-12-310000310158mrk:LicensesAndOtherMembermrk:VerquvoMember2024-12-310000310158mrk:BayerAGMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2024-01-012024-12-310000310158mrk:BayerAGMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-01-012023-12-310000310158mrk:BayerAGMembermrk:AdempasMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2024-01-012024-12-310000310158mrk:BayerAGMembermrk:AdempasMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-01-012023-12-310000310158mrk:BayerAGMembermrk:AdempasMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-01-012022-12-310000310158mrk:BayerAGMembermrk:VerquvoMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2024-01-012024-12-310000310158mrk:BayerAGMembermrk:VerquvoMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-01-012023-12-310000310158mrk:BayerAGMembermrk:VerquvoMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-01-012022-12-310000310158mrk:BayerAGMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2024-12-310000310158mrk:BayerAGMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-12-310000310158mrk:RidgebackBiotherapeuticsLPMembermrk:LagevrioMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2024-01-012024-12-310000310158mrk:RidgebackBiotherapeuticsLPMembermrk:LagevrioMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-01-012023-12-310000310158mrk:RidgebackBiotherapeuticsLPMembermrk:LagevrioMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-01-012022-12-310000310158mrk:RidgebackBiotherapeuticsLPMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2024-01-012024-12-310000310158mrk:RidgebackBiotherapeuticsLPMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-01-012023-12-310000310158mrk:RidgebackBiotherapeuticsLPMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-01-012022-12-310000310158mrk:RidgebackBiotherapeuticsLPMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2024-12-310000310158mrk:RidgebackBiotherapeuticsLPMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-12-310000310158mrk:DaiichiSankyoMembermrk:PatritumabDeruxtecanMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-10-310000310158mrk:DaiichiSankyoMembermrk:IfinatamabDeruxtecanMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-10-310000310158mrk:DaiichiSankyoMembermrk:RaludotatugDeruxtecanMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-10-310000310158mrk:DaiichiSankyoMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-01-012023-12-310000310158mrk:DaiichiSankyoMembermrk:PatritumabDeruxtecanAndRalduotatugDeruxtecanMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-12-310000310158mrk:DaiichiSankyoMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2024-08-012024-08-310000310158mrk:DaiichiSankyoMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2024-01-012024-12-310000310158mrk:DaiichiSankyoMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2024-12-310000310158mrk:DaiichiSankyoMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-12-310000310158mrk:ModernaIncMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-01-012022-12-310000310158mrk:ModernaIncMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2024-12-310000310158mrk:ModernaIncMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2024-01-012024-12-310000310158mrk:ModernaIncMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-01-012023-12-310000310158mrk:ModernaIncMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-12-310000310158mrk:BristolMyersSquibbMembersrt:MinimumMemberus-gaap:LicensingAgreementsMember2024-01-012024-12-310000310158mrk:BristolMyersSquibbMembersrt:MaximumMemberus-gaap:LicensingAgreementsMember2024-01-012024-12-310000310158mrk:BristolMyersSquibbMemberus-gaap:LicensingAgreementsMember2024-01-012024-12-310000310158mrk:BristolMyersSquibbMembermrk:AllianceRevenueReblozylMemberus-gaap:LicensingAgreementsMember2024-12-310000310158mrk:RegulatoryMilestonesMembermrk:BristolMyersSquibbMemberus-gaap:LicensingAgreementsMember2022-01-012022-12-310000310158mrk:BristolMyersSquibbCompanyMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2024-01-012024-12-310000310158mrk:BristolMyersSquibbCompanyMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023-01-012023-12-310000310158mrk:BristolMyersSquibbCompanyMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-01-012022-12-310000310158mrk:RestructuringProgram2024Member2024-12-310000310158mrk:RestructuringProgram2024Member2024-01-012024-12-310000310158mrk:RestructuringProgram2024Member2023-01-012023-12-310000310158mrk:RestructuringProgram2019Member2023-01-012023-12-310000310158mrk:RestructuringProgram2019Member2022-01-012022-12-310000310158us-gaap:CostOfSalesMembermrk:RestructuringProgram2024Member2024-01-012024-12-310000310158us-gaap:EmployeeSeveranceMembermrk:RestructuringProgram2024Memberus-gaap:CostOfSalesMember2024-01-012024-12-310000310158mrk:AcceleratedDepreciationMembermrk:RestructuringProgram2024Memberus-gaap:CostOfSalesMember2024-01-012024-12-310000310158us-gaap:OtherRestructuringMembermrk:RestructuringProgram2024Memberus-gaap:CostOfSalesMember2024-01-012024-12-310000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:RestructuringProgram2024Member2024-01-012024-12-310000310158us-gaap:EmployeeSeveranceMembermrk:RestructuringProgram2024Memberus-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-12-310000310158us-gaap:OtherRestructuringMembermrk:RestructuringProgram2024Memberus-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-12-310000310158mrk:AcceleratedDepreciationMembermrk:RestructuringProgram2024Memberus-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-12-310000310158us-gaap:OtherRestructuringMembermrk:RestructuringProgram2024Memberus-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-12-310000310158mrk:AcceleratedDepreciationMembermrk:RestructuringProgram2024Memberus-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-12-310000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:RestructuringProgram2024Member2024-01-012024-12-310000310158us-gaap:EmployeeSeveranceMembermrk:RestructuringProgram2024Memberus-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-12-310000310158mrk:AcceleratedDepreciationMembermrk:RestructuringProgram2024Memberus-gaap:RestructuringChargesMember2024-01-012024-12-310000310158us-gaap:OtherRestructuringMembermrk:RestructuringProgram2024Memberus-gaap:RestructuringChargesMember2024-01-012024-12-310000310158us-gaap:RestructuringChargesMembermrk:RestructuringProgram2024Member2024-01-012024-12-310000310158us-gaap:EmployeeSeveranceMembermrk:RestructuringProgram2024Memberus-gaap:RestructuringChargesMember2024-01-012024-12-310000310158mrk:AcceleratedDepreciationMembermrk:RestructuringProgram2024Member2024-01-012024-12-310000310158us-gaap:EmployeeSeveranceMembermrk:RestructuringProgram2024Member2024-01-012024-12-310000310158us-gaap:OtherRestructuringMembermrk:RestructuringProgram2024Member2024-01-012024-12-310000310158us-gaap:CostOfSalesMembermrk:RestructuringProgram2024Member2023-01-012023-12-310000310158us-gaap:OtherRestructuringMembermrk:RestructuringProgram2024Memberus-gaap:CostOfSalesMember2023-01-012023-12-310000310158mrk:AcceleratedDepreciationMembermrk:RestructuringProgram2024Memberus-gaap:CostOfSalesMember2023-01-012023-12-310000310158us-gaap:EmployeeSeveranceMembermrk:RestructuringProgram2024Memberus-gaap:CostOfSalesMember2023-01-012023-12-310000310158mrk:AcceleratedDepreciationMembermrk:RestructuringProgram2024Memberus-gaap:RestructuringChargesMember2023-01-012023-12-310000310158us-gaap:RestructuringChargesMembermrk:RestructuringProgram2024Member2023-01-012023-12-310000310158us-gaap:OtherRestructuringMembermrk:RestructuringProgram2024Memberus-gaap:RestructuringChargesMember2023-01-012023-12-310000310158us-gaap:EmployeeSeveranceMembermrk:RestructuringProgram2024Memberus-gaap:RestructuringChargesMember2023-01-012023-12-310000310158mrk:AcceleratedDepreciationMembermrk:RestructuringProgram2024Member2023-01-012023-12-310000310158us-gaap:EmployeeSeveranceMembermrk:RestructuringProgram2024Member2023-01-012023-12-310000310158us-gaap:OtherRestructuringMembermrk:RestructuringProgram2024Member2023-01-012023-12-310000310158mrk:AcceleratedDepreciationMembermrk:RestructuringProgram2019Memberus-gaap:CostOfSalesMember2023-01-012023-12-310000310158us-gaap:CostOfSalesMembermrk:RestructuringProgram2019Member2023-01-012023-12-310000310158us-gaap:OtherRestructuringMembermrk:RestructuringProgram2019Memberus-gaap:CostOfSalesMember2023-01-012023-12-310000310158us-gaap:EmployeeSeveranceMembermrk:RestructuringProgram2019Memberus-gaap:CostOfSalesMember2023-01-012023-12-310000310158mrk:AcceleratedDepreciationMembermrk:RestructuringProgram2019Memberus-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-12-310000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:RestructuringProgram2019Member2023-01-012023-12-310000310158us-gaap:EmployeeSeveranceMembermrk:RestructuringProgram2019Memberus-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-12-310000310158us-gaap:OtherRestructuringMembermrk:RestructuringProgram2019Memberus-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-12-310000310158mrk:AcceleratedDepreciationMembermrk:RestructuringProgram2019Memberus-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-12-310000310158us-gaap:EmployeeSeveranceMembermrk:RestructuringProgram2019Memberus-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-12-310000310158us-gaap:OtherRestructuringMembermrk:RestructuringProgram2019Memberus-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-12-310000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:RestructuringProgram2019Member2023-01-012023-12-310000310158us-gaap:EmployeeSeveranceMembermrk:RestructuringProgram2019Memberus-gaap:RestructuringChargesMember2023-01-012023-12-310000310158mrk:AcceleratedDepreciationMembermrk:RestructuringProgram2019Memberus-gaap:RestructuringChargesMember2023-01-012023-12-310000310158us-gaap:RestructuringChargesMembermrk:RestructuringProgram2019Member2023-01-012023-12-310000310158us-gaap:OtherRestructuringMembermrk:RestructuringProgram2019Memberus-gaap:RestructuringChargesMember2023-01-012023-12-310000310158mrk:AcceleratedDepreciationMembermrk:RestructuringProgram2019Member2023-01-012023-12-310000310158us-gaap:EmployeeSeveranceMembermrk:RestructuringProgram2019Member2023-01-012023-12-310000310158us-gaap:OtherRestructuringMembermrk:RestructuringProgram2019Member2023-01-012023-12-310000310158mrk:AcceleratedDepreciationMembermrk:RestructuringProgram2024And2019Member2023-01-012023-12-310000310158us-gaap:EmployeeSeveranceMembermrk:RestructuringProgram2024And2019Member2023-01-012023-12-310000310158us-gaap:OtherRestructuringMembermrk:RestructuringProgram2024And2019Member2023-01-012023-12-310000310158mrk:RestructuringProgram2024And2019Member2023-01-012023-12-310000310158us-gaap:EmployeeSeveranceMembermrk:RestructuringProgram2019Memberus-gaap:CostOfSalesMember2022-01-012022-12-310000310158us-gaap:OtherRestructuringMembermrk:RestructuringProgram2019Memberus-gaap:CostOfSalesMember2022-01-012022-12-310000310158mrk:AcceleratedDepreciationMembermrk:RestructuringProgram2019Memberus-gaap:CostOfSalesMember2022-01-012022-12-310000310158us-gaap:CostOfSalesMembermrk:RestructuringProgram2019Member2022-01-012022-12-310000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:RestructuringProgram2019Member2022-01-012022-12-310000310158us-gaap:OtherRestructuringMembermrk:RestructuringProgram2019Memberus-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-12-310000310158us-gaap:EmployeeSeveranceMembermrk:RestructuringProgram2019Memberus-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-12-310000310158mrk:AcceleratedDepreciationMembermrk:RestructuringProgram2019Memberus-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-12-310000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:RestructuringProgram2019Member2022-01-012022-12-310000310158us-gaap:EmployeeSeveranceMembermrk:RestructuringProgram2019Memberus-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-12-310000310158us-gaap:OtherRestructuringMembermrk:RestructuringProgram2019Memberus-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-12-310000310158mrk:AcceleratedDepreciationMembermrk:RestructuringProgram2019Memberus-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-12-310000310158us-gaap:RestructuringChargesMembermrk:RestructuringProgram2019Member2022-01-012022-12-310000310158us-gaap:OtherRestructuringMembermrk:RestructuringProgram2019Memberus-gaap:RestructuringChargesMember2022-01-012022-12-310000310158us-gaap:EmployeeSeveranceMembermrk:RestructuringProgram2019Memberus-gaap:RestructuringChargesMember2022-01-012022-12-310000310158mrk:AcceleratedDepreciationMembermrk:RestructuringProgram2019Memberus-gaap:RestructuringChargesMember2022-01-012022-12-310000310158mrk:AcceleratedDepreciationMembermrk:RestructuringProgram2019Member2022-01-012022-12-310000310158us-gaap:EmployeeSeveranceMembermrk:RestructuringProgram2019Member2022-01-012022-12-310000310158us-gaap:OtherRestructuringMembermrk:RestructuringProgram2019Member2022-01-012022-12-310000310158mrk:AcceleratedDepreciationMember2022-12-310000310158us-gaap:EmployeeSeveranceMember2022-12-310000310158us-gaap:OtherRestructuringMember2022-12-310000310158mrk:AcceleratedDepreciationMember2023-01-012023-12-310000310158us-gaap:EmployeeSeveranceMember2023-01-012023-12-310000310158us-gaap:OtherRestructuringMember2023-01-012023-12-310000310158mrk:AcceleratedDepreciationMember2023-12-310000310158us-gaap:EmployeeSeveranceMember2023-12-310000310158us-gaap:OtherRestructuringMember2023-12-310000310158mrk:AcceleratedDepreciationMember2024-01-012024-12-310000310158us-gaap:EmployeeSeveranceMember2024-01-012024-12-310000310158us-gaap:OtherRestructuringMember2024-01-012024-12-310000310158mrk:AcceleratedDepreciationMember2024-12-310000310158us-gaap:EmployeeSeveranceMember2024-12-310000310158us-gaap:OtherRestructuringMember2024-12-310000310158srt:MaximumMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-01-012024-12-310000310158srt:MaximumMemberus-gaap:NondesignatedMember2024-01-012024-12-310000310158us-gaap:ForeignExchangeContractMember2024-01-012024-12-310000310158us-gaap:ForeignExchangeContractMember2023-01-012023-12-310000310158us-gaap:ForeignExchangeContractMember2022-01-012022-12-310000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:ForeignExchangeContractMember2024-01-012024-12-310000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:ForeignExchangeContractMember2023-01-012023-12-310000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:ForeignExchangeContractMember2022-01-012022-12-310000310158mrk:EurodominatedNotesMember2024-01-012024-12-310000310158mrk:EurodominatedNotesMember2023-01-012023-12-310000310158mrk:EurodominatedNotesMember2022-01-012022-12-310000310158us-gaap:OtherNonoperatingIncomeExpenseMembermrk:EurodominatedNotesMember2024-01-012024-12-310000310158us-gaap:OtherNonoperatingIncomeExpenseMembermrk:EurodominatedNotesMember2023-01-012023-12-310000310158us-gaap:OtherNonoperatingIncomeExpenseMembermrk:EurodominatedNotesMember2022-01-012022-12-310000310158us-gaap:InterestRateSwapMembermrk:A450NotesDue2033Member2024-12-310000310158mrk:A450NotesDue2033Memberus-gaap:SeniorNotesMember2023-05-310000310158us-gaap:InterestRateSwapMembermrk:A500NotesDue2053Memberus-gaap:SubsequentEventMember2025-01-310000310158mrk:A500NotesDue2053Memberus-gaap:SeniorNotesMemberus-gaap:SubsequentEventMember2025-01-310000310158us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000310158us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-12-310000310158us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentAssetsMember2024-12-310000310158us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentAssetsMember2023-12-310000310158us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentAssetsMember2023-12-310000310158us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentAssetsMember2024-12-310000310158us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentLiabilitiesMember2023-12-310000310158us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentLiabilitiesMember2024-12-310000310158us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentLiabilitiesMember2023-12-310000310158us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentLiabilitiesMember2024-12-310000310158us-gaap:DesignatedAsHedgingInstrumentMember2024-12-310000310158us-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000310158us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2023-12-310000310158us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2024-12-310000310158us-gaap:NondesignatedMember2024-12-310000310158us-gaap:NondesignatedMember2023-12-310000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:InterestRateSwapMember2024-01-012024-12-310000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:InterestRateSwapMember2023-01-012023-12-310000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:InterestRateSwapMember2022-01-012022-12-310000310158us-gaap:ForeignExchangeContractMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-12-310000310158us-gaap:ForeignExchangeContractMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310000310158us-gaap:ForeignExchangeContractMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310000310158us-gaap:InterestRateContractMember2024-01-012024-12-310000310158us-gaap:InterestRateContractMember2023-01-012023-12-310000310158us-gaap:InterestRateContractMember2022-01-012022-12-310000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:CurrencySwapMember2024-01-012024-12-310000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:CurrencySwapMember2023-01-012023-12-310000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:CurrencySwapMember2022-01-012022-12-310000310158us-gaap:SalesMemberus-gaap:ForeignExchangeFutureMember2024-01-012024-12-310000310158us-gaap:SalesMemberus-gaap:ForeignExchangeFutureMember2023-01-012023-12-310000310158us-gaap:SalesMemberus-gaap:ForeignExchangeFutureMember2022-01-012022-12-310000310158us-gaap:CommercialPaperMember2024-12-310000310158us-gaap:CommercialPaperMember2023-12-310000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-12-310000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310000310158us-gaap:CorporateDebtSecuritiesMember2024-12-310000310158us-gaap:CorporateDebtSecuritiesMember2023-12-310000310158us-gaap:EquityFundsMember2024-12-310000310158us-gaap:EquityFundsMember2023-12-310000310158us-gaap:EquityFundsMember2022-12-310000310158us-gaap:EquityFundsMember2024-01-012024-12-310000310158us-gaap:EquityFundsMember2023-01-012023-12-310000310158us-gaap:EquityFundsMember2022-01-012022-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2024-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2024-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2024-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2024-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2023-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2023-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2023-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2023-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2024-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2023-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000310158us-gaap:FairValueMeasurementsRecurringMember2024-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000310158us-gaap:FairValueMeasurementsRecurringMember2023-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMember2024-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMember2023-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeOptionMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeOptionMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeOptionMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeOptionMember2024-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeOptionMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeOptionMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeOptionMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeOptionMember2023-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateSwapMember2024-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateSwapMember2023-12-310000310158us-gaap:FairValueInputsLevel2Member2024-12-310000310158us-gaap:FairValueInputsLevel2Member2023-12-310000310158mrk:SanofiPasteurMember2024-12-310000310158mrk:SanofiPasteurMember2024-01-012024-12-310000310158mrk:LyfnuaMember2024-01-012024-12-310000310158mrk:McKessonCorporationMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2024-01-012024-12-310000310158mrk:CencoraInc.Memberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2024-01-012024-12-310000310158mrk:CardinalHealthIncMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2024-01-012024-12-310000310158mrk:AccountsReceivableFactoringCollectionsMember2024-12-310000310158mrk:AccountsReceivableFactoringCollectionsMember2023-12-310000310158mrk:InventoryNotExpectedtobeSoldWithinOneYearMember2024-12-310000310158mrk:InventoryNotExpectedtobeSoldWithinOneYearMember2023-12-310000310158mrk:InventoriesProducedinPreparationforProductLaunchesMember2024-12-310000310158mrk:InventoriesProducedinPreparationforProductLaunchesMember2023-12-310000310158mrk:PharmaceuticalsegmentMember2022-12-310000310158mrk:AnimalHealthsegmentMember2022-12-310000310158mrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158mrk:AnimalHealthsegmentMember2023-01-012023-12-310000310158mrk:PharmaceuticalsegmentMember2023-12-310000310158mrk:AnimalHealthsegmentMember2023-12-310000310158mrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158mrk:AnimalHealthsegmentMember2024-01-012024-12-310000310158mrk:PharmaceuticalsegmentMember2024-12-310000310158mrk:AnimalHealthsegmentMember2024-12-310000310158us-gaap:DevelopedTechnologyRightsMember2024-12-310000310158us-gaap:DevelopedTechnologyRightsMember2023-12-310000310158us-gaap:InProcessResearchAndDevelopmentMember2024-12-310000310158us-gaap:InProcessResearchAndDevelopmentMember2023-12-310000310158us-gaap:TradeNamesMember2024-12-310000310158us-gaap:TradeNamesMember2023-12-310000310158mrk:LicensesAndOtherMember2024-12-310000310158mrk:LicensesAndOtherMember2023-12-310000310158us-gaap:DevelopedTechnologyRightsMembermrk:WinrevairMember2024-12-310000310158us-gaap:DevelopedTechnologyRightsMembermrk:ReblozylMember2024-12-310000310158us-gaap:DevelopedTechnologyRightsMembermrk:ZerbaxaMember2024-12-310000310158mrk:AnimalHealthMember2024-12-310000310158us-gaap:DevelopedTechnologyRightsMembermrk:AnimalHealthMember2024-12-310000310158us-gaap:TradeNamesMembermrk:AnimalHealthMember2024-12-310000310158mrk:NemtabrutinibMemberus-gaap:InProcessResearchAndDevelopmentMember2024-12-310000310158mrk:GefapixantMemberus-gaap:InProcessResearchAndDevelopmentMember2023-01-012023-12-310000310158mrk:LyfnuaMember2024-12-310000310158mrk:NemtabrutinibMemberus-gaap:InProcessResearchAndDevelopmentMember2022-01-012022-12-310000310158mrk:NemtabrutinibMemberus-gaap:InProcessResearchAndDevelopmentMember2022-07-012022-09-300000310158mrk:NemtabrutinibMemberus-gaap:InProcessResearchAndDevelopmentMember2022-12-012022-12-310000310158mrk:LicensesAndOtherMembermrk:DerazantinibMember2022-01-012022-12-310000310158mrk:NotesSubjectToRepaymentAtOptionOfHolderMember2024-12-310000310158mrk:NotesSubjectToRepaymentAtOptionOfHolderMember2023-12-310000310158us-gaap:CommercialPaperMember2024-01-012024-12-310000310158us-gaap:CommercialPaperMember2023-01-012023-12-310000310158mrk:A215NotesDue2031Member2024-12-310000310158mrk:A215NotesDue2031Member2023-12-310000310158mrk:A275NotesDue2051Member2024-12-310000310158mrk:A275NotesDue2051Member2023-12-310000310158mrk:A3.70NotesDue2045Member2024-12-310000310158mrk:A3.70NotesDue2045Member2023-12-310000310158mrk:A3.40NotesDue2029Member2024-12-310000310158mrk:A3.40NotesDue2029Member2023-12-310000310158mrk:A450NotesDue2033Member2024-12-310000310158mrk:A450NotesDue2033Member2023-12-310000310158mrk:A170NotesDue2027Member2024-12-310000310158mrk:A170NotesDue2027Member2023-12-310000310158mrk:A290NotesDue2061Member2024-12-310000310158mrk:A290NotesDue2061Member2023-12-310000310158mrk:A500NotesDue2053Member2024-12-310000310158mrk:A500NotesDue2053Member2023-12-310000310158mrk:A4.00NotesDue2049Member2024-12-310000310158mrk:A4.00NotesDue2049Member2023-12-310000310158mrk:A415NotesDue2043Member2024-12-310000310158mrk:A415NotesDue2043Member2023-12-310000310158mrk:A145NotesDue2030Member2024-12-310000310158mrk:A145NotesDue2030Member2023-12-310000310158mrk:A245NotesDue2050Member2024-12-310000310158mrk:A245NotesDue2050Member2023-12-310000310158mrk:A1.875EuroNotesDue2026Member2024-12-310000310158mrk:A1.875EuroNotesDue2026Member2023-12-310000310158mrk:A075NotesDue2026Member2024-12-310000310158mrk:A075NotesDue2026Member2023-12-310000310158mrk:A190NotesDue2028Member2024-12-310000310158mrk:A190NotesDue2028Member2023-12-310000310158mrk:A515NotesDue2063Member2024-12-310000310158mrk:A515NotesDue2063Member2023-12-310000310158mrk:A3.90NotesDue2039Member2024-12-310000310158mrk:A3.90NotesDue2039Member2023-12-310000310158mrk:A235NotesDue2040Member2024-12-310000310158mrk:A235NotesDue2040Member2023-12-310000310158mrk:A3.25EuroNotesDue2032Member2024-12-310000310158mrk:A3.25EuroNotesDue2032Member2023-12-310000310158mrk:A3.50EuroNotesDue2037Member2024-12-310000310158mrk:A3.50EuroNotesDue2037Member2023-12-310000310158mrk:A3.70EuroNotesDue2044Member2024-12-310000310158mrk:A3.70EuroNotesDue2044Member2023-12-310000310158mrk:A3.75EuroNotesDue2054Member2024-12-310000310158mrk:A3.75EuroNotesDue2054Member2023-12-310000310158mrk:A430NotesDue2030Member2024-12-310000310158mrk:A430NotesDue2030Member2023-12-310000310158mrk:A490NotesDue2044Member2024-12-310000310158mrk:A490NotesDue2044Member2023-12-310000310158mrk:A650NotesDue2033Member2024-12-310000310158mrk:A650NotesDue2033Member2023-12-310000310158mrk:A1.375eurodenominatednotesdue2036Member2024-12-310000310158mrk:A1.375eurodenominatednotesdue2036Member2023-12-310000310158mrk:A25EuroDenominatedNotesDue2034Member2024-12-310000310158mrk:A25EuroDenominatedNotesDue2034Member2023-12-310000310158mrk:A405NotesDue2028Member2024-12-310000310158mrk:A405NotesDue2028Member2023-12-310000310158mrk:A360NotesDue2042Member2024-12-310000310158mrk:A360NotesDue2042Member2023-12-310000310158mrk:A655NotesDue2037Member2024-12-310000310158mrk:A655NotesDue2037Member2023-12-310000310158mrk:A575NotesDue2036Member2024-12-310000310158mrk:A575NotesDue2036Member2023-12-310000310158mrk:A595DebenturesDue2028Member2024-12-310000310158mrk:A595DebenturesDue2028Member2023-12-310000310158mrk:A585NotesDue2039Member2024-12-310000310158mrk:A585NotesDue2039Member2023-12-310000310158mrk:A640DebenturesDue2028Member2024-12-310000310158mrk:A640DebenturesDue2028Member2023-12-310000310158mrk:A63DebenturesDue2026Member2024-12-310000310158mrk:A63DebenturesDue2026Member2023-12-310000310158mrk:A2.75NotesDue2025Member2024-12-310000310158mrk:A2.75NotesDue2025Member2023-12-310000310158mrk:OtherLongTermDebtMember2024-12-310000310158mrk:OtherLongTermDebtMember2023-12-310000310158mrk:OtherVariableRateDebtMember2024-12-310000310158mrk:OtherVariableRateDebtMember2023-12-310000310158us-gaap:SeniorNotesMember2024-05-310000310158mrk:A3.25NotesDue2032Memberus-gaap:SeniorNotesMember2024-05-310000310158mrk:A3.50NotesDue2037Memberus-gaap:SeniorNotesMember2024-05-310000310158mrk:A3.70NotesDue2044Memberus-gaap:SeniorNotesMember2024-05-310000310158mrk:A3.75NotesDue2054Memberus-gaap:SeniorNotesMember2024-05-310000310158us-gaap:BuildingMember2024-12-310000310158us-gaap:VehiclesMember2024-12-310000310158country:USus-gaap:PendingLitigationMembermrk:Dr.SchollsMember2024-12-310000310158country:USus-gaap:PendingLitigationMembermrk:GardasilGardasil9Member2024-12-310000310158us-gaap:NonUsMemberus-gaap:PendingLitigationMembermrk:GardasilGardasil9Member2024-12-310000310158country:USus-gaap:PendingLitigationMembermrk:RotateqMember2024-01-012024-12-310000310158mrk:CommercialandOtherLitigationMemberus-gaap:PendingLitigationMember2024-01-012024-12-310000310158country:USus-gaap:SettledLitigationMembermrk:QuiTamMember2023-07-012023-07-310000310158mrk:CommercialandOtherLitigationMemberus-gaap:PendingLitigationMember2024-12-310000310158us-gaap:PendingLitigationMemberus-gaap:PatentsMembermrk:BridionMember2022-12-192022-12-190000310158us-gaap:SettledLitigationMemberus-gaap:PatentsMembermrk:BridionMember2023-06-012023-06-300000310158us-gaap:PatentsMembermrk:BridionMember2024-01-012024-12-310000310158us-gaap:PendingLitigationMemberus-gaap:PatentsMembermrk:BridionMember2024-12-310000310158mrk:JanuviaJanumetMember2024-01-012024-12-310000310158mrk:TheJohnsHopkinsUniversityMember2023-04-012023-05-310000310158mrk:TheJohnsHopkinsUniversityMember2024-06-012024-10-310000310158mrk:LegalDefenseCostsMember2024-12-310000310158mrk:LegalDefenseCostsMember2023-12-310000310158us-gaap:CommonStockMember2024-01-012024-12-310000310158us-gaap:CommonStockMember2023-01-012023-12-310000310158us-gaap:CommonStockMember2022-01-012022-12-310000310158us-gaap:EmployeeStockOptionMember2024-01-012024-12-310000310158us-gaap:EmployeeStockOptionMembersrt:MinimumMember2024-01-012024-12-310000310158us-gaap:EmployeeStockOptionMembersrt:MaximumMember2024-01-012024-12-310000310158us-gaap:PerformanceSharesMember2024-01-012024-12-310000310158us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-12-310000310158us-gaap:RestrictedStockUnitsRSUMember2023-12-310000310158us-gaap:PerformanceSharesMember2023-12-310000310158us-gaap:RestrictedStockUnitsRSUMember2024-12-310000310158us-gaap:PerformanceSharesMember2024-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMember2024-01-012024-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMember2023-01-012023-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMember2022-01-012022-12-310000310158us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-01-012024-12-310000310158us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2023-01-012023-12-310000310158us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-01-012022-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-01-012024-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-01-012023-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-01-012022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMember2023-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMember2022-12-310000310158us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2023-12-310000310158us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMember2024-12-310000310158us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-12-310000310158us-gaap:PensionPlansDefinedBenefitMember2024-12-310000310158us-gaap:PensionPlansDefinedBenefitMember2023-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMember2024-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:PensionPlansDefinedBenefitMember2023-12-310000310158us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2024-12-310000310158us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2024-12-310000310158us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2024-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2024-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2024-12-310000310158us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2023-12-310000310158us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2023-12-310000310158us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2023-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2023-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2023-12-310000310158us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitiesInvestmentFundsMember2024-12-310000310158us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitiesInvestmentFundsMember2024-12-310000310158us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitiesInvestmentFundsMember2024-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitiesInvestmentFundsMember2024-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitiesInvestmentFundsMember2024-12-310000310158us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitiesInvestmentFundsMember2023-12-310000310158us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitiesInvestmentFundsMember2023-12-310000310158us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitiesInvestmentFundsMember2023-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitiesInvestmentFundsMember2023-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitiesInvestmentFundsMember2023-12-310000310158us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:EmergingMarketsEquitiesInvestmentFundsMember2024-12-310000310158us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:EmergingMarketsEquitiesInvestmentFundsMember2024-12-310000310158us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:EmergingMarketsEquitiesInvestmentFundsMember2024-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:EmergingMarketsEquitiesInvestmentFundsMember2024-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMembermrk:EmergingMarketsEquitiesInvestmentFundsMember2024-12-310000310158us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:EmergingMarketsEquitiesInvestmentFundsMember2023-12-310000310158us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:EmergingMarketsEquitiesInvestmentFundsMember2023-12-310000310158us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:EmergingMarketsEquitiesInvestmentFundsMember2023-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:EmergingMarketsEquitiesInvestmentFundsMember2023-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMembermrk:EmergingMarketsEquitiesInvestmentFundsMember2023-12-310000310158us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2024-12-310000310158us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2024-12-310000310158us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2024-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2024-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2024-12-310000310158us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2023-12-310000310158us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2023-12-310000310158us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2023-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2023-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2023-12-310000310158us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitySecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitySecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitySecuritiesMember2024-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitySecuritiesMember2024-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitySecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitySecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitySecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitySecuritiesMember2023-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitySecuritiesMember2023-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitySecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember2024-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember2024-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember2023-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember2023-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:CorporateObligationsFixedIncomeSecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:CorporateObligationsFixedIncomeSecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:CorporateObligationsFixedIncomeSecuritiesMember2024-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:CorporateObligationsFixedIncomeSecuritiesMember2024-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMembermrk:CorporateObligationsFixedIncomeSecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:CorporateObligationsFixedIncomeSecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:CorporateObligationsFixedIncomeSecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:CorporateObligationsFixedIncomeSecuritiesMember2023-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:CorporateObligationsFixedIncomeSecuritiesMember2023-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMembermrk:CorporateObligationsFixedIncomeSecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2024-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2024-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2023-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2023-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanDerivativeMember2024-12-310000310158us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanDerivativeMember2024-12-310000310158us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanDerivativeMember2024-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanDerivativeMember2024-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanDerivativeMember2024-12-310000310158us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanDerivativeMember2023-12-310000310158us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanDerivativeMember2023-12-310000310158us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanDerivativeMember2023-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanDerivativeMember2023-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanDerivativeMember2023-12-310000310158us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMember2024-12-310000310158us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMember2024-12-310000310158us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMember2024-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMember2024-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMember2024-12-310000310158us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMember2023-12-310000310158us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMember2023-12-310000310158us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMember2023-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMember2023-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMember2023-12-310000310158us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMember2024-12-310000310158us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMember2024-12-310000310158us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMember2024-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMember2024-12-310000310158us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMember2023-12-310000310158us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMember2023-12-310000310158us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMember2023-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMembercountry:USus-gaap:PensionPlansDefinedBenefitMember2023-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2024-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2024-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2024-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2024-12-310000310158us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2024-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2023-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2023-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2023-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2023-12-310000310158us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2023-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitiesInvestmentFundsMember2024-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitiesInvestmentFundsMember2024-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitiesInvestmentFundsMember2024-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitiesInvestmentFundsMember2024-12-310000310158us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitiesInvestmentFundsMember2024-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitiesInvestmentFundsMember2023-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitiesInvestmentFundsMember2023-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitiesInvestmentFundsMember2023-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitiesInvestmentFundsMember2023-12-310000310158us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitiesInvestmentFundsMember2023-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsInvestmentFundsMember2024-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsInvestmentFundsMember2024-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsInvestmentFundsMember2024-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsInvestmentFundsMember2024-12-310000310158us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsInvestmentFundsMember2024-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsInvestmentFundsMember2023-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsInvestmentFundsMember2023-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsInvestmentFundsMember2023-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsInvestmentFundsMember2023-12-310000310158us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsInvestmentFundsMember2023-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2024-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2024-12-310000310158us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000310158us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:EmergingMarketsEquitiesInvestmentFundsMember2024-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:EmergingMarketsEquitiesInvestmentFundsMember2024-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:EmergingMarketsEquitiesInvestmentFundsMember2024-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:EmergingMarketsEquitiesInvestmentFundsMember2024-12-310000310158us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:EmergingMarketsEquitiesInvestmentFundsMember2024-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:EmergingMarketsEquitiesInvestmentFundsMember2023-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:EmergingMarketsEquitiesInvestmentFundsMember2023-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:EmergingMarketsEquitiesInvestmentFundsMember2023-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:EmergingMarketsEquitiesInvestmentFundsMember2023-12-310000310158us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:EmergingMarketsEquitiesInvestmentFundsMember2023-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:FixedIncomeObligationsInvestmentFundsMember2024-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:FixedIncomeObligationsInvestmentFundsMember2024-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:FixedIncomeObligationsInvestmentFundsMember2024-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:FixedIncomeObligationsInvestmentFundsMember2024-12-310000310158us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:FixedIncomeObligationsInvestmentFundsMember2024-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:FixedIncomeObligationsInvestmentFundsMember2023-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:FixedIncomeObligationsInvestmentFundsMember2023-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:FixedIncomeObligationsInvestmentFundsMember2023-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:FixedIncomeObligationsInvestmentFundsMember2023-12-310000310158us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:FixedIncomeObligationsInvestmentFundsMember2023-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2024-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2024-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2024-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2024-12-310000310158us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2024-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2023-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2023-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2023-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2023-12-310000310158us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2023-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitySecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitySecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitySecuritiesMember2024-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitySecuritiesMember2024-12-310000310158us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitySecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitySecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitySecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitySecuritiesMember2023-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitySecuritiesMember2023-12-310000310158us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitySecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember2024-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember2024-12-310000310158us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember2023-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember2023-12-310000310158us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:CorporateObligationsFixedIncomeSecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:CorporateObligationsFixedIncomeSecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:CorporateObligationsFixedIncomeSecuritiesMember2024-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:CorporateObligationsFixedIncomeSecuritiesMember2024-12-310000310158us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:CorporateObligationsFixedIncomeSecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:CorporateObligationsFixedIncomeSecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:CorporateObligationsFixedIncomeSecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:CorporateObligationsFixedIncomeSecuritiesMember2023-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:CorporateObligationsFixedIncomeSecuritiesMember2023-12-310000310158us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:CorporateObligationsFixedIncomeSecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2024-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2024-12-310000310158us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2023-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2023-12-310000310158us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:InsuranceContractsOtherInvestmentsMember2024-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:InsuranceContractsOtherInvestmentsMember2024-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:InsuranceContractsOtherInvestmentsMember2024-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:InsuranceContractsOtherInvestmentsMember2024-12-310000310158us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:InsuranceContractsOtherInvestmentsMember2024-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:InsuranceContractsOtherInvestmentsMember2023-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:InsuranceContractsOtherInvestmentsMember2023-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:InsuranceContractsOtherInvestmentsMember2023-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:InsuranceContractsOtherInvestmentsMember2023-12-310000310158us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:InsuranceContractsOtherInvestmentsMember2023-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMember2024-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMember2024-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMember2024-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMember2024-12-310000310158us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMember2024-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMember2023-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMember2023-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMember2023-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMember2023-12-310000310158us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMember2023-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2023-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2023-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2023-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2023-12-310000310158us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:InsuranceContractsOtherInvestmentsMember2023-12-310000310158us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:InsuranceContractsOtherInvestmentsMember2022-12-310000310158us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMember2022-12-310000310158us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMember2022-12-310000310158us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:InsuranceContractsOtherInvestmentsMember2024-01-012024-12-310000310158us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMember2024-01-012024-12-310000310158us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMember2024-01-012024-12-310000310158us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:InsuranceContractsOtherInvestmentsMember2023-01-012023-12-310000310158us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMember2023-01-012023-12-310000310158us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMember2023-01-012023-12-310000310158us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMembermrk:InsuranceContractsOtherInvestmentsMember2024-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:InsuranceContractsOtherInvestmentsMember2022-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMember2022-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:InsuranceContractsOtherInvestmentsMember2024-01-012024-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMember2024-01-012024-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-01-012024-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMembermrk:InsuranceContractsOtherInvestmentsMember2023-01-012023-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMember2023-01-012023-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2023-01-012023-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:CashAndCashEquivalentsMember2024-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:CashAndCashEquivalentsMember2024-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:CashAndCashEquivalentsMember2024-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:CashAndCashEquivalentsMember2024-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:CashAndCashEquivalentsMember2024-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:CashAndCashEquivalentsMember2023-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:CashAndCashEquivalentsMember2023-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:CashAndCashEquivalentsMember2023-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:CashAndCashEquivalentsMember2023-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:CashAndCashEquivalentsMember2023-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:DevelopedMarketsEquitiesInvestmentFundsMember2024-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:DevelopedMarketsEquitiesInvestmentFundsMember2024-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:DevelopedMarketsEquitiesInvestmentFundsMember2024-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:DevelopedMarketsEquitiesInvestmentFundsMember2024-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:DevelopedMarketsEquitiesInvestmentFundsMember2024-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:DevelopedMarketsEquitiesInvestmentFundsMember2023-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:DevelopedMarketsEquitiesInvestmentFundsMember2023-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:DevelopedMarketsEquitiesInvestmentFundsMember2023-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:DevelopedMarketsEquitiesInvestmentFundsMember2023-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:DevelopedMarketsEquitiesInvestmentFundsMember2023-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:EmergingMarketsEquitiesInvestmentFundsMember2024-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:EmergingMarketsEquitiesInvestmentFundsMember2024-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:EmergingMarketsEquitiesInvestmentFundsMember2024-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:EmergingMarketsEquitiesInvestmentFundsMember2024-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:EmergingMarketsEquitiesInvestmentFundsMember2024-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:EmergingMarketsEquitiesInvestmentFundsMember2023-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:EmergingMarketsEquitiesInvestmentFundsMember2023-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:EmergingMarketsEquitiesInvestmentFundsMember2023-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:EmergingMarketsEquitiesInvestmentFundsMember2023-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:EmergingMarketsEquitiesInvestmentFundsMember2023-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2024-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2024-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2024-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2024-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2024-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2023-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2023-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2023-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2023-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2023-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:DevelopedMarketsEquitySecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:DevelopedMarketsEquitySecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:DevelopedMarketsEquitySecuritiesMember2024-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:DevelopedMarketsEquitySecuritiesMember2024-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:DevelopedMarketsEquitySecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:DevelopedMarketsEquitySecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:DevelopedMarketsEquitySecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:DevelopedMarketsEquitySecuritiesMember2023-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:DevelopedMarketsEquitySecuritiesMember2023-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:DevelopedMarketsEquitySecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2024-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2024-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember2024-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember2024-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember2023-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember2023-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2024-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2024-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2024-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2023-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2023-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2023-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanDerivativeMember2024-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanDerivativeMember2024-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanDerivativeMember2024-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanDerivativeMember2024-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanDerivativeMember2024-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanDerivativeMember2023-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanDerivativeMember2023-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanDerivativeMember2023-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanDerivativeMember2023-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanDerivativeMember2023-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-12-310000310158us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-12-310000310158country:USsrt:MinimumMemberus-gaap:DefinedBenefitPlanEquitySecuritiesUsMember2024-12-310000310158country:USsrt:MaximumMemberus-gaap:DefinedBenefitPlanEquitySecuritiesUsMember2024-12-310000310158country:USsrt:MinimumMemberus-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember2024-12-310000310158country:USsrt:MaximumMemberus-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember2024-12-310000310158country:USsrt:MinimumMemberus-gaap:FixedIncomeInvestmentsMember2024-12-310000310158country:USsrt:MaximumMemberus-gaap:FixedIncomeInvestmentsMember2024-12-310000310158country:USsrt:MaximumMembermrk:DefinedBenefitPlanCashandOtherInvestmentsMember2024-12-310000310158country:US2024-12-310000310158country:US2024-01-012024-12-310000310158country:US2023-01-012023-12-310000310158country:US2022-01-012022-12-310000310158country:US2023-12-310000310158country:US2022-12-310000310158country:USus-gaap:SubsequentEventMembersrt:ScenarioForecastMember2025-01-012025-12-310000310158mrk:ZetiaantitrustlitigationMember2023-01-012023-12-310000310158us-gaap:OtherAssetsMember2024-12-310000310158us-gaap:OtherAssetsMember2023-12-310000310158us-gaap:ForeignCountryMember2024-12-310000310158us-gaap:DomesticCountryMember2024-12-310000310158us-gaap:DomesticCountryMember2024-01-012024-12-310000310158us-gaap:DomesticCountryMember2023-01-012023-12-310000310158us-gaap:DomesticCountryMember2022-01-012022-12-310000310158us-gaap:ForeignCountryMember2024-01-012024-12-310000310158us-gaap:ForeignCountryMember2023-01-012023-12-310000310158us-gaap:ForeignCountryMember2022-01-012022-12-310000310158mrk:TaxYear2019And2020Member2024-01-012024-12-310000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-12-310000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-12-310000310158us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-01-012022-12-310000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-01-012022-12-310000310158us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-12-310000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-12-310000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-12-310000310158us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-01-012023-12-310000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-12-310000310158us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-12-310000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-12-310000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-12-310000310158us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-01-012024-12-310000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-01-012024-12-310000310158us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-12-310000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-12-310000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-12-310000310158us-gaap:AccumulatedTranslationAdjustmentMember2024-12-310000310158mrk:PensionPlanNetLossMember2024-12-310000310158mrk:PensionPlanNetLossMember2023-12-310000310158mrk:OtherPostretirementBenefitPlanNetLossMember2024-12-310000310158mrk:OtherPostretirementBenefitPlanNetLossMember2023-12-310000310158mrk:PensionPlanPriorServiceCostMember2024-12-310000310158mrk:PensionPlanPriorServiceCostMember2023-12-310000310158mrk:OtherPostretirementBenefitPlanPriorServiceCostMember2024-12-310000310158mrk:OtherPostretirementBenefitPlanPriorServiceCostMember2023-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:KeytrudaMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:KeytrudaMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158us-gaap:OperatingSegmentsMembermrk:KeytrudaMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:KeytrudaMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:KeytrudaMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158us-gaap:OperatingSegmentsMembermrk:KeytrudaMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:KeytrudaMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:KeytrudaMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:KeytrudaMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:AlliancerevenueLynparzaMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:AlliancerevenueLynparzaMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158us-gaap:OperatingSegmentsMembermrk:AlliancerevenueLynparzaMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:AlliancerevenueLynparzaMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:AlliancerevenueLynparzaMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158us-gaap:OperatingSegmentsMembermrk:AlliancerevenueLynparzaMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:AlliancerevenueLynparzaMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:AlliancerevenueLynparzaMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:AlliancerevenueLynparzaMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:LenvimaMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:LenvimaMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158us-gaap:OperatingSegmentsMembermrk:LenvimaMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:LenvimaMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:LenvimaMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158us-gaap:OperatingSegmentsMembermrk:LenvimaMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:LenvimaMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:LenvimaMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:LenvimaMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:WeliregMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:WeliregMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158us-gaap:OperatingSegmentsMembermrk:WeliregMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:WeliregMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:WeliregMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158us-gaap:OperatingSegmentsMembermrk:WeliregMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:WeliregMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:WeliregMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:WeliregMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:ReblozylMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:ReblozylMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158us-gaap:OperatingSegmentsMembermrk:ReblozylMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:ReblozylMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:ReblozylMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158us-gaap:OperatingSegmentsMembermrk:ReblozylMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:ReblozylMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:ReblozylMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:ReblozylMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:GardasilGardasil9Membermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:GardasilGardasil9Membermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158us-gaap:OperatingSegmentsMembermrk:GardasilGardasil9Membermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:GardasilGardasil9Membermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:GardasilGardasil9Membermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158us-gaap:OperatingSegmentsMembermrk:GardasilGardasil9Membermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:GardasilGardasil9Membermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:GardasilGardasil9Membermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:GardasilGardasil9Membermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:ProQuadMMRIIVarivaxMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:ProQuadMMRIIVarivaxMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158us-gaap:OperatingSegmentsMembermrk:ProQuadMMRIIVarivaxMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:ProQuadMMRIIVarivaxMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:ProQuadMMRIIVarivaxMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158us-gaap:OperatingSegmentsMembermrk:ProQuadMMRIIVarivaxMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:ProQuadMMRIIVarivaxMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:ProQuadMMRIIVarivaxMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:ProQuadMMRIIVarivaxMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:VaxneuvanceMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:VaxneuvanceMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158us-gaap:OperatingSegmentsMembermrk:VaxneuvanceMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:VaxneuvanceMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:VaxneuvanceMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158us-gaap:OperatingSegmentsMembermrk:VaxneuvanceMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:VaxneuvanceMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:VaxneuvanceMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:VaxneuvanceMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:RotateqMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:RotateqMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158us-gaap:OperatingSegmentsMembermrk:RotateqMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:RotateqMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:RotateqMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158us-gaap:OperatingSegmentsMembermrk:RotateqMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:RotateqMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:RotateqMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:RotateqMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:Pneumovax23Membermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:Pneumovax23Membermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158us-gaap:OperatingSegmentsMembermrk:Pneumovax23Membermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:Pneumovax23Membermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:Pneumovax23Membermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158us-gaap:OperatingSegmentsMembermrk:Pneumovax23Membermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:Pneumovax23Membermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:Pneumovax23Membermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:Pneumovax23Membermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:BridionMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:BridionMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158us-gaap:OperatingSegmentsMembermrk:BridionMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:BridionMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:BridionMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158us-gaap:OperatingSegmentsMembermrk:BridionMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:BridionMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:BridionMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:BridionMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:PrevymisMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PrevymisMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158us-gaap:OperatingSegmentsMembermrk:PrevymisMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:PrevymisMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PrevymisMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158us-gaap:OperatingSegmentsMembermrk:PrevymisMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:PrevymisMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PrevymisMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:PrevymisMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:DificidMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:DificidMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158us-gaap:OperatingSegmentsMembermrk:DificidMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:DificidMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:DificidMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158us-gaap:OperatingSegmentsMembermrk:DificidMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:DificidMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:DificidMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:DificidMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:ZerbaxaMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:ZerbaxaMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158us-gaap:OperatingSegmentsMembermrk:ZerbaxaMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:ZerbaxaMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:ZerbaxaMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158us-gaap:OperatingSegmentsMembermrk:ZerbaxaMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:ZerbaxaMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:ZerbaxaMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:ZerbaxaMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:NoxafilMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:NoxafilMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158us-gaap:OperatingSegmentsMembermrk:NoxafilMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:NoxafilMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:NoxafilMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158us-gaap:OperatingSegmentsMembermrk:NoxafilMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:NoxafilMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:NoxafilMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:NoxafilMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:WinrevairMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:WinrevairMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158us-gaap:OperatingSegmentsMembermrk:WinrevairMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:WinrevairMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:WinrevairMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158us-gaap:OperatingSegmentsMembermrk:WinrevairMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:WinrevairMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:WinrevairMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:WinrevairMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:AllianceRevenueAdempasVerquvoMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:AllianceRevenueAdempasVerquvoMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158us-gaap:OperatingSegmentsMembermrk:AllianceRevenueAdempasVerquvoMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:AllianceRevenueAdempasVerquvoMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:AllianceRevenueAdempasVerquvoMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158us-gaap:OperatingSegmentsMembermrk:AllianceRevenueAdempasVerquvoMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:AllianceRevenueAdempasVerquvoMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:AllianceRevenueAdempasVerquvoMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:AllianceRevenueAdempasVerquvoMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:AdempasMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:AdempasMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158us-gaap:OperatingSegmentsMembermrk:AdempasMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:AdempasMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:AdempasMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158us-gaap:OperatingSegmentsMembermrk:AdempasMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:AdempasMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:AdempasMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:AdempasMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:LagevrioMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:LagevrioMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158us-gaap:OperatingSegmentsMembermrk:LagevrioMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:LagevrioMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:LagevrioMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158us-gaap:OperatingSegmentsMembermrk:LagevrioMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:LagevrioMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:LagevrioMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:LagevrioMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158us-gaap:OperatingSegmentsMembermrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158us-gaap:OperatingSegmentsMembermrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:DelstrigoMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:DelstrigoMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158us-gaap:OperatingSegmentsMembermrk:DelstrigoMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:DelstrigoMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:DelstrigoMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158us-gaap:OperatingSegmentsMembermrk:DelstrigoMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:DelstrigoMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:DelstrigoMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:DelstrigoMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:PifeltroMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PifeltroMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158us-gaap:OperatingSegmentsMembermrk:PifeltroMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:PifeltroMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PifeltroMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158us-gaap:OperatingSegmentsMembermrk:PifeltroMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:PifeltroMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PifeltroMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:PifeltroMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:BelsomraMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:BelsomraMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158us-gaap:OperatingSegmentsMembermrk:BelsomraMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:BelsomraMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:BelsomraMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158us-gaap:OperatingSegmentsMembermrk:BelsomraMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:BelsomraMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:BelsomraMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:BelsomraMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:SimponiMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:SimponiMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158us-gaap:OperatingSegmentsMembermrk:SimponiMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:SimponiMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:SimponiMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158us-gaap:OperatingSegmentsMembermrk:SimponiMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:SimponiMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:SimponiMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:SimponiMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:RemicadeMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:RemicadeMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158us-gaap:OperatingSegmentsMembermrk:RemicadeMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:RemicadeMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:RemicadeMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158us-gaap:OperatingSegmentsMembermrk:RemicadeMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:RemicadeMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:RemicadeMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:RemicadeMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:JanuviaMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:JanuviaMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158us-gaap:OperatingSegmentsMembermrk:JanuviaMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:JanuviaMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:JanuviaMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158us-gaap:OperatingSegmentsMembermrk:JanuviaMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:JanuviaMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:JanuviaMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:JanuviaMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:JanumetMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:JanumetMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158us-gaap:OperatingSegmentsMembermrk:JanumetMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:JanumetMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:JanumetMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158us-gaap:OperatingSegmentsMembermrk:JanumetMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:JanumetMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:JanumetMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:JanumetMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:OtherPharmaceuticalMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:OtherPharmaceuticalMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158us-gaap:OperatingSegmentsMembermrk:OtherPharmaceuticalMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:OtherPharmaceuticalMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:OtherPharmaceuticalMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158us-gaap:OperatingSegmentsMembermrk:OtherPharmaceuticalMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:OtherPharmaceuticalMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:OtherPharmaceuticalMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:OtherPharmaceuticalMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2024-01-012024-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2023-01-012023-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:LivestockMembermrk:AnimalHealthsegmentMember2024-01-012024-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:LivestockMembermrk:AnimalHealthsegmentMember2024-01-012024-12-310000310158us-gaap:OperatingSegmentsMembermrk:LivestockMembermrk:AnimalHealthsegmentMember2024-01-012024-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:LivestockMembermrk:AnimalHealthsegmentMember2023-01-012023-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:LivestockMembermrk:AnimalHealthsegmentMember2023-01-012023-12-310000310158us-gaap:OperatingSegmentsMembermrk:LivestockMembermrk:AnimalHealthsegmentMember2023-01-012023-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:LivestockMembermrk:AnimalHealthsegmentMember2022-01-012022-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:LivestockMembermrk:AnimalHealthsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:LivestockMembermrk:AnimalHealthsegmentMember2022-01-012022-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:CompanionAnimalsMembermrk:AnimalHealthsegmentMember2024-01-012024-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:CompanionAnimalsMembermrk:AnimalHealthsegmentMember2024-01-012024-12-310000310158us-gaap:OperatingSegmentsMembermrk:CompanionAnimalsMembermrk:AnimalHealthsegmentMember2024-01-012024-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:CompanionAnimalsMembermrk:AnimalHealthsegmentMember2023-01-012023-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:CompanionAnimalsMembermrk:AnimalHealthsegmentMember2023-01-012023-12-310000310158us-gaap:OperatingSegmentsMembermrk:CompanionAnimalsMembermrk:AnimalHealthsegmentMember2023-01-012023-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:CompanionAnimalsMembermrk:AnimalHealthsegmentMember2022-01-012022-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:CompanionAnimalsMembermrk:AnimalHealthsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:CompanionAnimalsMembermrk:AnimalHealthsegmentMember2022-01-012022-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:AnimalHealthsegmentMember2024-01-012024-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:AnimalHealthsegmentMember2024-01-012024-12-310000310158us-gaap:OperatingSegmentsMembermrk:AnimalHealthsegmentMember2024-01-012024-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:AnimalHealthsegmentMember2023-01-012023-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:AnimalHealthsegmentMember2023-01-012023-12-310000310158us-gaap:OperatingSegmentsMembermrk:AnimalHealthsegmentMember2023-01-012023-12-310000310158country:USus-gaap:OperatingSegmentsMembermrk:AnimalHealthsegmentMember2022-01-012022-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:AnimalHealthsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:AnimalHealthsegmentMember2022-01-012022-12-310000310158country:USus-gaap:OperatingSegmentsMember2024-01-012024-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMember2024-01-012024-12-310000310158us-gaap:OperatingSegmentsMember2024-01-012024-12-310000310158country:USus-gaap:OperatingSegmentsMember2023-01-012023-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMember2023-01-012023-12-310000310158us-gaap:OperatingSegmentsMember2023-01-012023-12-310000310158country:USus-gaap:OperatingSegmentsMember2022-01-012022-12-310000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMember2022-01-012022-12-310000310158country:USus-gaap:CorporateNonSegmentMember2024-01-012024-12-310000310158mrk:InternationalMemberus-gaap:CorporateNonSegmentMember2024-01-012024-12-310000310158us-gaap:CorporateNonSegmentMember2024-01-012024-12-310000310158country:USus-gaap:CorporateNonSegmentMember2023-01-012023-12-310000310158mrk:InternationalMemberus-gaap:CorporateNonSegmentMember2023-01-012023-12-310000310158us-gaap:CorporateNonSegmentMember2023-01-012023-12-310000310158country:USus-gaap:CorporateNonSegmentMember2022-01-012022-12-310000310158mrk:InternationalMemberus-gaap:CorporateNonSegmentMember2022-01-012022-12-310000310158us-gaap:CorporateNonSegmentMember2022-01-012022-12-310000310158country:US2024-01-012024-12-310000310158mrk:InternationalMember2024-01-012024-12-310000310158country:US2023-01-012023-12-310000310158mrk:InternationalMember2023-01-012023-12-310000310158country:US2022-01-012022-12-310000310158mrk:InternationalMember2022-01-012022-12-310000310158us-gaap:EMEAMember2024-01-012024-12-310000310158us-gaap:EMEAMember2023-01-012023-12-310000310158us-gaap:EMEAMember2022-01-012022-12-310000310158country:CN2024-01-012024-12-310000310158country:CN2023-01-012023-12-310000310158country:CN2022-01-012022-12-310000310158srt:LatinAmericaMember2024-01-012024-12-310000310158srt:LatinAmericaMember2023-01-012023-12-310000310158srt:LatinAmericaMember2022-01-012022-12-310000310158country:JP2024-01-012024-12-310000310158country:JP2023-01-012023-12-310000310158country:JP2022-01-012022-12-310000310158srt:AsiaPacificMember2024-01-012024-12-310000310158srt:AsiaPacificMember2023-01-012023-12-310000310158srt:AsiaPacificMember2022-01-012022-12-310000310158mrk:OtherCountriesMember2024-01-012024-12-310000310158mrk:OtherCountriesMember2023-01-012023-12-310000310158mrk:OtherCountriesMember2022-01-012022-12-310000310158country:US2024-12-310000310158country:US2023-12-310000310158country:US2022-12-310000310158us-gaap:EMEAMember2024-12-310000310158us-gaap:EMEAMember2023-12-310000310158us-gaap:EMEAMember2022-12-310000310158srt:AsiaPacificMember2024-12-310000310158srt:AsiaPacificMember2023-12-310000310158srt:AsiaPacificMember2022-12-310000310158country:CN2024-12-310000310158country:CN2023-12-310000310158country:CN2022-12-310000310158country:JP2024-12-310000310158country:JP2023-12-310000310158country:JP2022-12-310000310158srt:LatinAmericaMember2024-12-310000310158srt:LatinAmericaMember2023-12-310000310158srt:LatinAmericaMember2022-12-310000310158mrk:OtherCountriesMember2024-12-310000310158mrk:OtherCountriesMember2023-12-310000310158mrk:OtherCountriesMember2022-12-3100003101582024-10-012024-12-31

As filed with the Securities and Exchange Commission on February 25, 2025
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
_________________________________
FORM 10-K

 
Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the Fiscal Year Ended December 31, 2024

OR
Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the transition period from                  to                 

Commission File No. 1-6571
02852_Merck_Logo_Horizontal_Teal&Grey_RGB.jpg
Merck & Co., Inc.
126 East Lincoln Avenue
RahwayNew Jersey07065
(908740-4000
New Jersey22-1918501
(State or other jurisdiction of incorporation)
(I.R.S. Employer Identification No.)
Securities Registered pursuant to Section 12(b) of the Act:
Title of Each ClassTrading Symbol(s)Name of Each Exchange on which Registered
Common Stock ($0.50 par value)MRKNew York Stock Exchange
1.875% Notes due 2026MRK/26New York Stock Exchange
3.250% Notes due 2032
MRK/32
New York Stock Exchange
2.500% Notes due 2034MRK/34New York Stock Exchange
1.375% Notes due 2036MRK 36ANew York Stock Exchange
3.500% Notes due 2037
MRK/37
New York Stock Exchange
3.700% Notes due 2044
MRK/44
New York Stock Exchange
3.750% Notes due 2054
MRK/54
New York Stock Exchange
Securities Registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.     Yes ☒    No
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes ☐    No 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes   No  
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes   No  
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filerAccelerated filerNon-accelerated filerSmaller reporting companyEmerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes    No  
Number of shares of Common Stock ($0.50 par value) outstanding as of January 31, 2025: 2,526,036,240.
Aggregate market value of Common Stock ($0.50 par value) held by non-affiliates on June 28, 2024 based on the closing price on June 28, 2024, the last business day of the registrant’s most recently completed second fiscal quarter: approximately $313,799,000,000.
Documents Incorporated by Reference:
Document Part of Form 10-K
Proxy Statement for the Annual Meeting of Shareholders to be held May 27, 2025, to be filed with the
Securities and Exchange Commission within 120 days after the close of the fiscal year covered by this report
 Part III


Table of Contents
   Page
Item 1.
Item 1A.
Item 1B.
Item 1C.
Item 2.
Item 3.
Item 4.
Item 5.
Item 6.
 45
Item 7.
Item 7A.
Item 8.
(a)
Item 9.
Item 9A.
Item 9B.
Item 9C.
Item 10.
Item 11.
Item 12.
Item 13.
Item 14.
Item 15.
Item 16.


PART I
 
Item 1.Business.
Merck & Co., Inc. (Merck or the Company) is a global health care company that delivers innovative health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company’s operations are principally managed on a product basis and include two operating segments, Pharmaceutical and Animal Health, both of which are reportable segments.
The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities.
The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors, animal producers, farmers and pet owners.
All product or service marks appearing in type form different from that of the surrounding text are trademarks or service marks owned, licensed to, promoted or distributed by Merck, its subsidiaries or affiliates, except as noted. All other trademarks or service marks are those of their respective owners.
Product Sales
Total Company sales, including sales of the Company’s top pharmaceutical products, as well as sales of animal health products, were as follows:
($ in millions)202420232022
Total Sales$64,168 $60,115 $59,283 
Pharmaceutical57,400 53,583 52,005 
Keytruda29,482 25,011 20,937 
Gardasil/Gardasil 9
8,583 8,886 6,897 
ProQuad/M-M-R II/Varivax
2,485 2,368 2,241 
Januvia/Janumet2,268 3,366 4,513 
Bridion1,764 1,842 1,685 
Alliance revenue - Lynparza(1)
1,311 1,199 1,116 
Alliance revenue - Lenvima(1)
1,010 960 876 
Lagevrio964 1,428 5,684 
Vaxneuvance
808 665 170 
Prevymis
785 605 428 
RotaTeq711 769 783 
Animal Health5,877 5,625 5,550 
Livestock3,462 3,337 3,300 
Companion Animal
2,415 2,288 2,250 
Other Revenues(2)
891 907 1,728 
(1)Alliance revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(2)Other revenues are primarily comprised of miscellaneous corporate revenues, including revenue hedging activities, as well as revenue from third-party manufacturing arrangements.
Pharmaceutical
The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. Certain of the products within the Company’s franchises are as follows:
1

Oncology
Keytruda is an anti-PD-1 (programmed death receptor-1) therapy that has been approved as monotherapy for the treatment of certain patients with cervical cancer, classical Hodgkin lymphoma (cHL), cutaneous squamous cell carcinoma, esophageal or gastroesophageal junction (GEJ) carcinoma, head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma (HCC), melanoma, Merkel cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors (including MSI-H/dMMR colorectal cancer and endometrial carcinoma), non-small-cell lung cancer (NSCLC), primary mediastinal large B-cell lymphoma (PMBCL), tumor mutational burden-high (TMB-H) solid tumors, and urothelial cancer including non-muscle invasive bladder cancer. Keytruda is also approved as monotherapy for the adjuvant treatment of certain patients with melanoma, and for certain patients with renal cell carcinoma (RCC) post-surgery. Keytruda is approved for adjuvant treatment following resection and platinum-based chemotherapy for certain patients with NSCLC. Additionally, Keytruda is approved for patients with certain types of resectable NSCLC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. Keytruda is also approved for certain patients with high-risk early stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. In addition, Keytruda is approved in combination with chemotherapy for the treatment of certain patients with advanced NSCLC, advanced malignant pleural mesothelioma, HNSCC, advanced biliary tract cancer, advanced esophageal cancer, advanced TNBC, and advanced or recurrent endometrial carcinoma; in combination with chemotherapy with or without bevacizumab, and in combination with chemoradiotherapy, for the treatment of certain patients with advanced cervical cancer; in combination with trastuzumab and chemotherapy for the treatment of certain patients with advanced human epidermal growth factor receptor 2 (HER2)-positive gastric or GEJ adenocarcinoma with programmed death-ligand 1 (PD-L1) (CPS ≥1), and in combination with chemotherapy for the treatment of certain patients with advanced HER2-negative gastric or GEJ adenocarcinoma; in combination with axitinib for the treatment of certain patients with advanced RCC; in combination with Lenvima (lenvatinib) for the treatment of certain patients with advanced RCC or advanced endometrial carcinoma; and in combination with enfortumab vedotin for certain patients with locally advanced or metastatic urothelial cancer. Welireg (belzutifan) is a medication for the treatment of adult patients with certain von Hippel-Lindau (VHL) disease-associated tumors not requiring immediate surgery, and for the treatment of adult patients with advanced RCC following a PD-1 or PD-L1 inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor. In addition, the Company recognizes alliance revenue related to sales of Lynparza (olaparib), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, for certain types of advanced or recurrent ovarian, early or metastatic breast, metastatic pancreatic, and metastatic castration-resistant prostate cancers; alliance revenue related to sales of Lenvima, an oral receptor tyrosine kinase inhibitor, for certain types of thyroid cancer, RCC, HCC, in combination with everolimus for certain patients with advanced RCC, and in combination with Keytruda for certain patients with advanced endometrial carcinoma or advanced RCC; and alliance revenue related to Reblozyl (luspatercept-aamt) for the treatment of certain types of anemia.
Vaccines
Gardasil (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant)/Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant), vaccines to help prevent certain cancers and diseases caused by certain types of human papillomavirus (HPV); ProQuad (Measles, Mumps, Rubella and Varicella Virus Vaccine Live), a pediatric combination vaccine to help protect against measles, mumps, rubella and varicella; M−M−R II (Measles, Mumps and Rubella Virus Vaccine Live), a vaccine to help prevent measles, mumps and rubella; Varivax (Varicella Virus Vaccine Live), a vaccine to help prevent chickenpox (varicella); Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine), a vaccine to help prevent invasive pneumococcal disease in individuals 6 weeks of age and older; RotaTeq (Rotavirus Vaccine, Live Oral, Pentavalent), a vaccine to help protect against rotavirus gastroenteritis in infants and children; and Pneumovax 23 (pneumococcal vaccine polyvalent), a vaccine to help prevent pneumococcal disease.
Hospital Acute Care
Bridion (sugammadex), a medication for the reversal of two types of neuromuscular blocking agents used during surgery; Prevymis (letermovir) for the prophylaxis of cytomegalovirus (CMV) infection and disease, or of CMV disease, in certain high risk adult and pediatric recipients of an allogeneic hematopoietic stem cell transplant or of a kidney transplant, respectively; Dificid (fidaxomicin) for the treatment of C. difficile-associated diarrhea; Zerbaxa (ceftolozane and tazobactam) for injection, a combination antibacterial and beta-lactamase inhibitor for the treatment of certain bacterial infections; and Noxafil (posaconazole), an antifungal agent for the prevention of certain invasive fungal infections.
Cardiovascular
Winrevair (sotatercept-csrk), an activin signaling inhibitor indicated for the treatment of adults with pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group 1) to increase exercise capacity,
2

improve WHO functional class and reduce the risk of clinical worsening events; Adempas (riociguat), a cardiovascular drug for the treatment of chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension in certain patients; and Verquvo (vericiguat), a medicine to reduce the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous diuretics in certain adults with symptomatic chronic heart failure and reduced ejection fraction.
Virology
Lagevrio (molnupiravir), an investigational oral antiviral COVID-19 medicine available in the U.S. under Emergency Use Authorization (EUA); Isentress/Isentress HD (raltegravir), an HIV integrase inhibitor for use in combination with other antiretroviral agents for the treatment of HIV-1 infection; Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate), a complete regimen for the treatment of HIV-1 infection in adult patients with no prior antiretroviral treatment history or to replace the current antiretroviral regime in certain patients who are virologically suppressed on a stable antiretroviral regimen; and Pifeltro (doravirine), a non-nucleoside reverse transcriptase inhibitor for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adult patients with no prior antiretroviral treatment history or to replace the current antiretroviral regime in certain patients who are virologically suppressed on a stable antiretroviral regimen.
Neuroscience
Belsomra (suvorexant), an orexin receptor antagonist, indicated for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
Diabetes
Januvia (sitagliptin) and Janumet (sitagliptin/metformin HCl) for the treatment of type 2 diabetes.
Animal Health
The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceuticals, vaccines and health management solutions and services, as well as an extensive suite of digitally connected identification, traceability and monitoring products. Principal products in this segment include:
Livestock Products
Nuflor (Florfenicol) antibiotic range for use in cattle and swine; Bovilis/Vista vaccine lines for infectious diseases in cattle, including Bovilis Cryptium for protection against Cryptosporidium parvum; Banamine (Flunixin meglumine) bovine and swine anti-inflammatory; Estrumate (cloprostenol sodium) for the treatment of fertility disorders in cattle; Matrix (altrenogest) fertility management for swine; Resflor (florfenicol and flunixin meglumine), a combination broad-spectrum antibiotic and non-steroidal anti-inflammatory drug for bovine respiratory disease; Zuprevo (tildipirosin) for bovine respiratory disease; Revalor (trenbolone acetate and estradiol) to improve production efficiencies in beef cattle; Safe-Guard (fenbendazole) de-wormer for cattle; M+Pac (Mycoplasma Hyopneumoniae Bacterin) swine pneumonia vaccine; Porcilis (Lawsonia intracellularis baterin) and Circumvent (Porcine Circovirus Vaccine, Type 2, Killed Baculovirus Vector) vaccine lines for infectious diseases in swine; Nobilis/Innovax (Live Marek’s Disease Vector), vaccine lines for poultry; Paracox and Coccivac coccidiosis vaccines; Exzolt, a systemic treatment for poultry red mite infestations; Slice (emamectin benzoate) parasiticide and Imvixa (lufenuron) for sea lice control in salmon; Clynav vaccine for protection against pancreas disease in salmon; Aquavac (Avirulent Live Culture)/Norvax vaccines against bacterial and viral disease in fish; Aquaflor (florfenicol) antibiotic for farm-raised fish; Flexolt (fluralaner) against lice in sheep; and Allflex Livestock Intelligence solutions for animal identification, monitoring and traceability.
Companion Animal Products
Bravecto, a line of oral, topical and injectable parasitic control products, including the original Bravecto (fluralaner) products for dogs and cats that last up to 12 weeks; Bravecto (fluralaner) One-Month, a monthly product for dogs, Bravecto (fluralaner) Injectable/Quantum, an injectable product for dogs that lasts up to one-year, and Bravecto Plus (fluralaner/moxidectin), a two-month product for cats; Sentinel, a line of oral parasitic products for dogs including Sentinel Spectrum (milbemycin oxime, lufenuron, and praziquantel) and Sentinel Flavor Tabs (milbemycin oxime, lufenuron); Optimmune (cyclosporine), an ophthalmic ointment; Nobivac vaccine lines for flexible dog and cat vaccination, including Nobivac NXT for canine flu and feline leukemia virus; GilvetMab, an immune checkpoint inhibitor monoclonal antibody conditionally licensed for melanoma and mastocytoma tumors; Otomax (gentamicin sulfate, USP; Betamethasone valerate USP; and Clotrimazole USP ointment)/Mometamax (gentamicin sulfate, USP, Mometasone Furoate Monohydrate and Clotrimazole, USP, Otic Suspension)/Mometamax Ultra (gentamicin sulfate, mometasone furoate monohydrate and posaconazole suspension)/Posatex (orbifloxacin, mometasone furoate monohydrate and posaconazole, suspension) ear ointments for acute and chronic otitis; Caninsulin/Vetsulin (porcine insulin zinc suspension) diabetes mellitus treatment for dogs and cats; Panacur (fenbendazole)/Safeguard (fenbendazole) broad-spectrum anthelmintic (de-wormer) for use in many animals; Regumate (altrenogest) fertility management for horses; Prestige vaccine line for horses; Scalibor (Deltamethrin)/Exspot for protecting against bites
3

from fleas, ticks, mosquitoes and sandflies; and Sure Petcare products for companion animal identification and well-being, including the microchip and pet recovery system Home Again.
For a further discussion of sales of the Company’s products, see Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations” below.
Product Approvals
Set forth below is a summary of significant product approvals received by the Company in 2024 and, to date, in 2025.
ProductDateApproval
Keytruda
January 2024
U.S. Food and Drug Administration (FDA) approval in combination with chemoradiotherapy for the treatment of patients with FIGO (International Federation of Gynecology and Obstetrics) 2014 Stage III-IVA cervical cancer, based on the KEYNOTE-A18 trial.
January 2024
FDA full approval for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1 containing regimen. The conversion from an accelerated to full (regular) approval is based on the KEYNOTE-394 trial.
February 2024
China’s National Medical Products Administration (NMPA) approval in combination with gemcitabine and cisplatin for the first-line treatment of patients with locally advanced or metastatic biliary tract carcinoma, based on the KEYNOTE-966 trial.
March 2024
European Commission (EC) approval in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment, for resectable NSCLC at high risk of recurrence in adults, based on the KEYNOTE-671 trial.
May 2024
Japan’s Ministry of Health, Labor and Welfare (MHLW) approval in combination with fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma, based on the KEYNOTE-859 trial.
May 2024
Japan’s MHLW approval in combination with standard of care chemotherapy (gemcitabine and cisplatin) for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer, based on the KEYNOTE-966 trial.
June 2024
FDA approval in combination with carboplatin and paclitaxel, followed by Keytruda as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma, based on the KEYNOTE-868 trial.
June 2024
China’s NMPA approval in combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic HER2 positive gastric or GEJ adenocarcinoma whose tumors express PD-L1 as determined by a fully validated test, based on the KEYNOTE-811 trial.
September 2024
EC approval in combination with Padcev (enfortumab vedotin-ejfv), an antibody-drug conjugate, for the first-line treatment of unresectable or metastatic urothelial carcinoma in adults, based on the KEYNOTE-A39 trial that was conducted in collaboration with Seagen (now Pfizer Inc.) and Astellas.
September 2024
FDA approval in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma, based on the IND.227/KEYNOTE-483 trial.
September 2024
Japan’s MHLW approval in combination with chemotherapy as a neoadjuvant treatment, then continued as monotherapy as an adjuvant treatment for patients with NSCLC, based on the KEYNOTE-671 trial.
4

Keytruda
September 2024
Japan’s MHLW approval in combination with Padcev for the first-line treatment of patients with radically unresectable urothelial carcinoma, based on the KEYNOTE-A39 trial.
September 2024
Japan’s MHLW approval as monotherapy in patients with radically unresectable urothelial carcinoma who are not eligible for any platinum-containing chemotherapy, based on the KEYNOTE-052 trial.
September 2024
China’s NMPA approval for the first-line treatment of adult patients with unresectable or metastatic melanoma, and conversion from conditional to full approval for the second-line treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy, based on the LEAP-003 trial.
October 2024
EC approval in combination with chemoradiotherapy for the treatment of FIGO 2014 Stage III-IVA locally advanced cervical cancer in adults who have not received prior definitive therapy, based on the KEYNOTE-A18 trial.
October 2024
EC approval in combination with carboplatin and paclitaxel followed by Keytruda as a single agent for the first-line treatment of primary advanced or recurrent endometrial carcinoma in adults who are candidates for systemic therapy, based on the KEYNOTE-868 trial.
November 2024
Japan’s MHLW approval in combination with chemoradiotherapy as treatment for patients with locally advanced cervical cancer, based on the KEYNOTE-A18 trial.
December 2024
Japan’s MHLW approval in combination with carboplatin and paclitaxel as treatment for adult patients with advanced or recurrent endometrial carcinoma, based on the KEYNOTE-868 trial.
December 2024
China’s NMPA approval in combination with platinum-containing chemotherapy as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment after surgery for patients with resectable stage II, IIIA, or IIIB NSCLC, based on the KEYNOTE-671 trial.
December 2024
China’s NMPA approval in combination with chemoradiotherapy for the treatment of patients with FIGO 2014 Stage III-IVA cervical cancer, based on the KEYNOTE-A18 trial.
January 2025
China’s NMPA approval in combination with Padcev for adult patients with locally advanced or metastatic urothelial cancer, based on the KEYNOTE-A39 trial.
Bravecto
January 2024
EC approval of injectable formulation for dogs for the persistent killing of fleas and ticks for 12 months after treatment.
Capvaxive
June 2024
FDA approval for the prevention of invasive pneumococcal disease and pneumococcal pneumonia caused by certain serotypes in individuals 18 years of age and older.
Gardasil
January 2025
China’s NMPA approval for use in males 9-26 years of age to help prevent certain HPV-related cancers and diseases.
Lynparza(1)
January 2025
China’s NMPA approval for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative high-risk early breast cancer who have been previously treated with neoadjuvant or adjuvant chemotherapy, based on the OlympiA trial.
5

Welireg
November 2024
China’s NMPA approval for the treatment of adult patients with VHL disease who require therapy for associated RCC, central nervous system hemangioblastomas or pancreatic neuroendocrine tumors.
February 2025
EC conditional approval as monotherapy both for the treatment of adult patients with VHL disease who require therapy for associated, localized RCC, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors, and for whom localized procedures are unsuitable, and for the treatment of adult patients with advanced clear cell RCC that progressed following two or more lines of therapy that included a PD-1 or PD-L1 inhibitor and at least two VEGF targeted therapies. The EC approval of these two indications is based on results from the LITESPARK-004 and LITESPARK-005 trials.
Winrevair
March 2024
FDA approval for the treatment of adults with PAH (WHO Group 1) to increase exercise capacity, improve WHO functional class (FC), and reduce the risk of clinical worsening events.
August 2024
EC approval in combination with other PAH therapies, for the treatment of PAH in adult patients with WHO FC II to III, to improve exercise capacity.
(1) Being jointly developed and commercialized in a worldwide collaboration with AstraZeneca.
Competition and the Health Care Environment
Competition
The markets in which the Company conducts its business and the pharmaceutical industry in general are highly competitive and highly regulated. The Company’s competitors include other worldwide research-based pharmaceutical companies, smaller research companies with more limited therapeutic focus, generic drug manufacturers, and animal health care companies. The Company’s operations may be adversely affected by generic and biosimilar competition as the Company’s products mature, as well as technological advances of competitors, industry consolidation, patents granted to competitors, competitive combination products, new products of competitors, the generic availability of competitors’ branded products, and new information from clinical trials of marketed products or post-marketing surveillance. In addition, patent rights are increasingly being challenged by competitors, and the outcome can be highly uncertain. An adverse result in a patent dispute can preclude commercialization of products or negatively affect sales of existing products and could result in the payment of royalties or in the recognition of an impairment charge with respect to intangible assets associated with certain products.
Pharmaceutical competition involves a rigorous search for technological innovations and the ability to market these innovations effectively. With its long-standing emphasis on research and development, the Company is well-positioned to compete in the search for technological innovations. The Company is active in acquiring and marketing products through external alliances, such as licensing arrangements and collaborations, and has been refining its sales and marketing efforts to address changing industry conditions. However, the introduction of new products and processes by competitors may result in price reductions and product displacements, even for products protected by patents. For example, the number of compounds available to treat a particular disease typically increases over time and can result in slowed sales growth or reduced sales of the Company’s products in that therapeutic category.
The highly competitive animal health business is affected by several factors including regulatory and legislative issues, scientific and technological advances, product innovation, the quality and price of the Company’s products as well as competitors’ products, effective promotional efforts and the frequent introduction of generic products by competitors.
Health Care Environment and Government Regulation
Global efforts toward health care cost containment continue to exert pressure on product pricing and market access. Changes to the U.S. health care system as part of health care reform, as well as increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, have contributed to pricing pressure. In several international markets, government-mandated pricing actions have reduced prices of generic and patented drugs. In addition, the Company’s sales performance in 2024 was negatively affected by other cost-reduction measures taken by governments and other third parties to lower health care costs. In the U.S., the Executive Branch and Congress continue to discuss legislation designed to control health care costs, including the cost of drugs. The Company anticipates all of these actions and additional actions in the future will continue to negatively affect sales and profits.
6

In addressing global cost containment pressures, the Company engages in public policy advocacy with policymakers and continues to work to demonstrate that its medicines provide value to patients and to those who pay for health care. The Company advocates with government policymakers to encourage a long-term approach to sustainable health care financing that ensures access to innovative medicines and does not disproportionately target pharmaceuticals as a source of budget savings. In markets with historically low rates of health care spending, the Company encourages those governments to increase their investments and adopt market reforms in order to improve their citizens’ access to appropriate health care, including medicines.
Operating conditions have become more challenging under the global pressures of competition, industry regulation and cost containment efforts. Although no one can predict the effect of these and other factors on the Company’s business, the Company continually takes measures to evaluate, adapt and improve the organization and its business practices to better meet customer needs and believes that it is well-positioned to respond to the evolving health care environment and market forces.
United States
The Company faces increasing pricing pressure from managed care organizations, government agencies and programs that could negatively affect the Company’s sales and profit margins, including, through (i) practices of managed care organizations, federal and state exchanges, and institutional and governmental purchasers, and (ii) federal laws and regulations related to Medicare and Medicaid, including the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, the Patient Protection and Affordable Care Act of 2010 (ACA), the American Rescue Plan Act of 2021 (American Rescue Plan Act), and the Inflation Reduction Act of 2022 (IRA). Additionally, increased utilization of the 340B Federal Drug Discount Program and restrictions on the Company’s ability to identify inappropriate discounts are having a negative impact on Company performance.
In the U.S., federal and state governments for many years have pursued methods to reduce the cost of drugs and vaccines for which they pay. For example, federal and state laws require the Company to pay specified rebates for medicines reimbursed by Medicaid and to provide discounts for medicines purchased by certain state and federal entities such as the Department of Defense, Veterans Affairs, Public Health Service entities and hospitals serving a disproportionate share of low income or uninsured patients.
Additionally in the U.S., consolidation and integration among health care entities is a major factor in the competitive marketplace for pharmaceutical products. Health plans and pharmacy benefit managers have been consolidating into fewer, larger entities, thus enhancing their purchasing strength and importance. Private third-party insurers, as well as governments, employ formularies to control costs by negotiating discounted prices in exchange for formulary inclusion. Failure to obtain timely or adequate pricing or formulary placement for Merck’s products or obtaining such placement at unfavorable pricing could adversely affect revenue. In addition to formulary tier co-pay differentials, private health insurance companies and self-insured employers have been increasing the cost-sharing required from beneficiaries, particularly for branded pharmaceuticals and biotechnology products. Private health insurance companies, as well as governments, also are increasingly imposing utilization management tools, such as clinical protocols, requiring prior authorization for a branded product or requiring the patient to first fail on one or more generic products before permitting access to a branded medicine. These same management tools are also used in treatment areas in which the payor has taken the position that multiple branded products are therapeutically comparable. As the U.S. payor market concentrates further, the Company may face greater pricing pressure from private third-party payors.
Legislative Changes
In 2022, Congress passed the IRA, which makes significant changes to how drugs are covered and paid for under the Medicare program, including the creation of financial penalties for drugs whose prices rise faster than the rate of inflation, redesign of the Medicare Part D program to require manufacturers to bear more of the liability for certain drug benefits, which has taken effect in 2025, and government price setting for certain Medicare Part D drugs, starting in 2026, and Medicare Part B drugs starting in 2028. Government price setting may also impact pricing in the private market negatively affecting the Company’s performance. In August 2023, the U.S. Department of Health and Human Services (HHS), through the Centers for Medicare & Medicaid Services (CMS), selected Januvia for the first year of the IRA’s “Drug Price Negotiation Program” (Program). Pursuant to the IRA’s Program, a government price was set for Januvia, which will become effective on January 1, 2026. In January 2025, HHS announced that Janumet and Janumet XR have been selected for government price setting, which will become effective on January 1, 2027. In addition, the Company expects that Keytruda will be selected in 2026 for government price setting, which would become effective on January 1, 2028 and the Company expects that, as a result, U.S. sales of Keytruda will decline after that time. The Company has sued the U.S. government regarding the IRA’s Program (see Item 8 “Financial Statements and Supplementary Data,” Note 10. “Contingencies and Environmental Liabilities” below). Furthermore,
7

the Executive Branch and Congress continue to discuss legislation designed to control health care costs, including the cost of drugs.
The long-term implications of the IRA remain uncertain and subject to various factors, including the manner in which HHS decides to implement the statute. Many experts and analysts, both within the industry and outside, have predicted that the law will harm innovation in the pharmaceutical industry and result in fewer new treatments being developed and approved over time. Merck is working to mitigate the potentially harmful effects that the law could have, which could include a detrimental impact on innovation.
In addition, in 2021, Congress passed the American Rescue Plan Act, which included a provision that eliminates the statutory cap on rebates drug manufacturers pay to Medicaid beginning in January 2024. These rebates act as a discount off the list price and eliminating the cap means that manufacturer discounts paid to Medicaid can increase. Prior to this change, manufacturers have not been required to pay more than 100% of the Average Manufacturer Price (AMP) in rebates to state Medicaid programs for Medicaid-covered drugs. As a result of this provision, manufacturers may have to pay state Medicaid programs more in rebates than they received on sales of particular products. This change presents a risk to Merck for drugs that have high Medicaid utilization and rebate exposure that is more than 100% of the AMP.
The Company also faces increasing pricing pressure in the states, which are looking to exert greater influence over the price of prescription drugs. A number of states have passed pharmaceutical price and cost transparency laws. These laws typically require manufacturers to report certain product price information or other financial data to the state. Some laws also require manufacturers to provide advance notification of price increases. The Company expects that states will continue their focus on pharmaceutical pricing and will increasingly shift to more aggressive price control tools such as Prescription Drug Affordability Boards that have the authority to conduct affordability reviews and establish upper payment limits and that Company products may be selected for such reviews. In addition, in 2024, the FDA authorized, for a two-year period, Florida’s application to import prescription drugs from Canada.
Regulatory Changes
The pharmaceutical industry also could be considered a potential source of savings via other legislative and administrative proposals that have been debated but not enacted. These types of revenue generating or cost saving proposals include additional direct price controls.
European Union
Efforts toward health care cost containment remain intense in the European Union (EU). The Company faces competitive pricing pressure resulting from generic and biosimilar drugs. In addition, a majority of countries in the EU attempt to contain drug costs by engaging in reference pricing in which authorities examine pre-determined markets for published prices of drugs. Reference pricing may either compare a product’s prices in other markets (external reference pricing), or compare a product’s price with those of other products in a national class (internal reference pricing). The authorities then use the price data to set new local prices for brand-name drugs, including the Company’s drugs. Reference pricing mechanisms are usually set at the national level and can be changed pursuant to local regulations or guidance.
Some EU Member States have established free-pricing systems, but regulate the pricing for drugs through profit control plans. Others seek to negotiate or set prices based on the cost-effectiveness of a product or an assessment of whether it offers a therapeutic benefit over other products in the relevant class.
The downward pressure on health care costs in general, particularly prescription drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In some EU Member States, cross-border imports from low-priced markets also exert competitive pressure that may reduce pricing within an EU Member State.
Additionally, EU Member States have the power to restrict the range of pharmaceutical products for which their national health insurance systems provide reimbursement. In the EU, pricing and reimbursement plans vary widely from Member State to Member State. Some EU Member States provide that drug products may be marketed only after a reimbursement price has been agreed. Some EU Member States may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to already available therapies or a so-called health technology assessment (HTA), in order to obtain reimbursement or pricing approval. The HTA of pharmaceutical products is becoming an increasingly common part of the pricing and reimbursement procedures in most EU Member States. The HTA process, which is currently governed by the national laws of these countries, involves the assessment of the cost-effectiveness, public health impact, therapeutic impact and/or the economic and social impact of use of a given pharmaceutical product in the national health care system of the individual country in
8

which it is conducted. Ultimately, an HTA measures the added value of a new health technology compared to existing ones.
The EU Health Technology Assessment Regulation 2021/2282 (HTAR) applies in 2025. This provides for the conduct of an EU level comparative Joint Clinical Assessment (JCA) of a new product versus relevant comparators identified by the EU Member States. JCAs will be carried out in parallel with the review of a marketing authorization application, so that a JCA report is available shortly after the product is authorized. The HTAR applies to all new active substance oncology products and advanced therapy medicinal products, including cell and gene therapies, beginning January 1, 2025; to new active substance orphan medicinal products beginning January 1, 2028; and to all products approved via the centralized procedure beginning in 2030.
EU Member States remain responsible for pricing and reimbursement decisions but must take “due consideration” of JCA reports when making national market access decisions. This means that EU Member State pricing and reimbursement processes are likely to evolve and more EU Member States may use HTAs as part of their decision-making.
The outcome of HTAs regarding specific pharmaceutical products will increasingly influence the pricing and reimbursement status granted to these pharmaceutical products by the market access authorities of individual EU Member States. A negative HTA of one of the Company’s products may mean that the product is not reimbursable or may force the Company to reduce its reimbursement price or offer discounts or rebates.
A negative HTA by a leading and recognized HTA body could also undermine the Company’s ability to obtain reimbursement for the relevant product outside a jurisdiction. For example, EU Member States that have not yet developed HTA mechanisms may rely to some extent on JCAs under the HTAR or an HTA performed in other countries with a developed HTA framework, to inform their pricing and reimbursement decisions. HTA procedures require additional data, reviews and administrative processes, all of which increase the complexity, timing and costs of obtaining product reimbursement and exert downward pressure on available reimbursement.
To obtain reimbursement or pricing approval in some EU Member States, the Company may be required to conduct studies that compare the cost-effectiveness of the Company’s product candidates to other therapies that are considered the local standard of care. There can be no assurance that any EU Member State will allow favorable pricing, reimbursement and market access conditions for any of the Company’s products, or that it will be feasible to conduct additional cost-effectiveness studies, if required.
Japan
In Japan, the pharmaceutical industry is subject to government-mandated annual price reductions of pharmaceutical products and certain vaccines. Furthermore, the government can order re-pricings for specific products if it determines that use of such product will exceed certain thresholds defined under applicable re-pricing rules. In addition, if a Merck product has the same medical action or composition of another product that is subject to market expansion re-pricing, the Merck product could also be subject to re-pricing unless it meets exception criteria. The next government-mandated price reduction is scheduled to occur in April 2025.
China
The Company’s business in China has grown in the past few years, and the importance of China to the Company’s overall pharmaceutical and vaccines business has increased accordingly. Continued growth of the Company’s business in China is dependent upon ongoing development of a favorable environment for innovative pharmaceutical products and vaccines, sustained access for the Company’s currently marketed products, and the absence of trade impediments or adverse pricing controls. In recent years, the Chinese government has introduced and implemented a number of structural reforms to accelerate the shift to innovative products and reduce costs. There have been multiple new policies introduced by the government to improve access to new innovation, reduce the complexity of regulatory filings, and accelerate the review and approval process. This has led to a significant increase in the number of new products being approved each year. While the mechanism for drugs being added to the government’s National Reimbursement Drug List (NRDL) evolves, inclusion may require a price negotiation which could impact the outlook in the market for selected brands. A new NRDL was recently completed in which new entries averaged 63% price reductions. While pricing pressure has always existed in China, health care reform has increased this pressure in part due to the acceleration of generic substitution through volume-based procurement (VBP). In 2019, the government implemented the VBP program through a tendering process for mature products which have generic substitutes with a Generic Quality Consistency Evaluation approval. Mature products that have entered into the last five rounds of VBP had, on average, a price reduction of more than 50%. The Company expects VBP to be a semi-annual process that will have a significant impact on mature products moving forward.

9

Emerging Markets
The Company’s focus on emerging markets, in addition to China, has continued. Governments in many emerging markets are also focused on constraining health care costs and have enacted price controls and measures impacting intellectual property, including in exceptional cases, threats of compulsory licenses, that aim to put pressure on the price of innovative pharmaceuticals or result in constrained market access to innovative medicine. The Company anticipates that pricing pressures and market access challenges will continue in the future to varying degrees in the emerging markets.
Beyond pricing and market access challenges, other conditions in emerging market countries can affect the Company’s efforts to continue to grow in these markets, including potential political instability, changes in trade sanctions and embargoes, significant currency fluctuation and controls, financial crises, limited or changing availability of funding for health care, credit worthiness of health care partners, such as hospitals, and other developments that may adversely impact the business environment for the Company. Further, the Company may engage third-party agents to assist in operating in emerging market countries, which may affect its ability to realize continued growth and may also increase the Company’s risk exposure.
Regulation
The pharmaceutical industry is also subject to regulation by regional, country, state and local agencies around the world focused on standards and processes for determining drug safety and effectiveness, as well as conditions for sale or reimbursement.
Of particular importance is the FDA in the U.S., which administers requirements covering the testing, approval, safety, effectiveness, manufacturing, labeling, and marketing of prescription pharmaceuticals. In some cases, the FDA requirements and practices have increased the amount of time and resources necessary to develop new products and bring them to market in the U.S. At the same time, the FDA has committed to expediting the development and review of products bearing the “breakthrough therapy” designation, which has accelerated the regulatory review process for medicines with this designation. The FDA has also undertaken efforts to bring generic competition to market more efficiently and in a more timely manner.
The EU has adopted directives and other legislation concerning the classification, approval for marketing, labeling, advertising, manufacturing, wholesale distribution, integrity of the supply chain, pharmacovigilance and safety monitoring of medicinal products for human use. These provide mandatory standards throughout the EU, which may be supplemented or implemented with additional regulations by the EU Member States. In particular, EU regulators may approve products subject to a number of post-authorization conditions. Examples of typical post-authorization commitments include additional pharmacovigilance, the conduct of clinical trials, the establishment of patient registries, physician or patient education and controlled distribution and prescribing arrangements. Non-compliance with post-authorization conditions, pharmacovigilance and other obligations can lead to regulatory action, including the variation, suspension or withdrawal of the marketing authorizations, or other enforcement or regulatory actions, including the imposition of financial penalties. The Company’s policies and procedures are already consistent with the substance of these directives; consequently, it is believed that they will not have any material effect on the Company’s business.
The Company believes that it will continue to be able to conduct its operations, including launching new drugs, in this regulatory environment. (See “Research and Development” below for a discussion of the regulatory approval process.)
Access to Medicines
As a global health care company, Merck’s primary role is to discover and develop innovative medicines and vaccines. The Company also recognizes that, in collaboration with key stakeholders, it has a role to play in helping to ensure that its science advances health care, and its products are accessible and affordable globally. The Company is committed to ensuring a high-quality, safe, reliable, supply of its medicines and vaccines, and to implementing innovative solutions that address barriers to sustainable access to its products.
Merck’s approach is designed to enable it to serve the greatest number of patients today, while meeting the needs of patients in the future. The Company's wide-ranging efforts to expand access to health encompass a set of principles embedded in its business strategies and operations. These principles guide its global approach to addressing significant public health burdens and unmet medical needs. The Company systematically evaluates its pipeline candidates to assess their potential in low and middle-income countries and underserved health care settings. Throughout the life cycle of its products, Merck seeks to evaluate their potential and adapt to changes in the external environment. Collaborating with various stakeholders, including private, governmental, multilateral, and non-profit organizations, the Company seeks to design and deliver sustainable access solutions at the payer, provider,
10

and patient levels. Furthermore, the Company incorporates access to health metrics in its scorecard, making it a component of calculating annual incentive pay for the majority of its global employees.
In addition, through social investments, including philanthropic programs and impact investing, Merck is helping to strengthen health systems and build capacity, particularly in communities underserved by health care. The Merck Patient Assistance Program provides certain medicines and adult vaccines for free to people in the U.S. and U.S. territories who do not have prescription drug or health insurance coverage and who, without the Company’s assistance, cannot afford their Merck medicines and vaccines. Globally, Merck has made substantial contributions to access to health through key initiatives, including product donations for humanitarian assistance in low-income countries through the Medical Outreach Program. The Mectizan Donation Program, the longest running disease-specific drug donation program of its kind, supports the elimination of two neglected tropical diseases – onchocerciasis and lymphatic filariasis. Additionally, through Merck for Mothers, the Company provides funding, and scientific and business acumen to help global health partners strengthen health systems, expand access to critical maternal health services, and end preventable deaths from complications of pregnancy and childbirth. Merck also supports the Merck Foundation, an independent grantmaking organization helping to address systemic barriers to access to health care.
Privacy and Data Protection
The Company is subject to a significant number of privacy and data protection laws and regulations globally, many of which place restrictions on the Company’s ability to collect, transfer, access and use personal data across its business. The legislative and regulatory landscape for privacy and data protection continues to evolve. There has been increased attention to privacy and data protection issues in both developed and emerging markets with the potential to affect directly the Company’s business, including the EU General Data Protection Regulation (GDPR), which imposes penalties of up to 4% of global revenue.
The GDPR and related implementing laws in individual EU Member States govern the collection and use of personal health data and other personal data in the EU. The GDPR increased responsibility and liability in relation to personal data that the Company processes. It also imposes a number of strict obligations and restrictions on the ability to process (which includes collection, analysis and transfer of) personal data, including health data from clinical trials and adverse event reporting. The GDPR also includes requirements relating to the consent of the individuals to whom the personal data relates, the information provided to the individuals prior to processing their personal data or personal health data, notification of data processing obligations to the national data protection authorities, and the security and confidentiality of the personal data. Further, the GDPR prohibits the transfer of personal data to countries outside of the EU that are not considered by the EC to provide an adequate level of data protection, including to the U.S., except if the data controller meets very specific requirements. Following the Schrems II decision of the Court of Justice of the EU in 2020, uncertainty has existed as to the permissibility of international data transfers under the GDPR. In light of the implications of this decision, the Company may face difficulties regarding the transfer of personal data from the EU to third countries. Since then, the Company entered into the EU-approved Standard Contractual Clauses with its vendors, suppliers, collaboration partners and clinical trial sites in order to facilitate the lawful transfer of personal data from the EU to the U.S. In addition, former President Biden issued Executive Order 14086 in October 2022 to address the data privacy concerns raised in the Schrems II decision through introducing, among other measures, further safeguards and oversight of personal data collection by U.S. signals intelligence activities and providing individuals with a redress mechanism in the U.S. for their data protection concerns. Further certainty for the international transfer of personal data from the EU via the EU-U.S. Data Privacy Framework (successor to the invalidated EU-U.S. Privacy Shield) came about by way of a new EU Adequacy Decision, issued by the EC in July 2023. However, the new Adequacy Decision has already been contested by privacy advocates and is subject to legal review.
Failure to comply with the requirements of the GDPR and the related national data protection laws of the EU Member States may result in significant monetary fines and other administrative penalties as well as civil liability claims from individuals whose personal data was processed. Data protection authorities from the different EU Member States may still implement certain variations, enforce the GDPR and national data protection laws differently, and introduce additional national regulations and guidelines, which adds to the complexity of processing personal data in the EU. Guidance developed at both the EU level and at the national level in individual EU Member States concerning implementation and compliance practices is often updated or otherwise revised.
There is, moreover, a growing trend towards required public disclosure of clinical trial data in the EU which adds to the complexity of obligations relating to processing health data from clinical trials. Failing to comply with these obligations could lead to government enforcement actions and significant penalties against the Company, harm to its reputation, and adversely impact its business and operating results. The uncertainty regarding the interplay between
11

different regulatory frameworks further adds to the complexity that the Company faces with regard to data protection regulation.
In 2021, China passed the Personal Information Protection Law (PIPL) that aims to standardize the handling of personal information in China. The PIPL currently applies to the processing of personal information of natural persons in China, the processing of personal information outside China where the purpose is to provide products and services in China, and to analyze the activities of individuals in China. While similar to the GDPR, the PIPL contains unique requirements not found in the GDPR. The Company has developed and implemented comprehensive plans to ensure compliance with the PIPL, including plans relating to data localization and cross-border transfers.
Additional laws and regulations enacted in Canada, Europe, Asia, Latin America, the Middle East and 19 states in the U.S. have increased enforcement and litigation activity in the U.S. and other developed markets, as well as increased regulatory cooperation among privacy authorities globally. The Company has adopted a comprehensive global privacy program to manage these evolving requirements and risks and to facilitate the transfer of personal information across international borders.
Distribution
The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccines are sold primarily to physicians, wholesalers, distributors and government entities. The Company’s professional representatives communicate the effectiveness, safety and value of the Company’s pharmaceutical and vaccine products to health care professionals in private practice, group practices, hospitals and managed care organizations. The Company sells its animal health products to veterinarians, distributors, animal producers, farmers and pet owners.
Raw Materials
The Company obtains raw materials essential to its business from numerous suppliers worldwide. Most of the principal materials the Company uses in its manufacturing operations are available from more than one source. However, the Company obtains certain raw or intermediate materials primarily from only one source. The Company attempts, if possible, to mitigate the potential risk associated with raw materials, components and supplies through inventory and appropriate supplier management.
Patents, Trademarks and Licenses
Patent protection is considered, in the aggregate, to be of material importance to the Company’s marketing of its products in the U.S. and in most major foreign markets. Patents may not only cover a product per se, but also pharmaceutical formulations of a product, processes for making a product, including intermediates useful in those processes, and methods of treatment or other uses of a product. Patent protection for individual products extends for varying periods in accordance with the legal life of patents in individual countries. The protection afforded, which may also vary from country to country, depends upon the type of patent and its scope of coverage.
Patent portfolios developed for products introduced by the Company normally provide varying degrees of market exclusivity. Key patents, which generally cover the product per se, may be subject to a patent term restoration (also known as patent term extension or PTE) of up to five years in the U.S., Japan, and certain other jurisdictions. In Europe, up to five years of extended term may be available in the form of a Supplementary Protection Certificate (SPC). PTEs and SPCs are awarded to offset a portion of the patent term lost during the clinical testing and regulatory review process of a product prior to approval. The Food and Drug Administration Modernization Act includes a Pediatric Exclusivity Provision that may provide an additional six months of market exclusivity (added to the patent term for all Orange Book-listed patents, and to the regulatory data exclusivity term for small molecule and biologic products) in the U.S. for indications of new or currently marketed drugs if certain agreed upon pediatric studies are completed by the applicant. The EU also provides an additional six months of pediatric market exclusivity attached to a product’s SPC term for both small molecule and biologic products. Japan attaches the additional term for pediatric studies to market exclusivity and this extension is unrelated to patent term. In some countries, one or more regulatory exclusivities, including data exclusivity, may provide parallel market protection that is complementary to patent protection and, in some cases, may provide more effective or longer lasting marketing exclusivity than a product’s patent portfolio. In the U.S., the regulatory data/marketing protection term generally runs five years from first marketing approval of a new chemical entity, extended to seven years for an orphan drug indication, and twelve years from first marketing approval of a biological product.

12

The table below provides a list of expiration dates, which include any pending PTE and SPC periods where indicated, for the key patent protection in the U.S., the EU, Japan and China for the following marketed products:
ProductYear of Expiration (U.S.)
Year of Expiration (EU)(1)
Year of Expiration (Japan)(2)
Year of Expiration (China)
Januvia
2026(3)
Expired2025-2026Expired
Janumet
2026(3)
ExpiredN/AExpired
Janumet XR
2026(3)
N/AN/AExpired
Isentress
Expired(4)
Expired
2026(5)
Expired
Lenvima(6)
2026
2026(7)
2026Expired
Bridion
2026
Expired
Expired
Expired
Bravecto
2027
2029
20292025
Gardasil2028ExpiredExpired
Expired
Gardasil 9
2028
2030(7)
2030
2025
Keytruda
2028(8)
20312032-20332028
Lynparza(9)
2027(7) (with pending PTE)
2029(7)
2028-2029
Expired
Winrevair
2027(10)
2026(10)
N/A
N/A
Adempas(11)
N/A(12)
2028(7)
2027-2028
Expired
Belsomra2029N/A2031N/A
Prevymis
2029
2029(13)
2029
Expired
Vaxneuvance
2031(14)
No Patent(15)
No Patent(15)
N/A
Welireg2035 (with pending PTE)N/AN/AN/A
Capvaxive
2038
N/A
N/A
N/A
Note:    Compound patent unless otherwise noted. Certain of the products listed may be the subject of patent litigation. See Item 8. “Financial Statements and Supplementary Data,” Note 10. “Contingencies and Environmental Liabilities” below.
N/A:    Currently no marketing approval.
(1)The EU date represents the expiration date for the following four countries: France, Germany, Italy, and Spain (Major EU Markets). If SPC applications have been filed but have not been granted in all Major EU Markets, both the patent expiry date and the SPC expiry date are listed.
(2)The PTE system in Japan allows for a patent to be extended more than once provided the later approval is directed to a different indication from that of the previous approval. This may result in multiple PTE approvals for a given patent, each with its own expiration date.
(3)As a result of settlement agreements related to a patent directed to the specific sitagliptin salt form of the products, exclusivity will extend through May 2026 for Januvia and Janumet, and through July 2026 for Janumet XR.
(4)Generic entry is not anticipated in 2025.
(5)Expiry date reflects granted PTE for the 600 mg tablet in Japan.
(6)Part of a global strategic oncology collaboration with Eisai Co., Ltd.
(7)Eligible for six months pediatric market exclusivity.
(8)The compound patent family contains two additional patents that expire in 2029 due to patent term adjustment resulting from patent office delay. These patents are based on the initial discovery of the active ingredient in Keytruda. While these patents may provide additional protection, the Company expects that they will be the subject of litigation in the future.
(9)Part of a global strategic oncology collaboration with AstraZeneca.
(10)Eligible for 12 years of data exclusivity in the U.S. and 10 years in the EU, which will expire in 2036 and 2034, respectively. Granted patents covering methods of treating pulmonary arterial hypertension with Winrevair, which will expire in 2037 (absent PTE or SPC), may provide additional exclusivity.
(11)Commercialized under a worldwide collaboration with Bayer AG.
(12)The Company has no marketing rights in the U.S.
(13)Data exclusivity has also been granted in the EU and expires in January 2028; eligible for two additional years of market exclusivity based on pediatric studies for an orphan product.
(14)PTE pending but is not included in the listed patent expiry date. Data exclusivity has been granted in the U.S. and expires in July 2033.
(15)Data exclusivity has been granted in the EU and Japan, and expires in December 2031 and September 2030, respectively.

13

The Company has the following key U.S. patent protection for drug candidates under review in the U.S. by the FDA:
Under Review in the U.S. Currently Anticipated
Year of Expiration (in the U.S.)
MK-1022 (patritumab deruxtecan)(1)
2035
MK-1654 (clesrovimab)
2036
(1)    Being developed in a collaboration with Daiichi Sankyo. The FDA issued a Complete Response Letter for the application in June 2024.
The Company also has the following key U.S. patent protection for drug candidates in Phase 3 development: 
Phase 3 Drug CandidateCurrently Anticipated
Year of Expiration (in the U.S.)
MK-8591A (doravirine + islatravir)(1)
2032
MK-2400 (ifinatamab deruxtecan)(2)
2034
MK-1308A (quavonlimab + pembrolizumab)
2035
MK-1026 (nemtabrutinib)
2035
V940(2)
2036
MK-3543 (bomedemstat)
2036
MK-5684 (opevesostat)
2037
MK-8591D (islatravir + lenacapavir)(1)(2)
2037 (with pending PTE for lenacapavir patent)
MK-2140 (zilovertamab vedotin)
2038
MK-4482 Lagevrio(2)(3)
2038
MK-2870 (sacituzumab tirumotecan)(2)
2040
MK-3475A (pembrolizumab + hyaluronidase subcutaneous)2039
MK-0616 (enlicitide decanoate)
2040
MK-1084
2040
MK-7240 (tulisokibart)
2040
MK-3000(4)
2041
(1)On partial clinical hold for higher doses of islatravir than those used in current clinical trials.
(2)Being developed in a collaboration.
(3)Available in the U.S. under Emergency Use Authorization.
(4)Program is in a Phase 2/3 study.
Unless otherwise noted, the patents in the above tables cover the product per se (also known as compound patents). For those drug candidates under review or in development, the key U.S. patents may be subject to a future PTE of up to five years and/or six months of pediatric market exclusivity. In addition, depending on the circumstances surrounding any final regulatory approval of the product, there may be other granted patents or pending patent applications that could have relevance to the product as finally approved.
While the expiration of the compound patent generally results in loss of market exclusivity for the covered pharmaceutical product, other patents may provide additional market exclusivity associated with certain aspects of the product that extends beyond the compound patent expiration, including those derived from the initial discovery of the product’s active ingredient(s) or from product-related innovation that occurs after this initial discovery. These include later-expiring patents directed to (i) processes and intermediates related to methods of manufacture of the active ingredient(s), (ii) use(s) of the product, and (iii) novel compositions and formulations of the product. The effect of product patent expiration on pharmaceutical product sales may also depend upon many other factors such as the nature of the market and the position of the product in it, the growth of the market, the complexities and economics of the process for manufacture of the active ingredient(s) of the product and the requirements of new drug provisions of the Federal Food, Drug and Cosmetic Act or similar laws and regulations in other countries. In addition, in the U.S. and certain other countries, a variety of different regulatory exclusivities that impact market exclusivity may be available under relevant law.
For further information with respect to the Company’s patents, see Item 1A. “Risk Factors” and Item 8. “Financial Statements and Supplementary Data,” Note 10. “Contingencies and Environmental Liabilities” below.
14

Worldwide, all of the Company’s important products are sold under trademarks that are considered in the aggregate to be of material importance. Trademark protection continues in some countries as long as used; in other countries, as long as registered. Registration is for fixed terms and can be renewed indefinitely.
Royalty income in 2024 on patent and know-how licenses and other rights amounted to $1.1 billion. Merck also incurred royalty expenses amounting to $1.9 billion in 2024 under patent and know-how licenses it holds.
Research and Development
The Company’s business is characterized by the introduction of new products or new uses for existing products through a strong research and development program. At December 31, 2024, approximately 23,500 people were employed in the Company’s research activities. The Company prioritizes its research and development efforts and focuses on candidates that it believes represent breakthrough science for unmet medical needs that will make a difference for patients and payers.
The Company maintains a number of long-term exploratory and fundamental research programs in biology and chemistry as well as research programs directed toward product development. The Company’s research and development model is designed to increase productivity and improve the probability of success by prioritizing the Company’s research and development resources on candidates the Company believes are capable of providing unambiguous, promotable advantages to patients and payers and delivering the maximum value of its approved medicines and vaccines through new indications and new formulations. Merck is pursuing emerging product opportunities independent of therapeutic area or modality. The Company is committed to ensuring that externally sourced programs remain an important component of its pipeline strategy, with a focus on supplementing its internal research through acquisitions as well as a licensing and external alliance strategy focused on the entire spectrum of collaborations from early research to late-stage compounds, as well as access to new technologies.
The Company’s clinical pipeline includes candidates in multiple disease areas, including cancer, cardiovascular diseases, metabolic diseases, infectious diseases, neurosciences, immunology, ophthalmology, respiratory diseases, and vaccines.
In the development of human health products, industry practice and government regulations in the U.S. and most foreign countries provide for the determination of effectiveness and safety of new chemical compounds through preclinical tests and controlled clinical evaluation. Before a new drug or vaccine may be marketed in the U.S., recorded data on preclinical and clinical experience are included in the New Drug Application (NDA) for a drug or the Biologics License Application (BLA) for a vaccine or biologic submitted to the FDA for the required approval.
Once the Company’s scientists discover a new small molecule compound or biologic that they believe has promise to treat a medical condition, the Company commences preclinical testing with that compound. Preclinical testing includes laboratory testing and animal safety studies to gather data on chemistry, pharmacology, immunogenicity and toxicology. Pending acceptable preclinical data, the Company will initiate clinical testing in accordance with established regulatory requirements. The clinical testing begins with Phase 1 studies, which are designed to assess safety, tolerability, pharmacokinetics, and preliminary pharmacodynamic activity of the compound in humans. If favorable, additional, larger Phase 2 studies are initiated to determine the efficacy of the compound in the affected population, define appropriate dosing for the compound, as well as identify any adverse effects that could limit the compound’s usefulness. In some situations, the clinical program incorporates adaptive design methodology to use accumulating data to decide how to modify aspects of the ongoing clinical study as it continues, without undermining the validity and integrity of the trial. One type of adaptive clinical trial is an adaptive Phase 2a/2b trial design, a two-stage trial design consisting of a Phase 2a proof-of-concept stage and a Phase 2b dose-optimization finding stage. If data from the Phase 2 trials are satisfactory, the Company commences large-scale Phase 3 trials to confirm the compound’s efficacy and safety. Another type of adaptive clinical trial is an adaptive Phase 2/3 trial design, a study that includes an interim analysis and an adaptation that changes the trial from having features common in a Phase 2 study (e.g., multiple dose groups) to a design similar to a Phase 3 trial. An adaptive Phase 2/3 trial design reduces timelines by eliminating activities which would be required to start a separate study. Upon completion of Phase 3 trials, if satisfactory, the Company submits regulatory filings with the appropriate regulatory agencies around the world to have the product candidate approved for marketing. There can be no assurance that a compound that is the result of any particular program will obtain the regulatory approvals necessary for it to be marketed.
Vaccine development follows the same general pathway as for drugs. Preclinical testing focuses on the vaccine’s safety and ability to elicit a protective immune response (immunogenicity). Pre-marketing vaccine clinical trials are typically done in three phases. Initial Phase 1 clinical studies are conducted in normal subjects to evaluate the safety, tolerability and immunogenicity of the vaccine candidate. Phase 2 studies are dose-ranging studies and provide additional data on safety, immunogenicity and/or effectiveness. Finally, Phase 3 trials are conducted in the
15

intended population for licensure and provide data on immunogenicity and/or effectiveness, as well as safety, to support applications for regulatory approvals. If successful, the Company submits regulatory filings with the appropriate regulatory agencies.
United States
In the U.S., the FDA review process begins once a complete NDA or BLA is submitted, received and accepted for review by the agency. Within 60 days after receipt, the FDA determines if the application is sufficiently complete to permit a substantive review. The FDA also assesses, at that time, whether the application will be granted a priority review or standard review. Pursuant to the Prescription Drug User Fee Act VII (PDUFA), the FDA review period target for NDAs or original BLAs is either six months, for priority review, or ten months, for a standard review, from the time the application is deemed sufficiently complete. For original efficacy supplements to an NDA or BLA, the FDA review period target is six months, for priority review, or ten months, for a standard review, from the time the supplemental application is received. Once the review timelines are determined, the FDA will generally act upon the application within those timeline goals, unless a major amendment has been submitted (either at the Company’s own initiative or the FDA’s request) to the pending application. If this occurs, the FDA may extend the review period to allow for review of the new information, but by no more than three months. Extensions to the review period are communicated to the Company. The FDA can act on an application either by issuing an approval letter or by issuing a Complete Response Letter (CRL) stating that the application will not be approved in its present form and describing all deficiencies that the FDA has identified. Should the Company wish to pursue an application after receiving a CRL, it can resubmit the application with information that addresses the questions or issues identified by the FDA in order to support approval. Resubmissions are subject to review period targets, which vary depending on the underlying submission type and the content of the resubmission.
The FDA has four program designations — Fast Track, Breakthrough Therapy, Accelerated Approval, and Priority Review — to facilitate and expedite development and review of new drugs to address unmet medical needs in the treatment of serious or life-threatening conditions. The Fast Track designation provides pharmaceutical manufacturers with opportunities for frequent interactions with FDA reviewers during the product’s development and the ability for the manufacturer to do a rolling submission of the NDA/BLA. A rolling submission allows completed portions of the application to be submitted and reviewed by the FDA on an ongoing basis. The Breakthrough Therapy designation provides manufacturers with all of the features of the Fast Track designation as well as intensive guidance on implementing an efficient development program for the product and a commitment by the FDA to involve senior managers and experienced staff in the review. The Accelerated Approval designation allows the FDA to approve a product based on an effect on a surrogate or intermediate endpoint that is reasonably likely to predict a product’s clinical benefit and generally requires the manufacturer to conduct required post-approval confirmatory trials to verify the clinical benefit. The Priority Review designation means that the FDA’s goal is to take action on the NDA/BLA within six months, compared to ten months under standard review. More than one of these special designations can be granted for a given application (i.e., a product designated as a Breakthrough Therapy may also be eligible for Priority Review).
Due to the COVID-19 public health crisis, in 2020, the U.S. Secretary of Health and Human Services (Secretary) exercised statutory authority to determine that a public health emergency existed, and declared those circumstances justified the emergency use of drugs and biological products as authorized by the FDA. In 2023, the Secretary issued an amended determination that a public health emergency or a significant potential for a public health emergency existed, and declared that circumstances continued to justify authorization of emergency use of these products. While in effect, this declaration (as amended) enables the FDA to issue Emergency Use Authorizations (EUAs) permitting distribution and use of specific medical products absent NDA/BLA submission or approval, including products to treat or prevent diseases or conditions caused by the SARS-CoV-2 virus, subject to the terms of any such EUAs. The Company is currently marketing Lagevrio in the U.S. pursuant to an EUA. The FDA must make certain findings to grant an EUA, including that it is reasonable to believe based on the totality of evidence that the drug or biologic may be effective, and that known or potential benefits when used under the terms of the EUA outweigh known or potential risks. Additionally, the FDA must find that there is no adequate, approved and available alternative to the emergency use of the authorized drug or biologic. The FDA may revise or revoke an EUA if the circumstances justifying its issuance no longer exist, the criteria for its issuance are no longer met, or other circumstances make a revision or revocation appropriate to protect the public health or safety.
European Union
The primary method the Company uses to obtain marketing authorization of pharmaceutical products in the EU is through the “centralized procedure.” This procedure is compulsory for certain pharmaceutical products, in particular those using biotechnological processes, and is also available for certain new chemical compounds and products. A company seeking to market an innovative pharmaceutical product through the centralized procedure must file a complete set of safety data and efficacy data as part of a Marketing Authorization Application (MAA) with the
16

European Medicines Agency (EMA). After the EMA evaluates the MAA, it provides a recommendation to the EC and the EC then approves or denies the MAA. It is also possible for new chemical products to obtain marketing authorization in the EU through a “mutual recognition procedure” in which an application is made to a single member state and, if the member state approves the pharmaceutical product under a national procedure, the applicant may submit that approval to the mutual recognition procedure of some or all other EU Member States.
Japan
In Japan, the Company submits new drug applications to the PMDA for its pharmaceutical regulatory review. The PMDA is an independent administrative agency which is under the jurisdiction of the Ministry of Health, Labor and Welfare (MHLW). The PMDA considers multiple factors in its review process, including the drug’s safety, efficacy, quality, and manufacturing process in accordance with the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices. In addition, there are various other regulations and guidelines issued by the MHLW or the PMDA that must also be complied with in order to secure approval. The length of the PMDA review process can vary, but it typically takes around one year for a new drug to be approved in Japan. The review period may be shortened if the drug candidate is designated by the MHLW as an innovative drug satisfying certain conditions.
China
In China, the Company submits marketing applications to the NMPA for an independent review. The NMPA considers multiple factors in its review process, including the drug‘s safety, efficacy, quality, and manufacturing process. Moreover, the NMPA implements strict regulations to ensure that all drugs meet the same standards as those set by the WHO. The agency establishes stringent safety and efficacy requirements for drug approval. The length of the NMPA review process can vary, but it typically takes around one to two years for a new drug to be approved in China.
Other Markets
Outside of the U.S., the EU, Japan and China, the Company submits marketing applications to national regulatory authorities. Examples of such are Health Canada, Agência Nacional de Vigilância Sanatária in Brazil, Korea Food and Drug Administration in South Korea, and the Therapeutic Goods Administration in Australia. Each country has a separate and independent review process and timeline. In many markets, approval times can be longer as the regulatory authority requires approval in a major market, such as the U.S. or the EU, and issuance of a Certificate of Pharmaceutical Product from that market before initiating their local review process.
Research and Development Update
The Company currently has several candidates under regulatory review in the U.S. and internationally or in late-stage clinical development.
MK-1022, patritumab deruxtecan, is a potential first-in-class HER3 directed DXd antibody drug conjugate (ADC), under review by the FDA for the treatment of adult patients with locally advanced or metastatic EGFR-mutated NSCLC previously treated with two or more systemic therapies. The BLA is based on the primary results from the HERTHENA-Lung01 pivotal Phase 2 trial and data results presented at the IASLC 2023 World Conference on Lung Cancer, which were simultaneously published in the Journal of Clinical Oncology. In June 2024, the FDA issued a CRL for the BLA due to findings pertaining to an inspection of a third-party manufacturing facility. The CRL did not identify any issues with the efficacy or safety data submitted. Patritumab deruxtecan (HER3-DXd) was discovered by Daiichi Sankyo and is being jointly developed by Daiichi Sankyo and Merck. Merck is working with Daiichi Sankyo to address FDA feedback.
MK-6482, Welireg, is under review in Japan both for the treatment of adults with VHL disease based on the LITESPARK-004 clinical trial and for the treatment of certain adults with previously treated advanced RCC based on the LITESPARK-005 clinical trial. Additionally, in January 2025, the FDA accepted for priority review a supplemental NDA seeking approval of Welireg for the treatment of adult and pediatric patients (12 years and older) with advanced, unresectable, or metastatic pheochromocytoma and paraganglioma, based on the LITESPARK-015 trial. The FDA set a PDUFA, or target action, date of May 26, 2025.
V116, Capvaxive, a 21-valent pneumococcal conjugate vaccine designed to help prevent invasive pneumococcal disease and pneumococcal pneumonia caused by certain serotypes in adults, is under review in the EU and Japan. The applications are supported by results from multiple Phase 3 clinical studies evaluating V116 in both vaccine-naïve and vaccine-experienced adult patient populations. In January 2025, the Committee for Medicinal Products for Human Use (CHMP) of the EMA recommended the approval of Capvaxive for active immunization for the prevention of invasive disease and pneumonia caused by certain types of Streptococcus pneumoniae in individuals 18 years of age and older. The CHMP’s recommendation will now be reviewed by the EC for marketing authorization in the EU, and a final decision is expected by the second quarter of 2025.
17

MK-7962, Winrevair, Merck’s novel activin signaling inhibitor, is under review in Japan for the treatment of adult patients with PAH based on the Phase 3 STELLAR trial. In November 2024, Merck announced positive topline results from the Phase 3 ZENITH study, evaluating Winrevair in adults with PAH with WHO Group 1 FC III or IV at high risk of mortality. Based on the positive results of an interim analysis, an independent data monitoring committee recommended that the study be stopped early due to overwhelming efficacy. In addition, in January 2025, Merck announced the Phase 3 HYPERION study evaluating Winrevair in newly diagnosed adults with PAH FC II or III at intermediate or high risk of disease progression was also stopped early based on the positive results from the interim analysis of the ZENITH trial and a review of the totality of data from the Winrevair clinical program to date. All participants in both the ZENITH and HYPERION studies will be offered the opportunity to receive Winrevair as part of the open-label, long-term extension study, SOTERIA.
MK-1654, clesrovimab, is an investigational prophylactic long-acting monoclonal antibody designed to protect infants from respiratory syncytial virus (RSV) disease during their first RSV season. In December 2024, the FDA accepted the BLA for clesrovimab and set a PDUFA date of June 10, 2025. Clesrovimab is also under review in the EU.
MK-3475, Keytruda, is an anti-PD-1 therapy approved for the treatment of many cancers that is in clinical development for expanded indications. These studies encompass more than 30 cancer types including: biliary, estrogen receptor positive breast, triple-negative breast, cervical, colorectal, endometrial, esophageal, gastric, glioblastoma, head and neck, hepatocellular, Hodgkin lymphoma, non-Hodgkin lymphoma, non-small-cell lung, small-cell lung, melanoma, malignant pleural mesothelioma, ovarian, prostate, renal, and urothelial, several of which are currently in Phase 3 clinical development. Further trials are being planned for other cancers.
Keytruda is under review in the EU and Japan for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma, based on the Phase 2/3 IND.227/KEYNOTE-483 trial. In November 2024, the EMA’s CHMP adopted a positive opinion recommending approval of Keytruda in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult patients with unresectable non-epithelioid malignant pleural mesothelioma. In December 2024, the Company requested a re-examination from the EMA’s CHMP for an extension of the indication to include approval in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adults and adolescents aged 12 years and older with unresectable advanced or metastatic malignant pleural mesothelioma, based on final results from the KEYNOTE-483 trial.
The Company is diversifying its oncology portfolio and executing on its strategy which is broadly based on three strategic pillars: immuno-oncology, precision molecular targeting and tissue targeting. Merck has numerous Phase 3 oncology programs within these pillars.
Immuno-oncology
MK-1308A is the coformulation of quavonlimab, Merck’s novel investigational anti-CTLA-4 antibody, in combination with pembrolizumab, being evaluated for the treatment of RCC.
MK-3475, Keytruda, is being evaluated in the therapeutic areas of hepatocellular, ovarian and small-cell lung cancers.
MK-3475A is the subcutaneous coformulation of pembrolizumab in combination with hyaluronidase being evaluated for comparability with intravenous pembrolizumab in metastatic NSCLC.
V940 (mRNA-4157) is an investigational individualized neoantigen therapy being evaluated in combination with Keytruda as an adjuvant treatment in patients with certain types of melanoma. The FDA and EMA granted Breakthrough Therapy designation and Priority Medicines (PRIME) scheme designation, respectively, for V940 (mRNA-4157) in combination with Keytruda for the adjuvant treatment of patients with certain stages of high-risk melanoma following complete resection. V940 (mRNA-4157) is also being evaluated as adjuvant and perioperative treatment for certain patients with NSCLC. V940 is being developed as part of a collaboration with Moderna, Inc.
Precision molecular targeting
MK-1026, nemtabrutinib, is an oral, reversible, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor, being evaluated for the treatment of hematological malignancies, including chronic lymphocytic leukemia and small lymphocytic lymphoma.
MK-1084 is an investigational oral selective KRAS G12C inhibitor being evaluated in combination with Keytruda for the first-line treatment of certain patients with metastatic NSCLC.
MK-3543, bomedemstat, is an investigational orally available lysine-specific demethylase 1 inhibitor, being evaluated for the treatment of certain patients with essential thrombocythemia. Bomedemstat has FDA
18

Orphan Drug and Fast Track Designation for the treatment of essential thrombocythemia and myelofibrosis, Orphan Drug Designation for the treatment of acute myeloid leukemia and PRIME scheme designation by the EMA for the treatment of myelofibrosis.
MK-5684, opevesostat, is an investigational cytochrome P450 11A1 (CYP11A1) inhibitor being evaluated for the treatment of certain patients with metastatic castration-resistant prostate cancer.
MK-7339, Lynparza, is an oral PARP inhibitor being evaluated in combination with Keytruda for expanded indications in the therapeutic areas of NSCLC and SCLC. Lynparza is being developed as part of a collaboration with AstraZeneca PLC.
MK-7902, Lenvima, is an oral receptor tyrosine kinase inhibitor being evaluated in combination with Keytruda for expanded indications in the therapeutic area of esophageal cancer. Lenvima is being developed as part of a collaboration with Eisai Co., Ltd.
Tissue targeting
MK-1022, patritumab deruxtecan, is being evaluated in the therapeutic area of NSCLC as noted above.
MK-2140, zilovertamab vedotin, is an ADC targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1) being evaluated for the treatment of hematological malignancies, including diffuse large B cell lymphoma.
MK-2400, ifinatamab deruxtecan, is an ADC being evaluated in patients with relapsed SCLC versus chemotherapy. MK-2400 is being developed as part of a collaboration with Daiichi Sankyo.
MK-2870, sacituzumab tirumotecan, is an investigational trophoblast cell-surface antigen 2 (TROP2)-directed ADC being evaluated for certain patients with breast, cervical, endometrial, gastric and non-small-cell lung cancers. The FDA granted Breakthrough Therapy designation to sacituzumab tirumotecan for the treatment of patients with advanced or metastatic nonsquamous NSCLC with EGFR mutations whose disease progressed on or after tyrosine kinase inhibitor and platinum-based chemotherapy. Sacituzumab tirumotecan is being developed as part of a collaboration with Kelun-Biotech.
Additionally, the Company currently has candidates in Phase 3 clinical development in several other therapeutic areas.
MK-3000 is an investigational, potentially first-in-class tetravalent, tri-specific antibody that acts as an agonist of the Wingless-related integration site signaling pathway, which is in clinical development for the treatment of diabetic macular edema and neovascular age-related macular degeneration. MK-3000 was obtained in connection with the July 2024 acquisition of Eyebiotech Limited.
MK-8591A is a once-daily oral combination of doravirine and islatravir, an investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI), being evaluated for the treatment of HIV infection in previously untreated adults and as a switch in antiretroviral therapy in virologically suppressed adults. MK-8591D is an oral once-weekly combination of islatravir and Gilead Sciences Inc.’s lenacapavir being evaluated for the treatment of HIV infection in virologically suppressed adults. In 2021, the FDA placed clinical holds on the islatravir investigational NDAs based on observations of decreases in total lymphocyte and CD4+ T-cell counts in some participants receiving islatravir in clinical studies. The investigational NDAs for the doravirine/islatravir and the islatravir/lenacapavir once-weekly treatment regimens remain under a partial clinical hold for any studies that would use islatravir doses higher than the doses considered for the revised clinical programs.
MK-0616, enlicitide decanoate, is an investigational, oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor being evaluated for hypercholesterolemia, including in studies evaluating low-density lipoprotein cholesterol reduction and a cardiovascular outcomes study.
MK-7240, tulisokibart, is a humanized monoclonal antibody directed to tumor necrosis factor-like ligand 1A, a target associated with both intestinal inflammation and fibrosis, being evaluated for the treatment of Crohn’s disease and ulcerative colitis.
MK-4482, Lagevrio, is an investigational oral antiviral medicine for the treatment of mild to moderate COVID-19 in adults who are at risk for progressing to severe disease. Merck is developing Lagevrio in collaboration with Ridgeback Biotherapeutics LP (Ridgeback). The FDA granted Emergency Use Authorization for Lagevrio in December 2021, which was last reissued in November 2023. Lagevrio is authorized for the treatment of adults with a current diagnosis of mild to moderate COVID-19, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by the FDA are not accessible or clinically appropriate. Lagevrio is not approved for any use in the U.S. and is authorized only for the duration of the declaration that circumstances exist justifying the authorization of its emergency use under the Food, Drug and Cosmetic Act, unless the authorization is terminated or revoked sooner. In 2024, an additional Phase 3 clinical trial
19

(MOVe-NOW) was initiated to evaluate Lagevrio for the treatment of adults with COVID-19 at high risk for disease progression. MOVe-NOW will build on existing Lagevrio data to assess efficacy in the current COVID-19 environment and support applications for licensure.
The Company also terminated certain of its development programs in 2024.
MK-7264, gefapixant, is a non-narcotic, oral selective P2X3 receptor antagonist for the treatment of refractory or unexplained chronic cough in adults. In December 2023, the FDA issued a second CRL regarding the resubmission of Merck’s NDA for gefapixant. In the CRL, the FDA concluded that Merck’s application did not meet substantial evidence of effectiveness for treating refractory or unexplained chronic cough. The CRL was not related to the safety of gefapixant. Merck has withdrawn its application for gefapixant from the FDA and does not plan to refile.
In December 2024, Merck announced the discontinuation of the Phase 3 KeyVibe-003 and KeyVibe-007 trials, which were evaluating MK-7684A, the fixed-dose combination of vibostolimab, an anti-TIGIT antibody, and pembrolizumab, in certain patients with NSCLC, based on the recommendation of an independent data monitoring committee. In a pre-planned analysis, both trials met the pre-specified futility criteria for the primary endpoint of overall survival. Considering the totality of data from the Phase 3 KeyVibe studies, including the efficacy outcomes from KeyVibe-003 and KeyVibe-007, the Company decided to discontinue the Phase 3 KeyVibe-006 trial and other vibostolimab studies.
Also in December 2024, Merck announced the discontinuation of the clinical development program for favezelimab, an anti-LAG-3 antibody, and will stop enrollment in the Phase 3 KEYFORM-008 trial evaluating the fixed-dose combination of favezelimab and pembrolizumab (MK-4280A) in patients with relapsed or refractory cHL whose disease has progressed following prior anti-PD-1 therapy. The Company made this decision after a thorough evaluation of data from the favezelimab clinical program. Data analyses for the Phase 3 trials are ongoing, and the results will be shared with the scientific community.
Based on the topline results of the MK-2060 Phase 2 study, Merck will not proceed to Phase 3 clinical development. The Phase 2 study results will be presented at a scientific meeting later in 2025.
The Phase 2b clinical trial for MK-8189 as a monotherapy for acute schizophrenia did not meet its primary efficacy endpoint and further development in schizophrenia, bipolar, and dementia indications has stopped. Potential alternative indications for MK-8189 are being explored.

20

The chart below reflects the Company’s research pipeline as of February 21, 2025. Candidates shown in Phase 3 include the date such candidate entered into Phase 3 development. Candidates shown in Phase 2 include the most advanced compound with a specific mechanism or, if listed compounds have the same mechanism, they are each currently intended for commercialization in a given therapeutic area. Small molecules and biologics are given MK-number designations and vaccine candidates are given V-number designations. Except as otherwise noted, candidates in Phase 1, additional indications in the same therapeutic area (other than with respect to cancer and immunology) and additional claims, line extensions or formulations for in-line products are not shown.
Phase 2
Alzheimer’s
MK-1167
Cancer
MK-1022 (patritumab deruxtecan)(1)
Biliary
Bladder
Cervical
Colorectal
Endometrial
Esophageal
Gastric
Head and Neck
Hepatocellular
Melanoma
Ovarian
Pancreatic
Prostate
MK-1308 (quavonlimab)(2)
Non-Small-Cell Lung
MK-1308A (quavonlimab+pembrolizumab)
Colorectal
MK-2400 (ifinatamab deruxtecan)(1)
Biliary
Bladder
Breast
Cervical
Colorectal
Endometrial
Esophageal
Head and Neck
Hepatocellular
Melanoma
Ovarian
Pancreatic
MK-2870 (sacituzumab tirumotecan)(1)(3)
Biliary
Colorectal
Neoplasm Malignant
Pancreatic
MK-3475 Keytruda
Advanced Solid Tumors
Prostate
MK-3475A (pembrolizumab+hyaluronidase subcutaneous)
Cutaneous Squamous Cell
Hematological Malignancies







Cancer
MK-5890 (boserolimab)(2)
Neoplasm Malignant
MK-5909 (raludotatug deruxtecan)(1)
Bladder
Cervical
Endometrial
Ovarian
Renal Cell
MK-6482 Welireg(3)
Breast
Endometrial
Esophageal
Hepatocellular
MK-7339 Lynparza(1)(3)
Advanced Solid Tumors


Cancer
V940 (1)(2)
Bladder
Renal Cell
Dengue Fever Virus Vaccine
V181
HIV-1 Infection
MK-8591B (islatravir+MK-8507)(4)
HIV-1 Pre-Exposure Prophylaxis
MK-8527
Immunology
MK-6194
Lupus
Vitiligo
MK-7240 (tulisokibart)
Systemic Sclerosis
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
MK-6024 (efinopegdutide)
Pulmonary Hypertension-Chronic Obstructive Pulmonary Disease
MK-5475
Pulmonary Hypertension Due To Left Heart Disease
MK-7962 Winrevair


21

Phase 3 (Phase 3 entry date)Under Review
Antiviral COVID-19
     MK-4482 Lagevrio (U.S.) (May 2021)(1)(6)
Cancer
MK-1022 (patritumab deruxtecan)(1)
     Non-Small-Cell Lung (May 2022) (EU)
MK-1026 (nemtabrutinib)
     Hematological Malignancies (March 2023)
MK-1084 (2)
     Non-Small-Cell Lung (May 2024)
MK-1308A (quavonlimab+pembrolizumab)
Renal Cell (April 2021)
MK-2140 (zilovertamab vedotin)
Hematological Malignancies (September 2024)
MK-2400 (ifinatamab deruxtecan)(1)
Small-Cell Lung (July 2024)
MK-2870 (sacituzumab tirumotecan)(1)(3)
Breast (April 2024)
Cervical (July 2024)
Endometrial (December 2023)
Gastric (May 2024)
Non-Small-Cell Lung (November 2023)
MK-3475 Keytruda
Hepatocellular (May 2016) (EU)
Ovarian (December 2018)
Small-Cell Lung (May 2017)
MK-3475A (pembrolizumab+hyaluronidase subcutaneous)
Non-Small-Cell Lung (February 2023)
MK-3543 (bomedemstat)
Myeloproliferative Disorders (December 2023)
MK-5684 (opevesostat)
Prostate (December 2023)
MK-7339 Lynparza(1)(2)
Non-Small-Cell Lung (June 2019)
Small-Cell Lung (December 2020)
MK-7902 Lenvima(1)(2)
Esophageal (July 2021)
V940(1)(2)
Melanoma (July 2023)
Non-Small-Cell Lung (December 2023)
Diabetic Macular Edema
MK-3000(7)
HIV-1 Infection
MK-8591A (doravirine+islatravir) (February 2020)(5)
MK-8591D (islatravir+lenacapavir) (October 2024)(1)(5)
Hypercholesterolemia
MK-0616 (enlicitide decanoate) (August 2023)
Immunology
MK-7240 (tulisokibart)
Crohn’s Disease (June 2024)
Ulcerative Colitis (October 2023)

New Molecular Entities
Cancer
MK-1022 (patritumab deruxtecan)(1)(8)
     Non-Small-Cell Lung (U.S.)
MK-6482 Welireg
Renal Cell (JPN)
Von Hippel-Lindau (VHL)
Disease (JPN)
Pneumococcal Vaccine Adult
V116 Capvaxive (EU) (JPN)
Pulmonary Arterial Hypertension
MK-7962 Winrevair (JPN)
Respiratory Syncytial Virus
MK-1654 (clesrovimab) (U.S.) (EU)





Certain Supplemental Filings
Cancer
MK-3475 Keytruda
• First-Line Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma
(KEYNOTE-483) (EU) (JPN)

MK-6482 Welireg
• Advanced, Unresectable, or Metastatic Pheochromocytoma and Paraganglioma
(LITESPARK-015) (U.S.)
Footnotes:
(1) Being developed in a collaboration.
(2) Being developed in combination with Keytruda.
(3) Being developed as monotherapy and/or in combination with Keytruda.
(4) FDA lifted clinical hold on December 4, 2024.
(5) On FDA partial clinical hold for higher doses of islatravir than those used in current clinical trials.
(6) Available in the U.S. under Emergency Use Authorization.
(7) Program is in a Phase 2/3 study that commenced in August 2024.
(8) In June 2024, the FDA issued a CRL for the BLA for patritumab deruxtecan. Merck is working with Daiichi Sankyo to address FDA feedback.

Human Capital
As of December 31, 2024, the Company had approximately 75,000 employees worldwide, with approximately 31,000 employed in the U.S., including Puerto Rico, and approximately 15,000 third-party contractors globally. Third-party contractors include the Company’s temporary workers, independent contractors, and freelancers who are viewed as full-time equivalent employees; they exclude outsourced service providers. Approximately 73,000 of the Company’s employees are full-time employees. Globally, women comprise 52% of employees, and in the U.S. individuals from underrepresented ethnic groups comprise 37% of its workforce (the Company defines workforce as its employees). Women comprise 46% of the members of the Board of Directors. Additionally, the Company’s senior management team is made up of 39% women. Approximately 21% of the Company’s employees are represented by various collective bargaining groups. The Company’s voluntary turnover rate was approximately 4.6% and 5.6%, in 2024 and 2023, respectively.
The Company recognizes that its employees are critical to meet the needs of its patients and customers and that its ability to excel depends on the integrity, skill, and collaboration of its employees.
Talent Acquisition
The Company uses a comprehensive approach to ensure recruiting, retention and leadership development goals are systematically executed throughout the Company and that it hires talented leaders with a wide
22

range of knowledge, skills, backgrounds and perspectives. In addition, the Company utilizes a comprehensive communications strategy, employee branding and marketing outreach, social media and strategic alliance partnerships to reach a broad pool of talent in its critical business areas. In 2024, the Company hired approximately 7,300 employees across the globe through various channels including the Company’s external career site, direct passive candidate sourcing, employee referrals, universities and other external sources.
Enabling a Collaborative Work Environment
Fostering a collaborative environment is fundamental to the Company’s success and core to future innovation. The Company strives to create an environment of acceptance, engagement and empowerment. The Company seeks to hire and develop the best talent by providing equal opportunity to all people. The Company creates competitive advantages by leveraging practices which help to meet the needs of all our patients worldwide. This includes evaluating social determinants of health when developing commercialization strategies and leveraging employee insights to improve performance.
Compensation and Benefits
The Company provides a valuable suite of compensation and benefits programs that reflect its commitment to attract, retain and motivate its talent, and support its employees and their families in every stage of life. The Company continuously monitors and adjusts its compensation and benefit programs to ensure they are competitive, contemporary, helpful and engaging, and that they support strategic imperatives such as fairness, flexibility, quality, security and affordability. For example, the Company regularly monitors and evaluates its pay practices and policies to ensure that it is paying employees fairly. The Company offers a personal health care concierge service to assist U.S. employees participating in the Company medical plan with their health care needs. Aligned with its business and in support of its cancer care strategy, the Company provides enhanced cancer screening benefits with cash incentives, immediate access to two leading cancer centers of excellence for U.S. employees and high value cancer support resources (e.g., caregiving and mental health) for employees and their families. Globally, the Company implemented a minimum standard of 12 weeks of paid parental leave. In the U.S., the Company’s benefits rank in the top quartile of Fortune 100 companies under the Aon 2024 Benefits Index. The Company has been included in the Seramount (previously the Working Mother) 100 Best Companies ranking for 38 consecutive years and was named a top ten Best Company for Moms in 2024.
Employee Well-being
The Company is committed to helping its employees and their families improve their own health and well-being, whether physical, mental, financial, or social. The Company’s programs ensure quality, competitive value, protection from significant financial hardship and access to tools and resources to support employees and their families in all stages of their career and their lives, earning the Company accolades such as the Business Group on Health’s Best Employers Excellence in Health & Well-being and the CEO Roundtable on Cancer’s Global Gold Standard Employer accreditation in 2024. As part of the Company’s overall culture of well-being, the Company fosters an array of flexible work arrangements and offers onsite services so employees can thrive. For example, in the U.S., these include onsite health care professionals at many major sites, cafeterias committed to healthy menu offerings, onsite childcare, onsite gyms, and the convenient option to bank through an employee credit union.
Engaging Employees
The Company strengthens employee engagement by fostering a safe, positive, and supportive workplace. Merck encourages candid employee feedback through global employee surveys and peer feedback processes. The Company encourages professional networking and collaboration, enabling employees to connect and grow. Additionally, Merck provides community volunteering opportunities, reflecting its commitment to social responsibility. By building strong relationships with its employees, the Company strives to ensure that every voice is heard, fostering an engaging employee experience that drives Merck forward.
Talent Management and Development
As the Company pursues its goal of becoming the world’s premier research-based biopharmaceutical company, there is a consistent focus on the importance of continuously developing its motivated and talented people. The Company is committed to talent growth for all, allowing its employees to move more fluidly across the organization, unlocking an environment that allows them to shape their career pathways via non-linear and wide-ranging opportunities and experience. Merck’s current talent management system supports company-wide performance management, leadership development, talent reviews and succession planning. Annual performance reviews help further the professional development of the Company’s employees and ensure that the Company’s workforce is aligned with the Company’s objectives. The Company seeks to continuously build the skills and capabilities of its workforce to accelerate talent, improve performance and mitigate risk through relevant continuous learning experiences. This includes, but is not limited to, building leadership and management skills, as well as providing technical and functional training to all employees.
23

Environmental Matters
Environmental Sustainability
The Company is committed to enabling a safe, sustainable and healthy future and strives to be a strong environmental steward, evolving its efforts in the face of a changing world. The Company’s environmental sustainability strategy has three focus areas:
Driving operational efficiency;
Designing new products to minimize environmental impact; and
Reducing any impacts in the Company’s upstream and downstream value chain.
The Company ensures its ongoing commitment to these areas through thoughtful governance. Its Environmental, Health and Safety Council (EHS Council) is a cross-functional body with leadership representation from each area of the Company’s business and is responsible for overseeing its environmental sustainability strategy, policy, and risk mitigation controls. The EHS Council monitors performance against the Company’s goals and increases transparency on environmental issues within the Company, senior management, and the Board of Directors (the Board). The Global Safety and Environment (GSE) vice president communicates progress on environmental sustainability goals, objectives and other important issues to the Board, senior management and the EHS Council. Additionally, the head of the Environmental Sustainability Center of Excellence is a member of the Environmental, Social and Governance Strategy Management Team, a group of functional experts that advises, shapes, and drives the Company’s long-term sustainability strategy with guidance from an internal cross divisional forum of senior leaders. The Company’s cross-functional Environmental Sustainability Implementation Steering Committee was designated by the EHS Council to oversee the progress of initiatives that support the achievement of the Company’s public goals and provide guidance on resourcing of the Company’s environmental sustainability strategy.
Merck believes that climate change could present risks to its business, as discussed in further detail in Item 1A. “Risk Factors” below under the headings “Climate change or legal, regulatory or market measures to address climate change may negatively affect the Company’s business, results of operations, cash flows and prospects” and “Environmental, social and governance matters may impact the Company’s business and reputation.” Some of the potential impacts of climate change to the Company’s business include increased operating costs due to additional regulatory requirements, physical risks to the Company’s facilities, water limitations and disruptions to its supply chain. These potential risks are integrated into the Company’s business planning, including investment in reducing energy usage, water use and greenhouse gas (GHG) emissions.
The Company has adopted a set of climate goals to help position it to succeed in an increasingly resource-constrained world. These goals address the rising expectations of the Company’s customers, investors, external stakeholders and employees regarding the environmental impact of its operations and supply chain. The Company’s climate goals include reducing Scope 1 and 2 operational GHG emissions 46% by 2030 (from a 2019 baseline), sourcing 100% of its purchased electricity from renewable sources by 2025, and reducing Scope 3 GHG emissions 30% by 2030 (from a 2019 baseline). In 2024, the Company committed to a net-zero target for its GHG emissions across its global operations (Scopes 1, 2 and 3) by 2045, aligned with the guidelines of the Science Based Targets initiative (SBTi). Other environmental sustainability initiatives of the Company include:
Partnering for progress across the Company’s value chain. The Company is working to reduce its Scope 3 emissions through a robust supplier engagement approach to drive collaboration upstream and downstream in its value chain. By engaging with its suppliers, the Company can identify key ways to reduce its GHG emissions and pinpoint additional tangible benefits for the business.
Playbooks for a sustainable environment. To help direct and track projects in support of its goals, the Company has developed a series of guidance documents for its global sites. In 2021, the Company launched its Low Carbon Transition Playbook (LCTP), a common platform that includes a gap assessment to help the Company’s global sites evaluate the maturity of their energy programs and help create short- and long-term plans to reduce sites’ carbon intensity and build toward a low-carbon future. Based on learnings from use, the Company issued LCTP 2.0 in 2022 with a capability to facilitate knowledge sharing across sites. In 2022, the Company also created the Waste Diversion Playbook, which takes a similar approach to guide sites on developing a roadmap to their and the Company’s shared 2025 goals on waste diversion, including local waste-diversion strategies and environmentally responsible procurement practices. In 2024, the Company expanded this list with the addition of a Water Conservation Playbook. This approach guides projects consistently across the Company’s global network of sites and enables continuous improvement toward meetings its goals.
24

Realizing the benefits of green and sustainable science. The Company believes that meeting its environmental sustainability goals is intrinsically linked to the creation of innovative, cost-efficient manufacturing processes with low environmental impact. The Company aims to develop efficient and sustainable processes at product launch, with the goal of minimizing material use and waste from its commercial manufacturing. The Company utilizes an innovative “green-by-design” development strategy with a goal to progress from an initial early clinical supply route to a fully optimized and sustainable commercial manufacturing process. In 2024, for the fifth year in a row, the Company received the Peter J. Dunn Award for Green Chemistry and Engineering Impact, an award given by the American Chemical Society in recognition of outstanding implementation of novel green chemistry in the pharmaceutical industry.
Waste diversion. The Company continuously evaluates its sites’ waste disposal methods to gain a better understanding of its network and changes therein, as well as to identify risks and opportunities in its value chain. Based on its evaluation, the Company implemented programs to divert non-hazardous landfill waste from its two highest landfill-generating sites. The Company remains committed to its 2025 public waste diversion goals of no more than 20% of the Company’s global operational waste sent to landfills or incinerators (without energy recovery) and that 50% of its sites will send zero waste to landfills by 2025.
Water as a shared resource. As water is a key input to the Company’s manufacturing operations, the Company assesses water risk throughout its network as a standard business practice. Both of the Company’s priority water-stress risk sites have conservation plans in place, and site staff are actively working on water use reduction and recycling improvement projects. These projects are consistent with the Company’s ongoing commitment to achieving its stated goal of maintaining global water use at or below 2015 levels by 2025. The Company’s sites are employing various technologies and techniques aimed at reducing its water footprint and improving operational performance. The Company’s endorsement of the United Nations CEO Water Mandate enables alignment of the Company’s water program with the mandate’s principles. The Company has continued to identify partnerships to help it advance its water stewardship priorities in the areas in which it operates.
The Company continues to review and explore other opportunities to further its environmental strategy and will evaluate potential impacts and commitments.
Management does not believe that expenditures related to these initiatives should have a material adverse effect on the Company’s financial condition, results of operations, liquidity or capital resources for any year.
Environmental Regulation and Remediation
The Company believes that there are no compliance issues associated with applicable environmental laws and regulations that would have a material adverse effect on the Company. The Company is also remediating environmental contamination resulting from past industrial activity at certain of its sites. Expenditures for remediation and environmental liabilities were $4 million in 2024 and are estimated to be $26 million in the aggregate for the years 2025 through 2029. These amounts do not consider potential recoveries from other parties. The Company has taken an active role in identifying and accruing for these costs and, in management’s opinion, the liabilities for all environmental matters that are probable and reasonably estimable have been accrued and totaled $41 million and $42 million at December 31, 2024 and 2023, respectively. Although it is not possible to predict with certainty the outcome of these matters, or the ultimate costs of remediation, management does not believe that any reasonably possible expenditures that may be incurred in excess of the liabilities accrued should exceed approximately $46 million in the aggregate. Management also does not believe that these expenditures should result in a material adverse effect on the Company’s financial condition, results of operations or liquidity for any year.
Geographic Area Information
The Company’s operations outside the U.S. are conducted primarily through subsidiaries. Sales worldwide by subsidiaries outside the U.S. as a percentage of total Company sales was 50% in 2024, 53% in 2023 and 54% in 2022.
The Company’s worldwide business is subject to risks of currency fluctuations, governmental actions and other governmental proceedings abroad. The Company does not regard these risks as a deterrent to further expansion of its operations abroad. However, the Company closely reviews its methods of operations and adopts strategies responsive to changing economic and political conditions.
25

Merck has operations in countries located in Latin America, the Middle East, Africa, Eastern Europe and Asia Pacific. Business in these developing areas, while sometimes less stable, offers important opportunities for growth over time.
Available Information
The Company’s Internet website address is merck.com. The Company will make available, free of charge at the “Investors” portion of its website, its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and all amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, as soon as reasonably practicable after such reports are electronically filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC). The address of that website is sec.gov. In addition, the Company will provide without charge a copy of its Annual Report on Form 10-K, including financial statements and schedules, upon the written request of any shareholder to the Office of the Secretary, Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, NJ 07065 U.S.A.
The Company’s corporate governance guidelines and the charters of the Board of Directors’ four standing committees are available on the Company’s website at www.merck.com/company-overview/leadership/board-of-directors/ and all such information is available in print to any shareholder who requests it from the Company.
The Company’s 2023/2024 Impact Report, which provides enhanced sustainability disclosures, is available in the Sustainability section of the Company’s website at www.merck.com. Information in the Company’s Impact Report is not incorporated by reference into this Form 10-K.
Item 1A.Risk Factors.
Summary Risk Factors
The Company is subject to a number of risks that if realized could materially adversely affect its business, results of operations, cash flows, financial condition or prospects. The following is a summary of the principal risk factors facing the Company:
The Company is dependent on its patent rights, and if its patent rights are invalidated or circumvented, its business could be materially adversely affected.
As the Company’s products lose market exclusivity, the Company generally experiences a significant and rapid loss of sales from those products.
Key products generate a significant amount of the Company’s profits and cash flows, and any events that adversely affect the markets for its leading products could have a material adverse effect on the Company’s results of operations and financial condition.
The Company’s research and development efforts may not succeed in developing commercially successful products and the Company may not be able to acquire commercially successful products in other ways; consequently, the Company may not be able to replace sales of successful products that lose patent protection.
The Company’s success is dependent on the successful development and marketing of new products, which are subject to substantial risks.
The Company faces continued pricing pressure with respect to its products.
Unfavorable or uncertain economic conditions, together with cost-reduction measures being taken by certain governments, could negatively affect the Company’s operating results.
The Company faces intense competition from both lower cost generic and biosimilar products and competitors’ products.
The Company has significant global operations, which expose it to additional risks, and any adverse event could have a material adverse effect on the Company’s results of operations and financial condition.
Climate change or legal, regulatory or market measures to address climate change may negatively affect the Company’s business, results of operations, cash flows and prospects.
Environmental, social and governance matters may impact the Company’s business and reputation.
Failure to attract and retain highly qualified personnel could affect the Company’s ability to successfully develop and commercialize products.
26

The Company may experience difficulties and delays in manufacturing certain of its products, including vaccines.
The Company’s business in China has grown in the past few years, and the importance of China to the Company’s overall pharmaceutical and vaccines business has increased accordingly. In 2024, the Company experienced lower sales of Gardasil/Gardasil 9 in China and expects that sales of Gardasil/Gardasil 9 in China will decline significantly in 2025.
The Company may not be able to realize the expected benefits of its investments in emerging markets.
The Company is exposed to market risk from fluctuations in currency exchange rates and interest rates.
Pharmaceutical products can develop unexpected safety or efficacy concerns.
Reliance on third-party relationships and outsourcing arrangements could materially adversely affect the Company’s business.
Negative events in the animal health industry could have a material adverse effect on future results of operations and financial condition of the Company or its Animal Health business.
Biologics and vaccines carry unique risks and uncertainties, which could have a material adverse effect on the Company’s future results of operations and financial condition.
The health care industry in the U.S. has been, and will continue to be, subject to increasing regulation and political action.
The Company’s products, including products in development, cannot be marketed unless the Company obtains and maintains regulatory approval.
Developments following regulatory approval may adversely affect sales of the Company’s products.
The Company is subject to a variety of U.S. and international laws and regulations.
The Company is subject to evolving and complex tax laws, which may result in additional liabilities that may affect results of operations and financial condition.
Adverse outcomes in current or future legal matters could negatively affect Merck’s business.
Product liability insurance for products may be limited, cost prohibitive or unavailable.
The Company is increasingly dependent on sophisticated software applications and computing infrastructure, including the use of cloud-based applications and environments. The Company continues to be a target of cyber-attacks that could lead to a disruption of its worldwide operations, including manufacturing, research and sales operations.
The Company is increasing its use of artificial intelligence (AI) systems to automate processes, analyze data, and support decision-making which poses inherent risks.
Social media and mobile messaging platforms present risks and challenges.
The above list is not exhaustive, and the Company faces additional challenges and risks. Investors should carefully consider all of the information set forth in this Form 10-K, including the following risk factors, before deciding to invest in any of the Company’s securities.
Risk Factors
The risks below are not the only ones the Company faces. Additional risks not currently known to the Company or that the Company presently deems immaterial may also impair its business operations. The Company’s business, financial condition, results of operations, cash flows or prospects could be materially adversely affected by any of these risks. This Form 10-K also contains forward-looking statements that involve risks and uncertainties. The Company’s results could materially differ from those anticipated in these forward-looking statements as a result of certain factors, including the risks it faces described below and elsewhere. See “Cautionary Factors that May Affect Future Results” below.

27

Risks Related to the Company’s Business
The Company is dependent on its patent rights, and if its patent rights are invalidated or circumvented, its business could be materially adversely affected.
Patent protection is considered, in the aggregate, to be of material importance to the Company’s marketing of human health and animal health products in the U.S. and in most major foreign markets. Patents covering products that it has introduced normally provide market exclusivity, which is important for the successful marketing and sale of its products. The Company seeks patents covering each of its products in each of the markets where it intends to sell the products and where meaningful patent protection is available.
Even if the Company succeeds in obtaining patents covering its products, third parties or government authorities may challenge or seek to invalidate or circumvent its patents and patent applications. It is important for the Company’s business to successfully assert and defend the patent rights that provide market exclusivity for its products. The Company is often involved in patent disputes relating to challenges to its patents or claims by third parties of infringement against the Company. The Company asserts and defends its patents both within and outside the U.S., including by filing claims of infringement against other parties. See Item 8. “Financial Statements and Supplementary Data,” Note 10. “Contingencies and Environmental Liabilities” below. In particular, manufacturers of generic or biosimilar pharmaceutical products from time to time file abbreviated NDAs or BLAs with the FDA seeking to market generic/biosimilar forms of the Company’s products prior to the expiration of relevant patents owned or licensed by the Company. The Company normally responds by asserting one or more of its patents with a lawsuit alleging patent infringement. Patent litigation and other challenges to the Company’s patents are costly and unpredictable and may deprive the Company of market exclusivity for a patented product or, in some cases, third-party patents may prevent the Company from marketing and selling a product in a particular geographic area.
Additionally, certain foreign governments have indicated that compulsory licenses to patents may be granted in the case of national emergencies or in other circumstances, which could diminish or eliminate sales and profits from those regions and negatively affect the Company’s results of operations. Further, court decisions relating to other companies’ patents, potential legislation in both the U.S. and certain foreign markets relating to patents, as well as regulatory initiatives may result in a more general weakening of intellectual property protection.
If one or more important products lose patent protection in profitable markets, sales of those products are likely to decline significantly as a result of generic versions of those products becoming available. The Company’s results of operations may be adversely affected by the lost sales unless and until the Company has launched commercially successful products that replace the lost sales. In addition, if products that were measured at fair value and capitalized in connection with acquisitions experience difficulties in the market that negatively affect product cash flows, the Company may recognize material non-cash impairment charges with respect to the value of those products.
A chart listing the key patent protection for certain of the Company’s marketed products, and U.S. patent protection for candidates in Phase 3 clinical development is set forth above in Item 1. “Business — Patents, Trademarks and Licenses.”
As the Company’s products lose market exclusivity, the Company generally experiences a significant and rapid loss of sales from those products.
The Company depends upon patents to provide it with exclusive marketing rights for its products for some period of time. Loss of patent protection for one of the Company’s products typically leads to a significant and rapid loss of sales for that product as lower priced generic versions of that drug become available. In the case of products that contribute significantly to the Company’s sales, the loss of market exclusivity can have a material adverse effect on the Company’s business, cash flows, results of operations, financial condition and prospects. The Company lost market exclusivity for Bridion in Europe and Japan in 2023 and 2024, respectively, and the Company has experienced a substantial decline in Bridion sales in those markets. Bridion will lose market exclusivity in the U.S. in 2026 (subject to patent litigation discussed below) and the Company expects that sales of Bridion in the U.S. will decline substantially thereafter. In addition, the Company expects U.S. sales of Keytruda to decline beginning in January 2028 upon implementation of government pricing under the IRA, and to further decline upon loss of market exclusivity following expiration of the U.S. compound patent in December 2028. The Company expects to lose market exclusivity in Europe for Keytruda in 2031 following compound patent expiration. There may, however, be attempts by one or more companies to challenge the patent or launch a biosimilar product despite the patent in some European jurisdictions following the expiration of data exclusivity in Europe in July 2026.
28

Key products generate a significant amount of the Company’s profits and cash flows, and any events that adversely affect the markets for its leading products could have a material adverse effect on the Company’s results of operations and financial condition.
The Company’s ability to generate profits and operating cash flows depends largely upon the continued profitability of the Company’s key products, such as Keytruda, Gardasil/Gardasil 9, Lynparza, Bravecto, and Bridion. In 2024, the Company’s oncology portfolio, led by Keytruda, represented substantially all of the Company’s revenue growth. In particular, in the aggregate, in 2024, sales of Keytruda represented 46% of the Company’s total sales. As a result of the Company’s dependence on key products, any event that adversely affects any of these products or the markets for any of these products, such as the slowing demand for Gardasil/Gardasil 9 in China which the Company has experienced, could have a significant adverse impact on results of operations and financial condition. Other events could include loss of patent protection, increased costs associated with manufacturing, generic or over-the-counter availability of the Company’s product or a competitive product, the discovery of previously unknown side effects, results of post-approval trials, increased competition from the introduction of new, more effective treatments and discontinuation or removal from the market of the product for any reason. Such events could have a material adverse effect on the sales of any such products.
The Company’s research and development efforts may not succeed in developing commercially successful products and the Company may not be able to acquire commercially successful products in other ways; consequently, the Company may not be able to replace sales of successful products that lose patent protection.
In order to remain competitive, the Company, like other major pharmaceutical companies, must continue to launch new products. Expected declines in sales of products after the loss of market exclusivity mean that the Company’s future success is dependent on its pipeline of new products, including new products that it may develop through collaborations and joint ventures and products that it is able to obtain through license or acquisition. To accomplish this, the Company commits substantial effort, funds and other resources to research and development, both through its own dedicated resources and through various collaborations with third parties. There is a high rate of failure inherent in the research and development process for new drugs and vaccines. As a result, there is a high risk that funds invested by the Company in research programs will not generate financial returns. This risk profile is compounded by the fact that this research has a long investment cycle. To bring a pharmaceutical compound from the discovery phase to market may take a decade or more and failure can occur at any point in the process, including later in the process after significant funds have been invested.
For a description of the research and development process, see Item 1. “Business — Research and Development” above. Each phase of testing is highly regulated and during each phase there is a substantial risk that the Company will encounter serious obstacles or will not achieve its goals. Therefore, the Company may abandon a product in which it has invested substantial amounts of time and resources. Some of the risks encountered in the research and development process include the following: preclinical testing of a new compound may yield disappointing results; competing products from other manufacturers may reach the market first; clinical trials of a new drug may not be successful; a new drug may not be effective or may have harmful side effects; a new drug may not be approved by the regulators for its intended use; it may not be possible to obtain a patent for a new drug; payers may refuse to cover or reimburse the new product; or sales of a new product may be disappointing.
The Company cannot state with certainty when or whether any of its products now under development will be approved or launched; whether it will be able to develop, license or otherwise acquire compounds, product candidates or products; or whether any products, once launched, will be commercially successful. The Company must maintain a continuous flow of successful new products and successful new indications for existing products sufficient both to cover its substantial research and development costs and to replace sales that are lost as profitable products lose market exclusivity or are displaced by competing products or therapies. Failure to do so in the short term or long term would have a material adverse effect on the Company’s business, results of operations, cash flows, financial condition and prospects.
The Company’s success is dependent on the successful development and marketing of new products, which are subject to substantial risks.
Products that appear promising in development may fail to reach the market or fail to succeed for numerous reasons, including the following:
findings of ineffectiveness, superior safety or efficacy of competing products, or harmful side effects in clinical or preclinical testing;
29

failure to receive the necessary regulatory approvals, including delays in the approval of new products and new indications, or the anticipated labeling, and uncertainties about the time required to obtain regulatory approvals and the benefit/risk standards applied by regulatory agencies in determining whether to grant approvals;
failure in certain markets to obtain reimbursement commensurate with the level of innovation and clinical benefit presented by the product;
lack of economic feasibility due to manufacturing costs or other factors; and
preclusion from commercialization by the proprietary rights of others.
In the future, if certain pipeline programs are cancelled or if the Company believes that their commercial prospects have been reduced, the Company may recognize material non-cash impairment charges for those programs that were measured at fair value and capitalized in connection with acquisitions or certain collaborations.
Failure to successfully develop and market new products in the short term or long term would have a material adverse effect on the Company’s business, results of operations, cash flows, financial condition and prospects.
The Company faces continued pricing pressure with respect to its products.
The Company faces continued pricing pressure globally and, particularly in mature markets, from managed care organizations, government agencies and programs that could negatively affect the Company’s sales and profit margins. In the U.S., these include (i) U.S. federal laws and regulations related to Medicare and Medicaid, including the Medicare Prescription Drug Improvement and Modernization Act of 2003, the ACA, and the IRA, (ii) practices of managed care groups and institutional and governmental purchasers, and (iii) state activities aimed at increasing price transparency, including new laws as noted above in Item 1. “Competition and the Health Care Environment.” Changes to the health care system enacted as part of health care reform in the U.S., as well as increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, could result in further pricing pressures. As noted in Item 1. “Competition and the Health Care Environment,” in 2023, HHS selected Januvia for the first year of the IRA’s price setting program, which will result in a government set price becoming effective on January 1, 2026. Government price setting may also impact pricing in the private market, negatively affecting the Company’s performance. In January 2025, HHS announced that Janumet and Janumet XR have been selected for government price setting, which will become effective on January 1, 2027. Furthermore, the Company expects that in 2026 HHS will include Keytruda in a subsequent selection of products to undergo IRA price setting, with such price to become effective on January 1, 2028 and the Company expects that, as a result, U.S. sales of Keytruda will decline after that time. In addition, in the U.S., larger customers have received higher rebates on drugs in certain highly competitive categories. The Company must also compete to be placed on formularies of managed care organizations. Exclusion of a product from a formulary can lead to reduced usage in the managed care organization. The Company is also facing pricing pressure from purchasers of certain vaccines in highly competitive categories.
Outside the U.S., numerous major markets, including the EU, Japan and China have pervasive government involvement in funding health care and, in that regard, fix the pricing and reimbursement of pharmaceutical and vaccine products. Consequently, in those markets, the Company is subject to government decision making and budgetary actions with respect to its products. In Japan, the pharmaceutical industry is subject to government-mandated annual price reductions of pharmaceutical products and certain vaccines. Furthermore, the Japanese government can order re-pricing for specific products if it determines that use of such product will exceed certain thresholds defined under applicable re-pricing rules.
The Company expects pricing pressures to continue in the future.
Unfavorable or uncertain economic conditions, together with cost-reduction measures being taken by certain governments, could negatively affect the Company’s operating results.
The Company’s business may be adversely affected by local and global economic conditions, including with respect to inflation, interest rates, and costs of raw materials and packaging. Uncertainty in global economic and geopolitical conditions may result in a slowdown to the global economy that could affect the Company’s business by reducing the prices that drug wholesalers and retailers, hospitals, government agencies and managed health care providers may be able or willing to pay for the Company’s products or by reducing the demand for the Company’s products, which could in turn negatively impact the Company’s sales and result in a material adverse effect on the Company’s business, cash flows, results of operations, financial condition and prospects.
30

As discussed above in Item 1. “Competition and the Health Care Environment,” global efforts toward health care cost containment continue to exert pressure on product pricing and market access worldwide. Changes to the U.S. health care system as part of health care reform, as well as increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, have contributed to pricing pressure. In several international markets, government-mandated pricing actions have reduced prices of generic and patented drugs. In addition, the Company’s sales performance in 2024 was negatively affected by other cost-reduction measures taken by governments and other third parties to lower health care costs, including in the U.S., the expansion of the Federal 340B Drug Discount Program. The Company anticipates all of these actions, and additional actions in the future, will continue to negatively affect sales and profits.
If credit and economic conditions worsen, the resulting economic and currency impacts in the affected markets and globally could have a material adverse effect on the Company’s results.
The Company faces intense competition from both lower cost generic and biosimilar products and competitors’ products.
In general, the Company faces increasing competition from lower-cost generic and biosimilar products. The patent rights that protect its products are of varying strengths and durations. In addition, in some countries, patent protection is significantly weaker than in the U.S. or in the EU. In the U.S. and the EU, political pressure to reduce spending on prescription drugs has led to legislation and other measures that encourage the use of generic and biosimilar products. Although it is the Company’s policy to actively protect its patent rights, generic challenges to the Company’s products can arise at any time, and the Company’s patents may not prevent the emergence of generic competition for its products.
Loss of patent protection for a product typically is followed promptly by generic or biosimilar substitutes, reducing the Company’s sales of that product. Availability of generic substitutes for the Company’s drugs may adversely affect its results of operations and cash flows. In addition, proposals emerge from time to time in the U.S. and other countries for legislation to further encourage the early and rapid approval of generic drugs. Any such proposal that is enacted into law could worsen this substantial negative effect on the Company’s sales, business, cash flows, results of operations, financial condition and prospects.
Also, the Company’s products face intense competition from competitors’ products. This competition may increase as new products enter the market. In such an event, the competitors’ products may be safer or more effective, more convenient to use, have better insurance coverage or reimbursement levels or be more effectively marketed and sold than the Company’s products. Alternatively, in the case of generic competition, including the generic availability of competitors’ branded products, they may be equally safe and effective products that are sold at a substantially lower price than the Company’s products. As a result, if the Company fails to maintain its competitive position, this could have a material adverse effect on its business, cash flows, results of operations, financial condition and prospects. In addition, if products that were measured at fair value and capitalized in connection with acquisitions experience difficulties in the market that negatively impact product cash flows, the Company may recognize material non-cash impairment charges with respect to the value of those products.
The Company has significant global operations, which expose it to additional risks, and any adverse event could have a material adverse effect on the Company’s results of operations and financial condition.
The extent of the Company’s operations outside the U.S. is significant. Risks inherent in conducting a global business include:
changes in medical reimbursement policies and programs and pricing restrictions in key markets;
multiple regulatory requirements that could restrict the Company’s ability to manufacture and sell its products in key markets;
trade protection measures and import or export licensing requirements, including the imposition of trade sanctions or similar restrictions by the U.S. or other governments;
foreign exchange fluctuations;
diminished protection of intellectual property in some countries; and
possible nationalization and expropriation.
The U.S. government has announced plans to significantly increase tariffs on foreign imports into the U.S., particularly from Canada and Mexico and has already increased tariffs on imports from China. It is too early for the
31

Company to assess if, or to what extent, such policies will be implemented or continue to be implemented, and the extent of any measures that have been or will be taken by any impacted countries. In addition, there may be changes to the Company’s business if there is instability, disruption or destruction in a significant geographic region, regardless of cause, including war, terrorism, riot, civil insurrection or social unrest; and natural or man-made disasters, including famine, flood, fire, earthquake, storm or disease. Events like these, such as the ongoing war between Russia and Ukraine, and the conflict in the Middle East, and/or policy changes with respect to international trade protection measures, could result in material adverse effects on macroeconomic conditions, currency exchange rates and financial markets, and may adversely affect the Company’s business, results of operations, cash flows and financial condition.
Climate change or legal, regulatory or market measures to address climate change may negatively affect the Company’s business, results of operations, cash flows and prospects.
The Company believes that climate change has the potential to negatively affect its business, results of operations, cash flows and prospects. The Company is exposed to physical risks (such as extreme weather conditions, inland flooding or rising sea levels), risks in transitioning to a low-carbon economy (such as additional legal or regulatory requirements, changes in technology, market risk and reputational risk) and social and human effects (such as population dislocations and harm to health and well-being) associated with climate change. These risks can be either acute (short-term) or chronic (long-term).
The adverse impacts of climate change include increased frequency and severity of natural disasters and extreme weather events such as hurricanes, tornados, wildfires (exacerbated by drought), flooding, and extreme heat. Extreme weather, inland flooding and sea-level rise pose physical risks to the Company’s facilities as well as those of its suppliers. Such risks include losses incurred as a result of physical damage to facilities, loss or spoilage of inventory, and business interruption caused by such natural disasters and extreme weather events. Other potential physical impacts due to climate change include reduced access to high-quality water in certain regions and the loss of biodiversity, which could impact future product development. These risks could disrupt the Company’s operations and its supply chain, which may result in increased costs.
New legal and regulatory requirements are being enacted to prevent, mitigate, or adapt to the implications of a changing climate and its effects on the environment. These regulations, which may differ across jurisdictions, could result in the Company being subject to new or expanded carbon pricing or taxes, increased compliance costs, restrictions on GHG emissions, investment in new technologies, increased GHG emission disclosure (including costs resulting from mandatory or voluntary reporting, diligence or disclosure) and transparency, recurring investments in data gathering and reporting systems, upgrades of facilities to meet new building codes, and the redesign of utility systems, which could increase the Company’s operating costs, including the cost of electricity and energy used by the Company. The Company’s supply chain would likely be subject to these same transitional risks and would likely pass along any increased costs to the Company, which may affect the Company’s ability to procure raw materials or other supplies required for the operation of the Company’s business at the quantities and levels required.
Environmental, social and governance matters may impact the Company’s business and reputation.
Governmental authorities, non-governmental organizations, customers, investors, external stakeholders and employees are sensitive to environmental, social and governance concerns, such as human capital, climate change, water use, recyclability or recoverability of packaging, and plastic waste. The focus on these concerns may lead to new requirements that could result in increased costs associated with developing, manufacturing and distributing the Company’s products, and related reporting obligations. The Company’s ability to compete could also be affected by changing customer preferences and requirements, such as growing demand for validated net zero GHG emission targets and more environmentally friendly products, packaging or supplier practices, or by failure to meet such customer expectations or demand. The Company risks negative shareholder reaction, including from proxy advisory services, as well as damage to its brand and reputation and inability to attract and retain employee talent, if the Company fails to act responsibly, or if the Company is perceived to not be acting responsibly, in key areas, including equitable access to medicines and vaccines, product quality and safety, environmental stewardship, reduction of GHG emissions, support for local communities, corporate governance and transparency, and addressing human capital factors in the Company’s operations. Responding to these considerations as well as any applicable regulatory requirements and implementation of the Company’s goals and initiatives involves risks and uncertainties, requires investments, and depends in part on third-party performance or data that is outside of the Company’s control. In addition, some governmental authorities, non-governmental organizations, and stakeholders may disagree with the Company’s goals and initiatives. If the Company does not meet the evolving and varied regulatory requirements and expectations of its investors, customers and other stakeholders, the Company could experience negative impacts to the Company’s business and results of operations. In addition, the Company is subject to expanding mandatory and voluntary reporting, diligence and disclosure requirements, including the EU’s Corporate
32

Sustainability Reporting Directive (CSRD) and potentially the SEC’s climate-related reporting requirements (which are currently stayed), the legislation in California requiring reporting of GHG emissions and climate risk, and similar regulatory requirements in other jurisdictions outside the U.S. These evolving regulatory requirements are likely to result in increased costs and complexities of compliance in order to collect, measure and report on the relevant information.
Failure to attract and retain highly qualified personnel could affect the Company’s ability to successfully develop and commercialize products.
The Company’s success is largely dependent on its continued ability to attract and retain highly qualified scientific, technical and management personnel, as well as personnel with expertise in clinical research and development, governmental regulation and commercialization. Competition for qualified personnel in the pharmaceutical industry, both in the U.S. and internationally, is intense. The Company cannot be sure that it will be able to attract and retain qualified personnel or that the costs of doing so will not materially increase.
The Company may experience difficulties and delays in manufacturing certain of its products, including vaccines.
Merck from time to time experiences difficulties in manufacturing certain of its products, including vaccines. For example, the Company is currently experiencing manufacturing delays related to Varivax and ProQuad which will result in supply constraints in 2025. The Company may, in the future, experience other difficulties and delays in manufacturing its products, such as (i) failure of the Company or any of its vendors or suppliers to comply with Current Good Manufacturing Practices and other applicable regulations and quality assurance guidelines that could lead to manufacturing shutdowns, product shortages and delays in product manufacturing; (ii) delays related to the construction of new facilities or the expansion of existing facilities, including those intended to support future demand for the Company’s products; and (iii) other manufacturing or distribution problems including supply chain delays, shortages in raw materials, changes in manufacturing production sites and limits to manufacturing capacity due to regulatory requirements, changes in types of products produced, or physical limitations that could impact continuous supply. In addition, the Company could experience difficulties or delays in manufacturing its products caused by natural disasters, such as hurricanes. Manufacturing difficulties can result in product shortages, leading to lost sales and reputational harm to the Company.
The Company’s business in China has grown in the past few years, and the importance of China to the Company’s overall pharmaceutical and vaccines business has increased accordingly. In 2024, the Company experienced lower sales of Gardasil/Gardasil 9 in China and expects that sales of Gardasil/Gardasil 9 in China will decline significantly in 2025.
The Company’s business in China has grown in the past few years, and the importance of China to the Company’s overall pharmaceutical and vaccines business has increased accordingly. Beginning in mid-2024, the Company observed a significant decline in shipments from its distributor and commercialization partner in China, Chongqing Zhifei Biological Products Co., Ltd. (Zhifei), to disease and control prevention institutions and correspondingly into the points of vaccination, resulting in above normal inventory levels at Zhifei. Accordingly, the Company shipped less than its contracted doses to Zhifei in the latter part of 2024. Lower demand in China persisted and, at the end of 2024, overall channel inventory levels in China remained elevated at above normal levels. Therefore, the Company made a decision to temporarily pause shipments to China beginning in February 2025 through at least the middle of the year and as a result, combined sales of Gardasil/Gardasil 9 will decline significantly in 2025 compared with 2024. Furthermore, the government's anti-corruption campaign, particularly the increased number of inspections and audits, could substantially increase the administrative burden on health care institutions and health care professionals throughout the whole industry in China and potentially have a negative impact on the Company's sales. In addition to its commercial operations, the Company has significant research and manufacturing operations in China, including working with Chinese entities such as Wuxi Apptech Co., Ltd. If geopolitical tensions were to increase and disrupt the Company’s operations in China, such disruption could result in a material adverse effect on the Company’s product development, sales, business, cash flows, results of operations, financial condition and prospects.
Also, continued growth of the Company’s business in China is dependent upon ongoing development of a favorable environment for innovative pharmaceutical products and vaccines, sustained access for the Company’s currently marketed products, and the absence of trade impediments or adverse pricing controls. As noted above in Item 1. “Competition and the Health Care Environment,” pricing pressure in China has increased as the Chinese government has been taking steps to reduce costs, including implementing health care reform that has led to the acceleration of generic substitution, where available. While the mechanism for drugs being added to the NRDL evolves, inclusion may require a price negotiation which could impact the outlook in the market for selected brands. A
33

new NRDL was recently completed in which new entries averaged 63% price reductions. While pricing pressure has always existed in China, health care reform has increased this pressure in part due to the acceleration of generic substitution through the government’s VBP program. In 2019, the government implemented the VBP program through a tendering process for mature products which have generic substitutes with a Generic Quality Consistency Evaluation approval. Mature products that have entered into the last five rounds of VBP had, on average, a price reduction of more than 50%. The Company expects VBP to be a semi-annual process that will have a significant impact on mature products moving forward.
The Company may not be able to realize the expected benefits of its investments in emerging markets.
The Company has been taking steps to increase its sales in emerging markets. However, there is no guarantee that the Company’s efforts to expand sales in these markets will succeed. Some countries within emerging markets may be especially vulnerable to periods of global financial instability or may have very limited resources to spend on health care. In order for the Company to operate successfully in emerging markets, it must attract and retain qualified personnel. The Company may also be required to increase its reliance on third-party agents within less developed markets, which may affect its ability to realize continued growth and may also increase the Company’s risk exposure. In addition, many of these countries have currencies that fluctuate substantially and, if such currencies devalue and the Company cannot offset the devaluations, the Company’s financial performance within such countries could be adversely affected.
For all these reasons, sales within emerging markets carry significant risks. However, at the same time, macro-economic growth of selected emerging markets is expected to lead to significant increased health care spending in those countries and access to innovative medicines for patients. A failure to maintain the Company’s presence in emerging markets could therefore have a material adverse effect on the Company’s business, cash flows, results of operations, financial condition and prospects.
The Company is exposed to market risk from fluctuations in currency exchange rates and interest rates.
The Company operates in multiple jurisdictions and virtually all sales are denominated in currencies of the local jurisdiction. Additionally, the Company has entered and will enter into business development transactions, borrowings or other financial transactions that may give rise to currency and interest rate exposure.
Since the Company cannot, with certainty, foresee and mitigate against such adverse changes, fluctuations in currency exchange rates, interest rates and inflation could negatively affect the Company’s business, cash flows, results of operations, financial condition and prospects. For example, Argentina is currently experiencing hyperinflation, which is affecting the Company’s operations in that market.
In order to mitigate against the adverse impact of these market fluctuations, the Company will from time to time enter into hedging agreements. While hedging agreements, such as currency options and forwards, and interest rate swaps, may limit some of the exposure to exchange rate and interest rate fluctuations, such attempts to mitigate these risks may be costly and not always successful.
Pharmaceutical products can develop unexpected safety or efficacy concerns.
Unexpected safety or efficacy concerns can arise with respect to marketed products, whether or not scientifically justified, leading to product recalls, withdrawals, or declining sales, as well as product liability, consumer fraud and/or other claims, including potential civil or criminal governmental actions.
Reliance on third-party relationships and outsourcing arrangements could materially adversely affect the Company’s business.
The Company depends on third parties, including suppliers, distributors, alliances with other pharmaceutical and biotechnology companies, and third-party service providers, for key aspects of its business including development, manufacture and commercialization of its products and support for its information technology (IT) systems. Failure of these third parties to meet their contractual, regulatory and other obligations to the Company or the development of factors that materially disrupt the relationships between the Company and these third parties could have a material adverse effect on the Company’s business.
34

Negative events in the animal health industry could have a material adverse effect on future results of operations and financial condition of the Company or its Animal Health business.
Future sales of key animal health products could be adversely affected by a number of risk factors including certain risks that are specific to the animal health business. For example, the outbreak of disease carried by animals, such as Avian Influenza or African Swine Fever, could lead to their widespread death and precautionary destruction as well as the reduced consumption and demand for animals, which could adversely affect the Company’s results of operations. Also, the outbreak of any highly contagious diseases near the Company’s main production sites could require the Company to immediately halt the manufacture of its animal health products at such sites or force the Company to incur substantial expenses in procuring raw materials or products elsewhere. Other risks specific to animal health include epidemics and pandemics affecting livestock, government procurement and pricing practices, weather and global agribusiness economic events. In addition, in 2024, sales of Bravecto were $1.1 billion, which represented 19% of the Company’s Animal Health segment sales. Any negative event with respect to Bravecto could have a material adverse effect on the Company’s Animal Health sales. If the Animal Health segment of the Company’s business becomes more significant, the impact of any such events on future results of operations could also become more significant.
Biologics and vaccines carry unique risks and uncertainties, which could have a material adverse effect on the Company’s future results of operations and financial condition.
The successful development, testing, manufacturing and commercialization of biologics and vaccines, particularly human and animal health vaccines, is a long, complex, expensive and uncertain process. There are unique risks and uncertainties related to biologics and vaccines, including:
There may be limited access to, and supply of, normal and diseased tissue samples, cell lines, pathogens, bacteria, viral strains and other biological materials. In addition, government regulations in multiple jurisdictions, such as the U.S. and the EU, could result in restricted access to, or transport or use of, such materials. If the Company loses access to sufficient sources of such materials, or if tighter restrictions are imposed on the use of such materials, the Company may not be able to conduct research activities as planned and may incur additional development costs.
The development, manufacturing and marketing of biologics and vaccines are subject to regulation by the FDA, the EMA and other regulatory bodies. These regulations are often more complex and extensive than the regulations applicable to other pharmaceutical products. For example, in the U.S., a BLA, including both preclinical and clinical trial data and extensive data regarding the manufacturing procedures, is required for human vaccine candidates, and FDA approval is generally required for the release of each manufactured commercial human vaccine lot.
Manufacturing biologics and vaccines, especially in large quantities, is complex and may require the use of innovative technologies to handle living micro-organisms. Each lot of an approved biologic and vaccine must undergo thorough testing for identity, strength, quality, purity and potency. Manufacturing biologics requires facilities specifically designed for and validated for this purpose, and sophisticated quality assurance and quality control procedures are necessary. Slight deviations anywhere in the manufacturing process, including filling, labeling, packaging, storage and shipping, and quality control and testing, may result in lot failures, product recalls or spoilage. When changes are made to the manufacturing process, the Company may be required to provide preclinical and clinical data showing the comparable identity, strength, quality, purity or potency of the biologics and vaccines before and after such changes.
Biologics and vaccines are costly to manufacture because production ingredients are derived from living animal or plant material, and most biologics and vaccines cannot be made synthetically. In particular, keeping up with the demand for vaccines may be difficult due to the complexity of producing vaccines.
The use of biologically derived ingredients can lead to variability in the manufacturing process and could lead to allegations of harm, including infections or allergic reactions, which allegations would be reviewed through a standard investigation process that could lead to closure of product facilities due to possible contamination. Any of these events could result in substantial costs.

35

Risks Relating to Government Regulation and Legal Proceedings
The health care industry in the U.S. has been, and will continue to be, subject to increasing regulation and political action.
As discussed above in Item 1. “Competition and the Health Care Environment,” the Company believes that the health care industry will continue to be subject to increasing regulation as well as political and legal action, as future proposals to reform the health care system are considered by the Executive Branch, Congress and state legislatures.
In 2022, Congress passed the IRA, which makes significant changes to how drugs are covered and paid for under the Medicare program, including the creation of financial penalties for drugs whose prices rise faster than the rate of inflation, redesign of the Medicare Part D program to require manufacturers to bear more of the liability for certain drug benefits, which has taken effect in 2025, and government price setting for certain Medicare Part D drugs, starting in 2026, and Medicare Part B drugs starting in 2028. Furthermore, government price setting may also impact pricing in the private market, negatively affecting the Company’s performance. As noted in Item 1. “Competition and the Health Care Environment,” in 2023, HHS selected Januvia for the first year of the IRA’s price setting program, which will result in a government set price becoming effective on January 1, 2026. On January 17, 2025, HHS announced that Janumet and Janumet XR have been selected for government price setting, which will become effective on January 1, 2027. Furthermore, the Company expects that in 2026 HHS will include Keytruda in a subsequent selection of products to undergo IRA price setting, with such price to become effective on January 1, 2028 and the Company expects that, as a result, U.S. sales of Keytruda will decline after that time.
In addition, in 2021, Congress passed the American Rescue Plan Act, which included a provision that eliminates the statutory cap on rebates drug manufacturers pay to Medicaid beginning in January 2024. These rebates act as a discount off the list price and eliminating the cap means that manufacturer discounts paid to Medicaid can increase. Prior to this change, manufacturers have not been required to pay more than 100% of the Average Manufacturer Price (AMP) in rebates to state Medicaid programs for Medicaid-covered drugs. As a result of this provision, manufacturers may have to pay state Medicaid programs more in rebates than they received on sales of particular products. This change presents a risk to Merck for drugs that have high Medicaid utilization and rebate exposure that is more than 100% of the AMP. Additionally, increased utilization of the 340B Federal Drug Discount Program and restrictions on the Company’s ability to identify inappropriate discounts are having a negative impact on the Company’s performance. Also, the Company expects that states will continue their focus on pharmaceutical pricing and will increasingly shift to more aggressive price control tools such as Prescription Drug Affordability Boards that have the authority to conduct affordability reviews and establish upper payment limits and that Company products may be selected for such reviews.
In the U.S., members of the government have made public statements in favor of, and may take steps to implement, various regulatory changes that could negatively impact the pharmaceutical industry, including the Company. Those potential changes include some related to vaccines and vaccine development, as well as personnel and policy changes at the FDA and other government agencies and programs. For example, HHS could undergo changes that could make it more difficult for the FDA to grant regulatory approvals for drugs and vaccines and the U.S. Centers for Disease Control and Prevention (CDC) to issue or maintain recommendations for vaccines. Additionally, if the FDA drug user fee programs were eliminated, that could cause significant delays to facility inspections and approvals of new products. It is too early for the Company to assess which, if any, of the policy changes that have been publicly referenced would be implemented, and the Company cannot predict what additional future changes in the health care industry in general, or the pharmaceutical industry in particular, will occur; however, any changes could have a material adverse effect on the Company’s business, cash flows, results of operations, financial condition and prospects.
The Company’s products, including products in development, cannot be marketed unless the Company obtains and maintains regulatory approval.
The Company’s activities, including research, preclinical testing, clinical trials and the manufacturing and marketing of its products, are subject to extensive regulation by numerous federal, state and local governmental authorities in the U.S., including the FDA, and by foreign regulatory authorities, including in the EU, Japan and China. In the U.S., the FDA administers requirements covering the testing, approval, safety, effectiveness, manufacturing, labeling and marketing of prescription pharmaceuticals and vaccines. In some cases, the FDA requirements have increased the amount of time and resources necessary to develop new products and bring them to market in the U.S. Regulation outside the U.S. also is primarily focused on drug safety and effectiveness and, in many cases, reduction in the cost of drugs. The FDA and foreign regulatory authorities, including in the EU, Japan and China, have substantial discretion to require additional testing, to delay or withhold registration and marketing approval and to otherwise preclude distribution and sale of a product.
36

Even if the Company is successful in developing new products, it will not be able to market any of those products unless and until it has obtained all required regulatory approvals (which in limited circumstances may include authorizations for emergency use) in each jurisdiction where it proposes to market the new products. Once obtained, the Company must maintain approval as long as it plans to market its new products in each jurisdiction where approval is required. The Company’s failure to obtain approval, significant delays in the approval process, or its failure to maintain approval in any jurisdiction will prevent it from selling the products in that jurisdiction and realizing sales.
Developments following regulatory approval may adversely affect sales of the Company’s products.
Even after a product reaches the market, certain developments following regulatory approval may decrease demand for the Company’s products, including the following:
results in post-approval Phase 4 trials or other studies;
the re-review of products that are already marketed;
the recall or loss of marketing approval of products that are already marketed;
changing government standards or public expectations regarding safety, efficacy, quality or labeling changes;
scrutiny of advertising and promotion; and
the withdrawal of indications granted pursuant to accelerated approvals.
In the past, clinical trials and post-marketing surveillance of certain marketed drugs of the Company and of competitors within the industry have raised concerns that have led to recalls, withdrawals or adverse labeling of marketed products. Clinical trials and post-marketing surveillance of certain marketed drugs also have raised concerns among some prescribers and patients relating to the safety or efficacy of pharmaceutical products in general that have negatively affected the sales of such products. In addition, increased scrutiny of the outcomes of clinical trials has led to increased volatility in market reaction. Further, these matters often attract litigation and, even where the basis for the litigation is groundless, considerable resources may be needed to respond.
In addition, following in the wake of product withdrawals and other significant safety issues, health authorities such as the FDA, the EMA, Japan’s PMDA and China’s NMPA have increased their focus on safety when assessing the benefit/risk balance of drugs. Some health authorities appear to have become more cautious when making decisions about approvability of new products or indications.
If previously unknown side effects are discovered or if there is an increase in negative publicity regarding known side effects of any of the Company’s products, it could significantly reduce demand for the product or require the Company to take actions that could negatively affect sales, including removing the product from the market, restricting its distribution or applying for labeling changes. Further, in the environment in which all pharmaceutical companies operate, the Company is at risk for product liability and consumer protection claims and civil and criminal governmental actions related to its products, research and/or marketing activities. In addition, dissemination of promotional materials through evolving digital channels serves to increase visibility and scrutiny in the marketplace.
The Company is subject to a variety of U.S. and international laws and regulations.
The Company is currently subject to a number of government laws and regulations and, in the future, could become subject to new government laws and regulations. The costs of compliance with such laws and regulations, or the negative results of non-compliance, could adversely affect the business, cash flows, results of operations, financial condition and prospects of the Company; these laws and regulations include (i) additional health care reform initiatives in the U.S. or in other countries, including additional mandatory discounts or fees; (ii) the U.S. Foreign Corrupt Practices Act (FCPA) or other anti-bribery and corruption laws; (iii) new laws, regulations and judicial or other governmental decisions affecting pricing, drug reimbursement, and access or marketing within or across jurisdictions; (iv) changes in intellectual property laws; (v) changes in accounting standards; (vi) new and increasing data privacy regulations and enforcement, particularly in the EU, the U.S., and China; (vii) legislative mandates or preferences for local manufacturing of pharmaceutical or vaccine products; (viii) emerging and new global regulatory requirements for reporting payments and other value transfers to health care professionals; (ix) sustainability regulations, such as the EU’s CSRD; and (x) the potential impact of importation restrictions, embargoes, trade sanctions and legislative and/or other regulatory changes.
37

The Company is subject to evolving and complex tax laws, which may result in additional liabilities that may affect results of operations and financial condition.
The Company is subject to evolving and complex tax laws in the jurisdictions in which it operates. Significant judgment is required for determining the Company’s tax liabilities, and the Company’s tax returns are routinely examined by various tax authorities. The Internal Revenue Service (IRS) is currently conducting examinations of the Company’s tax returns for the years 2017 and 2018, including the one-time transition tax enacted under the Tax Cuts and Jobs Act of 2017 (TCJA). If the IRS disagrees with the Company’s transition tax position, it may result in a significant tax liability. The IRS is also currently conducting examinations of the Company’s tax returns for the years 2021 and 2022. In addition, various state and foreign tax examinations are in progress. In connection with the Organization for Economic Cooperation and Development (OECD) Base Erosion and Profit Shifting project, companies are required to disclose more information to tax authorities on operations around the world, which may lead to greater audit scrutiny of profits earned in other countries. The Company believes that its accrual for tax contingencies is adequate for all open years based on past experience, interpretations of tax law, and judgments about potential actions by tax authorities; however, due to the complexity of tax contingencies, the ultimate resolution of any tax matters may result in payments greater or less than amounts accrued. In addition, the Company may be negatively affected by changes in tax laws, or new tax laws, affecting, for example, tax rates, and/or revised tax law interpretations in domestic or foreign jurisdictions, including, among others, any potential changes to the existing U.S. tax law by the Executive Branch and Congress, as well as any changes in tax law resulting from the implementation of the OECD’s two-pillar solution to reform the international tax landscape.
The Company has taken the position, based on the opinions of tax counsel, that its distribution of Organon & Co. (Organon) common stock in connection with the 2021 spin-off (Spin-Off) qualifies as a transaction that is tax-free for U.S. federal income tax purposes. If any facts, assumptions, representations, and undertakings from the Company and Organon regarding the past and future conduct of their respective businesses and other matters are incorrect or not otherwise satisfied, the Spin-Off may not qualify for tax-free treatment, which could result in significant U.S. federal income tax liabilities for the Company and its shareholders.
Adverse outcomes in current or future legal matters could negatively affect Merck’s business.
Current or future litigation, claims, proceedings and government investigations could preclude or delay the commercialization of Merck’s products or could adversely affect Merck’s business, results of operations, cash flows, financial condition and prospects. Such legal matters may include, but are not limited to: (i) intellectual property disputes; (ii) adverse decisions in litigation, including product safety and liability matters, such as the litigation involving Gardasil, consumer protection and commercial cases; (iii) anti-bribery regulations, such as the FCPA, including compliance with ongoing reporting obligations to the government resulting from any settlements; (iv) recalls or withdrawals of pharmaceutical products or forced closings of manufacturing plants; (v) product pricing and promotional matters; (vi) lawsuits, claims and administrative proceedings asserting, or investigations into, violations of securities, antitrust, federal and state pricing, consumer protection, data privacy and other laws and regulations; (vii) environmental, health, safety and sustainability matters, including regulatory actions in response to climate change; and (viii) tax liabilities resulting from assessments from tax authorities.
See Item 8. “Financial Statements and Supplementary Data,” Note 10, “Contingencies and Environmental Liabilities” for more information on the Company’s legal matters.
Product liability insurance for products may be limited, cost prohibitive or unavailable.
As a result of a number of factors, product liability insurance has become less available while the cost of such insurance has increased significantly. The Company is subject to a substantial number of product liability claims. See Item 8. “Financial Statements and Supplementary Data,” Note 10. “Contingencies and Environmental Liabilities” below for more information on the Company’s current product liability litigation. With respect to product liability, the Company self-insures substantially all of its risk, as the availability of commercial insurance has become more restrictive. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities. The Company will continually assess the most efficient means to address its risk; however, there can be no guarantee that insurance coverage will be obtained or, if obtained, will be sufficient to fully cover product liabilities that may arise.

38

Risks Related to Technology
The Company is increasingly dependent on sophisticated software applications and computing infrastructure, including the use of cloud-based applications and environments. The Company continues to be a target of cyber-attacks that could lead to a disruption of its worldwide operations, including manufacturing, research and sales operations.
The Company is increasingly dependent on sophisticated software applications, complex information technology systems, computing infrastructure, and cloud service providers (collectively, IT systems) to conduct critical operations and financial reporting. Certain of these systems are managed, hosted, provided or used by third parties to assist in conducting the Company’s business. Disruption, degradation, or manipulation of these IT systems through intentional or accidental means by the Company’s employees, third parties with authorized access or unauthorized third parties could adversely affect key business processes. Cyber-attacks against the Company’s IT systems or third-party providers’ IT systems, such as cloud-based systems, could result in exposure of confidential information, the modification of critical data, and/or the failure of critical operations. Misuse of any of these IT systems could result in the disclosure of sensitive personal information or the theft of trade secrets, intellectual property, or other confidential business information. The Company continues to leverage new and innovative technologies across the enterprise to replace outmoded technology and improve the efficacy and efficiency of its business processes, including data acquisition, the use of which can create new risks. In addition, the Company’s Animal Health business sells technology products that, when deployed, could potentially be compromised by a third party and cause disruption both internally and externally.
Although the aggregate impact of cyber-attacks and network disruptions on the Company’s operations and financial condition has not been material to date, the Company continues to be a target of events of this nature and expects them to continue. The Company monitors its data, information technology and personnel usage of Company IT systems to identify and attempt to reduce these risks and continues to do so on an ongoing basis for any current or potential threats. There can be no assurance that the Company’s efforts to protect its data and IT systems or the efforts of third-party providers to protect their IT systems will be successful in preventing disruptions to the Company’s operations, including its manufacturing, research, and sales operations. Such disruptions have in the past and could in the future result in loss of revenue, or the loss of critical or sensitive information from the Company’s or the Company’s third-party providers’ databases or IT systems and have in the past and could in the future also result in financial, legal, business or reputational harm to the Company and substantial remediation costs.
The Company is increasing its use of artificial intelligence (AI) systems to automate processes, analyze data, and support decision-making which poses inherent risks.
The Company’s growing use of artificial intelligence (AI) systems to automate processes, analyze data, and support decision-making poses inherent risks. Flaws, biases, or malfunctions in these systems could lead to operational disruptions, data loss, or erroneous decision-making, impacting the Company’s business operations, financial condition, and reputation. Ethical and legal challenges may arise, including biases or discrimination in AI outcomes, non-compliance with data protection regulations and laws specifically governing the use of AI systems and tools, and lack of transparency. Furthermore, the deployment of AI systems could expose the Company to increased cybersecurity threats, such as data breaches and unauthorized access leading to financial losses, legal liabilities, and reputational damage. The Company also faces competitive risks if it fails to adopt AI or other machine learning technologies in a timely fashion.
Social media and mobile messaging platforms present risks and challenges.
The inappropriate and/or unauthorized use of certain social media and mobile messaging channels could cause brand damage or information leakage or could lead to legal implications, including from the improper collection and/or dissemination of personally identifiable information. In addition, negative or inaccurate posts or comments about the Company or its products on any social networking platforms could damage the Company’s reputation, brand image and goodwill. Further, the disclosure of non-public Company-sensitive information by the Company’s workforce or others through external media channels could lead to information loss. Although there are internal Company Social Media and Mobile Messaging Policies that guide employees on appropriate personal and professional use of these platforms for communication about the Company, the processes in place may not completely secure and protect information. Identifying potential new points of unauthorized entry as new communication tools expand also presents new challenges.
39

Cautionary Factors that May Affect Future Results
(Cautionary Statements Under the Private Securities Litigation Reform Act of 1995)
This report and other written reports and oral statements made from time to time by the Company may contain so-called “forward-looking statements,” all of which are based on management’s current expectations and are subject to risks and uncertainties which may cause results to differ materially from those set forth in the statements. One can identify these forward-looking statements by their use of words such as “anticipates,” “expects,” “plans,” “will,” “estimates,” “forecasts,” “projects” and other words of similar meaning, or negative variations of any of the foregoing. One can also identify them by the fact that they do not relate strictly to historical or current facts. These statements are likely to address the Company’s growth strategy, financial results, product approvals, product potential, development programs, environmental or other sustainability initiatives. One must carefully consider any such statement and should understand that many factors could cause actual results to differ materially from the Company’s forward-looking statements. These factors include inaccurate assumptions and a broad variety of other risks and uncertainties, including some that are known and some that are not. No forward-looking statement can be guaranteed and actual future results may vary materially. The Company does not assume the obligation to update any forward-looking statement. The Company cautions you not to place undue reliance on these forward-looking statements. Although it is not possible to predict or identify all such factors, they may include the following:
Competition from generic and/or biosimilar products as the Company’s products lose patent protection.
Increased “brand” competition in therapeutic areas important to the Company’s long-term business performance.
The difficulties and uncertainties inherent in new product development. The outcome of the lengthy and complex process of new product development is inherently uncertain. A drug candidate can fail at any stage of the process and one or more late-stage product candidates could fail to receive regulatory approval. New product candidates may appear promising in development but fail to reach the market because of efficacy or safety concerns, the inability to obtain necessary regulatory approvals, the difficulty or excessive cost to manufacture and/or the infringement of patents or intellectual property rights of others. Furthermore, the sales of new products may prove to be disappointing and fail to reach anticipated levels.
Pricing pressures, both in the U.S. and abroad, including rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and health care reform, pharmaceutical reimbursement and pricing in general.
Changes in government laws and regulations, including laws governing intellectual property, and the enforcement thereof affecting the Company’s business.
Efficacy or safety concerns with respect to marketed products, whether or not scientifically justified, leading to product recalls, withdrawals or declining sales.
Significant changes in customer relationships or changes in the behavior and spending patterns of purchasers of health care products and services, including delaying medical procedures, rationing prescription medications, reducing the frequency of physician visits and foregoing health care insurance coverage.
Legal factors, including product liability claims, antitrust litigation and governmental investigations, including tax disputes, environmental concerns and patent disputes with branded and generic competitors, any of which could preclude commercialization of products or negatively affect the profitability of existing products.
Cyber-attacks on the Company’s or third-party providers’ IT systems, which could disrupt the Company’s operations.
Lost market opportunity resulting from delays and uncertainties in the approval process of the FDA and/or foreign regulatory authorities.
Increased focus on privacy issues in countries around the world, including the U.S., the EU, and China. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing amount of focus on privacy and data protection issues with the potential to affect directly the Company’s business, including laws in a majority of states in the U.S. requiring security breach notification.
Changes in tax laws including changes related to the taxation of foreign earnings.
Changes in accounting pronouncements promulgated by standard-setting or regulatory bodies, including the Financial Accounting Standards Board and the SEC, that are adverse to the Company.
40

Economic factors over which the Company has no control, including changes in inflation, interest rates and foreign currency exchange rates.
This list should not be considered an exhaustive statement of all potential risks and uncertainties. See “Risk Factors” above.
Item 1B.Unresolved Staff Comments.
None.
Item 1C.    Cybersecurity.
The Company’s cybersecurity measures are primarily focused on ensuring the security and protection of its IT systems and data. The Company’s information security program is managed by a dedicated Chief Information Security Officer (CISO), whose group is responsible for leading enterprise-wide cybersecurity risk management, strategy, policy, standards, architecture, and processes. The CISO has worked in the cybersecurity and national security fields for more than 30 years. He has a Master of Science in Telecommunications and Computers. He has served as a board member of the Health Information Sharing and Analysis Center for 10 years. Oversight of the information security program has been integrated into the Company’s overall enterprise risk management program.
The CISO provides periodic reports to the Audit Committee (Audit Committee) of the Board of Directors (Board), the full Board, as well as to the Company’s Chief Executive Officer and other members of senior management, as appropriate. These reports include updates on the Company’s cybersecurity risks and threats, the status of projects intended to strengthen its information security systems, assessments of the information security program (including remediation, mitigation, and management of identified vulnerabilities), and the emerging threat landscape. The information security program is regularly evaluated by internal and external consultants and auditors with the results of those reviews reported to senior management and the Audit Committee, which is comprised entirely of independent directors and has oversight responsibility for these risks.
The Company’s information security group monitors the Company’s information systems to prevent, detect, mitigate, and remediate cybersecurity incidents. The Company uses tools and techniques to continually assess and monitor, manage and mitigate cybersecurity threats to its IT systems in a manner consistent with industry practice. The Company engages with key vendors, industry participants, and intelligence and law enforcement communities as part of its continuing efforts to obtain current threat intelligence, collaborate on security enhancements, and evaluate and improve the effectiveness of its information security program. As part of this program, the Company conducts periodic tabletop and red-teaming exercises to assess its cybersecurity incident response processes and defenses. The Company also maintains vendor management diligence and oversight processes to identify and monitor potential risks from cybersecurity threats attendant to its use of third-party service providers. Additionally, the Company monitors cybersecurity threat intelligence received from key third-party service providers associated with the Company.
In the event of a cybersecurity incident, the Company has a process in place whereby members of the information security group will alert the CISO and the CISO will alert the appropriate levels of management, including an incident assessment team, as well as the legal and finance departments so that the materiality of any such event can be assessed in furtherance of fulfilling any reporting requirements. If warranted, senior management will notify the Audit Committee or the full Board, as appropriate.
The Company has been and continues to be the target of cyber-attacks and network disruptions. To date, the risks posed by such cybersecurity threats have not materially affected the Company and its business strategy, results of operations and financial condition, and as of the date of this report, the Company is not aware of any material risks from cybersecurity threats that are reasonably likely to do so, but there can be no assurance that the Company will not be materially affected by such risks in the future. For further information, see Item 1A. “Risk Factors — The Company is increasingly dependent on sophisticated software applications and computing infrastructure. The Company continues to be a target of cyber-attacks that could lead to a disruption of its worldwide operations, including manufacturing, research and sales operations.”
Item 2.Properties.
The Company’s corporate headquarters are located in Rahway, New Jersey. The Company also maintains divisional headquarters in Upper Gwynedd, Pennsylvania. Principal U.S. research facilities are located in Rahway, New Jersey; West Point, Pennsylvania; Boston and Cambridge, Massachusetts; South San Francisco, California; and Elkhorn, Nebraska (Animal Health). Principal research facilities outside the U.S. are located in the United Kingdom, Switzerland and China. Merck’s manufacturing operations are currently headquartered in Rahway, New Jersey. The Company also has production facilities for human health products at six locations in the U.S. and Puerto Rico.
41

Outside the U.S., through subsidiaries, the Company owns or has an interest in manufacturing plants or other properties in Western Europe, Africa and Asia.
The Company and its subsidiaries own their principal facilities and manufacturing plants under titles that they consider to be satisfactory. The Company believes that its properties are in good operating condition and that its machinery and equipment have been well maintained. The Company believes that its plants for the manufacture of products are suitable for their intended purposes and have capacities and projected capacities, including previously disclosed capital expansion projects, that will be adequate for current and projected needs for existing Company products. Some capacity of the plants is being converted, with any needed modification, to the requirements of newly introduced and future products.
Item 3.Legal Proceedings.
The information called for by this Item is incorporated herein by reference to Item 8. “Financial Statements and Supplementary Data,” Note 10. “Contingencies and Environmental Liabilities.”
Item 4.Mine Safety Disclosures.
Not Applicable.
42


Executive Officers of the Registrant (ages as of February 1, 2025)
All officers listed below serve at the pleasure of the Board of Directors. None of these officers was elected pursuant to any arrangement or understanding between the officer and any other person(s).
NameAgeOffices and Business Experience
Robert M. Davis58
Chairman, Chief Executive Officer and President (since December 2022); Chief Executive Officer and President (July 2021-December 2022); Executive Vice President, Global Services, and Chief Financial Officer (April 2016-July 2021)
Sanat Chattopadhyay65
Executive Vice President and President, Merck Manufacturing Division (since March 2016)
Richard R. DeLuca, Jr.62
Executive Vice President and President, Merck Animal Health (since September 2011)
Cristal Downing 56
Executive Vice President and Chief Communications & Public Affairs Officer (since August 2021); Prior to that, Vice President Medical Devices, Global Communications and Public Affairs Johnson & Johnson (December 2020-August 2021); Vice President Financial Communication, Johnson & Johnson (January 2018-December 2020)
Chirfi Guindo59
Senior Vice President, Chief Marketing Officer, Human Health (since July 2022); Prior to that, Executive Vice President, Head of Global Product Strategy and Commercialization, Biogen Inc. (July 2018-July 2022)
Betty D. Larson
49
Executive Vice President and Chief Human Resources Officer (since April 2024); Prior to that, Chief People Officer, GE HealthCare (February 2022-April 2024); Executive Vice President and Chief Human Resources Officer, Becton Dickinson (June 2018-February 2022)
Dean Li62
Executive Vice President, President, Merck Research Laboratories (since January 2021); Senior Vice President, Discovery Sciences and Translational Medicine, Merck Research Laboratories (November 2017-January 2021)
Caroline Litchfield56
Executive Vice President and Chief Financial Officer (since April 2021); Senior Vice President, Corporate Treasurer (January 2018-March 2021)
Johannes J. Oosthuizen
57
Senior Vice President and President Merck U.S. Human Health (since January 2022); Senior Vice President and Head of Global Oncology Commercial (January 2021-December 2021); Senior Vice President and President of MSD K.K. (July 2016-December 2020)
Joseph Romanelli51
Senior Vice President and President MSD International Human Health (since July 2022); Prior to that, Chief Executive Officer JiXing Pharmaceuticals (July 2021-July 2022); President MSD China (December 2016-July 2021)
Dalton Smart
58
Senior Vice President Finance – Global Controller (since December 2023); Vice President, Assistant Controller (September 2023-December 2023); Vice President, Internal Audit (March 2015-September 2023)
David M. Williams56
Executive Vice President, Chief Information and Digital Officer (since August 2020); Acting Chief Information and Digital Officer (December 2019-August 2020)
Jennifer Zachary47
Executive Vice President and General Counsel (since April 2018)




43

PART II
 
Item 5.Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.
The principal market for trading of the Company’s Common Stock is the New York Stock Exchange (NYSE) under the symbol MRK.
As of January 31, 2025, there were approximately 85,700 shareholders of record of the Company’s Common Stock.
Issuer purchases of equity securities for the three months ended December 31, 2024 were as follows:
Issuer Purchases of Equity Securities
Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs($ in millions)
Period
Total Number
of Shares
Purchased(1)
Average Price
Paid Per
Share
Approximate Dollar Value of Shares
That May Yet Be Purchased
Under the Plans or Programs(1)
October 1 — October 312,428,680 $108.452,428,680 $2,620
November 1 — November 30993,250$99.29993,250$2,522
December 1 — December 311,215,000$99.511,215,000$2,401
Total4,636,930 $104.154,636,930 
(1)    All shares purchased during the period were made as part of a plan approved by the Board of Directors in October 2018 to purchase up to $10 billion in Merck shares for its treasury. In January 2025, the Board of Directors approved a plan to purchase up to an additional $10 billion in Merck shares for its treasury.

44

Performance Graph
The following graph assumes a $100 investment on December 31, 2019, and reinvestment of all dividends, in each of the Company’s Common Stock, the S&P 500 Index, and a composite peer group of major U.S. and European-based pharmaceutical companies, which are: AbbVie Inc., Amgen Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Johnson & Johnson, Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Roche Holding AG, and Sanofi SA.
Comparison of Five-Year Cumulative Total Return
Merck & Co., Inc., Composite Peer Group and S&P 500 Index
End of
Period Value
2024/2019
CAGR*
MERCK$1346%
PEER GROUP**1549%
S&P 50019715%
1261
201920202021202220232024
MERCK$100.0 $92.8 $94.5 $141.1 $142.5 $133.6 
PEER GROUP100.0 106.5 130.4 138.1 142.0 153.7 
S&P 500100.0 118.4 152.3 124.7 157.5 196.8 
*    Compound Annual Growth Rate
**    Peer group average was calculated on a market cap weighted basis as of December 31, 2019.

This Performance Graph will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except to the extent that the Company specifically incorporates it by reference. In addition, the Performance Graph will not be deemed to be “soliciting material” or to be “filed” with the SEC or subject to Regulation 14A or 14C, other than as provided in Regulation S-K, or to the liabilities of section 18 of the Securities Exchange Act of 1934, except to the extent that the Company specifically requests that such information be treated as soliciting material or specifically incorporates it by reference into a filing under the Securities Act or the Exchange Act.
Item 6.     [Reserved]
45

Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations.
The following section of this Form 10-K generally discusses 2024 and 2023 results and year-to-year comparisons between 2024 and 2023. Discussion of 2022 results and year-to-year comparisons between 2023 and 2022 that are not included in this Form 10-K can be found in Part II, Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed on February 26, 2024.
Description of Merck’s Business
Merck & Co., Inc. (Merck or the Company) is a global health care company that delivers innovative health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company’s operations are principally managed on a product basis and include two operating segments, Pharmaceutical and Animal Health, both of which are reportable segments.
The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities.
The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors, animal producers, farmers and pet owners.
Overview
Financial Highlights
($ in millions except per share amounts)2024% Change% Change
Excluding Foreign
Exchange
2023% Change% Change
Excluding Foreign
Exchange
2022
Sales$64,168 7 %10 %$60,115 %%$59,283 
Net Income Attributable to Merck & Co., Inc.:
GAAP$17,117 **$365 (97)%(95)%$14,519 
Non-GAAP (1)
$19,444 **$3,837 (80)%(75)%$19,005 
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders:
GAAP$6.74 **$0.14 (98)%(95)%$5.71 
Non-GAAP (1)
$7.65 **$1.51 (80)%(75)%$7.48 
* > 100%
(1) Non-GAAP net income and non-GAAP earnings per share (EPS) exclude acquisition- and divestiture-related costs, restructuring costs, income and losses from investments in equity securities, and certain other items from Merck’s results prepared in accordance with generally accepted accounting principles in the U.S. (GAAP). For further discussion and a reconciliation of GAAP to non-GAAP net income and EPS, see “Non-GAAP Income and Non-GAAP EPS” below.
Executive Summary
Merck’s performance during 2024 was driven by continued demand across its innovative portfolio, including for recently launched products, enabled by the operational and commercial execution of its science-led strategy. The Company maintained its focus on the pursuit of breakthrough science and innovation, making disciplined investments in compelling science to drive long-term value for patients, customers, and shareholders. Merck advanced its robust early- and late-phase pipeline which includes growing diversity across new therapeutic areas and modalities and completed several promising business development transactions. The Company continued to return capital to shareholders, primarily through dividends.
46

1031
Worldwide sales were $64.2 billion in 2024, an increase of 7% compared with 2023, or 10% excluding the unfavorable effect of foreign exchange. The sales increase was primarily due to growth in oncology, cardiovascular and animal health, partially offset by declines in diabetes, virology (driven largely by lower sales of COVID-19 medication Lagevrio), immunology (as Merck’s marketing rights to these products ended in 2024) and vaccines.
Merck continues to execute value creating business development opportunities focused on innovation to augment its robust internal pipeline with compelling external science. Highlights of 2024 activity include the following:
Closed an exclusive global license to develop, manufacture and commercialize MK-2010 (LM-299), a novel investigational programmed death receptor-1 (PD-1)/vascular endothelial growth factor (VEGF) bispecific antibody from LaNova Medicines Ltd (LaNova).
Closed an exclusive global license to develop, manufacture and commercialize MK-4082 (HS-10535), an investigational preclinical oral small molecule GLP-1 receptor agonist from Hansoh Pharma (Hansoh).
Acquired global rights to MK-1045 (formerly CN201), a novel investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases from Curon Pharmaceutical (Curon).
Acquired Eyebiotech Limited (EyeBio), a privately held ophthalmology-focused biotechnology company developing candidates for the prevention and treatment of vision loss.
Acquired Harpoon Therapeutics, Inc. (Harpoon), a clinical-stage immunotherapy company developing a novel class of T-cell engagers designed to harness the power of the body’s immune system to treat patients suffering from cancer and other diseases.
During 2024, Merck continued its efforts to address unmet medical needs by launching new products with significant patient benefit, including the U.S. launches of Winrevair, for the treatment of certain adults with pulmonary arterial hypertension (PAH), and Capvaxive, for the prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults. Winrevair was also approved in the EU.
The Company received more than 25 regulatory approvals in major markets in 2024, including the Winrevair and Capvaxive approvals noted above, along with numerous approvals in oncology. Keytruda received approval for additional indications in the U.S. and/or internationally as monotherapy in the therapeutic areas of hepatocellular carcinoma (HCC), melanoma and urothelial carcinoma, in combination with chemotherapy in the therapeutic areas of biliary tract cancer, cervical cancer, endometrial carcinoma, gastric or gastroesophageal junction (GEJ) adenocarcinoma, malignant pleural mesothelioma and non-small-cell lung cancer (NSCLC), as well as in combination with Padcev (enfortunab vedotin-ejfv) for advanced urothelial carcinoma. Also in 2024, Welireg was approved in China for the treatment of adult patients with certain von Hippel-Lindau (VHL) disease-associated tumors not requiring immediate surgery. Lynparza, which is being developed in collaboration with AstraZeneca PLC (AstraZeneca), received approval in China for the treatment of certain adult patients with germline BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer.
In addition to the regulatory approvals discussed above, the Company advanced its late-stage pipeline with several regulatory submissions.
MK-1022, patritumab deruxtecan, is a potential first-in-class HER3 directed DXd antibody drug conjugate (ADC), under review by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated NSCLC previously treated with two or more systemic therapies. In June 2024, the FDA issued a complete response letter (CRL) for the Biologics License Application (BLA) due to findings pertaining to an inspection of a third-party manufacturing facility. The CRL did not identify any issues with the efficacy or safety data submitted. Patritumab deruxtecan (HER3-DXd) was discovered by Daiichi Sankyo and is
47

being jointly developed by Daiichi Sankyo and Merck. Merck is working with Daiichi Sankyo to address FDA feedback.
MK-6482, Welireg, is under review in Japan both for the treatment of adults with VHL disease and for the treatment of certain adults with previously treated advanced renal cell carcinoma (RCC). Welireg is also under priority review in the U.S. for the treatment of certain patients with advanced, unresectable or metastatic pheochromocytoma and paraganglioma.
V116, Capvaxive, a 21-valent pneumococcal conjugate vaccine designed to help prevent invasive pneumococcal disease and pneumococcal pneumonia caused by certain serotypes in adults, is under review in the EU and Japan.
MK-7962, Winrevair, Merck’s novel activin signaling inhibitor, is under review in Japan for the treatment of adult patients with PAH.
MK-1654, clesrovimab, is an investigational prophylactic long-acting monoclonal antibody designed to protect infants from respiratory syncytial virus (RSV) disease during their first RSV season under review by the FDA. Clesrovimab is also under review in the EU.
Additionally, Keytruda is under review in the EU and Japan for a supplemental indication for the treatment of certain patients with malignant pleural mesothelioma.
During 2024, the Company initiated more than 20 Phase 3 studies spanning cardiometabolic, immunology, infectious diseases, oncology, ophthalmology and vaccines.
The Company is diversifying its oncology portfolio and executing on its strategy which is broadly based on three strategic pillars: immuno-oncology, precision molecular targeting and tissue targeting. Merck’s Phase 3 oncology programs within these pillars are as follows:
Immuno-oncology
MK-1308A, the coformulation of quavonlimab, Merck’s novel investigational anti-CTLA-4 antibody, in combination with pembrolizumab for RCC;
MK-3475, Keytruda, in the therapeutic areas of hepatocellular, ovarian and small-cell lung cancers;
MK-3475A, the subcutaneous coformulation of pembrolizumab in combination with hyaluronidase, being evaluated for comparability with intravenous pembrolizumab in metastatic NSCLC; and
V940 (mRNA-4157), an investigational individualized neoantigen therapy, in combination with Keytruda, as an adjuvant treatment in patients with certain types of melanoma and NSCLC, being developed as part of a collaboration with Moderna, Inc.
Precision molecular targeting
MK-1026, nemtabrutinib, an oral, reversible, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor, for hematological malignancies, including chronic lymphocytic leukemia and small lymphocytic lymphoma;
MK-1084, an investigational oral selective KRAS G12C inhibitor, in combination with Keytruda, for metastatic NSCLC;
MK-3543, bomedemstat, an investigational orally available lysine-specific demethylase 1 inhibitor for myeloproliferative disorders;
MK-5684, opevesostat, an investigational cytochrome P450 11A1 (CYP11A1) inhibitor for metastatic castration-resistant prostate cancer;
MK-7339, Lynparza, in combination with Keytruda, for non-small-cell lung and small-cell lung cancers; and
MK-7902, Lenvima, being developed as part of a collaboration with Eisai Co., Ltd. (Eisai), in combination with Keytruda, for esophageal cancer.
Tissue targeting
MK-1022, patritumab deruxtecan, being developed in collaboration wtih Daiichi Sankyo, for NSCLC as noted above;
MK-2140, zilovertamab vedotin, an ADC targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1) for hematological malignancies, including diffuse large B cell lymphoma;
MK-2400, ifinatamab deruxtecan, an ADC being evaluated in patients with relapsed SCLC versus chemotherapy, being developed as part of a collaboration with Daiichi Sankyo; and
48

MK-2870, sacituzumab tirumotecan, an investigational trophoblast cell-surface antigen 2 (TROP2)-directed ADC, being developed as part of a collaboration with Kelun-Biotech for breast, cervical, endometrial, gastric and non-small-cell lung cancers.
Additionally, the Company currently has candidates in Phase 3 clinical development in several other therapeutic areas:
MK-3000, an investigational, potentially first-in-class tetravalent, tri-specific antibody that acts as an agonist of the Wingless-related integration site signaling pathway, for the treatment of diabetic macular edema and neovascular age-related macular degeneration;
MK-8591A, a once-daily oral combination of doravirine and islatravir, an investigational nucleoside reverse transcriptase translocation inhibitor, for the treatment of HIV-1 infection (which is on partial clinical hold for higher doses of islatravir than those used in current clinical trials);
MK-8591D, islatravir in combination with lenacapavir for the treatment of HIV-1 infection (which is on partial clinical hold for higher doses of islatravir than those used in current clinical trials), being developed in collaboration with Gilead Sciences Inc.;
MK-0616, enlicitide decanoate, an investigational, oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor for hypercholesterolemia, including in studies evaluating low-density lipoprotein cholesterol reduction and a cardiovascular outcomes study;
MK-7240, tulisokibart, a humanized monoclonal antibody directed to tumor necrosis factor-like ligand 1A, a target associated with both intestinal inflammation and fibrosis, for Crohn’s disease and ulcerative colitis; and
MK-4482, Lagevrio, which is reflected in Phase 3 development in the U.S. as it remains investigational following Emergency Use Authorization (EUA) in 2021.
Merck’s capital allocation strategy continues to prioritize investments in its business to drive near- and long-term growth, including investing in the Company’s key growth drivers and expansive pipeline of novel candidates, each of which has potential to address important unmet medical needs. Research and development expenses in 2024 reflect increased development spending particularly in the therapeutic areas of oncology, immunology and cardiometabolic. In addition, Merck remains committed to its dividend and will continue to pursue the most compelling external science and technologies through value-enhancing business development transactions.
9486
In November 2024, Merck’s Board of Directors approved an increase to the Company’s quarterly dividend, raising it to $0.81 per share from $0.77 per share on the Company’s outstanding common stock. During 2024, the Company returned $9.1 billion to shareholders through dividends of $7.8 billion and share repurchases of $1.3 billion. In January 2025, Merck’s Board of Directors authorized a new share repurchase program of up to an additional $10 billion of Merck’s common stock for its treasury.
49


97899790
GAAP and non-GAAP EPS were negatively affected in 2024, 2023 and 2022 by $1.28, $6.21, and $0.22, respectively, of charges for certain upfront and pre-approval milestone payments related to collaborations and licensing agreements, as well as charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions.
Pricing
Global efforts toward health care cost containment continue to exert pressure on product pricing and market access worldwide. Changes to the U.S. health care system as part of health care reform, as well as increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, have contributed to pricing pressure. In 2021, the U.S. Congress passed the American Rescue Plan Act, which included a provision that eliminated the statutory cap on rebates drug manufacturers pay to Medicaid beginning in January 2024. As a result of this provision, the Company paid state Medicaid programs more in rebates than it received on Medicaid sales of Januvia, Janumet and Janumet XR in 2024. In 2022, the U.S. Congress passed the Inflation Reduction Act (IRA), which made significant changes to how drugs are covered and paid for under the Medicare program, including the creation of financial penalties for drugs whose prices rise faster than the rate of inflation, redesign of the Medicare Part D program to require manufacturers to bear more of the liability for certain drug benefits (which has taken effect in 2025), and government price setting for certain Medicare Part D drugs (starting in 2026) and Medicare Part B drugs (starting in 2028). Government price setting may also impact pricing in the private market negatively affecting the Company’s performance. In 2023, the U.S. Department of Health and Human Services (HHS), through the Centers for Medicare & Medicaid Services (CMS), selected Januvia for the first year of the IRA’s “Drug Price Negotiation Program” (Program). Pursuant to the IRA’s Program, a government price was set for Januvia, which will become effective on January 1, 2026. In January 2025, the U.S. Department of HHS, through the CMS, announced that Janumet and Janumet XR would be in included in the second year of the IRA’s Program, with government price setting to become effective on January 1, 2027. The Company has sued the U.S. government regarding the IRA’s Program (see Note 10 to the consolidated financial statements). Additionally, increased utilization of the 340B Federal Drug Discount Program and restrictions on the Company’s ability to identify inappropriate discounts are having a negative impact on Company performance. Furthermore, the Executive Branch and Congress continue to discuss legislation designed to control health care costs, including the cost of drugs. In several international markets, government-mandated pricing actions have reduced prices of generic and patented drugs. In addition, the Company’s sales performance in 2024 was negatively affected by other cost-reduction measures taken by governments and other third parties to lower health care costs. The Company anticipates all of these actions and additional actions in the future will continue to negatively affect sales and profits.
Operating Results
Sales
($ in millions)2024% Change% Change
Excluding Foreign
Exchange
2023% Change% Change
Excluding Foreign
Exchange
2022
United States$32,277 13 %13 %$28,480 %%$27,206 
International31,891 1 %6 %31,635 (1)%%32,077 
Total$64,168 7 %10 %$60,115 %%$59,283 
Worldwide sales were $64.2 billion in 2024, representing growth of 7% compared with 2023, or 10% excluding the unfavorable effect of foreign exchange. The devaluation of the Argentine peso contributed approximately 2 percentage points of the negative impact of foreign exchange, which was largely offset by inflation-related price increases consistent with practice in that market. Global sales growth was primarily due to higher sales in the oncology franchise, largely due to strong growth of Keytruda and Welireg, as well as increased alliance revenue from Reblozyl and Lynparza. Also contributing to revenue growth were higher sales in the cardiovascular
50

franchise, largely attributable to the launch of Winrevair, higher sales of certain hospital acute care products, particularly Prevymis, as well as higher sales of animal health products. Sales growth in 2024 was partially offset by lower sales in the diabetes franchise, due to Januvia and Janumet, and lower sales in the virology franchise largely attributable to Lagevrio. Lower sales in the immunology franchise due to the return of the marketing rights for Remicade and Simponi in former Merck territories to Johnson & Johnson on October 1, 2024, and lower sales in the vaccines franchise primarily due to Gardasil/Gardasil 9 also offset sales growth in 2024.
Sales in the U.S. grew 13% to $32.3 billion in 2024 primarily driven by higher sales of Keytruda, Winrevair, Gardasil 9, Welireg, Bridion, Lagevrio, and Prevymis, as well as higher alliance revenue from Reblozyl, partially offset by lower sales of Januvia and Vaxneuvance.
International sales grew 1% in 2024, or 6% excluding the unfavorable effect of foreign exchange. The devaluation of the Argentine peso contributed approximately 3 percentage points of the negative impact of foreign exchange, which was largely offset by inflation-related price increases consistent with practice in that market. International sales growth was primarily due to higher sales of Keytruda, Vaxneuvance, Prevymis, as well as higher sales of animal health products, partially offset by lower sales of Gardasil/Gardasil 9, Lagevrio, Bridion, Janumet, Januvia, and Simponi. International sales represented 50% and 53% of total sales in 2024 and 2023, respectively.
See Note 18 to the consolidated financial statements for details on sales of the Company’s products. A discussion of performance for select products in the franchises follows.
Pharmaceutical Segment
Oncology
($ in millions)2024% Change% Change
Excluding Foreign
Exchange
2023% Change% Change
Excluding Foreign
Exchange
2022
Keytruda$29,482 18 %22 %$25,011 19 %21 %$20,937 
Alliance Revenue - Lynparza (1)
1,311 9 %11 %1,199 %%1,116 
Alliance Revenue - Lenvima (1)
1,010 5 %6 %960 10 %11 %876 
Welireg509 **218 77 %77 %123 
Alliance Revenue - Reblozyl (2)
371 75 %75 %212 28 %28 %166 
* > 100%
(1)    Alliance revenue for Lynparza and Lenvima represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 4 to the consolidated financial statements).
(2)    Alliance revenue for Reblozyl represents royalties and, for 2022, also includes a payment received related to the achievement of a regulatory approval milestone (see Note 4 to the consolidated financial statements).
Keytruda is an anti-PD-1 therapy that has been approved in over 40 indications in the U.S., including 18 tumor types and 2 tumor-agnostic indications, and has similarly been approved in markets worldwide for many of these indications. The Keytruda clinical development program includes studies across a broad range of cancer types.
Global sales of Keytruda grew 18% in 2024, or 22% excluding the unfavorable effect of foreign exchange. The negative impact of foreign exchange was primarily due to the devaluation of the Argentine peso, which was largely offset by inflation-related price increases consistent with practice in that market. Keytruda sales growth in the U.S. reflects higher demand across the multiple approved metastatic indications, in particular for the treatment of certain types of bladder, endometrial, microsatellite instability-high (MSI-H) and renal cell cancers, as well as increased uptake across earlier-stage indications, including in certain types of high-risk early-stage triple-negative breast cancer (TNBC), NSCLC and RCC, and higher pricing. Keytruda sales growth in international markets reflects higher demand predominately for the TNBC, melanoma and RCC earlier-stage indications, as well as uptake in cervical, gastric and renal cell cancer metastatic indications. The Company expects that the 2025 launch and reimbursement of new indications for Keytruda in the EU will have a negative impact on pricing in those markets.
Summarized below are the Keytruda regulatory approvals received in 2024 and, to date, in 2025.
DateApproval
January 2024
FDA approval in combination with chemoradiotherapy for the treatment of patients with FIGO (International Federation of Gynecology and Obstetrics) 2014 Stage III-IVA cervical cancer, based on the KEYNOTE-A18 trial.
51

January 2024
FDA full approval for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/programmed death-ligand 1 (PD-L1) containing regimen. The conversion from an accelerated to full (regular) approval is based on the KEYNOTE-394 trial.
February 2024
China’s National Medical Products Administration (NMPA) approval in combination with gemcitabine and cisplatin for the first-line treatment of patients with locally advanced or metastatic biliary tract carcinoma, based on the KEYNOTE-966 trial.
March 2024
European Commission (EC) approval in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment, for resectable NSCLC at high risk of recurrence in adults, based on the KEYNOTE-671 trial.
May 2024
Japan’s Ministry of Health, Labor and Welfare (MHLW) approval in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma, based on the KEYNOTE-859 trial.
May 2024
Japan’s MHLW approval in combination with standard of care chemotherapy (gemcitabine and cisplatin) for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer, based on the KEYNOTE-966 trial.
June 2024
FDA approval in combination with carboplatin and paclitaxel, followed by Keytruda as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma, based on the KEYNOTE-868 trial.
June 2024
China’s NMPA approval in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic HER2 positive gastric or GEJ adenocarcinoma whose tumors express PD-L1 as determined by a fully validated test, based on the KEYNOTE-811 trial.
September2024
EC approval in combination with Padcev, an ADC, for the first-line treatment of unresectable or metastatic urothelial carcinoma in adults, based on the KEYNOTE-A39 trial that was conducted in collaboration with Seagen (now Pfizer Inc.) and Astellas.
September 2024
FDA approval in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma, based on the IND.227/KEYNOTE-483 trial.
September 2024
Japan’s MHLW approval in combination with chemotherapy as a neoadjuvant treatment, then continued as monotherapy as an adjuvant treatment, for patients with NSCLC, based on the KEYNOTE-671 trial.
September 2024
Japan’s MHLW approval in combination with Padcev for the first-line treatment of patients with radically unresectable urothelial carcinoma, based on the KEYNOTE-A39 trial.
September 2024
Japan’s MHLW approval as monotherapy in patients with radically unresectable urothelial carcinoma who are not eligible for any platinum-containing chemotherapy, based on the KEYNOTE-052 trial.
September 2024
China’s NMPA approval for the first-line treatment of adult patients with unresectable or metastatic melanoma, and conversion from conditional to full approval for the second-line treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy, based on the LEAP-003 trial.
October 2024
EC approval in combination with chemoradiotherapy for the treatment of FIGO 2014 Stage III-IVA locally advanced cervical cancer in adults who have not received prior definitive therapy, based on the KEYNOTE-A18 trial.
October 2024
EC approval in combination with carboplatin and paclitaxel followed by Keytruda as a single agent for the first-line treatment of primary advanced or recurrent endometrial carcinoma in adults who are candidates for systemic therapy, based on the KEYNOTE-868 trial.
November 2024
Japan’s MHLW approval in combination with chemoradiotherapy as treatment for patients with locally advanced cervical cancer, based on the KEYNOTE-A18 trial.
December 2024
China’s NMPA approval in combination with platinum-containing chemotherapy as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment after surgery for patients with resectable stage II, IIIA, or IIIB NSCLC, based on the KEYNOTE-671 trial.
December 2024
Japan’s MHLW approval in combination with carboplatin and paclitaxel as a treatment for adult patients with advanced or recurrent endometrial carcinoma, based on the KEYNOTE-868 trial.
52

December 2024
China’s NMPA approval in combination with chemoradiotherapy for the treatment of patients with FIGO 2014 Stage III-IVA cervical cancer, based on the KEYNOTE-A18 trial.
January 2025
China’s NMPA approval in combination with Padcev for adult patients with locally advanced or metastatic urothelial cancer, based on the KEYNOTE-A39 trial.
The Company is a party to license agreements pursuant to which the Company pays royalties on sales of Keytruda. Under the terms of the more significant of these agreements, Merck paid a royalty of 6.5% on worldwide sales of Keytruda through December 2023 to one third party; this royalty declined to 2.5% in 2024 and will continue through 2026 terminating thereafter. The Company pays an additional 2% royalty on worldwide sales of Keytruda to another third party, the termination date of which varies by country; this royalty expired in the U.S. in September 2024 and will expire on varying dates in major European markets in the second half of 2025. The royalty expenses are included in Cost of sales.
Lynparza is an oral poly (ADP-ribose) polymerase (PARP) inhibitor being developed and commercialized as part of a collaboration with AstraZeneca (see Note 4 to the consolidated financial statements). Lynparza is approved for the treatment of certain types of advanced or recurrent ovarian, early or metastatic breast, metastatic pancreatic and metastatic castration-resistant prostate cancers. Alliance revenue related to Lynparza grew 9% in 2024 largely due to higher demand in most international markets. In January 2025, China’s NMPA approved Lynparza as adjuvant treatment for adult patients with germline BRCA-mutated, HER2-negative high-risk early breast cancer, based on the OlympiA trial.
Lenvima is an oral receptor tyrosine kinase inhibitor being developed and commercialized as part of a collaboration with Eisai (see Note 4 to the consolidated financial statements). Lenvima is approved for the treatment of certain types of thyroid cancer, RCC, HCC, in combination with everolimus for certain patients with advanced RCC, and in combination with Keytruda for certain patients with advanced endometrial carcinoma or advanced RCC. Alliance revenue related to Lenvima grew 5% in 2024 primarily reflecting higher demand and pricing in the U.S.
Sales of Welireg, for the treatment of adult patients with certain VHL disease-associated tumors and certain adult patients with previously treated advanced RCC, more than doubled in 2024 primarily due to higher demand in the U.S. reflecting in part continued uptake of the RCC indication following approval by the FDA in December 2023. In November 2024, Welireg was approved in China for the treatment of adult patients with certain VHL disease-associated tumors not requiring immediate surgery based on the LITESPARK-004 clinical trial. In February 2025, the EC conditionally approved Welireg as monotherapy both for the treatment of adult patients with VHL disease who require therapy for associated, localized RCC, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors, and for whom localized procedures are unsuitable, and for the treatment of adult patients with advanced clear cell RCC that progressed following two or more lines of therapy that included a PD-1 or PD-L1 inhibitor and at least two VEGF targeted therapies. The EC approval of these two indications is based on results from the LITESPARK-004 and LITESPARK-005 trials. The conditional approval of Welireg will be valid for one year, subject to yearly renewal, pending certain additional clinical data. Timing for commercial availability of Welireg in individual EU countries will depend on multiple factors, including the completion of national reimbursement procedures.
Reblozyl is a first-in-class erythroid maturation recombinant fusion protein that is being commercialized through a global collaboration with Bristol Myers Squibb Company (BMS) (see Note 4 to the consolidated financial statements). Reblozyl is approved for the treatment of anemia in certain rare blood disorders. Alliance revenue related to this collaboration (consisting of royalties) increased 75% in 2024 due to strong underlying sales performance.
Vaccines
($ in millions)2024% Change% Change
Excluding Foreign
Exchange
2023% Change% Change
Excluding Foreign
Exchange
2022
Gardasil/Gardasil 9
$8,583 (3)%(2)%$8,886 29 %33 %$6,897 
ProQuad920 6 %6 %870 %%839 
M-M-R II
464 8 %9 %430 %%411 
Varivax1,102 3 %4 %1,068 %%991 
Vaxneuvance808 22 %23 %665 **170 
Pneumovax 23
263 (36)%(34)%412 (32)%(31)%602 
* > 100%
53

Combined worldwide sales of Gardasil and Gardasil 9, vaccines to help prevent certain cancers and other diseases caused by certain types of human papillomavirus (HPV), declined 3% in 2024 primarily driven by lower demand in China. Outside of China, Gardasil/Gardasil 9 achieved strong growth in most other international markets due to higher demand, particularly in Japan due to a national catch-up immunization program, and in the U.S. due to public sector buying patterns, higher pricing and demand. Beginning in mid-2024, the Company observed a significant decline in shipments from its distributor and commercialization partner in China, Chongqing Zhifei Biological Products Co., Ltd. (Zhifei), to disease and control prevention institutions and correspondingly into the points of vaccination, resulting in above normal inventory levels at Zhifei. Accordingly, the Company shipped less than its contracted doses to Zhifei in the latter part of 2024. Lower demand in China persisted and, at the end of 2024, overall channel inventory levels in China remained elevated at above normal levels. Therefore, the Company made a decision to temporarily pause shipments to China beginning in February 2025 through at least the middle of the year and, as a result, Gardasil/Gardasil 9 sales will decline significantly in 2025 compared with 2024. In January 2025, China’s NMPA approved Gardasil for use in males 9-26 years of age to help prevent certain HPV-related cancers and diseases.
The Company is a party to license agreements pursuant to which the Company pays royalties on sales of Gardasil/Gardasil 9. Under the terms of the more significant of these agreements, Merck pays a 7% royalty on sales of Gardasil/Gardasil 9 in the U.S. to one third party (this royalty expires in December 2028). Merck paid an additional 7% royalty on worldwide sales of Gardasil/Gardasil 9 to another third party; this royalty expired in December 2023. The royalty expenses are included in Cost of sales.
Global sales of ProQuad, a pediatric combination vaccine to help protect against measles, mumps, rubella and varicella, grew 6% in 2024 primarily due to higher pricing in the U.S. Worldwide sales of M-M-R II, a vaccine to help protect against measles, mumps and rubella, grew 8% in 2024 primarily due to higher demand in certain international markets, partially offset by lower demand in the U.S. Global sales of Varivax, a vaccine to help prevent chickenpox (varicella), grew 3% in 2024 primarily attributable to higher pricing in the U.S., partially offset by lower sales in Latin America due to supply constraints. The Company is experiencing manufacturing delays related to ProQuad and Varivax. As a result, the Company anticipates that some international markets will experience supply constraints during 2025. In order to ensure consistent supply in the U.S., in January 2025, the Company borrowed doses of ProQuad from the U.S. Centers for Disease Control and Prevention (CDC) Pediatric Vaccine Stockpile. The borrowing will reduce sales of ProQuad in the first quarter of 2025 by approximately $70 million. These doses will be used to support routine vaccination in the U.S.
Worldwide sales of Vaxneuvance, a vaccine to help protect against invasive pneumococcal disease caused by certain serotypes, rose 22% in 2024 primarily due to continued uptake following launches in the pediatric indication in Europe, Japan, and other countries in the Asia Pacific region, partially offset by lower demand in the U.S. due to competition. Merck is a party to license agreements pursuant to which the Company pays royalties on sales of Vaxneuvance. Under the most significant of these agreements, Merck pays a royalty of 7.25% on net sales of Vaxneuvance through 2026; this royalty will decline to 2.5% on net sales from 2027 through 2035. The royalty expenses are included in Cost of sales.
Worldwide sales of Pneumovax 23, a vaccine to help prevent pneumococcal disease, declined 36% in 2024 due to lower global demand, particularly in the U.S. as the market has shifted toward newer adult pneumococcal conjugate vaccines.
In June 2024, the FDA approved Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) for the prevention of invasive pneumococcal disease and pneumococcal pneumonia caused by certain serotypes in individuals 18 years of age and older. The approval was supported by results from multiple Phase 3 clinical studies evaluating Capvaxive in both vaccine-naïve and vaccine-experienced adult patient populations, including STRIDE-3, STRIDE-4, STRIDE-5 and STRIDE-6. Sales of Capvaxive were $97 million in 2024. Merck is a party to license agreements pursuant to which the Company pays royalties on sales of Capvaxive. Under the most significant of these agreements, Merck pays a royalty of 7.25% on net sales of Capvaxive through 2026; this royalty will decline to 2.5% on net sales from 2027 through 2035. The royalty expenses are included in Cost of sales.
Hospital Acute Care
($ in millions)2024% Change% Change
Excluding Foreign
Exchange
2023% Change% Change
Excluding Foreign
Exchange
2022
Bridion$1,764 (4)%(3)%$1,842 %11 %$1,685 
Prevymis785 30 %33 %605 41 %43 %428 
54

Global sales of Bridion, for the reversal of two types of neuromuscular blocking agents used during surgery, declined 4% in 2024 primarily driven by lower demand in certain international markets due to generic competition, particularly in the EU and the Asia Pacific region, including in Japan. The Bridion sales decline was partially offset by higher demand and pricing in the U.S. The patents that provided market exclusivity for Bridion in the EU and Japan expired in July 2023 and January 2024, respectively. Accordingly, the Company is experiencing sales declines of Bridion in these markets and expects the declines to continue.
Worldwide sales of Prevymis, a medicine for prophylaxis (prevention) of cytomegalovirus (CMV) infection and disease in certain high risk adult and pediatric recipients of an allogenic hematopoietic stem cell transplant and for prophylaxis of CMV disease in certain high risk adult and pediatric recipients of a kidney transplant, grew 30% in 2024 largely due to higher global demand, particularly in the U.S.
Cardiovascular
($ in millions)2024% Change% Change
Excluding Foreign
Exchange
2023% Change% Change
Excluding Foreign
Exchange
2022
Winrevair
$419  % %$— — %— %$— 
Alliance Revenue - Adempas/Verquvo (1)
415 13 %13 %367 %%341 
Adempas287 12 %14 %255 %%238 
(1) Alliance revenue for Adempas and Verquvo represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 4 to the consolidated financial statements).
In March 2024, the FDA approved Winrevair for the treatment of adults with pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group 1) to increase exercise capacity, improve WHO functional class (FC), and reduce the risk of clinical worsening events. In August 2024, the EC approved Winrevair, in combination with other PAH therapies, for the treatment of PAH in adult patients with WHO FC II to III, to improve exercise capacity. The FDA and EC approvals were based on the STELLAR trial. Winrevair has since launched in Germany. Timing for commercial availability of Winrevair in the remaining EU countries will depend on multiple factors, including the completion of national reimbursement procedures, which is expected to occur in most other major EU markets in the second half of 2025. Winrevair is the subject of a licensing agreement pursuant to which Merck pays a 22% royalty on sales of Winrevair to BMS. The royalty expenses are included in Cost of sales.
Adempas and Verquvo are part of a worldwide collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators (see Note 4 to the consolidated financial statements). Adempas is approved for the treatment of certain types of PAH and chronic pulmonary hypertension (PH). Verquvo is approved to reduce the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous diuretics in adults with symptomatic chronic heart failure and reduced ejection fraction. Alliance revenue from the collaboration grew 13% in 2024 reflecting higher demand in Bayer’s marketing territories. Revenue also includes sales of Adempas and Verquvo in Merck’s marketing territories. Sales of Adempas in Merck’s marketing territories grew 12% in 2024 primarily due to higher demand.
Virology
($ in millions)2024% Change% Change
Excluding Foreign
Exchange
2023% Change% Change
Excluding Foreign
Exchange
2022
Lagevrio964 (33)%(28)%1,428 (75)%(74)%5,684 
Lagevrio is an investigational oral antiviral COVID-19 medicine being developed in a collaboration with Ridgeback Biotherapeutics LP (Ridgeback) (see Note 4 to the consolidated financial statements). Sales of Lagevrio declined 33% in 2024 primarily due to lower demand and pricing in several markets in the Asia Pacific region, particularly in Japan, partially offset by uptake from commercial distribution in the U.S. under Emergency Use Authorization.

55

Immunology
($ in millions)2024% Change% Change
Excluding Foreign
Exchange
2023% Change% Change
Excluding Foreign
Exchange
2022
Simponi
$543 (24)%(23)%$710 %— %$706 
Remicade
114 (39)%(36)%187 (9)%(8)%207 
Simponi and Remicade are treatments for certain inflammatory diseases that the Company marketed in Europe, Russia and Türkiye. The Company’s marketing rights with respect to these products reverted to Johnson & Johnson on October 1, 2024 resulting in sales declines for these products versus prior year.
Diabetes
($ in millions)2024% Change% Change
Excluding Foreign
Exchange
2023% Change% Change
Excluding Foreign
Exchange
2022
Januvia/Janumet$2,268 (33)%(29)%$3,366 (25)%(23)%$4,513 
Worldwide combined sales of Januvia and Janumet, medicines that help lower blood sugar levels in adults with type 2 diabetes, declined 33% in 2024 primarily due to lower sales in the U.S., largely reflecting lower pricing and lower demand due to competitive pressures, as well as the ongoing impact of the loss of exclusivity in most markets in Europe, the Asia Pacific region, and in Canada.
The American Rescue Plan Act enacted in the U.S. in 2021 included a provision that eliminated the statutory cap on rebates drug manufacturers pay to Medicaid beginning in January 2024. As a result of this provision, the Company paid state Medicaid programs more in rebates than it received on Medicaid sales of Januvia, Janumet and Janumet XR in 2024.
In early 2025, Merck lowered the list price of the Januvia family of products to more closely align them with net prices. The lower list price will reduce the rebate amount Merck pays to Medicaid, resulting in higher realized net pricing, which will be partially offset by continuing volume declines. The Company expects higher U.S. net sales of these products in 2025 compared with 2024.
While the key U.S. patent for Januvia, Janumet and Janumet XR claiming the sitagliptin compound expired in January 2023, as a result of favorable court rulings and settlement agreements related to a later expiring patent directed to the specific sitagliptin salt form of the products (see Note 10 to the consolidated financial statements), the Company expects that Januvia and Janumet will not lose market exclusivity in the U.S. until May 2026 and Janumet XR will not lose market exclusivity in the U.S. until July 2026, although a non-automatically substitutable form of sitagliptin that differs from the form in the Company’s sitagliptin products has been approved by the FDA. Additionally, in 2023, the U.S. Department of HHS, through the CMS, announced that Januvia would be included in the first year of the IRA’s Program. Pursuant to the IRA’s Program, a government price was set for Januvia, which will become effective on January 1, 2026. Also, in January 2025, the U.S. Department of HHS, through the CMS, announced that Janumet and Janumet XR would be in included in the second year of the IRA’s Program, with government price setting to become effective on January 1, 2027. The Company has sued the U.S. government regarding the IRA’s Program (see Note 10 to the consolidated financial statements). As a result of the anticipated patent expiries in 2026, the government price setting in 2026 and 2027 noted above, as well as ongoing competitive pressures, the Company anticipates significant sales declines for Januvia, Janumet and Janumet XR in the U.S. in 2026 and thereafter.
The Company lost market exclusivity for Januvia in all of the EU and for Janumet in some European countries in September 2022. Exclusivity for Janumet was lost in other European countries in April 2023. Accordingly, the Company is experiencing sales declines in these markets and expects the declines to continue. Generic equivalents of Januvia and Janumet have also launched in China.

56

Animal Health Segment
($ in millions)2024% Change% Change
Excluding Foreign
Exchange
2023% Change% Change
Excluding Foreign
Exchange
2022
Livestock$3,462 4 %9 %$3,337 %%$3,300 
Companion Animal2,415 6 %7 %2,288 %%2,250 
$5,877 4 %8 %$5,625 %%$5,550 
Animal Health sales grew 4% in 2024, or 8% excluding the unfavorable effect of foreign exchange. The devaluation of the Argentine peso contributed approximately 2 percentage points of the negative impact of foreign exchange, which was largely offset by inflation-related price increases consistent with practice in that market.
Sales of livestock products grew 4% in 2024 primarily due to higher pricing, increased demand for poultry and swine products, as well as the inclusion of sales from the July 2024 acquisition of the aqua business of Elanco Animal Health Incorporated (Elanco aqua business). See Note 3 to the consolidated financial statements for additional information related to the acquisition of the Elanco aqua business.
Sales of companion animal products grew 6% in 2024 reflecting higher pricing. Sales of the Bravecto line of products were $1.1 billion in 2024, an increase of 6% compared with 2023, or 8% excluding the impact of foreign exchange.
Costs, Expenses and Other
($ in millions)2024% Change2023% Change2022
Cost of sales$15,193 (6)%$16,126 (7)%$17,411 
Selling, general and administrative10,816 3 %10,504 %10,042 
Research and development17,938 (41)%30,531 *13,548 
Restructuring costs309 (48)%599 78 %337 
Other (income) expense, net(24)*466 (69)%1,501 
 $44,232 (24)%$58,226 36 %$42,839 
* >100%
Cost of Sales
Cost of sales was $15.2 billion in 2024 and $16.1 billion in 2023. Cost of sales includes the amortization of intangible assets recorded in connection with acquisitions, collaborations, and licensing arrangements, which totaled $2.4 billion in 2024 and $2.0 billion in 2023. Amortization expense in 2024 and 2023 includes $48 million and $154 million, respectively, of cumulative catch-up amortization related to Merck’s collaborations with AstraZeneca and Eisai, respectively. (See Note 4 to the consolidated financial statements for more information on Merck’s collaborative arrangements). Also included in cost of sales are expenses associated with restructuring activities, which amounted to $495 million in 2024 and $211 million in 2023, primarily reflecting accelerated depreciation and asset impairment charges related to the planned sale or closure of manufacturing facilities. Separation costs associated with manufacturing-related headcount reductions have been incurred and are reflected in Restructuring costs as discussed below.
Gross margin was 76.3% in 2024 compared with 73.2% in 2023. The gross margin improvement was primarily due to the favorable effects of product mix (including lower royalty rates related to Keytruda and Gardasil/Gardasil 9 sales) and foreign exchange, partially offset by increased amortization of intangible assets, higher restructuring costs (primarily reflecting asset impairment charges), and increased manufacturing-related costs (including inventory write-offs).
Selling, General and Administrative
Selling, general and administrative (SG&A) expenses were $10.8 billion in 2024, an increase of 3% compared with 2023. The increase was primarily due to higher administrative costs (including compensation and benefits), and increased promotional costs (reflecting prioritization in support of key growth drivers including new product launches), as well as higher selling and acquisition-related costs, partially offset by the favorable effect of foreign exchange and lower restructuring costs.

57

Research and Development
Research and development (R&D) expenses were $17.9 billion in 2024, a decline of 41% compared with 2023. The decline was primarily due to lower charges for business development activity and the favorable effect of foreign exchange.
Significant business development transactions in 2024 include charges of:
$1.35 billion for the acquisition of EyeBio and $100 million for a related developmental milestone
$750 million for the acquisition of MK-1045 (formerly CN201) from Curon
$656 million for the acquisition of Harpoon
$588 million for a global license agreement with LaNova
$112 million for a global license agreement with Hansoh
Significant business development transactions in 2023 include charges of:
$10.2 billion for the acquisition of Prometheus
$5.5 billion related to the formation of a collaboration with Daiichi Sankyo
$1.2 billion for the acquisition of Imago
$175 million for a license and collaboration agreement with Kelun-Biotech
The decline in R&D expenses was partially offset by higher compensation and benefit costs (reflecting in part increased headcount) and increased clinical development spending, including for recently acquired programs.
R&D expenses are comprised of the costs directly incurred by Merck Research Laboratories (MRL), the Company’s research and development division that focuses on human health-related activities, which were $10.1 billion in 2024 and $9.0 billion in 2023. Also included in R&D expenses are Animal Health research costs, upfront payments for collaboration and licensing agreements (including charges for the transactions with LaNova, Hansoh, Daiichi Sankyo and Kelun-Biotech noted above), charges for transactions accounted for as asset acquisitions (including charges for the acquisitions of EyeBio, MK-1045, Harpoon, Prometheus and Imago noted above) and costs incurred by other divisions in support of R&D activities, including depreciation, production and general and administrative, which in the aggregate were $7.7 billion in 2024 and $20.7 billion in 2023. R&D expenses also include an impairment charge of $779 million in 2023 (related to gefapixant). See Note 8 to the consolidated financial statements for additional information related to this impairment charge. The Company may recognize additional impairment charges in the future related to the cancellation or delay of other pipeline programs that were measured at fair value and capitalized in connection with business combinations and such charges could be material.
Restructuring Costs
In January 2024, the Company approved a new restructuring program (2024 Restructuring Program) intended to continue the optimization of the Company’s Human Health global manufacturing network as the future pipeline shifts to new modalities and also optimize the Animal Health global manufacturing network to improve supply reliability and increase efficiency. The actions contemplated under the 2024 Restructuring Program are expected to be substantially completed by the end of 2031, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $4.0 billion. Approximately 60% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested. The remainder of the costs will result in cash outlays, relating primarily to facility shut-down costs. The Company expects to record charges of approximately $550 million in 2025 related to the 2024 Restructuring Program. The Company anticipates the actions under the 2024 Restructuring Program will result in cumulative annual net cost savings of approximately $750 million by the end of 2031.
In 2019, Merck approved a global restructuring program (2019 Restructuring Program) as part of a worldwide initiative focused on optimizing the Company’s manufacturing and supply network, as well as reducing its global real estate footprint. The actions under the 2019 Restructuring Program were substantially complete at the end of 2023 and, as of January 1, 2024, any remaining activities are being accounted for as part of the 2024 Restructuring Program.
Restructuring costs of $309 million in 2024 and $599 million in 2023 include separation and other costs associated with these restructuring activities. Separation costs incurred were associated with actual headcount reductions, as well as estimated expenses under existing severance programs for involuntary headcount reductions that were probable and could be reasonably estimated. Other expenses in Restructuring costs include facility shut-down and other related costs, as well as employee-related costs such as curtailment, settlement and termination
58

charges associated with pension and other postretirement benefit plans and share-based compensation plan costs. For segment reporting, restructuring costs are unallocated expenses.
Additional costs associated with the Company’s restructuring activities are included in Cost of sales, Selling, general and administrative expenses and Research and development costs. The Company recorded aggregate pretax costs related to restructuring program activities of $888 million in 2024 and $933 million in 2023 (of which $190 million related to the 2024 Restructuring Program). See Note 5 to the consolidated financial statements for additional details.
Other (Income) Expense, Net
Other (income) expense, net, was $24 million of income in 2024 compared with $466 million of expense in 2023 primarily reflecting a $572.5 million charge in 2023 related to settlements with certain plaintiffs in the Zetia antitrust litigation. The favorability was also due to $170 million of income in 2024 related to the expansion of an existing development and commercialization agreement with Daiichi Sankyo, as well as lower foreign exchange losses in 2024. Other (income) expense, net, was unfavorably affected in 2024 by lower income from investments in equity securities and higher net interest expense compared with 2023.
For details on the components of Other (income) expense, net, see Note 14 to the consolidated financial statements.
Segment Profits
($ in millions)202420232022
Pharmaceutical segment profits$44,533 $38,880 $36,852 
Animal Health segment profits1,938 1,737 1,963 
Non-segment activity
(26,535)(38,728)(22,371)
Income Before Taxes
$19,936 $1,889 $16,444 
Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as SG&A expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as SG&A and R&D expenses directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, R&D expenses incurred by MRL, or general and administrative expenses not directly incurred by the segments, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. Also excluded from the determination of segment profits are costs related to restructuring activities and acquisition- and divestiture-related costs, including the amortization of intangible assets and amortization of purchase accounting adjustments, intangible asset impairment charges, and expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration. Additionally, segment profits do not reflect other expenses from corporate and manufacturing cost centers and other miscellaneous income or expense. These unallocated items are reflected in “Non-segment activity” in the above table. Also included in “Non-segment activity” are miscellaneous corporate profits (losses), as well as operating profits (losses) related to third-party manufacturing arrangements.
Pharmaceutical segment profits grew 15% in 2024 primarily due to higher sales, partially offset by higher administrative and promotional costs, as well as the unfavorable effect of foreign exchange. Animal Health segment profits increased 12% in 2024 primarily due to higher sales and lower manufacturing-related costs, partially offset by increased administrative costs, as well as the unfavorable effect of foreign exchange.
Taxes on Income
The effective income tax rate of 14.1% in 2024 reflects a favorable mix of income and expense, as well as a 2.6 percentage point favorable impact due to a $519 million reduction in reserves for unrecognized income tax benefits resulting from the expiration in 2024 of the statute of limitations for assessments related to the 2019 and 2020 federal tax return years. The effective income tax rate in 2024 also reflects a 1.5 percentage point combined unfavorable impact of charges for the acquisition of Harpoon, for which no tax benefit was recognized, and the acquisitions of EyeBio and MK-1045 for which minimal tax benefits were realized.
While many jurisdictions in which Merck operates have adopted the global minimum tax provision of the Organization for Economic Cooperation and Development (OECD) Pillar 2, effective for tax years beginning in January 2024, it resulted in a minimal impact to the Company’s 2024 effective income tax rate due to the accounting
59

for the tax effects of intercompany transactions. The Company expects the impact of the global minimum tax will increase its effective income tax rate by approximately 2% in 2025. In addition, beginning in 2026, the tax rates on foreign earnings and export income are scheduled to increase under existing provisions of the Tax Cuts and Jobs Act of 2017 (TCJA) and may result in an increase to the Company’s effective income tax rate. Also, in the event that the provision of the TCJA requiring capitalization and amortization of R&D expenses for tax purposes is repealed along the lines proposed in the Tax Relief for American Families and Workers Act of 2024, the Company will again be able to realize the benefit of U.S. R&D expenses as incurred, but expects no material impact to its effective income tax rate.
The effective income tax rate of 80.0% in 2023 includes a 65.6 percentage point combined unfavorable impact of charges for the acquisitions of Prometheus and Imago (for which no tax benefits were recognized) and the Daiichi Sankyo collaboration. These charges reduced domestic pretax income by approximately $16.9 billion in 2023. In addition, the effective income tax rate in 2023 reflects higher foreign taxes and the impact of the R&D capitalization provision of the TCJA on the Company’s U.S. global intangible low-taxed income inclusion, partially offset by a favorable mix of income and expense, as well as higher foreign tax credits.
The Internal Revenue Service (IRS) is currently conducting examinations of the Company’s tax returns for the years 2017 and 2018, including the one-time transition tax enacted under the TCJA. If the IRS disagrees with the Company’s transition tax position, it may result in a significant tax liability. The IRS is also currently conducting examinations of the Company’s tax returns for the years 2021 and 2022. In addition, various state and foreign tax examinations are in progress.
Non-GAAP Income and Non-GAAP EPS
Non-GAAP income and non-GAAP EPS are alternative views of the Company’s performance that Merck is providing because management believes this information enhances investors’ understanding of the Company’s results since management uses non-GAAP measures to assess performance. Non-GAAP income and non-GAAP EPS exclude certain items because of the nature of these items and the impact that they have on the analysis of underlying business performance and trends. The excluded items (which should not be considered non-recurring) consist of acquisition- and divestiture-related costs, restructuring costs, income and losses from investments in equity securities, and certain other items. These excluded items are significant components in understanding and assessing financial performance.
Non-GAAP income and non-GAAP EPS are important internal measures for the Company. Senior management receives a monthly analysis of operating results that includes a non-GAAP EPS metric. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the Company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. Since non-GAAP income and non-GAAP EPS are not measures determined in accordance with GAAP, they have no standardized meaning prescribed by GAAP and, therefore, may not be comparable to the calculation of similar measures of other companies. The information on non-GAAP income and non-GAAP EPS should be considered in addition to, but not as a substitute for or superior to, net income and EPS prepared in accordance with GAAP.

60

A reconciliation between GAAP financial measures and non-GAAP financial measures is as follows:
($ in millions except per share amounts)202420232022
Income before taxes as reported under GAAP
$19,936 $1,889 $16,444 
Increase (decrease) for excluded items:
Acquisition- and divestiture-related costs (1)
2,519 2,876 3,704 
Restructuring costs888 933 666 
Loss (income) from investments in equity securities, net45 (279)1,348 
Other items:
Charge for Zetia antitrust litigation settlements 573 — 
Non-GAAP income before taxes
23,388 5,992 22,162 
Taxes on income as reported under GAAP
2,803 1,512 1,918 
Estimated tax benefit on excluded items (2)
606 631 1,232 
Tax benefit resulting from the expiration of the statute of limitations for assessments related to the 2019 and 2020 federal tax return years519 — — 
Non-GAAP taxes on income
3,928 2,143 3,150 
Non-GAAP net income
19,460 3,849 19,012 
Less: Net income attributable to noncontrolling interests as reported under GAAP16 12 
Non-GAAP net income attributable to Merck & Co., Inc.
$19,444 $3,837 $19,005 
EPS assuming dilution as reported under GAAP (3)
$6.74 $0.14 $5.71 
EPS difference0.91 1.37 1.77 
Non-GAAP EPS assuming dilution (3)
$7.65 $1.51 $7.48 
(1)Amounts in 2024, 2023 and 2022 include $39 million, $792 million and $1.7 billion, respectively, of intangible asset impairment charges.
(2) The estimated tax impact on the excluded items is determined by applying the statutory rate of the originating territory of the non-GAAP adjustments.
(3)    GAAP and non-GAAP EPS were negatively affected in 2024, 2023 and 2022 by $1.28, $6.21, and $0.22, respectively, of charges for certain upfront and pre-approval milestone payments related to collaborations and licensing agreements, as well as charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions.
Acquisition- and Divestiture-Related Costs
Non-GAAP income and non-GAAP EPS exclude the impact of certain amounts recorded in connection with acquisitions and divestitures of businesses. These amounts include the amortization of intangible assets and amortization of purchase accounting adjustments to inventories, as well as intangible asset impairment charges, and expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration. Also excluded are integration, transaction, and certain other costs associated with acquisitions and divestitures. Non-GAAP income and non-GAAP EPS also exclude amortization of intangible assets related to collaborations and licensing arrangements.
Restructuring Costs
Non-GAAP income and non-GAAP EPS exclude costs related to restructuring actions (see Note 5 to the consolidated financial statements). These amounts include employee separation costs and accelerated depreciation associated with facilities to be closed or divested. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. Restructuring costs also include other exits costs, such as asset impairment, facility shut-down and other related costs, as well as employee-related costs such as curtailment, settlement and termination charges associated with pension and other postretirement benefit plans and share-based compensation costs.
Income and Losses from Investments in Equity Securities
Non-GAAP income and non-GAAP EPS exclude realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds.
Certain Other Items
Non-GAAP income and non-GAAP EPS exclude certain other items. These items are adjusted for after evaluating them on an individual basis, considering their quantitative and qualitative aspects. Typically, these items
61

are unusual in nature, significant to the results of a particular period or not indicative of future operating results. Excluded from non-GAAP income and non-GAAP EPS in 2024 is a benefit due to reductions in reserves for unrecognized income tax benefits resulting from the expiration of the statute of limitations for assessments related to the 2019 and 2020 federal tax return years (see Note 15 to the consolidated financial statements). Excluded from non-GAAP income and non-GAAP EPS in 2023 is a charge related to settlements with certain plaintiffs in the Zetia antitrust litigation (see Note 10 to the consolidated financial statements).
Research and Development
Research Pipeline
The Company currently has several candidates under regulatory review in the U.S. and internationally, as well as in late-stage clinical development. A chart reflecting the Company’s current research pipeline as of February 21, 2025 and related discussion is set forth in Item 1. “Business — Research and Development” above.
Acquisitions, Research Collaborations and Licensing Agreements
Merck continues to remain focused on pursuing opportunities that have the potential to drive both near- and long-term growth. Certain recent transactions are summarized below; additional details are included in Note 3 to the consolidated financial statements. Merck actively monitors the landscape for growth opportunities that meet the Company’s strategic criteria.
In December 2024, Merck closed an exclusive global license to develop, manufacture and commercialize MK-2010 (LM-299), a novel investigational PD-1/VEGF bispecific antibody from LaNova. Merck recorded a charge of $588 million to Research and development expenses in 2024, or $0.18 per share, for the upfront payment, which was made in January 2025. LaNova is also eligible to receive milestone payments associated with the technology transfer, development, regulatory approval and commercialization of MK-2010 (LM-299) across multiple indications.
Also in December 2024, Merck closed an exclusive global license to develop, manufacture and commercialize MK-4082 (HS-10535), an investigational preclinical oral small molecule GLP-1 receptor agonist from Hansoh. Merck recorded a charge of $112 million to Research and development expenses in 2024, or $0.04 per share, for the upfront payment, which was made in February 2025. Hansoh is also eligible to receive future contingent milestone payments associated with the development, regulatory approval and commercialization of MK-4082 (HS-10535) as well as tiered royalties on future net sales of MK-4082 (HS-10535), if approved. Under the agreement, Hansoh may co-promote or solely commercialize MK-4082 (HS-10535) in Chinese mainland, Hong Kong and Macau, subject to certain conditions.
In September 2024, Merck acquired MK-1045 (formally CN201), a novel investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases, from Curon Biopharmaceutical (Curon) for an upfront payment of $700 million. In addition, Curon is eligible to receive future contingent developmental and regulatory milestone payments. The transaction was accounted for as an asset acquisition. Merck recorded a charge of $750 million (reflecting the upfront payment and other related costs) to Research and development expenses, or $0.29 per share, in 2024 related to the execution of the transaction. In connection with the agreement, Merck is also obligated to pay a third party future contingent developmental, regulatory and sales-based milestone payments, as well as tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales of MK-1045, if approved.
In July 2024, Merck acquired EyeBio, a privately held ophthalmology-focused biotechnology company, for $1.2 billion (including payments to settle share-based equity awards) and also incurred $207 million of transaction costs. The acquisition agreement also provides for former EyeBio shareholders to receive future contingent developmental, regulatory and sales-based milestone payments. EyeBio’s lead candidate, MK-3000 (formerly EYE103), is an investigational, potentially first-in-class tetravalent, tri-specific antibody that acts as an agonist of the Wingless-related integration site signaling pathway, which is in clinical development for the treatment of diabetic macular edema and neovascular age-related macular degeneration. The transaction was accounted for as an asset acquisition. Merck recorded net assets of $21 million, as well as a charge of $1.35 billion to Research and development expenses, or $0.52 per share, in 2024 related to the acquisition. Additionally, a $100 million developmental milestone was triggered and paid in 2024 upon initiation of a Phase 2/3 clinical trial evaluating MK-3000 for the treatment of diabetic macular edema, which was also recorded as a charge to Research and development expenses ($0.04 per share).
In March 2024, Merck acquired Harpoon, a clinical-stage immunotherapy company developing a novel class of T-cell engagers designed to harness the power of the body’s immune system to treat patients suffering from cancer and other diseases for $765 million and also incurred $56 million of transaction costs. Harpoon’s lead candidate, MK-6070 (formerly HPN328), is a T-cell engager targeting delta-like ligand 3 (DLL3), an inhibitory
62

canonical Notch ligand that is expressed at high levels in small-cell lung cancer and neuroendocrine tumors. The transaction was accounted for as an asset acquisition. The Company recorded net assets of $165 million, as well as a charge of $656 million to Research and development expenses, or $0.26 per share, in 2024 related to the transaction. There are no future contingent payments associated with the acquisition. In August 2024, Merck and Daiichi Sankyo expanded their existing global co-development and co-commercialization agreement to include MK-6070. Merck recognized income (recorded within Other (income) expense, net) of $170 million, or $0.05 per share, due to the receipt of an upfront cash payment from Daiichi Sankyo and has also satisfied a contingent quid obligation from the original collaboration agreement.
Acquired In-Process Research and Development
In connection with business combinations, the Company records the fair value of in-process research projects which, at the time of acquisition, had not yet reached technological feasibility. At December 31, 2024, the balance of in-process research and development (IPR&D) was $430 million, primarily consisting of MK-1026 (nemtabrutinib), $418 million, which is in Phase 3 clinical development.
The IPR&D projects that remain in development are subject to the inherent risks and uncertainties in drug development and it is possible that the Company will not be able to successfully develop and complete the IPR&D programs and profitably commercialize the underlying product candidates. The time periods to receive approvals from the FDA and other regulatory agencies are subject to uncertainty. Significant delays in the approval process, or the Company’s failure to obtain approval at all, would delay or prevent the Company from realizing revenues from these products. Additionally, if the IPR&D programs require additional clinical trial data than previously anticipated, or if the programs fail or are abandoned during development, then the Company will not recover the fair value of the IPR&D recorded as an asset as of the acquisition date. If such circumstances were to occur, the Company’s future operating results could be adversely affected and the Company may recognize impairment charges, which could be material.
In 2023 and 2022, the Company recorded IPR&D impairment charges within Research and development expenses of $779 million and $1.6 billion, respectively (see Note 8 to the consolidated financial statements).
Additional research and development will be required before any of the remaining programs reach technological feasibility. The costs to complete the research projects will depend on whether the projects are brought to their final stages of development and are ultimately submitted to the FDA or other regulatory agencies for approval.
Capital Expenditures
Capital expenditures were $3.4 billion in 2024, $3.9 billion in 2023 and $4.4 billion in 2022. Expenditures in the U.S. were $2.4 billion in 2024, $2.5 billion in 2023 and $2.7 billion in 2022. The Company plans to invest approximately $20 billion in capital projects from 2024-2028, more than $11 billion of which relates to investments in the U.S., including expanding manufacturing capacity for oncology, vaccine and animal health products.
Depreciation expense was $2.1 billion in 2024, $1.8 billion in 2023 and $1.8 billion in 2022, of which $1.4 billion in 2024, $1.2 billion in 2023 and $1.3 billion in 2022, related to locations in the U.S. Total depreciation expense in 2024, 2023 and 2022 included accelerated depreciation of $254 million, $140 million and $120 million, respectively, associated with restructuring activities (see Note 5 to the consolidated financial statements).
Analysis of Liquidity and Capital Resources
Merck’s strong financial profile enables it to fund research and development, finance acquisitions and external alliances, support in-line products and maximize upcoming launches while providing significant cash returns to shareholders.
Selected Data
($ in millions)202420232022
Working capital$10,362 $6,474 $11,483 
Total debt to total liabilities and equity31.7 %32.9 %28.1 %
Cash provided by operating activities to total debt
0.6:1
0.4:10.6:1
Cash provided by operating activities was $21.5 billion in 2024 compared with $13.0 billion in 2023 reflecting stronger operating performance. Cash provided by operating activities was reduced by upfront, milestone, option and continuation payments related to certain collaborations of $1.1 billion in 2024 compared with $4.2 billion in 2023 (including payments related to the formation of a collaboration with Daiichi Sankyo). Cash provided by operating activities in 2023 was also reduced by a payment of $572.5 million for the previously disclosed Zetia antitrust settlement. Cash provided by operating activities continues to be the Company’s primary source of funds to finance
63

operating needs, with excess cash serving as the primary source of funds to finance business development transactions, capital expenditures, dividends paid to shareholders and treasury stock purchases.
Cash used in investing activities was $7.7 billion in 2024 compared with $14.1 billion in 2023. The lower use of cash in investing activities was primarily due to lower cash used for acquisitions, lower capital expenditures, as well as lower purchases of securities and other investments, partially offset by lower proceeds from sales of securities and other investments.
Cash used in financing activities was $7.0 billion in 2024 compared with $4.8 billion in 2023. The higher use of cash in financing activities was primarily due to lower proceeds from the issuance debt (see below) and higher dividends paid to shareholders, partially offset by lower payments on long-term debt (see below), higher proceeds from the exercise of stock options and lower purchases of treasury stock.
In May 2024, MSD Netherlands Capital B.V., a wholly owned finance subsidiary of Merck, completed a registered public offering of €3.4 billion in aggregate principal amount of euro-dominated senior notes. The net cash proceeds from the offering were used for general corporate purposes. In May 2023, the Company issued $6.0 billion in aggregate principal amount of senior unsecured notes. The Company used a portion of the $5.9 billion net proceeds from this offering to fund a portion of the cash consideration paid for the acquisition of Prometheus, including related fees and expenses, and used the remaining net proceeds for general corporate purposes including to repay commercial paper borrowings and other indebtedness with upcoming maturities.
In 2024, the Company’s $750 million, 2.90% notes and the Company’s €500 million, 0.50% euro-denominated notes matured in accordance with their terms and were repaid. In 2023, the Company’s $1.75 billion, 2.80% notes matured in accordance with their terms and were repaid. In 2022, the Company’s $1.25 billion, 2.35% notes and the Company’s $1.0 billion, 2.40% notes matured in accordance with their terms and were repaid.
The Company has a $6.0 billion credit facility that matures in May 2028. The facility provides backup liquidity for the Company’s commercial paper borrowing facility and is to be used for general corporate purposes. The Company has not drawn funding from this facility.
In March 2024, the Company filed a securities registration statement with the U.S. Securities and Exchange Commission (SEC) under the automatic shelf registration process available to “well-known seasoned issuers” which is effective for three years.
Effective as of November 3, 2009, the Company executed a full and unconditional guarantee of the then existing debt of its subsidiary Merck Sharp & Dohme Corp. (MSD) and MSD executed a full and unconditional guarantee of the then existing debt of the Company (excluding commercial paper), including for payments of principal and interest. These guarantees do not extend to debt issued subsequent to that date.
In November 2024, Merck’s Board of Directors increased the quarterly dividend, declaring a quarterly dividend of $0.81 per share on the Company’s outstanding common stock for the first quarter of 2025 that was paid in January 2025. In January 2025, the Board of Directors declared a quarterly dividend of $0.81 per share on the Company’s outstanding common stock for the second quarter of 2025 payable in April 2025.
In 2018, Merck’s Board of Directors authorized purchases of up to $10 billion of Merck’s common stock for its treasury. The treasury stock purchase authorization has no time limit and will be made over time in open-market transactions, block transactions on or off an exchange, or in privately negotiated transactions. In 2024, the Company purchased $1.3 billion (approximately 11 million shares) of its common stock for its treasury under this program. As of December 31, 2024, the Company’s remaining share repurchase authorization was $2.4 billion. The Company purchased $1.3 billion of its common stock during 2023 under the authorized share repurchase program. The Company did not purchase any shares of its common stock under this program in 2022. In January 2025, Merck’s Board of Directors authorized purchases of up to an additional $10 billion of Merck’s common stock for its treasury.
The Company believes it maintains a conservative financial profile. The Company places its cash and investments in instruments that meet high credit quality standards, as specified in its investment policy guidelines. These guidelines also limit the amount of credit exposure to any one issuer. The Company does not participate in any off-balance sheet arrangements involving unconsolidated subsidiaries that provide financing or potentially expose the Company to unrecorded financial obligations.
The Company expects foreseeable liquidity and capital resource requirements to be met through existing cash and cash equivalents and anticipated cash flows from operations, as well as commercial paper borrowings and long-term borrowings if needed. Merck believes that its sources of financing will be adequate to meet its future requirements. The Company’s material cash requirements arising in the normal course of business primarily include:
64

Debt Obligations and Interest Payments — See Note 9 to the consolidated financial statements for further detail of the Company’s debt obligations and the timing of expected future principal and interest payments.
Tax Liabilities — In connection with the enactment of the TCJA, the Company is required to pay a one-time transition tax, which the Company has elected to pay over a period of eight years through 2025 as permitted under the TCJA. Additionally, the Company has liabilities for unrecognized tax benefits, including interest and penalties. See Note 15 to the consolidated financial statements for further information pertaining to the transition tax and liabilities for unrecognized tax benefits.
Operating Leases — See Note 9 to consolidated financial statements for further details of the Company’s lease obligations and the timing of expected future lease payments.
Collaboration-Related Payments — At December 31, 2024, the Company has accrued liabilities for contingent sales-based milestone payments related to a collaboration with AstraZeneca where the related sales-based milestones were achieved, but payment was not yet due according to the payment terms. These sales-based milestones were subsequently paid in January 2025. Additionally, the Company has an accrued liability for a future continuation payment related to a collaboration with Daiichi Sankyo. See Note 4 to the consolidated financial statements for additional information related to these payments.
Purchase Obligations — Purchase obligations are enforceable and legally binding obligations for purchases of goods and services including minimum inventory contracts, research and development and advertising. Purchase obligations also include future inventory purchases the Company has committed to in connection with certain divestitures. As of December 31, 2024, the Company had total purchase obligations of $7.2 billion, of which $2.8 billion is estimated to be payable in 2025.
Financial Instruments Market Risk Disclosures
The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.
A significant portion of the Company’s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives of and accounting related to the Company’s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.
Foreign Currency Risk Management
The Company has established revenue hedging, balance sheet risk management, and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.
The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S. dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than two years into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and foreign exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts, and purchased collar options.
The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or Other Comprehensive Income (Loss) (OCI), depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in Accumulated Other Comprehensive Loss (AOCL) and reclassified into Sales when the hedged anticipated revenue is recognized. The amount reclassified into earnings as a result of the discontinuation of cash flow hedges because it was no longer deemed probable the forecasted hedged transactions would occur was not material for the years ended December 31, 2024, 2023 or 2022. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in Sales each period. The cash flows from both designated and non-designated contracts are reported as operating activities in the Consolidated Statement of Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.
65

Because Merck principally sells foreign currency in its revenue hedging program, a uniform weakening of the U.S. dollar would yield the largest overall potential loss in the market value of these hedge instruments. The market value of Merck’s hedges would have declined by an estimated $569 million and $754 million at December 31, 2024 and 2023, respectively, from a uniform 10% weakening of the U.S. dollar. The market value was determined using a foreign exchange option pricing model and holding all factors except exchange rates constant. Although not predictive in nature, the Company believes that a 10% threshold reflects reasonably possible near-term changes in Merck’s major foreign currency exposures relative to the U.S. dollar.
The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of foreign exchange on monetary assets and liabilities. Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in Other (income) expense, net. The Company also uses a balance sheet risk management program to mitigate the exposure of such assets and liabilities from the effects of volatility in foreign exchange. Merck principally utilizes forward exchange contracts to offset the effects of foreign exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the foreign exchange rate and the cost of the hedging instrument (primarily the euro, Swiss franc, Japanese yen, and Chinese renminbi). The forward contracts are not designated as hedges and are marked to market through Other (income) expense, net. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than six months. The cash flows from these contracts are reported as operating activities in the Consolidated Statement of Cash Flows.
A sensitivity analysis to changes in the value of the U.S. dollar on foreign currency denominated derivatives, investments and monetary assets and liabilities indicated that if the U.S. dollar uniformly weakened by 10% against all currency exposures of the Company at December 31, 2024 and 2023, Income Before Taxes would have declined by approximately $239 million and $221 million in 2024 and 2023, respectively. Because the Company was in a net short (payable) position relative to its major foreign currencies after consideration of forward contracts, a uniform weakening of the U.S. dollar will yield the largest overall potential net loss in earnings due to exchange. This measurement assumes that a change in one foreign currency relative to the U.S. dollar would not affect other foreign currencies relative to the U.S. dollar. Although not predictive in nature, the Company believes that a 10% threshold reflects reasonably possible near-term changes in Merck’s major foreign currency exposures relative to the U.S. dollar. The cash flows from these contracts are reported as operating activities in the Consolidated Statement of Cash Flows.
The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in foreign exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within OCI and remain in AOCL until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded components). Changes in fair value of the excluded components are recognized in OCI. The Company recognizes in earnings the initial value of the excluded components on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Consolidated Statement of Cash Flows.
Foreign exchange risk is also managed through the use of foreign currency debt. Certain of the Company’s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within OCI.
Interest Rate Risk Management
The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal at risk.
At December 31, 2024, the Company was a party to six pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of the fixed-rate notes as detailed in the table below.
66

($ in millions)
2024
Debt Instrument
Par Value of DebtNumber of Interest Rate Swaps HeldTotal Swap Notional Amount
4.50% notes due 2033
$1,500 $1,500 
The interest rate swap contracts are designated hedges of the fair value changes in the notes attributable to changes in the benchmark Secured Overnight Financing Rate (SOFR) swap rate. The fair value changes in the notes attributable to changes in the SOFR swap rate are recorded in interest expense along with the offsetting fair value changes in the swap contracts. In January 2025, the Company entered into an additional interest rate swap with a notional amount of $250 million related to its 5.00% notes due 2053. The cash flows from these contracts are reported as operating activities in the Consolidated Statement of Cash Flows.
The Company’s investment portfolio includes cash equivalents and short-term investments, the market values of which are not significantly affected by changes in interest rates. The market value of the Company’s medium- to long-term fixed-rate investments is modestly affected by changes in U.S. interest rates. Changes in medium- to long-term U.S. interest rates have a more significant impact on the market value of the Company’s fixed-rate borrowings, which generally have longer maturities. A sensitivity analysis to measure potential changes in the market value of Merck’s investments and debt from a change in interest rates indicated that a one percentage point increase in interest rates at December 31, 2024 and 2023 would have positively affected the net aggregate market value of these instruments by $2.4 billion and $2.5 billion, respectively. A one percentage point decrease at December 31, 2024 and 2023 would have negatively affected the net aggregate market value by $2.9 billion and $3.0 billion, respectively. The fair value of Merck’s debt was determined using pricing models reflecting one percentage point shifts in the appropriate yield curves. The fair values of Merck’s investments were determined using a combination of pricing and duration models.
Critical Accounting Estimates
The Company’s consolidated financial statements are prepared in conformity with GAAP and, accordingly, include certain amounts that are based on management’s best estimates and judgments. Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities in a business combination (primarily IPR&D, other intangible assets and contingent consideration), as well as subsequent fair value measurements. Additionally, estimates are used in determining such items as provisions for sales discounts, rebates and returns, depreciable and amortizable lives, recoverability of inventories, including those produced in preparation for product launches, amounts recorded for contingencies, environmental liabilities, accruals for contingent sales-based milestone payments and other reserves, pension and other postretirement benefit plan assumptions, share-based compensation assumptions, restructuring costs, impairments of long-lived assets (including intangible assets and goodwill) and investments, and taxes on income. Because of the uncertainty inherent in such estimates, actual results may differ from these estimates. Application of the following accounting policies result in accounting estimates having the potential for the most significant impact on the financial statements.
Acquisitions and Dispositions
To determine whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses, the Company makes certain judgments, which include assessment of the inputs, processes, and outputs associated with the acquired set of activities. If the Company determines that substantially all of the fair value of gross assets included in a transaction is concentrated in a single asset (or a group of similar assets), the assets would not represent a business. To be considered a business, the assets in a transaction need to include an input and a substantive process that together significantly contribute to the ability to create outputs.
In a business combination, the acquisition method of accounting requires that the assets acquired and liabilities assumed be recorded as of the date of the acquisition at their respective fair values with limited exceptions. The fair values of intangible assets are determined utilizing information available near the acquisition date based on expectations and assumptions that are deemed reasonable by management. Given the considerable judgment involved in determining fair values, the Company typically obtains assistance from third-party valuation specialists for significant items. Assets acquired and liabilities assumed in a business combination that arise from contingencies are generally recognized at fair value. If fair value cannot be determined, the asset or liability is recognized if probable and reasonably estimable; if these criteria are not met, no asset or liability is recognized. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Accordingly, the Company may be required to value assets at fair value measures that do not reflect the Company’s intended use of those assets. Any excess of the purchase price (consideration transferred) over the estimated fair values of net assets acquired is recorded as goodwill. Transaction costs and costs to
67

restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Company’s consolidated financial statements after the date of the acquisition.
The judgments made in determining estimated fair values assigned to assets acquired and liabilities assumed in a business combination, as well as asset lives, can materially affect the Company’s results of operations.
The fair values of identifiable intangible assets related to currently marketed products are primarily determined by using an income approach through which fair value is estimated based on each asset’s discounted projected net cash flows. The Company’s estimates of market participant net cash flows consider historical and projected pricing, margins and expense levels; the performance of competing products where applicable; relevant industry and therapeutic area growth drivers and factors; current and expected trends in technology and product life cycles; the time and investment that will be required to develop products and technologies; the ability to obtain additional marketing and regulatory approvals; the ability to manufacture and commercialize the products; the extent and timing of potential new product introductions by the Company’s competitors; and the life of each asset’s underlying patent and related patent term extension, if any. The net cash flows are then probability-adjusted where appropriate to consider the uncertainties associated with the underlying assumptions, as well as the risk profile of the net cash flows utilized in the valuation. The probability-adjusted future net cash flows of each product are then discounted to present value utilizing an appropriate discount rate.
The fair values of identifiable intangible assets related to IPR&D are also determined using an income approach, through which fair value is estimated based on each asset’s probability-adjusted future net cash flows, which reflect the different stages of development of each product and the associated probability of successful completion. The net cash flows are then discounted to present value using an appropriate discount rate. Amounts allocated to acquired IPR&D are capitalized and accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each IPR&D project, Merck will make a determination as to the then-useful life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization.
Certain of the Company’s business combinations involve the potential for future payment of consideration that is contingent upon the achievement of performance milestones, including product development milestones and royalty payments on future product sales. The fair value of contingent consideration liabilities is determined at the acquisition date using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period until the contingency is resolved, the contingent consideration liability is remeasured at current fair value with changes (either expense or income) recorded in earnings. Changes in any of the inputs may result in a significantly different fair value adjustment.
If the Company determines the transaction will not be accounted for as an acquisition of a business, the transaction will be accounted for as an asset acquisition rather than a business combination and, therefore, no goodwill will be recorded. In an asset acquisition, acquired IPR&D with no alternative future use is charged to expense and contingent consideration is not recognized at the acquisition date.
Contingent Sales-Based Milestones
The terms of certain business development transactions, including collaborative arrangements, licensing agreements and asset acquisitions, require the Company to make payments contingent upon the achievement of sales-based milestones. Sales-based milestones payable by Merck are accrued and capitalized, subject to cumulative amortization catch-up, when determined by the Company to be probable of being achieved based on future sales forecasts. The amortization catch-up is calculated either from the time of the first regulatory approval for products that were unapproved at the time the transaction was completed or, for new indications of products that were approved prior to the transaction, from the time the transaction was completed. The related intangible asset that is recognized is amortized over its remaining useful life, subject to impairment testing.
Revenue Recognition
Recognition of revenue requires evidence of a contract, probable collection of sales proceeds and completion of substantially all performance obligations. Merck acts as the principal in substantially all of its customer arrangements and therefore records revenue on a gross basis. The majority of the Company’s contracts related to the Pharmaceutical and Animal Health segments have a single performance obligation - the promise to transfer goods. Shipping is considered immaterial in the context of the overall customer arrangement and damages or loss of goods in transit are rare. Therefore, shipping is not deemed a separately recognized performance obligation.
68

The vast majority of revenues from sales of products are recognized at a point in time when control of the goods is transferred to the customer, which the Company has determined is when title and risks and rewards of ownership transfer to the customer and the Company is entitled to payment. For certain services in the Animal Health segment, revenue is recognized over time, generally ratably over the contract term as services are provided. These service revenues are not material.
The nature of the Company’s business gives rise to several types of variable consideration including discounts and returns, which are estimated at the time of sale generally using the expected value method, although the most likely amount method is used for prompt pay discounts.
In the U.S., sales discounts are issued to customers at the point-of-sale, through an intermediary wholesaler (known as chargebacks), or in the form of rebates. Additionally, sales are generally made with a limited right of return under certain conditions. Revenues are recorded net of provisions for sales discounts and returns, which are established at the time of sale. In addition, if collection of accounts receivable is expected to be in excess of one year, sales are recorded net of time value of money discounts, which have not been material.
The U.S. provision for aggregate customer discounts covers chargebacks and rebates. Chargebacks are discounts that occur when a contracted customer purchases through an intermediary wholesaler. The wholesaler then charges the Company back for the difference between the price initially paid by the wholesaler and the contract price agreed to between Merck and the customer. The provision for chargebacks is based on expected sell-through levels by the Company’s wholesale customers to contracted customers, as well as estimated wholesaler inventory levels. Rebates are amounts owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part D) benefit providers after the final dispensing of the product to a benefit plan participant. The provision for rebates is based on expected patient usage, as well as inventory levels in the distribution channel to determine the contractual obligation to the benefit providers. The Company uses historical customer segment utilization mix, sales forecasts, changes to product mix and price, inventory levels in the distribution channel, government pricing calculations and prior payment history in order to estimate the expected provision. Amounts accrued for aggregate customer discounts are evaluated on a quarterly basis through comparison of information provided by the wholesalers, health maintenance organizations, pharmacy benefit managers, federal and state agencies, and other customers to the amounts accrued. Merck remains committed to the 340B Program and to providing 340B discounts to eligible covered entities. See Note 10 to the consolidated financial statements for information regarding 340B legal proceedings.
Summarized information about changes in the aggregate customer discount accrual related to U.S. sales is as follows:
($ in millions)20242023
Balance January 1$2,486 $2,918 
Current provision13,450 12,540 
Adjustments to prior years(139)(70)
Payments(13,334)(12,902)
Balance December 31$2,463 $2,486 
Accruals for chargebacks are reflected as a direct reduction to accounts receivable and accruals for rebates as current liabilities. The accrued balances relative to these provisions included in Accounts receivable and Accrued and other current liabilities were $293 million and $2.2 billion, respectively, at December 31, 2024 and were $188 million and $2.3 billion, respectively, at December 31, 2023.
Outside of the U.S., variable consideration in the form of discounts and rebates are a combination of commercially-driven discounts in highly competitive product classes, discounts required to gain or maintain reimbursement, or legislatively mandated rebates. In certain European countries, legislatively mandated rebates are calculated based on an estimate of the government’s total unbudgeted spending and the Company’s specific payback obligation. Rebates may also be required based on specific product sales thresholds. The Company applies an estimated factor against its actual invoiced sales to represent the expected level of future discount or rebate obligations associated with the sale.
The Company maintains a returns policy that allows its U.S. pharmaceutical customers to return product within a specified period prior to and subsequent to the expiration date (generally, three to six months before and 12 months after product expiration). The estimate of the provision for returns is based upon historical experience with actual returns. Additionally, the Company considers factors such as levels of inventory in the distribution channel, product dating and expiration period, whether products have been discontinued, entrance in the market of generic or other competition, changes in formularies or launch of over-the-counter products, among others. The product returns
69

provision for U.S. pharmaceutical sales as a percentage of U.S. net pharmaceutical sales was 0.8% in 2024, 1.0% in 2023 and 1.1% in 2022. Outside of the U.S., returns are only allowed in certain countries on a limited basis.
Merck’s payment terms for U.S. pharmaceutical customers are typically 36 days from receipt of invoice and for U.S. animal health customers are typically 30 days from receipt of invoice; however, certain products have longer payment terms, including Keytruda, which has payment terms of 90 days. Payment terms for vaccine sales in the U.S. typically range from 30 days to 60 days. Outside of the U.S., payment terms are typically 30 days to 90 days, although certain markets have longer payment terms.
Through its distribution programs with U.S. wholesalers, the Company encourages wholesalers to align purchases with underlying demand and maintain inventories below specified levels. The terms of the programs allow the wholesalers to earn fees upon providing visibility into their inventory levels, as well as by achieving certain performance parameters such as inventory management, customer service levels, reducing shortage claims and reducing product returns. Information provided through the wholesaler distribution programs includes items such as sales trends, inventory on-hand, on-order quantity and product returns.
Inventories Produced in Preparation for Product Launches
The Company capitalizes inventories produced in preparation for product launches sufficient to support estimated initial market demand. Capitalization of such inventory does not begin until regulatory approval is considered by the Company to be probable. The Company monitors the status of each respective product during the research and regulatory approval process. If the Company is aware of any specific risks or contingencies other than the normal regulatory approval process or if there are any specific issues identified during the research process relating to safety, efficacy, manufacturing, marketing or labeling, the related inventory would generally not be capitalized. Expiry dates of the inventory are affected by the stage of completion. The Company manages the levels of inventory at each stage to optimize the shelf life of the inventory in relation to anticipated market demand in order to avoid product expiry issues. For inventories that are capitalized, anticipated future sales and shelf lives support the realization of the inventory value as the inventory shelf life is sufficient to meet initial product launch requirements. Inventories produced in preparation for product launches capitalized at December 31, 2024 and 2023 were $412 million and $790 million, respectively.
Contingencies and Environmental Liabilities
The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, commercial litigation and securities litigation, as well as certain additional matters, including governmental and environmental matters (see Note 10 to the consolidated financial statements). The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. Generally, for product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable.
Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company’s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of December 31, 2024 and 2023 of approximately $225 million and $210 million, respectively, represents the Company’s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.
The Company and its subsidiaries are parties to a number of proceedings brought under the Comprehensive Environmental Response, Compensation and Liability Act, commonly known as Superfund, and other federal and state equivalents. When a legitimate claim for contribution is asserted, a liability is initially accrued based upon the estimated transaction costs to manage the site. Accruals are adjusted as site investigations, feasibility studies and related cost assessments of remedial techniques are completed, and as the extent to which other potentially responsible parties who may be jointly and severally liable can be expected to contribute is determined.
70

The Company is also remediating environmental contamination resulting from past industrial activity at certain of its sites and takes an active role in identifying and accruing for these costs. In the past, Merck performed a worldwide survey to assess all sites for potential contamination resulting from past industrial activities. Where assessment indicated that physical investigation was warranted, such investigation was performed, providing a better evaluation of the need for remedial action. Where such need was identified, remedial action was then initiated. As definitive information became available during the course of investigations and/or remedial efforts at each site, estimates were refined and accruals were established or adjusted accordingly. These estimates and related accruals continue to be refined annually.
The Company believes that there are no compliance issues associated with applicable environmental laws and regulations that would have a material adverse effect on the Company. Expenditures for remediation and environmental liabilities were $4 million in 2024 and are estimated to be $26 million in the aggregate for the years 2025 through 2029. In management’s opinion, the liabilities for all environmental matters that are probable and reasonably estimable have been accrued and totaled $41 million and $42 million at December 31, 2024 and 2023, respectively. These liabilities are undiscounted, do not consider potential recoveries from other parties and will be paid out over the periods of remediation for the applicable sites, which are expected to occur primarily over the next 15 years. Although it is not possible to predict with certainty the outcome of these matters, or the ultimate costs of remediation, management does not believe that any reasonably possible expenditures that may be incurred in excess of the liabilities accrued should exceed approximately $46 million in the aggregate. Management also does not believe that these expenditures should result in a material adverse effect on the Company’s financial condition, results of operations or liquidity for any year.
Share-Based Compensation
The Company expenses all share-based payment awards to employees, including grants of stock options, over the requisite service period based on the grant date fair value of the awards. The Company determines the fair value of certain share-based awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options. Total pretax share-based compensation expense was $761 million in 2024, $645 million in 2023 and $541 million in 2022. At December 31, 2024, there was $1.1 billion of total pretax unrecognized compensation expense related to nonvested stock option, restricted stock unit and performance share unit awards which will be recognized over a weighted-average period of 1.9 years. For segment reporting, share-based compensation costs are unallocated expenses.
Pensions and Other Postretirement Benefit Plans
Net periodic benefit cost for pension plans totaled $107 million in 2024, $126 million in 2023 and $554 million in 2022. Net periodic benefit credit for other postretirement benefit plans was $84 million in 2024, $61 million in 2023 and $93 million in 2022. Pension and other postretirement benefit plan information for financial reporting purposes is calculated using actuarial assumptions including a discount rate for plan benefit obligations and an expected rate of return on plan assets. The changes in net periodic benefit cost year over year for pension plans are primarily attributable to lower settlement charges incurred by certain plans in 2024 and 2023 compared with 2022, as well as changes in expected returns and the discount rates.
The Company reassesses its benefit plan assumptions on a regular basis. For both the pension and other postretirement benefit plans, the discount rate is evaluated on measurement dates and modified to reflect the prevailing market rate of a portfolio of high-quality fixed-income debt instruments that would provide the future cash flows needed to pay the benefits included in the benefit obligation as they come due. The discount rates for the Company’s U.S. pension and other postretirement benefit plans ranged from 5.50% to 5.70% at December 31, 2024, compared with a range of 5.25% to 5.45% at December 31, 2023.
The expected rate of return for both the pension and other postretirement benefit plans represents the average rate of return to be earned on plan assets over the period the benefits included in the benefit obligation are to be paid. In developing the expected rate of return, the Company considers long-term compound annualized returns of historical market data, current market conditions and actual returns on the Company’s plan assets. Using this reference information, the Company develops forward-looking return expectations for each asset category and a weighted-average expected long-term rate of return for a target portfolio allocated across these investment categories. The expected portfolio performance reflects the contribution of active management as appropriate. For 2025, the expected rate of return for the Company’s U.S. pension and other postretirement benefit plans will be 7.70% compared with 7.75% in 2024.
The Company has established investment guidelines for its U.S. pension and other postretirement plans to create an asset allocation that is expected to deliver a rate of return sufficient to meet the long-term obligation of each plan, given an acceptable level of risk. The target investment portfolio of the Company’s U.S. pension and other
71

postretirement benefit plans is allocated 25% to 40% in U.S. equities, 15% to 30% in international equities, 40% to 50% in fixed-income investments, and up to 8% in cash and other investments. The portfolio’s equity weighting is consistent with the long-term nature of the plans’ benefit obligations. The expected annual standard deviation of returns of the target portfolio, which approximates 12%, reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests. For international pension plans, the targeted investment portfolio varies based on the duration of pension liabilities and local government rules and regulations. Although a significant percentage of plan assets are invested in U.S. equities, concentration risk is mitigated through the use of strategies that are diversified within management guidelines.
Actuarial assumptions are based upon management’s best estimates and judgment. A reasonably possible change of plus (minus) 25 basis points in the discount rate assumption, with other assumptions held constant, would have had an estimated $45 million favorable (unfavorable) impact on the Company’s net periodic benefit cost in 2024. A reasonably possible change of plus (minus) 25 basis points in the expected rate of return assumption, with other assumptions held constant, would have had an estimated $57 million favorable (unfavorable) impact on Merck’s net periodic benefit cost in 2024. Required funding obligations for 2025 relating to the Company’s pension and other postretirement benefit plans are not expected to be material. The preceding hypothetical changes in the discount rate and expected rate of return assumptions would not impact the Company’s funding requirements.
Net gain/loss amounts, which primarily reflect differences between expected and actual returns on plan assets as well as the effects of changes in actuarial assumptions, are recorded as a component of AOCL. Expected returns for pension plans are based on a calculated market-related value of assets. Net gain/loss amounts in AOCL in excess of certain thresholds are amortized into net periodic benefit cost over the average remaining service life of employees.
Restructuring Costs
Restructuring costs have been recorded in connection with restructuring program activities. As a result, the Company has made estimates and judgments regarding its future plans, including future employee termination costs to be incurred in conjunction with involuntary separations when such separations are probable and estimable. When accruing termination costs, the Company will recognize the amount within a range of costs that is the best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company recognizes the minimum amount within the range. In connection with these actions, management also assesses the recoverability of long-lived assets employed in the business. In certain instances, asset lives have been shortened based on changes in the expected useful lives of the affected assets. Severance and employee-related costs, as well as other costs, such as facility shut-down costs, are reflected within Restructuring costs. Asset-related charges are reflected within Cost of sales, Selling, general and administrative expenses and Research and development expenses depending upon the nature of the asset.
Impairments of Long-Lived Assets
The Company assesses changes in economic, regulatory and legal conditions and makes assumptions regarding estimated future cash flows in evaluating the value of the Company’s property, plant and equipment, goodwill and other intangible assets.
The Company periodically evaluates whether current facts or circumstances indicate that the carrying values of its long-lived assets to be held and used may not be recoverable. If such circumstances are determined to exist, an estimate of the undiscounted future cash flows of these assets, or appropriate asset groupings, is compared to the carrying value to determine whether an impairment exists. If the asset is determined to be impaired, the loss is measured based on the difference between the asset’s fair value and its carrying value. If quoted market prices are not available, the Company will estimate fair value using a discounted value of estimated future cash flows approach.
Goodwill represents the excess of the consideration transferred over the fair value of net assets acquired in a business combination. Goodwill is assigned to reporting units and evaluated for impairment at least annually, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. Some of the factors considered in the assessment include general macroeconomic conditions, conditions specific to the industry and market, cost factors which could have a significant effect on earnings or cash flows, the overall financial performance of the reporting unit, and whether there have been sustained declines in the Company’s share price. If the Company concludes it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed. If the carrying value of a reporting unit is greater than its fair value, a goodwill impairment charge will be recorded for the difference (up to the carrying value of goodwill).
Other acquired intangible assets (excluding IPR&D) are initially recorded at fair value, assigned an estimated useful life, and amortized primarily on a straight-line basis over their estimated useful lives. When events or
72

circumstances warrant a review, the Company will assess recoverability from future operations using pretax undiscounted cash flows derived from the lowest appropriate asset groupings. Impairments are recognized in operating results to the extent that the carrying value of the intangible asset exceeds its fair value, which is determined based on the net present value of estimated future cash flows.
IPR&D that the Company acquires in conjunction with a business combination represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. The Company evaluates IPR&D for impairment at least annually, or more frequently if impairment indicators exist (such as unfavorable clinical trial data, changes in the commercial landscape or delays in the clinical development program and related regulatory filing and approval timelines), by performing a quantitative test that compares the fair value of the IPR&D intangible asset with its carrying value. For impairment testing purposes, the Company may combine separately recorded IPR&D intangible assets into one unit of account based on the relevant facts and circumstances. Generally, the Company will combine IPR&D intangible assets for testing purposes if they operate as a single asset and are essentially inseparable. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results.
The judgments made in evaluating impairment of long-lived intangibles can materially affect the Company’s results of operations.
Taxes on Income
The Company’s effective tax rate is based on pretax income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates. An estimated effective tax rate for a year is applied to the Company’s quarterly operating results. In the event that there is a significant unusual or one-time item recognized, or expected to be recognized, in the Company’s quarterly operating results, the tax attributable to that item would be separately calculated and recorded at the same time as the unusual or one-time item. The Company considers the resolution of prior year tax matters to be such items. Significant judgment is required in determining the Company’s tax provision and in evaluating its tax positions. The recognition and measurement of a tax position is based on management’s best judgment given the facts, circumstances and information available at the reporting date. The Company evaluates tax positions to determine whether the benefits of tax positions are more likely than not of being sustained upon audit based on the technical merits of the tax position. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the amount of the benefit that is greater than 50% likely of being realized upon ultimate settlement in the financial statements. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit in the financial statements. If the more likely than not threshold is not met in the period for which a tax position is taken, the Company may subsequently recognize the benefit of that tax position if the tax matter is effectively settled, the statute of limitations expires, or if the more likely than not threshold is met in a subsequent period (see Note 15 to the consolidated financial statements).
Tax regulations require items to be included in the tax return at different times than the items are reflected in the financial statements. Timing differences create deferred tax assets and liabilities. Deferred tax assets generally represent items that can be used as a tax deduction or credit in the tax return in future years for which the Company has already recorded the tax benefit in the financial statements. The Company establishes valuation allowances for its deferred tax assets when the amount of expected future taxable income is not likely to support the use of the deduction or credit. Deferred tax liabilities generally represent tax expense recognized in the financial statements for which payment has been deferred or expense for which the Company has already taken a deduction on the tax return, but has not yet recognized as expense in the financial statements.
Recently Issued Accounting Standards
For a discussion of recently issued accounting standards, see Note 2 to the consolidated financial statements.
Cautionary Factors That May Affect Future Results
This report and other written reports and oral statements made from time to time by the Company may contain so-called “forward-looking statements,” all of which are based on management’s current expectations and are subject to risks and uncertainties which may cause results to differ materially from those set forth in the statements. One can identify these forward-looking statements by their use of words such as “anticipates,” “expects,” “plans,” “will,” “estimates,” “forecasts,” “projects” and other words of similar meaning, or negative variations of any of the foregoing. One can also identify them by the fact that they do not relate strictly to historical or current facts. These statements are likely to address the Company’s growth strategy, financial results, product approvals, product potential, development programs, environmental or other sustainability initiatives. One must carefully consider any
73

such statement and should understand that many factors could cause actual results to differ materially from the Company’s forward-looking statements. These factors include inaccurate assumptions and a broad variety of other risks and uncertainties, including some that are known and some that are not. No forward-looking statement can be guaranteed and actual future results may vary materially.
The Company does not assume the obligation to update any forward-looking statement. One should carefully evaluate such statements in light of factors, including risk factors, described in the Company’s filings with the Securities and Exchange Commission, especially on this Form 10-K and Forms 10-Q and 8-K. In Item 1A. “Risk Factors” of this annual report on Form 10-K the Company discusses in more detail various important risk factors that could cause actual results to differ from expected or historic results. The Company notes these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. One should understand that it is not possible to predict or identify all such factors. Consequently, the reader should not consider any such list to be a complete statement of all potential risks or uncertainties. 
Item 7A.Quantitative and Qualitative Disclosures about Market Risk.
The information required by this Item is incorporated by reference to the discussion under “Financial Instruments Market Risk Disclosures” in Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

74

Item 8.Financial Statements and Supplementary Data.                
(a)Financial Statements
The consolidated balance sheet of Merck & Co., Inc. and subsidiaries as of December 31, 2024 and 2023, and the related consolidated statements of income, of comprehensive income (loss), of equity and of cash flows for each of the three years in the period ended December 31, 2024, the notes to consolidated financial statements, and the report dated February 25, 2025 of PricewaterhouseCoopers LLP, independent registered public accounting firm, are as follows:
Consolidated Statement of Income
Merck & Co., Inc. and Subsidiaries
Years Ended December 31
($ in millions except per share amounts)
202420232022
Sales$64,168 $60,115 $59,283 
Costs, Expenses and Other
Cost of sales15,193 16,126 17,411 
Selling, general and administrative10,816 10,504 10,042 
Research and development17,938 30,531 13,548 
Restructuring costs309 599 337 
Other (income) expense, net(24)466 1,501 
 44,232 58,226 42,839 
Income Before Taxes
19,936 1,889 16,444 
Taxes on Income
2,803 1,512 1,918 
Net Income
17,133 377 14,526 
Less: Net Income Attributable to Noncontrolling Interests16 12 7 
Net Income Attributable to Merck & Co., Inc.$17,117 $365 $14,519 
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders
$6.76 $0.14 $5.73 
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders$6.74 $0.14 $5.71 
Consolidated Statement of Comprehensive Income (Loss)
Merck & Co., Inc. and Subsidiaries
Years Ended December 31
($ in millions)
202420232022
Net Income Attributable to Merck & Co., Inc.$17,117 $365 $14,519 
Other Comprehensive Income (Loss) Net of Taxes:
Net unrealized income (loss) on derivatives, net of reclassifications
266 (97)(71)
Benefit plan net gain (loss) and prior service credit (cost), net of amortization
466 (385)335 
Cumulative translation adjustment(516)89 (603)
 216 (393)(339)
Comprehensive Income (Loss) Attributable to Merck & Co., Inc.
$17,333 $(28)$14,180 
The accompanying notes are an integral part of these consolidated financial statements.
75

Consolidated Balance Sheet
Merck & Co., Inc. and Subsidiaries
December 31
($ in millions except per share amounts)
20242023
Assets
Current Assets
Cash and cash equivalents$13,242 $6,841 
Short-term investments447 252 
Accounts receivable (net of allowance for doubtful accounts of $89 in 2024
and $88 in 2023)
10,278 10,349 
Inventories (excludes inventories of $4,193 in 2024 and $3,348 in 2023
classified in Other assets - see Note 7)
6,109 6,358 
Other current assets8,706 8,368 
Total current assets38,782 32,168 
Investments463 252 
Property, Plant and Equipment (at cost)
Land307 326 
Buildings16,360 14,966 
Machinery, equipment and office furnishings18,283 17,763 
Construction in progress7,984 8,262 
42,934 41,317 
Less: accumulated depreciation19,155 18,266 
 23,779 23,051 
Goodwill21,668 21,197 
Other Intangibles, Net16,370 18,011 
Other Assets16,044 11,996 
 $117,106 $106,675 
Liabilities and Equity
Current Liabilities
Loans payable and current portion of long-term debt$2,649 $1,372 
Trade accounts payable4,079 3,922 
Accrued and other current liabilities15,694 15,766 
Income taxes payable3,914 2,649 
Dividends payable2,084 1,985 
Total current liabilities28,420 25,694 
Long-Term Debt34,462 33,683 
Deferred Income Taxes1,387 871 
Other Noncurrent Liabilities6,465 8,792 
Merck & Co., Inc. Stockholders’ Equity
Common stock, $0.50 par value
Authorized - 6,500,000,000 shares
Issued - 3,577,103,522 shares in 2024 and 2023
1,788 1,788 
Other paid-in capital44,704 44,509 
Retained earnings63,069 53,895 
Accumulated other comprehensive loss(4,945)(5,161)
104,616 95,031 
Less treasury stock, at cost: 1,049,466,187 shares in 2024 and 1,045,470,249 shares in 2023
58,303 57,450 
Total Merck & Co., Inc. stockholders’ equity46,313 37,581 
Noncontrolling Interests59 54 
Total equity46,372 37,635 
 $117,106 $106,675 
The accompanying notes are an integral part of this consolidated financial statement.
76

Consolidated Statement of Equity
Merck & Co., Inc. and Subsidiaries
Years Ended December 31
($ in millions except per share amounts)
Common
Stock
Other
Paid-In
Capital
Retained
Earnings
Accumulated
Other
Comprehensive
Loss
Treasury
Stock
Non-
controlling
Interests
Total
Balance January 1, 2022
$1,788 $44,238 $53,696 $(4,429)$(57,109)$73 $38,257 
Net income attributable to Merck & Co., Inc.— — 14,519 — — — 14,519 
Other comprehensive loss, net of taxes
— — — (339)— — (339)
Cash dividends declared on common stock ($2.80 per share)
— — (7,134)— — — (7,134)
Net income attributable to noncontrolling interests— — — — — 7 7 
Distributions attributable to noncontrolling interests— — — — — (13)(13)
Share-based compensation plans and other— 141 — — 620 — 761 
Balance December 31, 20221,788 44,379 61,081 (4,768)(56,489)67 46,058 
Net income attributable to Merck & Co., Inc.— — 365 — — — 365 
Other comprehensive loss, net of taxes— — — (393)— — (393)
Cash dividends declared on common stock ($2.96 per share)
— — (7,551)— — — (7,551)
Treasury stock shares purchased
— — — — (1,346)— (1,346)
Net income attributable to noncontrolling interests— — — — — 12 12 
Distributions attributable to noncontrolling interests— — — — — (25)(25)
Share-based compensation plans and other— 130 — — 385 — 515 
Balance December 31, 20231,788 44,509 53,895 (5,161)(57,450)54 37,635 
Net income attributable to Merck & Co., Inc.  17,117    17,117 
Other comprehensive income, net of taxes
   216   216 
Cash dividends declared on common stock ($3.12 per share)
  (7,943)   (7,943)
Treasury stock shares purchased    (1,306) (1,306)
Net income attributable to noncontrolling interests     16 16 
Distributions attributable to noncontrolling interests     (12)(12)
Share-based compensation plans and other 195   453 1 649 
Balance December 31, 2024$1,788 $44,704 $63,069 $(4,945)$(58,303)$59 $46,372 
The accompanying notes are an integral part of this consolidated financial statement.

77

Consolidated Statement of Cash Flows
Merck & Co., Inc. and Subsidiaries
Years Ended December 31
($ in millions)
202420232022
Cash Flows from Operating Activities
Net income
$17,133 $377 $14,526 
Adjustments to reconcile net income to net cash provided by operating activities:
Amortization2,395 2,044 2,085 
Depreciation2,104 1,828 1,824 
Intangible asset impairment charges39 792 1,749 
(Income) loss from investments in equity securities, net(14)(340)1,419 
Charges for certain research and development asset acquisitions
3,456 11,409  
Deferred income taxes(1,249)(1,899)(1,568)
Share-based compensation761 645 541 
Other510 355 1,301 
Net changes in assets and liabilities:
Accounts receivable(244)(1,148)(644)
Inventories(835)(816)(161)
Trade accounts payable182 (380)(289)
Accrued and other current liabilities(2,328)1,783 (50)
Income taxes payable1,023 214 380 
Noncurrent liabilities(49)456 (545)
Other(1,416)(2,314)(1,473)
Net Cash Provided by Operating Activities
21,468 13,006 19,095 
Cash Flows from Investing Activities
Capital expenditures(3,372)(3,863)(4,388)
Purchases of securities and other investments(519)(955)(1,204)
Proceeds from sale of Seagen Inc. common stock 1,145  
Proceeds from sales of securities and other investments377 1,658 721 
Acquisition of Eyebiotech Limited, net of cash acquired
(1,344)  
Acquisition of Elanco Animal Health Incorporated aqua business
(1,303)  
Acquisition of Harpoon Therapeutics, Inc., net of cash acquired
(746)  
Acquisition of MK-1045 from Curon Pharmaceutical
(700)  
Acquisition of Prometheus Biosciences, Inc., net of cash acquired (10,705) 
Acquisition of Imago BioSciences Inc., net of cash acquired (1,327) 
Other(127)(36)(89)
Net Cash Used in Investing Activities
(7,734)(14,083)(4,960)
Cash Flows from Financing Activities
Payments on debt(1,290)(1,755)(2,251)
Proceeds from issuance of debt3,599 5,939  
Purchases of treasury stock(1,306)(1,346) 
Dividends paid to stockholders(7,840)(7,445)(7,012)
Proceeds from exercise of stock options177 125 384 
Other(372)(328)(240)
Net Cash Used in Financing Activities
(7,032)(4,810)(9,119)
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash(293)23 (410)
Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash
6,409 (5,864)4,606 
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes $68, $79 and $71 of restricted cash at January 1, 2024, 2023 and 2022, respectively, included in Other current assets)
6,909 12,773 8,167 
Cash, Cash Equivalents and Restricted Cash at End of Year (includes $76, $68 and $79 of restricted cash at December 31, 2024, 2023 and 2022, respectively, included in Other current assets)
$13,318 $6,909 $12,773 
The accompanying notes are an integral part of this consolidated financial statement.
78

Notes to Consolidated Financial Statements
Merck & Co., Inc. and Subsidiaries
($ in millions except per share amounts)
1.   Nature of Operations
Merck & Co., Inc. (Merck or the Company) is a global health care company that delivers innovative health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company’s operations are principally managed on a product basis and include two operating segments, Pharmaceutical and Animal Health, both of which are reportable segments.
The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities.
The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors, animal producers, farmers and pet owners.
2.    Summary of Accounting Policies
Principles of Consolidation — The consolidated financial statements include the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. Intercompany balances and transactions are eliminated. Controlling interest is determined by majority ownership interest and the absence of substantive third-party participating rights or, in the case of variable interest entities, by majority exposure to expected losses, residual returns or both. For those consolidated subsidiaries where Merck ownership is less than 100%, the outside shareholders’ interests are shown as Noncontrolling interests in equity. Investments in affiliates over which the Company has significant influence but not a controlling interest, such as interests in entities owned equally by the Company and a third party that are under shared control, are carried on the equity method basis.
Acquisitions — In a business combination, the acquisition method of accounting requires that the assets acquired and liabilities assumed be recorded as of the date of the acquisition at their respective fair values with limited exceptions. Assets acquired and liabilities assumed in a business combination that arise from contingencies are generally recognized at fair value. If fair value cannot be determined, the asset or liability is recognized if probable and reasonably estimable; if these criteria are not met, no asset or liability is recognized. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Accordingly, the Company may be required to value assets at fair value measures that do not reflect the Company’s intended use of those assets. Any excess of the purchase price (consideration transferred) over the estimated fair values of net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Company’s consolidated financial statements after the date of the acquisition.
If the Company determines the assets acquired do not meet the definition of a business under the acquisition method of accounting, the transaction will be accounted for as an acquisition of assets rather than a business combination and, therefore, no goodwill will be recorded. In an asset acquisition, acquired in-process research and development (IPR&D) with no alternative future use is charged to expense and contingent consideration is not recognized at the acquisition date.
Foreign Currency Translation — The net assets of international subsidiaries where the local currencies have been determined to be the functional currencies are translated into U.S. dollars using current exchange rates and results of operations are translated at average exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries at changing rates are recorded in Other Comprehensive Income (OCI) and remain in Accumulated other comprehensive loss (AOCL) until either the sale or complete or substantially complete liquidation of the subsidiary. For those subsidiaries that operate in highly inflationary economies and for those subsidiaries where the U.S. dollar has been determined to be the functional currency, non-monetary foreign currency
79

assets and liabilities are translated using historical rates, while monetary assets and liabilities are translated at current rates, with the U.S. dollar effects of rate changes included in Other (income) expense, net.
Cash Equivalents — Cash equivalents are comprised of certain highly liquid investments with original maturities of less than three months.
Inventories — Inventories are valued at the lower of cost or net realizable value. The cost of a substantial majority of U.S. human health inventories is determined using the last-in, first-out (LIFO) method for both financial reporting and tax purposes. The cost of all other inventories is determined using the first-in, first-out (FIFO) method. Inventories consist of currently marketed products, as well as certain inventories produced in preparation for product launches that are considered by the Company to be probable of obtaining regulatory approval. In evaluating the recoverability of inventories produced in preparation for product launches, the Company considers the likelihood that revenue will be obtained from the future sale of the related inventory together with the status of the product during the research and regulatory approval process.
Investments — Investments in marketable debt securities classified as available-for-sale are reported at fair value. Fair values of the Company’s investments in marketable debt securities are determined using quoted market prices in active markets for identical assets or quoted prices for similar assets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Changes in fair value that are not impairment related are reported net of taxes in OCI. The Company considers available evidence in evaluating potential impairments of its investments in marketable debt securities, including the extent to which fair value is less than cost, whether an allowance for credit loss is required, as well as adverse factors that could affect the value of the securities. An impairment has occurred if the Company does not expect to recover the entire amortized cost basis of the marketable debt security. If the Company does not intend to sell the impaired debt security, and it is not more likely than not it will be required to sell the debt security before the recovery of its amortized cost basis, the amount of the impairment recognized in earnings, recorded in Other (income) expense, net, is limited to the portion attributed to credit loss. The remaining portion of the impairment related to other factors is recognized in OCI. Realized gains and losses for debt securities are included in Other (income) expense, net.
Investments in publicly traded equity securities are reported at fair value as determined using quoted market prices in active markets for identical assets or quoted prices for similar assets or other inputs that are observable or can be corroborated by observable market data. Changes in fair value are included in Other (income) expense, net. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period. Gains and losses from ownership interests in investment funds, which are accounted for as equity method investments, are reported on a one quarter lag. Investments in equity securities without readily determinable fair values are recorded at cost, plus or minus subsequent observable price changes in orderly transactions for identical or similar investments, minus impairments. Such adjustments are recognized in Other (income) expense, net. Realized gains and losses for equity securities are included in Other (income) expense, net.
Revenue Recognition — Recognition of revenue requires evidence of a contract, probable collection of sales proceeds and completion of substantially all performance obligations. Merck acts as the principal in substantially all of its customer arrangements and therefore records revenue on a gross basis. The majority of the Company’s contracts related to the Pharmaceutical and Animal Health segments have a single performance obligation - the promise to transfer goods. Shipping is considered immaterial in the context of the overall customer arrangement and damages or loss of goods in transit are rare. Therefore, shipping is not deemed a separately recognized performance obligation.
The vast majority of revenues from sales of products are recognized at a point in time when control of the goods is transferred to the customer, which the Company has determined is when title and risks and rewards of ownership transfer to the customer and the Company is entitled to payment. The Company recognizes revenue from the sales of vaccines to the U.S. federal government for placement into vaccine stockpiles in accordance with Securities and Exchange Commission (SEC) Interpretation, Commission Guidance Regarding Accounting for Sales of Vaccines and BioTerror Countermeasures to the Federal Government for Placement into the Pediatric Vaccine Stockpile or the Strategic National Stockpile. This interpretation allows companies to recognize revenue for sales of vaccines into U.S. government stockpiles even though these sales might not meet the criteria for revenue recognition under other accounting guidance. For certain services in the Animal Health segment, revenue is recognized over time, generally ratably over the contract term as services are provided. These service revenues are not material.
The nature of the Company’s business gives rise to several types of variable consideration including discounts and returns, which are estimated at the time of sale generally using the expected value method, although the most likely amount method is used for prompt pay discounts.
80

In the U.S., sales discounts are issued to customers at the point-of-sale, through an intermediary wholesaler (known as chargebacks), or in the form of rebates. Additionally, sales are generally made with a limited right of return under certain conditions. Revenues are recorded net of provisions for sales discounts and returns, which are established at the time of sale. In addition, if collection of accounts receivable is expected to be in excess of one year, sales are recorded net of time value of money discounts, which have not been material.
The U.S. provision for aggregate customer discounts covering chargebacks and rebates was $13.3 billion in 2024, $12.5 billion in 2023 and $12.3 billion in 2022. Chargebacks are discounts that occur when a contracted customer purchases through an intermediary wholesaler. The wholesaler then charges the Company back for the difference between the price initially paid by the wholesaler and the contract price agreed to between Merck and the customer. The provision for chargebacks is based on expected sell-through levels by the Company’s wholesale customers to contracted customers, as well as estimated wholesaler inventory levels. Rebates are amounts owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part D) benefit providers after the final dispensing of the product to a benefit plan participant. The provision for rebates is based on expected patient usage, as well as inventory levels in the distribution channel to determine the contractual obligation to the benefit providers. The Company uses historical customer segment utilization mix, sales forecasts, changes to product mix and price, inventory levels in the distribution channel, government pricing calculations and prior payment history in order to estimate the expected provision. Amounts accrued for aggregate customer discounts are evaluated on a quarterly basis through comparison of information provided by the wholesalers, health maintenance organizations, pharmacy benefit managers, federal and state agencies, and other customers to the amounts accrued. The accrued balances relative to the provisions for chargebacks and rebates included in Accounts receivable and Accrued and other current liabilities were $293 million and $2.2 billion, respectively, at December 31, 2024 and were $188 million and $2.3 billion, respectively, at December 31, 2023.
Outside of the U.S., variable consideration in the form of discounts and rebates are a combination of commercially-driven discounts in highly competitive product classes, discounts required to gain or maintain reimbursement, or legislatively mandated rebates. In certain European countries, legislatively mandated rebates are calculated based on an estimate of the government’s total unbudgeted spending and the Company’s specific payback obligation. Rebates may also be required based on specific product sales thresholds. The Company applies an estimated factor against its actual invoiced sales to represent the expected level of future discount or rebate obligations associated with the sale.
The Company maintains a returns policy that allows its U.S. pharmaceutical customers to return product within a specified period prior to and subsequent to the expiration date (generally, three to six months before and 12 months after product expiration). The estimate of the provision for returns is based upon historical experience with actual returns. Additionally, the Company considers factors such as levels of inventory in the distribution channel, product dating and expiration period, whether products have been discontinued, entrance in the market of generic or other competition, changes in formularies or launch of over-the-counter products, among others. Outside of the U.S., returns are only allowed in certain countries on a limited basis.
Merck’s payment terms for U.S. pharmaceutical customers are typically 36 days from receipt of invoice and for U.S. animal health customers are typically 30 days from receipt of invoice; however, certain products have longer payment terms, including Keytruda (pembrolizumab), which has payment terms of 90 days. Payment terms for vaccine sales in the U.S. typically range from 30 days to 60 days. Outside of the U.S., payment terms are typically 30 days to 90 days, although certain markets have longer payment terms.
See Note 18 for disaggregated revenue disclosures.
Depreciation — Depreciation is provided over the estimated useful lives of the assets, principally using the straight-line method. For tax purposes, accelerated tax methods are used. The estimated useful lives primarily range from 25 to 45 years for Buildings, and from 3 to 15 years for Machinery, equipment and office furnishings. Depreciation expense was $2.1 billion in 2024, $1.8 billion in 2023 and $1.8 billion in 2022.
Advertising and Promotion Costs — Advertising and promotion costs are expensed as incurred. The Company recorded advertising and promotion expenses of $2.4 billion in 2024, $2.3 billion in 2023 and $2.2 billion in 2022.
Software Capitalization — The Company capitalizes certain costs incurred in connection with obtaining or developing internal-use software including external direct costs of material and services, and payroll costs for employees directly involved with the software development. These costs are included in Property, plant and equipment. In addition, the Company capitalizes certain costs incurred to implement a cloud computing arrangement
81

that is considered a service agreement, which are included in Other Assets. Capitalized software costs are being amortized over periods ranging from 2 to 10 years, with the longer lives generally associated with enterprise-wide projects implemented over multiple years. Costs incurred during the preliminary project stage and post-implementation stage, as well as maintenance and training costs, are expensed as incurred.
Goodwill — Goodwill represents the excess of the consideration transferred over the fair value of net assets acquired in a business combination. Goodwill is assigned to reporting units and evaluated for impairment at least annually, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company concludes it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed. If the carrying value of a reporting unit is greater than its fair value, a goodwill impairment charge will be recorded for the difference (up to the carrying value of goodwill).
Acquired Intangibles — Intangibles acquired in a business combination include product rights, trade names and patents, licenses and other, which are initially recorded at fair value, assigned an estimated useful life, and amortized primarily on a straight-line basis over their estimated useful lives ranging from 2 to 24 years. The Company periodically evaluates whether current facts or circumstances indicate that the carrying values of its acquired intangibles may not be recoverable. If such circumstances are determined to exist, an estimate of the undiscounted future cash flows of these assets, or appropriate asset groupings, is compared to the carrying value to determine whether an impairment exists. If the asset is determined to be impaired, the loss is measured based on the difference between the carrying value of the intangible asset and its fair value, which is determined based on the net present value of estimated future cash flows.
Acquired In-Process Research and Development — IPR&D that the Company acquires in conjunction with a business combination represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each IPR&D project, Merck will make a determination as to the then-useful life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization. The Company evaluates IPR&D for impairment at least annually, or more frequently if impairment indicators exist, by performing a quantitative test that compares the fair value of the IPR&D intangible asset with its carrying value. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results.
Contingent Consideration for Business Combinations — Certain of the Company’s acquisitions involve the potential for future payment of consideration that is contingent upon the achievement of performance milestones, including product development milestones and royalty payments on future product sales. If the transaction is accounted for as a business combination, the fair value of contingent consideration liabilities is determined at the acquisition date using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period until the contingency is resolved, the contingent consideration liability is remeasured at current fair value with changes (either expense or income) recorded in earnings. Significant events that increase or decrease the probability of achieving development and regulatory milestones or that increase or decrease projected cash flows will result in corresponding increases or decreases in the fair values of the related contingent consideration obligations.
Research and Development — Research and development is expensed as incurred. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Research and development expenses include restructuring costs and IPR&D impairment charges. In addition, research and development expenses include expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration associated with IPR&D assets. Research and development expenses also include upfront and milestone payments related to asset acquisitions and licensing transactions involving clinical development programs that have not yet received regulatory approval.
Collaborative Arrangements — Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. When Merck is the principal on sales transactions with third parties, the Company recognizes sales, cost of sales and selling, general and administrative expenses on a gross basis. Profit sharing amounts it pays to its collaborative partners are recorded within Cost of sales. When the collaborative partner is the principal on sales transactions with third parties, the Company records profit sharing amounts received from its collaborative partners as alliance revenue
82

(within Sales). Alliance revenue is recorded net of cost of sales and includes an adjustment to share commercialization costs between the partners in accordance with the collaboration agreement. The adjustment is determined by comparing the commercialization costs Merck has incurred directly and reported within Selling, general and administrative expenses with the costs the collaborative partner has incurred. Research and development costs Merck incurs related to collaborations are recorded within Research and development expenses. Cost reimbursements to the collaborative partner or payments received from the collaborative partner to share these costs pursuant to the terms of the collaboration agreements are recorded as increases or decreases to Research and development expenses.
In addition, the terms of the collaboration agreements may require the Company to make payments based upon the achievement of certain developmental, regulatory approval or commercial milestones. Upfront and milestone payments payable by Merck to collaborative partners prior to regulatory approval are expensed as incurred and included in Research and development expenses. Payments due to collaborative partners upon or subsequent to regulatory approval are capitalized and amortized to Cost of sales over the estimated useful life of the corresponding intangible asset, provided that future cash flows support the amounts capitalized. Sales-based milestones payable by Merck to collaborative partners are accrued and capitalized, subject to cumulative amortization catch-up, when determined by the Company to be probable of being achieved based on future sales forecasts. The amortization catch-up is calculated either from the time of the first regulatory approval for products that were unapproved at the time the collaboration was formed or, for new indications of approved products, from the time of the formation of the collaboration. The related intangible asset that is recognized is amortized to Cost of sales over its remaining useful life, subject to impairment testing.
Share-Based Compensation — The Company expenses all share-based payments to employees over the requisite service period based on the grant-date fair value of the awards.
Restructuring Costs — The Company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. In accordance with existing benefit arrangements, future employee termination costs to be incurred in conjunction with involuntary separations are accrued when such separations are probable and estimable. When accruing these costs, the Company will recognize the amount within a range of costs that is the best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company recognizes the minimum amount within the range. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period.
Contingencies and Legal Defense Costs — The Company records accruals for contingencies and legal defense costs expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated.
Taxes on Income — Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. The Company evaluates tax positions to determine whether the benefits of tax positions are more likely than not of being sustained upon audit based on the technical merits of the tax position. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the amount of the benefit that is greater than 50% likely of being realized upon ultimate settlement in the financial statements. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit in the financial statements. The Company recognizes interest and penalties associated with uncertain tax positions as a component of Taxes on Income. The Company accounts for the tax effects of the tax on global intangible low-taxed income (GILTI) of certain foreign subsidiaries in the income tax provision in the period the tax arises. The Company’s policy for releasing disproportionate income tax effects from AOCL is to utilize the item-by-item approach.
Reclassifications — Certain reclassifications have been made to prior year amounts to conform to the current year presentation.
Use of Estimates — The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the U.S. (GAAP) and, accordingly, include certain amounts that are based on management’s best estimates and judgments. Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities in a business combination (primarily IPR&D, other intangible assets and contingent consideration), as well as subsequent fair value measurements. Additionally, estimates are used in determining such items as provisions for sales discounts, rebates and returns, depreciable and amortizable lives, recoverability of inventories, including those produced in preparation for product launches, amounts recorded for contingencies, environmental liabilities, accruals for contingent sales-
83

based milestone payments and other reserves, pension and other postretirement benefit plan assumptions, share-based compensation assumptions, restructuring costs, impairments of long-lived assets (including intangible assets and goodwill) and investments, and taxes on income. Because of the uncertainty inherent in such estimates, actual results may differ from these estimates.
Recently Adopted Accounting Standards — In August 2023, the Financial Accounting Standards Board (FASB) issued amended guidance that requires a newly formed joint venture to recognize and initially measure its assets and liabilities at fair value upon formation. The amended guidance includes exceptions to fair value measurement that are consistent with the accounting for business combinations guidance. The Company adopted the guidance effective July 1, 2024 on a prospective basis. There was no impact to the Company’s consolidated financial statements upon adoption.
In November 2023, the FASB issued guidance intended to improve reportable segment disclosure requirements, primarily through expanded disclosures for significant segment expenses. The Company adopted the guidance effective for the 2024 annual period. The guidance resulted in incremental disclosures to the Company’s segment reporting disclosures. See Note 18 for further details.
Recently Issued Accounting Standards Not Yet Adopted — In December 2023, the FASB issued guidance intended to improve the transparency of income tax disclosures by requiring consistent categories and disaggregation of information in the effective income tax rate reconciliation and income taxes paid disclosures by jurisdiction. The guidance also includes other amendments to improve the effectiveness of income tax disclosures by removing certain previously required disclosures. The guidance is effective for 2025 annual reporting. The guidance will result in incremental disclosures within the footnotes to the Company’s financial statements.
In November 2024, the FASB issued guidance intended to improve financial reporting by requiring entities to disclose additional information about specific expense categories at interim and annual reporting periods. The guidance is effective for 2027 annual reporting and 2028 interim reporting. Early adoption is permitted. The guidance, which can be applied on a prospective or retrospective basis, will result in incremental disclosures within the footnotes to the Company’s financial statements.
3.    Acquisitions, Divestitures, Research Collaborations and Licensing Agreements
The Company continues to pursue acquisitions and the establishment of external alliances such as research collaborations and licensing agreements to complement its internal research capabilities. These arrangements often include upfront payments; expense reimbursements or payments to the third party; milestone, royalty or profit share arrangements contingent upon the occurrence of certain future events linked to the success of the asset in development; and can also include option and continuation payments. The Company also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial results of the acquired entity are not significant when compared with the Company’s financial results.
Recent Transactions
In January 2025, Merck and WuXi Vaccines, a wholly owned subsidiary of WuXi Biologics, entered into a definitive agreement pursuant to which Merck will acquire WuXi Vaccines’ facility in Dundalk, Ireland for a payment of approximately $440 million at closing. The transaction is expected to close in the first quarter of 2025, subject to the satisfaction of customary closing conditions. There are no future contingent payments associated with the acquisition.
2024 Transactions
In December 2024, Merck closed an exclusive global license to develop, manufacture and commercialize MK-2010 (LM-299), a novel investigational PD-1/vascular endothelial growth factor (VEGF) bispecific antibody from LaNova Medicines Ltd (LaNova). Merck recorded a charge of $588 million to Research and development expenses in 2024 for the upfront payment, which was made in January 2025. LaNova is also eligible to receive $300 million upon technology transfer, which is anticipated to be completed in 2025, as well as future contingent developmental milestone payments of up to $140 million, regulatory milestone payments of up to $860 million and sales-based milestone payments of up to $1.4 billion.
Also in December 2024, Merck closed an exclusive global license to develop, manufacture and commercialize MK-4082 (HS-10535), an investigational preclinical oral small molecule GLP-1 receptor agonist from Hansoh Pharma (Hansoh). Merck recorded a charge of $112 million to Research and development expenses in 2024 for the upfront payment, which was made in February 2025. Hansoh is also eligible to receive future contingent
84

development-related milestone payments of up to $115 million, regulatory milestone payments of up to $315 million and sales-based milestone payments of up to $1.47 billion, as well as tiered royalties ranging from a high-single-digit rate to a low-double-digit rate on future net sales of MK-4082 (HS-10535), if approved. Under the agreement, Hansoh may co-promote or solely commercialize MK-4082 (HS-10535) in Chinese mainland, Hong Kong and Macau, subject to certain conditions.
In September 2024, Merck acquired MK-1045 (formally CN201), a novel investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases, from Curon Biopharmaceutical (Curon) for an upfront payment of $700 million. In addition, Curon is eligible to receive future contingent developmental milestone payments of up to $300 million and regulatory milestone payments of up to $300 million. The transaction was accounted for as an asset acquisition. Merck recorded a charge of $750 million (reflecting the upfront payment and other related costs) to Research and development expenses in 2024 related to the execution of the transaction. In connection with the agreement, Merck is also obligated to pay a third party future contingent developmental, regulatory and sales-based milestone payments of up to $128 million in the aggregate, as well as tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales of MK-1045, if approved.
In July 2024, Merck acquired the aqua business of Elanco Animal Health Incorporated (Elanco aqua business) for total consideration of $1.3 billion. The Elanco aqua business consists of an innovative portfolio of medicines and vaccines, nutritionals and supplements for aquatic species; two related aqua manufacturing facilities in Canada and Vietnam; as well as a research facility in Chile. The acquisition broadens Animal Health’s aqua portfolio with products, such as Clynav, a new generation DNA-based vaccine that protects Atlantic salmon against pancreas disease, and Imvixa, an anti-parasitic sea lice treatment. This acquisition also brings a portfolio of water treatment products for warm water production, complementing Animal Health’s warm water vaccine portfolio. In addition to these products, the DNA-based vaccine technology that is a part of the business has the potential to accelerate the development of novel vaccines to address the unmet needs of the aqua industry. There are no contingent payments associated with the acquisition, which was accounted for as a business combination.
The estimated fair values of assets acquired and liabilities assumed from the Elanco aqua business are as follows:
July 9, 2024
Inventories
$65 
Property, plant and equipment
66
Product rights - Clynav (useful life 15 years) (1)
340
Other product rights (useful lives 15 years) (1)
291
Other assets and liabilities, net23 
Total identifiable net assets785 
Goodwill (2)
518
Consideration transferred$1,303 
(1)    The estimated fair values of Clynav and other product rights were determined using an income approach, specifically the multi-period excess earnings method. The future probability-weighted net cash flows were discounted to present value utilizing a discount rate of 8.5%. Actual cash flows are likely to be different than those assumed.
(2)    The goodwill recognized is largely attributable to anticipated synergies expected to arise after the acquisition and was allocated to the Animal Health segment. The goodwill is expected to be deductible for tax purposes.
Also in July 2024, Merck acquired Eyebiotech Limited (EyeBio), a privately held ophthalmology-focused biotechnology company, for $1.2 billion (including payments to settle share-based equity awards) and also incurred $207 million of transaction costs. The acquisition agreement also provides for former EyeBio shareholders to receive future contingent developmental milestone payments of up to $200 million (of which $100 million was triggered and paid in 2024 as noted below), regulatory milestone payments of up to $1.0 billion and sales-based milestone payments of up to $500 million. EyeBio’s development work focused on candidates for the prevention and treatment of vision loss associated with retinal vascular leakage, a known risk factor for retinal diseases. EyeBio’s lead candidate, MK-3000 (formerly EYE103), is an investigational, potentially first-in-class tetravalent, tri-specific antibody that acts as an agonist of the Wingless-related integration site signaling pathway, which is in clinical development for the treatment of diabetic macular edema and neovascular age-related macular degeneration. The transaction was accounted for as an asset acquisition since MK-3000 accounted for substantially all of the fair value of the gross assets acquired (excluding cash and deferred income taxes). Merck recorded net assets of $21 million, as well as a charge of $1.35 billion to Research and development expenses in 2024 related to the acquisition. Additionally, a $100 million developmental milestone was triggered and paid in 2024 upon initiation of a Phase 2/3 clinical trial
85

evaluating MK-3000 for the treatment of diabetic macular edema, which was also recorded as a charge to Research and development expenses.
Additionally in July 2024, Merck and Orion Corporation (Orion) announced the mutual exercise of an option to convert the companies’ ongoing co-development and co-commercialization agreement for opevesostat (MK-5684/ODM-208), an investigational cytochrome P450 11A1 (CYP11A1) inhibitor in Phase 3 clinical development, and other candidates targeting CYP11A1, into an exclusive global license for Merck. With the exercise of the option, Merck assumed full responsibility for all past and future development and commercialization expenses associated with the candidates covered by the original agreement entered into in 2022 as discussed below. In addition, Orion became eligible to receive developmental milestone payments of up to $30 million, regulatory milestone payments of up to $625 million and sales-based milestone payments of up to $975 million, as well as annually tiered royalties ranging from a low double-digit rate up to a rate in the low twenties on net sales for any commercialized licensed product. Orion retained responsibility for the manufacture of clinical and commercial supply for Merck. No payment was associated with the exercise of the option, which became effective in September 2024.
Also in July 2024, Merck notified Kelun-Biotech (a holding subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.) it was terminating the license and collaboration agreement entered into in July 2022 in which Merck gained exclusive worldwide rights for the development, manufacture and commercialization of an investigational antibody drug conjugate (ADC) MK-1200 (SKB315) for the treatment of solid tumors. As a result of this termination, which became effective in September 2024, all rights to SKB315 have reverted to Kelun-Biotech.
In March 2024, Merck acquired Harpoon Therapeutics, Inc. (Harpoon), a clinical-stage immunotherapy company developing a novel class of T-cell engagers designed to harness the power of the body’s immune system to treat patients suffering from cancer and other diseases for $765 million and also incurred $56 million of transaction costs. Harpoon’s lead candidate, MK-6070 (formerly HPN328), is a T-cell engager targeting delta-like ligand 3 (DLL3), an inhibitory canonical Notch ligand that is expressed at high levels in small-cell lung cancer and neuroendocrine tumors. The transaction was accounted for as an asset acquisition since MK-6070 represented substantially all of the fair value of the gross assets acquired (excluding cash and deferred income taxes). Merck recorded net assets of $165 million, as well as a charge of $656 million to Research and development expenses in 2024 related to the transaction. There are no future contingent payments associated with the acquisition. In August 2024, Merck and Daiichi Sankyo expanded their existing global co-development and co-commercialization agreement to include MK-6070. See Note 4 for more information on Merck’s collaboration with Daiichi Sankyo.
2023 Transactions
In October 2023, Merck and Daiichi Sankyo entered into a global development and commercialization agreement for three of Daiichi Sankyo’s deruxtecan (DXd) ADC candidates: patritumab deruxtecan (HER3-DXd) (MK-1022), ifinatamab deruxtecan (I-DXd) (MK-2400) and raludotatug deruxtecan (R-DXd) (MK-5909). See Note 4 for additional information related to this collaboration.
In June 2023, Merck acquired Prometheus Biosciences, Inc. (Prometheus), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases. Total consideration paid of $11.0 billion included $1.2 billion of costs to settle share-based equity awards (including $700 million to settle unvested equity awards). Prometheus’ lead candidate, tulisokibart (MK-7240, formerly PRA023), is a humanized monoclonal antibody directed to tumor necrosis factor-like ligand 1A, a target associated with both intestinal inflammation and fibrosis. Tulisokibart is being developed for the treatment of immune-mediated diseases including ulcerative colitis, Crohn’s disease, and other autoimmune conditions. Phase 3 clinical trials evaluating tulisokibart for Crohn’s disease and ulcerative colitis are underway. The transaction was accounted for as an asset acquisition since tulisokibart accounted for substantially all of the fair value of the gross assets acquired (excluding cash and deferred income taxes). Merck recorded net assets of $877 million, including cash of $368 million, investments of $296 million, deferred tax assets of $218 million and other net liabilities of $5 million, as well as a charge of $10.2 billion to Research and development expenses in 2023 related to the transaction. There are no future contingent payments associated with the acquisition.
In February 2023, Merck and Kelun-Biotech closed a license and collaboration agreement expanding their relationship in which Merck gained exclusive rights for the research, development, manufacture and commercialization of up to seven investigational preclinical ADCs for the treatment of cancer. Kelun-Biotech retained the right to research, develop, manufacture and commercialize certain licensed and option ADCs for Chinese mainland, Hong Kong and Macau. Merck made an upfront payment of $175 million, which was recorded as a charge to Research and development expenses in 2023. In October 2023, Merck notified Kelun-Biotech it was terminating two of the seven candidates under the agreement. Subsequently, in April 2024, Merck notified Kelun-Biotech it was terminating one additional candidate under the agreement. In July 2024, Merck notified Kelun-Biotech that it was
86

exercising an existing license option for one of the candidates under the agreement, granting Merck a license for the development, manufacture and commercialization worldwide excluding China. There are now three candidates licensed under the original agreement and one candidate for which the license option remains unexercised. Merck paid Kelun-Biotech $38 million in connection with the July option exercise, following which Kelun-Biotech remains eligible to receive future contingent payments aggregating up to $540 million in development-related payments, $1.5 billion in regulatory milestones, and $3.1 billion in sales-based milestones, if Kelun-Biotech does not retain Chinese mainland, Hong Kong and Macau rights for the remaining option ADC and all remaining candidates achieve regulatory approval. In addition, Kelun-Biotech is eligible to receive tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales for any commercialized ADC product. Also, in connection with the agreement, Merck invested $100 million in Kelun-Biotech shares in January 2023.
In January 2023, Merck acquired Imago BioSciences, Inc. (Imago), a clinical-stage biopharmaceutical company developing new medicines for the treatment of myeloproliferative neoplasms and other bone marrow diseases, for $1.35 billion (including payments to settle share-based equity awards) and also incurred approximately $60 million of transaction costs. Imago’s lead candidate, bomedemstat (MK-3543, formerly IMG-7289), which is in Phase 3 clinical development, is an investigational orally available lysine-specific demethylase 1 inhibitor currently being evaluated in multiple clinical trials for the treatment of essential thrombocythemia, myelofibrosis, and polycythemia vera, in addition to other indications. The transaction was accounted for as an asset acquisition since bomedemstat represented substantially all of the fair value of the gross assets acquired (excluding cash and deferred income taxes). Merck recorded net assets of $219 million, as well as a charge of $1.2 billion to Research and development expenses in 2023 related to the transaction. There are no future contingent payments associated with the acquisition.
2022 Transactions
In October 2022, Merck and Royalty Pharma plc (Royalty Pharma) entered into a funding arrangement under which Royalty Pharma paid Merck $50 million to co-fund Merck’s development costs for a Phase 2b trial of MK-8189, an investigational oral phosphodiesterase 10A (PDE10A) inhibitor, which was being evaluated for the treatment of schizophrenia. As Royalty Pharma was sharing the risk of technical and regulatory success with Merck, the development funding was recognized by Merck as an obligation to perform contractual services. Accordingly, the payment received was recognized by Merck as a reduction to Research and development expenses ratably over the estimated Phase 2b research period. In 2024, it was determined the Phase 2b clinical trial for MK-8189 as a monotherapy for acute schizophrenia did not meet its primary efficacy endpoint; therefore, further development in schizophrenia, bipolar, and dementia indications has stopped, and the funding arrangement was terminated.
In September 2022, Merck exercised its option to jointly develop and commercialize V940 (mRNA-4157), an investigational individualized neoantigen therapy, pursuant to the terms of an existing collaboration and license agreement with Moderna, Inc. (Moderna). See Note 4 for additional information related to this collaboration.
In August 2022, Merck and Orna Therapeutics (Orna), a biotechnology company pioneering a new investigational class of engineered circular RNA (oRNA) therapies, entered into a collaboration agreement to discover, develop, and commercialize multiple programs, including vaccines and therapeutics in the areas of infectious disease and oncology. Under the terms of the agreement, Merck made an upfront payment to Orna of $150 million, which was recorded as a charge to Research and development expenses in 2022. In addition, Orna is eligible to receive future contingent payments aggregating up to $440 million in development-related payments, $675 million in regulatory milestones, and $2.4 billion in sales-based milestones associated with the progress of the multiple vaccine and therapeutic programs, as well as royalties ranging from a high-single-digit rate to a low-double-digit rate on any approved products derived from the collaboration. Merck also invested $100 million in Orna’s Series B preferred shares in 2022.
In July 2022, Merck and Orion Corporation (Orion) announced a global co-development and co-commercialization agreement for Orion’s investigational candidate opevesostat (MK-5684/ODM-208) and other drugs targeting cytochrome P450 11A1 (CYP11A1), an enzyme important in steroid production. Merck made an upfront payment to Orion of $290 million, which was recorded as a charge to Research and development expenses in 2022. Orion is responsible for the manufacture of clinical and commercial supply of opevesostat. In addition, the contract provided both parties with an option to convert the initial co-development and co-commercialization agreement into a global exclusive license to Merck, which was mutually exercised in July 2024 (as noted above).
In May 2022, in connection with an existing arrangement, Merck exercised its option to obtain an exclusive license outside of Chinese mainland, Hong Kong, Macau and Taiwan for the development, manufacture and commercialization of Kelun-Biotech’s trophoblast antigen 2 (TROP2)-targeting ADC programs, including its lead compound, sacituzumab tirumotecan (MK-2870/SKB-264), which is currently in Phase 3 clinical development. Under the terms of the agreement, Merck and Kelun-Biotech are collaborating on certain early clinical development plans,
87

including evaluating the potential of sacituzumab tirumotecan as a monotherapy and in combination with Keytruda for advanced solid tumors. Upon option exercise, Merck made a payment of $30 million, which was recorded as a charge to Research and development expenses in 2022. Additionally, Merck made an additional payment of $25 million upon technology transfer in 2023. Merck has also made all contingent developmental milestone payments under the agreement, which aggregated $90 million, nearly all of which were paid in 2024 and were recorded to Research and development expenses. In addition, Kelun-Biotech is eligible to receive future contingent milestone payments (which include all program compounds) aggregating up to $290 million in first commercial sale milestones, and $780 million in sales-based milestones. The agreement also provides for Merck to pay tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales.
Spin-Off of Organon & Co.
In connection with the 2021 spin-off of Organon & Co. (Organon), Merck and Organon entered into a series of interim operating agreements pursuant to which in various jurisdictions where Merck held licenses, permits and other rights in connection with marketing, import and/or distribution of Organon products prior to the separation, Merck continued to market, import and distribute such products on behalf of Organon until such time as the relevant licenses and permits transferred to Organon, with Organon receiving all of the economic benefits and burdens of such activities. As of December 31, 2024, only one jurisdiction remains under an interim operating agreement. Additionally, Merck and Organon entered into a number of manufacturing and supply agreements (MSAs) with terms ranging from four years to ten years. The amounts included in the consolidated statement of income for the above MSAs include sales of $392 million, $394 million and $383 million in 2024, 2023 and 2022, respectively, and related cost of sales of $390 million, $422 million and $404 million in 2024, 2023 and 2022, respectively. The amounts due from Organon under all spin-off related agreements were $330 million and $632 million at December 31, 2024 and 2023, respectively, and are reflected in Other current assets. The amounts due to Organon under these agreements were $113 million and $598 million at December 31, 2024 and 2023, respectively, and are included in Accrued and other current liabilities.
4.    Collaborative Arrangements
Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merck’s more significant collaborative arrangements are discussed below.
AstraZeneca PLC
In 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca’s Lynparza (olaparib) for multiple cancer types. Independently, Merck and AstraZeneca are developing and commercializing Lynparza in combinations with their respective PD-1 and PD-L1 medicines, Keytruda and Imfinzi. The companies are also jointly developing and commercializing AstraZeneca’s Koselugo (selumetinib) for multiple indications. Under the terms of the agreement, AstraZeneca and Merck share the development and commercialization costs for Lynparza and Koselugo monotherapy and non-PD-1/PD-L1 combination therapy opportunities.
Profits from Lynparza and Koselugo product sales generated through monotherapies or combination therapies are shared equally. AstraZeneca is the principal on Lynparza and Koselugo sales transactions. Merck records its share of Lynparza and Koselugo product sales, net of cost of sales and commercialization costs, as alliance revenue, and its share of development costs associated with the collaboration as part of Research and development expenses. Reimbursements received from AstraZeneca for research and development expenses are recognized as reductions to Research and development costs.
As part of the agreement, Merck made an upfront payment to AstraZeneca and also made payments over a multi-year period for certain license options. In addition, the agreement provides for contingent payments from Merck to AstraZeneca related to the successful achievement of sales-based and regulatory milestones.
In 2024, sales of Koselugo triggered a $100 million sales-based milestone payment from Merck to AstraZeneca. Accordingly, Merck recorded a $100 million liability (which remained accrued at December 31, 2024 and was subsequently paid in January 2025) and a corresponding increase to the intangible asset related to Koselugo. Merck also recognized $48 million of cumulative amortization catch-up expense related to the recognition of this milestone in 2024. Merck made a sales-based milestone payment to AstraZeneca of $400 million in 2022 (which had been previously accrued for). Additionally, in 2022, Merck determined it was probable that sales of Lynparza in the future would trigger a $600 million sales-based milestone payment from Merck to AstraZeneca. Accordingly, Merck recorded a $600 million liability (which remained accrued at December 31, 2024 and was
88

subsequently paid in January 2025) and a corresponding increase to the intangible asset related to Lynparza. Merck also recognized $250 million of cumulative amortization catch-up expense related to the recognition of this milestone in 2022. Potential future sales-based milestone payments of $2.0 billion have not yet been accrued as they are not deemed by the Company to be probable at this time.
Lynparza received regulatory approvals triggering capitalized milestone payments from Merck to AstraZeneca of $245 million, $105 million and $250 million in 2024, 2023 and 2022, respectively (each of which had been previously accrued for). In 2024, the partners agreed that no future regulatory milestone payments from Merck to AstraZeneca are likely under the agreement.
The intangible asset balances related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) and Koselugo (which reflects the 2024 capitalized sales-based milestone payment) were $1.2 billion and $49 million, respectively, at December 31, 2024 and are included in Other Intangibles, Net. The assets are being amortized over their estimated useful lives (through 2028 for Lynparza and through 2029 for Koselugo) as supported by projected future cash flows, subject to impairment testing.
Summarized financial information related to this collaboration is as follows:
Years Ended December 31202420232022
Alliance revenue - Lynparza$1,311 $1,199 $1,116 
Alliance revenue - Koselugo170 97 54 
Total alliance revenue$1,481 $1,296 $1,170 
Cost of sales (1)
378 311 492 
Selling, general and administrative165 192 185 
Research and development77 79 106 
December 3120242023
Receivables from AstraZeneca included in Other current assets
$424 $341 
Payables to AstraZeneca included in Accrued and other current liabilities (2)
713 256 
Payables to AstraZeneca included in Other Noncurrent Liabilities (2)
 600 
(1)    Represents amortization of capitalized milestone payments. Amounts in 2024 and 2022 include $48 million and $250 million, respectively, of cumulative amortization catch-up expense as noted above.
(2)    Includes accrued milestone payments.
Eisai Co., Ltd.
In 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Under the agreement, Merck and Eisai are developing and commercializing Lenvima jointly, both as monotherapy and in combination with Keytruda. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions) and Merck and Eisai share applicable profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue. Expenses incurred during co-development are shared by the two companies in accordance with the collaboration agreement and reflected in Research and development expenses. Certain expenses incurred solely by Merck or Eisai are not shareable under the collaboration agreement, including costs incurred in excess of agreed upon caps and costs related to certain combination studies of Keytruda and Lenvima.
Under the agreement, Merck made an upfront payment to Eisai and also made payments over a multi-year period for certain option rights. In addition, the agreement provides for contingent payments from Merck to Eisai related to the successful achievement of sales-based and regulatory milestones.
Merck made sales-based milestone payments to Eisai aggregating $125 million, $125 million and $600 million in 2024, 2023 and 2022, respectively. In 2023, Merck determined it was probable that sales of Lenvima in the future would trigger $250 million of sales-based milestone payments from Merck to Eisai. Accordingly, Merck recorded $250 million of liabilities (of which $125 million was subsequently paid in each of 2024 and 2023 as noted above) and corresponding increases to the intangible asset related to Lenvima. Merck also recognized $154 million of cumulative amortization catch-up expense related to the recognition of these milestones in 2023. Potential future sales-based milestone payments of $2.3 billion have not yet been accrued as they are not deemed by the Company to be probable at this time.
89

In 2022, Lenvima received regulatory approvals triggering capitalized milestone payments of $50 million from Merck to Eisai. There are no regulatory milestone payments remaining under the agreement.
The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was $442 million at December 31, 2024 and is included in Other Intangibles, Net. The amount is being amortized over its estimated useful life through 2026 as supported by projected future cash flows, subject to impairment testing.
Summarized financial information related to this collaboration is as follows:
Years Ended December 31202420232022
Alliance revenue - Lenvima$1,010 $960 $876 
Cost of sales (1)
241 381 212 
Selling, general and administrative159 189 158 
Research and development21 66 136 
December 3120242023
Receivables from Eisai included in Other current assets
$257 $226 
Payables to Eisai included in Accrued and other current liabilities (2)
 125 
(1)     Represents amortization of capitalized milestone payments. Amount in 2023 includes $154 million of cumulative amortization catch-up expense as noted above.
(2)     Represents an accrued milestone payment.
Bayer AG
In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Bayer’s Adempas (riociguat) and Verquvo (vericiguat). The two companies have implemented a joint development and commercialization strategy. Under the agreement, Bayer commercializes Adempas in the Americas, while Merck commercializes in the rest of the world. For Verquvo, Merck commercializes in the U.S. and Bayer commercializes in the rest of the world. Both companies share in development costs and profits on sales. Merck records sales of Adempas and Verquvo in its marketing territories, as well as alliance revenue. Alliance revenue represents Merck’s share of profits from sales of Adempas and Verquvo in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs. Cost of sales includes Bayer’s share of profits from sales in Merck’s marketing territories.
In addition, the agreement provided for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones. In 2022, Merck made the final $400 million sales-based milestone payment under this collaboration to Bayer.
The intangible asset balances related to Adempas (which includes the acquired intangible asset balance, as well as capitalized sales-based milestone payments attributed to Adempas) and Verquvo (which reflects the portion of the final sales-based milestone payment that was attributed to Verquvo) were $372 million and $42 million, respectively, at December 31, 2024 and are included in Other Intangibles, Net. The assets are being amortized over their estimated useful lives (through 2027 for Adempas and through 2031 for Verquvo) as supported by projected future cash flows, subject to impairment testing.

90

Summarized financial information related to this collaboration is as follows:
Years Ended December 31202420232022
Alliance revenue - Adempas/Verquvo$415 $367 $341 
Net sales of Adempas recorded by Merck287 255 238 
Net sales of Verquvo recorded by Merck37 36 22 
Total sales$739 $658 $601 
Cost of sales (1)
244 224 210 
Selling, general and administrative111 131 153 
Research and development102 90 75 
December 3120242023
Receivables from Bayer included in Other current assets
$160 $156 
Payables to Bayer included in Accrued and other current liabilities
82 80 
(1)    Includes amortization of intangible assets, cost of products sold by Merck, as well as Bayer’s share of profits from sales in Merck’s marketing territories.
Ridgeback Biotherapeutics LP
In 2020, Merck and Ridgeback Biotherapeutics LP (Ridgeback), a closely held biotechnology company, entered into a collaboration agreement to develop Lagevrio (molnupiravir), an investigational orally available antiviral candidate for the treatment of patients with COVID-19. Merck gained exclusive worldwide rights to develop and commercialize Lagevrio and related molecules. Following initial authorizations in certain markets in 2021, Lagevrio has since received multiple additional authorizations.
Under the terms of the agreement, Ridgeback received an upfront payment and is eligible to receive future contingent payments dependent upon the achievement of certain developmental and regulatory approval milestones. The agreement also provides for Merck to reimburse Ridgeback for a portion of certain third-party contingent milestone payments and royalties on net sales, which is part of the profit-sharing calculation. Merck is the principal on sales transactions, recognizing sales and related costs, with profit-sharing amounts recorded within Cost of sales. Profits from the collaboration are split equally between the partners. Reimbursements from Ridgeback for its share of research and development costs (deducted from Ridgeback’s share of profits) are reflected as decreases to Research and development expenses.
Summarized financial information related to this collaboration is as follows:
Years Ended December 31202420232022
Net sales of Lagevrio recorded by Merck
$964 $1,428 $5,684 
Cost of sales (1)
554 852 3,038 
Selling, general and administrative
57 97 147 
Research and development
13 60 88 
December 3120242023
Payables to Ridgeback included in Accrued and other current liabilities (2)
$68 $113 
(1)    Includes cost of products sold by Merck, Ridgeback’s share of profits, royalty expense, amortization of capitalized milestone payments and inventory reserves.
(2)    Includes accrued royalties.
Daiichi Sankyo
In October 2023, Merck and Daiichi Sankyo entered into a global development and commercialization agreement for three of Daiichi Sankyo’s DXd ADC candidates: patritumab deruxtecan (HER3-DXd) (MK-1022), ifinatamab deruxtecan (I-DXd) (MK-2400) and raludotatug deruxtecan (R-DXd) (MK-5909). All three potentially first-in-class DXd ADCs are in various stages of clinical development for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments. The companies will jointly develop and potentially commercialize these ADC candidates worldwide, except in Japan where Daiichi Sankyo will maintain exclusive rights. Daiichi Sankyo will be solely responsible for manufacturing and supply.
91

Under the terms of the agreement, Merck made payments to Daiichi Sankyo totaling $4.0 billion in 2023. These payments included $1.0 billion ($500 million each for patritumab deruxtecan and ifinatamab deruxtecan) which may be refundable on a pro-rated basis in the event of early termination of development with respect to either program. In addition, the agreement provided for a continuation payment of $750 million related to patritumab deruxtecan, which Merck paid in October 2024, and a continuation payment of $750 million related to raludotatug deruxtecan due from Merck in October 2025. If Merck does not make the remaining continuation payment for raludotatug deruxtecan, the rights for that program will revert to Daiichi Sankyo and the non-refundable upfront payments already paid will be retained by Daiichi Sankyo. The agreement also provides for contingent payments from Merck to Daiichi Sankyo of up to an additional $5.5 billion for each DXd ADC upon the successful achievement of certain sales-based milestones.
In conjunction with this transaction, Merck recorded an aggregate pretax charge of $5.5 billion to Research and development expenses in 2023 for the $4.0 billion of upfront payments and the $1.5 billion of continuation payments. Merck determined it was appropriate to expense the $1.0 billion refundable portion of the consideration in 2023 because of the significant number of clinical studies that were underway and planned in the near future, as well as certain studies in advanced stages, making it highly likely that the programs would continue to progress and incur substantial expenses, and therefore the likelihood of the programs terminating before the end of the refundable period was deemed remote. Merck also determined that it was appropriate to expense the continuation payments upon execution of the agreement because such payments do not result in the Company gaining any additional intellectual property rights. In addition, the significant number of ongoing and planned clinical studies and the short-term nature of the option period makes the likelihood of Merck not making these payments remote.
Merck and Daiichi Sankyo equally share research and development costs, except for raludotatug deruxtecan, where Merck is responsible for 75% of the first $2.0 billion of research and development expenses. Merck includes its share of development costs associated with the collaboration as part of Research and development expenses. Following regulatory approval, Daiichi Sankyo will generally record sales worldwide (Daiichi Sankyo will be the principal on sales transactions) and the companies will equally share expenses as well as profits worldwide except for Japan where Daiichi Sankyo retains exclusive rights and Merck will receive a 5% sales-based royalty. Merck will record its share of product sales, net of cost of sales and commercialization costs, as alliance revenue.
In August 2024, Merck and Daiichi Sankyo expanded their agreement to include MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, which Merck obtained through its acquisition of Harpoon (see Note 3). The companies are planning to evaluate MK-6070 in combination with ifinatamab deruxtecan in certain patients with SCLC, as well as other potential combinations. Merck received an upfront cash payment of $170 million from Daiichi Sankyo (recorded within Other (income) expense, net) and has also satisfied a contingent quid obligation from the original collaboration agreement. The companies will jointly develop and commercialize MK-6070 worldwide and share research and development and commercialization expenses. Research and development expenses related to MK-6070 in combination with ifinatamab deruxtecan will be shared in a manner consistent with the original agreement for ifinatamab deruxtecan. Merck will be solely responsible for manufacturing and supply of MK-6070. If approved, Merck will generally record sales for MK-6070 worldwide (Merck will be the principal on sales transactions) and the companies will equally share expenses as well as profits worldwide, except for Japan where Merck retains exclusive rights and Daiichi Sankyo will receive a 5% sales-based royalty.
Summarized financial information related to this collaboration is as follows:
Years Ended December 3120242023
Selling, general and administrative
$26 $3 
Research and development (1)
351 5,549 
December 3120242023
Receivables from Daiichi Sankyo included in Other current assets
$8 $ 
Payables to Daiichi Sankyo included in Accrued and other current liabilities (2)
817 800 
Payables to Daiichi Sankyo included in Other Noncurrent Liabilities (2)
 750 
(1)    Expenses in 2023 include the $5.5 billion charge for the upfront and continuing option payments noted above.
(2)    Includes accrued continuation payment.

92

Moderna, Inc.
In 2022, Merck exercised its option to jointly develop and commercialize V940 (mRNA-4157), an investigational individualized neoantigen therapy, pursuant to the terms of an existing collaboration and license agreement with Moderna, Inc. (Moderna), which resulted in a $250 million payment that was charged to Research and development expenses in 2022. V940 (mRNA-4157) is currently being evaluated in combination with Keytruda in multiple Phase 3 clinical trials. Merck and Moderna share costs and will share any profits equally under this worldwide collaboration. Merck records its share of development costs associated with the collaboration as part of Research and development expenses. Any reimbursements received from Moderna for research and development expenses are recognized as reductions to Research and development costs. Merck has also capitalized certain of the shared costs, mainly related to facility costs, which aggregated $198 million at December 31, 2024 and will be amortized over the assets’ estimated useful lives.
Summarized financial information related to this collaboration is as follows:
Years Ended December 31202420232022
Selling, general and administrative
$16 $5 $ 
Research and development (1)
358 218 288 
December 3120242023
Payables to Moderna included in Accrued and other current liabilities
$57 $63 
(1)    Expenses in 2022 include the $250 million option exercise payment noted above.
Bristol-Myers Squibb Company
Reblozyl (luspatercept-aamt) is a first-in-class erythroid maturation recombinant fusion protein that is being commercialized through a global collaboration with Bristol-Myers Squibb Company (BMS). Reblozyl is approved in the U.S., Europe, and certain other markets for the treatment of anemia in certain rare blood disorders and is also being evaluated for additional indications for hematology therapies. BMS is the principal on sales transactions for Reblozyl; however, Merck co-promotes Reblozyl (and may co-promote any future products approved under this collaboration) in North America, which is reimbursed by BMS. Merck receives tiered royalties ranging from 20% to 24% based on sales levels. This royalty will be reduced by 50% upon the earlier of patent expiry or generic entry on an indication-by-indication basis in each market. Additionally, Merck is eligible to receive future contingent sales-based milestone payments of up to $80 million. Alliance revenue related to this collaboration (recorded within Sales) consists of royalties and, for 2022, also includes the receipt of a regulatory approval milestone payment of $20 million. Merck recorded alliance revenue related to this collaboration of $371 million in 2024, $212 million in 2023 and $166 million in 2022.
5.    Restructuring
In January 2024, the Company approved a new restructuring program (2024 Restructuring Program) intended to continue the optimization of the Company’s Human Health global manufacturing network as the future pipeline shifts to new modalities and also optimize the Animal Health global manufacturing network to improve supply reliability and increase efficiency. The actions contemplated under the 2024 Restructuring Program are expected to be substantially completed by the end of 2031, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $4.0 billion. Approximately 60% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested. The remainder of the costs will result in cash outlays, relating primarily to facility shut-down costs. The Company recorded total pretax costs of $888 million and $190 million in 2024 and 2023, respectively, related to the 2024 Restructuring Program, bringing total cumulative pretax costs incurred through December 31, 2024 to $1.1 billion.
In 2019, Merck approved a global restructuring program (2019 Restructuring Program) as part of a worldwide initiative focused on optimizing the Company’s manufacturing and supply network, as well as reducing its global real estate footprint. The Company recorded total pretax costs of $743 million in 2023 and $666 million in 2022 related to the 2019 Restructuring Program. The actions under the 2019 Restructuring Program were substantially complete at the end of 2023 and, as of January 1, 2024, any remaining activities are being accounted for as part of the 2024 Restructuring Program.
For segment reporting, restructuring charges are unallocated expenses.

93

The following table summarizes the charges related to the restructuring programs by type of cost:
Accelerated
Depreciation
Separation
Costs
Other Exit Costs
Total
Year Ended December 31, 2024
2024 Restructuring Program
Cost of sales$254 $ $241 $495 
Selling, general and administrative  83 83 
Research and development  1 1 
Restructuring costs 122 187 309 
$254 $122 $512 $888 
Year Ended December 31, 2023
2024 Restructuring Program
Cost of sales$ $ $62 $62 
Restructuring costs 115 13 128 
 115 75 190 
2019 Restructuring Program
Cost of sales131  18 149 
Selling, general and administrative9  113 122 
Research and development  1 1 
Restructuring costs 339 132 471 
 140 339 264 743 
$140 $454 $339 $933 
Year Ended December 31, 2022    
2019 Restructuring Program
Cost of sales$72 $ $133 $205 
Selling, general and administrative19  75 94 
Research and development29  1 30 
Restructuring costs 212 125 337 
 $120 $212 $334 $666 
Accelerated depreciation costs primarily relate to manufacturing, research and administrative facilities and equipment to be sold or closed as part of the programs. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. All the sites will continue to operate up through the respective closure dates and, since future undiscounted cash flows are sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of the site assets. Anticipated site closure dates, particularly related to manufacturing locations, have been and may continue to be adjusted to reflect changes resulting from regulatory or other factors.
Separation costs are associated with actual headcount reductions, as well as involuntary headcount reductions which were probable and could be reasonably estimated.
Other exit costs in 2024, 2023 and 2022 include asset impairment, facility shut-down and other related costs, as well as pretax gains and losses resulting from the sales of facilities and related assets. Additionally, other activity includes certain employee-related costs associated with pension and other postretirement benefit plans (see Note 13) and share-based compensation.

94

The following table summarizes the charges and spending relating to restructuring program activities:
Accelerated
Depreciation
Separation
Costs
Other Exit Costs
Total
Restructuring reserves January 1, 2023
$ $479 $34 $513 
Expenses140 454 339 933 
(Payments) receipts, net (252)(158)(410)
Non-cash activity(140) (184)(324)
Restructuring reserves December 31, 2023
 681 31 712 
Expenses254 122 512 888 
(Payments) receipts, net (239)(206)(445)
Non-cash activity(254) (337)(591)
Restructuring reserves December 31, 2024
$ $564 $ $564 
6.    Financial Instruments
Derivative Instruments and Hedging Activities
The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.
A significant portion of the Company’s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives of and accounting related to the Company’s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.

Foreign Currency Risk Management
The Company has established revenue hedging, balance sheet risk management and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.
The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S. dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than two years into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and foreign exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts, and purchased collar options.
The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or OCI depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in AOCL and reclassified into Sales when the hedged anticipated revenue is recognized. The amount reclassified into earnings as a result of the discontinuation of cash flow hedges because it was no longer deemed probable the forecasted hedged transactions would occur was not material for the years ended December 31, 2024, 2023 or 2022. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in Sales each period. The cash flows from both designated and non-designated contracts are reported as operating activities in the Consolidated Statement of Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.
The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of foreign exchange on monetary assets and liabilities. Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in Other (income) expense, net. The Company also uses a balance sheet risk management program to mitigate the exposure of such assets and liabilities from the effects of volatility in foreign exchange. Merck principally utilizes forward exchange contracts to
95

offset the effects of foreign exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the foreign exchange rate and the cost of the hedging instrument (primarily the euro, Swiss franc, Japanese yen, and Chinese renminbi). The forward contracts are not designated as hedges and are marked to market through Other (income) expense, net. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than six months. The cash flows from these contracts are reported as operating activities in the Consolidated Statement of Cash Flows.
The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in foreign exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within OCI, and remain in AOCL until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded components). Changes in fair value of the excluded components are recognized in OCI. The Company recognizes in earnings the initial value of the excluded components on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Consolidated Statement of Cash Flows.
Foreign exchange risk is also managed through the use of foreign currency debt. Certain of the Company’s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within OCI.
The effects of the Company’s net investment hedges on OCI and the Consolidated Statement of Income are shown below:
Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income (1)
Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing
Years Ended December 31202420232022202420232022
Net Investment Hedging Relationships
Foreign exchange contracts$(30)$ $(48)$(4)$1 $(1)
Euro-denominated notes(192)105 (162)   
(1)    No amounts were reclassified from AOCL into income related to the sale of a subsidiary.

Interest Rate Risk Management
The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal at risk.
At December 31, 2024, the Company was a party to six pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of the fixed-rate notes as detailed in the table below.
Par Value of DebtNumber of Interest Rate Swaps HeldTotal Swap Notional Amount
4.50% notes due 2033
$1,500 6 $1,500 
The interest rate swap contracts are designated hedges of the fair value changes in the notes attributable to changes in the benchmark Secured Overnight Financing Rate (SOFR) swap rate. The fair value changes in the notes attributable to changes in the SOFR swap rate are recorded in interest expense along with the offsetting fair value changes in the swap contracts. In January 2025, the Company entered into an additional interest rate swap contract with a notional amount of $250 million related to its 5.00% notes due 2053. The cash flows from these contracts are reported as operating activities in the Consolidated Statement of Cash Flows.

96

The table below presents the location of amounts recorded in the Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges as of December 31:
Carrying Amount of Hedged Liabilities
Cumulative Amount of Fair Value Hedging Adjustment Increase Included in the Carrying Amount
2024202320242023
Balance Sheet Caption
Long-Term Debt $1,509 $1,056 $17 $56 
Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments as of December 31:
  20242023
  Fair Value of
Derivative
U.S. Dollar
Notional
Fair Value of
Derivative
U.S. Dollar
Notional
 AssetLiabilityAssetLiability
Derivatives Designated as Hedging InstrumentsBalance Sheet Caption      
Interest rate swap contracts
Other Assets
$17 $ $1,500 $57 $— $1,000 
Foreign exchange contractsOther current assets323  8,662 106 — 6,138 
Foreign exchange contractsOther Assets66  2,125 26 — 1,929 
Foreign exchange contractsAccrued and other current liabilities 1 162 — 76 3,680 
Foreign exchange contractsOther Noncurrent Liabilities 1 16 — 1 7 
  $406 $2 $12,465 $189 $77 $12,754 
Derivatives Not Designated as Hedging InstrumentsBalance Sheet Caption      
Foreign exchange contractsOther current assets$323 $ $12,544 $153 $— $9,693 
Foreign exchange contractsAccrued and other current liabilities 343 13,551 — 162 8,104 
  $323 $343 $26,095 $153 $162 $17,797 
  $729 $345 $38,560 $342 $239 $30,551 
As noted above, the Company records its derivatives on a gross basis in the Consolidated Balance Sheet. The Company has master netting agreements with several of its financial institution counterparties (see Concentrations of Credit Risk below). The following table provides information on the Company’s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes as of December 31:
20242023
AssetLiabilityAssetLiability
Gross amounts recognized in the consolidated balance sheet$729 $345 $342 $239 
Gross amounts subject to offset in master netting arrangements not offset in the consolidated balance sheet(299)(299)(215)(215)
Cash collateral received
(165) (3) 
Net amounts$265 $46 $124 $24 

97

The table below provides information regarding the location and amount of pretax gains and losses of derivatives designated in fair value or cash flow hedging relationships:
Years Ended December 31202420232022202420232022202420232022
Financial Statement Caption in which Effects of Fair Value or Cash Flow Hedges are RecordedSales
Other (income) expense, net (1)
Other comprehensive income (loss)
$64,168 $60,115 $59,283 $(24)$466 $1,501 $216 $(393)$(339)
(Gain) loss on fair value hedging relationships:
Interest rate swap contracts
Hedged items — — (39)56 (13) — — 
Derivatives designated as hedging instruments — — 39 (57)4  — — 
Impact of cash flow hedging relationships:
Foreign exchange contracts
Amount of gain recognized in OCI on derivatives
 — —  — — 508 114 684 
Increase in Sales as a result of AOCL reclassifications
167 249 773  — — (167)(249)(773)
Interest rate contracts
Amount of gain recognized in Other (income) expense, net on derivatives
 — — (1)(1)(2) — — 
Amount of (loss) gain recognized in OCI on derivatives
 — —  — — (1)13 (2)
(1)    Interest expense is a component of Other (income) expense, net.
The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:
Amount of Derivative Pretax Loss (Gain) Recognized in Income
Years Ended December 31202420232022
Derivatives Not Designated as Hedging InstrumentsIncome Statement Caption
Foreign exchange contracts (1)
Other (income) expense, net$251 $(6)$(49)
Foreign exchange contracts (2)
Sales(28)5 (37)
(1)    These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates.
(2)     These derivative contracts serve as economic hedges of forecasted transactions.
At December 31, 2024, the Company estimates $262 million of pretax net unrealized gains on derivatives maturing within the next 12 months that hedge foreign currency denominated sales over that same period will be reclassified from AOCL to Sales. The amount ultimately reclassified to Sales may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual foreign exchange rates at maturity.

98

Investments in Debt and Equity Securities
Information on investments in debt and equity securities at December 31 is as follows:
 
 20242023
 Amortized
Cost
Gross UnrealizedFair
Value
Amortized
Cost
Gross UnrealizedFair
Value
GainsLossesGainsLosses
Commercial paper$348 $ $ $348 $252 $ $ $252 
U.S. government and agency securities188   188 72  72 
Corporate notes and bonds    13   13 
Total debt securities$536 $ $ $536 $337 $ $ $337 
Publicly traded equity securities (1)
920 764 
Total debt and publicly traded equity securities$1,456 $1,101 
(1)    Unrealized net losses of $30 million were recorded in Other (income) expense, net in 2024 on equity securities still held at December 31, 2024. Unrealized net gains of $411 million were recorded in Other (income) expense, net in 2023 on equity securities still held at December 31, 2023.
At December 31, 2024 and 2023, the Company also had $863 million and $832 million, respectively, of equity investments without readily determinable fair values included in Other Assets. The Company records unrealized gains on these equity investments based on favorable observable price changes from transactions involving similar investments of the same investee and records unrealized losses based on unfavorable observable price changes, which are included in Other (income) expense, net. During 2024, the Company recorded unrealized gains of $19 million and unrealized losses of $51 million related to certain of these equity investments still held at December 31, 2024. During 2023, the Company recorded unrealized gains of $10 million and unrealized losses of $61 million related to certain of these equity investments still held at December 31, 2023. Cumulative unrealized gains and cumulative unrealized losses based on observable price changes for investments in equity investments without readily determinable fair values still held at December 31, 2024 were $309 million and $107 million, respectively.
At December 31, 2024, 2023 and 2022, the Company also had $267 million, $417 million and $598 million, respectively, recorded in Other Assets for equity securities held through ownership interests in investment funds. Losses recorded in Other (income) expense, net relating to these investment funds were $29 million, $106 million and $1.0 billion for the years ended December 31, 2024, 2023 and 2022, respectively.
Fair Value Measurements
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest:
Level 1 — Quoted prices (unadjusted) in active markets for identical assets or liabilities.
Level 2 — Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3 — Unobservable inputs that are supported by little or no market activity. Level 3 assets or liabilities are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as assets or liabilities for which the determination of fair value requires significant judgment or estimation.
If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.


99

Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
Financial assets and liabilities measured at fair value on a recurring basis at December 31 are summarized below:
 Fair Value Measurements UsingFair Value Measurements Using
Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
  20242023
Assets
Investments
Commercial paper$ $348 $ $348 $ $252 $ $252 
U.S. government and agency securities 99  99     
Publicly traded equity securities463   463 252   252 
 463 447  910 252 252  504 
Other assets (1)
U.S. government and agency securities89   89 72   72 
Corporate notes and bonds    13   13 
Publicly traded equity securities (2)
457   457 512   512 
546   546 597   597 
Derivative assets (3)
Forward exchange contracts 499  499  202  202 
Purchased currency options 213  213  83  83 
Interest rate swaps 17  17  57  57 
  729  729  342  342 
Total assets$1,009 $1,176 $ $2,185 $849 $594 $ $1,443 
Liabilities
Other liabilities
Contingent consideration$ $ $193 $193 $ $ $354 $354 
Derivative liabilities (3)
Forward exchange contracts 338  338  239  239 
Written currency options 7  7     
 345  345  239  239 
Total liabilities$ $345 $193 $538 $ $239 $354 $593 
(1)    Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.
(2)    Balance at December 31, 2024 includes securities with a fair value of $81 million, which are subject to a contractual sale restriction that expires in March 2025. Balance at December 31, 2023 includes securities with a fair value of $177 million, which were subject to a contractual sale restriction that expired in July 2024.
(3)    The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company’s own credit risk, the effects of which were not significant.
As of December 31, 2024 and 2023, Cash and cash equivalents included $12.3 billion and $6.0 billion of cash equivalents, respectively (which would be considered Level 2 in the fair value hierarchy).
Contingent Consideration
Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:
20242023
Fair value January 1$354 $456 
Changes in estimated fair value (1)
(10)15 
Payments(151)(117)
Fair value December 31 (2)
$193 $354 
(1)    Recorded in Cost of sales, Research and development expenses, and Other (income) expense, net. Includes cumulative translation adjustments.
(2)    Balance at December 31, 2024 includes $148 million of current liabilities, of which $123 million relates to the termination of the Sanofi Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate to present value the cash flows.
100

The payments of contingent consideration in 2024 include $126 million related to the Sanofi Pasteur MSD liabilities described above and $25 million related to the first commercial sale of Lyfnua (gefapixant) in the European Union (EU). The payments of contingent consideration in 2023 relate to the Sanofi Pasteur MSD liabilities.
Other Fair Value Measurements
Some of the Company’s financial instruments, such as cash and cash equivalents, receivables and payables, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.
The estimated fair value of loans payable and long-term debt (including current portion) at December 31, 2024, was $32.6 billion compared with a carrying value of $37.1 billion and at December 31, 2023, was $32.0 billion compared with a carrying value of $35.1 billion. Fair value was estimated using recent observable market prices and would be considered Level 2 in the fair value hierarchy.
Concentrations of Credit Risk
On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government issuers of securities and financial institutions with which it conducts business. Credit exposure limits are established to limit a concentration with any single issuer or institution. Cash and investments are placed in instruments that meet high credit quality standards, as specified in the Company’s investment policy guidelines.
The majority of the Company’s accounts receivable arise from product sales in the U.S., Europe and China and are primarily due from drug wholesalers, distributors and retailers, hospitals and government agencies. The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company also continues to monitor global economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets and its business. 
The Company’s customers with the largest accounts receivable balances are: McKesson Corporation, Cencora, Inc. and Cardinal Health, Inc., which represented approximately 21%, 21% and 13%, respectively, of total accounts receivable at December 31, 2024. Vaccines distributed by Chongqing Zhifei Biological Products Co., Ltd. (Zhifei) represent a substantial portion of total sales in China; however, nearly all of the accounts receivable for Zhifei were factored as of December 31, 2024, as part of the Company’s factoring program discussed below. The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business. Bad debts have been minimal. The Company does not normally require collateral or other security to support credit sales.
The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $2.1 billion and $3.0 billion of accounts receivable as of December 31, 2024 and 2023, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions, generally within thirty days after receipt. At December 31, 2024 and 2023, the Company had collected $55 million and $44 million, respectively, on behalf of the financial institutions, which is reflected as restricted cash in Other current assets, and the related obligation to remit the cash is recorded in Accrued and other current liabilities. The net cash flows related to these collections are reported as financing activities in the Consolidated Statement of Cash Flows. The cost of factoring such accounts receivable was de minimis.
Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements. The master agreements with several of the Company’s financial institution counterparties also include credit support annexes. These annexes contain provisions that require collateral to be exchanged depending on the value of the derivative assets and liabilities, the Company’s credit rating, and the credit rating of the counterparty. Cash collateral received by the Company from various counterparties was $165 million and $3 million at December 31, 2024 and 2023, respectively. The obligation to return such collateral is recorded in Accrued and other current liabilities.

101

7.    Inventories
Inventories at December 31 consisted of:
20242023
Finished goods$2,022 $1,954 
Raw materials and work in process8,831 8,037 
Supplies289 277 

11,142 10,268 
Decrease to LIFO cost(840)(562)
 $10,302 $9,706 
Recognized as:
Inventories$6,109 $6,358 
Other Assets4,193 3,348 
Inventories valued under the LIFO method comprised approximately $3.4 billion and $3.1 billion at December 31, 2024 and 2023, respectively, after reflecting the decrease to LIFO cost. Amounts recognized as Other Assets are comprised almost entirely of raw materials and work in process inventories. At December 31, 2024 and 2023, these amounts included $3.8 billion and $2.6 billion, respectively, of inventories not expected to be sold within one year. In addition, these amounts included $412 million and $790 million at December 31, 2024 and 2023, respectively, of inventories produced in preparation for product launches.
8.    Goodwill and Other Intangibles
The following table summarizes goodwill activity by segment:
PharmaceuticalAnimal HealthTotal
Balance January 1, 2023
$17,936 $3,268 $21,204 
Other (1)
(14)7 (7)
Balance December 31, 2023 (2)
17,922 3,275 21,197 
Acquisitions
 518 518 
Other (1)
(19)(28)(47)
Balance December 31, 2024 (2)
$17,903 $3,765 $21,668 
(1)    Includes cumulative translation adjustments on goodwill balances.
(2)    Accumulated goodwill impairment losses were $531 million at both December 31, 2024 and 2023.
Other acquired intangibles at December 31 consisted of:
 20242023
Gross
Carrying
Amount
Accumulated
Amortization
NetGross
Carrying
Amount
Accumulated
Amortization
Net
Product rights
$29,988 $19,066 $10,922 $23,643 $17,765 $5,878 
IPR&D430  430 6,816 — 6,816 
Trade names2,881 954 1,927 2,881 776 2,105 
Licenses and other8,863 5,772 3,091 8,263 5,051 3,212 
 $42,162 $25,792 $16,370 $41,603 $23,592 $18,011 
Some of the more significant acquired intangibles included in product rights, on a net basis, related to human health marketed products at December 31, 2024 were Winrevair, $5.9 billion; Reblozyl, $2.8 billion; and Zerbaxa, $260 million. Additionally, the Company had $4.3 billion of net acquired intangibles related to animal health at December 31, 2024, of which $1.7 billion related to product rights and $1.9 billion was attributable to trade names, primarily related to Allflex. At December 31, 2024, IPR&D primarily relates to MK-1026 (nemtabrutinib), obtained through the acquisition of ArQule, Inc. (ArQule), which had a balance of $418 million. Some of the more significant net intangible assets included in licenses and other above at December 31, 2024 include Lynparza, $1.2 billion, related to a collaboration with AstraZeneca; Lenvima, $442 million, related to a collaboration with Eisai; and Adempas, $372 million, related to a collaboration with Bayer. See Note 4 for additional information related to the intangible assets associated with these collaborations.
102

IPR&D that the Company acquires through business combinations represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. Amounts capitalized as IPR&D are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each IPR&D project, the Company will make a separate determination as to the then-useful life of the asset and begin amortization.
In 2023, the Company recorded a $779 million IPR&D impairment charge within Research and development expenses related to MK-7264, gefapixant, a non-narcotic, oral selective P2X3 receptor antagonist, that was in development for the treatment of refractory or unexplained chronic cough in adults. In December 2023, the FDA issued a Complete Response Letter (CRL) regarding the resubmission of Merck’s New Drug Application (NDA) for gefapixant. In the CRL, the FDA concluded that Merck’s application did not meet substantial evidence of effectiveness for treating refractory chronic cough and unexplained chronic cough. The CRL was not related to the safety of gefapixant. The marketing application for gefapixant was based on results from the COUGH-1 and COUGH-2 clinical trials. In January 2022, the FDA issued a CRL regarding Merck’s original NDA for gefapixant. In that CRL, the FDA requested additional information related to the cough counting system that was used to assess efficacy. Receipt of the second CRL from the FDA constituted a triggering event that required the evaluation of the gefapixant intangible asset for impairment. The Company estimated the current fair value of gefapixant utilizing an income approach, which calculates the present value of projected future cash flows. The market participant assumptions used to derive the forecasted cash flows were updated to reflect revised market launch plans, resulting in a reduction in the estimated fair value. The revised estimated fair value of gefapixant when compared with its related carrying value resulted in the impairment charge noted above. The remaining intangible asset balance related to Lyfnua (gefapixant) at December 31, 2024 of $21 million is included in product rights in the table above and is being amortized over its expected useful life as supported by projected future cash flows in the markets where it is approved including Japan and the EU.
In 2022, the Company recorded $1.7 billion of intangible asset impairment charges within Research and development expenses, of which $1.6 billion represents IPR&D impairment charges related to nemtabrutinib (MK-1026), an oral, reversible, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor currently being evaluated for the treatment of hematological malignancies that was obtained through the 2020 acquisition of ArQule. Following discussions with regulatory authorities in the third quarter of 2022, the development period for nemtabrutinib was extended, which constituted a triggering event that required the evaluation of the nemtabrutinib intangible asset for impairment. The Company estimated the current fair value of nemtabrutinib utilizing an income approach which calculates the present value of projected future cash flows. The market participant assumptions used to derive the forecasted cash flows were updated to reflect a delay in the anticipated launch date for nemtabrutinib, which resulted in lower cumulative revenue forecasts and a reduction in the estimated fair value. The revised estimated fair value of nemtabrutinib when compared with its related carrying value resulted in a $807 million impairment charge recorded in the third quarter of 2022. In December 2022, regulatory authorities provided additional feedback with respect to clinical study design that led to a further reassessment of the development plan for nemtabrutinib, which was expected to result in changes to the clinical study design, and corresponding delays in the anticipated approval and launch timelines, which constituted a triggering event. Utilizing an income approach, the forecasted cash flows were updated to reflect a decline in forecasted revenue coupled with an increase in development cost forecasts, which reduced projected cash flows lowering the estimated fair value of nemtabrutinib. The revised estimated fair value of nemtabrutinib when compared with its then-related carrying value resulted in a $780 million impairment charge. The remaining IPR&D intangible asset related to nemtabrutinib is $418 million. If the assumptions used to estimate the fair value of nemtabrutinib prove to be incorrect and the development of nemtabrutinib does not progress as anticipated thereby adversely affecting projected future cash flows, the Company may record an additional impairment charge in the future and such charge could be material. The Company also recorded an $80 million intangible asset impairment charge in 2022 related to derazantinib resulting from the termination of the out-licensing agreement and the decision by Merck not to pursue development of derazantinib.
The IPR&D projects that remain in development are subject to the inherent risks and uncertainties in drug development and it is possible that the Company will not be able to successfully develop and complete the IPR&D programs and profitably commercialize the underlying product candidates.
The Company may recognize additional non-cash impairment charges in the future related to marketed products or pipeline programs and such charges could be material.
Aggregate amortization expense primarily recorded within Cost of sales was $2.4 billion in 2024, $2.0 billion in 2023 and $2.1 billion in 2022. The estimated aggregate amortization expense for each of the next five years is as follows: 2025, $2.4 billion; 2026, $2.3 billion; 2027, $2.1 billion; 2028, $1.8 billion; 2029, $1.5 billion.

103

9.    Loans Payable, Long-Term Debt and Leases
Loans Payable
Loans payable at December 31, 2024 included $2.5 billion of notes due in 2025 and $149 million of long-dated notes that are subject to repayment at the option of the holders. Loans payable at December 31, 2023 included $1.3 billion of notes due in 2024 and $69 million of long-dated notes that are subject to repayment at the option of the holders. The weighted-average interest rate of commercial paper borrowings was 5.18% and 5.14% for the years ended December 31, 2024 and 2023, respectively. There were no commercial paper borrowings outstanding at December 31, 2024 or 2023.

Long-Term Debt
Long-term debt at December 31 consisted of:
20242023
2.15% notes due 2031
$1,989 $1,988 
2.75% notes due 2051
1,980 1,980 
3.70% notes due 2045
1,980 1,979 
3.40% notes due 2029
1,742 1,740 
4.50% notes due 2033
1,509 1,547 
1.70% notes due 2027
1,497 1,495 
2.90% notes due 2061
1,484 1,484 
5.00% notes due 2053
1,482 1,481 
4.00% notes due 2049
1,474 1,473 
4.15% notes due 2043
1,240 1,240 
1.45% notes due 2030
1,240 1,238 
2.45% notes due 2050
1,216 1,214 
1.875% euro-denominated notes due 2026
1,041 1,103 
0.75% notes due 2026
998 996 
1.90% notes due 2028
996 995 
5.15% notes due 2063
987 987 
3.90% notes due 2039
987 986 
2.35% notes due 2040
986 985 
3.25% euro-denominated notes due 2032
880  
3.50% euro-denominated notes due 2037
877  
3.70% euro-denominated notes due 2044
876  
3.75% euro-denominated notes due 2054
873  
4.30% notes due 2030
746 745 
4.90% notes due 2044
740 740 
6.50% notes due 2033
702 707 
1.375% euro-denominated notes due 2036
517 548 
2.50% euro-denominated notes due 2034
517 548 
4.05% notes due 2028
498 497 
3.60% notes due 2042
492 492 
6.55% notes due 2037
404 406 
5.75% notes due 2036
339 339 
5.95% debentures due 2028
307 307 
5.85% notes due 2039
271 271 
6.40% debentures due 2028
251 250 
6.30% debentures due 2026
135 135 
2.75% notes due 2025
 2,498 
Other209 289 
$34,462 $33,683 
Other (as presented in the table above) includes borrowings at variable rates that resulted in effective interest rates of 5.02% and 4.82% for 2024 and 2023, respectively.
With the exception of the 6.30% debentures due 2026, the notes listed in the table above are redeemable in whole or in part, at Merck’s option at any time, at varying redemption prices. Effective as of November 3, 2009, the Company executed a full and unconditional guarantee of the then existing debt of its subsidiary Merck Sharp & Dohme LLC. (MSD) and MSD executed a full and unconditional guarantee of the then existing debt of the Company
104

(excluding commercial paper), including for payments of principal and interest. These guarantees do not extend to debt issued subsequent to that date.
In May 2024, MSD Netherlands Capital B.V., a wholly owned finance subsidiary of Merck, completed a registered public offering of €3.4 billion in aggregate principal amount of euro-dominated senior notes comprised of €850 million of 3.25% senior notes due 2032, €850 million of 3.50% senior notes due 2037, €850 million of 3.70% senior notes due 2044 and €850 million of 3.75% senior notes due 2054 (collectively, the Euronotes). The Company has fully and unconditionally guaranteed all of MSD Netherlands Capital B.V.’s obligations under the Euronotes and no other subsidiary of the Company will guarantee these obligations. MSD Netherlands Capital B.V. is a “finance subsidiary” as defined in Rule 13-01(a)(4)(vi) of Regulation S-X of the Exchange Act, with no assets or operations other than those related to the issuance, administration and repayment of the Euronotes. The financial condition, results of operations and cash flows of MSD Netherlands Capital B.V. are consolidated in the financial statements of the Company. The net cash proceeds from the offering were used for general corporate purposes.
Certain of the Company’s borrowings require that Merck comply with covenants and, at December 31, 2024, the Company was in compliance with these covenants.
The aggregate maturities of long-term debt for each of the next five years are as follows: 2025, $2.6 billion; 2026, $2.2 billion; 2027, $1.5 billion; 2028, $2.1 billion; 2029, $1.7 billion. Interest payments related to these debt obligations are as follows: 2025, $1.2 billion; 2026, $1.2 billion; 2027, $1.1 billion; 2028, $1.1 billion; 2029, $1.0 billion.
The Company has a $6.0 billion credit facility that matures in May 2028. The facility provides backup liquidity for the Company’s commercial paper borrowing facility and is to be used for general corporate purposes. The Company has not drawn funding from this facility.
Leases
The Company has operating leases primarily for manufacturing facilities, research and development facilities, corporate offices, employee housing, vehicles and certain equipment. The Company determines if an arrangement is a lease at inception. When evaluating contracts for embedded leases, the Company exercises judgment to determine if there is an explicit or implicit identified asset in the contract and if Merck controls the use of that asset. Embedded leases, primarily associated with contract manufacturing organizations, are immaterial. The lease term includes options to extend or terminate the lease when it is reasonably certain that Merck will exercise that option. Real estate leases for facilities have an average remaining lease term of approximately six years, which include options to extend the leases for up to five years where applicable. Vehicle leases are generally in effect for four years. The Company elected to exclude short-term leases (leases with an initial term of 12 months or less) from the lease assets and liabilities on the balance sheet.
Lease expense for operating lease payments is recognized on a straight-line basis over the term of the lease. Operating lease assets and liabilities are recognized based on the present value of lease payments over the lease term. Since the Company’s leases do not have a readily determinable implicit discount rate, the Company uses its incremental borrowing rate to calculate the present value of lease payments by asset class. On a quarterly basis, an updated incremental borrowing rate is determined based on the average remaining lease term of each asset class and the Company’s pretax cost of debt for that same term. The updated rates for each asset class are applied prospectively to new leases. The Company does not separate lease components (e.g., payments for rent, real estate taxes and insurance costs) from non-lease components (e.g. common-area maintenance costs) in the event that the agreement contains both. Merck includes both the lease and non-lease components for purposes of calculating the right-of-use asset and related lease liability (if the non-lease components are fixed). For vehicle leases and employee housing, the Company applies a portfolio approach to account for the operating lease assets and liabilities.
Certain of the Company’s lease agreements contain variable lease payments that are adjusted periodically for inflation or for actual operating expense true-ups compared with estimated amounts; however, these amounts are immaterial. Sublease income was immaterial and there were no sale and leaseback transactions in 2024. Merck’s lease agreements do not contain any material residual value guarantees or material restrictive covenants.
Operating lease cost was $348 million in 2024, $339 million in 2023 and $334 million in 2022. Cash paid for amounts included in the measurement of operating lease liabilities was $357 million in 2024, $347 million in 2023 and $335 million in 2022. Operating lease assets obtained in exchange for lease obligations were $47 million in 2024, $122 million in 2023 and $57 million in 2022.

105

Supplemental balance sheet information related to operating leases is as follows:
December 3120242023
Assets
Other Assets (1)
$1,370 $1,437 
Liabilities
Accrued and other current liabilities282 285 
Other Noncurrent Liabilities877 928 
$1,159 $1,213 
Weighted-average remaining lease term (years)6.07.0
Weighted-average discount rate3.2 %3.3 %
(1)    Includes prepaid leases that have no related lease liability.
Maturities of operating leases liabilities are as follows:
2025$329 
2026292 
2027235 
2028146 
2029116 
Thereafter403 
Total lease payments1,521 
Less: Imputed interest362 
$1,159 
At December 31, 2024, the Company had entered into additional real estate operating leases that had not yet commenced; the obligations associated with these leases total $183 million.
10.    Contingencies and Environmental Liabilities
The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, commercial litigation, and securities litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of the Company, it is unlikely that the resolution of these matters will be material to the Company’s financial condition, results of operations or cash flows.
Given the nature of the litigation discussed below and the complexities involved in these matters, the Company is unable to reasonably estimate a possible loss or range of possible loss for such matters until the Company knows, among other factors, (i) what claims, if any, will survive dispositive motion practice, (ii) the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii) how the discovery process will affect the litigation, (iv) the settlement posture of the other parties to the litigation and (v) any other factors that may have a material effect on the litigation.
The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. Generally, for product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.
The Company’s decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.
106

Product Liability Litigation
Dr Scholl’s Foot Powder
As previously disclosed, Merck is a defendant in product liability lawsuits in the U.S. arising from consumers’ alleged exposure to talc in Dr. Scholl’s foot powder, which Merck acquired through its merger with Schering-Plough Corporation and sold as part of the divestiture of Merck’s consumer care business to Bayer in 2014. In these actions, plaintiffs allege that they were exposed to asbestos-contaminated talc and developed mesothelioma as a result. As of December 31, 2024, approximately 415 cases were pending against Merck in various state courts.
Gardasil/Gardasil 9
As previously disclosed, Merck is a defendant in product liability lawsuits in the U.S. involving Gardasil (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant) and Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant). As of December 31, 2024, approximately 225 cases were filed and pending against Merck in either federal or state court. In these actions, plaintiffs allege, among other things, that they suffered various personal injuries after vaccination with Gardasil or Gardasil 9, with postural orthostatic tachycardia syndrome (POTS) as a predominate alleged injury. In August 2022, the U.S. Judicial Panel on Multidistrict Litigation ordered that Gardasil/Gardasil 9 product liability cases pending in federal courts nationwide be transferred to Judge Robert J. Conrad in the Western District of North Carolina for coordinated pre-trial proceedings. In February 2024, the multidistrict litigation was reassigned to Judge Kenneth D. Bell. As previously disclosed, there are fewer than 15 product liability cases pending outside the U.S.
On January 28, 2025, a trial commenced in California state court. Plaintiff claims that she suffers from POTS and fibromyalgia as a result of her Gardasil vaccinations. On February 14, 2025, after four weeks of trial and an opportunity to litigate plaintiff’s claims before a jury, plaintiff’s counsel approached Merck and proposed that the jury be discharged and the case adjourned. Merck agreed, subject to an explicit stipulation that Merck would provide no financial or other consideration in exchange for the agreement to adjourn. The case has thus been adjourned until a new trial date of September 15, 2025. Merck is vigorously defending this case and believes that evidence presented in court will show that Gardasil had no role in causing any of plaintiff’s conditions.
Governmental Proceedings
Civil Investigative Demands
As previously disclosed, in June 2024, Merck received a Civil Investigative Demand (CID) from the U.S. Department of Justice, pursuant to a False Claims Act investigation, seeking documents and materials related to Steglatro, Januvia and certain related drugs. The CID states that it is investigating Merck’s price reporting under the Medicaid Drug Rebate Program as well as compliance with anti-kickback requirements in connection with patient assistance programs. The Company is cooperating with the investigation.
As previously disclosed, in June 2020, Merck received a CID from the U.S. Department of Justice. The CID requests answers to interrogatories, as well as various documents, regarding temperature excursions at a third-party storage facility containing certain Merck products. Merck is cooperating with the government’s investigation and intends to produce information and/or documents as necessary in response to the CID.
Inflation Reduction Act
As previously disclosed, in June 2023, Merck filed a complaint in the U.S. District Court for the District of Columbia against the U.S. government regarding the Inflation Reduction Act’s “Drug Price Negotiation Program” for Medicare (the Program). This litigation seeks relief from the Program by challenging its constitutionality as violative of the First and Fifth Amendments to the U.S. Constitution.
Other Matters
As previously disclosed, in April 2019, Merck received a set of investigative interrogatories from the California Attorney General’s Office pursuant to its investigation of conduct and agreements that allegedly affected or delayed competition to Lantus in the insulin market. The interrogatories seek information concerning Merck’s development of an insulin glargine product, and its subsequent termination, as well as Merck’s patent litigation against Sanofi S.A. concerning Lantus and the resolution of that litigation. Merck is cooperating with the California Attorney General’s investigation.
As previously disclosed, from time to time, the Company’s subsidiaries in China receive inquiries regarding their operations from various Chinese governmental agencies. Some of these inquiries may be related to matters involving other multinational pharmaceutical companies, as well as Chinese entities doing business with such companies. The Company’s policy is to cooperate with these authorities and to provide responses as appropriate.
107

As previously disclosed, from time to time, the Company receives inquiries and is the subject of preliminary investigation activities from competition and other governmental authorities in markets outside the U.S. These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings. Should those proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required.
Securities Litigation
In February 2025, a putative class action was filed against Merck and certain of its officers in the U.S. District Court for the District of New Jersey purportedly on behalf of all purchasers of Merck common stock between February 2022 and February 2025. Plaintiff alleges that Merck violated federal securities laws by making materially false and misleading statements and material omissions regarding demand for Gardasil/Gardasil 9 in China. Plaintiff seeks unspecified monetary damages, pre-judgment and post-judgment interest, and fees and costs.
Commercial and Other Litigation
Zetia Antitrust Litigation
As previously disclosed, Merck, MSD, Schering Corporation, Schering-Plough Corporation, and MSP Singapore Company LLC (collectively, the Merck Defendants) were defendants in a number of lawsuits filed in 2018 on behalf of direct and indirect purchasers of Zetia (ezetimibe) alleging violations of federal and state antitrust laws, as well as other state statutory and common law causes of action. The cases were consolidated in a federal multidistrict litigation (Zetia MDL) before Judge Rebecca Beach Smith in the Eastern District of Virginia. In April 2023, the Merck Defendants reached settlements with the direct purchaser and retailer plaintiffs and a settlement with the indirect purchaser class that the court approved in October 2023.
As previously disclosed, in 2020 and 2021, United Healthcare Services, Inc. (United Healthcare), Humana Inc. (Humana), Centene Corporation and others (Centene), and Kaiser Foundation Health Plan, Inc. (Kaiser) (collectively, the Insurer Plaintiffs), each filed a lawsuit in a jurisdiction outside of the Eastern District of Virginia against the Merck Defendants and others, making similar allegations as those made in the Zetia MDL, as well as additional allegations about Vytorin. These cases were transferred to the Eastern District of Virginia to proceed with the Zetia MDL.
In December 2023, the U.S. Judicial Panel on Multidistrict Litigation remanded the four Insurer Plaintiff cases to the transferor courts in the Northern District of California (Kaiser), the District of Minnesota (United Healthcare), and the District of New Jersey (Humana and Centene). The Merck Defendants filed motions to dismiss in each of the Insurer Plaintiff cases. On December 30, 2024, the court granted in part and denied in part the motions to dismiss in the Humana and Centene cases, and on January 29, 2025, Humana and Centene filed amended complaints.
RotaTeq Antitrust Litigation
As previously disclosed, in March 2023, the Mayor and City Council of Baltimore filed a putative class action against MSD in the Eastern District of Pennsylvania on behalf of all third-party payors in 35 states that indirectly purchased, paid, and/or provided reimbursement for some or all of the purchase price of RotaTeq (Rotavirus Vaccine, Live Oral, Pentavalent), other than for resale, from March 3, 2019 to the present. Plaintiff alleges that MSD violated federal and state antitrust laws and state consumer protection laws. Plaintiff alleges that MSD has implemented an anticompetitive vaccine bundling scheme whereby MSD leverages its alleged monopoly power in certain pediatric vaccine markets to maintain its alleged monopoly power in the U.S. market for rotavirus vaccines in order to charge supracompetitive prices for RotaTeq. Plaintiff seeks permanent injunctive relief and unspecified monetary damages on purchases of RotaTeq, trebled, and fees and costs. In May 2023, MSD moved to dismiss the complaint. In November 2023, the court granted in part and denied in part the motion to dismiss, dismissing plaintiff’s Idaho and Utah consumer law claims and allowing all other claims to proceed.
Bravecto Litigation
As previously disclosed, in January 2020, the Company was served with a complaint in the U.S. District Court for the District of New Jersey. Following motion practice, the plaintiffs filed a third amended complaint in August 2024, seeking to certify a nationwide class action of purchasers or users of Bravecto (fluralaner) products in the U.S. or its territories between May 1, 2014 and July 1, 2021. Plaintiffs contend Bravecto causes neurological events in dogs and cats and alleges violations of the New Jersey Consumer Fraud Act, Breach of Warranty, Product Liability, and related theories. The Company moved to dismiss or, alternatively, to strike the class allegations from the third amended complaint, and that motion is pending. A similar case was filed in Quebec, Canada in May 2019. The
108

Superior Court certified a class of dog owners in Quebec who gave Bravecto Chew to their dogs between February 16, 2017 and November 2, 2018 whose dogs experienced one of the conditions in the post-marketing adverse reactions section of the labeling approved on November 2, 2018. The Company and plaintiffs each appealed the class certification decision. The Court of Appeal of Quebec amended the class period to start July 2, 2014, allowed the second plaintiff to serve as a class representative, and modified the list of conditions in the class definition. The Company sought leave to appeal to the Supreme Court of Canada, which was denied. The case is proceeding in the Superior Court.
340B Program Litigation
As previously disclosed, Merck filed a complaint in the U.S. District Court for the District of Columbia to challenge the letter Merck received from the U.S. Health Resources and Services Administration (HRSA) in May 2022 regarding Merck’s 340B Program integrity initiative. On September 17, 2024, the court entered a consent judgment granting Merck the relief it had sought in the litigation, including declarations that HRSA’s May 2022 letter was unlawful and that the version of Merck’s 340B Program integrity initiative at issue in the litigation did not violate Section 340B on its face.
Qui Tam Litigation
As previously disclosed, in June 2012, the U.S. District Court for the Eastern District of Pennsylvania unsealed a complaint that had been filed against the Company under the federal False Claims Act by two former employees alleging, among other things, that the Company defrauded the U.S. government by falsifying data in connection with a clinical study conducted on the mumps component of the Company’s M-M-R II vaccine. The complaint alleges the fraud took place between 1999 and 2001. The U.S. government had the right to participate in and take over the prosecution of this lawsuit but notified the court that it declined to exercise that right. The two former employees pursued the lawsuit without the involvement of the U.S. government. In July 2023, the court denied relators’ motion for summary judgment, granted two of the Company’s motions for summary judgment, and denied the Company’s remaining motions for summary judgment as moot. The court entered judgment in favor of the Company and dismissed relators’ amended complaint in full with prejudice. Relators appealed that decision, and in August 2024, the Third Circuit affirmed the district court’s decision.
In addition, as previously disclosed, two putative class action lawsuits on behalf of direct purchasers of the M‑M‑R II vaccine, which charge that the Company misrepresented the efficacy of the M-M-R II vaccine in violation of federal antitrust laws and various state consumer protection laws, are pending in the Eastern District of Pennsylvania. The court granted the Company’s motion for summary judgment as to plaintiffs’ state law claims and denied the motion as to plaintiffs’ antitrust claim. The Company appealed, and on October 7, 2024, the Third Circuit reversed-in-part the district court’s order and remanded the case with instructions to enter summary judgment for the Company. On November 20, 2024, plaintiffs-appellees filed a petition for rehearing and rehearing en banc, and on February 10, 2025, the court denied the petition.
Merck KGaA Litigation
As previously disclosed, in January 2016, to protect its long-established brand rights in the U.S., the Company filed a lawsuit against Merck KGaA, Darmstadt, Germany (KGaA), historically operating as the EMD Group in the U.S., alleging it improperly uses the name “Merck” in the U.S. KGaA has filed suit against the Company in a number of jurisdictions outside of the U.S. alleging, among other things, unfair competition, trademark infringement and/or corporate name infringement. In certain of those jurisdictions, KGaA also alleges breach of the parties’ coexistence agreement. The litigation is ongoing in the U.S. with no trial date set, and also ongoing in jurisdictions outside of the U.S.
Patent Litigation
From time to time, generic manufacturers of pharmaceutical products file abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration (FDA) seeking to market generic forms of the Company’s products prior to the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file patent infringement lawsuits against such generic companies. Similar lawsuits defending the Company’s patent rights may exist in other countries. The Company intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened periods of exclusivity for these products and, with respect to products acquired through acquisitions accounted for as business combinations, potentially significant intangible asset impairment charges.
Bridion As previously disclosed, between January and November 2020, the Company received multiple Paragraph IV Certification Letters under the Hatch-Waxman Act notifying the Company that generic drug companies had filed applications to the FDA seeking pre-patent expiry approval to sell generic versions of Bridion (sugammadex)
109

Injection. In March, April and December 2020, the Company filed patent infringement lawsuits in the U.S. District Courts for the District of New Jersey and the Northern District of West Virginia against those generic companies. All actions in the District of New Jersey were consolidated. The West Virginia case was jointly dismissed with prejudice in August 2022 in favor of proceeding in New Jersey. The remaining defendants in the New Jersey action have stipulated to infringement of the asserted claims and withdrew all remaining claims and defenses other than a defense seeking to shorten the patent term extension (PTE) of the sugammadex patent to December 2022. The U.S. District Court for the District of New Jersey held a one-day trial in December 2022 on this remaining PTE calculation defense. The court ordered a post-trial briefing on this defense and held closing arguments in February 2023.
As previously disclosed, in June 2023, the U.S. District Court for the District of New Jersey ruled in Merck’s favor. The court held that Merck’s calculation of PTE for the sugammadex patent covering the compound is not invalid and that the U.S. Patent & Trademark Office correctly granted a full five-year extension. This ruling affirms and validates Merck’s U.S. patent protection for Bridion through at least January 2026. Also in June 2023, the U.S. District Court for the District of New Jersey issued a final judgment prohibiting the FDA from approving any of the pending or tentatively approved generic applications until January 27, 2026, except for any subsequent agreements between defendants and Merck or further order by the court.
In July 2023, defendants filed a notice of appeal with the U.S. Court of Appeals for the Federal Circuit. The appeal is currently pending. Oral argument took place on February 4, 2025.
While the New Jersey action was pending, the Company settled with five generic companies providing that these generic companies can bring their generic versions of Bridion to the market in January 2026 (which may be delayed by any applicable pediatric exclusivity) or earlier under certain circumstances. The Company agreed to stay the lawsuit filed against two generic companies, which in exchange agreed to be bound by a judgment on the merits of the consolidated action in the District of New Jersey. One of the generic companies in the consolidated action requested dismissal of the action against it and the Company did not oppose this request, which was subsequently granted by the court. The Company does not expect this company to bring its generic version of Bridion to the market before January 2026 or later, depending on any applicable pediatric exclusivity.
In February 2024, the Company received another Paragraph IV Certification Letter under the Hatch-Waxman Act notifying the Company that Hikma Pharmaceuticals USA Inc. (Hikma) had filed an application to the FDA seeking pre-patent expiry approval to sell a generic version of Bridion Injection. In March 2024, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Hikma, postponing FDA approval of the Hikma generic drug for 30 months or until expiration of the sugammadex patent (January 27, 2026) and any potentially applicable pediatric exclusivity or an adverse court decision, if any, whichever may occur earlier. Expiration of the patent, and any potentially applicable pediatric exclusivity, will occur earlier than expiry of the 30-month stay. On April 16, 2024, the district court stayed the case during the pendency of the Federal Circuit appeal noted above.
Januvia, Janumet, Janumet XR As previously disclosed, the FDA granted pediatric exclusivity with respect to Januvia (sitagliptin), Janumet (sitagliptin/metformin HCl), and Janumet XR (sitagliptin and metformin HCl extended-release), which provides a further six months of exclusivity in the U.S. beyond the expiration of all patents listed in the FDA’s Orange Book. Adding this exclusivity to the term of the key patent protection extended exclusivity on these products to January 2023. However, Januvia, Janumet, and Janumet XR contain sitagliptin phosphate monohydrate and the Company has another patent covering certain phosphate salt and polymorphic forms of sitagliptin that expires in May 2027, including pediatric exclusivity (salt/polymorph patent).
As previously disclosed, beginning in 2019, a number of generic drug companies filed ANDAs seeking approval of generic forms of Januvia and Janumet along with paragraph IV certifications challenging the validity of the salt/polymorph patent. The Company responded by filing infringement suits which have all been settled. The Company has settled with a total 26 generic companies providing that these generic companies can bring their generic versions of Januvia and Janumet to the market in the U.S. in May 2026 or earlier under certain circumstances, and their generic versions of Janumet XR to the market in July 2026 or earlier under certain circumstances.
In March 2021, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc., and Cadila Healthcare Ltd. (collectively, Zydus). In that lawsuit, the Company alleged infringement of the salt/polymorph patent based on the filing of Zydus’s NDA seeking approval of a form of sitagliptin that is a different from than that used in Januvia. In December 2022, the parties reached settlement that included dismissal of the case without prejudice enabling Zydus to seek final approval of a non-automatically substitutable product.
110

In January 2023, the Company received a Paragraph IV Certification Letter under the Hatch-Waxman Act notifying the Company that Zydus filed an ANDA seeking approval of sitagliptin/metformin HCl tablets and certifying that no valid or enforceable claim of any of the patents listed in FDA’s Orange Book for Janumet will be infringed by the proposed Zydus product. In March 2023, the parties reached settlement enabling Zydus to seek final approval of a non-automatically substitutable product containing a different form of sitagliptin than that used in Janumet. In November 2023, the Company received a Paragraph IV Certification Letter under the Hatch-Waxman Act notifying the Company that Zydus filed an ANDA seeking approval of sitagliptin/metformin HCl Extended Release tablets. In January 2024, the parties reached settlement enabling Zydus to seek final approval of a non-automatically substitutable version containing a different form of sitagliptin than that used in Janumet XR.
As a result of these settlement agreements related to the later expiring salt/polymorph patent directed to the specific sitagliptin salt form of the products, the Company expects that Januvia and Janumet will not lose market exclusivity in the U.S. until May 2026 and Janumet XR will not lose market exclusivity in the U.S. until July 2026, although Zydus has received FDA approval for a non-automatically substitutable form of sitagliptin that differs from the form in the Company’s sitagliptin products.
In March 2024, the Company received another Paragraph IV Certification Letter under the Hatch-Waxman Act from Azurity Pharmaceuticals, Inc. (Azurity) asserting that a different sitagliptin product subject to its ANDA does not infringe the salt/polymorph patent. In May 2024, Merck filed a civil action in the U.S. District Court of Delaware alleging infringement. The case was dismissed without prejudice in July 2024. Following the dismissal, the Company granted Azurity a covenant not to assert the salt/polymorph patent against the Azurity product that is the subject of such ANDA.
Supplementary Protection Certificates (SPCs) for Janumet expired in April 2023 for the majority of European countries. Prior to expiration, generic companies sought revocation of the Janumet SPCs in a number of European countries. In February 2022, a Finnish court referred certain questions to the Court of Justice of the European Union that could impact the validity of the Janumet SPCs in Europe. A decision was rendered on December 19, 2024. The decision provides guidance on points of law and does not directly apply these to the Janumet SPCs. Thus, additional proceedings in certain countries where generic companies were prevented from launching products during the SPC period may be necessary to determine whether the SPCs are valid and if not, whether damages are appropriate. Those countries include Belgium, Czech Republic, Ireland, Finland, France, Slovakia and Switzerland. If the Janumet SPCs are ultimately upheld, the Company has reserved its rights related to the pursuit of damages for those countries where a generic launched prior to expiry of the Janumet SPC.
In October 2023, the Company filed a patent infringement lawsuit against Sawai Pharmaceuticals Co., Ltd. and Medisa Shinyaku Co., Ltd (collectively, Defendants) in the Tokyo District Court seeking an injunction to stop the manufacture, sale and offer for sale of the Defendants’ sitagliptin dihydrogen phosphate product, while the Company’s patents and patent term extensions are in force. The lawsuit is in response to the Defendants’ application for marketing authorization to sell a generic sitagliptin dihydrogen phosphate product, in the anhydrate form, which was approved in August 2023. Merck asserts that the Defendants’ activity infringes a patent term extension associated with Merck’s patent directed to the sitagliptin compound patent.
Keytruda As previously disclosed, in November 2022, the Company filed a complaint against The Johns Hopkins University (JHU) in the U.S. District Court of Maryland. This action concerns patents emerging from a joint research collaboration between Merck and JHU regarding the use of pembrolizumab, which Merck sells under the trade name Keytruda. Merck and JHU partnered to design and conduct a clinical study administering Keytruda to cancer patients having tumors that had the genetic biomarker known as microsatellite instability-high (MSI-H). After the conclusion of the study, JHU secured U.S. patents citing the joint research study. Merck alleges that JHU has breached the collaboration agreement by filing and obtaining these patents without informing or involving Merck and then licensing the patents to others. Merck therefore brought this action for breach of contract, declaratory judgment of noninfringement, and promissory estoppel. JHU answered the complaint in April and May 2023, denying Merck’s claims, and counterclaiming for willful infringement of nine issued U.S. patents, including a demand for damages. Between November 30, 2023 and March 13, 2024, the Company filed inter partes review petitions with the United States Patent & Trademark Office Patent Trial and Appeal Board (PTAB), challenging the validity of all nine patents asserted in the case. Between June 2024 and October 2024, the PTAB instituted a review of all nine asserted patents. In July 2024, the district court granted Merck’s motion to stay the case in its entirety pending the outcome of the PTAB proceeding instituted in June 2024.
Lynparza As previously disclosed, in December 2022, AstraZeneca Pharmaceuticals LP received a Paragraph IV Certification Letter under the Hatch-Waxman Act notifying AstraZeneca that Natco Pharma Limited (Natco) has filed an application to the FDA seeking pre-patent expiry approval to sell generic versions of Lynparza (olaparib) tablet. In February 2023, AstraZeneca and the Company filed a patent infringement lawsuit in the U.S.
111

District Court for the District of New Jersey against Natco. This lawsuit, which asserts one or more patents covering olaparib, automatically stays FDA approval of the generic application until June 2025 or until an adverse court decision, if any, whichever may occur earlier. In May, June, July, and November 2024, AstraZeneca and the Company filed additional patent infringement lawsuits in the U.S. District Court for the District of New Jersey against Natco asserting additional patents covering olaparib.
In December 2023, AstraZeneca Pharmaceuticals LP received a second Paragraph IV Certification Letter under the Hatch-Waxman Act notifying AstraZeneca that Sandoz Inc. has filed an application to the FDA seeking pre-patent expiry approval to sell generic versions of Lynparza (olaparib) tablet. In February 2024, AstraZeneca and the Company filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Sandoz. This lawsuit, which asserts one or more patents covering olaparib, automatically stays FDA approval of the generic application until June 2026 or until an adverse court decision, if any, whichever may occur earlier. In May, July, and November 2024, AstraZeneca and the Company filed additional patent infringement lawsuits in the U.S. District Court for the District of New Jersey against Sandoz asserting additional patents covering olaparib.
In May 2024, AstraZeneca Pharmaceuticals LP received a third Paragraph IV Certification Letter under the Hatch-Waxman Act notifying AstraZeneca that Cipla USA, Inc. and Cipla Limited (collectively, Cipla) filed an application to the FDA seeking pre-patent expiry approval to sell generic versions of Lynparza (olaparib) tablet. In June 2024, AstraZeneca and the Company filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Cipla. This lawsuit, which asserts one or more patents covering olaparib, automatically stays FDA approval of the generic application until November 2026 or until an adverse court decision, if any, whichever may occur earlier. In June, July, and November 2024, AstraZeneca and the Company filed additional patent infringement lawsuits in the U.S. District Court for the District of New Jersey against Cipla asserting additional patents covering olaparib.
In November 2024, AstraZeneca Pharmaceuticals LP received another Paragraph IV Certification Letter under the Hatch-Waxman Act notifying AstraZeneca that Zydus Pharmaceuticals (USA) Inc. filed an application to the FDA seeking pre-patent expiry approval to sell generic versions of Lynparza (olaparib) tablet. In November 2024, AstraZeneca and the Company filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Zydus. This lawsuit, which asserts one or more patents covering olaparib, automatically stays FDA approval of the generic application until May 2027 or until an adverse court decision, if any, whichever may occur earlier. In November 2024, AstraZeneca and the Company filed an additional patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Zydus asserting an additional patent covering olaparib.
Other Litigation
There are various other pending legal proceedings involving the Company, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company’s financial condition, results of operations or cash flows either individually or in the aggregate.
Legal Defense Reserves
Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company’s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of December 31, 2024 and 2023 of approximately $225 million and $210 million, respectively, represents the Company’s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.
Environmental Matters
The Company and its subsidiaries are parties to a number of proceedings brought under the Comprehensive Environmental Response, Compensation and Liability Act, commonly known as Superfund, and other federal and state equivalents. These proceedings seek to require the operators of hazardous waste disposal facilities, transporters of waste to the sites and generators of hazardous waste disposed of at the sites to clean up the sites or
112

to reimburse the government for cleanup costs. The Company has been made a party to these proceedings as an alleged generator of waste disposed of at the sites. In each case, the government alleges that the defendants are jointly and severally liable for the cleanup costs. Although joint and several liability is alleged, these proceedings are frequently resolved so that the allocation of cleanup costs among the parties more nearly reflects the relative contributions of the parties to the site situation. The Company’s potential liability varies greatly from site to site. For some sites the potential liability is de minimis and for others the final costs of cleanup have not yet been determined. While it is not feasible to predict the outcome of many of these proceedings brought by federal or state agencies or private litigants, in the opinion of the Company, such proceedings should not ultimately result in any liability which would have a material adverse effect on the financial condition, results of operations or liquidity of the Company. The Company has taken an active role in identifying and accruing for these costs and such amounts do not include any reduction for anticipated recoveries of cleanup costs from former site owners or operators or other recalcitrant potentially responsible parties.
In management’s opinion, the liabilities for all environmental matters that are probable and reasonably estimable have been accrued and totaled $41 million and $42 million at December 31, 2024 and 2023, respectively. These liabilities are undiscounted, do not consider potential recoveries from other parties and will be paid out over the periods of remediation for the applicable sites, which are expected to occur primarily over the next 15 years. Although it is not possible to predict with certainty the outcome of these matters, or the ultimate costs of remediation, management does not believe that any reasonably possible expenditures that may be incurred in excess of the liabilities accrued should exceed approximately $46 million in the aggregate. Management also does not believe that these expenditures should result in a material adverse effect on the Company’s financial condition, results of operations or liquidity for any year.
11.    Equity
The Merck certificate of incorporation authorizes 6,500,000,000 shares of common stock and 20,000,000 shares of preferred stock.
Capital Stock
A summary of common stock and treasury stock transactions (shares in millions) is as follows:
 202420232022
  Common
Stock
Treasury
Stock
Common
Stock
Treasury
Stock
Common
Stock
Treasury
Stock
Balance January 13,577 1,045 3,577 1,039 3,577 1,049 
Purchases of treasury stock 11  13   
Issuances (1)
 (7) (7) (10)
Balance December 313,577 1,049 3,577 1,045 3,577 1,039 
(1)    Issuances primarily reflect activity under share-based compensation plans.
12.    Share-Based Compensation Plans
The Company has share-based compensation plans under which the Company grants restricted stock units (RSUs) and performance share units (PSUs) to certain management level employees. In addition, employees and non-employee directors may be granted options to purchase shares of Company common stock at the fair market value at the time of grant. These plans were approved by the Company’s shareholders.
At December 31, 2024, 75 million shares collectively were authorized for future grants under the Company’s share-based compensation plans. These awards are settled with treasury shares.
Employee stock options are granted to purchase shares of Company stock at the fair market value at the time of grant. These awards generally vest one-third each year over a three-year period, with a contractual term of 7-10 years. RSUs are stock awards that are granted to employees and entitle the holder to shares of common stock as the awards vest. The fair value of the stock option and RSU awards is determined and fixed on the grant date based on the Company’s stock price. PSUs are stock awards where the ultimate number of shares issued will be contingent on the Company’s performance against a pre-set objective or set of objectives. The fair value of each PSU is determined on the date of grant based on the Company’s stock price. For RSUs and PSUs, dividends declared during the vesting period are payable to the employees only upon vesting. Over the PSU performance period, the number of shares of stock that are expected to be issued will be adjusted based on the probability of achievement of a performance target and final compensation expense will be recognized based on the ultimate number of shares issued. RSU and PSU distributions will be in shares of Company stock after the end of the vesting or performance
113

period, subject to the terms applicable to such awards. PSU awards generally vest after three years. RSU awards generally vest one-third each year over a three-year period.
Total pretax share-based compensation cost recorded in 2024, 2023 and 2022 was $761 million, $645 million and $541 million, respectively. Income tax benefits for share-based compensation expense recognized in 2024, 2023 and 2022 were $117 million, $96 million and $78 million, respectively.
The Company uses the Black-Scholes option pricing model for determining the fair value of option grants. In applying this model, the Company uses both historical data and current market data to estimate the fair value of its options. The Black-Scholes model requires several assumptions including expected dividend yield, risk-free interest rate, volatility, and term of the options. The expected dividend yield is based on historical patterns of dividend payments. The risk-free interest rate is based on the rate at grant date of zero-coupon U.S. Treasury Notes with a term equal to the expected term of the option. Expected volatility is estimated using a blend of historical and implied volatility. The historical component is based on historical monthly price changes. The implied volatility is obtained from market data on the Company’s traded options. The expected life represents the amount of time that options granted are expected to be outstanding, based on historical and forecasted exercise behavior.
The weighted average exercise price of options granted in 2024, 2023 and 2022 was $129.22, $117.89 and $87.10 per option, respectively. The weighted average fair value of options granted in 2024, 2023 and 2022 was $25.60, $21.69 and $15.45 per option, respectively, and were determined using the following assumptions:
Years Ended December 31202420232022
Expected dividend yield3.0 %3.1 %3.1 %
Risk-free interest rate4.7 %3.4 %3.0 %
Expected volatility20.5 %22.4 %22.5 %
Expected life (years)5.85.85.9
Summarized information relative to stock option plan activity (options in thousands) is as follows:
Number
of Options
Weighted
Average
Exercise
Price
Weighted
Average
Remaining
Contractual
Term (Years)
Aggregate
Intrinsic
Value
Outstanding January 1, 2024
13,527 $77.54 
Granted1,753 129.22 
Exercised(2,581)68.90 
Forfeited(199)111.48   
Outstanding December 31, 2024
12,500 $86.04 5.9$249 
Vested and expected to vest December 31, 202412,201 $85.10 5.9$249 
Exercisable December 31, 20249,084 $74.00 4.9$241 
Additional information pertaining to stock option plans is provided in the table below:
Years Ended December 31202420232022
Total intrinsic value of stock options exercised$144 $95 $225 
Fair value of stock options vested32 30 30 
Cash received from the exercise of stock options177 125 384 

114

A summary of nonvested RSU and PSU activity (shares in thousands) is as follows:
 RSUsPSUs
  Number
of Shares
Weighted
Average
Grant Date
Fair Value
Number
of Shares
Weighted
Average
Grant Date
Fair Value
Nonvested January 1, 2024
12,542 $100.10 1,966 $90.80 
Granted6,356 128.79 968 121.91 
Vested(6,091)92.97 (1,109)73.50 
Forfeited(575)113.18 (59)121.12 
Nonvested December 31, 202412,232 $117.94 1,766 $117.57 
Expected to vest December 31, 202410,976 $117.25 1,669 $116.26 
At December 31, 2024, there was $1.1 billion of total pretax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards which will be recognized over a weighted average period of 1.9 years. For segment reporting, share-based compensation costs are unallocated expenses.
13.    Pension and Other Postretirement Benefit Plans
The Company has defined benefit pension plans covering eligible employees in the U.S. and in certain of its international subsidiaries. In addition, the Company provides medical benefits, principally to its eligible U.S. retirees and their dependents, through its other postretirement benefit plans. The Company uses December 31 as the year-end measurement date for all of its pension plans and other postretirement benefit plans.
Net Periodic Benefit Cost
The net periodic benefit cost (credit) for pension and other postretirement benefit plans consisted of the following components:
Pension Benefits
U.S.InternationalOther Postretirement Benefits
Years Ended December 31202420232022202420232022202420232022
Service cost$373 $326 $372 $243 $196 $283 $30 $32 $48 
Interest cost537 526 457 294 299 145 56 63 46 
Expected return on plan assets(826)(735)(753)(554)(517)(383)(80)(64)(86)
Amortization of unrecognized prior service (credit) cost
 (1)(32)(13)2 (14)(43)(49)(57)
Net loss (gain) amortization43  128 5 (3)96 (51)(42)(43)
Termination benefits5 3 2 1  1 4   
Curtailments 8 12  (1)  (1)(1)
Settlements 28 239 (1)(5)1    
Net periodic benefit cost (credit)$132 $155 $425 $(25)$(29)$129 $(84)$(61)$(93)
In connection with restructuring actions (see Note 5), termination charges were recorded in 2024, 2023 and 2022 on pension and other postretirement benefit plans related to expanded eligibility for certain employees exiting Merck. Also, in connection with these restructuring activities, curtailments and settlements were recorded on certain pension plans. Lump sum payments to U.S. pension plan participants also contributed to the settlements recorded during 2023 and 2022.
The components of net periodic benefit cost (credit) other than the service cost component are included in Other (income) expense, net (see Note 14), with the exception of certain amounts for termination benefits, curtailments and settlements, which are recorded in Restructuring costs if the event giving rise to the termination benefits, curtailment or settlement is related to restructuring actions.

115

Obligations and Funded Status
Summarized information about the changes in plan assets and benefit obligations, the funded status and the amounts recorded at December 31 is as follows:

Pension BenefitsOther
Postretirement
Benefits
U.S.International
202420232024202320242023
Fair value of plan assets January 1$9,804 $9,094 $9,562 $8,473 $1,045 $947 
Actual return on plan assets266 1,077 637 832 35 115 
Company contributions262 307 198 249 46 74 
Effects of exchange rate changes  (522)283   
Benefits paid(615)(497)(250)(256)(89)(95)
Settlements (177)(14)(53) (2)
Other  36 34 3 6 
Fair value of plan assets December 31$9,717 $9,804 $9,647 $9,562 $1,040 $1,045 
Benefit obligation January 1$10,446 $9,854 $9,042 $7,755 $1,104 $1,157 
Service cost373 326 243 196 30 32 
Interest cost537 526 294 299 56 63 
Actuarial (gains) losses (1)
(595)403 (549)766 32 (58)
Benefits paid(615)(497)(250)(256)(89)(95)
Effects of exchange rate changes  (473)288 (4)1 
Plan amendments  (56)14   
Curtailments 8  (1)  
Termination benefits5 3 1  4  
Settlements (177)(14)(53) (2)
Other  36 34 3 6 
Benefit obligation December 31$10,151 $10,446 $8,274 $9,042 $1,136 $1,104 
Funded status December 31$(434)$(642)$1,373 $520 $(96)$(59)
Recognized as:
Other Assets$26 $ $1,785 $1,019 $51 $107 
Accrued and other current liabilities(55)(49)(18)(19)(7)(8)
Other Noncurrent Liabilities(405)(593)(394)(480)(140)(158)
(1)    Actuarial (gains) losses primarily reflect changes in discount rates.
At December 31, 2024 and 2023, the accumulated benefit obligation was $18.1 billion and $19.1 billion, respectively, for all pension plans, of which $10.0 billion and $10.3 billion, respectively, related to U.S. pension plans.

116

Information related to the funded status of selected pension plans at December 31 is as follows:
U.S.International
2024202320242023
Pension plans with a projected benefit obligation in excess of plan assets
Projected benefit obligation
$9,517 $10,446 $1,847 $2,961 
Fair value of plan assets9,057 9,804 1,435 2,462 
Pension plans with an accumulated benefit obligation in excess of plan assets
Accumulated benefit obligation$442 $9,700 $1,768 $1,791 
Fair value of plan assets 9,186 1,385 1,336 
Plan Assets
Entities are required to use a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest:
Level 1 — Quoted prices (unadjusted) in active markets for identical assets or liabilities.
Level 2 — Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3 — Unobservable inputs that are supported by little or no market activity. The Level 3 assets are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as instruments for which the determination of fair value requires significant judgment or estimation. At December 31, 2024 and 2023, $700 million and $788 million, respectively, or approximately 4% of the Company’s pension investments were categorized as Level 3 assets.
If the inputs used to measure the financial assets fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.

117

The fair values of the Company’s pension plan assets at December 31 by asset category are as follows:
 Fair Value Measurements UsingFair Value Measurements Using
Level 1Level 2Level 3
NAV (1)
TotalLevel 1Level 2Level 3
NAV (1)
Total
20242023
U.S. Pension Plans
Cash and cash equivalents$43 $ $ $121 $164 $34 $ $ $124 $158 
Investment funds
Developed markets equities170   2,385 2,555 224   2,573 2,797 
Emerging markets equities   1,265 1,265    740 740 
Real estate   174 174    113 113 
Equity securities
Developed markets2,171    2,171 2,071    2,071 
Fixed income securities
Government and agency obligations 2,101   2,101  2,307   2,307 
Corporate obligations 1,293   1,293  1,485   1,485 
Mortgage and asset-backed securities 21   21  21   21 
Other investments (liabilities)
Derivatives(29)   (29)109    109 
Other  2  2   3  3 
Plan assets at fair value$2,355 $3,415 $2 $3,945 $9,717 $2,438 $3,813 $3 $3,550 $9,804 
International Pension Plans
Cash and cash equivalents$112 $ $ $11 $123 $98 $ $ $20 $118 
Investment funds
Developed markets equities599 3,537  96 4,232 507 3,257  106 3,870 
Government and agency obligations262 2,974  149 3,385 234 3,123  166 3,523 
Corporate obligations23 8  149 180 23 8  166 197 
Emerging markets equities54   91 145 44   66 110 
Other fixed income obligations8 7  4 19 9 8  3 20 
Real estate   12 12    10 10 
Equity securities
Developed markets287    287 278    278 
Fixed income securities
Government and agency obligations 368   368  423   423 
Corporate obligations 141   141  160   160 
Mortgage and asset-backed securities 54   54  61   61 
Other investments
Insurance contracts (2)
 1 698 2 701  1 785 2 788 
Other     4    4 
Plan assets at fair value$1,345 $7,090 $698 $514 $9,647 $1,197 $7,041 $785 $539 $9,562 
(1)    Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December 31, 2024 and 2023.
(2)    The plans’ Level 3 investments in insurance contracts are generally valued using a crediting rate that approximates market returns and invest in underlying securities whose market values are unobservable and determined using pricing models, discounted cash flow methodologies, or similar techniques.
118

The table below provides a summary of the changes in fair value, including transfers in and/or out, of all financial assets measured at fair value using significant unobservable inputs (Level 3) for the Company’s pension plan assets:
 20242023
Insurance
Contracts
OtherTotalInsurance
Contracts
OtherTotal
U.S. Pension Plans
Balance January 1$ $3 $3 $ $4 $4 
Actual return on plan assets:
Relating to assets still held at December 31 (2)(2) (2)(2)
Relating to assets sold during the year 2 2  2 2 
Purchases and sales, net (1)(1) (1)(1)
Balance December 31$ $2 $2 $ $3 $3 
International Pension Plans
Balance January 1$785 $ $785 $761 $ $761 
Actual return on plan assets:
Relating to assets still held at December 31(26) (26)77  77 
Purchases and sales, net(61) (61)(53) (53)
Balance December 31$698 $ $698 $785 $ $785 
The fair values of the Company’s other postretirement benefit plan assets at December 31 by asset category are as follows:
 Fair Value Measurements UsingFair Value Measurements Using
Level 1Level 2Level 3
NAV (1)
TotalLevel 1Level 2Level 3
NAV (1)
Total
20242023
Cash and cash equivalents$ $ $ $5 $5 $ $ $ $13 $13 
Investment funds
Developed markets equities3   46 49 24   277 301 
Emerging markets equities   24 24    80 80 
Real estate   3 3    12 12 
Equity securities
Developed markets41   41 223    223 
Fixed income securities
Corporate obligations 598  598  157   157 
Government and agency obligations 266  266  245   245 
Mortgage and asset-backed securities 54   54  2   2 
Other Investments (liabilities)
Derivatives     12    12 
Plan assets at fair value$44 $918 $ $78 $1,040 $259 $404 $ $382 $1,045 
(1)    Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December 31, 2024 and 2023.
The Company has established investment guidelines for its U.S. pension and other postretirement plans to create an asset allocation that is expected to deliver a rate of return sufficient to meet the long-term obligation of each plan, given an acceptable level of risk. The target investment portfolio of the Company’s U.S. pension and other postretirement benefit plans is allocated 25% to 40% in U.S. equities, 15% to 30% in international equities, 40% to 50% in fixed-income investments, and up to 8% in cash and other investments. The portfolio’s equity weighting is consistent with the long-term nature of the plans’ benefit obligations. The expected annual standard deviation of returns of the target portfolio, which approximates 12%, reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests. For international pension plans, the targeted investment portfolio varies based on the duration of pension liabilities and local government rules and regulations.
119

Although a significant percentage of plan assets are invested in U.S. equities, concentration risk is mitigated through the use of strategies that are diversified within management guidelines.
Expected Contributions
Contributions during 2025 are expected to be approximately $270 million for U.S. pension plans, approximately $180 million for international pension plans and approximately $70 million for other postretirement benefit plans.
Expected Benefit Payments
Expected benefit payments are as follows:
U.S. Pension BenefitsInternational Pension
Benefits
Other
Postretirement
Benefits
2025$771 $291 $86 
2026775 275 87 
2027789 286 89 
2028799 300 91 
2029822 314 96 
2030 — 2034
4,386 1,792 515 
Expected benefit payments are based on the same assumptions used to measure the benefit obligations and include estimated future employee service.
Amounts Recognized in Other Comprehensive Income (Loss)
Net gain/loss amounts reflect differences between expected and actual returns on plan assets as well as the effects of changes in actuarial assumptions. Net gain/loss amounts in excess of certain thresholds are amortized into net periodic benefit cost over the average remaining service life of employees. The following amounts were reflected as components of OCI:
 Pension PlansOther Postretirement
Benefit Plans
U.S.International
Years Ended December 31202420232022202420232022202420232022
Net gain (loss) arising during the period
$35 $(69)$(42)$634 $(438)$116 $(78)$110 $ 
Prior service credit (cost) arising during the period
   56 (16)(4)   
 $35 $(69)$(42)$690 $(454)$112 $(78)$110 $ 
Net loss (gain) amortization included in benefit cost$43 $ $128 $5 $(3)$96 $(51)$(42)$(43)
Prior service (credit) cost amortization included in benefit cost
 (1)(32)(13)2 (14)(43)(49)(57)
Settlements and curtailments 36 251 (1)(6)1  (1)(1)
 $43 $35 $347 $(9)$(7)$83 $(94)$(92)$(101)
120

Actuarial Assumptions
The Company reassesses its benefit plan assumptions on a regular basis. The weighted average assumptions used in determining U.S. pension and other postretirement benefit plan and international pension plan information are as follows:
 U.S. Pension and Other
Postretirement Benefit Plans
International Pension Plans
December 31202420232022202420232022
Net periodic benefit cost      
Discount rate5.30 %5.50 %3.00 %3.40 %3.90 %1.50 %
Expected rate of return on plan assets7.75 %7.00 %6.70 %5.20 %5.00 %3.70 %
Salary growth rate4.60 %4.60 %4.60 %3.20 %3.20 %2.90 %
Interest crediting rate5.30 %5.30 %5.00 %3.40 %3.30 %3.00 %
Benefit obligation      
Discount rate5.70 %5.30 %5.50 %3.70 %3.40 %3.90 %
Salary growth rate4.80 %4.60 %4.60 %3.10 %3.20 %3.20 %
Interest crediting rate5.40 %5.30 %5.30 %3.50 %3.40 %3.30 %
For both the pension and other postretirement benefit plans, the discount rate is evaluated on measurement dates and modified to reflect the prevailing market rate of a portfolio of high-quality fixed-income debt instruments that would provide the future cash flows needed to pay the benefits included in the benefit obligation as they come due. The expected rate of return for both the pension and other postretirement benefit plans represents the average rate of return to be earned on plan assets over the period the benefits included in the benefit obligation are to be paid and is determined on a plan basis. The expected rate of return for each plan is developed considering long-term historical returns data, current market conditions, and actual returns on the plan assets. Using this reference information, the long-term return expectations for each asset category and a weighted-average expected return for each plan’s target portfolio is developed according to the allocation among those investment categories. The expected portfolio performance reflects the contribution of active management as appropriate. For 2025, the expected rate of return for the Company’s U.S. pension and other postretirement benefit plans will be 7.70%, as compared to 7.75% in 2024.
The health care cost trend rate assumptions for other postretirement benefit plans are as follows:
December 3120242023
Health care cost trend rate assumed for next year7.90 %7.80 %
Rate to which the cost trend rate is assumed to decline4.50 %4.50 %
Year that the trend rate reaches the ultimate trend rate20402038

Savings Plans
The Company also maintains defined contribution savings plans in the U.S. The Company matches a percentage of each employee’s contributions consistent with the provisions of the plan for which the employee is eligible. Total employer contributions to these plans in 2024, 2023 and 2022 were $215 million, $199 million and $175 million, respectively.

121

14.    Other (Income) Expense, Net
Other (income) expense, net, consisted of:
Years Ended December 31202420232022
Interest income$(415)$(365)$(157)
Interest expense1,271 1,146 962 
Exchange losses227 370 237 
(Income) loss from investments in equity securities, net (1)
(14)(340)1,419 
Net periodic defined benefit plan (credit) cost other than service cost(633)(498)(279)
Other, net(460)153 (681)
 $(24)$466 $1,501 
(1)    Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag.
Other, net (as reflected in the table above) in 2024 includes $170 million of income related to the expansion of a collaboration agreement with Daiichi Sankyo (see Note 4). Other, net, in 2023 includes a $572.5 million charge related to settlements with certain plaintiffs in the Zetia antitrust litigation (see Note 10).
Interest paid was $1.3 billion in 2024, $1.1 billion in 2023 and $937 million in 2022.
15.    Taxes on Income
A reconciliation between the effective tax rate and the U.S. statutory rate is as follows:
 202420232022
AmountTax RateAmountTax RateAmountTax Rate
U.S. statutory rate applied to income before taxes
$4,186 21.0 %$397 21.0 %$3,453 21.0 %
Differential arising from:
Foreign earnings(1,301)(6.5)(941)(49.8)(1,821)(11.1)
Tax settlements and statute lapses
(557)(2.8)  (10)(0.1)
R&D tax credit(202)(1.0)(214)(11.3)(117)(0.7)
Inventory donations
(71)(0.4)(65)(3.5)(52)(0.3)
State taxes(39)(0.2)(117)(6.2)(110)(0.7)
Charges for certain research and development asset acquisitions
554 2.8 253 13.4   
Valuation allowances54 0.3 70 3.7 108 0.7 
Restructuring52 0.3 41 2.2 11 0.1 
GILTI and the foreign-derived intangible income deduction29 0.1 (80)(4.3)462 2.8 
Acquisition-related costs, including amortization
18 0.1 42 2.2 (3) 
Acquisition of Prometheus
  2,139 113.3   
Other80 0.4 (13)(0.7)(3) 
 $2,803 14.1 %$1,512 80.0 %$1,918 11.7 %
Where applicable, the impact of changes in uncertain tax positions is reflected in the reconciling items above.
The Company’s remaining transition tax liability under the Tax Cuts and Jobs Act (TCJA) of 2017, which has been reduced by payments and the expected utilization of foreign tax credits, was a net liability of $518 million at December 31, 2024, which is comprised of a $1.2 billion tax liability included in Income taxes payable, offset by $702 million of foreign tax credits included in Other Assets that Merck expects to be applied upon the completion of the IRS’s examination of the Company’s tax returns for the 2017 and 2018 federal tax years. As a result of the transition tax under the TCJA, the Company is no longer indefinitely reinvested with respect to its undistributed earnings from foreign subsidiaries and has provided a deferred tax liability for foreign withholding taxes that would apply. The
122

Company remains indefinitely reinvested with respect to its financial statement basis in excess of tax basis of its foreign subsidiaries. A determination of the net deferred tax liability with respect to this basis difference is not practicable.
The foreign earnings tax rate differentials in the tax rate reconciliation above primarily reflect the impacts of operations in jurisdictions with different effective tax rates than the U.S., particularly Ireland, the Netherlands and Switzerland, as well as Singapore and Puerto Rico which operate under tax incentive grants (which begin to expire in 2025), thereby yielding a favorable impact on the effective tax rate compared with the U.S. statutory rate of 21%. The Company has an additional Cantonal tax holiday in Switzerland that provides for a tax rate reduction and is effective through 2032. The Company’s income that is subject to tax incentive grants and the Cantonal tax holiday in Switzerland is subject to the global minimum tax provision of the Organization for Economic Cooperation and Development (OECD) Pillar 2, effective in 2024.
Income before taxes consisted of:
Years Ended December 31202420232022
Domestic$(1,849)$(15,622)$1,011 
Foreign21,785 17,511 15,433 
 $19,936 $1,889 $16,444 
Taxes on income consisted of:
Years Ended December 31202420232022
Current provision
Federal$944 $928 $2,265 
Foreign3,123 2,435 1,164 
State(15)48 57 
 4,052 3,411 3,486 
Deferred provision
Federal(1,475)(1,559)(1,510)
Foreign212 (233)71 
State14 (107)(129)
 (1,249)(1,899)(1,568)
 $2,803 $1,512 $1,918 

123

Deferred income taxes at December 31 consisted of:
 20242023
AssetsLiabilitiesAssetsLiabilities
Product intangibles and licenses$71 $978 $— $1,308 
R&D capitalization3,062  2,099 — 
Inventory related84 413 86 370 
Accelerated depreciation 645 — 626 
Undistributed foreign earnings
275 371 76 118 
Equity investments 90 — 73 
Pensions and other postretirement benefits224 400 323 249 
Compensation related400  357 — 
Unrecognized tax benefits152  147 — 
Net operating losses and other tax credit carryforwards910  868 — 
Other802 159 755 214 
Subtotal5,980 3,056 4,711 2,958 
Valuation allowance(710) (656) 
Total deferred taxes$5,270 $3,056 $4,055 $2,958 
Net deferred income taxes$2,214 $1,097 
Recognized as:
Other Assets$3,601 $1,968 
Deferred Income Taxes $1,387  $871 
The Company has net operating loss (NOL) carryforwards in several jurisdictions. As of December 31, 2024, $324 million of deferred tax assets on NOL carryforwards relate to foreign jurisdictions. Valuation allowances of $264 million have been established on these foreign NOL carryforwards and other foreign deferred tax assets. In addition, the Company has $586 million of deferred tax assets relating to various U.S. tax credit carryforwards and NOL carryforwards. Valuation allowances of $446 million have been established on these U.S. tax credit carryforwards and NOL carryforwards.
Income taxes paid in 2024, 2023 and 2022 consisted of:
Years Ended December 31202420232022
Domestic (1)
$974 $2,258 $1,891 
Foreign2,954 2,080 1,348 
 $3,928 $4,338 $3,239 
(1)    Includes TCJA transition tax payments.
Tax benefits relating to stock option exercises were $26 million in 2024, $12 million in 2023 and $45 million in 2022.
A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:
202420232022
Balance January 1$2,384 $1,835 $1,529 
Additions related to current year positions421 553 344 
Additions related to prior year positions35 91 48 
Reductions for tax positions of prior years
(33)(20)(40)
Settlements
(18)(23)(6)
Lapse of statute of limitations (1)
(528)(52)(40)
Balance December 31$2,261 $2,384 $1,835 
(1)    Amount in 2024 reflects a reduction of $451 million resulting from the expiration of the statute of limitations related to the 2019 and 2020 federal tax return years.
124

If the Company were to recognize the unrecognized tax benefits of $2.3 billion at December 31, 2024, the income tax provision would reflect a favorable net impact of $2.2 billion.
The Company is under examination by numerous tax authorities in various jurisdictions globally. The Company believes that it is reasonably possible that the total amount of unrecognized tax benefits as of December 31, 2024 could decrease by up to approximately $22 million in the next 12 months as a result of various audit closures, settlements or the expiration of the statute of limitations. The ultimate finalization of the Company’s examinations with relevant taxing authorities can include formal administrative and legal proceedings, which could have a significant impact on the timing of the reversal of unrecognized tax benefits. The Company believes that its reserves for uncertain tax positions are adequate to cover existing risks or exposures.
Interest and penalties associated with uncertain tax positions amounted to an expense of $51 million in 2024, $131 million in 2023 and $54 million in 2022. These amounts reflect the beneficial impacts of various tax settlements. Liabilities for accrued interest and penalties were $437 million and $388 million as of December 31, 2024 and 2023, respectively.
In 2024, the Company recorded a benefit of $519 million due to a reduction in reserves for unrecognized income tax benefits resulting from the expiration in 2024 of the statute of limitations for assessments related to the 2019 and 2020 federal tax return years. The Internal Revenue Service (IRS) is currently conducting examinations of the Company’s tax returns for the years 2017 and 2018, including the one-time transition tax enacted under the TCJA. If the IRS disagrees with the Company’s transition tax position, it may result in a significant tax liability. The IRS is also currently conducting examinations of the Company’s tax returns for the years 2021 and 2022. In addition, various state and foreign tax examinations are in progress and for these jurisdictions, the Company’s income tax returns are open for examination for the period 2009 through 2024.
16.    Earnings per Share
The calculations of earnings per share (shares in millions) are as follows:
Years Ended December 31202420232022
Net Income Attributable to Merck & Co., Inc.$17,117 $365 $14,519 
Average common shares outstanding2,532 2,537 2,532 
Common shares issuable (1)
9 10 10 
Average common shares outstanding assuming dilution2,541 2,547 2,542 
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders
$6.76 $0.14 $5.73 
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders
$6.74 $0.14 $5.71 
(1)     Issuable primarily under share-based compensation plans.
In 2024, 2023 and 2022, 6 million, 5 million and 2 million, respectively, of common shares issuable under share-based compensation plans were excluded from the computation of earnings per common share assuming dilution because the effect would have been antidilutive.

125

17.   Other Comprehensive Income (Loss)
Changes in each component of other comprehensive income (loss) are as follows:
DerivativesEmployee
Benefit
Plans
 Foreign Currency
Translation
Adjustment
Accumulated Other
Comprehensive Loss
Balance at January 1, 2022, net of taxes
$144 $(2,743)$(1,830)$(4,429)
Other comprehensive income (loss) before reclassification adjustments, pretax684 70 (584)170 
Tax(143)12 (19)(150)
Other comprehensive income (loss) before reclassification adjustments, net of taxes541 82 (603)20 
Reclassification adjustments, pretax(775)
(1)
329 
(2)
 (446)
Tax163 (76) 87 
Reclassification adjustments, net of taxes(612)253  (359)
Other comprehensive income (loss), net of taxes(71)335 (603)(339)
Balance at December 31, 2022, net of taxes73 (2,408)(2,433)(4,768)
Other comprehensive income (loss) before reclassification adjustments, pretax114 (413)17 (282)
Tax(24)86 63 125 
Other comprehensive income (loss) before reclassification adjustments, net of taxes90 (327)80 (157)
Reclassification adjustments, pretax(237)
(1)
(64)
(2)
9 (292)
Tax50 6  56 
Reclassification adjustments, net of taxes(187)(58)9 (236)
Other comprehensive income (loss), net of taxes(97)(385)89 (393)
Balance at December 31, 2023, net of taxes(24)(2,793)
(3)
(2,344)(5,161)
Other comprehensive income (loss) before reclassification adjustments, pretax508 647 (559)596 
Tax(109)(138)23 (224)
Other comprehensive income (loss) before reclassification adjustments, net of taxes399 509 (536)372 
Reclassification adjustments, pretax(168)
(1)
(60)
(2)
20 (208)
Tax35 17  52 
Reclassification adjustments, net of taxes(133)(43)20 (156)
Other comprehensive income (loss), net of taxes266 466 (516)216 
Balance at December 31, 2024, net of taxes$242 $(2,327)
(3)
$(2,860)$(4,945)
(1)    Primarily relates to foreign currency cash flow hedges that were reclassified from AOCL to Sales (see Note 6).
(2)    Includes net amortization of prior service cost, actuarial gains and losses, settlements and curtailments included in net periodic benefit cost (see Note 13).
(3)    Includes pension plan net loss of $3.0 billion and $3.5 billion at December 31, 2024 and 2023, respectively, and other postretirement benefit plan net gain of $400 million and $500 million at December 31, 2024 and 2023, respectively, as well as pension plan prior service credit of $174 million and $141 million at December 31, 2024 and 2023, respectively, and other postretirement benefit plan prior service credit of $61 million and $95 million at December 31, 2024 and 2023, respectively.

126

18.    Segment Reporting
The Company’s operations are principally managed on a product basis and include two operating segments, Pharmaceutical and Animal Health, both of which are reportable segments.
The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. A large component of pediatric and adolescent vaccine sales are made to the U.S. Centers for Disease Control and Prevention Vaccines for Children program, which is funded by the U.S. government. Additionally, the Company sells vaccines to the Federal government for placement into vaccine stockpiles.
The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors, animal producers, farmers and pet owners.

127

Sales of the Company’s products were as follows:
Years Ended December 31202420232022
U.S.Int’lTotalU.S.Int’lTotalU.S.Int’lTotal
Pharmaceutical:
Oncology
Keytruda$17,872 $11,610 $29,482 $15,114 $9,897 $25,011 $12,686 $8,251 $20,937 
Alliance revenue - Lynparza (1)
626 685 1,311 607 592 1,199 584 532 1,116 
Alliance revenue - Lenvima (1)
705 305 1,010 657 303 960 579 297 876 
Welireg466 43 509 209 10 218 123  123 
Alliance revenue - Reblozyl (2)
303 68 371 168 43 212 123 43 166 
Vaccines
Gardasil/Gardasil 9
2,425 6,158 8,583 2,083 6,803 8,886 2,065 4,832 6,897 
ProQuad/M-M-R II/Varivax1,919 566 2,485 1,837 531 2,368 1,724 518 2,241 
Vaxneuvance461 347 808 561 103 665 163 7 170 
RotaTeq472 239 711 493 276 769 508 275 783 
Pneumovax 23
56 207 263 127 285 412 346 256 602 
Hospital Acute Care
Bridion1,401 363 1,764 1,156 686 1,842 922 762 1,685 
Prevymis371 414 785 264 341 605 188 240 428 
Dificid303 37 340 274 28 302 241 22 263 
Zerbaxa146 106 252 119 100 218 89 79 169 
Noxafil7 170 177 32 181 213 51 187 238 
Cardiovascular
Winrevair
408 11 419       
Alliance revenue - Adempas/Verquvo (3)
388 27 415 350 16 367 329 12 341 
Adempas 287 287  255 255  238 238 
Virology
Lagevrio176 787 964 10 1,418 1,428 1,523 4,161 5,684 
Isentress/Isentress HD185 209 394 215 268 483 274 359 633 
Delstrigo
56 193 249 49 152 201 39 111 151 
Pifeltro
113 50 163 101 41 142 87 30 118 
Neuroscience
Belsomra72 150 222 81 150 231 79 179 258 
Immunology
Simponi 543 543  710 710  706 706 
Remicade 114 114  187 187  207 207 
Diabetes
Januvia469 865 1,334 1,151 1,039 2,189 1,248 1,565 2,813 
Janumet161 774 935 223 954 1,177 355 1,344 1,700 
Other pharmaceutical (4)
729 1,782 2,510 658 1,675 2,333 663 1,803 2,462 
Total Pharmaceutical segment sales30,290 27,110 57,400 26,539 27,044 53,583 24,989 27,016 52,005 
Animal Health:
Livestock732 2,729 3,462 700 2,637 3,337 710 2,590 3,300 
Companion Animal1,129 1,287 2,415 1,104 1,184 2,288 1,112 1,138 2,250 
Total Animal Health segment sales1,861 4,016 5,877 1,804 3,821 5,625 1,822 3,728 5,550 
Total segment sales32,151 31,126 63,277 28,343 30,865 59,208 26,811 30,744 57,555 
Other (5)
126 765 891 137 770 907 395 1,333 1,728 
 $32,277 $31,891 $64,168 $28,480 $31,635 $60,115 $27,206 $32,077 $59,283 
U.S. plus international may not equal total due to rounding.
(1)    Alliance revenue for Lynparza and Lenvima represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 4).
(2)    Alliance revenue for Reblozyl represents royalties and, for 2022, also includes a payment received related to the achievement of a regulatory approval milestone (see Note 4).
(3)    Alliance revenue for Adempas/Verquvo represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 4).
(4)    Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.
(5)    Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities which increased sales by $195 million, $244 million and $810 million in 2024, 2023 and 2022, respectively, as well as revenue from third-party manufacturing arrangements (including sales to Organon). Other for 2024, 2023 and 2022 also includes $106 million, $118 million and $165 million, respectively, related to upfront and milestone payments received by Merck for out-licensing arrangements.
128

Consolidated sales by geographic area where derived are as follows:
Years Ended December 31202420232022
United States$32,277 $28,480 $27,206 
Europe, Middle East and Africa14,041 13,254 14,493 
China5,494 6,802 5,191 
Latin America3,459 3,086 2,582 
Japan3,280 3,164 3,629 
Asia Pacific (other than China and Japan)3,058 3,225 3,614 
Other2,559 2,104 2,568 
 $64,168 $60,115 $59,283 
A reconciliation of segment profits to Income Before Taxes is as follows:
Years Ended December 31202420232022
Pharma-ceutical
Animal Health
Total
Pharma-ceutical
Animal Health
Total
Pharma-ceutical
Animal Health
Total
Segment sales
$57,400 $5,877 $63,277 $53,583 $5,625 $59,208 $52,005 $5,550 $57,555 
Less segment costs: (1)
Cost of sales
6,828 2,469 8,849 2,498 9,678 2,259 
Selling, general and administrative
6,128 1,084 5,903 1,038 5,474 999 
Research and development (2)
 385  353  329 
Other segment items (3)
(89)1 (49)(1)1  
Total segment profits44,533 1,938 46,471 38,880 1,737 40,617 36,852 1,963 38,815 
Other profits492 474 1,160 
Unallocated:
Interest income415 365 157 
Interest expense(1,271)(1,146)(962)
Amortization(2,395)(2,044)(2,085)
Depreciation(1,843)(1,625)(1,642)
Research and development(17,350)(30,008)(13,011)
Restructuring costs(309)(599)(337)
Charge for Zetia antitrust litigation settlements (573) 
Other unallocated, net(4,274)(3,572)(5,651)
$19,936 $1,889 $16,444 
(1)    The significant expense categories and amounts align with the segment level information that is regularly provided to the chief operating decision maker.
(2)    Human health-related research and development expenses incurred by Merck Research Laboratories are not allocated to segment profits as noted below.
(3)    Includes equity (income) loss from affiliates and other miscellaneous non-operating expenses.

Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as selling, general and administrative expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as selling, general and administrative expenses and research and development costs directly incurred by the segment. The chief operating decision maker (Merck’s Chief Executive Officer) uses segment profit to allocate resources predominately during the planning and forecasting process. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred by Merck Research Laboratories, the Company’s research and development division that focuses on human health-related activities, or general and administrative expenses not directly incurred by the segments, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. In addition, costs related to restructuring activities, as well as the amortization of intangible assets and amortization of purchase accounting adjustments are not allocated to segments.

129

Other profits are primarily comprised of miscellaneous corporate profits, as well as operating profits (losses) related to third-party manufacturing arrangements.
Other unallocated, net, includes expenses from corporate and manufacturing cost centers, intangible asset impairment charges, gains or losses on sales of businesses, expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration, and other miscellaneous income or expense items.
Equity income from affiliates and depreciation included in segment profits is as follows:
PharmaceuticalAnimal HealthTotal
Year Ended December 31, 2024
Equity income from affiliates$144 $ $144 
Depreciation5 256 261 
Year Ended December 31, 2023
Equity income from affiliates$111 $ $111 
Depreciation5 198 203 
Year Ended December 31, 2022
Equity income from affiliates
$39 $ $39 
Depreciation5 177 182 
Property, plant and equipment, net, by geographic area where located is as follows:
December 31202420232022
United States$14,724 $13,915 $12,891 
Europe, Middle East and Africa7,548 7,562 6,993 
Asia Pacific (other than China and Japan)982 1,022 966 
China202 193 207 
Japan143 133 135 
Latin America133 222 225 
Other47 4 5 
 $23,779 $23,051 $21,422 
The Company does not disaggregate assets on a products and services basis for internal management reporting and, therefore, such information is not presented.
130

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Stockholders of Merck & Co., Inc.
Opinions on the Financial Statements and Internal Control over Financial Reporting
We have audited the accompanying consolidated balance sheet of Merck & Co., Inc. and its subsidiaries (the “Company”) as of December 31, 2024 and 2023, and the related consolidated statements of income, of comprehensive income (loss), of equity and of cash flows for each of the three years in the period ended December 31, 2024, including the related notes (collectively referred to as the “consolidated financial statements”). We also have audited the Company’s internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2024 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO.
Basis for Opinions
The Company’s management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management’s Report on Internal Control Over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company’s consolidated financial statements and on the Company’s internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.
Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.
Definition and Limitations of Internal Control over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

131

Critical Audit Matters
The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.
U.S. Rebate Accruals - Medicaid, Managed Care and Medicare Part D
As described in Note 2 to the consolidated financial statements, the Company records certain variable consideration including discounts, which are estimated at the time of sale generally using the expected value method. Amounts accrued for aggregate customer discounts are evaluated on a quarterly basis through comparison of information provided by the wholesalers, health maintenance organizations, pharmacy benefit managers, federal and state agencies, and other customers to the amounts accrued. Certain of these discounts representing a portion of the accrual take the form of rebates, which are amounts owed based upon definitive contractual agreements or legal requirements with private sector (Managed Care) and public sector (Medicaid and Medicare Part D) benefit providers, after the final dispensing of the product to a benefit plan participant. The provision for rebates is based on expected patient usage, as well as inventory levels in the distribution channel to determine the contractual obligation to the benefit providers. Management uses historical customer segment utilization mix, sales forecasts, changes to product mix and price, inventory levels in the distribution channel, government pricing calculations and prior payment history in order to estimate the expected provision. The accrued balance relative to the provision for rebates included in accrued and other current liabilities was $2.2 billion as of December 31, 2024, of which the majority relates to U.S. rebate accruals – Medicaid, Managed Care and Medicare Part D.
The principal considerations for our determination that performing procedures relating to U.S. rebate accruals - Medicaid, Managed Care and Medicare Part D is a critical audit matter are the significant judgment by management due to the significant measurement uncertainty involved in developing the rebate accruals, as the accruals are based on assumptions developed using pricing information and historical customer segment utilization mix, and a high degree of auditor judgment, subjectivity and effort in performing procedures and evaluating evidence related to these assumptions.
Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to U.S. rebate accruals - Medicaid, Managed Care and Medicare Part D, including management’s controls over the assumptions used to estimate the corresponding rebate accruals. These procedures also included, among others (i) developing an independent estimate of the rebate accruals by utilizing third party data on historical customer segment utilization mix in the U.S., pricing information, the terms of the specific rebate programs, and the historical trend of actual rebate claims paid, (ii) comparing the independent estimate to the rebate accruals recorded by management, and (iii) testing rebate claims paid, including evaluating those claims for consistency with the contractual terms of the Company’s rebate agreements.
PWC Sig..gif
PricewaterhouseCoopers LLP
Florham Park, New Jersey
February 25, 2025
We have served as the Company’s auditor since 2002.
132

Item 9.     Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.
Not applicable.
Item 9A.      Controls and Procedures.
Management of the Company, with the participation of its Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures. Based on their evaluation, as of the end of the period covered by this Form 10-K, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Act)) are effective. For the fourth quarter of 2024, there have been no changes in internal control over financial reporting that materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) of the Act. Management conducted an evaluation of the effectiveness of internal control over financial reporting based on the framework in Internal Control — Integrated Framework issued in 2013 by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, management concluded that internal control over financial reporting was effective as of December 31, 2024. PricewaterhouseCoopers LLP, an independent registered public accounting firm, has performed its own assessment of the effectiveness of the Company’s internal control over financial reporting and its attestation report is included in this Form 10-K filing.
Management’s Report
Management’s Responsibility for Financial Statements
Responsibility for the integrity and objectivity of the Company’s financial statements rests with management. The financial statements report on management’s stewardship of Company assets. These statements are prepared in conformity with generally accepted accounting principles and, accordingly, include amounts that are based on management’s best estimates and judgments. Nonfinancial information included in the Annual Report on Form 10-K has also been prepared by management and is consistent with the financial statements.
To assure that financial information is reliable and assets are safeguarded, management maintains an effective system of internal controls and procedures, important elements of which include: careful selection, training and development of operating and financial managers; an organization that provides appropriate division of responsibility; and communications aimed at assuring that Company policies and procedures are understood throughout the organization. A staff of internal auditors regularly monitors the adequacy and application of internal controls on a worldwide basis.
To ensure that personnel continue to understand the system of internal controls and procedures, and policies concerning good and prudent business practices, annually all employees of the Company are required to complete Code of Conduct training. This training reinforces the importance and understanding of internal controls by reviewing key corporate policies, procedures and systems. In addition, the Company has compliance programs, including an ethical business practices program to reinforce the Company’s long-standing commitment to high ethical standards in the conduct of its business.
The financial statements and other financial information included in the Annual Report on Form 10-K fairly present, in all material respects, the Company’s financial condition, results of operations and cash flows. Our formal certification to the Securities and Exchange Commission is included in this Form 10-K filing.
Management’s Report on Internal Control Over Financial Reporting
Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the Securities Exchange Act of 1934. The Company’s internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States of America. Management conducted an evaluation of the effectiveness of internal control over financial reporting based on the framework in Internal Control — Integrated Framework issued in 2013 by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, management concluded that internal control over financial reporting was effective as of December 31, 2024.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls
133

may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
The effectiveness of the Company’s internal control over financial reporting as of December 31, 2024, has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report which appears herein.
electronicsignaturedavisa06.jpg
Caroline Sig..jpg
Robert M. DavisCaroline Litchfield
Chairman, Chief Executive Officer and President
Executive Vice President and Chief Financial Officer

Item 9B.    Other Information.
Insider Trading Arrangements
During the three months ended December 31, 2024, none of the Company’s directors or executive officers adopted or terminated any Rule 10b5-1 trading arrangements or non-Rule 10b5-1 trading arrangements.
Item 9C.    Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.
Not Applicable.
134

PART III
 
Item 10.Directors, Executive Officers and Corporate Governance.
The required information on directors and nominees is incorporated by reference from the discussion under Proposal 1. Election of Directors of the Company’s Proxy Statement for the Annual Meeting of Shareholders to be held on May 27, 2025. Information on executive officers is set forth in Part I of this document on page 43.
The required information on compliance with Section 16(a) of the Securities Exchange Act of 1934, if applicable, is incorporated by reference from the discussion under the heading “Stock Ownership Information” of the Company’s Proxy Statement for the Annual Meeting of Shareholders to be held on May 27, 2025.
The Company has a Code of Conduct — Our Values and Standards applicable to all employees, including the principal executive officer, principal financial officer, and principal accounting officer. The Code of Conduct is available on the Company’s website at www.merck.com/company-overview/culture-and-values/code-of-conduct/values-and-standards/. The Company intends to disclose future amendments to certain provisions of the Code of Conduct, and waivers of the Code of Conduct granted to executive officers and directors, if any, on the website within four business days following the date of any amendment or waiver. Every Merck employee is responsible for adhering to business practices that are in accordance with the law and with ethical principles that reflect the highest standards of corporate and individual behavior.
The required information on the identification of the audit committee and the audit committee financial expert is incorporated by reference from the discussion under the heading “Board Meetings and Committees” of the Company’s Proxy Statement for the Annual Meeting of Shareholders to be held on May 27, 2025.
The required information about the Company’s insider trading policy is incorporated by reference from the discussion under the heading “Insider Trading Policy” of the Company's Proxy Statement for the Annual Meeting of Shareholders to be held on May 27, 2025.
Item 11.Executive Compensation.
The information required on executive compensation is incorporated by reference from the discussion under the headings “Compensation Discussion and Analysis,” “Summary Compensation Table,” “All Other Compensation” table, “CEO Pay Ratio,” “Pay versus Performance” table, “Grants of Plan-Based Awards” table, “Outstanding Equity Awards” table, “Option Exercises and Stock Vested” table, “Pension Benefits” table, “Nonqualified Deferred Compensation” table, and “Potential Payments Upon Termination or a Change in Control”, as well as all footnote information to the various tables, of the Company’s Proxy Statement for the Annual Meeting of Shareholders to be held on May 27, 2025.
The required information on director compensation is incorporated by reference from the discussion under the heading “Director Compensation” and related “2024 Schedule of Director Fees” table and “2024 Director Compensation” table of the Company’s Proxy Statement for the Annual Meeting of Shareholders to be held on May 27, 2025.
The required information under the headings “Compensation and Management Development Committee Interlocks and Insider Participation” and “Compensation and Management Development Committee Report” is incorporated by reference from the Company’s Proxy Statement for the Annual Meeting of Shareholders to be held on May 27, 2025.

135

Item 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
Information with respect to security ownership of certain beneficial owners and management is incorporated by reference from the discussion under the heading “Stock Ownership Information” of the Company’s Proxy Statement for the Annual Meeting of Shareholders to be held on May 27, 2025.
Equity Compensation Plan Information
The following table summarizes information about the options, warrants and rights and other equity compensation under the Company’s equity compensation plans as of the close of business on December 31, 2024. The table does not include information about tax qualified plans such as the Merck U.S. Savings Plan.
Plan CategoryNumber of
securities to be
issued upon
exercise of
outstanding
options, warrants
and rights
(a)
Weighted-average
exercise price of
outstanding
options, warrants
and rights
(b)
Number of
securities remaining
available for future
issuance under equity
compensation plans
(excluding
securities
reflected in column (a))
(c)
Equity compensation plans approved by security holders(1)
12,500,010(2)
$86.04 74,988,831 
Equity compensation plans not approved by security holders— — — 
Total12,500,010 $86.04 74,988,831 
(1)Includes options to purchase shares of Company Common Stock and other rights under the following shareholder-approved plans: the Merck & Co., Inc. 2010 and 2019 Incentive Stock Plans, and the Merck & Co., Inc. 2010 Non-Employee Directors Stock Option Plan.
(2)Excludes approximately 12,232,051 shares of restricted stock units and 3,531,246 performance share units (assuming maximum payouts) under the Merck Sharp & Dohme 2010 and 2019 Incentive Stock Plans. Also excludes 153,540 shares of phantom stock deferred under the MSD Employee Deferral Program and 518,423 shares of phantom stock deferred under the Merck & Co., Inc. Plan for Deferred Payment of Directors’ Compensation.
Item 13.Certain Relationships and Related Transactions, and Director Independence.
The required information on transactions with related persons is incorporated by reference from the discussion under the heading “Related Person Transactions” of the Company’s Proxy Statement for the Annual Meeting of Shareholders to be held on May 27, 2025.
The required information on director independence is incorporated by reference from the discussion under the heading “Independence of Directors” of the Company’s Proxy Statement for the Annual Meeting of Shareholders to be held on May 27, 2025.
Item 14.Principal Accountant Fees and Services.
The information required for this item is incorporated by reference from the discussion under Proposal 3. Ratification of Appointment of Independent Registered Public Accounting Firm for 2025 beginning with the caption “Pre-Approval Policy for Services of Independent Registered Public Accounting Firm” through “Fees for Services Provided by the Independent Registered Public Accounting Firm” of the Company’s Proxy Statement for the Annual Meeting of Shareholders to be held on May 27, 2025.
136

PART IV
 
Item 15.Exhibits and Financial Statement Schedules.
(a)    The following documents are filed as part of this Form 10-K
1.    Financial Statements
Consolidated statement of income for the years ended December 31, 2024, 2023 and 2022
Consolidated statement of comprehensive income (loss) for the years ended December 31, 2024, 2023 and 2022
Consolidated balance sheet as of December 31, 2024 and 2023
Consolidated statement of equity for the years ended December 31, 2024, 2023 and 2022
Consolidated statement of cash flows for the years ended December 31, 2024, 2023 and 2022
Notes to consolidated financial statements
Report of PricewaterhouseCoopers LLP, independent registered public accounting firm (PCAOB ID 238)
2.    Financial Statement Schedules
Schedules are omitted because they are either not required or not applicable.
Financial statements of affiliates carried on the equity basis have been omitted because, considered individually or in the aggregate, such affiliates do not constitute a significant subsidiary.
137

3.    Exhibits
Exhibit
Number
 Description
3.1
3.2
4.1Indenture, dated as of April 1, 1991, between Merck Sharp & Dohme Corp. (f/k/a Schering Corporation) and U.S. Bank Trust National Association (as successor to Morgan Guaranty Trust Company of New York), as Trustee (the 1991 Indenture) — Incorporated by reference to Exhibit 4 to MSD’s Registration Statement on Form S-3 (No. 33-39349)
4.2
4.3
4.4
4.5
4.6
4.7
4.8
4.9
4.10
4.11
*10.1
*10.2
*10.3
*10.4
*10.5
138

*10.6
*10.7
*10.8
*10.9
*10.10
*10.11
*10.12
*10.13
*10.14
*10.15
*10.16
*10.17
*10.18
*10.19
*10.20
*10.21
139

*10.22
*10.23
*10.24
*10.25
*10.26
*10.27
*10.28
*10.29
*10.30
*10.31
*10.32
*10.33
*10.34
*10.35
*10.36
19
21
23
24.1
24.2
31.1
31.2
32.1
32.2
97
140

Exhibit 101:
101.INSXBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.
101.SCHXBRL Taxonomy Extension Schema Document.
101.CALXBRL Taxonomy Extension Calculation Linkbase Document.
101.DEFXBRL Taxonomy Extension Definition Linkbase Document.
101.LABXBRL Taxonomy Extension Label Linkbase Document.
101.PREXBRL Taxonomy Extension Presentation Linkbase Document.
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
                
*Management contract or compensatory plan or arrangement.
Long-term debt instruments under which the total amount of securities authorized does not exceed 10% of Merck & Co., Inc.’s total consolidated assets are not filed as exhibits to this report. Merck & Co., Inc. will furnish a copy of these agreements to the Securities and Exchange Commission on request.

Item 16.    Form 10-K Summary

Not applicable.
141




SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Dated:    February 25, 2025
 
MERCK & CO., INC.
By:ROBERT M. DAVIS
(Chairman, Chief Executive Officer and President)
By:/s/ JENNIFER ZACHARY
Jennifer Zachary
(Attorney-in-Fact)
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
SignaturesTitleDate
ROBERT M. DAVIS
Chairman, Chief Executive Officer and President; Principal Executive Officer
February 25, 2025
CAROLINE LITCHFIELD
Executive Vice President and Chief Financial
Officer; Principal Financial Officer
February 25, 2025
DALTON SMART
Senior Vice President Finance-Global Controller; Principal Accounting Officer
February 25, 2025
DOUGLAS M. BAKER, JR.DirectorFebruary 25, 2025
MARY ELLEN COEDirectorFebruary 25, 2025
PAMELA J. CRAIGDirectorFebruary 25, 2025
THOMAS H. GLOCERDirectorFebruary 25, 2025
SURENDRALAL L. KARSANBHAI
Director
February 25, 2025
RISA J. LAVIZZO-MOUREYDirectorFebruary 25, 2025
STEPHEN L. MAYODirectorFebruary 25, 2025
PAUL B. ROTHMANDirectorFebruary 25, 2025
PATRICIA F. RUSSODirectorFebruary 25, 2025
CHRISTINE E. SEIDMANDirectorFebruary 25, 2025
INGE G. THULINDirectorFebruary 25, 2025
KATHY J. WARDENDirectorFebruary 25, 2025
Jennifer Zachary, by signing her name hereto, does hereby sign this document pursuant to powers of attorney duly executed by the persons named, filed with the Securities and Exchange Commission as an exhibit to this document, on behalf of such persons, all in the capacities and on the date stated, such persons including a majority of the directors of the Company.
 
By:/S/ JENNIFER ZACHARY
Jennifer Zachary
(Attorney-in-Fact)
142
EX-4.11 2 exh411-descriptionofsecuri.htm EX-4.11 DESCRIPTION OF SECURITIES Document
Exhibit 4.11
DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934
As of February 25, 2025, Merck & Co., Inc. had eight classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: (i) Common Stock, (ii), 1.875% Notes due 2026, (iii) 3.250% Notes due 2032, (iv) 2.500% Notes due 2034, (v) 1.375% Notes due 2036, (vi) 3.500% Notes due 2037, (vii) 3.700% Notes due 2044 and (viii) 3.750% Notes due 2054.
Description of the Registrant’s Common Stock
Registered under Section 12 of the Securities Exchange Act of 1934
The following sets forth a description of the material terms of the common stock of Merck & Co., Inc. (“Merck”). The description is qualified in its entirety by reference to Merck’s certificate of incorporation and by-laws, copies of which are included or incorporated by reference as exhibits to Merck’s most recently filed Annual Report on Form 10-K. You are encouraged to read Merck’s certificate of incorporation and by-laws and the applicable provisions of the New Jersey Business Corporation Act for additional information.
Under its certificate of incorporation, Merck is authorized to issue an aggregate of 6,520,000,000 shares of capital stock, divided into classes as follows:
6,500,000,000 shares of common stock, par value $0.50 per share; and
20,000,000 shares of preferred stock, par value $1.00 per share, issuable in one or more series.
Subject to the preferences, qualifications, limitations, voting and other rights and restrictions with respect to each class of Merck’s capital stock having any preference or priority over Merck’s common stock, the holders of the common stock shall have and possess all rights appertaining to Merck’s capital stock. The holders of shares of Merck’s common stock are entitled to one vote per share for each share held of record on all matters voted on by shareholders, including the election of directors.
A majority of votes cast by shares of Merck’s common stock entitled to vote is required for:
adoption of a proposed amendment to the certificate of incorporation;
approval of a proposed plan of merger or consolidation;
approval of a sale, lease, exchange or other disposition of all, or substantially all, of Merck’s assets, not in the usual and regular course of business;
approval of a proposed plan of exchange; and
approval of a proposed plan of dissolution.
In addition, unless approved by the affirmative vote of holders of at least two-thirds of the shares of Merck’s common stock voted thereon by disinterested shareholders, Merck is generally prohibited from purchasing shares of Merck’s common stock at a price in excess of a fair market price from a person known to Merck to be the beneficial owner of more than 5% of the voting power of the then outstanding shares of Merck’s common stock, subject to exceptions for certain open market transactions, certain public transactions, purchases pursuant to an offer to purchase made on the same terms and conditions to all holders of Merck’s common stock and shares held by such a beneficial owner for longer than two years.
1


Holders of Merck’s common stock are entitled to participate equally in dividends when and as such dividends may be declared by Merck’s board of directors out of funds legally available therefor. As a New Jersey corporation, Merck is subject to statutory limitations on the declaration and payment of dividends. In the event of Merck’s liquidation, dissolution or winding up, holders of Merck’s common stock have the right to a ratable portion of assets remaining after satisfaction in full of the prior rights of creditors, including holders of Merck’s indebtedness, all liabilities and the aggregate liquidation preferences of any outstanding shares of Merck’s preferred stock. The holders of Merck’s common stock have no conversion, redemption, preemptive or cumulative voting rights. All of the shares of Merck’s common stock issued by Merck are validly issued, fully paid and non-assessable.
The transfer agent and registrar for Merck’s common stock is Equinity Trust Company.
Takeover Defense
Certain provisions of Merck’s certificate of incorporation and by-laws and of the New Jersey Business Corporation Act (the “NJBCA”) may have anti-takeover effects and could delay, defer or prevent a tender offer or takeover attempt that a shareholder might consider to be in such shareholder’s best interests, including attempts that might result in a premium over the market price for the shares held by shareholders, and may make removal of the incumbent management and directors more difficult.
Authorized Shares; Undesignated Preferred Stock. Merck’s certificate of incorporation authorizes the issuance of up to 6,500,000,000 shares of common stock and 20,000,000 shares of preferred stock. These additional authorized shares may be used by Merck’s board of directors, to the extent consistent with its fiduciary duty, to deter future attempts to gain control of Merck, and may discourage attempts by others to attempt to acquire control of Merck without negotiation with Merck’s board of directors.
Merck’s board of directors has the sole authority, subject to the rights of any outstanding series of Merck’s preferred stock, to fix the numbers, designations, rights, preferences and limitations of any one or more series of preferred stock, including with respect to voting, dividends, conversion, redemption and liquidation preferences. As a result of the ability to fix voting rights for a series of preferred stock, Merck’s board of directors has the power, to the extent consistent with its fiduciary duty, to issue a series of preferred stock to persons friendly to management in order to attempt to block a tender offer, merger or other transaction by which a third party seeks control of Merck, and thereby assist members of management to retain their positions.
No Shareholder Action by Written Consent. Merck’s certificate of incorporation provides that shareholders may not act by written consent. Any shareholder action must be taken at a duly called annual or special meeting.
Special Meetings of Shareholders. In addition to what is provided by the NJBCA, a special meeting may be called at any time by Merck’s board of directors and, subject to the rights of the holders of any class or series of preferred stock then outstanding, generally may be called at any time upon the written request, in the form prescribed in Merck’s by-laws, of the holders of record of at least 15% or more of the capital stock entitled to vote in the election of directors.
Notification of Proposed Business and Nominations for Annual Meetings. Merck’s by-laws require that written notice of any shareholder proposal for business at an annual meeting of shareholders, or any shareholder director nomination for an annual meeting of shareholders, be received at least 120 days but no more than 150 days prior to the anniversary date of the preceding year’s annual meeting; provided, however, in the event that the date of the annual meeting is more than 30 days earlier or later than the anniversary date of the most recent annual meeting of shareholders, the shareholders’ notice must be so delivered not later than the close of business on the later of (i) the 120th day prior to such annual meeting of shareholders or (ii) the 10th day following the day on which a public announcement of the annual meeting date is first made. Also, Merck’s by-laws allow a shareholder or a group of no more than 20 shareholders, who or which has maintained continuous qualifying ownership of at least 3% of Merck’s
2


outstanding common stock for at least three years and has complied with the other requirements set forth in the by-laws, to include director nominees constituting up to 20% of the board of directors in Merck’s proxy materials for an annual meeting of shareholders. A request to include such a nominee must be received at least 120 days but no more than 150 days prior to the anniversary of the date Merck commenced mailing of its proxy materials in connection with the most recent annual meeting of shareholders.
No Cumulative Voting. Merck’s certificate of incorporation does not permit cumulative voting in the election of directors.
Business Combinations with Interested Shareholder. The NJBCA provides that no corporation organized under the laws of New Jersey (a “resident domestic corporation”) may engage in any “business combination” (as defined in the NJBCA) with any interested shareholder (generally a 10% or greater shareholder) of such corporation for a period of five years following such interested shareholder’s stock acquisition, unless either (i) such stock acquisition is approved by the board of directors of such corporation prior to the stock acquisition and any subsequent business combinations with the interested shareholder are approved by (A) members of the board of directors independent of the interested shareholder and (B) the holders of a majority of the voting stock not beneficially owned by the interested shareholder or (ii) such business combination is approved by the board of directors of such corporation prior to the stock acquisition.
In addition, no resident domestic corporation may engage, at any time, in any business combination with any interested shareholder of such corporation other than: (i) a business combination approved by the board of directors prior to the stock acquisition, (ii) a business combination approved by the affirmative vote of the holders of two-thirds of the voting stock not beneficially owned by such interested shareholder at a meeting called for such purpose, (iii) a business combination in which the interested shareholder pays a formula price designed to ensure that all other shareholders receive at least the highest price per share paid by such interested shareholder or (iv) a business combination approved (A) by the board of directors independent of the interested shareholder prior to the consummation of the business combination and (B) the holders of a majority of the voting stock not beneficially owned by the interested shareholder at a meeting called for such purpose if the interested shareholder’s stock acquisition was approved by the board of directors prior to the consummation of such stock acquisition.
Board of Directors. Merck’s certificate of incorporation provides that, subject to the rights of the holders of shares of any series of preferred stock then outstanding, the number of directors composing Merck’s board of directors will not exceed eighteen, and that a director can only be removed by shareholder vote if there is cause for the director’s removal. A majority of the directors then constituting Merck’s board of directors are authorized to fill vacancies on the board of directors, whether created by removal for cause, resignation or otherwise.
3


Description of the Registrant’s 1.875% Notes due 2026, 2.500% Notes due 2034 and 1.375% Notes due 2036
Registered under Section 12 of the Securities Exchange Act of 1934
In this description, unless the context requires otherwise:
“2026 notes” means the 1.875% Notes due 2026 of Merck & Co., Inc.;
“2034 notes” means the 2.500% Notes due 2034 of Merck & Co., Inc.;
“2036 notes” means the 1.375% Notes due 2034 of Merck & Co., Inc.;
“holder” means a direct holder and not a street name or other indirect holder of notes;
“notes” means the 2026 notes, 2034 notes and 2036 notes, collectively; and
“we,” “our” and “us” refer to Merck & Co., Inc., but not to any of Merck & Co., Inc.’s subsidiaries.
The following sets forth a description of the material terms of the notes. The description is qualified in its entirety by reference to the indenture, dated as of January 6, 2010, between us and U.S. Bank Trust National Association, as trustee (a copy of which is included as Exhibit 4.1 to our Current Report on Form 8-K filed on December 10, 2010) and, as applicable, the officers’ certificate pursuant to such indenture with respect to the 2026 notes, dated October 15, 2014, including the form of the 2026 notes (a copy of which is included as Exhibit 4.2 to our Current Report on Form 8-K filed on October 15, 2014), the officers’ certificate pursuant to such indenture with respect to the 2034 notes, dated October 15, 2014, including the form of the 2034 notes (a copy of which is included as Exhibit 4.3 to our Current Report on Form 8-K filed on October 15, 2014) or the officers’ certificate pursuant to such indenture with respect to the 2036 notes, dated November 2, 2016, including the form of the 2036 notes (a copy of which is included as Exhibit 4.2 to our Current Report on Form 8-K filed on November 2, 2016). You are encouraged to read such indenture and officers’ certificates for additional information.
The 2026 notes, the 2034 notes and the 2036 notes are each a separate series of notes under the indenture.
The 2026 notes are initially limited to €1,000,000,000 aggregate principal amount, which amount remains outstanding as of February 25, 2025, and will mature on October 15, 2026. The 2034 notes are initially limited to €500,000,000 aggregate principal amount, which amount remains outstanding as of February 25, 2025, and will mature on October 15, 2034. The 2036 notes are initially limited to €500,000,000 aggregate principal amount, which amount remains outstanding as of February 25, 2025, and will mature on November 2, 2036.
The notes are unsecured and rank equally with all our other unsecured and unsubordinated indebtedness from time to time outstanding. The notes are not guaranteed by any of our subsidiaries and are therefore structurally subordinated to all liabilities of our subsidiaries from time to time outstanding, including any guarantees provided by our subsidiaries. The notes also are effectively subordinated to any secured debt we or our subsidiaries incur to the extent of the value of any assets securing such debt.
The notes were issued in denominations of €100,000 and integral multiples of €1,000 in excess thereof.
We may issue as many distinct series of debt securities under the indenture as we wish. A series of debt securities may be guaranteed by one or more of our subsidiaries. There is no limit on the amount of debt securities we may issue under the indenture and the provisions of the indenture allow us to issue debt securities with terms different from those previously issued under the indenture. Also, as discussed below under “Further Issues,” we
4


may “reopen” a previous issue of a series of debt securities and issue additional debt securities of that series. We also may issue other debt under other indentures or documentation, containing provisions different from those included in the indenture or applicable to the notes.
The notes are listed on the New York Stock Exchange. We have no obligation to maintain such listing and we may delist the notes at any time.
Elavon Financial Services DAC, UK Branch initially acts as principal paying agent (the “paying agent”) (and with respect to the 2026 notes and the 2034 notes, also serves as the transfer agent). Elavon Financial Services DAC initially acts as security registrar (the “security registrar”) (and with respect to the 2036 notes, also serves as the transfer agent) and U.S. Bank Trust National Association initially acts as trustee (“trustee”) for the notes. We have entered into an issuing and paying agency agreement in relation to the notes between us, U.S. Bank Trust National Association, as trustee, Elavon Financial Services DAC, UK Branch, as principal paying agent (and with respect to the 2026 notes and the 2034 notes, as transfer agent) and Elavon Financial Services DAC as security registrar (and with respect to the 2036 notes, as transfer agent). Payment of principal of and interest on the notes is made through the office of the principal paying agent in London. The terms “principal paying agent” and “paying agent” shall include any successors appointed from time to time in accordance with the provisions of the issuing and paying agency agreement, and any reference to an “agent” or “agents” shall mean any or all (as applicable) of such persons.
Interest
The 2026 notes bear interest at a rate of 1.875% per annum, the 2034 notes bear interest at a rate of 2.500% per annum and the 2036 notes bear interest at a rate of 1.375% per annum. Interest on the 2026 notes and the 2034 notes is payable annually on October 15 of each year and interest on the 2036 notes is payable annually on November 2 of each year to the person in whose name such notes were registered at the close of business on the fifteenth calendar day before the next interest payment date. If any payment date for the notes is not a business day, payment is made on the next business day, but we are not liable for any additional interest as a result of the delay in payment. With respect to the notes, by business day, we mean any Monday, Tuesday, Wednesday, Thursday or Friday which is not a day when banking institutions are authorized or obligated by law or executive order to be closed in The City of New York or London and, for any place of payment outside of The City of New York or London, in such place of payment, and on which the Trans-European Automated Real-time Gross Settlement Express Transfer system (the TARGET2 system), or any successor thereto, operates.
With respect to each series of notes, we compute the amount of interest payable on the basis of (i) the actual number of days in the period for which interest is being calculated and (ii) the actual number of days from (and including) the last date on which interest was paid on the notes of such series (or October 15, 2014 with respect to the 2026 notes and the 2034 notes, and November 2, 2016 with respect to the 2036 notes, if no interest has been paid on the notes of such series) to (but excluding) the next scheduled interest payment date. This payment convention is referred to as ACTUAL/ACTUAL (ICMA) as defined in the rulebook of the International Capital Market Association.
Payments in Euros
All payments of interest and principal, including payments made upon any redemption of the notes, are payable in euros. If, at any time, the euro is unavailable to us due to the imposition of exchange controls or other circumstances beyond our control or if the euro is no longer being used by the then member states of the European Monetary Union that have adopted the euro as their currency or for the settlement of transactions by public institutions of or within the international banking community, then all payments in respect of the notes will be made in U.S. dollars until the euro is again available to us or so used. In such circumstances, the amount payable on any date in euros will be converted into U.S. dollars on the basis of the most recently available market exchange rate for
5


euros. Any payment in respect of the notes so made in U.S. dollars will not constitute an event of default under the notes or the indenture governing the notes. Neither the trustee nor the paying agent shall have any responsibility for any calculation or conversion in connection with the foregoing.
Investors are subject to foreign exchange risks as to payments of principal and interest that may have important economic and tax consequences to them.
Optional Redemption
Each series of notes is redeemable in whole or in part, at our option at any time or from time to time, at a redemption price equal to the greater of (i) 100% of the principal amount of the notes to be redeemed or (ii) the sum of the present values of the Remaining Scheduled Payments (as defined below) (not including any portion of such payment of interest accrued as of the date of redemption) discounted to the redemption date on an annual basis (ACTUAL/ACTUAL (ICMA)) at the applicable Comparable Government Bond Rate (as defined below), plus 15 basis points with respect to the 2026 notes, the Comparable Government Bond Rate plus 15 basis points with respect to the 2034 notes and the Comparable Government Bond Rate plus 15 basis points with respect to the 2036 notes, plus, in each case, accrued and unpaid interest on the principal amount being redeemed to, but excluding, the redemption date.
On or after July 15, 2026 for the 2026 notes, July 15, 2034 for the 2034 notes and August 2, 2036 for the 2036 notes (three months prior to the maturity date of the 2026 notes, the 2034 notes or the 2036 notes, as applicable), we may redeem in whole or in part the 2026 notes, the 2034 notes or the 2036 notes, as applicable, at any time or from time to time, at our option, at a redemption price equal to 100% of the principal amount of the applicable notes being redeemed, plus accrued and unpaid interest on the principal amount being redeemed to, but excluding, the redemption date.
We are required to give notice of redemption at least 30 days, but no more than 60 days, prior to the redemption date. The notice will be mailed to the registered address of each holder of that series of notes. The principal amount of a note remaining outstanding after a redemption in part shall be €100,000 or an integral multiple of €1,000 in excess thereof.
“Comparable Government Bond Rate” means, with respect to any redemption date, the price, expressed as a percentage (rounded to three decimal places, with 0.0005 being rounded upwards), at which the gross redemption yield on the notes to be redeemed, if they were to be purchased at such price on the third business day prior to the date fixed for redemption, would be equal to the gross redemption yield on such business day of the Comparable Government Bond (as defined below) on the basis of the middle market price of the Comparable Government Bond prevailing at 11:00 a.m. (London time) on such business day as determined by an independent investment bank selected by us.
“Comparable Government Bond” means, in relation to any Comparable Government Bond Rate calculation, at the discretion of an independent investment bank selected by us, a German federal government bond whose maturity is closest to the maturity of the notes to be redeemed, or if such independent investment bank in its discretion determines that such similar bond is not in issue, such other German government bond as such independent investment bank may, with the advice of three brokers of, and/or market makers in, German government bonds selected by us, determine to be appropriate for determining the Comparable Government Bond Rate.
“Remaining Scheduled Payments” means, with respect to each note to be redeemed, the remaining scheduled payments of principal of and interest on the note that would be due after the related redemption date but for the redemption. If that redemption date is not an interest payment date with respect to a note, the amount of the
6


next succeeding scheduled interest payment on the note will be reduced by the amount of interest accrued on the note to the redemption date.
If fewer than all of the notes of any series are to be redeemed, the trustee will select the particular notes or portions thereof for redemption from the outstanding notes not previously called, pro rata or by lot, or in such other manner as we direct each in accordance with the depositary’s procedures.
Unless we default in payment of the redemption price, on and after the redemption date interest will cease to accrue on the notes or portions thereof called for redemption.
The notes are also subject to redemption if certain events occur involving United States taxation. See “Taxation Redemption.”
Additional Amounts
All payments of principal and interest in respect of the notes are made free and clear of, and without deduction or withholding for or on account of any present or future taxes, duties, assessments or other governmental charges of whatsoever nature imposed, levied, collected, withheld or assessed by the United States or any political subdivision or taxing authority of or in the United States (collectively, “Taxes”), unless such withholding or deduction is required by law.
In the event such withholding or deduction of Taxes is required by law, subject to the limitations described below, we will pay to the holder of any note that is not beneficially owned by a U.S. Holder (as defined below) such additional amounts (“Additional Amounts”) as may be necessary in order that every net payment received by the beneficial owner of such note of principal of or interest or any other amount payable on the notes (including upon redemption), after deduction or withholding for or on account of such Taxes, will not be less than the amount provided for in such note to be then due and payable before deduction or withholding for or on account of such Taxes.
However, our obligation to pay Additional Amounts shall not apply to:
(a)any Taxes which would not have been so imposed but for:
(1)the existence of any present or former connection between such holder or beneficial owner (or between a fiduciary, settlor, beneficiary, member or shareholder or other equity owner of, or a person having a power over, such holder or beneficial owner, if such holder or beneficial owner is an estate, a trust, a limited liability company, a partnership, a corporation or other entity) and the United States, including, without limitation, such holder or beneficial owner (or such fiduciary, settlor, beneficiary, member, shareholder or other equity owner or person having such a power) being or having been a citizen or resident or treated as a resident of the United States or being or having been engaged in a trade or business in the United States or being or having been present in the United States or having or having had a permanent establishment in the United States;
(2)the failure of such holder or beneficial owner to comply with any certification, information or other reporting requirement, if compliance is required under United States tax laws and regulations to establish entitlement to a partial or complete exemption from such Taxes (including, but not limited to, the requirement to provide Internal Revenue Service Form W-8BEN, Form W-8BEN-E, Form W-8ECI, or any subsequent versions thereof or successor thereto); or
7


(3)such holder’s or beneficial owner’s present or former status as a personal holding company or a foreign personal holding company with respect to the United States, as a controlled foreign corporation with respect to the United States, as a passive foreign investment company with respect to the United States, as a foreign tax exempt organization with respect to the United States or as a corporation which accumulates earnings to avoid United States federal income tax;
(b)any Taxes imposed by reason of the holder or beneficial owner:
(1)owning or having owned, directly or indirectly, actually or constructively, 10% or more of the total combined voting power of all classes of our stock, as described in section 871(h)(3) of the Internal Revenue Code of 1986, as amended (the “Internal Revenue Code”),
(2)being a bank receiving interest described in section 881(c)(3)(A) of the Internal Revenue Code, or
(3)being a controlled foreign corporation with respect to the United States that is related to us by stock ownership;
(c)any Taxes which would not have been so imposed but for the presentation by the holder or beneficial owner of such note for payment on a date more than 30 days after the date on which such payment became due and payable or the date on which payment of the note is duly provided for and notice is given to holders, whichever occurs later, except to the extent that the holder or beneficial owner would have been entitled to such Additional Amounts on presenting such note on any date during such 30-day period;
(d)any estate, inheritance, gift, sales, excise, transfer, personal property, wealth or similar Taxes;
(e)any Taxes which are payable otherwise than by withholding from a payment on such note;
(f)any Taxes which are payable by a holder that is not the beneficial owner of the note, or a portion of the note, or that is a fiduciary, partnership, limited liability company or other similar entity, but only to the extent that a beneficial owner, a beneficiary or settlor with respect to such fiduciary or member of such partnership, limited liability company or similar entity would not have been entitled to the payment of an additional amount had such beneficial owner, settlor, beneficiary or member received directly its beneficial or distributive share of the payment;
(g)any Taxes required to be withheld by any paying agent from any payment on any note, if such payment can be made without such withholding by at least one other paying agent;
(h)any Taxes imposed under Sections 1471 through 1474 of the Internal Revenue Code (or any amended or successor provisions), any current or future regulations or official interpretations thereof, any agreement entered into pursuant to Section 1471(b) of the Code or any fiscal or regulatory legislation, rules or practices adopted pursuant to any intergovernmental agreement entered into in connection with the implementation of such sections of the Code; or
(i)any combination of items (a), (b), (c), (d), (e), (f), (g) and (h).
For purposes of this section, the acquisition, ownership, enforcement, or holding of or the receipt of any payment with respect to a note will not constitute a connection (1) between the holder or beneficial owner and the
8


United States or (2) between a fiduciary, settlor, beneficiary, member or shareholder or other equity owner of, or a person having a power over, such holder or beneficial owner if such holder or beneficial owner is an estate, a trust, a limited liability company, a partnership, a corporation or other entity and the United States.
Any reference in this description, in the indenture or in the notes to principal or interest or other payment on the notes shall be deemed to refer also to Additional Amounts which may be payable under the provisions of this section.
We will pay all stamp and other duties, if any, which may be imposed by the United States or any political subdivision thereof or taxing authority therein with respect to the issuance of the notes pursuant to this offering.
Except as specifically provided under the heading “Additional Amounts,” we will not be required to make any payment with respect to any tax, duty, assessment or other governmental charge imposed by any government or any political subdivision or taxing authority of or in the United States.
A “U.S. Holder” is a beneficial owner of a note or notes that is for U.S. federal income tax purposes:
an individual who is a citizen or resident of the United States;
a corporation created or organized in or under the laws of the United States, any state thereof or the District of Columbia;
an estate, the income of which is subject to U.S. federal income taxation regardless of the source of that income; or
a trust, if (1) a U.S. court is able to exercise primary supervision over the trust’s administration and one or more “United States persons” (within the meaning of the Internal Revenue Code) have the authority to control all of the trust’s substantial decisions, or (2) the trust has a valid election in effect under applicable Treasury regulations to be treated as a “United States person.”
Taxation Redemption
The notes may be redeemed at our option, in whole but not in part, at a redemption price equal to 100% of the principal amount of the notes to be redeemed, together with interest accrued and unpaid to, but excluding, the redemption date, at any time, on giving not less than 30 nor more than 60 days’ notice in accordance with “Notices” below if:
(a)we have or will become obligated to pay Additional Amounts as a result of (i) any change in or amendment to the laws, regulations or rulings of the United States or any political subdivision or any taxing authority of or in the United States affecting taxation, or (ii) any change in or amendment to an official application, interpretation, administration or enforcement of such laws, regulations or rulings, which change or amendment is announced or becomes effective, with respect to the 2026 notes and the 2034 notes, on or after October 6, 2014, and with respect to the 2036 notes, on or after October 26, 2016; provided we reasonably determine that such obligation cannot be avoided by our taking reasonable measures available to us without significant difficulty, cost or expense, or
(b)any action shall have been taken by a taxing authority, or any action has been brought in a court of competent jurisdiction, in the United States or any political subdivision or taxing authority of or in the United States, including any of those actions specified in (a) above, whether or not such action was taken or brought with respect to us, or any change, clarification, amendment, application or
9


interpretation of such laws, regulations or rulings shall be officially proposed, in any such case, with respect to the 2026 notes and the 2034 notes, on or after October 6, 2014, and with respect to the 2036 notes, on or after October 26, 2016, which results in a substantial likelihood that we will be required to pay Additional Amounts on the next interest payment date.
However, no such notice of redemption shall be given earlier than 90 days prior to the earliest date on which we would be, in the case of a redemption for the reasons specified in (a) above, or there would be a substantial likelihood that we would be, in the case of a redemption for the reasons specified in (b) above, obligated to pay such Additional Amounts if a payment in respect of the notes were then due and, at the time such notification of redemption is given, such circumstance remains in effect.
Prior to the publication of any notice of redemption pursuant to this section, in the case of a redemption for the reasons specified in (a) or (b) above, we will deliver to the trustee:
(1)a certificate signed by one of our duly authorized officers stating that we are entitled to effect such redemption and setting forth a statement of facts showing that the conditions precedent to our right so to redeem have occurred, and
(2)a written opinion of independent legal counsel of recognized standing to the effect that we have or will become obligated to pay such Additional Amounts as a result of such change or amendment or that there is a substantial likelihood that we will be required to pay such Additional Amounts as a result of such action or proposed change, clarification, amendment, application or interpretation, as the case may be.
Such notice, once delivered by us to the trustee, will be irrevocable.
Modification and Waiver
There are three types of changes we can make to the indenture and the notes.
Changes Requiring Holder Approval. First, there are changes that cannot be made to the notes of any series without specific approval by each holder of the notes of such series affected thereby. Following is a list of those types of changes:
change the payment due date of any installment of the principal or any premium or interest on a note stated in the note;
reduce any amounts due on a note;
change the place or currency of payment on a note;
impair the holders’ right to sue for payment;
reduce the percentage of notes of any series the holders of which must consent to modify or amend the indenture;
reduce the percentage of notes of any series the holders of which must consent to waive compliance with certain provisions of the indenture or to waive certain defaults; and
modify any other aspect of the provisions dealing with modification and waiver of the indenture except to increase any such percentage or to provide that certain other provisions of the indenture
10


cannot be modified or waived without the consent of the holder of each outstanding security affected thereby.
Changes Requiring a Majority Vote. The second type of change to the indenture and the notes is the kind that requires a vote in favor by holders owning not less than a majority of the principal amount of the notes of the particular series affected. Most changes fall into this category, such as if we wish to obtain a waiver of all or part of the restrictive covenants described below, or a waiver of a past default. However, we cannot obtain a waiver of a payment default or any other aspect of the indenture or the notes listed in the first category above under “Changes Requiring Holder Approval” unless we obtain the individual consent of each holder of the notes of such series affected thereby to the waiver.
Changes Not Requiring Approval. The third type of change does not require any vote by holders of notes. This type is limited to the addition or release of a guarantee, corrections and clarifications and other changes that would not adversely affect holders of the notes.
Further Details Concerning Voting. When taking a vote, we use the U.S. dollar equivalent to decide how much principal amount to attribute to a note.
Notes will not be considered outstanding and therefore will not carry voting rights if we have deposited or set aside in trust for the holders thereof money for their payment or redemption. Notes will also not be eligible to vote if they have been fully defeased as described under “DefeasanceFull Defeasance.”
We may set any day as a record date for the purpose of determining the holders of outstanding notes that are entitled to vote or take other action under the indenture. In some circumstances, the trustee may set a record date for action by holders.
Street name and other indirect holders should consult their banks or brokers for information on how approval may be granted or denied if we seek to change the indenture or the notes or request a waiver.
Mergers and Similar Events
We may consolidate or merge with another company or firm. We may also convey, transfer or lease all of our properties and assets substantially as an entirety to another firm, or buy or lease substantially all of the assets of another firm. However, we may not take any of these actions unless the following conditions, among others, are met:
We are the surviving entity or, when we merge out of existence or convey, transfer or lease all of our properties and assets substantially as an entirety, the other firm must be a corporation, limited liability company, partnership or trust organized under the laws of a U.S. state or the District of Columbia or under federal law and it must agree to be legally responsible for the notes.
The merger, sale of assets or other transaction must not cause a default on the notes, and we must not already be in default unless the merger or other transaction would cure the default. For purposes of this no-default test, a default would include an event of default, as described under “—Events of Default,” that has occurred and not been cured. A default for this purpose would also include the occurrence of any event that would be an event of default if we received the required notice of our default or if under the indenture the default would become an event of default after existing for a specific period of time.
It is possible that the merger, sale of assets or other transaction would cause some of our property to become subject to a mortgage or other legal mechanism giving lenders preferential rights in that property over other lenders or over our general creditors if we fail to pay them back. We have
11


promised to limit these preferential rights, as discussed under “Restrictive Covenants.” If a merger or other transaction would create any liens on any of our property, we must comply with those restrictive covenants. We would do this either by deciding that the liens were permitted, or by following the requirements of the restrictive covenants to grant an equivalent or higher-ranking lien to the holders of the notes on the same property that we own.
If the conditions described above are satisfied with respect to any series of notes, we do not need to obtain the approval of the holders of those notes in order to merge or consolidate or to sell our assets. Also, these conditions apply only if we wish to merge or consolidate with another entity or convey, transfer or lease all of our properties and assets substantially as an entirety. We do not need to satisfy these conditions if we enter into other types of transactions, including any transaction in which we acquire the stock or assets of another entity, any transaction that involves a change of control but in which we do not merge or consolidate and any transaction in which we convey, transfer or lease less than all of our properties and assets substantially as an entirety. It is possible that these other types of transactions may result in a reduction in our credit rating, may reduce our operating results or may impair our financial condition. However, the holders of notes have no approval right with respect to any transaction of this type.
Restrictive Covenants
Restrictions on Secured Debt. Some of our property may be subject to a mortgage or other legal mechanism that gives our lenders preferential rights in that property over other lenders, including the holders of the notes, or over our general creditors if we fail to pay them back. These preferential rights are called liens. Debt which is protected by these preferential rights is called secured debt. In the indenture, we promise that neither we nor our domestic subsidiaries (as defined below) will incur any new secured debt that is secured by a lien on any of our or our domestic subsidiaries’ principal domestic manufacturing properties (as defined below), or on any shares of stock of any of our domestic subsidiaries that own or lease a principal domestic manufacturing property, unless we grant an equivalent or higher-ranking lien on the same property to the holders of the notes and other outstanding debt securities issued under the indenture.
We do not need to comply with this restriction if the amount of all debt that would be secured by liens on principal domestic manufacturing properties, including the new debt, the notes and other outstanding debt securities issued under the indenture which we would so secure as described in the previous sentence, and all attributable debt (as defined below) that results from a sale and leaseback transaction involving principal domestic manufacturing properties, is less than 10% of our consolidated net tangible assets (as defined below).
This restriction on secured debt does not apply to debt secured by certain types of liens, and we can disregard this secured debt when we calculate the limits imposed by this restriction. These types of liens are:
liens on the property of any of our domestic subsidiaries, or on their shares of stock, if those liens existed at the time the corporation became our domestic subsidiary;
with respect to any series of notes, any lien existing on the date of issuance of such notes;
liens in favor of us or our domestic subsidiaries;
liens in favor of U.S. governmental bodies that we granted in order to assure our payments to such bodies that we owe by law or because of a contract we entered into;
liens in favor of any customer arising in respect of payments made by or on behalf of a customer for goods produced for, or services rendered to, customers in the ordinary course of business not exceeding the amount of those payments;
12


statutory liens, liens for taxes or assessments or governmental charges or levies not yet due or delinquent or which can be paid without penalty or are being contested in good faith, landlord’s liens on leased property, easements and other liens of a similar nature;
liens on property or shares of stock that existed at the time we acquired them, including property we may acquire through a merger or similar transaction, or that we granted in order to purchase the property, which are sometimes called purchase money mortgages; and
debt secured by liens that extend, renew or replace any of these types of liens.
We and our subsidiaries may have as much unsecured debt as we may choose.
Restrictions on Sales and Leasebacks. We promise that neither we nor any of our domestic subsidiaries will enter into any sale and leaseback transaction involving a principal domestic manufacturing property, unless we comply with this restrictive covenant. A sale and leaseback transaction generally is an arrangement between us or a domestic subsidiary and a bank, insurance company or other lender or investor where we or the domestic subsidiary sell a property to a lender or investor more than 120 days after the acquisition of the property or the completion of construction of the property and the beginning of its full operation and we lease the property back from the lender.
We can comply with this restrictive covenant in either of two ways:
First, we will be in compliance if we or our domestic subsidiary could grant a lien on the principal domestic manufacturing property in an amount equal to the attributable debt for the sale and leaseback transaction without being required to grant an equivalent or higher-ranking lien to the holders of the notes and other outstanding debt securities issued under the indenture under the restriction on secured debt described above.
Second, we can comply if we retire an amount of our or any domestic subsidiary’s funded debt (as defined below) which is not subordinated in right of payment to any outstanding notes or other outstanding debt securities issued under the indenture, within 120 days of the transaction, equal to the greater of the net proceeds of the sale of the principal domestic manufacturing property that we lease in the transaction or the fair market value of that property, subject to credits for voluntary retirements of notes and other outstanding debt securities issued under the indenture and funded debt we or the domestic subsidiary may make.
This restriction on sales and leasebacks does not apply to any sale and leaseback transaction that is between us and one of our domestic subsidiaries or between domestic subsidiaries, or that involves a lease for a period of three years or less.
Definitions Relating to our Restrictive Covenants. Following are summaries of the meanings of the terms that are important in understanding the restrictive covenants previously described:
“Attributable debt” means the total net amount of rent, discounted at 1% per annum over the weighted average yield to maturity of the outstanding notes and other outstanding debt securities issued under the indenture compounded semi-annually, that is required to be paid during the remaining term of any lease.
“Consolidated net tangible assets” is the total amount of assets, less reserves and certain other permitted deductible items, after subtracting all current liabilities and all goodwill, trade names, trademarks, patents, unamortized debt discounts and expenses and similar intangible assets, as such amounts appear on our most recent consolidated balance sheet and computed in accordance with generally accepted accounting principles.
13


A “domestic subsidiary” means any of our subsidiaries which transacts substantially all of its business in the United States, has substantially all of its fixed assets located in the United States, or owns or leases principal domestic manufacturing property. However, a subsidiary whose principal business is financing our operations outside of the United States is not a domestic subsidiary. A subsidiary is a corporation in which we and/or one or more of our other subsidiaries owns at least 50% of the voting stock (generally defined as stock that ordinarily permits its owners to vote for the election of directors).
“Funded debt” means all debt for borrowed money that either has a maturity of 12 months or more from the date on which the calculation of funded debt is made or has a maturity of less than 12 months from that date but is by its terms renewable or extendible beyond 12 months from that date at the option of the borrower.
A “principal domestic manufacturing property” is any building or other structure or facility, and the land on which it sits and its associated fixtures, that we use primarily for manufacturing, processing or warehousing, that is located in the United States and that has a gross book value in excess of 1% of our consolidated net tangible assets, other than a building, structure or other facility that our board of directors has determined is not of material importance to the total business that we and our subsidiaries conduct or a building or structure which is financed by obligations issued by a state, a territory, or a possession of the United States, or any political subdivision of any of the foregoing, or the District of Columbia, the interest of which is excludable from gross income of the holders under provisions of the tax code.
Further Issues
We may, without the consent of holders of any series of the notes, issue additional notes having the same ranking and the same interest rate, maturity and other terms as the notes of that series. Any additional notes of any series, together with the outstanding notes of the applicable series, will constitute a single series of notes under the indenture. No additional notes may be issued if an event of default has occurred and is continuing with respect to the applicable series of notes. Additional notes cannot be issued under the same CUSIP, ISIN or Common Code number unless the additional notes and original notes are fungible for U.S. federal income tax purposes.
Defeasance
Full Defeasance. If there is a change in federal tax law, as described below, we can legally release ourselves from any payment or other obligations on the notes of a series if we put in place other arrangements for the holders of such notes to be repaid. This is called full defeasance. In order to achieve full defeasance, we must do the following, among other things:
We must deposit in trust for the benefit of all holders of the notes of the series any combination of money (in euros) and Federal Republic of Germany obligations (as defined below) that will generate enough cash to make interest, principal and any other payments on the notes of that series on their various due dates.
There must be a change in current federal tax law or an IRS ruling that lets us make the above deposit without causing holders or beneficial owners of the notes of the series to be taxed on such notes any differently than if we did not make the deposit and just repaid such notes ourselves. (Under current federal tax law, the deposit and our legal release from such notes would be treated as though we took back beneficial owners’ notes and gave them their share of the cash and notes or bonds deposited in trust. In that event, beneficial owners could recognize gain or loss on the notes they give back to us.)
We must deliver to the trustee a legal opinion of our counsel confirming the tax law change described above.
14


If we ever did accomplish full defeasance, as described above, holders of defeased notes would have to rely solely on the trust deposit for repayment on such notes. Holders of such notes could not look to us for repayment in the unlikely event of any shortfall.
Covenant Defeasance. Under current federal tax law, we can make the same type of deposit described above and be released from some of the restrictive covenants in the notes. This is called covenant defeasance. In that event, holders of notes would lose the protection of those restrictive covenants but would gain the protection of having money and securities set aside in trust to repay the notes. In order to achieve covenant defeasance of the notes of a series, we must do the following:
We must deposit in trust for the benefit of all holders of the notes of the series any combination of money (in euros) and Federal Republic of Germany obligations that will generate enough cash to make interest, principal and any other payments on the notes on their various due dates.
We must deliver to the trustee a legal opinion of our counsel confirming that under current federal income tax law we may make the above deposit without causing holders or beneficial owners of the notes to be taxed on the notes any differently than if we did not make the deposit and just repaid the notes ourselves.
If we accomplish covenant defeasance, the following provisions of the indenture and the notes would no longer apply:
Our promises regarding conduct of our business previously described under “Restrictive Covenants.”
Restrictions regarding mergers or similar transactions, as described under “Mergers and Similar Events.”
The events of default relating to mergers or similar transactions and either of the restrictive covenants described under “Restrictive Covenants.”
If we accomplish covenant defeasance, holders of notes can still look to us for repayment of the notes if there were a shortfall in the trust deposit. In fact, if one of the remaining events of default occurred, such as our bankruptcy, and the notes become immediately due and payable, there may be such a shortfall in the trust deposit.
“Federal Republic of Germany obligations” means (1) securities that are direct obligations of the Federal Republic of Germany for the payment of which its full faith and credit is pledged or (2) obligations of a person controlled or supervised by and acting as an agency or instrumentality of the Federal Republic of Germany, the payment of which is unconditionally guaranteed as a full faith and credit obligation by the Federal Republic of Germany, which, in either case under clauses (1) or (2) are not callable or redeemable at the option of the issuer thereof.
Events of Default
Holders of notes have special rights if an event of default occurs and is not cured, as described later in this subsection.
The term event of default with respect to each series of notes means any of the following:
We do not pay the principal or any premium on such series of notes on its due date.
15


We do not pay interest on such series of notes within 30 days of its due date.
We remain in breach of either of the restrictive covenants described under “Restrictive Covenants” or any other covenant or warranty in the indenture for 90 days after we receive a notice of default stating we are in breach. The notice must be sent by either the trustee or holders of at least 25% of the principal amount of notes of the affected series.
We file for bankruptcy or other specific events of bankruptcy, insolvency or reorganization occur.
We do not pay Additional Amounts on such series of notes within 30 days after such payment is due.
Any payment in respect of the notes made in U.S. dollars due to the unavailability or nonuse of the euro as discussed under “Payments in Euros” will not constitute an event of default under the notes or the indenture governing the notes.
If an event of default has occurred and has not been cured, the trustee or the holders of at least 25% in principal amount of the outstanding notes of the affected series may declare the entire principal amount of all the notes of that series to be due and immediately payable. This is called a declaration of acceleration. The holders of at least a majority in principal amount of the notes of the affected series may cancel a declaration of acceleration of maturity.
Except in cases of default, where the trustee has some special duties, the trustee is not required to take any action under the indenture at the request of any holders unless such holders offer the trustee reasonable protection, called an indemnity, against expenses and liability. If reasonable indemnity is provided, the holders of a majority in principal amount of the outstanding notes of the relevant series may direct the time, method and place of conducting any lawsuit or other formal legal action seeking any remedy available to the trustee. These majority holders may also direct the trustee in performing any other action under the indenture with respect to the notes of the applicable series.
Before a holder of notes of any series bypasses the trustee and brings its own lawsuit or other formal legal action or takes other steps to enforce its rights or protect its interests relating to the notes of such series, the following must occur:
The holder must give the trustee written notice that an event of default has occurred and remains uncured.
The holders of at least 25% in principal amount of all outstanding notes of the relevant series must make a written request that the trustee take action because of the default, and must offer indemnity reasonably satisfactory to the trustee against the cost and other liabilities of taking that action.
The trustee must have not received from holders of a majority in principal amount of the outstanding notes of that series a direction inconsistent with the written notice.
The trustee must have not taken action for 60 days after receipt of the above notice and offer of indemnity.
However, a holder of notes is entitled at any time to bring a lawsuit for the payment of money due on its notes on or after their due date.
16


Street name and other indirect holders should consult their banks or brokers for information on how to give notice or direction to or make a request of the trustee and to make or cancel a declaration of acceleration.
We furnish to the trustee every year a written statement of our principal executive, financial or accounting officer certifying that to the best of such signer’s knowledge we are in compliance with the indenture and the notes, or else specifying any default.
Form, Exchange and Registration of Transfer
We issued the notes only in fully registered form and without interest coupons.
A holder of notes may have its notes broken into more notes of smaller denominations of not less than €100,000 or combined into fewer notes of larger denominations, as long as the total principal amount is not changed. This is called an exchange.
A holder of notes may exchange or register a transfer of notes at the office of the trustee. The trustee acts as our agent for registering notes in the names of holders and registering transfers of notes. We may change this appointment to another entity or perform it ourselves. The entity performing the role of maintaining the list of registered holders is called the security registrar. It also registers transfers. A holder of notes may also replace lost, stolen or mutilated notes at that office. The trustee’s agent may require an indemnity before replacing any notes.
A holder of notes is not required to pay a service charge to register a transfer of notes or to exchange notes, but may be required to pay for any tax or other governmental charge associated with the transfer or exchange. The security registrar makes the registration of transfer or exchange only if it is satisfied with such holder’s proof of ownership.
We may cancel the designation of any trustee. We may also approve a change in the office through which any trustee acts.
If we redeem less than all of the notes of a particular series, we may block the issuance of, registration of transfer or exchange of notes during the period beginning 15 days before the day we mail the notice of redemption and ending on the day of that mailing, in order to freeze the list of holders to prepare the mailing. We may also refuse to register transfers or exchanges of notes selected for redemption, except that we will continue to permit transfers and exchanges of the unredeemed portion of any note being partially redeemed.
The rules for exchange described above apply to exchange of notes for other notes of the same series and tenor.
Payment and Paying Agents
We pay interest to a holder of notes on each date interest is due if the holder is a direct holder listed in the trustee’s records at the close of business on the fifteenth calendar day before the next interest payment date, even if such holder no longer owns the note on the interest due date. That particular day is called the regular record date. Holders buying and selling notes must work out between them how to compensate for the fact that we pay all the interest for an interest period to the one who is the registered holder on the regular record date.
We pay interest, principal and any other money due on the notes at the office of the paying agent in London, UK. That office is currently located at 125 Old Broad Street, Fifth Floor, London EC2N 1AR United Kingdom. A holder of notes must make arrangements to have its payments picked up at or wired from that office. We may also choose to pay interest by mailing checks.
17


Street name and other indirect holders should consult their banks or brokers for information on how they may receive payments.
We may also arrange for additional payment offices, and may cancel or change these offices. These offices are called paying agents. We may also choose to act as our own paying agent. We must notify holders of notes of changes in the paying agents for any particular notes of the series.
Notices
We and the trustee send notices regarding the notes only to holders, using their addresses as listed in the trustee’s records.
All paying agents must return to us upon our request all money paid by us that remains unclaimed two years after the amount is due to holders. After that two-year period, holders of notes may look only to us for payment and not to the trustee, any other paying agent or anyone else.
Book-Entry System
Upon issuance, the notes of each series are represented by one or more global notes. Each global note is deposited with, or on behalf of, a common depositary, and registered in the name of the nominee of the common depositary for the accounts of Clearstream and Euroclear.
Investors may elect to hold interests in the global notes held by the depository through Clearstream Banking, société anonyme, “Clearstream,” or Euroclear Bank SA/NV, as operator of the Euroclear System, “Euroclear,” if they are participants of such systems, or indirectly through organizations that are participants in such systems. Clearstream and Euroclear hold interests on behalf of their participants through customers’ securities accounts in Clearstream’s and Euroclear’s names on the books of their respective depositories. Book-entry interests in the notes and all transfers relating to the notes are reflected in the book-entry records of Clearstream and Euroclear. Because holders acquire, hold and transfer security entitlements with respect to the notes through Clearstream, Euroclear and their participants, a beneficial holder’s rights with respect to the notes is subject to the laws (including Article 8 of the Uniform Commercial Code) and contractual provisions governing a holder’s relationship with its securities intermediary and the relationship between its securities intermediary and each other securities intermediary and between it and us, as the issuer. Except as set forth below, the global notes may be transferred, in whole and not in part, only to another nominee of the depository or to a successor of the depository or its nominee.
No global note may be exchanged in whole or in part for notes registered, and no transfer of a global note in whole or in part may be registered, in the name of any person other than the depository or any nominee of the depository unless (i) the depository has notified us that it is unwilling or unable to continue as depository for such global note or has ceased to be qualified to act as such as required by the indenture, (ii) there has occurred and is continuing an event of default with respect to the notes or (iii) we determine in our sole discretion at any time that the global note shall be so exchangeable.
Any global note that is exchangeable pursuant to the preceding sentence shall be exchangeable in whole for separate notes in registered form of any authorized denomination and of like tenor and aggregate principal amount. These notes shall be registered in the name or names of such person or persons as the depository instructs the trustee. We expect that these instructions would be based upon directions received by the depository from its participants with respect to ownership of beneficial interests in such global note.
Except in the limited circumstances referred to above, owners of beneficial interests in a global note are not entitled to have such global note registered in their names, will not receive and are not entitled to receive physical delivery of notes in exchange therefor and are not considered to be the owners or holders of such global note for any
18


purpose under the notes or the indenture. Accordingly, each person owning a beneficial interest in the global note must rely on the procedures of the participant through which such person owns its interest to exercise any rights of a holder under the indenture.
The indenture provides that the depository, as a holder, may appoint agents and otherwise authorize participants to give or take any request, demand, authorization, direction, notice, consent, waiver, or other action which a holder is entitled to give or take under the indenture.
Governing Law
The indenture and the notes are governed by, and construed and enforced in accordance with, the laws of the State of New York applicable to agreements made or instruments entered into and performed in New York State.
Relationship with Trustee
U.S. Bank Trust National Association is the trustee under the indenture. U.S. Bank Trust National Association performs services for us in the ordinary course of business and serves as the trustee with respect to certain of our other outstanding debt securities.
Open Market Purchases
We may at any time and from time to time purchase notes in the open market or otherwise.
The Paying Agent, Transfer Agent and Security Registrar
Elavon Financial Services DAC, UK Branch is the paying agent to the notes (and with respect to the 2026 notes and the 2034 notes, is also the transfer agent). Elavon Financial Services DAC is the security registrar with respect to the notes (and with respect to the 2036 notes, is also the transfer agent).
19


Description of MSD Netherlands Capital B.V.’s 3.250% Notes due 2032, 3.500% Notes due 2037, 3.700% Notes due 2044 and 3.750% Notes due 2054, Guaranteed by the Registrant
Registered under Section 12 of the Securities Exchange Act of 1934
In this description, unless the context requires otherwise:
“2032 notes” means the 3.250% Notes due 2032 of MSD Netherlands Capital B.V.;
“2037 notes” means the 3.500% Notes due 2037 of MSD Netherlands Capital B.V.;
“2044 notes” means the 3.700% Notes due 2044 of MSD Netherlands Capital B.V.;
“2054 notes” means the 3.750% Notes due 2054 of MSD Netherlands Capital B.V.;
“holder” means a direct holder and not a street name or other indirect holder of notes;
“notes” means the 2032 notes, 2037 notes, 2044 notes and 2054 notes, collectively;
“we,” “our,” “us” and the “Issuer” refer to MSD Netherlands Capital B.V.; and
“Parent” refers to Merck & Co., Inc., but not to any of Merck & Co., Inc.’s consolidated subsidiaries.
The following sets forth a description of the material terms of the notes. The description is qualified in its entirety by reference to the indenture, dated as of May 30, 2024, among the Issuer, Parent and U.S. Bank Trust National Association, as trustee (a copy of which is included as Exhibit 4.1 to our Current Report on Form 8-K filed on May 30, 2024) and, as applicable, the officers’ certificate pursuant to such indenture with respect to the 2032 notes, dated May 30, 2024, including the form of the 2032 notes (a copy of which is included as Exhibit 4.2 to our Current Report on Form 8-K filed on May 30, 2024), the officers’ certificate pursuant to such indenture with respect to the 2037 notes, dated May 30, 2024, including the form of the 2037 notes (a copy of which is included as Exhibit 4.3 to our Current Report on Form 8-K filed on May 30, 2024), the officers’ certificate pursuant to such indenture with respect to the 2044 notes, dated May 30, 2024, including the form of the 2044 notes (a copy of which is included as Exhibit 4.4 to our Current Report on Form 8-K filed on May 30, 2024) or the officers’ certificate pursuant to such indenture with respect to the 2054 notes, dated May 30, 2024, including the form of the 2054 notes (a copy of which is included as Exhibit 4.5 to our Current Report on Form 8-K filed on May 30, 2024). You are encouraged to read such indenture and officers’ certificates for additional information.
The 2032 notes, the 2037 notes, the 2044 notes and the 2054 notes are each a separate series of notes under the indenture.
The 2032 notes are initially limited to €850,000,000 aggregate principal amount, which amount remains outstanding as of February 25, 2025, and will mature on May 30, 2032. The 2037 notes are initially limited to €850,000,000 aggregate principal amount, which amount remains outstanding as of February 25, 2025, and will mature on May 30, 2037. The 2044 notes are initially limited to €850,000,000 aggregate principal amount, which amount remains outstanding as of February 25, 2025, and will mature on May 30, 2044. The 2054 notes are initially limited to €850,000,000 aggregate principal amount, which amount remains outstanding as of February 25, 2025, and will mature on May 30, 2054.
The notes are fully and unconditionally guaranteed (the “note guarantee”) on an unsecured senior basis by Parent.
20


The notes are unsecured and rank equally with all our other unsecured and unsubordinated indebtedness from time to time outstanding. The note guarantee is unsecured and ranks equally with all of Parent’s other unsecured and unsubordinated indebtedness from time to time outstanding. The notes are obligations of the Issuer and are not guaranteed by any of Parent’s other subsidiaries and therefore the notes and the note guarantee are structurally subordinated to all liabilities of Parent’s subsidiaries other than the Issuer from time to time outstanding, including any guarantees provided by Parent’s subsidiaries other than the Issuer. The notes also are effectively subordinated to any secured debt Parent or its subsidiaries incur to the extent of the value of any assets securing such debt.
The notes were issued in denominations of €100,000 and integral multiples of €1,000 in excess thereof.
We may issue as many distinct series of debt securities under the indenture as we wish. There is no limit on the amount of debt securities we may issue under the indenture and the provisions of the indenture allow us to issue debt securities with terms different from those previously issued under the indenture. Also, as discussed below under “—Further Issues,” we may “reopen” a previous issue of a series of debt securities and issue additional debt securities of that series. We also may issue other debt under other indentures or documentation, containing provisions different from those included in the indenture or applicable to the notes.
The notes are listed on the New York Stock Exchange. The Issuer has no obligation to maintain such listing and may delist the notes at any time.
Elavon Financial Services DAC initially acts as principal paying agent (the “paying agent”) and U.S. Bank Trust National Association initially acts as transfer agent (the “transfer agent”), security registrar (the “security registrar”) and trustee (“trustee”) for the notes. We have entered into an issuing and paying agency agreement in relation to the notes between us, U.S. Bank Trust National Association, as trustee, transfer agent and security registrar and Elavon Financial Services DAC, as principal paying agent. Payment of principal of and interest on the notes is made through the office of the principal paying agent in Dublin. The terms “principal paying agent” and “paying agent” shall include any successors appointed from time to time in accordance with the provisions of the issuing and paying agency agreement, and any reference to an “agent” or “agents” shall mean any or all (as applicable) of such persons.
Interest
The 2032 notes bear interest at a rate of 3.250% per annum, the 2037 notes will bear interest at a rate of 3.500% per annum, the 2044 notes bear interest at a rate of 3.700% per annum and the 2054 notes bear interest at a rate of 3.750% per annum. Interest on the notes is payable annually in arrears on May 30 of each year to the person in whose name such notes were registered at the close of business on the preceding May 15. If any payment date for the notes is not a business day, payment is made on the next business day, but we are not liable for any additional interest as a result of the delay in payment. With respect to the notes, by business day, we mean any Monday, Tuesday, Wednesday, Thursday or Friday which is not a day when banking institutions are authorized or obligated by law or executive order to be closed in The City of New York, London or the Netherlands and, for any place of payment outside of The City of New York, London or the Netherlands, in such place of payment, and on which the Trans-European Automated Real-time Gross Settlement Express Transfer system (the TARGET2 system), or any successor thereto, operates.
With respect to each series of notes, we compute the amount of interest payable on the basis of (i) the actual number of days in the period for which interest is being calculated and (ii) the actual number of days from (and including) the last date on which interest was paid on the notes of such series (or May 30, 2024 if no interest has been paid on the notes of such series) to (but excluding) the next scheduled interest payment date. This payment convention is referred to as ACTUAL/ACTUAL (ICMA) as defined in the rulebook of the International Capital Market Association.
21


Payments in Euros
All payments of interest and principal, including payments made upon any redemption of the notes, are payable in euros. If, at any time, the euro is unavailable to us or Parent due to the imposition of exchange controls or other circumstances beyond our or Parent’s control or if the euro is no longer being used by the then member states of the European Monetary Union that have adopted the euro as their currency or for the settlement of transactions by public institutions of or within the international banking community, then all payments in respect of the notes and the note guarantee will be made in U.S. dollars until the euro is again available to us or Parent, as applicable, or so used. In such circumstances, the amount payable on any date in euros will be converted into U.S. dollars on the basis of the most recently available market exchange rate for euros, as determined by us or Parent, as applicable, in our or Parent’s sole discretion. Any payment in respect of the notes or the note guarantee so made in U.S. dollars will not constitute an event of default under the notes or the indenture governing the notes. Neither the trustee nor the paying agent shall have any responsibility for any calculation or conversion in connection with the foregoing.
Investors are subject to foreign exchange risks as to payments of principal and interest that may have important economic and tax consequences to them.
Optional Redemption
Prior to the applicable Par Call Date with respect to a series of notes, each such series of notes is redeemable in whole or in part, at our option at any time or from time to time, at a redemption price equal to the greater of (i) 100% of the principal amount of the notes to be redeemed or (ii) the sum of the present values of the Remaining Scheduled Payments (as defined below) (not including any portion of such payment of interest accrued as of the date of redemption) discounted to the redemption date (assuming the notes matured on the applicable Par Call Date) on an annual basis (ACTUAL/ACTUAL (ICMA)) at the applicable Comparable Government Bond Rate (as defined below), plus 15 basis points with respect to the 2032 notes, the Comparable Government Bond Rate plus 15 basis points with respect to the 2037 notes, the Comparable Government Bond Rate plus 20 basis points with respect to the 2044 notes and the Comparable Government Bond Rate plus 20 basis points with respect to the 2054 notes, plus, in each case, accrued and unpaid interest on the principal amount being redeemed to, but excluding, the redemption date.
On or after the Par Call Date with respect to a series of notes, we may redeem in whole or in part the notes of such series at any time or from time to time, at our option, at a redemption price equal to 100% of the principal amount of the applicable notes being redeemed, plus accrued and unpaid interest on the principal amount being redeemed to, but excluding, the redemption date.
“Par Call Date” means February 29, 2032, the date that is three months prior to the maturity of the 2032 notes, February 28, 2037, the date that is three months prior to the maturity of the 2037 notes, November 30, 2043, the date that is six months prior to the maturity of the 2044 notes and November 30, 2053, the date that is six months prior to the maturity of the 2054 notes.
We are required to give notice of redemption at least 10 days’, but no more than 60 days’, prior to the redemption date. The notice will be delivered electronically or mailed to the registered address of each holder of that series of notes. The principal amount of a note remaining outstanding after a redemption in part shall be €100,000 or an integral multiple of €1,000 in excess thereof. Subject to the following paragraph, once notice of redemption is delivered, the notes called for redemption will become due and payable on the redemption date at the applicable redemption price, plus accrued and unpaid interest applicable to such notes to, but excluding, the redemption date.
Any redemption notice may, at the Issuer’s discretion, be subject to one or more conditions precedent, including completion of a corporate transaction. In such event, the related notice of redemption shall describe each such condition and, if applicable, shall state that, at our discretion, the date of redemption may be delayed until such
22


time (including more than 60 days after the notice of redemption was given) as any or all such conditions shall be satisfied or waived, or such redemption may not occur and such notice may be rescinded in the event that any or all such conditions shall not have been satisfied (or waived by the Issuer in its sole discretion) by the date of redemption, or by the date of redemption as so delayed.
“Comparable Government Bond Rate” means, with respect to any redemption date, the price, expressed as a percentage (rounded to three decimal places, with 0.0005 being rounded upwards), at which the gross redemption yield on the notes to be redeemed, if they were to be purchased at such price on the third business day prior to the date fixed for redemption, would be equal to the gross redemption yield on such business day of the Comparable Government Bond (as defined below) on the basis of the middle market price of the Comparable Government Bond prevailing at 11:00 a.m. (London time) on such business day as determined by an independent investment bank selected by us.
“Comparable Government Bond” means, in relation to any Comparable Government Bond Rate calculation, at the discretion of an independent investment bank selected by us, a German federal government bond whose maturity is closest to the maturity of the notes to be redeemed (assuming the notes matured on the applicable Par Call Date), or if such independent investment bank in its discretion determines that such similar bond is not in issue, such other German government bond as such independent investment bank may, with the advice of three brokers of, and/or market makers in, German government bonds selected by us, determine to be appropriate for determining the Comparable Government Bond Rate.
“Remaining Scheduled Payments” means, with respect to each note to be redeemed, the remaining scheduled payments of principal of and interest on the note that would be due after the related redemption date but for the redemption. If that redemption date is not an interest payment date with respect to a note, the amount of the next succeeding scheduled interest payment on the note will be reduced by the amount of interest accrued on the note to the redemption date.
If fewer than all of the notes of any series are to be redeemed, the trustee will select the particular notes or portions thereof for redemption from the outstanding notes not previously called, pro rata or by lot, or in such other manner as we direct each in accordance with the depositary’s procedures.
Unless we default in payment of the redemption price, on and after the redemption date interest will cease to accrue on the notes or portions thereof called for redemption.
The notes are also subject to redemption if certain events occur involving United States and Dutch taxation. See “—Taxation Redemption.”
Additional Amounts
All payments of principal and interest in respect of the notes are made free and clear of, and without deduction or withholding for or on account of any present or future taxes, duties, assessments or other governmental charges of whatsoever nature imposed, levied, collected, withheld or assessed by the United States or the Netherlands or any political subdivision or taxing authority of or in the United States or the Netherlands (collectively, “Taxes”), unless such withholding or deduction is required by law.
In the event such withholding or deduction of Taxes is required by law, subject to the limitations described below, we will pay to the holder of any note such additional amounts (“Additional Amounts”) as may be necessary in order that every net payment received by the beneficial owner of such note of principal of or interest or any other amount payable on the notes (including upon redemption), after deduction or withholding for or on account of such Taxes, will not be less than the amount provided for in such note to be then due and payable before deduction or withholding for or on account of such Taxes.
23


However, our obligation to pay Additional Amounts shall not apply to:
(a)any Taxes which would not have been so imposed but for:
(1)the existence of any present or former connection between such holder or beneficial owner (or between a fiduciary, settlor, beneficiary, member or shareholder or other equity owner of, or a person having a power over, such holder or beneficial owner, if such holder or beneficial owner is an estate, a trust, a limited liability company, a partnership, a corporation or other entity) and the United States or the Netherlands, including, without limitation, such holder or beneficial owner (or such fiduciary, settlor, beneficiary, member, shareholder or other equity owner or person having such a power) being or having been a citizen or resident or treated as a resident of the United States or the Netherlands or being or having been engaged in a trade or business in the United States or the Netherlands or being or having been present in the United States or the Netherlands or having or having had a permanent establishment in the United States or the Netherlands;
(2)the failure of such holder or beneficial owner to comply with any certification, information or other reporting requirement, if compliance is required under United States or Dutch tax laws and regulations to establish entitlement to a partial or complete exemption from such Taxes (including, but not limited to, the requirement to provide Internal Revenue Service Form W-8BEN, Form W-8BEN-E, Form W-8ECI, or any subsequent versions thereof or successor thereto); or
(3)such holder’s or beneficial owner’s present or former status as a personal holding company or a foreign personal holding company with respect to the United States, as a controlled foreign corporation with respect to the United States, as a passive foreign investment company with respect to the United States, as a foreign tax exempt organization with respect to the United States or as a corporation which accumulates earnings to avoid United States federal income tax;
(b)any Taxes imposed by reason of the holder or beneficial owner:
(1)owning or having owned, directly or indirectly, actually or constructively, 10% or more of the total combined voting power of all classes of our stock or the stock of Parent, as described in section 871(h)(3) of the Internal Revenue Code of 1986, as amended (the “Internal Revenue Code”),
(2)being a bank receiving interest described in section 881(c)(3)(A) of the Internal Revenue Code, or
(3)being a controlled foreign corporation with respect to the United States that is related to us or Parent by stock ownership;
(c)any Taxes which would not have been so imposed but for the presentation by the holder or beneficial owner of such note for payment on a date more than 30 days after the date on which such payment became due and payable or the date on which payment of the note is duly provided for and notice is given to holders, whichever occurs later, except to the extent that the holder or beneficial owner would have been entitled to such Additional Amounts on presenting such note on any date during such 30-day period;
24


(d)any estate, inheritance, gift, sales, excise, transfer, personal property, wealth or similar Taxes;
(e)any Taxes which are payable otherwise than by withholding from a payment on such note;
(f)any Taxes which are payable by a holder that is not the beneficial owner of the note, or a portion of the note, or that is a fiduciary, partnership, limited liability company or other similar entity, but only to the extent that a beneficial owner, a beneficiary or settlor with respect to such fiduciary or member of such partnership, limited liability company or similar entity would not have been entitled to the payment of an additional amount had such beneficial owner, settlor, beneficiary or member received directly its beneficial or distributive share of the payment;
(g)any Taxes required to be withheld by any paying agent from any payment on any note, if such payment can be made without such withholding by at least one other paying agent;
(h)any Taxes imposed under Sections 1471 through 1474 of the Internal Revenue Code (or any amended or successor provisions), any current or future regulations or official interpretations thereof, any agreement entered into pursuant to Section 1471(b) of the Code or any fiscal or regulatory legislation, rules or practices adopted pursuant to any intergovernmental agreements or treaties (and any related legislation, rules, or official administrative practices) implementing the foregoing;
(i)any U.S. federal backup withholding Taxes imposed pursuant to Section 3406 of the Internal Revenue Code;
(j)any Taxes imposed under or in connection with the Dutch Withholding Tax Act 2021 (Wet bronbelasting 2021) as amended from time to time; or
(k)any combination of items (a), (b), (c), (d), (e), (f), (g), (h), (i) and (j).
For purposes of this section, the acquisition, ownership, disposition, enforcement, or holding of, or the receipt of any payment with respect to, a note will not constitute a connection (1) between the holder or beneficial owner and the United States or the Netherlands or (2) between a fiduciary, settlor, beneficiary, member or shareholder or other equity owner of, or a person having a power over, such holder or beneficial owner if such holder or beneficial owner is an estate, a trust, a limited liability company, a partnership, a corporation or other entity and the United States or the Netherlands.
Any reference in this description, in the indenture or in the notes to principal or interest or other payment on the notes shall be deemed to refer also to Additional Amounts which may be payable under the provisions of this section.
We will pay all stamp and other duties, if any, which may be imposed by the United States or the Netherlands, or any political subdivision thereof or taxing authority therein, with respect to the issuance of the notes pursuant to this offering.
Except as specifically provided under the heading “—Additional Amounts,” we will not be required to make any payment with respect to any tax, duty, assessment or other governmental charge imposed by any government or any political subdivision or taxing authority of or in the United States or the Netherlands.
25


Taxation Redemption
The notes of any series may be redeemed at our option, in whole but not in part, at a redemption price equal to 100% of the principal amount of the notes of the applicable series to be redeemed, together with interest accrued and unpaid to, but excluding, the redemption date, at any time, on giving not less than 10 nor more than 60 days’ notice in accordance with “Notices” below if:
(a)we have or will become obligated to pay Additional Amounts as a result of (i) any change in or amendment to the laws, regulations or rulings of the United States or the Netherlands or any political subdivision or any taxing authority of or in the United States or the Netherlands affecting taxation, or (ii) any change in or amendment to an official application, interpretation, administration or enforcement of such laws, regulations or rulings, which change or amendment is announced or becomes effective on or after May 16, 2024; or
(b)any action shall have been taken by a taxing authority, or any action has been brought in a court of competent jurisdiction, in the United States or the Netherlands or any political subdivision or taxing authority of or in the United States or the Netherlands, including any of those actions specified in (a) above, whether or not such action was taken or brought with respect to us, or any change, clarification, amendment, application or interpretation of such laws, regulations or rulings shall be officially proposed, in any such case on or after May 16, 2024, which results in a substantial likelihood that we will be required to pay Additional Amounts on the next interest payment date.
However, no such notice of redemption shall be given earlier than 90 days prior to the earliest date on which we would be, in the case of a redemption for the reasons specified in (a) above, or there would be a substantial likelihood that we would be, in the case of a redemption for the reasons specified in (b) above, obligated to pay such Additional Amounts if a payment in respect of the notes were then due and, at the time such notification of redemption is given, such circumstance remains in effect.
Prior to the publication of any notice of redemption pursuant to this section, in the case of a redemption for the reasons specified in (a) or (b) above, we will deliver to the trustee:
(1)a certificate signed by one of our duly authorized officers stating that we are entitled to effect such redemption and setting forth a statement of facts showing that the conditions precedent to our right so to redeem have occurred, and
(2)a written opinion of independent legal counsel of recognized standing to the effect that we have or will become obligated to pay such Additional Amounts as a result of such change or amendment or that there is a substantial likelihood that we will be required to pay such Additional Amounts as a result of such action or proposed change, clarification, amendment, application or interpretation, as the case may be.
Such notice, once delivered by us to the trustee, will be irrevocable.
Modification and Waiver
There are three types of changes we can make to the indenture and the notes.
26


Changes Requiring Holder Approval. First, there are changes that cannot be made to the notes of any series without specific approval by each holder of the notes of such series affected thereby. Following is a list of those types of changes:
change the payment due date of any installment of the principal or any premium or interest on a note stated in the note;
reduce any amounts due on a note;
release Parent from its obligations in respect of the guarantee of any note or modify Parent’s obligations thereunder in any manner materially adverse to holders of such note, in each case other than in accordance with the indenture;
change the place or currency of payment on a note;
impair the holders’ right to sue for payment;
reduce the percentage of notes of any series the holders of which must consent to modify or amend the indenture;
reduce the percentage of notes of any series the holders of which must consent to waive compliance with certain provisions of the indenture or to waive certain defaults; and
modify any other aspect of the provisions dealing with modification and waiver of the indenture except to increase any such percentage or to provide that certain other provisions of the indenture cannot be modified or waived without the consent of the holder of each outstanding security affected thereby.
Changes Requiring a Majority Vote. The second type of change to the indenture and the notes is the kind that requires a vote in favor by holders owning not less than a majority of the principal amount of the notes of the particular series affected. Most changes fall into this category, such as if we wish to obtain a waiver of all or part of the restrictive covenants described below, or a waiver of a past default. However, we cannot obtain a waiver of a payment default or any other aspect of the indenture or the notes listed in the first category above under “—Changes Requiring Holder Approval” unless we obtain the individual consent of each holder of the notes of such series affected thereby to the waiver.
Changes Not Requiring Approval. The third type of change does not require any vote by holders of notes. This type is limited to the addition of a guarantee, the release of a guarantee (other than the Parent guarantee), corrections and clarifications and other changes that would not adversely affect holders of the notes.
Further Details Concerning Voting. When taking a vote, we use the U.S. dollar equivalent to decide how much principal amount to attribute to a note.
Notes will not be considered outstanding and therefore will not carry voting rights if we have deposited or set aside in trust for the holders thereof money for their payment or redemption. Notes will also not be eligible to vote if they have been fully defeased as described under “—Defeasance—Full Defeasance.”
We may set any day as a record date for the purpose of determining the holders of outstanding notes that are entitled to vote or take other action under the indenture. In some circumstances, the trustee may set a record date for action by holders.
Street name and other indirect holders should consult their banks or brokers for information on how approval may be granted or denied if we seek to change the indenture or the notes or request a waiver.
27


Mergers and Similar Events
We or Parent may consolidate or merge with another company or firm. We or Parent may also convey, transfer or lease all of our or Parent’s properties and assets substantially as an entirety to another firm, or buy or lease substantially all of the assets of another firm. However, we and Parent may not take any of these actions unless the following conditions, among others, are met:
In the case of the Issuer, we are the surviving entity or, when we merge out of existence or convey, transfer or lease all of our properties and assets substantially as an entirety, the other firm must be Parent or a corporation, limited liability company, partnership or trust organized under the laws of a U.S. state or the District of Columbia or under federal law or under the laws of Switzerland, the United Kingdom, The Netherlands or any other member state of the European Union as of the date of the indenture and it must agree to be legally responsible for the notes.
In the case of Parent, Parent is the surviving entity or, when Parent merges out of existence or conveys, transfers or leases all of its properties and assets substantially as an entirety, the other firm must be a corporation, limited liability company, partnership or trust organized under the laws of a U.S. state or the District of Columbia or under Federal law and it must agree to be legally responsible for the guarantees of the notes.
The merger, sale of assets or other transaction must not cause a default on the notes, and we and Parent must not already be in default unless the merger or other transaction would cure the default. For purposes of this no-default test, a default would include an event of default, as described under “—Events of Default,” that has occurred and not been cured. A default for this purpose would also include the occurrence of any event that would be an event of default if we or Parent received the required notice of our or Parent’s default or if under the indenture the default would become an event of default after existing for a specific period of time.
It is possible that the merger, sale of assets or other transaction would cause some of our or Parent’s property to become subject to a mortgage or other legal mechanism giving lenders preferential rights in that property over other lenders or over our or Parent’s, as the case may be, general creditors if we or Parent, as the case may be, fail to pay them back. Parent has promised to limit these preferential rights, as discussed under “—Restrictive Covenants.” If a merger or other transaction would create any liens on any of Parent’s property, Parent must comply with those restrictive covenants. Parent would do this either by deciding that the liens were permitted, or by following the requirements of the restrictive covenants to grant an equivalent or higher-ranking lien to the holders of the notes on the same property that Parent owns.
If the conditions described above are satisfied with respect to any series of notes, we and Parent do not need to obtain the approval of the holders of those notes in order to merge or consolidate or to sell assets. Also, these conditions apply only if we or Parent, as the case may be, wish to merge or consolidate with another entity or convey, transfer or lease all of our or Parent’s properties and assets substantially as an entirety. We and Parent will not need to satisfy these conditions if we or Parent enter into other types of transactions, including any transaction in which we or Parent, as the case may be, acquire the stock or assets of another entity, any transaction that involves a change of control but in which we or Parent, as the case may be, do not merge or consolidate and any transaction in which we or Parent, as the case may be, convey, transfer or lease less than all of our or Parent’s, as the case may be, properties and assets substantially as an entirety. It is possible that these other types of transactions may result in a reduction in our or Parent’s credit rating, may reduce Parent’s operating results or may impair Parent’s financial condition. However, the holders of notes have no approval right with respect to any transaction of this type.
28


Restrictive Covenants
Restrictions on Secured Debt. Some of Parent’s property may be subject to a mortgage or other legal mechanism that gives Parent’s lenders preferential rights in that property over other lenders, including the holders of the notes, or over Parent’s general creditors if Parent fails to pay them back. These preferential rights are called liens. Debt which is protected by these preferential rights is called secured debt. In the indenture, Parent promises that neither Parent nor its domestic subsidiaries (as defined below) will incur any new secured debt that is secured by a lien on any of Parent’s or its domestic subsidiaries’ principal domestic manufacturing properties (as defined below), or on any shares of stock of any of Parent’s domestic subsidiaries that own or lease a principal domestic manufacturing property, unless Parent grants an equivalent or higher-ranking lien on the same property to the holders of the notes and other outstanding debt securities issued under the indenture.
Parent does not need to comply with this restriction if the amount of all debt that would be secured by liens on principal domestic manufacturing properties, including the new debt and all attributable debt (as defined below) that results from a sale and leaseback transaction involving principal domestic manufacturing properties, is less than 10% of Parent’s consolidated net tangible assets (as defined below).
This restriction on secured debt does not apply to debt secured by certain types of liens, and Parent can disregard this secured debt when Parent calculates the limits imposed by this restriction. These types of liens are:
liens on the property of any of Parent’s domestic subsidiaries, or on their shares of stock, if those liens existed at the time the corporation became Parent’s domestic subsidiary;
with respect to any series of notes, any lien existing on the date of issuance of such notes;
liens in favor of Parent or its domestic subsidiaries;
liens in favor of U.S. governmental bodies that Parent granted in order to assure Parent’s payments to such bodies that Parent owes by law or because of a contract Parent entered into;
liens in favor of any customer arising in respect of payments made by or on behalf of a customer for goods produced for, or services rendered to, customers in the ordinary course of business not exceeding the amount of those payments;
statutory liens, liens for taxes or assessments or governmental charges or levies not yet due or delinquent or which can be paid without penalty or are being contested in good faith, landlord’s liens on leased property, easements and other liens of a similar nature;
liens on property or shares of stock that existed at the time Parent acquired them, including property Parent may acquire through a merger or similar transaction, or that Parent granted in order to purchase the property, which are sometimes called purchase money mortgages; and
debt secured by liens that extend, renew or replace any of these types of liens.
Parent and its subsidiaries may have as much unsecured debt as they may choose.
Restrictions on Sales and Leasebacks. Parent promises that neither Parent nor any of its domestic subsidiaries will enter into any sale and leaseback transaction involving a principal domestic manufacturing property, unless Parent complies with this restrictive covenant. A sale and leaseback transaction generally is an arrangement between Parent or a domestic subsidiary and a bank, insurance company or other lender or investor where Parent or the domestic subsidiary sells a property to a lender or investor more than 120 days after the acquisition of the property or the completion of construction of the property and the beginning of its full operation and Parent or any of its domestic subsidiaries’ leases the property back from the lender.
29


Parent can comply with this restrictive covenant in either of two ways:
First, Parent will be in compliance if Parent or its domestic subsidiary could grant a lien on the principal domestic manufacturing property in an amount equal to the attributable debt for the sale and leaseback transaction without being required to grant an equivalent or higher-ranking lien to the holders of the notes and other outstanding debt securities issued under the indenture under the restriction on secured debt described above.
Second, Parent can comply if Parent retires an amount of Parent’s or any of its domestic subsidiaries’ funded debt (as defined below) which is not subordinated in right of payment to any outstanding notes or other outstanding debt securities issued under the indenture, within 120 days of the transaction, equal to the greater of the net proceeds of the sale of the principal domestic manufacturing property that Parent or any of its domestic subsidiaries leases in the transaction or the fair market value of that property, subject to credits for voluntary retirements of notes and other outstanding debt securities issued under the indenture and funded debt Parent or the domestic subsidiary may make.
This restriction on sales and leasebacks does not apply to any sale and leaseback transaction that is between Parent and one of its domestic subsidiaries or between domestic subsidiaries, or that involves a lease for a period of three years or less.
Definitions Relating to the Restrictive Covenants. Following are summaries of the meanings of the terms that are important in understanding the restrictive covenants previously described:
Attributable debt” means the total net amount of rent, discounted at 1% per annum over the weighted average yield to maturity of the outstanding notes and other outstanding debt securities issued under the indenture compounded semi-annually, that is required to be paid during the remaining term of any lease.
Consolidated net tangible assets” is the total amount of assets, less reserves and certain other permitted deductible items, after subtracting all current liabilities and all goodwill, trade names, trademarks, patents, unamortized debt discounts and expenses and similar intangible assets, as such amounts appear on Parent’s most recent consolidated balance sheet and computed in accordance with generally accepted accounting principles.
A “domestic subsidiary” means any of Parent’s subsidiaries which transacts substantially all of its business in the United States, has substantially all of its fixed assets located in the United States, or owns or leases any principal domestic manufacturing property. However, a subsidiary whose principal business is financing Parent’s operations outside of the United States is not a domestic subsidiary. A subsidiary is a corporation in which Parent and/or one or more of its other subsidiaries owns at least 50% of the voting stock (generally defined as stock that ordinarily permits its owners to vote for the election of directors).
Funded debt” means all debt for borrowed money that either has a maturity of 12 months or more from the date on which the calculation of funded debt is made or has a maturity of less than 12 months from that date but is by its terms renewable or extendible beyond 12 months from that date at the option of the borrower.
A “principal domestic manufacturing property” is any building or other structure or facility, and the land on which it sits and its associated fixtures, that Parent uses primarily for manufacturing, processing or warehousing, that is located in the United States and that has a gross book value in excess of 1% of Parent’s consolidated net tangible assets, other than a building, structure or other facility that Parent’s board of directors has determined is not of material importance to the total business that Parent and its subsidiaries conduct or a building or structure which is financed by obligations issued by a state, a territory, or a possession of the United States, or any political subdivision of any of the foregoing, or the District of Columbia, the interest of which is excludable from gross income of the holders under provisions of the tax code.
30


Further Issues
We may, without the consent of holders of any series of the notes, issue additional notes having the same ranking and the same interest rate, maturity and other terms as the notes of that series. Any additional notes of any series, together with the outstanding notes of the applicable series, will constitute a single series of notes under the indenture. No additional notes may be issued if an event of default has occurred and is continuing with respect to the applicable series of notes. Additional notes cannot be issued under the same CUSIP, ISIN or Common Code number unless the additional notes and original notes are fungible for U.S. federal income tax purposes.
Defeasance
Full Defeasance. We can legally release ourselves and Parent from any payment or other obligations on the notes of a series and Parent’s related guarantee thereof if we put in place other arrangements for the holders of such notes to be repaid. This is called full defeasance. In order to achieve full defeasance, we or Parent must do the following, among other things:
We or Parent must deposit or cause to be deposited in trust for the benefit of all holders of the notes of the series any combination of money (in euros) and Federal Republic of Germany obligations (as defined below) that will generate enough cash to make interest, principal and any other payments on the notes of that series on their various due dates.
We or Parent must deliver to the trustee a legal opinion of counsel confirming that (x) there has been a change in the applicable U.S. federal income tax law or (y) we or Parent have received from, or there has been published by, the IRS a ruling, in either case, to the effect that, and based thereon such opinion shall confirm that, holders or beneficial owners of the notes of the series will not be subject to U.S. federal income tax on the notes any differently than if we or Parent did not make or cause to be made the deposit and just repaid the notes ourselves.
If we ever did accomplish full defeasance, as described above, holders of defeased notes would have to rely solely on the trust deposit for repayment on such notes. Holders of such notes could not look to us or Parent for repayment in the unlikely event of any shortfall.
Covenant Defeasance. We or Parent can make or cause to be made the same type of deposit described above and we and Parent can be released from some of the restrictive covenants in the notes. This is called covenant defeasance. In that event, holders of notes would lose the protection of those restrictive covenants but would gain the protection of having money and securities set aside in trust to repay the notes. In order to achieve covenant defeasance of the notes of a series, we or Parent must do or cause to be done the following:
We or Parent must deposit or cause to be deposited in trust for the benefit of all holders of the notes of the series any combination of money (in euros) and Federal Republic of Germany obligations that will generate enough cash to make interest, principal and any other payments on the notes on their various due dates.
We or Parent must deliver to the trustee a legal opinion of counsel confirming that holders or beneficial owners of the notes will not be subject to U.S. federal income tax on the notes any differently than if we or Parent did not make or cause to be made the deposit and just repaid the notes ourselves.
If we accomplish covenant defeasance, the following provisions of the indenture and the notes would no longer apply:
Parent’s promises regarding conduct of its business previously described under “—Restrictive Covenants.”
31


Restrictions regarding mergers or similar transactions, as described under “—Mergers and Similar Events.”
The events of default relating to mergers or similar transactions and either of the restrictive covenants described under “—Restrictive Covenants.”
If we accomplish covenant defeasance, holders of notes can still look to us and Parent for repayment of the notes if there were a shortfall in the trust deposit. In fact, if one of the remaining events of default occurred, such as our or Parent’s bankruptcy, and the notes become immediately due and payable, there may be such a shortfall in the trust deposit.
“Federal Republic of Germany obligations” means (1) securities that are direct obligations of the Federal Republic of Germany for the payment of which its full faith and credit is pledged or (2) obligations of a person controlled or supervised by and acting as an agency or instrumentality of the Federal Republic of Germany, the payment of which is unconditionally guaranteed as a full faith and credit obligation by the Federal Republic of Germany, which, in either case under clauses (1) or (2) are not callable or redeemable at the option of the issuer thereof.
Events of Default
Holders of notes have special rights if an event of default occurs and is not cured, as described later in this subsection.
The term event of default with respect to each series of notes means any of the following:
Failure to pay the principal or any premium on such series of notes on its due date.
Failure to pay interest on such series of notes within 30 days of its due date.
We or Parent, as the case may be, remain in breach of either of the restrictive covenants described under “—Restrictive Covenants” or any other covenant or warranty in the indenture for 90 days after we or Parent, as applicable, receive a notice of default stating we are or Parent is in breach. The notice must be sent by either the trustee or holders of at least 25% of the principal amount of notes of the affected series.
We or Parent file for bankruptcy or other specific events of bankruptcy, insolvency or reorganization occur.
Parent’s guarantee of the notes is determined in a final, non-appealable judgment to be unenforceable or invalid or Parent denies or disaffirms in writing its obligations under its guarantee, other than in accordance with the terms thereof or upon release of the guarantee in accordance with the indenture.
Failure to pay Additional Amounts on such series of notes within 30 days after such payment is due.
Any payment in respect of the notes made in U.S. dollars due to the unavailability or nonuse of the euro as discussed under “—Payments in Euros” will not constitute an event of default under the notes or the indenture governing the notes.
If an event of default has occurred and has not been cured, the trustee or the holders of at least 25% in principal amount of the outstanding notes of the affected series may declare the entire principal amount of all the notes of that series to be due and immediately payable. This is called a declaration of acceleration. The holders of at
32


least a majority in principal amount of the notes of the affected series may cancel a declaration of acceleration of maturity.
Except in cases of default, where the trustee has some special duties, the trustee is not required to take any action under the indenture at the request of any holders unless such holders offer the trustee reasonable protection, called an indemnity, against costs, expenses and liability. If reasonable indemnity is provided, the holders of a majority in principal amount of the outstanding notes of the relevant series may direct the time, method and place of conducting any lawsuit or other formal legal action seeking any remedy available to the trustee. These majority holders may also direct the trustee in performing any other action under the indenture with respect to the notes of the applicable series.
Before a holder of notes of any series bypasses the trustee and brings its own lawsuit or other formal legal action or takes other steps to enforce its rights or protect its interests relating to the notes of such series, the following must occur:
The holder must give the trustee written notice that an event of default has occurred and remains uncured.
The holders of at least 25% in principal amount of all outstanding notes of the relevant series must make a written request that the trustee take action because of the default, and must offer indemnity reasonably satisfactory to the trustee against the cost, expenses and other liabilities of taking that action.
The trustee must have not received from holders of a majority in principal amount of the outstanding notes of that series a direction inconsistent with the written notice.
The trustee must have not taken action for 60 days after receipt of the above notice and offer of indemnity.
However, a holder of notes is entitled at any time to bring a lawsuit for the payment of money due on its notes on or after their due date.
Street name and other indirect holders should consult their banks or brokers for information on how to give notice or direction to or make a request of the trustee and to make or cancel a declaration of acceleration.
We furnish to the trustee every year a written statement of one of our officers certifying that to the best of such signer’s knowledge we are in compliance with the indenture and the notes, or else specifying any default.
Form, Exchange and Registration of Transfer
We issued the notes only in fully registered form and without interest coupons.
A holder of notes may have its notes broken into more notes of smaller denominations of not less than €100,000 or combined into fewer notes of larger denominations, as long as the total principal amount is not changed. This is called an exchange.
A holder of notes may exchange or register a transfer of notes at the office of the trustee. The trustee acts as our agent for registering notes in the names of holders and registering transfers of notes. We may change this appointment to another entity or perform it ourselves. The entity performing the role of maintaining the list of registered holders is called the security registrar. It also registers transfers. A holder of notes may also replace lost, stolen or mutilated notes at that office. The trustee’s agent may require an indemnity before replacing any notes.
33


A holder of notes is not required to pay a service charge to register a transfer of notes or to exchange notes, but may be required to pay for any tax or other governmental charge associated with the transfer or exchange. The security registrar makes the registration of transfer or exchange only if it is satisfied with such holder’s proof of ownership.
We may cancel the designation of any trustee. We may also approve a change in the office through which any trustee acts.
If we redeem less than all of the notes of a particular series, we may block the issuance of, registration of transfer or exchange of notes during the period beginning 15 days before the day we transmit the notice of redemption and ending on the day of that transmission, in order to freeze the list of holders to prepare the transmission. We may also refuse to register transfers or exchanges of notes selected for redemption, except that we will continue to permit transfers and exchanges of the unredeemed portion of any note being partially redeemed. 
The rules for exchange described above apply to exchange of notes for other notes of the same series and tenor.
Payment and Paying Agents
We pay interest to a holder of notes on each date interest is due if the holder is a direct holder listed in the trustee’s records at the close of business on the May 15 preceding the next interest payment date, even if such holder no longer owns the note on the interest due date. That particular day is called the regular record date. Holders buying and selling notes must work out between them how to compensate for the fact that we pay all the interest for an interest period to the one who is the registered holder on the regular record date.
We pay interest, principal and any other money due on the notes at the office of the paying agent in Dublin, Ireland. That office is currently located at Block F1, Cherrywood Business Park, Cherrywood, Dublin 18, Ireland D18 W2X7. A holder of notes must make arrangements to have its payments picked up at or wired from that office. We may also choose to pay interest by mailing checks.
Street name and other indirect holders should consult their banks or brokers for information on how they may receive payments.
We may also arrange for additional payment offices, and may cancel or change these offices. These offices are called paying agents. We may also choose to act as our own paying agent. We must notify holders of notes of changes in the paying agents for any particular notes of the series.
Notices
We and the trustee send notices regarding the notes only to holders, using their addresses as listed in the trustee’s records.
All paying agents must return to us upon our request all money paid by us that remains unclaimed two years after the amount is due to holders. After that two-year period, holders of notes may look only to us or Parent for payment and not to the trustee, any other paying agent or anyone else.
Prescription
Under New York’s statute of limitations, any legal action to enforce our payment obligations evidenced by the notes or the note guarantee must be commenced within six years after the payment thereof is due; thereafter our and Parent’s payment obligations will generally become unenforceable.
34


Book-Entry System
Upon issuance, the notes of each series are represented by one or more global notes. Each global note is deposited with, or on behalf of, a common depositary, and registered in the name of the nominee of the common depositary for the accounts of Clearstream and Euroclear.
Investors may elect to hold interests in the global notes held by the depository through Clearstream Banking, société anonyme, “Clearstream,” or Euroclear Bank SA/NV, as operator of the Euroclear System, “Euroclear,” if they are participants of such systems, or indirectly through organizations that are participants in such systems. Clearstream and Euroclear hold interests on behalf of their participants through customers’ securities accounts in Clearstream’s and Euroclear’s names on the books of their respective depositories. Book-entry interests in the notes and all transfers relating to the notes are reflected in the book-entry records of Clearstream and Euroclear. Because holders acquire, hold and transfer security entitlements with respect to the notes through Clearstream, Euroclear and their participants, a beneficial holder’s rights with respect to the notes is subject to the laws (including Article 8 of the Uniform Commercial Code) and contractual provisions governing a holder’s relationship with its securities intermediary and the relationship between its securities intermediary and each other securities intermediary and between it and us, as the issuer. Except as set forth below, the global notes may be transferred, in whole and not in part, only to another nominee of the depository or to a successor of the depository or its nominee.
No global note may be exchanged in whole or in part for notes registered, and no transfer of a global note in whole or in part may be registered, in the name of any person other than the depository or any nominee of the depository unless (i) the depository has notified us that it is unwilling or unable to continue as depository for such global note or has ceased to be qualified to act as such as required by the indenture, (ii) there has occurred and is continuing an event of default with respect to the notes or (iii) we determine in our sole discretion at any time that the global note shall be so exchangeable.
Any global note that is exchangeable pursuant to the preceding sentence shall be exchangeable in whole for separate notes in registered form of any authorized denomination and of like tenor and aggregate principal amount. These notes shall be registered in the name or names of such person or persons as the depository instructs the trustee. We expect that these instructions would be based upon directions received by the depository from its participants with respect to ownership of beneficial interests in such global note.
Except in the limited circumstances referred to above, owners of beneficial interests in a global note are not entitled to have such global note registered in their names, will not receive and are not entitled to receive physical delivery of notes in exchange therefor and are not considered to be the owners or holders of such global note for any purpose under the notes or the indenture. Accordingly, each person owning a beneficial interest in the global note must rely on the procedures of the participant through which such person owns its interest to exercise any rights of a holder under the indenture.
The indenture provides that the depository, as a holder, may appoint agents and otherwise authorize participants to give or take any request, demand, authorization, direction, notice, consent, waiver, or other action which a holder is entitled to give or take under the indenture.
Governing Law
The indenture, the notes and the note guarantee are governed by, and construed and enforced in accordance with, the laws of the State of New York applicable to agreements made or instruments entered into and performed in New York State.
35


Consent to Jurisdiction and Service of Process
The indenture provides that the Issuer will appoint Parent as agent for service of process in any suit, action or proceeding with respect to the indenture, the notes or the note guarantee brought in any federal or state court located in the Borough of Manhattan in the City, County and State of New York and the Issuer and Parent will submit to such jurisdiction.
Open Market Purchases
We may at any time and from time to time purchase notes in the open market or otherwise.
The Trustee, Paying Agent, Transfer Agent and Security Registrar
U.S. Bank Trust National Association is the trustee, transfer agent and security registrar with respect to the notes. U.S. Bank Trust National Association currently serves as the trustee with respect to certain of Parent’s other outstanding notes.
Elavon Financial Services DAC is the paying agent with respect to the notes.
36
EX-10.1 3 exh101-eipplan.htm EX-10.1 EXECUTIVE INCENTIVE PLAN Document

exhibitcover.jpg



I.INTRODUCTION
The Plan is designed to provide for awards to selected salaried employees in managerial or other important positions, who, individually or as members of a group, contribute in a substantial degree to the success of the Company, and who are in a position to have a direct and significant impact on the growth and success of the Company, thus affording to them a means of participating in that success and an incentive to contribute further to that success. This amendment and restatement of the Plan is effective as of January 1, 2025. Unless otherwise defined herein, capitalized terms in this Plan have the meanings set forth in Section X.
II.ADMINISTRATION
The Plan shall be administered by the Committee. The Committee may, by majority vote, establish the Administrative Regulations it deems necessary for the proper administration of the Plan and make such determinations and take such action in connection with or in relation to the Plan as it deems necessary. Each determination made by the Committee shall be final, binding and conclusive for all purposes and upon all persons.
III.ELIGIBILITY
A.Generally. Only those Employees who are Section 16 Officers are eligible to participate in the Plan.
B.New Hires. An Employee newly hired or rehired during the Plan Year must be actively employed on or before October 1 of the Plan Year to be a Participant with respect to such Plan Year. An Employee newly hired or rehired after October 1 of the Plan Year is not eligible to be a Participant with respect to such Plan Year. If an Employee is rehired, such Employee’s eligibility to participate in the Plan is based on such Employee’s date of rehire and does not include prior service in the same Plan Year.
C.Promotions. An Employee who becomes a Section 16 Officer due to a promotion during the Plan Year is eligible to receive a prorated EIP Award based on the time such Employee is active at each of the Employee’s applicable bonus target and annual salary levels during the Plan Year. If an Employee is a Participant as of the end of the Plan Year, such Employee’s annual cash incentive payment for the Plan Year will be paid under the Plan (i.e., any incentive payment will not be split between the Plan and any other annual bonus plan of the Company, a Subsidiary or affiliate).
D.Leaves of Absence. Subject to applicable law, the Committee may determine the effect of any leave of absence on an Employee’s eligibility for an EIP Award and the amount of any EIP Award in its discretion.
E.Termination of Employment; Ceasing to be a Section 16 Officer. Except as otherwise determined by the Committee in its discretion (including pursuant to Administrative Regulations), an individual must be an Employee and a Section 16 Officer on December 31 of a Plan Year to be eligible for an EIP Award. Notwithstanding anything contained in the Plan to the contrary, if a Participant’s employment is terminated by the Company, a Subsidiary, or affiliate for cause after the end of a Plan Year but before the payment of an EIP Award, the Committee may cause the Participant to forfeit all or a portion of such EIP Award. Whether the Participant’s employment is terminated for cause and the amount of EIP Award forfeited will be determined by the Committee in its discretion.
IV.AWARD DETERMINATION
A.EIP Target. A Participant’s target award under the Plan (such Participant’s “EIP Target”) will be a percentage of EIP-Eligible Pay, as determined by the Committee each Plan Year.
B.Company Scorecard. A Participant’s EIP Award will be determined based on achievement of the Company’s performance objectives, as reflected in the Company Scorecard. The Company Scorecard will be expressed as a percentage, ranging from 0% to 200%, provided that the Company Scorecard must equal at least 50% before any EIP Awards will be paid for a Plan Year. The Committee may adjust the Company Scorecard based on compliance, health, safety outcomes, and any other factors deemed
2


appropriate by the Committee.
C.Individual Performance. EIP Awards for the Chief Executive Officer of the Company and Executive Team members will not be subject to an individual performance modifier. The Committee may apply an individual performance modifier in determining the EIP Award of any other Participant, based on the recommendation of such Participant’s manager during the Company’s compensation planning process and any other factors deemed appropriate by the Committee.
D.EIP Award Calculation. A Participant’s EIP Award for a Plan Year will be determined by multiplying such Participant’s EIP-Eligible Pay (as of December 31 of the Plan Year), EIP Target for the Plan Year, the Company Scorecard result, and, if applicable, the individual performance modifier.
E.Proration. If a Participant transfers during the Plan Year between two positions that are eligible under the Plan or a Participant’s EIP Target changes during a Plan Year, such Participant’s EIP Award will be based on the number of days worked at each EIP Target and the Participant’s EIP-Eligible Pay as of the last day at each applicable EIP Target during the Plan Year.
F.Committee Discretion. Notwithstanding anything herein to the contrary, the Committee may increase or decrease a Participant’s EIP Award in its discretion.
V.TIME AND FORM OF PAYMENT
A Participant may elect, subject to the approval of, and within limits established by, the Committee, to designate all or any portion of an EIP Award as a “Deferred Award” as defined under the Merck & Co., Inc. Deferral Program (the “Deferral Program”). Such election shall be subject to the requirements for deferral set forth in the Deferral Program and pursuant to the requirements, if any, of Section 409A of the Code. Any portion of a Participant’s EIP Award which is not so deferred shall be paid no later than March 15 of the year following the Plan Year for which the EIP Award is paid. Each EIP Award will be paid in cash.
VI.RECOUPMENT; OFFSET
A.Recoupment. EIP Awards are subject to the Company’s right to reclaim benefits for compliance violations or in the event of a restatement of financial results pursuant to the processes described in the “Policy and Procedures for Discretionary Recoupment of Compensation for Compliance Violations” and the “Policy and Procedures for Recoupment of Incentive-Based Compensation” (or any other recovery, recoupment, clawback and/or other forfeiture policy maintained by the Company from time to time).
B.Offset. The Company may offset against any payments to be made to a Participant or his/her beneficiary under this Plan any amounts owing to the Company, its Subsidiaries or affiliates from the Participant for any reason.
VII.GOVERNING LAW; SEVERABILITY
A.Governing Law. The Plan and all rights thereunder shall be governed and construed in accordance with the laws of the state of New Jersey, wherein venue shall lie for any dispute arising hereunder. This Plan shall also be subject to all applicable non-U.S. laws as to Participants employed by Subsidiaries or affiliates located outside of the United States.
B.Severability. In the event any provision of the Plan is held illegal or invalid for any reason, the illegality or invalidity will not affect the remaining parts of the Plan, and the Plan will be construed and enforced as if the illegal or invalid provision had not been included.
VIII.PLAN AMENDMENT, SUSPENSION OR TERMINATION
Each of the Board of Directors of the Company and the Committee has the right by resolution to amend, suspend, or terminate the Plan at any time.
3


IX.GENERAL PROVISIONS
A.Tax Withholding. All EIP Awards are subject to any applicable U.S. and non-U.S. federal, state or local tax withholding requirements. Each Participant will bear the cost of any taxes not withheld on payments provided under the Plan, regardless of whether withholding is required.
C.Code Section 409A. Payments under the Plan are intended to be exempt from, or comply with, Section 409A, and the Plan will be interpreted to achieve this result. If an EIP Award is subject to Section 409A, any payment to a Participant who is a “specified employee” (within the meaning of Section 409A) of the Company or any Subsidiary or affiliate and that is payable upon such Participant’s “separation from service” (within the meaning of Section 409A), shall not be made before the date that is six months after the Participant’s separation from service, to the extent required to avoid the adverse consequences of Section 409A. Nothing in the Plan shall be interpreted or construed to transfer any liability for any tax (including a tax or penalty due as a result of a failure to comply with Section 409A) to the Company or to any other individual or entity, and the Company shall have no liability to a Participant, or any other party, if an EIP Award that is intended to be exempt from, or compliant with, Section 409A is not so exempt or compliant.
B.No Rights to Assets. Benefits under the Plan will be paid from the Company’s general assets. Participation in the Plan does not create, in favor of any Employee, any right or lien in or against any asset of the Company. Nothing contained in the Plan, and no action taken under its provisions, will create or be construed to create a trust of any kind, or a fiduciary relationship, between the Company and an Employee or any other person. The Company’s promise to pay benefits under the Plan will at all times remain unfunded as to each Employee, whose rights under the Plan are limited to those of a general and unsecured creditor of the Company.
C.No Right to Transfer Interest. EIP Awards are not transferable by a Participant except upon a death by will or the laws of descent and distribution and will not be subject in any manner to anticipation, alienation, sale, transfer, assignment, pledge, encumbrance, or charge, and any such attempted action will be void.
D.No Employment Rights. Neither the action of the Company in establishing the Plan nor any action taken by it or by the Committee under the provisions hereof, nor any provision of the Plan, shall be construed as giving to any Employee the right to be retained in the employ of the Company, its Subsidiaries or affiliates.
E.Effect on Other Employee Benefit Plans; Nonduplication. Nothing contained in the Plan shall prevent the Company from adopting other or additional compensation arrangements for its employees or other service providers; provided, however, that no other annual incentive cash payment shall be made under another incentive plan or arrangement of the Company or its Subsidiaries or affiliates in addition to payment under this Plan, unless expressly stated under the terms of such other arrangement. The value of any EIP Award shall not be included as compensation, earnings, salaries, or other similar terms used when calculating any Participant’s benefits under any employee benefit plan sponsored by the Company or any Subsidiary or affiliate, except as such plan otherwise expressly provides. The Company expressly reserves its rights to amend, modify, or terminate any of the Company’s employee benefit plans.
F.Headings. The headings used in this document are for convenience of reference only and may not be given any weight in interpreting any provision of the Plan.
X.TERMS
The following words and phrases used herein have the meanings set forth below:
A.Administrative Regulations” means any procedures and regulations established by the Committee pursuant to Section II hereof for the purpose of administering the Plan.
B.Code” means the Internal Revenue Code of 1986, as amended, or any successor thereto.
4


C.Committee means the Compensation and Management Development Committee of the Board of Directors of the Company.
D.Company means Merck & Co., Inc. or any successor thereto.
E.Company Scorecard means the Company’s overall performance, based on the performance objectives established by the Committee.
F.EIP Award” means an award under the Plan.
G.EIP-Eligible Pay” means a Participant’s annual base salary, as reflected in the Company’s books and records.
H.Employee” means any salaried employee of the Company, a Subsidiary or an affiliate, whether full-time or part-time and whether or not an officer or director, excluding, however, any temporary employee or any person serving the Company only in the capacity of director. An “Employee” does not include any person who is an independent contractor, or agrees or has agreed that he/she is an independent contractor, or has any agreement or understanding with the Company, Subsidiary or an affiliate that he/she is not an employee or an eligible employee, even if he/she previously had been an employee or eligible employee or is employed by a temporary or other employment agency, regardless of the amount of control, supervision or training provided by the Company, Subsidiary or an affiliate, or he/she is a “leased employee” as defined under section 414(n) of the Code, as amended. Such a person is not eligible to participate in the Plan even if a court, agency or other authority rules that he/she is a common-law employee of the Company, a Subsidiary or an affiliate.
I.Executive Team” means the Executive Team of the Company, as reflected in the Company’s books and records.
J.Participant” means an Employee who is a Section 16 Officer eligible to participate in the Plan pursuant to Section III hereof.
K.Plan” means this Merck & Co., Inc. Executive Incentive Plan, as amended from time to time.
L.Plan Year” means the calendar year.
M.Section 16 Officer” means an officer designated by the Company as such for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.
N.Section 409Ameans Section 409A of the Code.
O.Subsidiary” means any corporation, domestic or foreign (other than the Company), 50% or more of the total voting power of which is held by the Company and/or a Subsidiary or Subsidiaries.
5
EX-10.13 4 exh1013-mrkseparationplan2.htm EX-10.13 MERCK & CO., INC. U.S. SEPARATION BENEFITS PLAN Document


MERCK & CO. INC. U.S. SEPARATION BENEFITS PLAN
Amended and Restated as of January 1, 2019



MERCK & CO., INC., U.S. SEPARATION BENEFITS PLAN
SECTION 1
PREAMBLE
Merck Sharp & Dohme Corp. established the MSD Separation Benefits Plan (the "MSD Plan"), as amended from time to time, to provide benefits to eligible non-union employees whose employment with Merck Sharp & Dohme Corp. or a participating wholly owned subsidiary (collectively, "MSD") was terminated under certain circumstances at the initiative of MSD.
Schering-Plough Corporation established the Schering-Plough Separation Benefits Plan (the "Schering Plan"), as amended from time to time, for the purpose of providing severance benefits to eligible union and non-union employees whose employment with Schering Corporation and certain of its U.S. affiliated companies was terminated under certain circumstances.
Effective January 1, 2012, the Schering Plan merged into the MSD Plan with the MSD Plan being renamed the Merck & Co., Inc. U.S. Separation Benefits Plan (the "Plan"). The Plan was amended and restated in its entirety at that time. Effective January 1, 2013, September 1, 2013, October 1, 2013, November 15, 2014 and January 1, 2017, the Plan was reinstated in its entirety. Effective January 1, 2019, the Plan is again being amended and restated in its entirety as set forth herein.
The purpose of the Plan is to provide benefits to eligible employees whose employment with an Employer is terminated at the initiative of the Employer for reasons described below. This Plan is part of the MSD Separation Allowance Plan (Plan No. 514).
1


SECTION 2
DEFINITIONS
For the purposes of this Plan, the following terms shall have the following meanings:
2.1Annual Base Salary means
(a)With respect to a Participant who is exempt as of his or her Separation Date, his or her annual base salary in effect as of his or her Separation Date, according to the Employer’s payroll records, without reduction for any contributions to Employer-sponsored benefit plans. For the avoidance of doubt, (i) with respect to a Participant who is exempt and regularly scheduled to work less than full-time as of his or her Separation Date, Annual Base Salary is the reduced annual base salary in effect on his or her Separation Date applicable to the less than full time position, according to the Employer’s payroll records, without reduction for any contributions to the Employer-sponsored benefit plans and (ii) no adjustment is made to Annual Base Salary if the Participant’s annual base salary in effect during any period prior to his or her Separation Date is higher or lower (for any reason, including promotion/demotion or a move to or from full-time or part-time status) than his or her annual base salary in effect as of his or her Separation Date, according to the Employer’s payroll records.
(b)With respect to a Participant who is non-exempt as of his or her Separation Date, the hourly rate according to the Employer’s payroll records in effect as of his or her Separation Date multiplied by the number of hours the Eligible Employee is regularly scheduled to work as of his or her Separation Date (up to a maximum of 2080 hours).
Annual Base Salary does not include bonuses, commissions, overtime pay, shift pay, premium pay, lump sum merit increases, cost of living allowances, income from stock options or other incentives under an Incentive Stock Plan of the Employer (or the Parent or any of its subsidiaries), stock grants or other incentives, or other pay not specifically included above.
For example, a Participant who is regularly scheduled to work less than full-time on his Separation Date has 10 Complete Years of Continuous Service (9 at full-time and 1 at less than full-time), had an annual base salary of $100,000 as a full-time employee but on his Separation Date has an annual base salary of $50,000 according to the Employer’s payroll records because it was reduced as applicable for the less than full-time position. The Participant’s Separation Pay will be calculated using 10 Complete Years of Continuous Service and an Annual Base Salary of $50,000. There is no adjustment in Annual Base Salary for prior years of higher annual base salary due to full-time service.
2.2Base Pay Rate means
(a)    With respect to an Eligible Employee who is exempt, his/her annual base pay according to the Employer’s payroll records in effect as of the date the Eligible Employee is offered a Qualified Alternative Position or a Negotiated Job Offer. For an Eligible Employee who is regularly scheduled to work less than full-time, annual base pay is the reduced annual base pay to the less than full-time position.
(b)    With respect to an Eligible Employee who is non-exempt, the hourly rate according to the Employer’s payroll records in effect as of the date the Eligible Employee is
2


offered a Qualified Alternative Position or a Negotiated Job Offer multiplied by the number of hours the Eligible Employee is regularly scheduled to work (up to a maximum of 2080 hours).
Base Pay Rate is calculated without reduction for any contributions to Employer-sponsored benefit plans. Base Pay Rate includes applicable shift pay and premium pay but does not include bonuses, commissions, overtime pay, lump sum merit increases, cost of living allowances, income from awards granted under an Incentive Stock Plan of the Employer (or the Parent or its subsidiaries), or other pay not specifically included above.
2.3Basic Life Insurancemeans life insurance provided to an Eligible Employee under a plan sponsored by Parent or a subsidiary of Parent equal to 1x "base pay" as defined under the life insurance plan in which the Eligible Employee participates, as it may be amended from time to time.
2.4Benefits Continuation Periodmeans the period of time, as set forth on Schedule B-2, during which a Participant is eligible to receive Separation Benefits, provided, however that the Participant may elect to end the period earlier than indicated on Schedule B-2 by notifying the Employer's health and insurance plan administrator (i) within the later of thirty (30) days from the Participant's Separation Date or the date by which the Participant is provided to review the Separation Letter so that the Benefit Continuation Period ends on the date it would have otherwise begun, or (ii) during the Employer's annual open enrollment period for health and insurance benefits so that the Benefit Continuation Period ends the following January 1 (provided that date is not beyond the period set forth on Schedule B-2), or (iii) mid-year with a qualified status change that otherwise permits the Participant to make a change to the Participant's healthcare coverage in accordance with the terms of the Employer's healthcare plan so that the Benefits Continuation Period ends on the date the mid-year change would otherwise be effective under the terms of the Employer's healthcare plan (provided that date is not beyond the period set forth on Schedule B- 2).
2.5Change in Controlshall have the meaning set forth in the CIC Plan (and, for avoidance of doubt, a valid amendment of that definition under the CIC Plan shall constitute an amendment of this Plan without further action).
2.6CIC Planmeans the Merck & Co., Inc. Change in Control Separation Benefits Plan, as amended and restated effective January 1, 2013 and as it may be further amended from time to time, and any successor thereto.
2.7Claims Reviewermeans the Merck & Co., Inc. Employee Benefits Committee (or its delegate) whose members are appointed by the Parent's Executive Vice President of Human Resources or his or her delegate; provided, however, for Section 16 Officers, Claims Reviewer means the Compensation and Benefits Committee of the Board of Directors of Parent or its delegate.
2.8Codemeans the Internal Revenue Code of 1986, as amended and the regulations promulgated thereunder.
2.9Complete Years of Continuous Servicemeans (a) for a Legacy Schering Employee, a year from the Participant’s Most Recent Hire Date with a Legacy Schering Entity to its anniversary, and thereafter from each anniversary to the next, (b) for a Legacy Merck Employee, a year from the Participant's Most Recent Hire Date with a Legacy Merck
3


Entity to its anniversary, and thereafter from each anniversary to the next, (c) for a Legacy Inspire Employee, a year from the Participant’s Most Recent Hire Date with a Merck Entity to its anniversary, and thereafter from each anniversary to the next, and (d) for a Non-Legacy Company Employee, from the Participant’s Most Recent Hire Date with a Merck Entity, and thereafter from each anniversary to the next.
2.10Continuous Servicemeans (a) for a Legacy Schering Employee, the period of a Participant's continuous employment with a Legacy Schering Entity commencing on the Participant's Most Recent Hire Date with a Legacy Schering Entity and ending on the Separation Date as reflected on the Employer’s employee database, (b) for a Legacy Merck Employee, the period of a Participant's continuous employment with a Legacy Merck Entity commencing on the Participant's Most Recent Hire Date with a Legacy Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database, (c) for a Legacy Inspire Employee, the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database, and (d) for a Non-Legacy Company Employee, the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database. For the avoidance of doubt, service prior to November 4, 2009 by a Legacy Schering Employee with a Legacy Merck Entity or a Legacy Merck Employee with a Legacy Schering Entity is excluded from “Continuous Service.” Notwithstanding anything contained in this Plan to the contrary, employment with a Legacy Schering Entity, Legacy Merck Entity or a Merck Entity as an Excluded Person does not count as "Continuous Service".
2.11Eligible Employeemeans (a) any regular full-time or regular part-time employee of an Employer who is on the Employer's normal U.S. payroll and as to whom the terms and conditions of employment are not covered by a collective bargaining agreement unless the collective bargaining agreement specifically provides for coverage under the Plan; or (b) a U.S. Expatriate on an Employer's normal U.S. payroll.
The term “Eligible Employee” shall not include:
(i)an employee (x) who is a party to an employment agreement with the Employer or with the Parent (or any of its subsidiaries) or (y) who is entitled, upon termination of employment with the Employer, to separation, severance, termination or other similar payments (1) under another plan or program sponsored by the Employer or Parent (or any of its subsidiaries); or (2) pursuant to a separate agreement with the Employer or Parent (or any of its subsidiaries) or (z) who is a party to an agreement with the Employer or Parent (or any of its subsidiaries) that provides that no payment or benefits are due to the employee in connection with his or her termination of employment; provided, however, in each case under the foregoing clauses (x), (y) and (z) unless the plan, program or agreement expressly provides for benefits under this Plan;
(ii)a participant in the CIC Plan (but this clause shall only apply during the Protection Period (as defined in Section 8.1));
(iii)temporary employees (including college coops, summer employees, high school coops, flexible workforce employees, post-doctorate research fellows and any other such
4


temporary classifications ) and/or employees called by the Employer at any time for employment in the U.S. on a non-scheduled and non-recurring basis, and who becomes an employee of the Employer only after reporting to work for the period of time during which the person is working;
(iv)an Excluded Person;
(v)employees of a non-US subsidiary of an Employer (or who are dual employees of a non- US subsidiary of an Employer) who are on assignment in the US;
(vi)employees whose employment ends for any reason while on unapproved leaves of absence;
(vii)employees whose employment ends for any reason while on approved leaves of absence for a period equal to or more than six continuous months regardless of the reason(s) for the leave excluding the following approved leaves of absence: medical disability leaves, military leaves and family medical leaves under federal or state family medical leave laws;
(viii)employees whose employment ends for any reason while on approved leaves of absence for medical disability for a period equal to or more than one year;
(ix)employees who are covered by the IAM Agreement at the Kenilworth, NJ site who elect to retain their recall rights.
For purposes of the foregoing clauses (vii) and (viii), a series of leaves of absence is considered one continuous leave for purposes of calculating the six-month or one-year requirement if the employee does not return to active employment for any reason, including but not limited to because the employee’s former position is unavailable and the employee is unable to secure a new position.
Whether an individual is an Eligible Employee or not is determined as of the date of his/her Termination due to Workforce Restructuring or for Rebadged Employees as of the date of his/her termination of employment due to an outsource transaction .
2.12Employermeans individually and collectively, the entities identified on Schedule A attached hereto.
2.13ERISAmeans the Employee Retirement Income Security Act of 1974, as amended, and the regulations promulgated thereunder.
2.14Excluded Personmeans a person who (i) is an independent contractor, or agrees or has agreed that he/she is an independent contractor, or (ii) has any agreement or understanding with the Employer, or any of its affiliates that he/she is not an employee or an Eligible Employee, or (iii) is employed by a temporary or other employment agency, regardless of the amount of control, supervision or training provided by the Employer or its affiliates, or (iv) is a “leased employee” as defined under Section 414(n) of the Internal Revenue Code of 1986, as amended, or (v) is not treated by the Employer as an employee for purposes of withholding federal income taxes, regardless of any contrary Internal Revenue Service, governmental or judicial determination
5


relating to such employment status or tax withholding. An Excluded Person is not eligible to participate in the Plan even if a court, agency or other authority rules that he/she is a common-law employee of the Employer or its affiliates.
2.15Intentionally Omitted.
2.16Intentionally Omitted.
2.17IAM Agreementmeans a collective bargaining agreement between Merck Sharp & Dohme Corp. and District 15, Lodge 315 of the International Association of Machinists and Aerospace Workers.
2.18Legacy Inspire Employeemeans an Eligible Employee who (a) as of December 31, 2012 is employed by a Merck Entity and either continues to be employed by such entity until his/her Separation Date or is rehired or transferred to such entity after December 31, 2012, and (b) as of his/her Separation Date is (i) employed by an Employer, and (ii) coded in the employee data base of Parent as S6 (Legacy Inspire) under infotype 35, and (iii) not covered by a collective bargaining agreement.
2.19"Legacy Merck Employee" means an Eligible Employee who (a) as of December 31, 2012 is employed by a Merck Entity and either continues to be employed by such entity until his/her Separation Date or is rehired or transferred to such entity after December 31, 2012, and (b) as of his/her Separation Date is (i) employed by an Employer, and (ii) coded in the employee data base of Parent with a blank indicator under infotype 35, and (iii) not covered by a collective bargaining agreement, other than one of the IAM Agreements. For the avoidance of doubt, “Legacy Merck Employee” excludes employees who are covered by the IAM Agreement at the Kenilworth, NJ site who elect to retain their recall rights.
2.20"Legacy Merck Entity" means (a) for the period prior to November 4, 2009, Old Merck and its direct or indirect wholly owned subsidiaries and (b) for the period beginning November 4, 2009, New Merck and its direct or indirect wholly owned subsidiaries.
2.21"Legacy Schering Employee" means an Eligible Employee who (a) as of December 31, 2012 is employed by a Merck Entity and either continues to be employed by such entity until his/her Separation Date or is rehired by or transferred to such entity after December 31, 2012, and
(b) as of his/her Separation Date is (i) employed by an Employer, (ii) coded in the employee data base of Parent as S1 (Legacy Organon), S2 (Legacy Intervet) or S5 (Legacy Schering-Plough) under infotype 35, and (iii) not covered by a collective bargaining agreement other than one of the IAM Agreements or an agreement that specifically provides for benefits under this Plan. For the avoidance of doubt, “Legacy Schering Employee” excludes employees who are covered by the IAM Agreement at the Kenilworth, NJ site who elect to retain their recall rights.
2.22"Legacy Schering Entity" means (a) for the period prior to November 4, 2009, Schering- Plough Corporation and its direct or indirect wholly owned subsidiaries and (b) for the period beginning November 4, 2009, New Merck and its direct or indirect wholly owned subsidiaries.
2.23Merck Entitymeans for the period beginning November 4, 2009, New Merck and its direct or indirect wholly owned subsidiaries.
6


2.24Merck Retiree Medical Planmeans the retiree medical plan sponsored by Merck Sharp & Dohme which includes the following components: (i) the Merck Group Retiree Medical Plan which provides group retiree medical and prescription drug benefits to eligible retirees and their eligible dependents, in each case who are under age 65 or not Medicare-eligible as more fully described in the Merck Group Retiree Medical Plan SPD, and (ii) the Merck Retiree HRA which provides reimbursement benefits to eligible retirees and their eligible dependents who are eligible for subsidized retiree medical benefits and, in each case ,who are age 65 or older and Medicare- eligible as more fully described in the Merck Retiree Health Reimbursement Account SPD.
2.25Misconductmeans conduct which includes (a) falsification of an Employer's or Parent's records/misrepresentation; (b) theft; (c) acts or threats of violence; (d) refusal to carry out assigned work; (e) unauthorized possession of alcohol or illegal drugs on an Employer's or Parent's premises; (f) being under the influence of alcohol or illegal drugs during work hours; (g) willful intent to damage or destroy an Employer's or Parent's property; (h) violation of the Parent's "Our Values and Standards"; (i) acts of discrimination/harassment; (j) conduct jeopardizing the integrity of the products of an Employer, Parent or one or more of its subsidiaries; (k) violation of rules, policies, and/or practices of an Employer or Parent; or (l) other conduct considered to be detrimental to an Employer, the Parent or one or more of its subsidiaries.
2.26Most Recent Hire Datemeans (a) for a Legacy Schering Employee, his or her most recent hire date at a Legacy Schering Entity or an entity acquired by a Legacy Schering Entity as reflected on the Employer’s employee data system, (b) for a Legacy Merck Employee, his or her most recent hire date at a Legacy Merck Entity or an entity acquired by a Legacy Merck Entity as reflected on the Employer’s employee data system, (c) for a Legacy Inspire Employee, his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer’s employee data system, and (d) for a Non-Legacy Company Employee, his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer’s employee data system. Notwithstanding the foregoing, the most recent hire date for a Legacy Merck Employee who was employed by a Legacy Merck Entity on December 31, 1997, transferred from that entity to Merial as of January 1, 1998, remained continuously employed by Merial through the date he or she transferred employment from Merial to a Legacy Merck Entity and whose transfer to a Legacy Merck Entity occurred between October 1, 2000 and June 1, 2001, is his or her most recent hire date on the Employer's employee data system at a Legacy Merck Entity prior to his or her transfer to Merial. Notwithstanding the foregoing, the most recent hire date for a Legacy Merck Employee who was employed by a Legacy Merck Entity on December 31, 2007, transferred from that entity to PRWT as of January 1, 2008, remained continuously employed by PRWT through September 3, 2010 and who was rehired by a Legacy Merck Entity as of September 3, 2010, is his or her most recent hire date on the Employer’s employee data system at a Legacy Merck Entity prior to his or her transfer to PRWT. For the avoidance of doubt, the most recent hire date at an acquired entity may occur before the date the entity was acquired by a Legacy Schering Entity, Legacy Merck Entity or Merck Entity, provided such date is reflected on the Employer’s employee data system.
2.27"Negotiated Job Offer" means an offer of employment (or an offer of continued employment) with a successor employer or outsource vendor the terms and conditions of which are negotiated by an Employer, Parent or one of its subsidiaries or affiliates and may include, among other things, a reduction in Base Pay Rate.
7


2.28New Merckmeans Merck & Co., Inc. (formerly known as Schering-Plough Corporation) on and after November 4, 2009.
2.29Non-Legacy Company Employeemeans an Eligible Employee who (a) is first hired by a Merck Entity on or after January 1, 2013, and (b) as of his/her Separation Date is (i) employed by an Employer, and (ii) coded in the employee data base of Parent with a blank indicator under infotype 35, and (iii) not covered by a collective bargaining agreement. For purposes of determining whether an Eligible Employee is a “Non-Legacy Company Employee” only, an Eligible Employee who was an employee of an entity on the date that it was acquired by a Merck Entity is considered to be first hired by a Merck Entity on the date the entity became a wholly owned subsidiary of New Merck or one of its wholly owned subsidiaries.
2.30"Offer Outside Geographic Parameters" means (A) for an Eligible Employee who is not eligible to participate in the Company’s sales incentive plan and who does not qualify as other field-based personnel, a Negotiated Job Offer that results in the relocation of the Eligible Employee's principal business location to a new principal business location (x) where the distance between the Eligible Employee’s residence immediately prior to the extension of the Negotiated Job Offer and his/her new principal business location is more than 50 miles greater than the distance between the Eligible Employee's residence and his/her principal business location at the time the Negotiated Job Offer is extended or (y) more than 75 miles from the Eligible Employee's residence at the time the Negotiated Job Offer is extended and not closer to the Eligible Employee's residence at that time, and (B) for an Eligible Employee who is eligible to participate in the Company’s sales incentive plan or who qualifies as other field-based personnel, a Negotiated Job Offer that results in the relocation of the Eligible Employee's geographic workload center location to a new geographic workload center location (x) where the distance between the Eligible Employee’s residence immediately prior to the extension of the Negotiated Job Offer and his/her new geographic workload center location is more than 50 miles greater than the distance between the Eligible Employee's residence and his/her geographic workload center location at the time the Negotiated Job Offer is extended and (y) more than 75 miles from the Eligible Employee's residence at the time the Negotiated Job Offer is extended and not closer to the Eligible Employee's residence at that time.
The Employer, in its sole and absolute discretion, will determine (i) whether an Eligible Employee qualifies as other field-based personnel, (ii) distance using a nationally recognized mapping service, (iii) principal business location, and (iv) the geographic workload center.
Whether a position is an Offer Outside Geographic Parameters shall be determined at the time a Negotiated Job Offer is offered or communicated to the Eligible Employee by the Employer.
2.31Old Merckmeans Merck & Co., Inc. prior to November 4, 2009 (subsequently known as Merck Sharp & Dohme Corp).
2.32Outplacement Benefitsmeans benefits for outplacement counseling or other outplacement services made available to a Participant as provided pursuant to Section 4.4 of this Plan.
2.33Parentmeans New Merck.
2.34Participantmeans an Eligible Employee who has experienced a Termination due to Workforce Restructuring and who has signed, and, if a revocation period is applicable, not
8


revoked, a Release of Claims in a form that is satisfactory to the Employer in its sole and absolute discretion.
The term "Participant" shall also include, where and as applicable a Rebadged Employee who has signed and, if a revocation period is applicable, not revoked a Release of Claims in a form that is satisfactory to the Employer in its sole and absolute discretion.
2.35Planmeans the Merck & Co., Inc., U.S. Separation Benefits Plan as set forth herein, and as may be amended from time to time.
2.36Plan Administratormeans the Parent or its delegate.
2.37Plan Yearmeans the calendar year January 1 through December 31 on which the records of the Plan are kept.
2.38Qualified Alternative Positionmeans a position with an Employer, the Parent or any of its subsidiaries which does not result in either of the following:
(i)a reduction in the Eligible Employee's Base Pay Rate; or
(ii)(A) for an Eligible Employee who is not eligible to participate in the Company’s sales incentive plan, relocation of the Eligible Employee's principal business location to a new principal business location (x) where the distance between the Eligible Employee’s residence immediately prior to the relocation and his/her new principal business location is more than 50 miles greater than the distance between the the Eligible Employee's residence and his/her principal business location immediately prior to the relocation or (y) that is more than 75 miles from the Eligible Employee's residence immediately prior to the relocation and not closer to the Eligible Employee's residence at that time, and (B) for an Eligible Employee who is eligible to participate in the Company’s sales incentive plan or who qualifies as other field- based personnel, relocation of the Eligible Employee's geographic workload center location to a new geographic workload center location (x) where the distance between the Eligible Employee’s residence immediately prior to the relocation and his/her new geographic workload center location is more than 50 miles greater than the distance between the Eligible Employee's residence and his/her geographic workload center location immediately prior to the relocation and (y) more than 75 miles from the Eligible Employee's residence at the time the Negotiated Job Offer is extended and not closer to the Eligible Employee's residence at that time.
The Employer, in its sole and absolute discretion, will determine (i) whether an Eligible Employee qualifies as other field-based personnel, (ii) distance using a nationally recognized mapping service, (iii) principal business location, and (iv) the geographic workload center.
Whether a position is a Qualified Alternative Position shall be determined at the time such position is offered or communicated to the Eligible Employee by his/her manager.
2.39"Rebadged Employeemeans an Eligible Employee whose employment with the Employer is terminated by the Employer in connection with the outsourcing of work by
9


the Employer in a transaction with a third-party vendor where the Eligible Employee is offered a Negotiated Job Offer and:
(a)(i) accepts the Negotiated Job Offer; or (ii) declines the Negotiated Job Offer, provided the Negotiated Job Offer is not an Offer Outside Geographic Parameters; and
(b)remains employed with the Employer through the date established by the Employer as the employee's Separation Date unless the Employer expressly waives this provision.
Whether an Eligible Employee is a Rebadged Employee shall be determined by the Employer or Parent in its sole discretion. An Eligible Employee shall not be considered to be a Rebadged Employee if his or her employment with the Employer (i) does not end as set forth in this Section 2.38 (ii) ends due to the declination of a Negotiated Job Offer that is an Offer Outside Geographic Parameters, or (iii) ends as a result of any of the events described in Section 3.1(e).
For the avoidance of doubt, a Rebadged Employee shall not be considered to have experienced a Termination due to Workforce Restructuring for purposes of the Plan.
2.40Release of Claimsmeans the agreement that an Eligible Employee must execute in order to become a Participant and to receive Separation Plan Benefits, which shall be prepared by the Employer or the Parent and shall contain such terms and conditions as determined by the Employer or the Parent, including but not limited to a general release of claims, known or unknown, that the Eligible Employee may have against the Employer (and the Parent and any of its subsidiaries and/or affiliates), including claims related to the employment and termination of employment of the Eligible Employee; such Release of Claims may also contain, in the Employer’s or the Parent's discretion, other terms and conditions including, without limitation, cooperation in litigation, non-disclosure, confidentiality, non-disparagement, non-solicitation and/or non-competition provisions.
2.41Section 16 Officermeans an “officer” as such term is defined in Rule 16(a)-1(f) of the Securities Exchange Act of 1934 of the Parent who is also an Eligible Employee of an Employer.
2.42Separation Benefitsmeans the benefits provided pursuant to Sections 4.2 and 4.3 of this Plan.
2.43Separation Datemeans the Eligible Employee’s last day of employment with the Employer due to a Termination due to Workforce Restructuring or, in the case of a Rebadged Employee, due to the outsourcing transaction. The Separation Date of an Eligible Employee who dies prior to his or her scheduled Separation Date but after he or she was notified of a scheduled Separation Date shall be deemed to have occurred on the day before his/her date of death.
2.44Separation Paymeans the cash benefit payable under this Plan pursuant to Section 4.1 or to a Rebadged Employee pursuant to Section 4.5.
2.45Separation Plan Benefitsmeans, collectively, Separation Pay, Separation Benefits and Outplacement Benefits.
10


2.46"Termination Due to Non-Performance" means a termination of an Eligible Employee's employment as determined and caused by the Employer due to the Eligible Employee's failure to perform his or her job assignments in a satisfactory manner.
2.47Termination due to Workforce Restructuringmeans the termination of an Eligible Employee's employment as determined and caused by the Employer due to:
(a)the elimination of an Eligible Employee's job;
(b)organizational changes; or
(c)a general reduction of the workforce.
Whether an Eligible Employee's job is eliminated is determined by the Employer but excludes the maintenance of the position with the elimination of a part-time or job share arrangement or other flexible work arrangement.
Organizational changes are determined by the Employer and include the following actions: discontinuance of operations, location closings, corporate restructuring but exclude a reduction in job title, grade or band level, Base Pay Rate, short term incentive opportunity (e.g., cash bonuses under any bonus or incentive plan or program of the Parent), long-term incentive compensation opportunity, equity compensation opportunity and/or other forms of remuneration of an Eligible Employee with or without a change in the Eligible Employee's job duties where such reduction is due to (i) a general change in the Employer’s or the Parent’s compensation framework as it applies to similarly situated Eligible Employees (e.g., a change in the general compensation framework applicable to similar jobs with the Employer, or an identifiable segment of the Employer such as a subsidiary, division or department); (ii) an action to align the Eligible Employee with the Employer's or the Parent's compensation and career framework as it applies to similarly situated Eligible Employees; or (iii) a demotion or other action taken as a result of the Eligible Employee's performance or behaviors.
An Eligible Employee shall not be considered to have incurred a Termination due to Workforce Restructuring if his or her employment with the Employer (i) does not end due to this Section 2.46 (a), (b) or (c) or (ii) ends as a result of any of the events described in Section 3.1(d).
For the avoidance of doubt with respect to outsourcing transactions, (x) an Eligible Employee whose employment with the Employer is terminated by the Employer in connection with the outsourcing of work by the Employer in a transaction with a third-party vendor where the individual is offered a Negotiated Job Offer and declines the Negotiated Job Offer because it is an Offer Outside Geographic Parameters, is considered to have incurred a Termination due to Workforce Restructuring provided his or her employment with the Employer does not end as a result of any of the events described in Section 3.1 (d), and (y) a Rebadged Employee shall not be considered to have experienced a Termination due to Workforce Restructuring for purposes the Plan.
2.48U.S. Expatriatemeans a U.S. citizen or individual with U.S. Permanent Resident status who is employed by the Employer and on assignment outside the U.S. and who is not an Excluded Person.
11


SECTION 3 ELIGIBILITY FOR BENEFITS
3.1Eligibility.
a)
(a)An Eligible Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) when he/she experiences a Termination due to Workforce Restructuring; provided, however, that a Legacy Inspire Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) only if he/she experiences a Termination due to Workforce Restructuring on or after May 17, 2013.    Separation Plan Benefits shall be provided under this Plan to an Eligible Employee who experiences a Termination due to Workforce Restructuring only if the Eligible Employee has executed and, if a revocation period is applicable, not revoked a Release of Claims in a form satisfactory to the Employer or Parent in its sole and nonreviewable discretion. An Eligible Employee who has executed and, if a revocation period is applicable, not revoked a Release of Claims is a Participant.
(b)A Rebadged Employee will be eligible for Separation Pay described in Section 4.5; provided, however, that a Rebadged Employee who is a Legacy Inspire Employee will be eligible for Separation Pay described in Section 4.5 only if his/her employment with an Employer is terminated by the Employer in connection with the outsourcing of work on or after May 17, 2013. Separation Pay shall be provided under this Plan to a Rebadged Employee only if the Rebadged Employee has executed and, if a revocation period is applicable, not revoked a Release of Claims in a form satisfactory to the Employer or Parent in its sole and nonreviewable discretion. A Rebadged Employee who has executed and, if a revocation period is applicable, not revoked a Release of Claims is a Participant. A Rebadged Employee is not eligible for Separation Benefits or Outplacement Benefits.
(c)An Eligible Employee will also be entitled to receive those pension benefits set forth in Schedule D (Change in Control/Pension) and retiree medical benefits set forth in Schedule E (Change in Control/Retiree Medical) if (i) a Change in Control has occurred and (ii) within two years thereafter, the Eligible Employee’s employment with the Employer (or successor employer) is terminated by the Employer (or successor employer) for any reason other than for Misconduct, death or "Permanent Disability" (as such term is defined in the CIC Plan), and (iii) the Eligible Employee signs and returns the release of claims in use under the CIC Plan and in accordance with the process established under the CIC Plan.
(d)Notwithstanding anything herein to the contrary, an Eligible Employee shall not be considered to have incurred a Termination due to Workforce Restructuring under the Plan if his or her employment ends as a result of any of the following events:
(i)a divestiture of a subsidiary, division or other identifiable segment of the Employer or Parent or a transfer of the Eligible Employee to a joint venture or other business entity in which the Employer or the Parent directly or indirectly will own some outstanding voting or other ownership interest, in each case where either
(x)the Eligible Employee is offered and accepts, or continues in, a Negotiated Job Offer; or
12


(y)the Eligible Employee is offered and declines a Negotiated Job Offer, unless the Negotiated Job Offer is an Offer Outside Geographic Parameters with the acquiring entity or vendor;
(ii)the Employer's decision to outsource work to a third-party vendor where the Eligible Employee is a Rebadged Employee;
(iii)the Eligible Employee's voluntary resignation for any reason including after reaching early or normal retirement age under the retirement plan applicable to the Eligible Employee;
(iv)a termination for Misconduct;
(v)death (unless the Eligible Employee dies after he/she has been notified of his/her scheduled Separation Date but before the Separation Date occurs and a valid Release of Claims is executed by the Eligible Employee's estate) in which case the Eligible Employee's Separation Date shall be deemed to have occurred on the day before his/her date of death;
(vi)the Eligible Employee terminating employment with the Employer prior to the date identified as the date the employee would experience a Termination due to Workforce Restructuring unless the Employer expressly agreed to waive this provision;
(vii)failure by the Eligible Employee to return to work at the Employer (or the Parent or any of its subsidiaries) for any reason, including, but not limited to the Eligible Employee’s failure to secure a position at the Employer (or the Parent or any of its subsidiaries) upon a return from a leave of absence for any reason; or
(viii)Intentionally Omitted;
(ix)the Eligible Employee's decision to decline a Qualified Alternative Position for any reason (including, but not limited to because the employee is a part-time employee and is offered a full-time position, is a shift-worker and the position offered is on a different shift or has a job share or other flexible work arrangement and the position offered is not a job share or does not include a flexible work arrangement) that is offered to the Eligible Employee prior to the Eligible Employee's Separation Date; or
(x)the Eligible Employee's decision to accept an alternate position with the Employer, Parent or any of its subsidiaries (whether or not the position is a Qualified Alternative Position) and to later decline it; or
(xi)Termination Due to Non-Performance.
(e)Notwithstanding anything herein to the contrary, an Eligible Employee shall not be considered to be a Rebadged Employee under the Plan if his or her employment ends as a result of any of the following events:
(i)a divestiture of a subsidiary, division or other identifiable segment of the Employer or Parent or a transfer of the Eligible Employee to a joint venture or other business entity in which the Employer or the Parent directly or indirectly will own some outstanding voting or other ownership interest;
(ii)the Employer's decision to outsource work to a third-party vendor where the Eligible Employee is offered a Negotiated Job Offer and declines it because it is an Offer Outside Geographic Parameters;
13


(iii)the Eligible Employee's voluntary resignation for any reason including after reaching early or normal retirement age under the retirement plan applicable to the Eligible Employee;
(iv)a termination for Misconduct;
(v)death (unless the Eligible Employee dies after he/she has been notified of his/her scheduled Separation Date but before the Separation Date occurs and a valid Release of Claims is executed by the Eligible Employee's estate) in which case the Eligible Employee's Separation Date shall be deemed to have occurred on the day before his/her date of death;
(vi)the Eligible Employee terminating employment with the Employer prior to the date identified by the Employer as the Separation Date unless the Employer expressly agreed to waive this provision;
(vii)failure by the Eligible Employee to return to work at the Employer (or the Parent or any of its subsidiaries) for any reason, including, but not limited to the Eligible Employee’s failure to secure a position at the Employer (or the Parent or any of its subsidiaries) upon a return from a leave of absence for any reason; or
Intentionally Omitted
(viii)Termination Due to Non-Performance.
3.2Termination of Eligibility for Benefits. A Participant shall cease to participate in the Plan, and all Separation Plan Benefits shall cease upon the occurrence of the earliest of:
(a)Termination of the Plan prior to, or more than two years following, a Change in Control;
(b)Inability of the Employer to pay Separation Plan Benefits when due;
(c)Completion of payment to the Participant of the Separation Plan Benefits for which the Participant is eligible; and
(d)The Claims Reviewer's determination, in its sole discretion, of the occurrence of the Eligible Employee’s Misconduct, regardless of whether such determination occurs before or after the Eligible Employee’s Separation Date, unless the Claims Reviewer determines in its sole discretion that Misconduct shall not cause the cessation of Separation Plan Benefits in a particular case.
14


SECTION 4
BENEFITS
4.1Separation Pay. Separation Pay shall be payable under this Plan to a Participant who is not a Rebadged Employee as set forth on Schedule B-1. The terms of Schedule B-1 are hereby fully incorporated into and shall be considered as part of Section 4 of this Plan. For Separation Pay payable under this Plan to a Rebadged Employee, see Section 4.5 of this Plan.
4.2
(a)A Participant who is covered under any of the Employer's group employee medical and dental plans as of his or her Separation Date will be provided the opportunity to continue such employee coverage during his or her Benefits Continuation Period, as determined in accordance with Schedule B-2 of this SPD. as such coverage may be amended from time to time, in accordance with the terms and conditions of such plans, provided the Participant timely pays the required contribution to continue coverage. The required contribution is calculated at active employee rates, as the same may be changed from time to time, during his or her Benefits Continuation Period.
(b)A Participant who, prior to his or her Separation Date, had elected no employee medical or dental coverage under the applicable employee medical or dental plan will not be permitted to change from no medical and/or dental coverage to coverage as a result of a Termination due to Workforce Restructuring.
(c)Employee medical and dental continuation coverage, as it may be amended from time to time, at active rates shall continue during the Benefits Continuation Period. The Benefits Continuation Period begins on the first day of the month following the Participant's Separation Date and shall end on the last day of the month in which the Benefits Continuation Period ends as determined in accordance with Schedule B-2 of this SPD, provided the Participant pays the required contributions for coverage in the time and manner required. If the Participant fails to pay the required contributions for coverage in the time and manner required, or the Participant elects to terminate active medical and/or dental coverage, coverage will end as of the last day of the month for which the contribution was paid and it will not be reinstated during the Benefits Continuation Period. If the Participant has medical and/or dental coverage on the last day of the Benefits Continuation Period, the Participant may be eligible to continue coverage in effect at the end of the Benefits Continuation Period in accordance with COBRA by timely electing and paying the full COBRA premium.
(d)If, as of his or her Separation Date, a Participant is eligible to participate in the Merck Retiree Medical Plan at subsidized rates, then he or she (i) shall be eligible to continue employee medical and dental benefits in accordance with this Section 4.2 and, (ii) following the completion of the Benefits Continuation Period, shall be eligible for retiree medical benefits at subsidized rates under the Merck Retiree Medical Plan, as it may be amended from time to time, provided that those eligible dependents who are age 65 or older and Medicare-eligible will only be eligible to participate in the Merck HRA component of the Merck Retiree Medical Plan. If a Participant is not eligible to continue active medical coverage during the Benefits Continuation Period (i.e., because the Participant had no employee coverage on his/her Separation) or the Participant's
15


employee medical coverage ends during the Benefits Continuation Period (for any reason, including non-payment), the Participant cannot enroll for medical coverage as a retiree until the end of the Benefits Continuation Period. If the Participant elects to end the Benefits Continuation Period earlier than the period set forth on Schedule B-2 as permitted in Section 2.4, all employee medical and/or dental benefit coverage that the Participant would otherwise have been eligible to receive during the maximum Benefits Continuation Period will be permanently and irrevocably forfeited. A Participant cannot be covered as an employee and as a retiree (even under the retiree no coverage option, if available) in a medical plan of an Employer (or Parent) during the same period; provided, however, that a Participant may be covered through COBRA at full COBRA rates for dental coverage even if during that period the Participant is also covered as a retiree for medical coverage.
(e)Rebadged Employees are not eligible for continuation of employee medical and dental benefits at active contribution rates during the Benefits Continuation Period described in this Section 4.2.
4.3Life Insurance Benefits
(a)A Participant shall be eligible to continue Basic Life Insurance coverage at no cost to the Participant during his or her Benefits Continuation Period, as determined in accordance with Schedule B-2, subject to and in accordance with the terms of the applicable life insurance plan as they may be amended from time to time. The Participant is responsible for paying applicable tax on imputed income, if any, for Basic Life Insurance coverage during his or her Benefits Continuation Period. The terms of such Schedule B-2 are hereby fully incorporated into and shall be considered as part of Section 4 of this Plan.
(b)Basic Life Insurance coverage shall end on the last day of the month in which the Benefits Continuation Period ends. If the Participant elects to end the Benefits Continuation Period earlier than the period set forth on Schedule B-2 as permitted in Section 2.4, all Basic Life Insurance coverage that the Participant would otherwise have been eligible to receive during the maximum Benefits Continuation Period will be permanently and irrevocably forfeited.
(c)Rebadged Employees are not eligible for the life insurance benefits described in this Section 4.3.
4.4Outplacement Benefits. Benefits for outplacement counseling or other outplacement services, as set forth in Schedule C, will be made available to a Participant. The terms of such Schedule C are hereby fully incorporated into and shall be considered as part of Section 4 of this Plan. Outplacement benefits shall be provided in kind; cash shall not be paid in lieu of outplacement benefits nor will Separation Pay be increased if a Participant declines or does not use the outplacement benefits. Rebadged Employees are not eligible for outplacement benefits described in this Section 4.4.
4.5Separation Pay for Rebadged Employees. A Rebadged Employee who is a Participant shall be eligible for Separation Pay under this Plan in an amount equal to 50% of the Separation Pay that would be payable had he or she experienced a Termination due to Workforce Restructuring.
For the avoidance of doubt, a Rebadged Employee shall not be eligible for any Separation Plan Benefits other than the Separation Pay described in this Section 4.5.
16


4.6Reduction of Benefits. Notwithstanding anything in this Plan to the contrary, a Participant's Separation Pay (including Separation Pay described in Section 4.5) and Separation Benefits, if applicable, shall be reduced by:
(a)any amount the Plan Administrator reasonably concludes the Participant owes the Employer (or the Parent or any subsidiary or affiliate of the Parent) including, without limitation, unpaid bills under the corporate credit card program, and for vacation used, but not earned;
(b)any severance or severance type benefits that the Employer (or the Parent or any subsidiary or affiliate of the Parent) must pay to a Participant under applicable law;
(c)where permitted by law, any payments received by the Participant pursuant to state workers compensation laws;
(d)short-term disability benefits where state law does not permit Separation Pay to be offset from short-term disability benefits (or where the Employer in its sole and absolute discretion determines it is administratively easier for the Employer to reduce Separation Pay by short-term disability benefits in lieu of reducing short-term disability benefits by Separation Pay);
(e)For Participants whose employment ends on or after January 1, 2017 who experienced one or more one-way transfers from a non-U.S. subsidiary to another non-U.S. subsidiary and/or to a U.S. subsidiary, any severance or severance type benefits paid by the Parent or any subsidiary or affiliate of the Parent to the Participant as a result of such transfer(s), provided such amount is determined using the exchange rate on the date(s) of the one-way transfer(s) or the Separation Date, whichever provides the lowest amount.
Notwithstanding anything in the Plan to the contrary, a Participant’s Separation Pay (including Separation Pay described in Section 4.5) and Separation Benefits are not meant to duplicate pay and benefits provided by the Employer (or the Parent or any of its subsidiaries) in connection with any Participant's Termination due to Workforce Restructuring or in connection with a Participant's termination due to the outsourcing of work to a third-party vendor, including pay and benefits under the federal Worker Adjustment Retraining and Notification Act and any state or local equivalent (collectively, the "WARN Act"). If the Plan Administrator determines that a Participant is entitled to WARN Act damages or WARN Act notice, the Plan Administrator in its sole and absolute discretion may reduce the Participant's Separation Pay and Separation Benefits under the Plan by the WARN Act damages or pay and benefits after receiving WARN Act notice, but not below $500, with the remaining Separation Pay and Separation Benefits provided to the Participant in accordance with the terms of the Plan in satisfaction of the Participant's WARN Act notice rights or damages. In all other cases, Separation Pay paid under the Plan in excess of $500 will be treated as having been paid to satisfy any WARN Act damages, if applicable.
17


SECTION 5
FORM AND TIMING OF BENEFITS; FORFEITURE AND REPAYMENT OF BENEFITS
5.1Form and Time of Payment
(a)Except as otherwise provided in subsection (b), Separation Pay, less taxes and applicable deductions shall be paid in a lump sum as soon as practicable after the Participant's Termination due to Workforce Restructuring (or in the case of a Rebadged Employee, after termination of employment due to the outsourcing transaction) and the expiration of any period during which the Participant may consider, sign and, if a revocation period is applicable, revoke the Release of Claims, but in no event later than March 15 of the calendar year following the year of a Participant's Separation Date.
(b)If it is determined by the Employer or Parent in its discretion, that (i) the Participant is, as of his or her Separation Date, a "specified employee" (as such term is defined in Section 409A(2)(B) of the Code); and (ii) the Separation Pay payable pursuant to the terms of the Plan constitutes nonqualified deferred compensation that would subject the Participant to “additional tax” under Section 409A(a)(1)(B) of the Code (the "409A Tax"), then the payment of Separation Pay will be postponed to the first business day of the seventh month following the Separation Date or, if earlier, the date of the Participant's death.
5.2Taxes. Separation Pay payable under this Plan shall be subject to the withholding of appropriate federal, state and local taxes.
Notwithstanding anything in this Plan to the contrary, the Employer or Parent will take such actions as it deems necessary, in its sole and absolute discretion, to avoid the imposition of a 409A Tax at such time and in such manner as permitted under Section 409A of the Code, including, but not limited to, reducing or eliminating benefits and changing the time or form of payment of benefits.
5.3Forfeiture of Benefits. The Employer reserves the right, in its sole and absolute discretion, to cancel all Separation Plan Benefits and seek the return of Separation Pay in the event a Participant engages in any activity that the Employer considers detrimental to its interests (or the interests of the Parent or any of its subsidiaries) as determined by the Parent’s Executive Vice President and General Counsel and the Parent’s Executive Vice President, Human Resources. Activities that the Employer considers detrimental to its interest (or the interests of the Parent or any of its subsidiaries) include, but are not limited to:
(a)breach of any obligations of the Participant's terms and conditions of employment;
(b)making false or misleading statements about the Employer, the Parent or any of its subsidiaries or their products, officers or employees to competitors, customers, potential customers of the Employer, the Parent or any of its subsidiaries or to current or former employees of the Employer, the Parent or any of its subsidiaries; and
(c)breaching any terms of the Release of Claims, including any non-solicitation or non-competition provisions, if applicable.
18


5.4Cessation of Separation Pay and Separation Benefits. Separation Pay, Outplacement Benefits and Separation Benefits shall cease in the event a Participant is rehired by the Employer, the Parent or one of its subsidiaries or affiliates.
5.5Return of Separation Pay. Upon the occurrence of an event described in Section 5.3 or 5.4 of this Plan, the Participant shall repay to the Employer that portion of the lump sum amount that would not have been paid had the Separation Pay been paid in weekly installments from the Participant's Separation Date. If the Participant receives short-term disability benefits from the Employer after his or her Separation Date, the Employer reserves the right to seek repayment by the Participant of that portion of the Separation Pay that would not have been paid in accordance with Section 4.6 had the Separation Pay been paid in installments.
5.6Death of Participant.
For Participants Who Die Before January 1, 2017:
If a Participant dies before January 1, 2017 following his or her Separation Date and a valid Release of Claims was signed by the Participant or is signed by the Participant's estate then
(a)any unpaid Separation Pay will be paid to the Participant's estate; and
(b)if the Participant was eligible to continue medical and/or dental coverage during the Benefits Continuation Period on the Participant's date of death and the Participant’s surviving dependents were covered under the Participant's medical and dental coverages (other than coverages applicable to retirees and their dependents) on that date, they may continue such employee coverage for the balance of the Benefits Continuation Period, provided they continue to remain eligible dependents and they pay the applicable contributions at active employee rates, as they may change from time to time, to continue coverage. Thereafter, if, as of his or her Separation Date, such Participant (i) was eligible to participate in the Merck Retiree Medical Plan at subsidized rates, then following the completion of the Benefits Continuation Period, surviving eligible dependents shall be eligible for retiree medical benefits at subsidized rates under the terms of the Merck Retiree Medical Plan applicable to such Participant, as may be amended from time to time, provided that those eligible dependents who are age 65 or older and Medicare-eligible will only be eligible to participate in the Merck HRA component of the Merck Retiree Medical Plan, or (ii) was eligible to participate in the Merck Retiree Medical Plan at unsubsidized rates, then following the completion of the Benefits Continuation Period the surviving dependents may be eligible to continue coverage in effect at the end of the Benefits Continuation Period for the remaining COBRA period, if any, in accordance with COBRA by paying the full COBRA premium and thereafter may be eligible for retiree medical benefits at unsubsidized rates under the terms of the Merck Retiree Medical Plan applicable to such Participant, as may be amended from time to time, provided that those eligible dependents who are age 65 or older and Medicare- eligible will not be eligible to participate in the Merck Retiree Medical Plan or (iii) was not eligible to participate in the Merck Retiree Medical Plan at subsidized or unsubsidized rates, then following the completion of the Benefits Continuation Period the surviving dependents may be eligible to continue coverage in effect at the end of the Benefits Continuation Period for the remaining COBRA period, if any, in accordance with COBRA by paying the full COBRA premium, or (iv) was not eligible to participate in the Merck Retiree Medical Plan at subsidized or unsubsidized rates but had at least 25 years of service as of his/her date of death, then following the completion of the Benefits Continuation Period, surviving eligible dependents shall be eligible
19


for medical benefits at subsidized rates under the terms of medical plan that would have been applicable to such Participant if he/she had been eligible for long term disability benefits, as may be amended from time to time; and
(c)if the if the Participant was eligible to continue medical coverage during the Benefits Continuation Period on the Participant's date of death and the Participant’s surviving dependents were not covered under the Participant's medical coverage at the time of the Participant’s death or if the Participant was not eligible to continue medical coverage during the Benefits Continuation Period and, in either case, if as of his or her Separation Date, such Participant (i) was eligible to participate in the Merck Retiree Medical Plan at subsidized or unsubsidized rates, then following the date of death, surviving eligible dependents who were not then enrolled for coverage under the Participant’s medical coverage shall be eligible to enroll for retiree medical benefits at the subsidized or unsubsidized rates, as applicable, under the terms of the Merck Retiree Medical Plan applicable to such Participant, as may be amended from time to time, provided that those eligible dependents who are age 65 or older and Medicare-eligible will only be eligible to participate in the Merck HRA component of the Merck Retiree Medical Plan and will only be eligible for such coverage if they are eligible for subsidized coverage (dependents eligible for unsubsidized coverage are not eligible to participate in the Merck HRA component of the Merck Retiree Medical Plan), or (ii) was not eligible to participate in the Merck Retiree Medical Plan at subsidized or unsubsidized rates but had at least 25 years of service as of his/her date of death, then following the date of death, surviving eligible dependents who were not then enrolled for coverage under the Participant’s medical coverage shall be eligible to enroll for medical benefits at subsidized rates under the terms of medical plan that would have been applicable to such Participant if he/she had been eligible for long term disability benefits, as may be amended from time to time.
Medical and dental coverage under this Section 5.6 shall be subject to and in accordance with the terms of the applicable plans as they may be amended from time to time.
The Separation Date of an Eligible Employee who dies prior to his or her scheduled Separation Date but after he or she was notified of a scheduled Separation Date shall be deemed to have occurred on the day before his/her date of death.
For Participants Who Die On or After January 1, 2017:
If a Participant dies on or after January 1, 2017 following his or her Separation Date and a valid Release of Claims was signed by the Participant or is signed by the Participant's estate then
(a)any unpaid Separation Pay will be paid to the Participant's estate; and
(b)if the Participant was eligible to continue medical and/or dental coverage during the Benefits Continuation Period on the Participant's date of death and the Participant’s surviving dependents were covered under the Participant's medical and dental coverages at the time of the Participant’s death, they may continue such employee coverage for the balance of the Benefits Continuation Period, provided they continue to remain eligible dependents and they pay the applicable contributions at active employee rates, as they may change from time to time, to continue coverage. Thereafter, if, as of his or her Separation Date, such Participant (i) was eligible to participate in the Merck Retiree Medical Plan at subsidized rates, then following the completion of the Benefits Continuation Period, surviving eligible dependents shall be eligible for retiree medical benefits at subsidized rates under the terms of Merck Retiree Medical Plan, as may be
20


amended from time to time, provided that those eligible dependents who are age 65 or older and Medicare-eligible will only be eligible to participate in the Merck HRA component of the Merck Retiree Medical Plan, or (ii) was not eligible to participate in the Merck Retiree Medical Plan at subsidized rates, then following the completion of the Benefits Continuation Period the surviving dependents may be eligible to continue coverage in effect at the end of the Benefits Continuation Period in accordance with COBRA by timely electing COBRA coverage and paying the full COBRA premium; or (iii) was not eligible to participate in the Merck Retiree Medical Plan at subsidized rates but had at least 25 years of service as of his/her Separation Date, then following the completion of the Benefits Continuation Period, surviving eligible dependents shall be eligible for retiree medical benefits at subsidized rates under the terms of the Merck Retiree Medical Plan, as may be amended from time to time, provided that those eligible dependents who are age 65 or older and Medicare-eligible will only be eligible to participate in the Merck HRA component of the Merck Retiree Medical Plan; and
(c)if the Participant was eligible to continue medical coverage during the Benefits Continuation Period on the Participant's date of death and the Participant’s surviving dependents were not covered under the Participant's medical coverage at the time of the Participant’s death or if the Participant was not eligible to continue medical coverage during the Benefits Continuation Period and, in either case, if as of his or her Separation Date, such Participant (i) was eligible to participate in the Merck Retiree Medical Plan at subsidized rates, then following the date of death, surviving eligible dependents who were not then enrolled for coverage under the Participant’s medical coverage shall be eligible to enroll for retiree medical benefits at subsidized rates under the terms of Merck Retiree Medical Plan, as may be amended from time to time, provided that those eligible dependents who are age 65 or older and Medicare-eligible will only be eligible to participate in the Merck HRA component of the Merck Retiree Medical Plan; or (ii) was not eligible to participate in the Merck Retiree Medical Plan at subsidized rates but had at least 25 years of service as of his/her Separation Date, then following the date of death, surviving eligible dependents who were not then enrolled for coverage under the Participant’s medical coverage shall be eligible to enroll for medical benefits at subsidized rates under the terms of the Merck Retiree Medical Plan, as may be amended from time to time, provided that those eligible dependents who are age 65 or older and Medicare-eligible will only be eligible to participate in the Merck HRA component of the Merck Retiree Medical Plan.
Medical and dental coverage under this Section 5.6 shall be subject to and in accordance with the terms of the applicable plans as they may be amended from time to time.
The Separation Date of an Eligible Employee who dies prior to his or her scheduled Separation Date but after he or she was notified of a scheduled Separation Date shall be deemed to have occurred on the day before his/her date of death.
21


SECTION 6
PLAN ADMINISTRATION
6.1Plan Administrator. Parent or its delegate is the Plan Administrator for purposes of ERISA.
6.2Powers and Duties of Plan Administrator. The Plan Administrator or its delegate shall have the full discretionary power and authority to: (i) construe and interpret the Plan (including, without limitation, supplying omissions from, correcting deficiencies in, or resolving inconsistencies or ambiguities in, the language of the Plan); (ii) determine all questions of fact arising under the Plan, including questions as to eligibility for and the amount of benefits; (iii) establish such rules and regulations (consistent with the terms of the Plan) as it deems necessary or appropriate for administration of the Plan; (iv) delegate responsibilities to others to assist in administering the Plan; and (v) perform all other acts it believes reasonable and proper in connection with the administration of the Plan. The Plan Administrator or its delegate shall be entitled to rely on the records of the Employer in determining any Participant's entitlement to and the amount of benefits payable under the Plan. Any determination of the Plan Administrator or its delegate, including interpretations of the Plan and determinations of questions of fact, shall be final and binding on all parties.
With respect to determining claims and appeals for benefits under this Plan, the Claims Reviewer (and its delegate) shall be deemed to be the delegate of the Plan Administrator and shall have all of the powers and duties of the Plan Administrator described above.
6.3Additional Discretionary Authority. The Plan Administrator may, upon written approval of the Parent’s Executive Vice President, Human Resources (written approval of the Compensation and Benefits Committee of the Board of Directors of the Parent or its delegate with respect to Section 16 Officers), take the following actions under the Plan:
(a)grant some, all or any portion of the benefits under this Plan to an employee who would not otherwise be eligible for such benefits under Section 3 above;
(b)waive the requirement set forth in Section 3 for any individual Eligible Employee or group of Eligible Employees to execute a Release of Claims; and
(c)grant additional Separation Plan Benefits to a Participant.
22


SECTION 7
CLAIMS AND APPEALS PROCEDURES
7.1Claims.
(a)Any request or claim for benefits under the Plan must be filed by a claimant or the claimant’s authorized representative within 60 days after the date claimant’s employment with an Employer ends; provided, however, for claims under Section 5.3, claims must be filed within 60 days after the date Separation Plan Benefits are cancelled.
(b)Any request or claim for benefits under the Plan shall be deemed to be filed when a written request made by the claimant or the claimant's authorized representative addressed to the Claims Reviewer at the address below is received by the Claims Reviewer.
Claims Reviewer for the Separation Benefits Plan
c/o Secretary of the Merck & Co., Inc. Employee Benefits Committee Merck & Co., Inc.
2000 Galloping Hill Road Mailstop K-1 3029
Kenilworth, NJ 07033
The claim for benefits shall be reviewed by, and a determination shall be made by, the Claims Reviewer, within the timeframe required for notice of adverse benefit determinations described below.
(c)The Claims Reviewer shall provide written or electronic notification to the claimant or the claimant’s authorized representative of any “adverse benefit determination.” Such notice shall be provided within a reasonable time but not later than 90 days after the receipt by the Claims Reviewer of the claimant's claim, unless the Claims Reviewer determines that special circumstances require an extension of time for processing the claim. If the Claims Reviewer determines that an extension of time for processing is required, written notice of the extension shall be furnished to the claimant before the expiration of the initial 90-day period indicating the special circumstances requiring an extension and the date by which the Claims Reviewer expects to render the benefit determination. No extension can exceed 90 days from the end of the initial 90-day period (i.e., 180 days from the receipt of the claim by the Claims Reviewer) without the consent of the claimant or the claimant’s authorized representative.
(d)An “adverse benefit determination” is a denial, reduction, or termination of, or a failure to provide or make payment (in whole or part) for a benefit, including one that is based on a determination of a claimant’s eligibility to participate in the Plan.
(e)The notice of adverse benefit determination shall be written in a manner calculated to be understood by the claimant and shall:
(i)set forth the specific reasons for the adverse benefit determination;
(ii)contain specific references to Plan provisions on which the determination is based;
(iii) describe any material or information necessary for the claim for benefits to be allowed and an explanation of why such information is necessary; and
23


(iv) describe the Plan’s appeal procedures and the time limits applicable to such procedures, including a statement of the claimant’s right to bring a civil action under section 502(a) of ERISA following an adverse benefit determination on review.
7.2Appeals of Adverse Benefit Determinations.
(a)Any request to review the Claims Reviewer’s adverse benefit determination under the Plan must be filed by a claimant or the claimant’s authorized representative in writing within 60 days after receipt by the claimant of written notification of adverse benefit determination by the Claims Reviewer. If the claimant or the claimant’s authorized representative fails to file a request for review of the Claims Reviewer’s adverse benefit determination in writing within 60 days after receipt by the claimant of written notification of adverse benefit determination, the Claims Reviewer’s determination shall become final and conclusive.
(b)Any request to review an adverse benefit determination under the Plan shall be deemed to be filed when a written request is made by the claimant or the claimant's authorized representative addressed to the Employee Benefits Committee at the address below is received by the Secretary of the Employee Benefits Committee.
Merck & Co., Inc. Employee Benefits Committee c/o Secretary Employee Benefits Committee Merck & Co., Inc.
2000 Galloping Hill Road Mailstop K-1 3029
Kenilworth, NJ 07033
(c)If the claimant or the claimant’s authorized representative timely files a request for review of the Claims Reviewer’s adverse benefit determination as specified in this Section 7.2, the Employee Benefits Committee shall re-examine all issues relevant to the original adverse benefit determination taking into account all comments, documents, records, and other information submitted by the claimant or the claimant’s authorized representative relating to the claim, without regard to whether such information was submitted or considered in the initial benefit determination. Any such claimant or his or her duly authorized representative may:
(i)upon request and free of charge have reasonable access to, and copies of, all documents, records, and other information relevant to the claimant’s claim for benefits; whether an item is relevant shall be determined by the Employee Benefits Committee in accordance with 29 CFR 2560.503-1 (m)(8); and
(ii)submit in writing any comments, documents, records, and other information relating to the claim for benefits.
(d)The Claims Reviewer shall provide written or electronic notice to the claimant or the claimant’s authorized representative of its benefit determination on review. Such notice shall be provided within a reasonable time but not later than 60 days after the receipt by the Claims Reviewer of the claimant's request for review, unless the Claims Reviewer determines that special circumstances require an extension of time for processing the request for review. If the Claims Reviewer determines that an extension of time for processing is required, written notice of the extension shall be furnished to the claimant before the expiration of the initial 60-day period indicating the special circumstances requiring an extension and the date by which the Claims
24


Reviewer expects to render the benefit determination. No extension can exceed 60 days from the end of the initial 60-day period (i.e., 120 days from the date the request for review is received by the Claims Reviewer) without the consent of the claimant or the claimant’s authorized representative.
(e)If the claimant’s appeal is denied, the notice of adverse benefit determination on review shall be written in a manner calculated to be understood by the claimant and shall:
(i)set forth the specific reasons for the adverse benefit determination on review;
(ii)contain specific references to Plan provisions on which the benefit determination is based;
(iii)contain a statement that the claimant is entitled to receive,
upon request and free of charge, reasonable access to, and copies of, all documents, records, and other information relevant to the claimant’s claim for benefits; whether an item is relevant shall be determined by the Claims Reviewer in accordance with 29 CFR 2560.503-1 (m)(8); and
(iv)include a statement of the claimant’s right to bring a civil action under section 502(a) of ERISA.
25


SECTION 8
AMENDMENT AND TERMINATION
8.1Amendment and Termination.
(a)Except as otherwise set forth in subsection (b) below, Parent or its delegate has the right to amend, suspend or terminate the Plan at any time without prior notice to or the consent of any employee; provided, however, that amendments that apply only to Section 16 Officers must also be approved by the Compensation and Benefits Committee of the Board of Directors of Parent or its delegate. No such amendment shall give the Employer or Parent the right to recover any amount paid to a Participant prior to the date of such amendment. Any such amendment, however, may cause the cessation and discontinuance of payments of Separation Plan Benefits to any person or persons under the Plan. Parent may delegate the authority to amend, suspend or terminate the Plan to the person, entity or committee selected by the Chief Executive Officer and as set forth in the applicable written corporate grant signed by the Chief Executive Officer (the “Corporate Grant”). Such Corporate Grant shall allow for the delegation of the authority to an individual, entity or committee; provided the financial impact of such amendment, suspension or termination does not exceed certain predetermined thresholds identified in the applicable Corporate Grant. The person, entity or committee provide with the authority to amend, suspend or terminate the Plan by the Corporate Grant, may further delegate the authority to amend, suspend or terminate the Plan to an individual, entity or committee, in accordance with the appropriate corporate action. Amendments to the Plan must be in writing and approved in accordance with the Corporate Grant.
(b)Except to the extent required by applicable law, for the entirety of the Protection Period, the material terms of the Plan, including this Section 8.1, shall not be modified in any manner that is materially adverse to a Qualifying Participant.
(c)Parent or any such successor to Parent, shall pay all legal fees and related expenses (including the costs of experts, evidence and counsel) reasonably and in good faith incurred by a Qualifying Participant if the Qualifying Participant prevails on at least one material item of his or her claim for relief in an action (x) by the Qualifying Participant claiming that the provisions of this Section 8.1 have been violated (but, for the avoidance of doubt, excluding claims for plan benefits in the ordinary course) and (y) if applicable, by the Employer, Parent or its successor to enforce post-termination covenants against the Qualifying Participant.
(d)Definitions. For purposes of this Section 8.1:
(i)Protection Period” shall mean the period beginning on the date of the Change in Control and ending on the second anniversary of the date of the Change in Control; and
(ii)Qualifying Participant” shall mean an individual who is an Eligible Employee or a Participant as of the date immediately prior to the Change in Control.
26


SECTION 9
GENERAL PROVISIONS
9.1Unfunded Obligation. Separation Plan Benefits provided under this Plan shall constitute an unfunded obligation of the Employer. Payments shall be made, as due, from the general funds of the Employer. This Plan shall constitute solely an unsecured promise by the Employer to pay such benefits to Participants to the extent provided herein.
9.2Applicable Law. It is intended that the Plan be an "employee welfare benefit plan" within the meaning of Section 3(1) of ERISA, and the Plan shall be administered in a manner consistent with such intent. The Plan and all rights thereunder shall be governed and construed in accordance with ERISA and, to the extent not preempted by federal law, with the laws of the state of New Jersey, wherein venue shall lie for any dispute arising hereunder.
9.3Severability. If any provision of this Plan shall be held illegal or invalid for any reason, said illegality or invalidity shall not affect the remaining parts of this Plan, but this Plan shall be construed and enforced as if said illegal or invalid provision had never been included herein.
9.4Employment at Will. Nothing contained in this Plan shall give an employee the right to be retained in the employment of the Employer or shall otherwise modify the employee's at will employment relationship with the Employer. This Plan is not a contract of employment between the Employer and any employee.
9.5Heirs, Assigns, and Personal Representatives. The Plan shall be binding upon the heirs, executors, administrators, successors, and assigns of the parties, including each Participant, present and future.
9.6Payments to Incompetent Persons, Etc. Any benefit payable to or for the benefit of a minor, an incompetent person or other person incapable of receipting therefore shall be deemed paid when paid to such person’s guardian or to the party providing or reasonably appearing to provide for the care of such person, and such payment shall fully discharge the Employer, Parent, the Plan Administrator, the Claims Administrator and all other parties with respect thereto.
9.7Lost Payees. Benefits shall be deemed forfeited if the Plan Administrator is unable to locate a Participant to whom Separation Plan Benefits are due. Such Separation Plan Benefits shall be reinstated if application is made by the Participant for the forfeited Separation Plan Benefits within one year of the Participant’s Separation Date and while the Plan is in operation.
27


SCHEDULE A
List of participating Employers:
All U.S. direct and indirect wholly owned subsidiaries of Merck & Co. Inc. excluding the following and their subsidiaries, successors and assigns:
Comsort, Inc.
Merck Global Health Innovation Fund, LLC
HMR Weight Management Services Corp.
ILUM Health Solutions, LLC (formerly known as Healthcare Services and Solutions, LLC)
28


SCHEDULE B-1
Separation Pay for Participants with a Separation Date Occurring on or after January 1, 2013
Amount of Separation Pay in weeks (Annual Base Salary divided by 52)
Complete Years of Continuous Service at Separation Date
BAND LEVEL
Band 200
Band 300
Band 400
Band 500
Band 600
Band 700/800
0101218242626
1101218243240
2101218243240
3101218243240
4101218243240
5121420263442
6141622283644
7161824303846
8182026324048
9202228344250
10222430364452
11242632384654
12262834404856
13283036425058
14303238445260
15323440465462
16343642485664
17363844505866
18384046526068
19404248546270
20424450566472
21444652586674
22464854606876
23485056627078
24505258647278
25525460667478
26545662687678
27565864707878
28586066727878
29606268747878
30626470767878
31646672787878
32666874787878
33687076787878
34707278787878
35727478787878
36747678787878
37767878787878
38+787878787878
29


SCHEDULE B-2
MEDICAL / DENTAL AND LIFE INSURANCE CONTINUATION
COMPLETE YEARS OF CONTINUOUS SERVICE AT SEPARATION DATE
BENEFITS CONTINUATION PERIOD
< 526 weeks
5 – 9.939 weeks*
10 – 19.952 weeks*
20+78 weeks*
*For Participants who are eligible for subsidized retiree medical benefits under the Merck Retiree Medical Plan on their Separation Date, the Benefits Continuation Period shall continue to the last day of the month in which the number of weeks set forth above occurs.
30


SCHEDULE C
OUTPLACEMENT BENEFITS
BAND LEVELBENEFITDURATION
Band 200
Quick Start Plus
3 Months
Band 300
Professional--Career Assistance
3 Months
Band 400
Professional--Career Transition
6 Months
Band 600/500
Executive
12 Months
Band 800/700
Executive Premium
12 Months
The Outplacement Benefits are provided through a third party vendor. The vendor and/or the programs may change from time to time.
31


SCHEDULE D (Change in Control/Pension) Description of Change-in-Control Benefits under the Pension Plan
This Schedule describes benefits under the Pension Plan and the Supplemental Plan (as each is defined below) provided to an Eligible Employee under the Plan if such Eligible Employee signs and returns the Release of Claims in use under the CIC Plan and in accordance with the process established under the CIC Plan.
I.If an Eligible Employee’s employment is terminated in circumstances entitling him or her to the benefits provided in Section 3.1 (c) of the Plan:
1.For an Eligible Employee who participates in the Retirement Plan for Salaried Employees of MSD or its successor (the “MSD Pension Plan) and on his or her Separation Date is not at least age 55 with at least ten years of Credited Service under the MSD Pension Plan but would attain at least age 50 and have at least ten years of Credited Service under the MSD Pension Plan within two years following the date of the Change in Control (assuming continued employment during the entirety of such two-year period), then the Eligible Employee shall be deemed to be eligible for a subsidized early retirement benefit on his “Prior Plan Formula” (as defined in the MSD Pension Plan) under the MSD Pension Plan commencing in accordance with the terms of the MSD Plan.
2.For an Eligible Employee who participates in the MSD Pension Plan or the Legacy Schering Retirement Plan, or their successors (collectively the “Pension Plan”) and on his or her Separation Date is not at least age 65 but would attain at least age 65 within two years following the date of the Change in Control (assuming continued employment during the entirety of such two-year period), then the Eligible Employee shall be deemed to be eligible for a Prior Plan Formula benefit unreduced for early commencement under the Pension Plan commencing in accordance with the terms of the Pension Plan.
3.For an Eligible Employee who participates in the MSD Pension Plan and on his or her Separation Date is not eligible for the “Rule of 85 Transition Benefit” (as such term is defined in the MSD Pension Plan) but would have been eligible for the Rule of 85 Transition Benefit within two years following the date of the Change in Control (assuming continued employment during the entirety of such two-year period), then the Eligible Employee shall be deemed to be eligible for the Rule of 85 Transition Benefit upon commencement of his or her pension benefit under the MSD Pension Plan.
4.    For an Eligible Employee who participates in the Pension Plan on his or her Separation Date who is not vested in his or her accrued benefit under the Pension Plan, he or she shall be vested in his accrued benefit under the Pension Plan on his or her Separation Date.
II.The benefits described in this Schedule D shall be payable from the Pension Plan and, to the extent that such benefits cannot be paid from the Pension Plan the Employer may, to the extent it deems necessary or appropriate (including to comply with applicable law and to preserve grandfathered status of arrangements subject to Section 409A of the Code), cause such benefits to be paid under a Supplemental Retirement Plan of MSD or the Legacy Schering Benefits Excess Plan, as applicable and any successors thereto (collectively, the “Supplemental Plan”) or under new arrangements or from the Employer's general assets.
32


SCHEDULE E (Change in Control/Retiree Medical)
Description of Change-in-Control Benefits under Health Plan
This Schedule describes benefits under the Health Plan provided to an Eligible Employee under the Plan if such Eligible Employee signs and returns the Release of Claims in use under the CIC Plan and in accordance with the process established under the CIC Plan.
I.If an Eligible Employee’s employment is terminated in circumstances entitling him or her to the benefits provided in Section 3.1 (c) of the Plan:
If the Eligible Employee is eligible to participate in the Health Plan and on his or her Separation Date is not at least age 55 with the requisite amount of service with an Employer to satisfy the requirements to be considered a retiree eligible for subsidized retiree medical benefits under the Health Plan but would attain at least age 50 and meet the service requirements to be considered a retiree eligible for subsidized retiree medical benefits under the Health Plan within two years following the date of the Change in Control (assuming continued employment during the entirety of such two-year period), then the Eligible Employee shall be eligible for subsidized retiree medical benefits under the Health Plan on the date his or her Benefits Continuation Period Ends on the same terms and conditions applicable to salaried U.S.- based employees of the Employer whose employment terminated the last day of the month prior to the Eligible Employee’s Separation Date who were treated as retirees eligible for subsidized retiree medical benefits under the Health Plan as of that date.
II.The Employer may, to the extent it deems necessary or appropriate (including to comply with applicable law and to preserve grandfathered status of arrangements subject to Section 409A of the Code), cause the benefits set forth in this Schedule E to be provided from insured arrangements, or pursuant to new arrangements, individual arrangements or otherwise. Further, notwithstanding anything to the contrary, to the extent any benefits to which an Eligible Employee is entitled under this Schedule E would reasonably be likely to constitute a discriminatory benefit under Section 105(h) of the Code or a similar law or regulation at the time the benefit is to be provided to the Eligible Employee, as determined in the sole discretion of the Parent, the Employer may, to the extent it deems necessary or appropriate (including to comply with applicable law), modify the benefit so that the benefit would no longer constitute a discriminatory benefit under Section 105(h) of the Code or such similar law, including, but not limited to, eliminating all subsidy from the Parent or the Employer, requiring that the Eligible Employee pay for participation in the benefit program with after-tax funds or causing the full employer and employee portions of the cost of the benefit to be imputed as gross income to the Eligible Employee.
III.For purposes of this Schedule E, “Health Plan” means one or more plans sponsored by the Parent or one of its subsidiaries that provide medical benefits to Eligible Employees and to former Eligible Employees who are considered retirees thereunder and to the eligible dependents of each of the foregoing.



AMENDMENT 2019-1
MERCK & CO., INC. U.S. SEPARATION BENEFITS PLAN
(as Amended and Restated as of January 1, 2019)
WHEREAS, Merck, Sharp & Dohme Corp. (the "Company"), a subsidiary of Merck & Co., Inc. ("Merck"), sponsors the Merck & Co., Inc. U.S. Separation Benefits Plan (as Amended and Restated as of January 1, 2019) (the "Plan");
WHEREAS, pursuant to Article 8.1 of the Plan, the Company (or its duly authorized representative) has reserved the right to amend or terminate the Plan at any time;
WHEREAS, pursuant to the grant of authority of Merck's Chief Executive Officer, the Company has delegated the authority to amend the Plan to the Merck & Co., Inc. Executive Oversight Committee (the "Executive Committee") in accordance with its charter;
WHEREAS, in accordance with its charter the Executive Committee has delegated to the Merck & Co., Inc. Oversight Committee (the "Committee"} the authority to make certain amendments to the Plan in accordance with the charter of the Committee; and
WHEREAS, the Committee desires to ratify and adopt the amendment to the Plan described herein.
NOW, THEREFORE, an amendment to the Plan be and hereby is ratified and adopted and is incorporated as follows:
1.Section 2.7 of the Plan is hereby amended in its entirety to read as follows:
"2.7    "Claims Reviewer" means the Merck & Co., Inc. Employee Benefits Committee (or its delegate); provided, however, for Section 16 Officers, Claims Reviewer means the Compensation and Benefits Committee of the Board of Directors of Parent or its delegate."
2.The first paragraph of Section 5.3 is hereby amended and restated to read as follows:
"5.3    Forfeiture of Benefits. The Employer reserves the right, in its sole and absolute discretion, to cancel all Separation Plan Benefits and seek the return of Separation Pay in the event a Participant engages in any activity that the Employer considers detrimental to its interests (or the interests of the Parent or any of its subsidiaries) as determined by the Parent's Executive Vice President and General Counsel and the Parent's Executive Vice President & Chief Human Resources Officer or by such other individual who acts as the successor or equivalent thereto of either of the aforementioned positions. Activities that the Employer considers detrimental to its interest (or the interests of the Parent or any of its subsidiaries) include, but are not limited to:"
3.The first paragraph of Section 6.3 is hereby amended to read as follows:
"6.3    Additional Discretionary Authority. The Plan Administrator may, upon written approval of the Parent's Executive Vice President & Chief Human Resources Officer, or by such other individual who acts as the successor or equivalent thereto of such position, (written approval of the Compensation and Benefits Committee of the Board of Directors of the Parent or its delegate with respect to Section 16 Officers), take the following actions under the Plan
2


4.Schedule A of the Plan is hereby updated to read as follows:
"SCHEDULE A
List of Participating Employers:
All U. S. direct and indirect wholly owned subsidiaries of Merck & Co., Inc. excluding the following and their subsidiaries:
Comsort, Inc. (and its subsidiaries)
Merck Global Health Innovation Fund LLC (and its subsidiaries)
HMR Weight Management Services Corp. (and its subsidiaries)
ILUM Health Solutions, LLC (and its subsidiaries)
Peloton Therapeutics, Inc. (and its subsidiaries) for the period of time after the date Peloton Therapeutics, Inc. became a subsidiary of the Company and before January 1, 2020
Tilos Therapeutics (and its subsidiaries) for the period of time after the date Tilos Therapeutics became a subsidiary of the Company and before January 1, 2020
Antelliq Corporation (and its subsidiaries) for the period of time after the date Antelliq Corporation became a subsidiary of the Company and before such date in 2020 as of which the Plan Administrator determines Antelliq Corporation shall become an Employer."
IN WITNESS WHEREOF, the Committee has caused this Amendment 2019-1 to the Plan to be executed by the undersigned on this 19th day of December, 2019.
picture1.jpg
By
Michael Arseneault
Executive Director, Managing Counsel
Global Compensation and Benefits
3


AMENDMENT 2020-1
MERCK & CO., INC. U.S. SEPARATION BENEFITS PLAN
(as Amended and Restated as of January 1, 2019)
WHEREAS, Merck, Sharp & Dohme Corp. (the "Company"), a subsidiary of Merck & Co., Inc. ("Merck"), sponsors the Merck & Co., Inc. U.S. Separation Benefits Plan (as Amended and Restated as of January 1, 2019) (the "Plan");
WHEREAS, pursuant to Article 8.1 of the Plan, the Company (or its duly authorized representative) has reserved the right to amend or terminate the Plan at any time;
WHEREAS, pursuant to the grant of authority of Merck's Chief Executive Officer, the Company has delegated the authority to amend the Plan to the Merck & Co., Inc. Executive Oversight Committee (the "Executive Committee") in accordance with its charter;
WHEREAS, in accordance with its charter the Executive Committee has delegated to the Merck & Co., Inc. Oversight Committee (the "Committee") the authority to make certain amendments to the Plan in accordance with the charter of the Committee; and
WHEREAS, the Committee desires to ratify and adopt the amendment to the Plan described herein.
NOW, THEREFORE, an amendment to the Plan be and hereby is ratified and adopted and is incorporated as follows:
1.The first paragraph of Section 6.3 is hereby amended to read as follows:
"6.3    Additional Discretionary Authority. The Plan Administrator may, upon written approval of the Parent's Executive Vice President & Chief Human Resources Officer (or his or her delegate), or by such other individual who acts as the successor or equivalent thereto of such position (or his or her delegate), (written approval of the Compensation and Benefits Committee of the Board of Directors of the Parent or its delegate with respect to Section 16 Officers), take the following actions under the Plan:"
IN WITNESS WHEREOF, the Committee has caused this Amendment 2020-1 to the Plan to be executed by the undersigned on this 25th day of February. 2020.
picture1.jpg
By
Michael Arseneault
Executive Director, Managing Counsel Global Compensation and Benefits



AMENDMENT 2020-2
MERCK & CO. INC. U.S. SEPARATION BENEFITS PLAN
(Amended and Restated as of January 1, 2019)
WHEREAS, Merck & Co, Inc. (the “Company”), a subsidiary of Merck & Co., Inc. (“Merck”), sponsors the Merck & Co., Inc. U.S. Separation Benefits Plan (Amended and Restated as of January 1, 2019) (the “Plan”);
WHEREAS, pursuant to Article 8.1 of the Plan, the Company (or its duly authorized representative) has reserved the right to amend or terminate the Plan at any time;
WHEREAS, pursuant to the grant of authority of Merck’s Chief Executive Officer, the Company has delegated the authority to amend the Plan to the Merck & Co., Inc. Executive Oversight Committee (the “Executive Committee”) in accordance with its charter;
WHEREAS, in accordance with its charter the Executive Committee has delegated to the Merck & Co., Inc. Oversight Committee (the “Committee”) the authority to make certain amendments to the Plan in accordance with the charter of the Committee; and
WHEREAS, the Committee desires to ratify and adopt the amendment to the Plan described herein.
NOW, THEREFORE, an amendment to the Plan be and hereby is ratified and adopted and is incorporated as follows:
1.A new definition of Legacy Quantified Ag, Antelliq Corporation, or ArQule, Inc. Employee is hereby added to the Plan’s Article II in the correct alphabetical order to read as follows:
Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc. Employee” means an Eligible Employee who was formerly an employee of Quantified Ag, Antelliq Corporation, or ArQule, Inc. respectively who became an employee of Merck & Co, Inc. or one of its subsidiaries in 2019 or 2020 and continues to be employed by such entity until his/her Separation Date, and as of his/her Separation Date is employed by an Employer.”
2.Section 2.9 “Complete Years of Continuous Service” of the Plan is hereby amended in its entirety to read as follows:
“2.9 “Complete Years of Continuous Service” means (a) for a Legacy Schering Employee, a year from the Participant’s Most Recent Hire Date with a Legacy Schering Entity to its anniversary, and thereafter from each anniversary to the next, (b) for a Legacy Merck Employee, a year from the Participant's Most Recent Hire Date with a Legacy Merck Entity to its anniversary, and thereafter from each anniversary to the next, (c) for a Legacy Inspire Employee, a year from the Participant’s Most Recent Hire Date with a Merck Entity to its anniversary, and thereafter from each anniversary to the next, (d) for a Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc., Employee a year from the Participant’s Most Recent Hire Date with a Merck Entity to its anniversary, and thereafter from each anniversary to the next, and (e) for a Non-Legacy Company Employee, from the



Participant’s Most Recent Hire Date with a Merck Entity, and thereafter from each anniversary to the next.”
3.Section 2.10 “Continuous Service” of the Plan is hereby amended in its entirety to read as follows:
2.10 “Continuous Service” means (a) for a Legacy Schering Employee, the period of a Participant's continuous employment with a Legacy Schering Entity commencing on the Participant's Most Recent Hire Date with a Legacy Schering Entity and ending on the Separation Date as reflected on the Employer’s employee database, (b) for a Legacy Merck Employee, the period of a Participant's continuous employment with a Legacy Merck Entity commencing on the Participant's Most Recent Hire Date with a Legacy Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database, (c) for a Legacy Inspire Employee, the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database, (d) for a Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc. Employee the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database, and (e) for a Non-Legacy Company Employee, the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database. For the avoidance of doubt, service prior to November 4, 2009 by a Legacy Schering Employee with a Legacy Merck Entity or a Legacy Merck Employee with a Legacy Schering Entity is excluded from “Continuous Service.” Notwithstanding anything contained in this Plan to the contrary, employment with a Legacy Schering Entity, Legacy Merck Entity or a Merck Entity as an Excluded Person does not count as "Continuous Service".
4.Section 2.24 “Most Recent Hire Date” of the Plan is hereby amended in its entirety to read as follows:
“2.24 Most Recent Hire Date” means (a) for a Legacy Schering Employee, his or her most recent hire date at a Legacy Schering Entity or an entity acquired by a Legacy Schering Entity as reflected on the Employer’s employee data system, (b) for a Legacy Merck Employee, his or her most recent hire date at a Legacy Merck Entity or an entity acquired by a Legacy Merck Entity as reflected on the Employer’s employee data system,
(c)for a Legacy Inspire Employee, his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer’s employee data system,
(d)for a Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc. Employee his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer’s employee data system, and (e) for a Non-Legacy Company Employee, his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer’s employee data system. Notwithstanding the
2


foregoing, the most recent hire date for a Legacy Merck Employee who was employed by a Legacy Merck Entity on December 31, 1997, transferred from that entity to Merial as of January 1, 1998, remained continuously employed by Merial through the date he or she transferred employment from Merial to a Legacy Merck Entity and whose transfer to a Legacy Merck Entity occurred between October 1, 2000 and June 1, 2001, is his or her most recent hire date on the Employer's employee data system at a Legacy Merck Entity prior to his or her transfer to Merial. Notwithstanding the foregoing, the most recent hire date for a Legacy Merck Employee who was employed by a Legacy Merck Entity on December 31, 2007, transferred from that entity to PRWT as of January 1, 2008, remained continuously employed by PRWT through September 3, 2010 and who was rehired by a Legacy Merck Entity as of September 3, 2010, is his or her most recent hire date on the Employer’s employee data system at a Legacy Merck Entity prior to his or her transfer to PRWT.”
5.Section 3.1(a) Eligibility of the Plan is hereby amended in its entirety to read as follows: “3.1(a) Eligibility.
(a) An Eligible Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) when he/she experiences a Termination due to Workforce Restructuring; provided, however, that (1) a Legacy Inspire Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) only if he/she experiences a Termination due to Workforce Restructuring on or after May 17, 2013 and (2) a Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc. Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) only if he/she experiences a Termination due to Workforce Restructuring after the date in 2020 as of which he/she first became entitled to benefits under the Plan and which is set forth on Schedule A to the Plan and provided further that in no case shall an eligible Legacy ArQule, Inc. Employee receive benefits under the Plan equal to less than six months of Annul Base Salary. A Grandfathered Legacy Schering Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) if he or she experiences a Grandfathered Legacy Schering Termination. Separation Plan Benefits shall be provided under this Plan to an Eligible Employee who experiences a Termination due to Workforce Restructuring or to a Grandfathered Legacy Schering Employee who experiences a Grandfathered Legacy Schering Termination, in each case only if the Eligible Employee or Grandfathered Legacy Schering Employee has executed and, if a revocation period is applicable, not revoked a Release of Claims in a form satisfactory to the Employer or Parent in its sole and nonreviewable discretion. An Eligible Employee or a Grandfathered Legacy Schering Employee who has executed and, if a revocation period is applicable, not revoked a Release of Claims is a Participant.”
3


6.Schedule A of the Plan is hereby updated to read as follows:
“SCHEDULE A
List of participating Employers:
All U. S. direct and indirect wholly owned subsidiaries of Merck & Co. Inc. excluding the following and their subsidiaries:
Comsort, Inc. (and its subsidiaries)
Merck Global Health Innovation Fund LLC (and its subsidiaries)
HMR Weight Management Services Corp. (and its subsidiaries)
ILUM Health Solutions, LLC (and its subsidiaries)
Peloton Therapeutics, Inc. (and its subsidiaries) for the period of time after the date Peloton Therapeutics, Inc. became a subsidiary of the Company and before January 1, 2020
Effective for the period between June 17, 2020 through October 1, 2020, Quantified Ag. Effective as of October 1, 2020, Quantified Ag became an employer under the Plan.
Effective for the period between April 1, 2019, through July 1, 2020 Antelliq Corporation. Effective as of July 1, 2020, Antelliq Corporation became an employer under the Plan.
Effective for the period between January 1, 2020, through January 31, 2020 ArQule, Inc. Effective as of February 1, 2020, ArQule, Inc. became an employer under the Plan.”
IN WITNESS WHEREOF, the Merck & Co, Inc. Oversight Committee has caused this Amendment 2020-2 of the Merck & Co., Inc. U.S. Separation Benefits Plan (Amended and Restated as of January 1, 2019) (the “Plan”); to be executed as of the 10th day of December, 2020.
By
picture1.jpg
Michael Arseneault
Exec. Dir., Managing Counsel Global Compensation & Employee Benefits/Merck Office of General Counsel
4


AMENDMENT 2021-1 TO THE
MERCK & CO., INC., U.S. SEPARATION BENEFITS PLAN
(Amended and Restated as of January 1, 2019)
WHEREAS, Merck & Co, Inc. (the “Company”), a subsidiary of Merck & Co., Inc. (“Merck”), sponsors the Merck & Co., Inc., U.S. Separation Benefits Plan (Amended and Restated as of January 1, 2019) (the “Plan”);
WHEREAS, pursuant to Article 8.1 of the Plan, the Company (or its duly authorized representative) has reserved the right to amend or terminate the Plan at any time;
WHEREAS, pursuant to the grant of authority of Merck’s Chief Executive Officer, the Company has delegated the authority to amend the Plan to the Merck & Co., Inc. Executive Oversight Committee (the “Executive Committee”) in accordance with its charter;
WHEREAS, in accordance with its charter the Executive Committee has delegated to the Merck & Co., Inc. Oversight Committee (the “Committee”) the authority to make certain amendments to the Plan in accordance with the charter of the Committee; and
WHEREAS, the Committee desires to ratify and adopt the amendment to the Plan described herein.
NOW, THEREFORE, an amendment to the Plan be and hereby is ratified and adopted and is incorporated as follows:
1.A new definition of Legacy Pandion Employee is hereby added to the Plan’s Article II in the correct alphabetical order to read as follows:
Legacy Pandion Employee” means an Eligible Employee who was formerly an employee of Pandion Therapeutics, Inc. who became an employee of Merck & Co, Inc. or one of its subsidiaries in 2021 and continues to be employed by such entity until his/her Separation Date, and as of his/her Separation Date is employed by an Employer.”
2.Section 2.9 “Complete Years of Continuous Service” of the Plan is hereby amended in its entirety to read as follows:
“2.9 “Complete Years of Continuous Service” means (a) for a Legacy Schering Employee, a year from the Participant’s Most Recent Hire Date with a Legacy Schering Entity to its anniversary, and thereafter from each anniversary to the next, (b) for a Legacy Merck Employee, a year from the Participant's Most Recent Hire Date with a Legacy Merck Entity to its anniversary, and thereafter from each anniversary to the next, (c) for a Legacy Inspire Employee, a year from the Participant’s Most Recent Hire Date with a Merck Entity to its anniversary, and thereafter from each anniversary to the next, (d) for a Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc., Employee a year from the Participant’s Most Recent Hire Date with a Merck Entity to its anniversary, and thereafter from each anniversary to the next, (e) for a Legacy Pandion Employee a year from the Participant’s Most Recent Hire Date with a Merck Entity to its anniversary, and thereafter



from each anniversary to the next, and (f) for a Non-Legacy Company Employee, from the Participant’s Most Recent Hire Date with a Merck Entity, and thereafter from each anniversary to the next.”
3.Section 2.10 “Continuous Service” of the Plan is hereby amended in its entirety to read as follows:
2.10 “Continuous Service” means (a) for a Legacy Schering Employee, the period of a Participant's continuous employment with a Legacy Schering Entity commencing on the Participant's Most Recent Hire Date with a Legacy Schering Entity and ending on the Separation Date as reflected on the Employer’s employee database, (b) for a Legacy Merck Employee, the period of a Participant's continuous employment with a Legacy Merck Entity commencing on the Participant's Most Recent Hire Date with a Legacy Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database, (c) for a Legacy Inspire Employee, the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database, (d) for a Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc. Employee the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database, (d) for a Legacy Pandion Employee the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database, and (f) for a Non-Legacy Company Employee, the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database. For the avoidance of doubt, service prior to November 4, 2009 by a Legacy Schering Employee with a Legacy Merck Entity or a Legacy Merck Employee with a Legacy Schering Entity is excluded from “Continuous Service.” Notwithstanding anything contained in this Plan to the contrary, employment with a Legacy Schering Entity, Legacy Merck Entity or a Merck Entity as an Excluded Person does not count as "Continuous Service."
4.Section 2.27 “Most Recent Hire Date” of the Plan is hereby amended in its entirety to read as follows:
“2.27 Most Recent Hire Date” means (a) for a Legacy Schering Employee, his or her most recent hire date at a Legacy Schering Entity or an entity acquired by a Legacy Schering Entity as reflected on the Employer’s employee data system, (b) for a Legacy Merck Employee, his or her most recent hire date at a Legacy Merck Entity or an entity acquired by a Legacy Merck Entity as reflected on the Employer’s employee data system, (c) for a Legacy Inspire Employee, his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer’s employee data system, (d) for a Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc. Employee his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected
2


on the Employer’s employee data system, (d) for a Legacy Pandion Employee his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer’s employee data system, and (e) for a Non-Legacy Company Employee, his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer’s employee data system. Notwithstanding the foregoing, the most recent hire date for a Legacy Merck Employee who was employed by a Legacy Merck Entity on December 31, 1997, transferred from that entity to Merial as of January 1, 1998, remained continuously employed by Merial through the date he or she transferred employment from Merial to a Legacy Merck Entity and whose transfer to a Legacy Merck Entity occurred between October 1, 2000 and June 1, 2001, is his or her most recent hire date on the Employer's employee data system at a Legacy Merck Entity prior to his or her transfer to Merial. Notwithstanding the foregoing, the most recent hire date for a Legacy Merck Employee who was employed by a Legacy Merck Entity on December 31, 2007, transferred from that entity to PRWT as of January 1, 2008, remained continuously employed by PRWT through September 3, 2010 and who was rehired by a Legacy Merck Entity as of September 3, 2010, is his or her most recent hire date on the Employer’s employee data system at a Legacy Merck Entity prior to his or her transfer to PRWT.”
5.Section 3.1(a) Eligibility of the Plan is hereby amended in its entirety to read as follows: “3.1(a) Eligibility.
(a)An Eligible Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) when he/she experiences a Termination due to Workforce Restructuring; provided, however, that (1) a Legacy Inspire Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) only if he/she experiences a Termination due to Workforce Restructuring on or after May 17, 2013, (2) a Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc. Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) only if he/she experiences a Termination due to Workforce Restructuring after the date in 2020 as of which he/she first became entitled to benefits under the Plan and which is set forth on Schedule A to the Plan and provided further that in no case shall an eligible Legacy ArQule, Inc. Employee receive benefits under the Plan equal to less than six months of Annual Base Salary, and (3) a Legacy Pandion Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) only if he/she experiences a Termination due to Workforce Restructuring after the date in 2021 as of which he/she first became entitled to benefits under the Plan and which is set forth on Schedule A to the Plan and provided further that in the case of a Termination due to Workforce Restructuring that occurs on or before April 1, 2022 (i) an eligible Legacy Pandion Employee shall receive benefits under the Plan equal to no less than 26 weeks of Annual Base Salary and (ii) notwithstanding the foregoing clause (iii), the two individuals specified in Section 7.1(a) of the Company Disclosure Letter to the Agreement and Plan of Merger, dated as of February 24, 2021 among Merck Sharp & Dohme Corp., Panama Merger Sub, Inc. and Pandion Therapeutics, Inc. shall receive benefits under the Plan equal to no less than 39 weeks of Annual Base Salary if and only if such individuals otherwise qualify as eligible Legacy Pandion Employees. A Grandfathered Legacy Schering Employee will be
3


eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) if he or she experiences a Grandfathered Legacy Schering Termination. Separation Plan Benefits shall be provided under this Plan to an Eligible Employee who experiences a Termination due to Workforce Restructuring or to a Grandfathered Legacy Schering Employee who experiences a Grandfathered Legacy Schering Termination, in each case only if the Eligible Employee or Grandfathered Legacy Schering Employee has executed and, if a revocation period is applicable, not revoked a Release of Claims in a form satisfactory to the Employer or Parent in its sole and nonreviewable discretion. An Eligible Employee or a Grandfathered Legacy Schering Employee who has executed and, if a revocation period is applicable, not revoked a Release of Claims is a Participant.”
6.IN WITNESS WHEREOF, the Merck & Co, Inc. Oversight Committee has caused this Amendment 2021-1 of the Merck & Co., Inc., U.S. Separation Benefits Plan (Amended and Restated as of January 1, 2019) (the “Plan”); to be executed as of the 31st day of March, 2021.
By
picture1.jpg
Michael Arseneault
Exec. Dir., Managing Counsel Global Compensation & Employee Benefits/Merck Office of General Counsel
4


AMENDMENT 2021-2
TO THE
MERCK & CO., INC., U.S. SEPARATION BENEFITS PLAN
(Amended and Restated as of January 1, 2019)
WHEREAS, Merck & Co, Inc. (the “Company”), a subsidiary of Merck & Co., Inc. (“Merck”), sponsors the Merck & Co., Inc., U.S. Separation Benefits Plan (Amended and Restated as of January 1, 2019) (the “Plan”);
WHEREAS, pursuant to Article 8.1 of the Plan, the Company (or its duly authorized representative) has reserved the right to amend or terminate the Plan at any time;
WHEREAS, pursuant to the grant of authority of Merck’s Chief Executive Officer, the Company has delegated the authority to amend the Plan to the Merck & Co., Inc. Executive Oversight Committee (the “Executive Committee”) in accordance with its charter;
WHEREAS, in accordance with its charter the Executive Committee has delegated to the Merck & Co., Inc. Oversight Committee (the “Committee”) the authority to make certain amendments to the Plan in accordance with the charter of the Committee; and
WHEREAS, the Committee desires to ratify and adopt the amendment to the Plan described herein.
NOW, THEREFORE, an amendment to the Plan be and hereby is ratified and adopted and is incorporated as follows:
1.A new definition of Legacy Pandion Employee is hereby added to the Plan’s Article II in the correct alphabetical order to read as follows:
Legacy IdentiGEN Employee” means an Eligible Employee who was formerly an employee of IdentiGEN who became an employee of Merck & Co, Inc. or one of its subsidiaries in 2020 and continues to be employed by such entity until his/her Separation Date, and as of his/her Separation Date is employed by an Employer.”
2.Section 2.9 “Complete Years of Continuous Service” of the Plan is hereby amended in its entirety to read as follows:
“2.9 “Complete Years of Continuous Service” means (a) for a Legacy Schering Employee, a year from the Participant’s Most Recent Hire Date with a Legacy Schering Entity to its anniversary, and thereafter from each anniversary to the next, (b) for a Legacy Merck Employee, a year from the Participant's Most Recent Hire Date with a Legacy Merck Entity to its anniversary, and thereafter from each anniversary to the next, (c) for a Legacy Inspire Employee, a year from the Participant’s Most Recent Hire Date with a Merck Entity to its anniversary, and thereafter from each anniversary to the next, (d) for a Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc., Employee a year from the Participant’s Most Recent Hire Date with a Merck Entity to its anniversary, and thereafter from each anniversary to the next, (e) for a Legacy Pandion Employee a year from the Participant’s Most Recent Hire Date with a Merck Entity to its anniversary, and thereafter from each anniversary to the next, (f) for a Legacy IdentiGEN Employee a year from the
5


Participant’s Most Recent Hire Date with a Merck Entity to its anniversary, and thereafter from each anniversary to the next, and (g) for a Non-Legacy Company Employee, from the Participant’s Most Recent Hire Date with a Merck Entity, and thereafter from each anniversary to the next.”
3.Section 2.10 “Continuous Service” of the Plan is hereby amended in its entirety to read as follows:
2.10 “Continuous Service” means (a) for a Legacy Schering Employee, the period of a Participant's continuous employment with a Legacy Schering Entity commencing on the Participant's Most Recent Hire Date with a Legacy Schering Entity and ending on the Separation Date as reflected on the Employer’s employee database, (b) for a Legacy Merck Employee, the period of a Participant's continuous employment with a Legacy Merck Entity commencing on the Participant's Most Recent Hire Date with a Legacy Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database, (c) for a Legacy Inspire Employee, the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database, (d) for a Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc. Employee the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database, (d) for a Legacy Pandion Employee the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database, (e) for a Legacy IdentiGEN Employee the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database, and (f) for a Non-Legacy Company Employee, the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database. For the avoidance of doubt, service prior to November 4, 2009 by a Legacy Schering Employee with a Legacy Merck Entity or a Legacy Merck Employee with a Legacy Schering Entity is excluded from “Continuous Service.” Notwithstanding anything contained in this Plan to the contrary, employment with a Legacy Schering Entity, Legacy Merck Entity or a Merck Entity as an Excluded Person does not count as "Continuous Service."
4.Section 2.27 “Most Recent Hire Date” of the Plan is hereby amended in its entirety to read as follows:
“2.27 Most Recent Hire Date” means (a) for a Legacy Schering Employee, his or her most recent hire date at a Legacy Schering Entity or an entity acquired by a Legacy Schering Entity as reflected on the Employer’s employee data system, (b) for a Legacy Merck Employee, his or her most recent hire date at a Legacy Merck Entity or an entity acquired by a Legacy Merck Entity as reflected on the Employer’s employee data system, (c)or a Legacy Inspire Employee, his or her most recent hire date at a Merck Entity or an entity acquired by
6


a Merck Entity as reflected on the Employer’s employee data system, (d) for a Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc. Employee his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer’s employee data system, (d) for a Legacy Pandion Employee his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer’s employee data system, (e) for a Legacy IdentiGEN Employee his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer’s employee data system and (f) for a Non-Legacy Company Employee his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer’s employee data system. Notwithstanding the foregoing, the most recent hire date for a Legacy Merck Employee who was employed by a Legacy Merck Entity on December 31, 1997, transferred from that entity to Merial as of January 1, 1998,remained continuously employed by Merial through the date he or she transferred employment from Merial to a Legacy Merck Entity and whose transfer to a Legacy Merck Entity occurred between October 1, 2000 and June 1, 2001, is his or her most recent hire date on the Employer's employee data system at a Legacy Merck Entity prior to his or her transfer to Merial. Notwithstanding the foregoing, the most recent hire date for a Legacy Merck Employee who was employed by a Legacy Merck Entity on December 31, 2007, transferred from that entity to PRWT as of January 1, 2008, remained continuously employed by PRWT through September 3, 2010 and who was rehired by a Legacy Merck Entity as of September 3, 2010, is his or her most recent hire date on the Employer’s employee data system at a Legacy Merck Entity prior to his or her transfer to PRWT.”
5.Section 3.1(a) Eligibility of the Plan is hereby amended in its entirety to read as follows: “3.1(a) Eligibility.
(a) An Eligible Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) when he/she experiences a Termination due to Workforce Restructuring; provided, however, that (1) a Legacy Inspire Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) only if he/she experiences a Termination due to Workforce Restructuring on or after May 17, 2013, (2) a Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc. Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) only if he/she experiences a Termination due to Workforce Restructuring after the date in 2020 as of which he/she first became entitled to benefits under the Plan and which is set forth on Schedule A to the Plan and provided further that in no case shall an eligible Legacy ArQule, Inc. Employee receive benefits under the Plan equal to less than six months of Annual Base Salary, (3) a Legacy Pandion Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) only if he/she experiences a Termination due to Workforce Restructuring after the date in 2021 as of which he/she first became entitled to benefits under the Plan and which is set forth on Schedule A to the Plan and provided further that in the case of a Termination due to Workforce Restructuring that occurs on or before April 1, 2022 (i) an eligible Legacy Pandion Employee shall receive benefits under the Plan equal to no less than 26 weeks of Annual Base Salary and (ii) notwithstanding the foregoing clause (iii), the two individuals specified in Section 7.1(a) of the Company
7


Disclosure Letter to the Agreement and Plan of Merger, dated as of February 24, 2021 among Merck Sharp & Dohme Corp., Panama Merger Sub, Inc. and Pandion Therapeutics, Inc. shall receive benefits under the Plan equal to no less than 39 weeks of Annual Base Salary if and only if such individuals otherwise qualify as eligible Legacy Pandion Employees, and (4) a Legacy IdentiGEN Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) only if he/she experiences a Termination due to Workforce Restructuring after the date in 2021 as of which he/she first became entitled to benefits under the Plan and which is set forth on Schedule A to the Plan A Grandfathered Legacy Schering Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) if he or she experiences a Grandfathered Legacy Schering Termination. Separation Plan Benefits shall be provided under this Plan to an Eligible Employee who experiences a Termination due to Workforce Restructuring or to a Grandfathered Legacy Schering Employee who experiences a Grandfathered Legacy Schering Termination, in each case only if the Eligible Employee or Grandfathered Legacy Schering Employee has executed and, if a revocation period is applicable, not revoked a Release of Claims in a form satisfactory to the Employer or Parent in its sole and nonreviewable discretion. An Eligible Employee or a Grandfathered Legacy Schering Employee who has executed and, if a revocation period is applicable, not revoked a Release of Claims is a Participant.”
6.Schedule A of the Plan is hereby updated to read as follows:
SCHEDULE A
List of participating Employers:
All U. S. direct and indirect wholly owned subsidiaries of Merck & Co. Inc. excluding the following and their subsidiaries:
Antimicrobial Stewardship, LLC
Merck Global Health Innovation Fund LLC (and its subsidiaries)
Peloton Therapeutics, Inc. (and its subsidiaries) for the period of time after the date Peloton Therapeutics, Inc. became a subsidiary of the Company and before January 1, 2020
Effective for the period between June 17, 2020 through September 30, 2020, Quantified Ag. Effective as of October 1, 2020, Quantified Ag became an employer under the Plan.
Effective for the period between April 1, 2019, through June 30, 2020 Antelliq Corporation. Effective as of July 1, 2020, Antelliq Corporation became an employer under the Plan.
Effective for the period between January 1, 2020, through January 31, 2020 ArQule, Inc. Effective as of February 1, 2020, ArQule, Inc. became an employer under the Plan.
Effective February 25, 2021, Pandion, Inc. became an employer under the Plan
Effective for the period between August 5, 2020, through December 31, 2021 IdentiGEN Effective as of January 1, 2022, IdentiGEN, Inc. became an employer under the Plan”
8


IN WITNESS WHEREOF, the Merck & Co, Inc. Oversight Committee has caused this Amendment 2021-2 of the Merck & Co., Inc. U.S. Separation Benefits Plan (Amended and Restated as of January 1, 2019)(the “Plan”); to be executed as of the 16th day of December, 2021.
picture1.jpg
By
Michael Arseneault
Exec. Dir., Managing Counsel Global Compensation &
Employee Benefits/Merck Office of General Counsel
9


AMENDMENT NUMBER 2022-1 TO
MERCK & CO. INC. U.S. SEPARATION BENEFITS PLAN
As Amended and Restated effective January 1, 2013
The Merck & Co., Inc. U.S. Separation Benefits Plan (the Plan) is hereby amended effective as of May 1, 2022, as follows:
1.The Preamble of the Plan is hereby amended to insert the following new paragraph after the 3rd paragraph to read as follows:
On May 1, 2022, Merck Sharp & Dohme Corp. converted to a limited liability company named Merck Sharp & Dohme LLC.
2.Section 2.16 of the Plan is amended in its entirety to read as follows:
“’IAM Agreement” means a collective bargaining agreement between Merck Sharp & Dohme LLC or Merck Sharp & Dohme Corp., and District 15, Lodge 315 of the International Association of Machinists and Aerospace Workers.”
3.Section 2.26 of the Plan is amended to add LLC after the words Merck Sharp & Dohme
4.Section 2. 33 of the Plan is amended in its entirety to read as follows:
“Old Merck” means Merck & Co., Inc. prior to November 4, 2009 (subsequently known on and after November 4, 2009 and prior to May 1, 2022 as Merck Sharp & Dohme Corp., and on and after May 1, 2022 as Merck Sharp & Dohme LLC).”
5.Section 3.1 Paragraph #4 of the Plan is amended in its entirety to read as follows:
“#4. notwithstanding the foregoing sub-clause (A), the two individuals specified in Section 7.1(a) of the Company Disclosure Letter to the Agreement and Plan of Merger, dated as of February 24, 2021 among Merck Sharp & Dohme LLC, Panama Merger Sub, Inc. and Pandion Therapeutics, Inc. shall receive benefits under Schedule B-1 of the Plan equal to no less than 39 weeks of Annual Base Salary if and only if such individuals otherwise qualify as eligible Legacy Pandion Employees; and”
6.Schedule A of the Plan is amended in its entirety to read as follows:
“All U. S. direct and indirect wholly owned subsidiaries of Merck & Co., Inc. excluding the following and their subsidiaries:
Comsort Inc. (and its subsidiaries)
Merck Global Health Innovation Fund LLC (and its subsidiaries)
Antimicrobrial Stewardship LLC (and its subsidiaries)
Peloton Therapeutics, Inc. (and its subsidiaries) for the period of time after the date Peloton Therapeutics, Inc. became a subsidiary of the Company and before January 1, 2020



Tilos Therapeutics (and its subsidiaries) for the period of time after the date Tilos Therapeutics became a subsidiary of the Company and before January 1, 2020
Antelliq Corporation (and its subsidiaries) for the period of time after the date Antelliq Corporation became a subsidiary of the Company and before such date in 2020 as of which the Plan Administrator determines Antelliq Corporation shall become an Employer.”
IN WITNESS WHEREOF, the Director, Global Compensation & Employee Benefits, Merck Office of General Counsel on behalf of the Merck & Co, Inc. Oversight Committee has caused this Amendment 2022- 1 of the Plan to be executed as of this 14th day of December, 2022.
By
picture1.jpg
Michael Arseneault
Dir., Global Compensation & Employee Benefits
Merck Office of General Counsel



AMENDMENT 2022-2
TO THE
MERCK & CO., INC., U.S. SEPARATION BENEFITS PLAN
(Amended and Restated as of January 1, 2019)
WHEREAS, Merck & Co, Inc. (the “Company”), a subsidiary of Merck & Co., Inc. (“Merck”), sponsors the Merck & Co., Inc., U.S. Separation Benefits Plan (Amended and Restated as of January 1, 2019) (the “Plan”);
WHEREAS, pursuant to Article 8.1 of the Plan, the Company (or its duly authorized representative) has reserved the right to amend or terminate the Plan at any time;
WHEREAS, pursuant to the grant of authority of Merck’s Chief Executive Officer, the Company has delegated the authority to amend the Plan to the Merck & Co., Inc. Executive Oversight Committee (the “Executive Committee”) in accordance with its charter;
WHEREAS, in accordance with its charter the Executive Committee has delegated to the Merck & Co., Inc. Oversight Committee (the “Committee”) the authority to make certain amendments to the Plan in accordance with the charter of the Committee; and
WHEREAS, the Committee desires to ratify and adopt the amendment to the Plan described herein.
NOW, THEREFORE, an amendment to the Plan be and hereby is ratified and adopted and is incorporated as follows:
1.A new definition of Acceleron Pharma Inc. Employee and Vence employee is hereby added to the Plan’s Article II in the correct alphabetical order to read as follows:
Acceleron Pharma Inc. Employee means an Eligible Employee who was formerly an employee of Acceleron Pharma Inc. who became an employee of Merck & Co, Inc. or one of its subsidiaries in 2021 and continues to be employed by such entity until his/her Separation Date, and as of his/her Separation Date is employed by an Employer.”
Vence Employee means an Eligible Employee who was formerly an employee of Vence who became an employee of Merck & Co, Inc. or one of its subsidiaries in 2022 and continues to be employed by such entity until his/her Separation Date, and as of his/her Separation Date is employed by an Employer.”
2.Section 2.10 “Complete Years of Continuous Service” of the Plan is hereby amended In its entirety to read as follows:
“2.10 “Complete Years of Continuous Service” means (a) for a Legacy Schering Employee, a year from the Participant’s Most Recent Hire Date with a Legacy Schering Entity to its anniversary, and thereafter from each anniversary to the next, (b) for a Legacy Merck Employee, a year from the Participant's Most Recent Hire Date with a Legacy Merck Entity to its anniversary, and thereafter from each anniversary to the next, (c) for a Legacy Inspire Employee, a year from the Participant’s Most Recent Hire Date with a Merck Entity to its anniversary, and thereafter from each anniversary to the next, (d) for a Legacy Quantified Ag, Antelliq Corporation, ArQule, Inc., Pandion Employee, IdentiGEN, Acceleron Pharma Inc. or Vence from the Participant’s Most Recent Hire Date with a Merck Entity, and thereafter from each anniversary to the next and (e) for a Non-Legacy Company



Employee, from the Participant’s Most Recent Hire Date with a Merck Entity, and thereafter from each anniversary to the next.”
3.Section 2.11 “Continuous Service” of the Plan is hereby amended in its entirety to read as follows:
2.11 “Continuous Service” means (a) for a Legacy Schering Employee, the period of a Participant's continuous employment with a Legacy Schering Entity commencing on the Participant's Most Recent Hire Date with a Legacy Schering Entity and ending on the Separation Date as reflected on the Employer’s employee database, (b) for a Legacy Merck Employee, the period of a Participant's continuous employment with a Legacy Merck Entity commencing on the Participant's Most Recent Hire Date with a Legacy Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database, (c) for a Legacy Inspire Employee, the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database, (d) for a Legacy Quantified Ag, Antelliq Corporation, ArQule, Inc., Pandion, IdentiGEN, Acceleron Pharma or Vence Employee, the period of a Participant's continuous employment with a Legacy and Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database, and (e) for a Non-Legacy Company Employee, the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database. For the avoidance of doubt, service prior to November 4, 2009 by a Legacy Schering Employee with a Legacy Merck Entity or a Legacy Merck Employee with a Legacy Schering Entity is excluded from “Continuous Service.” Notwithstanding anything contained in this Plan to the contrary, employment with a Legacy Schering Entity, Legacy Merck Entity or a Merck Entity as an Excluded Person does not count as "Continuous Service."
4.Section 2.29 “Most Recent Hire Date” of the Plan is hereby amended in its entirety to read as follows:
“2.29 Most Recent Hire Date” means (a) for a Legacy Schering Employee, his or her most recent hire date at a Legacy Schering Entity or an entity acquired by a Legacy Schering Entity as reflected on the Employer’s employee data system, (b) for a Legacy Merck Employee, his or her most recent hire date at a Legacy Merck Entity or an entity acquired by a Legacy Merck Entity as reflected on the Employer’s employee data system, (c) for a Legacy Inspire Employee, his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer’s employee data system, (d) for a Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc. Employee his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer’s employee data system, (d) for a Legacy Pandion, IdentiGEN, Acceleron Pharma, Inc. or Vence Employee his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer’s employee data system, and (e) for a Non-Legacy Company Employee, his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer’s employee data system. Notwithstanding the foregoing, the most recent hire date for a Legacy Merck Employee who was employed by a Legacy Merck Entity on December 31, 1997, transferred from that entity to Merial as of January 1, 1998, remained continuously employed by Merial through the date he or she transferred employment from Merial to a Legacy Merck Entity and whose transfer to a Legacy Merck Entity occurred between October 1, 2000 and June 1, 2001, is his or her most recent hire date on the Employer's employee data system at a Legacy Merck Entity prior to his or her transfer to Merial. Notwithstanding the



foregoing, the most recent hire date for a Legacy Merck Employee who was employed by a Legacy Merck Entity on December 31, 2007, transferred from that entity to PRWT as of January 1, 2008, remained continuously employed by PRWT through September 3, 2010 and who was rehired by a Legacy Merck Entity as of September 3, 2010, is his or her most recent hire date on the Employer’s employee data system at a Legacy Merck Entity prior to his or her transfer to PRWT.”
5.    Section 3.1(a) Eligibility of the Plan is hereby amended in its entirety to read as follows: “3.1(a) Eligibility.
(a) An Eligible Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) when he/she experiences a Termination due to Workforce Restructuring; provided, however, that (1) a Legacy Inspire Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) only if he/she experiences a Termination due to Workforce Restructuring on or after May 17, 2013, (2) a Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc. Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) only if he/she experiences a Termination due to Workforce Restructuring after the date in 2020 as of which he/she first became entitled to benefits under the Plan and which is set forth on Schedule A to the Plan and provided further that in no case shall an eligible Legacy ArQule, Inc. Employee receive benefits under the Plan equal to less than six months of Annual Base Salary, (3) a Legacy Pandion, IdentiGEN, Acceleron or Vence Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) only if he/she experiences a Termination due to Workforce Restructuring after the date as of which he/she first became entitled to benefits under the Plan and which is set forth on Schedule A to the Plan and provided further that in the case of a Termination due to Workforce Restructuring that occurs on or before April 1, 2022 (i) an eligible Legacy Pandion Employee shall receive benefits under the Plan equal to no less than 26 weeks of Annual Base Salary and (ii) notwithstanding the foregoing clause (iii), the two individuals specified in Section 7.1(a) of the Company Disclosure Letter to the Agreement and Plan of Merger, dated as of February 24, 2021 among Merck Sharp & Dohme Corp., Panama Merger Sub, Inc. and Pandion Therapeutics, Inc. shall receive benefits under the Plan equal to no less than 39 weeks of Annual Base Salary if and only if such individuals otherwise qualify as eligible Legacy Pandion Employees, and (4) a Legacy IdentiGEN Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) only if he/she experiences a Termination due to Workforce Restructuring after the date in 2021 as of which he/she first became entitled to benefits under the Plan and which is set forth on Schedule A to the Plan A Grandfathered Legacy Schering Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) if he or she experiences a Grandfathered Legacy Schering Termination. Separation Plan Benefits shall be provided under this Plan to an Eligible Employee who experiences a Termination due to Workforce Restructuring or to a Grandfathered Legacy Schering Employee who experiences a Grandfathered Legacy Schering Termination, in each case only if the Eligible Employee or Grandfathered Legacy Schering Employee has executed and, if a revocation period is applicable, not revoked a Release of Claims in a form satisfactory to the Employer or Parent in its sole and nonreviewable discretion. An Eligible Employee or a Grandfathered Legacy Schering Employee who has executed and, if a revocation period is applicable, not revoked a Release of Claims is a Participant.”



6.Schedule A of the Plan is hereby updated to read as follows:
“SCHEDULE A
List of participating Employers:
All U. S. direct and indirect wholly owned subsidiaries of Merck & Co. Inc. excluding the following and their subsidiaries:
Antimicrobial Stewardship, LLC
Merck Global Health Innovation Fund LLC (and its subsidiaries)
Peloton Therapeutics, Inc. (and its subsidiaries) for the period of time after the date Peloton Therapeutics, Inc. became a subsidiary of the Company and before January 1, 2020
Effective for the period between June 17, 2020 through September 30, 2020, Quantified Ag. Effective as of October 1, 2020, Quantified Ag became an employer under the Plan.
Effective for the period between April 1, 2019, through June 30, 2020 Antelliq Corporation. Effective as of July 1, 2020, Antelliq Corporation became an employer under the Plan.
Effective for the period between January 1, 2020, through January 31, 2020 ArQule, Inc. Effective as of February 1, 2020, ArQule, Inc. became an employer under the Plan.
Effective February 25, 2021, Pandion, Inc. became an employer under the Plan
Effective for the period between August 5, 2020, through December 31, 2021 IdentiGEN Effective as of January 1, 2022, IdentiGEN, Inc. became an employer under the Plan
Effective as of November 19, 2022, Acceleron Pharma Inc. became an employer under the Plan
Effective January 1, 2023, Vence shall become and employer under the Plan”
IN WITNESS WHEREOF, the Merck & Co, Inc. Oversight Committee has caused this Amendment 2022-2 of the Merck & Co., Inc. U.S. Separation Benefits Plan (Amended and Restated as of January 1, 2019)(the “Plan”); to be executed as of the 13th day of December, 2021
picture1.jpg
By
Michael Arseneault
Counsel, Global Compensation & Employee Benefits/Merck Office of General Counsel



AMENDMENT 2023-1
TO THE
MERCK & CO., INC. U.S. SEPARATION BENEFITS PLAN
(Amended and Restated as of January 1, 2019)
WHEREAS, Merck Sharp & Dohme LLC (the “Company”), a subsidiary of Merck & Co., Inc. (“Merck”), sponsors the Merck & Co., Inc. U.S. Separation Benefits Plan (Amended and Restated as of January 1, 2019) (the “Plan”);
WHEREAS, pursuant to Article 8.1 of the Plan, the Company (or its duly authorized representative) has reserved the right to amend or terminate the Plan at any time;
WHEREAS, pursuant to the grant of authority of Merck’s Chief Executive Officer, the Company has delegated the authority to amend the Plan to the Merck & Co., Inc. Executive Oversight Committee (the “Executive Committee”) in accordance with its charter;
WHEREAS, in accordance with its charter the Executive Committee has delegated to the Merck & Co., Inc. Oversight Committee (the “Committee”) the authority to make certain amendments to the Plan in accordance with the charter of the Committee; and
WHEREAS, the Committee desires to amend the Plan to provide that: (i) Imago BioSciences, Inc. is not a participating Employer under the Plan, effective as of January 11, 2023; (ii) Prometheus Biosciences, Inc. (“Prometheus”) will become a participating Employer under the Plan 18 months after the closing of the merger between Merck and Prometheus, effective as of December 17, 2024; and (iii) to make certain clarifying changes.
NOW, THEREFORE, the Plan is hereby amended, effective as of the dates set forth herein, as follows:
1.Section 2.10 of the Plan (“Complete Years of Continuous Service”) is hereby amended in its entirety, effective as of December 17, 2024, to read as follows:
“2.10 “Complete Years of Continuous Servicemeans (a) for a Legacy Schering Employee, a year from the Participant’s Most Recent Hire Date with a Legacy Schering Entity to its anniversary, and thereafter from each anniversary to the next, (b) for a Legacy Merck Employee, a year from the Participant’s Most Recent Hire Date with a Legacy Merck Entity to its anniversary, and thereafter from each anniversary to the next, (c) for a Legacy Inspire Employee, a year from the Participant’s Most Recent Hire Date with a Merck Entity to its anniversary, and thereafter from each anniversary to the next, (d) for a Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc. Employee, Legacy Pandion Employee, Legacy IdentiGEN Employee, Acceleron Pharma Inc. Employee, Vence Employee or Prometheus Biosciences, Inc. Employee from the Participant’s Most Recent Hire Date with a Merck Entity, and thereafter from each anniversary to the next, and (e) for a Non-Legacy Company Employee, from the Participant’s Most Recent Hire Date with a Merck Entity, and thereafter from each anniversary to the next.”
2.Section 2.11 of the Plan (“Continuous Service”) is hereby amended in its entirety, effective as of December 17, 2024, to read as follows:
2.11     “Continuous Servicemeans (a) for a Legacy Schering Employee, the period of a Participant's continuous employment with a Legacy Schering Entity commencing on the Participant's Most Recent Hire Date with a Legacy Schering Entity and ending on the Separation



Date as reflected on the Employer’s employee database, (b) for a Legacy Merck Employee, the period of a Participant's continuous employment with a Legacy Merck Entity commencing on the Participant's Most Recent Hire Date with a Legacy Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database, (c) for a Legacy Inspire Employee, the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database, (d) for a Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc. Employee, Legacy Pandion Employee, Legacy IdentiGEN Employee, Acceleron Pharma Inc. Employee, Vence Employee or Prometheus Biosciences, Inc. Employee, the period of a Participant’s continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database, and (e) for a Non-Legacy Company Employee, the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database. For the avoidance of doubt, service prior to November 4, 2009 by a Legacy Schering Employee with a Legacy Merck Entity or a Legacy Merck Employee with a Legacy Schering Entity is excluded from “Continuous Service.” Notwithstanding anything contained in this Plan to the contrary, employment with a Legacy Schering Entity, Legacy Merck Entity or a Merck Entity as an Excluded Person does not count as "Continuous Service."
3.Section 2.31 of the Plan (“Most Recent Hire Date”) is hereby amended in its entirety, effective as of December 17, 2024, to read as follows:
“2.31     “Most Recent Hire Datemeans (a) for a Legacy Schering Employee, his or her most recent hire date at a Legacy Schering Entity or an entity acquired by a Legacy Schering Entity as reflected on the Employer’s employee data system, (b) for a Legacy Merck Employee, his or her most recent hire date at a Legacy Merck Entity or an entity acquired by a Legacy Merck Entity as reflected on the Employer’s employee data system, (c) for a Legacy Inspire Employee, his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer’s employee data system, (d) for a Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc. Employee, Legacy Pandion Employee, Legacy IdentiGen Employee, Acceleron Pharma, Inc. Employee, Vence Employee or Prometheus Bioscience, Inc. Employee, his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer’s employee data system, and (e) for a Non-Legacy Company Employee, his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer’s employee data system. Notwithstanding the foregoing, the most recent hire date for a Legacy Merck Employee who was employed by a Legacy Merck Entity on December 31, 1997, transferred from that entity to Merial as of January 1, 1998, remained continuously employed by Merial through the date he or she transferred employment from Merial to a Legacy Merck Entity and whose transfer to a Legacy Merck Entity occurred between October 1, 2000 and June 1, 2001, is his or her most recent hire date on the Employer's employee data system at a Legacy Merck Entity prior to his or her transfer to Merial. Notwithstanding the foregoing, the most recent hire date for a Legacy Merck Employee who was employed by a Legacy Merck Entity on December 31, 2007, transferred from that entity to PRWT as of January 1, 2008, remained continuously employed by PRWT through September 3, 2010 and who was rehired by a Legacy Merck Entity as of September 3, 2010, is his or her most recent hire date on the Employer’s employee data system at a Legacy Merck Entity prior to his or her transfer to PRWT.”



4.Section II of the Plan (“Definitions”) is hereby amended, effective as of December 17, 2024, to add a new definition of “Prometheus Biosciences, Inc. Employee,” in the correct alphabetical order, to read as follows:
2.42    Prometheus Biosciences, Inc. Employee means an Eligible Employee who was formerly an employee of Prometheus Biosciences, Inc. who became an employee of Merck & Co., Inc. or one of its subsidiaries in 2023 and continues to be employed by such entity until his/her Separation Date, and as of his/her Separation Date is employed by an Employer.”
5.Section 3.1(a) of the Plan (“Eligibility”) is hereby amended in its entirety, effective as of December 17, 2024, to read as follows:
3.1    Eligibility.
(a)    An Eligible Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) when he/she experiences a Termination due to Workforce Restructuring; provided, however, that:
(i)     a Legacy Inspire Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) only if he/she experiences a Termination due to Workforce Restructuring on or after May 17, 2013,
(ii)     a Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc. Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) only if he/she experiences a Termination due to Workforce Restructuring after the date in 2020 as of which he/she first became entitled to benefits under the Plan and which is set forth on Schedule A to the Plan and provided further that in no case shall an eligible Legacy ArQule, Inc. Employee receive benefits under the Plan equal to less than six months of Annual Base Salary,
(iii)     a Legacy Pandion Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) only if he/she experiences a Termination due to Workforce Restructuring after the date in 2021 as of which he/she first became entitled for benefits under the Plan and which is set forth on Schedule A to the Plan and provided further that in the case of a Termination due to Workforce Restructuring that occurs on or before April 1, 2022 (i) an eligible Legacy Pandion Employee shall receive benefits under the Plan equal to no less than 26 weeks of Annual Base Salary and (ii) notwithstanding the foregoing sub-clause (i), the two individuals specified in Section 7.1(a) of the Company Disclosure Letter to the Agreement and Plan of Merger, dated as of February 24, 2021 among Merck Sharp & Dohme LLC, Panama Merger Sub, Inc. and Pandion Therapeutics, Inc. shall receive benefits under Schedule B-1 of the Plan equal to no less than 39 weeks of Annual Base Salary if and only if such individuals otherwise qualify as eligible Legacy Pandion Employees, and
(iii)     a Legacy IdentiGEN Employee, Acceleron Pharma Inc. Employee, Vence Employee and Prometheus Biosciences, Inc. Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) only if he/she experiences a Termination due to Workforce Restructuring after the date as of which he/she first became eligible for benefits under the Plan and which is set forth on Schedule A to the Plan.
A Grandfathered Legacy Schering Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) if he or she experiences a Grandfathered Legacy Schering Termination.



Separation Plan Benefits shall be provided under this Plan to an Eligible Employee who experiences a Termination due to Workforce Restructuring or to a Grandfathered Legacy Schering Employee who experiences a Grandfathered Legacy Schering Termination, in each case only if the Eligible Employee or Grandfathered Legacy Schering Employee has executed and, if a revocation period is applicable, not revoked a Release of Claims in a form satisfactory to the Employer or Parent in its sole and nonreviewable discretion. An Eligible Employee or a Grandfathered Legacy Schering Employee who has executed and, if a revocation period is applicable, not revoked a Release of Claims is a Participant.”
6.Schedule A of the Plan (“List of participating Employers”) is hereby amended in its entirety, effective as of January 1, 2023, to read as follows:
“SCHEDULE A
List of participating Employers:
All U.S. direct and indirect wholly owned subsidiaries of Merck & Co., Inc. excluding the following and their subsidiaries:
Antimicrobial Stewardship, LLC
Merck Global Health Innovation Fund LLC (and its subsidiaries)
Peloton Therapeutics, Inc. (and its subsidiaries) for the period of time after the date Peloton Therapeutics, Inc. became a subsidiary of the Company and before January 1, 2020
Effective for the period between June 17, 2020 and September 30, 2020, Quantified Ag. Effective as of October 1, 2020, Quantified Ag became an Employer under the Plan.
Effective for the period between April 1, 2019 and June 30, 2020, Antelliq Corporation. Effective as of July 1, 2020, Antelliq Corporation became an Employer under the Plan.
Effective for the period between January 1, 2020 and January 31, 2020, ArQule, Inc. Effective as of February 1, 2020, ArQule, Inc. became an Employer under the Plan.
Effective February 25, 2021, Pandion, Inc. became an Employer under the Plan
Effective for the period between August 5, 2020 and December 31, 2021, IdentiGEN, Inc. Effective as of January 1, 2022, IdentiGEN, Inc. became an Employer under the Plan
Effective as of November 19, 2022, Acceleron Pharma Inc. became an Employer under the Plan
Effective as of January 1, 2023, Vence Corp. become an Employer under the Plan
Effective as of January 11, 2023, Imago BioSciences, Inc.
Effective for the period between June 16, 2023 and December 16, 2024, Prometheus Biosciences, Inc. Effective as of December 17, 2024, Prometheus Biosciences, Inc. will become a participating Employer under the Plan”
IN WITNESS WHEREOF, the Merck & Co., Inc. Oversight Committee approved this Amendment 2023-1 of the Merck & Co., Inc. U.S. Separation Benefits Plan as of the 15th day of December, 2023.
image_6.jpg
By
Thea Davis
Executive Director, Managing Counsel –
Global Compensation & Employee Benefits
Merck Office of General Counsel



AMENDMENT 2024-1
TO THE
MERCK & CO., INC. U.S. SEPARATION BENEFITS PLAN
(Amended and Restated as of January 1, 2019)
WHEREAS, Merck Sharp & Dohme LLC (the “Company”), a subsidiary of Merck & Co., Inc. (“Merck”), sponsors the Merck & Co., Inc. U.S. Separation Benefits Plan (Amended and Restated as of January 1, 2019) (the “Plan”);
WHEREAS, pursuant to Article 8.1 of the Plan, the Company (or its duly authorized representative) has reserved the right to amend or terminate the Plan at any time;
WHEREAS, pursuant to the grant of authority of Merck’s Chief Executive Officer, the Company has delegated the authority to amend the Plan to the Merck & Co., Inc. Executive Oversight Committee (the “Executive Committee”) in accordance with its charter;
WHEREAS, in accordance with its charter the Executive Committee has delegated to the Merck & Co., Inc. Oversight Committee (the “Committee”) the authority to make certain amendments to the Plan in accordance with the charter of the Committee; and
WHEREAS, the Committee desires to amend the Plan to provide that Caraway Therapeutics, Inc. is not a participating Employer under the Plan.
NOW, THEREFORE, the Plan is hereby amended, effective as of the dates set forth herein, as follows:
1.Schedule A of the Plan (“List of participating Employers”) is hereby amended in its entirety to read as follows:
“SCHEDULE A
List of participating Employers:
All U.S. direct and indirect wholly owned subsidiaries of Merck & Co., Inc. excluding the following and their subsidiaries:
Antimicrobial Stewardship, LLC
Merck Global Health Innovation Fund LLC (and its subsidiaries)
Peloton Therapeutics, Inc. (and its subsidiaries) for the period of time after the date Peloton Therapeutics, Inc. became a subsidiary of the Company and before January 1, 2020
Effective for the period between June 17, 2020 and September 30, 2020, Quantified Ag. Effective as of October 1, 2020, Quantified Ag became an Employer under the Plan.
Effective for the period between April 1, 2019 and June 30, 2020, Antelliq Corporation. Effective as of July 1, 2020, Antelliq Corporation became an Employer under the Plan.
Effective for the period between January 1, 2020 and January 31, 2020, ArQule, Inc. Effective as of February 1, 2020, ArQule, Inc. became an Employer under the Plan.
Effective February 25, 2021, Pandion, Inc. became an Employer under the Plan
Effective for the period between August 5, 2020 and December 31, 2021, IdentiGEN, Inc. Effective as of January 1, 2022, IdentiGEN, Inc. became an Employer under the Plan
Effective as of November 19, 2022, Acceleron Pharma Inc. became an Employer under the Plan
Effective as of January 1, 2023, Vence Corp. become an Employer under the Plan



Effective as of January 11, 2023, Imago BioSciences, Inc.
Effective for the period between June 16, 2023 and December 16, 2024, Prometheus Biosciences, Inc. Effective as of December 17, 2024, Prometheus Biosciences, Inc. will become a participating Employer under the Plan
Effective as of November 20, 2023, Caraway Therapeutics, Inc.
IN WITNESS WHEREOF, the Merck & Co., Inc. Oversight Committee approved this Amendment 2024-1 of the Merck & Co., Inc. U.S. Separation Benefits Plan as of the 22th day of October, 2024.
image_6.jpg
By
Thea Davis
Executive Director, Managing Counsel –
Global Compensation & Employee Benefits
Merck Office of General Counsel

EX-10.31 5 exh1031-2024annualrsuterms.htm EX-10.31 2024 ANNUAL RSU TERMS & CONDITIONS Document

GLOBAL TERMS AND CONDITIONS
2024 RESTRICTED STOCK UNIT GRANTS
UNDER THE MERCK & CO., INC. 2019 INCENTIVE STOCK PLAN
I.GENERAL. Merck & Co., Inc. (the “Company”) has granted to you the Restricted Stock Unit (“RSU”) award specified in this document (“RSU Award”) pursuant to the Merck & Co., Inc. 2019 Incentive Stock Plan, including any sub-plan thereto for your country (the “Plan”). This RSU Award is subject to the terms and conditions of the Plan and these Global Terms and Conditions, including any additional terms and conditions for your country in Appendix B (the “Terms”). Unless otherwise defined in this document, capitalized terms used in these Terms are as defined in the Plan.
Grant Type:RSU - Annual
Grant Date:
April 30, 2024
Vesting DatesPortion that Vests
April 30, 2025First:    33.333%
April 30, 2026Second:    33.333%
April 30, 2027Third:    Balance
IMPORTANT NOTICE: This grant requires you to affirmatively accept it. You MUST log onto the Morgan Stanley website at (http://www.morganstanley.com/spc/knowledge/managing-equity/managing-your-existing-awards/accepting-awards-grants/) to accept the grant.
Follow the procedures described on the Morgan Stanley website to accept your RSU Award within 90 days. Failure to accept the terms and conditions of your RSU Award within 90 days may result in Forfeiture of the RSU Award.
A.Restricted (Vesting) Period. The Restricted Period is the period during which this RSU Award is subject to forfeiture and is eligible to vest. The RSU Award will vest with respect to one-third of this RSUs subject to the RSU Award on each of the First, Second, and Third anniversaries of the Grant Date (each a “Vesting Date”) as shown in the box above, except as otherwise provided in Article II below. No voting rights apply to this RSU Award. No fractional shares will be issued upon settlement of the RSU Award; all calculations are subject to rounding.
B.Dividend Equivalents. During the period commencing on the Grant Date and ending on the date immediately prior to the date the RSU Awards are settled in accordance with paragraph I(C), dividend equivalents will be accrued for the holder (“you”) if and to the extent dividends are paid by the Company on Merck Common Stock. Payment of such dividends will be made in cash via local payroll, without interest or earnings, at or around the time of distribution of the shares of Common Stock in settlement of the underlying RSUs. If any portion of this RSU Award lapses, is forfeited or expires, no dividend equivalents will be credited or paid on such portion. Any payment of dividend equivalents will be reduced to the extent necessary for the Company to satisfy any tax or other withholding obligations in accordance with paragraph IV.
C.Distribution (Settlement of RSU Award). Upon vesting of the RSU Award (including as a result of the events set forth in Article II), you (or your estate, in the event the RSU Award vests pursuant to paragraph II(E)) will be issued a number of shares of Merck Common Stock equal to the number of RSUs (unless otherwise provided in paragraph II(H)) with respect to which the RSU Award has vested and the dividend equivalents that accrued on that portion; provided, however, that in the event the RSU Awards vests upon a Change in Control (as defined below) pursuant to paragraph II(H) that does not constitute a “change in control event” within the meaning of U.S. Treasury Regulations Section 1.409A-3(i)(5), the RSU Awards will instead be settled on the original Vesting Dates set forth in paragraph I(A). Any amount required to be withheld, including amounts required to satisfy Tax-Related Items, in connection with the distribution of the



RSU Award (or otherwise arising from your participation in the Plan) will be recovered from you as described in paragraph IV.
D.409A Compliance. Anything to the contrary notwithstanding, no distribution of RSUs may be made unless in compliance with Section 409A of the Code or any successor thereto. Specifically, distributions made upon or by reference to the date of an employment termination shall not be paid unless such termination constitutes a “separation from service (as defined in Section 409A)” and any such payment to a “Specified Employee” as defined in Treas. Reg. Sec. 1.409A-1(i) or any successor thereto, to the extent required by Section 409A of the Code will instead be made on the first day the seventh month following the separation from service, in the same form as they would have been made had this restriction not applied; provided further, that dividend equivalents that otherwise would have accrued will accrue during the period during which distribution is suspended.
E.Subject to Recoupment. This RSU Award will be subject to recoupment in the event of certain violations of Company policy in accordance with the Company’s Policy and Procedures for Discretionary Recoupment of Compensation for Compliance Violations, as set forth in Appendix A.1, and with the Company’s Policy and Procedures for Recoupment of Incentive-Based Compensation, applicable only for Section 16 Officers, as set forth in Appendix A.2 (as may be amended from time to time).
II.TERMINATION OF EMPLOYMENT
If your employment with the Company or, if different, the subsidiary, affiliate or joint venture (“JV”) of the Company by which you are employed (the “Employer”) is terminated during the Restricted Period described in paragraph I(A), your right to the RSU Award will be determined according to the terms in this Article II and for grantees outside the United States, also in paragraph 12 of Section A (“Nature of Grant”) of Appendix B, Part I. For avoidance of doubt, if your employment terminates on a Vesting Date not for misconduct, you will be entitled to vest in that unvested portion of the RSU Award that is scheduled to vest on that Vesting Date.
A.General Rule. If your employment is terminated during the Restricted Period for any reason other than those specified in the following paragraphs, the unvested portion of this RSU Award (and any accrued dividend equivalents) will be forfeited on the date your employment terminates. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.
B.Involuntary Termination. If the Company determines that your employment is involuntarily terminated during the Restricted Period on or after the first anniversary of the Grant Date, the RSU Award will vest on the next subsequent Vesting Date following your employment termination with respect to a pro rata portion of your unvested RSU Award and dividend equivalents that have accrued through the corresponding Vesting Date equal to (i) the total number of RSUs subject to the RSU Award (whether or not vested), multiplied by (ii) a fraction, numerator of which is equal to the number of completed monthly periods during the period commencing on the Grant Date and ending the date employment terminates, and the denominator of which is 36, (iii) reduced by the number of RSUs that have vested pursuant to paragraph A. The remaining portion, if any, of the RSU Award and any accrued dividends will be forfeited on the date your employment terminates. An “involuntary termination” includes termination of your employment by the Company or the Employer, as applicable, as the result of a restructuring or job elimination, but excludes non-performance of your duties and the reasons listed under paragraphs C through H of this section. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this RSU Award nevertheless will be forfeited according to this paragraph notwithstanding such rehire.
C.Sale. If your employment is terminated during the Restricted Period and the Company determines that such termination resulted from the sale of your subsidiary, affiliate, division or JV, the RSU Award will continue to vest on the following original Vesting Date(s) set forth in paragraph I(A) with respect to the following unvested portion of your RSU Award and dividend equivalents that have accrued through the corresponding Vesting Dates: if employment terminates on or after the Grant Date but before the first anniversary thereof, then one-third of your RSU Award will vest on the first Vesting Date; if employment terminates on or after the first anniversary of the Grant Date, the portion of your RSU Award that was eligible to vest on the



second and third Vesting Dates, respectively, will vest on the corresponding Vesting Dates. The remaining portion, if any, of the RSU Award that does not vest pursuant to the foregoing sentence will be forfeited on the date your employment terminates. Notwithstanding the foregoing, the Committee may determine, for purposes of this RSU Award, whether employment with an entity that is established from the Company’s spin off, split off, split up or distribution of equity securities in connection with that entity constitutes a termination of employment, and may make adjustments, if any, as it deems appropriate, and to the extent not inconsistent with the Plan, at the time of the distribution of such equity securities, in the kind and/or number of shares subject to this RSU Award. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this RSU Award nevertheless will be forfeited according to this paragraph notwithstanding such rehire.
D.Retirement. If your employment terminates by retirement during the Restricted Period, the RSU Award will vest on the next subsequent Vesting Date following your termination with respect to a pro rata portion of your unvested RSU Award and dividend equivalents that have accrued through the corresponding Vesting Date equal to (i) the total number of RSUs subject to this RSU Award (whether or not vested), multiplied by (ii) a fraction, the numerator of which is equal to the number of completed monthly periods during the period commencing on the Grant Date and ending on the date employment terminates, and the denominator of which is 36, (iii) reduced by the number of RSUs that have vested pursuant to paragraph A. The remaining portion of the RSU Award and any accrued dividends will be forfeited on the date your employment terminates. For grantees who are employed in the U.S., “retirement” means a termination of employment after attaining the earliest of (a) age 55 with at least 10 years of service (b) such age and service that provides eligibility for subsidized retiree medical coverage or (c) age 65 without regard to years of service. For other grantees, “retirement” is determined by the Company. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.
E.Death. If your employment terminates due to your death during the Restricted Period but prior to an employment termination contemplated under paragraphs B, C, D, G or H, the RSU Award will immediately vest with respect to any portion of this RSU Award that has not vested as of your death and dividend equivalents that have accrued though such date. If you die during the Restricted Period, but after your employment terminates for the reasons listed under paragraphs B, C, D, G or H of this section, the RSU Award will immediately vest with respect to the remaining, non-forfeited portion of this RSU Award and dividend equivalents that have accrued through the date of death.
F.Misconduct. If your employment is terminated as a result of your deliberate, willful or gross misconduct, this RSU Award and accrued dividend equivalents will be forfeited immediately upon your receipt of notice of such termination.
G.Disability. If your employment is terminated during the Restricted Period and the Company determines that such termination resulted from inability to perform the material duties of your role by reason of a physical or mental infirmity that is expected to last for at least six months or to result in your death, whether or not you are eligible for disability benefits from any applicable disability program, then the RSU Award will continue to vest on the original Vesting Dates set forth in paragraph I(A) with respect to the unvested portion of RSU Award and dividend equivalents that have accrued through the corresponding Vesting Date. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this RSU Award nevertheless will expire according to this paragraph notwithstanding such rehire.
H.Change in Control. If this RSU Award is assumed, converted or otherwise remains outstanding in connection with a Change in Control and your employment is terminated during the Restricted Period without Cause before the second anniversary of the closing of the Change in Control, then the RSU Award will continue to vest on the original Vesting Dates set forth in paragraph I(A) with respect to the unvested portion of the RSU Award and dividend equivalents that have accrued through the corresponding Vesting Date. If this RSU Award does not remain outstanding following the Change in Control and is not converted into a successor RSU, then the RSU Award will immediately vest with respect to the portion of the RSU



Award that is unvested as of the Change in Control and dividend equivalents that have accrued though such date and, at the election of the Company, you will be entitled to receive cash for such portion of this RSU Award in an amount equal to the fair market value of the consideration paid to Merck stockholders for a share of Merck Common Stock in the Change in Control. On the second anniversary of the closing of the Change in Control, this paragraph shall expire. “Cause” and “Change in Control” are defined in the Merck & Co., Inc. Change in Control Separation Benefits Plan (excluding an MSD Change in Control).
I.Transfer of Employment. Transfer of employment between the Company, a subsidiary, affiliate, JV, JV partner or affiliate of the Company who provides services to the JV with such partner or affiliate or other entity in which the Company has determined that it has a significant business or ownership interest (together, the “Company Group”) is not considered termination of employment for purposes of this RSU Award. Such employment must be approved by the Company and contiguous with employment by the entity in the Company Group you were employed by immediately prior to the relevant transfer. The terms set out in paragraphs A through H above shall continue to apply to this RSU Award following a transfer of employment accordance with this section.
III.TRANSFERABILITY
Prior to distribution pursuant to Article I(C), the RSU Award and any interest therein shall not be sold, assigned, transferred, pledged or otherwise disposed of, alienated or encumbered, either voluntarily or involuntarily, other than by will or the laws of descent and distribution in connection with your death.
IV.TAX WITHHOLDING
Regardless of any action the Company and/or the Employer take with respect to any or all income tax, social insurance, payroll tax, payment on account or other tax-related items arising out of your participation in the Plan and legally applicable or deemed applicable to you (“Tax-Related Items”), you acknowledge that the ultimate liability for all Tax-Related Items is and remains your responsibility and may exceed the amount actually withheld by the Company and/or the Employer, if any. You further acknowledge that the Company and/or the Employer (i) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the RSU Award or underlying shares of Common Stock, including, but not limited to, the grant, vesting or settlement of the RSU, the subsequent sale of shares of Common Stock acquired upon the lapsing of the Restricted Period and the receipt of any dividends and/or dividend equivalents; and (ii) do not commit and are under no obligation to structure the terms of the grant or any aspect of the RSU Award to reduce or eliminate your liability for Tax-Related Items or achieve any particular tax result. Furthermore, if you have become subject to tax in more than one jurisdiction, you acknowledge that the Company and/or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.
Prior to the relevant taxable or tax withholding event, as applicable, you shall pay or make arrangements satisfactory to the Company and/or the Employer to satisfy any applicable withholding obligations or rights with regard to all Tax-Related Items. In this regard, you authorize the Company and/or the Employer, or their respective agents, at their discretion, to satisfy the Tax-Related Items by one or a combination of the following: (i) withholding from your wages or other cash compensation paid to you by the Company, the Employer and/or any subsidiary, affiliate or JV of the Company; or (ii) withholding from proceeds of the sale of shares of Common Stock acquired at lapsing of the Restricted Period either through a voluntary sale or through a mandatory sale arranged by the Company (on your behalf pursuant to this authorization); or (iii) withholding in shares of Common Stock to be issued upon lapsing of the Restricted Period; provided, however, that if you are a Section 16 officer of the Company under the Exchange Act, then the Company will satisfy the Tax-Related Items (other than U.S. Federal Insurance Contribution Act taxes or other Tax-Related Items which become payable in a year prior to the year in which shares of Common Stock are issued upon settlement of the RSUs) by withholding in shares of Common Stock pursuant to (iii) above, unless the use of such withholding method is problematic under applicable tax or securities law or has materially adverse accounting consequences, in which case, the obligation for Tax-Related Items may be satisfied by a one or a combination of (i) or (ii) above.



The Company may withhold or account for Tax-Related Items by considering applicable minimum statutory withholding amounts or other applicable withholding rates, including maximum applicable rates in your jurisdiction(s). In the event of over-withholding, you may receive a refund of any over-withheld amount in cash (with no entitlement to the equivalent in Common Stock), or if not refunded, you may seek a refund from the local tax authorities. In the event of under-withholding, you may be required to pay additional Tax-Related Items directly to the applicable tax authority or to the Company and/or the Employer. If the obligation for Tax-Related Items is satisfied by withholding in shares of Common Stock, for tax purposes, you will be deemed to have been issued the full number of shares of Common Stock subject to the vested RSUs, notwithstanding that a number of the shares is held back solely for the purpose of paying the Tax-Related Items due as a result of any aspect of your participation in the Plan.
You shall pay to the Company or the Employer any amount of Tax-Related Items that the Company or the Employer may be required to withhold or account for as a result of your participation in the Plan that cannot be satisfied by the means previously described in this section. The Company may refuse to issue or deliver the shares of Common Stock or the proceeds of the sale of shares if you fail to comply with your obligations in connection with the Tax-Related Items.
V.DATA PRIVACY
The Company is located at 126 East Lincoln Avenue, Rahway, NJ 07065, U.S.A. and grants employees of the Company and any subsidiary, affiliate or JV of the Company, the opportunity to participate in the Plan, at the Company's sole discretion. If you would like to participate in the Plan, you understand that you should review the following information about the Company’s data processing practices and declare your consent.
A.Data Collection and Usage. The Company collects, processes and uses your personal data, including, name, home address, email address and telephone number, date of birth, social insurance number or other identification number, salary, citizenship, job title, any shares of Common Stock or directorships held in the Company, and details of all awards, canceled, vested, or outstanding in your favor, which the Company receives from you or your Employer. If the Company offers you the opportunity to participate in the Plan, then the Company will collect your personal data for purposes of allocating Common Stock and implementing, administering and managing the Plan. The Company’s legal basis for the processing of your personal data would be your consent.
B.Stock Plan Administration Service Providers. The Company transfers participant data to Morgan Stanley, an independent service provider based in the United States, which assists the Company with the implementation, administration and management of the Plan. In the future, the Company may select a different service provider and share your data with another company that serves in a similar manner. The Company’s service provider will open an account for you. You will be asked to agree on separate terms and data processing practices with the service provider, which is a condition to your ability to participate in the Plan.
C.International Data Transfers. The Company and its service providers are based in the United States. If you are outside of the United States, you should note that your country has enacted data privacy laws that are different from the United States. The Company’s legal basis for the transfer of your personal data is your consent.
D.Voluntariness and Consequences of Consent Denial or Withdrawal. Your participation in the Plan and your grant of consent is purely voluntary. You may deny or withdraw your consent at any time. If you do not consent, or if you withdraw your consent, you cannot participate in the Plan. This would not affect your salary as an employee; you would merely forfeit the opportunities associated with the Plan.
E.Data Subject Rights. You have a number of rights under data privacy laws in your country. Depending on where you are based, your rights may include the right to (i) request access or copies of personal data the Company processes, (ii) rectification of incorrect data, (iii) deletion of data, (iv) restrictions on processing, (v) portability of data, (vi) to lodge complaints with competent authorities in your country, and/or (vii) a list with the names and addresses of any potential recipients of the your personal data. To receive clarification



regarding your rights or to exercise your rights please contact the Company at Attn: Global Privacy Office, 351 N. Sumneytown Pike, North Wales, Pennsylvania, U.S.A. 19454.
F.The collection, use and transfer of your personal data for the purpose of implementing, administering and managing your participation in the Plan is conducted in accordance with the Company’s Global Privacy and Data Protection Policy. You also understand that the Company may, in the future, request you to provide another data privacy consent.  If applicable and upon request of the Company, you agree to provide an executed acknowledgement or data privacy consent form to the Company or the Employer (or any other acknowledgements, agreements or consents) that the Company and/or the Employer may deem necessary to obtain under the data privacy laws in your country, either now or in the future.  You understand that you will not be able to participate in the Plan if you fail to execute any such acknowledgement, agreement or consent requested by the Company and/or the Employer.
If you agree with the data processing practices described in this Article, you will declare your consent by clicking to "Accept" these Terms on the Morgan Stanley website.
VI.GOVERNING LAW
This document may be amended only by another written agreement between the parties. This document will be interpreted and enforced under the laws of the State of New Jersey, United States (without regard to its choice-of-law provisions). For purposes of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this grant or this document, the parties hereby submit to and consent to the exclusive jurisdiction of the State of New Jersey and agree that such litigation shall be conducted only in the courts of Union County, New Jersey, or the federal courts for the United States for the District of New Jersey, and no other courts, where this grant is made and/or to be performed.
VII.SEVERABILITY
The provisions of this document are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.
VIII.WAIVER
You acknowledge that a waiver by the Company of breach of any provision of these Terms shall not operate or be construed as a waiver of any other provision of these Terms or of any subsequent breach by you or any other grantee.
IX.ELECTRONIC ACCEPTANCE
The Company may, in its sole discretion, decide to deliver any documents related to the RSU or future RSUs that may be granted under the Plan by electronic means or request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an online or electronic system established and maintained by the Company or a third party designated by the Company.
X.COUNTY-SPECIFIC APPENDIX
The RSU Award shall be subject to any additional provisions set forth in Appendix B for your country, if any. If you relocate to one of the countries included in Appendix B during the life of the RSU Award, the additional provisions for such country shall apply to you, to the extent the Company determines that the application of such provisions is necessary or advisable in order to comply with local law or facilitate the administration of the Plan.
XI.ADMINISTRATION
The Committee is responsible for construing and interpreting this grant, including the right to construe disputed or doubtful Plan provisions, and may establish, amend and construe such rules and regulations as it may deem



necessary or desirable for the proper administration of this RSU Award. Any decision or action taken or to be taken by the Committee, arising out of or in connection with the construction, administration, interpretation and effect of this RSU Award shall, to the maximum extent permitted by applicable law, be within its absolute discretion (except as otherwise specifically provided herein) and shall be final, binding and conclusive upon the Company, all Eligible Employees and any person claiming under or through any Eligible Employee. All determinations by the Committee including, without limitation, determinations of the Eligible Employees, the form, amount and timing of Incentives, the terms and provisions of Incentives and the writings evidencing Incentives, need not be uniform and may be made selectively among eligible employees who receive, or are eligible to receive, Incentives hereunder, whether or not such Eligible Employees are similarly situated.
This RSU Award is subject to the provisions of the 2019 Incentive Stock Plan. For further information regarding your RSU Award, you may access the Merck Global Long-Term Incentives homepage via Sync > HR > Money > Long-Term Incentive Program



APPENDIX A.1
Policy and Procedures for Discretionary Recoupment of
Compensation for Compliance Violations
Policy
It is the policy of the Compensation and Management Development Committee (the “Committee”) of the Board of Directors (the “Board”) of Merck & Co., Inc. (the “Company”) that the Committee will exercise its discretion to determine whether to seek Recoupment of any Covered Compensation paid or awarded to an Affected Employee, where it determines, in consultation with the Audit Committee, that: a) the Affected Employee engaged in misconduct, or failed to reasonably supervise an employee who engaged in misconduct, that resulted in a Material Violation; and b) the Committee concludes that the Material Violation caused Significant Harm to the Company.
Definitions
1.An “Affected Employee” is an employee in Band 600 or higher who (i) engaged in misconduct that results in a Material Violation; or (ii) failed in his or her supervisory responsibilities to reasonably manage or monitor the conduct of an employee who engaged in misconduct that results in a Material Violation.
2.“Covered Compensation” means all (a) incentive‐based cash compensation granted to an Affected Employee, including, without limitation, any annual bonuses and other short‐ and long‐term cash incentives, (b) equity‐based compensation, including, without limitation, stock options, restricted stock, restricted stock units, performance share units (“PSUs”), (c) any proceeds or earnings received in respect of (a) and (b), and (d) any other forms of compensation that the Committee determines to be subject to this policy. For the avoidance of doubt, the foregoing includes any compensation that was previously paid, earned, vested, deferred or paid or payable as a component of severance or termination compensation.
3.“Executive” means current and former executive officers of the Company, as “executive officer” is defined for the purposes of the Securities Exchange Act of 1934, as amended.
4.A “Material Violation” is defined as (i) a material violation of a written Company policy relating to the research, development, manufacturing, sales, or marketing of Company products or (ii) conduct detrimental to the Company, including the Company’s overall goodwill or reputation.
5.“Recoupment” is defined to include any and all of the following actions to the extent permitted by law: (a) reducing the amount of a current or future bonus or other cash or noncash incentive compensation award, (b) requiring reimbursement of a bonus or other cash-based incentive compensation award paid with respect to the most recently completed performance period, (c) cancelling all or a portion of a future‐vesting equity award, (d) cancelling all or a portion of an equity award that vested within the previous twelve‐month period, (e) requiring return of shares paid upon vesting and/or reimbursement of any proceeds received from the sale of an equity award, in each case that vested within the previous twelve‐month period, and (f) any other method of reducing the total compensation paid to an employee for any prior twelve‐month period or any current or future period.
6.“Significant Harm” means a significant negative impact on the Company’s financial operating results or reputation.
Procedures
a.Subject to any delegation to the Chief Executive Officer, as discussed below, the Committee, acting in consultation with the Audit Committee, shall administer this policy and have full discretion to interpret and to make any and all determinations under this policy. Any determinations made by the Committee shall be final, binding, and conclusive on all parties. Notwithstanding the foregoing, the full Board shall approve any determination to seek or waive Recoupment from the Chief Executive Officer.
b.The General Counsel, in consultation with the Chief Ethics and Compliance Officer and the Executive Vice President, Human Resources, is responsible for determining whether to refer a matter to the Committee for review under this policy and for assisting the Committee with its review. In administering this policy, the Committee may consult with other committees of the Board and any external or internal advisors as it deems appropriate.
c.If the Committee, acting in consultation with the Audit Committee, determines that there is a basis for seeking Recoupment under this policy, the Committee shall exercise its discretion to determine for each Affected Employee, on an individual basis, whether, and to what extent and in which manner, to seek Recoupment.
d.In exercising its discretion, the Committee may take into consideration, as it deems appropriate, all of the facts and circumstances of the particular matter and the general interests of the Company.



Delegation to Management for Recoupment Decisions
The Committee may delegate to the Chief Executive Officer (who may further delegate as deemed appropriate) the authority to administer this policy and to make any and all decisions under it regarding Affected Employees who are not Executives of the Company. Management shall report to the Committee on any affirmative decisions to seek Recoupment pursuant to this delegation of authority.
Public Disclosures
The Company will comply with all applicable securities laws and regulations, including Securities and Exchange Commission disclosure requirements regarding executive compensation and any applicable New York Stock Exchange listing standard or requirements, with respect to this policy. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.
Miscellaneous
Nothing in this policy shall limit or otherwise affect any of the following: 1) management’s ability to take any disciplinary action with respect to any Affected Employee; 2) the Committee’s ability to use its negative discretion with respect to any incentive compensation performance target at any time; or 3) the Committee’s or management’s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non‐cash incentive compensation award to any Affected Employee for any reason as they may deem appropriate and to the extent permitted by law. Any right of Recoupment under this policy is in addition to, and not in lieu of, any other remedies or rights of Recoupment that may be available to the Company pursuant to the terms of any similar policy in any incentive plan, employment agreement, equity award agreement, or similar agreement, including, without limitation, the Company’s Policy and Procedures for Recoupment of Incentive‐Based Compensation, and any other legal remedies available to the Company. The Company shall not indemnify or agree to indemnify any current or former Executive against the loss of incentive compensation subject to this policy nor shall the Company pay or reimburse or agree to pay or reimburse any insurance premium to cover the loss of such incentive compensation. The Committee may amend, modify, or terminate this policy in whole or in part at any time and from time to time in its sole discretion.



APPENDIX A.2
Policy and Procedures for Recoupment of
Incentive-Based Compensation
Policy
The Compensation and Management Development Committee (the “Committee”) of the Board of Directors (the “Board”) has adopted this Incentive‐Based Compensation Recoupment Policy (the “Policy”) to comply with Section 10D of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), Rule 10D‐1 promulgated thereunder (“Rule 10D‐1”) and Paragraph 303A.14 of the Listing Standards Manual of the New York Stock Exchange (“NYSE”), which require the recovery of certain Incentive‐Based Compensation in the event of an accounting restatement resulting from a material error in the consolidated financial statements of Merck & Co, Inc. (the “Company”). This Policy shall be administered by the Committee, which shall have express discretionary authority to interpret and construe this Policy and to make all determinations with respect to this Policy, in its sole discretion. It is intended that this Policy be interpreted in a manner that is consistent with the requirements of Section 10D of the Exchange Act and Rule 10D‐1 (or any successor statute or rule) and any other applicable rules or listing standards adopted by the U.S. Securities and Exchange Commission (the “SEC”) or NYSE. All interpretations, constructions and determinations made by the Committee under this Policy shall be final and binding on all parties. This Policy may be amended with the approval of the Committee and may be amended from time to time as necessary to reflect changes in applicable regulations and/or listing standards adopted by the SEC or NYSE. Compliance with this Policy cannot be waived.
Definitions
1."Accounting Restatement” is the restatement of the Company’s financial statements due to material noncompliance with any financial reporting requirement under the federal securities laws, including any required accounting restatement to correct an error in previously issued financial statements (i) that is material to the previously issued financial statements, or (ii) that would result in a material misstatement if the error were corrected in the current period only or left uncorrected in the current period.
2.A “Covered Officer” is anyone who serves or has served as an executive officer of the Company at any time during the performance period for Incentive‐Based Compensation.
3.“Executive officer” is the equivalent to an “officer” as defined under Section 16a‐1(f) of the Exchange Act (“Section 16 officer”).
4.“Financial reporting measure” is a measure that is (i) determined and presented in accordance with the accounting principles used in preparing the Company’s financial statements, or (ii) derived wholly or in part from such measures. For purposes of this Policy, the term “financial reporting measure” includes the Company’s stock price and total shareholder return, whether expressed as an absolute or relative metric. For the avoidance of doubt, a financial reporting measure need not be presented in the Company’s financial statements or included in a filing with the SEC.
5.“Incentive‐Based Compensation” is any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a financial reporting measure. Incentive‐Based Compensation may include awards under the Executive Incentive Plan and Performance Share Units under the Merck & Co., Inc. 2019 Stock Incentive Plan, or any successor thereto. Incentive‐Based Compensation does not include (i) base salary; (ii) “sign‐on” bonuses or other compensation granted solely due to the commencement of employment with the Company; (iii) compensation exclusively based on completion of a specific period of employment or service, without any performance condition; or (iv) compensation awarded based on subjective, non‐financial, strategic, or operational measures that are not financial reporting measures.
6.Incentive‐Based Compensation is deemed to be “received” in the fiscal period during which the financial reporting measure specified in the Incentive‐Based Compensation award is attained, even if the payment or grant of the Incentive‐Based Compensation occurs after the end of that fiscal period. Incentive‐Based Compensation in the form of an equity award that vests solely upon the basis of a financial reporting measure performance condition will be deemed to be received in the fiscal period in which it vests.
7.“Recoupment Period” is the three completed fiscal years of the Company immediately preceding the date, and any transition period of less than nine months that results from a change in the Company’s fiscal year within or immediately following those three completed fiscal years, on which the Company is required to perform an Accounting Restatement, which date is the earlier of (i) the date the Board, or a committee of the Board, concludes, or reasonably should have



concluded, that the Company is required to perform an Accounting Restatement; or (ii) a date that a court, regulator or other legallyauthorized body directs the Company to perform an Accounting Restatement.
Procedures for Recoupment of Incentive‐Based Compensation
1.In the event the Company is required to perform an Accounting Restatement, the Company shall, as promptly as reasonably possible, recoup any Incentive‐Based Compensation erroneously received by a Covered Officer during the Recoupment Period. The amount of erroneously received Incentive‐Based Compensation will be the excess of the Incentive‐Based Compensation received by the Covered Officer (whether in cash or in shares) based on the erroneous data in the original financial statements over the Incentive‐Based Compensation (whether in cash or in shares) that would have been received by the Covered Officer had it been based on the restated results, without respect to any tax liabilities incurred or paid by the Covered Officer. For Incentive‐Based Compensation based on total shareholder return or Company stock price, where the amount of erroneously awarded compensation is not subject to mathematical recalculation directly from the information in the Accounting Restatement, the amount shall be based on the Committee’s reasonable estimate of the effect of the Accounting Restatement on the applicable measure and the Committee shall maintain documentation of the determination of that reasonable estimate and provide it to the NYSE. Notwithstanding the foregoing, Incentive‐Based Compensation shall not be recouped under this Policy to the extent received by any person before the date such person served as a Covered Officer.
2.The Committee shall determine, in its sole discretion, the method of recouping any erroneously received Incentive‐Based Compensation pursuant to this Policy.
3.No recoupment shall be required if any of the following conditions are met and the Committee determines that, on such basis, recovery would be impracticable: (i) the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount to be recouped, which determination must be made only after a reasonable and documented attempt by the Company to recoup the Incentive‐Based Compensation (with documentation of such reasonable attempt to recover to be provided to the NYSE); (ii) recovery would violate home country law where that law was adopted prior to November 28, 2022, which determination must be made only after the Company has obtained an opinion of home country counsel, acceptable to the NYSE, that recovery would result in such violation (with a copy of such opinion to be provided to the NYSE); or (iii) recoupment would likely cause an otherwise tax‐qualified retirement plan, under which benefits are broadly available to Company employees, to fail to meet the requirements of Section 401(a)(13) or Section 411(a) of the Internal Revenue Code of 1986, as amended, and U.S. Treasury regulations promulgated thereunder.
Indemnification Not Permitted
The Company shall not indemnify any current or former Covered Officer against the loss of erroneously awarded compensation, and shall not pay, or reimburse any Covered Officer for, premiums incurred or paid for any insurance policy to fund such Covered Officer’s potential recoupment obligations.
Disclosure of Recoupment Decisions
The Company will comply with all applicable securities laws and regulations, including SEC disclosure requirements, with respect to this Policy, and any applicable NYSE listing standard or requirements. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.
Effective Date
This Policy shall be effective as of December 1, 2023 (the “Effective Date”). The terms of this Policy shall apply to any Incentive‐Based Compensation that is received by Covered Officers on or after the Effective Date, even if such Incentive‐Based Compensation was approved, awarded, granted, or paid to Covered Officers prior to the Effective Date.
Miscellaneous
Nothing in this Policy shall limit or otherwise affect any of the following: 1) management’s ability to take any disciplinary action with respect to any Covered Officer; 2) the Committee’s ability to use its negative discretion with respect to any Incentive‐Based Compensation performance target at any time; or 3) the Committee’s or management’s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non‐cash incentive compensation award to any executive or other employee for any reason as they may deem appropriate and to the extent permitted by law. Any right of recoupment under this Policy is in addition to, and not in lieu of, any other



remedies or rights of recoupment that may be available to the Company pursuant to the terms of any similar policy in any incentive plan, employment agreement, equity award agreement, or similar agreement and any other legal remedies available to the Company. This Policy shall be binding and enforceable against all Covered Officers and their beneficiaries, heirs, executors, administrators, or other legal representatives.



APPENDIX B
ADDITIONAL TERMS AND CONDITIONS FOR GRANTEES OUTSIDE THE U.S.
This Appendix, which is part of the Global Terms and Conditions for 2024 Restricted Stock Unit Grants under the Merck & Co., Inc. 2019 Incentive Stock Plan, contains additional “terms and conditions” that will apply to you if you reside outside the United States.
The terms and conditions in Part I of this Appendix apply to all grantees who reside outside the United States. The additional terms and conditions in Part II of this Appendix will also apply to you if you reside in one of the countries referenced in Part II.
The information in this Appendix is based on the laws in effect in the respective countries as of November 2023. Such laws are often complex and change frequently. As a result, the Company strongly recommends that you not rely on the information in this Appendix B as the only source of information relating to the consequences of your participation in the Plan because the information may be out of date at the time that the Restricted Period lapses and shares of Common Stock are issued to you or you sell shares of Common Stock acquired under the Plan.
In addition, the information contained in this Appendix is general in nature and may not apply to your particular situation, and the Company is not in a position to assure you of a particular result. Accordingly, you should seek appropriate professional advice as to how the relevant laws in your country may apply to your situation.
Finally, if you are a citizen or resident of a country, or are considered a resident of a country, other than that in which you are currently working, or transfer residence and/or employment after the Grant Date, the information contained herein may not apply to you in the same manner. The Company shall, in its sole discretion, determine to what extent the terms and conditions included herein will apply under these circumstances.



APPENDIX B - PART I: ADDITIONAL TERMS AND CONDITIONS FOR ALL COUNTRIES OUTSIDE OF THE UNITED STATES
The following additional terms and conditions will apply to you if you reside in any country outside the United States.
A.Nature of Grant
In accepting the RSU Award, you acknowledge and agree that:
1.the Plan is established voluntarily by the Company, is discretionary in nature, and may be amended, suspended, or terminated by the Company at any time;
2.the grant of the RSU Award is exceptional, voluntary, and occasional and does not create any contractual or other right to receive future grants of RSUs, or benefits in lieu of RSUs, even if RSUs have been granted in the past;
3.all decisions with respect to future RSU grants, if any, will be at the sole discretion of the Company;
4.your participation in the Plan is voluntary;
5.your participation in the Plan shall not create a right to employment or be interpreted as forming or amending an employment or service contract with the Company and shall not interfere with the ability of the Employer to terminate your employment or service relationship (if any) at any time;
6.the RSU Award and any shares of Common Stock acquired under the Plan, and income from and value of same, are extraordinary items that do not constitute compensation of any kind for services of any kind rendered to the Employer, the Company, or any subsidiary, affiliate or JV of the Company, and that are outside the scope of your employment or service contract, if any;
7.unless otherwise agreed with the Company in writing, the RSU Award and any shares of Common Stock acquired under the Plan, and the income from and value of same, are not granted as consideration for, or in connection with, the service you may provide as a director of a subsidiary, affiliate or JV of the Company;
8.the RSU Award and any shares of Common Stock acquired under the Plan, and the income from and value of same, are not intended to replace any pension rights or compensation;
9.the RSU Award and any shares of Common Stock acquired under the Plan, and the income and value of same, are not part of normal or expected compensation or salary for any purposes, including, but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments, and in no event should be considered as compensation for, or relating in any way to, past services for the Employer, the Company or any subsidiary, affiliate or JV of the Company;
10.the future value of the shares of Common Stock underlying the RSU is unknown, indeterminable and cannot be predicted with certainty;
11.no claim or entitlement to compensation or damages shall arise from (a) termination of the RSU Award resulting from termination of your employment by the Company or the Employer (for any reason whatsoever and whether or not in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any) and/or (b) termination of the RSU Award or



recoupment of any shares of Common Stock, cash or other benefits acquired upon settlement of the RSU Award resulting from the application of Article I(E) of the Terms;
12.for purposes of the RSU Award, your employment relationship will be considered terminated as of the date you are no longer providing services to the Employer or the Company or any subsidiary, affiliate or JV (regardless of the reason for such termination and whether or not later found to be invalid or in breach of the employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and unless otherwise expressly provided in the Terms, your right to vest in the RSU under the Plan, if any, will terminate effective as of such date and will not be extended by any notice period or any period of “garden leave” or similar period mandated under local law; the Committee shall have the exclusive discretion to determine when you are no longer providing services for purposes of the grant (including whether you may still be considered to be providing services while on a leave of absence);
13.the RSU Award and the benefits under the Plan, if any, will not automatically transfer to another company in the case of a merger, take-over or transfer of liability;
14.the Company is not providing any tax, legal, or financial advice, nor is the Company making any recommendation regarding your participation in the Plan, or the acquisition or sale of underlying shares; you should consult with your personal tax, legal and financial advisors regarding the decision to participate in the Plan and before taking any action related to the Plan; and
15.neither the Employer, nor the Company or any subsidiary, affiliate or JV shall be liable for any foreign exchange rate fluctuation between your local currency and the United States Dollar that may affect the value of the RSU Award or any amounts due to you pursuant to the vesting of the RSU Award, the subsequent sale of shares acquired under the Plan or the receipt of any dividends and/or dividend equivalents.
B.Insider Trading/Market Abuse Laws
You acknowledge that, depending on your or your broker’s country of residence or where shares of Common Stock are listed, you may be subject to insider trading restrictions and/or market abuse laws, which may affect your ability to accept, acquire, sell or otherwise dispose of shares of Common Stock, rights to shares of Common Stock (e.g., RSUs) or rights linked to the value of shares of Common Stock under the Plan during such times that you are considered to have “inside information” regarding the Company (as defined by the laws or regulations in the applicable jurisdictions or your country). Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you placed before you possessed inside information. Furthermore, you could be prohibited from (i) disclosing the inside information to any third party and (ii) “tipping” third parties or causing them otherwise to buy or sell securities. You should keep in mind that third parties include fellow employees. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. You understand you are responsible for ensuring compliance with any restrictions and should consult with your personal legal advisor on this matter.
C.Foreign Asset/Account, Exchange Control and Tax Obligations
You acknowledge that, depending on your country, you may be subject to foreign asset/account, exchange control and/or tax reporting requirements as the result of the acquisition of shares of Common Stock or cash (including dividend equivalents, dividends, and the proceeds of the sale of shares of Common Stock) derived from your participation in the Plan, in, to and/or from a brokerage/bank account or legal entity located outside your country. The applicable laws of your country may require that you report such accounts, assets, the



balances therein, the value thereof and/or the transactions related thereto to the applicable authorities in your country. You may also be required to repatriate cash received from participating in the Plan to your country within a certain time after receipt. You acknowledge that you are responsible for ensuring compliance with any applicable foreign asset/account, exchange control and tax reporting requirements and should consult your personal tax, legal and/or financial advisors regarding the same.
D.Language
You acknowledge that you are proficient in the English language or have consulted with an advisor who is sufficiently proficient, to allow you to understand the terms and conditions of this document. If you have received this document, or any other document related to the RSU Award and/or the Plan translated into a language other than English, and if the translated version is different than the English version, the English version will control unless otherwise required by local law.
E.Imposition of Other Requirements and Issuance of Shares
The Company reserves the right to impose other requirements on this RSU Award and the shares of Common Stock acquired pursuant to the RSU Award, to the extent the Company determines it is necessary or advisable to comply with local laws or facilitate the administration of the Plan, and to require you to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.
In particular, if advisable due to local law requirements, the Committee, in its sole and absolute discretion, may require the immediate forced sale of the shares of Common Stock issuable upon vesting of the RSUs. Alternatively, unless otherwise set forth in this Appendix, the Committee, in its sole and absolute discretion, may determine to pay out the RSUs in cash equal to the fair market value of the shares of Common Stock underlying the RSUs.



APPENDIX B - PART II: COUNTRY-SPECIFIC ADDITIONAL TERMS AND CONDITIONS AND NOTIFICATIONS
Country
Additional Terms and Conditions and Notifications
Algeria
Payment of Award
Any RSU Award granted to you will be settled in cash only. This means that upon vesting of your RSU Award, you will receive in cash the value of the underlying shares of Common Stock at vesting, less any Tax-Related Items and broker’s fees or commissions, which will be remitted to you via local payroll. The Company reserves the right to settle the RSU Award in shares of Common Stock and to force the immediate sale of such shares of Common Stock depending on the development of applicable exchange control laws and regulations.
Argentina
Securities Law Information
Neither the Award nor the underlying shares of Common Stock are publicly offered, listed on any stock exchange in Argentina or registered with the Argentine Securities Commission (Comisión Nacional de Valores).
Labor Law Acknowledgement
This provision supplements the “Nature of Grant” section in Part I of this Appendix B:
In accepting the grant of the RSU Award, you acknowledge and agree that the grant of the RSU Award is made by the Company, not the Employer, in its sole discretion and the value of any RSU Award and shares of Common Stock acquired under the Plan shall not constitute salary or wages for any purpose under Argentine labor law, including, but not limited to, the calculation of (i) any labor benefits including, without limitation, vacation pay, thirteenth salary, compensation in lieu of notice, annual bonus, disability, and leave of absence payments, or (ii) any termination or severance indemnities.
If, notwithstanding the foregoing, any benefits under the Plan are considered as salary or wages for any purpose under Argentine labor law, you acknowledge and agree that such benefits shall not accrue more frequently than on an annual basis.
Australia
Securities Law Information
The offer of the RSU Award is being made under Division 1A Part 7.12 of the Corporations Act 2001 (Cth). If you offer shares of Common Stock acquired under the Plan for sale to a person or entity resident in Australia, your offer may be subject to disclosure requirements under Australian law. You should obtain legal advice on applicable disclosure obligations prior to making any such offer.
Tax Information
The Plan is a plan to which Subdivision 83A-C of the Income Tax Assessment Act 1997 (Cth) (the “Tax Assessment Act”) applies (subject to the conditions in the Tax Assessment Act).
Austria
There are no country-specific provisions.
Belgium
There are no country-specific provisions.



Country
Additional Terms and Conditions and Notifications
Bermuda
Securities Law Information
The Plan and the Terms, including this Appendix B, are not subject to, and have not received approval from either the Bermuda Monetary Authority or the Registrar of Companies in Bermuda and no statement to the contrary, explicit or implicit, is authorized to be made in this regard. If any shares of Common Stock acquired under the Plan are offered or sold in Bermuda, the offer or sale must comply with the provisions of the Investment Business Act 2003 of Bermuda. Alternatively, the shares may be sold on the New York Stock Exchange on which they are listed.
Brazil
Compliance with Law
By accepting the RSU Award, you acknowledge that you agree to comply with applicable Brazilian laws and pay any and all applicable taxes associated with the expiration of the Restricted Period, the sale of shares obtained pursuant to the expiration of the Restricted Period, and the receipt of any dividends or dividend equivalents.
Labor Law Acknowledgment
By accepting the RSU Award, you agree that you are (i) making an investment decision and (ii) the value of the underlying shares of Common Stock is not fixed and may increase or decrease in value over the Restricted Period without compensation to you.
Further, you acknowledge and agree that, for all legal purposes, (i) any benefits provided to you under the Plan are unrelated to your employment or service; (ii) the Plan is not a part of the terms and conditions of your employment or service; and (iii) the income from your participation in the Plan, if any, is not part of your remuneration from employment or service.
Bulgaria
There are no country-specific provisions.



Country
Additional Terms and Conditions and Notifications
Canada
Termination of Employment
This provision replaces paragraph (9) of the “Nature of Grant” section in Part I of this Appendix B:
Except to the extent explicitly required under local employment standards legislation, the RSU Award and any shares of Common Stock acquired under the Plan, and the income and value of same, are not part of normal or expected compensation or salary for any purposes, including, but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments, and in no event should be considered as compensation for, or relating in any way to, past services for the Employer, the Company or any parent, subsidiary, affiliate or JV of the Company;
This provision replaces paragraph (11) of the “Nature of Grant” section in Part I of this Appendix B:
Except to the extent explicitly required under local employment standards legislation, no claim or entitlement to compensation or damages shall arise from (a) termination of the RSU Award resulting from termination of your employment by the Company or the Employer (for any reason whatsoever and whether or not in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any) and/or (b) termination of the RSU Award or recoupment of any shares of Common Stock, cash or other benefits acquired upon settlement of the RSU Award resulting from the application of Article I(E) of the Terms;
This provision replaces paragraph (12) of the “Nature of Grant” section in Part I of this Appendix B:
For purposes of the RSU Award, except to the extent expressly provided in your Terms or expressly required by applicable legislation, your employment relationship will be considered terminated (regardless of the reason for such termination) and your right to vest in the RSU Award under the Plan, if any, will terminate as of the date that is the earliest of (a) the date you are no longer employed or providing services to the Company or any parent, subsidiary, affiliate or JV, (b) the date you receive written notice of termination of employment, or (c) the date written notice of termination is delivered to your last known address (together, the “Termination Date”). Except to the extent explicitly required by applicable legislation, the Termination Date will exclude any notice period or period of pay in lieu of such notice required under statute, contract, common/civil law or otherwise. You will not earn, or be entitled to earn, any pro-rated vesting for that portion of time before the date on which your right to vest terminates, nor will you be entitled to any compensation for lost vesting. In case of any dispute as to whether termination of employment has occurred that cannot be reasonably determined under your Terms and the Plan, the Committee shall have the sole discretion, subject to applicable legislation, to determine whether such termination of employment has occurred and the effective date of such termination.



Country
Additional Terms and Conditions and Notifications
Notwithstanding the foregoing, if applicable employment standards legislation explicitly requires continued entitlement to vesting during a statutory notice period, your right to vest in the RSU Award under the Plan, if any, will terminate effective as of the last day of your minimum statutory notice period, but you will not earn or be entitled to pro-rated vesting if the vesting date falls after the end of your statutory notice period, nor will you be entitled to any compensation for lost vesting.
Securities Law Information
You are permitted to sell shares of Common Stock acquired through the Plan through the broker designated by the Company under the Plan, if any, provided the resale of shares of Common Stock acquired under the Plan takes place outside of Canada through the facilities of a stock exchange on which the shares of Common Stock are listed. The shares are currently listed on the New York Stock Exchange.
Payment of Award
Notwithstanding any discretion contained in Section 11(d) of the Plan, the grant of the RSU Award does not provide any right for you to receive a cash payment and the RSU Award is payable in shares of Common Stock only.
The following provisions will apply to you if you are a resident of Quebec:
Language. A French translation of the Plan and the Terms will be made available to you. Unless you indicate otherwise, the French translation of the Plan and the Terms will govern your participation in the Plan.
Langue. Une traduction française du Régime et de la Convention sera mise à votre disposition. À moins que vous n'indiquiez le contraire, la traduction française du Régime et de la Convention régira votre participation au Régime.
Data Privacy
This provision supplements the “Data Privacy” section in the Terms:
You hereby authorize the Company and the Company’s representatives to discuss with and obtain all relevant information from all personnel, professional or not, involved in the administration and operation of the Plan. You further authorize the Company, and its subsidiaries, affiliates or JVs and Morgan Stanley Smith Barney and any other stock plan service provider that may be selected by the Company to assist with the Plan to disclose and discuss the Plan with their respective advisors. You further authorize the Company and its subsidiaries, affiliates and JVs to record such information and to keep such information in your employee file. You acknowledge and agree that your personal information, including any sensitive personal information, may be transferred or disclosed outside the province of Quebec, including to the U.S. If applicable, you also acknowledge and authorize the Company and its subsidiaries, affiliates and JVs, the administrator of the Plan and any third party brokers/administrators that are assisting the Company with the operation and administration of the Plan to use technology for profiling purposes and to make automated decisions that may have an impact on you or the administration of the Plan.



Country
Additional Terms and Conditions and Notifications
Chile
Securities Law Information
The offer of this RSU Award will be effective as of the Grant Date. The offer is made subject to general ruling N° 345 (“NCG 345”) of the Chilean Commission for the Financial Market (“CMF”). The offer refers to securities not registered at the securities registry or at the foreign securities registry of the CMF, and, therefore, such securities are not subject to oversight of the CMF. Given that the Plan is not registered in Chile, the Company is not required to provide public information about the Plan or the shares of Common Stock in Chile. Unless the securities and/or the shares of Common Stock are registered with the CMF, a public offering of such securities cannot be made in Chile, unless the offer complies with the conditions set forth in NCG 345.



Country
Additional Terms and Conditions and Notifications
The People's Republic of China
The following terms and conditions apply only to grantees who are citizens of the PRC or are otherwise determined to be subject to the requirements imposed by the State Administration of Foreign Exchange (“SAFE”) as determined by the Company.
The following terms and conditions apply only if you are classified as Band 600 and higher on the Grant Date.
Payment of Award and Termination of Employment
You will be permitted to hold shares of Common Stock issued to you at the end of the Restricted Period. Notwithstanding anything to the contrary in the Plan or Terms, due to exchange control laws in China, you agree that any shares of Common Stock acquired under the Plan and held by you at the time of your termination of employment with the Company or the Employer will be sold on your behalf, pursuant to this authorization, as soon as administratively practicable following the termination of your employment, but no later than six-months following termination of employment. The Company is under no obligation to arrange for such sale at any particular price. You will receive the sale proceeds, less any broker’s fees or commissions and subject to satisfaction of any Tax-Related Items. If the Terms provide that all or a portion of your outstanding RSU Award will become distributable at some time following your termination of employment, that portion will automatically vest and be sold on your behalf as described above. Any other portion of your RSU Award that is not vested as described above will expire immediately upon your termination of employment.
Due to local regulatory requirements, you agree that the Company may force the sale of any shares of Common Stock issued under the Plan. The sale may occur (i) immediately upon vesting or (ii) within any other time frame as the Company determines to be necessary or advisable for legal or administrative reasons.
Broker Account
Any shares of Common Stock issued to you at expiration of the Restricted Period must be maintained in an account with Morgan Stanley Smith Barney or such other stock plan service provider as may be selected by the Company in the future until the shares of Common Stock are sold through that broker.
Exchange Control Compliance
You understand and agree that, to comply with exchange control laws in the PRC, any cash dividends, dividend equivalents and the proceeds from the sale of the shares of Common Stock will be immediately repatriated to China through a special exchange control account established by the Company (or any subsidiary, affiliate or JV) or the Employer prior to being delivered to you. The funds may be paid to you in U.S. dollars or local currency at the Company’s discretion. To the extent the funds are paid to you in U.S. dollars, you understand that you will be required to set up a U.S. dollar bank account in China and provide the bank account details to the Employer and/or the Company so that the funds may be deposited into this account. In the more likely event that the Company converts cash received under the Plan into local currency, the Company is under no obligation to secure any exchange conversion rate and the Company may face delays in converting



Country
Additional Terms and Conditions and Notifications
the proceeds to local currency due to exchange control restrictions in China. You agree to bear any currency fluctuation risk between that time and the time the funds are distributed through any such special exchange account. You further agree to comply with any other requirements that may be imposed by the Company in the future in order to facilitate compliance with exchange control requirements in China.
The following terms and conditions apply only if you are classified as below Band 600 on the Grant Date.
Payment of Award
To facilitate compliance with exchange control laws in China, any RSU Award granted to you will be settled in cash only. This means that upon vesting of your RSU Award, you will receive in cash the value of the underlying shares of Common Stock at expiration of the Restricted Period, less any broker’s fees or commissions and Tax-Related Items, which will be remitted to you in accordance with applicable exchange control laws and regulations. You will not be permitted to hold shares of Common Stock after vesting. The Company reserves the right to settle the RSU Award in shares of Common Stock and to force the immediate sale of such shares of Common Stock depending on the development of applicable exchange control laws and regulations.
Exchange Control Compliance
You understand and agree that, to comply with exchange control laws in the PRC, the cash payable to you at expiration of the Restricted Period will be immediately repatriated to China through a special exchange control account established by the Company (or any subsidiary, affiliate or JV) or the Employer prior to being delivered to you. The funds may be paid to you in U.S. dollars or local currency at the Company’s discretion. To the extent the funds are paid to you in U.S. dollars, you understand that you will be required to set up a U.S. dollar bank account in China and provide the bank account details to the Employer and/or the Company so that the funds may be deposited into this account. In the more likely event that the Company converts cash received under the Plan into local currency, the Company is under no obligation to secure any exchange conversion rate and the Company may face delays in converting the proceeds to local currency due to exchange control restrictions in China. You agree to bear any currency fluctuation risk between that time and the time the funds are distributed through any such special exchange account. You further agree to comply with any other requirements that may be imposed by the Company in the future in order to facilitate compliance with exchange control requirements in China.
Termination of Employment
Notwithstanding any terms or conditions of the Plan or the “Termination of Employment” section of the Terms to the contrary, the cash equivalent of any shares of Common Stock that vest upon termination of your employment will be distributed to you no later than six months from the date of termination of your employment, as determined by the Company in accordance with the Terms, or within any other such timeframe as may be required by SAFE. If the Terms provide that all or a portion of your outstanding RSU Award will become distributable at some time following your termination of employment, that portion will automatically vest and become distributable immediately upon your termination of employment as described above. Any other portion of your RSU Award that is not vested as described above will expire immediately upon your termination of employment.



Country
Additional Terms and Conditions and Notifications
Colombia
Securities Law Information.
The shares of Common Stock are not and will not be registered with the Colombian registry of publicly traded securities (Registro Nacional de Valores y Emisores) and therefore the shares of Common Stock may not be offered to the public in Colombia. Nothing in this Appendix B should be construed as the making of a public offer of securities in Colombia.
Labor Law Acknowledgment
This provision supplements the “Nature of Grant” section in Part I of this Appendix B:
You acknowledge that pursuant to Article 128 of the Colombian Labor Code, the Plan, the RSU Award and any income realized under the Plan do not constitute a component of your “salary” for any legal purpose. Therefore, they will not be included and/or considered for purposes of calculating any and all labor benefits, such as legal/fringe benefits, vacations, indemnities, payroll taxes, social insurance contributions and/or any other labor-related amount which may be payable.
Costa Rica
There are no country-specific provisions.
Croatia
There are no country-specific provisions.
Cyprus
There are no country-specific provisions.
Czech Republic
There are no country-specific provisions.
Denmark
Labor Law Acknowledgment
This provision supplements the “Nature of Grant” section Part I of this Appendix B:
By accepting the RSU Award, you understand and agree that this grant relates to future services to be performed and is not a bonus or compensation for past services.
Stock Option Act
You acknowledge that you received the Employer Statement (attached as Appendix C below) which summarizes select terms of your RSUs.
As set forth in Section 1 of the Stock Option Act, the Stock Option Act only applies to “employees” as that term is defined in Section 2 of the Stock Option Act and to the extent you are subject to Danish law. If you are a member of the registered management of the Company's subsidiary, affiliate or JV in Denmark or otherwise do not satisfy the definition of employee or are not subject to Danish law, you will not be subject to the Stock Option Act and the Employer Statement will not apply to you.
Please note the Stock Option Act was revised as of January 1, 2019. The standard termination provisions in the Terms will apply for any grants made under the Plan. The relevant termination provisions are detailed in the “Termination of Employment” section in your Terms.
Ecuador
There are no country-specific provisions.
Egypt
There are no country-specific provisions.



Country
Additional Terms and Conditions and Notifications
Estonia
Language Consent
By accepting the grant of the RSU Award, you confirm having read and understood the documents related to the grant (the Terms and the Plan), which were provided in the English language, and that you do not need the translation thereof into the Estonian language. You accept the terms of those documents accordingly.
Võttes vastu Award-de pakkumise kinnitad, et oled ingliskeelsena esitatud pakkumisega seotud dokumendid (Tingimused ja Plaan) läbi lugenud ja nendest aru saanud ning et ei vaja nende tõlkimist eesti keelde. Sellest tulenevalt nõustud viidatud dokumentide tingimustega
Finland
There are no country-specific provisions.



Country
Additional Terms and Conditions and Notifications
France
Language Consent
By accepting the RSU Award, you confirm having read and understood the Plan and your Terms, which were provided in the English language. You accept the terms of those documents accordingly.
En acceptant l’attribution, vous confirmez avoir lu et compris le Plan de travail et vos conditions générales et dispositions, qui ont été transmis en langue anglaise. Vous acceptez les termes de ces documents en connaissance de cause.
French-Qualified RSUs
The following provisions apply only if you are eligible to be granted French-Qualified RSUs under the French Sub-Plan (defined below). If you are ineligible to be granted French-Qualified RSUs under the French Sub-Plan, the RSU Award will not qualify for the special French tax and social security treatment under Sections L. 225-197-1 to L. 225-197-5 and Sections L. 22-10-59 to L. 22-10-60 of the French Commercial Code, as amended.
Type of Grant. The RSUs are granted as French-Qualified RSUs and are intended to qualify for the special tax and social security treatment applicable to shares of Common Stock granted for no consideration under Sections L. 225-197-1 to L. 225-197-5 and Sections L. 22-10-59 to L. 22-10-60 of the French Commercial Code, as amended. The French-Qualified RSUs are granted subject to the terms and conditions of the Sub-Plan for RSU Awards to French Participants (the “French Sub-Plan”).
Certain events may affect the status of the RSUs as French-Qualified RSUs or the underlying shares of Common Stock, and the French-Qualified RSUs or the underlying shares of Common Stock may be disqualified in the future. The Company does not make any undertaking or representation to maintain the qualified status of the French-Qualified RSUs or of the underlying shares of Common Stock.
Capitalized terms not defined herein, in the Terms or in the Plan shall have the meanings ascribed to them in the French Sub-Plan.
Restrictions on Sale or Transfer of Shares.
(a)Minimum Mandatory Vesting Period. No vesting shall occur prior to the first anniversary of the Grant Date, or such other minimum vesting period appliable to French-Qualified RSUs under Section L. 225-197-1 of the French Commercial Code, as amended, or by the French Tax Code or the French Social Security Code, as amended, to benefit from the special tax and social security regime in France.



Country
Additional Terms and Conditions and Notifications
(b)Minimum Mandatory Holding Period. You may not sell or transfer any shares of Common Stock issued at vesting until the second anniversary of the Grant Date, or such other period as is required to comply with the minimum mandatory holding period applicable to shares underlying French-Qualified RSUs under Section L. 225-197-1 of the French Commercial Code, as amended, or by the French Tax Code or the French Social Security Code, as amended, to benefit from the special tax and social security regime in France.
(c)Closed Periods. You may not sell any shares of Common Stock issued upon vesting of the French-Qualified RSUs during certain Closed Periods, to the extent applicable to the shares underlying the French-Qualified RSUs granted by the Company, as described in the French Sub-Plan.
(d)Effect of Termination of Service. Except in the case of your termination due to death or Disability, the restrictions described in provisions (a), (b) and (c) above will continue to apply even if you are no longer an employee or managing corporate officer of the Company or a French Entity.
No Transfer of French-Qualified RSUs. French-Qualified RSUs may not be sold, assigned, transferred, pledged, hypothecated, or otherwise disposed of in any manner during a French Participant's lifetime and upon death only in accordance with Section 6 of the French Sub-Plan, and only to the extent required by applicable laws (including the provisions of Sections L. 225-197-1 to L. 225-197-6 of the French Commercial Code, as amended).
Termination of Service Due to Death. The following provision replaces paragraph II(E) of the Terms:
If your employment terminates due to your death during the Restricted Period but prior to an employment termination contemplated under paragraphs B, C, D, G or H, the French-Qualified RSUs that have not vested as of such date and dividend equivalents that have accrued through such date may be requested by your legal heirs within six months of the date of death and, if so requested, the shares of Common Stock subject to the French-Qualified RSUs will be issued to your legal heirs.
Germany
There are no country-specific provisions.
Greece
There are no country-specific provisions.
Guatemala
Consent to Receive Information in English
By participating in the Plan, you acknowledge that you have reviewed the Terms and are sufficiently proficient in English, or, alternatively, you will seek appropriate assistance, to understand the terms and conditions of this RSU Award.
Honduras
There are no country-specific provisions.



Country
Additional Terms and Conditions and Notifications
Hong Kong
Securities Law Information
Warning: The contents of this document have not been reviewed by any regulatory authority in Hong Kong. You should exercise caution in relation to the offer. If you are in any doubt about any of the contents of the Plan and the Terms, including this Appendix B, you should obtain independent professional advice. The RSU Award and any shares of Common Stock issued pursuant to the RSU Award do not constitute a public offering of securities under Hong Kong law and are available only to Eligible Employees of the Company or its subsidiaries, affiliates and JVs. The Terms, including this Appendix B, the Plan and other incidental communication materials distributed in connection with the RSU Award (i) have not been prepared in accordance with and are not intended to constitute a “prospectus” for a public offering of securities under the applicable securities legislation in Hong Kong and (ii) are intended only for the personal use of each Eligible Employee of the Employer, the Company or its subsidiaries, affiliates and JVs and may not be distributed to any other person.
Payment of Award
Notwithstanding any discretion contained in Section 11(d) of the Plan, the grant of the RSU Award does not provide any right for you to receive a cash payment and the RSU Award is payable in shares of Common Stock only.
Sale of Shares
Shares of Common Stock received at vesting are accepted as a personal investment. In the event the Restricted Period on your RSU Award expires within six months of the Grant Date and shares of Common Stock are issued to you, you agree that you will not offer to the public or otherwise dispose of the shares of Common Stock prior to the six-month anniversary of the Grant Date.
Hungary
Payment of Award
Any RSU Award granted to you will be settled in cash only. This means that upon vesting of your RSU Award, you will receive in cash the value of the underlying shares of Common Stock at vesting, less any Tax-Related Items and broker’s fees or commissions, which will be remitted to you via local payroll. The Company reserves the right to settle the RSU Award in shares of Common Stock and to force the immediate sale of such shares of Common Stock depending on the development of applicable securities laws and regulations.
Iceland
There are no country-specific provisions.
India
There are no country-specific provisions.



Country
Additional Terms and Conditions and Notifications
Indonesia
Language Acknowledgment
A translation of the documents relating to this grant into Bahasa Indonesia can be provided to you upon request to mellisa.riana.dewi@merck.com. By accepting the RSU Award, you (i) confirm having read and understood the documents relating to this grant (i.e., your Terms, including this Appendix B, and the Plan) which were provided in the English language, (ii) accept the terms of these documents accordingly, and (iii) agree not to challenge the validity of this document based on Law No. 24 of 2009 on National Flag, Language, Coat of Arms and National Anthem or the implementing Presidential Regulation (when issued).
Persetujuan dan Pemberitahuan Bahasa.
Terjemahan dari dokumen-dokumen terkait dengan pemberian ini ke Bahasa Indonesia dapat disediakan untuk anda berdasarkan permintaan kepada mellisa.riana.dewi@merck.com. Dengan menerima Penghargaan ini, anda (i) mengkonfirmasi bahwa telah membaca dan memahami dokumen-dokumen berkaitan dengan pemberian ini (yaitu, Syarat-syarat anda, termasuk suplemen ini dan Program) yang disediakan dalam Bahasa Inggris, (ii) menerima persyaratan di dalam dokumen-dokumen tersebut, dan (iii) setuju untuk tidak mengajukan keberatan atas keberlakuan dari dokumen ini berdasarkan Undang-Undang No. 24 Tahun 2009 tentang Bendera, Bahasa dan Lambang Negara serta Lagu Kebangsaan ataupun Peraturan Presiden sebagai pelaksanaannya (ketika diterbitkan).
Ireland
There are no country-specific provisions.



Country
Additional Terms and Conditions and Notifications
Israel
Securities Law Information
The grant of the RSU Award under the Plan is being made pursuant to an exemption from the requirement to file and publish a prospectus in Israel regarding the Plan obtained from the Israeli Securities Authority. Copies of the Plan and the Form S-8 registration statement for the Plan filed with the U.S. Securities and Exchange Commission will be sent to you, at no charge, on written request being mailed to Investor Relations at Merck & Co., Inc., 126 East Lincoln Avenue, P.O. Box 2000, Rahway, NJ 07065, U.S.A. The telephone number at the executive offices is 1-908-740-4000. Alternatively, copies of the Plan and the Form S-8 registration statement for the Plan filed with the U.S. Securities and Exchange Commission are available by searching the Company’s filings on the following web site: http://www.sec.gov/edgar/searchedgar/companysearch.html.
Trust Arrangement
You understand and agree that the RSU Award is offered subject to and in accordance with the terms of the Plan, the Addendum A - Israel to the Plan (the “Israeli Sub-Plan”), the Trust Agreement (the “Trust Agreement”) between the Company and the Company’s trustee appointed by the Company or its subsidiary or affiliate in Israel, currently ESOP Management and Trust Services Ltd. (the “Trustee”), and the Terms. In the event of any inconsistencies between the Israeli Sub-Plan, the Terms and/or the Plan, the Israeli Sub-Plan will govern the RSU Award granted to you in Israel. Capitalized terms used but not defined in this Appendix B for Israel, the Plan or the Terms have the meanings set forth in the Israeli Sub-Plan.
Requirement to Return Signed Confirmation Letter
If requested by the Employer or the Trustee, you are required to execute the Confirmation Letter - Trustee 102 Awards (“Confirmation Letter”) provided to you in connection with Awards granted to you under the Israeli Sub-Plan. In particular, you must print, sign and deliver a signed copy of the Confirmation Letter to the Trustee within thirty (30) days of the Grant Date, or by such other date as may be determined by your Employer or the Trustee not to exceed ninety (90) days from the Grant Date, for the RSU Award to qualify for preferential tax treatment. By accepting this RSU Award, you acknowledge and agree that the terms and conditions of the Confirmation Letter are hereby incorporated by reference into the Terms and shall apply to shares of Common Stock acquired upon expiration of the Restricted Period of the RSU Award. If the Trustee does not receive the signed Confirmation Letter within 30 days of the Grant Date, or by such other date as may be determined by your Employer or the Trustee not to exceed ninety (90) days from the Grant Date, the RSU Award may not qualify for favorable tax treatment. For more details, please contact Daphna Ben-Ari at daphna.ben-ari@merck.com or +972 9533306.
Confirmation of Section 102 Capital Gains Award Terms
The RSU Award is intended to be Capital Gain Awards that qualify for the tax treatment for Approved 102 Awards that are designated by the Company to qualify under the capital gain tax treatment in accordance with the provisions of Section 102(b)(2) of the Ordinance. Notwithstanding the foregoing, by accepting the RSU Award, you acknowledge that the Company cannot guarantee that the Capital Gain Award tax treatment will apply to the Awards granted to you.



Country
Additional Terms and Conditions and Notifications
By accepting the RSU Award, you: (a) acknowledge receipt of and represent that you have read and understand the Plan, the Israeli Sub-Plan, the Confirmation Letter and the Terms; (b) accept the RSU Award subject to all of the terms and conditions of the Plan, the Israeli Sub-Plan, the Confirmation Letter and the Terms; and (c) agree that the shares of Common Stock issued to upon expiration of the Restricted Period of the RSU Award will be issued to and deposited with the Trustee and shall be held in trust for your benefit as required by the Ordinance, the Israeli Sub-Plan and any approval by the Israeli Tax Authority pursuant to the terms of the Ordinance, the Israeli Sub-Plan and the Trust Agreement. Furthermore, by accepting the RSU Award, you confirm that you understand the terms and provisions of Section 102 of the Ordinance, particularly the capital gains track described in subsection (b)(2) and (b)(3) thereof, and agree that you will not require the Trustee to release the shares of Common Stock acquired upon expiration of the Restricted Period of the RSU Award to you or sell the shares of Common Stock to a third party, during the Holding Period, unless permitted to do so by the Ordinance or the Israeli Sub-Plan.
Italy
Plan Document Acknowledgment
By accepting the RSU Award, you further acknowledge that you have received a copy of the Plan, have reviewed the Plan and the Terms in their entirety and fully understand and accept all provisions of the Plan and the Terms; in particular, you acknowledge that you have read and specifically and expressly approve the following provisions in the Plan and the Terms: (a) your RSU Award cannot be transferred other than by will or the laws of descent and distribution; (b) in the event of involuntary termination of your employment, your right to receive Awards and to receive distributions from Awards, if any, will terminate as of the date that you are no longer actively employed by the Employer, unless otherwise expressly provided in the Terms; (c) the Plan is discretionary in nature and may be suspended or terminated by the Company at any time; (d) you are responsible for all Tax-Related Items; (e) if a reorganization, recapitalization, reclassification or other corporate event that results in an adjustment of the shares of Common Stock described in the Plan occurs, your RSU Award may be adjusted; (f) if a Change in Control, as described in the Plan, occurs, your RSU Award may immediately vest; (g) all decisions with respect to future grants will be at the sole discretion of the Company; and (h) the “Data Privacy” section of your Terms.
Japan
There are no country-specific provisions.
Jordan
There are no country-specific provisions.
Korea
Domestic Broker Requirement for Selling Shares
Korean residents are not permitted to sell foreign securities (including shares of Common Stock) through non-Korean brokers (such as Morgan Stanley Smith Barney) or deposit funds resulting from the sale of shares of Common Stock in an account with an overseas financial institution. If you wish to sell shares of Common Stock acquired under the Plan, you may be required to transfer the shares to a domestic investment broker in Korea and to effect the sale through such broker. You are solely responsible for engaging the domestic broker in Korea, and non-compliance with the requirement to sell shares of Common Stock through a domestic broker can result in significant penalties. You should consult your personal advisor(s) prior to selling any shares of Common Stock acquired under the Plan to ensure compliance.
Latvia
There are no country-specific provisions.



Country
Additional Terms and Conditions and Notifications
Lebanon
Securities Law Information
The grant of Awards and distribution of the Plan and the Terms, including this Appendix B, to Eligible Employees does not constitute the marketing or offering of securities to the public in Lebanon pursuant to Law No. 161 (2011), the Capital Markets Law. Offers under the Plan are being made only to Eligible Employees of the Employer or the Company or any other subsidiary, affiliate or JV of the Company.
Lithuania
There are no country-specific provisions.



Country
Additional Terms and Conditions and Notifications
Malaysia
Director Notification
If you are a director of the Company’s Malaysian subsidiary, affiliate or JV, you are subject to certain notification requirements under the Malaysian Companies Act. Among these requirements is an obligation to notify the Malaysian subsidiary, affiliate or JV in writing when you receive or dispose of an interest (e.g., RSU Awards or shares of Common Stock) in the Company or any related company. Such notifications must be made within 14 days of receiving or disposing of any interest in the Company or any related company.
Data Privacy
This provision replaces the “Data Privacy” section in your Terms:
You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in the Terms and any other grant materials by and among, as applicable, the Employer, the Company and its subsidiaries, affiliates and JVs for the exclusive purpose of implementing, administering and managing your participation in the Plan.
You understand that the Company and the Employer may hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of Common Stock or directorships held in the Company, details of all Awards or any other entitlement to shares of Common Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the exclusive purpose of implementing, administering and managing the Plan (“Data”). The Data is supplied by the Employer and also by you through information collected in connection with the Terms and the Plan.
You understand that Data will be transferred to Morgan Stanley Smith Barney or such other stock plan service provider as may be selected by the Company in the future, which is assisting the Company with the implementation, administration and management of the Plan. You understand that the recipients of the Data may be located in the United States or elsewhere, and that the recipients’ country (e.g., the United States) may have different data privacy laws and protections than your country. You understand that you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative at kon.li.yoong@merck.com. You authorize the Company, Morgan Stanley Smith Barney and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing your participation in the Plan. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan. You understand that you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative. Further, you understand that you are providing the consents herein on a purely voluntary basis. If you do not consent, or if you later seek to revoke your consent, your employment status or service with the Employer will not be adversely affected; the only adverse consequence of refusing or withdrawing your consent is that the Company would not be able to grant RSU Awards to the you or administer or maintain such RSU Awards. Therefore, you



Country
Additional Terms and Conditions and Notifications
understand that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.
Privasi Data
Peruntukan ini menggantikan bahagian “Privasi Data” dalam Terma-terma anda:
Anda dengan ini secara eksplisit dan tanpa sebarang keraguan mengizinkan pengumpulan, penggunaan dan pemindahan, dalam bentuk elektronik atau lain-lain, data peribadi anda seperti yang diterangkan dalam Terma-terma atau apa-apa bahan geran oleh dan di antara, seperti mana yang terpakai, Majikan, Syarikat dan mana-mana anak syarikat, syarikat sekutu atau usahasamanya untuk tujuan ekslusif bagi melaksanakan, mentadbir dan menguruskan penyertaan anda dalam Pelan.
Anda memahami bahawa Syarikat dan Majikan mungkin memegang maklumat peribadi tertentu tentang anda, termasuk, tetapi tidak terhad kepada, nama anda, alamat rumah dan nombor telefon, tarikh lahir, nombor insurans sosial atau nombor pengenalan lain, gaji, kewarganegaraan, jawatan, apa-apa saham atau jawatan pengarah yang dipegang dalam Syarikat, butir-butir tentang semua Anugerah atau apa-apa hak lain untuk saham biasa yang dianugerahkan, dibatalkan, dilaksanakan, terletak hak, tidak diletak hak ataupun yang belum dijelaskan bagi faedah anda, untuk tujuan eksklusif bagi melaksanakan, mentadbir dan menguruskan Pelan tersebut ("“Data"”). Data tersebut dibekalkan oleh Majikan dan juga oleh anda melalui maklumat yang dikumpul berkenaan dengan Terma-terma dan Pelan.
Anda memahami bahawa Data ini akan dipindahkan kepada Morgan Stanley Smith Barney atau pembekal perkhidmatan pelan saham lain yang mungkin dipilih oleh Syarikat pada masa depan, yang membantu Syarikat dengan pelaksanaan, pentadbiran dan pengurusan Pelan. Anda memahami bahawa penerima-penerima Data mungkin berada di Amerika Syarikat atau di tempat lain, dan bahawa negara penerima (contohnya, Amerika Syarikat) mungkin mempunyai undang-undang privasi data dan perlindungan yang berbeza daripada negara anda. Anda memahami bahawa anda boleh meminta satu senarai yang mengandungi nama dan alamat penerima-penerima Data yang berpotensi dengan menghubungi wakil sumber manusia tempatan di kon.li.yoong@merck.com. Anda memberi kuasa kepada Syarikat, Morgan Stanley Smith Barney dan mana-mana penerima lain yang mungkin membantu Syarikat (pada masa kini atau masa depan) untuk melaksanakan, mentadbir dan menguruskan Pelan untuk menerima, memiliki, menggunakan, mengekalkan dan memindahkan Data, dalam bentuk elektronik atau lain-lain, semata-mata dengan tujuan untuk melaksanakan, mentadbir dan menguruskan penyertaan anda dalam Pelan. Anda memahami bahawa Data hanya akan disimpan untuk tempoh yang perlu bagi melaksanakan, mentadbir, dan menguruskan penyertaan anda dalam Pelan. Anda memahami bahawa anda boleh, pada bila-bila masa, melihat data, meminta maklumat tambahan mengenai penyimpanan dan pemprosesan Data, meminta bahawa pindaan-pindaan dilaksanakan ke atas Data atau menolak atau menarik balik persetujuan dalam ini, dalam mana-mana kes, tanpa kos, dengan menghubungi secara bertulis wakil sumber manusia tempatan. Selanjutnya, anda memahami bahawa anda memberikan persetujuan di sini secara sukarela. Jika anda tidak bersetuju, atau jika anda kemudian membatalkan persetujuan anda, status pekerjaan atau perkhidmatan anda dengan Majikan tidak akan terjejas; satu-satunya akibat buruk jika anda tidak bersetuju atau menarik balik persetujuan anda adalah bahawa Syarikat tidak akan dapat



Country
Additional Terms and Conditions and Notifications
memberikan Anugerah kepada anda atau mentadbir atau mengekalkan anugerah tersebut. Oleh itu, anda memahami bahawa keengganan atau penarikan balik persetujuan anda boleh menjejaskan keupayaan anda untuk mengambil bahagian dalam Pelan. Untuk maklumat lanjut mengenai akibat keengganan anda untuk memberikan keizinan atau penarikan balik keizinan, anda memahami bahawa anda boleh menghubungi wakil sumber manusia tempatan.
Mexico
Securities Law Information
Any RSU Award offered under the Plan and the shares of Common Stock underlying the RSU Award have not been registered with the National Register of Securities maintained by the Mexican National Banking and Securities Commission and cannot be offered or sold publicly in Mexico. In addition, the Plan and any other document relating to any Award may not be publicly distributed in Mexico. These materials are addressed to you only because of your existing relationship with the Company and its subsidiaries, affiliates and JVs and these materials should not be reproduced or copied in any form. The offer contained in these materials does not constitute a public offering of securities but rather constitutes a private placement of securities addressed specifically to individuals who are present Employees of the Company or one of its subsidiaries, affiliates and JVs, made in accordance with the provisions of the Mexican Securities Market Law, and any rights under such offering shall not be assigned or transferred.
Labor Law Acknowledgement
These provisions supplement the “Nature of Grant” section in Part I of this Appendix B:
By accepting the RSU Award, you understand and agree that: (i) the RSU Award is not related to the salary and other contractual benefits granted to you by the Employer and (ii) any modification of the Plan or its termination shall not constitute a change or impairment of the terms and conditions of your employment.
Policy Statement
The invitation the Company is making under the Plan is unilateral and discretionary and, therefore, the Company reserves the absolute right to amend it and discontinue it at any time without any liability to you.
The Company, with registered offices at 126 East Lincoln Avenue, P.O. Box 2000, Rahway, NJ 07065, U.S.A., is solely responsible for the administration of the Plan and your participation in the Plan and the acquisition of shares of Common Stock does not, in any way, establish an employment relationship between you and the Company since you are participating in the Plan on a wholly commercial basis. Based on the foregoing, you expressly recognize that the Plan and the benefits that you may derive from participating in the Plan do not establish any rights between you and the Employer and do not form part of the employment conditions and/or benefits provided by the Employer, and any modification of the Plan or its termination shall not constitute a change or impairment of the terms and conditions of your employment.
Finally, you hereby declare that you do not reserve to yourself any action or right to bring any claim against the Company for any compensation or damages regarding any provision of the Plan or the benefits derived under the Plan, and you therefore grant a full and broad release to the Company, its subsidiaries, affiliates, JVs, branches, representation offices, shareholders, officers, agents or legal representatives, with respect to any claim that may arise.



Country
Additional Terms and Conditions and Notifications
Plan Document Acknowledgment
By accepting the RSU Award, you acknowledge that you have received a copy of the Plan, have reviewed the Plan and the Terms, including this Appendix B, in their entirety and fully understand and accept all provisions of the Plan and the Terms.
In addition, by accepting the benefits under this grant, you further acknowledge that you have read and specifically and expressly approve the terms and conditions in the “Nature of Grant” section in Part I of this Appendix B, in which the following is clearly described and established: (i) your participation in the Plan does not constitute an acquired right; (ii) the Plan and your participation in the Plan is offered by the Company on a wholly discretionary basis; (iii) your participation in the Plan is voluntary; and (iv) the Company and its subsidiaries, affiliates and JVs are not responsible for any decrease in the value of the shares of Common Stock underlying your RSU Award.
Morocco
Payment of Award
Any RSU Award granted to you will be settled in cash only. This means that upon vesting of your RSU Award, you will receive in cash the value of the underlying shares of Common Stock at vesting, less any Tax-Related Items and broker’s fees or commissions, which will be remitted to you via local payroll. The Company reserves the right to settle the RSU Award in shares of Commons Stock and to force the immediate sale of such shares of Common Stock depending on the development of applicable exchange control laws and regulations.
Netherlands
There are no country-specific provisions.



Country
Additional Terms and Conditions and Notifications
New Zealand
Securities Law Information
WARNING: This is an offer of rights to receive shares of Common Stock upon vesting of the RSU Award subject to the terms of the Plan and the Terms. The RSU Award gives you a stake in the ownership of the Company. You may receive a return if dividends are paid on the shares of Common Stock.
If the Company runs into financial difficulties and is wound up, you will be paid only after all creditors have been paid. You may lose some or all of your investment.
The shares of Common Stock are listed on the New York Stock Exchange. If you acquire shares of Common Stock under the Plan, you may be able to sell them on the New York Stock Exchange if there are interested buyers. The price of the shares of Common Stock is subject to fluctuation and will depend on the demand for the shares of Common Stock.
New Zealand law normally requires people who offer financial products to give information to investors before they invest. This information is designed to help investors to make an informed decision. The usual rules do not apply to this offer because it is made under an employee share purchase scheme. As a result, you may not be given all the information usually required. You will also have fewer other legal protections for this investment.
You should ask questions, read all documents carefully, and seek independent financial advice before committing to participate in the Plan.
In addition, you are hereby notified that the documents listed below are available for review at http://one.merck.com/sites/hr/Lists/ChannelContent/CustDispForm.aspx?ID=63&Channel=Money. Filings made with the U.S. SEC can also be found at www.sec.gov.
(i)    this Appendix B which together with the Terms and the Plan sets forth the terms and conditions of your participation in the Plan;
(ii)    a copy of the Company’s most recent annual report (i.e., Form 10-K);
(iii)     a copy of the Company’s most recent published financial statements;
(iv)    a copy of the Plan; and
(v)    a copy of the Plan Prospectus.
A copy of the above documents will be sent to you free of charge on written request being mailed to Investor Relations at Merck & Co., Inc., 126 East Lincoln Avenue, P.O. Box 2000, Rahway, NJ 07065, U.S.A. The telephone number at the executive offices is 1-908-740-4000.
As noted above, you are advised to carefully read the materials provided before making a decision whether to participate in the Plan. You are also encouraged to contact your tax advisor for specific information concerning your personal tax situation with regard to Plan participation.



Country
Additional Terms and Conditions and Notifications
Norway
There are no country-specific provisions.
Panama
Securities Law Information
Your RSU Award is granted pursuant to the Plan and the shares of Common Stock which may be issued on the expiration of the Restricted Period are offered in a private transaction. This is not an offer to the public and the offer is not subject to the protections established by Panamanian securities laws, nor registration requirements.
Peru
Securities Law Notification
The offering of the RSU Award is considered a private offering in Peru; therefore, neither the grant of the RSU Award, nor the issuance of shares at the expiration of the Restricted Period, is subject to securities registration in Peru. For more information concerning this offer, please refer to the Plan, the Terms, the Plan Prospectus and any other grant documents made available to you by the Company. For more information regarding the Company, please refer to the Company’s most recent annual report on Form 10-K and quarterly report on Form 10-Q available at www.sec.gov, as well as the Company’s “Investor Relations” website at http://investors.merck.com.
Philippines
Payment of Award
Any RSU Award granted to you will be settled in cash only. This means that upon vesting of your RSU Award, you will receive in cash the value of the underlying shares of Common Stock at vesting, less any Tax-Related Items and broker’s fees or commissions, which will be remitted to you via local payroll. The Company reserves the right to settle the RSU Award in shares of Common Stock and to force the immediate sale of such shares of Common Stock depending on the development of applicable securities laws and regulations.
Poland
There are no country-specific provisions.
Portugal
Language Consent
You hereby expressly declare that you have full knowledge of the English language and have read, understood and fully accept and agree with the terms and conditions established in the Plan and the Terms.
Conhecimento da Lingua.
O Contratado, pelo presente instrumento, declara expressamente que tem pleno conhecimento da língua inglesa e que leu, compreendeu e livremente aceitou e concordou com os termos e condições estabelecidas no Plano e no Acordo de Atribuição (Terms em inglês).
Puerto Rico
There are no country-specific provisions.



Country
Additional Terms and Conditions and Notifications
Romania
Language Consent
By accepting the RSU Award, you acknowledge that you are proficient in reading and understanding English or have consulted with an advisor who is sufficiently proficient in English as to allow you to fully understood the terms of the documents related to the grant (the Terms, including this Appendix B and the Plan), which were provided in the English language. You accept the terms of these documents accordingly.
Consimtamant cu privire la limba
Prin acceptarea de aceasta Acordare, confirmati ca aveti un nivel adecvat de cunoastere in ce priveste cititirea si intelegerea limbii engleze sau ati consultat un consultant care este suficient de competent in limba engleza pentru a va permite sa intelegeti pe deplin termenii documentelor referitoare la acordare (anuntul, Acordul si Planul), care au fost furnizate in limba engleza. Acceptati termenii acestor documente in consecinta.
Russia
Payment of Award
If the Company in its sole discretion determines that the issuance of shares of Common Stock pursuant to this RSU Award would not comply with applicable laws, rules and regulations and/or that the approval of a governmental agency that it deems necessary or appropriate has not been obtained or has lapsed for whatever reason by the relevant Vesting Date, the Company will settle this RSU Award in cash only. Alternatively, the Company may permit this RSU Award to vest on the Vesting Date but delay settlement of this RSU Award until such time as it determines it is permissible to issuance shares of Common Stock as determined in accordance with Section 23 of the Plan. In the event that this RSU Award is settled in cash, upon settlement of your RSU Award, you will receive in cash the value of the underlying shares of Common Stock at vesting, less any Tax-Related Items and broker’s fees or commissions, which will be remitted to you via local payroll.
Securities Law Information and U.S. Transaction
The Terms, the Plan and all other materials that may be distributed regarding participation in the Plan do not constitute advertising or an offering of securities in Russia, and your acceptance of the RSU Award results in an agreement between the Company and you that is completed in the United States and is governed by the laws of the State of New Jersey. Any securities issued under the Plan have not and will not be registered in Russia, nor will they be admitted for listing on any Russian exchange for trading within Russia. Thus, the securities described in the Terms, the Plan and all other materials that may be distributed regarding participation in the Plan may not be used for an offering or private or public circulation in Russia. In no event will the shares of Common Stock to be issued pursuant to the RSU Award be delivered to you in Russia and all shares of Common Stock will be maintained on your behalf in a brokerage account outside of Russia. You will not be permitted to sell or otherwise transfer the shares of Common Stock directly to a Russian legal entity or resident. You are permitted to sell the shares of Common Stock only on the New York Stock Exchange and only through a United States broker.



Country
Additional Terms and Conditions and Notifications
Saudi Arabia
Payment of Award
Any RSU Award granted to you will be settled in cash only. This means that upon vesting of your RSU Award, you will receive in cash the value of the underlying shares of Common Stock at vesting, less any Tax-Related Items and broker’s fees or commissions, which will be remitted to you via local payroll. The Company reserves the right to settle the RSU Award in shares of Common Stock and to force the immediate sale of such shares of Common Stock depending on the development of applicable securities laws and regulations.
Serbia
Securities Law Information
The RSU Award is not subject to the regulations concerning public offers and private placements under the Law on Capital Market. As set forth in the Terms, the RSU Award is subject to the laws of the State of New Jersey, U.S.A. (without regard to its conflict of law provisions).



Country
Additional Terms and Conditions and Notifications
Singapore
Restriction on Sale and Transferability
You hereby agree that any shares of Common Stock acquired pursuant to the RSU Award will not be offered for sale in Singapore prior to the six-month anniversary of the Grant Date of the RSU Award, unless such sale or offer is made pursuant to one or more exemptions under Part XII Division 1 Subdivision (4) (other than section 280) of the Securities and Futures Act (Chap. 289, 2006 Ed.) (“SFA”) or pursuant to, and in accordance with, the conditions of any other applicable provision(s) of the SFA.
Securities Law Information
The RSU Award is being granted to you pursuant to the “Qualifying Person” exemption under section 273(1)(f) of the SFA, on which basis it is exempt from the prospectus and registration requirements under the SFA, and is not made to you with a view of the RSU Award being subsequently offered for sale to any other party. The Plan has not been lodged or registered as a prospectus with the Monetary Authority of Singapore.
Director Notification
If you are a director (including an alternate, substitute, associate or shadow director) of a Singaporean subsidiary, affiliate or JV of the Company, you are subject to certain notification requirements under the Singapore Companies Act. Among these requirements is an obligation to notify the Singapore subsidiary, affiliate or JV in writing when you receive an interest (e.g., RSU Awards, shares of Common Stock) in the Company or any related companies. In addition, you must notify the Singaporean subsidiary, affiliate or JV when you sell shares of the Company’s Common Stock or any related company (including when you sell shares of Common Stock acquired upon the expiration of the Restricted Period). These notifications must be made within two business days of acquiring or disposing of any interest in the Company or any related company. In addition, a notification must be made of your interests in the Company or any related company within two days of either after the director becomes aware of the change in respect of the particulars of any of the aforesaid, the date on which the director becomes a holder of, or acquires an interest in, the shares, debentures, rights, contracts, participatory interests, other securities or securities-based derivatives contacts, whichever last occurs. There is no prescribed form for such disclosure, although in practice, the company secretary normally would prepare a formatted disclosure form that requests the following information: equity award granted, number of shares acquired, description of consideration, if applicable, and the date of the transaction.
A director shall be deemed to have an interest in securities or securities-based derivative contracts referred to above if a family member of the director (not being him or herself a director), holds or has an interest in those securities or securities-based derivatives contract and any contract entered into by, or any grant made to, a family member of a director of a Company (not being himself a director) shall be deemed to have been entered into by, made or exercised by or made to the director. A “family member” means a spouse, or a son, adopted son, step-son, daughter, adopted daughter or step-daughter below the age of 21 years.
Slovak Republic
There are no country-specific provisions.



Country
Additional Terms and Conditions and Notifications
Slovenia
Language Consent
By accepting the grant of the RSU Award, you acknowledge that you are proficient in reading and understanding English and fully understand the terms of the documents related to the grant (this Appendix B, the Terms and the Plan), which were provided in the English language. You accept the terms of those documents accordingly.
Soglasje za Uporabo Angleškega Jezika
S sprejetjem dodelitve Nagrade (the RSU Award) potrjujete in priznavate, da ste sposobni brati in razumeti angleški jezik ter da v celoti razumete določila dokumentov, povezanih z dodelitvijo (ta dodatek, Določila (the Terms) in Načrt (the Plan)), ki so bili posredovani v angleškem jeziku. Skladno s tem sprejemate določila teh dokumentov.
South Africa
Tax Notification
By accepting the RSU Award, you agree to notify your Employer of the amount of any gain you realize upon the expiration of the Restricted Period. If you fail to advise your Employer of the gain realized upon expiration of the Restricted Period, you may be liable for a fine. You will be responsible for paying any difference between the actual tax liability and the amount withheld.
Securities Law Information
In compliance with South African Securities Law, you acknowledge that you have been notified that the documents listed below are available for your review on the Company intranet site at the web addresses listed below:
1. the Company’s most recent Annual Report (Form 10-K) – http://investors.merck.com/investors/financial-reports/quarterly-financials/default.aspx
2. the Company’s most recent Plan Prospectus - http://one.merck.com/sites/hr/Lists/ChannelContent/CustDispForm.aspx?ID=63&Channel=Money
You acknowledge that you may have copies of the above documents sent to you, at no charge, on written request being mailed to Investor Relations at Merck & Co., Inc., 126 East Lincoln Avenue, P.O. Box 2000, Rahway, NJ 07065, U.S.A. The telephone number at the executive offices is 1-908-740-4000.



Country
Additional Terms and Conditions and Notifications
Spain
Labor Law Acknowledgment
This provision supplements the “Nature of Grant” section in Part I of this Appendix B:
By accepting this RSU Award, you acknowledge that you understand and agree that you consent to participation in the Plan and that you have received a copy of the Plan.
You understand that the Company, in its sole discretion, has unilaterally and gratuitously decided to distribute Awards under the Plan to individuals who may be employees of the Company or its subsidiaries, affiliates or JVs throughout the world. The decision is a limited decision that is entered into upon the express assumption and condition that any grant will not economically or otherwise bind the Company or any of its subsidiaries, affiliates or JVs over and above the specific terms of the Plan on an ongoing basis. Consequently, you understand that any RSU Award is given on the assumption and condition that it shall not become a part of any employment contract (either with the Company or any of its subsidiaries, affiliates or JVs) and shall not be considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever. Further, you understand and freely accept that there is no guarantee that any benefit whatsoever shall arise from any gratuitous and discretionary Award since the future value of the RSU Award and shares of Common Stock is unknown and unpredictable. In addition, you understand that the RSU Award would not be made to you but for the assumptions and conditions referred to above; thus, you acknowledge and freely accept that should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, then any RSU Award shall be null and void.
You also understand and agree that, as a condition of the grant of the RSU Award, the termination of your employment for any reason (including the reasons listed below), the RSU Award will cease vesting immediately effective on the date you are no longer providing services to the Employer or the Company or any of its subsidiaries, affiliates or JVs, unless otherwise specifically provided in the Terms. In particular, you understand and agree that the RSU Award will be forfeited without entitlement to the underlying shares of Common Stock or to any amount as indemnification in the event of a termination of your employment as described in the Terms prior to expiration of the Restricted Period by reason of, including but not limited to, resignation, retirement, disciplinary dismissal adjudged to be with cause, disciplinary dismissal adjudged or recognized to be without good cause (i.e., subject to “despido improcednte”), individual or collective dismissal on objective grounds, whether adjudged or recognized to be with or without cause, material modification of the terms of employment under Article 41 of the Workers’ Statute, relocation under Article 40 of the Workers’ Statute, Article 50 of the Workers’ Statute, unilateral withdrawal by the Employer and under Article 10.3 of the Royal Decree 1382/1985.
Securities Law Information
No “offer of securities to the public,” as defined under Spanish law, has taken place or will take place in the Spanish territory in connection with the grant of the RSU Award. The Plan and the Terms have not been nor will they be registered with the Comisión Nacional del Mercado de Valores, and do not constitute a public offering prospectus.



Country
Additional Terms and Conditions and Notifications
Sweden
Authorization to Withhold
The following provision supplements the “Tax Withholding” section of the Terms:
Without limiting the Company’s and the Employer’s authority to satisfy their withholding obligations for Tax-Related Items as set forth in the “Tax Withholding” section of the Terms, in accepting the RSU Award, you authorize the Company and/or the Employer to withhold shares of Common Stock or to sell shares of Common Stock otherwise deliverable to you upon vesting to satisfy Tax-Related Items, regardless of whether the Company and/or the Employer have an obligation to withhold such Tax-Related Items.
Switzerland
Securities Law Information
The offering of participation in the Plan is considered a private offering in Switzerland; therefore, it is not subject to registration in Switzerland. Neither this document nor any other materials relating to the Plan (i) constitute a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services (“FinSA”), (ii) may be publicly distributed nor otherwise made publicly available in Switzerland to any person other than an employee of the Company or Employer or (iii) has been or will be filed with, approved or supervised by any Swiss reviewing body according to article 51 FinSA or any Swiss regulatory authority, including the Swiss Financial Market Supervisory Authority.
Taiwan
Securities Law Information
The RSU Award and the shares of Common Stock to be issued pursuant to the Plan are available only to Eligible Employees of the Company and its subsidiaries, affiliates and JVs. The grant of the RSU Award and offer of participation in the Plan do not constitute a public offer of securities by a Taiwanese company.
Thailand
There are no country-specific provisions.
Türkiye
Securities Law Information
Under Turkish law, you are not permitted to sell shares of the Company’s Common Stock in Türkiye; instead, the sale must take place outside Türkiye, which will be the case if the shares of Common Stock are sold on the New York Stock Exchange on which the shares are currently listed.
You may be required to engage a Turkish financial intermediary to assist with the sale of shares of Common Stock acquired under the Plan. While you should not need to engage a Turkish financial intermediary with respect to the acquisition of such shares of Common Stock (as no consideration is paid for the RSU Award or underlying shares of Common Stock), this is less certain. In light of this uncertainty, you should consult your personal legal advisor prior to the expiration of the Restricted Period or any sale of shares of Common Stock to ensure compliance with the financial intermediary requirements.
Ukraine
Payment of Award
Any RSU Award granted to you will be settled in cash only. This means that upon vesting of your RSU Award, you will receive in cash the value of the underlying shares of Common Stock at vesting, less any Tax-Related Items and broker’s fees or commissions, which will be remitted to you via local payroll. The Company reserves the right to settle the RSU Award in shares of Common Stock and to force the immediate sale of such shares of Common Stock depending on the development of applicable tax laws and regulations.



Country
Additional Terms and Conditions and Notifications
United Arab Emirates
Securities Law Information
The Plan is only being offered to Eligible Employees of the Company and its subsidiaries, affiliates and JVs and is in the nature of an “exempt personal offer” of equity incentives to Eligible Employees of the Company’s subsidiary in the United Arab Emirates. The Plan, the Terms and any other grant documents you may receive from the Company are intended for distribution only to such Eligible Employees and must not be delivered to, or relied on by, any other person. Prospective recipients of the securities offered (i.e., shares of the Company’s Common Stock) should conduct their own due diligence on the securities. If you do not understand the contents of the Plan and the Terms, you should consult an authorized financial adviser. The Ministry of Economy, the Dubai Department of Economic Development, Emirates Securities and Commodities Authority, Central Bank and the Dubai Financial Services Authority, as applicable depending on your Employer’s location in the United Arab Emirates, have not approved the Plan or the Terms or taken steps to verify the information set out therein, and have no responsibility for such documents.
United Kingdom
Tax Acknowledgment
You agree that you are liable for all Tax-Related Items and hereby covenant to pay all such Tax-Related Items, as and when requested by the Company or, if different, your Employer or by HM Revenue and Customs (“HRMC”) (or any other tax authority or any other relevant authority). You also agree to indemnify and keep indemnified the Company and, if different, your Employer against any Tax-Related Items that they are required to pay or withhold or have paid or will pay to HMRC (or any other tax authority or any other relevant authority) on your behalf.
Notwithstanding the foregoing, if you are a director or executive officer of the Company (within the meaning of Section 13(k) of the U.S. Securities Exchange Act of 1934, as amended), the amount of any income tax not collected from or paid by you within ninety (90) days of the end of the U.K. tax year in which the event giving rise to the Tax-Related Items occurs may constitute a benefit to you on which additional income tax and National Insurance contributions may be payable. You understand that you will be responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for paying to the Company and/or the Employer (as appropriate) the amount of any employee National Insurance contributions due on this additional benefit, which may also be recovered from you through any means set forth in the “Tax Withholding” section of the Terms.
Uruguay
There are no country-specific provisions.
Vietnam
Payment of Award
Any RSU Award granted to you will be settled in cash only. This means that upon vesting of your RSU Award, you will receive in cash the value of the underlying shares of Common Stock at vesting, less any Tax-Related Items and broker’s fees or commissions, which will be remitted to you via local payroll. The Company reserves the right to settle the RSU Award in shares of Common Stock and to force the immediate sale of such shares of Common Stock depending on the development of applicable exchange control laws and regulations.



APPENDIX C
MERCK & CO., INC.
SPECIAL NOTICE FOR EMPLOYEES IN DENMARK
ARBEJDSGIVERERKLÆRING/EMPLOYER STATEMENT
I henhold til § 3, stk. 1, i lov om brug af køberet eller tegningsret til aktier m.v. i ansættelsesforhold som ændret pr. 1 . januar 2019 ("Aktieoptionsloven") er du berettiget til i en særskilt skriftlig erklæring at modtage følgende oplysninger om betingede aktieenheder ("Tildeling") tildelt dig af Merck & Co., Inc. ("Selskabet") i henhold til Selskabets 2019 Incentive Stock Plan (“Planen”).
Pursuant to Section 3(1) of the Danish Act on the Use of Rights to Purchase or Subscribe for Shares etc. in Employment Relationships as amended with effect from 1 January 2019 (the “Stock Option Act”), you are entitled to receive the following information regarding restricted stock units (the “Award”) granted to you by Merck & Co., Inc. (the “Company”) under its 2019 Incentive Stock Plan (the “Plan”) in a separate written statement.
Denne erklæring indeholder kun de oplysninger, der er nævnt i Aktieoptionsloven.  De fuldstændige vilkår og betingelser, der gælder for din Tildeling, fremgår af Planen, vilkårene for 2019 tildeling af betingede aktieenheder for ikke-amerikanske medarbejdere (Global Terms and Conditions) (“Vilkårene”) og af landetillægget, som alle er udleveret til dig. 
This statement contains only the information mentioned in the Stock Option Act.  The terms and conditions of your Award are set forth in their entirety in the Plan and the Global Terms and Conditions including Appendix B thereto (the “Terms”), which have been made available to you. 
I tilfælde af uoverensstemmelse mellem indholdet af denne erklæring og Planen, Vilkårene, har Planen of Vilkårene forrang.
In the event of any inconsistency between the contents of this statement and the Plan and the Terms, the terms and conditions of the Plan and the Terms will prevail.
1. Tidspunkt for tildeling af den vederlagsfri ret til at modtage ordinære aktier mod opfyldelse af visse betingelser
1. Date of grant of unfunded right to receive shares of Common Stock upon satisfying certain conditions
Tildelingstidspunktet er den dato, hvor Vederlagsudvalget under Selskabets Bestyrelse eller et underudvalg under samme, eller et eventuelt andet bestyrelsesudvalg, der måtte efterfølge dette, ("Udvalget") godkendte tildeling til dig og besluttede, at denne skulle træde i kraft som anført i Vilkårene.
The Grant Date of your Award is the date that the Compensation and Benefits Committee of the Board of Directors of the Company or subcommittee thereof, or such other successor committee of the Board of Directors (the “Committee”) approved a grant for you and determined it would be effective, which is set forth in the Terms.
2. Vilkår for tildeling af ret til at modtage ordinære aktier mod opfyldelse af visse betingelser
2. Terms or conditions for grant of a right to receive shares of Common Stock upon satisfying certain conditions
Tildelinger i henhold til Planen sker alene efter Udvalgets eget frie skøn.  Selskabet har meget vide beføjelser til at bestemme, hvem der kan modtage Tildelinger og hvornår, og til at fastsætte betingelserne for Tildelingerne.  Selskabet kan efter dets eget frie skøn vælge fremover ikke at give Tildelinger.   I henhold til bestemmelserne i Planen og Vilkårene har du ikke nogen ret til eller noget krav på fremtidige tildelinger i henhold til Planen.
The grant of Awards under the Plan is made at the sole discretion of the Committee.  The Company has very broad powers to determine who will receive Awards and when, and to set the terms of the Awards.  The Company may decide, in its sole discretion, not to make any grants of Awards in the future.  Under the terms of the Plan and the Terms, you have no entitlement or claim to receive future grants under the Plan.



3. Modningstidspunkt eller -periode
3. Vesting date or period
Din Tildeling modnes med 33,333 % på hhv. 1 og 2 årsdag for Tildelingstidspunktet og balancen skal modnes på 3-årsdagen for tildelingstidspunktet (hver af disse er en "Modningsdag"), medmindre den af de i Vilkårene anførte årsager inden da er modnet eller ophørt.  På modningstidspunktet konverteres din Tildeling til et tilsvarende antal ordinære aktier i Selskabet.
Your Award shall vest 33.333% on each of the first and second anniversaries of the Grant Date and the balance shall vest on the third anniversary of the Grant Date (each a “Vesting Date”), unless vested or terminated earlier for the reasons set forth in the Terms.  Your Award shall be converted into an equivalent number of Company shares of Common Stock upon vesting of the Award.
4. Udnyttelseskurs
4. Exercise price
Der betales ingen udnyttelseskurs i forbindelse med modning af din Tildeling eller Selskabets udstedelse af ordinære aktier til dig i overensstemmelse med den ovenfor beskrevne modningstidsplan.
No exercise price is payable upon the vesting of your Award or the issuance of shares of the Company’s Common Stock to you in accordance with the vesting schedule described above.
5. Din retsstilling i forbindelse med fratræden
5. Your rights upon termination of employment
Ved din fratræden vil din Tildeling blive behandlet i overensstemmelse med bestemmelsen “Ansættelsesforholdets ophør” (defineret som Termination of Employment i Vilkårene), hvilken bestemmelse er opsummeret umiddelbart nedenfor.
The treatment of your Award upon termination of employment will be determined in accordance with the “Termination of Employment” section of the Terms summarized immediately below.
A. Generel regel. Hvis dit ansættelsesforhold inden for den Betingede Periode (defineret som Restricted Period i Vilkårene) ophører af nogen anden årsag end de nedenfor anførte, fortabes din Tildeling (og eventuelt optjent udbyttemodværdi) på tidspunktet for ophøret af dit ansættelsesforhold.
A. General Rule. If your employment is terminated during the Restricted Period (as defined in the Terms), for any reason other than those specified in the following paragraphs, your Award (and any accrued dividend equivalents) will be forfeited on the date your employment ends.
B. Ufrivilligt ophør af ansættelsesforholdet. Hvis Selskabet vurderer, at dit ansættelsesforhold er ophørt ufrivilligt inden for den Betingede Periode, men på eller efter 1-årsdagen for Tildelingen, vil en forholdsmæssig andel af din umodnede Tildeling og eventuelt optjent udbyttemodværdimodne på den efterfølgende Modningsdag.. Denne forholdsmæssige andel vil være svarende til Tildelingens fulde beløb (uanset om Tildelingen er modnet eller ej) gange antal fuldt forløbne måneder inden for den Betingede Periode og forud for tidspunktet for ansættelsesforholdets ophør, delt med 36; reduceret med antal modnede betingede aktieenheder. Resten, inklusive eventuelt optjent udbyttemodværdi, fortabes på tidspunktet for ansættelsesforholdets ophør.
B. Involuntary Termination. If the Company determines that your employment is involuntarily terminated during the Restricted Period but on or after the first anniversary, a pro rata portion of your unvested Award and accrued dividend equivalents will vest on the next subsequent Vesting Date. The pro rata portion will equal the full amount of the Award (whether or not vested) times the number of completed months during the Restricted Period and prior to the date employment terminates, divided by 36; reduced by the number of restricted stock units that have vested. The remainder and any accrued dividend equivalents will be forfeited on the date your employment ends.



C. Salg. Hvis dit ansættelsesforhold inden for den Betingede Periode (som defineret i Vilkårene) ophører, og Selskabet vurderer, at ophøret skyldes et salg af dit datterselskab, afdeling eller joint venture, vil følgende del af din Tildeling og eventuelt optjent udbyttemodværdi blive udbetalt til dig på det tidspunkt, hvor sådan udbetaling ville være sket, hvis dit ansættelsesforhold ikke var ophørt: En tredjedel, hvis ansættelsesforholdet ophører på eller efter Tildelingstidspunktet, men før 1-årsdagen for tildelingen; og hele Tildelingen, hvis ansættelsesforholdet ophører på eller efter 1-årsdagen for tildelingen. Såfremt der består en resterende andel af din Tildeling, der ikke modnet i henhold til fornævnte sætning, vil en sådan andel bortfalde den dag din ansættelse ophører.
C. Sale. If your employment is terminated during the Restricted Period and the Company determines that such termination resulted from the sale of your subsidiary, affiliate, division or joint venture, the following portion of your Award and accrued dividend equivalents will be distributed to you at such time as it would have been paid if your employment had continued: one-third if employment terminates on or after the Grant Date but before the first anniversary thereof; and all if employment terminates on or after the first anniversary of the Grant Date. The remaining portion, if any, of the Award that does not vest pursuant the foregoing sentence will be forfeited on the date your employment ends.
D. Pensionering. Hvis dit ansættelsesforhold inden for den Betingede Periode ophører som følge af pensionering, vil en forholdsmæssig andel af din umodnede Tildeling og eventuelt optjent udbyttemodværdimodne på den efterfølgende Modningsdag efter ophøret af dit ansættelsesforhold. . Denne forholdsmæssige andel vil være svarende til Tildelingens fulde beløb (uanset om Tildelingen er modnet eller ej) gange antal fuldt forløbne måneder inden for den Betingede Periode og forud for tidspunktet for ansættelsesforholdets ophør, delt med 36; reduceret med antal modnede betingede aktieenheder. Resten, inklusive eventuelt optjent udbyttemodværdi, fortabes på tidspunktet for ansættelsesforholdets ophør.
D. Retirement. If your employment terminates by retirement during the Restricted Period, a pro rata portion of your unvested Award and accrued dividend equivalents will vest on the next subsequent Vesting Date following your termination. The pro rata portion will equal the full amount of the Award (whether or not vested) times the number of completed months during the Restricted Period and prior to the date employment terminates, divided by 36; reduced by the number of restricted stock units that have vested. The remainder and any accrued dividend equivalents will be forfeited on the date your employment ends.
E. Dødsfald. Død. Hvis din ansættelse opsiges på grund af din død i den begrænsede periode, men forud for en ansættelsesopsigelse, som er påtænkt i B, C, D, G eller H, vil hele denne tildeling og optjente udbytteækvivalenter straks optjenes. Hvis du dør i den begrænsede periode, men efter at dit ansættelsesforhold ophører af de årsager, der er anført i B, C, D, G eller H, vil den resterende, ikke-fortabte del af denne Award og optjente udbytteækvivalenter som er optjent indtil dødsdagen straks optjenes.
E. Death. If your employment terminates due to your death during the Restricted Period but prior to an employment termination contemplated in B, C, D, G or H, all of this Award and accrued dividend equivalents will immediately vest. If you die during the Restricted Period but after your employment terminates for the reasons contemplated in B, C, D, G or H, the remaining, non-forfeited portion of this Award and accrued dividend equivalents that have accrued through the date of death will immediately vest.
F. Uredelighed eller pligtforsømmelse. Hvis dit ansættelsesforhold ophører som følge af bevidst uredelighed eller forsætlig eller grov pligtforsømmelse fra din side, fortabes denne Tildeling og eventuelt optjent udbyttemodværdi samtidig med din modtagelse af meddelelse om ansættelsesforholdets ophør.
F. Misconduct. If your employment is terminated as a result of your deliberate, willful or gross misconduct, this Award and accrued dividend equivalents will be forfeited immediately upon your receipt of notice of such termination.



G. Uarbejdsdygtighed. Hvis dit ansættelsesforhold inden for den Betingede Periode ophører, og Selskabet vurderer, at ophøret skyldes din manglende evne til at opfylde de forpligtelser, der påhviler dig i kraft af din stilling, som følge af fysisk eller mental svagelighed, der forventes at ville vare ved i mindst 6 måneder eller medføre din død, vil - uanset, om du måtte være berettiget til invaliditetsydelser fra nogen invaliditetsordning - denne Tildeling forblive i kraft og kvalificeret til udbetaling i overensstemmelse med Vilkårene på samme måde, som hvis ansættelsesforholdet ikke var ophørt, idet udbetaling i så fald vil ske samtidig med tilsvarende udbetalinger til aktive medarbejdere.
G. Disability. If your employment is terminated during the Restricted Period and the Company determines that such termination resulted from inability to perform the material duties of your role by reason of a physical or mental infirmity that is expected to last for at least six months or to result in your death, whether or not you are eligible for disability benefits from any applicable disability program, then this Award will continue and be distributable in accordance with its terms as if employment had continued and will be distributed at the time active employees receive distributions with respect to this Award.
H. Kontrolskifte. Hvis Selskabet eller noget moderselskabs, datterselskabs, tilknyttet parts eller joint venture af Selskabet inden for den Betingede Periode uden Berettigelse bringer dit ansættelsesforhold til ufrivillig opsigelse før den anden årsdag for gennemførelsen af et hvilket som helst Kontrolskifte (defineret som Change in Control i følgende plan: Merck & Co., Inc. Change in Control Separate Benefits Plan (eksklusiv en MSD Change in Control)) , vil denne Tildeling forblive i kraft i overensstemmelse med Vilkårene på samme måde, som hvis ansættelsesforholdet ikke var ophørt, idet udbetaling i så fald vil ske samtidig med tilsvarende udbetalinger til aktive medarbejdere. Hvis denne Tildeling efter et kontrolskifte ikke længere er udestående og heller ikke er konverteret til en anden Tildeling, vil denne Tildeling straks modne for så vidt angår den andel af Tildelingen der er umodnet på tidspunktet for Kontrolskifte og optjente udbytteækvivalenter som er optjent indtil en sådan dag og, ved valget af Selskabet, vil du være berettiget til for en sådan andel af denne Tildeling at modtage kontant betaling med et beløb svarende fair markedsværdi af det vederlag, kapitalejerne i Selskabet modtog i forbindelse medKontrolskiftet. . Dette afsnit bortfalder, når der er gået 2 år fra Kontrolskiftets gennemførelse.
H. Change in Control. If the Company or a parent, subsidiary, affiliate or joint venture of the Company involuntarily terminates your employment during the Restricted Period without Cause before the second anniversary of the closing of any Change in Control (as defined in the Merck & Co., Inc. Change in Control Separate Benefits Plan (excluding an MSD Change in Control)), then this Award will continue in accordance with its terms as if employment had continued and will be distributed at the time active employees receive distributions with respect to this Award. If this Award does not remain outstanding following the change in control and is not converted into a successor Award, then this Award will immediately vest with respect to the portion of the Award that is unvested as of the Change in Control and dividend equivalents that have accrued through such date and, at the election of the Company, you will be entitled to receive cash for such portion of this Award in an amount equal to the fair market value of the consideration paid to Company stockholders for a share of Company Common Stock in the Change in Control. On the second anniversary of the closing of the Change in Control, this paragraph shall expire.



I. Transfer of Employment. Overførsel af ansættelsesforhold mellem Selskabet, et datterselskab, tilknyttet part, Joint Venture, Joint Venture partner eller tilknyttet part til Selskabet der yder ydelser til UV med en sådan partner eller tilknyttet part eller enhver anden enhed, som Selskabet har bestemt at Selskabet har en betydelig forretningsinteresse eller ejerandel i (samlet: " Selskabsgruppen"), anses i forhold til denne Tildeling ikke for ophør af ansættelsesforholdet. Sådan ansættelse skal godkendes af Selskabet og være sammenhængende med ansættelsen i enheden i Selskabsgruppen som du var ansat i umiddelbart inden den pågældende overførsel. Vilkårene i punkt A til H ovenfor finder fortsat anvendelse på denne Tildeling efter en overførsel af ansættelsesforhold i overensstemmelse med dette punkt.
I. Transfer of Employment. Transfer of employment between the Company, a subsidiary, affiliate, JV, JV partner or affiliate of the Company who provides services to the UV with such partner or affiliate or other entity in which the Company has determined that it has a significant business or ownership interested (together, the “Company Group”) is not considered termination of employment for purposes of this Award. Such employment must be approved by the Company and contiguous with employment by the entity in the Company Group you were employed by immediately prior to the relevant transfer. The terms set out in paragraphs A though H above shall continue to apply to this Award following a transfer of employment in accordance with this section.
6. Økonomiske aspekter ved deltagelse i Planen
6. Financial aspects of participating in the Plan
Tildelingen har ingen umiddelbare økonomiske konsekvenser for dig.  Det er først ved modning af Tildelingen og det efterfølgende salg af de modtagne ordinære aktier ved modning, at du vil kunne realisere nogen indtægt under Planen.
The grant of the Award has no immediate financial consequences for you.  It is not until vesting of the Award and the subsequent sale of shares of Common Stock acquired at vesting that you may realize any income under the Plan.
Værdien af Tildelingen indgår ikke i beregningen af feriepenge, pensionsbidrag, fratrædelsesgodtgørelse, godtgørelser eller andre lovpligtige, vederlagsafhængige ydelser.

The value of the Award is not taken into account when calculating holiday allowances, pension contributions, severance pay, statutory allowance, compensation or other statutory remuneration calculated on the basis of salary.
Investering i aktier er ikke uden økonomisk risiko.  Værdien af aktierne på modningstidspunkterne afhænger ikke kun af Selskabets økonomiske udvikling, men også af den generelle udvikling på aktiemarkedet.  Der kan derfor ikke gives nogen garanti for, at en investering i aktier vil være overskudsgivende.
Investing in shares of Common Stock involves some financial risk.  The value of the shares at the time of vesting and sale will not only be dependent on the Company's financial development, but also on the general development on the stock market.  Consequently, there is no guarantee that investment in shares of Common Stock will yield a profit.
Denne erklæring berører ikke de skattemæssige konsekvenser af deltagelse i Planen, modtagelse af eventuelt udbytte eller et efterfølgende salg af de i medfør af Planen erhvervede ordinære aktier.  Du anbefales at drøfte dette med din personlige økonomiske rådgiver eller skatterådgiver.
This statement does not address the tax consequences of participating in the Plan, the receipt of any dividends or the subsequent sale of any shares of Common Stock acquired under the Plan.  You are encouraged to discuss this matter with your personal financial or tax advisor.
MERCK & CO., INC.
126 East Lincoln Avenue
Rahway, New Jersey
U.S.A. 07065
MERCK & CO., INC.
126 East Lincoln Avenue
Rahway, New Jersey
U.S.A. 07065

EX-10.32 6 exh1032-2024annualpsuterms.htm EX-10.32 2024 ANNUAL PSU TERMS & CONDITIONS Document

GLOBAL TERMS AND CONDITIONS
2024 PERFORMANCE SHARE UNIT GRANTS
UNDER THE MERCK & CO., INC. 2019 INCENTIVE STOCK PLAN
I.GENERAL. Merck & Co., Inc. (the “Company”) has granted to you the award of Performance Share Units (“PSUs”) specified in this document (“PSU Award”) pursuant to the Merck & Co., Inc. 2019 Incentive Stock Plan, including any sub-plan thereto for your country (the “Plan”). This PSU Award is subject to the terms and conditions of the Plan and these Global Terms and Conditions, including any additional terms and conditions for your country in Appendix B (the “Terms”). Unless otherwise defined in this document, capitalized terms used in these Terms are as defined in the Plan
Grant Type:
PSU - Annual
Grant Date:
March 28, 2024
Award Period:
Jan. 1, 2024
Dec. 31, 2026
IMPORTANT NOTICE: This grant requires you to affirmatively accept it. You MUST log onto the Morgan Stanley website at
(http://www.morganstanley.com/spc/knowledge/managing-equity/managing-your-existing-awards/accepting-awards-grants/) to accept the grant.
Follow the procedure described on the Morgan Stanley website to accept your PSU Award within 90 days. Failure to accept the terms and conditions of your PSU Award within 90 days may result in forfeiture of the PSU Award.
II.DEFINITIONS. For the purpose of these Terms:
Award Period means the three-year period commencing on January 1, 2024 and ending on December 31, 2026.
Earnings Per Share or EPS means the Company’s net income divided by the weighted average of the number of shares of Company common stock on a fully diluted basis during the Award Period.
The above result shall be adjusted to exclude charges or items from the measurement of performance relating to (1) restructurings, discontinued operations, purchase accounting items, merger-related costs, the impact of significant acquisitions and/ or divestitures, extraordinary items and other unusual or non-recurring charges and/ or events; (2) an event either not directly related to Company operations or not reasonably within the control of Company management; (3) fluctuations in foreign exchange versus Plan rates; (4) the impact of Share Repurchases above or below planned levels; and (5) the effects of accounting changes in accordance with U.S. generally accepted accounting principles, or other significant legislative changes, including tax.
EPS Performance Payout means the percentage reflecting the attainment level of the Company’s EPS goal as determined under paragraph C of Section III.
Final Award means the number of PSUs that become eligible to vest based on the attainment level of the goals for each performance metric, as calculated in accordance with Section III hereof.
Grant Date means the date as of which a Performance Share Unit is granted.



Peer Healthcare Companies are the healthcare companies used by the Committee in evaluating the Company’s TSR performance for the entire Award Period. For 2024 and for so long thereafter during the Award Period that such companies are publicly traded on a nationally recognized stock exchange, the following are the Peer Healthcare Companies except as described below.
AbbVie
Eli Lilly
Novartis
Amgen
GlaxoSmithKline
Pfizer
Astra Zeneca
Roche
Sanofi-Aventis
Bristol-Myers Squibb
Johnson & Johnson
Gilead Sciences
The Committee intends that the list of Peer Healthcare Companies may be subject to such adjustment as may be necessary to reflect a merger, reorganization, recapitalization, extraordinary cash dividend, combination of shares, consolidation, rights offering, spin off, split off, split up, bankruptcy, liquidation, acquisition, or other similar change in any Peer Healthcare Company.
Performance Share Unit or PSU means an award representing the right to vest in shares of Common Stock based upon the attainment level of the performance metrics in accordance with Section III and as otherwise described in these Terms. Until distributed pursuant to Section VI, these PSUs shall not entitle the holder to any of the rights of a holder of Common Stock, including voting rights; provided, however, that the Committee retains the right to make adjustments as described in Section 7 of the Plan.
Target Shares means the number of shares of Common Stock that would become eligible to vest if the performance metrics set forth in Section  III are each achieved at the level identified as “target” for the entire Award Period.
Total Shareholder Return or TSR means the change in value of one share of a company’s common stock over the Award Period, taking into account both stock price appreciation (or depreciation) and the reinvestment of dividends. The beginning and ending stock prices will be based on the average closing stock prices during the months of December as applicable. TSR will be calculated on a compound annualized basis over the Award Period.
TSR Performance Payout means the percentage reflecting the attainment level of Company’s TSR performance as determined under paragraph B of Section III.
III.CALCULATION OF FINAL AWARD OF PERFORMANCE SHARE UNITS
You shall vest in the number of PSUs to the extent provided for in this Section III unless otherwise provided for in Section V (“Termination of Employment”).
A.Performance Metrics. The Final Award will equal the TSR Performance Payout plus the EPS Performance Payout in the proportions determined in Paragraph D below.
B.TSR Performance Payout. The TSR Performance Payout shall be determined as follows:
1.If the Company’s annualized TSR is greater than the median of the annualized TSR of the Peer Healthcare Companies, then the TSR Performance Payout will equal 100% plus five times the difference in percentage points up to a maximum of 200%; provided, however, that if the Company’s annualized TSR is negative, then in no event will the TSR Performance Payout be greater than 100%.




For example, if the Company’s annualized TSR is 25% and the median annualized TSR of the Peer Healthcare Companies is 20%, then the TSR Performance Payout would be 125% [100% + ((25% - 20%) x 5%)].
2.If the Company’s TSR is less than the median of the annualized TSR among the Peer Healthcare Companies, then the TSR Performance Payout will equal 100% minus five times the difference in percentage points; provided, however, that if such median exceeds the Company’s annualized TSR by more than 10 percentage points, then the TSR Performance Payout will be 0%.
C.EPS Performance Payout. The EPS Performance Payout shall be determined in accordance with the following performance schedule:
Earnings Per Share Goals
Payout Percentage
Less than $26.18
0%
$26.18 (Threshold)
25%
$28.77 (Target)
100%
                      $30.50
150%
$32.22 (Stretch)
200%
Payout Percentages corresponding to performance between two discrete values in the table will be interpolated.
D.The Final Award will equal the sum of (x) TSR Payout Percent for the entire Award Period TIMES Target Shares TIMES 50 percent and (y) EPS Payout Percentage TIMES Target Shares TIMES 50 percent.
E.Maximum Award. Anything in these Terms to the contrary notwithstanding, the Final Award shall be reduced to the extent necessary to reflect that the value of the Final Award, valued based on the closing price of the Common Stock as of the date the Final Award is determined, may not exceed four times the value of the Target Shares, valued based on the closing price of the Common Stock as of the Grant Date.
IV.DIVIDEND EQUIVALENTS
During the Award Period, dividend equivalents will be accrued on the PSUs if and to the extent dividends are paid by the Company in the Common Stock. Payment of such dividend equivalents will be made, without interest or earnings, at the same time that the Final Award is paid. Such dividend equivalents shall be paid as additional shares in an amount equal to the sum of the dividends paid during the period between the Grant Date and the date immediately prior to the date the PSU Award is settled in accordance with Section VI divided by the price of a share of Common Stock on the date the Final Award is determined. If any portion of this PSU Award lapses, is forfeited or expires, no dividend equivalents will be credited or paid on such portion. Any payment of dividend equivalents will be reduced to the extent necessary for the Company to satisfy any tax or other withholding obligations in accordance with Section X.
V.TERMINATION OF EMPLOYMENT
If your employment with the Company or, if different, the subsidiary, affiliate or joint venture (“JV”) of the Company by which you are employed (the “Employer”) is terminated during the Award Period, your right to the PSU Award, where references to the Final Award in this section include any accrued dividend equivalents, will be determined according to the terms in this Section V and for grantees outside the United States, also in paragraph 12 of Section A (“Nature of Grant”) of Appendix B, Part I. For avoidance of doubt, if your




employment terminates on the last day of the Award Period not for misconduct, you will be entitled to vest in this PSU Award.
A.General Rule. If your employment is terminated during the Award Period for any reason other than those specified in the following paragraphs, this PSU Award will be forfeited on the date your employment terminates. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.
B.Involuntary Termination. If your employment terminates during the Award Period and the Company determines that employment was involuntarily terminated on or after the first anniversary of the first day of the Award Period, a pro rata portion of the Final Award will become eligible to vest when the Final Award is determined. The pro rata portion shall be determined by multiplying the Final Award by a fraction, the numerator of which is the number of completed months in the Award Period during which you were employed by the Company or the Employer, as applicable, and the denominator of which is 36. The right to the remaining PSUs will be forfeited on the date your employment terminates. An “involuntary termination” includes termination of employment by the Company as the result of a restructuring or job elimination, but excludes non-performance of duties and the reasons listed under paragraphs C through G of this section. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this PSU Award nevertheless will be forfeited according to this paragraph notwithstanding such rehire.
C.Sale. If your employment is terminated during the Award Period and the Company determines that such termination resulted from the sale of the subsidiary, affiliate, division or JV that employed you, the following portion of the Final Award will become eligible to vest on the date the Final Award is determined: one third of the Final Award if employment terminates on or after the Grant Date but before the first anniversary of the first day of the Award Period; and all of the Final Award if employment terminates on or after the first anniversary of the first day of the Award Period. The right to the remaining PSUs underlying the Final Award will be forfeited on the date your employment terminates. Notwithstanding the foregoing, the Committee may determine, for purposes of this PSU Award, whether employment with an entity that is established from the Company’s spin off, split off, split up or distribution of equity securities in connection with that entity constitutes a termination of employment, and may make adjustments, if any, as it deems appropriate, and to the extent not inconsistent with the Plan, at the time of the distribution of such equity securities, in the kind and/or number of shares subject to this PSU Award. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this PSU Award nevertheless will be forfeited according to this paragraph notwithstanding such rehire.
D.Retirement. If you terminate employment during the Award Period by retirement (including early and disability retirement), a pro rata portion of the Final Award will become eligible to vest on the date the Final Award is determined. The pro rata portion shall be determined by multiplying the Final Award by a fraction, the numerator of which is the number of completed months in the Award Period during which you were employed by the Company or the Employer, as applicable, and the denominator of which is 36. For grantees who are employed in the U.S., “retirement” means a termination of employment after attaining the earliest of (a) age 55 with at least 10 years of service (b) such age and service that provides eligibility for subsidized retiree medical coverage or (c) age 65 without regard to years of service. For other grantees, “retirement” is determined by the Company. The right to the remaining PSUs underlying the Final Award will be forfeited on the date your employment terminates. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.




E.Death. If your employment terminates due to death during the Award Period but prior to the date of an employment termination contemplated under paragraphs B, C, D, G or H the Final Award will become eligible to vest on the date the Final Award is determined. If you die during the Award Period, but after your employment terminates for the reasons listed under paragraphs B, C, D, G or H of this section, any portion of the Final Award that remains outstanding at your death will become eligible to vest on the date the Final Award is determined.
F.Misconduct. If your employment is terminated as a result of deliberate, willful or gross misconduct, this PSU Award will be forfeited immediately upon your receipt of notice of such termination.
G.Disability. If your employment is terminated during the Award Period and the Company determines that such termination resulted from inability to perform the material duties of his or her role by reason of a physical or mental infirmity that is expected to last for at least six months or to result in death, whether or not he or she is eligible for disability benefits from any applicable disability program, then the Final Award will become eligible to vest on the date the Final Award is determined. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this PSU Award nevertheless will expire according to this paragraph notwithstanding such rehire.
H.Change in Control. Upon the occurrence of a Change in Control (as such term is defined in the Plan), the Final Award shall mean a number of PSUs equal to the Target Shares. If this PSU Award is assumed, converted or otherwise remains outstanding in connection with a Change in Control and your employment is terminated during the Award Period without Cause before the second anniversary of the closing of the Change in Control, then this PSU Award and dividend equivalents that have accrued through the end of the Award Period will continue to vest at the end of the original Award Period. If this PSU Award does not remain outstanding following the Change in Control and is not assumed, converted, or otherwise remains outstanding, then the PSU Award and dividend equivalents that have accrued through such date will immediately vest and, at the election of the Company, you will be entitled to receive cash for such portion of this PSU Award in an amount equal to the fair market value of the consideration paid to Merck stockholders for a share of Merck Common Stock in the Change in Control. On the second anniversary of the closing of the Change in Control, this paragraph shall expire. “Cause” and “Change in Control” are defined in the Merck & Co., Inc. Change in Control Separation Benefits Plan (excluding MSD Change in Control).
I.Transfer of Employment. Transfer of employment between the Company, a subsidiary, affiliate, JV, JV partner or affiliate of the Company who provides services to the JV with such partner or affiliate or other entity in which the Company has determined that it has a significant business or ownership interest (together, the “Company Group”) is not considered termination of employment for purposes of this PSU Award. Such employment must be approved by the Company and contiguous with employment by the entity in the Company Group you were employed by immediately prior to the relevant transfer. The terms set out in paragraphs A through H above shall continue to apply to this PSU Award following a transfer of employment accordance with this section.
VI.DISTRIBUTION OF SHARES
Following the end of the Award Period, you (or your estate, in the case of PSUs that vest pursuant to Section V(E)) shall be entitled to receive a number of shares of Common Stock equal to the Final Award (as modified to the extent provided under Section V and subject to Section X) plus the shares for accrued dividend equivalents set forth in Section IV, rounded to the nearest whole number (no fractional shares shall be issued). Such distribution shall be made as soon as administratively feasible following the last day of the Award Period, but in no event later than the end of the calendar year immediately following the Award Period.




VII.SECTION 409A COMPLIANCE
Anything in the Plan or these Terms to the contrary notwithstanding, no distribution of PSUs may be made unless in compliance with Section 409A of the Code or any successor thereto. In addition, distributions, if any, made upon or by reference to the date of an employment termination shall not be paid unless such termination constitutes a “separation from service (as defined in Section 409A of the Code)” and any such payment to a “Specified Employee” as defined in Treas. Reg. Sec. 1.409A-1(i) or any successor thereto, to the extent required by Section 409A of the Code will instead be made on the first day the seventh month following the separation from service, in the same form as they would have been made had this restriction not applied; provided further, that no dividend or dividend equivalents will be paid, accrued or accumulated in respect of the period during which distribution was suspended.
VIII.SUBJECT TO RECOUPMENT
This PSU Award will be subject to recoupment in the event of certain violations of Company policy in accordance with the Company’s Policy and Procedures for Discretionary Recoupment of Compensation for Compliance Violations, as set forth in Appendix A.1, and with the Company’s Policy and Procedures for Recoupment of Incentive-Based Compensation, applicable only for Section 16 Officers, as set forth in Appendix A.2 (as may be amended from time to time).
IX.TRANSFERABILITY
Prior to distribution pursuant to Section VI, the PSU Award and any interest therein shall not be sold, assigned, transferred, pledged or otherwise disposed of, alienated or encumbered, either voluntarily or involuntarily, other than by will or the laws of descent and distribution in connection with your death.
X.TAX WITHHOLDING
Regardless of any action the Company and/or the Employer take with respect to any or all income tax, social insurance, payroll tax, payment on account or other tax-related items arising out of your participation in the Plan and legally applicable or deemed applicable to you (“Tax-Related Items”), you acknowledge that the ultimate liability for all Tax-Related Items is and remains your responsibility and may exceed the amount actually withheld by the Company and/or the Employer, if any. You further acknowledge that the Company and/or the Employer (i) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the PSU Award or underlying shares of Common Stock, including, but not limited to, the grant, vesting or settlement of the PSU, the subsequent sale of shares of Common Stock acquired upon the expiration of the Award Period and the receipt of any dividends and/or dividend equivalents; and (ii) do not commit and are under no obligation to structure the terms of the grant or any aspect of the PSU to reduce or eliminate your liability for Tax-Related Items or achieve any particular tax result. Furthermore, if you have become subject to tax in more than one jurisdiction, you acknowledge that the Company and/or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.
Prior to the relevant taxable or tax withholding event, as applicable, you shall pay or make arrangements satisfactory to the Company and/or the Employer to satisfy any applicable withholding obligations or rights with regard to all Tax-Related Items. In this regard, you authorize the Company and/or the Employer, or their respective agents, at their discretion, to satisfy the Tax-Related Items by one or a combination of the following: (i) withholding from your wages or other cash compensation paid to you by the Company, the Employer and/or any subsidiary, affiliate or JV of the Company; or (ii) withholding from proceeds of the sale of shares of Common Stock acquired at expiration of the Award Period either through a voluntary sale or through a mandatory sale arranged by the Company (on your behalf pursuant to this authorization); or (iii)




withholding in shares of Common Stock to be issued upon expiration of the Award Period; provided, however, that if you are a Section 16 officer of the Company under the Exchange Act, then the Company will satisfy the Tax-Related Items (other than U.S. Federal Insurance Contribution Act taxes or other Tax-Related Items which become payable in a year prior to the year in which shares of Common Stock are issued upon settlement of the PSUs) by withholding in shares of Common Stock pursuant to (iii) above, unless the use of such withholding method is problematic under applicable tax or securities law or has materially adverse accounting consequences, in which case, the obligation for Tax-Related Items may be satisfied by a one or a combination of (i) or (ii) above.
The Company may withhold or account for Tax-Related Items by considering applicable minimum statutory withholding amounts or other applicable withholding rates, including maximum applicable rates in your jurisdiction(s). In the event of over-withholding, you may receive a refund of any over-withheld amount in cash (with no entitlement to the equivalent in Common Stock), or if not refunded, you may seek a refund from the local tax authorities. In the event of under-withholding, you may be required to pay additional Tax-Related Items directly to the applicable tax authority or to the Company and/or the Employer. If the obligation for Tax-Related Items is satisfied by withholding in shares of Common Stock, for tax purposes, you will be deemed to have been issued the full number of shares of Common Stock subject to the vested PSUs, notwithstanding that a number of the shares is held back solely for the purpose of paying the Tax-Related Items due as a result of any aspect of your participation in the Plan.
You shall pay to the Company or the Employer any amount of Tax-Related Items that the Company or the Employer may be required to withhold or account for as a result of your participation in the Plan that cannot be satisfied by the means previously described in this section. The Company may refuse to issue or deliver the shares of Common Stock or the proceeds of the sale of shares if you fail to comply with your obligations in connection with the Tax-Related Items.
XI.DATA PRIVACY
The Company is located at 126 East Lincoln Avenue, Rahway, NJ 07065, U.S.A. and grants employees of the Company and any subsidiary, affiliate or JV of the Company, the opportunity to participate in the Plan, at the Company's sole discretion. If you would like to participate in the Plan, you understand that you should review the following information about the Company’s data processing practices and declare your consent.
A.Data Collection and Usage. The Company collects, processes and uses your personal data, including, name, home address, email address and telephone number, date of birth, social insurance number or other identification number, salary, citizenship, job title, any shares of Common Stock or directorships held in the Company, and details of all awards, canceled, vested, or outstanding in your favor, which the Company receives from you or your Employer. If the Company offers you the opportunity to participate in the Plan, then the Company will collect your personal data for purposes of allocating Common Stock and implementing, administering and managing the Plan. The Company’s legal basis for the processing of your personal data would be your consent.
B.Stock Plan Administration Service Providers. The Company transfers participant data to Morgan Stanley, an independent service provider based in the United States, which assists the Company with the implementation, administration and management of the Plan. In the future, the Company may select a different service provider and share your data with another company that serves in a similar manner. The Company’s service provider will open an account for you. You will be asked to agree on separate terms and data processing practices with the service provider, which is a condition to your ability to participate in the Plan.




C.International Data Transfers. The Company and its service providers are based in the United States. If you are outside of the United States, you should note that your country has enacted data privacy laws that are different from the United States. The Company’s legal basis for the transfer of your personal data is your consent.
D.Voluntariness and Consequences of Consent Denial or Withdrawal. Your participation in the Plan and your grant of consent is purely voluntary. You may deny or withdraw your consent at any time. If you do not consent, or if you withdraw your consent, you cannot participate in the Plan. This would not affect your salary as an employee; you would merely forfeit the opportunities associated with the Plan.
E.Data Subject Rights. You have a number of rights under data privacy laws in your country. Depending on where you are based, your rights may include the right to (i) request access or copies of personal data the Company processes, (ii) rectification of incorrect data, (iii) deletion of data, (iv) restrictions on processing, (v) portability of data, (vi) to lodge complaints with competent authorities in your country, and/or (vii) a list with the names and addresses of any potential recipients of the your personal data. To receive clarification regarding your rights or to exercise your rights please contact the Company at Attn: Global Privacy Office, 351 N. Sumneytown Pike, North Wales, Pennsylvania, U.S.A. 19454.
F.The collection, use and transfer of your personal data for the purpose of implementing, administering and managing your participation in the Plan is conducted in accordance with the Company’s Global Privacy and Data Protection Policy. You also understand that the Company may, in the future, request you to provide another data privacy consent.  If applicable and upon request of the Company, you agree to provide an executed acknowledgement or data privacy consent form to the Company or the Employer (or any other acknowledgements, agreements or consents) that the Company and/or the Employer may deem necessary to obtain under the data privacy laws in your country, either now or in the future.  You understand that you will not be able to participate in the Plan if you fail to execute any such acknowledgement, agreement or consent requested by the Company and/or the Employer.
If you agree with the data processing practices described in this Section, you will declare your consent by clicking to "Accept" these Terms on the Morgan Stanley website.
XII.GOVERNING LAW
This document may be amended only by another written agreement between the parties. This document will be interpreted and enforced under the laws of the State of New Jersey, United States (without regard to its choice-of-law provisions). For purposes of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this grant or this document, the parties hereby submit to and consent to the exclusive jurisdiction of the State of New Jersey and agree that such litigation shall be conducted only in the courts of Union County, New Jersey, or the federal courts for the United States for the District of New Jersey, and no other courts, where this grant is made and/or to be performed.
XIII.SEVERABILITY
The provisions of this document are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.




XIV.WAIVER
You acknowledge that a waiver by the Company of breach of any provision of these Terms shall not operate or be construed as a waiver of any other provision of these Terms or of any subsequent breach by you or any other grantee.
XV.ELECTRONIC ACCEPTANCE
The Company may, in its sole discretion, decide to deliver any documents related to the PSU or future PSUs that may be granted under the Plan by electronic means or request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an online or electronic system established and maintained by the Company or a third party designated by the Company.
XVI.COUNTRY-SPECIFIC APPENDIX
The PSU Award shall be subject to any additional provisions set forth in Appendix B for your country, if any. If you relocate to one of the countries included in Appendix B during the life of the PSU Award, the additional provisions for such country shall apply to you, to the extent the Company determines that the application of such provisions is necessary or advisable in order to comply with local law or facilitate the administration of the Plan.
XVII.ADMINISTRATION
The Committee is responsible for construing and interpreting this PSU Award, including the right to construe disputed or doubtful Plan provisions, and may establish, amend and construe such rules and regulations as it may deem necessary or desirable for the proper administration of this PSU Award. Any decision or action taken or to be taken by the Committee, arising out of or in connection with the construction, administration, interpretation and effect of this grant shall, to the maximum extent permitted by applicable law, be within its absolute discretion (except as otherwise specifically provided herein) and shall be final, binding and conclusive upon the Company, all Eligible Employees and any person claiming under or through any eligible employee. All determinations by the Committee including, without limitation, determinations of the Eligible Employees, the form, amount and timing of Incentives, the terms and provisions of Incentives and the writings evidencing Incentives, need not be uniform and may be made selectively among Eligible Employees who receive, or are eligible to receive, Incentives hereunder, whether or not such Eligible Employees are similarly situated.
In addition to the Committee’s powers set forth in the Plan, anything in these Terms to the contrary notwithstanding, the Committee may revise the terms of any PSU not yet granted or, granted but prior to the end of an Award Period if unforeseen events occur and which, in the judgment of the Committee, make the application of the Terms of this PSU Award unfair and contrary to their intentions unless a revision is made.
This PSU Award is subject to the provisions of the 2019 Incentive Stock Plan. For further information regarding your PSU Award, you may access the Merck Global Long-Term Incentives homepage via Sync > HR > Money > Long-Term Incentive Program




APPENDIX A.1
Policy and Procedures for Discretionary Recoupment of
Compensation for Compliance Violations
Policy
It is the policy of the Compensation and Management Development Committee (the “Committee”) of the Board of Directors (the “Board”) of Merck & Co., Inc. (the “Company”) that the Committee will exercise its discretion to determine whether to seek Recoupment of any Covered Compensation paid or awarded to an Affected Employee, where it determines, in consultation with the Audit Committee, that: a) the Affected Employee engaged in misconduct, or failed to reasonably supervise an employee who engaged in misconduct, that resulted in a Material Violation; and b) the Committee concludes that the Material Violation caused Significant Harm to the Company.
Definitions
1.An “Affected Employee” is an employee in Band 600 or higher who (i) engaged in misconduct that results in a Material Violation; or (ii) failed in his or her supervisory responsibilities to reasonably manage or monitor the conduct of an employee who engaged in misconduct that results in a Material Violation.
2.“Covered Compensation” means all (a) incentive‐based cash compensation granted to an Affected Employee, including, without limitation, any annual bonuses and other short‐ and long‐term cash incentives, (b) equity‐based compensation, including, without limitation, stock options, restricted stock, restricted stock units, performance share units (“PSUs”), (c) any proceeds or earnings received in respect of (a) and (b), and (d) any other forms of compensation that the Committee determines to be subject to this policy. For the avoidance of doubt, the foregoing includes any compensation that was previously paid, earned, vested, deferred or paid or payable as a component of severance or termination compensation.
3.“Executive” means current and former executive officers of the Company, as “executive officer” is defined for the purposes of the Securities Exchange Act of 1934, as amended.
4.A “Material Violation” is defined as (i) a material violation of a written Company policy relating to the research, development, manufacturing, sales, or marketing of Company products or (ii) conduct detrimental to the Company, including the Company’s overall goodwill or reputation.
5.“Recoupment” is defined to include any and all of the following actions to the extent permitted by law: (a) reducing the amount of a current or future bonus or other cash or noncash incentive compensation award, (b) requiring reimbursement of a bonus or other cash-based incentive compensation award paid with respect to the most recently completed performance period, (c) cancelling all or a portion of a future‐vesting equity award, (d) cancelling all or a portion of an equity award that vested within the previous twelve‐month period, (e) requiring return of shares paid upon vesting and/or reimbursement of any proceeds received from the sale of an equity award, in each case that vested within the previous twelve‐month period, and (f) any other method of reducing the total compensation paid to an employee for any prior twelve‐month period or any current or future period.
6.“Significant Harm” means a significant negative impact on the Company’s financial operating results or reputation.
Procedures
a.Subject to any delegation to the Chief Executive Officer, as discussed below, the Committee, acting in consultation with the Audit Committee, shall administer this policy and have full discretion to interpret and to make any and all determinations under this policy. Any determinations made by the Committee shall be final, binding, and conclusive on all parties. Notwithstanding the foregoing, the full Board shall approve any determination to seek or waive Recoupment from the Chief Executive Officer.
b.The General Counsel, in consultation with the Chief Ethics and Compliance Officer and the Executive Vice President, Human Resources, is responsible for determining whether to refer a matter to the Committee for review under this policy and for assisting the Committee with its review. In administering this policy, the




Committee may consult with other committees of the Board and any external or internal advisors as it deems appropriate.
c.If the Committee, acting in consultation with the Audit Committee, determines that there is a basis for seeking Recoupment under this policy, the Committee shall exercise its discretion to determine for each Affected Employee, on an individual basis, whether, and to what extent and in which manner, to seek Recoupment.
d.In exercising its discretion, the Committee may take into consideration, as it deems appropriate, all of the facts and circumstances of the particular matter and the general interests of the Company.
Delegation to Management for Recoupment Decisions
The Committee may delegate to the Chief Executive Officer (who may further delegate as deemed appropriate) the authority to administer this policy and to make any and all decisions under it regarding Affected Employees who are not Executives of the Company. Management shall report to the Committee on any affirmative decisions to seek Recoupment pursuant to this delegation of authority.
Public Disclosures
The Company will comply with all applicable securities laws and regulations, including Securities and Exchange Commission disclosure requirements regarding executive compensation and any applicable New York Stock Exchange listing standard or requirements, with respect to this policy. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.
Miscellaneous
Nothing in this policy shall limit or otherwise affect any of the following: 1) management’s ability to take any disciplinary action with respect to any Affected Employee; 2) the Committee’s ability to use its negative discretion with respect to any incentive compensation performance target at any time; or 3) the Committee’s or management’s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non‐cash incentive compensation award to any Affected Employee for any reason as they may deem appropriate and to the extent permitted by law. Any right of Recoupment under this policy is in addition to, and not in lieu of, any other remedies or rights of Recoupment that may be available to the Company pursuant to the terms of any similar policy in any incentive plan, employment agreement, equity award agreement, or similar agreement, including, without limitation, the Company’s Policy and Procedures for Recoupment of Incentive‐Based Compensation, and any other legal remedies available to the Company. The Company shall not indemnify or agree to indemnify any current or former Executive against the loss of incentive compensation subject to this policy nor shall the Company pay or reimburse or agree to pay or reimburse any insurance premium to cover the loss of such incentive compensation. The Committee may amend, modify, or terminate this policy in whole or in part at any time and from time to time in its sole discretion.




APPENDIX A.2
Policy and Procedures for Recoupment of
Incentive-Based Compensation
Policy
The Compensation and Management Development Committee (the “Committee”) of the Board of Directors (the “Board”) has adopted this Incentive‐Based Compensation Recoupment Policy (the “Policy”) to comply with Section 10D of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), Rule 10D‐1 promulgated thereunder (“Rule 10D‐1”) and Paragraph 303A.14 of the Listing Standards Manual of the New York Stock Exchange (“NYSE”), which require the recovery of certain Incentive‐Based Compensation in the event of an accounting restatement resulting from a material error in the consolidated financial statements of Merck & Co, Inc. (the “Company”). This Policy shall be administered by the Committee, which shall have express discretionary authority to interpret and construe this Policy and to make all determinations with respect to this Policy, in its sole discretion. It is intended that this Policy be interpreted in a manner that is consistent with the requirements of Section 10D of the Exchange Act and Rule 10D‐1 (or any successor statute or rule) and any other applicable rules or listing standards adopted by the U.S. Securities and Exchange Commission (the “SEC”) or NYSE. All interpretations, constructions and determinations made by the Committee under this Policy shall be final and binding on all parties. This Policy may be amended with the approval of the Committee and may be amended from time to time as necessary to reflect changes in applicable regulations and/or listing standards adopted by the SEC or NYSE. Compliance with this Policy cannot be waived.
Definitions
1. "Accounting Restatement” is the restatement of the Company’s financial statements due to material noncompliance with any financial reporting requirement under the federal securities laws, including any required accounting restatement to correct an error in previously issued financial statements (i) that is material to the previously issued financial statements, or (ii) that would result in a material misstatement if the error were corrected in the current period only or left uncorrected in the current period.
2. A “Covered Officer” is anyone who serves or has served as an executive officer of the Company at any time during the performance period for Incentive‐Based Compensation.
3. “Executive officer” is the equivalent to an “officer” as defined under Section 16a‐1(f) of the Exchange Act (“Section 16 officer”).
4. “Financial reporting measure” is a measure that is (i) determined and presented in accordance with the accounting principles used in preparing the Company’s financial statements, or (ii) derived wholly or in part from such measures. For purposes of this Policy, the term “financial reporting measure” includes the Company’s stock price and total shareholder return, whether expressed as an absolute or relative metric. For the avoidance of doubt, a financial reporting measure need not be presented in the Company’s financial statements or included in a filing with the SEC.
5. “Incentive‐Based Compensation” is any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a financial reporting measure. Incentive‐Based Compensation may include awards under the Executive Incentive Plan and Performance Share Units under the Merck & Co., Inc. 2019 Stock Incentive Plan, or any successor thereto. Incentive‐Based Compensation does not include (i) base salary; (ii) “sign‐on” bonuses or other compensation granted solely due to the commencement of employment with the Company; (iii) compensation exclusively based on completion of a specific period of employment or service, without any performance condition; or (iv) compensation awarded based on subjective, non‐financial, strategic, or operational measures that are not financial reporting measures.
6. Incentive‐Based Compensation is deemed to be “received” in the fiscal period during which the financial reporting measure specified in the Incentive‐Based Compensation award is attained, even if the payment or grant of the Incentive‐Based Compensation occurs after the end of that fiscal period. Incentive‐Based Compensation in the form of an equity award that vests solely upon the basis of a financial reporting measure performance condition will be deemed to be received in the fiscal period in which it vests.




7. “Recoupment Period” is the three completed fiscal years of the Company immediately preceding the date, and any transition period of less than nine months that results from a change in the Company’s fiscal year within or immediately following those three completed fiscal years, on which the Company is required to perform an Accounting Restatement, which date is the earlier of (i) the date the Board, or a committee of the Board, concludes, or reasonably should have concluded, that the Company is required to perform an Accounting Restatement; or (ii) a date that a court, regulator or other legally authorized body directs the Company to perform an Accounting Restatement.
Procedures for Recoupment of Incentive‐Based Compensation
1. In the event the Company is required to perform an Accounting Restatement, the Company shall, as promptly as reasonably possible, recoup any Incentive‐Based Compensation erroneously received by a Covered Officer during the Recoupment Period. The amount of erroneously received Incentive‐Based Compensation will be the excess of the Incentive‐Based Compensation received by the Covered Officer (whether in cash or in shares) based on the erroneous data in the original financial statements over the Incentive‐Based Compensation (whether in cash or in shares) that would have been received by the Covered Officer had it been based on the restated results, without respect to any tax liabilities incurred or paid by the Covered Officer. For Incentive‐Based Compensation based on total shareholder return or Company stock price, where the amount of erroneously awarded compensation is not subject to mathematical recalculation directly from the information in the Accounting Restatement, the amount shall be based on the Committee’s reasonable estimate of the effect of the Accounting Restatement on the applicable measure and the Committee shall maintain documentation of the determination of that reasonable estimate and provide it to the NYSE. Notwithstanding the foregoing, Incentive‐Based Compensation shall not be recouped under this Policy to the extent received by any person before the date such person served as a Covered Officer.
2. The Committee shall determine, in its sole discretion, the method of recouping any erroneously received Incentive‐Based Compensation pursuant to this Policy.
3. No recoupment shall be required if any of the following conditions are met and the Committee determines that, on such basis, recovery would be impracticable: (i) the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount to be recouped, which determination must be made only after a reasonable and documented attempt by the Company to recoup the Incentive‐Based Compensation (with documentation of such reasonable attempt to recover to be provided to the NYSE); (ii) recovery would violate home country law where that law was adopted prior to November 28, 2022, which determination must be made only after the Company has obtained an opinion of home country counsel, acceptable to the NYSE, that recovery would result in such violation (with a copy of such opinion to be provided to the NYSE); or (iii) recoupment would likely cause an otherwise tax‐qualified retirement plan, under which benefits are broadly available to Company employees, to fail to meet the requirements of Section 401(a)(13) or Section 411(a) of the Internal Revenue Code of 1986, as amended, and U.S. Treasury regulations promulgated thereunder.
Indemnification Not Permitted
The Company shall not indemnify any current or former Covered Officer against the loss of erroneously awarded compensation, and shall not pay, or reimburse any Covered Officer for, premiums incurred or paid for any insurance policy to fund such Covered Officer’s potential recoupment obligations.
Disclosure of Recoupment Decisions
The Company will comply with all applicable securities laws and regulations, including SEC disclosure requirements, with respect to this Policy, and any applicable NYSE listing standard or requirements. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.




Effective Date
This Policy shall be effective as of December 1, 2023 (the “Effective Date”). The terms of this Policy shall apply to any Incentive‐Based Compensation that is received by Covered Officers on or after the Effective Date, even if such Incentive‐Based Compensation was approved, awarded, granted, or paid to Covered Officers prior to the Effective Date.
Miscellaneous
Nothing in this Policy shall limit or otherwise affect any of the following: 1) management’s ability to take any disciplinary action with respect to any Covered Officer; 2) the Committee’s ability to use its negative discretion with respect to any Incentive‐Based Compensation performance target at any time; or 3) the Committee’s or management’s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non‐cash incentive compensation award to any executive or other employee for any reason as they may deem appropriate and to the extent permitted by law. Any right of recoupment under this Policy is in addition to, and not in lieu of, any other remedies or rights of recoupment that may be available to the Company pursuant to the terms of any similar policy in any incentive plan, employment agreement, equity award agreement, or similar agreement and any other legal remedies available to the Company. This Policy shall be binding and enforceable against all Covered Officers and their beneficiaries, heirs, executors, administrators, or other legal representatives.


EX-10.33 7 exh1033-2024annualnqsoterm.htm EX-10.33 2024 ANNUAL NQSO TERMS & CONDITIONS Document

GLOBAL TERMS AND CONDITIONS
2024 NON-QUALIFIED STOCK OPTION (NQSO) GRANTS
UNDER THE MERCK & CO., INC. 2019 INCENTIVE STOCK PLAN
I.GENERAL. Merck & Co., Inc. (the “Company”) has granted to you the stock option specified in this document pursuant to the Merck & Co., Inc. 2019 Incentive Stock Plan, including any sub-plan thereto for your country (the “Plan”). This stock option is subject to the terms and conditions of the Plan and these Global Terms and Conditions, including any additional terms and conditions for your country in Appendix B (the “Terms”). Unless otherwise defined in this document, capitalized terms used in these Terms are as defined in the Plan.
Grant Type:NQSO – Annual
Option Price:$XX.XX
Grant Date:
April 30, 2024
Expiration Date:April 29, 2034
Vesting DatesPortion that Vests
April 30, 2025First:     33.333%
April 30, 2026Second:     33.333%
April 30, 2027Third:     Balance
IMPORTANT NOTICE: This grant requires you to affirmatively accept it. You MUST log onto the Morgan Stanley website at: (http://www.morganstanley.com/spc/knowledge/managing-equity/managing-your-existing-awards/accepting-awards-grants/) to accept the grant.
Follow the procedures described on the Morgan Stanley website to accept your stock option within 90 days. Failure to accept the terms and conditions of your stock option within 90 days may result in Forfeiture of the stock option.
A.Vesting & Expiration Dates. This stock option becomes exercisable in equal installments (subject to a rounding process) on the Vesting Dates indicated in the box above. This stock option expires on its Expiration Date, which is the day before the tenth anniversary of the Grant Date. If your employment with the Company or, if different, the subsidiary, affiliate or joint venture (“JV”) of the Company by which you are employed (the “Employer”) is terminated, your right to exercise this stock option will be determined according to the terms in Section II and for grantees outside the United States, also in paragraph 12 of Section A (“Nature of Grant”) of Appendix B, Part I.
B.Subject to Recoupment. This stock option will be subject to recoupment in the event of certain violations of Company policy in accordance with the Company’s Policy and Procedures for Discretionary Recoupment of Compensation for Compliance Violations, as set forth in Appendix A.1, and with the Company’s Policy and Procedures for Recoupment of Incentive-Based Compensation, applicable only for Section 16 Officers,, as set forth in Appendix A.2 (as may be amended from time to time).
II.TERMINATION OF EMPLOYMENT
A.General Rule. If your employment is terminated for any reason other than those specified in the following paragraphs, the portion of this stock option that is unvested will expire on the date your employment ends (for avoidance of doubt, if your employment terminates on a Vesting Date not for misconduct, you will be entitled to vest in that unvested portion of the stock option that is scheduled to vest on that Vesting Date); the portion of this stock option that is vested will expire unless exercised before the New York Stock Exchange closes (the “Close of Business”) on the same day of the third month (“Within Three Months”) after the date of the termination (but in no event after the expiration of the



Option Period). Close of Business for any day on which the New York Stock Exchange is not open means the close of business prior to that date when the Exchange is open. Where there is no corresponding day of a month, the last day of the month is deemed to be the same day as a later date (e.g., November 28, 29 and 30 all correspond to February 28 in non-leap years). If you are rehired by the Company or the Employer, as applicable, this option nevertheless will expire unless exercised Within Three Months, or the original Expiration Date if earlier.
B.Involuntary Termination. If the Company determines that your employment is involuntarily terminated, including the result of a restructuring or job elimination, but excluding non-performance of your duties and the reasons listed under paragraphs C through H, the portion of this stock option that is unvested will expire on the date your employment ends (for avoidance of doubt, if your employment terminates on a Vesting Date not for misconduct, you will be entitled to vest in that unvested portion of the stock option that is scheduled to vest on that Vesting Date); the portion of this stock option that is vested will expire on the one year anniversary of the date your employment ends, but in no event later than the original Expiration Date. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this option nevertheless will expire according to this paragraph notwithstanding such rehire.
C.Sale. If your employment is terminated and the Company determines that such termination resulted from the sale of your subsidiary, affiliate, division or JV, the following portion of this stock option award will vest and become exercisable immediately upon such termination: if employment terminates on or after the Grant Date but before the first anniversary thereof, then one-third of this stock option award will vest and become exercisable; if employment terminates on or after the first anniversary of the Grant Date, then all unvested stock options will vest and become exercisable. The remaining portion, if any, of this stock option that does not vest pursuant to the foregoing sentence will be forfeited on the date your employment terminates. Whether already vested on the date your employment terminates or vested as a result of such sale, this stock option will expire on the first anniversary of the date your employment with the Company or the Employer, as applicable, ends, but in no event later than the original Expiration Date. Notwithstanding the foregoing, the Committee may determine, for purposes of this stock option grant, whether employment with an entity that is established from the Company’s spin off, split off, split up or distribution of equity securities in connection with that entity constitutes a  termination of employment, and may make adjustments, if any, as it deems appropriate, and not inconsistent with the Plan, at the time of the distribution of such equity securities, in the kind and/or number of shares subject to this option, and/or in the option price of such option. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this option nevertheless will expire according to this paragraph notwithstanding such rehire.
D.Retirement. If your employment terminates as the result of your retirement, the portion of this stock option that would have become exercisable according to its original schedule within one year of the date your employment terminates will vest and become exercisable on its applicable Vesting Date and the remainder will expire immediately. Whether already vested on the date your employment terminates or vested as a result of such retirement, this option will expire on the earlier of (a) the fifth anniversary of the termination date or (b) its original Expiration Date. For grantees who are employed in the U.S., “retirement” means a termination of employment after attaining the earliest of (a) age 55 with at least 10 years of service (b) such age and service that provides eligibility for subsidized retiree medical coverage or (c) age 65 without regard to years of service. For other grantees, “retirement” is determined by the Company. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this option nevertheless will expire according to this paragraph notwithstanding such rehire.



E.Death. If your employment terminates as a result of your death, the portion of this stock option that is unvested will vest immediately upon your death. Whether already vested on the date of your death or vested as a result of your death, this stock option will expire on the second anniversary of your death, even if such date is later than the Original Expiration date. This stock option will expire on such earlier date than otherwise specified in this paragraph as may be required under applicable non-U.S. law. If you die while any portion of this stock option remains outstanding, but after your employment terminates for the reasons listed under paragraphs B, C, D, G or H of this section, the portion that remains outstanding after such employment termination will become immediately exercisable and will continue to be exercisable until the expiration date prescribed in paragraph B, C, D, G or H as applicable (and at least a year from your death in those jurisdictions where such extension is required by law).
F.Misconduct. If your employment is terminated as a result of your deliberate, willful or gross misconduct, this stock option (whether vested or unvested) will expire immediately upon your receipt of notice of such termination.
G.Disability. If your employment is terminated and the Company determines that such termination resulted from your inability to perform the material duties of your role by reason of a physical or mental infirmity that is expected to last for at least six months or to result in your death, whether or not you are eligible for disability benefits from any applicable disability program, then this stock option will continue to become exercisable on applicable Vesting Dates and will expire on the earlier of (a) the fifth anniversary of the day your employment terminates and (b) its original Expiration Date. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this option nevertheless will expire according to this paragraph notwithstanding such rehire.
H.Change in Control. If this stock option is assumed, converted or otherwise remains outstanding in connection with a Change in Control and your employment is involuntarily terminated without Cause before the second anniversary after the closing of a Change in Control, each unvested stock option that is outstanding immediately prior to the Change in Control will immediately become fully vested and exercisable. All options, including options vested prior to such time, will expire on the fifth anniversary of the termination of your employment following a Change in Control (but not beyond the Expiration Date). This extended exercise period does not apply in the case of termination by reasons of retirement, involuntary termination, sale, misconduct, death or disability, as described in paragraphs B through G above or termination prior to a Change in Control. If this stock option does not remain outstanding following the Change in Control and is not converted into a successor stock option, then each unvested stock option that is outstanding immediately prior to the Change in Control will lapse as of the Change in Control and at the election of the Company, you will be entitled to receive cash for this stock option in an amount at least equal to the difference between the price paid to stockholders in the Change in Control and the Option Price of this stock option. “Cause” and “Change in Control” are defined in the Merck & Co., Inc. Change in Control Separation Benefits Plan (excluding an MSD Change in Control).
I.Transfer of Employment. Transfer of employment between the Company, a subsidiary, affiliate, JV, JV partner or affiliate of the Company who provides services to the JV with such partner or affiliate or other entity in which the Company has determined that it has a significant business or ownership interest (together, the “Company Group”) is not considered termination of employment for purposes of this stock option. Such employment must be approved by the Company and contiguous with employment by the entity in the Company Group you were employed by immediately prior to the relevant transfer. The terms set out in paragraphs A through H above shall continue to apply to this stock option following a transfer of employment accordance with this section.



III.TRANSFERABILITY
This stock option and any interest therein shall not be sold, assigned, transferred, pledged or otherwise disposed of, alienated or encumbered, either voluntarily or involuntarily, other than by will or the laws of descent and distribution in connection with your death.
IV.TAX WITHHOLDING
Regardless of any action the Company and/or the Employer take with respect to any or all income tax, social insurance, payroll tax, payment on account or other tax-related items arising out of your participation in the Plan and legally applicable or deemed applicable to you (“Tax-Related Items”), you acknowledge that the ultimate liability for all Tax-Related Items is and remains your responsibility and may exceed the amount actually withheld by the Company and/or the Employer, if any. You further acknowledge that the Company and/or the Employer (i) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the stock option or underlying shares of Common Stock, including, but not limited to, the grant, vesting or exercise of the stock option, the subsequent sale of shares of Common Stock acquired pursuant to such exercise and the receipt of any dividends; and (ii) do not commit and are under no obligation to structure the terms of the grant or any aspect of the stock option to reduce or eliminate your liability for Tax-Related Items or achieve any particular tax result. Furthermore, if you have become subject to tax in more than one jurisdiction, you acknowledge that the Company and/or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.
Prior to the relevant taxable or tax withholding event, as applicable, you shall pay or make arrangements satisfactory to the Company and/or the Employer to satisfy any applicable withholding obligations or rights with regard to all Tax-Related Items. In this regard, you authorize the Company and/or the Employer, or their respective agents, at their discretion, to satisfy the Tax-Related Items by one or a combination of the following: (i) withholding from your wages or other cash compensation paid to you by the Company, the Employer and/or any subsidiary, affiliate or JV of the Company; or (ii) withholding from proceeds of the sale of shares of Common Stock acquired at exercise of the stock option either through a voluntary sale or through a mandatory sale arranged by the Company (on your behalf pursuant to this authorization); or (iii) withholding in shares of Common Stock to be issued at exercise of the stock option; provided, however, that if you are a Section 16 officer of the Company under the Exchange Act, then the Committee must approve any decision to satisfy the Tax-Related Items by the method described in (iii) above.
The Company may withhold or account for Tax-Related Items by considering applicable minimum statutory withholding amounts or other applicable withholding rates, including maximum applicable rates in your jurisdiction(s). In the event of over-withholding, you may receive a refund of any over-withheld amount in cash (with no entitlement to the equivalent in common stock), or if not refunded, you may seek a refund from the local tax authorities. In the event of under-withholding, you may be required to pay additional Tax-Related Items directly to the applicable tax authority or to the Company and/or the Employer. If the obligation for Tax-Related Items is satisfied by withholding in shares of Common Stock, for tax purposes, you will be deemed to have been issued the full number of shares of Common Stock subject to the exercised stock options, notwithstanding that a number of the shares is held back solely for the purpose of paying the Tax-Related Items due as a result of any aspect of your participation in the Plan.
You shall pay to the Company or the Employer any amount of Tax-Related Items that the Company or the Employer may be required to withhold or account for as a result of your participation in the Plan that cannot be satisfied by the means previously described in this section. The Company may refuse to issue or deliver the shares of Common Stock or the proceeds of the sale of shares, if you fail to comply with your obligations in connection with the Tax-Related Items.



V.DATA PRIVACY
The Company is located at 126 East Lincoln Avenue, Rahway, NJ 07065, U.S.A. and grants employees of the Company and any subsidiary, affiliate or JV of the Company, the opportunity to participate in the Plan, at the Company's sole discretion. If you would like to participate in the Plan, you understand that you should review the following information about the Company’s data processing practices and declare your consent.
A.Data Collection and Usage. The Company collects, processes and uses your personal data, including, name, home address, email address and telephone number, date of birth, social insurance number or other identification number, salary, citizenship, job title, any shares of Common Stock or directorships held in the Company, and details of all awards, canceled, vested, or outstanding in your favor, which the Company receives from you or your Employer. If the Company offers you the opportunity to participate in the Plan, then the Company will collect your personal data for purposes of allocating Common Stock and implementing, administering and managing the Plan. The Company’s legal basis for the processing of your personal data would be your consent.
B.Stock Plan Administration Service Providers. The Company transfers participant data to Morgan Stanley, an independent service provider based in the United States, which assists the Company with the implementation, administration and management of the Plan. In the future, the Company may select a different service provider and share your data with another company that serves in a similar manner. The Company’s service provider will open an account for you. You will be asked to agree on separate terms and data processing practices with the service provider, which is a condition to your ability to participate in the Plan.
C.International Data Transfers. The Company and its service providers are based in the United States. If you are outside of the United States, you should note that your country has enacted data privacy laws that are different from the United States. The Company’s legal basis for the transfer of your personal data is your consent.
D.Voluntariness and Consequences of Consent Denial or Withdrawal. Your participation in the Plan and your grant of consent is purely voluntary. You may deny or withdraw your consent at any time. If you do not consent, or if you withdraw your consent, you cannot participate in the Plan. This would not affect your salary as an employee; you would merely forfeit the opportunities associated with the Plan.
E.Data Subject Rights. You have a number of rights under data privacy laws in your country. Depending on where you are based, your rights may include the right to (i) request access or copies of personal data the Company processes, (ii) rectification of incorrect data, (iii) deletion of data, (iv) restrictions on processing, (v) portability of data, (vi) to lodge complaints with competent authorities in your country, and/or (vii) a list with the names and addresses of any potential recipients of the your personal data. To receive clarification regarding your rights or to exercise your rights please contact the Company at Attn: Global Privacy Office, 351 N. Sumneytown Pike, North Wales, Pennsylvania, U.S.A. 19454.
F.The collection, use and transfer of your personal data for the purpose of implementing, administering and managing your participation in the Plan is conducted in accordance with the Company’s Global Privacy and Data Protection Policy. You also understand that the Company may, in the future, request you to provide another data privacy consent.  If applicable and upon request of the Company, you agree to provide an executed acknowledgement or data privacy consent form to the Company or the Employer (or any other acknowledgements, agreements or consents) that the Company and/or the Employer may deem necessary to obtain under the data privacy laws in your country, either now or in the future.  You understand that you will not be able to participate in the Plan if you fail to execute any such acknowledgement, agreement or consent requested by the Company and/or the Employer.



If you agree with the data processing practices described in this Section, you will declare your consent by clicking to "Accept" these Terms on the Morgan Stanley website.
VI.GOVERNING LAW
This document may be amended only by another written agreement between the parties. This document will be interpreted and enforced under the laws of the State of New Jersey, United States (without regard to its choice-of-law provisions). For purposes of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this grant or this document, the parties hereby submit to and consent to the exclusive jurisdiction of the State of New Jersey and agree that such litigation shall be conducted only in the courts of Union County, New Jersey, or the federal courts for the United States for the District of New Jersey, and no other courts, where this grant is made and/or to be performed.
VII.SEVERABILITY
The provisions of this document are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.
VIII.WAIVER
You acknowledge that a waiver by the Company of breach of any provision of these Terms shall not operate or be construed as a waiver of any other provision of these Terms or of any subsequent breach by you or any other grantee.
IX.ELECTRONIC ACCEPTANCE
The Company may, in its sole discretion, decide to deliver any documents related to the stock option or future options that may be granted under the Plan by electronic means or request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an online or electronic system established and maintained by the Company or a third party designated by the Company.
X.COUNTY-SPECIFIC APPENDIX
This stock option shall be subject to any additional provisions set forth in Appendix B for your country, if any. If you relocate to one of the countries included in Appendix B during the life of this stock option, the additional provisions for such country shall apply to you, to the extent the Company determines that the application of such provisions is necessary or advisable in order to comply with local law or facilitate the administration of the Plan.
XI.ADMINISTRATION
The Committee is responsible for construing and interpreting this stock option, including the right to construe disputed or doubtful Plan provisions, and may establish, amend and construe such rules and regulations as it may deem necessary or desirable for the proper administration of this stock option grant. Any decision or action taken or to be taken by the Committee, arising out of or in connection with the construction, administration, interpretation and effect of this stock option grant shall, to the maximum extent permitted by applicable law, be within its absolute discretion (except as otherwise specifically provided herein) and shall be final, binding and conclusive upon the Company, all Eligible Employees and any person claiming under or through any eligible employee. All determinations by the Committee including, without limitation, determinations of the Eligible Employees, the form, amount and timing of incentives, the terms and provisions of incentives and the writings evidencing incentives, need not be uniform and may be made



selectively among Eligible Employees who receive, or are eligible to receive, Incentives hereunder, whether or not such Eligible Employees are similarly situated.
This stock option is subject to the provisions of the 2019 Incentive Stock Plan. For further information regarding your stock options, you may access the Merck Global Long-Term Incentives homepage via Sync > HR > Money > Long-Term Incentive Program.



APPENDIX A.1
Policy and Procedures for Discretionary Recoupment of
Compensation for Compliance Violations
Policy
It is the policy of the Compensation and Management Development Committee (the “Committee”) of the Board of Directors (the “Board”) of Merck & Co., Inc. (the “Company”) that the Committee will exercise its discretion to determine whether to seek Recoupment of any Covered Compensation paid or awarded to an Affected Employee, where it determines, in consultation with the Audit Committee, that: a) the Affected Employee engaged in misconduct, or failed to reasonably supervise an employee who engaged in misconduct, that resulted in a Material Violation; and b) the Committee concludes that the Material Violation caused Significant Harm to the Company.
Definitions
1.An “Affected Employee” is an employee in Band 600 or higher who (i) engaged in misconduct that results in a Material Violation; or (ii) failed in his or her supervisory responsibilities to reasonably manage or monitor the conduct of an employee who engaged in misconduct that results in a Material Violation.
2.“Covered Compensation” means all (a) incentive‐based cash compensation granted to an Affected Employee, including, without limitation, any annual bonuses and other short‐ and long‐term cash incentives, (b) equity‐based compensation, including, without limitation, stock options, restricted stock, restricted stock units, performance share units (“PSUs”), (c) any proceeds or earnings received in respect of (a) and (b), and (d) any other forms of compensation that the Committee determines to be subject to this policy. For the avoidance of doubt, the foregoing includes any compensation that was previously paid, earned, vested, deferred or paid or payable as a component of severance or termination compensation.
3.“Executive” means current and former executive officers of the Company, as “executive officer” is defined for the purposes of the Securities Exchange Act of 1934, as amended.
4.A “Material Violation” is defined as (i) a material violation of a written Company policy relating to the research, development, manufacturing, sales, or marketing of Company products or (ii) conduct detrimental to the Company, including the Company’s overall goodwill or reputation.
5.“Recoupment” is defined to include any and all of the following actions to the extent permitted by law: (a) reducing the amount of a current or future bonus or other cash or noncash incentive compensation award, (b) requiring reimbursement of a bonus or other cash-based incentive compensation award paid with respect to the most recently completed performance period, (c) cancelling all or a portion of a future‐vesting equity award, (d) cancelling all or a portion of an equity award that vested within the previous twelve‐month period, (e) requiring return of shares paid upon vesting and/or reimbursement of any proceeds received from the sale of an equity award, in each case that vested within the previous twelve‐month period, and (f) any other method of reducing the total compensation paid to an employee for any prior twelve‐month period or any current or future period.
6.“Significant Harm” means a significant negative impact on the Company’s financial operating results or reputation.
Procedures
a.Subject to any delegation to the Chief Executive Officer, as discussed below, the Committee, acting in consultation with the Audit Committee, shall administer this policy and have full discretion to interpret and to make any and all determinations under this policy. Any determinations made by the Committee shall be final, binding, and conclusive on all parties. Notwithstanding the foregoing, the full Board shall approve any determination to seek or waive Recoupment from the Chief Executive Officer.
b.The General Counsel, in consultation with the Chief Ethics and Compliance Officer and the Executive Vice President, Human Resources, is responsible for determining whether to refer a matter to the Committee for review under this policy and for assisting the Committee with its review. In administering this policy, the Committee may consult with other committees of the Board and any external or internal advisors as it deems appropriate.
c.If the Committee, acting in consultation with the Audit Committee, determines that there is a basis for seeking Recoupment under this policy, the Committee shall exercise its discretion to determine for each Affected Employee, on an individual basis, whether, and to what extent and in which manner, to seek Recoupment.



d.In exercising its discretion, the Committee may take into consideration, as it deems appropriate, all of the facts and circumstances of the particular matter and the general interests of the Company.
Delegation to Management for Recoupment Decisions
The Committee may delegate to the Chief Executive Officer (who may further delegate as deemed appropriate) the authority to administer this policy and to make any and all decisions under it regarding Affected Employees who are not Executives of the Company. Management shall report to the Committee on any affirmative decisions to seek Recoupment pursuant to this delegation of authority.
Public Disclosures
The Company will comply with all applicable securities laws and regulations, including Securities and Exchange Commission disclosure requirements regarding executive compensation and any applicable New York Stock Exchange listing standard or requirements, with respect to this policy. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.
Miscellaneous
Nothing in this policy shall limit or otherwise affect any of the following: 1) management’s ability to take any disciplinary action with respect to any Affected Employee; 2) the Committee’s ability to use its negative discretion with respect to any incentive compensation performance target at any time; or 3) the Committee’s or management’s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non‐cash incentive compensation award to any Affected Employee for any reason as they may deem appropriate and to the extent permitted by law. Any right of Recoupment under this policy is in addition to, and not in lieu of, any other remedies or rights of Recoupment that may be available to the Company pursuant to the terms of any similar policy in any incentive plan, employment agreement, equity award agreement, or similar agreement, including, without limitation, the Company’s Policy and Procedures for Recoupment of Incentive‐Based Compensation, and any other legal remedies available to the Company. The Company shall not indemnify or agree to indemnify any current or former Executive against the loss of incentive compensation subject to this policy nor shall the Company pay or reimburse or agree to pay or reimburse any insurance premium to cover the loss of such incentive compensation. The Committee may amend, modify, or terminate this policy in whole or in part at any time and from time to time in its sole discretion.



APPENDIX A.2
Policy and Procedures for Recoupment of
Incentive-Based Compensation
Policy
The Compensation and Management Development Committee (the “Committee”) of the Board of Directors (the “Board”) has adopted this Incentive‐Based Compensation Recoupment Policy (the “Policy”) to comply with Section 10D of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), Rule 10D‐1 promulgated thereunder (“Rule 10D‐1”) and Paragraph 303A.14 of the Listing Standards Manual of the New York Stock Exchange (“NYSE”), which require the recovery of certain Incentive‐Based Compensation in the event of an accounting restatement resulting from a material error in the consolidated financial statements of Merck & Co, Inc. (the “Company”). This Policy shall be administered by the Committee, which shall have express discretionary authority to interpret and construe this Policy and to make all determinations with respect to this Policy, in its sole discretion. It is intended that this Policy be interpreted in a manner that is consistent with the requirements of Section 10D of the Exchange Act and Rule 10D‐1 (or any successor statute or rule) and any other applicable rules or listing standards adopted by the U.S. Securities and Exchange Commission (the “SEC”) or NYSE. All interpretations, constructions and determinations made by the Committee under this Policy shall be final and binding on all parties. This Policy may be amended with the approval of the Committee and may be amended from time to time as necessary to reflect changes in applicable regulations and/or listing standards adopted by the SEC or NYSE. Compliance with this Policy cannot be waived.
Definitions
1. "Accounting Restatement” is the restatement of the Company’s financial statements due to material noncompliance with any financial reporting requirement under the federal securities laws, including any required accounting restatement to correct an error in previously issued financial statements (i) that is material to the previously issued financial statements, or (ii) that would result in a material misstatement if the error were corrected in the current period only or left uncorrected in the current period.
2. A “Covered Officer” is anyone who serves or has served as an executive officer of the Company at any time during the performance period for Incentive‐Based Compensation.
3. “Executive officer” is the equivalent to an “officer” as defined under Section 16a‐1(f) of the Exchange Act (“Section 16 officer”).
4. “Financial reporting measure” is a measure that is (i) determined and presented in accordance with the accounting principles used in preparing the Company’s financial statements, or (ii) derived wholly or in part from such measures. For purposes of this Policy, the term “financial reporting measure” includes the Company’s stock price and total shareholder return, whether expressed as an absolute or relative metric. For the avoidance of doubt, a financial reporting measure need not be presented in the Company’s financial statements or included in a filing with the SEC.
5. “Incentive‐Based Compensation” is any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a financial reporting measure. Incentive‐Based Compensation may include awards under the Executive Incentive Plan and Performance Share Units under the Merck & Co., Inc. 2019 Stock Incentive Plan, or any successor thereto. Incentive‐Based Compensation does not include (i) base salary; (ii) “sign‐on” bonuses or other compensation granted solely due to the commencement of employment with the Company; (iii) compensation exclusively based on completion of a specific period of employment or service, without any performance condition; or (iv) compensation awarded based on subjective, non‐financial, strategic, or operational measures that are not financial reporting measures.
6. Incentive‐Based Compensation is deemed to be “received” in the fiscal period during which the financial reporting measure specified in the Incentive‐Based Compensation award is attained, even if the payment or grant of the Incentive‐Based Compensation occurs after the end of that fiscal period. Incentive‐Based Compensation in the form of an equity award that vests solely upon the basis of a financial reporting measure performance condition will be deemed to be received in the fiscal period in which it vests.
7. “Recoupment Period” is the three completed fiscal years of the Company immediately preceding the date, and any transition period of less than nine months that results from a change in the Company’s fiscal year within or immediately following those three completed fiscal years, on which the Company is required to perform an Accounting Restatement,



which date is the earlier of (i) the date the Board, or a committee of the Board, concludes, or reasonably should have concluded, that the Company is required to perform an Accounting Restatement; or (ii) a date that a court, regulator or other legally authorized body directs the Company to perform an Accounting Restatement.
Procedures for Recoupment of Incentive‐Based Compensation
1. In the event the Company is required to perform an Accounting Restatement, the Company shall, as promptly as reasonably possible, recoup any Incentive‐Based Compensation erroneously received by a Covered Officer during the Recoupment Period. The amount of erroneously received Incentive‐Based Compensation will be the excess of the Incentive‐Based Compensation received by the Covered Officer (whether in cash or in shares) based on the erroneous data in the original financial statements over the Incentive‐Based Compensation (whether in cash or in shares) that would have been received by the Covered Officer had it been based on the restated results, without respect to any tax liabilities incurred or paid by the Covered Officer. For Incentive‐Based Compensation based on total shareholder return or Company stock price, where the amount of erroneously awarded compensation is not subject to mathematical recalculation directly from the information in the Accounting Restatement, the amount shall be based on the Committee’s reasonable estimate of the effect of the Accounting Restatement on the applicable measure and the Committee shall maintain documentation of the determination of that reasonable estimate and provide it to the NYSE. Notwithstanding the foregoing, Incentive‐Based Compensation shall not be recouped under this Policy to the extent received by any person before the date such person served as a Covered Officer.
2. The Committee shall determine, in its sole discretion, the method of recouping any erroneously received Incentive‐Based Compensation pursuant to this Policy.
3. No recoupment shall be required if any of the following conditions are met and the Committee determines that, on such basis, recovery would be impracticable: (i) the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount to be recouped, which determination must be made only after a reasonable and documented attempt by the Company to recoup the Incentive‐Based Compensation (with documentation of such reasonable attempt to recover to be provided to the NYSE); (ii) recovery would violate home country law where that law was adopted prior to November 28, 2022, which determination must be made only after the Company has obtained an opinion of home country counsel, acceptable to the NYSE, that recovery would result in such violation (with a copy of such opinion to be provided to the NYSE); or (iii) recoupment would likely cause an otherwise tax‐qualified retirement plan, under which benefits are broadly available to Company employees, to fail to meet the requirements of Section 401(a)(13) or Section 411(a) of the Internal Revenue Code of 1986, as amended, and U.S. Treasury regulations promulgated thereunder.
Indemnification Not Permitted
The Company shall not indemnify any current or former Covered Officer against the loss of erroneously awarded compensation, and shall not pay, or reimburse any Covered Officer for, premiums incurred or paid for any insurance policy to fund such Covered Officer’s potential recoupment obligations.
Disclosure of Recoupment Decisions
The Company will comply with all applicable securities laws and regulations, including SEC disclosure requirements, with respect to this Policy, and any applicable NYSE listing standard or requirements. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.
Effective Date
This Policy shall be effective as of December 1, 2023 (the “Effective Date”). The terms of this Policy shall apply to any Incentive‐Based Compensation that is received by Covered Officers on or after the Effective Date, even if such Incentive‐Based Compensation was approved, awarded, granted, or paid to Covered Officers prior to the Effective Date.
Miscellaneous
Nothing in this Policy shall limit or otherwise affect any of the following: 1) management’s ability to take any disciplinary action with respect to any Covered Officer; 2) the Committee’s ability to use its negative discretion with respect to any Incentive‐Based Compensation performance target at any time; or 3) the Committee’s or management’s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non‐cash incentive



compensation award to any executive or other employee for any reason as they may deem appropriate and to the extent permitted by law. Any right of recoupment under this Policy is in addition to, and not in lieu of, any other remedies or rights of recoupment that may be available to the Company pursuant to the terms of any similar policy in any incentive plan, employment agreement, equity award agreement, or similar agreement and any other legal remedies available to the Company. This Policy shall be binding and enforceable against all Covered Officers and their beneficiaries, heirs, executors, administrators, or other legal representatives.



APPENDIX B
ADDITIONAL TERMS AND CONDITIONS FOR GRANTEES OUTSIDE THE U.S.
This Appendix, which is part of the Global Terms and Conditions for 2024 Non-Qualified Stock Option Grants under the Merck & Co., Inc. 2019 Incentive Stock Plan, contains additional “terms and conditions” that will apply to you if you reside outside the United States.
The terms and conditions in Part I of this Appendix apply to all grantees who reside outside the United States. The additional terms and conditions in Part II of this Appendix will also apply to you if you reside in one of the countries referenced in Part II.
The information in this Appendix is based on the laws in effect in the respective countries as of November 2023. Such laws are often complex and change frequently. As a result, the Company strongly recommends that you not rely on the information in this Appendix as the only source of information relating to the consequences of your participation in the Plan because the information may be out of date at the time that the stock option vests, you exercise the stock option and shares of Common Stock are issued to you or you sell shares of Common Stock acquired upon exercise of the stock option under the Plan.
In addition, the information contained in this Appendix is general in nature and may not apply to your particular situation, and the Company is not in a position to assure you of a particular result. Accordingly, you should seek appropriate professional advice as to how the relevant laws in your country may apply to your situation.
Finally, if you are a citizen or resident of a country, or are considered a resident of a country, other than that in which you are currently working, or transfer residence and/or employment after the Grant Date, the information contained herein may not apply to you in the same manner. The Company shall, in its sole discretion, determine to what extent the terms and conditions included herein will apply under these circumstances.



APPENDIX B - PART I: ADDITIONAL TERMS AND CONDITIONS FOR ALL COUNTRIES OUTSIDE OF THE UNITED STATES
The following additional terms and conditions will apply to you if you reside in any country outside the United States.
A.Nature of Grant
In accepting the stock option, you acknowledge and agree that:
1.the Plan is established voluntarily by the Company, is discretionary in nature, and may be amended, suspended, or terminated by the Company at any time;
2.the grant of the stock option is exceptional, voluntary, and occasional and does not create any contractual or other right to receive future grants of stock options, or benefits in lieu of stock options, even if stock options have been granted in the past;
3.all decisions with respect to future stock option grants, if any, will be at the sole discretion of the Company;
4.your participation in the Plan is voluntary;
5.your participation in the Plan shall not create a right to employment or be interpreted as forming or amending an employment or service contract with the Company and shall not interfere with the ability of the Employer to terminate your employment or service relationship (if any) at any time;
6.the stock option and any shares of Common Stock acquired under the Plan, and the income from and value of same, are extraordinary items that do not constitute compensation of any kind for services of any kind rendered to the Employer, the Company, or any subsidiary, affiliate, or JV of the Company, and that are outside the scope of your employment or service contract, if any;
7.unless otherwise agreed with the Company in writing, the stock option and any shares of Common Stock acquired under the Plan, and the income and value of same, are not granted as consideration for, or in connection with, the service you may provide as a director of a subsidiary, affiliate, or JV of the Company;
8.the stock option and any shares of Common Stock acquired under the Plan, and the income from and value of same, are not intended to replace any pension rights or compensation;
9.the stock option and any shares of Common Stock acquired under the Plan, and the income from and value of same, are not part of normal or expected compensation or salary for any purposes, including, but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments and in no event should be considered as compensation for, or relating in any way to, past services for the Employer, the Company or any subsidiary, affiliate or JV of the Company;
10.the future value of the shares of Common Stock underlying the stock option is unknown, indeterminable and cannot be predicted with certainty;
11.if the underlying shares of Common Stock do not increase in value, the stock option will have no value;
12.if you exercise the stock option and acquire shares of Common Stock, the value of such shares of Common Stock may increase or decrease in value, even below the Option Price;
13.no claim or entitlement to compensation or damages shall arise from (a) termination of the stock option resulting from termination of your employment by the Company or the Employer (for any reason whatsoever and whether or not in breach of the employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any) and/or (b) termination of the stock option or recoupment of any shares of Common Stock, cash or other benefits acquired at exercise of the stock option resulting from the application of Section I(B) of the Terms;



14.for purposes of the stock option, your employment relationship will be considered terminated as of the date you are no longer providing services to the Employer or the Company or any subsidiary, affiliate or JV of the Company (regardless of the reason for such termination and whether or not later found to be invalid or in breach of the employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and unless otherwise expressly provided in this document, your right to vest in the stock option under the Plan, if any, will terminate effective as of such date and will not be extended by any notice period or any period of “garden leave” or similar period mandated under local; similarly, any right to exercise the stock option after termination of employment will be measured as of the date you are no longer providing services to the Employer or the Company or any subsidiary, affiliate or JV and will not be extended by any notice period or any period of “garden leave” or similar period mandated under local law; the Committee shall have the exclusive discretion to determine when you are no longer providing services for purposes of the grant (including whether you may still be considered to be providing services while on a leave of absence);
15.the stock option and the benefits under the Plan, if any, will not automatically transfer to another company in the case of a merger, take-over or transfer of liability;
16.the Company is not providing any tax, legal or financial advice, nor is the Company making any recommendation regarding your participation in the Plan, or the acquisition or sale of underlying shares; you should consult with your personal tax, legal, and financial advisors regarding the decision to participate in the Plan and before taking any action related to the Plan; and
17.neither the Employer, nor the Company or any subsidiary, affiliate, or JV shall be liable for any foreign exchange rate fluctuation between your local currency and the United States Dollar that may affect the value of the stock option or any amounts due to you pursuant to the exercise of the stock option, the subsequent sale of shares acquired under the Plan or the receipt of any dividends.
B.Insider Trading/Market Abuse Laws
You acknowledge that, depending on your or your broker’s country of residence or where shares of Common Stock are listed, you may be subject to insider trading restrictions and/or market abuse laws, which may affect your ability to accept, acquire, sell or otherwise dispose of shares of Common Stock, rights to shares of Common Stock (e.g., stock options) or rights linked to the value of shares of Common Stock under the Plan during such times that you are considered to have “inside information” regarding the Company (as defined by the laws or regulations in the applicable jurisdictions or your country). Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you placed before you possessed inside information. Furthermore, you could be prohibited from (i) disclosing the inside information to any third party and (ii) “tipping” third parties or causing them otherwise to buy or sell securities. You should keep in mind that third parties include fellow employees. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. You understand you are responsible for ensuring compliance with any restrictions and should consult with your personal legal advisor on this matter.
C.Foreign Asset/Account, Exchange Control and Tax Obligations
You acknowledge that, depending on your country, you may be subject to foreign asset/account, exchange control and/or tax reporting requirements as the result of the acquisition of shares of Common Stock or cash (including dividends and the proceeds of the sale of shares of Common Stock) derived from your participation in the Plan, in, to and/or from a brokerage/bank account or legal entity located outside your country. The applicable laws of your country may require that you report such accounts, assets, the balances therein, the value thereof and/or the transactions related thereto to the applicable authorities in your country. You may also be required to repatriate cash received from participating in the Plan to your country within a certain time after receipt. You acknowledge that you are responsible for ensuring compliance with any applicable foreign asset/account, exchange control and tax reporting requirements and should consult your personal tax, legal and/or financial advisors regarding the same.



D.Language
You acknowledge that you are proficient in the English language, or have consulted with an advisor who is sufficiently proficient, to allow you to understand the terms and conditions of this document. If you have received this document, or any other document related to the stock option and/or the Plan translated into a language other than English, and if the translated version is different than the English version, the English version will control unless otherwise required by local law.
E.Imposition of Other Requirements and Issuance of Shares
The Company reserves the right to impose other requirements on the stock option and the shares of Common Stock purchased upon exercise of the stock options, to the extent the Company determines it is necessary or advisable to comply with local laws or facilitate the administration of the Plan, and to require you to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.
In particular, if advisable due to local law requirements, the Committee, in its sole and absolute discretion, may restrict the methods of exercise available such that, for example, you may be required to immediately sell all of the shares of Common Stock underlying the exercised stock option and will receive only the sale proceeds less the Option Price and any applicable Tax-Related Items.



APPENDIX B - PART II: COUNTRY-SPECIFIC ADDITIONAL TERMS AND CONDITIONS AND NOTIFICATIONS
Country
Additional Terms and Conditions and Notifications
Australia
Tax Information
The Plan is a plan to which Subdivision 83A-C of the Income Tax Assessment Act 1997 (Cth) (the “Tax Assessment Act”) applies (subject to the conditions in the Tax Assessment Act).
Belgium
Acceptance
Stock options granted to you shall not be accepted earlier than the 61st day following the “Offer Date” for tax at exercise. The Offer Date is the date on which the Company notifies you of the material terms and conditions of the stock option grant. Any acceptance given by you before the 61st day following the Offer Date shall be null and void.
Brazil
Compliance with Law
By accepting the stock option, you acknowledge that you agree to comply with applicable Brazilian laws and pay any and all applicable taxes associated with the exercise of stock options, the sale of shares, and the receipt of any dividends.
Labor Law Acknowledgment
By accepting the stock option, you agree that you are (i) making an investment decision and (ii) the value of the underlying shares of Common Stock is not fixed and may increase or decrease in value without compensation to you.
Further, you acknowledge and agree that, for all legal purposes, (i) any benefits provided to you under the Plan are unrelated to your employment or service; (ii) the Plan is not a part of the terms and conditions of your employment or service; and (iii) the income from your participation in the Plan, if any, is not part of your remuneration from employment or service.



Country
Additional Terms and Conditions and Notifications
Canada
Termination of Employment
This provision replaces paragraph (9) of the “Nature of Grant” section in Part I of this Appendix B:
Except to the extent explicitly required under local employment standards legislation, the stock option and any shares of Common Stock acquired under the Plan, and the income from and value of same, are not part of normal or expected compensation or salary for any purposes, including, but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments and in no event should be considered as compensation for, or relating in any way to, past services for the Employer, the Company or any subsidiary, affiliate or JV of the Company;
This provision replaces paragraph (14) of the “Nature of Grant” section in Part I of this Appendix B:
Except to the extent explicitly required under local employment standards legislation, no claim or entitlement to compensation or damages shall arise from (a) termination of the stock option resulting from termination of your employment by the Company or the Employer (for any reason whatsoever and whether or not in breach of the employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any) and/or (b) termination of the stock option or recoupment of any shares of Common Stock, cash or other benefits acquired at exercise of the stock option resulting from the application of Section I(B) of the Terms;
This provision replaces paragraph (14) of the “Nature of Grant” section in Part I of this Appendix B:
For purposes of the stock option, except to the extent expressly provided in your Terms or expressly required by applicable legislation, your employment relationship will be considered terminated (regardless of the reason for such termination), your right to vest in the stock option under the Plan, if any, will terminate as of the date that is the earliest of (a) the date you are no longer employed or providing services to the Company or any parent, subsidiary, affiliate or JV, (b) the date you receive written notice of termination of employment, or (c) the date written notice of termination is delivered to your last known address (together, the “Termination Date”). Similarly, except to the extent expressly provided in your Terms or expressly required by applicable legislation, any right to exercise the stock option after termination of employment will be measured as of the Termination Date. Except to the extent explicitly required by applicable legislation, the Termination Date will exclude any notice period or period of pay in lieu of such notice required under statute, contract, common/civil law or otherwise. You will not earn, or be entitled to earn, any pro-rated vesting or extended exercisability for that portion of time before the date on which your right to vest terminates, nor will you be entitled to any compensation for lost vesting or exercisability. In case of any dispute as to whether termination of employment has occurred that cannot be reasonably determined under your Terms and the Plan, the Committee shall have the sole discretion, subject to applicable legislation, to determine whether such termination of employment has occurred and the effective date of such termination.
Notwithstanding the foregoing, if applicable employment standards legislation explicitly requires continued entitlement to vesting or exercisability during a statutory notice period, your right to vest in or exercise the stock option under the Plan, if any, will terminate effective as of the last day of your minimum statutory notice period, but you will not earn or be entitled to pro-rated vesting or extended exercisability if the Vesting Date(s) or exercisability period falls after the end of your statutory notice period, nor will you be entitled to any compensation for lost vesting or exercisability.
Securities Law Information
You are permitted to sell shares of Common Stock acquired through the Plan through the broker designated by the Company under the Plan, if any, provided the resale of shares of Common Stock acquired under the Plan takes place outside of Canada through the facilities of a stock exchange on



Country
Additional Terms and Conditions and Notifications
which the shares of Common Stock are listed. The shares are currently listed on the New York Stock Exchange.
Payment of Option Price
Notwithstanding anything in the Plan, you are prohibited from surrendering shares of Common Stock that you already own or attesting to the ownership of shares of Common Stock to pay the option price of the shares or any Tax-Related Items in connection with the stock option.
The People's Republic of China
The following terms and conditions apply only to grantees who are citizens of the PRC or are otherwise determined to be subject to the requirements imposed by the State Administration of Foreign Exchange (“SAFE”) as determined by the Company.
Exercise of Stock Option and Termination of Employment
You will be permitted to hold shares of Common Stock issued to you at exercise of the stock option. Notwithstanding anything to the contrary in the Plan or Terms, due to exchange control laws in China, you agree that any shares of Common Stock acquired under the Plan and held by you at the time of your termination of employment with the Company or the Employer will be sold on your behalf, pursuant to this authorization, as soon as administratively practicable following the termination of your employment, but no later than six-months following termination of employment. The Company is under no obligation to arrange for such sale at any particular price. You will receive the sale proceeds, less any broker’s fees or commissions and subject to satisfaction of any Tax-Related Items. If the Terms provide that all or a portion of your outstanding stock option will vest and become exercisable at some time following your termination of employment, in no case will the post-termination exercise period extend beyond six months after termination of employment. Any other portion of your stock option that is not vested and exercisable as described above will expire immediately upon your termination of employment.
Due to local regulatory requirements, you agree that the Company may force the sale of any shares of Common Stock issued under the Plan. The sale may occur (i) immediately upon exercise or (ii) within any other time frame as the Company determines to be necessary or advisable for legal or administrative reasons.
Broker Account
Any shares of Common Stock issued to you upon exercise of your stock options must be maintained in an account with Morgan Stanley Smith Barney or such other stock plan service provider as may be selected by the Company in the future until the shares of Common Stock are sold through that broker.
Exchange Control Notification
You understand and agree that, to comply with exchange control laws in the PRC, any cash dividends and the proceeds from the sale of the shares of Common Stock will be immediately repatriated to China through a special exchange control account established by the Company (or any subsidiary, affiliate or JV) or the Employer prior to being delivered to you. The funds may be paid to you in U.S. dollars or local currency at the Company’s discretion. To the extent the funds are paid to you in U.S. dollars, you understand that you will be required to set up a U.S. dollar bank account in China and provide the bank account details to the Employer and/or the Company so that the funds may be deposited into this account. In the more likely event that the Company converts cash received under the Plan into local currency, the Company is under no obligation to secure any exchange conversion rate and the Company may face delays in converting the proceeds to local currency due to exchange control restrictions in China. You agree to bear any currency fluctuation risk between that time and the time the funds are distributed through any such special exchange account. You further agree to comply with any other requirements that may be imposed by the Company in the future in order to facilitate compliance with exchange control requirements in China.



Country
Additional Terms and Conditions and Notifications
Denmark
Labor Law Acknowledgment
This provision supplements the “Nature of Grant” section Part I of this Appendix B:
By accepting the stock option, you understand and agree that this grant relates to future services to be performed and is not a bonus or compensation for past services.
France
Tax Notification
Your stock option is not intended to be French tax-qualified.
Language Consent
By accepting the stock option, you confirm having read and understood the Plan and your Terms, which were provided in the English language. You accept the terms of those documents accordingly.
En acceptant l’attribution, vous confirmez avoir lu et compris le Plan de travail et vos conditions générales et dispositions, qui ont été transmis en langue anglaise. Vous acceptez les termes de ces documents en connaissance de cause.
Germany
There are no country-specific provisions.
Ireland
There are no country-specific provisions.



Country
Additional Terms and Conditions and Notifications
Israel
Securities Law Information
The grant of the stock option under the Plan is being made pursuant to an exemption from the requirement to file and publish a prospectus in Israel regarding the Plan obtained from the Israeli Securities Authority. Copies of the Plan and the Form S-8 registration statement for the Plan filed with the U.S. Securities and Exchange Commission will be sent to you, at no charge, on written request being mailed to Investor Relations at Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, NJ 07065, U.S.A. The telephone number at the executive offices is 1-908-740-4000. Alternatively, copies of the Plan and the Form S-8 registration statement for the Plan filed with the U.S. Securities and Exchange Commission are available by searching the Company’s filings on the following web site: http://www.sec.gov/edgar/searchedgar/companysearch.html.
Trust Arrangement
You understand and agree that the stock option is offered subject to and in accordance with the terms of the Plan, the Addendum A - Israel to the Plan (the “Israeli Sub-Plan”), the Trust Agreement (the “Trust Agreement”) between the Company and the Company’s trustee appointed by the Company or its subsidiary or affiliate in Israel, currently ESOP Management and Trust Services Ltd. (the “Trustee”), and the Terms. In the event of any inconsistencies between the Israeli Sub-Plan, the Terms and/or the Plan, the Israeli Sub-Plan will govern the stock option granted to you in Israel. Capitalized terms used but not defined in this Appendix B for Israel, the Plan or the Terms have the meanings set forth in the Israeli Sub-Plan.
Requirement to Return Signed Confirmation Letter
If requested by the Employer or the Trustee, you are required to execute the Section 102 Capital Gains Award Confirmation Letter (“Confirmation Letter”) provided to you in connection with the stock option granted to you under the Israeli Sub-Plan. In particular, you must print, sign and deliver a signed copy of the Confirmation Letter to the Trustee within thirty (30) days of the Grant Date, or by such other date as may be determined by your Employer or the Trustee not to exceed ninety (90) days from the Grant Date, for the stock option to qualify for preferential tax treatment. By accepting this stock option, you acknowledge and agree that the terms and conditions of the Confirmation Letter are hereby incorporated by reference into the Terms and shall apply to shares of Common Stock acquired upon exercise of the stock option. If the Trustee does not receive the signed Confirmation Letter within 30 days of the Grant Date, or by such other date as may be determined by your Employer or the Trustee not to exceed ninety (90) days from the Grant Date, the stock option may not qualify for favorable tax treatment. For more details, please contact Daphna Ben-Ari at daphna.ben-ari@merck.com or +972 9533306.
Confirmation of Section 102 Capital Gains Award Terms
The stock option is intended to be a Capital Gain Award that qualifies for the tax treatment for Approved 102 Awards that are designated by the Company to qualify under the capital gain tax treatment in accordance with the provisions of Section 102(b)(2) of the Ordinance. Notwithstanding the foregoing, by accepting the stock option, you acknowledge that the Company cannot guarantee that the Capital Gain Award tax treatment will apply to the stock option granted to you.



Country
Additional Terms and Conditions and Notifications
By accepting the stock option, you: (a) acknowledge receipt of and represent that you have read and understand the Plan, the Israeli Sub-Plan, the Confirmation Letter and the Terms; (b) accept the stock options subject to all of the terms and conditions of the Plan, the Israeli Sub-Plan, the Confirmation Letter and the Terms; and (c) agree that the shares of Common Stock issued to upon exercise of the stock option will be issued to and deposited with the Trustee and shall be held in trust for your benefit as required by the Ordinance, the Israeli Sub-Plan and any approval by the Israeli Tax Authority pursuant to the terms of the Ordinance, the Israeli Sub-Plan and the Trust Agreement. Furthermore, by accepting the stock option, you confirm that you understand the terms and provisions of Section 102 of the Ordinance, particularly the capital gains track described in subsection (b)(2) and (b)(3) thereof, and agree that you will not require the Trustee to release the shares of Common Stock acquired upon exercise of the stock option to you or sell the shares of Common Stock to a third party, during the Holding Period, unless permitted to do so by the Ordinance or the Israeli Sub-Plan.
Italy
Restriction on the Method of Exercise
Due to regulatory requirements in Italy, you will be restricted to the full cashless (also called the “cashless sell-all”) method of exercising the stock option pursuant to which all shares of Common Stock subject to the exercised stock option will be sold immediately upon exercise and the cash proceeds of the sale, less the Option Price, any Tax-Related Items and broker’s fees or commissions, will be remitted to you. You will not be permitted to hold shares after exercise. You acknowledge that the Company’s designated broker is under no obligation to arrange for the sale of shares of Common Stock at any particular price. The Company reserves the right to provide additional methods of exercise depending on local developments.
Plan Document Acknowledgement
By accepting the stock option granted hereunder, you further acknowledge that you have received a copy of the Plan and the Terms, have reviewed the Plan and the Terms in their entirety and fully understand and accept all provisions of the Plan and the Terms; in particular, you acknowledge that you have read and specifically and expressly approve the following provisions in the Plan and the Terms: (a) your stock option cannot be transferred other than by will or the laws of descent and distribution; (b) in the event of involuntary termination of your employment, your right to exercise your stock option will terminate as of the date that you are no longer actively employed by the Employer, unless otherwise expressly provided in the Terms; (c) the Plan is discretionary in nature and may be suspended or terminated by the Company at any time; (d) you are responsible for all Tax-Related Items; (e) if a reorganization, recapitalization, reclassification or other corporate event that results in an adjustment of the shares of Common Stock described in the Plan occurs, your stock option may be adjusted; (f) if a Change in Control, as described in the Plan occurs, your stock option may immediately vest; (g) all decisions with respect to future grants will be at the sole discretion of the Company; and (h) the “Data Privacy” section of your Terms.
Japan
There are no country-specific provisions.



Country
Additional Terms and Conditions and Notifications
Mexico
Securities Law Information
Any stock option offered under the Plan and the shares of Common Stock acquired at exercise of the stock option have not been registered with the National Register of Securities maintained by the Mexican National Banking and Securities Commission and cannot be offered or sold publicly in Mexico. In addition, the Plan and any other document relating to any Award may not be publicly distributed in Mexico. These materials are addressed to you only because of your existing relationship with the Company and its subsidiaries, affiliates and JVs and these materials should not be reproduced or copied in any form. The offer contained in these materials does not constitute a public offering of securities but rather constitutes a private placement of securities addressed specifically to individuals who are present Employees of the Company or one of its subsidiaries, affiliates and JVs, made in accordance with the provisions of the Mexican Securities Market Law, and any rights under such offering shall not be assigned or transferred.
Labor Law Acknowledgement
These provisions supplement the “Nature of Grant” section in Part I of this Appendix B:
By accepting the stock option, you understand and agree that: (i) the stock option is not related to the salary and other contractual benefits granted to you by the Employer and (ii) any modification of the Plan or its termination shall not constitute a change or impairment of the terms and conditions of your employment.
Policy Statement
The invitation the Company is making under the Plan is unilateral and discretionary and, therefore, the Company reserves the absolute right to amend it and discontinue it at any time without any liability to you.
The Company, with registered offices at 126 East Lincoln Avenue, P.O. Box 2000, Rahway, NJ 07065, U.S.A., is solely responsible for the administration of the Plan and your participation in the Plan and the acquisition of shares of Common Stock does not, in any way, establish an employment relationship between you and the Company since you are participating in the Plan on a wholly commercial basis. Based on the foregoing, you expressly recognize that the Plan and the benefits that you may derive from participating in the Plan do not establish any rights between you and the Employer and do not form part of the employment conditions and/or benefits provided by the Employer, and any modification of the Plan or its termination shall not constitute a change or impairment of the terms and conditions of your employment.
Finally, you hereby declare that you do not reserve to yourself any action or right to bring any claim against the Company for any compensation or damages regarding any provision of the Plan or the benefits derived under the Plan, and you therefore grant a full and broad release to the Company, its subsidiaries, affiliates, JVs, branches, representation offices, shareholders, officers, agents or legal representatives, with respect to any claim that may arise.
Plan Document Acknowledgment
By accepting the stock option, you acknowledge that you have received a copy of the Plan, have reviewed the Plan and the Terms, including this Appendix B, in their entirety and fully understand and accept all provisions of the Plan and the Terms.



Country
Additional Terms and Conditions and Notifications
In addition, by accepting the benefits under this grant, you further acknowledge that you have read and specifically and expressly approve the terms and conditions in the “Nature of Grant” section in Part I of this Appendix B, in which the following is clearly described and established: (i) your participation in the Plan does not constitute an acquired right; (ii) the Plan and your participation in the Plan is offered by the Company on a wholly discretionary basis; (iii) your participation in the Plan is voluntary; and (iv) the Company and its subsidiaries, affiliates and JVs are not responsible for any decrease in the value of the shares of Common Stock acquired by you at exercise of the stock option.
Netherlands
There are no country-specific provisions.
Singapore
Restriction on Sale and Transferability
You hereby agree that any shares of Common Stock acquired pursuant to the stock option will not be offered for sale in Singapore prior to the six-month anniversary of the Grant Date, unless such sale or offer is made pursuant to one or more exemptions under Part XII Division 1 Subdivision (4) (other than section 280) of the Securities and Futures Act (Chap. 289, 2006 Ed.) (“SFA”) or pursuant to, and in accordance with, the conditions of any other applicable provision(s) of the SFA.
Securities Law Information
The stock option is being granted to you pursuant to the “Qualifying Person” exemption under section 273(1)(f) of the SFA, on which basis it is exempt from the prospectus and registration requirements under the SFA, and is not made to you with a view of the stock option being subsequently offered for sale to any other party. The Plan has not been lodged or registered as a prospectus with the Monetary Authority of Singapore.
Director Notification
If you are a director (including an alternate, substitute, associate or shadow director) of a Singaporean subsidiary, affiliate or JV of the Company, you are subject to certain notification requirements under the Singapore Companies Act. Among these requirements is an obligation to notify the Singapore subsidiary, affiliate or JV in writing when you receive an interest (e.g., stock options or shares of Common Stock) in the Company or any related companies. In addition, you must notify the Singaporean subsidiary, affiliate or JV when you sell shares of the Company’s common stock or any related company (including when you sell shares of Common Stock acquired under the Plan). These notifications must be made within two business days of acquiring or disposing of any interest in the Company or any related company. In addition, a notification must be made of your interests in the Company or any related company within two days of either after the director becomes aware of the change in respect of the particulars of any of the aforesaid, the date on which the director becomes a holder of, or acquires an interest in, the shares, debentures, rights, contracts, participatory interests, other securities or securities-based derivatives contacts, whichever last occurs. There is no prescribed form for such disclosure, although in practice, the company secretary normally would prepare a formatted disclosure form that requests the following information: equity award granted, number of shares acquired, description of consideration, if applicable, and the date of the transaction.
A director shall be deemed to have an interest in securities or securities-based derivative contracts referred to above if a family member of the director (not being him or herself a director), holds or has an interest in those securities or securities-based derivatives contract and any contract entered into by, or any grant made to, a family member of a director of a corporation (not being himself a director) shall be deemed to have been entered into by, made or exercised by or made to the director. A “family member” means a spouse, or a son, adopted son, step-son, daughter, adopted daughter or step-daughter below the age of 21 years.



Country
Additional Terms and Conditions and Notifications
Spain
Labor Law Acknowledgment
This provision supplements the “Nature of Grant” section in Part I of this Appendix B:
By accepting your stock option grant, you acknowledge, understand and agree that you consent to participation in the Plan and that you have received a copy of the Plan.
You understand that the Company, in its sole discretion, has unilaterally and gratuitously decided to distribute stock options under the Plan to individuals who may be employees of the Company or its subsidiaries, affiliates or JVs throughout the world. The decision is a limited decision that is entered into upon the express assumption and condition that any grant will not economically or otherwise bind the Company or any of its subsidiaries, affiliates or JVs on an ongoing basis over and above the specific terms of the Plan. Consequently, you understand that any stock option is given on the assumption and condition that it shall not become a part of any employment contract (either with the Company or any of its subsidiaries, affiliates or JVs) and shall not be considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever. Further, you understand and freely accept that there is no guarantee that any benefit whatsoever shall arise from any gratuitous and discretionary stock option since the future value of the stock options and shares is unknown and unpredictable. In addition, you understand that the grant would not be made to you but for the assumptions and conditions referred to above; thus, you acknowledge and freely accept that should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, then any stock option grant shall be null and void.
You also understand and agree that, as a condition of the stock option grant, the termination of your employment for any reason (including the reasons listed below), the stock option will cease vesting and any entitlement to exercise vested stock options will start to run immediately effective on the date you are no longer providing services to the Employer or the Company or any of its subsidiaries, affiliates or JVs unless otherwise specifically provided in the Terms. In particular, you understand and agree that any unvested stock option or any vested stock option not exercised within the period set forth in the “Termination of Employment” section in the Terms will be forfeited without entitlement to the underlying shares of Common Stock or to any amount as indemnification in the event of a termination of your employment as described in the Terms prior to vesting of the stock option by reason of, including but not limited to, resignation, retirement, disciplinary dismissal adjudged to be with cause, disciplinary dismissal adjudged or recognized to be without good cause (i.e., subject to a “despido improcedente”), individual or collective dismissal on objective grounds, whether adjudged or recognized to be with or without cause, material modification of the terms of employment under Article 41 of the Workers’ Statute, relocation under Article 40 of the Workers’ Statute, Article 50 of the Workers’ Statute, unilateral withdrawal by the Employer and under Article 10.3 of the Royal Decree 1382/1985.
Securities Law Information
No “offer of securities to the public,” as defined under Spanish law, has taken place or will take place in the Spanish territory in connection with the grant of the stock option. The Plan and the Terms have not been nor will they be registered with the Comisión Nacional del Mercado de Valores, and do not constitute a public offering prospectus.



Country
Additional Terms and Conditions and Notifications
Sweden
Authorization to Withhold
The following provision supplements the “Tax Withholding” section of the Terms:
Without limiting the Company’s and the Employer’s authority to satisfy their withholding obligations for Tax-Related Items as set forth in the “Tax Withholding” section of the Terms, in accepting the stock option, you authorize the Company and/or the Employer to withhold shares of Common Stock or to sell shares of Common Stock otherwise deliverable to you upon exercise to satisfy Tax-Related Items, regardless of whether the Company and/or the Employer have an obligation to withhold such Tax-Related Items.
Switzerland
Securities Law Information
The offering of participation in the Plan is considered a private offering in Switzerland; therefore, it is not subject to registration in Switzerland. Neither this document nor any other materials relating to the Plan (i) constitute a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services (“FinSA”), (ii) may be publicly distributed nor otherwise made publicly available in Switzerland to any person other than an employee of the Company or Employer or (iii) has been or will be filed with, approved or supervised by any Swiss reviewing body according to article 51 FinSA or any Swiss regulatory authority, including the Swiss Financial Market Supervisory Authority.
United Kingdom
Tax Acknowledgment
You agree that you are liable for all Tax-Related Items and hereby covenant to pay all such Tax-Related Items, as and when requested by the Company or, if different, your Employer or by HM Revenue and Customs (“HRMC”) (or any other tax authority or any other relevant authority). You also agree to indemnify and keep indemnified the Company and, if different, your Employer against any Tax-Related Items that they are required to pay or withhold or have paid or will pay to HMRC (or any other tax authority or any other relevant authority) on your behalf.
Notwithstanding the foregoing, if you are a director or executive officer of the Company (within the meaning of Section 13(k) of the U.S. Securities Exchange Act of 1934, as amended), the amount of any income tax not collected from or paid by you within ninety (90) days of the end of the U.K. tax year in which the event giving rise to the Tax-Related Items occurs may constitute a benefit to you on which additional income tax and National Insurance contributions may be payable. You understand that you will be responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for paying to the Company and/or the Employer (as appropriate) the amount of any employee National Insurance contributions due on this additional benefit, which may also be recovered from you through any means set forth in the “Tax Withholding” section of the Terms.

EX-10.34 8 exh1034-2024specialretenti.htm EX-10.34 2024 SPECIAL RETENTION RSU TERMS & CONDITIONS Document

GLOBAL TERMS AND CONDITIONS
2024 RETENTION RESTRICTED STOCK UNIT GRANT FOR RICHARD DELUCA
UNDER THE MERCK & CO., INC. 2019 INCENTIVE STOCK PLAN
I.GENERAL. Merck & Co., Inc. (the “Company”) has granted to you the Restricted Stock Unit (“RSU”) award specified in this document (“RSU Award”) pursuant to the Merck & Co., Inc. 2019 Incentive Stock Plan, including any sub-plan thereto for your country (the “Plan”). This RSU Award is subject to the terms and conditions of the Plan and these Global Terms and Conditions (the “Terms”). Unless otherwise defined in this document, capitalized terms used in these Terms are as defined in the Plan.
Grant Type:RSU - Annual
Grant Date:
April 30, 2024
Vesting DatesPortion that Vests
April 30, 2027100%
IMPORTANT NOTICE: This grant requires you to affirmatively accept it. You MUST log onto the Morgan Stanley website at (http://www.morganstanley.com/spc/knowledge/managing-equity/managing-your-existing-awards/accepting-awards-grants/) to accept the grant.
Follow the procedures described on the Morgan Stanley website to accept your RSU Award within 90 days. Failure to accept the terms and conditions of your RSU Award within 90 days may result in Forfeiture of the RSU Award.
A.Restricted (Vesting) Period. The Restricted Period is the period during which this RSU Award is subject to forfeiture. The restricted period begins on the Grant Date and ends on the third anniversary of the Grant Date unless ended earlier under article II below. No voting rights apply to this RSU Award. No fractional shares will be issued upon settlement of the RSU Award; all calculations are subject to rounding.
B.Dividend Equivalents. During the period commencing on the Grant Date and ending on the date immediately prior to the date the RSU Awards are settled in accordance with paragraph I(C), dividend equivalents will be accrued for the holder (“you”) if and to the extent dividends are paid by the Company on Merck Common Stock. Payment of such dividends will be made in cash via local payroll, without interest or earnings, at or around the time of distribution of the shares of Common Stock in settlement of the underlying RSUs. If any portion of this RSU Award lapses, is forfeited or expires, no dividend equivalents will be credited or paid on such portion. Any payment of dividend equivalents will be reduced to the extent necessary for the Company to satisfy any tax or other withholding obligations in accordance with paragraph IV.
C.Distribution (Settlement of RSU Award). Upon vesting of the RSU Award (including as a result of the events set forth in Article II), you (or your estate, in the event the RSU Award vests pursuant to paragraph II(E)) will be issued a number of shares of Merck Common Stock equal to the number of RSUs (unless otherwise provided in paragraph II(H)) with respect to which the RSU Award has vested and the dividend equivalents that accrued on that portion; provided, however, that in the event the RSU Awards vests upon a Change in Control (as defined below) pursuant to paragraph II(H) that does not constitute a “change in control event” within the meaning of U.S. Treasury Regulations



Section 1.409A-3(i)(5), the RSU Awards will instead be settled on the original Vesting Dates set forth in paragraph I(A). Any amount required to be withheld, including amounts required to satisfy Tax-Related Items, in connection with the distribution of the RSU Award (or otherwise arising from your participation in the Plan) will be recovered from you as described in paragraph IV.
D.409A Compliance. Anything to the contrary notwithstanding, no distribution of RSUs may be made unless in compliance with Section 409A of the Code or any successor thereto. Specifically, distributions made upon or by reference to the date of an employment termination shall not be paid unless such termination constitutes a “separation from service (as defined in Section 409A)” and any such payment to a “Specified Employee” as defined in Treas. Reg. Sec. 1.409A-1(i) or any successor thereto, to the extent required by Section 409A of the Code will instead be made on the first day the seventh month following the separation from service, in the same form as they would have been made had this restriction not applied; provided further, that dividend equivalents that otherwise would have accrued will accrue during the period during which distribution is suspended.
E.Subject to Recoupment. This RSU Award will be subject to recoupment in the event of certain violations of Company policy in accordance with the Company’s Policy and Procedures for Discretionary Recoupment of Compensation for Compliance Violations, as set forth in Appendix A.1, and with the Company’s Policy and Procedures for Recoupment of Incentive-Based Compensation, applicable only for Section 16 Officers, as set forth in Appendix A.2 (as may be amended from time to time).
II.TERMINATION OF EMPLOYMENT
If your employment with the Company or, if different, the subsidiary, affiliate or joint venture (“JV”) of the Company by which you are employed (the “Employer”) is terminated during the Restricted Period described in paragraph I(A), your right to the RSU Award will be determined according to the terms in this Article II. For avoidance of doubt, if your employment terminates on a Vesting Date
not for misconduct, you will be entitled to vest in that unvested portion of the RSU Award that is
scheduled to vest on that Vesting Date.
A.General Rule. If your employment is terminated during the Restricted Period for any reason other than those specified in the following paragraphs, the unvested portion of this RSU Award (and any accrued dividend equivalents) will be forfeited on the date your employment terminates. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.
B.Involuntary Termination. If the Company determines that your employment is involuntarily terminated during the Restricted Period on or after the first anniversary of the Grant Date, the RSU Award will vest on the Vesting Date with respect to a pro rata portion of your unvested RSU Award and dividend equivalents that have accrued through the corresponding Vesting Date equal to (i) the total number of RSUs subject to the RSU Award, multiplied by (ii) a fraction, numerator of which is equal to the number of completed monthly periods during the period commencing on the Grant Date and ending the date employment terminates, and the denominator of which is 36. The remaining portion, if any, of the RSU Award and any accrued dividends will be forfeited on the date your employment terminates. An “involuntary termination” includes termination of your employment by the Company or the Employer, as applicable, as the result of a restructuring or job elimination, but excludes non-performance of your duties and the reasons listed under paragraphs C through H of this section. If your employment is terminated as described in this paragraph and you are later rehired by



the Company or the Employer, as applicable, this RSU Award nevertheless will be forfeited according to this paragraph notwithstanding such rehire.
C.Sale. If your employment is terminated during the Restricted Period and the Company determines that such termination resulted from the sale of your subsidiary, affiliate, division or JV, the RSU Award will continue to vest on the original Vesting Date set forth in paragraph I(A) with respect to the following unvested portion of your RSU Award and dividend equivalents that have accrued through the corresponding Vesting Date: if employment terminates on or after the Grant Date but before the first anniversary thereof, then one-third of your RSU Award will vest on the Vesting Date; if employment terminates on or after the first anniversary of the Grant Date, the entire RSU Award will vest on the Vesting Date. The remaining portion, if any, of the RSU Award that does not vest pursuant to the foregoing sentence will be forfeited on the date your employment terminates. Notwithstanding the foregoing, the Committee may determine, for purposes of this RSU Award, whether employment with an entity that is established from the Company’s spin off, split off, split up or distribution of equity securities in connection with that entity constitutes a termination of employment, and may make adjustments, if any, as it deems appropriate, and to the extent not inconsistent with the Plan, at the time of the distribution of such equity securities, in the kind and/or number of shares subject to this RSU Award. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this RSU Award nevertheless will be forfeited according to this paragraph notwithstanding such rehire.
D.Retirement. If your employment terminates by retirement during the Restricted Period, the unvested portion of this RSU Award and any accrued dividend equivalents will be forfeited on the date your employment terminates. For grantees who are employed in the U.S., “retirement” means a termination of employment after attaining the earliest of (a) age 55 with at least 10 years of service (b) such age and service that provides eligibility for subsidized retiree medical coverage or (c) age 65 without regard to years of service. For other grantees, “retirement” is determined by the Company. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.
E.Death. If your employment terminates due to your death during the Restricted Period but prior to an employment termination contemplated under paragraphs B, C, D, G or H, the RSU Award will immediately vest, including dividend equivalents that have accrued though such date. If you die during the Restricted Period, but after your employment terminates for the reasons listed under paragraphs B, C, G or H of this section, the RSU Award will immediately vest with respect to the remaining, non-forfeited portion of this RSU Award and dividend equivalents that have accrued through the date of death.
F.Misconduct. If your employment is terminated as a result of your deliberate, willful or gross misconduct, this RSU Award and accrued dividend equivalents will be forfeited immediately upon your receipt of notice of such termination.
G.Disability. If your employment is terminated during the Restricted Period and the Company determines that such termination resulted from inability to perform the material duties of your role by reason of a physical or mental infirmity that is expected to last for at least six months or to result in your death, whether or not you are eligible for disability benefits from any applicable disability program, then the RSU Award will continue to vest on the original Vesting Date set forth in paragraph I(A). If your employment is terminated as described in this paragraph and you are later



rehired by the Company or the Employer, as applicable, this RSU Award nevertheless will expire according to this paragraph notwithstanding such rehire.
H.Change in Control. If this RSU Award is assumed, converted or otherwise remains outstanding in connection with a Change in Control and your employment is terminated during the Restricted Period without Cause before the second anniversary of the closing of the Change in Control, then the RSU Award will continue to vest on the original Vesting Date set forth in paragraph I(A) with respect to the unvested portion of the RSU Award and dividend equivalents that have accrued through the corresponding Vesting Date. If this RSU Award does not remain outstanding following the Change in Control and is not converted into a successor RSU, then the RSU Award will immediately vest with respect to the portion of the RSU Award that is unvested as of the Change in Control and dividend equivalents that have accrued though such date and, at the election of the Company, you will be entitled to receive cash for such portion of this RSU Award in an amount equal to the fair market value of the consideration paid to Merck stockholders for a share of Merck Common Stock in the Change in Control. On the second anniversary of the closing of the Change in Control, this paragraph shall expire. “Cause” and “Change in Control” are defined in the Merck & Co., Inc. Change in Control Separation Benefits Plan (excluding an MSD Change in Control).
I.Transfer of Employment. Transfer of employment between the Company, a subsidiary, affiliate, JV, JV partner or affiliate of the Company who provides services to the JV with such partner or affiliate or other entity in which the Company has determined that it has a significant business or ownership interest (together, the “Company Group”) is not considered termination of employment for purposes of this RSU Award. Such employment must be approved by the Company and contiguous with employment by the entity in the Company Group you were employed by immediately prior to the relevant transfer. The terms set out in paragraphs A through H above shall continue to apply to this RSU Award following a transfer of employment accordance with this section.
III.TRANSFERABILITY
Prior to distribution pursuant to Article I(C), the RSU Award and any interest therein shall not be sold, assigned, transferred, pledged or otherwise disposed of, alienated or encumbered, either voluntarily or involuntarily, other than by will or the laws of descent and distribution in connection with your death.
IV.TAX WITHHOLDING
Regardless of any action the Company and/or the Employer take with respect to any or all income tax, social insurance, payroll tax, payment on account or other tax-related items arising out of your participation in the Plan and legally applicable or deemed applicable to you (“Tax-Related Items”), you acknowledge that the ultimate liability for all Tax-Related Items is and remains your responsibility and may exceed the amount actually withheld by the Company and/or the Employer, if any. You further acknowledge that the Company and/or the Employer (i) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the RSU Award or underlying shares of Common Stock, including, but not limited to, the grant, vesting or settlement of the RSU, the subsequent sale of shares of Common Stock acquired upon the lapsing of the Restricted Period and the receipt of any dividends and/or dividend equivalents; and (ii) do not commit and are under no obligation to structure the terms of the grant or any aspect of the RSU Award to reduce or eliminate your liability for Tax-Related Items or achieve any particular tax result. Furthermore, if you have become subject to tax in more than one jurisdiction, you acknowledge that the Company and/or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.



Prior to the relevant taxable or tax withholding event, as applicable, you shall pay or make arrangements satisfactory to the Company and/or the Employer to satisfy any applicable withholding obligations or rights with regard to all Tax-Related Items. In this regard, you authorize the Company and/or the Employer, or their respective agents, at their discretion, to satisfy the Tax-Related Items by one or a combination of the following: (i) withholding from your wages or other cash compensation paid to you by the Company, the Employer and/or any subsidiary, affiliate or JV of the Company; or (ii) withholding from proceeds of the sale of shares of Common Stock acquired at lapsing of the Restricted Period either through a voluntary sale or through a mandatory sale arranged by the Company (on your behalf pursuant to this authorization); or (iii) withholding in shares of Common Stock to be issued upon lapsing of the Restricted Period; provided, however, that if you are a Section 16 officer of the Company under the Exchange Act, then the Company will satisfy the Tax-Related Items (other than U.S. Federal Insurance Contribution Act taxes or other Tax-Related Items which become payable in a year prior to the year in which shares of Common Stock are issued upon settlement of the RSUs) by withholding in shares of Common Stock pursuant to (iii) above, unless the use of such withholding method is problematic under applicable tax or securities law or has materially adverse accounting consequences, in which case, the obligation for Tax-Related Items may be satisfied by a one or a combination of (i) or (ii) above.
The Company may withhold or account for Tax-Related Items by considering applicable minimum statutory withholding amounts or other applicable withholding rates, including maximum applicable rates in your jurisdiction(s). In the event of over-withholding, you may receive a refund of any over-withheld amount in cash (with no entitlement to the equivalent in Common Stock), or if not refunded, you may seek a refund from the local tax authorities. In the event of under-withholding, you may be required to pay additional Tax-Related Items directly to the applicable tax authority or to the Company and/or the Employer. If the obligation for Tax-Related Items is satisfied by withholding in shares of Common Stock, for tax purposes, you will be deemed to have been issued the full number of shares of Common Stock subject to the vested RSUs, notwithstanding that a number of the shares is held back solely for the purpose of paying the Tax-Related Items due as a result of any aspect of your participation in the Plan.
You shall pay to the Company or the Employer any amount of Tax-Related Items that the Company or the Employer may be required to withhold or account for as a result of your participation in the Plan that cannot be satisfied by the means previously described in this section. The Company may refuse to issue or deliver the shares of Common Stock or the proceeds of the sale of shares if you fail to comply with your obligations in connection with the Tax-Related Items.
V.DATA PRIVACY
The Company is located at 126 East Lincoln Avenue, Rahway, NJ 07065, U.S.A. and grants employees of the Company and any subsidiary, affiliate or JV of the Company, the opportunity to participate in the Plan, at the Company's sole discretion. If you would like to participate in the Plan, you understand that you should review the following information about the Company’s data processing practices and declare your consent.
A.Data Collection and Usage. The Company collects, processes and uses your personal data, including, name, home address, email address and telephone number, date of birth, social insurance number or other identification number, salary, citizenship, job title, any shares of Common Stock or directorships held in the Company, and details of all awards, canceled, vested, or outstanding in your favor, which the Company receives from you or your Employer. If the Company offers you the opportunity to participate in the Plan, then the Company will collect your personal data for purposes



of allocating Common Stock and implementing, administering and managing the Plan. The Company’s legal basis for the processing of your personal data would be your consent.
B.Stock Plan Administration Service Providers. The Company transfers participant data to Morgan Stanley, an independent service provider based in the United States, which assists the Company with the implementation, administration and management of the Plan. In the future, the Company may select a different service provider and share your data with another company that serves in a similar manner. The Company’s service provider will open an account for you. You will be asked to agree on separate terms and data processing practices with the service provider, which is a condition to your ability to participate in the Plan.
C.International Data Transfers. The Company and its service providers are based in the United States. If you are outside of the United States, you should note that your country has enacted data privacy laws that are different from the United States. The Company’s legal basis for the transfer of your personal data is your consent.
D.Voluntariness and Consequences of Consent Denial or Withdrawal. Your participation in the Plan and your grant of consent is purely voluntary. You may deny or withdraw your consent at any time. If you do not consent, or if you withdraw your consent, you cannot participate in the Plan. This would not affect your salary as an employee; you would merely forfeit the opportunities associated with the Plan.
E.Data Subject Rights. You have a number of rights under data privacy laws in your country. Depending on where you are based, your rights may include the right to (i) request access or copies of personal data the Company processes, (ii) rectification of incorrect data, (iii) deletion of data, (iv) restrictions on processing, (v) portability of data, (vi) to lodge complaints with competent authorities in your country, and/or (vii) a list with the names and addresses of any potential recipients of the your personal data. To receive clarification regarding your rights or to exercise your rights please contact the Company at Attn: Global Privacy Office, 351 N. Sumneytown Pike, North Wales, Pennsylvania, U.S.A. 19454.
F.The collection, use and transfer of your personal data for the purpose of implementing, administering and managing your participation in the Plan is conducted in accordance with the Company’s Global Privacy and Data Protection Policy. You also understand that the Company may, in the future, request you to provide another data privacy consent.  If applicable and upon request of the Company, you agree to provide an executed acknowledgement or data privacy consent form to the Company or the Employer (or any other acknowledgements, agreements or consents) that the Company and/or the Employer may deem necessary to obtain under the data privacy laws in your country, either now or in the future.  You understand that you will not be able to participate in the Plan if you fail to execute any such acknowledgement, agreement or consent requested by the Company and/or the Employer.
If you agree with the data processing practices described in this Article, you will declare your consent by clicking to "Accept" these Terms on the Morgan Stanley website.
VI.GOVERNING LAW
This document may be amended only by another written agreement between the parties. This document will be interpreted and enforced under the laws of the State of New Jersey, United States (without regard to its choice-of-law provisions). For purposes of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this grant or this document, the parties hereby submit to



and consent to the exclusive jurisdiction of the State of New Jersey and agree that such litigation shall be conducted only in the courts of Union County, New Jersey, or the federal courts for the United States for the District of New Jersey, and no other courts, where this grant is made and/or to be performed.
VII.SEVERABILITY
The provisions of this document are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.
VIII.WAIVER
You acknowledge that a waiver by the Company of breach of any provision of these Terms shall not operate or be construed as a waiver of any other provision of these Terms or of any subsequent breach by you or any other grantee.
IX.ELECTRONIC ACCEPTANCE
The Company may, in its sole discretion, decide to deliver any documents related to the RSU or future RSUs that may be granted under the Plan by electronic means or request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an online or electronic system established and maintained by the Company or a third party designated by the Company.
X.ADMINISTRATION
The Committee is responsible for construing and interpreting this grant, including the right to construe disputed or doubtful Plan provisions, and may establish, amend and construe such rules and regulations as it may deem necessary or desirable for the proper administration of this RSU Award. Any decision or action taken or to be taken by the Committee, arising out of or in connection with the construction, administration, interpretation and effect of this RSU Award shall, to the maximum extent permitted by applicable law, be within its absolute discretion (except as otherwise specifically provided herein) and shall be final, binding and conclusive upon the Company, all Eligible Employees and any person claiming under or through any Eligible Employee. All determinations by the Committee including, without limitation, determinations of the Eligible Employees, the form, amount and timing of Incentives, the terms and provisions of Incentives and the writings evidencing Incentives, need not be uniform and may be made selectively among eligible employees who receive, or are eligible to receive, Incentives hereunder, whether or not such Eligible Employees are similarly situated.
This RSU Award is subject to the provisions of the 2019 Incentive Stock Plan. For further information regarding your RSU Award, you may access the Merck Global Long-Term Incentives homepage via Sync > HR > Money > Long-Term Incentive Program



APPENDIX A.1
Policy and Procedures for Discretionary Recoupment of
Compensation for Compliance Violations
Policy
It is the policy of the Compensation and Management Development Committee (the “Committee”) of the Board of Directors (the “Board”) of Merck & Co., Inc. (the “Company”) that the Committee will exercise its discretion to determine whether to seek Recoupment of any Covered Compensation paid or awarded to an Affected Employee, where it determines, in consultation with the Audit Committee, that: a) the Affected Employee engaged in misconduct, or failed to reasonably supervise an employee who engaged in misconduct, that resulted in a Material Violation; and b) the Committee concludes that the Material Violation caused Significant Harm to the Company.
Definitions
1.An “Affected Employee” is an employee in Band 600 or higher who (i) engaged in misconduct that results in a Material Violation; or (ii) failed in his or her supervisory responsibilities to reasonably manage or monitor the conduct of an employee who engaged in misconduct that results in a Material Violation.
2.“Covered Compensation” means all (a) incentive‐based cash compensation granted to an Affected Employee, including, without limitation, any annual bonuses and other short‐ and long‐term cash incentives, (b) equity‐based compensation, including, without limitation, stock options, restricted stock, restricted stock units, performance share units (“PSUs”), (c) any proceeds or earnings received in respect of (a) and (b), and (d) any other forms of compensation that the Committee determines to be subject to this policy. For the avoidance of doubt, the foregoing includes any compensation that was previously paid, earned, vested, deferred or paid or payable as a component of severance or termination compensation.
3.“Executive” means current and former executive officers of the Company, as “executive officer” is defined for the purposes of the Securities Exchange Act of 1934, as amended.
4.A “Material Violation” is defined as (i) a material violation of a written Company policy relating to the research, development, manufacturing, sales, or marketing of Company products or (ii) conduct detrimental to the Company, including the Company’s overall goodwill or reputation.
5.“Recoupment” is defined to include any and all of the following actions to the extent permitted by law: (a) reducing the amount of a current or future bonus or other cash or noncash incentive compensation award, (b) requiring reimbursement of a bonus or other cash-based incentive compensation award paid with respect to the most recently completed performance period, (c) cancelling all or a portion of a future‐vesting equity award, (d) cancelling all or a portion of an equity award that vested within the previous twelve‐month period, (e) requiring return of shares paid upon vesting and/or reimbursement of any proceeds received from the sale of an equity award, in each case that vested within the previous twelve‐month period, and (f) any other method of reducing the total compensation paid to an employee for any prior twelve‐month period or any current or future period.
6.“Significant Harm” means a significant negative impact on the Company’s financial operating results or reputation.
Procedures
a.Subject to any delegation to the Chief Executive Officer, as discussed below, the Committee, acting in consultation with the Audit Committee, shall administer this policy and have full discretion to interpret and to make any and all determinations under this policy. Any determinations made by the Committee shall be final, binding, and conclusive on all parties. Notwithstanding the foregoing, the full Board shall approve any determination to seek or waive Recoupment from the Chief Executive Officer.
b.The General Counsel, in consultation with the Chief Ethics and Compliance Officer and the Executive Vice President, Human Resources, is responsible for determining whether to refer a matter to the Committee for review under this policy and for assisting the Committee with its review. In administering this policy, the



Committee may consult with other committees of the Board and any external or internal advisors as it deems appropriate.
c.If the Committee, acting in consultation with the Audit Committee, determines that there is a basis for seeking Recoupment under this policy, the Committee shall exercise its discretion to determine for each Affected Employee, on an individual basis, whether, and to what extent and in which manner, to seek Recoupment.
d.In exercising its discretion, the Committee may take into consideration, as it deems appropriate, all of the facts and circumstances of the particular matter and the general interests of the Company.
Delegation to Management for Recoupment Decisions
The Committee may delegate to the Chief Executive Officer (who may further delegate as deemed appropriate) the authority to administer this policy and to make any and all decisions under it regarding Affected Employees who are not Executives of the Company. Management shall report to the Committee on any affirmative decisions to seek Recoupment pursuant to this delegation of authority.
Public Disclosures
The Company will comply with all applicable securities laws and regulations, including Securities and Exchange Commission disclosure requirements regarding executive compensation and any applicable New York Stock Exchange listing standard or requirements, with respect to this policy. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.
Miscellaneous
Nothing in this policy shall limit or otherwise affect any of the following: 1) management’s ability to take any disciplinary action with respect to any Affected Employee; 2) the Committee’s ability to use its negative discretion with respect to any incentive compensation performance target at any time; or 3) the Committee’s or management’s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non‐cash incentive compensation award to any Affected Employee for any reason as they may deem appropriate and to the extent permitted by law. Any right of Recoupment under this policy is in addition to, and not in lieu of, any other remedies or rights of Recoupment that may be available to the Company pursuant to the terms of any similar policy in any incentive plan, employment agreement, equity award agreement, or similar agreement, including, without limitation, the Company’s Policy and Procedures for Recoupment of Incentive‐Based Compensation, and any other legal remedies available to the Company. The Company shall not indemnify or agree to indemnify any current or former Executive against the loss of incentive compensation subject to this policy nor shall the Company pay or reimburse or agree to pay or reimburse any insurance premium to cover the loss of such incentive compensation. The Committee may amend, modify, or terminate this policy in whole or in part at any time and from time to time in its sole discretion.



APPENDIX A.2
Policy and Procedures for Recoupment of
Incentive-Based Compensation
Policy
The Compensation and Management Development Committee (the “Committee”) of the Board of Directors (the “Board”) has adopted this Incentive‐Based Compensation Recoupment Policy (the “Policy”) to comply with Section 10D of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), Rule 10D‐1 promulgated thereunder (“Rule 10D‐1”) and Paragraph 303A.14 of the Listing Standards Manual of the New York Stock Exchange (“NYSE”), which require the recovery of certain Incentive‐Based Compensation in the event of an accounting restatement resulting from a material error in the consolidated financial statements of Merck & Co, Inc. (the “Company”). This Policy shall be administered by the Committee, which shall have express discretionary authority to interpret and construe this Policy and to make all determinations with respect to this Policy, in its sole discretion. It is intended that this Policy be interpreted in a manner that is consistent with the requirements of Section 10D of the Exchange Act and Rule 10D‐1 (or any successor statute or rule) and any other applicable rules or listing standards adopted by the U.S. Securities and Exchange Commission (the “SEC”) or NYSE. All interpretations, constructions and determinations made by the Committee under this Policy shall be final and binding on all parties. This Policy may be amended with the approval of the Committee and may be amended from time to time as necessary to reflect changes in applicable regulations and/or listing standards adopted by the SEC or NYSE. Compliance with this Policy cannot be waived.
Definitions
1. "Accounting Restatement” is the restatement of the Company’s financial statements due to material noncompliance with any financial reporting requirement under the federal securities laws, including any required accounting restatement to correct an error in previously issued financial statements (i) that is material to the previously issued financial statements, or (ii) that would result in a material misstatement if the error were corrected in the current period only or left uncorrected in the current period.
2. A “Covered Officer” is anyone who serves or has served as an executive officer of the Company at any time during the performance period for Incentive‐Based Compensation.
3. “Executive officer” is the equivalent to an “officer” as defined under Section 16a‐1(f) of the Exchange Act (“Section 16 officer”).
4. “Financial reporting measure” is a measure that is (i) determined and presented in accordance with the accounting principles used in preparing the Company’s financial statements, or (ii) derived wholly or in part from such measures. For purposes of this Policy, the term “financial reporting measure” includes the Company’s stock price and total shareholder return, whether expressed as an absolute or relative metric. For the avoidance of doubt, a financial reporting measure need not be presented in the Company’s financial statements or included in a filing with the SEC.
5. “Incentive‐Based Compensation” is any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a financial reporting measure. Incentive‐Based Compensation may include awards under the Executive Incentive Plan and Performance Share Units under the Merck & Co., Inc. 2019 Stock Incentive Plan, or any successor thereto. Incentive‐Based Compensation does not include (i) base salary; (ii) “sign‐on” bonuses or other compensation granted solely due to the commencement of employment with the Company; (iii) compensation exclusively based on completion of a specific period of employment or service, without any performance condition; or (iv) compensation awarded based on subjective, non‐financial, strategic, or operational measures that are not financial reporting measures.



6. Incentive‐Based Compensation is deemed to be “received” in the fiscal period during which the financial reporting measure specified in the Incentive‐Based Compensation award is attained, even if the payment or grant of the Incentive‐Based Compensation occurs after the end of that fiscal period. Incentive‐Based Compensation in the form of an equity award that vests solely upon the basis of a financial reporting measure performance condition will be deemed to be received in the fiscal period in which it vests.
7. “Recoupment Period” is the three completed fiscal years of the Company immediately preceding the date, and any transition period of less than nine months that results from a change in the Company’s fiscal year within or immediately following those three completed fiscal years, on which the Company is required to perform an Accounting Restatement, which date is the earlier of (i) the date the Board, or a committee of the Board, concludes, or reasonably should have concluded, that the Company is required to perform an Accounting Restatement; or (ii) a date that a court, regulator or other legallyauthorized body directs the Company to perform an Accounting Restatement.
Procedures for Recoupment of Incentive‐Based Compensation
1. In the event the Company is required to perform an Accounting Restatement, the Company shall, as promptly as reasonably possible, recoup any Incentive‐Based Compensation erroneously received by a Covered Officer during the Recoupment Period. The amount of erroneously received Incentive‐Based Compensation will be the excess of the Incentive‐Based Compensation received by the Covered Officer (whether in cash or in shares) based on the erroneous data in the original financial statements over the Incentive‐Based Compensation (whether in cash or in shares) that would have been received by the Covered Officer had it been based on the restated results, without respect to any tax liabilities incurred or paid by the Covered Officer. For Incentive‐Based Compensation based on total shareholder return or Company stock price, where the amount of erroneously awarded compensation is not subject to mathematical recalculation directly from the information in the Accounting Restatement, the amount shall be based on the Committee’s reasonable estimate of the effect of the Accounting Restatement on the applicable measure and the Committee shall maintain documentation of the determination of that reasonable estimate and provide it to the NYSE. Notwithstanding the foregoing, Incentive‐Based Compensation shall not be recouped under this Policy to the extent received by any person before the date such person served as a Covered Officer.
2. The Committee shall determine, in its sole discretion, the method of recouping any erroneously received Incentive‐Based Compensation pursuant to this Policy.
3. No recoupment shall be required if any of the following conditions are met and the Committee determines that, on such basis, recovery would be impracticable: (i) the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount to be recouped, which determination must be made only after a reasonable and documented attempt by the Company to recoup the Incentive‐Based Compensation (with documentation of such reasonable attempt to recover to be provided to the NYSE); (ii) recovery would violate home country law where that law was adopted prior to November 28, 2022, which determination must be made only after the Company has obtained an opinion of home country counsel, acceptable to the NYSE, that recovery would result in such violation (with a copy of such opinion to be provided to the NYSE); or (iii) recoupment would likely cause an otherwise tax‐qualified retirement plan, under which benefits are broadly available to Company employees, to fail to meet the requirements of Section 401(a)(13) or Section 411(a) of the Internal Revenue Code of 1986, as amended, and U.S. Treasury regulations promulgated thereunder.
Indemnification Not Permitted
The Company shall not indemnify any current or former Covered Officer against the loss of erroneously awarded compensation, and shall not pay, or reimburse any Covered Officer for, premiums incurred or paid for any insurance policy to fund such Covered Officer’s potential recoupment obligations.



Disclosure of Recoupment Decisions
The Company will comply with all applicable securities laws and regulations, including SEC disclosure requirements, with respect to this Policy, and any applicable NYSE listing standard or requirements. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.
Effective Date
This Policy shall be effective as of December 1, 2023 (the “Effective Date”). The terms of this Policy shall apply to any Incentive‐Based Compensation that is received by Covered Officers on or after the Effective Date, even if such Incentive‐Based Compensation was approved, awarded, granted, or paid to Covered Officers prior to the Effective Date.
Miscellaneous
Nothing in this Policy shall limit or otherwise affect any of the following: 1) management’s ability to take any disciplinary action with respect to any Covered Officer; 2) the Committee’s ability to use its negative discretion with respect to any Incentive‐Based Compensation performance target at any time; or 3) the Committee’s or management’s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non‐cash incentive compensation award to any executive or other employee for any reason as they may deem appropriate and to the extent permitted by law. Any right of recoupment under this Policy is in addition to, and not in lieu of, any other remedies or rights of recoupment that may be available to the Company pursuant to the terms of any similar policy in any incentive plan, employment agreement, equity award agreement, or similar agreement and any other legal remedies available to the Company. This Policy shall be binding and enforceable against all Covered Officers and their beneficiaries, heirs, executors, administrators, or other legal representatives.

EX-10.35 9 exh1035-bettylarsonofferle.htm EX-10.35 OFFER LETTER (LARSON) Document
Confidential
logo.jpg
January 16, 2024
Betty Larson
159 Abingdon Avenue
Kenilworth, IL 60043
Dear Betty,
It is my pleasure to offer you a position with Merck Sharp & Dohme LLC (“MSD” or the “Company”), a wholly-owned subsidiary of Merck & Co., Inc. (“Merck”), as its EVP. Chief Human Resources Officer (the “Position”) on the terms and conditions set forth in this offer letter (“letter” or “offer letter”). We are a global health care leader with a diversified portfolio of prescription medicines, vaccines and animal health products. Today we are building a new kind of healthcare company - one that is ready to help create a healthier future for all of us.
Our ability to excel depends on the integrity, knowledge, imagination, skill, diversity and teamwork of people like you. We strive to create an environment of mutual respect, encouragement and teamwork that enables our employees to achieve our mission. As part of our global team, you'll have the opportunity to collaborate with talented and dedicated colleagues while developing and expanding your career.
Your position is subject to the approval of your appointment by the full Board of Directors of Merck. If approved, you will report to me, will be a member of the Executive Team and will be an Officer of Merck (as defined in Section 16 of the Securities Exchange Act of 1934). The Position will be based at our corporate headquarters in Rahway. NJ.
Our offer includes the following:
Total Compensation
Base Salary: You will be paid a gross annual salary of $800,000. This will be paid (bi-weekly) at a rate of approximately $30,769 per pay period. Your base salary will be subject to applicable payroll deductions and withholdings.
Executive Incentive Plan (EIP): You will be eligible to participate in the Executive Incentive Plan (EIP) as it applies to similarly situated employees, subject to the terms of the plan. The target bonus for performance year 2024 for the Position is 100% of your annual base salary. The bonus is discretionary and the amount of the bonus, if any, will be determined based on Merck performance. To be eligible for an EIP award, you must be actively employed on or before October I and remain actively employed through December 31 of the plan year. Your EIP award, if any, will be pro-rated based on the time you were in an EIP-eligible position during that plan year. Bonuses, if any, for the current performance year will be paid in or about March of the following year.
Long-Term Incentive (LTI) Program: You will be eligible for consideration for annual grants of stock based incentives under the Incentive Stock Plan beginning in the year you begin employment and, for as long as you remain employed, for each annual cycle thereafter. For Executive Team members, annual grants generally include a mix of non-qualified stock options and performance share units (PSUs), with the number and proportion of shares covered by such incentives determined by the Compensation and Management Development Committee of the
Page 1 of 8

Confidential
Board of Directors of Merck (the "Committee"). The current annual grant value for the Position is $2,650,000, comprised of 70% PSUs and 30% non-qualified stock options. The exact number of shares granted will be determined based on the value of Merck stock on the date of grant. Currently, annual grants of Merck & Co., Inc. stock options vest in equal installments over three years and PSUs are subject to a 3-year performance period. For clarity, you will be eligible for a 2024 annual grant provided that you commence employment on or before May 1,2024 and the grants will be made at the same time grants are made for similarly situated employees, except that, in the event that your employment begins after the grant date for PSUs (generally the last business day in March), the PSU portion of your 2024 grant will be made as soon as administratively feasible after your start date.
Distribution of shares in connection with PSUs and stock options is dependent on continued employment with Merck, MSD or one of Merck or MSD's subsidiaries ("Merck Entity"); additionally, the level of PSU payout is contingent on Merck performance. Please note that the value and terms and conditions of any future grants may change from time to time. The specific terms and conditions of your grant(s) will be provided to you shortly after the grant(s) are made.
You will be subject to our stock ownership guidelines. The guidelines are intended to reinforce our philosophy concerning "ownership" and. in a concrete way, quantify our expectations concerning ownership of Merck. The guidelines provide that you should acquire Merck stock, over time, equal in value to three times your annual base salary. Importantly, the LTI program - and retention of shares earned in connection therewith - is intended to facilitate the acquisition of shares. Also, there is no required time frame under which you will be required to achieve your stock ownership requirement, however, you will be subject to a 75% retention requirement until you achieve the required base salary multiple.
Sign-On Incentives
Sign-On Cash: You will receive a cash sign-on bonus in the aggregate amount of $725,000, less applicable payroll deductions and withholdings, payable within thirty days of your start date. Your right to retain the sign-on bonus is conditioned upon your continued employment with a Merck Entity for two years. By your signature below, you agree that, if prior to completing two years of employment, you voluntarily terminate your employment with a Merck Entity without Good Reason, as defined below, or if a Merck Entity terminates your employment for Cause, as defined below, you will reimburse the full amount of the sign-on bonus ("Repayment Obligation"). You further authorize the Company to withhold any and all monies otherwise owed to you, to the extent permitted by law, as payment against such Repayment Obligation. In such case, such monies will be credited towards the Repayment Obligation, but will not relieve you of your obligation to pay the balance of any Repayment Obligation.
"Cause" as used in this offer letter means an act or omission by you, which constitutes: (i) a deliberate (and not justified and appropriate in the performance of your duties) or reckless disclosure of proprietary or other confidential information relating to a Merck Entity, its personnel, research or business; (ii) embezzlement, theft or other misappropriation of the assets of a Merck Entity; (iii) deliberate or reckless falsification of records or reports; (iv) deliberate bad faith or reckless action that causes actual or potential significant injury or loss to a Merck Entity and/or its and/or their employees; (v) insubordination (meaning the repeated refusal to carry out work assignments and/or direction); (vi) willful or repeated failure to perform assigned job duties; (vii) an illegal act on the property of a Merck Entity or in representing a Merck Entity; (viii) a material violation of a Company policy relating to the research, development, manufacturing, sales, or marketing of Company products or the overall goodwill of reputation of he Company; (ix) any action that would trigger the claw back provisions of any Bonus or Long-Term Incentive Plans applicable to you; or a (x) breach by you of your representations as set forth in this letter.
“Good Reason” is defined to include the following: a) a material reduction in your total direct compensation (base salary, target bonus and/or) target LTI) without your consent, unless such reduction is part of an across-the-board
Page 2 of 8

Confidential
reduction affecting other Executive Team members in similar proportions, b) your involuntary reassignment to any position other than a position on the Executive Team reporting to the Company's Chief Executive Officer within the period beginning on date of hire and ending when the Sign-on Equity Grant has vested fully, c) a demand by the Company that you relocate to New jersey within the period beginning on date of hire and ending when the Sign-on Equity Grant has vested fully, or d) a material breach of this letter, provided that you deliver written notice of n claim of Good Reason to the Company's Chief Executive Officer within thirty(30) days of the facts giving rise to within Good Reason. MSD fails to cure the circumstances giving rise to Good Reason within thirty (30) days of receiving such notice and you actually terminate employment within thirty (30) days after MSD's failure to cure.
Sign-On Equity: Yaw will receive total sign-on equity incentive valued at approximately $5,900,000.
Restricted Stock Unit (RSUs) Grant
You will receive an RSU grant valued at approximately $4,400,000. Merck & Co., Inc. RSU grants are currently scheduled to be made shortly after the release of company earnings each quarter. The date of your grant will be the quarterly grant date immediately following your start date. Subject to is terms, this RSU grant will vest one-third on each anniversary of the grant date. A summary of terms and conditions associated with this RSU grant will be provided to you shortly after she grant is made*.
Stock Option Grant
You will receive a stock option grant valued at approximately $1,500,000. Merck & Co., Inc. stock option grants are currently scheduled to be made shortly after the release of company earnings each quarter. The date of your grant will be the quarterly grant date immediately following your start date. Subject to is terms, thus stock option grant will vest in equal installments on the first. second and third anniversaries of the grant date and expire on she day before she tenth anniversary of the grant date. A summary of terms and conditions associated with this stock option grant will be provided to you shortly alter the grant is made.
Contingent Sign-On Bonus. It is our understanding that you believe that accepting our offer of employment may result in you being required to repay a sign-on bonus and/or relocation monies provided so you by your current employer It is also our understanding that should your current employer terminate your employment, as a result of your providing notice of your intent to accept our offer of employment. then you may forfeit a performance bonus for calender year 2023 should such termination occur prior so the time such bonus is paid and you may forfeit certain equity compensation due to vest on March 1.2024 should such termination occur prior to March 1,2024. In the event of such repayment obligations and/or forfeitures, subject to the conditions act forth in Appendix I, MSD would provide you with an additional sign-on bonus to cash, at its discretion.
Benefits
Health and Insurance Benefits Program: You will be eligible to participate in the Health and Insurance Benefits Program, which automatically provides you with basic life insurance and short-term disability coverage. It also allows you to choose from various options including medical, dental, vision, voluntary and dependent life insurance, long-term disability and flexible spending accounts. For most benefits, participation begins on your date of hire. The Benefits Service Center at Fidelity will mail a Benefits New Hire Package to you within 2 weeks of your hire date. This Package provides important information and instructions for enrolling in your benefits. You will have 30 days from the date Fidelity mails your benefits information to enroll. If you do not enroll by the date indicated in the Package, you automatically will be enrolled in medical coverage for you only in the Horizon BlueCross BlueShield PPO plan option (which includes prescription drug coverage), dental coverage for you only, company-provided basic life insurance and short-term and long-term disability coverage. If you enroll dependents under your medical coverage, you will receive an e-mail and/or letter from HMS Employer Solutions (an independent third-party vendor designated to conduct dependent eligibility
Page 3 of 8

Confidential
verifications) requesting documentation to verify your dependent eligibility. Failure to respond or provide required documentation within the required timeframe will result in the removal of your dependent(s) from benefits coverage.
Pension Plan: You will be eligible to participate in the tax-qualified and non-qualified U.S. Pension Plan, which is a defined benefit pension plan that uses a cash balance formula to calculate your benefit. Your benefit is expressed as a notional account balance that grows with annual Pay Credits ranging from 4.5% to 10.0% of your total pay (based on age and service) and Interest Credits of 3% plus the annual rate of change in the Consumer Price Index (not less than 3.3%). You are 100% vested in your Pension Plan benefit after three years of service.
401(k)/Savings Plan: You will be eligible to participate in the U.S. Savings Plan (“Savings Plan”). You will be mailed a separate enrollment kit for the Savings Plan from the Company Benefits Service Center at Fidelity. You may contribute to the Savings Plan on a before-tax, Roth, and after-tax basis. The Savings Plan provides a 75% match of the first 6% of total pay (4.5% of total pay) that you contribute per pay period (subject to plan limits and IRS limits). If you do not make an active election within 60 days of your hire date, you automatically will be enrolled to contribute 6% base pay and 6% EIP on a before-tax basis, with an annual increase of 1% until you reach a contribution rate of 10%. To maximize the company match, you must contribute at least 6% of your base pay and 6% of your EIP. You are always fully vested in your Savings Plan account.
Deferral Program: Beginning in 2025. you will be eligible to defer (1) a portion of your base salary and or (2) all or part of your EIP bonus, if any. You will receive detailed information just prior to the annual enrollment period in December 2024. In addition, the company will contribute 4.5% of your eligible pay exceeding the Internal Revenue Code pay limit to an account established on your behalf.
Financial Planning: You will be eligible to participate in the executive financial planning program, which provides an annual cash allowance of $10,000 payable in December of each calendar year. If your start date is on or before October 1 of this calendar year, you will be eligible to commence this benefit in the same calendar year. If you start after October 1, you will be eligible to commence the benefit in the subsequent calendar year.
Vacation and Paid Holiday Policy: You will be eligible for 25 vacation days per year in accordance with Company policy, as well as 12 company paid holidays and 4 year-end shutdown days between the Christmas and New Year’s Day holidays. The number of vacation days for which you are eligible in your first year of employment is dependent upon your date of hire.
Military Reservists: Merck is a Military Friendly Employer and we proudly offer a generous military leave policy for those that are eligible.
Workplace Accommodations: We support employees of all abilities. The Company’s Workplace EnABLEment program offers employees the resources they need to contribute at the highest level and to advance the business goals of the Company. If you need an accommodation, contact the Workplace Accommodation Team via email at workacc@merck.com or by phone at 1-866-675-4748.
Relocation: You will be eligible for benefits under our Domestic Relocation Project Assignment Policy for a period of 36 months from your start date. As part of our standard domestic relocation project assignment benefits. MSD will pay or reimburse you for certain expenses in accordance with this Policy including corporate housing, rental car and two trips home per month. A global mobility representative will be assigned to you and will be available to explain your specific benefits as well as address any questions you may have.
Page 4 of 8

Confidential
Severance: As an employee of MSD, you will be an employee at-will. This means that either you or MSD may terminate the employment relationship at any time for any lawful reason or for no reason. In order to accommodate any concerns you may have in joining MSD, MSD agrees that in the event MSD terminates your employment for a reason other than Cause (as defined above) or you terminate your employment for Good Reason (as defined above) prior to such time when all of your Sign-On Equity is fully vested, then you will be entitled to continue to vest in the Sign-On Equity granted to you (“Severance Benefit”); provided that your right to receive the Severance Benefit would be conditioned upon your signing and refraining from revoking a Severance Agreement in a format prescribed by MSD, which Agreement will contain a full release, non-solicitation, non-disclosure, non-disparagement and cooperation in litigation covenants and such other reasonable and customary terms as MSD provides. This Severance Benefit would be in addition to any other severance or separation pay that you may be entitled to under any applicable plan or policy of MSD or Merck.
Change in Control
Merck has adopted a “Change in Control” (CIC) Program. The Merck CIC Program specifies the types of compensation and benefits-related protections to be provided to eligible Merck employees in the event of a change in control of Merck & Co., Inc. You will participate as an Executive Team member at the band level applicable under the program.
Right to Amend or Terminate Plans, Programs and Policies
The compensation and benefits described in this letter are provided under and subject to the terms and conditions of the applicable plans, programs and policies of MSD, Merck and/or the applicable Merck Entity. Nothing in this letter in any way limits the right of Merck & Co., Inc. and/or a Merck Entity to amend or terminate those plans, programs or policies.
Section 409A
This offer letter shall be interpreted to comply with section 409A of the Internal Revenue Code of 1986, as amended and the regulations promulgated thereunder (“section 409A”) or an exemption thereto. Notwithstanding anything in this offer letter to the contrary, payments made pursuant to the offer letter may only be made in a manner and upon an event permitted by section 409A, and all payments to be paid to you upon termination of employment may only be made upon a “separation from service” as defined under section 409A. if section 409A applies to payments under this offer letter, this offer letter shall be administered in accordance with section 409A, including the six-month delay for “specified employees,” if applicable. Each payment under this offer letter, that is part of a series of installment payments, shall be treated as a separate payment for purposed of 409A. In no event may you, directly or indirectly, designate the calendar year of any payment. You are solely responsible for any taxes under this offer letter and in no event will Merck have any liability with respect to any tax, interest or other penalty imposed under section 409A.
Except as otherwise expressly provided herein, to the extent any expense reimbursement or the provision of any in-kind benefit under this offer letter (or otherwise referenced herein) is determined to be subject to (and not exempt from) section 409A. the amount of any such expenses eligible for reimbursement, or the provision of any in-kind benefit. in one calendar year will not affect the expenses eligible for reimbursement or in-kind benefits to be provided in any other calendar year, in no event will any expenses be reimbursed after the last day of the calendar year following the calendar year Or which you incurred such expenses, and in no event will any right to reimbursement or the provision of any in-kind benefit be subjected to liquidation or exchange for another benefit.
Representations
This offer is made to you based upon your representations that (i) your employment with Merck will not conflict with, or result in the breach of, or violation of, any other agreement, instrument, order, judgment or decree to which you are a party
Page 5 of 8

Confidential
or by which you are bound, and (ii) you are not a party to or bound by any employment agreement, non-compete agreement or confidentiality agreement with any other person or entity that would restrict your employment with Merck and not provided to Merck for its independent review.
The compensation and benefits described in this letter are provided under and subject to the terns and conditions of the applicable plans, programs and policies of Merck Sharp & Dohme Corp. Nothing in this letter in any way limits the right of Merck Sharp & Dohme Corp . to amend or terminate those plans, programs or policies.
The Company does not require vaccination against COVID-19 as a condition of employment at this time. Company policy with respect to COVID-19 however, is subject to change as the virus evolves. Where permitted by applicable law, the Company reserves the right to require COVID-19 (or other) vaccinations where the Company, in its discretion, determines such a requirement is necessary to protect the health and safety of its workforce and/or the general public. Any such policy change will be accompanied by an exemption process as required by law. All Company employees will be expected to abide by any such policies as they may be developed and implemented.
By your signature below, you affirm that these representations are true.
In addition to Board approval for your position appointment, this offer is contingent upon your successful completion of a pre-placement drug screen, satisfactory verification of your employment, education, criminal check, satisfactory references and background check results and if applicable, proof of your eligibility to work in the United States. (A List of Acceptable Documents that establishes your eligibility to work in the U.S., which you are required to bring with you on your first day of work, will be forwarded to you upon your acceptance of the offer). Your employment with Merck is at-will (meaning that you and the Company remain free to end the employment relationship at any time, for any lawful reason, either with or without prior notice) and additionally will be subject to certain terms and conditions of employment, which have been provided to you with this offer. We advise you not to alter your current employment status until all of the shall be have been satisfied. Nothing herein shall be construed as contract for a specific duration between you and the Company.
Page 6 of 8

Confidential
Please call Steve Mizell at 732-594-8888 upon receipt of this letter to acknowledge your acceptance of this offer and to begin your “on boarding” process for employment based on the successful completion of the above contingencies. In addition, please print, sign, scan and return this offer letter via email to Steve at steven.mizell@merck.com.
With your abilities and experience, I know you will be able to contribute to the Company and benefit from its growth. I believe this position offers an outstanding career opportunity and look forward to your acceptance.
Sincerely
image_8x1.jpg
Robert Davis
I accept the employment offer and its terms contained in this letter.
image_9.jpg
image_10.jpg
Page 7 of 8

Confidential
Appendix 1
In the event of repayment obligations and/or forfeitures as described in the Contingent Sign-On Bonus section above. MSD would provide you with an additional sign-on bonus in cash equal to the sum of:
(A)The amount of sign-on bonus you are required to repay your current employer but in no event more than S675,000, provided that you (i) provide to the Company a copy of any and all correspondence demanding such repayment; (ii) have offered to stay at your current employer through the date that would relieve you of any repayment obligation; (iii) have refrained from any conduct that would have made you otherwise ineligible for payment;; and (iv) provide the Company with proof that you actually tendered any demanded repayment; plus
(B)The amount of relocation monies you are required to repay your current employer, provided that you (i) provide to the Company a copy of any and all correspondence demanding such repayment; (ii) have offered to stay at your current employer through the date that would relieve you of any repayment obligation; (iii) have refrained from any conduct that would have made you otherwise ineligible for payment; and (iv) provide the Company with proof that you actually tendered any demanded repayment; plus
(C)The amount of your 2023 performance bonus forfeited because you were terminated due to our offer of employment prior to the time such bonus payment became payable, provided that you (i) provide to the Company a copy of the applicable plan document as well as documentation establishing the amount of bonus at issue; (ii) have offered to stay at your current employer through the date required for payment under the applicable plan; and (iii) have refrained from any conduct that would have made you otherwise ineligible for payment; plus
(D)The amount of equity forfeited because you were terminated due to our offer of employment prior to March 1, 2024, as determined by number of shares that would have vested multiplied by your current company's closing price as of March 1, 2024, provided that you (i) provide to the Company a copy of the applicable equity terms; (ii) have offered to stay at your current employer through the date required for vesting under the applicable equity grant terms; and (iii) have refrained from any conduct that would have made you otherwise ineligible to vest in the grant (collectively the “Contingent Bonus”).
Merck will pay the Contingent Sign on Bonus, if at all, in a reasonable period of time after it is satisfied that all conditions applicable to any element of the Contingent Sign-On Bonus that may be at issue have been met. You acknowledge that your right to retain any portion of any Contingent Sign-On Bonus is conditioned upon your continued employment with MSD or a Merck Entity for twenty-four months after such cash payment. By your signature above, you agree that, in the event that MSD or a Merck Entity terminates your employment for Cause (as defined in the Offer Letter) or in the event that you terminate your employment for any reason other than Good Reason within the twenty-four-month period following the payment of the Contingent Sign-On Bonus (such obligation also a “Repayment Obligation"), you will reimburse the full amount of the Contingent Sign-On Bonus. You further authorize the Company to withhold any and all monies otherwise owed to you, to the extent permitted by law, as payment against such Repayment Obligation. In such case, such monies will be credited towards the Repayment Obligation, but will not relieve you of your obligation to pay the balance of any Repayment Obligation.
Page 8 of 8
EX-10.36 10 exh1036-2024annualrsusignx.htm EX-10.36 2024 ANNUAL RSU SIGN-ON TERMS & CONDITIONS (LARSON) Document

GLOBAL TERMS AND CONDITIONS
2024 SIGN-ON EQUITY GRANT OF RESTRICTED STOCK UNIT GRANTS FOR BETTY LARSON
UNDER THE MERCK & CO., INC. 2019 INCENTIVE STOCK PLAN
I.GENERAL. Merck & Co., Inc. (the “Company”) has granted to you the Restricted Stock Unit (“RSU”) award specified in this document (“RSU Award”) pursuant to the Merck & Co., Inc. 2019 Incentive Stock Plan, including any sub-plan thereto for your country (the “Plan”). This RSU Award is subject to the terms and conditions of the Plan and these Global Terms and Conditions (the “Terms”). Unless otherwise defined in this document, capitalized terms used in these Terms are as defined in the Plan.
Grant Type:RSU - Annual
Grant Date:
April 30, 2024
Vesting DatesPortion that Vests
April 30, 2025First:    33.333%
April 30, 2026Second:    33.333%
April 30, 2027Third:    Balance
IMPORTANT NOTICE: This grant requires you to affirmatively accept it. You MUST log onto the Morgan Stanley website at (http://www.morganstanley.com/spc/knowledge/managing-equity/managing-your-existing-awards/accepting-awards-grants/) to accept the grant.
Follow the procedures described on the Morgan Stanley website to accept your RSU Award within 90 days. Failure to accept the terms and conditions of your RSU Award within 90 days may result in Forfeiture of the RSU Award.
A.Restricted (Vesting) Period. The Restricted Period is the period during which this RSU Award is subject to forfeiture and is eligible to vest. The RSU Award will vest with respect to one-third of this RSUs subject to the RSU Award on each of the First, Second, and Third anniversaries of the Grant Date (each a “Vesting Date”) as shown in the box above, except as otherwise provided in Article II below. No voting rights apply to this RSU Award. No fractional shares will be issued upon settlement of the RSU Award; all calculations are subject to rounding.
B.Dividend Equivalents. During the period commencing on the Grant Date and ending on the date immediately prior to the date the RSU Awards are settled in accordance with paragraph I(C), dividend equivalents will be accrued for the holder (“you”) if and to the extent dividends are paid by the Company on Merck Common Stock. Payment of such dividends will be made in cash via local payroll, without interest or earnings, at or around the time of distribution of the shares of Common Stock in settlement of the underlying RSUs. If any portion of this RSU Award lapses, is forfeited or expires, no dividend equivalents will be credited or paid on such portion. Any payment of dividend equivalents will be reduced to the extent necessary for the Company to satisfy any tax or other withholding obligations in accordance with paragraph IV.
C.Distribution (Settlement of RSU Award). Upon vesting of the RSU Award (including as a result of the events set forth in Article II), you (or your estate, in the event the RSU Award vests pursuant to paragraph II(E)) will be issued a number of shares of Merck Common Stock equal to the number of RSUs (unless otherwise provided in paragraph II(H)) with respect to which the RSU Award has vested and the dividend equivalents that accrued on that portion; provided, however, that in the event the RSU Awards vests upon a Change in Control (as defined below) pursuant to paragraph II(H) that does not constitute a “change in control event” within the meaning of U.S. Treasury Regulations Section 1.409A-3(i)(5), the RSU Awards will instead be settled on the original Vesting Dates set forth in paragraph I(A). Any amount required to be withheld, including amounts required to satisfy Tax-Related Items, in connection with the distribution of the RSU



Award (or otherwise arising from your participation in the Plan) will be recovered from you as described in paragraph IV.
D.409A Compliance. Anything to the contrary notwithstanding, no distribution of RSUs may be made unless in compliance with Section 409A of the Code or any successor thereto. Specifically, distributions made upon or by reference to the date of an employment termination shall not be paid unless such termination constitutes a “separation from service (as defined in Section 409A)” and any such payment to a “Specified Employee” as defined in Treas. Reg. Sec. 1.409A-1(i) or any successor thereto, to the extent required by Section 409A of the Code will instead be made on the first day the seventh month following the separation from service, in the same form as they would have been made had this restriction not applied; provided further, that dividend equivalents that otherwise would have accrued will accrue during the period during which distribution is suspended.
E.Subject to Recoupment. This RSU Award will be subject to recoupment in the event of certain violations of Company policy in accordance with the Company’s Policy and Procedures for Discretionary Recoupment of Compensation for Compliance Violations, as set forth in Appendix A.1, and with the Company’s Policy and Procedures for Recoupment of Incentive-Based Compensation, applicable only for Section 16 Officers, as set forth in Appendix A.2 (as may be amended from time to time).
II.TERMINATION OF EMPLOYMENT
If your employment with the Company or, if different, the subsidiary, affiliate or joint venture (“JV”) of the Company by which you are employed (the “Employer”) is terminated during the Restricted Period described in paragraph I(A), your right to the RSU Award will be determined according to the terms in this Article II. For avoidance of doubt, if your employment terminates on a Vesting Date not for misconduct, you will be entitled to vest in that unvested portion of the RSU Award that is scheduled to vest on that Vesting Date.
A.General Rule. If your employment is terminated during the Restricted Period for any reason other than those specified in the following paragraphs, the unvested portion of this RSU Award (and any accrued dividend equivalents) will be forfeited on the date your employment terminates. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.
B.Involuntary Termination. If the Company determines that your employment is involuntarily terminated during the Restricted Period for a reason other than Cause, the RSU Award, and any accrued dividends, will continue to vest on the original Vesting Date(s) set forth in paragraph I(A), provided you sign and refrain from revoking a severance agreement in a format prescribed the Company, which agreement will contain a full release, non-solicitation, non-disclosure, non-disparagement and cooperation in litigation covenants and such other reasonable and customary terms as the Company provides. If the Company determines that your employment is involuntarily terminated during the Restricted Period and you do not sign and refrain from revoking a severance agreement as outlined above, and you are involuntarily terminated on or after the first anniversary of the Grant Date, the RSU Award will vest on the next subsequent Vesting Date following your employment termination with respect to a pro rata portion of your unvested RSU Award and dividend equivalents that have accrued through the corresponding Vesting Date equal to (i) the total number of RSUs subject to the RSU Award (whether or not vested), multiplied by (ii) a fraction, numerator of which is equal to the number of completed monthly periods during the period commencing on the Grant Date and ending the date employment terminates, and the denominator of which is 36, (iii) reduced by the number of RSUs that have vested pursuant to paragraph A. The remaining portion, if any, of the RSU Award and any accrued dividends will be forfeited on the date your employment terminates. An “involuntary termination” includes termination of your employment by the Company or the Employer, as applicable, as the result of a restructuring or job elimination, but excludes non-performance of your duties and the reasons listed under paragraphs C through I of this section. If your employment is terminated as described in this paragraph and



you are later rehired by the Company or the Employer, as applicable, this RSU Award nevertheless will be forfeited according to this paragraph notwithstanding such rehire.
C.Sale. If your employment is terminated during the Restricted Period and the Company determines that such termination resulted from the sale of your subsidiary, affiliate, division or JV, the RSU Award will continue to vest on the following original Vesting Date(s) set forth in paragraph I(A) with respect to the following unvested portion of your RSU Award and dividend equivalents that have accrued through the corresponding Vesting Dates: if employment terminates on or after the Grant Date but before the first anniversary thereof, then one-third of your RSU Award will vest on the first Vesting Date; if employment terminates on or after the first anniversary of the Grant Date, the portion of your RSU Award that was eligible to vest on the second and third Vesting Dates, respectively, will vest on the corresponding Vesting Dates. The remaining portion, if any, of the RSU Award that does not vest pursuant to the foregoing sentence will be forfeited on the date your employment terminates. Notwithstanding the foregoing, the Committee may determine, for purposes of this RSU Award, whether employment with an entity that is established from the Company’s spin off, split off, split up or distribution of equity securities in connection with that entity constitutes a termination of employment, and may make adjustments, if any, as it deems appropriate, and to the extent not inconsistent with the Plan, at the time of the distribution of such equity securities, in the kind and/or number of shares subject to this RSU Award. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this RSU Award nevertheless will be forfeited according to this paragraph notwithstanding such rehire.
D.Retirement. If your employment terminates by retirement during the Restricted Period, the RSU Award will vest on the next subsequent Vesting Date following your termination with respect to a pro rata portion of your unvested RSU Award and dividend equivalents that have accrued through the corresponding Vesting Date equal to (i) the total number of RSUs subject to this RSU Award (whether or not vested), multiplied by (ii) a fraction, the numerator of which is equal to the number of completed monthly periods during the period commencing on the Grant Date and ending on the date employment terminates, and the denominator of which is 36, (iii) reduced by the number of RSUs that have vested pursuant to paragraph A. The remaining portion of the RSU Award and any accrued dividends will be forfeited on the date your employment terminates. For grantees who are employed in the U.S., “retirement” means a termination of employment after attaining the earliest of (a) age 55 with at least 10 years of service (b) such age and service that provides eligibility for subsidized retiree medical coverage or (c) age 65 without regard to years of service. For other grantees, “retirement” is determined by the Company. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.
E.Death. If your employment terminates due to your death during the Restricted Period but prior to an employment termination contemplated under paragraphs B, C, D, G or H, the RSU Award will immediately vest with respect to any portion of this RSU Award that has not vested as of your death and dividend equivalents that have accrued though such date. If you die during the Restricted Period, but after your employment terminates for the reasons listed under paragraphs B, C, D, G or H of this section, the RSU Award will immediately vest with respect to the remaining, non-forfeited portion of this RSU Award and dividend equivalents that have accrued through the date of death.
F.Misconduct. If your employment is terminated as a result of your deliberate, willful or gross misconduct, this RSU Award and accrued dividend equivalents will be forfeited immediately upon your receipt of notice of such termination.
G.Disability. If your employment is terminated during the Restricted Period and the Company determines that such termination resulted from inability to perform the material duties of your role by reason of a physical or mental infirmity that is expected to last for at least six months or to result in your death, whether or not you are eligible for disability benefits from any applicable disability program, then the RSU Award will



continue to vest on the original Vesting Dates set forth in paragraph I(A) with respect to the unvested portion of RSU Award and dividend equivalents that have accrued through the corresponding Vesting Date. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this RSU Award nevertheless will expire according to this paragraph notwithstanding such rehire.
H.Change in Control. If this RSU Award is assumed, converted or otherwise remains outstanding in connection with a Change in Control and your employment is terminated during the Restricted Period without Cause before the second anniversary of the closing of the Change in Control, then the RSU Award will continue to vest on the original Vesting Dates set forth in paragraph I(A) with respect to the unvested portion of the RSU Award and dividend equivalents that have accrued through the corresponding Vesting Date. If this RSU Award does not remain outstanding following the Change in Control and is not converted into a successor RSU, then the RSU Award will immediately vest with respect to the portion of the RSU Award that is unvested as of the Change in Control and dividend equivalents that have accrued though such date and, at the election of the Company, you will be entitled to receive cash for such portion of this RSU Award in an amount equal to the fair market value of the consideration paid to Merck stockholders for a share of Merck Common Stock in the Change in Control. On the second anniversary of the closing of the Change in Control, this paragraph shall expire. “Cause” and “Change in Control” are defined in the Merck & Co., Inc. Change in Control Separation Benefits Plan (excluding an MSD Change in Control).
I.Good Reason. If you terminate your employment for Good Reason, the RSU Award, and any accrued dividends, will continue to vest on the original Vesting Date(s) set forth in paragraph I(A). “Good Reason” is defined in your offer letter from the Company to include the following: a) a material reduction in your total direct compensation (base salary, target bonus and/or target LTI) without your consent, unless such reduction is part of an across-the-board reduction affecting other Executive Team members in like proportions, b) your involuntary reassignment to any position other than a position on the Executive Team reporting to the Company’s Chief Executive Officer within the period beginning on date of hire and ending when the Sign-on Equity Grant has fully vested, or c) a demand by the Company that you relocate to New Jersey within the period beginning on date of hire and ending on April 30, 2027, or d) a material breach of your offer letter, provided that you deliver written notice of a claim of Good Reason to the Company’s Chief Executive Officer within thirty (30) days of the facts giving rise to such Good Reason, the Company fails to cure the circumstances giving rise to Good Reason within thirty (30) days of receiving such notice and you actually terminate employment within thirty (30) days after the Company’s failure to cure.
J.Transfer of Employment. Transfer of employment between the Company, a subsidiary, affiliate, JV, JV partner or affiliate of the Company who provides services to the JV with such partner or affiliate or other entity in which the Company has determined that it has a significant business or ownership interest (together, the “Company Group”) is not considered termination of employment for purposes of this RSU Award. Such employment must be approved by the Company and contiguous with employment by the entity in the Company Group you were employed by immediately prior to the relevant transfer. The terms set out in paragraphs A through H above shall continue to apply to this RSU Award following a transfer of employment accordance with this section.
III.TRANSFERABILITY
Prior to distribution pursuant to Article I(C), the RSU Award and any interest therein shall not be sold, assigned, transferred, pledged or otherwise disposed of, alienated or encumbered, either voluntarily or involuntarily, other than by will or the laws of descent and distribution in connection with your death.
IV.TAX WITHHOLDING
Regardless of any action the Company and/or the Employer take with respect to any or all income tax, social insurance, payroll tax, payment on account or other tax-related items arising out of your participation in the Plan



and legally applicable or deemed applicable to you (“Tax-Related Items”), you acknowledge that the ultimate liability for all Tax-Related Items is and remains your responsibility and may exceed the amount actually withheld by the Company and/or the Employer, if any. You further acknowledge that the Company and/or the Employer (i) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the RSU Award or underlying shares of Common Stock, including, but not limited to, the grant, vesting or settlement of the RSU, the subsequent sale of shares of Common Stock acquired upon the lapsing of the Restricted Period and the receipt of any dividends and/or dividend equivalents; and (ii) do not commit and are under no obligation to structure the terms of the grant or any aspect of the RSU Award to reduce or eliminate your liability for Tax-Related Items or achieve any particular tax result. Furthermore, if you have become subject to tax in more than one jurisdiction, you acknowledge that the Company and/or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.
Prior to the relevant taxable or tax withholding event, as applicable, you shall pay or make arrangements satisfactory to the Company and/or the Employer to satisfy any applicable withholding obligations or rights with regard to all Tax-Related Items. In this regard, you authorize the Company and/or the Employer, or their respective agents, at their discretion, to satisfy the Tax-Related Items by one or a combination of the following: (i) withholding from your wages or other cash compensation paid to you by the Company, the Employer and/or any subsidiary, affiliate or JV of the Company; or (ii) withholding from proceeds of the sale of shares of Common Stock acquired at lapsing of the Restricted Period either through a voluntary sale or through a mandatory sale arranged by the Company (on your behalf pursuant to this authorization); or (iii) withholding in shares of Common Stock to be issued upon lapsing of the Restricted Period; provided, however, that if you are a Section 16 officer of the Company under the Exchange Act, then the Company will satisfy the Tax-Related Items (other than U.S. Federal Insurance Contribution Act taxes or other Tax-Related Items which become payable in a year prior to the year in which shares of Common Stock are issued upon settlement of the RSUs) by withholding in shares of Common Stock pursuant to (iii) above, unless the use of such withholding method is problematic under applicable tax or securities law or has materially adverse accounting consequences, in which case, the obligation for Tax-Related Items may be satisfied by a one or a combination of (i) or (ii) above.
The Company may withhold or account for Tax-Related Items by considering applicable minimum statutory withholding amounts or other applicable withholding rates, including maximum applicable rates in your jurisdiction(s). In the event of over-withholding, you may receive a refund of any over-withheld amount in cash (with no entitlement to the equivalent in Common Stock), or if not refunded, you may seek a refund from the local tax authorities. In the event of under-withholding, you may be required to pay additional Tax-Related Items directly to the applicable tax authority or to the Company and/or the Employer. If the obligation for Tax-Related Items is satisfied by withholding in shares of Common Stock, for tax purposes, you will be deemed to have been issued the full number of shares of Common Stock subject to the vested RSUs, notwithstanding that a number of the shares is held back solely for the purpose of paying the Tax-Related Items due as a result of any aspect of your participation in the Plan.
You shall pay to the Company or the Employer any amount of Tax-Related Items that the Company or the Employer may be required to withhold or account for as a result of your participation in the Plan that cannot be satisfied by the means previously described in this section. The Company may refuse to issue or deliver the shares of Common Stock or the proceeds of the sale of shares if you fail to comply with your obligations in connection with the Tax-Related Items.
V.DATA PRIVACY
The Company is located at 126 East Lincoln Avenue, Rahway, NJ 07065, U.S.A. and grants employees of the Company and any subsidiary, affiliate or JV of the Company, the opportunity to participate in the Plan, at the Company's sole discretion. If you would like to participate in the Plan, you understand that you should review the following information about the Company’s data processing practices and declare your consent.



A.Data Collection and Usage. The Company collects, processes and uses your personal data, including, name, home address, email address and telephone number, date of birth, social insurance number or other identification number, salary, citizenship, job title, any shares of Common Stock or directorships held in the Company, and details of all awards, canceled, vested, or outstanding in your favor, which the Company receives from you or your Employer. If the Company offers you the opportunity to participate in the Plan, then the Company will collect your personal data for purposes of allocating Common Stock and implementing, administering and managing the Plan. The Company’s legal basis for the processing of your personal data would be your consent.
B.Stock Plan Administration Service Providers. The Company transfers participant data to Morgan Stanley, an independent service provider based in the United States, which assists the Company with the implementation, administration and management of the Plan. In the future, the Company may select a different service provider and share your data with another company that serves in a similar manner. The Company’s service provider will open an account for you. You will be asked to agree on separate terms and data processing practices with the service provider, which is a condition to your ability to participate in the Plan.
C.International Data Transfers. The Company and its service providers are based in the United States. If you are outside of the United States, you should note that your country has enacted data privacy laws that are different from the United States. The Company’s legal basis for the transfer of your personal data is your consent.
D.Voluntariness and Consequences of Consent Denial or Withdrawal. Your participation in the Plan and your grant of consent is purely voluntary. You may deny or withdraw your consent at any time. If you do not consent, or if you withdraw your consent, you cannot participate in the Plan. This would not affect your salary as an employee; you would merely forfeit the opportunities associated with the Plan.
E.Data Subject Rights. You have a number of rights under data privacy laws in your country. Depending on where you are based, your rights may include the right to (i) request access or copies of personal data the Company processes, (ii) rectification of incorrect data, (iii) deletion of data, (iv) restrictions on processing, (v) portability of data, (vi) to lodge complaints with competent authorities in your country, and/or (vii) a list with the names and addresses of any potential recipients of the your personal data. To receive clarification regarding your rights or to exercise your rights please contact the Company at Attn: Global Privacy Office, 351 N. Sumneytown Pike, North Wales, Pennsylvania, U.S.A. 19454.
F.The collection, use and transfer of your personal data for the purpose of implementing, administering and managing your participation in the Plan is conducted in accordance with the Company’s Global Privacy and Data Protection Policy. You also understand that the Company may, in the future, request you to provide another data privacy consent.  If applicable and upon request of the Company, you agree to provide an executed acknowledgement or data privacy consent form to the Company or the Employer (or any other acknowledgements, agreements or consents) that the Company and/or the Employer may deem necessary to obtain under the data privacy laws in your country, either now or in the future.  You understand that you will not be able to participate in the Plan if you fail to execute any such acknowledgement, agreement or consent requested by the Company and/or the Employer.
If you agree with the data processing practices described in this Article, you will declare your consent by clicking to "Accept" these Terms on the Morgan Stanley website.
VI.GOVERNING LAW
This document may be amended only by another written agreement between the parties. This document will be interpreted and enforced under the laws of the State of New Jersey, United States (without regard to its choice-of-law provisions). For purposes of litigating any dispute that arises directly or indirectly from the relationship of



the parties evidenced by this grant or this document, the parties hereby submit to and consent to the exclusive jurisdiction of the State of New Jersey and agree that such litigation shall be conducted only in the courts of Union County, New Jersey, or the federal courts for the United States for the District of New Jersey, and no other courts, where this grant is made and/or to be performed.
VII.SEVERABILITY
The provisions of this document are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.
VIII.WAIVER
You acknowledge that a waiver by the Company of breach of any provision of these Terms shall not operate or be construed as a waiver of any other provision of these Terms or of any subsequent breach by you or any other grantee.
IX.ELECTRONIC ACCEPTANCE
The Company may, in its sole discretion, decide to deliver any documents related to the RSU or future RSUs that may be granted under the Plan by electronic means or request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an online or electronic system established and maintained by the Company or a third party designated by the Company.
X.ADMINISTRATION
The Committee is responsible for construing and interpreting this grant, including the right to construe disputed or doubtful Plan provisions, and may establish, amend and construe such rules and regulations as it may deem necessary or desirable for the proper administration of this RSU Award. Any decision or action taken or to be taken by the Committee, arising out of or in connection with the construction, administration, interpretation and effect of this RSU Award shall, to the maximum extent permitted by applicable law, be within its absolute discretion (except as otherwise specifically provided herein) and shall be final, binding and conclusive upon the Company, all Eligible Employees and any person claiming under or through any Eligible Employee. All determinations by the Committee including, without limitation, determinations of the Eligible Employees, the form, amount and timing of Incentives, the terms and provisions of Incentives and the writings evidencing Incentives, need not be uniform and may be made selectively among eligible employees who receive, or are eligible to receive, Incentives hereunder, whether or not such Eligible Employees are similarly situated.
This RSU Award is subject to the provisions of the 2019 Incentive Stock Plan. For further information regarding your RSU Award, you may access the Merck Global Long-Term Incentives homepage via Sync > HR > Money > Long-Term Incentive Program



APPENDIX A.1
Policy and Procedures for Discretionary Recoupment of
Compensation for Compliance Violations
Policy
It is the policy of the Compensation and Management Development Committee (the “Committee”) of the Board of Directors (the “Board”) of Merck & Co., Inc. (the “Company”) that the Committee will exercise its discretion to determine whether to seek Recoupment of any Covered Compensation paid or awarded to an Affected Employee, where it determines, in consultation with the Audit Committee, that: a) the Affected Employee engaged in misconduct, or failed to reasonably supervise an employee who engaged in misconduct, that resulted in a Material Violation; and b) the Committee concludes that the Material Violation caused Significant Harm to the Company.
Definitions
1.An “Affected Employee” is an employee in Band 600 or higher who (i) engaged in misconduct that results in a Material Violation; or (ii) failed in his or her supervisory responsibilities to reasonably manage or monitor the conduct of an employee who engaged in misconduct that results in a Material Violation.
2.“Covered Compensation” means all (a) incentive‐based cash compensation granted to an Affected Employee, including, without limitation, any annual bonuses and other short‐ and long‐term cash incentives, (b) equity‐based compensation, including, without limitation, stock options, restricted stock, restricted stock units, performance share units (“PSUs”), (c) any proceeds or earnings received in respect of (a) and (b), and (d) any other forms of compensation that the Committee determines to be subject to this policy. For the avoidance of doubt, the foregoing includes any compensation that was previously paid, earned, vested, deferred or paid or payable as a component of severance or termination compensation.
3.“Executive” means current and former executive officers of the Company, as “executive officer” is defined for the purposes of the Securities Exchange Act of 1934, as amended.
4.A “Material Violation” is defined as (i) a material violation of a written Company policy relating to the research, development, manufacturing, sales, or marketing of Company products or (ii) conduct detrimental to the Company, including the Company’s overall goodwill or reputation.
5.“Recoupment” is defined to include any and all of the following actions to the extent permitted by law: (a) reducing the amount of a current or future bonus or other cash or noncash incentive compensation award, (b) requiring reimbursement of a bonus or other cash-based incentive compensation award paid with respect to the most recently completed performance period, (c) cancelling all or a portion of a future‐vesting equity award, (d) cancelling all or a portion of an equity award that vested within the previous twelve‐month period, (e) requiring return of shares paid upon vesting and/or reimbursement of any proceeds received from the sale of an equity award, in each case that vested within the previous twelve‐month period, and (f) any other method of reducing the total compensation paid to an employee for any prior twelve‐month period or any current or future period.
6.“Significant Harm” means a significant negative impact on the Company’s financial operating results or reputation.
Procedures
1.Subject to any delegation to the Chief Executive Officer, as discussed below, the Committee, acting in consultation with the Audit Committee, shall administer this policy and have full discretion to interpret and to make any and all determinations under this policy. Any determinations made by the Committee shall be final, binding, and conclusive on all parties. Notwithstanding the foregoing, the full Board shall approve any determination to seek or waive Recoupment from the Chief Executive Officer.
2.The General Counsel, in consultation with the Chief Ethics and Compliance Officer and the Executive Vice President, Human Resources, is responsible for determining whether to refer a matter to the Committee for review under this policy and for assisting the Committee with its review. In administering this policy, the Committee may consult with other committees of the Board and any external or internal advisors as it deems appropriate.
3.If the Committee, acting in consultation with the Audit Committee, determines that there is a basis for seeking Recoupment under this policy, the Committee shall exercise its discretion to determine for each Affected Employee, on an individual basis, whether, and to what extent and in which manner, to seek Recoupment.
4.In exercising its discretion, the Committee may take into consideration, as it deems appropriate, all of the facts and circumstances of the particular matter and the general interests of the Company.



Delegation to Management for Recoupment Decisions
The Committee may delegate to the Chief Executive Officer (who may further delegate as deemed appropriate) the authority to administer this policy and to make any and all decisions under it regarding Affected Employees who are not Executives of the Company. Management shall report to the Committee on any affirmative decisions to seek Recoupment pursuant to this delegation of authority.
Public Disclosures
The Company will comply with all applicable securities laws and regulations, including Securities and Exchange Commission disclosure requirements regarding executive compensation and any applicable New York Stock Exchange listing standard or requirements, with respect to this policy. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.
Miscellaneous
Nothing in this policy shall limit or otherwise affect any of the following: 1) management’s ability to take any disciplinary action with respect to any Affected Employee; 2) the Committee’s ability to use its negative discretion with respect to any incentive compensation performance target at any time; or 3) the Committee’s or management’s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non‐cash incentive compensation award to any Affected Employee for any reason as they may deem appropriate and to the extent permitted by law. Any right of Recoupment under this policy is in addition to, and not in lieu of, any other remedies or rights of Recoupment that may be available to the Company pursuant to the terms of any similar policy in any incentive plan, employment agreement, equity award agreement, or similar agreement, including, without limitation, the Company’s Policy and Procedures for Recoupment of Incentive‐Based Compensation, and any other legal remedies available to the Company. The Company shall not indemnify or agree to indemnify any current or former Executive against the loss of incentive compensation subject to this policy nor shall the Company pay or reimburse or agree to pay or reimburse any insurance premium to cover the loss of such incentive compensation. The Committee may amend, modify, or terminate this policy in whole or in part at any time and from time to time in its sole discretion.



APPENDIX A.2
Policy and Procedures for Recoupment of
Incentive-Based Compensation
Policy
The Compensation and Management Development Committee (the “Committee”) of the Board of Directors (the “Board”) has adopted this Incentive‐Based Compensation Recoupment Policy (the “Policy”) to comply with Section 10D of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), Rule 10D‐1 promulgated thereunder (“Rule 10D‐1”) and Paragraph 303A.14 of the Listing Standards Manual of the New York Stock Exchange (“NYSE”), which require the recovery of certain Incentive‐Based Compensation in the event of an accounting restatement resulting from a material error in the consolidated financial statements of Merck & Co, Inc. (the “Company”). This Policy shall be administered by the Committee, which shall have express discretionary authority to interpret and construe this Policy and to make all determinations with respect to this Policy, in its sole discretion. It is intended that this Policy be interpreted in a manner that is consistent with the requirements of Section 10D of the Exchange Act and Rule 10D‐1 (or any successor statute or rule) and any other applicable rules or listing standards adopted by the U.S. Securities and Exchange Commission (the “SEC”) or NYSE. All interpretations, constructions and determinations made by the Committee under this Policy shall be final and binding on all parties. This Policy may be amended with the approval of the Committee and may be amended from time to time as necessary to reflect changes in applicable regulations and/or listing standards adopted by the SEC or NYSE. Compliance with this Policy cannot be waived.
Definitions
1. "Accounting Restatement” is the restatement of the Company’s financial statements due to material noncompliance with any financial reporting requirement under the federal securities laws, including any required accounting restatement to correct an error in previously issued financial statements (i) that is material to the previously issued financial statements, or (ii) that would result in a material misstatement if the error were corrected in the current period only or left uncorrected in the current period.
2. A “Covered Officer” is anyone who serves or has served as an executive officer of the Company at any time during the performance period for Incentive‐Based Compensation.
3. “Executive officer” is the equivalent to an “officer” as defined under Section 16a‐1(f) of the Exchange Act (“Section 16 officer”).
4. “Financial reporting measure” is a measure that is (i) determined and presented in accordance with the accounting principles used in preparing the Company’s financial statements, or (ii) derived wholly or in part from such measures. For purposes of this Policy, the term “financial reporting measure” includes the Company’s stock price and total shareholder return, whether expressed as an absolute or relative metric. For the avoidance of doubt, a financial reporting measure need not be presented in the Company’s financial statements or included in a filing with the SEC.
5. “Incentive‐Based Compensation” is any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a financial reporting measure. Incentive‐Based Compensation may include awards under the Executive Incentive Plan and Performance Share Units under the Merck & Co., Inc. 2019 Stock Incentive Plan, or any successor thereto. Incentive‐Based Compensation does not include (i) base salary; (ii) “sign‐on” bonuses or other compensation granted solely due to the commencement of employment with the Company; (iii) compensation exclusively based on completion of a specific period of employment or service, without any performance condition; or (iv) compensation awarded based on subjective, non‐financial, strategic, or operational measures that are not financial reporting measures.
6. Incentive‐Based Compensation is deemed to be “received” in the fiscal period during which the financial reporting measure specified in the Incentive‐Based Compensation award is attained, even if the payment or grant of the Incentive‐Based Compensation occurs after the end of that fiscal period. Incentive‐Based Compensation in the form of an equity award that vests solely upon the basis of a financial reporting measure performance condition will be deemed to be received in the fiscal period in which it vests.
7. “Recoupment Period” is the three completed fiscal years of the Company immediately preceding the date, and any transition period of less than nine months that results from a change in the Company’s fiscal year within or immediately following those three completed fiscal years, on which the Company is required to perform an Accounting Restatement,



which date is the earlier of (i) the date the Board, or a committee of the Board, concludes, or reasonably should have concluded, that the Company is required to perform an Accounting Restatement; or (ii) a date that a court, regulator or other legally authorized body directs the Company to perform an Accounting Restatement.
Procedures for Recoupment of Incentive‐Based Compensation
1. In the event the Company is required to perform an Accounting Restatement, the Company shall, as promptly as reasonably possible, recoup any Incentive‐Based Compensation erroneously received by a Covered Officer during the Recoupment Period. The amount of erroneously received Incentive‐Based Compensation will be the excess of the Incentive‐Based Compensation received by the Covered Officer (whether in cash or in shares) based on the erroneous data in the original financial statements over the Incentive‐Based Compensation (whether in cash or in shares) that would have been received by the Covered Officer had it been based on the restated results, without respect to any tax liabilities incurred or paid by the Covered Officer. For Incentive‐Based Compensation based on total shareholder return or Company stock price, where the amount of erroneously awarded compensation is not subject to mathematical recalculation directly from the information in the Accounting Restatement, the amount shall be based on the Committee’s reasonable estimate of the effect of the Accounting Restatement on the applicable measure and the Committee shall maintain documentation of the determination of that reasonable estimate and provide it to the NYSE. Notwithstanding the foregoing, Incentive‐Based Compensation shall not be recouped under this Policy to the extent received by any person before the date such person served as a Covered Officer.
2. The Committee shall determine, in its sole discretion, the method of recouping any erroneously received Incentive‐Based Compensation pursuant to this Policy.
3. No recoupment shall be required if any of the following conditions are met and the Committee determines that, on such basis, recovery would be impracticable: (i) the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount to be recouped, which determination must be made only after a reasonable and documented attempt by the Company to recoup the Incentive‐Based Compensation (with documentation of such reasonable attempt to recover to be provided to the NYSE); (ii) recovery would violate home country law where that law was adopted prior to November 28, 2022, which determination must be made only after the Company has obtained an opinion of home country counsel, acceptable to the NYSE, that recovery would result in such violation (with a copy of such opinion to be provided to the NYSE); or (iii) recoupment would likely cause an otherwise tax‐qualified retirement plan, under which benefits are broadly available to Company employees, to fail to meet the requirements of Section 401(a)(13) or Section 411(a) of the Internal Revenue Code of 1986, as amended, and U.S. Treasury regulations promulgated thereunder.
Indemnification Not Permitted
The Company shall not indemnify any current or former Covered Officer against the loss of erroneously awarded compensation, and shall not pay, or reimburse any Covered Officer for, premiums incurred or paid for any insurance policy to fund such Covered Officer’s potential recoupment obligations.
Disclosure of Recoupment Decisions
The Company will comply with all applicable securities laws and regulations, including SEC disclosure requirements, with respect to this Policy, and any applicable NYSE listing standard or requirements. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.
Effective Date
This Policy shall be effective as of December 1, 2023 (the “Effective Date”). The terms of this Policy shall apply to any Incentive‐Based Compensation that is received by Covered Officers on or after the Effective Date, even if such Incentive‐Based Compensation was approved, awarded, granted, or paid to Covered Officers prior to the Effective Date.
Miscellaneous
Nothing in this Policy shall limit or otherwise affect any of the following: 1) management’s ability to take any disciplinary action with respect to any Covered Officer; 2) the Committee’s ability to use its negative discretion with respect to any Incentive‐Based Compensation performance target at any time; or 3) the Committee’s or management’s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non‐cash incentive compensation



award to any executive or other employee for any reason as they may deem appropriate and to the extent permitted by law. Any right of recoupment under this Policy is in addition to, and not in lieu of, any other remedies or rights of recoupment that may be available to the Company pursuant to the terms of any similar policy in any incentive plan, employment agreement, equity award agreement, or similar agreement and any other legal remedies available to the Company. This Policy shall be binding and enforceable against all Covered Officers and their beneficiaries, heirs, executors, administrators, or other legal representatives.

EX-19 11 exh19-insidertradingpolicy.htm EX-19 INSIDER TRADING POLICY Document
Corporate Policy 11.0: Insider Trading                        Exhibit 19
What You Need to Know
As employees of Merck & Co., Inc., Rahway, NJ, USA known as MSD outside the United States and Canada (our Company), we, our family members and related persons do not trade in our Company securities – or tip others to do so – based on material, non-public (or “inside”) information. We recognize that insider trading undermines investor confidence in the fairness and integrity of the securities markets, and is not only unethical, but also illegal.
What You Need to Do At a High Level...
Know the definition of inside information and the types of information that could be considered inside information. Be alert to situations that are governed by this policy – it applies when buying or selling securities, including common stock, options for common stock, any other securities that our Company may issue or that may be issued by other companies, or any instruments that may be based on securities issued by our Company or other companies.
What You Need to Do In Your Everyday Work...
Protect inside information. Don’t trade on it and don’t tip others who could trade on it. Follow not only the letter, but the spirit of the laws and policies in the countries where we do business and seek help anytime you have a question. Know and adhere to the following key operating principles of this policy:
1.    Inside Information.
Your work at our Company may expose you to inside information about our Company or companies with which we do business. You may not trade in our Company stock (or make a gift of Company stock) if you possess inside information, and you may not trade in the stock of other companies if your job exposes you to inside information about those companies.
2.    Tipping.
Don’t disclose inside information to anyone, including family members as well as business associates (inside or outside of our Company, intentionally or otherwise). This includes participation in investment clubs and communications in Internet forums and any other social media. This policy does not prevent you from sharing information with other employees who have a need to know the information and will keep that information confidential. If you are not sure whether you are allowed to share information, ask.
3. Conflicts of Interest.
You may gain access to Company proprietary or other information that is not “inside information” but that would create a potential conflict of interest if you were to acquire shares of the company discussed. For example, your job might require you to be involved in a transaction involving Company X (e.g., conducting reviews of companies we are looking to acquire for Corporate Transactions), ownership of stock in Company X may create a conflict of interest.
Whether a conflict is potential, actual or non-existent would depend on a variety of factors, including the size of the company you are investing in, the relationship of that company to Merck’s business, your job at Merck, the size of the investment, the reason
1

Corporate Policy 11.0: Insider Trading                        Exhibit 19
for the investment, and other factors. If you have questions about whether an ownership position in a certain company could create or has created a conflict of interest, you should consult with the Ethics & Compliance Office. All potential conflicts of interest must be identified promptly by entering them in the WorkDay Potential Conflicts of Interest Tool.
4.    Transaction Timing.
To ensure compliance and avoid liability, if you possess inside information, don’t trade until the beginning of the second full trading day after information has been communicated to the public through an official announcement, even if you no longer work at the Company. In addition, if your role at our Company exposes you to inside information regarding any matter reasonably likely to be a focus of the Company’s quarterly or annual earnings releases or related earnings calls (e.g., the Company’s financial or operating results or future outlook), don’t trade in our Company stock during any blackout period, other than automatic purchases under Company-sponsored plans. Certain individuals may receive notification from Legal imposing additional restrictions. You must follow the restrictions outlined in that notification. For your protection and the protection of our Company, contact your Company Legal representative if you are unsure whether a transaction may be permissible, and all Section 16 officers and members of the Board of Directors must pre-clear all transactions in the Company’s securities with Corporate Legal.
5.    Stock Options and Incentives.
The Merck Long-Term Incentive (LTI) Program provides an opportunity for eligible employees to share in the Company’s long-term success by becoming shareholders. You are accountable for exercising LTI grants consistent with this policy. If you are in doubt as to whether exercising rights granted under our Company’s stock option and incentive program (including stock acquired through options or the vesting of Restricted Share or Performance Shares) would violate our insider trading standards, contact the Office of the General Counsel or Assistant General Counsel-Corporate staff before exercising.
To ensure compliance with this policy, the Company reserves the right to institute a freeze on the trading of Company securities held in accounts maintained by the Company’s stock option and incentive program administrator or designated broker. If you have not worked at the Company for six months or longer, the Company has the discretion (but no obligation) to remove this freeze, in which case you will still be responsible for determining if you possess inside information before trading in our Company securities.
6.    Hedging and Pledging.
All Section 16 officers, members of the Board of Directors and employees in Bands 400-700, as well as any of their family members, are prohibited from engaging in: short sales, derivative transactions, hedging transactions and pledging of Company securities.
7.    Rule 10b5-1 Trading Plans.
Only Section 16 officers and members of the Board of Directors are permitted to enter into a Rule 10b5-1 trading plan and they must contact Corporate Legal before entering
2

Corporate Policy 11.0: Insider Trading                        Exhibit 19
into, modifying or terminating any such plan. The Company requires any Rule 10b5-1 trading plan to comply with applicable law, including any mandatory “cooling off” periods, restrictions on overlapping plans and requirements that these plans be entered into, operated, modified and terminated in good faith.
8.    Company Transactions.
The Company will not engage in transactions in its securities, such as share repurchases, while aware of inside information related to the Company or its securities, other than pursuant to Rule 10b5-1 trading plans entered into while the Company is not aware of inside information.
9.    Speak up.
You are our Company. Protect the reputation we’ve earned as a company that operates with integrity and report any conduct that could put our reputation at risk. If you see or suspect employee misconduct, unethical or illegal activity, talk to your manager, another Company resource (e.g., Compliance, Legal, or Human Resources) or, where permitted by law, Speak Up at msdethics.com to address your questions or concerns confidentially without fear of retaliation.
To uphold the Company’s commitment to ethics, integrity and compliance with laws, regulations, Company policy and the Company’s Code of Conduct (Our Values and Standards), actions inconsistent with this policy shall be subject to Corporate Policy 15: Reporting and Responding to Misconduct.
Questions About this Policy?
Contact: [***]
Be aware that procedures for applying our policy may vary from location to location. Whenever a local law, regulation, or industry code reflects a more restrictive standard, follow the more restrictive standard.
Terms You Need to Know
Blackout Period. Starting on the fifteenth calendar day of the last month of each fiscal quarter and continuing until the beginning of the second full trading day after the Company’s quarterly or annual results have been communicated to the public through an official announcement.
Derivative Transactions. Transactions in puts, calls or other derivative instruments that change in value based on the change in value of any security, whether listed on an exchange or in any other organized market or in a private transaction.
Family Member. Includes people within your family who live with you, are financially dependent on you or whose transactions in securities are directed by you or subject to your influence or control.
3

Corporate Policy 11.0: Insider Trading                        Exhibit 19
Hedging. Transactions, such as zero-cost dollars and forward-sale contracts, that allow the covered individual to lock in a portion of the value of the securities in exchange for all or part of the potential upside appreciation.
Inside Information. Material, non-public information about a company that is not available to the public but, if it was, might influence a reasonable investor to buy or sell company securities. Information is “material” if a reasonable investor would consider it important in deciding whether to buy, sell or hold stock. Information is considered “nonpublic” if it has not been disseminated to the public (for example, through a press release). Examples of inside information can include estimates of future earnings, information about planned mergers or acquisitions, changes in executive management, significant new product plans, clinical trial results or regulatory approvals and significant lawsuits or legal settlements.
Insider Trading. Using inside information to gain profits or avoid losses in the stock market.
Pledging. Buying securities or securing a loan using other securities (like Merck securities) as collateral. (This does not refer to employee loans from a qualified savings plan sponsored by Merck or a subsidiary.)
Related Persons. Anyone else who lives in your household and any entities that you influence or control, including any corporations, partnerships or trusts.
Rule 10b5-1 Trading Plan. A contract with a broker that authorizes purchases and sales of Company stock, even during a blackout period, according to pre-established criteria satisfying applicable legal requirements.
Short Sale. Selling a security that is not currently owned.

4
EX-21 12 exh21-subsidiarylistasof12.htm EX-21 SUBSIDIARY LIST Document

Exhibit 21 - MERCK & CO., INC. SUBSIDIARIES
changes as 12/31/2024
    The following is a list of subsidiaries of the Company, doing business under the name stated.
Name
Country or State of Incorporation
7728026 Canada Inc.
Canada
Abceutics, Inc.
Delaware
Abmaxis Inc.
Delaware
Acceleron Pharma Inc.
Delaware
Afferent Pharmaceuticals, Inc.
Delaware
Agrident GmbH
Germany
Allflex Argentina S.A.
Argentina
Allflex Australia Pty. Ltd.
Australia
Allflex (China) Intelligent Technology Co. Ltd.
China
Allflex dan-mark ApS
Denmark
Allflex Europe S.A.S.
France
Allflex Group Germany GmbH
Germany
Allflex Holdings 1 Inc.
Delaware
Allflex Holdings 2 Inc.
Delaware
Allflex Holdings 3 Inc.
Delaware
Allflex India Private Limited
India
Allflex International do Brasil Ltda.
Brazil
Allflex Maroc S.A.R.L.
Morocco
Allflex New Zealand Limited
New Zealand
Allflex Polska Spolka z ograniczona odpowiedzialnoscia
Poland
Allflex Romania S.R.L.
Romania
Allflex UK Group Limited
United Kingdom
Allflex USA LLC
Delaware
Antelliq Finance, Inc.
Delaware
ArQule, Inc.
Delaware
Biomark LLC
Idaho
BRC Ltd.
Bermuda
Burgwedel Biotech GmbH
Germany
Calporta Therapeutics, Inc.
Delaware
Canji, Inc.
Delaware
Caraway Therapeutics Inc.
Delaware
cCam Biotherapeutics Ltd.
Israel
Cherokee Pharmaceuticals LLC
Delaware
Controladora MSD Mexicana Sociedad de Responsabilidad Limitada de Capital Variable
Mexico
Cooper Veterinary Products (Proprietary) Limited
South Africa
Corporation Allflex ULC
Canada
Cosmas B.V.
Netherlands
Cubist Pharmaceuticals LLC
Delaware
Dialstat Trading 91 Pty Ltd T/A Allflex SA
South Africa
Diosynth Holding B.V.
Netherlands
Diosynth Produtos Farmo-quimicos Ltda.
Brazil
Elastec S.R.L
Argentina
Essex Pharmaceuticals, Inc.
Philippines
1



Eyebiotech Ltd.
UK
Eyebiotech Inc.
Delaware
Farmacox - Companhia Farmaceutica, Lda
Portugal
Farmasix-Produtos Farmaceuticos, Lda
Portugal
Financiere MSD
France
Fontelabor-Produtos Farmaceuticos, Lda.
Portugal
Frosst Laboratories, Inc.; ;
Delaware
Frosst Portuguesa - Produtos Farmaceuticos, Lda.
Portugal
GlycoFi, Inc.
Delaware
Hangzhou MSD Pharmaceutical Co., Ltd.1
China
Harpoon Therapeutics Inc.
Delaware
Harrisvaccines LLC
Iowa
Hawk and Falcon L.L.C.
Delaware
Healthcare Services and Solutions, LLC
Delaware
Heptafarma Companhia Farmaceutica, Lda
Portugal
Hydrochemie GmbH
Germany
Idenix GmbH
Switzerland
IdentiGEN Limited
Ireland
IdentiGEN North America Inc.
Delaware
Imago Biosciences, Inc.
Delaware
Immune Design Corp.
Delaware
International Indemnity Ltd.
Bermuda
Intervet (Ireland) Limited
Ireland
Intervet (Israel) Ltd.
Israel
Intervet (M) Sdn. Bhd.
Malaysia
Intervet (Proprietary) Limited
South Africa
Intervet (Thailand) Ltd.
Thailand
Intervet Agencies B.V.
Netherlands
Intervet Animal Health Taiwan Limited
China
Intervet Argentina S.A.
Argentina
Intervet Australia Pty Limited
Australia
Intervet Canada Corp.
Canada
Intervet Central America S. de R.L.
Panama
Intervet Deutschland GmbH
Germany
Intervet Ecuador S.A.
Ecuador
Intervet Egypt for Animal Health SAE
Egypt
Intervet GesmbH
Austria
Intervet Hellas A.E.
Greece
Intervet Holding B.V.
Netherlands
Intervet Holdings France SAS
France
Intervet Hungaria Értékesítő Kft
Hungary
Intervet Inc.
Delaware
Intervet India Private Limited
India
Intervet International B.V.
Netherlands
Intervet International GmbH
Germany
Intervet International Sarl
France
Intervet LLC
Russian Federation
Intervet Maroc S.A.
Morocco
Intervet Mexico S.A. de C.V.
Mexico
2



Intervet Middle East Limited
Cyprus
Intervet Nederland B.V.
Netherlands
Intervet Philippines, Inc.
Philippines
Intervet Productions S.A.
France
Intervet Productions S.r.l.
Italy
Intervet Romania SRL
Romania
Intervet SAS
France
Intervet Schering-Plough Animal Health Pty. Ltd.
Australia
Intervet South Africa (Proprietary) Limited
South Africa
Intervet Sp. z.o.o.
Poland
Intervet UK Production Limited
United Kingdom
Intervet Venezolana S.A.
Venezuela
Intervet Veterinaria Chile Ltda
Chile
Intervet Veteriner Ilaclari Pazarlama ve Ticaret Ltd. Sirketi
Turkey
Intervet, s.r.o.
Czech Republic
Interveterinaria SA de CV
Mexico
IOmet Pharma Limited
Scotland
Laboratoires Merck Sharp & Dohme – Chibret SNC
France
Laboratorios Abello, S.A.
Spain
Laboratorios Quimico-Farmaceuticos Chibret, Lda
Portugal
Lemifar S. A.
Uruguay
Lexington Biopharma II Limited
Cayman Islands
Maya Tibbi Ürünler Ticaret Limited Sirketi
Turkey
MCM Vaccine B.V.1
Netherlands
Merck and Company LLC
Delaware
Merck Canada Inc.
Canada
Merck Capital Ventures, LLC1
Delaware
Merck Frosst Canada & Co.
Canada
Merck Frosst Company
Canada
Merck Global Health Innovation Fund, LLC
Delaware
Merck Global Health Innovation, Private Equity, LLC
Delaware
Merck HDAC Research, LLC
Delaware
Merck Holdings II Corp.
Delaware
Merck Holdings IV Corp.
Delaware
Merck Holdings LLC
Delaware
Merck Lumira Biosciences Fund L.P.1
Canada
Merck Registry Holdings, Inc.
New Jersey
Merck Research Investments LLC
Delaware
Merck Research Laboratories Massachusetts, LLC
Delaware
Merck Sharp & Dohme (Argentina) LLC
Delaware
Merck Sharp & Dohme (Asia) Limited
Hong Kong
Merck Sharp & Dohme (Australia) Pty. Limited
Australia
Merck Sharp & Dohme (Chile) Ltda.
Chile
Merck Sharp & Dohme (China) Limited
Hong Kong
Merck Sharp & Dohme (Enterprises) B.V.
Netherlands
Merck Sharp & Dohme (Holdings) Pty Ltd
Australia
Merck Sharp & Dohme (I.A.) LLC
Delaware
Merck Sharp & Dohme (International) Limited
Bermuda
Merck Sharp & Dohme (Israel - 1996) Company Ltd.
Israel
3



Merck Sharp & Dohme (Malaysia) SDN. BHD.
Malaysia
Merck Sharp & Dohme (New Zealand) Limited
New Zealand
Merck Sharp & Dohme (Sweden) A.B.
Sweden
Merck Sharp & Dohme (Switzerland) GmbH
Switzerland
Merck Sharp & Dohme (UK) Limited
United Kingdom
Merck Sharp & Dohme Animal Health, S.L.
Spain
Merck Sharp & Dohme Asia Pacific Services Pte. Ltd.
Singapore
Merck Sharp & Dohme B.V.
Netherlands
Merck Sharp & Dohme BH d.o.o.
Bosnia
Merck Sharp & Dohme Bulgaria EOOD
Bulgaria
Merck Sharp & Dohme Colombia S.A.S.
Colombia
Merck Sharp & Dohme Comercializadora, S. de R.L. de C.V.
Mexico
Merck Sharp & Dohme Cyprus Limited
Cyprus
Merck Sharp & Dohme d.o.o.
Croatia
Merck Sharp & Dohme d.o.o. Belgrade
Serbia
Merck Sharp & Dohme de Espana, SAU
Spain
Merck Sharp & Dohme Farmaceutica Ltda.
Brazil
Merck Sharp & Dohme Finance Europe Limited
United Kingdom
Merck Sharp & Dohme Gesellschaft m.b.H.
Austria
Merck Sharp & Dohme Holdings Corp.
Delaware
Merck Sharp & Dohme IDEA GmbH
Switzerland
Merck Sharp & Dohme inovativna zdravila d.o.o.
Slovenia
Merck Sharp & Dohme International Services B.V.
Netherlands
Merck Sharp & Dohme Ireland (Human Health) Limited
Ireland
Merck Sharp & Dohme Latvija
Latvia
Merck Sharp & Dohme Limitada
Bolivia
Merck Sharp & Dohme LLC
New Jersey
Merck Sharp & Dohme OU
Estonia
Merck Sharp & Dohme Peru SRL
Peru
Merck Sharp & Dohme Pharmaceutical Industrial and Commercial Societe Anonyme
Greece
Merck Sharp & Dohme Research GmbH
Switzerland
Merck Sharp & Dohme Romania SRL
Romania
Merck Sharp & Dohme S.A.
Morocco
Merck Sharp & Dohme s.r.o.
Czech Republic
Merck Sharp & Dohme Salud Animal Perú S.A.
Peru
Merck Sharp & Dohme Salud Animal Colombia S.A.S.
Colombia
Merck Sharp & Dohme Saude Animal Ltda.
Brazil
Merck Sharp & Dohme Singapore Trading Pte. Ltd.
Singapore
Merck Sharp & Dohme Tunisie SARL
Tunisia
Merck Sharp & Dohme, Limitada
Portugal
Merck Sharp & Dohme, S. de R.L. de C.V.
Mexico
Merck Sharp & Dohme, s.r.o.
Slovakia
Merck Sharp Dohme Ilaclari Limited Sirketi
Turkey
Merck Teknika LLC
Delaware
Merko Acquisition S.A.
Belgium
Merko Dalton B.V.
Netherlands
Merko N.V.
Belgium
ML Holdings (Canada) Inc.
Canada
Modifi Biosciences, Inc.
Delaware
4



MRL San Francisco, LLC
Delaware
MRL Ventures Fund LLC
Delaware
MSD (Hainan) Innovative Healthcare Co., Ltd.
China
MSD (I.A.) B.V.
Netherlands
MSD (Ningbo) Animal Health Technology Co., Ltd.
China
MSD (Norge) AS
Norway
MSD (Proprietary) Limited
South Africa
MSD (Shanghai) Pharmaceuticals Consultancy Co., Ltd.
China
MSD (Thailand) Ltd.
Thailand
MSD Agencies B.V.
Netherlands
MSD Animal Health UK Limited
United Kingdom
MSD Animal Health (Phils.), Inc
Philippines
MSD Animal Health (Shanghai) Trading Co., Ltd.
China
MSD Animal Health A/S
Denmark
MSD Animal Health B.V.
Belgium
MSD Animal Health Danube Biotech GmbH
Austria
MSD Animal Health FZ-LLC
United Arab Emirates
MSD Animal Health GmbH
Switzerland
MSD Animal Health Holdings BV
Netherlands
MSD Animal Health Innovation AS
Norway
MSD Animal Health Innovation GmbH
Germany
MSD Animal Health Innovation Pte. Ltd.
Singapore
MSD Animal Health K.K.
Japan
MSD Animal Health Korea Ltd.
Korea
MSD Animal Health Norge AS
Norway
MSD Animal Health Oy
Finland
MSD Pensions Trustee Limited
United Kingdom
MSD Animal Health S.r.l.
Italy
MSD Animal Health Sweden AB
Sweden
MSD Animal Health Vietnam Company Limited
Vietnam
MSD Animal Health, Lda.
Portugal
MSD Argentina SRL
Argentina
MSD Asia Holdings Pte. Ltd.
Singapore
MSD BD-4 GmbH
Switzerland
MSD BD-5 GmbH
Switzerland
MSD Belgium BV – SRL
Belgium
MSD Biotech B.V.
Netherlands
MSD Brazil Investments B.V.
Netherlands
MSD Central America Services S. de R.L.
Panama
MSD Central America Services Guatemala
Guatemala
MSD China (Investments) B.V.
Netherlands
MSD China B.V.
Netherlands
MSD China Holding Co., Ltd.
China
MSD Cubist Holdings BV
Switzerland
MSD Cubist Holdings Unlimited Company
Ireland
MSD Czech Republic s.r.o.
Czech Republic
MSD Danmark ApS
Denmark
MSD Egypt LLC
Egypt
MSD Eurofinance
Bermuda
5



MSD Europe Belgium SRL
Belgium
MSD Farmaceutica C.A.
Venezuela
MSD FI BV
Netherlands
MSD Finland Oy
Finland
MSD France
France
MSD Global Holdings B.V.
Netherlands
MSD HH Vietnam Ltd
Vietnam
MSD Human Health Holding B.V.
Netherlands
MSD Human Health Holding II B.V.
Netherlands
MSD IDEA Algerie SPA
Algeria
MSD IDEA Pharmaceuticals Nigeria Limited
Nigeria
MSD IDEA Tunisie SARL
Tunisia
MSD Innovation and Development GmbH
Switzerland
MSD International B.V.
Netherlands
MSD International Business GmbH
Switzerland
MSD International Finance B.V.
Netherlands
MSD International GmbH
Switzerland
MSD International Manufacturing GmbH
Switzerland
MSD Italia s.r.l.
Italy
MSD Japan Holdings B.V.
Netherlands
MSD Japan Holdings GK
Japan
MSD K.K.
Japan
MSD KSA GmbH
Switzerland
MSD Korea Co., Ltd.
Korea
MSD Laboratories India LLC
Delaware
MSD Latin America Services S. de R.L.
Panama
MSD Latin America Services S. de R.L. de C.V.
Mexico
MSD Limited
United Kingdom
MSD Luxembourg S.a.r.l.
Luxembourg
MSD Merck Sharp & Dohme AG
Switzerland
MSD Netherlands Capital B.V.
Netherlands
MSD NL 4 B.V.
Netherlands
MSD Panama International Services S. de R.L.
Panama
MSD Participations B.V.
Netherlands
MSD Pharma (Singapore) Pte. Ltd.
Singapore
MSD Pharma GmbH
Germany
MSD Pharma Hungary Korlatolt Felelossegu Tarsasag
Hungary
MSD Pharmaceuticals LLC
Russian Federation
MSD Pharmaceuticals Private Limited
India
MSD Polska Dystrybucja Sp. z.o.o.
Poland
MSD Polska Sp.z.o.o.
Poland
MSD R&D (China) Co., Ltd.
China
MSD R&D Innovation Centre Limited
United Kingdom
MSD RDC Costa Rica Sociedad de Responsabilidad Limitada
Costa Rica
MSD Registry Holdings, Inc.
New Jersey
MSD Shared Business Services EMEA Limited
Ireland
MSD Sharp & Dohme Gesellschaft mit beschränkter Haftung
Germany
MSD Switzerland Investments 4 Unlimited Company
Ireland
MSD Ukraine Limited Liability Company
Ukraine
6



MSD Vaccins
France
MSD Vaccins Holdings
France
MSD Venezuela Holding GmbH
Switzerland
MSD Verwaltungs GmbH
Germany
MSD Vietnam Company Limited
Vietnam
MSD Vietnam Holdings B.V.
Netherlands
MSDIG Holdings Unlimited Company
Ireland
MSDIG Holdings 2 Unlimited Company
Ireland
MSP Vaccine Company1
Pennsylvania
Multilan AG
Switzerland
Nihon MSD G.K.
Japan
Nourifarma - Produtos Quimicos e Farmaceuticos, Sociedade Uniperssoal, Lda
Portugal
O.PI.VI S.R.L.
Italy
OBS Holdings B.V.
Netherlands
Oncoethix GmbH
Switzerland
OncoImmune, Inc.
Delaware
Organon Latin America S.A.
Uruguay
OS ID AS
Norway
OSID Stallmästaren AB
Sweden
P.T. Merck Sharp & Dohme Indonesia
Indonesia
Pandion Operations, Inc.
Delaware
Pandion Therapeutics, Inc.
Delaware
Peloton Therapeutics, Inc.
Delaware
Polnet ID Spolka z ograniczona odpowiedzialnoscia
Poland
PrognostiX-Poultry Limited
United Kingdom
Prometheus Biosciences, Inc.
Delaware
Prondil Sociedad Anónima
Uruguay
PT Intervet Indonesia
Indonesia
Putexin Investments Limited
New Zealand
Rigontec GmbH
Germany
Rosetta Inpharmatics LLC
Delaware
S.C.R. (Engineers) Limited
Israel
Schering-Plough, S.A.S.
France
Schering-Plough (Ireland) Unlimited Company
Ireland
Schering-Plough Animal Health Limited
New Zealand
Schering-Plough Canada Inc.
Canada
Schering-Plough Corporation
Philippines
Schering-Plough Corporation, U.S.A.
Delaware
Schering-Plough Holdings Limited
United Kingdom
Schering-Plough S.A.S
France
Schering-Plough S.A.
Paraguay
Schering-Plough S.A.
Spain
SCR Allflex Management, Ltd
Israel
Servicios Veternarios Servet, Sociedad Anónima
Costa Rica
Shanghai MSD Pharmaceutical Trading Co., Ltd.
China
Sistemas de Identificacao Animal Ltda
Brazil
SmartCells, Inc.
Delaware
SOL Limited
Bermuda
SureFlap Limited
United Kingdom
7



Themis Bio Holdings LLC
Delaware
Theriak B.V.
Netherlands
Tilos Therapeutics, Inc.
Delaware
UAB Merck Sharp & Dohme
Lithuania
Vaki Fiskeldiskerfi ehf.
Iceland
VelosBio Inc.
Delaware
VelosBio Canada Inc.
Canada
Vence Corp
Delaware
Vence Corp AU Pty Ltd
Australia
Venco Farmaceutica S.A.
Venezuela
Venco Holding GmbH
Switzerland
Vet Pharma Friesoythe GmbH
Germany
Veterinaria Premium, Sociedad Anonima
Guatemala
VetInvent, LLC
Delaware
Vetrex B.V.
Netherlands
Vetrex Egypt L.L.C.
Egypt
Vree Health Italia S.r.l.
Italy
Werthenstein Biopharma GmbH
Switzerland
Zoöpharm B.V.
Netherlands

___________
1 own less than 100%
8

EX-23 13 exh23-consentofindependent.htm EX-23 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Document

Exhibit 23


CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos. 333-254700 and 333-254703) and on Form S-8 (Nos. 333-173025, 333-173024, 333-162883, 333-162884, 333-162885, 333-162886, 333-121089, and 333-233226) of Merck & Co., Inc. of our report dated February 25, 2025 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.

/s/ PricewaterhouseCoopers LLP
Florham Park, New Jersey
February 25, 2025

EX-24.1 14 exh241-powerofattorney.htm EX-24.1 POWER OF ATTORNEY Document

Exhibit 24.1

POWER OF ATTORNEY
Each of the undersigned does hereby appoint JENNIFER ZACHARY as his/her true and lawful attorney to execute on behalf of the undersigned (whether on behalf of the Company, or as an officer or director thereof, or by attesting the seal of the Company, or otherwise) the Annual Report on Form 10-K of Merck & Co., Inc. for the fiscal year ended December 31, 2024 under the Securities Exchange Act of 1934, including amendments thereto and all exhibits and other documents in connection therewith.
IN WITNESS WHEREOF, this instrument has been duly executed as of the 25th day of February 2025.
MERCK & CO., INC.

/s/ Robert M. DavisChairman, Chief Executive Officer and President
Robert M. Davis(Principal Executive Officer; Director)
/s/ Caroline LitchfieldExecutive Vice President and Chief Financial Officer
Caroline Litchfield (Principal Financial Officer)
/s/ Dalton SmartSenior Vice President Finance—Global Controller
Dalton Smart(Principal Accounting Officer)
DIRECTORS
 
/s/ Douglas M. Baker, Jr./s/ Stephen L. Mayo
Douglas M. Baker, Jr.Stephen L. Mayo
/s/ Mary Ellen Coe/s/ Paul B. Rothman
Mary Ellen CoePaul B. Rothman
/s/ Pamela J. Craig/s/ Patricia F. Russo
Pamela J. CraigPatricia F. Russo
/s/ Thomas H. Glocer/s/ Christine E. Seidman
Thomas H. GlocerChristine E. Seidman
/s/ Surendralal L. Karsanbhai/s/ Inge G. Thulin
Surendralal L. KarsanbhaiInge G. Thulin
/s/ Risa J. Lavizzo-Mourey/s/ Kathy J. Warden
Risa J. Lavizzo-MoureyKathy J. Warden

EX-24.2 15 exh242-certificationofboar.htm EX-24.2 CERTIFICATION OF BOARD RESOLUTION Document

Exhibit 24.2

I, Kelly Grez, Corporate Secretary of Merck & Co., Inc. (the “Company”), a corporation duly organized and existing under the laws of the State of New Jersey, do hereby certify that the following is a true copy of a resolution adopted by unanimous written consent of the Board of Directors of the Company on February 25, 2025 in accordance with the provisions of the By-Laws of the Company:

“Special Resolution No. [13] – 2025

RESOLVED, that the proposed form of the Annual Report on Form 10-K of the Company for the fiscal year ended December 31, 2024, attached hereto, is hereby approved with such changes as the proper officers of the Company, with the advice of counsel, deem appropriate;

FURTHER RESOLVED, that each officer and director who may be required to execute the aforesaid Annual Report on Form 10-K or any amendments thereto (whether on behalf of the Company or as an officer or director thereof, or by attesting the seal of the Company, or otherwise) is hereby authorized to execute a power of attorney appointing Jennifer Zachary as his/her true and lawful attorney to execute in his/her name, place and stead (in any such capacity) such Annual Report on Form 10‑K and any and all amendments thereto and any and all exhibits and other documents necessary or incidental in connection therewith and to file the same with the Securities and Exchange Commission, the attorney to have power to act and to have full power and authority to do and perform in the name and on behalf of each of said officers and directors, or both, as the case may be, every act whatsoever necessary or advisable to be done in the premises as fully and to all intents and purposes as any such officer or director might or could do in person; and

FURTHER RESOLVED that an executed copy of the Action by Unanimous Written Consent be filed with the minutes of the meetings of the Board of Directors of the Company."

IN WITNESS WHEREOF, I have hereunto subscribed my signature and affixed the seal of the Company this 25th day of February 2025.

[Corporate Seal]/s/ Kelly Grez
Kelly Grez
Corporate Secretary

EX-31.1 16 exh311-rule13ax14a15dx14ac.htm EX-31.1 RULE 13A-14(A)/15D-14(A) CERTIFICATION OF CEO Document

Exhibit 31.1
CERTIFICATION
I, Robert M. Davis, certify that:
1.    I have reviewed this annual report on Form 10-K of Merck & Co., Inc.;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: February 25, 2025

By:     /s/ Robert M. Davis
ROBERT M. DAVIS
Chairman, Chief Executive Officer and President

EX-31.2 17 exh312-rule13ax14a15dx14ac.htm EX-31.2 RULE 13A-14(A)/15D-14(A) CERTIFICATION OF CFO Document

Exhibit 31.2
CERTIFICATION
I, Caroline Litchfield, certify that:
1.    I have reviewed this annual report on Form 10-K of Merck & Co., Inc.;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date:   February 25, 2025

By:      /s/ Caroline Litchfield
CAROLINE LITCHFIELD
Executive Vice President, Chief Financial Officer

EX-32.1 18 exh321-section1350certific.htm EX-32.1 SECTION 1350 CERTIFICATION OF CEO Document

Exhibit 32.1
Section 1350
Certification of Chief Executive Officer
Pursuant to 18 U.S.C. Section 1350, the undersigned officer of Merck & Co., Inc. (the “Company”), hereby certifies that the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: February 25, 2025 /s/ Robert M. Davis
 Name: ROBERT M. DAVIS
 Title: Chairman, Chief Executive Officer and President

EX-32.2 19 exh322-section1350certific.htm EX-32.2 SECTION 1350 CERTIFICATION OF CFO Document

Exhibit 32.2
Section 1350
Certification of Chief Financial Officer
Pursuant to 18 U.S.C. Section 1350, the undersigned officer of Merck & Co., Inc. (the “Company”), hereby certifies that the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: February 25, 2025/s/ Caroline Litchfield
Name: CAROLINE LITCHFIELD
Title: Executive Vice President, Chief Financial Officer

EX-101.SCH 20 mrk-20241231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Document - Audit Information link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - Consolidated Statement of Income link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - Consolidated Statement of Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - Consolidated Balance Sheet link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - Consolidated Balance Sheet (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - Consolidated Statement of Equity link:presentationLink link:calculationLink link:definitionLink 9952156 - Statement - Consolidated Statement of Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952157 - Statement - Consolidated Statement of Cash Flows link:presentationLink link:calculationLink link:definitionLink 9952158 - Statement - Consolidated Statement of Cash Flows (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - Nature of Operations link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - Summary of Accounting Policies link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - Acquisitions, Divestitures, Research Collaborations and Licensing Agreements link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - Collaborative Arrangements link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - Restructuring link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - Financial Instruments link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - Goodwill and Other Intangibles link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - Loans Payable, Long-Term Debt and Leases link:presentationLink link:calculationLink link:definitionLink 9952168 - Disclosure - Contingencies and Environmental Liabilities link:presentationLink link:calculationLink link:definitionLink 9952169 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 9952170 - Disclosure - Share-Based Compensation Plans link:presentationLink link:calculationLink link:definitionLink 9952171 - Disclosure - Pension and Other Postretirement Benefit Plans link:presentationLink link:calculationLink link:definitionLink 9952172 - Disclosure - Other (Income) Expense, Net link:presentationLink link:calculationLink link:definitionLink 9952173 - Disclosure - Taxes on Income link:presentationLink link:calculationLink link:definitionLink 9952174 - Disclosure - Earnings per Share link:presentationLink link:calculationLink link:definitionLink 9952175 - Disclosure - Other Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 9952176 - Disclosure - Segment Reporting link:presentationLink link:calculationLink link:definitionLink 9955511 - Disclosure - Summary of Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9955512 - Disclosure - Acquisitions, Divestitures, Research Collaborations and Licensing Agreements (Tables) link:presentationLink link:calculationLink link:definitionLink 9955513 - Disclosure - Collaborative Arrangements (Tables) link:presentationLink link:calculationLink link:definitionLink 9955514 - Disclosure - Restructuring (Tables) link:presentationLink link:calculationLink link:definitionLink 9955515 - Disclosure - Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 9955516 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 9955517 - Disclosure - Goodwill and Other Intangibles (Tables) link:presentationLink link:calculationLink link:definitionLink 9955518 - Disclosure - Loans Payable, Long-Term Debt and Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 9955519 - Disclosure - Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 9955520 - Disclosure - Share-Based Compensation Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 9955521 - Disclosure - Pension and Other Postretirement Benefit Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 9955522 - Disclosure - Other (Income) Expense, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 9955523 - Disclosure - Taxes on Income (Tables) link:presentationLink link:calculationLink link:definitionLink 9955524 - Disclosure - Earnings per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9955525 - Disclosure - Other Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 9955526 - Disclosure - Segment Reporting (Tables) link:presentationLink link:calculationLink link:definitionLink 9955527 - Disclosure - Nature of Operations (Details) link:presentationLink link:calculationLink link:definitionLink 9955528 - Disclosure - Summary of Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 9955529 - Disclosure - Acquisitions, Divestitures, Research Collaborations and Licensing Agreements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955530 - Disclosure - Acquisitions, Divestitures, Research Collaborations and Licensing Agreements - Estimated Fair Value of Assets Acquired and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 9955531 - Disclosure - Collaborative Arrangements - AstraZeneca PLC - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955532 - Disclosure - Collaborative Arrangements - AstraZeneca PLC (Details) link:presentationLink link:calculationLink link:definitionLink 9955533 - Disclosure - Collaborative Arrangements - Eisai Co., Ltd. - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955534 - Disclosure - Collaborative Arrangements - Eisai Co., Ltd. (Details) link:presentationLink link:calculationLink link:definitionLink 9955535 - Disclosure - Collaborative Arrangements - Bayer AG (Details) link:presentationLink link:calculationLink link:definitionLink 9955536 - Disclosure - Collaborative Arrangements - Ridgeback Biotherapeutics LP (Details) link:presentationLink link:calculationLink link:definitionLink 9955537 - Disclosure - Collaborative Arrangements - Daiicho Sankyo - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955538 - Disclosure - Collaborative Arrangements - Daiicho Sankyo (Details) link:presentationLink link:calculationLink link:definitionLink 9955539 - Disclosure - Collaborative Arrangements - Moderna, Inc. - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955540 - Disclosure - Collaborative Arrangements - Moderna, Inc. (Details) link:presentationLink link:calculationLink link:definitionLink 9955541 - Disclosure - Collaborative Arrangements - Bristol Meyers Squibb Company - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955542 - Disclosure - Restructuring - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955543 - Disclosure - Restructuring - Charges Activities by Type of Cost (Details) link:presentationLink link:calculationLink link:definitionLink 9955544 - Disclosure - Restructuring - Activities by Program (Details) link:presentationLink link:calculationLink link:definitionLink 9955545 - Disclosure - Financial Instruments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955546 - Disclosure - Financial Instruments - Effect of Net Investment Hedges (Details) link:presentationLink link:calculationLink link:definitionLink 9955547 - Disclosure - Financial Instruments - Summary of Interest Rate Swaps Held (Details) link:presentationLink link:calculationLink link:definitionLink 9955548 - Disclosure - Financial Instruments - Amounts Recorded on Balance Sheet Related to Fair Value Hedges (Details) link:presentationLink link:calculationLink link:definitionLink 9955549 - Disclosure - Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9955550 - Disclosure - Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details) link:presentationLink link:calculationLink link:definitionLink 9955551 - Disclosure - Financial Instruments - Location and Pretax (Gains) or Loss Amounts for Derivatives (Details) link:presentationLink link:calculationLink link:definitionLink 9955552 - Disclosure - Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9955553 - Disclosure - Financial Instruments - Information on Debt and Equity Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9955554 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 9955555 - Disclosure - Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 9955556 - Disclosure - Inventories - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 9955556 - Disclosure - Inventories - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 9955557 - Disclosure - Inventories - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955558 - Disclosure - Goodwill and Other Intangibles - Goodwill Activity by Segment (Details) link:presentationLink link:calculationLink link:definitionLink 9955559 - Disclosure - Goodwill and Other Intangibles - Other Intangibles (Details) link:presentationLink link:calculationLink link:definitionLink 9955559 - Disclosure - Goodwill and Other Intangibles - Other Intangibles (Details) link:presentationLink link:calculationLink link:definitionLink 9955560 - Disclosure - Goodwill and Other Intangibles - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955561 - Disclosure - Loans Payable, Long-Term Debt and Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955562 - Disclosure - Loans Payable, Long-Term Debt and Leases - Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9955563 - Disclosure - Loans Payable, Long-Term Debt and Leases - Balance Sheet Information (Details) link:presentationLink link:calculationLink link:definitionLink 9955564 - Disclosure - Loans Payable, Long-Term Debt and Leases - Maturity Schedule (Details) link:presentationLink link:calculationLink link:definitionLink 9955564 - Disclosure - Loans Payable, Long-Term Debt and Leases - Maturity Schedule (Details) link:presentationLink link:calculationLink link:definitionLink 9955565 - Disclosure - Contingencies and Environmental Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9955566 - Disclosure - Equity - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955567 - Disclosure - Equity - Shareholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 9955568 - Disclosure - Share-Based Compensation Plans - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955569 - Disclosure - Share-Based Compensation Plans - Assumptions Used to Determine Weighted-Average Fair Value of Options Granted (Details) link:presentationLink link:calculationLink link:definitionLink 9955570 - Disclosure - Share-Based Compensation Plans - Summary of Information Relative to Stock Option Plan Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9955571 - Disclosure - Share-Based Compensation Plans - Additional Information Pertaining to Stock Option Plans (Details) link:presentationLink link:calculationLink link:definitionLink 9955572 - Disclosure - Share-Based Compensation Plans - Summary of Nonvested RSU and PSU Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9955573 - Disclosure - Pension and Other Postretirement Benefit Plans - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955574 - Disclosure - Pension and Other Postretirement Benefit Plans - Components of Net Periodic Benefit Cost (Details) link:presentationLink link:calculationLink link:definitionLink 9955575 - Disclosure - Pension and Other Postretirement Benefit Plans - Obligation and Funded Status (Details) link:presentationLink link:calculationLink link:definitionLink 9955575 - Disclosure - Pension and Other Postretirement Benefit Plans - Obligation and Funded Status (Details) link:presentationLink link:calculationLink link:definitionLink 9955576 - Disclosure - Pension and Other Postretirement Benefit Plans - Accumulated and Projected Benefit Obligation in Excess of Plan Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9955577 - Disclosure - Pension and Other Postretirement Benefit Plans - Fair Values of Pension Plan Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9955578 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Changes in Fair Value of Company's Level 3 Pension Plan Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9955579 - Disclosure - Pension and Other Postretirement Benefit Plans - Fair Values of Other Postretirement Benefit Plan Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9955580 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Expected Benefit Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9955581 - Disclosure - Pension and Other Postretirement Benefit Plans - Components of Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 9955582 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Weighted Average Assumptions Used in Determining Pension Plan and U.S. Pension and Other Postretirement Benefit Plan Information (Details) link:presentationLink link:calculationLink link:definitionLink 9955583 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Health Care Cost Trend Rate Assumptions for Other Postretirement Benefit Plans (Details) link:presentationLink link:calculationLink link:definitionLink 9955584 - Disclosure - Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details) link:presentationLink link:calculationLink link:definitionLink 9955585 - Disclosure - Other (Income) Expense, Net - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955586 - Disclosure - Taxes on Income - Reconciliation Between Effective Tax Rate and US Statutory Rate (Details) link:presentationLink link:calculationLink link:definitionLink 9955587 - Disclosure - Taxes on Income - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955588 - Disclosure - Taxes on Income - Income Before Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9955589 - Disclosure - Taxes on Income - Taxes on Income (Details) link:presentationLink link:calculationLink link:definitionLink 9955590 - Disclosure - Taxes on Income - Deferred Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9955591 - Disclosure - Taxes on Income - Income Tax Authority (Details) link:presentationLink link:calculationLink link:definitionLink 9955592 - Disclosure - Taxes on Income - Unrecognized Tax Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 9955593 - Disclosure - Earnings Per Share - Calculations of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9955594 - Disclosure - Earnings Per Share - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955595 - Disclosure - Other Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 9955596 - Disclosure - Segment Reporting - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955597 - Disclosure - Segment Reporting - Sales of Company's Products (Details) link:presentationLink link:calculationLink link:definitionLink 9955598 - Disclosure - Segment Reporting - Consolidated Revenues by Geographic Area (Details) link:presentationLink link:calculationLink link:definitionLink 9955599 - Disclosure - Segment Reporting - Reconciliation of Segment Profits to Income Before Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9955600 - Disclosure - Segment Reporting - Equity Income from Affiliates and Depreciation Included in Segment Profits (Details) link:presentationLink link:calculationLink link:definitionLink 9955601 - Disclosure - Segment Reporting - Property, Plant and Equipment, Net by Geographic Area (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 21 mrk-20241231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 22 mrk-20241231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 23 mrk-20241231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 2026 Defined Benefit Plan, Expected Future Benefit Payment, Year Two Weighted Average Remaining Contractual Term, Vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Daiichi Sankyo Daiichi Sankyo [Member] Daiichi Sankyo Payments on debt Repayments of Long-Term Debt U.S. statutory rate applied to income before taxes Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 1.70% notes due 2027 1.70% notes due 2027 [Member] 1.70% notes due 2027 Transition tax for accumulated foreign earnings, liability Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability Cover [Abstract] Cover [Abstract] 2.35% notes due 2040 2.35% Notes Due 2040 [Member] 2.35% Notes Due 2040 Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect IPR&D In Process Research and Development [Member] Schedule of Maturities of Operating Lease Liabilities Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] International Foreign Plan [Member] Inventory related, Assets Deferred Tax Assets, Inventory Income Tax Jurisdiction [Domain] Income Tax Jurisdiction [Domain] Hedged items Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge Trading Symbol Trading Symbol Foreign Exchange Future Foreign Exchange Future [Member] Gross amounts recognized in the consolidated balance sheet, asset Derivative Asset, Subject to Master Netting Arrangement, before Offset Non-NEOs Non-NEOs [Member] Income tax benefits related to share-based compensation Share-Based Payment Arrangement, Expense, Tax Benefit 3.250% Notes due 2032 3.250% Notes Due 2032 [Member] 3.250% Notes Due 2032 Charges for certain research and development asset acquisitions Income Tax Rate Reconciliation, Asset Acquisition Two, Amount Income Tax Rate Reconciliation, Asset Acquisition Two, Amount Common stock, dividends declared (in dollars per share) Common Stock, Dividends, Per Share, Declared Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] 2027 Defined Benefit Plan, Expected Future Benefit Payment, Year Three Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Future contingent developmental milestone payments (up to) Asset Acquisition, Maximum Aggregate Contingent Development-Related Payments Asset Acquisition, Maximum Aggregate Contingent Development-Related Payments Distributions attributable to noncontrolling interests Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Disposal Group Name [Domain] Disposal Group Name [Domain] Lagevrio Lagevrio [Member] Lagevrio 2.50% euro-denominated notes due 2034 2.5% euro-denominated Notes Due 2034 [Member] 2.5% euro-denominated Notes Due 2034 [Member] Accounts receivable Increase (Decrease) in Accounts Receivable (Income) loss from investments in equity securities, net (Income) loss from investments in equity securities, net Equity Securities, FV-NI, Gain (Loss) Currency Swap Currency Swap [Member] Inventories Inventory, Policy [Policy Text Block] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Proceeds from exercise of stock options Cash received from the exercise of stock options Proceeds from Stock Options Exercised Award Timing Disclosures [Line Items] Amount of gain recognized in Other (income) expense, net on derivatives Derivative, Gain (Loss) on Derivative, Net Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Restricted Cash and Cash Equivalents [Axis] Restricted Cash and Cash Equivalents [Axis] Loss contingency, pending claims Loss Contingency, Pending Claims, Number Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] United States UNITED STATES Common shares issuable (in shares) Weighted Average Number of Shares Outstanding, Diluted, Adjustment Other Assets Other Assets Other Assets, Noncurrent Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. [Member] Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Finite-lived intangible assets, gross carrying amount Finite-Lived Intangible Assets, Gross Tax Rate Effective Income Tax Rate Reconciliation, Percent [Abstract] Operating Segments Total segment profits Operating Segments [Member] Net Cash Provided by Operating Activities Net Cash Provided by (Used in) Operating Activities Cash Flows from Operating Activities Net Cash Provided by (Used in) Operating Activities [Abstract] Changes in AOCI by Component Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Share-based compensation plans and other Stockholders' Equity, Other Award Timing Method Award Timing Method [Text Block] Net periodic benefit cost (credit) Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Number of antibody drug conjugates terminated Collaborative Arrangement, Terminated, Number Of Antibody Drug Conjugates Collaborative Arrangement, Terminated, Number Of Antibody Drug Conjugates Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Restructuring Type [Axis] Restructuring Type [Axis] Measurement Frequency [Axis] Measurement Frequency [Axis] Emerging markets equities Emerging Markets Equities Investment Funds [Member] Emerging markets equities investment funds. Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Change in Unrecognized Tax Benefit, Reasonably Possible [Table] Change in Unrecognized Tax Benefit, Reasonably Possible [Table] Insider Trading Policies and Procedures [Line Items] Pension Plan Prior Service Credit Pension Plan Prior Service Cost [Member] Pension Plan Prior Service Cost [Member] Pension plans with an accumulated benefit obligation in excess of plan assets, fair value of plan assets Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets Use of Estimates Use of Estimates, Policy [Policy Text Block] Adjustment to Compensation, Amount Adjustment to Compensation Amount Other paid-in capital Additional Paid in Capital, Common Stock Acquisition of Prometheus Biosciences, Inc., net of cash acquired Payments to Acquire Business Three, Net of Cash Acquired Compensation Amount Outstanding Recovery Compensation Amount Insurance contracts Insurance Contracts Insurance Contracts Other Investments [Member] Insurance contracts other investments. Disposal Group Classification [Axis] Disposal Group Classification [Axis] Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected Measure Amount Tabular List, Table Tabular List [Table Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Accrued liabilities for environmental matters Accrual for Environmental Loss Contingencies Expected rate of return on plan assets Expected rate of return on plan assets Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets Antidilutive shares (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Legal defense costs reserve Estimated Litigation Liability derazantinib derazantinib [Member] derazantinib LIFO inventory amount LIFO Inventory Amount Asset Acquisition [Axis] Asset Acquisition [Axis] Animal Health Animal Health segment [Member] Animal Health segment [Member] Other fixed income obligations Fixed Income Obligations Investment Funds [Member] Fixed income obligations investment funds. Contingent consideration Asset Acquisition, Consideration Transferred, Contingent Consideration Goodwill Goodwill, beginning balance Goodwill, ending balance Goodwill Royalty percentage Collaborative Arrangement, Rights And Obligations, Royalty Percentage Collaborative Arrangement, Rights And Obligations, Royalty Percentage Other Comprehensive Income (Loss) Net of Taxes: Other Comprehensive Income (Loss), Net of Tax [Abstract] Inventories Inventory Disclosure [Text Block] Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table] Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table] Employee Stock Option Share-Based Payment Arrangement, Option [Member] Schedule of Available-for-sale Securities [Table] Debt Securities, Available-for-Sale [Table] Depreciation Depreciation Depreciation 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Other Proceeds from (Payments for) Other Financing Activities Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items] Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items] Comprehensive Income (Loss) Attributable to Merck & Co., Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent Pension Benefits Pension Plan [Member] Income taxes payable Accrued Income Taxes, Current Real estate Employee Benefit Plan, Real Estate [Member] Other Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Award Type [Axis] Award Type [Axis] Corporate notes and bonds Corporate obligations Corporate Debt Securities [Member] Harpoon Therapeutics, Inc. Harpoon Therapeutics, Inc. [Member] Harpoon Therapeutics, Inc. Total Inventory, Gross Property, plant and equipment, net Property, plant and equipment, net Property, Plant and Equipment, Net ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Liabilities Liabilities Third-Party Third-Party [Member] Third-Party Noncontrolling Interests Equity, Attributable to Noncontrolling Interest Sanofi Pasteur Sanofi Pasteur [Member] Sanofi Pasteur [Member] Weighted Average Exercise Price, Exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Januvia Januvia [Member] Januvia [Member] . Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Legal Entity Type of Counterparty [Domain] Legal Entity Type of Counterparty [Domain] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Foreign Currency Translation Foreign Currency Transactions and Translations Policy [Policy Text Block] Differential arising from: Effective Income Tax Rate Reconciliation, Differential Arising From, Percent [Abstract] Effective Income Tax Rate Reconciliation, Differential Arising From, Percent [Abstract] Expiration Date Trading Arrangement Expiration Date Cash Flows from Investing Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Accrued and other current liabilities Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Amount Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Eligible future contingent development-related payments (up to) Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Contingent Development-Related Payments Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Contingent Development-Related Payments Pension and other postretirement benefit plans, net loss (gain) and prior service (credit) included in AOCI Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax Upfront cash payment Proceeds from Upfront Payment, Cash Proceeds from Upfront Payment, Cash Aggregate upfront payments due upon lapse of time Collaborative Arrangement, Rights And Obligations, Aggregate Upfront Payments Due Upon Lapse Of Time Collaborative Arrangement, Rights And Obligations, Aggregate Upfront Payments Due Upon Lapse Of Time Property, plant and equipment (at cost) Property, Plant and Equipment, Gross Number of Options, Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Settlements Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement Amount of gain recognized in OCI on derivatives Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Prior service credit (cost) arising during the period Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax RotaTeq Rotateq [Member] RotaTeq [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Research and development Research and Development Expense [Member] Lapse of statute of limitations Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations Aggregate possible expenditure on environmental matters in excess of amounts accrued Environmental Exit Costs, Reasonably Possible Additional Loss Average common shares outstanding assuming dilution (in shares) Weighted Average Number of Shares Outstanding, Diluted Expected restructuring and related cost Restructuring and Related Cost, Expected Cost Other (income) expense, net Other Nonoperating Income (Expense) [Member] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Accumulated Other Comprehensive Income (Loss) [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Total Merck & Co., Inc. stockholders’ equity Equity, Attributable to Parent Other pharmaceutical Other Pharmaceutical [Member] Other pharmaceutical. Subtotal, Assets Deferred Tax Assets, Gross Proceeds from issuance of debt Proceeds from Issuance of Debt Collaborative Arrangements Collaborative Arrangement Disclosure [Text Block] Financial Instruments Financial Instruments Disclosure [Text Block] Litigation Case [Axis] Litigation Case [Axis] Currency Options Foreign Exchange Option [Member] Cash recorded for asset acquisition Asset Acquisition, Cash and Equivalents Asset Acquisition, Cash and Equivalents Construction in progress Construction in Progress, Gross Maximum aggregate sales-based milestone payments Asset Acquisition, Maximum Aggregate Sales-Based Milestone Payments Asset Acquisition, Maximum Aggregate Sales-Based Milestone Payments Goodwill Activity by Segment Schedule of Goodwill [Table Text Block] Capitalized Software Software and Software Development Costs [Member] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Selling, general and administrative Selling, General and Administrative Expense Employer contributions to defined contribution savings plans Defined Contribution Plan, Cost Unrealized losses recognized on investments in equity securities without readily determinable fair values Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount Proceeds from sales of securities and other investments Proceeds from Sale and Maturity of Other Investments 4.90% notes due 2044 4.90% notes due 2044 [Member] 4.90% notes due 2044 Cost of sales Cost of Sales [Member] Pneumovax 23 Pneumovax 23 [Member] Pneumovax 23[Member]. Cash and cash equivalents Defined Benefit Plan, Cash and Cash Equivalents [Member] Document Fiscal Period Focus Document Fiscal Period Focus Long-term debt, maturities, repayments of principal in 2028 Long-Term Debt, Maturity, Year Four All Executive Categories All Executive Categories [Member] Statement of Financial Position Location, Balance [Domain] Statement of Financial Position Location, Balance [Domain] Publicly traded equity securities Equity Securities [Member] Charges and Spending Relating to Restructuring Activities by Program Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Acquisition-related costs, including amortization Effective Income Tax Rate Reconciliation, Acquisition-Related Costs And Amortization, Percent Effective Income Tax Rate Reconciliation, Acquisition-Related Costs And Amortization, Percent Estimated aggregate amortization expense, 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Two Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Weighted Average Remaining Contractual Term, Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Maximum aggregate contingent milestone payments, per product Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Contingent Milestone Payments, Per Product Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Contingent Milestone Payments, Per Product Assets Assets [Abstract] Retirement Plan Type [Domain] Retirement Plan Type [Domain] Other comprehensive income (loss), net of taxes Other comprehensive income (loss), net of taxes Other Comprehensive Income (Loss), Net of Tax Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Number of patents allegedly infringed under review Loss Contingency, Patents Allegedly Infringed Under Review, Number Loss Contingency, Patents Allegedly Infringed Under Review, Number Document Type Document Type U.S. equities Defined Benefit Plan, Equity Securities, US [Member] Derivative Contract [Domain] Derivative Contract [Domain] Actuarial (gains) losses Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) Software Capitalization Internal Use Software, Policy [Policy Text Block] Equity Loss from Affiliates and Depreciation Included in Segment Profits Schedule of Segment Reporting Information, by Segment [Table Text Block] Derivative Liability, Statement of Financial Position [Extensible Enumeration] Derivative Liability, Statement of Financial Position [Extensible Enumeration] Number of jurisdictions under interim operating agreement Disposal Group, Including Discontinued Operation, Under Interim Operating Agreement, Number Of Jurisdiction Disposal Group, Including Discontinued Operation, Under Interim Operating Agreement, Number Of Jurisdiction Weighted Average Remaining Contractual Term, Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Other Income and Expenses [Abstract] Other Income and Expenses [Abstract] Defined Benefit Plan [Table] Defined Benefit Plan [Table] Loss contingency, motion for summary judgements granted Loss Contingency, Motion For Summary Judgements Granted, Number Loss Contingency, Motion For Summary Judgements Granted, Number Debt securities, amortized cost Debt Securities, Available-for-Sale, Amortized Cost Sales Sales [Member] Investments recorded for asset acquisition Asset Acquisition, Investments Asset Acquisition, Investments Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Maximum Maximum [Member] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Accumulated goodwill impairment losses Goodwill, Impaired, Accumulated Impairment Loss Intangible assets Finite-lived intangible assets, net Finite-Lived Intangible Assets, Net Trade accounts payable Accounts Payable, Current Loss related to settlement litigation Charge for Zetia antitrust litigation settlements Gain (Loss) from Litigation Settlement Isentress/Isentress HD Isentress/Isentress HD [Member] Isentress/Isentress HD [Member]. Raw materials and work in process Inventory, Work in Process and Raw Materials, Excluding Supplies Inventory, Work in Process and Raw Materials, Excluding Supplies Assumptions Used to Determine Weighted-Average Fair Value of Options Granted Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Statistical Measurement [Axis] Statistical Measurement [Axis] Long-term debt, interest payments in 2027 Long-term Debt, Interest Payable, Year Three Long-term Debt, Interest Payable, Year Three Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Income Before Taxes Income Before Taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6.40% debentures due 2028 6.40% Debentures Due 2028 [Member] 6.40% Debentures Due 2028 Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Accelerated depreciation, Liabilities Deferred Tax Liabilities, Property, Plant and Equipment Name Outstanding Recovery, Individual Name GILTI and the foreign-derived intangible income deduction Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income Foreign Derived Intangible Income Deduction, Amount Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income Foreign Derived Intangible Income Deduction, Amount Decrease to LIFO cost Inventory, LIFO Reserve Loss contingency, claims settled (in cases) Loss Contingency, Claims Settled, Number Consideration transferred Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Award Timing Predetermined Award Timing Predetermined [Flag] Deferred tax assets relating to various U.S. tax credit carryforwards and NOL carryforwards Deferred tax assets credit loss carryforwards and NOL carryforwards domestic Deferred tax assets credit loss carryforwards and NOL carryforwards domestic Subsequent Event Type [Domain] Subsequent Event Type [Domain] Dividends paid to stockholders Payments of Ordinary Dividends, Common Stock Component of Other Income / Expense of Nonoperating [Table] Component of Other Income / Expense of Nonoperating [Table] Component of Other Income / Expense of Nonoperating [Table] Amortization of unrecognized prior service (credit) cost Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Forecast Forecast [Member] Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) Earnings Per Share, Diluted Counterparty Name [Domain] Counterparty Name [Domain] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Domestic Income (Loss) from Continuing Operations before Income Taxes, Domestic 6.55% notes due 2037 6.55% Notes Due 2037 [Member] 6.55% Notes Due 2037 Total current provision Current Income Tax Expense (Benefit) Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Quantity of stock options that vest per year Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage 5.85% notes due 2039 5.85% Notes Due 2039 [Member] 5.85% Notes Due 2039 Acquired Intangibles Intangible Assets, Finite-Lived, Policy [Policy Text Block] Retirement Benefits [Abstract] Retirement Benefits [Abstract] Exchange losses Gain (Loss), Foreign Currency Transaction, before Tax 3.70% notes due 2045 3.70% Notes Due 2045 [Member] 3.70% Notes Due 2045 [Member] Customer [Axis] Customer [Axis] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Winrevair Winrevair [Member] Winrevair Net amounts, liability Derivative Liability, Subject to Master Netting Arrangement, after Offset Inventories Schedule of Inventory, Noncurrent [Table Text Block] Deferred Income Taxes Assets And Liabilities Net [Table] Deferred Income Taxes Assets And Liabilities Net [Table] Deferred Income Taxes Assets And Liabilities Net [Table] R&D tax credit Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount Other, Liabilities Deferred Tax Liabilities, Other Deferred tax assets recorded for asset acquisition Asset Acquisition, Deferred Tax Assets Asset Acquisition, Deferred Tax Assets Net Income Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Inventories Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Amount of Derivative Pretax Loss (Gain) Recognized in Income Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Taxes on Income Taxes on income Income Tax Expense (Benefit) Interest cost Defined Benefit Plan, Interest Cost Available-for-sale debt securities included in Short-term investments Debt Securities, Available-for-Sale, Current Total Swap Notional Amount U.S dollar notional amount Derivative, Notional Amount Fair value of derivative, asset Derivative Asset Weighted average period in years of recognition for nonvested stock options, RSU and PSU awards Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Cash equivalents Cash Equivalents, at Carrying Value Cardinal Health, Inc. Cardinal Health, Inc. [Member] Cardinal Health, Inc. Net Cash Used in Investing Activities Net Cash Provided by (Used in) Investing Activities Number of Shares, Expected to Vest (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Expected to Vest, Number Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Expected to Vest, Number Income Tax Jurisdiction [Axis] Income Tax Jurisdiction [Axis] Business Acquisition [Line Items] Business Acquisition [Line Items] Cumulative costs since inception Restructuring and Related Cost, Cost Incurred to Date All Adjustments to Compensation All Adjustments to Compensation [Member] Short-term Debt, Type [Domain] Short-Term Debt, Type [Domain] 5.95% debentures due 2028 5.95% Debentures Due 2028 [Member] 5.95% Debentures Due 2028 Investments Marketable Securities, Noncurrent Other (Income) Expense, Net Schedule of Other Nonoperating Income (Expense) [Table Text Block] Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Restructuring costs Restructuring costs Restructuring Charges Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] 4.00% notes due 2049 4.00% Notes Due 2049 [Member] 4.00% Notes Due 2049 Estimate of cumulative pre tax costs that will be noncash Estimate Of Cumulative Pre Tax Costs That Will Be Noncash Estimate of cumulative pre tax costs that will be noncash. Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Carrying Amount of Hedged Liabilities Hedged Liability, Fair Value Hedge Simponi Simponi [Member] Simponi [Member]. 4.15% notes due 2043 4.15% Notes Due 2043 [Member] 4.15% Notes Due 2043 [Member] Regulatory milestone payments Collaborative Arrangement, Rights and Obligations, Milestone Payments, Regulatory Collaborative Arrangement, Rights and Obligations, Milestone Payments, Regulatory Compensation earned on arragement Research and Development Arrangement, Contract to Perform for Others, Compensation Earned Scenario [Domain] Scenario [Domain] Related Party Transaction [Axis] Related Party Transaction [Axis] Derivatives Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] U.S. government and agency securities US Government Agencies Debt Securities [Member] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity Address, State or Province Entity Address, State or Province Net periodic defined benefit plan (credit) cost other than service cost Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Other, net Other Nonoperating Income Expense, Other Other nonoperating income and expense items not separately disclosed. Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Defined Benefit Plan, Plan Assets, Category [Domain] Defined Benefit Plan, Plan Assets, Category [Domain] Inventory [Domain] Inventory [Domain] Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Number of unexercised license option antibody drug conjugates Collaborative Arrangement, Rights And Obligations, License Option Unexercised, Number Of Antibody Drug Conjugates Collaborative Arrangement, Rights And Obligations, License Option Unexercised, Number Of Antibody Drug Conjugates Summary of Health Care Cost Trend Rate Assumptions for Other Postretirement Benefit Plans Schedule of Health Care Cost Trend Rates [Table Text Block] Prior service (credit) cost amortization included in benefit cost Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax Financial Instruments [Domain] Financial Instruments [Domain] Keytruda Keytruda [Member] Keytruda [Member] Weighted Average Grant Date Fair Value, Nonvested January 1 (in dollars per share) Weighted Average Grant Date Fair Value, Nonvested December 31 (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Liabilities and Equity Liabilities and Equity [Abstract] Loss contingency, trial period Loss Contingency, Trial Period Loss Contingency, Trial Period Components of Net Periodic Benefit Cost Schedule of Net Benefit Costs [Table Text Block] 3.70% euro-denominated notes due 2044 3.70% Euro Notes Due 2044 [Member] 3.70% Euro Notes Due 2044 Valuation allowances Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Loss contingency, number of plaintiffs Loss Contingency, Number of Plaintiffs Supplemental Balance Sheet Information Lease Assets and Liabilities, Lessee [Table Text Block] Lease Assets and Liabilities, Lessee [Table Text Block] Total pretax restructuring costs Expenses Restructuring and Related Cost, Incurred Cost Restatement Determination Date Restatement Determination Date Number of Options, Vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Alliance revenue - Adempas/Verquvo Alliance revenue - Adempas/Verquvo [Member] Alliance revenue - Adempas/Verquvo Debt securities, available-for-sale, noncurrent Debt Securities, Available-for-Sale, Noncurrent Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Interest rate swap contracts Interest Rate Contract [Member] 3.25% euro-denominated notes due 2032 3.25% Euro Notes Due 2032 [Member] 3.25% Euro Notes Due 2032 Information on Investments in Debt and Equity Securities Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Interest crediting rate Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Weighted-Average Interest Crediting Rate Weighted Average Exercise Price, Options Outstanding, January 1 (in dollars per share) Weighted Average Exercise Price, Options Outstanding, December 31 (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Other Assets Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Number of Options, Outstanding, January 1 (in shares) Number of Options, Outstanding, December 31 (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Number of patents allegedly infringed Loss Contingency, Patents Allegedly Infringed, Number Short-term Debt, Type [Axis] Short-Term Debt, Type [Axis] Royalty Pharma Royalty Pharma [Member] Royalty Pharma Plan amendments Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment Dividends payable Dividends Payable, Current Curtailments Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment Earnings per Share Earnings Per Share [Text Block] Developed markets Developed Markets Equity Securities [Member] Developed markets equity securities. Manufacturing and supply agreements Manufacturing and supply agreements [Member] Manufacturing and supply agreements Subsequent Event Subsequent Event [Member] Costs, Expenses and Other Costs and Expenses [Abstract] R&D tax credit Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent Inventory [Axis] Inventory [Axis] Transition tax liability, current Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability, Current Weighted Average Grant Date Fair Value, Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Product Rights - Clynay Product Rights [Member] Product Rights Taxes on Income Income Tax, Policy [Policy Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Differential arising from: Effective Income Tax Rate Reconciliation, Differential Arising From, Amount [Abstract] Effective Income Tax Rate Reconciliation, Differential Arising From, Amount [Abstract] Restructuring Plan [Axis] Restructuring Plan [Axis] Segments [Domain] Segments [Domain] Reconciliation of Unrecognized Tax Benefits [Roll Forward] Unrecognized Tax Benefits [Roll Forward] Total current and noncurrent inventories Inventory Net And Inventory Noncurrent Total of current and noncurrent inventories. PEO PEO [Member] 2.75% notes due 2051 2.75% notes due 2051 [Member] 2.75% notes due 2051 Name Trading Arrangement, Individual Name Funded status December 31 Defined Benefit Plan, Funded (Unfunded) Status of Plan Notes Subject To Repayment At Option Of Holder Notes Subject To Repayment At Option Of Holder [Member] Notes Subject To Repayment At Option Of Holder [Member] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] 1.375% Notes due 2036 1.375% Notes due 2036 [Member] 1.375% Notes due 2036 [Member] Entity Public Float Entity Public Float Disposal Group Name [Axis] Disposal Group Name [Axis] Equity income from affiliates Income (Loss) from Equity Method Investments Less treasury stock, at cost: 1,049,466,187 shares in 2024 and 1,045,470,249 shares in 2023 Treasury Stock, Common, Value Benefit obligation January 1 Benefit obligation December 31 Defined Benefit Plan, Benefit Obligation Cumulative Amount of Fair Value Hedging Adjustment Increase Included in the Carrying Amount Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease) Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Reasonably possible amount that liability for unrecognized tax benefits could decline up to in next 12 months (up to) Decrease in Unrecognized Tax Benefits is Reasonably Possible Retirement Plan Sponsor Location [Domain] Retirement Plan Sponsor Location [Domain] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Developed markets equities Developed Markets Equities Investment Funds [Member] Developed markets equities investment funds. Ridgeback Biotherapeutics LP Ridgeback Biotherapeutics LP [Member] Ridgeback Biotherapeutics LP First Commercial Sale Milestones First Commercial Sale Milestones [Member] First Commercial Sale Milestones Local Phone Number Local Phone Number Intangible assets, gross carrying amount Intangible Assets, Gross (Excluding Goodwill) Valuation allowance, Assets Deferred Tax Assets, Valuation Allowance Total costs, expenses and other Costs Expenses And Other Total of cost of sales, operating expenses and nonoperating income or expense. Debt, carrying amount Debt, Long-Term and Short-Term, Combined Amount Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Bristol Myers Squibb Bristol Myers Squibb [Member] Bristol Myers Squibb Other Exit Costs Other Restructuring [Member] Regulatory Milestones Regulatory Milestones [Member] Regulatory Milestones [Member] Additional Information Pertaining to Stock Option Plans Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures [Table Text Block] Additional information pertaining to stock option plans. Royalty rate, percentage Royalty Rate, Percentage Royalty Rate, Percentage Net changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] PEO Total Compensation Amount PEO Total Compensation Amount Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Gross amounts recognized in the consolidated balance sheet, liability Derivative Liability, Subject to Master Netting Arrangement, before Offset Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Axis] Income Tax [Line Items] Income Tax [Line Items] Income Tax [Line Items] Weighted Average Exercise Price, Vested and expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Defined Benefit Plan, Plan Assets, Category [Axis] Defined Benefit Plan, Plan Assets, Category [Axis] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Common Stock ($0.50 par value) Common Stock Common Stock [Member] Cash collateral received/posted, liability Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Cash Not Offset Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Summarized Information about the Changes in Liabilities for Contingent Consideration Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Segment Reporting [Abstract] Segment Reporting [Abstract] Entity Central Index Key Entity Central Index Key Scenario [Axis] Scenario [Axis] Inventories Schedule of Inventory, Current [Table Text Block] Option payment made to collaborative partner Option Payment Made to Collaborative Partner Option Payment Made to Collaborative Partner Liabilities for accrued interest and penalties Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Foreign Currency Translation Adjustment Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Legal Entity of Counterparty, Type [Axis] Legal Entity of Counterparty, Type [Axis] Bristol Myers Squibb Company Bristol Myers Squibb Company [Member] Bristol Myers Squibb Company Equity Equity [Text Block] CN201, Curon Biopharmaceutical MK-1045/CN201, Curon Biopharmaceutical [Member] MK-1045/CN201, Curon Biopharmaceutical Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] McKesson Corporation McKesson Corporation [Member] McKesson Corporation Financial Instrument [Axis] Financial Instrument [Axis] Long-term debt, current maturities Long-Term Debt, Current Maturities Segment Reporting Segment Reporting Disclosure [Text Block] 3.60% notes due 2042 3.60% Notes Due 2042 [Member] 3.60% Notes Due 2042 Accrual for chargebacks reflected as direct reduction to accounts receivable Accrual For Chargebacks Accrual for chargebacks reflected as a direction reduction to accounts receivable. Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Title Trading Arrangement, Individual Title Prevymis Prevymis [Member] Prevymis Income Before Taxes Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Unrecognized tax benefits Balance January 1 Balance December 31 Unrecognized Tax Benefits City Area Code City Area Code Transaction costs Asset Acquisition, Consideration Transferred, Transaction Cost Current Liabilities Liabilities, Current [Abstract] Auditor Location Auditor Location 2.500% Notes due 2034 2.500% Notes due 2034 [Member] 2.500% Notes due 2034 [Member] Contingent consideration Contingent consideration, beginning balance Contingent consideration, ending balance Business Combination, Contingent Consideration, Liability Disposal Group Classification [Domain] Disposal Group Classification [Domain] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Milestone payments sales-based Milestone Payments Sales-Based Milestone Payments Sales-Based Components of Other Comprehensive Income (Loss) Schedule of Defined Benefit Plan Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block] Purchases of treasury stock Payments for Repurchase of Common Stock Milestone payment to be made to a collaborative partner Milestone Payment Made to Collaborative Partner Milestone Payment Made to Collaborative Partner Number of antibody drug conjugates Collaborative Arrangement, Number Of Antibody Drug Conjugates Collaborative Arrangement, Number Of Antibody Drug Conjugates Document Information [Line Items] Document Information [Line Items] Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, liability Derivative Liability, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset Undistributed foreign earnings, Liabilities Deferred Tax Liabilities, Undistributed Foreign Earnings Long-Term Debt Long-Term Debt, Excluding Current Maturities Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] GILTI and the foreign-derived intangible income deduction Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income Foreign Derived Intangible Income Deduction, Percent Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income Foreign Derived Intangible Income Deduction, Percent Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Koselugo Koselugo [Member] Koselugo Subsequent Event Type [Axis] Subsequent Event Type [Axis] Collaborative Arrangement, Revenue Not from Contract with Customer, Statement of Income or Comprehensive Income [Extensible Enumeration] Collaborative Arrangement, Revenue Not from Contract with Customer, Statement of Income or Comprehensive Income [Extensible Enumeration] Aggregate, regulatory milestones payments, maximum Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments Earnings Per Share [Abstract] Earnings Per Share [Abstract] Equity [Abstract] Equity [Abstract] Retained earnings Retained Earnings (Accumulated Deficit) Other Goodwill, Translation and Measurement Period Adjustments Class of Stock [Domain] Class of Stock [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Product return period and expiration Revenue Recognition, Goods, Goods Return Period After to Expiration Date Revenue Recognition, Goods, Goods Return Period After to Expiration Date Inventories Increase (Decrease) in Inventories 3.50% euro-denominated notes due 2037 3.50% Euro Notes Due 2037 [Member] 3.50% Euro Notes Due 2037 Unrealized net gains (losses) Equity Securities, FV-NI, Unrealized Gain (Loss) Long-term debt, maturities, repayments of principal in 2026 Long-Term Debt, Maturity, Year Two Payment terms Revenue, Performance Obligation, Payment Terms Revenue, Performance Obligation, Payment Terms Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Total operating lease liability Total operating lease liability Operating Lease, Liability Purchases and sales, net Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement Underlying Securities Award Underlying Securities Amount Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] PSUs Performance Shares [Member] Total Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax Net periodic benefit cost Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract] Cash dividends declared on common stock Dividends, Common Stock, Cash Amendment Flag Amendment Flag Patritumab Deruxtecan Patritumab Deruxtecan [Member] Patritumab Deruxtecan Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Expected annual standard deviation in returns of the target portfolio which reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests Expected Annual Standard Deviation In Returns Of Target Portfolio Which Reflects Both Equity Allocation And Diversification Benefits Among Asset Classes In Which Portfolio Invests Expected annual standard deviation in returns of the target portfolio which reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests. Machinery, equipment and office furnishings Machinery and Equipment [Member] Weighted Average Grant Date Fair Value, Expected to vest (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Expected to Vest, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Expected to Vest, Weighted Average Grant Date Fair Value Proceeds from sale of Seagen Inc. common stock Proceeds from Sale of Equity Securities, FV-NI Other (Income) Expense, Net Other Income and Other Expense Disclosure [Text Block] Other comprehensive income (loss) before reclassification adjustments, net of taxes Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Actual return on plan assets Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) Vehicles Vehicles [Member] Loans Payable, Long-Term Debt and Leases Debt Disclosure [Text Block] Acquisition of Imago BioSciences Inc., net of cash acquired Payments to Acquire Business Two, Net of Cash Acquired Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Other Postretirement Benefit Plan Net Gain Other Postretirement Benefit Plan Net Loss [Member] Other Postretirement Benefit Plan Net Loss [Member] Par Value of Debt Face amount of debt Debt Instrument, Face Amount Government and agency obligations Government And Agency Obligations Fixed Income Securities [Member] Government and agency obligations fixed income securities. Payments of contingent consideration Payments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Entity Address, Postal Zip Code Entity Address, Postal Zip Code Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Advertising and promotion costs Advertising Expense Interest rate swap contracts Interest rate swap contracts Interest Rate Swap [Member] Developmental milestone payment triggered and paid Asset Acquisition, Milestone Payment Triggered and Paid, Development Asset Acquisition, Milestone Payment Triggered and Paid, Development Land Land 4.50% notes due 2033 4.50% notes due 2033 [Member] 4.50% notes due 2033 Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Litigation Status [Axis] Litigation Status [Axis] IPR&D impairment charges Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill) Other Payments for (Proceeds from) Other Investing Activities Other Assets Other Noncurrent Assets [Member] Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] 1.45% notes due 2030 1.45% Notes Due 2030 [Member] 1.45% Notes Due 2030 Auditor Name Auditor Name Tax Reclassification from AOCI, Current Period, Tax Weighted Average Grant Date Fair Value, Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Pretax net unrealized losses on derivatives maturing within the next 12 months estimated to be reclassified from AOCI to sales Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months Current provision Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Accrued and other current liabilities Other Current Liabilities [Member] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Business Acquisition, Contingent Consideration [Line Items] Business Acquisition, Contingent Consideration [Line Items] Inventories Produced in Preparation for Product Launches Inventories Produced in Preparation for Product Launches [Member] Inventories Produced in Preparation for Product Launches [Member] Estimated useful life of property, plant and equipment Property, Plant and Equipment, Useful Life Number of Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Reduction in reserves resulting from lapse of statute of limitations Unrecognized Tax Benefits, Including Accrued Interest, Reduction Resulting from Lapse of Applicable Statute of Limitations Unrecognized Tax Benefits, Including Accrued Interest, Reduction Resulting from Lapse of Applicable Statute of Limitations Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Amortization Amortization Amortization Derivatives Designated as Hedging Instruments Designated as Hedging Instrument [Member] Net income attributable to Merck & Co., Inc., basic Net Income (Loss) Available to Common Stockholders, Basic Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Effects of exchange rate changes Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) Stock, Class of Stock [Table] Stock, Class of Stock [Table] 3.750% Notes due 2054 3.750% Notes Due 2054 [Member] 3.750% Notes Due 2054 Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Machinery, equipment and office furnishings Machinery and Equipment, Gross Pension plans with a projected benefit obligation in excess of plan assets, projected benefit obligation Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation Total Assets Assets Cost of sales Cost of Goods and Services Sold Advertising and Promotion Costs Advertising Cost [Policy Text Block] Transition tax asset, credit, noncurrent Tax Cuts and Jobs Act, Transition Tax Credit for Accumulated Foreign Earnings, Assets, Other, Noncurrent Tax Cuts and Jobs Act, Transition Tax Credit for Accumulated Foreign Earnings, Assets, Other, Noncurrent Valuation allowance on foreign NOL carryforwards Operating Loss Carryforwards, Valuation Allowance Capital expenditures Payments to Acquire Property, Plant, and Equipment Other Noncurrent Liabilities Other Liabilities, Noncurrent Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Derivative Instruments and Hedging Activities Disclosures [Table] Derivative Instruments and Hedging Activities Disclosures [Table] Share-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Janumet Janumet [Member] Janumet [Member]. Reconciliation Between Effective Tax Rate and U.S. Statutory Rate Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Termination Date Trading Arrangement Termination Date Nature of Operations Nature of Operations [Text Block] Financial Assets and Liabilities Measured at Fair Value on Recurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two Long-term debt, maturities, repayments of principal in 2025 Long-Term Debt, Maturity, Year One Derivatives Not Designated as Hedging Instruments Derivatives Not Designated as Hedging Instruments Not Designated as Hedging Instrument [Member] Term for paying off environmental liabilities Term For Paying Off Environmental Liabilities Term for paying off environmental liabilities. Proceeds from collaborators Proceeds from Collaborators Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Debt Instrument [Axis] Debt Instrument [Axis] Schedule Of Other Intangibles [Table] Schedule Of Other Intangibles [Table] Schedule Of Other Intangibles [Table] Cash collateral received from counterparties Cash collateral received/posted, asset Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Cash Not Offset Revenue from collaborative arrangement Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer Net Income Attributable to Merck & Co., Inc. Net Income Attributable to Merck & Co., Inc. Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] 2030 — 2034 Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Adempas Adempas [Member] Adempas Schedule of Allocation of Plan Assets Schedule of Allocation of Plan Assets [Table Text Block] Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Entity File Number Entity File Number Alliance revenue - Lynparza Alliance revenue - Lynparza [Member] Alliance revenue - Lynparza [Member] Summary of Weighted Average Assumptions Used in Determining Pension Plan and U.S. Pension and Other Postretirement Benefit Plan Information Defined Benefit Plan, Assumptions [Table Text Block] nemtabrutinib Nemtabrutinib [Member] Nemtabrutinib Pension plans with a projected benefit obligation in excess of plan assets, fair value of plan assets Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets Non- controlling Interests Noncontrolling Interest [Member] Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Federal Current Federal Tax Expense (Benefit) Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Restructuring Plan [Domain] Restructuring Plan [Domain] Name Forgone Recovery, Individual Name Aggregate Intrinsic Value, Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Operating lease, weighted average remaining lease term Weighted-average remaining lease term (years) Operating Lease, Weighted Average Remaining Lease Term Other unallocated, net Segment Reporting Unallocated Other Expenses Net Other net expenses not allocated to segments. Upfront payment made to collaborative partner Collaborative Arrangement, Rights And Obligations, Upfront Payment Due Upon Execution Collaborative Arrangement, Rights And Obligations, Upfront Payment Due Upon Execution Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Inventory Not Expected to be Sold Within One Year Inventory Not Expected to be Sold Within One Year [Member] Inventory Not Expected to be Sold Within One Year [Member] Investments Investment, Policy [Policy Text Block] Other Other Noncash Income (Expense) Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Summary of Expected Benefit Payments Schedule of Expected Benefit Payments [Table Text Block] Buildings Buildings and Improvements, Gross Reductions for tax positions of prior years Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Orna Therapeutics Orna Therapeutics [Member] Orna Therapeutics 1.375% euro-denominated notes due 2036 1.375% euro-denominated notes due 2036 [Member] 1.375% euro-denominated notes due 2036 [Member] Long-term debt, interest payments in 2029 Long-term Debt, Interest Payable, Year Five Long-term Debt, Interest Payable, Year Five PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Total Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, before Tax Adjustment to Compensation: Adjustment to Compensation [Axis] Accounts Receivable Accounts Receivable [Member] Less: Net Income Attributable to Noncontrolling Interests Net income attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Increase in Sales as a result of AOCL reclassifications Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Number of licensed antibody drug conjugates Collaborative Arrangement, Rights And Obligations, Number Of Licensed Antibody Drug Conjugates Collaborative Arrangement, Rights And Obligations, Number Of Licensed Antibody Drug Conjugates Litigation Case [Domain] Litigation Case [Domain] Benefit plan net gain (loss) and prior service credit (cost), net of amortization Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent Percentage of Company's pension investments categorized as level 3 assets Company Pension Investments Which Are Categorized As Level Three Assets Percentage Company pension investments which are categorized as level three assets percentage. Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Cash, cash equivalents, and restricted cash Restricted Cash and Cash Equivalents Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Related Party [Axis] Related and Nonrelated Parties [Axis] Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Inventory classified in Other assets Other Assets Inventory, Noncurrent Inventory donations Effective Income Tax Rate Reconciliation, Deduction, Inventory Donations, Amount Effective Income Tax Rate Reconciliation, Deduction, Inventory Donations, Amount Document Information [Table] Document Information [Table] Total equity Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Property, plant and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Target allocation Defined Benefit Plan, Plan Assets, Target Allocation, Percentage Maximum planning cycle of hedges (less than) Derivative, Average Remaining Maturity Name Awards Close in Time to MNPI Disclosures, Individual Name Patritumab Deruxtecan and Ralduotatug Deruxtecan Patritumab Deruxtecan and Ralduotatug Deruxtecan [Member] Patritumab Deruxtecan and Ralduotatug Deruxtecan Number of Options, Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period 3.75% euro-denominated notes due 2054 3.75% Euro Notes Due 2054 [Member] 3.75% Euro Notes Due 2054 Entity Filer Category Entity Filer Category Unrecognized tax benefits, Assets Deferred Tax Assets Unrecognized Tax Benefits Deferred tax assets unrecognized tax benefits. Product return period Revenue Recognition, Goods, Goods Return Period Prior to Expiration Date Revenue Recognition, Goods, Goods Return Period Prior to Expiration Date Loss Contingencies [Line Items] Loss Contingencies [Line Items] Acquisition of Eyebiotech Limited, net of cash acquired Payments to Acquire Business Five, Net of Cash Acquired Payments to Acquire Business Five, Net of Cash Acquired Acquisitions Goodwill, Acquired During Period Statistical Measurement [Domain] Statistical Measurement [Domain] Debt securities, gross unrealized losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Future regulatory milestone payments (up to) Asset Acquisition, Maximum Aggregate Regulatory Milestone Payments Asset Acquisition, Maximum Aggregate Regulatory Milestone Payments Delstrigo Delstrigo [Member] Delstrigo Collaborative Arrangements [Abstract] Collaborative Arrangements [Abstract] Collaborative Arrangements [Abstract] Aggregate upfront payments due upon execution in collaborative arrangement Collaborative Arrangement, Rights And Obligations, Aggregate Upfront Payments Due Upon Execution Collaborative Arrangement, Rights And Obligations, Aggregate Upfront Payments Due Upon Execution Accrued and other current liabilities Other Liabilities, Current Favorable net impact to income tax provision if unrecognized tax benefits were recognized Unrecognized Tax Benefits that Would Impact Effective Tax Rate Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Hedged Liability, Statement of Financial Position [Extensible Enumeration] Hedged Liability, Statement of Financial Position [Extensible Enumeration] All Trading Arrangements All Trading Arrangements [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Calculations of Earnings Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Contractual term of options Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Derivative [Line Items] Derivative [Line Items] Pay vs Performance Disclosure [Line Items] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Long-term debt, interest payments in 2026 Long-term Debt, Interest Payable, Year Two Long-term Debt, Interest Payable, Year Two Derivative [Table] Derivative [Table] Income Tax Contingency [Table] Income Tax Contingency [Table] Reblozyl Alliance revenue - Reblozyl Reblozyl [Member] Reblozyl Moderna Moderna, Inc. [Member] Moderna, Inc. Restructuring Costs Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block] Deferred provision Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Patent extension, term Patent Extension, Term Patent Extension, Term Fair Value of Derivatives on a Gross Basis Segregated Between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Interest crediting rate Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Weighted-Average Interest Crediting Rate Other Increase (Decrease) in Other Operating Assets and Liabilities, Net Other Performance Measure, Amount Other Performance Measure, Amount Salary growth rate Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase Estimated aggregate amortization expense, 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Three Goodwill [Line Items] Goodwill [Line Items] Loans Payable, Long-Term Debt and Leases Lessee, Operating Leases [Text Block] Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Operating lease, cost Operating Lease, Cost Tax settlements and statute lapses Effective Income Tax Rate Reconciliation, Tax Settlement, Amount Bayer AG Bayer AG [Member] Bayer AG [Member] Discontinued Operations, Disposed of by Means Other than Sale, Spinoff Discontinued Operations, Disposed of by Means Other than Sale, Spinoff [Member] Shares collectively authorized for future grants under share-based compensation plans (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Other Noncurrent Liabilities Operating Lease, Liability, Noncurrent Benefits paid Defined Benefit Plan, Benefit Obligation, Benefits Paid Liable contracted portion amount of research and development expenses to incur costs for Collaborative Arrangement, Rights And Obligations, Liable Contracted Portion Amount Of Research And Development Expenses To Incur Costs For Collaborative Arrangement, Rights And Obligations, Liable Contracted Portion Amount Of Research And Development Expenses To Incur Costs For Contingent developmental milestone payments Collaborative Arrangement, Rights and Obligations, Milestone Payments, Developmental-Related Collaborative Arrangement, Rights and Obligations, Milestone Payments, Developmental-Related Service cost Defined Benefit Plan, Service Cost Long-term debt, interest payments in 2028 Long-term Debt, Interest Payable, Year Four Long-term Debt, Interest Payable, Year Four Other assets and liabilities, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other, Net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other, Net Entity Tax Identification Number Entity Tax Identification Number Intangible Asset, Finite-Lived [Table] Intangible Asset, Finite-Lived [Table] Schedule of Long-term Debt Instruments Schedule of Long-Term Debt Instruments [Table Text Block] Additions related to prior year positions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Purchases of treasury stock (in shares) Treasury Stock, Shares, Acquired Foreign Deferred Foreign Income Tax Expense (Benefit) Retirement Plan Type [Axis] Retirement Plan Type [Axis] Rate to which the cost trend rate is assumed to decline Defined Benefit Plan, Ultimate Health Care Cost Trend Rate Selling, general and administrative Selling, General and Administrative Expenses [Member] Salary growth rate Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase Other Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Other Change Patents Patents [Member] Treasury Stock Treasury Stock, Common [Member] Legal Defense Costs Legal Defense Costs [Member] Legal Defense Costs [Member] Equity Components [Axis] Equity Components [Axis] Other current assets Other Assets, Current Research and Development Research and Development Expense, Policy [Policy Text Block] Debt securities, fair value Investments Debt Securities, Available-for-Sale Trade names Trade Names [Member] Customer discounts Sales Discounts Sales Discounts Derivative asset, notional amount Derivative Asset, Notional Amount AstraZeneca AstraZeneca [Member] AstraZeneca [Member] Audit Information [Abstract] Audit Information [Abstract] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Aggregate Intrinsic Value, Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Product rights Developed Technology Rights [Member] Geographical [Axis] Geographical [Axis] Charges Related to Restructuring Program Activities by Type of Cost Restructuring and Related Costs [Table Text Block] Deferred income taxes, Assets Deferred Tax Assets, Net Accounts Receivable Factoring Collections Accounts Receivable Factoring Collections [Member] Accounts Receivable Factoring Collections Period of continuing involvement after disposal Discontinued Operation, Period of Continuing Involvement after Disposal 2029 Lessee, Operating Lease, Liability, to be Paid, Year Five Europe, Middle East and Africa EMEA [Member] Derivatives Defined Benefit Plan, Derivative [Member] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Contingent consideration, liability, current Business Combination, Contingent Consideration, Liability, Current Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] (Payments) receipts, net Payments for Restructuring Undistributed foreign earnings, Assets Deferred Tax Assets, Undistributed Foreign Earnings Deferred Tax Assets, Undistributed Foreign Earnings Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes $68, $79 and $71 of restricted cash at January 1, 2024, 2023 and 2022, respectively, included in Other current assets) Cash, Cash Equivalents and Restricted Cash at End of Year (includes $76, $68 and $79 of restricted cash at December 31, 2024, 2023 and 2022, respectively, included in Other current assets) Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Equity securities Equity Securities, FV-NI, Current Alliance revenue - Koselugo Alliance revenue - Koselugo [Member] Alliance revenue - Koselugo LM-299, LaNova Medicines Ltd MK-2010 (LM-299), LaNova Medicines Ltd [Member] MK-2010 (LM-299), LaNova Medicines Ltd Total pre tax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Foreign Current Foreign Tax Expense (Benefit) Net gain (loss) arising during the period Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax Current Assets Assets, Current [Abstract] Consolidation Items [Axis] Consolidation Items [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] 3.700% Notes due 2044 3.700% Notes Due 2044 [Member] 3.700% Notes Due 2044 Mortgage and asset-backed securities Mortgage And Asset Backed Securities Fixed Income Securities [Member] Mortgage and asset backed securities fixed income securities. 3.40% notes due 2029 3.40% Notes Due 2029 [Member] 3.40% Notes Due 2029 Treasury stock, shares (in shares) Balance January 1, treasury stock (in shares) Balance December 31, treasury stock (in shares) Treasury Stock, Common, Shares Derivatives designated as hedging instruments Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Product and Service [Domain] Product and Service [Domain] Weighted-average interest rate of commercial paper Short-Term Debt, Weighted Average Interest Rate, over Time Effect of Net Investment Hedges Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Weighted Average Grant Date Fair Value, Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Goodwill [Roll Forward] Goodwill [Roll Forward] Number of Interest Rate Swaps Held Number of Interest Rate Derivatives Held Short-term investments Marketable Securities, Current Relating to assets still held at December 31 Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Actual Return (Loss) on Plan Assets Still Held Consolidated Revenues by Geographic Area Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block] Security Exchange Name Security Exchange Name Related Party Transaction [Domain] Related Party Transaction [Domain] Property, Plant and Equipment, Net by Geographic Area Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block] Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Member] Weighted Average Exercise Price, Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 2.15% notes due 2031 2.15% notes due 2031 [Member] 2.15% notes due 2031 Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] State Current State and Local Tax Expense (Benefit) Settled Litigation Settled Litigation [Member] Settlements and curtailments Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement And Curtailment Gain (Loss), Reclassification Adjustment From AOCI, Before Tax Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement And Curtailment Gain (Loss), Reclassification Adjustment From AOCI, Before Tax Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Research and development Research and development Research and Development Expense Securities, fair value, which are subject to a contractual sale restriction Equity Security, FV-NI, Contractual Sale Restriction Revenue related to the sale of the marketing rights Proceeds from Sale of Intangible Assets Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Common stock, shares issued (in shares) Balance January 1, common stock (in shares) Balance December 31, common stock (in shares) Common Stock, Shares, Issued Other Assets Other Assets [Member] Net loss (gain) amortization included in benefit cost Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax Income taxes payable Increase (Decrease) in Income Taxes Payable Available borrowing capacity under credit facility Line of Credit Facility, Maximum Borrowing Capacity Percentage of accounts receivable represented by customers with largest balances Concentration Risk, Percentage Fair value of derivative, liability Derivative Liability Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Less: accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Funded Status of Selected Pension Plans Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block] Relating to assets sold during the year Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Actual Return (Loss) on Plan Assets Sold Restructuring Program, 2024 and 2019 Restructuring Program, 2024 and 2019 [Member] Restructuring Program, 2024 and 2019 Common stock, authorized (in shares) Common Stock, Shares Authorized Acquisition of Harpoon Therapeutics, Inc., net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Product intangibles and licenses, Assets Deferred Tax Assets, Goodwill and Intangible Assets Derivative liability, notional amount Derivative Liability, Notional Amount Settlements Defined Benefit Plan, Plan Assets, Payment for Settlement Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] 2024 Restructuring Program Restructuring Program, 2024 [Member] Restructuring Program, 2024 Entity Voluntary Filers Entity Voluntary Filers Related Party Related Party [Member] Net loss (gain) amortization Defined Benefit Plan, Amortization of Gain (Loss) Lessee, operating lease, renewal term Lessee, Operating Lease, Renewal Term Interest expense Interest expense Interest Expense, Nonoperating Statement of Financial Position Location, Balance [Axis] Statement of Financial Position Location, Balance [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Deferred income taxes Total deferred provision Deferred Income Tax Expense (Benefit) Discount rate Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate Settlements Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement Tax benefits relating to stock option exercises Share-Based Payment Arrangement, Exercise of Option, Tax Benefit Loans payable and current portion of long-term debt Debt, Current Other comprehensive income (loss), net of taxes Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Income Tax Contingency [Line Items] Income Tax Contingency [Line Items] Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Accounts receivable (net of allowance for doubtful accounts of $89 in 2024 and $88 in 2023) Accounts Receivable, after Allowance for Credit Loss, Current Belsomra Belsomra [Member] Belsomra [Member] Number of Options, Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Revenues from External Customers and Long-Lived Assets [Line Items] Revenues from External Customers and Long-Lived Assets [Line Items] Noncurrent liabilities Increase (Decrease) in Other Operating Liabilities Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Fair value of plan assets Fair value of plan assets January 1 Fair value of plan assets December 31 Plan assets at fair value Defined Benefit Plan, Plan Assets, Amount Alliance revenue - Lenvima Lenvima Lenvima [Member] Lenvima [Member] Funds collected from factoring of receivable, held in restricted cash Restricted Cash, Current Commercial paper Commercial Paper [Member] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Dr. Scholl's Dr. Scholl's [Member] Dr. Scholl's Document Annual Report Document Annual Report Restructuring costs Restructuring Charges [Member] 1.875% Notes due 2026 1.875% Notes due 2026 [Member] 1.875% Notes due 2026 [Member] 3.50% Notes due 2037 3.50% Notes due 2037 [Member] 3.50% Notes due 2037 Number of Shares, Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Indefinite-lived intangible assets IPR&D intangible asset Indefinite-Lived Intangible Assets (Excluding Goodwill) Amortization expense for intangible assets Amortization of Intangible Assets Outside of the United States Non-US [Member] Accounting Policies [Abstract] Accounting Policies [Abstract] Contingencies and Legal Defense Costs Commitments and Contingencies, Policy [Policy Text Block] Effective interest rate Long-Term Debt, Percentage Bearing Variable Interest, Percentage Rate Current Fiscal Year End Date Current Fiscal Year End Date Less: Imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Pifeltro Pifeltro [Member] Pifeltro Other net liabilities recorded for asset acquisition Asset Acquisition, Net Liabilities, Other Asset Acquisition, Net Liabilities, Other PEO Name PEO Name Collaborative Arrangement, Transaction with Party to Collaborative Arrangement Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member] Inventory [Table] Inventory [Table] Inventory [Table] Award Type [Domain] Award Type [Domain] Licenses and other Licenses and Other [Member] Licenses and Other Tax Other Comprehensive Income (Loss) before Reclassifications, Tax Issuances (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Licensing Agreements Licensing Agreements [Member] Other Defined Benefit Plan Other Changes Plan Assets Changes in plan assets, not otherwise separately disclosed in the financial statements. Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Other Noncurrent Liabilities Liability, Defined Benefit Plan, Noncurrent Other Intangibles Schedule of Intangible Assets and Goodwill [Table Text Block] Non-PEO NEO Non-PEO NEO [Member] Estimated useful life of intangible assets Finite-Lived Intangible Asset, Useful Life Other Paid-In Capital Additional Paid-in Capital [Member] Number of antibody drug conjugates obtained right and obligations Collaborative Arrangement, Rights And Obligations, Number of Antibody Drug Conjugates Collaborative Arrangement, Rights And Obligations, Number of Antibody Drug Conjugates Recognized as: Recognized As [Abstract] Recognized as. Imago BioSciences, Inc. Imago BioSciences, Inc. [Member] Imago BioSciences, Inc. Pension and Other Postretirement Benefit Plans Retirement Benefits [Text Block] Class of Stock [Line Items] Class of Stock [Line Items] Other Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Recently Adopted Accounting Standards and Recently Issued Accounting Standards Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Class of Stock [Axis] Class of Stock [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Type of Restructuring [Domain] Type of Restructuring [Domain] Intangible Assets Excluding Goodwill [Line Items] Intangible Assets Excluding Goodwill [Line Items] Intangible Assets Excluding Goodwill [Line Items] Number of operating segments Number of Operating Segments Raludotatug Deruxtecan Raludotatug Deruxtecan [Member] Raludotatug Deruxtecan Income taxes paid Income Taxes Paid Pending Litigation Pending Litigation [Member] Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Separation Costs Employee Severance [Member] China CHINA Restructuring Restructuring and Related Activities Disclosure [Text Block] Contingent consideration, measurement input, discount rate Business Combination, Contingent Consideration, Liability, Measurement Input Share-based compensation Pretax share-based compensation cost recorded, related to continuing operations Share-Based Payment Arrangement, Noncash Expense The Johns Hopkins University The Johns Hopkins University [Member] The Johns Hopkins University Elanco Animal Health Incorporated Aqua Business Elanco Animal Health Incorporated Aqua Business [Member] Elanco Animal Health Incorporated Aqua Business Summary of Nonvested RSU and PSU Activity Share-Based Payment Arrangement, Activity [Table Text Block] Noxafil Noxafil [Member] Noxafil [Member]. Total deferred taxes Deferred Tax Assets, Net of Valuation Allowance NAV Fair Value Measured at Net Asset Value Per Share [Member] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Employee Benefit Plans Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Stock investment in counterparty Collaborative Arrangement, Stock Investment In Counterparty Collaborative Arrangement, Stock Investment In Counterparty Stated interest rate Stated interest rate Debt Instrument, Interest Rate, Stated Percentage Other Other profits Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] Net income attributable to Merck & Co., Inc., diluted Net Income (Loss) Available to Common Stockholders, Diluted Settlements Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities Location and Pretax Gain or Loss Amounts for Derivatives Derivative Instruments, Gain (Loss) [Table Text Block] R&D capitalization, Assets Deferred Tax Asset, In-Process Research and Development Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Acquisition of Prometheus Income Tax Rate Reconciliation, Asset Acquisition Three, Amount Income Tax Rate Reconciliation, Asset Acquisition Three, Amount Auditor Firm ID Auditor Firm ID ProQuad/M-M-R II/Varivax ProQuad MMR II Varivax [Member] ProQuad/M-M-R II/Varivax [Member]. Total, Tax Rate Effective Income Tax Rate Reconciliation, Percent Valuation allowances Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Payment terms, vaccine sales Revenue, Performance Obligation, Vaccine Sales, Payment Terms Revenue, Performance Obligation, Vaccine Sales, Payment Terms Total Liabilities and Equity Liabilities and Equity Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Cash And Other Investments Defined Benefit Plan, Cash and Other Investments [Member] Defined Benefit Plan, Cash and Other Investments [Member] Deferred tax assets on NOL carryforwards relating to foreign jurisdictions Deferred Tax Assets, Operating Loss Carryforwards, Foreign International equities Defined Benefit Plan, Equity Securities, Non-US [Member] Hedging Designation [Axis] Hedging Designation [Axis] Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis Offsetting Assets And Liabilities [Table Text Block] Tabular disclosure of derivative positions subject to master netting arrangements as if they were presented on a net basis. Upfront payment made to collaborative partner Upfront Payment Made to Collaborative Partner Upfront Payment Made to Collaborative Partner Interest income Interest income Investment Income, Interest Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Total debt and publicly traded equity securities, fair value Debt Securities and Equity Securities, FV-NI Debt Securities and Equity Securities, FV-NI Aqua manufacturing facilities Aqua Manufacturing Facilities Aqua Manufacturing Facilities Commercial and Other Litigation Commercial and Other Litigation [Member] Commercial and Other Litigation [Member] Right-of-use asset obtained in exchange for operating lease liability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Underlying Security Market Price Change Underlying Security Market Price Change, Percent Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets 2019 Restructuring Program Restructuring Program, 2019 [Member] Restructuring Program, 2019 Individual: Individual [Axis] Accumulated Other Comprehensive Loss Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] 3.90% notes due 2039 3.90% Notes Due 2039 [Member] 3.90% Notes Due 2039 Non-cash activity Restructuring Reserve, Increase (Decrease) Noncash Activity Noncash activity affecting the restructuring reserve, including accelerated depreciation. Weighted Average Exercise Price, Forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 1.90% notes due 2028 1.90% notes due 2028 [Member] 1.90% notes due 2028 Expected life (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Inventories (excludes inventories of $4,193 in 2024 and $3,348 in 2023 classified in Other assets - see Note 7) Inventories Inventory, Net 3.70% Notes due 2044 3.70% Notes due 2044 [Member] 3.70% Notes due 2044 Product and Service [Axis] Product and Service [Axis] Statement [Line Items] Statement [Line Items] Summary of Common Stock and Treasury Stock Transactions Schedule of Stockholders Equity [Table Text Block] Reconciliation of Segment Profits to Income Before Taxes Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Total identifiable net assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Benefits paid Defined Benefit Plan, Plan Assets, Benefits Paid Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Term of derivative contract Derivative, Term of Contract 2.90% notes due 2061 2.90% notes due 2061 [Member] 2.90% notes due 2061 Asia Pacific (other than China and Japan) Asia Pacific [Member] Pension Plan Net Loss Pension Plan Net Loss [Member] Pension Plan Net Loss [Member] Minimum Minimum [Member] Adoption Date Trading Arrangement Adoption Date Cencora, Inc. Cencora, Inc. [Member] Cencora, Inc. Funded Status of Selected Pension Plans Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Table Text Block] 5.00% notes due 2053 5.00% Notes Due 2053 [Member] 5.00% Notes Due 2053 Segments [Axis] Segments [Axis] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Tax Period [Axis] Tax Period [Axis] Preferred stock investment in counterparty Collaborative Arrangement, Preferred Stock Investment In Counterparty Collaborative Arrangement, Preferred Stock Investment In Counterparty U.S. statutory rate applied to income before taxes Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Inventory [Line Items] Inventory [Line Items] Derivative Instrument [Axis] Derivative Instrument [Axis] Exercise Price Award Exercise Price Deferred Income Taxes Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Liable contracted portion amount of research and development expenses to incur costs for, percentage Collaborative Arrangement, Rights And Obligations, Liable Contracted Portion Amount Of Research And Development Expenses To Incur Costs For, Percentage Collaborative Arrangement, Rights And Obligations, Liable Contracted Portion Amount Of Research And Development Expenses To Incur Costs For, Percentage Refundable upfront payments Collaborative Arrangement, Rights And Obligations, Refundable Upfront Payments Collaborative Arrangement, Rights And Obligations, Refundable Upfront Payments Health care cost trend rate assumed for next year Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year Arrangement Duration Trading Arrangement Duration Restructuring Effective Income Tax Rate Reconciliation, Nondeductible Expense, Restructuring Charges, Percent Goodwill and Other Intangibles Goodwill and Intangible Assets Disclosure [Text Block] Contingent consideration dependent upon technology transfer Asset Acquisition, Contingent Consideration Received Upon Transfer Of Technology Asset Acquisition, Contingent Consideration Received Upon Transfer Of Technology Merck & Co., Inc. Stockholders’ Equity Equity, Attributable to Parent [Abstract] Federal Domestic Tax Jurisdiction [Member] Investments Investments Derivative Asset, Statement of Financial Position [Extensible Enumeration] Derivative Asset, Statement of Financial Position [Extensible Enumeration] Lynparza Lynparza [Member] Lynparza [Member] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Consideration transferred, to settle equity awards, unvested Asset Acquisition, Consideration Transferred, Equity Interest Settled, Unvested Asset Acquisition, Consideration Transferred, Equity Interest Settled, Unvested Trade accounts payable Increase (Decrease) in Accounts Payable, Trade Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, asset Derivative Asset, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset Estimated aggregate amortization expense, 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Four Equity Funds Equity Funds [Member] All Individuals All Individuals [Member] Acquisition-related costs, including amortization Effective Income Tax Rate Reconciliation, Acquisition-Related Costs And Amortization, Amount Effective Income Tax Rate Reconciliation, Acquisition-Related Costs And Amortization, Amount Buildings Building [Member] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Zetia antitrust litigation Zetia antitrust litigation [Member] Zetia antitrust litigation [Member] Fair value of loans payable and long-term debt, including current portion Debt Instrument, Fair Value Disclosure Effects of exchange rate changes Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) Other Variable Rate Debt Other Variable Rate Debt [Member] Other Variable Rate Debt [Member] Other (income) expense, net Other (income) expense, net Other segment items Other Nonoperating Income (Expense) Acquisitions, Divestitures, Research Collaborations and Licensing Agreements Acquisitions Research Collaborations And License Agreements [Text Block] Information related to acquisitions, research collaborations and license agreements. Other Postretirement Benefits Other Postretirement Benefits Plan [Member] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Other Intangibles, Net Intangible assets, net Other intangibles, net Intangible Assets, Net (Excluding Goodwill) Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax 5.15% notes due 2063 5.15% Notes Due 2063 [Member] 5.15% Notes Due 2063 Probable contingent payments Collaborative Arrangement, Rights and Obligations, Probable Contingent Payments Collaborative Arrangement, Rights and Obligations, Probable Contingent Payments Fixed Income Investments Fixed Income Investments [Member] Debt securities, gross unrealized gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Curtailments Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Curtailment Alliance Revenue-Reblozyl Alliance Revenue-Reblozyl [Member] Alliance Revenue-Reblozyl Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] Contractual payment Collaborative Arrangement, Rights And Obligations, Contractual Payment Collaborative Arrangement, Rights And Obligations, Contractual Payment Accrued and other current liabilities Liability, Defined Benefit Plan, Current Inventory related, Liabilities Deferred Tax Liabilities, Inventory Pensions and other postretirement benefits, Liabilities Deferred Tax Liabilities Pensions And Other Postretirement Benefit Plans Amount of deferred tax liability attributable to taxable temporary differences from pensions and other postretirement benefits. Assets Assets, Fair Value Disclosure [Abstract] Related Party [Domain] Related and Nonrelated Parties [Domain] Other Noncurrent Liabilities Liabilities, Noncurrent Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Qui Tam Qui Tam [Member] Qui Tam gefapixant Gefapixant [Member] Gefapixant HS-10535 Hansoh Pharma MK-4082 (HS-10535) Hansoh Pharma [Member] MK-4082 (HS-10535) Hansoh Pharma Deferred Income Taxes Deferred Income Taxes Deferred Income Tax Liabilities, Net Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Foreign earnings Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Retirement Plan Sponsor Location [Axis] Retirement Plan Sponsor Location [Axis] Period over which share-based payment awards vest Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period Acquisition of Prometheus Effective Income Tax Rate Reconciliation, Asset Acquisition Three, Percent Effective Income Tax Rate Reconciliation, Asset Acquisition Three, Percent Product rights and other Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Eyebiotech Limited Eyebiotech Limited [Member] Eyebiotech Limited Federal Deferred Federal Income Tax Expense (Benefit) Other Postretirement Benefit Plan Prior Service Credit Other Postretirement Benefit Plan Prior Service Cost [Member] Other Postretirement Benefit Plan Prior Service Cost [Member] Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Intangible asset impairment charge related to finite-lived intangible asset Impairment of Intangible Assets, Finite-Lived Contingencies and Environmental Liabilities Commitments and Contingencies Disclosure [Text Block] Defined Benefit Plan, Change in Benefit Obligation [Roll Forward] Defined Benefit Plan, Change in Benefit Obligation [Roll Forward] Measure: Measure [Axis] Depreciation Depreciation, Depletion, and Amortization [Policy Text Block] Additions related to current year positions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Other Other Countries [Member] Other Countries [Member] Preferred stock, authorized (in shares) Preferred Stock, Shares Authorized Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax 2025 Defined Benefit Plan, Expected Future Benefit Payment, Year One Entity Emerging Growth Company Entity Emerging Growth Company Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Charges for certain research and development asset acquisitions Effective Income Tax Rate Reconciliation, Asset Acquisition Two, Percent Effective Income Tax Rate Reconciliation, Asset Acquisition Two, Percent Total liabilities Liabilities, Fair Value Disclosure 4.05% notes due 2028 4.05% Notes Due 2028 [Member] 4.05% Notes Due 2028 Other Other Other Investments [Member] Long-term debt, maturities, repayments of principal in 2029 Long-Term Debt, Maturity, Year Five Net operating losses and other tax credit carryforwards, Assets Deferred Tax Assets Operating Loss Carryforwards And Other Tax Credit Carryforwards Deferred tax assets operating loss carryforwards and other tax credit carryforwards. Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Other Product Rights Other Product Rights [Member] Other Product Rights Reclassification adjustments, pretax Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax Pension plans with an accumulated benefit obligation in excess of plan assets, accumulated benefit obligation Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation Equity Component [Domain] Equity Component [Domain] Environmental Loss Contingency Statement Of Financial Position Extensible Enumeration Not Disclosed Flag Environmental Loss Contingency Statement Of Financial Position Extensible Enumeration Not Disclosed Flag Environmental Loss Contingency Statement Of Financial Position Extensible Enumeration Not Disclosed Flag Japan JAPAN Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Reclassification adjustments, net of taxes Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Changes in estimated fair value Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code 2028 Defined Benefit Plan, Expected Future Benefit Payment, Year Four Restructuring Effective Income Tax Rate Reconciliation, Nondeductible Expense, Restructuring Charges, Amount SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Verquvo Verquvo [Member] Verquvo Statement [Table] Statement [Table] Sales milestone payments Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Sales-Based Milestone Payments Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Sales-Based Milestone Payments Measurement Frequency [Domain] Measurement Frequency [Domain] Counterparty Name [Axis] Counterparty Name [Axis] Summary of Accounting Policies Significant Accounting Policies [Text Block] Consolidation Items [Domain] Consolidation Items [Domain] Ifinatamab Deruxtecan Ifinatamab Deruxtecan [Member] Ifinatamab Deruxtecan Other Other Long Term Debt [Member] Other long term debt. Income Statement Effects of Derivatives Not Designated as Hedging Instruments Derivatives Not Designated as Hedging Instruments [Table Text Block] Net amounts, asset Derivative Asset, Subject to Master Netting Arrangement, after Offset Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Cumulative upward price adjustment Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount Level 1 Fair Value, Inputs, Level 1 [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Total current assets Other current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Senior Notes Senior Notes [Member] Tax settlements and statute lapses Effective Income Tax Rate Reconciliation, Tax Settlement, Percent Factored accounts receivable Accounts Receivable, Sale Compensation related, Assets Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation Accrued and other current liabilities Increase (Decrease) in Accrued Liabilities Net assets acquired Asset Acquisition, Assets Acquired And Liabilities Assumed, Net Asset Acquisition, Assets Acquired And Liabilities Assumed, Net Tax Period [Domain] Tax Period [Domain] Number of Options, Exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Long-term debt, maturities, repayments of principal in 2027 Long-Term Debt, Maturity, Year Three Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Government and agency obligations Government And Agency Obligations Investment Funds [Member] Government and agency obligations investment funds. Company contributions Defined Benefit Plan, Plan Assets, Contributions by Employer Weighted average fair value of options granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Equity investments without readily determinable fair values Equity Securities without Readily Determinable Fair Value, Amount Lessee, operating lease, lease not yet commenced, amount Unrecorded Unconditional Purchase Obligation Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Taxes on Income Income Tax Disclosure [Text Block] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Four Sales of Company's Products Revenue from External Customers by Products and Services [Table Text Block] Euro-denominated notes Euro-dominated Notes [Member] Euro-dominated Notes [Member] Cumulative downward price adjustment Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount Number of exercised license option antibody drug conjugates Collaborative Arrangement, Rights And Obligations, License Option Exercised, Number Of Antibody Drug Conjugates Collaborative Arrangement, Rights And Obligations, License Option Exercised, Number Of Antibody Drug Conjugates Corporate obligations Corporate Obligations Fixed Income Securities [Member] Corporate obligations fixed income securities. Domestic Plan Domestic Plan [Member] Acquired In-Process Research and Development In Process Research and Development, Policy [Policy Text Block] Royalty rate, deduction, percentage Royalty Rate, Deduction, Percentage Royalty Rate, Deduction, Percentage Other Noncurrent Liabilities Other Noncurrent Liabilities [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Weighted-average discount rate Operating Lease, Weighted Average Discount Rate, Percent Aggregate contingent developmental, regulatory, and sales-based-related payments Asset Acquisition, Maximum Aggregate Contingent Development, Regulatory, and Sales-Based-Related Payments Asset Acquisition, Maximum Aggregate Contingent Development, Regulatory, and Sales-Based-Related Payments Net Cash Used in Financing Activities Net Cash Provided by (Used in) Financing Activities Bridion Bridion [Member] Bridion [Member]. Eisai Eisai [Member] Eisai [Member] Entity Registrant Name Entity Registrant Name Cash paid for acquisition of business Payments to Acquire Businesses, Gross Supplies Other Inventory, Supplies, Gross Welireg Welireg [Member] Welireg Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Cumulative translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent State Deferred State and Local Income Tax Expense (Benefit) Fair Value as of Grant Date Award Grant Date Fair Value Int’l International [Member] International [Member] Foreign earnings Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount Customer Concentration Risk Customer Concentration Risk [Member] Other Assets Assets for Plan Benefits, Defined Benefit Plan Aggregate Intrinsic Value, Vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Level 2 Fair Value, Inputs, Level 2 [Member] Geographical [Domain] Geographical [Domain] Capitalization of shared costs Prepaid Expense and Other Assets Collaborative Arrangements Collaborative Arrangement, Accounting Policy [Policy Text Block] Principles of Consolidation Consolidation, Policy [Policy Text Block] Restructuring Cost [Table] Restructuring Cost [Table] Restatement Determination Date: Restatement Determination Date [Axis] Lyfnua Lyfnua [Member] Lyfnua Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Movement in Common Stock and Treasury Stock [Roll Forward] Movement in Common Stock and Treasury Stock [Roll Forward] Movement in Common Stock and Treasury Stock [Roll Forward] Title of 12(b) Security Title of 12(b) Security Concentration Risk Type [Axis] Concentration Risk Type [Axis] Pharmaceutical Pharmaceutical segment [Member] Pharmaceutical segment. Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2024 and 2023 Common Stock, Value, Issued Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration] Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration] Document Financial Statement Error Correction [Flag] Document Financial Statement Error Correction [Flag] Expected contributions to the pension plans and other postretirement benefit plans during next fiscal year Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year Recognized as: Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract] Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Other comprehensive income (loss) before reclassification adjustments, pretax Other Comprehensive Income (Loss), before Reclassifications, before Tax Accrual for rebates included in accrued and other current liabilities Accrual For Rebates Accrual for rebates recorded as current liability. Equity securities held through ownership interests in investment funds Publicly traded equity securities Equity Securities, FV-NI, Noncurrent Income Taxes Paid Schedule of Income Taxes Paid [Table Text Block] Schedule of Income Taxes Paid State taxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Vaxneuvance Vaxneuvance [Member] Vaxneuvance Other, Assets Deferred Tax Assets, Other Intangible Assets Excluding Goodwill [Line Items] Finite-Lived Intangible Assets [Line Items] 0.75% notes due 2026 0.75% Notes due 2026 [Member] 0.75% Notes due 2026 Derivative Instruments and Hedging Activities Disclosures [Line Items] Derivative Instruments and Hedging Activities Disclosures [Line Items] Intangible asset impairment charges Impairment of Intangible Assets (Excluding Goodwill) Cash Flows from Financing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] 2029 Defined Benefit Plan, Expected Future Benefit Payment, Year Five 6.30% debentures due 2026 6.3% Debentures Due 2026 [Member] Six point three percentage debentures due on two thousand and twenty six. Acquisition of MK-1045 from Curon Pharmaceutical Payments to Acquire Global Rights Payments to Acquire Global Rights State taxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Finished goods Inventory, Finished Goods, Gross Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Subtotal, Liabilities Deferred Tax Liabilities, Gross Animal Health Animal Health [Member] Animal Health [Member] Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) Earnings Per Share, Basic Cash and cash equivalents Cash and Cash Equivalents [Member] Operating lease, payments Operating Lease, Payments Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Charges for certain research and development asset acquisitions Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation, Writeoff Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Goodwill [Table] Goodwill [Table] Gardasil/Gardasil 9 Gardasil/Gardasil 9 [Member] Gardasil/Gardasil 9 [Member]. Product intangibles and licenses, Liabilities Deferred Tax Liabilities, Intangible Assets Total current liabilities Liabilities, Current Equity method investments, Liabilities Deferred Tax Liabilities, Equity Method Investment Deferred Tax Liabilities, Equity Method Investment 2.75% notes due 2025 2.75% Notes Due 2025 [Member] 2.75% Notes Due 2025 [Member] Collaborative Arrangements Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Prometheus Biosciences, Inc. Prometheus Biosciences, Inc. [Member] Prometheus Biosciences, Inc. Remicade Remicade [Member] Remicade [Member]. Estimated aggregate amortization expense, 2025 Finite-Lived Intangible Asset, Expected Amortization, Year One Number of Shares, Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period 6.50% notes due 2033 6.50% Notes Due 2033 [Member] 6.50% Notes Due 2033 Actual return on plan assets: Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement [Abstract] Acquisition of Elanco Animal Health Incorporated aqua business Payments to Acquire Business Four Payments to Acquire Business Four Acquisitions Business Combinations Policy [Policy Text Block] 1.875% euro-denominated notes due 2026 1.875% Euro Notes Due 2026 [Member] 1.875% Euro Notes Due 2026 [Member] Discount rate Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate Orion Orion [Member] Orion Sales Revenues Share-Based Compensation Plans Share-Based Payment Arrangement [Text Block] 3.75% Notes due 2054 3.75% Notes due 2054 [Member] 3.75% Notes due 2054 Zerbaxa Zerbaxa [Member] Zerbaxa [Member] Consideration transferred, asset acquisition Asset Acquisition, Consideration Transferred Dificid Dificid [Member] Dificid [Member] Component of Other Income / Expense of Nonoperating [Line Items] Component of Other Income / Expense of Nonoperating [Line Items] [Line Items] for Component of Other Income / Expense of Nonoperating [Table] Entity Address, City or Town Entity Address, City or Town Summary of Changes in Fair Value of Company's Level 3 Pension Plan Assets Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets [Table Text Block] Summarized Information Relative to Stock Option Plan Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Total intrinsic value of stock options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Interest and penalties associated with uncertain tax positions, expense (benefit) Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Increase (decrease) in revenue hedging activities Increase (Decrease) In Hedge Revenue Increase (Decrease) In Hedge Revenue Weighted average exercise price of options granted (in dollars per share) Weighted Average Exercise Price, Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Other Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] Number of Shares, Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Loss Contingencies [Table] Loss Contingencies [Table] Accelerated Depreciation Accelerated Depreciation [Member] Accelerated Depreciation [Member] Benefit obligation Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract] Business Acquisition [Axis] Business Acquisition [Axis] Termination benefits Defined Benefit Plan, Cost of Providing Special and Contractual Termination Benefits Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Foreign Jurisdiction Foreign Tax Jurisdiction [Member] Discount rate Business Combination, Discount Rate Business Combination, Discount Rate Livestock Livestock [Member] Livestock [Member] Liabilities Liabilities, Fair Value Disclosure [Abstract] Document Fiscal Year Focus Document Fiscal Year Focus Pensions and other postretirement benefits, Assets Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits 2.45% notes due 2050 2.45% Notes Due 2050 [Member] 2.45% Notes Due 2050 3.500% Notes due 2037 3.500% Notes Due 2037 [Member] 3.500% Notes Due 2037 Treasury stock shares purchased Treasury Stock, Value, Acquired, Cost Method Tax Year 2019 and 2020 Tax Year 2019 and 2020 [Member] Tax Year 2019 and 2020 Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Property, Plant and Equipment (at cost) Property, Plant and Equipment, Gross [Abstract] 4.30% notes due 2030 4.30% Notes Due 2030 [Member] 4.30% Notes Due 2030 Total assets Assets, Fair Value Disclosure Foreign Income (Loss) from Continuing Operations before Income Taxes, Foreign Estimated aggregate amortization expense, 2029 Finite-Lived Intangible Asset, Expected Amortization, Year Five Document Period End Date Document Period End Date Summary of Interest Rate Derivatives Schedule of Interest Rate Derivatives [Table Text Block] Stockholders' equity before deduction for treasury stock Stockholders' Equity before Treasury Stock Consideration transferred, to settle share-based equity awards Asset Acquisition, Consideration Transferred, Share-Based Equity Interest Settled Asset Acquisition, Consideration Transferred, Share-Based Equity Interest Settled Total lease payments Lessee, Operating Lease, Liability, to be Paid Number of Shares, Nonvested January 1 (in shares) Number of Shares, Nonvested December 31 (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Insider Trading Arrangements [Line Items] 5.75% notes due 2036 5.75% Notes Due 2036 [Member] 5.75% Notes Due 2036 Contingent Consideration for Business Combinations Contingent Consideration [Policy Text Block] Discussion of the accounting policy for contingent consideration. Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] Other current assets Other Current Assets [Member] 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three Accumulated benefit obligation Defined Benefit Plan, Accumulated Benefit Obligation Januvia/Janumet Januvia/Janumet [Member] Januvia/Janumet Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration] Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration] Foreign exchange contracts Foreign Exchange Contract [Member] Reclassifications Reclassification, Comparability Adjustment [Policy Text Block] Document Transition Report Document Transition Report Unrealized gains recognized on investments in equity securities without readily determinable fair value Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount Latin America Latin America [Member] Unrecognized Tax Benefits Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Long-term debt, interest payments in 2025 Long-term Debt, Interest Payable, Year One Long-term Debt, Interest Payable, Year One Companion Animal Companion Animals [Member] Companion Animals [Member] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Customer [Domain] Customer [Domain] Entity Current Reporting Status Entity Current Reporting Status Retained Earnings Retained Earnings [Member] Litigation Status [Domain] Litigation Status [Domain] Asset Acquisition [Domain] Asset Acquisition [Domain] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Inventory donations Effective Income Tax Rate Reconciliation, Deduction, Inventory Donations, Percent Effective Income Tax Rate Reconciliation, Deduction, Inventory Donations, Percent RSUs Restricted Stock Units (RSUs) [Member] Payment resulting from the license option exercise Collaborative Arrangement, Rights And Obligations, Payment Resulting From Exercise Of License Option Collaborative Arrangement, Rights And Obligations, Payment Resulting From Exercise Of License Option Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Executive Category: Executive Category [Axis] Purchases of securities and other investments Payments to Acquire Investments Organon & Co. Organon & Co. [Member] Organon & Co. Taxes on Income Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] 3.25% Notes due 2032 3.25% Notes due 2032 [Member] 3.25% Notes due 2032 Obligation and Funded Status Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block] Restructuring reserve, beginning balance Restructuring reserve, ending balance Restructuring Reserve Fair value of stock options vested Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration] Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration] Statement of Income Location, Balance [Domain] Statement of Income Location, Balance [Domain] Net unrealized income (loss) on derivatives, net of reclassifications Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Company Selected Measure Name Company Selected Measure Name EX-101.PRE 24 mrk-20241231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 25 exhibitcover.jpg begin 644 exhibitcover.jpg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end GRAPHIC 26 image_10.jpg begin 644 image_10.jpg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image_6.jpg begin 644 image_6.jpg M_]C_X 02D9)1@ ! @$!] 'T #_VP!# (! 0$! 0(! 0$" @(" @0# @(" M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_ MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H* M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P 1" $^!%4# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#]_**** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBHFN1&Q\W@>IH EHJ-+J&56:)P=O7%-A MN#*>!QGK0!-14:W"-*8@PR.U24 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !5&>*>YF:*Y&(_X35ZF2LFT[B.!0!0:PFLU8 M62Y#=7,ZQQ6X)9G; Q^-9_ASXK^#/%2FWT_ MQ+IYFW;1$+V,L3TZ9S0!N66]HI MQ( R:JBVDL+58;3+8]:(I+ID/VA<#':@"R)$(W!N*-ZXSNXJNCVD=LS"3Y > M34%Y+++9*VG#=SQS0!H9&-V>*175^5;-06GVE[?;<+@XI;=$M00QZF@"9G5! MEC@4!@1N!X]:IR?:;JZ,3+^Z]15HH5C$:\CI0 HFC8X#BE+ '!-5C!;6I\QW M/K3TNK64^8LE $_2D61'^ZV<56M9;N6=ED4>7CY34-RMU:2C[$NX,?FR: +Y MD13AF JG?1"?K/L'J>].594]\4RY6WG@42N0F?E- ',_%;P'=_$'P3? M^$=.U%[)[ZU,(N8C@H3WK\7_ (Y^$/BU^P?^WMHWA&W^,6J:W#<"2)M8D$6GV,)DN9O[J#O7X8_MO?M,_#7]J7_@L1 MX1TOX+Z[_:>;>6)E( &\/"".">^: /VI_9@\>ZE\0_A-I_B/5K-X)IL[D?J. M!_C7HM<)^SWX=U#PI\.;+1-9MA#;%!8 ;B>*C MF6.49)^[4$=Y#*#!*^.PH M"6-N0XIP.>14$5G$BX5CBH[22^-TT:22:*+'F.!GIFHY,12>:Q MJ":&+4L0$.1B@"[D8W9XI#(@7<6&/6LF[O;^:\C@T]-T'1V]*T# AC\DG MB@"<$,,@T53MI;F.1HY%P@^Z:\E_:P_:U\$?LS_#W4M<\4ZTMK>PVWF6B-C! M/XF@#T?QC\4OA[\/K5[WQIXLM-.BC^^]RQ 'Z5Y]>_M^?L:Z;+Y%]^T/X=B? M.-K7#=?^^:_&3XY_M%?\%"_^"E/BB;3?@WX52_\ !MZS+]MM[QU;).!PJ'MG MO6C\(O\ @W>\8_$K=JOQIFURRG\LR;8;N8C>!D?Q#O0!^U/A+]JO]G;QY,EO MX/\ BYI&H.YPBV\I))_*N^CGAEC$T<@*D9#"OP>O_P#@G3^VE^QYK UO]G#P MY>ZE'8R;P;R\E'3IV:OHG]DC_@LK\1?"OBVR^"O[:MU;Z'XCFX2TBDWY12 3 ME@I[CM0!^K*RQM]UP:=7*?#KXA^$OB!X:@\3^&]1,]O<#]V^!S^OO70VLUVX MM4%U&)G^P7S[9&/R@5+&MU;OY,:Y0=#0!; MHI%R5&[K2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4C84[F8 >]+63XINX(M/=+J]6VC[SL< 4 21WLTM^T*M\H[]J?>>(O#UDF MS4=>LH21SYMTB_S-?!__ 4,_P""S?PW_8D\)R6?A&*R\4:SN:%[*UD+2J3\ MH.,CU_2OSCL_VGOVW?\ @I?K-XOAK1O%/@JV>4^1/$NQ64]",[O6@#]POB?^ MU!\*?AI*UMJ'B"RN5QEDM[Y&)_(FO"?%_P#P63_9^\ :A)8W&A7\RQ#_ )8[ MC_)*^)_V9?\ @@W^U9JEY%X[^(W[7NNW85]S6-[WU VLWA'6!E\ E''_M.O3?A7_P6 M"_9S^+-[#9Z=;36K2G -S-M_FHK(\1?\$H?A=XKBD@M]%L+9U! E$>.?6OE; M]K/_ ((B?$#2]-N=?^%OQ2NK*2),QQV# './]V@#]6?!?Q*\*^-]/2^T+4[> M57^ZL=PK']*T+V'4I'#6\X5<]Z_G@^&7_!0C]L3_ ();?$%?#'C?X:^)?%]A MI^ UW<1;D?!QV*U^H'[$O_!9KX.?M9642^/==TWPAWO)MC;L9V]30!] MT+"&B"W7/')HCL[=5_= ?6N#_X:4^"FH11P:5\2]+G1U'[Z.?(JY!\:OA'% M:?9F^)6FD_WO/_\ K4 =1*UU+)Y5M)C;UJ83E(3N.6 [5PFJ?M&_ SPU$)]2 M^*.DQA^-SW&/Z5R/C;]NS]F7P-HUQ?1_&30KJY";H;477S.?0#% 'K%S=3QY MO;N8"W'WE)Q7-?$_X[_#?X:^%IM_X*S?&']KOQJ/V?/V0+W4M-%Q< MG3]1:2VD>.3KW&T8Z5[;_P $=_\ @C+JWP+O[/XS_M&:9!?^-$G%Q::BB!=B MN=Y&"2?[O?M7U_\ LB_\$ROA#^SW;"X\0>%=.U?4E )U"6++L_'S9XYKZ@&D M6L5H%L;980@ 54'0#I0!D0ZAXNUJTM5N!A#*KTZ>/B#I'FO*0B?:.3S0!].7PE6V*P-AJDM"Y@7S#ELZS%I-G>:G?D1Q6T9=F?H !0 E M[8ZA%?)-ITH2(]?!/QC_X+,Z#X$_:L\/\ P!\+^&8M7MM5 MG,5QJ-N=RP$ 9R=P[^U?<6F^)=/U_2_MEK* ./\ C]\=_#G[/OA2 M\\6^,KA1 EM))&/,"DX!Z5^)7[17[2GQ)_X*P?M:Z#H'P:N;I/"FFZJUIKMM M/"S"55!4X/ ZX[&O;O\ @MC^UYK'QSUS1O@!\*;N1[JWUF&UU Z>V6"-* =W MM@U]@?\ !+7_ ()S> /V4?AQ#XAUVVM+W4=*T)\W9Y@8]/2@"*YTNVU&Q>V$?RRKAQZU\&?\%,/^"6O@'XO:+?_%7P M#X7CC\;PH5L-18 [ 1D\8!ZA>_:OO^U00IO9L;AG%0:U%93V;&ZLUF'>,C.: M /Q__P"":?[=?C'X!_&5_P!F?X^7MS(VE1*ID>-HXBS;EX+9'5?6OUQ\#ZZG MB;1X=>L[I'M[J,/"%<' KXA_X*@_\$]]-^*WP]_X3OX4Z>FAZY#.;F>\L$Q+ M(J$/M).?0_G7DW_!+W_@JOJ6I>)=0_9S^*FAR:7<>'Y?[.M;O4#M-TP .X<\ M]?TH _4:6WL9+Y99H]T@Z-Z4^]O&L&,\IRGH*IZ+.SZ.NI.=XE174^Q&15JW M3[5$+B5=P/\ ": +<,HGB651@,,BG4B ! %7 ]*6@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ ID[2+$S1#+8XI]!.!DT 5K:YF>+$RX?TI7O/)Y MGX!Z5(JHTOF#K5+[/-H?!SX+Z[!>>(948VUKD!FP,=1D]2*]3_P""P_[?>C?LM> Y M_APFJE-7U^R,6F^7)TM4_;8^(:?M%_M(S:E;G4]LQA,\DD6Y3 M@4D2Q0C9&,9J2@!GDILV 8XZBHUTZT*&.:%) >HD4'^=3T4 >-?M"_L:_!S] MH32)]$\5Z+9QF;=ND2Q3=S[\&OS'_:5_X-POA]9:]=>-?A+XIUS[8TGFB"VN MI8UR.@PK]*_965;;SB74[O6J>K21VND7ES9 K(D#,"?7% '\XGQ:^!__ 4J M_9[UV'P'\-/ U_?>:=EOY]]*2P'3JIIGA'X7_P#!;'4+](=;^"UW'$>K"^E_ M^-U]3?MM_MJ?''PA_P %0_AK\,+3Q&RZ=J.I[)H@K8*[,^M?L^AN'M$V-^\* M#G\* /P5TW]@S]OWXO6=O8?$GPEJEDFX;VBOY<]?8"O8/6OU^DCN&MP-WS4EA%/"&,[9]* /F[X'?\ M$U/@1\"O(@L$6_>$##7ML)"<>[$U]#:=X5T73M.CL-,LH8(H_NK!$$'Z5//] MCDNOWB9;UJW&%" (.* $CA2- @'2G%01MQ2T4 -)2)>3Q2.SX!04YU5QAJK7 M]PULT:H<9- %A7/\?%4M7U==*M9KRX8+&D3,&^@S5QR/+W$\XKX^_P""QG[7 MP_90_9=N?&ME?M;S&5XMZMC^$?XT ?EQ_P %'?VAOC__ ,%*/VEY/V;/A-9R M7EEX;UV.WU)K.=D:*+<&8G8/0U[;XT_X(">&_@Y\#_\ A>*K33( M[E+&2\FVF!7[56@AE7[5$/O4 M3T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% $#S-%,3(,+ZU\7_\ !8K]N&[_ &5_ MA*NEZ!<1BXU^T>W0,0"68E>/RK[+UP,-,FD0X*1,WY"OY_?^"O\ \6?'7[7? M[2_AOX2>$;\SQ:%XFAAO(@"V%\S<1P>.#0!Z]_P0^_83B_:GM==^//QR>YAU M2UUJ>;3P79\HTS8P21CC%?H]^V+\2M*_8R_9NN?%UOJ)5+;< \K>B^];G[#7 M[/EC\ OA!I&EZ79" W>EV\EP .K&-2?U-?%G_!Q5\2]:\1_LZ:O\(O"=\!?F M1\1@Y[8Z"@#YG_X(R_ 3QC^T]^WOXZ^+/Q;T^3^Q;JXZT 5(P89QIZD[3WJ\D:H@3&<>M1&US=B>IZ &20+*02<8 MI/LZ;MQY]C4E% %;5=.M]3T^73[B!'26-D8,H(P1BOQY_P""NG["&J? ;XM^ M&OCW\$M/F9(=3%_K30DQJ@&[.<=>U?L5=K.T?[@X.>:\_P#VA?A#I?QO^&>K M>#KVU$LMU8-"@/J: /*_^"9W[7=G^U_\#O\ A(8[R.4Z6([24QXX9 4(X]U- M?22+Y-N%M^17X=?#_P"(GQ/_ ."3O[;6D?LU/>M9>&=>NY;N\MXD8*V7#PG_ -7AL]L]?QH ZQ"2H+=:6D1@ZAAT-+0 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 CDA25'-1I,RQ M&2<8Q4IX&:CFC,\)0T (MU'+Q$4SKMF_=,V?O^A% 'Z2?"+XZ_#C MXWZ,^N_#S75OK9'V-(H'!Y]"?2NQ)QR:_+?_ ((+_"/]K'X:_ ZZTOXK:JKS M27V\?N67CU\,:GJ"*8VMM/FE!]2J$_P!*T5DEEU %$S&> M]<_\:9IX/AYK"64>9GTJX6%1_$QC8 ?G0!^$?[3_ (,^(_\ P4/_ &X/#EV+ MN\73?#'B)H[J!E!21%5UP<@^M?MW^S/\%O#_ ,%OAW:^%O#UA#:1B*,M'", MD+UKX<_X) ?!7Q_??$KX@:]\:_!J::8]:F?2GDB!,J^8N#T';-?I0NFQHRO& MQ&U< "@!TKI: .L>YB>2*;+;&: )%7 MS'#AN *EJNIFAE$:KE3U-6* "BBB@"*<18RQ /K6+X\U!-!\%ZGJA3VJS#.\@^U M//F2$TVWC9'(:EN)9T<"),@]: 'O' IWLHS3E*EJBOV06<2.%B *C@FOPQ_X. O D M/Q4^)^I>$;FZD"?:PVU6/]^@#]#/^"0/PWC\ ?L9>!/%"QB5M1T92V!TR2*^ MH?B?XR@\#>"+SQ1(H"VT.\BO,/\ @G=H*^%?V+_ 7AZW3>MOHZH"P]S7!_\ M!6/X^7/P2_9:\47>F.IO!IVZ&,XY.,T ?#'P)TUOC7_P6]M?CE;V9^SR+C>% MR/\ 7 ]:_9.V8+^X568I$!>R;)\IQE?]<5K]NXIYVMA)+& ^T'&.]? MAYKUOHU]_P ',5V/$*I1QSV$,ET27WC('I5^[C22/#GITJ"SN)F+1W M$8"C[N1UH ^$/^"N7[*.F_$[X,:W\=+#1D&OZ9#ML[I4S,ORGI_WR*YO_@B? M^V2?$OPTTC]FSQ82^MV:!YI;@_O#E0.1GU4]J^^?BIX&TWXA>!;SPIJ<*^1< MC# KD'@]OQK\0_@9?^)_V5O^"UVNV,EL]OX;A@C6&4G"9\V4=.G3% '[PQJ$ M0*#TI:R_!6OP^*/"UEK\$@9+J$.K#O6FSJO4T +12 AAD&EH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ /(Q47GB.3RB.O>I&)"DBH#"T[9<8 MH 2XMA.?W*Y_P 9?#CP?X^\J3Q5X>M[TVO,?GJ3C]?>NDAM5B?=N)_& MAPT;81<@]: .<\.Z5X:\'VIL_#?AB*TC!^["I _G6]8Z@UXH+0E<^M.8,LP0 M0J5/4[:GVJH^1 /H* *\MH=WF(V._%2P2,PPPZ4Y5R0J17Z#7@\R)EZ8!.:_%7_@XY^.][\1O&?PR^'?@FWEDELO%%I%> M?906X^TC.?3B@#ZO_P""$GP$A^#?PFUR_FLO*?6)VNI#MQN+R;R?UK[XMF^? M$1^3TKRC]D?X9+X'^"GAEX@(C#WE/#:8N/S-?GI_P7?^+6H:Q^T;X5_9BT^ZW+XJA6(P Y#9C!Z5 M]^? .Y3P+^QGIM]'Y) 2<8V@FOS.\!*_[=/[:^D_%6:$W:>%=:EA\Q MAN"A&*=?PH ^_P#_ ()@_LOW_P"R)^RI8_"P6(MI8"IV!;[ MY'-4;34+6*\728;3"!1\X'%7K>Y$DIA6/ 7OB@">BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** MC/!IN48^7BG55B+?;&':@"5F;&%IL329VL:F" 9)K&\>^)[+P;X8N/$-XZK' M ,L6/% 'XK_\%4M<7]K+]LW5?V3$8W)M)TF^SGD#,A'3_@-?K9^QGX#C^&7[ M./A;P8L/EMI^F"(KC&.37Y/_ +/W@ZX^+G_!=77_ (A,#-IEQ;1[.,IGS93U M_&OV@\-:1_8U@MJ@Q&B851VH N(\TY+(>AK\#O\ @JG-J?[)O_!5K5/VO]?5 MH=+B+ W"@@\2ENM?OI!,F"53O7Q/_P %A/\ @G=8?MF_ O4M(T.UB@U6Y+D7 M6!NY7WH ]M_8:^.?A;XZ_ G0?&WAR[$CWUGYC,7!->T^4^?-GYQWK^>[]AO] MO7XS_P#!/#XN7?P3^)'@S7;S2M,F6UMKB:SD$)!&,@C Q7Z\_!__ (*<_!7X MCZ?9+J>OZ;IKW,2EA@"7:LT>QQQ7Y-_\ !8SX2V7P&\2S_M)36PA%W?+'Y^,9 MPX/7_@5?K,N .U?FG_ ,'/FD7^H_L+VBZ*'6<:SDM&,G&8Z /MS]C;7E\4 M_LP^#O$$3;EN=)5P<_[1KTHLLCC-?.?_ 2U\:P:S^QSX%T&68&>TT)5ER>< M[C7T88B)01TH D?$4?RT1.7ZTUF+3>6>E2*H7H* %HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "@G')HH(R,&@"MYCF\V@<4Y"Z3DMT[5*(D5MP'-*R*_#4 M 1RRJCJ..:EICP)(P9AR*?0 4444 %%%% !1110!1O;B=?/4QX01,=WX&OQO M^%WP_P#"O[6W[?'BWPY<7ZWTOAW7%E\EQO\ +*@-QGI7ZB_MA_'&#X"?">Y\ M975YY*;73?NQV_\ KU^>?_!$SX4VX_;-^)'QI6W^77YWF$N/O?N@.M 'ZDZ% MIK:1X6T[P_"FV."RCBR.,!5 J;3GO+.]%@D9:'_GH:TB59>.@%$0QPGW: )* M*** "BBB@ HHHH 1\[>!4,%RSE@5^[4YR1@5"4AMR21]Z@!J2/,^X#@&OQI_ M;(\0-K7_ 4\U;PG* RJ5.T_]=6K]ET=!$1;GGM7XG7J2_$/_@X"\0^ _$/S MV<5H'V>XFD_PH ^MOV\/VOK#]F+]D_P]X6^UQQOXBTTV:!L9R[%.*XS_ ((' M_L\S^$/!'BGQ+K=N\CZQJDUY%+!TX-?MK^S!\&?#WP;^%6C:)H-IY1.E0"<8 ^8( M,_K0!WUKIL-K!Y603_>/6K$:HHPH'UI&92VT=:2-&#DF@"2BBB@ HH) &3VK M-N-1GGES9-\L9_>4 :5%5+>[DO&$ENY9QY/3/- %BHRJQOYGK33^RR3Q.JGH:^"?\ M@M9\9EUNU&V#=][Y?3_@5 'FG_ 1"^'/_ L^STS]INZA M+S7\:@S$9S@9Z_\ J_4>)XG7R5;D#G%?(__ 1/^$]K\*?V&?#GAM+7RVA_ MAQC^!*^N8;6*%S(@Y;K0 V-8;<^66Y:H+V-9&,3VZRK_ '77(JS);1R2"5AR M.E/VC=NQ0!\X?M;_ + GPG_::TB*QGT&PT^XW9DNK6S5)"<]2RC-?'WCG_@V MH^'OB>^6]MOC]XAL03G;;:I.WC\N,<5(!C@4 %%%% W0_2J=NHEE8D]#5BY9U3Y#R M35.[\^W>,VW\1^:@"Z)5"%VZ"OB7_@NCHNG:[^R5&M[M*?;B1N&?[E?:4\4[ MD1#[K#FOB7_@O'=-I7['2&$X(OF_]DH K_\ !(K5+V[\'PZ2&;RK:T"H-W & M*^Z&G6-EC;KBOS[_ .")MUKDWA^674C^Z:T_=_\ ?(K]!)+:*9Q*1R.E "A% M,NZDBG,DA0CI39!?:OLY^S??[ M4 345';&00#[0?FQS44^H1QS+&K=30!9HJLYOC=J4_U7>I)[A81R: ):*JR: MI;J @;YCTJ+^UHX)A9W$@$C?=YH OT54DNWM?WMRWR=L5(DLKJ)E/RGF@">B MH1.9T)@/2HX/M_VC][]R@"U14$EPT#'SC@'[M0237R.)<_NQR: +U%4WU 7, M>VS.6I(-1\\FU5OWJCF@"[161?\ B%/#MI-?:Y)MCC&[.>U?F-_P4L_X+Y_# MO]DGXNM\-M-\9?9Y_*9A&)P.F!Z^] 'ZH45X7^PS^T-JO[4/[->A?&>SO?M$ M>J(6$N[.#6;9L12-\XX;ZT 7:*JR2W)G#Q_ZO'-2&X$GRQ'F@": MBD7.T;NM,>YCCE$3'D]* )**CN)#%&TF'/:@#ZQ&16M:7<5Y%YT) MXH EHHHH **** "BBB@ HJK)?J\YM8#\XZBI96F2,,.P^:@"6BLO6O$5OIND M3:HTF$B'S'-,\'>*+3Q3I":E:R[@_0YH UZ*** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ )P,FD# G H8 M97BA%QR: %HHJ&68*>: /S7_ .#D7X_R^"/V.+K1- 9_MRWC#]R"6QA1T%>X M_P#!(3X8Z=H_[+?A7XB_V>([S5M*$D[D89CR.:^/O^"GSZ7^TE^TYJ/[.%Y? MJVV7?Y!YZN1T_"OTP_9"\(6'PY_9Y\,^"K=E L; 1@ >YH ]%&Z2%U4X/:G: M>CQP!)6RU)<,5G4*.#3-\_\ :.T1G9ZT 6Z*** "BBB@ HHHH ,@=34<\7G# M@TLRDKQ4&[C7+K&V$9.37\V7[87[;=I\$O^"T7B'X MLZ8LA$T/E#R6(X,B-5 4 < "O//V:?@GIWPH^"/AWP%:HL3Z79B M-Y%&&;!SS7I;O"EON3#%!C- $Y" [CCZTH(/(-589'O;/<(=7T32[.35]5U);>WM5WS2,>% [F@"[ M%&L_X*/_"C]J^2"/1O%=E+J$T89[6$\CC/:@#ZIT[RU'EA?G7[Q]:M MU!9PQ@&XC?(?D&IZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "C!SG-%027)CGVOPOK0 V.\6>X>V5<$#K45G:7=FTDL\VX$Y IQC6.4 MW$!#%O2J?B;QGX;\(6)NO$.J1VR[ M8:9^US\!KS65T&'X@V!N7)VQ!N37:Z!JF@ZQ>'5-)UE9U<<*I.* +'B?4HO# MGA^]UZ]8&.UA,AR>@%?AK^VY\6-<_:;_ ."O?@?P[X?FEET,J\-W'&I:,D&) M>3V[U^Q7[87B]?#?[/'BZY\[RY5T64Q8."3[5^4G_!%OX02?'GXC7WQH\36Y M>ZTSQ!>XX/_ &@#]AO@UX T_X:>![?PKIENL44/W53IT%=73(( M1!&(P>E/H **** "BBB@ HHHH **** $*AN"*;/&K(21R!Q3F.T9ILA/&!P: M (M/+M&3)U!XS7Y]_P#!QUXC7PY^Q9!=F0?-JA7 /O'7Z$._EG:JXK\D?^#B MWXKP?$/X2+\%=,N ]W!JH=H4/S8W*/Z4 ?7_ /P2@^'4.A?LY^&_%:0@'4=) M#[AWR2/Z5]80*R@[CWKQ?_@G;I']C?L9^ +*2+;)'H:!L]?O-7L\DZI((SWH M =O&_;BJUXT4IV21;O0^E3D;9=QZ52U[7=,T"QDU/4)TCAA0O+(W15 R30 3 M>7IVGRW.H7T<,:C/FRN%5![DU\A?ME_\%@?@W^Q?%=6NJ>1KT]L"3%83^:S8 M]DS7D?\ P4\_X*Z^!M!T>[^!OP)\36NLZKJT)MPMDX\R.7'(!..02*P.20 M._UK\FO^"T_Q:_9\_9K^$WAC]G+X:Z-HFJ:UINLP6UQY5JOG#=,BY)(SZU]_ M_P#!##X;ZWX4^#L_B#7=,>W75+!)HD<< %E/'Y4 ?>23FZMMT8VGM3(;=PQ> M9LC'2GQ>1YF%D'TJM/?WL5T8TM25]: ,WQ;XLTGPUX:U'Q#?JL:6$!D8N<# MK\*/^"I'_!9KQKIW[5=EX)^#_B*ZCC*.GE6!+Y9=H[5^BW_!9[]L'3/V;/@5 MJ&DW.H1VESK.DND +8)8D]/RK^=K_@F9\-_B-^U3_P %$-#\0:]HMU?Z5)JL M_FW,_P Z &88ZT ?TW_\$N?B/XR^,/[*6A>,?'LMS)>W'^M-TA5ON*>0?K7T MG#-')F%!@+7(_!+P#IGPM\&VW@C2+2.*"W'RK&F . /Z5UHLQ%O;=]\=Y9+N95*VQ+-DOCHM5?^"(/_ 4?U#]O3P+K M6NWVFWT2V,[(/M<+KD!\<;A7YI_\')'Q%M?B#XT\._#C2]<-Y-#XA@A:W#DD M$S#BOTK_ ."!/[-U_P# OX!27.M>'_L']H6D1'] 'T;^R#^S\/V;/@]IGPMM&C6V MTY"$BB(P. .WTKTGS;-9]OV;YB>M$UPD%P?L\F]^Z"CSDE8-=@1G/&>] %J> M,20>5&<$BBW@%M%^\(+>M-5T,@V/GBDFD:63R1QB@!+621Y7W$@ \9J9EAF. M\$9'0YJMY\4^,O$,5E;6Z;Y99CPHZT ?/ MW_!5_P#:XM/V4/V;[[QQ%JZ)<1EUV1R_/]WT'-?RY_$?X]_M :E^U'_PM])] M6AT_5==BFBD>V<*R[AT)'-?JG_P4)^,4_P#P5$_:3O\ ]E_X8Z_)>Z'9-/Y&))&5R>3CF@#[ ML_X(_?':_P#C?\!XKO4Y9'>SL8D?S E?E)_P;!?'W4? MC1\)?&-E?:6MLFCZA);)@ 9"3;>WTK]7;;R_+_=MD>U $E%%% !1110 4444 M 4KFX@M93*L!+'^("F 7#?O3+E6YVYZ5>:*-B2R@_456A2&%G9)0Q_NT >4? MM9^!/&/C7X2ZKIO@KQ -,GEAPDI8#:<'GFOEG_@GG\:O%O@OXTV_[-'CGQD- M5U&V13)*)0=W)7M]*]V_X**_M+>%_@)^SKXA\0ZIK4-M?VUON@MG."_!-?F' M_P $6;_XD_M$?MY6_P"TY=6=W_8]["@67?\ NOO%OZT ?N=1110 4444 %%% M% !1110 4444 %%%% !1110 $X&::)%*[@>E+)]PU D\,,9:X=47/+.< 4 2 MK<1.VT-S38KR&9S&C:K7!6[C#:?,K9/WT8$'\:FAMDA0'(#$?,0HVTMS4BNKC*FH'2% #)'D^M"WB [ A'OB@" M*BBGCF/D.N=O\7:@"PTT:XR>O2G*ZN, MJ:HW5_!:3I!*,[SQCM5Y-I7*8_"@!:*** "@D#DT5'<,53(H =)*L8P3UZ5B M^,O$6G^$]'FUW5Y=EO",NWM6N4\Y5/I7BG_!1/QK'\//V2_%'BQI-OV6VSN! M]C0!^=7@'PE9?&S_ (+2:CXQL5,VDSQ+L?KG]ZYK];] \,V&AZ9#9P*0L2X MQ7YS?\$:/ 4?Q3BTS]I?RPWVM%'FGJ>-W]:_2I;B)V,6.E $HZ4(-\OF"@"6BBB@ HHHH **** &RR>6N:C*O)AF' Z4ZZ1 MGB^7MS7(_$'XCV'A;P/K.OW,RPC3+-Y6+MMS@=LT ?,'_!9G]JCP#\*?V5_$ MW@.[U7RM*OZ#J5C?6^^.3*RC,4 .617^Z:))%C7>YXJ&T!&X>]$C M<[9#Q0 DVHVL=O+/(WR11LSGV R:_*W_ (+(?\%/;GP/?V?P%^ >O!]5\2$V M+0&3&Z0ACCCG^&OLW_@HO^TYH?[,?P4N?$5W>)%)>VTT$)$F#O*[1^I%?E9_ MP1F_9JUK]M'X_P#C;XP_'/3Y-3AT?6WN]$>[B*^6N5 VYZ_>/2@#$_8U_P"" M /CS]J/6(?'G[:OABX3[7,9&:,,P,;G<#\V.V*R/AA\%4_X)O_\ !1K5_"'P M8$L.A6@ABMA*Q'!DD7H/;%?OEX>_LO2])BM;-%M88(UC_>':!M&.I^E?AO\ M&*;4OBE_P5V\4>"=)O!MF6ZL ME=S[Y-=+7'_ G1[S0_A7HFFW9.Z&Q52".G)KL* "@D*,GM12.I9"H[B@!L,\ M_LN^" MOC+9_!BYT=YKF[OFM1=12,4##/)(&,<4 ?I!'*DJ[D/%*SJ@RQKA/@C\6-$^ M-?AF+QIX4NXWLY I'ER!AR,]17;W+#8 #SGM0 37L$#JDC8+=*>9%'4U$MM' M+AY@"1TIDMK^-.E_!OX/ZMJNL2?)<:9<8V_.@&,_6@#P[0OV5_^"V<$0^-VG>#\QP?, MLGF38PWS?W?:O5_V4/\ @M)^US^S)\5(_!W[8NK1Z?IZ21Q8$S??9BO\0'M7 M[Y:)\+=$TWP4?!TMFAMV508\\<#%?&G_ 4X_P""1_P:^/WPBGO_ ;X-M+; M7;<27#WC%>=H##KCN#0!P_\ P4+_ ."A/@KQ-\%O"FE>%M>#R^-=.$<2[Q^\ M+EAV^E>A?\$6?V<-4^"/P9U'_A)]/\B[U&^-U -N-RN[/GG_ 'A7\^_@OQ9\ M9;7]MS1/A/\ $?QJ+W2O"OBF.VMH&<;8HUYQG./XC7]6/P"U3P?JWPTT=O"< MENX72K82/;RAP&\I<\CWH ]"@\PQCS1\W>G!@?PJO!!;)V'^[7ZP_\ M%.?VF?#/[.W[,?B'Q!+JD"7D$(:.W6<>8WRL>%SDU^<__!%SX#ZO\9?VHD_; MLO[%S:ZQ;HH,L9#<%F[\_P = 'Z]_L\^%IO 7P7\/^$[V+RY;*Q$;ICH]>9?\$NO^"87C'XI>(X_P!IKXVJ ME]!K6V[MH+E0LD; <9!Y'/M0!S/_ 2]_P""'&L:]X[_ .&BOVG_ Y,FJ/? MMJ&F.4+*0[9!^;'8U^M/Q1\<^"_V:?A7+XFOY%M;&T4 N% QA?\ ZU=AI&F6 MGA[1+70+&+:EO;K%&%[ #%?E;_P<>?MHM\,?VPK^HO\ 93\ M0?#WX$>&/#9MQ'/;Z-#%<+MQA@.:_+#_ (-UOV&(M+L;7]I?QOI:W$VNV18S M,N&)V'_&OV(-W9:,L-A;VY"D;4 &<"@"TMC$C^8O453UO6%L-,O+M6P;:VDE M)_W5)_I5AUN?MBR>9A,=,U\\?\%+?C5+\#?@1=^)=/NS%)<6\\99#RZ9J1LQ"LG1_F../K7W+_P;:_\ !/K5 M?AA\&QXY^,.@BWUQ;I9;0^7_ ,S-G)YZ8K\S?V$OV6?$_[=7[=.M>.8X&EA MTGQ5Y]P9(^H 7U^M?U!?"#X5Z-\-_A[8Z#HELD,D=E"IVGN$ H [.0+:R?:' MXS4DDCSH/*Z$0W3% "K;&VMV%K]XU@>,O'.D> M#?#TVH^*+CRXUC;)S[>]:M_=31:E'&A(1AS@5\)?\%XOVMH/@+^ROJ4WA^20 MZDLCH%MLL_W<=%YH _!7_@H;\:=-^)G_ 4DCTK2K[SHH?'%IA2V<#SE-?U3 M?LX6VG0?L\>$8P@56\-VF_ _P"62U_+!^TE_P $T_V@?A_HOAC]N2[^T:C; M^(KV+48[>TMC)*@60=0N6'3N*^@9O^"YO[0FI?#BV^$/@GPWXMM-0@L([*WG M_L:YPC(H&<[,=J /W0_:S_X*'?L^?L9>%KK4/B'XE^QI:YWDLHQ@>YK\'_\ M@H9_P5_^-O\ P4(\?Q?"'X/:XM_X?;588X LQR8VD /"^U8.B?LJ?MW_ +6_ MAX_$+X\_$&XFT2X/[^WU.'RL@\\[SZ5ZE_P0)_X)_P"D7G[=GB;0?'6CQWEA MI\7F6A(&P,J,00>AY H _1S_ ((U?\$L_#O[.?@-/B!X@\/>5J&MVR7;L\/5 MV().3]*_15-/MK?;<,@4H !@56TK04T'1+/1=+VQ0VL(C1 > !5U$(MRDKAO MH: *ZZ="MR;^T!+OUJ:[L(+I%DN1R@J1 #'Y;RH[=E.>X-1:QXPT+0HYGUB_@MXX8V8O< M3! < GJ: (_$NJZ#X:T6\\3ZM-LM[&%IIF]% YK\^:B_X*_P#_ 6(U7QMXJM_V>?V=K;4H[R: M[_LZ_N+"WDF1BQ/)*C&,$5ZY_P $8/\ @EW>^"_"S_%3XY6$>H:]%])^+7Q7T"2V\81*@N/,0D# !ZMSUS7K/ M_!;7P=XD\7_L_P X\/6H=8-.E:3CH!DU]O:?I\=I:"U8#CM7SM_P4OBM4_9^ MUOS$!_XDMQC_ +X- 'YK_P#!IWXPTOPUX5^(_AC4YMD\WB&Z7;[_ &DU^V]M M#';PA8^E?S\?\&WGC.PT7XC^-]+=>9O%=V!S_P!/+5_0%;7LE1+'<1']X^1Z4 3?:H=^S=S4@((R*KH\+R &/GUJ&0W%K. M96?KW$RH!^)H M T4N&>Z,/;%>6?M+?M0?"O\ 97\.2>(_B5J_V1982\+9 SC([GVKY\_;6_X* M[_"']GRZO_">GQ_VC?P(RJ^G2&4D\@?% _I4'[%'_!/? MX0?LO^#[6UT_PE;Q:@T,;S31$^:^BXM1B2^_LY(2,=\<4 7**** " MBBB@ HHHH **** "BBB@ HHHH **** $D8JA8#.!TKY8_P""H/[6'B[]F']F MCQ!\0/#GAB6[EL8\H(P,GY6/^ G@S]I7X7:C\)O' M2DV^I+B143)Q@CV]: /SL_X)R_\ !PAX"^*GANP\/_&2\L?#\Q4&5[Y@&7(' M7!-?>.@?\%!_V.O%]HEQ9_M":#NVY95F?C_QVOY[?VH?^"4?PP_9M_;,U>U^ M,%S?:3\.P4CL+V$D%I"[#&-P']WO7VY^S-_P0)^%FN>%+;Q]X:U'5YM*U6W\ MZQF,C_.G3/W_ &- 'ZFQ?MQ_LCZ? SR_'O0R!W,K_P#Q-9\__!1_]B.WF,%U M^T=X=C/HTS__ !-?!X_X(&?#K4Y/L<]WJPA;AR)7_P#BJU-+_P"#7W]CSQ&P MO/$WB#78Y6^\%=O_ (Y0!]J:S_P43_9/%F9O#/QKT/4'VDJD4K$D_B*\I\2_ M\%1](CU9=+T/3X+F&1B//CQ@#UZUPG@7_@W)_8S^'UN+ME4 LG/_H5 'FOQC_X*@_$?PEX1FNO!'PTGU8KG M8T"H<\>["O'M)_X+4_MP27T%A9_L5:S-;R2JGVI8(<8)P3_K*^[_ Q^PU\' M_"VEC0[2-Y(Q_P ](@?YFO3M%\!^&/#.DPZ1INAVC) , M:IG^5 'SC\&/VJ MOC-\29M/?Q=\);S2_M04R^NR,#%7]/MH;6#RX"2/>@">BBB@!LK%$+"F@>?$":=(N]"M" 11@&@ C7;Q M7Q+_ ,%LOBI::9^RGXH^&L-THN[^R'E1@_,?E/3\Z^VRPVD@U^,__!$/@&MS_H^M6H#Q;NO[M.WXT ?5O_!OMX M] $J%I(\$8XI88_+3%1R7/ENB9^]4] !1110 4444 %%%% $-[@&2 M?05^9O\ P7A_;YA^ GPL_P"$0^&DJZE=:W9/;WBVC?- 6+#G./05]A_M_P#[ M4_A_]D[X+R>._$&IBU2X\R&)V(Y; '/NPK\9],\%ZE^UXWQ"^*/QP#C2[.* M6[T&56+AE"*0>< $E &E)P M?RKZH^('@KXF?\%1?VVKOX;Z#/?V7@FX*O#=VSXMCEST R>@':OG7]F#]IC4 M_%VG:U^R#\/'CF76]3F@2,8#';(PXQSWK]V?^"2'[#&F?LU_ 72)_$VE&+7( M0!+YD>6&%'<\T >!?M7_ +#'PP_9@_9'ATRQ\+V%_>6>ARB6Y^S_ #DC/)) MKB?^#4CQ"_B7X:_$8F/R5M_$5TBH.@ NF&*_17]N#X3>$?'7[/OBJ?7V8?9M M N7BPN>0A/K7YQ?\&J]O;:5X0^+$&G$F&'Q=?+GV%X] '[#2@$8/'O3E V8S M55;G[;:>9 >] $B;8R<\5'>1&6(E#S[4MPC-B1?2EAE"Q;I# M0!^(O_!R9\;/$GBOPYH'PP\*W,YFA\36R3I;O@[3<1@Y_#-?I#_P3!^ GA_X M._LT^'-;L=.AANM5T.*2Z*)AG8]<^O2OR^^(&FV/[8__ 5%\4_!+4B;B/1+ MZ*X6(?-M*NS=/^ 5^R%AX@\*_ 7X%:=-XANOLUAH>DKY[X'RHM 'D?\ P55_ M:PT;]F/]C_Q+XYT^_B35K( PV:G#M\CGCMV'YU^9W_!!CX6>//CS^V9=?MJ^ M/-#NOL.O64:I]J&4ROF-Q_WV*YS_ (*,_M0WG_!2;]LNQ_9W^ ^H_P!J^$-4 MBDBO65^=ZE%QAOUV_X)W_LJZ3^R_P#LQ:%\)X]-$$^G Y!BPP^5!]>U M 'T'9Q1P1B&! L:C" = *FJM8BY7,%JS0 4'I14=W] '&?M8_P#!0O\ ;:_;N\877AKX6?#[ MQ%::4TX'V_39$5&C)Y/#9QBOCGX]?LN^./A/\G:UXSOIM2UNX5Y&FE)D MA=E)(Z=:_J!^"W_!/OX#?L6_ C5'\*V"M<6.@7)W7-JN05B;N2:_"SPSX5\2 M_M^?\%#M/NGL%GTOP[XLEAG>(?<12R] />@#]L_^"'_A;Q3\,?V,K;1];U.Y MU.XWQ-YUP^YL;3ZU]J:8WVA/M4[;68U<7\#OA%HGP4\ VOA+P7$3;"&,G M4_MGWFFG]FSQIJ$TJ1R6FA3-$QZ@@=J]<^ MSQQQ>2?NU\)?\%HOVD+3X&_"_P#X0&WU 1R^*[%K9$)QO+%AC]* /EK_ (-[ M/C?XL\4Z/XDM);FXNXD\472!F?( %S(,5^QT%U(UH)I(L-Z&OR\_X-R/V6+G MX8_!77M>\16#13WFM2W461U#S2/GGZU^HYEMYF\@'GTH 5UCN4&2,TZ&(0\9 MZU#Y3Q-\H[U*ZR%P5'% $E%%% !5;4XY)X##&2">XJS32R%]IZT ?G[_ ,%Z M]:_L3]G#2K1-3,+3W8B8AL9W.H_K7GW_ ;Q?!6S^&VC>+=?MI06U,F5B!U) M9#_2M#_@Y)TG7Y?V??#TVAPEF_MF(MR1QYT==+_P0\N=7F^'US (AE;51+[< MK0!^@\!>Z3S&RN.,5XA^WC^T+:_L_P#P:OM-OVM_BO\9?C[-+>:>^C7DVH:6BDCSB%CP%QGU-?9W_!$7_@J%XT^'>O/ M^S)\;[">TN[C59(+:;5'!?RTE901R>,$5^B7_!/;]C[P)\,_V:M(U*PLL7?B M?1%.L!HA]YC@_7H*_/G_ (+"?\$TO%7P0^)/_#77[/\ H,C'0XFE:4 QJ'8! MCG;GNIH _:&PU^VO[1;K2)5N86^[*AX-79$%S$).C 9(K\Y/^"+/_!3(?'[P M'I/PP^)6LH/$X0-U?HO'))D2Q\JW0T +;W#2 Q2I[U/^7S\=Z ):*** "FE\'&*=3=F6)- "$ENU*B]S2@ M=*9<3>4I(H =( 1@MBN1^*7Q$TKX;^&+SQ%>31B.U@,DC/T4"N1_:H_:Z^%? M[)W@,^/?BSKXL+%RRI+QR0!ZD>HK\H_VIO\ @J9\8OVW?%]O\)OV'KB+7M'O M;G[)XD8RD&*(YR1L#>WI0!Y3_P % OC!\0_^"BO_ 4#T#X2?#^^O9/"MZKP M7]Q92?N%8%%PP_/M7[+?L%_LPZ%^RE\#M,^$MI:12_8/^7K9R?E [_2OGW_@ MFS_P2J\$_LZ>'XO&^OZ;(OB"6076)H]Q#N=[ M$M7\0W'RBRLWEA.?09K\6/C[X-\9?\%0_P!L_1;CQ3$\WA[3[U[2]>!R0%0[ M.@P/X: *W_!)3]ESQG^V[\:M/_;'^+VG75Q97ZIYFFZB-\?)W=.1W]:_;SPI MX-T'P5X>MM%TBVALX(4VQQ1+M ]@*Y#]F+]F'X??LG?"BV^%GPKM_P#0+7'E ML\05N!CMFO09Q9ZC%BZ,+7X:^!=1\:ZC(OE6,)D9GZ 5 M_,?_ ,%4O'][^WQ_P5 ?P[H_B60:1=QR*8H9#Y>?,4=!7ZR_\%Q/^"AFH?!O MP^W[/7@O4T^V^);/R882^"S%$+.WC9[6UVF0+R>!7O)$6X,4# MG/<=*XO]GC1K70/A/IEI'P%BP!^ KKXGC@D)N#@L?EH FNT-U;F,':3TQ7Y, M?\'&W[;G@[X6? 6'P5X>\06VH:P+XQ7&GHV7C#,BY.<>_P"5?5__ 53_P"" MB.E?L7_ _6/$?AW6$C\06BYMXG( (VL?\.U?SQ?M_AQH$[>+_'%S80R3ZKFBYK\P/\ @W*T3PIX=\"ZM;>'YRURMH!,A'1OE]Z_4/3I=2D0 M_P!H)@9_2@"6Y+7%L-G!]!2Q@RH%E7&WH34B*J,6_AJ&XN#.X2UYP?FH R?B M-XQT3P)X-O/%NOW<5M;6B9DGEZ**_$']H;X^7_[>G_!0V\_9WTBP.I>%YSN3 M4(\-"V9"/7/3VKZP_P""^'[>%I\%/AQJ7[..DZR(M:\0:>OV2WWX+$IGZ]Z\ MJ_X-ZOV&[RU^&>A_M%_$G3&7675!+(X+=@>IH _1KX/?LQ?#C3?@/I'@'Q?X M5L-1@L[(QPPW< 8)] >E8OA+]@K]G33=2FUI_@_H.]9BZ V"^M>YVT"K&L## M$2_ZO%6,O&-S( H[T ? O_!E MW_ /!"BZ\&/^Q+X,BT"Z,E\+#]^A X&T>] 'VU$9+U&BE8IM& <]:F MM+4VR;1,9.:?*D*D+(<%J6.,12A%'% "H4+8\SGTJ&YU'R#ME3"GJ37DWQ^_ M;6_9X_9KMI=5^*7BS["J9!.%ZCZL*_./]MG_ (.+?A?G_A&?V6/',.H:DV8E MB=U7Y^<#@F@#]1OB7\??@]\)M+EU;Q?XTL-/$*Y;SV(Q^0K\6O\ @IQ_P6'^ M,/QW^)U]^SC^SMX+O-0L$G BUW1V4>8KL5/.X'H,].]>;^#]"_X*L?\ !3'5 MQWDQC'(Z M_+Z]Z_2#P586>GZ>ME9:2EG'"HC6.-0 0.!_*OD+]JG_ (*H_LR_L;ZII/@^ MZ\:):?Z0L%Q&0@QR?]JOH7]EW]KCX-_M;^#O^$S^#GB :A:1*HN) %X;H>A/ M<&@#TP._VXKVKYR_X*:Q+_PS_K9:7'_$EN,?]\-7TFL:,_FK7RI_P5?U6XT_ M]G_51&<;M)G!_P"^30!^/7_!N_X;NM6^,OBZ[AE8+'XMN\XZ?\?#5_13IT,5 MK"D!;+;1S^%?@K_P;'^')M7\2>/-52+<8_%-V&K]Z[>$?+/+PP H G= M2/F%1^=(]!MM3T^Y.$=;EP2C=?NH>U ' MZX\Z3 M'8!AU]Q7PQ_P2Q_X*(?$#]GSXTZY^S/\?M8N)['1[[^S='BD1D1!M4C!.0>2 M>E?LS+;$:6UH?F#H5/T(Q7Y1?\%@_P#@GS>Z3XGT3X[?">![:;3KU=0U,:>F M#+M9L[^/3% 'ZK:'K.FZIHD&M60!CG@25<'/#*"/YU8:>2]M ]KE2?6OC?\ MX)1?MRZ9^U#\))AJ_EV=YHC"P^S2-\TAB)C)ZG^[7U_::S,WR)8E5]A0!-?Z MHNEPQBZ0L6.,@58MY3.!(C#!&<56U>ZV0HS6>_<>E % MWRUW;\M.1%0844M% !1110 V6584+MT%4+:._DO MFNI)&-0U6"3RQ:6[.Q M)]!7X3_M3-J?[47_ 62^'?B^+=^6"5-%F,/."YQVK\T_P#@B7\!X?V@-3\0?'#Q8 +[1?$MVEL+@98J+AP" M/P44 ?K=X=\.:;X;T]=/TV 1QKT45<>VBE.9%SCI3;%W> %P0?>IJ &-!$[! MF7D=*?SGKQ3&8DXQ3D.10 M%%% !5:>=[23S).5/ JS519A-^\?>(;Z)(+,9=3,%/0GO]*E^*7Q<\._"OP=J M7B?Q%?PVPLK*?Q!I MY'E0LI"P%?;_P#P M3L_X)Q>"OV+/A786NI1VNJZY9Q'[1J\B9ED 4=3@>_YU^;O_ TVS2+^T M+&"=RB8Y9 Q_G7TE!:&$[)FW#WH XW]IBSCU?]GKQA @YD\.W04>_EFOR6_X M-P/$R?"+4?B5X'UM&$NJ^,+XQ<8X-VYK]?\ XHZ*=7\ :SHT;Y^UZ=+$%'NI M%?BQH?C^+]@#]MO2?AOX@TX6T'B76Y9VN)A@*'8OGK[T ?MU#?PZ2@M6B)(] M!5J$+,#.>C#BLGP5XQ\,>.] C\0>'[^"]MW Q-"V5/%:Q@S\Z2<>@H DMDFC M#&9LC/ JOJ>HP:=:M=3(2@ZBIQ=0PH6:0%5^\?2O&_VHOVO?@K\$/"5U-XF\ M>:9;W,0)^S3RD-T- 'Y-?\$[=:\.1?\ !=SXP:]K?&_Q) MXR_X*8>+_%_PNU&>I4M_ME@V RN74\_1J_:3_ ()K_P#!(KP3\%+!/C)X M[U*V\07_ (@5;Z,WBEG@9L=.!SQ^M '.?\$:O^"2T'[-7A>#QY\8-(AN_$S7 M N+>]0 %56VV(.DIZ&@"\T_DIN?GCM5=;B6YE$L+80<$57UG6=-\/VSW^JWJ1P!=SR M2'A1ZU\6_MR_\%A/A9^RQ>OIW@?4=/\ $5^L>4LK:3<[MCD8R.] 'UM\5?BQ MX6^'?A^75=6UZSMS&K$K+=(IX&>A-?BQ_P %.O\ @OCKJWVH_#;X%RZI!>6+ MM#<7-O#)(C>^5&,8]ZY_QKXP_;#_ ."M_C5QI>G^(_ VDZ@P99X2$C4$]."W M:K'[7O[+7PS_ ."8WPGTC_A.;2Q\8:QXQ@^R-->)NDBD=C&&_AYXS0!\5_L< M? SXR?\ !3S]H'3?%?QLOSK5G%J++(LL9X7=C!R3CBOZ4/V-/V-_A9^R-\,[ M7PCX(\,I9+;;=BH1Q@>PKX1_X-^OV*(/ 7@76O'^MZ>%>]OWO+1)4^XKREP! M[8-?IC\5OBGH7PO\$2^+=?N8K>WBSN:8X7IF@#Y4_P""R/[2]O\ L]_ .ZOD MUJ.$ZG8S0;1, 3N!7'7WK\_/^#6GX?\ A+XG:S\2OB#KNG+<3KKL\\,N>F9Q MS^M>,_\ !0/XX_%S_@JU\6?%/P-\(6VHV&G>%?,N([VU/R3*@,A[GCY?2O:/ M^#7OQ/I_[-4/C/X8^)+I'O+S4I(5,Y^8L)0?Z4 ?N=8R!MJVXVQ@ 5)-=1; MS&ZDX-4(]58*L4=O@LH(Q5WS(6@5I" QZYH 6M+',][;EK8E M2..:DDX"@+D'K7E'[27[77PL_9L\.W.I>*_%%A:SPKG[/<28)XS0!L?'KX\^ M%O@;X"O/$/BF^BCV6TNPO,%^8+QU]Z_!W2O$GQW_ ."M'[:%W96OB%KK0?!? MB8$PRH2/)4 X!)Q_'6C_ ,%!_P#@HM\7O^"EGCN?]F?X&Z%J,-O#=*XU;22, M.CO@\Y/&%].]?HQ_P1L_X)86'[%G@M_'VO:VNI:GXBM!->1S#+QN<#G@<_+0 M!]C_ #^&/A'X6^ +'P]X5TK[*J64*W"C^)P@R>GKFNU6")7\P+SZU'8B,1[ M8X0@'& *GH " >HHHHH **** "FE8P^X\'UIU5[[RY8S#]H",: /@'_@OPRW MOP'T:'^[J2'/_;1*7_@AO=13>"]:A@8!EAQU[[EJ]_P7<\*ZIK?[.VF#1[1Y MV@NP[F,9. ZG^E>=_P#!OWXC3Q9IOBFPBNMKV#%)4!Y!#)UH _03XL?%G0_@ MKX)NO&?C$YMK7EV+8'0GK^%?C/\ LXQ:E^VQ_P %:O%$^LEKSPDT,4MC;L,J MK!Y3G/3LM?6G_!>+]J^T\,?L^:_\ O#]VJ:Y?1![?R6Q+PC#C\6%4O\ @@]^ MQZ? OP5T/X]>)YRVJZA!LG,X_><(.IQ_M&@#]#O FA67A?PK9>&;",)#9P". M-,]!69\6_A=HOQ:\&7?@;Q-:+<6%XN)H&(^;K_C6^UJL1,RW''4 4^&X^T*9 M2V-O:@#\+/\ @H%_P3[_ &B/V ?BG?\ [4?[/=]_9^B;]L%K9PEY%"L3T0YZ M'TKV'_@F[_P76T;QSJ:?#?XLP:BFHV9$$T]]&\2L^!S\Z^]?JYXN^'_@KXCZ M:^C>,M#M=2M7!_T>Y3 M%#^VM_P386YT^STOQ/X]BBF9DZ.,9R!R5^E=/X;_ .#D[]I?PI?+I_C?]C76 M=.A7[\MU;* /_(E '[>>;N'RTA28G@U^/>E_\'-_B2XP)_@-)']8Q_\ %UL1 M_P#!R-XSO4_XE?[/\\[$<+'&/_BZ /UN7"-,DUB?Q5ITBVT>^2*.^C+'VP#7YO_P#! M0?\ X+CZ+HL5Y\+OA)H>L)K4RG[/=VUM+(@QQU5?4CO63X'_ .".7[2/C;Q1 M_P )'XA_:9UU;:2X\UK.:Y^7:?X<;*^O_@9_P2^^$WP^NK>\\=Z+I^OW48&9 M[R+6S*5Y!/WG],=J M_4/_ ()__P#!*SX+?L?: NHVG@Z&'5IX0UW/&5^>3CG@>U?3/ACP?X.\&S#2 M?"O@RUL8(A^[%O%@#]:Z22$SA2#M [4 1V CEC 1,",;5SZ"A':2\:)SE13_ M +1%#((8P.?2H[U!:PS7I;!$3$#\* /B;_@M-^W/H/[)_P *K?PU-=L+OQ-: MM:VOE/R'M=%^V'^V5X0_9(^%]SXOUZ]ME:#<#',V.0*_&!= M&^-'_!:W]HV[\-WHU/P[X?T74TN;:[/$-VBD.5&-V0<8H QOV,_A)\'M=E-LM[ RXB#E5P6Z\&J/[0_@33/V<_\ @NKIFE3B.VMX M+4Y=F"J,2IWZ5^X_[%G[(O@3]E/P':^&?#V@VB3/:HMQ/#'@R, ,L?WK:I!&ZQ6]@/WAS\W''MZT ?KO^S[X@TO5?A/ MIFKM?P&!XLJYE&.@[YKPC_@HY_P4R^$'[(O@.\L[Z]CNM3N;,_8397(=D?KT M7)[&OR ^%G_!:[]LKP+\ =-_9VA_9F\1SWFFVK0-J8A7>Y88SG?_ $J;]BW_ M ()Y?M4_\%(?B;)\2_CYK'B#1+*PU SQZ?JQ^25#QMP >/F_2@#,^#]I^T5_ MP5U_:>LM:\07EU-X+N9'CN;&]M77=EU Y;V![5]>_P#!9G]DWP[^SO\ \$^O M#_PZ^'.C"RN--OF+L@!&W]UZ?0U^B?[*W[%WPM_9?\)P:3X:T"P^TQ*A$\,6 M&R!5']OW]DRU_;#^"]UX(GNQ:/;V\TJ.1RQVY Z'TH _/;_@V+\:VFKCQ;IE MS?1^=9@K(&D&2<)7[ 1RRWDHFB;]V.H]:_F,_98^-WQ-_P""27[9>J>"?&6E MWT6E>(?$OD1WES\L?ED#YNHX^6OZ#?AI^W5^S1XE\#V?B*7XPZ)$&LXFE!N# M\K% 2#Q0![3=N\R^3;G:1U)KP?\ ;C_;$\ _LH?"N_U;5M4@^VS:?(;;R[E= MP?D#CKVKQO\ ;&_X+3? OX ^&[F[\!^)=*\078#(EO:R[F/''I7Y='0?VFO^ M"S7Q@DCU(Z[X7T6QU%7B9CB*>/AL#&[CDC\* +O[+'@#XE?\%>?VN+'X]>.W MEO\ 0M UB:"2.ZA()C60H "WLM?OM\,/A%X*^$'A6+P7X(TI;33H<>7 ",#C M'H*\ _X)Y?L&>&/V%? *>$+*""]EO$666Z5.0Y^8D\#G)KZ?O7,MMF%N?:@! MZ^5)^[5.%HFEC,#94X Z4R*4)$H5M2@PJA#D8/4&@#X6_X+L_ V;X^_L) M>(/!/AK3G>_N-VPB,M_ PZ5^-_\ P3O_ ."JGCS_ ()K^/I_ /QELM8NM)TV M/RH;>"SE 7Y2.P-?TT:UX>\->);5M-US2H+JW;[T4JY4U\9?M!?\$:_@E\:? M$]SKT7A[2[5KF3<2(/?Z4 ?$OQC_ .#I_P"#OBS3H(?AYX(\0P7$<6)&^R3' M+8]HZ\'UC_@L+^V3^U!=G1/@9JNN:5/E7J^9N*/ 3^'2OI_X7?L*_LX_#U(I-,^$VB1RQ@;72UP: /Q/\*?\ M!*3_ (*O?MG7$6K_ !7^+4%[IERX=H+B#:<9R?O25]S_ +('_!OS\ ?A/'!J M_P 8?A]:W^IH [3H4_U@[]#7Z.:9HNC>'L6>AZ)%;1K]T1+@"M5G4P[V7) Z M4 (?\$)?^"OGAO]A;2KGX(?&:*\-Q=:DZ@LK(,"1O4'UK^BCXN_"/PI\:?# M%[X<\2:#;S+);M'&TZ9QGTK\ /\ @LM_P0_\:^!O%UQ\3O@C8W4SP*TR6^EQ M]7/ZU\;_P#!>']M_0_$ M?P TV/X:>++6-[R!DG6.[5B06(Q@'TK\)_"/PW_;+T6!;7Q/KGB;1W4(OBE827Y2_B5YXF(=(6 M>8+"T^F7&!D\Y@*DQGM\TM? MM/X,_8F_9:\#V<,&F_!'0$GBQ^^2TP2?7K7IFD>%_#WAVT%KH&F0V<>W 2%< M#% 'Y2?LO_\ !O#X>M=0M]8_:P\.V>O72D>?(FP9]?[U?H%\!?V%?V1& MGPM\"IIPB7";2.!^ %>SV\:&/!;=[U*J(@X H 9%;Q10K BX51@"G(B1+A1@ M4%_04TAB.AH 66&*X3;(N138;.W@SY:8SUJ1 0N#2T -CACB!"+C-.HHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** $?&PYZ550NS[(QE">35L@,,'O M58V\\=P#"<)W% %74[J_@3RK",,WH:QOB)\/],\??#S5?"^L6J/_ &E8/"^Z M,,5W#'&:ZKR4#F0#FF11R[R93D9XH _#?XI_#3]HG_@EM^U%9K\'/#S2>!+Z M]DO=;OIY67RR[>8>,$=6/<5^M_[(G[0>G_M&?"2S^(>CW23Q7.,.N.> >U/_ M &NOV<_#?Q]^%NI^'K_31-=W$.V(MC'3%?DW^S]^TY\7_P#@FQ^VJ?@O\2-2 MF7X>Z>JA;&&%U (+O"M[$8;R+S$C\]68#WKK#.\DZ_9SA<\T 7J*9),L?6DCN$ MDZ T 24449&<4 %%-\U=VVDDF6,9//TH 6;=Y9V=:KRVGVJ';,N,N=4O9E18K=VRS8Z*30!\/_P#!7K]H:7X$9Y)HO WB=$N@ZE@%7#G'3^_7[:?#+P[9^&/ .E:991; M&CTR!) /[PC4']: .C9A&N:C6Y#-MS7/_$/Q]IWP\\,OXAUB)WC0'<(^O _& MO&/V8?\ @H+\'OVHOB=K7PQ\#,\=_HCE;H33 \A=W3 [4 ?1012,\TT-B3:* M&N$C94/)(ZTS>OVO;GF@">BHKF\BM@"_.3CBG/M"QM"C;)"!R0/$[GQ9XOU&*:*V^_ M#!=+O/&>@R>U?C7^V=^T!^T=_P %5?B/_P *C_9XU.XMM*@OXY6CN[9V4PEP M6&P[U]8M8VJ1@E. .E &/XSUFR MT'PMJ.HW,@2)+&8JWN$)K^<_PQXYO/VJO^"CNM:/J#?:(/#?C)?)R=VT!4/X M?>K]K/\ @J5\4-<^$G[.]QKND7WD"99HP?\ @('K[U^6O_!NI\ M'^*/[5OQ M4\>^-M,-Q+)JS7%O(1CGRHN>10!^Z/@F&*#P+I$5F@W1:5;H !CI&HK3@N#* M@2Z^5NXI-)L%TZP2T@P%C0*H] !@4]5A,F)%R_K0 VZMXKA5'4+U!K\N/^"] M?[ 'B;X[:G;?M!?#?1I)=5\-V:M:B#*@L$V\E?I7ZFK"0K =".*S-8\*6/B3 M2+C0=<@$MK<#$J>HH _%G_@E;_P6/B_9W\)6'P(_:\\1)HVH0LOVB)Y [*!\ MIY;::^^M6_X+>_\ !/#PWHD>HZK\9DC$RX0^6G)_[[KS[]L#_@A=^SE\;_$M MSXY\.?#Z,:M+G;.Y0]3G^[7R_P"'?^#<'6-4\8D>/]!M;G18YE:& 1@$*#SU M)_E0!Z+^U+_P75TG5U.A?L=^(K?7;F[7:B2,JY;TXW5\N:%^QA^V]_P4T\;Q M^(_VE/"UYIFF7F1/)97DN I/H%4=*_3KX#_\$4_V+O@_'9:CIWPO6*^ME5C( M'3[X[__\$Y[+3?B) M\"O#LNH3QZC$;J2\W9$2R+N.3N[$U^FO_!.3_@JC\%OC#\/=.\'^)_&$::OH MUFD%Y;H%^20=1U'K7V!\9O@%X'^-7@ZZ\.^,M)%UYMO(J D?>*D#J#WK\2_V MKO\ @AE^VW\*?B)J'C/]D/5[/1K:^O7GG#6QI_$E(;J,D*I5/O=A][UK\AK/ M]D7_ (+MW5F?!J?&&T^RR'#)_9\O../^>]?07['G_!"CXZ?$CQ)%JW[;<=KK MMFX5I$CAV$L.3]YF]J *GQK_ ."N'[9O[3FH/X"_9C\/6VL:3=O]GDG6;:PB M/?Y4/\ZZ#]DK_@A9<_&3Q;:_&C]J$ZG9:NDOFK;&:21"&.3PS >G:OTC^ 7_ M 3@_9?_ &<].B'PX\""RN5098.I^;\%%>WV%A-:V?EW9SL&U/8#I0!P_P % MO@5X-^!_A"+P5X7T:V^QVRGRYS;*'/&.OX>M?BA_P&/V5X/%VJ:E';V6GZ/;_:I511MP@!KXJ_ MX*Q_\%3-%_:2\ ZE^SA^R1XC76?$-P6^S6B.$+9&TI)H ]N_X)4?\$XA\*/@OJ/Q7\;:&4\2^(?#MRE]%+'NP M[0LO4_7TK\S/B/XN\:?\$]_^"@.BVVL0?8--UOQ-)+*Q8@%&W-G'X5_2?%HU MGH^DIHVEQ[+=5VA/8U\&?\%_K0!]7_LW_'CP/\ 'GP):>-O"VK+ ]5\93_ -G6TA/E6NGS= >.CGM3 M(_CS_P %?OVXMO@MH$VD M_#KQ]%/KC0E;.V<*-TOI]X^GI7Y2^.=/_P""C7_!73XQQ:EXG\$2)X1N2\4] MY8W<@PI8!>%0#H#WKZ<_X)U_\$&/BEK^JOXV_;>L[;6Y3*)K)HX@A7I_>+>] M?KA\%OV:OAE\ /"B>&/AGH7V&%0IV9!Y ]@* /DS_@EI_P $6?6VA"3QWT._ ]6)]37VW$([*X,6C*"N<2*!@+]*V+9)1 $G.6[TVWL+: MU=I(4P7^]0 ^#;L!'7O3Z15"]*6@ HHHH **** "L_5H+& &_O9BJCJ16A5. M^TX:BQ@N1NB/44 >._MH?#IOBA\%[VQTNT%SLL)V0,N>=A-?E%_P2F_:Q^'G M_!/K7_B\WQU\0#2+BYOICI2/@A_WD9'WB.P-?MY<:+!+8/I1CS!)&49/52,$ M5^>?_!1#_@C!X,_:*\::7K7P\\,11P//OU@2!3YF0V>P[X]: /A-M?\ &?\ MP5:_X*1Z!\2/#Z-?^" DL-W=Q.2H)>,#Y1QT5N]?N=\%?A5X:^$WP[LOAMH7 MRV]E]P!,=@/Z5XE_P3V_X)W?"/\ 8W\"IX?T#PLMK=K(KAE*XR,YZ#WKZ>CL MD2Z:X Y(ZT 5Y5M(]L#R'TI)$AMW%J'X;DU9N;"*4%POS#H:A@L)F0M=8+@_ M*?:@!LEF;5?/L]CN"7?Y,<"BQ@OX[F1KAP4)^ M44 9][X3\'73&WU#1;.5G_YZVJ-_,5XI\?O^">WP*_:"6;2_$>D6UJDV=S6U MDBD9^F*^@+FPAF/FA?G'0T6]KM_>2C+^M 'PE>?\$!?V496\Q+^Z'T@_^SK> M\$_\$4OV;_!-TEQ8RS2%&R!)!G^;5]K?2F8D]: /*?AY^R)\)/AU;I!8Z%:2 MA,8,MDA_G7H=GX1\,Z="J:?H5G$!T,=JB_R%:AC5OO\ -1213( =JM,LQ;*MQ3B'V8!YH K/9VT4HGD^)$4/B&PLHH;2U.S#%1MQRWMZ5^D?[S06S+9EB/E;D@\@]S7Y@>#_\ @V$TR+Q\^J^*?"5K+I[7DC^6$7.PL2!W M[4 >"_$3XT?M;?\ !9GXJ/\ #NTT'S_ VI$,M]9W#!CN/HJ^GO7[._\ !/W] MB#P+^R[\(=&TBTL0FHPV@2Y+PC?GW/4UI_L;_P#!/[X,_LC>#+32/A]X5%C< MVN-C KQ@>P%?0$5LH7'S\QI+G2X+QEEN$RZ M6]\KVJ$ICO5Y)87C:.? 9U(9<>M20QW"O\ .W'TIS6<+2&1EYH M_.#_ (++?\$BO#G[:VG6/B30])<:GI:&6V^R1;"S_-C)7GO7Y,:K_P $I_\ M@I_X-U&3P!X4\!:E)I,CD>:=1G!V@X'\/H:_J(5"!@]NE,-G$\HGD7+#H: / MP/\ V2?^#=SQ;XN-GXF^/L>L6]XS*T\+W$KJ,<_Q$5^QW[+'[*'PU_9T\$V? MA[PC8Q&6VM?+9FMU#$^YZU[-A]_)XID5G! [21+@MUH I)+/);/'=QA6Z)CT MJ6R>.SL@]P<#U-3R6QD4EQENU(+-9;?R;@9% "6L,98SH>&Z4EQ# [[)7()Z M 4^WA>$E ?E'04XVZ._F2#)'2@"ND%I%)]F$AW>E20S9D:$ ':.*:;)C?_:@ M.*+NUF)#VAPV>30 EM-=L7:ZC "]#4\;1S?O8CTIP0M$$DYR.::L A39!P* M(YII.5B4$_2H8C=ABTR845;2/:"W\50+#=ER';Y2>E $J7-NT9<$8'7BH[E! M=0CRQQGM3A9HHV*/E/6E:&1%V0G !Z4 ,$T21>5'@D#FL[5O"VE>(+-X]7TJ MWGW<8F@5\_F*U!:(!N ^;'6B!)UC(D;GM0!\K?&3_@EI^SE\((%M; MN4Y:*VM%4#G/8BO:/@G^S]\./@WH4/ACPMI%KLM(M@E^R(&(]S7>G3(1-]K5 M/WO]ZHKK3IU99+(A6)^<^M #6DTRRF6%I<,?NC%6TDE:890;?6HVTJTF=)IX M\NHZU/*C^7MB.#0!%+#!&_F2,>:=MAN5PK=!3A )$ F&30L B/[L8H 9"L5N MXA#?G4S D<4AAC+^81S3J &JGN8H$)"EN,<#K7ZW? M3]J#X;?%[PK8WUKXBL4O)K6-GM1+\ZN0,KCUS3?VB?V6_ OQZT7^S-<8.X8S0 M!^M*;77>XXI))$B&Z- ?I7YM?L[_ /!7+XQ:#+!IG[:>C6WA>5<"Y7Y?E'?^ M%:^R?A5^V=\!OC!;QGX?>-(KZ1QG:H'3\S0!ZNM_(YVF BGF0I\Q//I45E?K M>6WVB!0.M-2:5'^T7:[5'6@"=%)S)ZCI50RRV4N&0R!S^53/.Y7SK==R MFFO=AT/DJ&('S<=* %F?;#]IC3('517PM_P6"_;JT_X,_!@Z'X0O4FUB6Y:" M2RMGS*H;:N2/Q/Y5[M^V-^VW\._V5_AIJ.N:QK\,.IVZ[HH)0,$8)[_A7Y5_ M 'X'_%G_ (*6?M@W?QB\8R55?\ V6OTHLH?L,!C)R%^ZOM6%\*O!NF_ M#?P#I/@G1+=!'IUJ(00@!(!)_K6_=SVJ7"QR28D(X6@#)\76%CJNC31:A9+< M(\3 0.,]17X,^-=;^,W_ 2E_;6\1_'"+P]JFKZ5XQUM=EM''\ENC80],<<9 MK]^GBMED,]PV#W7M7CG[3W['GPX_:QT9?#_CK3X((HE(BGCMEW=K;(3:3W&URV!D8)->M1_'[X-J/[?U#XF:5; MPCKYER !7YC_ +27_!![2OA1>MXN^"'C#7KN\CS+#:I?3*C,><8#D5XUI/[$ MO[<_Q( \#^-_#6L6.FR??N(KZ4,.W;% '[ :U^V!^S1H EOKCXV:#*0I*1&] M'7'2OC?]M+_@L?>^'E?P+\(/ ,VO-?J8DO=,4OY9QG/WO:O$OA+_ ,&\>E?$ M74Q-\3_B3XIL8U(==NJW."1SC_6"OM+]FW_@D=\&/V_>OU M"_9E_8V^$GP#\+6MII_A+3VU2*/$U^B'>_%>E:+H]AHVS2]$TFWAM !S! J# MCV K5M8+1;DK'-EAU6@!+6U$2M\GRI]Q?05+%?&4[6BP/4U.[HJ[<$QBG_P#!OG\.;70?!UY\ M0!8+"^MV7G,<8))"C^E=9_P5U_X)L3?MA^%(M-V74@&H++LC=L#YE/8^U?2? M["G[+.E_LY_"#1O"]JCH]MIXB<,"#U- 'N,*ETY2UN&<<^IHVQ0 M#R0>34L(V#9B@!]%%% !1110 4444 !Z54N]/LM50QWMJKC&/G%6^E0FX5B5 M2@#*@^'_ (0@F$ZZ';[L]=IK1@@M;+]U:VJHHZ;14@10-SL13EEAZ9S0 N#) M@],43KNC*TI9L?*/I3$G8G#C% #;9A&OEL/QK/\ $7@_0O$]LUIJ.GQ31N,. MKCAAZ5J20I,,9Q]*1(5A4G<<4 >=Z5^RW\"-!O3J&G?#C2X)BY=I$C.2Q.2> MM=UI.BZ1I%L+32;2.%!T6.G2QVMX^%F.1UP:FMK-+DW\ MC?>>>(DG]:3PM^S1\ O!$PD\*_"C2K%UZ/!$1_6NV%NR2>8":26>\0X2('WQ M0 ^#3+:TC2*QB6)%& J],59'2HH)3( 9.#4M !1110 4444 %%%% !1110 4 MC-M.,4M(5!.30 GF>U,,(D&2*DV"EH B2U5'W9J6C(]:* "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH CG\MQY,@R#34A2"+R8!C%2E5)R12X&#5O:O/'6A41/NKB@#P#XY?\$Y?V:/VC+F74OBSX0^VW$V?,;Y><]> MH-?*OQ._X)E?'GX-W4EQ^QQ#%I:*?W6Z,G"_\!([5^E)4'J*7 (VXXH _(Z> M_P#^"O7PBD/_ F?C>-K=#\H2&7[O_?=7W_X+'ZW^SKX7D/[1U_>W,T)S,84 M<<#KU!K]3-:\#^%/$*E=9T6&X!ZAQ7"^+OV+OV8/'D;Q>+O@[I-\K_?$T;'/ MZT ?F!X8_P"#G'X V_B!VU!=6.GS?);+M;ACQ_=]Q3_C'_P56^./QMMK6P_9 M6UFZM+K5EVVQFC<_,G- 'YA_ #_ ()R?MV?M/:Y!?\ [>E[!K.F M7+9E186!,9.0/G9OX:_3C]G']F;P#^S1X-M?A[\.-)%GI5F,00@#C@#L!Z"O M2+33K*QB6&TMU15 "@=@*FH HW$302![3C)^:G26%M>2+>.G[Q>AJV44]5H" MA>@H JW-D)XLL,M4R6Z"%5<9VBI:* *MS;1W0\R-?WB_=-):0W;1[+PY]:M! M0O04M %;,3OY##[O2H[R*\:=@8Q0!GSHR6AMM.X< M]*+:&/3H1<72_O6X)%7A&@.X*,T/&DHQ(H(]Z (82LBF1QD=14"W-A]L$>P[ M^U7@B*-H48IGV6W#^9Y0W#O0!2^R:C-J3?:&S!_"*G!FA8)GY<\5:I"JDY(H M CDB5I!(1R!2RL%&\5)@>E(5!&"* !#N4$TM P** "BBB@ HHHH .M1&*& M([]O-2TA4-P10!')_I$9V5'';B,[Y!5@*%X I2 1@B@"LNI6^_R@#G.*F>-7 M&Y1SVH^S09W>6,T_I0!7V70/RMQ3RDS+ACP>M2T4 5X[6WA^9%(/6E?[0_,9 MXJ? /:@ #I0!&L;,O[[FH3]ECD"A3DGBK5-,49.XH,T 5[E+UCF%N*?:K<@8 MG;-3T4 1L(XV&1U-2=:0JI.2*6@ HHHH **** "BBB@ HHHH **** "BBB@! M H'(%+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ? "_]D! end GRAPHIC 28 image_8x1.jpg begin 644 image_8x1.jpg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end GRAPHIC 29 image_9.jpg begin 644 image_9.jpg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end GRAPHIC 30 logo.jpg begin 644 logo.jpg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mrk-20241231_g1.jpg begin 644 mrk-20241231_g1.jpg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

M/GD^V?%S7+19,C;IMM:Z>$![ P1(>/7.??/->7^)OVY/C5XS:3^UOB[\3=06 M0."D_B>]>/#?>4*9,!3Z 8QVKRVBM.6*V1GS2>[.BU7XN>+-BJ)-VQ^*'B;3+I)[;Q%KM MO-&]%9NG![HT52:V9^SGP>_X. MF?#.HM##X^^%>N:3T$EUH.I17ZM_M"&982OT\QOKVKZ\^!?_ 6?_9N^/LD- MOI_Q*TO0M0FP/L?B%'TEU8]%\R8"%F/3"2-7\T]%9RPT'L:1Q,UN?U[:;J=O MK-A#=6=Q#=6MPH>*:%Q)'*IZ%6'!!]14U?RD_ 7]KOXG?LO:JMY\/_'7B3PN MRN)&@L[QOLLY!R/,@;,4@]G4BOT*_97_ .#G?QAX5:WT_P"+W@^Q\5V2X1]6 MT+%CJ '=G@8^3*W7A3"/ZX2PLEMJ;QQ47N?M917AO[)__!1_X-_MIV<8\!^- M-/NM6*[I-%O#]CU2+C)_<289P,J"BBBD,**** /D M/]N+_@M)\+?V _C/%X%\8Z#X^U+5IM-AU03:-8VDUN(I6D51NEN8FW QMD;< MSVOA^UM MK@Z(;M[V]NI3S(['H!T55&%51PJJ , 5SM=\<-&VI MP2Q4KZ'[O?\ $4!\ _\ H4?C!_X*M._^3J/^(H#X!_\ 0H_&#_P5:=_\G5^$ M-%'U: ?69G[O?\10'P#_ .A1^,'_ (*M._\ DZC_ (B@/@'_ -"C\8/_ 5: M=_\ )U?A#11]6@'UF9^[W_$4!\ _^A1^,'_@JT[_ .3J/^(H#X!_]"C\8/\ MP5:=_P#)U?A#11]6@'UF9^[W_$4!\ _^A1^,'_@JT[_Y.H_XB@/@'_T*/Q@_ M\%6G?_)U?A#11]6@'UF9^[W_ !% ? /_ *%'XP?^"K3O_DZOO;X*?%%?C7\* M-!\61Z'KWAN'Q!:+>PZ=K4,<-_;QORGFI')(JLRX;;O) 8 X;*C\-?\ @@K_ M ,$S/^&L?C&/B5XPT[SOAWX%NU:""=&)1"&#.!^^5 MGWLN0)8!]\[<\A5KYSKZ+"Y$E[U=_)?Y_Y'X'Q-XU3DW0R2%E_/):_]NQV7 MK*_^%'U9^TU_P60^-7[1;W-G;:Y_P@^@S$@6'A\M;R,G827.?.8XX.UE5LGY M<<5\K7-S)>7$DTTCRS2L7=W8LSL>223U)/>F45[U*C3I+EIJQ^)YGG&.S&K[ M;'595)>;O;T6R7DK(****T/-"BBB@ HHHH ]I_X)S:^OAO\ ;N^$MPVW$GB> MRM>03S-((1T]W^GKQ7]$=?S+?![QA_PKSXM^%O$&[9_8>KVFH;A_#Y4R29_\ M=K^FFOE^((^_"7D_Z_$_I+P+Q">#Q5#^647_ .!)K_VT****^?/W8**** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "OE7_@M5XA_L'_ ()Q>/(U;9)J M4NGVB$,!G-] S#WRB,,#UKZJKX-_X.$_&:Z'^QMH.DJ^)M<\40!ES]Z**"=V M..O#^5^?TSV8"/-B8+S1\KQQB%0X?QDW_P ^Y+_P))M:\-7_ >2PNFB$P'(610=LB_[+ CVKDZ M*4HIJS-*-:I2FJE*3C);-.S7HT?I#^R[_P '"?B3PT]OIOQ8\/0^)+/(5]8T M=$M;Y1W9X.(9#[(8A]:_2#]G3]L'X;_M7:(U[X%\5:?K3Q('N+/)AO;7_KI MX$BC/&[&TGH37\WU:7A'QCJW@#Q'::QH6IZAH^K6#B6VO+*=H)X&]5=2"#]# M7D8K):-36G[K_#[O\C]6X;\7LVP#5+'?OZ?GI->DNO\ V\FWW1_3U17Y+_L5 M?\%]M:\*/::!\9K)]>T[B-/$5A$J7T Z9GA&$F4"K7Q%X1US3_ !!HMX/W=U9R[USW5AU1QW5@&!X(%?-8K!5<.[5%IWZ' M]#<-\897GE/FP-3WEO!Z27JNJ\U=>9TE%%%U?RO>)?$=]XQ\1ZAJ^J7,E[J6J7,EY=W$A^>>:1B[NWNS$D_6O MUX_X.??VL?L^F^"?@QI=TN^X;_A)=<1'Y"KNBM(VQZGSW*G^[$<=#7X\UZ&& MC:-^YY^)G>5NP4445T'.%%%% !1110 4444 %%%% !1110 5_69^SU_R0+P/ M_P!B_8?^DT=?R9U_69^SU_R0+P/_ -B_8?\ I-'7'BNAUX7=G84445QG:%N> M.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110! M[O\ \$O_ /E(G\%?^QPT[_T>M?U"U_+U_P $O_\ E(G\%?\ L<-._P#1ZU_4 M+7#BMT=V%^%A1117*=05_*7^V-_R=W\5/^QPU;_TMFK^K2OY2_VQO^3N_BI_ MV.&K?^ELU=>%W9R8K9'F]%%%=IQ!1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110!T'PR^*OB;X+^,;7Q#X1U[5O#>N61S#?:==/;S(. MXW*02IQ@J>".""*_4[]@;_@Y2OM,EL?#?Q]T_P"W6O$2^+-)M0L\?/WKJU0! M7 [M 0!_JV))K\D:*B=.,MS2%24=C^M[X9_%'P[\9O!&G^)/">M:;X@T'5( M_-M;ZQG6:&4=^1T8'@J<%2"" 016]7\N_P"PW_P4.^)/[ 7C[^UO!6J&32KM MP=4T&\9I--U11Q\\8(VR ?=D3#CIDJ2I_H$_X)^?\%)/A_\ \%#OAS_:?A>Y M_LWQ'I\8.L>'+N4&]TQCQN' \V$G[LJC!R 0C90<%2BX:]#NI5E/3J?0E%%% M8FP4444 %%%% !1110 4444 %%%% !1110 444,P12S'"CDD]J "LGQSX^T/ MX8^%;S7/$FL:7H.BZ>GF7-]J%TEM;P+ZL[D*/Q-?"7_!07_@X"^''[+;WWAO MX>K:_$KQQ;DQ2-!-C1]-<<$2SKS*P/\ !%D=070C%?C#^UA^W+\4/VV/%G]J M_$+Q3?:O'#(9+33D/DZ=I^>,0P+\BG'&X@N0/F8UT4\/*6KT.>IB(QT6I^K_ M .VO_P '*_@WX;M=:+\%]%_X3G5XR4_MO4TDMM(A;U2/Y9KCG(_Y9+T(9A7Y M4?M3?M^_%S]LS5'F^('C75M6L?,WQ:5$_P!FTRVP21LMH\1Y'3>P+D 98UXY M179"E&.QQSK2EN%%%%:&84444 %%%% !1110 4444 %%%% !1110 4444 %% M%% $VFZG<:-J$%Y9W$UK=6L@EAFAE%3*"DK,J,G%W1 M_5M^RM^U/X/_ &RO@QIWCSP/>75WH>H.\.+FV:WGMYD.)(G0_P 2G@E2RGJ& M(YKT:OA#_@W*_P"4:6E_]C!J7_H:U]WUY=2-I-(]2$KQ384445)1^!/_ 0/GS) 0\>G@^BD+))COL3(VNI_(VN[#T MK+F9PXBK=\J"BBBNHY0HHHH **** "BBB@ KUS]AW]C[Q%^W-^T;H?P_\.JT M/VY_/U*_*%H]+LD(\ZX?Z @*"1N=D7(W9KRS1M'N_$6KVNGZ?:W%[?7TR6]M M;P1F26>1V"JB*.69F( Y)-?T=_\$>_^"<%K_P $_?V=(QJT,,OQ$\7+'>^( MKE<-]FP"8K)&'\$08Y()#2,YR5V@8UJG(O,VHT^>7D?1/P$^!OAS]FKX/>'_ M +X3L5T_P /^&[5;6UB'+-U9Y'/\4CN6=F[LQ/>NOHHKS3T@HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MLSQGXTTGX=^%K[7->U*ST?1],B,]U>7*O&FI?8[-28[6VB >ZU&;!(AA3(W,<=20H'+$#FOP]_;P_X*.>-_VZ M/%G_ !,YFT7PA92[]-\/VTI-O"1D"64\>=-@D;B,+DA0H)SZ.!RZIB7?:/?_ M "/@>-./\%D%/V;]^NUI!/;SD^B_%].K7TY^W_\ \%U=6\;RWWA3X+R7&B:+ MS%/XFD0QWUX.0?LR'F!#V=AYAR"!&1S^S7-S-+<7%P[2RRRN7>5V M.2S$\DDDDD]:BHKZ_#X6G0CRTU_FS^4^(.)OW"_X(3?%4?$+]@O3])>7S+GP;JMWI3AC\P1G%RA^ MF+C:/]S':O#SZG>C&?9_F?M/@CF"I9M6PC_Y>0NO6+7Z-GV51117R9_3X444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %?E/\ \''OQ%%SXM^&/A*. M3!L[.\U>XC_O>:\<41_#R9OS-?JQ7X0_\%J?BO\ \+1_X*">*H8Y!+9^%;>V MT*W(/3RXQ)*/PGEF'X5Z^2T^;$\W9-_I^I^6>,.8+#\/2H]:LHQ^Y\S_ /2? MQ/E&BBBOL3^2@HHHH **** "BBB@ HHHH *](_9E_:T\>?LB^.5U[P/KDVFR MR%1=VC_O+/4$!^Y-$3AAU /#+D[64\UYO14RC&2Y9*Z.C"XJMAJL:^'DXSCJ MFG9KT:/W=_X)_?\ !6/P3^VI;V^AZAY/A/X@*GSZ3<3 PZ@1U:TD.-_')C.' M49X95+U]7U_+Q8WTVF7L-S;32V]Q;NLL4L3E'B=3D,I'(((!!'2OU(_X)G_\ M%M/M\NG^ _C3J")(VVWT[Q9.P57/14O3T'IY_3^_W>OF4-5V_R/Z, MX%\6H8IQP&=M1GLJFT9>4ND7Y_"_+K^G]%-BF6>)9(V5XW 964Y# ]"#3J^? M/W0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "O-_VR/^30_BI_V)^K_^D4U>D5YO^V1_R:'\5/\ L3]7_P#2 M*:JCNA2V/Y2Z***]8\@**** "BBB@ HHHH **** "BBB@ HHHH ^F_\ @D-^ MUU_PQK^W3X1\07EU]F\-ZY)_8&O%GVQBTN65?,8_W8I1%*?:(CO7],-?R!U_ M2E_P1F_:W_X:]_8,\*:E>77VCQ)X53_A&];W,3(T]LBA)6)Y)EA,4A/3@ !)/H*L5\,_\ !P+^U?\ \,Z?L':CX?L+ MGR?$'Q.G_L"W"MB1+3&^\D [KY6(CZ?:%-5&/,[$RERJY^(?[='[3%U^V!^U MGXX^(5PTGV?7]2O):**]9*RLCR6[N["BBB M@ HHHH **** "BBB@ HHHH **** "OZS/V>O^2!>!_\ L7[#_P!)HZ_DSK^L MS]GK_D@7@?\ [%^P_P#2:.N/%=#KPN[.PHHHKC.T*X_]H7_D@7CC_L7[_P#] M)I*["N/_ &A?^2!>./\ L7[_ /\ 2:2G'<#^3.BBBO7/'"BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ]W_X)?\ _*1/X*_] MCAIW_H]:_J%K^7K_ ()?_P#*1/X*_P#8X:=_Z/6OZA:X<5NCNPOPL****Y3J M"OY2_P!L;_D[OXJ?]CAJW_I;-7]6E?RE_MC?\G=_%3_L<-6_]+9JZ\+NSDQ6 MR/-Z***[3B"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH *ZSX'_'/Q9^S?\ $W2_&'@K6KS0?$.D2>9;W5NV,C^)'4_*\;#A MD8%6!P0:Y.B@#^E#_@EK_P %2O#'_!17X8[6^RZ'\1=#A4ZYH8?AAPOVJVR< MO S$<A0KBBBN(+70]+BRD"-\]S? MRXR(H(A\TCGT48 Y8JH)'X5?\%(O^"XGQ$_;9N+[PWX8DN_ 7PUD9H_[.MIM MM]JT?3-Y,IY4\_N4(3G#>80&KYF_:G_:U\>?MF?%.Z\7>/\ 7)M6U*;*6\(_ M=VNG19R(8(ND:#T')/+%F))\VKNI8=1U>YPU<0Y:+8****Z#G"BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _H-_X-RO^4:6 ME_\ 8P:E_P"AK7W?7PA_P;E?\HTM+_[O_ $-:^[Z\NM\;/4I_ @HHHK,T M/P)_X.6O^4BEE_V)]A_Z/NJ_/FOT&_X.6O\ E(I9?]B?8?\ H^ZK\^:]2C\" M/+K?&PHHHK0S"BBB@ HHHH *_6;_ (-6/^1_^,W_ &#]*_\ 1EU7Y,U^LW_! MJQ_R/_QF_P"P?I7_ *,NJQK_ ,-FU#^(C]EJ***\T](**** "BBB@ HHHH * M*** "ODW_@KU_P %&K3_ ()]_LX2W&ES6TWQ"\5"2R\.6CX8PMC]Y>.IZQP@ M@X/#.R+C!8CZ(^.'QI\._L[?"77_ !MXLOET[P_X;M'O+N8\L57HB#^*1VPJ MJ.69@!UK^8_]N[]LKQ%^W9^TAK?C[7B]O%=-]FTK3_,+QZ59(3Y4"^XR68C& MYW=L#.!O0IJJ'?!V8*E))7948MNR/L[_@ MW:_X)E?VQ?P_M >-K#_1;1WB\&V^!M1C^QM4?#'A MG3_!7AO3]'TFSM].TO2K>.TL[6W0)%;0QJ%1%4@J]7F5*CG*[/3IT MU"-D%%%%9EA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 5XS^VO\ MP^#OV'_ (8R:YXCN!=:K>(ZZ1HT+XN=5E&. M!UV1KD;Y",*#W8JK7/VSOVQ/"_[%'P:N_%7B*07%TV8=*TN.0+<:KN222Q)8DGULMRUXA\\_A7X^1^8>(GB#3R.E]5PEI8F2T6Z@OYGY_P J^;TW ML?M2_M5^,OVP/BE<^*O&6H?:KILQ6EK$-EKIL&25AA3^%1GJK;"BBBJ.<**** "BBB@ HHHH **** M "BBB@ K]&O^#=CXTKH'QE\;> [F;;'XCTV/5+-6/!FMG*NJ_P"TTH%[+\&V?T<44V*99XEDC97C?%'XBZ]XFU)MVH>(= M1N-2N3G/[R:1I&_5C7[8?\%P/C\/@U^P_JFCVUQY6J^/;J/1(0KX<0']Y<-C MNIC3RS_UV'K7X:U]3D-&U.55]=/N/YH\;LX57'4,N@]*<7)^LME\DK_]O!11 M17OGX<%%%% !1110 4444 %%%% !1110 4444 ??G_!*W_@KS>?L^76G?#WX ME7D^H>!)'$&GZI*S23^'L\!6ZE[8>G6,=,J-H_8K3=2M]9TZWO+.XANK2ZC6 M:">%Q)',C %65APRD$$$<$&OY>:^^O\ @D1_P53F_9ZUFS^&_P 0M1DD\!WT M@CTN_F.X^'YF;[K'J+9B3G_GF3N&%+5\_FF5J2=:BM>J[^GF?NGAKXE2PTHY M3FTKT]H3?V>T9/\ E[/[.S]WX?V2HIL4RSQ+)&RO&X#*RG(8'H0:=7RY_2@4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 5YO\ MD?\FA_%3_L3]7_](IJ](KS?]LC_ )-#^*G_ &)^K_\ I%-51W0I M;'\I=%%%>L>0%%%% !1110 4444 %%%% !1110 4444 %?H9_P &Y?[77_"C MOVQ;CX?ZE=>5H'Q2MQ:1AVPD6I0!GMVYZ;U,L6!RS21^E?GG6AX2\5:AX%\5 MZ9KFDW4ECJNC7<5]97,9P]O-$X>-U]U901]*F<>:-BH2Y97/Z[**\S_8Y_:. MT_\ :V_9B\%_$33_ "E3Q-IL<]S#&^Y;6Z7Y+B'/_3.99$]]N:],KR7IH>LG M=7"BBB@ HHHH **** "BBB@ HHHH *_GD_X+_?M8M^T=^WGJF@V-UYWAWX8Q M'P]:JKYC:[!W7DF.S>=^Z/J+9:_;_P#;P_:8Y,5/3E*]%%%=IQ!1110 4444 %%%% !1110 4444 %%%% M !7]9G[/7_) O __ &+]A_Z31U_)G7]9G[/7_) O _\ V+]A_P"DT=<>*Z'7 MA=V=A1117&=H5Q_[0O\ R0+QQ_V+]_\ ^DTE=A7'_M"_\D"\;T445VG$%%%% !1110 4444 %% M:W@3P'K7Q/\ %^G^'_#NEWVM:WJLH@L[&SB,L]RYYVHHY)X/ KV'_AU_^T5_ MT17XD?\ @CG_ /B:7,EN-1;V/"**]W_X=?\ [17_ $17XD?^".?_ .)H_P"' M7_[17_1%?B1_X(Y__B:7,NX^678\(HKW?_AU_P#M%?\ 1%?B1_X(Y_\ XFF7 M'_!,;]HBUMY)&^"OQ+*QJ6(30+AV('/"A22?8#)HYEW#EEV/"Z*]"\8?LD_% M;X>1-)X@^&7Q"T.-1EFU#P[>6H QG)+QCL":\_DC:&1E965E."",$&JN2-HH MHH **** "BBB@ HHHH **** "OHC_@F7^WQK/_!/K]I;3_%%NUQ=>&-2*6/B M33$;B]LRW+JO3SHLET/'(*Y"NV?G>BE))JS'&33NC^NCP5XTTOXC>#]+\0:' M?6^J:+K=I%?6-W =T=S!(H='4^C*0?QK4K\E/^#:W]OAM;T34O@+XEOF:YTU M9-5\)O*^2\!):YM%_P!QCYRCDD/-T" 5^M=>74@XRL>I3GS1N%%%%06%%%% M!1110 445\!_\%G?^"P%I^Q/X4F\!^ ;VSOOBOK$/[QQB5/#$#KD3R+RIG8$ M&.-N@.]AMVK)48N3LB9245=C_P#@KS_P6@T?]B'2[SP+X$EM-:^+%U$N\LHF MM/#:.,B2<=&G*X*0GL0[_+M63\$O'?CS6OBAXQU+Q#XBU2^UK7-8G:YO;Z\E M,LUS(W5F8\G^@ X%5->U^^\5:Y>:GJ=Y=:AJ6H3/,$8=P047-1BY.R)E)1 M5V?#_P#P7Y_X*9G]IKXM-\*?!VH%O ?@>[9=1G@DS'KFI)E6;(X:*'YD3'#, M7;D;"/SFHHKU(1459'ESDY.["BBBJ)"BBB@ HHHH **** .D^#WPC\0?'KXH M:%X-\*Z?-JGB#Q%=I965M&/ONQZL>BHHRS,>%568X )K^FK_ ()]?L2Z!^P/ M^S9H_@?1_*NM0'^F:WJ2IM;5;YP/,E/<*,!$7LB+G)R3\C?\&_O_ 3(/[._ MPR3XP>--/,?C?QE:@:/:3IB31=-?D,01\LTXPQ[K'L'!:1:_2>N#$5>9\JV. M_#TN5%/#=XS?#SPA M[.."@Y6/K\I9OX\#NP&#EB*G+T6[/C>..+J609>\0[.I+2 M$>[[ORCN_DMV>*_MM?ME>)/VV_C5>>*=<9[6PBW0:1I2REX=+ML\(.@+G@N^ M 6;T 51X_117W%.G&$5"*LD?QGC<97Q=>>)Q,G*YK9LG^_NDBP.K2IZ5^U]?#YIA_8XAI;/5?,_LSPXX@6:Y M'2G)WJ4_C/$5G:,4VWV25V_N/R4_P""[W[28^,7[7,?A.QN/.T?X)_$E]XR\2ZAK&IW$EYJ6K7,EY=SR'+3RR M,7=S[EB3^-4:_0,/15*E&FNA_"W$&;U,TS&MCZF]23?HMDODK+Y!1116QXX4 M444 %%%% !1110 4444 %%%% !1110 4444 ?J3_ ,$2_P#@IBUR^G_!7Q[J M.6P(/">HW#=<<#3W8_\ D'/O'G_5K7ZAU_+O9WDVG7D5Q;RR07$#B2*6-BKQ ML#D,".00>017[J?\$E_^"@D?[:'P8.EZ]$HDAU13\K:E#]V.\4?[7W M9 /NN,X4.@KY?.,OY'[>FM.O^9_2GA+QT\3!9)CY>_%?NV_M)?9?G%;=UITU M^M****^?/W0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ KS?]LC_DT/XJ?]B?J__I%-7I%>;_MD?\FA_%3_ +$_5_\ TBFJ MH[H4MC^4NBBBO6/("BBB@ HHHH **** "BBB@ HHHH **** "BBB@#]?/^#8 M;]KO:_C#X)ZM=<-GQ+H"N>A^6.[B4G_MC(%'_39L=37[ 5_*7^R'^T5J7[)G M[2_@SXB:7YC3^%]2CN9HHSAKJW.4N(?^VD+2)_P*OZHO!OB[3_'_ (0TK7M) MN$O-*UNSAO[*X3[L\,J"2-Q[%6!_&O/Q,+2OW/0PT[QMV-*BBBN-OB)?>)]3DN+>*1MS6UJN([>$G_IG"D:?\!KS2O4 MIQY8I'EU)O^ M2!>!_P#L7[#_ -)HZ_DSK^LS]GK_ )(%X'_[%^P_])HZX\5T.O"[L["BBBN, M[0KC_P!H7_D@7CC_ +%^_P#_ $FDKL*X_P#:%_Y(%XX_[%^__P#2:2G'<#^3 M.BBBO7/'"BBB@ HHHH **** "ON#_@@9^RYX!_:V_;#\2>&_B)X=MO$VB67@ MVZU*"UGFEB6.X2]L8UDS&ZMD)+(,$X^;ITKX?K]'O^#7_P#Y/Z\7?]D_O/\ MTXZ;6=5M0;1I1UFKGZ;?\.3?V6_^B1Z/_P"#&^_^/T?\.3?V6_\ HD>C_P#@ MQOO_ (_7U117G>TEW9Z7LX]CY7_XQ\K_\ #DW]EO\ Z)'H M_P#X,;[_ ./T?\.3?V6_^B1Z/_X,;[_X_7U111[27=A[./8^5_\ AR;^RW_T M2/1__!C??_'Z/^')O[+?_1(]'_\ !C??_'Z^J**/:2[L/9Q['RO_ ,.3?V6_ M^B1Z/_X,;[_X_1_PY-_9;_Z)'H__ (,;[_X_7U111[27=A[./8^BBBNTX@HHHH **** "BBB@#Z/_X)#?\ *2WX.?\ 8P1_^@/7 M]-M?S)?\$AO^4EOP<_[&"/\ ] >OZ;:X<5\2.["_"PHHHKE.H**** "N)^*O M[-GP\^.EO)'XS\#>$O%0D7:6U328+J0#H,,ZEE([$$$=J[:BC8-S\_\ ]I'_ M (-R/@/\8;>>X\'_ -M_#/5Y,LCZ=<->V)8GJ]O.Q./18Y(P*_+W]M__ ((L M?&C]B:TO-:NM+B\9>"[0&1]=T,-*EJ@_BN(2/,AQW8AHQ_?K^D*AE#J5894\ M$'O6T,1./F8SP\9;:'\@=%?M]_P5G_X(+:-\9--U/XB?!/3;70_&<8>ZU'PY M !%9:Z>69H%^[#<'^Z,1R''"L2S?B/J&GW&D:A/:7<$UK=6LC130RH4DB=3A ME93R&!!!!Y!%=U.HIJZ.&I3<'9D-%%%:&84444 %%%% !1110!V'P ^-NM?L MW_&KPQXZ\.S>3K'A;4(K^WR2%EVGYHVQU1U+(P[JQ%?U2?!+XO:/\?OA#X;\ M;>'YFFT7Q1IT.I6C,,.J2(&VL.SJ258=F4CM7\E=?N%_P;)?M0MX]_9S\4_" MW4+@O>> [X:AIB.W/V&[+,R*/1+A9&)_Z>%KEQ4+QYCJPL[2Y3].J***X3N" MBBB@ HHKS?\ :V_:C\,_L;? +Q!\0/%4Q73M%AS%;HP$VH7#<16T6>KNV .P M&6. I($KNR!NVK/$?^"M?_!3K2?^"=_P6"Z>UIJ/Q(\31O'H&FR?.L '#7DZ MCI$A/ .#(_RC@.R_SG>./'&L?$OQAJ7B#Q!J5YK&M:Q-;?PYX)\-ZQXHUNYY6TTZV:9U7."[D<(@SR[$*.Y%?II^R)_P;%Z]XBC MMM4^-/BQ/#MNX#MH7AYDN+T=#MDNF!BC8<@A%E![,*B52,=RXTY2V/RA52[ M 9)X '>O?O@/_P $M_V@/VD8H9_"OPN\326%P T=_J,*Z79NI_B66Y,:N!_L M%CVP3Q7]!O[,W_!-WX)_LBQ02>!_A_H=EJD."-6NXS?:D6'\0N)BSID\D(57 MIP,#'N-"Z'Q-X6_X-[/V7?#Z*MWX-UK7"N MM=II/_!%+]EW17A:'X1:*_V?C!_P:Q7$<>#7RI>600>"#7]?%>)_M M5_\ !.SX._MG:?,OCSP3I=]JDB;(]9M4^R:I!@87%Q'AV"]0C[D]5-;QQ3^T MC"6%_E9_+?17Z6?MU?\ !N'X\^"L5UKWPAU"X^(WAV$&1M)G58] M H ))/ H \P_;2_:X\-_L0_L\:Y\0/$S^9;Z:GE65DKA9=4O'!\FVCS_$Q! M).#M578C"FOYC/VA?CYXE_:?^,NO^.O%U[]NU[Q%M?2'_!9;_@I' S/GX[KT:%/E5WN>?7JH##QVWHT:?+)*.A!1"")"1\L M?L9?LF>)/VV?VA]!^'OAE"MSJDOF7EXR%HM,M$P9KF3_ &44\#(W,54'+"OZ M=/V>>@%%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !117)_'/XR:-^SY\(?$' MC3Q!-Y.D^';-[N;'WI".$C7_ &W-;8MJ4L38?3M-)*L,]GG(9!Z(LG0E3 M7XUUV7[0?QQUK]I+XS>(?&_B"7S-4\07;7#J&++;IPL<*9_@C0*B^RBN-K[K M X18>DH=>OJ?Q3QMQ14SW,YXI_PU[L%VBMOF]WYNVR04445V'R(4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% %C2M5N="U2VOK.>6UO+.59X)HF* MO#(I#*RD<@@@$'U%?T/?L"_M66?[8W[,/A[QA')%_:WE_8=;@08^S7\0 E&. MRME9%']R1>^:_G9K['_X(P_ML_\ #+O[1R^&]5FV$]M1YH[QU_S/TSPMXJ64YJJ-=VI5K1EV3^S+[W9^ M3;Z'[BT445\8?UX%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^1O\ P7^_; 7Q MO\1M*^$>BW7F:?X59=1UPQGY9+YT_=1'U\J)B3CC=-@\IQ^BG[>61BSL?O\ P#\0\9.*EA\)')J# M]^IK/R@GHO\ MYK[D^YGT445]4?S,%%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 5Z)^RM^TEKW[)OQST/QQX?D;[1IH6S$>;;OU^5U MXS@[2%8A+EE%IIK=-:IG],GP6^+VB?'SX4Z M#XR\.7'VK1?$-HMW;.<;DSPT;@$X=&#(PSPRL.U=17Y&_P#! []M5O WQ!O/ M@]KUWC2?$SO>Z"\C<6U\JYD@'HLJ+N R!OCP 3(:_7*OA<=A7AZKIO;IZ']K M\&\2T\\RNGC8Z2VFNTEO\GNO)H****XSZH**** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "O-_VR/\ DT/XJ?\ 8GZO_P"D4U>D5YO^ MV1_R:'\5/^Q/U?\ ](IJJ.Z%+8_E+HHHKUCR HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH *_>S_@W&_:[_X7;^R!=?#W4[I9->^%]R+:$,WSS:;.6>!O M4['$T7'"JD7/-?@G7U-_P1Q_:[_X8[_;M\*:M>W7V?PSXE?_ (1[7=QPBV]P MRA)6]!%,(I"<$[48#K65:'-"QK1GRRN?TK4445YAZ84444 %%%% !1110 5\ M"_\ !Q%^U@OP#_8@?P?877D^(/BE'-,QQ$^6!\94445Z1YH4444 %%%% !1110 4444 %%%% !1110 4444 %? MUF?L]?\ ) O _P#V+]A_Z31U_)G7]9G[/7_) O __8OV'_I-'7'BNAUX7=G8 M4445QG:%N>.%%%% !1110 4444 %?H]_P:__ /)_7B[_ +)_>?\ IQTVOSAK M]'O^#7__ )/Z\7?]D_O/_3CIM9UO@9I1^-'[O4445Y9Z@4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !7\I?[8W_ "=W\5/^QPU;_P!+9J_JTK^4 MO]L;_D[OXJ?]CAJW_I;-77A=V[-&V,L[']B*Y_XK_#'1_C3\,O$'A'Q!:K>:+XD ML)M-O83_ !12H4;![,,Y!'((!'(K2G4<97,ZD%*-C^2.BNN^/OP>U']GWXW> M+/ ^K?-J'A/5KG2YG"[5F,4C()%']UP P]F%^/LGP)_P""D?@V&2;RM-\;I-X8O 3C?]H : ?7[3' /Q-?'-;7PY\< M7GPR^(6@^)-/.W4/#VHV^IVQSC$L,BR)S_O**F4;JQ496=S^N*BJ/AKQ!;^+ M/#FGZK9LS6>IVT=W 2.2DBAES^!%7J\D]8**** "OYY_^"Y7_!1Q_P!M3]HQ M_"_AO4#-\-O ,SVVG>3)F'5KS[LUZ<<,,YCC/(V L,>:PK])?^"^?[?C?LF? MLN_\(;X?O##XX^)DCWFO>(=:G M%O96-JFZ29SR?95 !9F8A54$D@ F@#!CC::15569F. ,DFOTH_X)S_\&\GB M_P"/D-AXL^,4FH> _",VV:#1T4)K6I)U&]6!%JAX^^#(1GY%R&K[:_X)7_\ M!#_PK^Q?9V/C+Q['I_B[XH,%EC8IYFG^'F_NVX8?/,.\S $=$"\LWWQ7'5Q' M2!V4L/UF<'^SS^S#X!_91\"1^&_A[X7TOPSI2[3(MK'^^NV48#S2MF29\?Q2 M,Q]Z[RBBN.]]SLVV"BBB@ HHHH **** "BBB@ HHHH **** "OF#_@H%_P $ MG?A?_P % =!N+G6+!?#OCA(MEEXGTZ("Z0@?*LZ\+<1#CY7^8#(5TSFOI^BJ MC)IW1,HIJS/Y=_VYO^">?Q'_ & /B%_8_C32S)I5X[#2M>M%9]/U51S\CX^6 M0#[T38=>N"I#'PNOZT_C/\$_"O[0_P .=2\)>--#L?$/A_54V7%I=)E3Z.K# M#(Z]5=2&4\@@U^!?_!5W_@C5XF_8)UBX\5>&3>^)OA3=SA8K]E#76B,Y.V&Z M"C[O0+, %8D A6(#=U&NI:/U>?,;'V9_P5#_;^TO\ X)\?LSWWB1FM MKKQ;K&ZP\-:;(?\ C[NR.9& Y\J$'>_0'Y4R"ZU_-/XW\:ZM\2/&.J>(->O[ MC5-:UNZDOKZ\G;=)25V.%55')8D@ #DDU#7ZO?\&[ MO_!,IO&/B"#X^^-M/_XE.DS,G@^TGCR+RY0E7OR",;(F!6,]Y S<&-2TU)J* MNRZ<'*5D?;'_ 1G_P"";,'[ W[/*WFNVL+?$KQG''=:[-PS:?&.8K%#Z1YR MY'WI"W+*J8^QJ**\N4G)W9Z<8J*L@HHHJ2@HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_*?_@X*_:\;4_$FC?!O M1[IEM]-":OXA$;8WS.N;:!O]U#YI!R#YD1ZK7Z:?&#XHZ7\$_A9X@\7:U)Y> ME^'+";4+@Y^9EC4MM7_:8@*!W) K^;SXQ_%35?CA\5?$'B_7)FFU3Q%?2WUP M9X\\$P)#,97S)JED,+%<\\LR\)(> M?FVL3^\ 'V?7\U/[.GQ_\0_LP?&/1/&WAFX\G5-%G$GEL3Y5W$>)() .L;KE M2.O.000"/Z$OV6/VF/#G[6_P4TGQMX9FW6>H)LN;9V!FTZY4#S+>3_:0D<]& M4JPX8$_'YM@?8S]I#X7^#/ZP\+>-5FN"^H8J7[^DNN\HK1/U6TOD^IZ)1117 MCGZP%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %-GGCM8'DD=8XXU+.[':J@TEEHX4_+>N2!+=G_KH5 7/1%7@%FKY4HHK[RC1C2@J<-D?Q/FV:8C,L M94QV*=YS=W^B7DEHO)!1116AYH4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110!>\,>)=0\&>)-/UC2KN:PU32[F.[M+F%MLEO+&P9'4]B& ( M^E?T5?L5_M,6/[7/[-?AGQQ:>5'2C(>]? MSCU^BG_!OK^U*W@WXOZY\*]2N&&G>+HFU+2D9_ECOH4_>*H]9(%))_Z=U'>O M'SG"^TH^T6\?RZ_YGZOX1\2/+\W^I57^[K^[Z37POYZQ^:['Z\4445\>?UB% M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7F_[9'_ M ":'\5/^Q/U?_P!(IJ](KS?]LC_DT/XJ?]B?J_\ Z1354=T*6Q_*71117K'D M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?TO?\$?\ ]KO_ (;( M_84\)Z]>W37/B30$_P"$?UUG;=(]W;*H$K$\EI8FBE)]9&':OIZOP9_X-P/V MNO\ A2W[7%]\.=4NEBT/XH6PAM][;5BU*W#/ 9&9H\#EG:(=A7[S5YE: M'+.QZ=&?-&X4445D:A1110 4444 >)?\%%_VI(OV./V-/'/CSS$CU/3[!K72 M%;_EI?S_ +JWX[A9'#L/[J-Z5_+I=74M]=23322333,7DD=BS.Q.223R23SD MU^K'_!SU^U?_ ,)%\1?!OP;TVY+6OAV+_A(=:16^4W4RM';1L/[TORCKT,/"T;]SS\1.\K=@HHHKH.<**** "BBB@ HHHH **** "BBB@ HHHH M**** "OZS/V>O^2!>!_^Q?L/_2:.OY,Z_K,_9Z_Y(%X'_P"Q?L/_ $FCKCQ7 M0Z\+NSL****XSM"N/_:%_P"2!>./^Q?O_P#TFDKL*X_]H7_D@7CC_L7[_P#] M)I*<=P/Y,Z***]<\<**** "BBB@ HHHH *_1[_@U_P#^3^O%W_9/[S_TXZ;7 MYPU^CW_!K_\ \G]>+O\ LG]Y_P"G'3:SK? S2C\:/W>HHHKRSU HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "OY2_VQO^3N_BI_V.&K?^ELU?U: M5_*7^V-_R=W\5/\ L<-6_P#2V:NO"[LY,5LCS>BBBNTX@HHHH **** "BBB@ M#Z/_ ."0W_*2WX.?]C!'_P"@/7]-M?S)?\$AO^4EOP<_[&"/_P! >OZ;:X<5 M\2.["_"PHHHKE.H**** "BBB@ HHHH **** /Y_?^#C_ .$4?PZ_X**RZW!& MJQ^.O#]EJTA7IYT>^S88]=MLC'UW9ZYKX%K]:O\ @ZI\-K:^-?@KK'R^9?66 MKV9.3NQ#)9N,CI_RW/3GKGM7Y*UZE%W@CS*RM-A1116AD%%%% !1110 4444 M ?U'_P#!-CQE_P )]_P3_P#@UJ3-YDC>#]-MY6Q]Z2&W2%ST'5HSTX],CFO; M:^7_ /@B[J,NI_\ !+_X0R3-N==+FA! Q\J7ZU"^N(;.QL87N+B>9PD<$:*69V)X"@ DD] *LU\ _\'$G[7K?L_?L M8+X)TNX,/B#XJ3OIGRG#1Z=&%:[;K_%NBA(QRLS^E$8\SL@G+EC=GXZ_\%(/ MVP;K]N/]KWQ5X[=YAH\LWV#0H),@VNG0DK ,'[K/EI6'9Y7KPNBBO5BK*R/* MDVW=A1113$%%%% !1110 445)9V ! M0!O_ C^$OB+XZ_$G1_"/A/2[K6O$&O7*VMG:0)N:1CU)_NJH!9F. JJ22 " M:_HJ_P""7'_!*_PK_P $[?AHLLBV>O?$C6(1_;6O>7GR\X)M;;<-R0*>IX:0 MCMS>['8[Z%'E]Y[A1117,=(4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !537] L?%6AWFEZI9VNH:;J$+VUU:W,0EAN8G!5T=& M!#*RD@@C!!JW10!YE^RA^R?X6_8U^&MWX0\&+>0^'YM5NM4MK:XE\S[%Y[!C M"C=3&I&%W9;& 23R?3:**&VW=@E;1!1110!^!/\ PI1^!'EUOC84445H9A1110 4444 M%?K-_P &K'_(_P#QF_[!^E?^C+JOR9K]9O\ @U8_Y'_XS?\ 8/TK_P!&758U M_P"&S:A_$1^RU%%%>:>D%%%% !6+\1OB)HOPC\!ZOXG\2:C;Z3H.@VLE[?7D MYPD$2#+$]R>P R22 20*VJ_$G_@X9_X*9_\+8\;3? OP7?AO#7AFZ#^)[N" M3*ZE?ITM00>8X#]X'K*,8'E G2G3K<6>@V8-AX>TQVS_ &?9*Q*[@./-G%)*R/,E)M MW84444Q!1110 4444 %%%;WPM^&.N?&CXBZ+X3\,Z?/JNO>(+N.QL;6(9:61 MS@9[!1U+'A0"20 30![M_P $L_\ @GYJ?_!0G]I>S\/D7%KX/T,I?^)M0C'_ M ![VN[B%&Z":8J43T&]\$(0?Z5O!G@W2_AWX1TS0=#L;?2]'T:VCL[*T@7;' M;0QJ%1%'H *\8_X)R_L+Z'_ ,$__P!FK2_!NF^3>:U<8O=?U15PVI7K ;V' M<1H $1>RJ"?F9B?>:\VM4YWIL>E1I\B\PHHHK$V"BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _/3_@X._:0 M;P/\"/#_ ,-["XVWGC6[-YJ"JWS"RMBK*K#T>8H0>_D,*_'ZOIK_ (*]?'EO MCU^W?XPFBE:33?"L@\.6(W9"K;%EEQ[&X,[#'9AUZU\RU]SEM#V6'BNKU?S/ MXM\1,[>9Y]7JIWC!\D?2.FGJ[OYA1117>?$A1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 5](?\$UO^"@&J?L*?&+[3-]HU#P3KS) M#KNG)RVT?=N8@3CS8\GCHZEE."59?F^BLZM*-2#A/9G=EF98C+\5#&827+.# MNG^C[I[-=5H?T[>!?'6C_$WP=IOB#0-0MM6T76+=;JSN[=MT<\;#((_D0<$$ M$$ @BM:OP\_X)4_\%0;S]C/Q2/"OBR6ZU#X:ZQ.#(!NDDT&9CS<1+WC;.9(Q MR<;E^8%7_;7PWXET_P 8^'[+5M)O;74M,U*%+FUNK:020W$;#*NK#@@@@@BO MB<=@9X:=GMT?]=3^R>#.,L+Q!@_;4_=JQ^.'5/NN\7T?R>J+U%%%<)]B%%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !117@7_ 4"_;W\-_L*_":34KQK?4?%>IHT>A:-O^>\E''F/CE84)!9 MN,\*#N(K2G3E4DH05VSCS#,,/@<-/%XJ2C"*NV_ZU;V2W;T1RW_!4+_@HOIW M[#OPN^Q:7);WOQ$\10NNCV9(862?=-Y,O/R*?NJ?]8P('"N5_"7Q#XAOO%NO MWVJ:I>7&H:EJ4[W5U=7$ADEN)78L[NQY+,Q))/4FMSXS_&7Q%^T#\3-6\7>* M]1DU37=:F\VXG88 P %1%'"HJ@*JC@ 5R]?:Y?@8X:G;[3W9_'/''&=?B#& M^TUC1A=0CV7=_P!Y]>VRVNRBBBN\^)"BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ KHOA%\3M2^"_Q2\/>+M'D\O4_#>H0ZC;Y/RL MT;AMK>JMC:1W!(KG:*4DFK,TI5)TYJI3=FG=/LULS^G#X:?$#3_BO\.M!\4: M3)YFE^(M/@U*U8]3'+&KKGWPPR.QKT%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %>;_MD?\FA_%3_ +$_5_\ TBFKTBO-_P!LC_DT/XJ?]B?J_P#Z1354=T*6 MQ_*71117K'D!1110 4444 %%%% !4U]I\^F3+'<0R02-&DH612I*.H=&^C*R ML#W!!J&ON_\ ;X_8X_XUH?LX_'#1[/\ Y@$7AWQ$T:=?GE>TG?'_ &TB+'_I MBN>@J92LTBHQNF?"%%%%42%%%% !1110 4444 :G@CQGJ7PY\9Z3X@T6ZDL= M8T.\AU"QN$^]!/$X>-Q[AE!_"OZI/V3?VAM+_:O_ & M%6W?99_NSP$^L'_!QY^UD?@I^QU9^ --NC#K MGQ0NS:RA&PR:=;[9+@Y[;W,$>#CA%5"/-*Q,Y;6Q7*[7/(Z***HD**** "BBB@ HHHH *_K,_9Z_Y M(%X'_P"Q?L/_ $FCK^3.OZS/V>O^2!>!_P#L7[#_ -)HZX\5T.O"[L["BBBN M,[0KC_VA?^2!>./^Q?O_ /TFDKL*X_\ :%_Y(%XX_P"Q?O\ _P!)I*<=P/Y, MZ***]<\<**** "BBB@ HHHH *_1[_@U__P"3^O%W_9/[S_TXZ;7YPU^CW_!K M_P#\G]>+O^R?WG_IQTVLZWP,TH_&C]WJ***\L]0**** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ K^4O\ ;&_Y.[^*G_8X:M_Z6S5_5I7\I?[8W_)W M?Q4_['#5O_2V:NO"[LY,5LCS>BBBNTX@HHHH **** "BBB@#Z/\ ^"0W_*2W MX.?]C!'_ .@/7]-M?S)?\$AO^4EOP<_[&"/_ - >OZ;:X<5\2.["_"PHHHKE M.H**** "BBB@ HHHH **** /Q[_X.L=1BEU+X%VBL?.ACUV9QCHKG3@O/U1O MRK\AZ_0[_@Y8^,,'CW]O73?#5K*LD?@;PY;6ERH.2EU.\ERW_D&2WX^OX?GC M7IT5:"/,K.\V%%%%:F04444 %%%% !1110!_3E_P22TZ32O^":_P;CFC\MF\ M.0S @Y5RSJ>/56!_'GFOHJO+/V&_"'_ @/[%OPDT5EVR:9X.TFWEXQF1;. M+><9/);)ZGK7J=>3+XF>M'X4%?SD_P#!=3]J$_M+?\%"?%,-K<&;0_ ./"]@ M ?E+6[-]I;TYN&F&1U5$K][/VQ/CW#^R]^RWX\^($QCW>%]&GN[99/NS7.W; M;QG_ 'YFC7_@5?RIZEJ5QK.HW%Y=327%U=2---*YW-([$EF)[DDDUTX6.KD< MV*EHHD-%%%=IQ!1110 4444 %%%% !7ZE_\ !NK_ ,$W8_BAXT;XZ^,-/670 M?#-RUOX6MITRM[J"??N\'@I!G"'D&7)!!AY_/K]DK]FO7/VO/VBO"OP[\/JW MV[Q)>K#)/MW+96Z_//<-_LQQ*[D=3MP,D@5_4A\&_A)H?P%^%7A_P9X9LUL= M!\,V,5A91<;MB+C(K:/\ V(UP,]6.6.68D^:UZ=&GR1L>96J<\KA1116ID%%%% !1110 M4444 %?N)_P;X?\ !,G_ (4C\/X_C9XUT[R_%WBJUQX=M9T_>:3ISCF<@_=E MN%P1W6(CD>8ZCXD_X(=?\$SW_;9^.O\ PEWBG3_,^&?@6X26]65/W>M7@P\= MF,\,@X>7K\FU3CS 1_0C'&L,:JJJJJ,*H& !Z"N/$5?L([,/2^VQU%%%<9V! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %(QJWA"37K;3\;'XAZEJ,^KZA<7=U(TUS=2--+(Q^:1V.6)] MR234-%%?H)_"#;;NPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ K[(_P""8'_!575OV,]9@\*>*&N=8^&M_<9>,9>? M0G8_-- .\9)R\7?EEPQ(?XWHK&O0A6@X5%H>IDV=8O*\7'&8*?+./W-=4UU3 MZK]3^G3P#X_T7XI>#=.\0>'=2M-8T75H5N+2[MGW1S(>A'H>Q!P0000""*V* M_G]_8&_X*0^,_P!A7Q8$L7?6_!=],)-3T&>7;'(3@&6%N?*FP!\P&&P P. 1 M^W7[,'[6/@C]KWX=P^)/!6K1WL.%6[LY,)>:;(1GRYX\DJW7!Y5L94D^/]:^*7C#4/$'B+5+S6-:U28SW M5Y=2&269SZGT'0 < 5CU]E@?4N6LIKJOR_I']1^">9.ME%3!R>M*>GE&2NO\ R92"BBBO#/V4 M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\W_ &R/^30_ MBI_V)^K_ /I%-7I%>;_MD?\ )H?Q4_[$_5__ $BFJH[H4MC^4NBBBO6/("BB MB@ HHHH **** "OZ,/V)/@#I/[4O_!$_P3\/M<7_ (EWBKP=]C:0#+6\F]VB MF7_:CE5''N@K^<^OZ;/^"0O_ "C1^#G_ &+Z?^C'KEQ6B3.G"ZR:\C^;'XH_ M#;5_@Y\2=>\)Z];_ &36O#6H3Z9?0YR$FAL&OU _X.7OV- MS\/?CAH/QBTBT9=)\<1C3-99$ 2'48$_=N2.\L"X ];9R3S7Y?UT4Y11GH6![5YA10]= 3L[H_KN\+^)K#QIX:T[6-*NHK[2]6MH[VSN8 MCF.XAD4.CJ?1E((]C5ZOSY_X-TOVN_\ A?'[&DG@34KKS?$'PMN!8*'/SRZ; M+N>U;_@!$L6!T6),GYJ_0:O)G'EE8]:$N:-PHHHJ2@K^;O\ X+:?M9_\-8?M M\^*)K.X\_P .^"S_ ,(SI.ULQNEN[>=*.QWW#2D,.J"/K@5^XG_!4#]J]?V, M_P!B3QMXRAN/)UQK7^R]# /S-?W&8XF7U\O+2D?W86[U_,+)(TTC,S,S,

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end GRAPHIC 32 mrk-20241231_g2.jpg begin 644 mrk-20241231_g2.jpg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�O&WAJYF:%=6T&^6 M9(YE +0R#[T4H#*3&X5@&!(Y%>0:_P#\%F/^"6GA;X^O^S#XA_;C\!6GC6'4 MO[/GTN74SY,-YNV&WDN]OV:.4/\ (4:0,&^4@'BOSN^ WQ?U#0/!'_!2_P#X M*H_L8Z#/X4^#OB3PL8/A->V=H;2WUK7M-TNYM[S7K2'"[(S=R"02 #S6=MV' MC<+]1_LP?\$__P!GG6_^#=KPW^S3J_PWTBXL/%_[/\.O:S+-8HTDNNWNE"]? M42Y&XW"7,N])2=RB- " H% 'Z$5P_P /OVDO@7\5_BQXX^!OPX^)>G:QXK^& MTEA'XYT>R9F?1Y+V.22V25MNS>Z12':K$KM^8*2,_%O_ 3DU']J[]OK_@@A M\%E^%O[45Y\-?&VM>&+?2=3^(D6CQZC?Q6-A>S6$[0K,P'VJ6"U"B;_\ ! _]FCP3^Q[_ ,%)/V\/V:CJ%Q/ MI5_:;I7[7'[3OAKP M5?ZQ$9=-TJ_FDFO)XMQ7SA;P))*(MP*^85"9!&<@UZ-\#_CS\&/VEOAKIWQB M^ 'Q/T3QAX7U5";#7- U!+FWE*G#)N0G:ZG*LC892"& (Q7YR_\ !.[Q#\$_ M#?\ P7#_ &T;W]JO6]%L/C$VOZ0/A_-XKN(HISX/^P_NAIK3$?N]OD^<(NXC MW=Z@_P""1OQS^#-[_P %NOVS?@9^R;J^FS_"O4+/0?$MK!X>=3I*Z]'#'::I M<6?E_N_WMP[K*R"-(\56-V;34=--W+.MC.#AHKB:&-XK= MU/#+(ZE2#N Q7T'J7Q8^%VC_ RD^-6J_$?0K?P=#H_]K2^*Y=6A73EL/+\S M[5]I+>7Y.SY_,W;=ISG%?(1^"7_!._\ X(=?\$K_ !#X&^-+6.L^ ;.SOF\4 M7'BJQMI]2\>:A=R2R"WG7:!>W4V\0H"#A$!.U$)7\][[X(?'GX?[25GJ6D6WQK_:=T2P\8^%KZ>036OA:YU.ZOX]*FW8<'8UM(4;!C90A *8 M !^KW[+O_!6/_@G)^VE\1;GX1_LP_M<^$_%GB>VBDE.AVL\D%S/''R[P).B& MX51R6BW@#DG'-=-^UO\ \% ?V,/V$-%T_7?VNOVB_#G@:+5F9=*M]5N6:ZO= MN-[0V\2O-(J[EW,J%5W#)&17QS_P<8>"_!GP$_9)^%G[9OPP\):;HGB[X#_& M#PQ=^#]1TJR2W>UL'NA;3Z:OE@8M9$D4-"/D(C QBOJ?2O\ @GQ\'=*_X*"> M(_\ @I-XQ\07NO>++_P59^'-!L]=B@DL_"ME 2\K6)*;X6F_P#!4O\ ;"_X*:?L6^'[:/X.>#?@ M3-X>U?Q'IEN(]+\;^-;%OMSWT&T!;GR(8GMVF&0WF*P+"8,WKG_!"/\ 9&^" MGQ"_X(E>%=$^+W@33O$TWQRTK5->^*=_JUJDT_B*[U"\N6::YD8$O(L9C16/ M*^6&&&YH _0NQOK+5+*'4],O(KBVN(EEM[B"0.DJ,,JRL.&!!!!'!!J6O@?_ M (-I?B3XQ\<_\$F_"'A'QQK"=8\5WUW]ETW3!=2P+?SDX6*WFFC2*X=CPJQNQ8_ M=!KN/^"@G[$_A3_@H7^R]K/[*/C[XAZ_X;T#Q#>V4NM7'AR2-)[N"WN4N/LK M%U/[J1HT#XP2!C(R:^)O^#BRP^ %[^Q=X._X)C_ GX6Z-J'QH\>^(='LO@-X M+\-V4<-UX;%M>122ZK'Y0!L+6*WAFB:8;5(=NJ)*4 /OS]I_]KO]F;]BWX;G MXM_M4?&K0O!'AXW*VT-_K=UL-S.02(88U!DGDVJS;(U9MJL<8!-4OV4/VW?V M3/VYO!5U\0OV2OCSH'CG2K"X6WU&31KD^;92L"52>&0++"6 )7>J[@"1G%?% M&I>&6_:!_P"#D3P7\+?C7+%XCT[X"?LJ?\))X?@OH0\/_"2WNJ16DVI"-LJ) M# 5P<95HD8$$ B]\5M)TC]F[_@Y4^#^N?#'2X-*C_:"^"WB+3/B!:V,0CBU2 MZTK-[;WTRKP]P%58O-/S;!MS@G(!]$?M(_\ !8G_ ()C_LB?%!O@M^T1^V5X M0\.^*H2@O-#:::ZGLBX!47 MHY!;$JRMB4H=I#=#FO>_AW\1O 'Q=\#Z7\3/ MA7XUTOQ'X=UNT6ZTC7-$OX[FTO(6Z21RQDJZ^X/8BOE_X._LN_L5?\$=/V4_ MBC\2/C)\0H+_ $;7]=U7Q3\4?B#X\M;:2^UN6\D+&"F:[IHN5\%Z-J*(-) MWVCG:T22H]R(C\LB2@]'H ^[;[]I+X%Z=^T'8?LIW?Q*TX?$34_#4WB&S\)J MS-=-ID4JPO=,%4K&GF.%&X@L0VT':V.XK\?_ -D?]B8?L2_\''WAOP_XA^.W MBSXG>,?&7[+.J>(?'GCWQES0[BOG"VMTDE$>X,OF%0I*D9R#7NE?.WPM_ M80^ W[-O[6'QE_X*(^,?&DFJ>)_B';6_VNOAG;_&+]F;XP:%XV\-7,S0KJV@WRS)', MH!:&0?>BE 928W"L P)'(KR#7_\ @LQ_P2T\+?'U_P!F'Q#^W'X"M/&L.I?V M?/I%C!\)KVSM#:6^M:]INEW-O>:]:0X79&;N02"0 >:SMNP\;A? MJ/\ 9@_X)_\ [/.M_P#!NUX;_9IU?X;Z1<6'B_\ 9_AU[699K%&DEUV]TH7K MZB7(W&X2YEWI*3N41H 0% H ^W?C7\<_@Y^SA\-M1^,/QZ^)NB^$/"^DH&U' M7=?U!+:VAW$*J[W(RS,0JH,LS$ D@5Y+^R?_P %7?\ @G5^W'XQN?AW^RO^ MUGX6\6^(+6!IWT*WEEMKR2)?OR10W*1O,BY&YHPP7(R1FOE#_@G=^S)X9_X* MX?\ !+S]B[XX_M4>,]7U6#X7$ZK/X8N%BGT_Q/>Z=)/IEM)J*2JQF,:VY<'/ MS-+)OW!C5/\ X*=:EX!_:;_X*[?LF?LT?LIZ+::A\7OA-\1;;QG\3/%.APKN M\)^#H%'VC3KV=!^[%ZKJB0,<\IE0)UW 'V9^UW_P4Q_8,_8-O=/TC]K?]I_P MSX+U#58//T_2;Z:2:]FAW%?.%M;I)*(]P9?,*A25(SD&NY_9S_:>_9[_ &NO MAG;_ !B_9F^,&A>-O#5S,T*ZMH-\LR1S* 6AD'WHI0&4F-PK ,"1R*\Q^%O[ M"'P&_9M_:P^,O_!1'QCXTDU3Q/\ $.VLY-3U[Q:TK;OGC=5 /TRHHHH **** "BBB@ HHHH M **** "BBB@ HHHH ***I^(=,NM:T"^T:QUBXTZ>[LY88=0M OFVKLA42IN! M&Y2=PR",@9% 'S1\8_\ @M;_ ,$J/@!\7[GX#_%S]N+P1I'BJQNS::CIINY9 MUL9P<-%<30QO%;NIX99'4J0=P&*^@]2^+'PNT?X92?&K5?B/H5OX.AT?^UI? M%*+CQ58VT^I>/-0NY)9!;SKM O;J;>(4!!PB G:B$K^>]]\$/ MCS\./^"+7["__!//]I*SU+2+;XU_M.Z)8>,?"U]/()K7PME3;L.#L M:VD*-@QLH0@%, _5[]EW_@K'_P3D_;2^(MS\(_V8?VN?"?BSQ/;122G0[6> M2"YGCCY=X$G1#<*HY+1;P!R3CFNF_:W_ ."@/[&'["&BZ?KO[77[1?ASP-%J MS,NE6^JW+-=7NW&]H;>)7FD5=R[F5"J[ADC(KXY_X.,/!?@SX"?LD_"S]LWX M8>$M-T3Q=\!_C!X8N_!^HZ59);O:V#W0MI]-7RP,6LB2*&A'R$1@8Q7U/I7_ M 3X^#NE?\%!/$?_ 4F\8^(+W7O%E_X*L_#F@V>NQ026?A6R@)>5K$E-\+3 M.7>1BQ/SN 0KL" =E^RQ^V=^RO\ MN> Y?B7^RA\=?#_ (YT:VN!!>W&B7>Z M2SE(W".>%@LL#D,+2 M\^R:AIMSJ3&.QN,X,-Q$UU6"YN[IY/ M].\0:LL4<, 1YEVRNID6.W7:"4S0!^H-C?66IV4.I:;>17%O<1++;W$$@=)4 M895E8<,""""."#4M?-'_ 1M\#W'PU_X);_ WP)=?&'1_'K:9X M(1XG\/ZD M+RQN%^8K#!,/]9' "+<'@X@P0I&T?2] !1110 4444 %%%% !1110 4444 % M%%% !1110!2\2^)?#G@SP]?>+O%^OV6E:3I=I)=:EJ>I7206]I!&I:2661R% MC15!8LQ !)-?-7P:_X+5_\ !*K]H+XP6WP%^$'[<'@G6/%=]=_9=-TP74L" MW\Y.%BMYIHTBN'8\*L;L6/W0:[C_ (*"?L3^%/\ @H7^R]K/[*/C[XAZ_P"& M] \0WME+K5QX[@M[E+C[*Q=3^ZD:- ^,$@8R,FOB;_@XLL/@!>_L7># MO^"8_P "?A;HVH?&CQ[XAT>R^ W@OPW91PW7AL6UY%)+JL?E &PM8K>&:)IA MM4AVZHDI0 ^_/VG_ -KO]F;]BWX;GXM_M4?&K0O!'AXW*VT-_K=UL-S.02(8 M8U!DGDVJS;(U9MJL<8!-4OV4/VW?V3/VYO!5U\0OV2OCSH'CG2K"X6WU&31K MD^;92L"52>&0++"6 )7>J[@"1G%?%&I>&6_:!_X.1/!?PM^-$/#OBJ$H+S0VFFNI[(N 5%P+:.06Q*LK8E M*':0W0YKWOX=_$;P!\7? ^E_$SX5^-=+\1^'=;M%NM(US1+^.YM+R%NDD5% %)=GPJEI#GYY_X(K?$/1/\ @GO_ ,$?OB)^V)^T MSHM[\/OAAK'Q)\1^/?AWX0OTQ"/V<_B#\5--TWQQ\1VNQX*\-2;WN=4%K$99V4(I"*J M G'+308SI&B(AP!-''=3S7#X4M/OW^H M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K M\.O^"H7_ 4-TC]JS_@H+XA_8[_:O\#?'#2?V7?AAJ(MM;\/?#7P!?W%S\3M M9@D DBN[J/9Y6F12*RA(V)EV!P)=1F9KF[5&'WT6>:55;^( 'C-> ?\$U/"'BS0_P#@ ML=_P4#\2ZUX7U&ST[6-=^'C:1J%U921P7PCT2Z60PNP"RA6(#;2<$@'%??E% M 'Y=_P#!1CXQ?L,C]M7Q%\-?^"TW[ .FWG@/2M+T^Z^!7QCT_P"'VJ:T-8C: M-FO=,NIM/BDEAFCN#\EN1Y;+EV"[T+]A_P $7?V?]=\1?M'?&W_@HI)^SG=? M"/P+X\M-$\)? [X>:AH*:5=6/A?2H67[7)9*!]E6ZF82I&0" K'YE9';]%** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K"^*'Q T?X3?#3Q%\4_$5 MI>W&G^&="N]5OH-.M6GN)(;>%YG6*->9)"J$*HY8D =:W:* /Y_OV?\ _@I5 M\%_VC?VJ9?V^/^"MGP$^._B'Q'X;UF;_ (4K\'=%^$M[>>&O EHK#R[QM^P7 MNI/M#&=UPA56 RL2P?:/_!1CQ=XG_P""E?[!7PM_X* _L2?!3QOJFO? GX[: M1X_TSP)XA\.R:=K6MV^E3O'>VD5L^6+.DGF*!EI!#M0,S!3^F%% 'Y*?MS?M M?^ O^"Y^F_"O]@+]B?X=_$#4K75?B9HOB#XU:]XC\!ZAI%GX,T33Y3<7%K=2 MW<2(]X[A%CCB:1&9" _(-=V7D/F.S$[B?GC]@O\ X*;6W_!*']AR#_@G5^US\ _B7)\=/A*= M2T/P5X5\/?#_ %+4+?XAQ?:IY=/N--N[>%X/)=)8HV,CJ5V,0"?D'Z[44 ?( M_P#P0V_8]^)?[$/_ 34\!?!_P"-UH+?QUJ#W_B'QG:!P?LM_J%W+=&W8J2- M\46ZR?$7XJZU\%;MY 2 3IVG(6 M+",@*L:!=X12P55CCC_<.B@#\U/VR/ M%.L?L0_\%6/AW_P5]O\ X8>+=8^#GC[X'/\ #_XF7_AWP[/?W?A-_MJ:E9:E M=6D"M-Y3?) Y16\ORV!!9D5X?V>O'7_#SS_@L/HO_!1'X8^!_$^G_ KX#?"G M4M$\+>-/$WAN[TS_ (2G7M1=AZC.=3OH+/^SK34XKZ.(VCV3((IVE\T$KOVAEVNWZ_44 ?CW^U MU\;OVF/^"(O_ 2/_9X_X)]_ #PWKK?$OQ'H8TWQ3XZ\->%9];B\%P[TGU6] MABA4K/<">\=+=6(#!'?@J =S_@E3_P % O\ @E_^R9%H7[,W[/O[._[1ESXN M^(WBJS@\6?$KQS\*KLW_ (DUB[G6+[?J=Z[DK&))F;^Y$K.0,EV;]:** /PZ M_P""H7_!0W2/VK/^"@OB']CO]J_P-\<-)_9=^&&HBVUOP]\-? %_<7/Q.UF" M0"2*[NH]GE:9%(K*$C8F78'!RR-!^C?_ 39_P""B7[*G[7=C>_!3]EOX#^/ M_ FD^ =#M%M=+\5?#J30;&"T),44-JI.T[0GW% P,5]544 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !6%\4/B!H_PF^&GB+XI^(K2]N-/\,Z%=ZK?0 M:=:M/<20V\+S.L4:\R2%4(51RQ( ZUNT4 ?S_?L__P#!2KX+_M&_M4R_M\?\ M%;/@)\=_$/B/PWK,W_"E?@[HOPEO;SPUX$M%8>7>-OV"]U)]H8SNN$*JP&5B M6#[1_P""C'B[Q/\ \%*_V"OA;_P4!_8D^"GC?5->^!/QVTCQ_IG@3Q#X=DT[ M6M;M]*G>.]M(K9\L6=)/,4#+2"':@9F"G],** /R4_;F_:_\!?\ !<_3?A7^ MP%^Q/\._B!J5KJOQ,T7Q!\:M>\1^ ]0TBS\&:)I\IN+BUNI;N)$>\=PBQQQ- M(C,A ?D&N/\ ^"V?_!0SQ!\4OVVF_P""%_V>?#NGPS_ !<\0?"O MP->7NJ>.+F6*.9=$@N$ 6WL?+E59I%)+L)8\$ 9_9NB@#X<_X)P_\%#OV0OC MEH,G[%'[ /[.7CWX9_\ "(^!+J[\+6WC;X7W.DZ+:+$\42!G,FZ9S-<)(Z[O M,E'FN6+98^9_"7_@O1;_ M^!]_\'/\ @I?^S?\ $#2?VD=$DO=.U+X7>$OA M9JE];>,)1+(+=])FBBFMI+>:(QC=),!G?C>NTM^E]% 'Q;_P0 _9*^-?[&7_ M 3,\)_"O]H#P]_8'B/4M8U37Y?"0EWCP[!?7;SPV'7"LB,&9?X7D=3R":^T MJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y@_P""OW[=7CW_ ()Z M?L0>(/CO\(/A-J/C7QM=7<.C>#-#L=+GNXSJ-PKE9[A( 7\B*..65@,;RBQ[ ME+AA^;?_ 3=_P""BW[!?[']YJO[2'[0/PN_:7^*7[17CRW63XB_%76O@K=O M("0"=.TY"P%I81D!5C0+O"*6"JL<>?\%A]%_X*(_#'P/XGT_X%? ;X4ZEHGA;QIXF\-W>F?\)3 MKVHNPN9+*WNHTF>VBM"RLY0$2*!M^85^F-% '\_K_P#!2[X.?MT_MEZC^T;_ M ,%3/@'\>-0^&_@/Q&Q^!WP&T/X3WMUHH6/A-:UC.T7EX^?E@8&./YE^920W MZ ?%+X>?!#_@XH_9H\/ZQ\//B1\9?A!I?PU^*4=_:_;_ JFE7MSJ=I:QR02 M_9[L.LD4?VI61\<2*P'W:_0*B@#\2/VW?^"4'[5WAK_@I!^R#X.;_@II^T-X MQ/B#5_&"#X@7Y@ENO _E:7 _F6TL:_:?PEHMWX;\*Z9X M=O\ 7KK59[#3X;:?5+X@SWCH@4S2$<%W(+''\_P#)K/P/_P"R@:C_ M .D(H \__P"#3;_E*9^UW_V\?^GR>OW^K^3W_@EW_P %A?AM_P $>_\ @H'^ MT5\2/B1\'=<\8P>,=^(' M_A16/^% '[?45^(/_$;S^RS_ -&/?$#_ ,**Q_PH_P"(WG]EG_HQ[X@?^%%8 M_P"% '[?45^(/_$;S^RS_P!&/?$#_P **Q_PH_XC>?V6?^C'OB!_X45C_A0! M^WU%?B#_ ,1O/[+/_1CWQ _\**Q_PH_XC>?V6?\ HQ[X@?\ A16/^% '[?45 M^(/_ !&\_LL_]&/?$#_PHK'_ H_XC>?V6?^C'OB!_X45C_A0!^WU%?B#_Q& M\_LL_P#1CWQ _P#"BL?\*/\ B-Y_99_Z,>^('_A16/\ A0!^WU%?B#_Q&\_L ML_\ 1CWQ _\ "BL?\*/^(WG]EG_HQ[X@?^%%8_X4 ?M]17X@_P#$;S^RS_T8 M]\0/_"BL?\*/^(WG]EG_ *,>^('_ (45C_A0!^WU%?B#_P 1O/[+/_1CWQ _ M\**Q_P */^(WG]EG_HQ[X@?^%%8_X4 ?M]17X@_\1O/[+/\ T8]\0/\ PHK' M_"C_ (C>?V6?^C'OB!_X45C_ (4 ?M]17X@_\1O/[+/_ $8]\0/_ HK'_"C M_B-Y_99_Z,>^('_A16/^% '[?45^(/\ Q&\_LL_]&/?$#_PHK'_"C_B-Y_99 M_P"C'OB!_P"%%8_X4 ?M]17X@_\ $;S^RS_T8]\0/_"BL?\ "C_B-Y_99_Z, M>^('_A16/^% '[?45^(/_$;S^RS_ -&/?$#_ ,**Q_PH_P"(WG]EG_HQ[X@? M^%%8_P"% '[?45^(/_$;S^RS_P!&/?$#_P **Q_PH_XC>?V6?^C'OB!_X45C M_A0!^WU%?B#_ ,1O/[+/_1CWQ _\**Q_PH_XC>?V6?\ HQ[X@?\ A16/^% ' M[?45^(/_ !&\_LL_]&/?$#_PHK'_ H_XC>?V6?^C'OB!_X45C_A0!^WU%?B M#_Q&\_LL_P#1CWQ _P#"BL?\*/\ B-Y_99_Z,>^('_A16/\ A0!^WU%?B#_Q M&\_LL_\ 1CWQ _\ "BL?\*/^(WG]EG_HQ[X@?^%%8_X4 ?M]17X@_P#$;S^R MS_T8]\0/_"BL?\*/^(WG]EG_ *,>^('_ (45C_A0!^WU%?B#_P 1O/[+/_1C MWQ _\**Q_P */^(WG]EG_HQ[X@?^%%8_X4 ?M]17X@_\1O/[+/\ T8]\0/\ MPHK'_"C_ (C>?V6?^C'OB!_X45C_ (4 ?M]17X@_\1O/[+/_ $8]\0/_ HK M'_"C_B-Y_99_Z,>^('_A16/^% '[?45^(/\ Q&\_LL_]&/?$#_PHK'_"C_B- MY_99_P"C'OB!_P"%%8_X4 ?M]17X@_\ $;S^RS_T8]\0/_"BL?\ "C_B-Y_9 M9_Z,>^('_A16/^% '[?45^(/_$;S^RS_ -&/?$#_ ,**Q_PH_P"(WG]EG_HQ M[X@?^%%8_P"% '[?45^(/_$;S^RS_P!&/?$#_P **Q_PH_XC>?V6?^C'OB!_ MX45C_A0!^WU%?B#_ ,1O/[+/_1CWQ _\**Q_PH_XC>?V6?\ HQ[X@?\ A16/ M^% '[?45^(/_ !&\_LL_]&/?$#_PHK'_ H_XC>?V6?^C'OB!_X45C_A0!^W MU%?B#_Q&\_LL_P#1CWQ _P#"BL?\*/\ B-Y_99_Z,>^('_A16/\ A0!^WU%? MB#_Q&\_LL_\ 1CWQ _\ "BL?\*/^(WG]EG_HQ[X@?^%%8_X4 ?M]17X@_P#$ M;S^RS_T8]\0/_"BL?\*/^(WG]EG_ *,>^('_ (45C_A0!^WU%?B#_P 1O/[+ M/_1CWQ _\**Q_P */^(WG]EG_HQ[X@?^%%8_X4 ?M]17X@_\1O/[+/\ T8]\ M0/\ PHK'_"C_ (C>?V6?^C'OB!_X45C_ (4 ?M]17X@_\1O/[+/_ $8]\0/_ M HK'_"C_B-Y_99_Z,>^('_A16/^% '[?45^(/\ Q&\_LL_]&/?$#_PHK'_" MC_B-Y_99_P"C'OB!_P"%%8_X4 ?M]17X@_\ $;S^RS_T8]\0/_"BL?\ "C_B M-Y_99_Z,>^('_A16/^% '[?45^(/_$;S^RS_ -&/?$#_ ,**Q_PH_P"(WG]E MG_HQ[X@?^%%8_P"% '[?45^(/_$;S^RS_P!&/?$#_P **Q_PH_XC>?V6?^C' MOB!_X45C_A0!^WU%?B#_ ,1O/[+/_1CWQ _\**Q_PH_XC>?V6?\ HQ[X@?\ MA16/^% '[?45^(/_ !&\_LL_]&/?$#_PHK'_ H_XC>?V6?^C'OB!_X45C_A M0!^WU%?B#_Q&\_LL_P#1CWQ _P#"BL?\*/\ B-Y_99_Z,>^('_A16/\ A0!^ MWU%?B#_Q&\_LL_\ 1CWQ _\ "BL?\*/^(WG]EG_HQ[X@?^%%8_X4 ?M]17X@ M_P#$;S^RS_T8]\0/_"BL?\*/^(WG]EG_ *,>^('_ (45C_A0!^WU%?B#_P 1 MO/[+/_1CWQ _\**Q_P */^(WG]EG_HQ[X@?^%%8_X4 ?M]17X@_\1O/[+/\ MT8]\0/\ PHK'_"C_ (C>?V6?^C'OB!_X45C_ (4 ?M]17X@_\1O/[+/_ $8] M\0/_ HK'_"C_B-Y_99_Z,>^('_A16/^% '[?45^(/\ Q&\_LL_]&/?$#_PH MK'_"C_B-Y_99_P"C'OB!_P"%%8_X4 ?M]17X@_\ $;S^RS_T8]\0/_"BL?\ M"C_B-Y_99_Z,>^('_A16/^% '[?45^(/_$;S^RS_ -&/?$#_ ,**Q_PH_P"( MWG]EG_HQ[X@?^%%8_P"% '[?45^(/_$;S^RS_P!&/?$#_P **Q_PH_XC>?V6 M?^C'OB!_X45C_A0!^WU%?B#_ ,1O/[+/_1CWQ _\**Q_PH_XC>?V6?\ HQ[X M@?\ A16/^% '[?45^(/_ !&\_LL_]&/?$#_PHK'_ H_XC>?V6?^C'OB!_X4 M5C_A0!^WU%?B#_Q&\_LL_P#1CWQ _P#"BL?\*/\ B-Y_99_Z,>^('_A16/\ MA0!^WU%?B#_Q&\_LL_\ 1CWQ _\ "BL?\*/^(WG]EG_HQ[X@?^%%8_X4 ?M] M17X@_P#$;S^RS_T8]\0/_"BL?\*/^(WG]EG_ *,>^('_ (45C_A0!^WU%?B# M_P 1O/[+/_1CWQ _\**Q_P */^(WG]EG_HQ[X@?^%%8_X4 ?M]17X@_\1O/[ M+/\ T8]\0/\ PHK'_"C_ (C>?V6?^C'OB!_X45C_ (4 ?M]17X@_\1O/[+/_ M $8]\0/_ HK'_"C_B-Y_99_Z,>^('_A16/^% '[?45^(/\ Q&\_LL_]&/?$ M#_PHK'_"C_B-Y_99_P"C'OB!_P"%%8_X4 ?M]17X@_\ $;S^RS_T8]\0/_"B ML?\ "C_B-Y_99_Z,>^('_A16/^% '[?45^(/_$;S^RS_ -&/?$#_ ,**Q_PH M_P"(WG]EG_HQ[X@?^%%8_P"% '[?45^(/_$;S^RS_P!&/?$#_P **Q_PH_XC M>?V6?^C'OB!_X45C_A0!^WU%?B#_ ,1O/[+/_1CWQ _\**Q_PH_XC>?V6?\ MHQ[X@?\ A16/^% '[?45^(/_ !&\_LL_]&/?$#_PHK'_ H_XC>?V6?^C'OB M!_X45C_A0!^WU%?B#_Q&\_LL_P#1CWQ _P#"BL?\*/\ B-Y_99_Z,>^('_A1 M6/\ A0!^WU%?B#_Q&\_LL_\ 1CWQ _\ "BL?\*/^(WG]EG_HQ[X@?^%%8_X4 M ?M]17X@_P#$;S^RS_T8]\0/_"BL?\*/^(WG]EG_ *,>^('_ (45C_A0!^WU M%?B#_P 1O/[+/_1CWQ _\**Q_P */^(WG]EG_HQ[X@?^%%8_X4 ?M]17X@_\ M1O/[+/\ T8]\0/\ PHK'_"C_ (C>?V6?^C'OB!_X45C_ (4 ?M]17X@_\1O/ M[+/_ $8]\0/_ HK'_"C_B-Y_99_Z,>^('_A16/^% '[?45^(/\ Q&\_LL_] M&/?$#_PHK'_"C_B-Y_99_P"C'OB!_P"%%8_X4 ?M]17X@_\ $;S^RS_T8]\0 M/_"BL?\ "C_B-Y_99_Z,>^('_A16/^% '[?45^(/_$;S^RS_ -&/?$#_ ,** MQ_PH_P"(WG]EG_HQ[X@?^%%8_P"% '[?45^(/_$;S^RS_P!&/?$#_P **Q_P MH_XC>?V6?^C'OB!_X45C_A0!^WU%?B#_ ,1O/[+/_1CWQ _\**Q_PH_XC>?V M6?\ HQ[X@?\ A16/^% '[?5^(/\ P>\_\FL_ _\ [*!J/_I"*/\ B-Y_99_Z M,>^('_A16/\ A7P'_P %]/\ @OI\(O\ @L)\(O 'PW^&_P ?$G@Z?P=XDNM 72N;G7-3MYTN$EMQ$$41#(((SDT ?_]D! end GRAPHIC 33 mrk-20241231_g3.jpg begin 644 mrk-20241231_g3.jpg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end GRAPHIC 34 mrk-20241231_g4.jpg begin 644 mrk-20241231_g4.jpg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end GRAPHIC 35 mrk-20241231_g5.jpg begin 644 mrk-20241231_g5.jpg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mrk-20241231_g6.jpg begin 644 mrk-20241231_g6.jpg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mrk-20241231_g7.gif begin 644 mrk-20241231_g7.gif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end GRAPHIC 38 mrk-20241231_g8.jpg begin 644 mrk-20241231_g8.jpg M_]C_X 02D9)1@ ! @$!+ $L #_X19,17AI9@ 34T *@ @ !P$2 , M ! $ $: 4 ! 8@$; 4 ! :@$H , ! ( $Q M ( F <@$R ( 4 F(=I 0 ! K -@ +<; G M$ MQL "<0061O8F4@4&AO=&]S:&]P($5L96UE;G1S(#$P+C @5VEN9&]W M

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end GRAPHIC 39 mrk-20241231_g9.jpg begin 644 mrk-20241231_g9.jpg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picture1.jpg begin 644 picture1.jpg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end XML 42 R1.htm IDEA: XBRL DOCUMENT v3.25.0.1
Cover Page - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Jan. 31, 2025
Jun. 28, 2024
Document Information [Line Items]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2024    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 1-6571    
Entity Registrant Name Merck & Co., Inc.    
Entity Address, Address Line One 126 East Lincoln Avenue    
Entity Address, City or Town Rahway    
Entity Address, State or Province NJ    
Entity Address, Postal Zip Code 07065    
City Area Code 908    
Local Phone Number 740-4000    
Entity Incorporation, State or Country Code NJ    
Entity Tax Identification Number 22-1918501    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Document Financial Statement Error Correction [Flag] false    
Entity Shell Company false    
Entity Common Stock, Shares Outstanding   2,526,036,240  
Entity Public Float     $ 313,799
Documents Incorporated by Reference
Proxy Statement for the Annual Meeting of Shareholders to be held May 27, 2025, to be filed with the
Securities and Exchange Commission within 120 days after the close of the fiscal year covered by this report
   
Amendment Flag false    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Entity Central Index Key 0000310158    
Common Stock ($0.50 par value)      
Document Information [Line Items]      
Title of 12(b) Security Common Stock ($0.50 par value)    
Trading Symbol MRK    
Security Exchange Name NYSE    
1.875% Notes due 2026      
Document Information [Line Items]      
Title of 12(b) Security 1.875% Notes due 2026    
Trading Symbol MRK/26    
Security Exchange Name NYSE    
3.250% Notes due 2032      
Document Information [Line Items]      
Title of 12(b) Security 3.250% Notes due 2032    
Trading Symbol MRK/32    
Security Exchange Name NYSE    
2.500% Notes due 2034      
Document Information [Line Items]      
Title of 12(b) Security 2.500% Notes due 2034    
Trading Symbol MRK/34    
Security Exchange Name NYSE    
1.375% Notes due 2036      
Document Information [Line Items]      
Title of 12(b) Security 1.375% Notes due 2036    
Trading Symbol MRK 36A    
Security Exchange Name NYSE    
3.500% Notes due 2037      
Document Information [Line Items]      
Title of 12(b) Security 3.500% Notes due 2037    
Trading Symbol MRK/37    
Security Exchange Name NYSE    
3.700% Notes due 2044      
Document Information [Line Items]      
Title of 12(b) Security 3.700% Notes due 2044    
Trading Symbol MRK/44    
Security Exchange Name NYSE    
3.750% Notes due 2054      
Document Information [Line Items]      
Title of 12(b) Security 3.750% Notes due 2054    
Trading Symbol MRK/54    
Security Exchange Name NYSE    

XML 43 R2.htm IDEA: XBRL DOCUMENT v3.25.0.1
Audit Information
12 Months Ended
Dec. 31, 2024
Audit Information [Abstract]  
Auditor Name PricewaterhouseCoopers LLP
Auditor Location Florham Park, New Jersey
Auditor Firm ID 238
XML 44 R3.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statement of Income - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Income Statement [Abstract]      
Sales $ 64,168 $ 60,115 $ 59,283
Costs, Expenses and Other      
Cost of sales 15,193 16,126 17,411
Selling, general and administrative 10,816 10,504 10,042
Research and development 17,938 30,531 13,548
Restructuring costs 309 599 337
Other (income) expense, net (24) 466 1,501
Total costs, expenses and other 44,232 58,226 42,839
Income Before Taxes 19,936 1,889 16,444
Taxes on Income 2,803 1,512 1,918
Net Income 17,133 377 14,526
Less: Net Income Attributable to Noncontrolling Interests 16 12 7
Net Income Attributable to Merck & Co., Inc. $ 17,117 $ 365 $ 14,519
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) $ 6.76 $ 0.14 $ 5.73
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) $ 6.74 $ 0.14 $ 5.71
XML 45 R4.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statement of Comprehensive Income (Loss) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Statement of Comprehensive Income [Abstract]      
Net Income Attributable to Merck & Co., Inc. $ 17,117 $ 365 $ 14,519
Other Comprehensive Income (Loss) Net of Taxes:      
Net unrealized income (loss) on derivatives, net of reclassifications 266 (97) (71)
Benefit plan net gain (loss) and prior service credit (cost), net of amortization 466 (385) 335
Cumulative translation adjustment (516) 89 (603)
Other comprehensive income (loss), net of taxes 216 (393) (339)
Comprehensive Income (Loss) Attributable to Merck & Co., Inc. $ 17,333 $ (28) $ 14,180
XML 46 R5.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Balance Sheet - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Current Assets    
Cash and cash equivalents $ 13,242 $ 6,841
Short-term investments 447 252
Accounts receivable (net of allowance for doubtful accounts of $89 in 2024 and $88 in 2023) 10,278 10,349
Inventories (excludes inventories of $4,193 in 2024 and $3,348 in 2023 classified in Other assets - see Note 7) 6,109 6,358
Other current assets 8,706 8,368
Total current assets 38,782 32,168
Investments 463 252
Property, Plant and Equipment (at cost)    
Land 307 326
Buildings 16,360 14,966
Machinery, equipment and office furnishings 18,283 17,763
Construction in progress 7,984 8,262
Property, plant and equipment (at cost) 42,934 41,317
Less: accumulated depreciation 19,155 18,266
Property, plant and equipment, net 23,779 23,051
Goodwill 21,668 21,197
Other Intangibles, Net 16,370 18,011
Other Assets 16,044 11,996
Total Assets 117,106 106,675
Current Liabilities    
Loans payable and current portion of long-term debt 2,649 1,372
Trade accounts payable 4,079 3,922
Accrued and other current liabilities 15,694 15,766
Income taxes payable 3,914 2,649
Dividends payable 2,084 1,985
Total current liabilities 28,420 25,694
Long-Term Debt 34,462 33,683
Deferred Income Taxes 1,387 871
Other Noncurrent Liabilities 6,465 8,792
Merck & Co., Inc. Stockholders’ Equity    
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2024 and 2023 1,788 1,788
Other paid-in capital 44,704 44,509
Retained earnings 63,069 53,895
Accumulated other comprehensive loss (4,945) (5,161)
Stockholders' equity before deduction for treasury stock 104,616 95,031
Less treasury stock, at cost: 1,049,466,187 shares in 2024 and 1,045,470,249 shares in 2023 58,303 57,450
Total Merck & Co., Inc. stockholders’ equity 46,313 37,581
Noncontrolling Interests 59 54
Total equity 46,372 37,635
Total Liabilities and Equity $ 117,106 $ 106,675
XML 47 R6.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Balance Sheet (Parenthetical) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts $ 89 $ 88
Inventory classified in Other assets $ 4,193 $ 3,348
Common stock, par value (in dollars per share) $ 0.50 $ 0.50
Common stock, authorized (in shares) 6,500,000,000 6,500,000,000
Common stock, shares issued (in shares) 3,577,103,522 3,577,103,522
Treasury stock, shares (in shares) 1,049,466,187 1,045,470,249
XML 48 R7.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statement of Equity - USD ($)
$ in Millions
Total
Common Stock
Other Paid-In Capital
Retained Earnings
Accumulated Other Comprehensive Loss
Treasury Stock
Non- controlling Interests
Beginning balance at Dec. 31, 2021 $ 38,257 $ 1,788 $ 44,238 $ 53,696 $ (4,429) $ (57,109) $ 73
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net Income Attributable to Merck & Co., Inc. 14,519     14,519      
Other comprehensive income (loss), net of taxes (339)       (339)    
Cash dividends declared on common stock (7,134)     (7,134)      
Net income attributable to noncontrolling interests 7           7
Distributions attributable to noncontrolling interests (13)           (13)
Share-based compensation plans and other 761   141     620  
Ending balance at Dec. 31, 2022 46,058 1,788 44,379 61,081 (4,768) (56,489) 67
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net Income Attributable to Merck & Co., Inc. 365     365      
Other comprehensive income (loss), net of taxes (393)       (393)    
Cash dividends declared on common stock (7,551)     (7,551)      
Treasury stock shares purchased (1,346)         (1,346)  
Net income attributable to noncontrolling interests 12           12
Distributions attributable to noncontrolling interests (25)           (25)
Share-based compensation plans and other 515   130     385  
Ending balance at Dec. 31, 2023 37,635 1,788 44,509 53,895 (5,161) (57,450) 54
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net Income Attributable to Merck & Co., Inc. 17,117     17,117      
Other comprehensive income (loss), net of taxes 216       216    
Cash dividends declared on common stock (7,943)     (7,943)      
Treasury stock shares purchased (1,306)         (1,306)  
Net income attributable to noncontrolling interests 16           16
Distributions attributable to noncontrolling interests (12)           (12)
Share-based compensation plans and other 649   195     453 1
Ending balance at Dec. 31, 2024 $ 46,372 $ 1,788 $ 44,704 $ 63,069 $ (4,945) $ (58,303) $ 59
XML 49 R8.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statement of Equity (Parenthetical) - $ / shares
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Statement of Stockholders' Equity [Abstract]      
Common stock, dividends declared (in dollars per share) $ 3.12 $ 2.96 $ 2.80
XML 50 R9.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statement of Cash Flows - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Cash Flows from Operating Activities      
Net income $ 17,133 $ 377 $ 14,526
Adjustments to reconcile net income to net cash provided by operating activities:      
Amortization 2,395 2,044 2,085
Depreciation 2,104 1,828 1,824
Intangible asset impairment charges 39 792 1,749
(Income) loss from investments in equity securities, net (14) (340) 1,419
Charges for certain research and development asset acquisitions 3,456 11,409 0
Deferred income taxes (1,249) (1,899) (1,568)
Share-based compensation 761 645 541
Other 510 355 1,301
Net changes in assets and liabilities:      
Accounts receivable (244) (1,148) (644)
Inventories (835) (816) (161)
Trade accounts payable 182 (380) (289)
Accrued and other current liabilities (2,328) 1,783 (50)
Income taxes payable 1,023 214 380
Noncurrent liabilities (49) 456 (545)
Other (1,416) (2,314) (1,473)
Net Cash Provided by Operating Activities 21,468 13,006 19,095
Cash Flows from Investing Activities      
Capital expenditures (3,372) (3,863) (4,388)
Purchases of securities and other investments (519) (955) (1,204)
Proceeds from sale of Seagen Inc. common stock 0 1,145 0
Proceeds from sales of securities and other investments 377 1,658 721
Acquisition of Eyebiotech Limited, net of cash acquired (1,344) 0 0
Acquisition of Elanco Animal Health Incorporated aqua business (1,303) 0 0
Acquisition of Harpoon Therapeutics, Inc., net of cash acquired (746) 0 0
Acquisition of MK-1045 from Curon Pharmaceutical (700) 0 0
Acquisition of Prometheus Biosciences, Inc., net of cash acquired 0 (10,705) 0
Acquisition of Imago BioSciences Inc., net of cash acquired 0 (1,327) 0
Other (127) (36) (89)
Net Cash Used in Investing Activities (7,734) (14,083) (4,960)
Cash Flows from Financing Activities      
Payments on debt (1,290) (1,755) (2,251)
Proceeds from issuance of debt 3,599 5,939 0
Purchases of treasury stock (1,306) (1,346) 0
Dividends paid to stockholders (7,840) (7,445) (7,012)
Proceeds from exercise of stock options 177 125 384
Other (372) (328) (240)
Net Cash Used in Financing Activities (7,032) (4,810) (9,119)
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash (293) 23 (410)
Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash 6,409 (5,864) 4,606
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes $68, $79 and $71 of restricted cash at January 1, 2024, 2023 and 2022, respectively, included in Other current assets) 6,909 12,773 8,167
Cash, Cash Equivalents and Restricted Cash at End of Year (includes $76, $68 and $79 of restricted cash at December 31, 2024, 2023 and 2022, respectively, included in Other current assets) $ 13,318 $ 6,909 $ 12,773
XML 51 R10.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statement of Cash Flows (Parenthetical) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Statement of Cash Flows [Abstract]        
Cash, cash equivalents, and restricted cash $ 76 $ 68 $ 79 $ 71
XML 52 R11.htm IDEA: XBRL DOCUMENT v3.25.0.1
Nature of Operations
12 Months Ended
Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature of Operations Nature of Operations
Merck & Co., Inc. (Merck or the Company) is a global health care company that delivers innovative health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company’s operations are principally managed on a product basis and include two operating segments, Pharmaceutical and Animal Health, both of which are reportable segments.
The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities.
The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors, animal producers, farmers and pet owners.
XML 53 R12.htm IDEA: XBRL DOCUMENT v3.25.0.1
Summary of Accounting Policies
12 Months Ended
Dec. 31, 2024
Accounting Policies [Abstract]  
Summary of Accounting Policies Summary of Accounting Policies
Principles of Consolidation — The consolidated financial statements include the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. Intercompany balances and transactions are eliminated. Controlling interest is determined by majority ownership interest and the absence of substantive third-party participating rights or, in the case of variable interest entities, by majority exposure to expected losses, residual returns or both. For those consolidated subsidiaries where Merck ownership is less than 100%, the outside shareholders’ interests are shown as Noncontrolling interests in equity. Investments in affiliates over which the Company has significant influence but not a controlling interest, such as interests in entities owned equally by the Company and a third party that are under shared control, are carried on the equity method basis.
Acquisitions — In a business combination, the acquisition method of accounting requires that the assets acquired and liabilities assumed be recorded as of the date of the acquisition at their respective fair values with limited exceptions. Assets acquired and liabilities assumed in a business combination that arise from contingencies are generally recognized at fair value. If fair value cannot be determined, the asset or liability is recognized if probable and reasonably estimable; if these criteria are not met, no asset or liability is recognized. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Accordingly, the Company may be required to value assets at fair value measures that do not reflect the Company’s intended use of those assets. Any excess of the purchase price (consideration transferred) over the estimated fair values of net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Company’s consolidated financial statements after the date of the acquisition.
If the Company determines the assets acquired do not meet the definition of a business under the acquisition method of accounting, the transaction will be accounted for as an acquisition of assets rather than a business combination and, therefore, no goodwill will be recorded. In an asset acquisition, acquired in-process research and development (IPR&D) with no alternative future use is charged to expense and contingent consideration is not recognized at the acquisition date.
Foreign Currency Translation — The net assets of international subsidiaries where the local currencies have been determined to be the functional currencies are translated into U.S. dollars using current exchange rates and results of operations are translated at average exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries at changing rates are recorded in Other Comprehensive Income (OCI) and remain in Accumulated other comprehensive loss (AOCL) until either the sale or complete or substantially complete liquidation of the subsidiary. For those subsidiaries that operate in highly inflationary economies and for those subsidiaries where the U.S. dollar has been determined to be the functional currency, non-monetary foreign currency
assets and liabilities are translated using historical rates, while monetary assets and liabilities are translated at current rates, with the U.S. dollar effects of rate changes included in Other (income) expense, net.
Cash Equivalents — Cash equivalents are comprised of certain highly liquid investments with original maturities of less than three months.
Inventories — Inventories are valued at the lower of cost or net realizable value. The cost of a substantial majority of U.S. human health inventories is determined using the last-in, first-out (LIFO) method for both financial reporting and tax purposes. The cost of all other inventories is determined using the first-in, first-out (FIFO) method. Inventories consist of currently marketed products, as well as certain inventories produced in preparation for product launches that are considered by the Company to be probable of obtaining regulatory approval. In evaluating the recoverability of inventories produced in preparation for product launches, the Company considers the likelihood that revenue will be obtained from the future sale of the related inventory together with the status of the product during the research and regulatory approval process.
Investments — Investments in marketable debt securities classified as available-for-sale are reported at fair value. Fair values of the Company’s investments in marketable debt securities are determined using quoted market prices in active markets for identical assets or quoted prices for similar assets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Changes in fair value that are not impairment related are reported net of taxes in OCI. The Company considers available evidence in evaluating potential impairments of its investments in marketable debt securities, including the extent to which fair value is less than cost, whether an allowance for credit loss is required, as well as adverse factors that could affect the value of the securities. An impairment has occurred if the Company does not expect to recover the entire amortized cost basis of the marketable debt security. If the Company does not intend to sell the impaired debt security, and it is not more likely than not it will be required to sell the debt security before the recovery of its amortized cost basis, the amount of the impairment recognized in earnings, recorded in Other (income) expense, net, is limited to the portion attributed to credit loss. The remaining portion of the impairment related to other factors is recognized in OCI. Realized gains and losses for debt securities are included in Other (income) expense, net.
Investments in publicly traded equity securities are reported at fair value as determined using quoted market prices in active markets for identical assets or quoted prices for similar assets or other inputs that are observable or can be corroborated by observable market data. Changes in fair value are included in Other (income) expense, net. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period. Gains and losses from ownership interests in investment funds, which are accounted for as equity method investments, are reported on a one quarter lag. Investments in equity securities without readily determinable fair values are recorded at cost, plus or minus subsequent observable price changes in orderly transactions for identical or similar investments, minus impairments. Such adjustments are recognized in Other (income) expense, net. Realized gains and losses for equity securities are included in Other (income) expense, net.
Revenue Recognition — Recognition of revenue requires evidence of a contract, probable collection of sales proceeds and completion of substantially all performance obligations. Merck acts as the principal in substantially all of its customer arrangements and therefore records revenue on a gross basis. The majority of the Company’s contracts related to the Pharmaceutical and Animal Health segments have a single performance obligation - the promise to transfer goods. Shipping is considered immaterial in the context of the overall customer arrangement and damages or loss of goods in transit are rare. Therefore, shipping is not deemed a separately recognized performance obligation.
The vast majority of revenues from sales of products are recognized at a point in time when control of the goods is transferred to the customer, which the Company has determined is when title and risks and rewards of ownership transfer to the customer and the Company is entitled to payment. The Company recognizes revenue from the sales of vaccines to the U.S. federal government for placement into vaccine stockpiles in accordance with Securities and Exchange Commission (SEC) Interpretation, Commission Guidance Regarding Accounting for Sales of Vaccines and BioTerror Countermeasures to the Federal Government for Placement into the Pediatric Vaccine Stockpile or the Strategic National Stockpile. This interpretation allows companies to recognize revenue for sales of vaccines into U.S. government stockpiles even though these sales might not meet the criteria for revenue recognition under other accounting guidance. For certain services in the Animal Health segment, revenue is recognized over time, generally ratably over the contract term as services are provided. These service revenues are not material.
The nature of the Company’s business gives rise to several types of variable consideration including discounts and returns, which are estimated at the time of sale generally using the expected value method, although the most likely amount method is used for prompt pay discounts.
In the U.S., sales discounts are issued to customers at the point-of-sale, through an intermediary wholesaler (known as chargebacks), or in the form of rebates. Additionally, sales are generally made with a limited right of return under certain conditions. Revenues are recorded net of provisions for sales discounts and returns, which are established at the time of sale. In addition, if collection of accounts receivable is expected to be in excess of one year, sales are recorded net of time value of money discounts, which have not been material.
The U.S. provision for aggregate customer discounts covering chargebacks and rebates was $13.3 billion in 2024, $12.5 billion in 2023 and $12.3 billion in 2022. Chargebacks are discounts that occur when a contracted customer purchases through an intermediary wholesaler. The wholesaler then charges the Company back for the difference between the price initially paid by the wholesaler and the contract price agreed to between Merck and the customer. The provision for chargebacks is based on expected sell-through levels by the Company’s wholesale customers to contracted customers, as well as estimated wholesaler inventory levels. Rebates are amounts owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part D) benefit providers after the final dispensing of the product to a benefit plan participant. The provision for rebates is based on expected patient usage, as well as inventory levels in the distribution channel to determine the contractual obligation to the benefit providers. The Company uses historical customer segment utilization mix, sales forecasts, changes to product mix and price, inventory levels in the distribution channel, government pricing calculations and prior payment history in order to estimate the expected provision. Amounts accrued for aggregate customer discounts are evaluated on a quarterly basis through comparison of information provided by the wholesalers, health maintenance organizations, pharmacy benefit managers, federal and state agencies, and other customers to the amounts accrued. The accrued balances relative to the provisions for chargebacks and rebates included in Accounts receivable and Accrued and other current liabilities were $293 million and $2.2 billion, respectively, at December 31, 2024 and were $188 million and $2.3 billion, respectively, at December 31, 2023.
Outside of the U.S., variable consideration in the form of discounts and rebates are a combination of commercially-driven discounts in highly competitive product classes, discounts required to gain or maintain reimbursement, or legislatively mandated rebates. In certain European countries, legislatively mandated rebates are calculated based on an estimate of the government’s total unbudgeted spending and the Company’s specific payback obligation. Rebates may also be required based on specific product sales thresholds. The Company applies an estimated factor against its actual invoiced sales to represent the expected level of future discount or rebate obligations associated with the sale.
The Company maintains a returns policy that allows its U.S. pharmaceutical customers to return product within a specified period prior to and subsequent to the expiration date (generally, three to six months before and 12 months after product expiration). The estimate of the provision for returns is based upon historical experience with actual returns. Additionally, the Company considers factors such as levels of inventory in the distribution channel, product dating and expiration period, whether products have been discontinued, entrance in the market of generic or other competition, changes in formularies or launch of over-the-counter products, among others. Outside of the U.S., returns are only allowed in certain countries on a limited basis.
Merck’s payment terms for U.S. pharmaceutical customers are typically 36 days from receipt of invoice and for U.S. animal health customers are typically 30 days from receipt of invoice; however, certain products have longer payment terms, including Keytruda (pembrolizumab), which has payment terms of 90 days. Payment terms for vaccine sales in the U.S. typically range from 30 days to 60 days. Outside of the U.S., payment terms are typically 30 days to 90 days, although certain markets have longer payment terms.
See Note 18 for disaggregated revenue disclosures.
Depreciation — Depreciation is provided over the estimated useful lives of the assets, principally using the straight-line method. For tax purposes, accelerated tax methods are used. The estimated useful lives primarily range from 25 to 45 years for Buildings, and from 3 to 15 years for Machinery, equipment and office furnishings. Depreciation expense was $2.1 billion in 2024, $1.8 billion in 2023 and $1.8 billion in 2022.
Advertising and Promotion Costs — Advertising and promotion costs are expensed as incurred. The Company recorded advertising and promotion expenses of $2.4 billion in 2024, $2.3 billion in 2023 and $2.2 billion in 2022.
Software Capitalization — The Company capitalizes certain costs incurred in connection with obtaining or developing internal-use software including external direct costs of material and services, and payroll costs for employees directly involved with the software development. These costs are included in Property, plant and equipment. In addition, the Company capitalizes certain costs incurred to implement a cloud computing arrangement
that is considered a service agreement, which are included in Other Assets. Capitalized software costs are being amortized over periods ranging from 2 to 10 years, with the longer lives generally associated with enterprise-wide projects implemented over multiple years. Costs incurred during the preliminary project stage and post-implementation stage, as well as maintenance and training costs, are expensed as incurred.
Goodwill — Goodwill represents the excess of the consideration transferred over the fair value of net assets acquired in a business combination. Goodwill is assigned to reporting units and evaluated for impairment at least annually, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company concludes it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed. If the carrying value of a reporting unit is greater than its fair value, a goodwill impairment charge will be recorded for the difference (up to the carrying value of goodwill).
Acquired Intangibles — Intangibles acquired in a business combination include product rights, trade names and patents, licenses and other, which are initially recorded at fair value, assigned an estimated useful life, and amortized primarily on a straight-line basis over their estimated useful lives ranging from 2 to 24 years. The Company periodically evaluates whether current facts or circumstances indicate that the carrying values of its acquired intangibles may not be recoverable. If such circumstances are determined to exist, an estimate of the undiscounted future cash flows of these assets, or appropriate asset groupings, is compared to the carrying value to determine whether an impairment exists. If the asset is determined to be impaired, the loss is measured based on the difference between the carrying value of the intangible asset and its fair value, which is determined based on the net present value of estimated future cash flows.
Acquired In-Process Research and Development — IPR&D that the Company acquires in conjunction with a business combination represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each IPR&D project, Merck will make a determination as to the then-useful life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization. The Company evaluates IPR&D for impairment at least annually, or more frequently if impairment indicators exist, by performing a quantitative test that compares the fair value of the IPR&D intangible asset with its carrying value. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results.
Contingent Consideration for Business Combinations — Certain of the Company’s acquisitions involve the potential for future payment of consideration that is contingent upon the achievement of performance milestones, including product development milestones and royalty payments on future product sales. If the transaction is accounted for as a business combination, the fair value of contingent consideration liabilities is determined at the acquisition date using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period until the contingency is resolved, the contingent consideration liability is remeasured at current fair value with changes (either expense or income) recorded in earnings. Significant events that increase or decrease the probability of achieving development and regulatory milestones or that increase or decrease projected cash flows will result in corresponding increases or decreases in the fair values of the related contingent consideration obligations.
Research and Development — Research and development is expensed as incurred. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Research and development expenses include restructuring costs and IPR&D impairment charges. In addition, research and development expenses include expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration associated with IPR&D assets. Research and development expenses also include upfront and milestone payments related to asset acquisitions and licensing transactions involving clinical development programs that have not yet received regulatory approval.
Collaborative Arrangements — Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. When Merck is the principal on sales transactions with third parties, the Company recognizes sales, cost of sales and selling, general and administrative expenses on a gross basis. Profit sharing amounts it pays to its collaborative partners are recorded within Cost of sales. When the collaborative partner is the principal on sales transactions with third parties, the Company records profit sharing amounts received from its collaborative partners as alliance revenue
(within Sales). Alliance revenue is recorded net of cost of sales and includes an adjustment to share commercialization costs between the partners in accordance with the collaboration agreement. The adjustment is determined by comparing the commercialization costs Merck has incurred directly and reported within Selling, general and administrative expenses with the costs the collaborative partner has incurred. Research and development costs Merck incurs related to collaborations are recorded within Research and development expenses. Cost reimbursements to the collaborative partner or payments received from the collaborative partner to share these costs pursuant to the terms of the collaboration agreements are recorded as increases or decreases to Research and development expenses.
In addition, the terms of the collaboration agreements may require the Company to make payments based upon the achievement of certain developmental, regulatory approval or commercial milestones. Upfront and milestone payments payable by Merck to collaborative partners prior to regulatory approval are expensed as incurred and included in Research and development expenses. Payments due to collaborative partners upon or subsequent to regulatory approval are capitalized and amortized to Cost of sales over the estimated useful life of the corresponding intangible asset, provided that future cash flows support the amounts capitalized. Sales-based milestones payable by Merck to collaborative partners are accrued and capitalized, subject to cumulative amortization catch-up, when determined by the Company to be probable of being achieved based on future sales forecasts. The amortization catch-up is calculated either from the time of the first regulatory approval for products that were unapproved at the time the collaboration was formed or, for new indications of approved products, from the time of the formation of the collaboration. The related intangible asset that is recognized is amortized to Cost of sales over its remaining useful life, subject to impairment testing.
Share-Based Compensation — The Company expenses all share-based payments to employees over the requisite service period based on the grant-date fair value of the awards.
Restructuring Costs — The Company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. In accordance with existing benefit arrangements, future employee termination costs to be incurred in conjunction with involuntary separations are accrued when such separations are probable and estimable. When accruing these costs, the Company will recognize the amount within a range of costs that is the best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company recognizes the minimum amount within the range. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period.
Contingencies and Legal Defense Costs — The Company records accruals for contingencies and legal defense costs expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated.
Taxes on Income — Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. The Company evaluates tax positions to determine whether the benefits of tax positions are more likely than not of being sustained upon audit based on the technical merits of the tax position. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the amount of the benefit that is greater than 50% likely of being realized upon ultimate settlement in the financial statements. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit in the financial statements. The Company recognizes interest and penalties associated with uncertain tax positions as a component of Taxes on Income. The Company accounts for the tax effects of the tax on global intangible low-taxed income (GILTI) of certain foreign subsidiaries in the income tax provision in the period the tax arises. The Company’s policy for releasing disproportionate income tax effects from AOCL is to utilize the item-by-item approach.
Reclassifications — Certain reclassifications have been made to prior year amounts to conform to the current year presentation.
Use of Estimates — The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the U.S. (GAAP) and, accordingly, include certain amounts that are based on management’s best estimates and judgments. Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities in a business combination (primarily IPR&D, other intangible assets and contingent consideration), as well as subsequent fair value measurements. Additionally, estimates are used in determining such items as provisions for sales discounts, rebates and returns, depreciable and amortizable lives, recoverability of inventories, including those produced in preparation for product launches, amounts recorded for contingencies, environmental liabilities, accruals for contingent sales-
based milestone payments and other reserves, pension and other postretirement benefit plan assumptions, share-based compensation assumptions, restructuring costs, impairments of long-lived assets (including intangible assets and goodwill) and investments, and taxes on income. Because of the uncertainty inherent in such estimates, actual results may differ from these estimates.
Recently Adopted Accounting Standards — In August 2023, the Financial Accounting Standards Board (FASB) issued amended guidance that requires a newly formed joint venture to recognize and initially measure its assets and liabilities at fair value upon formation. The amended guidance includes exceptions to fair value measurement that are consistent with the accounting for business combinations guidance. The Company adopted the guidance effective July 1, 2024 on a prospective basis. There was no impact to the Company’s consolidated financial statements upon adoption.
In November 2023, the FASB issued guidance intended to improve reportable segment disclosure requirements, primarily through expanded disclosures for significant segment expenses. The Company adopted the guidance effective for the 2024 annual period. The guidance resulted in incremental disclosures to the Company’s segment reporting disclosures. See Note 18 for further details.
Recently Issued Accounting Standards Not Yet Adopted — In December 2023, the FASB issued guidance intended to improve the transparency of income tax disclosures by requiring consistent categories and disaggregation of information in the effective income tax rate reconciliation and income taxes paid disclosures by jurisdiction. The guidance also includes other amendments to improve the effectiveness of income tax disclosures by removing certain previously required disclosures. The guidance is effective for 2025 annual reporting. The guidance will result in incremental disclosures within the footnotes to the Company’s financial statements.
In November 2024, the FASB issued guidance intended to improve financial reporting by requiring entities to disclose additional information about specific expense categories at interim and annual reporting periods. The guidance is effective for 2027 annual reporting and 2028 interim reporting. Early adoption is permitted. The guidance, which can be applied on a prospective or retrospective basis, will result in incremental disclosures within the footnotes to the Company’s financial statements.
XML 54 R13.htm IDEA: XBRL DOCUMENT v3.25.0.1
Acquisitions, Divestitures, Research Collaborations and Licensing Agreements
12 Months Ended
Dec. 31, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]  
Acquisitions, Divestitures, Research Collaborations and Licensing Agreements Acquisitions, Divestitures, Research Collaborations and Licensing Agreements
The Company continues to pursue acquisitions and the establishment of external alliances such as research collaborations and licensing agreements to complement its internal research capabilities. These arrangements often include upfront payments; expense reimbursements or payments to the third party; milestone, royalty or profit share arrangements contingent upon the occurrence of certain future events linked to the success of the asset in development; and can also include option and continuation payments. The Company also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial results of the acquired entity are not significant when compared with the Company’s financial results.
Recent Transactions
In January 2025, Merck and WuXi Vaccines, a wholly owned subsidiary of WuXi Biologics, entered into a definitive agreement pursuant to which Merck will acquire WuXi Vaccines’ facility in Dundalk, Ireland for a payment of approximately $440 million at closing. The transaction is expected to close in the first quarter of 2025, subject to the satisfaction of customary closing conditions. There are no future contingent payments associated with the acquisition.
2024 Transactions
In December 2024, Merck closed an exclusive global license to develop, manufacture and commercialize MK-2010 (LM-299), a novel investigational PD-1/vascular endothelial growth factor (VEGF) bispecific antibody from LaNova Medicines Ltd (LaNova). Merck recorded a charge of $588 million to Research and development expenses in 2024 for the upfront payment, which was made in January 2025. LaNova is also eligible to receive $300 million upon technology transfer, which is anticipated to be completed in 2025, as well as future contingent developmental milestone payments of up to $140 million, regulatory milestone payments of up to $860 million and sales-based milestone payments of up to $1.4 billion.
Also in December 2024, Merck closed an exclusive global license to develop, manufacture and commercialize MK-4082 (HS-10535), an investigational preclinical oral small molecule GLP-1 receptor agonist from Hansoh Pharma (Hansoh). Merck recorded a charge of $112 million to Research and development expenses in 2024 for the upfront payment, which was made in February 2025. Hansoh is also eligible to receive future contingent
development-related milestone payments of up to $115 million, regulatory milestone payments of up to $315 million and sales-based milestone payments of up to $1.47 billion, as well as tiered royalties ranging from a high-single-digit rate to a low-double-digit rate on future net sales of MK-4082 (HS-10535), if approved. Under the agreement, Hansoh may co-promote or solely commercialize MK-4082 (HS-10535) in Chinese mainland, Hong Kong and Macau, subject to certain conditions.
In September 2024, Merck acquired MK-1045 (formally CN201), a novel investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases, from Curon Biopharmaceutical (Curon) for an upfront payment of $700 million. In addition, Curon is eligible to receive future contingent developmental milestone payments of up to $300 million and regulatory milestone payments of up to $300 million. The transaction was accounted for as an asset acquisition. Merck recorded a charge of $750 million (reflecting the upfront payment and other related costs) to Research and development expenses in 2024 related to the execution of the transaction. In connection with the agreement, Merck is also obligated to pay a third party future contingent developmental, regulatory and sales-based milestone payments of up to $128 million in the aggregate, as well as tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales of MK-1045, if approved.
In July 2024, Merck acquired the aqua business of Elanco Animal Health Incorporated (Elanco aqua business) for total consideration of $1.3 billion. The Elanco aqua business consists of an innovative portfolio of medicines and vaccines, nutritionals and supplements for aquatic species; two related aqua manufacturing facilities in Canada and Vietnam; as well as a research facility in Chile. The acquisition broadens Animal Health’s aqua portfolio with products, such as Clynav, a new generation DNA-based vaccine that protects Atlantic salmon against pancreas disease, and Imvixa, an anti-parasitic sea lice treatment. This acquisition also brings a portfolio of water treatment products for warm water production, complementing Animal Health’s warm water vaccine portfolio. In addition to these products, the DNA-based vaccine technology that is a part of the business has the potential to accelerate the development of novel vaccines to address the unmet needs of the aqua industry. There are no contingent payments associated with the acquisition, which was accounted for as a business combination.
The estimated fair values of assets acquired and liabilities assumed from the Elanco aqua business are as follows:
July 9, 2024
Inventories
$65 
Property, plant and equipment
66
Product rights - Clynav (useful life 15 years) (1)
340
Other product rights (useful lives 15 years) (1)
291
Other assets and liabilities, net23 
Total identifiable net assets785 
Goodwill (2)
518
Consideration transferred$1,303 
(1)    The estimated fair values of Clynav and other product rights were determined using an income approach, specifically the multi-period excess earnings method. The future probability-weighted net cash flows were discounted to present value utilizing a discount rate of 8.5%. Actual cash flows are likely to be different than those assumed.
(2)    The goodwill recognized is largely attributable to anticipated synergies expected to arise after the acquisition and was allocated to the Animal Health segment. The goodwill is expected to be deductible for tax purposes.
Also in July 2024, Merck acquired Eyebiotech Limited (EyeBio), a privately held ophthalmology-focused biotechnology company, for $1.2 billion (including payments to settle share-based equity awards) and also incurred $207 million of transaction costs. The acquisition agreement also provides for former EyeBio shareholders to receive future contingent developmental milestone payments of up to $200 million (of which $100 million was triggered and paid in 2024 as noted below), regulatory milestone payments of up to $1.0 billion and sales-based milestone payments of up to $500 million. EyeBio’s development work focused on candidates for the prevention and treatment of vision loss associated with retinal vascular leakage, a known risk factor for retinal diseases. EyeBio’s lead candidate, MK-3000 (formerly EYE103), is an investigational, potentially first-in-class tetravalent, tri-specific antibody that acts as an agonist of the Wingless-related integration site signaling pathway, which is in clinical development for the treatment of diabetic macular edema and neovascular age-related macular degeneration. The transaction was accounted for as an asset acquisition since MK-3000 accounted for substantially all of the fair value of the gross assets acquired (excluding cash and deferred income taxes). Merck recorded net assets of $21 million, as well as a charge of $1.35 billion to Research and development expenses in 2024 related to the acquisition. Additionally, a $100 million developmental milestone was triggered and paid in 2024 upon initiation of a Phase 2/3 clinical trial
evaluating MK-3000 for the treatment of diabetic macular edema, which was also recorded as a charge to Research and development expenses.
Additionally in July 2024, Merck and Orion Corporation (Orion) announced the mutual exercise of an option to convert the companies’ ongoing co-development and co-commercialization agreement for opevesostat (MK-5684/ODM-208), an investigational cytochrome P450 11A1 (CYP11A1) inhibitor in Phase 3 clinical development, and other candidates targeting CYP11A1, into an exclusive global license for Merck. With the exercise of the option, Merck assumed full responsibility for all past and future development and commercialization expenses associated with the candidates covered by the original agreement entered into in 2022 as discussed below. In addition, Orion became eligible to receive developmental milestone payments of up to $30 million, regulatory milestone payments of up to $625 million and sales-based milestone payments of up to $975 million, as well as annually tiered royalties ranging from a low double-digit rate up to a rate in the low twenties on net sales for any commercialized licensed product. Orion retained responsibility for the manufacture of clinical and commercial supply for Merck. No payment was associated with the exercise of the option, which became effective in September 2024.
Also in July 2024, Merck notified Kelun-Biotech (a holding subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.) it was terminating the license and collaboration agreement entered into in July 2022 in which Merck gained exclusive worldwide rights for the development, manufacture and commercialization of an investigational antibody drug conjugate (ADC) MK-1200 (SKB315) for the treatment of solid tumors. As a result of this termination, which became effective in September 2024, all rights to SKB315 have reverted to Kelun-Biotech.
In March 2024, Merck acquired Harpoon Therapeutics, Inc. (Harpoon), a clinical-stage immunotherapy company developing a novel class of T-cell engagers designed to harness the power of the body’s immune system to treat patients suffering from cancer and other diseases for $765 million and also incurred $56 million of transaction costs. Harpoon’s lead candidate, MK-6070 (formerly HPN328), is a T-cell engager targeting delta-like ligand 3 (DLL3), an inhibitory canonical Notch ligand that is expressed at high levels in small-cell lung cancer and neuroendocrine tumors. The transaction was accounted for as an asset acquisition since MK-6070 represented substantially all of the fair value of the gross assets acquired (excluding cash and deferred income taxes). Merck recorded net assets of $165 million, as well as a charge of $656 million to Research and development expenses in 2024 related to the transaction. There are no future contingent payments associated with the acquisition. In August 2024, Merck and Daiichi Sankyo expanded their existing global co-development and co-commercialization agreement to include MK-6070. See Note 4 for more information on Merck’s collaboration with Daiichi Sankyo.
2023 Transactions
In October 2023, Merck and Daiichi Sankyo entered into a global development and commercialization agreement for three of Daiichi Sankyo’s deruxtecan (DXd) ADC candidates: patritumab deruxtecan (HER3-DXd) (MK-1022), ifinatamab deruxtecan (I-DXd) (MK-2400) and raludotatug deruxtecan (R-DXd) (MK-5909). See Note 4 for additional information related to this collaboration.
In June 2023, Merck acquired Prometheus Biosciences, Inc. (Prometheus), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases. Total consideration paid of $11.0 billion included $1.2 billion of costs to settle share-based equity awards (including $700 million to settle unvested equity awards). Prometheus’ lead candidate, tulisokibart (MK-7240, formerly PRA023), is a humanized monoclonal antibody directed to tumor necrosis factor-like ligand 1A, a target associated with both intestinal inflammation and fibrosis. Tulisokibart is being developed for the treatment of immune-mediated diseases including ulcerative colitis, Crohn’s disease, and other autoimmune conditions. Phase 3 clinical trials evaluating tulisokibart for Crohn’s disease and ulcerative colitis are underway. The transaction was accounted for as an asset acquisition since tulisokibart accounted for substantially all of the fair value of the gross assets acquired (excluding cash and deferred income taxes). Merck recorded net assets of $877 million, including cash of $368 million, investments of $296 million, deferred tax assets of $218 million and other net liabilities of $5 million, as well as a charge of $10.2 billion to Research and development expenses in 2023 related to the transaction. There are no future contingent payments associated with the acquisition.
In February 2023, Merck and Kelun-Biotech closed a license and collaboration agreement expanding their relationship in which Merck gained exclusive rights for the research, development, manufacture and commercialization of up to seven investigational preclinical ADCs for the treatment of cancer. Kelun-Biotech retained the right to research, develop, manufacture and commercialize certain licensed and option ADCs for Chinese mainland, Hong Kong and Macau. Merck made an upfront payment of $175 million, which was recorded as a charge to Research and development expenses in 2023. In October 2023, Merck notified Kelun-Biotech it was terminating two of the seven candidates under the agreement. Subsequently, in April 2024, Merck notified Kelun-Biotech it was terminating one additional candidate under the agreement. In July 2024, Merck notified Kelun-Biotech that it was
exercising an existing license option for one of the candidates under the agreement, granting Merck a license for the development, manufacture and commercialization worldwide excluding China. There are now three candidates licensed under the original agreement and one candidate for which the license option remains unexercised. Merck paid Kelun-Biotech $38 million in connection with the July option exercise, following which Kelun-Biotech remains eligible to receive future contingent payments aggregating up to $540 million in development-related payments, $1.5 billion in regulatory milestones, and $3.1 billion in sales-based milestones, if Kelun-Biotech does not retain Chinese mainland, Hong Kong and Macau rights for the remaining option ADC and all remaining candidates achieve regulatory approval. In addition, Kelun-Biotech is eligible to receive tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales for any commercialized ADC product. Also, in connection with the agreement, Merck invested $100 million in Kelun-Biotech shares in January 2023.
In January 2023, Merck acquired Imago BioSciences, Inc. (Imago), a clinical-stage biopharmaceutical company developing new medicines for the treatment of myeloproliferative neoplasms and other bone marrow diseases, for $1.35 billion (including payments to settle share-based equity awards) and also incurred approximately $60 million of transaction costs. Imago’s lead candidate, bomedemstat (MK-3543, formerly IMG-7289), which is in Phase 3 clinical development, is an investigational orally available lysine-specific demethylase 1 inhibitor currently being evaluated in multiple clinical trials for the treatment of essential thrombocythemia, myelofibrosis, and polycythemia vera, in addition to other indications. The transaction was accounted for as an asset acquisition since bomedemstat represented substantially all of the fair value of the gross assets acquired (excluding cash and deferred income taxes). Merck recorded net assets of $219 million, as well as a charge of $1.2 billion to Research and development expenses in 2023 related to the transaction. There are no future contingent payments associated with the acquisition.
2022 Transactions
In October 2022, Merck and Royalty Pharma plc (Royalty Pharma) entered into a funding arrangement under which Royalty Pharma paid Merck $50 million to co-fund Merck’s development costs for a Phase 2b trial of MK-8189, an investigational oral phosphodiesterase 10A (PDE10A) inhibitor, which was being evaluated for the treatment of schizophrenia. As Royalty Pharma was sharing the risk of technical and regulatory success with Merck, the development funding was recognized by Merck as an obligation to perform contractual services. Accordingly, the payment received was recognized by Merck as a reduction to Research and development expenses ratably over the estimated Phase 2b research period. In 2024, it was determined the Phase 2b clinical trial for MK-8189 as a monotherapy for acute schizophrenia did not meet its primary efficacy endpoint; therefore, further development in schizophrenia, bipolar, and dementia indications has stopped, and the funding arrangement was terminated.
In September 2022, Merck exercised its option to jointly develop and commercialize V940 (mRNA-4157), an investigational individualized neoantigen therapy, pursuant to the terms of an existing collaboration and license agreement with Moderna, Inc. (Moderna). See Note 4 for additional information related to this collaboration.
In August 2022, Merck and Orna Therapeutics (Orna), a biotechnology company pioneering a new investigational class of engineered circular RNA (oRNA) therapies, entered into a collaboration agreement to discover, develop, and commercialize multiple programs, including vaccines and therapeutics in the areas of infectious disease and oncology. Under the terms of the agreement, Merck made an upfront payment to Orna of $150 million, which was recorded as a charge to Research and development expenses in 2022. In addition, Orna is eligible to receive future contingent payments aggregating up to $440 million in development-related payments, $675 million in regulatory milestones, and $2.4 billion in sales-based milestones associated with the progress of the multiple vaccine and therapeutic programs, as well as royalties ranging from a high-single-digit rate to a low-double-digit rate on any approved products derived from the collaboration. Merck also invested $100 million in Orna’s Series B preferred shares in 2022.
In July 2022, Merck and Orion Corporation (Orion) announced a global co-development and co-commercialization agreement for Orion’s investigational candidate opevesostat (MK-5684/ODM-208) and other drugs targeting cytochrome P450 11A1 (CYP11A1), an enzyme important in steroid production. Merck made an upfront payment to Orion of $290 million, which was recorded as a charge to Research and development expenses in 2022. Orion is responsible for the manufacture of clinical and commercial supply of opevesostat. In addition, the contract provided both parties with an option to convert the initial co-development and co-commercialization agreement into a global exclusive license to Merck, which was mutually exercised in July 2024 (as noted above).
In May 2022, in connection with an existing arrangement, Merck exercised its option to obtain an exclusive license outside of Chinese mainland, Hong Kong, Macau and Taiwan for the development, manufacture and commercialization of Kelun-Biotech’s trophoblast antigen 2 (TROP2)-targeting ADC programs, including its lead compound, sacituzumab tirumotecan (MK-2870/SKB-264), which is currently in Phase 3 clinical development. Under the terms of the agreement, Merck and Kelun-Biotech are collaborating on certain early clinical development plans,
including evaluating the potential of sacituzumab tirumotecan as a monotherapy and in combination with Keytruda for advanced solid tumors. Upon option exercise, Merck made a payment of $30 million, which was recorded as a charge to Research and development expenses in 2022. Additionally, Merck made an additional payment of $25 million upon technology transfer in 2023. Merck has also made all contingent developmental milestone payments under the agreement, which aggregated $90 million, nearly all of which were paid in 2024 and were recorded to Research and development expenses. In addition, Kelun-Biotech is eligible to receive future contingent milestone payments (which include all program compounds) aggregating up to $290 million in first commercial sale milestones, and $780 million in sales-based milestones. The agreement also provides for Merck to pay tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales.
Spin-Off of Organon & Co.
In connection with the 2021 spin-off of Organon & Co. (Organon), Merck and Organon entered into a series of interim operating agreements pursuant to which in various jurisdictions where Merck held licenses, permits and other rights in connection with marketing, import and/or distribution of Organon products prior to the separation, Merck continued to market, import and distribute such products on behalf of Organon until such time as the relevant licenses and permits transferred to Organon, with Organon receiving all of the economic benefits and burdens of such activities. As of December 31, 2024, only one jurisdiction remains under an interim operating agreement. Additionally, Merck and Organon entered into a number of manufacturing and supply agreements (MSAs) with terms ranging from four years to ten years. The amounts included in the consolidated statement of income for the above MSAs include sales of $392 million, $394 million and $383 million in 2024, 2023 and 2022, respectively, and related cost of sales of $390 million, $422 million and $404 million in 2024, 2023 and 2022, respectively. The amounts due from Organon under all spin-off related agreements were $330 million and $632 million at December 31, 2024 and 2023, respectively, and are reflected in Other current assets. The amounts due to Organon under these agreements were $113 million and $598 million at December 31, 2024 and 2023, respectively, and are included in Accrued and other current liabilities.
XML 55 R14.htm IDEA: XBRL DOCUMENT v3.25.0.1
Collaborative Arrangements
12 Months Ended
Dec. 31, 2024
Collaborative Arrangements [Abstract]  
Collaborative Arrangements Collaborative Arrangements
Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merck’s more significant collaborative arrangements are discussed below.
AstraZeneca PLC
In 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca’s Lynparza (olaparib) for multiple cancer types. Independently, Merck and AstraZeneca are developing and commercializing Lynparza in combinations with their respective PD-1 and PD-L1 medicines, Keytruda and Imfinzi. The companies are also jointly developing and commercializing AstraZeneca’s Koselugo (selumetinib) for multiple indications. Under the terms of the agreement, AstraZeneca and Merck share the development and commercialization costs for Lynparza and Koselugo monotherapy and non-PD-1/PD-L1 combination therapy opportunities.
Profits from Lynparza and Koselugo product sales generated through monotherapies or combination therapies are shared equally. AstraZeneca is the principal on Lynparza and Koselugo sales transactions. Merck records its share of Lynparza and Koselugo product sales, net of cost of sales and commercialization costs, as alliance revenue, and its share of development costs associated with the collaboration as part of Research and development expenses. Reimbursements received from AstraZeneca for research and development expenses are recognized as reductions to Research and development costs.
As part of the agreement, Merck made an upfront payment to AstraZeneca and also made payments over a multi-year period for certain license options. In addition, the agreement provides for contingent payments from Merck to AstraZeneca related to the successful achievement of sales-based and regulatory milestones.
In 2024, sales of Koselugo triggered a $100 million sales-based milestone payment from Merck to AstraZeneca. Accordingly, Merck recorded a $100 million liability (which remained accrued at December 31, 2024 and was subsequently paid in January 2025) and a corresponding increase to the intangible asset related to Koselugo. Merck also recognized $48 million of cumulative amortization catch-up expense related to the recognition of this milestone in 2024. Merck made a sales-based milestone payment to AstraZeneca of $400 million in 2022 (which had been previously accrued for). Additionally, in 2022, Merck determined it was probable that sales of Lynparza in the future would trigger a $600 million sales-based milestone payment from Merck to AstraZeneca. Accordingly, Merck recorded a $600 million liability (which remained accrued at December 31, 2024 and was
subsequently paid in January 2025) and a corresponding increase to the intangible asset related to Lynparza. Merck also recognized $250 million of cumulative amortization catch-up expense related to the recognition of this milestone in 2022. Potential future sales-based milestone payments of $2.0 billion have not yet been accrued as they are not deemed by the Company to be probable at this time.
Lynparza received regulatory approvals triggering capitalized milestone payments from Merck to AstraZeneca of $245 million, $105 million and $250 million in 2024, 2023 and 2022, respectively (each of which had been previously accrued for). In 2024, the partners agreed that no future regulatory milestone payments from Merck to AstraZeneca are likely under the agreement.
The intangible asset balances related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) and Koselugo (which reflects the 2024 capitalized sales-based milestone payment) were $1.2 billion and $49 million, respectively, at December 31, 2024 and are included in Other Intangibles, Net. The assets are being amortized over their estimated useful lives (through 2028 for Lynparza and through 2029 for Koselugo) as supported by projected future cash flows, subject to impairment testing.
Summarized financial information related to this collaboration is as follows:
Years Ended December 31202420232022
Alliance revenue - Lynparza$1,311 $1,199 $1,116 
Alliance revenue - Koselugo170 97 54 
Total alliance revenue$1,481 $1,296 $1,170 
Cost of sales (1)
378 311 492 
Selling, general and administrative165 192 185 
Research and development77 79 106 
December 3120242023
Receivables from AstraZeneca included in Other current assets
$424 $341 
Payables to AstraZeneca included in Accrued and other current liabilities (2)
713 256 
Payables to AstraZeneca included in Other Noncurrent Liabilities (2)
 600 
(1)    Represents amortization of capitalized milestone payments. Amounts in 2024 and 2022 include $48 million and $250 million, respectively, of cumulative amortization catch-up expense as noted above.
(2)    Includes accrued milestone payments.
Eisai Co., Ltd.
In 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Under the agreement, Merck and Eisai are developing and commercializing Lenvima jointly, both as monotherapy and in combination with Keytruda. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions) and Merck and Eisai share applicable profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue. Expenses incurred during co-development are shared by the two companies in accordance with the collaboration agreement and reflected in Research and development expenses. Certain expenses incurred solely by Merck or Eisai are not shareable under the collaboration agreement, including costs incurred in excess of agreed upon caps and costs related to certain combination studies of Keytruda and Lenvima.
Under the agreement, Merck made an upfront payment to Eisai and also made payments over a multi-year period for certain option rights. In addition, the agreement provides for contingent payments from Merck to Eisai related to the successful achievement of sales-based and regulatory milestones.
Merck made sales-based milestone payments to Eisai aggregating $125 million, $125 million and $600 million in 2024, 2023 and 2022, respectively. In 2023, Merck determined it was probable that sales of Lenvima in the future would trigger $250 million of sales-based milestone payments from Merck to Eisai. Accordingly, Merck recorded $250 million of liabilities (of which $125 million was subsequently paid in each of 2024 and 2023 as noted above) and corresponding increases to the intangible asset related to Lenvima. Merck also recognized $154 million of cumulative amortization catch-up expense related to the recognition of these milestones in 2023. Potential future sales-based milestone payments of $2.3 billion have not yet been accrued as they are not deemed by the Company to be probable at this time.
In 2022, Lenvima received regulatory approvals triggering capitalized milestone payments of $50 million from Merck to Eisai. There are no regulatory milestone payments remaining under the agreement.
The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was $442 million at December 31, 2024 and is included in Other Intangibles, Net. The amount is being amortized over its estimated useful life through 2026 as supported by projected future cash flows, subject to impairment testing.
Summarized financial information related to this collaboration is as follows:
Years Ended December 31202420232022
Alliance revenue - Lenvima$1,010 $960 $876 
Cost of sales (1)
241 381 212 
Selling, general and administrative159 189 158 
Research and development21 66 136 
December 3120242023
Receivables from Eisai included in Other current assets
$257 $226 
Payables to Eisai included in Accrued and other current liabilities (2)
 125 
(1)     Represents amortization of capitalized milestone payments. Amount in 2023 includes $154 million of cumulative amortization catch-up expense as noted above.
(2)     Represents an accrued milestone payment.
Bayer AG
In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Bayer’s Adempas (riociguat) and Verquvo (vericiguat). The two companies have implemented a joint development and commercialization strategy. Under the agreement, Bayer commercializes Adempas in the Americas, while Merck commercializes in the rest of the world. For Verquvo, Merck commercializes in the U.S. and Bayer commercializes in the rest of the world. Both companies share in development costs and profits on sales. Merck records sales of Adempas and Verquvo in its marketing territories, as well as alliance revenue. Alliance revenue represents Merck’s share of profits from sales of Adempas and Verquvo in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs. Cost of sales includes Bayer’s share of profits from sales in Merck’s marketing territories.
In addition, the agreement provided for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones. In 2022, Merck made the final $400 million sales-based milestone payment under this collaboration to Bayer.
The intangible asset balances related to Adempas (which includes the acquired intangible asset balance, as well as capitalized sales-based milestone payments attributed to Adempas) and Verquvo (which reflects the portion of the final sales-based milestone payment that was attributed to Verquvo) were $372 million and $42 million, respectively, at December 31, 2024 and are included in Other Intangibles, Net. The assets are being amortized over their estimated useful lives (through 2027 for Adempas and through 2031 for Verquvo) as supported by projected future cash flows, subject to impairment testing.
Summarized financial information related to this collaboration is as follows:
Years Ended December 31202420232022
Alliance revenue - Adempas/Verquvo$415 $367 $341 
Net sales of Adempas recorded by Merck287 255 238 
Net sales of Verquvo recorded by Merck37 36 22 
Total sales$739 $658 $601 
Cost of sales (1)
244 224 210 
Selling, general and administrative111 131 153 
Research and development102 90 75 
December 3120242023
Receivables from Bayer included in Other current assets
$160 $156 
Payables to Bayer included in Accrued and other current liabilities
82 80 
(1)    Includes amortization of intangible assets, cost of products sold by Merck, as well as Bayer’s share of profits from sales in Merck’s marketing territories.
Ridgeback Biotherapeutics LP
In 2020, Merck and Ridgeback Biotherapeutics LP (Ridgeback), a closely held biotechnology company, entered into a collaboration agreement to develop Lagevrio (molnupiravir), an investigational orally available antiviral candidate for the treatment of patients with COVID-19. Merck gained exclusive worldwide rights to develop and commercialize Lagevrio and related molecules. Following initial authorizations in certain markets in 2021, Lagevrio has since received multiple additional authorizations.
Under the terms of the agreement, Ridgeback received an upfront payment and is eligible to receive future contingent payments dependent upon the achievement of certain developmental and regulatory approval milestones. The agreement also provides for Merck to reimburse Ridgeback for a portion of certain third-party contingent milestone payments and royalties on net sales, which is part of the profit-sharing calculation. Merck is the principal on sales transactions, recognizing sales and related costs, with profit-sharing amounts recorded within Cost of sales. Profits from the collaboration are split equally between the partners. Reimbursements from Ridgeback for its share of research and development costs (deducted from Ridgeback’s share of profits) are reflected as decreases to Research and development expenses.
Summarized financial information related to this collaboration is as follows:
Years Ended December 31202420232022
Net sales of Lagevrio recorded by Merck
$964 $1,428 $5,684 
Cost of sales (1)
554 852 3,038 
Selling, general and administrative
57 97 147 
Research and development
13 60 88 
December 3120242023
Payables to Ridgeback included in Accrued and other current liabilities (2)
$68 $113 
(1)    Includes cost of products sold by Merck, Ridgeback’s share of profits, royalty expense, amortization of capitalized milestone payments and inventory reserves.
(2)    Includes accrued royalties.
Daiichi Sankyo
In October 2023, Merck and Daiichi Sankyo entered into a global development and commercialization agreement for three of Daiichi Sankyo’s DXd ADC candidates: patritumab deruxtecan (HER3-DXd) (MK-1022), ifinatamab deruxtecan (I-DXd) (MK-2400) and raludotatug deruxtecan (R-DXd) (MK-5909). All three potentially first-in-class DXd ADCs are in various stages of clinical development for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments. The companies will jointly develop and potentially commercialize these ADC candidates worldwide, except in Japan where Daiichi Sankyo will maintain exclusive rights. Daiichi Sankyo will be solely responsible for manufacturing and supply.
Under the terms of the agreement, Merck made payments to Daiichi Sankyo totaling $4.0 billion in 2023. These payments included $1.0 billion ($500 million each for patritumab deruxtecan and ifinatamab deruxtecan) which may be refundable on a pro-rated basis in the event of early termination of development with respect to either program. In addition, the agreement provided for a continuation payment of $750 million related to patritumab deruxtecan, which Merck paid in October 2024, and a continuation payment of $750 million related to raludotatug deruxtecan due from Merck in October 2025. If Merck does not make the remaining continuation payment for raludotatug deruxtecan, the rights for that program will revert to Daiichi Sankyo and the non-refundable upfront payments already paid will be retained by Daiichi Sankyo. The agreement also provides for contingent payments from Merck to Daiichi Sankyo of up to an additional $5.5 billion for each DXd ADC upon the successful achievement of certain sales-based milestones.
In conjunction with this transaction, Merck recorded an aggregate pretax charge of $5.5 billion to Research and development expenses in 2023 for the $4.0 billion of upfront payments and the $1.5 billion of continuation payments. Merck determined it was appropriate to expense the $1.0 billion refundable portion of the consideration in 2023 because of the significant number of clinical studies that were underway and planned in the near future, as well as certain studies in advanced stages, making it highly likely that the programs would continue to progress and incur substantial expenses, and therefore the likelihood of the programs terminating before the end of the refundable period was deemed remote. Merck also determined that it was appropriate to expense the continuation payments upon execution of the agreement because such payments do not result in the Company gaining any additional intellectual property rights. In addition, the significant number of ongoing and planned clinical studies and the short-term nature of the option period makes the likelihood of Merck not making these payments remote.
Merck and Daiichi Sankyo equally share research and development costs, except for raludotatug deruxtecan, where Merck is responsible for 75% of the first $2.0 billion of research and development expenses. Merck includes its share of development costs associated with the collaboration as part of Research and development expenses. Following regulatory approval, Daiichi Sankyo will generally record sales worldwide (Daiichi Sankyo will be the principal on sales transactions) and the companies will equally share expenses as well as profits worldwide except for Japan where Daiichi Sankyo retains exclusive rights and Merck will receive a 5% sales-based royalty. Merck will record its share of product sales, net of cost of sales and commercialization costs, as alliance revenue.
In August 2024, Merck and Daiichi Sankyo expanded their agreement to include MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, which Merck obtained through its acquisition of Harpoon (see Note 3). The companies are planning to evaluate MK-6070 in combination with ifinatamab deruxtecan in certain patients with SCLC, as well as other potential combinations. Merck received an upfront cash payment of $170 million from Daiichi Sankyo (recorded within Other (income) expense, net) and has also satisfied a contingent quid obligation from the original collaboration agreement. The companies will jointly develop and commercialize MK-6070 worldwide and share research and development and commercialization expenses. Research and development expenses related to MK-6070 in combination with ifinatamab deruxtecan will be shared in a manner consistent with the original agreement for ifinatamab deruxtecan. Merck will be solely responsible for manufacturing and supply of MK-6070. If approved, Merck will generally record sales for MK-6070 worldwide (Merck will be the principal on sales transactions) and the companies will equally share expenses as well as profits worldwide, except for Japan where Merck retains exclusive rights and Daiichi Sankyo will receive a 5% sales-based royalty.
Summarized financial information related to this collaboration is as follows:
Years Ended December 3120242023
Selling, general and administrative
$26 $
Research and development (1)
351 5,549 
December 3120242023
Receivables from Daiichi Sankyo included in Other current assets
$8 $— 
Payables to Daiichi Sankyo included in Accrued and other current liabilities (2)
817 800 
Payables to Daiichi Sankyo included in Other Noncurrent Liabilities (2)
 750 
(1)    Expenses in 2023 include the $5.5 billion charge for the upfront and continuing option payments noted above.
(2)    Includes accrued continuation payment.
Moderna, Inc.
In 2022, Merck exercised its option to jointly develop and commercialize V940 (mRNA-4157), an investigational individualized neoantigen therapy, pursuant to the terms of an existing collaboration and license agreement with Moderna, Inc. (Moderna), which resulted in a $250 million payment that was charged to Research and development expenses in 2022. V940 (mRNA-4157) is currently being evaluated in combination with Keytruda in multiple Phase 3 clinical trials. Merck and Moderna share costs and will share any profits equally under this worldwide collaboration. Merck records its share of development costs associated with the collaboration as part of Research and development expenses. Any reimbursements received from Moderna for research and development expenses are recognized as reductions to Research and development costs. Merck has also capitalized certain of the shared costs, mainly related to facility costs, which aggregated $198 million at December 31, 2024 and will be amortized over the assets’ estimated useful lives.
Summarized financial information related to this collaboration is as follows:
Years Ended December 31202420232022
Selling, general and administrative
$16 $$— 
Research and development (1)
358 218 288 
December 3120242023
Payables to Moderna included in Accrued and other current liabilities
$57 $63 
(1)    Expenses in 2022 include the $250 million option exercise payment noted above.
Bristol-Myers Squibb Company
Reblozyl (luspatercept-aamt) is a first-in-class erythroid maturation recombinant fusion protein that is being commercialized through a global collaboration with Bristol-Myers Squibb Company (BMS). Reblozyl is approved in the U.S., Europe, and certain other markets for the treatment of anemia in certain rare blood disorders and is also being evaluated for additional indications for hematology therapies. BMS is the principal on sales transactions for Reblozyl; however, Merck co-promotes Reblozyl (and may co-promote any future products approved under this collaboration) in North America, which is reimbursed by BMS. Merck receives tiered royalties ranging from 20% to 24% based on sales levels. This royalty will be reduced by 50% upon the earlier of patent expiry or generic entry on an indication-by-indication basis in each market. Additionally, Merck is eligible to receive future contingent sales-based milestone payments of up to $80 million. Alliance revenue related to this collaboration (recorded within Sales) consists of royalties and, for 2022, also includes the receipt of a regulatory approval milestone payment of $20 million. Merck recorded alliance revenue related to this collaboration of $371 million in 2024, $212 million in 2023 and $166 million in 2022.
XML 56 R15.htm IDEA: XBRL DOCUMENT v3.25.0.1
Restructuring
12 Months Ended
Dec. 31, 2024
Restructuring and Related Activities [Abstract]  
Restructuring Restructuring
In January 2024, the Company approved a new restructuring program (2024 Restructuring Program) intended to continue the optimization of the Company’s Human Health global manufacturing network as the future pipeline shifts to new modalities and also optimize the Animal Health global manufacturing network to improve supply reliability and increase efficiency. The actions contemplated under the 2024 Restructuring Program are expected to be substantially completed by the end of 2031, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $4.0 billion. Approximately 60% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested. The remainder of the costs will result in cash outlays, relating primarily to facility shut-down costs. The Company recorded total pretax costs of $888 million and $190 million in 2024 and 2023, respectively, related to the 2024 Restructuring Program, bringing total cumulative pretax costs incurred through December 31, 2024 to $1.1 billion.
In 2019, Merck approved a global restructuring program (2019 Restructuring Program) as part of a worldwide initiative focused on optimizing the Company’s manufacturing and supply network, as well as reducing its global real estate footprint. The Company recorded total pretax costs of $743 million in 2023 and $666 million in 2022 related to the 2019 Restructuring Program. The actions under the 2019 Restructuring Program were substantially complete at the end of 2023 and, as of January 1, 2024, any remaining activities are being accounted for as part of the 2024 Restructuring Program.
For segment reporting, restructuring charges are unallocated expenses.
The following table summarizes the charges related to the restructuring programs by type of cost:
Accelerated
Depreciation
Separation
Costs
Other Exit Costs
Total
Year Ended December 31, 2024
2024 Restructuring Program
Cost of sales$254 $ $241 $495 
Selling, general and administrative  83 83 
Research and development  1 1 
Restructuring costs 122 187 309 
$254 $122 $512 $888 
Year Ended December 31, 2023
2024 Restructuring Program
Cost of sales$— $— $62 $62 
Restructuring costs— 115 13 128 
— 115 75 190 
2019 Restructuring Program
Cost of sales131 — 18 149 
Selling, general and administrative— 113 122 
Research and development— — 
Restructuring costs— 339 132 471 
 140 339 264 743 
$140 $454 $339 $933 
Year Ended December 31, 2022    
2019 Restructuring Program
Cost of sales$72 $— $133 $205 
Selling, general and administrative19 — 75 94 
Research and development29 — 30 
Restructuring costs— 212 125 337 
 $120 $212 $334 $666 
Accelerated depreciation costs primarily relate to manufacturing, research and administrative facilities and equipment to be sold or closed as part of the programs. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. All the sites will continue to operate up through the respective closure dates and, since future undiscounted cash flows are sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of the site assets. Anticipated site closure dates, particularly related to manufacturing locations, have been and may continue to be adjusted to reflect changes resulting from regulatory or other factors.
Separation costs are associated with actual headcount reductions, as well as involuntary headcount reductions which were probable and could be reasonably estimated.
Other exit costs in 2024, 2023 and 2022 include asset impairment, facility shut-down and other related costs, as well as pretax gains and losses resulting from the sales of facilities and related assets. Additionally, other activity includes certain employee-related costs associated with pension and other postretirement benefit plans (see Note 13) and share-based compensation.
The following table summarizes the charges and spending relating to restructuring program activities:
Accelerated
Depreciation
Separation
Costs
Other Exit Costs
Total
Restructuring reserves January 1, 2023
$— $479 $34 $513 
Expenses140 454 339 933 
(Payments) receipts, net— (252)(158)(410)
Non-cash activity(140)— (184)(324)
Restructuring reserves December 31, 2023
— 681 31 712 
Expenses254 122 512 888 
(Payments) receipts, net (239)(206)(445)
Non-cash activity(254) (337)(591)
Restructuring reserves December 31, 2024
$ $564 $ $564 
XML 57 R16.htm IDEA: XBRL DOCUMENT v3.25.0.1
Financial Instruments
12 Months Ended
Dec. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Financial Instruments Financial Instruments
Derivative Instruments and Hedging Activities
The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.
A significant portion of the Company’s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives of and accounting related to the Company’s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.

Foreign Currency Risk Management
The Company has established revenue hedging, balance sheet risk management and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.
The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S. dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than two years into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and foreign exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts, and purchased collar options.
The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or OCI depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in AOCL and reclassified into Sales when the hedged anticipated revenue is recognized. The amount reclassified into earnings as a result of the discontinuation of cash flow hedges because it was no longer deemed probable the forecasted hedged transactions would occur was not material for the years ended December 31, 2024, 2023 or 2022. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in Sales each period. The cash flows from both designated and non-designated contracts are reported as operating activities in the Consolidated Statement of Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.
The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of foreign exchange on monetary assets and liabilities. Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in Other (income) expense, net. The Company also uses a balance sheet risk management program to mitigate the exposure of such assets and liabilities from the effects of volatility in foreign exchange. Merck principally utilizes forward exchange contracts to
offset the effects of foreign exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the foreign exchange rate and the cost of the hedging instrument (primarily the euro, Swiss franc, Japanese yen, and Chinese renminbi). The forward contracts are not designated as hedges and are marked to market through Other (income) expense, net. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than six months. The cash flows from these contracts are reported as operating activities in the Consolidated Statement of Cash Flows.
The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in foreign exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within OCI, and remain in AOCL until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded components). Changes in fair value of the excluded components are recognized in OCI. The Company recognizes in earnings the initial value of the excluded components on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Consolidated Statement of Cash Flows.
Foreign exchange risk is also managed through the use of foreign currency debt. Certain of the Company’s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within OCI.
The effects of the Company’s net investment hedges on OCI and the Consolidated Statement of Income are shown below:
Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income (1)
Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing
Years Ended December 31202420232022202420232022
Net Investment Hedging Relationships
Foreign exchange contracts$(30)$— $(48)$(4)$$(1)
Euro-denominated notes(192)105 (162) — — 
(1)    No amounts were reclassified from AOCL into income related to the sale of a subsidiary.

Interest Rate Risk Management
The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal at risk.
At December 31, 2024, the Company was a party to six pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of the fixed-rate notes as detailed in the table below.
Par Value of DebtNumber of Interest Rate Swaps HeldTotal Swap Notional Amount
4.50% notes due 2033
$1,500 $1,500 
The interest rate swap contracts are designated hedges of the fair value changes in the notes attributable to changes in the benchmark Secured Overnight Financing Rate (SOFR) swap rate. The fair value changes in the notes attributable to changes in the SOFR swap rate are recorded in interest expense along with the offsetting fair value changes in the swap contracts. In January 2025, the Company entered into an additional interest rate swap contract with a notional amount of $250 million related to its 5.00% notes due 2053. The cash flows from these contracts are reported as operating activities in the Consolidated Statement of Cash Flows.
The table below presents the location of amounts recorded in the Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges as of December 31:
Carrying Amount of Hedged Liabilities
Cumulative Amount of Fair Value Hedging Adjustment Increase Included in the Carrying Amount
2024202320242023
Balance Sheet Caption
Long-Term Debt $1,509 $1,056 $17 $56 
Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments as of December 31:
  20242023
  Fair Value of
Derivative
U.S. Dollar
Notional
Fair Value of
Derivative
U.S. Dollar
Notional
 AssetLiabilityAssetLiability
Derivatives Designated as Hedging InstrumentsBalance Sheet Caption      
Interest rate swap contracts
Other Assets
$17 $ $1,500 $57 $— $1,000 
Foreign exchange contractsOther current assets323  8,662 106 — 6,138 
Foreign exchange contractsOther Assets66  2,125 26 — 1,929 
Foreign exchange contractsAccrued and other current liabilities 1 162 — 76 3,680 
Foreign exchange contractsOther Noncurrent Liabilities 1 16 — 
  $406 $2 $12,465 $189 $77 $12,754 
Derivatives Not Designated as Hedging InstrumentsBalance Sheet Caption      
Foreign exchange contractsOther current assets$323 $ $12,544 $153 $— $9,693 
Foreign exchange contractsAccrued and other current liabilities 343 13,551 — 162 8,104 
  $323 $343 $26,095 $153 $162 $17,797 
  $729 $345 $38,560 $342 $239 $30,551 
As noted above, the Company records its derivatives on a gross basis in the Consolidated Balance Sheet. The Company has master netting agreements with several of its financial institution counterparties (see Concentrations of Credit Risk below). The following table provides information on the Company’s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes as of December 31:
20242023
AssetLiabilityAssetLiability
Gross amounts recognized in the consolidated balance sheet$729 $345 $342 $239 
Gross amounts subject to offset in master netting arrangements not offset in the consolidated balance sheet(299)(299)(215)(215)
Cash collateral received
(165) (3)— 
Net amounts$265 $46 $124 $24 
The table below provides information regarding the location and amount of pretax gains and losses of derivatives designated in fair value or cash flow hedging relationships:
Years Ended December 31202420232022202420232022202420232022
Financial Statement Caption in which Effects of Fair Value or Cash Flow Hedges are RecordedSales
Other (income) expense, net (1)
Other comprehensive income (loss)
$64,168 $60,115 $59,283 $(24)$466 $1,501 $216 $(393)$(339)
(Gain) loss on fair value hedging relationships:
Interest rate swap contracts
Hedged items — — (39)56 (13) — — 
Derivatives designated as hedging instruments — — 39 (57) — — 
Impact of cash flow hedging relationships:
Foreign exchange contracts
Amount of gain recognized in OCI on derivatives
 — —  — — 508 114 684 
Increase in Sales as a result of AOCL reclassifications
167 249 773  — — (167)(249)(773)
Interest rate contracts
Amount of gain recognized in Other (income) expense, net on derivatives
 — — (1)(1)(2) — — 
Amount of (loss) gain recognized in OCI on derivatives
 — —  — — (1)13 (2)
(1)    Interest expense is a component of Other (income) expense, net.
The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:
Amount of Derivative Pretax Loss (Gain) Recognized in Income
Years Ended December 31202420232022
Derivatives Not Designated as Hedging InstrumentsIncome Statement Caption
Foreign exchange contracts (1)
Other (income) expense, net$251 $(6)$(49)
Foreign exchange contracts (2)
Sales(28)(37)
(1)    These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates.
(2)     These derivative contracts serve as economic hedges of forecasted transactions.
At December 31, 2024, the Company estimates $262 million of pretax net unrealized gains on derivatives maturing within the next 12 months that hedge foreign currency denominated sales over that same period will be reclassified from AOCL to Sales. The amount ultimately reclassified to Sales may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual foreign exchange rates at maturity.
Investments in Debt and Equity Securities
Information on investments in debt and equity securities at December 31 is as follows:
 
 20242023
 Amortized
Cost
Gross UnrealizedFair
Value
Amortized
Cost
Gross UnrealizedFair
Value
GainsLossesGainsLosses
Commercial paper$348 $ $ $348 $252 $— $— $252 
U.S. government and agency securities188   188 72— — 72 
Corporate notes and bonds    13 — — 13 
Total debt securities$536 $ $ $536 $337 $— $— $337 
Publicly traded equity securities (1)
920 764 
Total debt and publicly traded equity securities$1,456 $1,101 
(1)    Unrealized net losses of $30 million were recorded in Other (income) expense, net in 2024 on equity securities still held at December 31, 2024. Unrealized net gains of $411 million were recorded in Other (income) expense, net in 2023 on equity securities still held at December 31, 2023.
At December 31, 2024 and 2023, the Company also had $863 million and $832 million, respectively, of equity investments without readily determinable fair values included in Other Assets. The Company records unrealized gains on these equity investments based on favorable observable price changes from transactions involving similar investments of the same investee and records unrealized losses based on unfavorable observable price changes, which are included in Other (income) expense, net. During 2024, the Company recorded unrealized gains of $19 million and unrealized losses of $51 million related to certain of these equity investments still held at December 31, 2024. During 2023, the Company recorded unrealized gains of $10 million and unrealized losses of $61 million related to certain of these equity investments still held at December 31, 2023. Cumulative unrealized gains and cumulative unrealized losses based on observable price changes for investments in equity investments without readily determinable fair values still held at December 31, 2024 were $309 million and $107 million, respectively.
At December 31, 2024, 2023 and 2022, the Company also had $267 million, $417 million and $598 million, respectively, recorded in Other Assets for equity securities held through ownership interests in investment funds. Losses recorded in Other (income) expense, net relating to these investment funds were $29 million, $106 million and $1.0 billion for the years ended December 31, 2024, 2023 and 2022, respectively.
Fair Value Measurements
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest:
Level 1 — Quoted prices (unadjusted) in active markets for identical assets or liabilities.
Level 2 — Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3 — Unobservable inputs that are supported by little or no market activity. Level 3 assets or liabilities are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as assets or liabilities for which the determination of fair value requires significant judgment or estimation.
If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
Financial assets and liabilities measured at fair value on a recurring basis at December 31 are summarized below:
 Fair Value Measurements UsingFair Value Measurements Using
Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
  20242023
Assets
Investments
Commercial paper$ $348 $ $348 $— $252 $— $252 
U.S. government and agency securities 99  99 — — — — 
Publicly traded equity securities463   463 252 — — 252 
 463 447  910 252 252 — 504 
Other assets (1)
U.S. government and agency securities89   89 72 — — 72 
Corporate notes and bonds    13 — — 13 
Publicly traded equity securities (2)
457   457 512 — — 512 
546   546 597 — — 597 
Derivative assets (3)
Forward exchange contracts 499  499 — 202 — 202 
Purchased currency options 213  213 — 83 — 83 
Interest rate swaps 17  17 — 57 — 57 
  729  729 — 342 — 342 
Total assets$1,009 $1,176 $ $2,185 $849 $594 $— $1,443 
Liabilities
Other liabilities
Contingent consideration$ $ $193 $193 $— $— $354 $354 
Derivative liabilities (3)
Forward exchange contracts 338  338 — 239 — 239 
Written currency options 7  7 — — — — 
 345  345 — 239 — 239 
Total liabilities$ $345 $193 $538 $— $239 $354 $593 
(1)    Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.
(2)    Balance at December 31, 2024 includes securities with a fair value of $81 million, which are subject to a contractual sale restriction that expires in March 2025. Balance at December 31, 2023 includes securities with a fair value of $177 million, which were subject to a contractual sale restriction that expired in July 2024.
(3)    The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company’s own credit risk, the effects of which were not significant.
As of December 31, 2024 and 2023, Cash and cash equivalents included $12.3 billion and $6.0 billion of cash equivalents, respectively (which would be considered Level 2 in the fair value hierarchy).
Contingent Consideration
Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:
20242023
Fair value January 1$354 $456 
Changes in estimated fair value (1)
(10)15 
Payments(151)(117)
Fair value December 31 (2)
$193 $354 
(1)    Recorded in Cost of sales, Research and development expenses, and Other (income) expense, net. Includes cumulative translation adjustments.
(2)    Balance at December 31, 2024 includes $148 million of current liabilities, of which $123 million relates to the termination of the Sanofi Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate to present value the cash flows.
The payments of contingent consideration in 2024 include $126 million related to the Sanofi Pasteur MSD liabilities described above and $25 million related to the first commercial sale of Lyfnua (gefapixant) in the European Union (EU). The payments of contingent consideration in 2023 relate to the Sanofi Pasteur MSD liabilities.
Other Fair Value Measurements
Some of the Company’s financial instruments, such as cash and cash equivalents, receivables and payables, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.
The estimated fair value of loans payable and long-term debt (including current portion) at December 31, 2024, was $32.6 billion compared with a carrying value of $37.1 billion and at December 31, 2023, was $32.0 billion compared with a carrying value of $35.1 billion. Fair value was estimated using recent observable market prices and would be considered Level 2 in the fair value hierarchy.
Concentrations of Credit Risk
On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government issuers of securities and financial institutions with which it conducts business. Credit exposure limits are established to limit a concentration with any single issuer or institution. Cash and investments are placed in instruments that meet high credit quality standards, as specified in the Company’s investment policy guidelines.
The majority of the Company’s accounts receivable arise from product sales in the U.S., Europe and China and are primarily due from drug wholesalers, distributors and retailers, hospitals and government agencies. The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company also continues to monitor global economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets and its business. 
The Company’s customers with the largest accounts receivable balances are: McKesson Corporation, Cencora, Inc. and Cardinal Health, Inc., which represented approximately 21%, 21% and 13%, respectively, of total accounts receivable at December 31, 2024. Vaccines distributed by Chongqing Zhifei Biological Products Co., Ltd. (Zhifei) represent a substantial portion of total sales in China; however, nearly all of the accounts receivable for Zhifei were factored as of December 31, 2024, as part of the Company’s factoring program discussed below. The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business. Bad debts have been minimal. The Company does not normally require collateral or other security to support credit sales.
The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $2.1 billion and $3.0 billion of accounts receivable as of December 31, 2024 and 2023, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions, generally within thirty days after receipt. At December 31, 2024 and 2023, the Company had collected $55 million and $44 million, respectively, on behalf of the financial institutions, which is reflected as restricted cash in Other current assets, and the related obligation to remit the cash is recorded in Accrued and other current liabilities. The net cash flows related to these collections are reported as financing activities in the Consolidated Statement of Cash Flows. The cost of factoring such accounts receivable was de minimis.
Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements. The master agreements with several of the Company’s financial institution counterparties also include credit support annexes. These annexes contain provisions that require collateral to be exchanged depending on the value of the derivative assets and liabilities, the Company’s credit rating, and the credit rating of the counterparty. Cash collateral received by the Company from various counterparties was $165 million and $3 million at December 31, 2024 and 2023, respectively. The obligation to return such collateral is recorded in Accrued and other current liabilities.
XML 58 R17.htm IDEA: XBRL DOCUMENT v3.25.0.1
Inventories
12 Months Ended
Dec. 31, 2024
Inventory Disclosure [Abstract]  
Inventories Inventories
Inventories at December 31 consisted of:
20242023
Finished goods$2,022 $1,954 
Raw materials and work in process8,831 8,037 
Supplies289 277 

11,142 10,268 
Decrease to LIFO cost(840)(562)
 $10,302 $9,706 
Recognized as:
Inventories$6,109 $6,358 
Other Assets4,193 3,348 
Inventories valued under the LIFO method comprised approximately $3.4 billion and $3.1 billion at December 31, 2024 and 2023, respectively, after reflecting the decrease to LIFO cost. Amounts recognized as Other Assets are comprised almost entirely of raw materials and work in process inventories. At December 31, 2024 and 2023, these amounts included $3.8 billion and $2.6 billion, respectively, of inventories not expected to be sold within one year. In addition, these amounts included $412 million and $790 million at December 31, 2024 and 2023, respectively, of inventories produced in preparation for product launches.
XML 59 R18.htm IDEA: XBRL DOCUMENT v3.25.0.1
Goodwill and Other Intangibles
12 Months Ended
Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Other Intangibles Goodwill and Other Intangibles
The following table summarizes goodwill activity by segment:
PharmaceuticalAnimal HealthTotal
Balance January 1, 2023
$17,936 $3,268 $21,204 
Other (1)
(14)(7)
Balance December 31, 2023 (2)
17,922 3,275 21,197 
Acquisitions
 518 518 
Other (1)
(19)(28)(47)
Balance December 31, 2024 (2)
$17,903 $3,765 $21,668 
(1)    Includes cumulative translation adjustments on goodwill balances.
(2)    Accumulated goodwill impairment losses were $531 million at both December 31, 2024 and 2023.
Other acquired intangibles at December 31 consisted of:
 20242023
Gross
Carrying
Amount
Accumulated
Amortization
NetGross
Carrying
Amount
Accumulated
Amortization
Net
Product rights
$29,988 $19,066 $10,922 $23,643 $17,765 $5,878 
IPR&D430  430 6,816 — 6,816 
Trade names2,881 954 1,927 2,881 776 2,105 
Licenses and other8,863 5,772 3,091 8,263 5,051 3,212 
 $42,162 $25,792 $16,370 $41,603 $23,592 $18,011 
Some of the more significant acquired intangibles included in product rights, on a net basis, related to human health marketed products at December 31, 2024 were Winrevair, $5.9 billion; Reblozyl, $2.8 billion; and Zerbaxa, $260 million. Additionally, the Company had $4.3 billion of net acquired intangibles related to animal health at December 31, 2024, of which $1.7 billion related to product rights and $1.9 billion was attributable to trade names, primarily related to Allflex. At December 31, 2024, IPR&D primarily relates to MK-1026 (nemtabrutinib), obtained through the acquisition of ArQule, Inc. (ArQule), which had a balance of $418 million. Some of the more significant net intangible assets included in licenses and other above at December 31, 2024 include Lynparza, $1.2 billion, related to a collaboration with AstraZeneca; Lenvima, $442 million, related to a collaboration with Eisai; and Adempas, $372 million, related to a collaboration with Bayer. See Note 4 for additional information related to the intangible assets associated with these collaborations.
IPR&D that the Company acquires through business combinations represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. Amounts capitalized as IPR&D are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each IPR&D project, the Company will make a separate determination as to the then-useful life of the asset and begin amortization.
In 2023, the Company recorded a $779 million IPR&D impairment charge within Research and development expenses related to MK-7264, gefapixant, a non-narcotic, oral selective P2X3 receptor antagonist, that was in development for the treatment of refractory or unexplained chronic cough in adults. In December 2023, the FDA issued a Complete Response Letter (CRL) regarding the resubmission of Merck’s New Drug Application (NDA) for gefapixant. In the CRL, the FDA concluded that Merck’s application did not meet substantial evidence of effectiveness for treating refractory chronic cough and unexplained chronic cough. The CRL was not related to the safety of gefapixant. The marketing application for gefapixant was based on results from the COUGH-1 and COUGH-2 clinical trials. In January 2022, the FDA issued a CRL regarding Merck’s original NDA for gefapixant. In that CRL, the FDA requested additional information related to the cough counting system that was used to assess efficacy. Receipt of the second CRL from the FDA constituted a triggering event that required the evaluation of the gefapixant intangible asset for impairment. The Company estimated the current fair value of gefapixant utilizing an income approach, which calculates the present value of projected future cash flows. The market participant assumptions used to derive the forecasted cash flows were updated to reflect revised market launch plans, resulting in a reduction in the estimated fair value. The revised estimated fair value of gefapixant when compared with its related carrying value resulted in the impairment charge noted above. The remaining intangible asset balance related to Lyfnua (gefapixant) at December 31, 2024 of $21 million is included in product rights in the table above and is being amortized over its expected useful life as supported by projected future cash flows in the markets where it is approved including Japan and the EU.
In 2022, the Company recorded $1.7 billion of intangible asset impairment charges within Research and development expenses, of which $1.6 billion represents IPR&D impairment charges related to nemtabrutinib (MK-1026), an oral, reversible, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor currently being evaluated for the treatment of hematological malignancies that was obtained through the 2020 acquisition of ArQule. Following discussions with regulatory authorities in the third quarter of 2022, the development period for nemtabrutinib was extended, which constituted a triggering event that required the evaluation of the nemtabrutinib intangible asset for impairment. The Company estimated the current fair value of nemtabrutinib utilizing an income approach which calculates the present value of projected future cash flows. The market participant assumptions used to derive the forecasted cash flows were updated to reflect a delay in the anticipated launch date for nemtabrutinib, which resulted in lower cumulative revenue forecasts and a reduction in the estimated fair value. The revised estimated fair value of nemtabrutinib when compared with its related carrying value resulted in a $807 million impairment charge recorded in the third quarter of 2022. In December 2022, regulatory authorities provided additional feedback with respect to clinical study design that led to a further reassessment of the development plan for nemtabrutinib, which was expected to result in changes to the clinical study design, and corresponding delays in the anticipated approval and launch timelines, which constituted a triggering event. Utilizing an income approach, the forecasted cash flows were updated to reflect a decline in forecasted revenue coupled with an increase in development cost forecasts, which reduced projected cash flows lowering the estimated fair value of nemtabrutinib. The revised estimated fair value of nemtabrutinib when compared with its then-related carrying value resulted in a $780 million impairment charge. The remaining IPR&D intangible asset related to nemtabrutinib is $418 million. If the assumptions used to estimate the fair value of nemtabrutinib prove to be incorrect and the development of nemtabrutinib does not progress as anticipated thereby adversely affecting projected future cash flows, the Company may record an additional impairment charge in the future and such charge could be material. The Company also recorded an $80 million intangible asset impairment charge in 2022 related to derazantinib resulting from the termination of the out-licensing agreement and the decision by Merck not to pursue development of derazantinib.
The IPR&D projects that remain in development are subject to the inherent risks and uncertainties in drug development and it is possible that the Company will not be able to successfully develop and complete the IPR&D programs and profitably commercialize the underlying product candidates.
The Company may recognize additional non-cash impairment charges in the future related to marketed products or pipeline programs and such charges could be material.
Aggregate amortization expense primarily recorded within Cost of sales was $2.4 billion in 2024, $2.0 billion in 2023 and $2.1 billion in 2022. The estimated aggregate amortization expense for each of the next five years is as follows: 2025, $2.4 billion; 2026, $2.3 billion; 2027, $2.1 billion; 2028, $1.8 billion; 2029, $1.5 billion.
XML 60 R19.htm IDEA: XBRL DOCUMENT v3.25.0.1
Loans Payable, Long-Term Debt and Leases
12 Months Ended
Dec. 31, 2024
Debt Disclosure [Abstract]  
Loans Payable, Long-Term Debt and Leases Loans Payable, Long-Term Debt and Leases
Loans Payable
Loans payable at December 31, 2024 included $2.5 billion of notes due in 2025 and $149 million of long-dated notes that are subject to repayment at the option of the holders. Loans payable at December 31, 2023 included $1.3 billion of notes due in 2024 and $69 million of long-dated notes that are subject to repayment at the option of the holders. The weighted-average interest rate of commercial paper borrowings was 5.18% and 5.14% for the years ended December 31, 2024 and 2023, respectively. There were no commercial paper borrowings outstanding at December 31, 2024 or 2023.

Long-Term Debt
Long-term debt at December 31 consisted of:
20242023
2.15% notes due 2031
$1,989 $1,988 
2.75% notes due 2051
1,980 1,980 
3.70% notes due 2045
1,980 1,979 
3.40% notes due 2029
1,742 1,740 
4.50% notes due 2033
1,509 1,547 
1.70% notes due 2027
1,497 1,495 
2.90% notes due 2061
1,484 1,484 
5.00% notes due 2053
1,482 1,481 
4.00% notes due 2049
1,474 1,473 
4.15% notes due 2043
1,240 1,240 
1.45% notes due 2030
1,240 1,238 
2.45% notes due 2050
1,216 1,214 
1.875% euro-denominated notes due 2026
1,041 1,103 
0.75% notes due 2026
998 996 
1.90% notes due 2028
996 995 
5.15% notes due 2063
987 987 
3.90% notes due 2039
987 986 
2.35% notes due 2040
986 985 
3.25% euro-denominated notes due 2032
880 — 
3.50% euro-denominated notes due 2037
877 — 
3.70% euro-denominated notes due 2044
876 — 
3.75% euro-denominated notes due 2054
873 — 
4.30% notes due 2030
746 745 
4.90% notes due 2044
740 740 
6.50% notes due 2033
702 707 
1.375% euro-denominated notes due 2036
517 548 
2.50% euro-denominated notes due 2034
517 548 
4.05% notes due 2028
498 497 
3.60% notes due 2042
492 492 
6.55% notes due 2037
404 406 
5.75% notes due 2036
339 339 
5.95% debentures due 2028
307 307 
5.85% notes due 2039
271 271 
6.40% debentures due 2028
251 250 
6.30% debentures due 2026
135 135 
2.75% notes due 2025
 2,498 
Other209 289 
$34,462 $33,683 
Other (as presented in the table above) includes borrowings at variable rates that resulted in effective interest rates of 5.02% and 4.82% for 2024 and 2023, respectively.
With the exception of the 6.30% debentures due 2026, the notes listed in the table above are redeemable in whole or in part, at Merck’s option at any time, at varying redemption prices. Effective as of November 3, 2009, the Company executed a full and unconditional guarantee of the then existing debt of its subsidiary Merck Sharp & Dohme LLC. (MSD) and MSD executed a full and unconditional guarantee of the then existing debt of the Company
(excluding commercial paper), including for payments of principal and interest. These guarantees do not extend to debt issued subsequent to that date.
In May 2024, MSD Netherlands Capital B.V., a wholly owned finance subsidiary of Merck, completed a registered public offering of €3.4 billion in aggregate principal amount of euro-dominated senior notes comprised of €850 million of 3.25% senior notes due 2032, €850 million of 3.50% senior notes due 2037, €850 million of 3.70% senior notes due 2044 and €850 million of 3.75% senior notes due 2054 (collectively, the Euronotes). The Company has fully and unconditionally guaranteed all of MSD Netherlands Capital B.V.’s obligations under the Euronotes and no other subsidiary of the Company will guarantee these obligations. MSD Netherlands Capital B.V. is a “finance subsidiary” as defined in Rule 13-01(a)(4)(vi) of Regulation S-X of the Exchange Act, with no assets or operations other than those related to the issuance, administration and repayment of the Euronotes. The financial condition, results of operations and cash flows of MSD Netherlands Capital B.V. are consolidated in the financial statements of the Company. The net cash proceeds from the offering were used for general corporate purposes.
Certain of the Company’s borrowings require that Merck comply with covenants and, at December 31, 2024, the Company was in compliance with these covenants.
The aggregate maturities of long-term debt for each of the next five years are as follows: 2025, $2.6 billion; 2026, $2.2 billion; 2027, $1.5 billion; 2028, $2.1 billion; 2029, $1.7 billion. Interest payments related to these debt obligations are as follows: 2025, $1.2 billion; 2026, $1.2 billion; 2027, $1.1 billion; 2028, $1.1 billion; 2029, $1.0 billion.
The Company has a $6.0 billion credit facility that matures in May 2028. The facility provides backup liquidity for the Company’s commercial paper borrowing facility and is to be used for general corporate purposes. The Company has not drawn funding from this facility.
Leases
The Company has operating leases primarily for manufacturing facilities, research and development facilities, corporate offices, employee housing, vehicles and certain equipment. The Company determines if an arrangement is a lease at inception. When evaluating contracts for embedded leases, the Company exercises judgment to determine if there is an explicit or implicit identified asset in the contract and if Merck controls the use of that asset. Embedded leases, primarily associated with contract manufacturing organizations, are immaterial. The lease term includes options to extend or terminate the lease when it is reasonably certain that Merck will exercise that option. Real estate leases for facilities have an average remaining lease term of approximately six years, which include options to extend the leases for up to five years where applicable. Vehicle leases are generally in effect for four years. The Company elected to exclude short-term leases (leases with an initial term of 12 months or less) from the lease assets and liabilities on the balance sheet.
Lease expense for operating lease payments is recognized on a straight-line basis over the term of the lease. Operating lease assets and liabilities are recognized based on the present value of lease payments over the lease term. Since the Company’s leases do not have a readily determinable implicit discount rate, the Company uses its incremental borrowing rate to calculate the present value of lease payments by asset class. On a quarterly basis, an updated incremental borrowing rate is determined based on the average remaining lease term of each asset class and the Company’s pretax cost of debt for that same term. The updated rates for each asset class are applied prospectively to new leases. The Company does not separate lease components (e.g., payments for rent, real estate taxes and insurance costs) from non-lease components (e.g. common-area maintenance costs) in the event that the agreement contains both. Merck includes both the lease and non-lease components for purposes of calculating the right-of-use asset and related lease liability (if the non-lease components are fixed). For vehicle leases and employee housing, the Company applies a portfolio approach to account for the operating lease assets and liabilities.
Certain of the Company’s lease agreements contain variable lease payments that are adjusted periodically for inflation or for actual operating expense true-ups compared with estimated amounts; however, these amounts are immaterial. Sublease income was immaterial and there were no sale and leaseback transactions in 2024. Merck’s lease agreements do not contain any material residual value guarantees or material restrictive covenants.
Operating lease cost was $348 million in 2024, $339 million in 2023 and $334 million in 2022. Cash paid for amounts included in the measurement of operating lease liabilities was $357 million in 2024, $347 million in 2023 and $335 million in 2022. Operating lease assets obtained in exchange for lease obligations were $47 million in 2024, $122 million in 2023 and $57 million in 2022.
Supplemental balance sheet information related to operating leases is as follows:
December 3120242023
Assets
Other Assets (1)
$1,370 $1,437 
Liabilities
Accrued and other current liabilities282 285 
Other Noncurrent Liabilities877 928 
$1,159 $1,213 
Weighted-average remaining lease term (years)6.07.0
Weighted-average discount rate3.2 %3.3 %
(1)    Includes prepaid leases that have no related lease liability.
Maturities of operating leases liabilities are as follows:
2025$329 
2026292 
2027235 
2028146 
2029116 
Thereafter403 
Total lease payments1,521 
Less: Imputed interest362 
$1,159 
At December 31, 2024, the Company had entered into additional real estate operating leases that had not yet commenced; the obligations associated with these leases total $183 million.
Loans Payable, Long-Term Debt and Leases Loans Payable, Long-Term Debt and Leases
Loans Payable
Loans payable at December 31, 2024 included $2.5 billion of notes due in 2025 and $149 million of long-dated notes that are subject to repayment at the option of the holders. Loans payable at December 31, 2023 included $1.3 billion of notes due in 2024 and $69 million of long-dated notes that are subject to repayment at the option of the holders. The weighted-average interest rate of commercial paper borrowings was 5.18% and 5.14% for the years ended December 31, 2024 and 2023, respectively. There were no commercial paper borrowings outstanding at December 31, 2024 or 2023.

Long-Term Debt
Long-term debt at December 31 consisted of:
20242023
2.15% notes due 2031
$1,989 $1,988 
2.75% notes due 2051
1,980 1,980 
3.70% notes due 2045
1,980 1,979 
3.40% notes due 2029
1,742 1,740 
4.50% notes due 2033
1,509 1,547 
1.70% notes due 2027
1,497 1,495 
2.90% notes due 2061
1,484 1,484 
5.00% notes due 2053
1,482 1,481 
4.00% notes due 2049
1,474 1,473 
4.15% notes due 2043
1,240 1,240 
1.45% notes due 2030
1,240 1,238 
2.45% notes due 2050
1,216 1,214 
1.875% euro-denominated notes due 2026
1,041 1,103 
0.75% notes due 2026
998 996 
1.90% notes due 2028
996 995 
5.15% notes due 2063
987 987 
3.90% notes due 2039
987 986 
2.35% notes due 2040
986 985 
3.25% euro-denominated notes due 2032
880 — 
3.50% euro-denominated notes due 2037
877 — 
3.70% euro-denominated notes due 2044
876 — 
3.75% euro-denominated notes due 2054
873 — 
4.30% notes due 2030
746 745 
4.90% notes due 2044
740 740 
6.50% notes due 2033
702 707 
1.375% euro-denominated notes due 2036
517 548 
2.50% euro-denominated notes due 2034
517 548 
4.05% notes due 2028
498 497 
3.60% notes due 2042
492 492 
6.55% notes due 2037
404 406 
5.75% notes due 2036
339 339 
5.95% debentures due 2028
307 307 
5.85% notes due 2039
271 271 
6.40% debentures due 2028
251 250 
6.30% debentures due 2026
135 135 
2.75% notes due 2025
 2,498 
Other209 289 
$34,462 $33,683 
Other (as presented in the table above) includes borrowings at variable rates that resulted in effective interest rates of 5.02% and 4.82% for 2024 and 2023, respectively.
With the exception of the 6.30% debentures due 2026, the notes listed in the table above are redeemable in whole or in part, at Merck’s option at any time, at varying redemption prices. Effective as of November 3, 2009, the Company executed a full and unconditional guarantee of the then existing debt of its subsidiary Merck Sharp & Dohme LLC. (MSD) and MSD executed a full and unconditional guarantee of the then existing debt of the Company
(excluding commercial paper), including for payments of principal and interest. These guarantees do not extend to debt issued subsequent to that date.
In May 2024, MSD Netherlands Capital B.V., a wholly owned finance subsidiary of Merck, completed a registered public offering of €3.4 billion in aggregate principal amount of euro-dominated senior notes comprised of €850 million of 3.25% senior notes due 2032, €850 million of 3.50% senior notes due 2037, €850 million of 3.70% senior notes due 2044 and €850 million of 3.75% senior notes due 2054 (collectively, the Euronotes). The Company has fully and unconditionally guaranteed all of MSD Netherlands Capital B.V.’s obligations under the Euronotes and no other subsidiary of the Company will guarantee these obligations. MSD Netherlands Capital B.V. is a “finance subsidiary” as defined in Rule 13-01(a)(4)(vi) of Regulation S-X of the Exchange Act, with no assets or operations other than those related to the issuance, administration and repayment of the Euronotes. The financial condition, results of operations and cash flows of MSD Netherlands Capital B.V. are consolidated in the financial statements of the Company. The net cash proceeds from the offering were used for general corporate purposes.
Certain of the Company’s borrowings require that Merck comply with covenants and, at December 31, 2024, the Company was in compliance with these covenants.
The aggregate maturities of long-term debt for each of the next five years are as follows: 2025, $2.6 billion; 2026, $2.2 billion; 2027, $1.5 billion; 2028, $2.1 billion; 2029, $1.7 billion. Interest payments related to these debt obligations are as follows: 2025, $1.2 billion; 2026, $1.2 billion; 2027, $1.1 billion; 2028, $1.1 billion; 2029, $1.0 billion.
The Company has a $6.0 billion credit facility that matures in May 2028. The facility provides backup liquidity for the Company’s commercial paper borrowing facility and is to be used for general corporate purposes. The Company has not drawn funding from this facility.
Leases
The Company has operating leases primarily for manufacturing facilities, research and development facilities, corporate offices, employee housing, vehicles and certain equipment. The Company determines if an arrangement is a lease at inception. When evaluating contracts for embedded leases, the Company exercises judgment to determine if there is an explicit or implicit identified asset in the contract and if Merck controls the use of that asset. Embedded leases, primarily associated with contract manufacturing organizations, are immaterial. The lease term includes options to extend or terminate the lease when it is reasonably certain that Merck will exercise that option. Real estate leases for facilities have an average remaining lease term of approximately six years, which include options to extend the leases for up to five years where applicable. Vehicle leases are generally in effect for four years. The Company elected to exclude short-term leases (leases with an initial term of 12 months or less) from the lease assets and liabilities on the balance sheet.
Lease expense for operating lease payments is recognized on a straight-line basis over the term of the lease. Operating lease assets and liabilities are recognized based on the present value of lease payments over the lease term. Since the Company’s leases do not have a readily determinable implicit discount rate, the Company uses its incremental borrowing rate to calculate the present value of lease payments by asset class. On a quarterly basis, an updated incremental borrowing rate is determined based on the average remaining lease term of each asset class and the Company’s pretax cost of debt for that same term. The updated rates for each asset class are applied prospectively to new leases. The Company does not separate lease components (e.g., payments for rent, real estate taxes and insurance costs) from non-lease components (e.g. common-area maintenance costs) in the event that the agreement contains both. Merck includes both the lease and non-lease components for purposes of calculating the right-of-use asset and related lease liability (if the non-lease components are fixed). For vehicle leases and employee housing, the Company applies a portfolio approach to account for the operating lease assets and liabilities.
Certain of the Company’s lease agreements contain variable lease payments that are adjusted periodically for inflation or for actual operating expense true-ups compared with estimated amounts; however, these amounts are immaterial. Sublease income was immaterial and there were no sale and leaseback transactions in 2024. Merck’s lease agreements do not contain any material residual value guarantees or material restrictive covenants.
Operating lease cost was $348 million in 2024, $339 million in 2023 and $334 million in 2022. Cash paid for amounts included in the measurement of operating lease liabilities was $357 million in 2024, $347 million in 2023 and $335 million in 2022. Operating lease assets obtained in exchange for lease obligations were $47 million in 2024, $122 million in 2023 and $57 million in 2022.
Supplemental balance sheet information related to operating leases is as follows:
December 3120242023
Assets
Other Assets (1)
$1,370 $1,437 
Liabilities
Accrued and other current liabilities282 285 
Other Noncurrent Liabilities877 928 
$1,159 $1,213 
Weighted-average remaining lease term (years)6.07.0
Weighted-average discount rate3.2 %3.3 %
(1)    Includes prepaid leases that have no related lease liability.
Maturities of operating leases liabilities are as follows:
2025$329 
2026292 
2027235 
2028146 
2029116 
Thereafter403 
Total lease payments1,521 
Less: Imputed interest362 
$1,159 
At December 31, 2024, the Company had entered into additional real estate operating leases that had not yet commenced; the obligations associated with these leases total $183 million.
XML 61 R20.htm IDEA: XBRL DOCUMENT v3.25.0.1
Contingencies and Environmental Liabilities
12 Months Ended
Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
Contingencies and Environmental Liabilities Contingencies and Environmental Liabilities
The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, commercial litigation, and securities litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of the Company, it is unlikely that the resolution of these matters will be material to the Company’s financial condition, results of operations or cash flows.
Given the nature of the litigation discussed below and the complexities involved in these matters, the Company is unable to reasonably estimate a possible loss or range of possible loss for such matters until the Company knows, among other factors, (i) what claims, if any, will survive dispositive motion practice, (ii) the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii) how the discovery process will affect the litigation, (iv) the settlement posture of the other parties to the litigation and (v) any other factors that may have a material effect on the litigation.
The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. Generally, for product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.
The Company’s decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.
Product Liability Litigation
Dr Scholl’s Foot Powder
As previously disclosed, Merck is a defendant in product liability lawsuits in the U.S. arising from consumers’ alleged exposure to talc in Dr. Scholl’s foot powder, which Merck acquired through its merger with Schering-Plough Corporation and sold as part of the divestiture of Merck’s consumer care business to Bayer in 2014. In these actions, plaintiffs allege that they were exposed to asbestos-contaminated talc and developed mesothelioma as a result. As of December 31, 2024, approximately 415 cases were pending against Merck in various state courts.
Gardasil/Gardasil 9
As previously disclosed, Merck is a defendant in product liability lawsuits in the U.S. involving Gardasil (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant) and Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant). As of December 31, 2024, approximately 225 cases were filed and pending against Merck in either federal or state court. In these actions, plaintiffs allege, among other things, that they suffered various personal injuries after vaccination with Gardasil or Gardasil 9, with postural orthostatic tachycardia syndrome (POTS) as a predominate alleged injury. In August 2022, the U.S. Judicial Panel on Multidistrict Litigation ordered that Gardasil/Gardasil 9 product liability cases pending in federal courts nationwide be transferred to Judge Robert J. Conrad in the Western District of North Carolina for coordinated pre-trial proceedings. In February 2024, the multidistrict litigation was reassigned to Judge Kenneth D. Bell. As previously disclosed, there are fewer than 15 product liability cases pending outside the U.S.
On January 28, 2025, a trial commenced in California state court. Plaintiff claims that she suffers from POTS and fibromyalgia as a result of her Gardasil vaccinations. On February 14, 2025, after four weeks of trial and an opportunity to litigate plaintiff’s claims before a jury, plaintiff’s counsel approached Merck and proposed that the jury be discharged and the case adjourned. Merck agreed, subject to an explicit stipulation that Merck would provide no financial or other consideration in exchange for the agreement to adjourn. The case has thus been adjourned until a new trial date of September 15, 2025. Merck is vigorously defending this case and believes that evidence presented in court will show that Gardasil had no role in causing any of plaintiff’s conditions.
Governmental Proceedings
Civil Investigative Demands
As previously disclosed, in June 2024, Merck received a Civil Investigative Demand (CID) from the U.S. Department of Justice, pursuant to a False Claims Act investigation, seeking documents and materials related to Steglatro, Januvia and certain related drugs. The CID states that it is investigating Merck’s price reporting under the Medicaid Drug Rebate Program as well as compliance with anti-kickback requirements in connection with patient assistance programs. The Company is cooperating with the investigation.
As previously disclosed, in June 2020, Merck received a CID from the U.S. Department of Justice. The CID requests answers to interrogatories, as well as various documents, regarding temperature excursions at a third-party storage facility containing certain Merck products. Merck is cooperating with the government’s investigation and intends to produce information and/or documents as necessary in response to the CID.
Inflation Reduction Act
As previously disclosed, in June 2023, Merck filed a complaint in the U.S. District Court for the District of Columbia against the U.S. government regarding the Inflation Reduction Act’s “Drug Price Negotiation Program” for Medicare (the Program). This litigation seeks relief from the Program by challenging its constitutionality as violative of the First and Fifth Amendments to the U.S. Constitution.
Other Matters
As previously disclosed, in April 2019, Merck received a set of investigative interrogatories from the California Attorney General’s Office pursuant to its investigation of conduct and agreements that allegedly affected or delayed competition to Lantus in the insulin market. The interrogatories seek information concerning Merck’s development of an insulin glargine product, and its subsequent termination, as well as Merck’s patent litigation against Sanofi S.A. concerning Lantus and the resolution of that litigation. Merck is cooperating with the California Attorney General’s investigation.
As previously disclosed, from time to time, the Company’s subsidiaries in China receive inquiries regarding their operations from various Chinese governmental agencies. Some of these inquiries may be related to matters involving other multinational pharmaceutical companies, as well as Chinese entities doing business with such companies. The Company’s policy is to cooperate with these authorities and to provide responses as appropriate.
As previously disclosed, from time to time, the Company receives inquiries and is the subject of preliminary investigation activities from competition and other governmental authorities in markets outside the U.S. These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings. Should those proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required.
Securities Litigation
In February 2025, a putative class action was filed against Merck and certain of its officers in the U.S. District Court for the District of New Jersey purportedly on behalf of all purchasers of Merck common stock between February 2022 and February 2025. Plaintiff alleges that Merck violated federal securities laws by making materially false and misleading statements and material omissions regarding demand for Gardasil/Gardasil 9 in China. Plaintiff seeks unspecified monetary damages, pre-judgment and post-judgment interest, and fees and costs.
Commercial and Other Litigation
Zetia Antitrust Litigation
As previously disclosed, Merck, MSD, Schering Corporation, Schering-Plough Corporation, and MSP Singapore Company LLC (collectively, the Merck Defendants) were defendants in a number of lawsuits filed in 2018 on behalf of direct and indirect purchasers of Zetia (ezetimibe) alleging violations of federal and state antitrust laws, as well as other state statutory and common law causes of action. The cases were consolidated in a federal multidistrict litigation (Zetia MDL) before Judge Rebecca Beach Smith in the Eastern District of Virginia. In April 2023, the Merck Defendants reached settlements with the direct purchaser and retailer plaintiffs and a settlement with the indirect purchaser class that the court approved in October 2023.
As previously disclosed, in 2020 and 2021, United Healthcare Services, Inc. (United Healthcare), Humana Inc. (Humana), Centene Corporation and others (Centene), and Kaiser Foundation Health Plan, Inc. (Kaiser) (collectively, the Insurer Plaintiffs), each filed a lawsuit in a jurisdiction outside of the Eastern District of Virginia against the Merck Defendants and others, making similar allegations as those made in the Zetia MDL, as well as additional allegations about Vytorin. These cases were transferred to the Eastern District of Virginia to proceed with the Zetia MDL.
In December 2023, the U.S. Judicial Panel on Multidistrict Litigation remanded the four Insurer Plaintiff cases to the transferor courts in the Northern District of California (Kaiser), the District of Minnesota (United Healthcare), and the District of New Jersey (Humana and Centene). The Merck Defendants filed motions to dismiss in each of the Insurer Plaintiff cases. On December 30, 2024, the court granted in part and denied in part the motions to dismiss in the Humana and Centene cases, and on January 29, 2025, Humana and Centene filed amended complaints.
RotaTeq Antitrust Litigation
As previously disclosed, in March 2023, the Mayor and City Council of Baltimore filed a putative class action against MSD in the Eastern District of Pennsylvania on behalf of all third-party payors in 35 states that indirectly purchased, paid, and/or provided reimbursement for some or all of the purchase price of RotaTeq (Rotavirus Vaccine, Live Oral, Pentavalent), other than for resale, from March 3, 2019 to the present. Plaintiff alleges that MSD violated federal and state antitrust laws and state consumer protection laws. Plaintiff alleges that MSD has implemented an anticompetitive vaccine bundling scheme whereby MSD leverages its alleged monopoly power in certain pediatric vaccine markets to maintain its alleged monopoly power in the U.S. market for rotavirus vaccines in order to charge supracompetitive prices for RotaTeq. Plaintiff seeks permanent injunctive relief and unspecified monetary damages on purchases of RotaTeq, trebled, and fees and costs. In May 2023, MSD moved to dismiss the complaint. In November 2023, the court granted in part and denied in part the motion to dismiss, dismissing plaintiff’s Idaho and Utah consumer law claims and allowing all other claims to proceed.
Bravecto Litigation
As previously disclosed, in January 2020, the Company was served with a complaint in the U.S. District Court for the District of New Jersey. Following motion practice, the plaintiffs filed a third amended complaint in August 2024, seeking to certify a nationwide class action of purchasers or users of Bravecto (fluralaner) products in the U.S. or its territories between May 1, 2014 and July 1, 2021. Plaintiffs contend Bravecto causes neurological events in dogs and cats and alleges violations of the New Jersey Consumer Fraud Act, Breach of Warranty, Product Liability, and related theories. The Company moved to dismiss or, alternatively, to strike the class allegations from the third amended complaint, and that motion is pending. A similar case was filed in Quebec, Canada in May 2019. The
Superior Court certified a class of dog owners in Quebec who gave Bravecto Chew to their dogs between February 16, 2017 and November 2, 2018 whose dogs experienced one of the conditions in the post-marketing adverse reactions section of the labeling approved on November 2, 2018. The Company and plaintiffs each appealed the class certification decision. The Court of Appeal of Quebec amended the class period to start July 2, 2014, allowed the second plaintiff to serve as a class representative, and modified the list of conditions in the class definition. The Company sought leave to appeal to the Supreme Court of Canada, which was denied. The case is proceeding in the Superior Court.
340B Program Litigation
As previously disclosed, Merck filed a complaint in the U.S. District Court for the District of Columbia to challenge the letter Merck received from the U.S. Health Resources and Services Administration (HRSA) in May 2022 regarding Merck’s 340B Program integrity initiative. On September 17, 2024, the court entered a consent judgment granting Merck the relief it had sought in the litigation, including declarations that HRSA’s May 2022 letter was unlawful and that the version of Merck’s 340B Program integrity initiative at issue in the litigation did not violate Section 340B on its face.
Qui Tam Litigation
As previously disclosed, in June 2012, the U.S. District Court for the Eastern District of Pennsylvania unsealed a complaint that had been filed against the Company under the federal False Claims Act by two former employees alleging, among other things, that the Company defrauded the U.S. government by falsifying data in connection with a clinical study conducted on the mumps component of the Company’s M-M-R II vaccine. The complaint alleges the fraud took place between 1999 and 2001. The U.S. government had the right to participate in and take over the prosecution of this lawsuit but notified the court that it declined to exercise that right. The two former employees pursued the lawsuit without the involvement of the U.S. government. In July 2023, the court denied relators’ motion for summary judgment, granted two of the Company’s motions for summary judgment, and denied the Company’s remaining motions for summary judgment as moot. The court entered judgment in favor of the Company and dismissed relators’ amended complaint in full with prejudice. Relators appealed that decision, and in August 2024, the Third Circuit affirmed the district court’s decision.
In addition, as previously disclosed, two putative class action lawsuits on behalf of direct purchasers of the M‑M‑R II vaccine, which charge that the Company misrepresented the efficacy of the M-M-R II vaccine in violation of federal antitrust laws and various state consumer protection laws, are pending in the Eastern District of Pennsylvania. The court granted the Company’s motion for summary judgment as to plaintiffs’ state law claims and denied the motion as to plaintiffs’ antitrust claim. The Company appealed, and on October 7, 2024, the Third Circuit reversed-in-part the district court’s order and remanded the case with instructions to enter summary judgment for the Company. On November 20, 2024, plaintiffs-appellees filed a petition for rehearing and rehearing en banc, and on February 10, 2025, the court denied the petition.
Merck KGaA Litigation
As previously disclosed, in January 2016, to protect its long-established brand rights in the U.S., the Company filed a lawsuit against Merck KGaA, Darmstadt, Germany (KGaA), historically operating as the EMD Group in the U.S., alleging it improperly uses the name “Merck” in the U.S. KGaA has filed suit against the Company in a number of jurisdictions outside of the U.S. alleging, among other things, unfair competition, trademark infringement and/or corporate name infringement. In certain of those jurisdictions, KGaA also alleges breach of the parties’ coexistence agreement. The litigation is ongoing in the U.S. with no trial date set, and also ongoing in jurisdictions outside of the U.S.
Patent Litigation
From time to time, generic manufacturers of pharmaceutical products file abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration (FDA) seeking to market generic forms of the Company’s products prior to the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file patent infringement lawsuits against such generic companies. Similar lawsuits defending the Company’s patent rights may exist in other countries. The Company intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened periods of exclusivity for these products and, with respect to products acquired through acquisitions accounted for as business combinations, potentially significant intangible asset impairment charges.
Bridion As previously disclosed, between January and November 2020, the Company received multiple Paragraph IV Certification Letters under the Hatch-Waxman Act notifying the Company that generic drug companies had filed applications to the FDA seeking pre-patent expiry approval to sell generic versions of Bridion (sugammadex)
Injection. In March, April and December 2020, the Company filed patent infringement lawsuits in the U.S. District Courts for the District of New Jersey and the Northern District of West Virginia against those generic companies. All actions in the District of New Jersey were consolidated. The West Virginia case was jointly dismissed with prejudice in August 2022 in favor of proceeding in New Jersey. The remaining defendants in the New Jersey action have stipulated to infringement of the asserted claims and withdrew all remaining claims and defenses other than a defense seeking to shorten the patent term extension (PTE) of the sugammadex patent to December 2022. The U.S. District Court for the District of New Jersey held a one-day trial in December 2022 on this remaining PTE calculation defense. The court ordered a post-trial briefing on this defense and held closing arguments in February 2023.
As previously disclosed, in June 2023, the U.S. District Court for the District of New Jersey ruled in Merck’s favor. The court held that Merck’s calculation of PTE for the sugammadex patent covering the compound is not invalid and that the U.S. Patent & Trademark Office correctly granted a full five-year extension. This ruling affirms and validates Merck’s U.S. patent protection for Bridion through at least January 2026. Also in June 2023, the U.S. District Court for the District of New Jersey issued a final judgment prohibiting the FDA from approving any of the pending or tentatively approved generic applications until January 27, 2026, except for any subsequent agreements between defendants and Merck or further order by the court.
In July 2023, defendants filed a notice of appeal with the U.S. Court of Appeals for the Federal Circuit. The appeal is currently pending. Oral argument took place on February 4, 2025.
While the New Jersey action was pending, the Company settled with five generic companies providing that these generic companies can bring their generic versions of Bridion to the market in January 2026 (which may be delayed by any applicable pediatric exclusivity) or earlier under certain circumstances. The Company agreed to stay the lawsuit filed against two generic companies, which in exchange agreed to be bound by a judgment on the merits of the consolidated action in the District of New Jersey. One of the generic companies in the consolidated action requested dismissal of the action against it and the Company did not oppose this request, which was subsequently granted by the court. The Company does not expect this company to bring its generic version of Bridion to the market before January 2026 or later, depending on any applicable pediatric exclusivity.
In February 2024, the Company received another Paragraph IV Certification Letter under the Hatch-Waxman Act notifying the Company that Hikma Pharmaceuticals USA Inc. (Hikma) had filed an application to the FDA seeking pre-patent expiry approval to sell a generic version of Bridion Injection. In March 2024, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Hikma, postponing FDA approval of the Hikma generic drug for 30 months or until expiration of the sugammadex patent (January 27, 2026) and any potentially applicable pediatric exclusivity or an adverse court decision, if any, whichever may occur earlier. Expiration of the patent, and any potentially applicable pediatric exclusivity, will occur earlier than expiry of the 30-month stay. On April 16, 2024, the district court stayed the case during the pendency of the Federal Circuit appeal noted above.
Januvia, Janumet, Janumet XR As previously disclosed, the FDA granted pediatric exclusivity with respect to Januvia (sitagliptin), Janumet (sitagliptin/metformin HCl), and Janumet XR (sitagliptin and metformin HCl extended-release), which provides a further six months of exclusivity in the U.S. beyond the expiration of all patents listed in the FDA’s Orange Book. Adding this exclusivity to the term of the key patent protection extended exclusivity on these products to January 2023. However, Januvia, Janumet, and Janumet XR contain sitagliptin phosphate monohydrate and the Company has another patent covering certain phosphate salt and polymorphic forms of sitagliptin that expires in May 2027, including pediatric exclusivity (salt/polymorph patent).
As previously disclosed, beginning in 2019, a number of generic drug companies filed ANDAs seeking approval of generic forms of Januvia and Janumet along with paragraph IV certifications challenging the validity of the salt/polymorph patent. The Company responded by filing infringement suits which have all been settled. The Company has settled with a total 26 generic companies providing that these generic companies can bring their generic versions of Januvia and Janumet to the market in the U.S. in May 2026 or earlier under certain circumstances, and their generic versions of Janumet XR to the market in July 2026 or earlier under certain circumstances.
In March 2021, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc., and Cadila Healthcare Ltd. (collectively, Zydus). In that lawsuit, the Company alleged infringement of the salt/polymorph patent based on the filing of Zydus’s NDA seeking approval of a form of sitagliptin that is a different from than that used in Januvia. In December 2022, the parties reached settlement that included dismissal of the case without prejudice enabling Zydus to seek final approval of a non-automatically substitutable product.
In January 2023, the Company received a Paragraph IV Certification Letter under the Hatch-Waxman Act notifying the Company that Zydus filed an ANDA seeking approval of sitagliptin/metformin HCl tablets and certifying that no valid or enforceable claim of any of the patents listed in FDA’s Orange Book for Janumet will be infringed by the proposed Zydus product. In March 2023, the parties reached settlement enabling Zydus to seek final approval of a non-automatically substitutable product containing a different form of sitagliptin than that used in Janumet. In November 2023, the Company received a Paragraph IV Certification Letter under the Hatch-Waxman Act notifying the Company that Zydus filed an ANDA seeking approval of sitagliptin/metformin HCl Extended Release tablets. In January 2024, the parties reached settlement enabling Zydus to seek final approval of a non-automatically substitutable version containing a different form of sitagliptin than that used in Janumet XR.
As a result of these settlement agreements related to the later expiring salt/polymorph patent directed to the specific sitagliptin salt form of the products, the Company expects that Januvia and Janumet will not lose market exclusivity in the U.S. until May 2026 and Janumet XR will not lose market exclusivity in the U.S. until July 2026, although Zydus has received FDA approval for a non-automatically substitutable form of sitagliptin that differs from the form in the Company’s sitagliptin products.
In March 2024, the Company received another Paragraph IV Certification Letter under the Hatch-Waxman Act from Azurity Pharmaceuticals, Inc. (Azurity) asserting that a different sitagliptin product subject to its ANDA does not infringe the salt/polymorph patent. In May 2024, Merck filed a civil action in the U.S. District Court of Delaware alleging infringement. The case was dismissed without prejudice in July 2024. Following the dismissal, the Company granted Azurity a covenant not to assert the salt/polymorph patent against the Azurity product that is the subject of such ANDA.
Supplementary Protection Certificates (SPCs) for Janumet expired in April 2023 for the majority of European countries. Prior to expiration, generic companies sought revocation of the Janumet SPCs in a number of European countries. In February 2022, a Finnish court referred certain questions to the Court of Justice of the European Union that could impact the validity of the Janumet SPCs in Europe. A decision was rendered on December 19, 2024. The decision provides guidance on points of law and does not directly apply these to the Janumet SPCs. Thus, additional proceedings in certain countries where generic companies were prevented from launching products during the SPC period may be necessary to determine whether the SPCs are valid and if not, whether damages are appropriate. Those countries include Belgium, Czech Republic, Ireland, Finland, France, Slovakia and Switzerland. If the Janumet SPCs are ultimately upheld, the Company has reserved its rights related to the pursuit of damages for those countries where a generic launched prior to expiry of the Janumet SPC.
In October 2023, the Company filed a patent infringement lawsuit against Sawai Pharmaceuticals Co., Ltd. and Medisa Shinyaku Co., Ltd (collectively, Defendants) in the Tokyo District Court seeking an injunction to stop the manufacture, sale and offer for sale of the Defendants’ sitagliptin dihydrogen phosphate product, while the Company’s patents and patent term extensions are in force. The lawsuit is in response to the Defendants’ application for marketing authorization to sell a generic sitagliptin dihydrogen phosphate product, in the anhydrate form, which was approved in August 2023. Merck asserts that the Defendants’ activity infringes a patent term extension associated with Merck’s patent directed to the sitagliptin compound patent.
Keytruda As previously disclosed, in November 2022, the Company filed a complaint against The Johns Hopkins University (JHU) in the U.S. District Court of Maryland. This action concerns patents emerging from a joint research collaboration between Merck and JHU regarding the use of pembrolizumab, which Merck sells under the trade name Keytruda. Merck and JHU partnered to design and conduct a clinical study administering Keytruda to cancer patients having tumors that had the genetic biomarker known as microsatellite instability-high (MSI-H). After the conclusion of the study, JHU secured U.S. patents citing the joint research study. Merck alleges that JHU has breached the collaboration agreement by filing and obtaining these patents without informing or involving Merck and then licensing the patents to others. Merck therefore brought this action for breach of contract, declaratory judgment of noninfringement, and promissory estoppel. JHU answered the complaint in April and May 2023, denying Merck’s claims, and counterclaiming for willful infringement of nine issued U.S. patents, including a demand for damages. Between November 30, 2023 and March 13, 2024, the Company filed inter partes review petitions with the United States Patent & Trademark Office Patent Trial and Appeal Board (PTAB), challenging the validity of all nine patents asserted in the case. Between June 2024 and October 2024, the PTAB instituted a review of all nine asserted patents. In July 2024, the district court granted Merck’s motion to stay the case in its entirety pending the outcome of the PTAB proceeding instituted in June 2024.
Lynparza As previously disclosed, in December 2022, AstraZeneca Pharmaceuticals LP received a Paragraph IV Certification Letter under the Hatch-Waxman Act notifying AstraZeneca that Natco Pharma Limited (Natco) has filed an application to the FDA seeking pre-patent expiry approval to sell generic versions of Lynparza (olaparib) tablet. In February 2023, AstraZeneca and the Company filed a patent infringement lawsuit in the U.S.
District Court for the District of New Jersey against Natco. This lawsuit, which asserts one or more patents covering olaparib, automatically stays FDA approval of the generic application until June 2025 or until an adverse court decision, if any, whichever may occur earlier. In May, June, July, and November 2024, AstraZeneca and the Company filed additional patent infringement lawsuits in the U.S. District Court for the District of New Jersey against Natco asserting additional patents covering olaparib.
In December 2023, AstraZeneca Pharmaceuticals LP received a second Paragraph IV Certification Letter under the Hatch-Waxman Act notifying AstraZeneca that Sandoz Inc. has filed an application to the FDA seeking pre-patent expiry approval to sell generic versions of Lynparza (olaparib) tablet. In February 2024, AstraZeneca and the Company filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Sandoz. This lawsuit, which asserts one or more patents covering olaparib, automatically stays FDA approval of the generic application until June 2026 or until an adverse court decision, if any, whichever may occur earlier. In May, July, and November 2024, AstraZeneca and the Company filed additional patent infringement lawsuits in the U.S. District Court for the District of New Jersey against Sandoz asserting additional patents covering olaparib.
In May 2024, AstraZeneca Pharmaceuticals LP received a third Paragraph IV Certification Letter under the Hatch-Waxman Act notifying AstraZeneca that Cipla USA, Inc. and Cipla Limited (collectively, Cipla) filed an application to the FDA seeking pre-patent expiry approval to sell generic versions of Lynparza (olaparib) tablet. In June 2024, AstraZeneca and the Company filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Cipla. This lawsuit, which asserts one or more patents covering olaparib, automatically stays FDA approval of the generic application until November 2026 or until an adverse court decision, if any, whichever may occur earlier. In June, July, and November 2024, AstraZeneca and the Company filed additional patent infringement lawsuits in the U.S. District Court for the District of New Jersey against Cipla asserting additional patents covering olaparib.
In November 2024, AstraZeneca Pharmaceuticals LP received another Paragraph IV Certification Letter under the Hatch-Waxman Act notifying AstraZeneca that Zydus Pharmaceuticals (USA) Inc. filed an application to the FDA seeking pre-patent expiry approval to sell generic versions of Lynparza (olaparib) tablet. In November 2024, AstraZeneca and the Company filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Zydus. This lawsuit, which asserts one or more patents covering olaparib, automatically stays FDA approval of the generic application until May 2027 or until an adverse court decision, if any, whichever may occur earlier. In November 2024, AstraZeneca and the Company filed an additional patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Zydus asserting an additional patent covering olaparib.
Other Litigation
There are various other pending legal proceedings involving the Company, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company’s financial condition, results of operations or cash flows either individually or in the aggregate.
Legal Defense Reserves
Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company’s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of December 31, 2024 and 2023 of approximately $225 million and $210 million, respectively, represents the Company’s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.
Environmental Matters
The Company and its subsidiaries are parties to a number of proceedings brought under the Comprehensive Environmental Response, Compensation and Liability Act, commonly known as Superfund, and other federal and state equivalents. These proceedings seek to require the operators of hazardous waste disposal facilities, transporters of waste to the sites and generators of hazardous waste disposed of at the sites to clean up the sites or
to reimburse the government for cleanup costs. The Company has been made a party to these proceedings as an alleged generator of waste disposed of at the sites. In each case, the government alleges that the defendants are jointly and severally liable for the cleanup costs. Although joint and several liability is alleged, these proceedings are frequently resolved so that the allocation of cleanup costs among the parties more nearly reflects the relative contributions of the parties to the site situation. The Company’s potential liability varies greatly from site to site. For some sites the potential liability is de minimis and for others the final costs of cleanup have not yet been determined. While it is not feasible to predict the outcome of many of these proceedings brought by federal or state agencies or private litigants, in the opinion of the Company, such proceedings should not ultimately result in any liability which would have a material adverse effect on the financial condition, results of operations or liquidity of the Company. The Company has taken an active role in identifying and accruing for these costs and such amounts do not include any reduction for anticipated recoveries of cleanup costs from former site owners or operators or other recalcitrant potentially responsible parties.
In management’s opinion, the liabilities for all environmental matters that are probable and reasonably estimable have been accrued and totaled $41 million and $42 million at December 31, 2024 and 2023, respectively. These liabilities are undiscounted, do not consider potential recoveries from other parties and will be paid out over the periods of remediation for the applicable sites, which are expected to occur primarily over the next 15 years. Although it is not possible to predict with certainty the outcome of these matters, or the ultimate costs of remediation, management does not believe that any reasonably possible expenditures that may be incurred in excess of the liabilities accrued should exceed approximately $46 million in the aggregate. Management also does not believe that these expenditures should result in a material adverse effect on the Company’s financial condition, results of operations or liquidity for any year.
XML 62 R21.htm IDEA: XBRL DOCUMENT v3.25.0.1
Equity
12 Months Ended
Dec. 31, 2024
Equity [Abstract]  
Equity Equity
The Merck certificate of incorporation authorizes 6,500,000,000 shares of common stock and 20,000,000 shares of preferred stock.
Capital Stock
A summary of common stock and treasury stock transactions (shares in millions) is as follows:
 202420232022
  Common
Stock
Treasury
Stock
Common
Stock
Treasury
Stock
Common
Stock
Treasury
Stock
Balance January 13,577 1,045 3,577 1,039 3,577 1,049 
Purchases of treasury stock 11 — 13 — — 
Issuances (1)
 (7)— (7)— (10)
Balance December 313,577 1,049 3,577 1,045 3,577 1,039 
(1)    Issuances primarily reflect activity under share-based compensation plans.
XML 63 R22.htm IDEA: XBRL DOCUMENT v3.25.0.1
Share-Based Compensation Plans
12 Months Ended
Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Share-Based Compensation Plans Share-Based Compensation Plans
The Company has share-based compensation plans under which the Company grants restricted stock units (RSUs) and performance share units (PSUs) to certain management level employees. In addition, employees and non-employee directors may be granted options to purchase shares of Company common stock at the fair market value at the time of grant. These plans were approved by the Company’s shareholders.
At December 31, 2024, 75 million shares collectively were authorized for future grants under the Company’s share-based compensation plans. These awards are settled with treasury shares.
Employee stock options are granted to purchase shares of Company stock at the fair market value at the time of grant. These awards generally vest one-third each year over a three-year period, with a contractual term of 7-10 years. RSUs are stock awards that are granted to employees and entitle the holder to shares of common stock as the awards vest. The fair value of the stock option and RSU awards is determined and fixed on the grant date based on the Company’s stock price. PSUs are stock awards where the ultimate number of shares issued will be contingent on the Company’s performance against a pre-set objective or set of objectives. The fair value of each PSU is determined on the date of grant based on the Company’s stock price. For RSUs and PSUs, dividends declared during the vesting period are payable to the employees only upon vesting. Over the PSU performance period, the number of shares of stock that are expected to be issued will be adjusted based on the probability of achievement of a performance target and final compensation expense will be recognized based on the ultimate number of shares issued. RSU and PSU distributions will be in shares of Company stock after the end of the vesting or performance
period, subject to the terms applicable to such awards. PSU awards generally vest after three years. RSU awards generally vest one-third each year over a three-year period.
Total pretax share-based compensation cost recorded in 2024, 2023 and 2022 was $761 million, $645 million and $541 million, respectively. Income tax benefits for share-based compensation expense recognized in 2024, 2023 and 2022 were $117 million, $96 million and $78 million, respectively.
The Company uses the Black-Scholes option pricing model for determining the fair value of option grants. In applying this model, the Company uses both historical data and current market data to estimate the fair value of its options. The Black-Scholes model requires several assumptions including expected dividend yield, risk-free interest rate, volatility, and term of the options. The expected dividend yield is based on historical patterns of dividend payments. The risk-free interest rate is based on the rate at grant date of zero-coupon U.S. Treasury Notes with a term equal to the expected term of the option. Expected volatility is estimated using a blend of historical and implied volatility. The historical component is based on historical monthly price changes. The implied volatility is obtained from market data on the Company’s traded options. The expected life represents the amount of time that options granted are expected to be outstanding, based on historical and forecasted exercise behavior.
The weighted average exercise price of options granted in 2024, 2023 and 2022 was $129.22, $117.89 and $87.10 per option, respectively. The weighted average fair value of options granted in 2024, 2023 and 2022 was $25.60, $21.69 and $15.45 per option, respectively, and were determined using the following assumptions:
Years Ended December 31202420232022
Expected dividend yield3.0 %3.1 %3.1 %
Risk-free interest rate4.7 %3.4 %3.0 %
Expected volatility20.5 %22.4 %22.5 %
Expected life (years)5.85.85.9
Summarized information relative to stock option plan activity (options in thousands) is as follows:
Number
of Options
Weighted
Average
Exercise
Price
Weighted
Average
Remaining
Contractual
Term (Years)
Aggregate
Intrinsic
Value
Outstanding January 1, 2024
13,527 $77.54 
Granted1,753 129.22 
Exercised(2,581)68.90 
Forfeited(199)111.48   
Outstanding December 31, 2024
12,500 $86.04 5.9$249 
Vested and expected to vest December 31, 202412,201 $85.10 5.9$249 
Exercisable December 31, 20249,084 $74.00 4.9$241 
Additional information pertaining to stock option plans is provided in the table below:
Years Ended December 31202420232022
Total intrinsic value of stock options exercised$144 $95 $225 
Fair value of stock options vested32 30 30 
Cash received from the exercise of stock options177 125 384 
A summary of nonvested RSU and PSU activity (shares in thousands) is as follows:
 RSUsPSUs
  Number
of Shares
Weighted
Average
Grant Date
Fair Value
Number
of Shares
Weighted
Average
Grant Date
Fair Value
Nonvested January 1, 2024
12,542 $100.10 1,966 $90.80 
Granted6,356 128.79 968 121.91 
Vested(6,091)92.97 (1,109)73.50 
Forfeited(575)113.18 (59)121.12 
Nonvested December 31, 202412,232 $117.94 1,766 $117.57 
Expected to vest December 31, 202410,976 $117.25 1,669 $116.26 
At December 31, 2024, there was $1.1 billion of total pretax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards which will be recognized over a weighted average period of 1.9 years. For segment reporting, share-based compensation costs are unallocated expenses.
XML 64 R23.htm IDEA: XBRL DOCUMENT v3.25.0.1
Pension and Other Postretirement Benefit Plans
12 Months Ended
Dec. 31, 2024
Retirement Benefits [Abstract]  
Pension and Other Postretirement Benefit Plans Pension and Other Postretirement Benefit Plans
The Company has defined benefit pension plans covering eligible employees in the U.S. and in certain of its international subsidiaries. In addition, the Company provides medical benefits, principally to its eligible U.S. retirees and their dependents, through its other postretirement benefit plans. The Company uses December 31 as the year-end measurement date for all of its pension plans and other postretirement benefit plans.
Net Periodic Benefit Cost
The net periodic benefit cost (credit) for pension and other postretirement benefit plans consisted of the following components:
Pension Benefits
U.S.InternationalOther Postretirement Benefits
Years Ended December 31202420232022202420232022202420232022
Service cost$373 $326 $372 $243 $196 $283 $30 $32 $48 
Interest cost537 526 457 294 299 145 56 63 46 
Expected return on plan assets(826)(735)(753)(554)(517)(383)(80)(64)(86)
Amortization of unrecognized prior service (credit) cost
 (1)(32)(13)(14)(43)(49)(57)
Net loss (gain) amortization43 — 128 5 (3)96 (51)(42)(43)
Termination benefits5 1 — 4 — — 
Curtailments 12  (1)—  (1)(1)
Settlements 28 239 (1)(5) — — 
Net periodic benefit cost (credit)$132 $155 $425 $(25)$(29)$129 $(84)$(61)$(93)
In connection with restructuring actions (see Note 5), termination charges were recorded in 2024, 2023 and 2022 on pension and other postretirement benefit plans related to expanded eligibility for certain employees exiting Merck. Also, in connection with these restructuring activities, curtailments and settlements were recorded on certain pension plans. Lump sum payments to U.S. pension plan participants also contributed to the settlements recorded during 2023 and 2022.
The components of net periodic benefit cost (credit) other than the service cost component are included in Other (income) expense, net (see Note 14), with the exception of certain amounts for termination benefits, curtailments and settlements, which are recorded in Restructuring costs if the event giving rise to the termination benefits, curtailment or settlement is related to restructuring actions.
Obligations and Funded Status
Summarized information about the changes in plan assets and benefit obligations, the funded status and the amounts recorded at December 31 is as follows:

Pension BenefitsOther
Postretirement
Benefits
U.S.International
202420232024202320242023
Fair value of plan assets January 1$9,804 $9,094 $9,562 $8,473 $1,045 $947 
Actual return on plan assets266 1,077 637 832 35 115 
Company contributions262 307 198 249 46 74 
Effects of exchange rate changes — (522)283  — 
Benefits paid(615)(497)(250)(256)(89)(95)
Settlements (177)(14)(53) (2)
Other — 36 34 3 
Fair value of plan assets December 31$9,717 $9,804 $9,647 $9,562 $1,040 $1,045 
Benefit obligation January 1$10,446 $9,854 $9,042 $7,755 $1,104 $1,157 
Service cost373 326 243 196 30 32 
Interest cost537 526 294 299 56 63 
Actuarial (gains) losses (1)
(595)403 (549)766 32 (58)
Benefits paid(615)(497)(250)(256)(89)(95)
Effects of exchange rate changes — (473)288 (4)
Plan amendments — (56)14  — 
Curtailments  (1) — 
Termination benefits5 1 — 4 — 
Settlements (177)(14)(53) (2)
Other — 36 34 3 
Benefit obligation December 31$10,151 $10,446 $8,274 $9,042 $1,136 $1,104 
Funded status December 31$(434)$(642)$1,373 $520 $(96)$(59)
Recognized as:
Other Assets$26 $— $1,785 $1,019 $51 $107 
Accrued and other current liabilities(55)(49)(18)(19)(7)(8)
Other Noncurrent Liabilities(405)(593)(394)(480)(140)(158)
(1)    Actuarial (gains) losses primarily reflect changes in discount rates.
At December 31, 2024 and 2023, the accumulated benefit obligation was $18.1 billion and $19.1 billion, respectively, for all pension plans, of which $10.0 billion and $10.3 billion, respectively, related to U.S. pension plans.
Information related to the funded status of selected pension plans at December 31 is as follows:
U.S.International
2024202320242023
Pension plans with a projected benefit obligation in excess of plan assets
Projected benefit obligation
$9,517 $10,446 $1,847 $2,961 
Fair value of plan assets9,057 9,804 1,435 2,462 
Pension plans with an accumulated benefit obligation in excess of plan assets
Accumulated benefit obligation$442 $9,700 $1,768 $1,791 
Fair value of plan assets 9,186 1,385 1,336 
Plan Assets
Entities are required to use a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest:
Level 1 — Quoted prices (unadjusted) in active markets for identical assets or liabilities.
Level 2 — Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3 — Unobservable inputs that are supported by little or no market activity. The Level 3 assets are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as instruments for which the determination of fair value requires significant judgment or estimation. At December 31, 2024 and 2023, $700 million and $788 million, respectively, or approximately 4% of the Company’s pension investments were categorized as Level 3 assets.
If the inputs used to measure the financial assets fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.
The fair values of the Company’s pension plan assets at December 31 by asset category are as follows:
 Fair Value Measurements UsingFair Value Measurements Using
Level 1Level 2Level 3
NAV (1)
TotalLevel 1Level 2Level 3
NAV (1)
Total
20242023
U.S. Pension Plans
Cash and cash equivalents$43 $ $ $121 $164 $34 $— $— $124 $158 
Investment funds
Developed markets equities170   2,385 2,555 224 — — 2,573 2,797 
Emerging markets equities   1,265 1,265 — — — 740 740 
Real estate   174 174 — — — 113 113 
Equity securities
Developed markets2,171    2,171 2,071 — — — 2,071 
Fixed income securities
Government and agency obligations 2,101   2,101 — 2,307 — — 2,307 
Corporate obligations 1,293   1,293 — 1,485 — — 1,485 
Mortgage and asset-backed securities 21   21 — 21 — — 21 
Other investments (liabilities)
Derivatives(29)   (29)109 — — — 109 
Other  2  2 — — — 
Plan assets at fair value$2,355 $3,415 $2 $3,945 $9,717 $2,438 $3,813 $$3,550 $9,804 
International Pension Plans
Cash and cash equivalents$112 $ $ $11 $123 $98 $— $— $20 $118 
Investment funds
Developed markets equities599 3,537  96 4,232 507 3,257 — 106 3,870 
Government and agency obligations262 2,974  149 3,385 234 3,123 — 166 3,523 
Corporate obligations23 8  149 180 23 — 166 197 
Emerging markets equities54   91 145 44 — — 66 110 
Other fixed income obligations8 7  4 19 — 20 
Real estate   12 12 — — — 10 10 
Equity securities
Developed markets287    287 278 — — — 278 
Fixed income securities
Government and agency obligations 368   368 — 423 — — 423 
Corporate obligations 141   141 — 160 — — 160 
Mortgage and asset-backed securities 54   54 — 61 — — 61 
Other investments
Insurance contracts (2)
 1 698 2 701 — 785 788 
Other     — — — 
Plan assets at fair value$1,345 $7,090 $698 $514 $9,647 $1,197 $7,041 $785 $539 $9,562 
(1)    Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December 31, 2024 and 2023.
(2)    The plans’ Level 3 investments in insurance contracts are generally valued using a crediting rate that approximates market returns and invest in underlying securities whose market values are unobservable and determined using pricing models, discounted cash flow methodologies, or similar techniques.
The table below provides a summary of the changes in fair value, including transfers in and/or out, of all financial assets measured at fair value using significant unobservable inputs (Level 3) for the Company’s pension plan assets:
 20242023
Insurance
Contracts
OtherTotalInsurance
Contracts
OtherTotal
U.S. Pension Plans
Balance January 1$ $3 $3 $— $$
Actual return on plan assets:
Relating to assets still held at December 31 (2)(2)— (2)(2)
Relating to assets sold during the year 2 2 — 
Purchases and sales, net (1)(1)— (1)(1)
Balance December 31$ $2 $2 $— $$
International Pension Plans
Balance January 1$785 $ $785 $761 $— $761 
Actual return on plan assets:
Relating to assets still held at December 31(26) (26)77 — 77 
Purchases and sales, net(61) (61)(53)— (53)
Balance December 31$698 $ $698 $785 $— $785 
The fair values of the Company’s other postretirement benefit plan assets at December 31 by asset category are as follows:
 Fair Value Measurements UsingFair Value Measurements Using
Level 1Level 2Level 3
NAV (1)
TotalLevel 1Level 2Level 3
NAV (1)
Total
20242023
Cash and cash equivalents$ $ $ $5 $5 $— $— $— $13 $13 
Investment funds
Developed markets equities3   46 49 24 — — 277 301 
Emerging markets equities   24 24 — — — 80 80 
Real estate   3 3 — — — 12 12 
Equity securities
Developed markets41   41 223 — — — 223 
Fixed income securities
Corporate obligations 598  598 — 157 — — 157 
Government and agency obligations 266  266 — 245 — — 245 
Mortgage and asset-backed securities 54   54 — — — 
Other Investments (liabilities)
Derivatives     12 — — — 12 
Plan assets at fair value$44 $918 $ $78 $1,040 $259 $404 $— $382 $1,045 
(1)    Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December 31, 2024 and 2023.
The Company has established investment guidelines for its U.S. pension and other postretirement plans to create an asset allocation that is expected to deliver a rate of return sufficient to meet the long-term obligation of each plan, given an acceptable level of risk. The target investment portfolio of the Company’s U.S. pension and other postretirement benefit plans is allocated 25% to 40% in U.S. equities, 15% to 30% in international equities, 40% to 50% in fixed-income investments, and up to 8% in cash and other investments. The portfolio’s equity weighting is consistent with the long-term nature of the plans’ benefit obligations. The expected annual standard deviation of returns of the target portfolio, which approximates 12%, reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests. For international pension plans, the targeted investment portfolio varies based on the duration of pension liabilities and local government rules and regulations.
Although a significant percentage of plan assets are invested in U.S. equities, concentration risk is mitigated through the use of strategies that are diversified within management guidelines.
Expected Contributions
Contributions during 2025 are expected to be approximately $270 million for U.S. pension plans, approximately $180 million for international pension plans and approximately $70 million for other postretirement benefit plans.
Expected Benefit Payments
Expected benefit payments are as follows:
U.S. Pension BenefitsInternational Pension
Benefits
Other
Postretirement
Benefits
2025$771 $291 $86 
2026775 275 87 
2027789 286 89 
2028799 300 91 
2029822 314 96 
2030 — 2034
4,386 1,792 515 
Expected benefit payments are based on the same assumptions used to measure the benefit obligations and include estimated future employee service.
Amounts Recognized in Other Comprehensive Income (Loss)
Net gain/loss amounts reflect differences between expected and actual returns on plan assets as well as the effects of changes in actuarial assumptions. Net gain/loss amounts in excess of certain thresholds are amortized into net periodic benefit cost over the average remaining service life of employees. The following amounts were reflected as components of OCI:
 Pension PlansOther Postretirement
Benefit Plans
U.S.International
Years Ended December 31202420232022202420232022202420232022
Net gain (loss) arising during the period
$35 $(69)$(42)$634 $(438)$116 $(78)$110 $— 
Prior service credit (cost) arising during the period
 — — 56 (16)(4) — — 
 $35 $(69)$(42)$690 $(454)$112 $(78)$110 $— 
Net loss (gain) amortization included in benefit cost$43 $— $128 $5 $(3)$96 $(51)$(42)$(43)
Prior service (credit) cost amortization included in benefit cost
 (1)(32)(13)(14)(43)(49)(57)
Settlements and curtailments 36 251 (1)(6) (1)(1)
 $43 $35 $347 $(9)$(7)$83 $(94)$(92)$(101)
Actuarial Assumptions
The Company reassesses its benefit plan assumptions on a regular basis. The weighted average assumptions used in determining U.S. pension and other postretirement benefit plan and international pension plan information are as follows:
 U.S. Pension and Other
Postretirement Benefit Plans
International Pension Plans
December 31202420232022202420232022
Net periodic benefit cost      
Discount rate5.30 %5.50 %3.00 %3.40 %3.90 %1.50 %
Expected rate of return on plan assets7.75 %7.00 %6.70 %5.20 %5.00 %3.70 %
Salary growth rate4.60 %4.60 %4.60 %3.20 %3.20 %2.90 %
Interest crediting rate5.30 %5.30 %5.00 %3.40 %3.30 %3.00 %
Benefit obligation      
Discount rate5.70 %5.30 %5.50 %3.70 %3.40 %3.90 %
Salary growth rate4.80 %4.60 %4.60 %3.10 %3.20 %3.20 %
Interest crediting rate5.40 %5.30 %5.30 %3.50 %3.40 %3.30 %
For both the pension and other postretirement benefit plans, the discount rate is evaluated on measurement dates and modified to reflect the prevailing market rate of a portfolio of high-quality fixed-income debt instruments that would provide the future cash flows needed to pay the benefits included in the benefit obligation as they come due. The expected rate of return for both the pension and other postretirement benefit plans represents the average rate of return to be earned on plan assets over the period the benefits included in the benefit obligation are to be paid and is determined on a plan basis. The expected rate of return for each plan is developed considering long-term historical returns data, current market conditions, and actual returns on the plan assets. Using this reference information, the long-term return expectations for each asset category and a weighted-average expected return for each plan’s target portfolio is developed according to the allocation among those investment categories. The expected portfolio performance reflects the contribution of active management as appropriate. For 2025, the expected rate of return for the Company’s U.S. pension and other postretirement benefit plans will be 7.70%, as compared to 7.75% in 2024.
The health care cost trend rate assumptions for other postretirement benefit plans are as follows:
December 3120242023
Health care cost trend rate assumed for next year7.90 %7.80 %
Rate to which the cost trend rate is assumed to decline4.50 %4.50 %
Year that the trend rate reaches the ultimate trend rate20402038

Savings Plans
The Company also maintains defined contribution savings plans in the U.S. The Company matches a percentage of each employee’s contributions consistent with the provisions of the plan for which the employee is eligible. Total employer contributions to these plans in 2024, 2023 and 2022 were $215 million, $199 million and $175 million, respectively.
XML 65 R24.htm IDEA: XBRL DOCUMENT v3.25.0.1
Other (Income) Expense, Net
12 Months Ended
Dec. 31, 2024
Other Income and Expenses [Abstract]  
Other (Income) Expense, Net Other (Income) Expense, Net
Other (income) expense, net, consisted of:
Years Ended December 31202420232022
Interest income$(415)$(365)$(157)
Interest expense1,271 1,146 962 
Exchange losses227 370 237 
(Income) loss from investments in equity securities, net (1)
(14)(340)1,419 
Net periodic defined benefit plan (credit) cost other than service cost(633)(498)(279)
Other, net(460)153 (681)
 $(24)$466 $1,501 
(1)    Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag.
Other, net (as reflected in the table above) in 2024 includes $170 million of income related to the expansion of a collaboration agreement with Daiichi Sankyo (see Note 4). Other, net, in 2023 includes a $572.5 million charge related to settlements with certain plaintiffs in the Zetia antitrust litigation (see Note 10).
Interest paid was $1.3 billion in 2024, $1.1 billion in 2023 and $937 million in 2022.
XML 66 R25.htm IDEA: XBRL DOCUMENT v3.25.0.1
Taxes on Income
12 Months Ended
Dec. 31, 2024
Income Tax Disclosure [Abstract]  
Taxes on Income Taxes on Income
A reconciliation between the effective tax rate and the U.S. statutory rate is as follows:
 202420232022
AmountTax RateAmountTax RateAmountTax Rate
U.S. statutory rate applied to income before taxes
$4,186 21.0 %$397 21.0 %$3,453 21.0 %
Differential arising from:
Foreign earnings(1,301)(6.5)(941)(49.8)(1,821)(11.1)
Tax settlements and statute lapses
(557)(2.8)— — (10)(0.1)
R&D tax credit(202)(1.0)(214)(11.3)(117)(0.7)
Inventory donations
(71)(0.4)(65)(3.5)(52)(0.3)
State taxes(39)(0.2)(117)(6.2)(110)(0.7)
Charges for certain research and development asset acquisitions
554 2.8 253 13.4 — — 
Valuation allowances54 0.3 70 3.7 108 0.7 
Restructuring52 0.3 41 2.2 11 0.1 
GILTI and the foreign-derived intangible income deduction29 0.1 (80)(4.3)462 2.8 
Acquisition-related costs, including amortization
18 0.1 42 2.2 (3)— 
Acquisition of Prometheus
  2,139 113.3 — — 
Other80 0.4 (13)(0.7)(3)— 
 $2,803 14.1 %$1,512 80.0 %$1,918 11.7 %
Where applicable, the impact of changes in uncertain tax positions is reflected in the reconciling items above.
The Company’s remaining transition tax liability under the Tax Cuts and Jobs Act (TCJA) of 2017, which has been reduced by payments and the expected utilization of foreign tax credits, was a net liability of $518 million at December 31, 2024, which is comprised of a $1.2 billion tax liability included in Income taxes payable, offset by $702 million of foreign tax credits included in Other Assets that Merck expects to be applied upon the completion of the IRS’s examination of the Company’s tax returns for the 2017 and 2018 federal tax years. As a result of the transition tax under the TCJA, the Company is no longer indefinitely reinvested with respect to its undistributed earnings from foreign subsidiaries and has provided a deferred tax liability for foreign withholding taxes that would apply. The
Company remains indefinitely reinvested with respect to its financial statement basis in excess of tax basis of its foreign subsidiaries. A determination of the net deferred tax liability with respect to this basis difference is not practicable.
The foreign earnings tax rate differentials in the tax rate reconciliation above primarily reflect the impacts of operations in jurisdictions with different effective tax rates than the U.S., particularly Ireland, the Netherlands and Switzerland, as well as Singapore and Puerto Rico which operate under tax incentive grants (which begin to expire in 2025), thereby yielding a favorable impact on the effective tax rate compared with the U.S. statutory rate of 21%. The Company has an additional Cantonal tax holiday in Switzerland that provides for a tax rate reduction and is effective through 2032. The Company’s income that is subject to tax incentive grants and the Cantonal tax holiday in Switzerland is subject to the global minimum tax provision of the Organization for Economic Cooperation and Development (OECD) Pillar 2, effective in 2024.
Income before taxes consisted of:
Years Ended December 31202420232022
Domestic$(1,849)$(15,622)$1,011 
Foreign21,785 17,511 15,433 
 $19,936 $1,889 $16,444 
Taxes on income consisted of:
Years Ended December 31202420232022
Current provision
Federal$944 $928 $2,265 
Foreign3,123 2,435 1,164 
State(15)48 57 
 4,052 3,411 3,486 
Deferred provision
Federal(1,475)(1,559)(1,510)
Foreign212 (233)71 
State14 (107)(129)
 (1,249)(1,899)(1,568)
 $2,803 $1,512 $1,918 
Deferred income taxes at December 31 consisted of:
 20242023
AssetsLiabilitiesAssetsLiabilities
Product intangibles and licenses$71 $978 $— $1,308 
R&D capitalization3,062  2,099 — 
Inventory related84 413 86 370 
Accelerated depreciation 645 — 626 
Undistributed foreign earnings
275 371 76 118 
Equity investments 90 — 73 
Pensions and other postretirement benefits224 400 323 249 
Compensation related400  357 — 
Unrecognized tax benefits152  147 — 
Net operating losses and other tax credit carryforwards910  868 — 
Other802 159 755 214 
Subtotal5,980 3,056 4,711 2,958 
Valuation allowance(710) (656) 
Total deferred taxes$5,270 $3,056 $4,055 $2,958 
Net deferred income taxes$2,214 $1,097 
Recognized as:
Other Assets$3,601 $1,968 
Deferred Income Taxes $1,387  $871 
The Company has net operating loss (NOL) carryforwards in several jurisdictions. As of December 31, 2024, $324 million of deferred tax assets on NOL carryforwards relate to foreign jurisdictions. Valuation allowances of $264 million have been established on these foreign NOL carryforwards and other foreign deferred tax assets. In addition, the Company has $586 million of deferred tax assets relating to various U.S. tax credit carryforwards and NOL carryforwards. Valuation allowances of $446 million have been established on these U.S. tax credit carryforwards and NOL carryforwards.
Income taxes paid in 2024, 2023 and 2022 consisted of:
Years Ended December 31202420232022
Domestic (1)
$974 $2,258 $1,891 
Foreign2,954 2,080 1,348 
 $3,928 $4,338 $3,239 
(1)    Includes TCJA transition tax payments.
Tax benefits relating to stock option exercises were $26 million in 2024, $12 million in 2023 and $45 million in 2022.
A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:
202420232022
Balance January 1$2,384 $1,835 $1,529 
Additions related to current year positions421 553 344 
Additions related to prior year positions35 91 48 
Reductions for tax positions of prior years
(33)(20)(40)
Settlements
(18)(23)(6)
Lapse of statute of limitations (1)
(528)(52)(40)
Balance December 31$2,261 $2,384 $1,835 
(1)    Amount in 2024 reflects a reduction of $451 million resulting from the expiration of the statute of limitations related to the 2019 and 2020 federal tax return years.
If the Company were to recognize the unrecognized tax benefits of $2.3 billion at December 31, 2024, the income tax provision would reflect a favorable net impact of $2.2 billion.
The Company is under examination by numerous tax authorities in various jurisdictions globally. The Company believes that it is reasonably possible that the total amount of unrecognized tax benefits as of December 31, 2024 could decrease by up to approximately $22 million in the next 12 months as a result of various audit closures, settlements or the expiration of the statute of limitations. The ultimate finalization of the Company’s examinations with relevant taxing authorities can include formal administrative and legal proceedings, which could have a significant impact on the timing of the reversal of unrecognized tax benefits. The Company believes that its reserves for uncertain tax positions are adequate to cover existing risks or exposures.
Interest and penalties associated with uncertain tax positions amounted to an expense of $51 million in 2024, $131 million in 2023 and $54 million in 2022. These amounts reflect the beneficial impacts of various tax settlements. Liabilities for accrued interest and penalties were $437 million and $388 million as of December 31, 2024 and 2023, respectively.
In 2024, the Company recorded a benefit of $519 million due to a reduction in reserves for unrecognized income tax benefits resulting from the expiration in 2024 of the statute of limitations for assessments related to the 2019 and 2020 federal tax return years. The Internal Revenue Service (IRS) is currently conducting examinations of the Company’s tax returns for the years 2017 and 2018, including the one-time transition tax enacted under the TCJA. If the IRS disagrees with the Company’s transition tax position, it may result in a significant tax liability. The IRS is also currently conducting examinations of the Company’s tax returns for the years 2021 and 2022. In addition, various state and foreign tax examinations are in progress and for these jurisdictions, the Company’s income tax returns are open for examination for the period 2009 through 2024.
XML 67 R26.htm IDEA: XBRL DOCUMENT v3.25.0.1
Earnings per Share
12 Months Ended
Dec. 31, 2024
Earnings Per Share [Abstract]  
Earnings per Share Earnings per Share
The calculations of earnings per share (shares in millions) are as follows:
Years Ended December 31202420232022
Net Income Attributable to Merck & Co., Inc.$17,117 $365 $14,519 
Average common shares outstanding2,532 2,537 2,532 
Common shares issuable (1)
9 10 10 
Average common shares outstanding assuming dilution2,541 2,547 2,542 
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders
$6.76 $0.14 $5.73 
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders
$6.74 $0.14 $5.71 
(1)     Issuable primarily under share-based compensation plans.
In 2024, 2023 and 2022, 6 million, 5 million and 2 million, respectively, of common shares issuable under share-based compensation plans were excluded from the computation of earnings per common share assuming dilution because the effect would have been antidilutive.
XML 68 R27.htm IDEA: XBRL DOCUMENT v3.25.0.1
Other Comprehensive Income (Loss)
12 Months Ended
Dec. 31, 2024
Equity [Abstract]  
Other Comprehensive Income (Loss) Other Comprehensive Income (Loss)
Changes in each component of other comprehensive income (loss) are as follows:
DerivativesEmployee
Benefit
Plans
 Foreign Currency
Translation
Adjustment
Accumulated Other
Comprehensive Loss
Balance at January 1, 2022, net of taxes
$144 $(2,743)$(1,830)$(4,429)
Other comprehensive income (loss) before reclassification adjustments, pretax684 70 (584)170 
Tax(143)12 (19)(150)
Other comprehensive income (loss) before reclassification adjustments, net of taxes541 82 (603)20 
Reclassification adjustments, pretax(775)
(1)
329 
(2)
— (446)
Tax163 (76)— 87 
Reclassification adjustments, net of taxes(612)253 — (359)
Other comprehensive income (loss), net of taxes(71)335 (603)(339)
Balance at December 31, 2022, net of taxes73 (2,408)(2,433)(4,768)
Other comprehensive income (loss) before reclassification adjustments, pretax114 (413)17 (282)
Tax(24)86 63 125 
Other comprehensive income (loss) before reclassification adjustments, net of taxes90 (327)80 (157)
Reclassification adjustments, pretax(237)
(1)
(64)
(2)
(292)
Tax50 — 56 
Reclassification adjustments, net of taxes(187)(58)(236)
Other comprehensive income (loss), net of taxes(97)(385)89 (393)
Balance at December 31, 2023, net of taxes(24)(2,793)
(3)
(2,344)(5,161)
Other comprehensive income (loss) before reclassification adjustments, pretax508 647 (559)596 
Tax(109)(138)23 (224)
Other comprehensive income (loss) before reclassification adjustments, net of taxes399 509 (536)372 
Reclassification adjustments, pretax(168)
(1)
(60)
(2)
20 (208)
Tax35 17  52 
Reclassification adjustments, net of taxes(133)(43)20 (156)
Other comprehensive income (loss), net of taxes266 466 (516)216 
Balance at December 31, 2024, net of taxes$242 $(2,327)
(3)
$(2,860)$(4,945)
(1)    Primarily relates to foreign currency cash flow hedges that were reclassified from AOCL to Sales (see Note 6).
(2)    Includes net amortization of prior service cost, actuarial gains and losses, settlements and curtailments included in net periodic benefit cost (see Note 13).
(3)    Includes pension plan net loss of $3.0 billion and $3.5 billion at December 31, 2024 and 2023, respectively, and other postretirement benefit plan net gain of $400 million and $500 million at December 31, 2024 and 2023, respectively, as well as pension plan prior service credit of $174 million and $141 million at December 31, 2024 and 2023, respectively, and other postretirement benefit plan prior service credit of $61 million and $95 million at December 31, 2024 and 2023, respectively.
XML 69 R28.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment Reporting
12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Segment Reporting Segment Reporting
The Company’s operations are principally managed on a product basis and include two operating segments, Pharmaceutical and Animal Health, both of which are reportable segments.
The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. A large component of pediatric and adolescent vaccine sales are made to the U.S. Centers for Disease Control and Prevention Vaccines for Children program, which is funded by the U.S. government. Additionally, the Company sells vaccines to the Federal government for placement into vaccine stockpiles.
The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors, animal producers, farmers and pet owners.
Sales of the Company’s products were as follows:
Years Ended December 31202420232022
U.S.Int’lTotalU.S.Int’lTotalU.S.Int’lTotal
Pharmaceutical:
Oncology
Keytruda$17,872 $11,610 $29,482 $15,114 $9,897 $25,011 $12,686 $8,251 $20,937 
Alliance revenue - Lynparza (1)
626 685 1,311 607 592 1,199 584 532 1,116 
Alliance revenue - Lenvima (1)
705 305 1,010 657 303 960 579 297 876 
Welireg466 43 509 209 10 218 123 — 123 
Alliance revenue - Reblozyl (2)
303 68 371 168 43 212 123 43 166 
Vaccines
Gardasil/Gardasil 9
2,425 6,158 8,583 2,083 6,803 8,886 2,065 4,832 6,897 
ProQuad/M-M-R II/Varivax1,919 566 2,485 1,837 531 2,368 1,724 518 2,241 
Vaxneuvance461 347 808 561 103 665 163 170 
RotaTeq472 239 711 493 276 769 508 275 783 
Pneumovax 23
56 207 263 127 285 412 346 256 602 
Hospital Acute Care
Bridion1,401 363 1,764 1,156 686 1,842 922 762 1,685 
Prevymis371 414 785 264 341 605 188 240 428 
Dificid303 37 340 274 28 302 241 22 263 
Zerbaxa146 106 252 119 100 218 89 79 169 
Noxafil7 170 177 32 181 213 51 187 238 
Cardiovascular
Winrevair
408 11 419 — — — — — — 
Alliance revenue - Adempas/Verquvo (3)
388 27 415 350 16 367 329 12 341 
Adempas 287 287 — 255 255 — 238 238 
Virology
Lagevrio176 787 964 10 1,418 1,428 1,523 4,161 5,684 
Isentress/Isentress HD185 209 394 215 268 483 274 359 633 
Delstrigo
56 193 249 49 152 201 39 111 151 
Pifeltro
113 50 163 101 41 142 87 30 118 
Neuroscience
Belsomra72 150 222 81 150 231 79 179 258 
Immunology
Simponi 543 543 — 710 710 — 706 706 
Remicade 114 114 — 187 187 — 207 207 
Diabetes
Januvia469 865 1,334 1,151 1,039 2,189 1,248 1,565 2,813 
Janumet161 774 935 223 954 1,177 355 1,344 1,700 
Other pharmaceutical (4)
729 1,782 2,510 658 1,675 2,333 663 1,803 2,462 
Total Pharmaceutical segment sales30,290 27,110 57,400 26,539 27,044 53,583 24,989 27,016 52,005 
Animal Health:
Livestock732 2,729 3,462 700 2,637 3,337 710 2,590 3,300 
Companion Animal1,129 1,287 2,415 1,104 1,184 2,288 1,112 1,138 2,250 
Total Animal Health segment sales1,861 4,016 5,877 1,804 3,821 5,625 1,822 3,728 5,550 
Total segment sales32,151 31,126 63,277 28,343 30,865 59,208 26,811 30,744 57,555 
Other (5)
126 765 891 137 770 907 395 1,333 1,728 
 $32,277 $31,891 $64,168 $28,480 $31,635 $60,115 $27,206 $32,077 $59,283 
U.S. plus international may not equal total due to rounding.
(1)    Alliance revenue for Lynparza and Lenvima represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 4).
(2)    Alliance revenue for Reblozyl represents royalties and, for 2022, also includes a payment received related to the achievement of a regulatory approval milestone (see Note 4).
(3)    Alliance revenue for Adempas/Verquvo represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 4).
(4)    Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.
(5)    Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities which increased sales by $195 million, $244 million and $810 million in 2024, 2023 and 2022, respectively, as well as revenue from third-party manufacturing arrangements (including sales to Organon). Other for 2024, 2023 and 2022 also includes $106 million, $118 million and $165 million, respectively, related to upfront and milestone payments received by Merck for out-licensing arrangements.
Consolidated sales by geographic area where derived are as follows:
Years Ended December 31202420232022
United States$32,277 $28,480 $27,206 
Europe, Middle East and Africa14,041 13,254 14,493 
China5,494 6,802 5,191 
Latin America3,459 3,086 2,582 
Japan3,280 3,164 3,629 
Asia Pacific (other than China and Japan)3,058 3,225 3,614 
Other2,559 2,104 2,568 
 $64,168 $60,115 $59,283 
A reconciliation of segment profits to Income Before Taxes is as follows:
Years Ended December 31202420232022
Pharma-ceutical
Animal Health
Total
Pharma-ceutical
Animal Health
Total
Pharma-ceutical
Animal Health
Total
Segment sales
$57,400 $5,877 $63,277 $53,583 $5,625 $59,208 $52,005 $5,550 $57,555 
Less segment costs: (1)
Cost of sales
6,828 2,469 8,849 2,498 9,678 2,259 
Selling, general and administrative
6,128 1,084 5,903 1,038 5,474 999 
Research and development (2)
 385 — 353 — 329 
Other segment items (3)
(89)1 (49)(1)— 
Total segment profits44,533 1,938 46,471 38,880 1,737 40,617 36,852 1,963 38,815 
Other profits492 474 1,160 
Unallocated:
Interest income415 365 157 
Interest expense(1,271)(1,146)(962)
Amortization(2,395)(2,044)(2,085)
Depreciation(1,843)(1,625)(1,642)
Research and development(17,350)(30,008)(13,011)
Restructuring costs(309)(599)(337)
Charge for Zetia antitrust litigation settlements (573)— 
Other unallocated, net(4,274)(3,572)(5,651)
$19,936 $1,889 $16,444 
(1)    The significant expense categories and amounts align with the segment level information that is regularly provided to the chief operating decision maker.
(2)    Human health-related research and development expenses incurred by Merck Research Laboratories are not allocated to segment profits as noted below.
(3)    Includes equity (income) loss from affiliates and other miscellaneous non-operating expenses.

Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as selling, general and administrative expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as selling, general and administrative expenses and research and development costs directly incurred by the segment. The chief operating decision maker (Merck’s Chief Executive Officer) uses segment profit to allocate resources predominately during the planning and forecasting process. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred by Merck Research Laboratories, the Company’s research and development division that focuses on human health-related activities, or general and administrative expenses not directly incurred by the segments, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. In addition, costs related to restructuring activities, as well as the amortization of intangible assets and amortization of purchase accounting adjustments are not allocated to segments.
Other profits are primarily comprised of miscellaneous corporate profits, as well as operating profits (losses) related to third-party manufacturing arrangements.
Other unallocated, net, includes expenses from corporate and manufacturing cost centers, intangible asset impairment charges, gains or losses on sales of businesses, expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration, and other miscellaneous income or expense items.
Equity income from affiliates and depreciation included in segment profits is as follows:
PharmaceuticalAnimal HealthTotal
Year Ended December 31, 2024
Equity income from affiliates$144 $ $144 
Depreciation5 256 261 
Year Ended December 31, 2023
Equity income from affiliates$111 $— $111 
Depreciation198 203 
Year Ended December 31, 2022
Equity income from affiliates
$39 $— $39 
Depreciation177 182 
Property, plant and equipment, net, by geographic area where located is as follows:
December 31202420232022
United States$14,724 $13,915 $12,891 
Europe, Middle East and Africa7,548 7,562 6,993 
Asia Pacific (other than China and Japan)982 1,022 966 
China202 193 207 
Japan143 133 135 
Latin America133 222 225 
Other47 
 $23,779 $23,051 $21,422 
The Company does not disaggregate assets on a products and services basis for internal management reporting and, therefore, such information is not presented.
XML 70 R29.htm IDEA: XBRL DOCUMENT v3.25.0.1
Pay vs Performance Disclosure - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Pay vs Performance Disclosure      
Net Income Attributable to Merck & Co., Inc. $ 17,117 $ 365 $ 14,519
XML 71 R30.htm IDEA: XBRL DOCUMENT v3.25.0.1
Insider Trading Arrangements
3 Months Ended
Dec. 31, 2024
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 72 R31.htm IDEA: XBRL DOCUMENT v3.25.0.1
Insider Trading Policies and Procedures
12 Months Ended
Dec. 31, 2024
Insider Trading Policies and Procedures [Line Items]  
Insider Trading Policies and Procedures Adopted true
XML 73 R32.htm IDEA: XBRL DOCUMENT v3.25.0.1
Cybersecurity Risk Management and Strategy Disclosure
12 Months Ended
Dec. 31, 2024
Cybersecurity Risk Management, Strategy, and Governance [Line Items]  
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]
The Company’s cybersecurity measures are primarily focused on ensuring the security and protection of its IT systems and data. The Company’s information security program is managed by a dedicated Chief Information Security Officer (CISO), whose group is responsible for leading enterprise-wide cybersecurity risk management, strategy, policy, standards, architecture, and processes. The CISO has worked in the cybersecurity and national security fields for more than 30 years. He has a Master of Science in Telecommunications and Computers. He has served as a board member of the Health Information Sharing and Analysis Center for 10 years. Oversight of the information security program has been integrated into the Company’s overall enterprise risk management program.
The CISO provides periodic reports to the Audit Committee (Audit Committee) of the Board of Directors (Board), the full Board, as well as to the Company’s Chief Executive Officer and other members of senior management, as appropriate. These reports include updates on the Company’s cybersecurity risks and threats, the status of projects intended to strengthen its information security systems, assessments of the information security program (including remediation, mitigation, and management of identified vulnerabilities), and the emerging threat landscape. The information security program is regularly evaluated by internal and external consultants and auditors with the results of those reviews reported to senior management and the Audit Committee, which is comprised entirely of independent directors and has oversight responsibility for these risks.
The Company’s information security group monitors the Company’s information systems to prevent, detect, mitigate, and remediate cybersecurity incidents. The Company uses tools and techniques to continually assess and monitor, manage and mitigate cybersecurity threats to its IT systems in a manner consistent with industry practice. The Company engages with key vendors, industry participants, and intelligence and law enforcement communities as part of its continuing efforts to obtain current threat intelligence, collaborate on security enhancements, and evaluate and improve the effectiveness of its information security program. As part of this program, the Company conducts periodic tabletop and red-teaming exercises to assess its cybersecurity incident response processes and defenses. The Company also maintains vendor management diligence and oversight processes to identify and monitor potential risks from cybersecurity threats attendant to its use of third-party service providers. Additionally, the Company monitors cybersecurity threat intelligence received from key third-party service providers associated with the Company.
Cybersecurity Risk Management Processes Integrated [Flag] true
Cybersecurity Risk Management Processes Integrated [Text Block]
The Company’s cybersecurity measures are primarily focused on ensuring the security and protection of its IT systems and data. The Company’s information security program is managed by a dedicated Chief Information Security Officer (CISO), whose group is responsible for leading enterprise-wide cybersecurity risk management, strategy, policy, standards, architecture, and processes. The CISO has worked in the cybersecurity and national security fields for more than 30 years. He has a Master of Science in Telecommunications and Computers. He has served as a board member of the Health Information Sharing and Analysis Center for 10 years. Oversight of the information security program has been integrated into the Company’s overall enterprise risk management program.
Cybersecurity Risk Management Third Party Engaged [Flag] true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag] true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag] false
Cybersecurity Risk Board of Directors Oversight [Text Block] The CISO provides periodic reports to the Audit Committee (Audit Committee) of the Board of Directors (Board), the full Board, as well as to the Company’s Chief Executive Officer and other members of senior management, as appropriate. These reports include updates on the Company’s cybersecurity risks and threats, the status of projects intended to strengthen its information security systems, assessments of the information security program (including remediation, mitigation, and management of identified vulnerabilities), and the emerging threat landscape. The information security program is regularly evaluated by internal and external consultants and auditors with the results of those reviews reported to senior management and the Audit Committee, which is comprised entirely of independent directors and has oversight responsibility for these risks.
In the event of a cybersecurity incident, the Company has a process in place whereby members of the information security group will alert the CISO and the CISO will alert the appropriate levels of management, including an incident assessment team, as well as the legal and finance departments so that the materiality of any such event can be assessed in furtherance of fulfilling any reporting requirements. If warranted, senior management will notify the Audit Committee or the full Board, as appropriate.
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block] The information security program is regularly evaluated by internal and external consultants and auditors with the results of those reviews reported to senior management and the Audit Committee, which is comprised entirely of independent directors and has oversight responsibility for these risks.
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block] The CISO provides periodic reports to the Audit Committee (Audit Committee) of the Board of Directors (Board), the full Board, as well as to the Company’s Chief Executive Officer and other members of senior management, as appropriate. These reports include updates on the Company’s cybersecurity risks and threats, the status of projects intended to strengthen its information security systems, assessments of the information security program (including remediation, mitigation, and management of identified vulnerabilities), and the emerging threat landscape. The information security program is regularly evaluated by internal and external consultants and auditors with the results of those reviews reported to senior management and the Audit Committee, which is comprised entirely of independent directors and has oversight responsibility for these risks.
In the event of a cybersecurity incident, the Company has a process in place whereby members of the information security group will alert the CISO and the CISO will alert the appropriate levels of management, including an incident assessment team, as well as the legal and finance departments so that the materiality of any such event can be assessed in furtherance of fulfilling any reporting requirements. If warranted, senior management will notify the Audit Committee or the full Board, as appropriate.
Cybersecurity Risk Role of Management [Text Block]
The Company’s cybersecurity measures are primarily focused on ensuring the security and protection of its IT systems and data. The Company’s information security program is managed by a dedicated Chief Information Security Officer (CISO), whose group is responsible for leading enterprise-wide cybersecurity risk management, strategy, policy, standards, architecture, and processes. The CISO has worked in the cybersecurity and national security fields for more than 30 years. He has a Master of Science in Telecommunications and Computers. He has served as a board member of the Health Information Sharing and Analysis Center for 10 years. Oversight of the information security program has been integrated into the Company’s overall enterprise risk management program.
In the event of a cybersecurity incident, the Company has a process in place whereby members of the information security group will alert the CISO and the CISO will alert the appropriate levels of management, including an incident assessment team, as well as the legal and finance departments so that the materiality of any such event can be assessed in furtherance of fulfilling any reporting requirements. If warranted, senior management will notify the Audit Committee or the full Board, as appropriate.
Cybersecurity Risk Management Positions or Committees Responsible [Flag] true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block] The Company’s information security program is managed by a dedicated Chief Information Security Officer (CISO), whose group is responsible for leading enterprise-wide cybersecurity risk management, strategy, policy, standards, architecture, and processes.
Cybersecurity Risk Management Expertise of Management Responsible [Text Block] The CISO has worked in the cybersecurity and national security fields for more than 30 years. He has a Master of Science in Telecommunications and Computers. He has served as a board member of the Health Information Sharing and Analysis Center for 10 years.
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]
The CISO provides periodic reports to the Audit Committee (Audit Committee) of the Board of Directors (Board), the full Board, as well as to the Company’s Chief Executive Officer and other members of senior management, as appropriate. These reports include updates on the Company’s cybersecurity risks and threats, the status of projects intended to strengthen its information security systems, assessments of the information security program (including remediation, mitigation, and management of identified vulnerabilities), and the emerging threat landscape. The information security program is regularly evaluated by internal and external consultants and auditors with the results of those reviews reported to senior management and the Audit Committee, which is comprised entirely of independent directors and has oversight responsibility for these risks.
In the event of a cybersecurity incident, the Company has a process in place whereby members of the information security group will alert the CISO and the CISO will alert the appropriate levels of management, including an incident assessment team, as well as the legal and finance departments so that the materiality of any such event can be assessed in furtherance of fulfilling any reporting requirements. If warranted, senior management will notify the Audit Committee or the full Board, as appropriate.
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag] true
XML 74 R33.htm IDEA: XBRL DOCUMENT v3.25.0.1
Summary of Accounting Policies (Policies)
12 Months Ended
Dec. 31, 2024
Accounting Policies [Abstract]  
Principles of Consolidation
Principles of Consolidation — The consolidated financial statements include the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. Intercompany balances and transactions are eliminated. Controlling interest is determined by majority ownership interest and the absence of substantive third-party participating rights or, in the case of variable interest entities, by majority exposure to expected losses, residual returns or both. For those consolidated subsidiaries where Merck ownership is less than 100%, the outside shareholders’ interests are shown as Noncontrolling interests in equity. Investments in affiliates over which the Company has significant influence but not a controlling interest, such as interests in entities owned equally by the Company and a third party that are under shared control, are carried on the equity method basis.
Acquisitions
Acquisitions — In a business combination, the acquisition method of accounting requires that the assets acquired and liabilities assumed be recorded as of the date of the acquisition at their respective fair values with limited exceptions. Assets acquired and liabilities assumed in a business combination that arise from contingencies are generally recognized at fair value. If fair value cannot be determined, the asset or liability is recognized if probable and reasonably estimable; if these criteria are not met, no asset or liability is recognized. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Accordingly, the Company may be required to value assets at fair value measures that do not reflect the Company’s intended use of those assets. Any excess of the purchase price (consideration transferred) over the estimated fair values of net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Company’s consolidated financial statements after the date of the acquisition.
If the Company determines the assets acquired do not meet the definition of a business under the acquisition method of accounting, the transaction will be accounted for as an acquisition of assets rather than a business combination and, therefore, no goodwill will be recorded. In an asset acquisition, acquired in-process research and development (IPR&D) with no alternative future use is charged to expense and contingent consideration is not recognized at the acquisition date.
Foreign Currency Translation
Foreign Currency Translation — The net assets of international subsidiaries where the local currencies have been determined to be the functional currencies are translated into U.S. dollars using current exchange rates and results of operations are translated at average exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries at changing rates are recorded in Other Comprehensive Income (OCI) and remain in Accumulated other comprehensive loss (AOCL) until either the sale or complete or substantially complete liquidation of the subsidiary. For those subsidiaries that operate in highly inflationary economies and for those subsidiaries where the U.S. dollar has been determined to be the functional currency, non-monetary foreign currency
assets and liabilities are translated using historical rates, while monetary assets and liabilities are translated at current rates, with the U.S. dollar effects of rate changes included in Other (income) expense, net.
Cash Equivalents
Cash Equivalents — Cash equivalents are comprised of certain highly liquid investments with original maturities of less than three months.
Inventories
Inventories — Inventories are valued at the lower of cost or net realizable value. The cost of a substantial majority of U.S. human health inventories is determined using the last-in, first-out (LIFO) method for both financial reporting and tax purposes. The cost of all other inventories is determined using the first-in, first-out (FIFO) method. Inventories consist of currently marketed products, as well as certain inventories produced in preparation for product launches that are considered by the Company to be probable of obtaining regulatory approval. In evaluating the recoverability of inventories produced in preparation for product launches, the Company considers the likelihood that revenue will be obtained from the future sale of the related inventory together with the status of the product during the research and regulatory approval process.
Investments
Investments — Investments in marketable debt securities classified as available-for-sale are reported at fair value. Fair values of the Company’s investments in marketable debt securities are determined using quoted market prices in active markets for identical assets or quoted prices for similar assets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Changes in fair value that are not impairment related are reported net of taxes in OCI. The Company considers available evidence in evaluating potential impairments of its investments in marketable debt securities, including the extent to which fair value is less than cost, whether an allowance for credit loss is required, as well as adverse factors that could affect the value of the securities. An impairment has occurred if the Company does not expect to recover the entire amortized cost basis of the marketable debt security. If the Company does not intend to sell the impaired debt security, and it is not more likely than not it will be required to sell the debt security before the recovery of its amortized cost basis, the amount of the impairment recognized in earnings, recorded in Other (income) expense, net, is limited to the portion attributed to credit loss. The remaining portion of the impairment related to other factors is recognized in OCI. Realized gains and losses for debt securities are included in Other (income) expense, net.
Investments in publicly traded equity securities are reported at fair value as determined using quoted market prices in active markets for identical assets or quoted prices for similar assets or other inputs that are observable or can be corroborated by observable market data. Changes in fair value are included in Other (income) expense, net. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period. Gains and losses from ownership interests in investment funds, which are accounted for as equity method investments, are reported on a one quarter lag. Investments in equity securities without readily determinable fair values are recorded at cost, plus or minus subsequent observable price changes in orderly transactions for identical or similar investments, minus impairments. Such adjustments are recognized in Other (income) expense, net. Realized gains and losses for equity securities are included in Other (income) expense, net.
Revenue Recognition
Revenue Recognition — Recognition of revenue requires evidence of a contract, probable collection of sales proceeds and completion of substantially all performance obligations. Merck acts as the principal in substantially all of its customer arrangements and therefore records revenue on a gross basis. The majority of the Company’s contracts related to the Pharmaceutical and Animal Health segments have a single performance obligation - the promise to transfer goods. Shipping is considered immaterial in the context of the overall customer arrangement and damages or loss of goods in transit are rare. Therefore, shipping is not deemed a separately recognized performance obligation.
The vast majority of revenues from sales of products are recognized at a point in time when control of the goods is transferred to the customer, which the Company has determined is when title and risks and rewards of ownership transfer to the customer and the Company is entitled to payment. The Company recognizes revenue from the sales of vaccines to the U.S. federal government for placement into vaccine stockpiles in accordance with Securities and Exchange Commission (SEC) Interpretation, Commission Guidance Regarding Accounting for Sales of Vaccines and BioTerror Countermeasures to the Federal Government for Placement into the Pediatric Vaccine Stockpile or the Strategic National Stockpile. This interpretation allows companies to recognize revenue for sales of vaccines into U.S. government stockpiles even though these sales might not meet the criteria for revenue recognition under other accounting guidance. For certain services in the Animal Health segment, revenue is recognized over time, generally ratably over the contract term as services are provided. These service revenues are not material.
The nature of the Company’s business gives rise to several types of variable consideration including discounts and returns, which are estimated at the time of sale generally using the expected value method, although the most likely amount method is used for prompt pay discounts.
In the U.S., sales discounts are issued to customers at the point-of-sale, through an intermediary wholesaler (known as chargebacks), or in the form of rebates. Additionally, sales are generally made with a limited right of return under certain conditions. Revenues are recorded net of provisions for sales discounts and returns, which are established at the time of sale. In addition, if collection of accounts receivable is expected to be in excess of one year, sales are recorded net of time value of money discounts, which have not been material.
The U.S. provision for aggregate customer discounts covering chargebacks and rebates was $13.3 billion in 2024, $12.5 billion in 2023 and $12.3 billion in 2022. Chargebacks are discounts that occur when a contracted customer purchases through an intermediary wholesaler. The wholesaler then charges the Company back for the difference between the price initially paid by the wholesaler and the contract price agreed to between Merck and the customer. The provision for chargebacks is based on expected sell-through levels by the Company’s wholesale customers to contracted customers, as well as estimated wholesaler inventory levels. Rebates are amounts owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part D) benefit providers after the final dispensing of the product to a benefit plan participant. The provision for rebates is based on expected patient usage, as well as inventory levels in the distribution channel to determine the contractual obligation to the benefit providers. The Company uses historical customer segment utilization mix, sales forecasts, changes to product mix and price, inventory levels in the distribution channel, government pricing calculations and prior payment history in order to estimate the expected provision. Amounts accrued for aggregate customer discounts are evaluated on a quarterly basis through comparison of information provided by the wholesalers, health maintenance organizations, pharmacy benefit managers, federal and state agencies, and other customers to the amounts accrued. The accrued balances relative to the provisions for chargebacks and rebates included in Accounts receivable and Accrued and other current liabilities were $293 million and $2.2 billion, respectively, at December 31, 2024 and were $188 million and $2.3 billion, respectively, at December 31, 2023.
Outside of the U.S., variable consideration in the form of discounts and rebates are a combination of commercially-driven discounts in highly competitive product classes, discounts required to gain or maintain reimbursement, or legislatively mandated rebates. In certain European countries, legislatively mandated rebates are calculated based on an estimate of the government’s total unbudgeted spending and the Company’s specific payback obligation. Rebates may also be required based on specific product sales thresholds. The Company applies an estimated factor against its actual invoiced sales to represent the expected level of future discount or rebate obligations associated with the sale.
The Company maintains a returns policy that allows its U.S. pharmaceutical customers to return product within a specified period prior to and subsequent to the expiration date (generally, three to six months before and 12 months after product expiration). The estimate of the provision for returns is based upon historical experience with actual returns. Additionally, the Company considers factors such as levels of inventory in the distribution channel, product dating and expiration period, whether products have been discontinued, entrance in the market of generic or other competition, changes in formularies or launch of over-the-counter products, among others. Outside of the U.S., returns are only allowed in certain countries on a limited basis.
Merck’s payment terms for U.S. pharmaceutical customers are typically 36 days from receipt of invoice and for U.S. animal health customers are typically 30 days from receipt of invoice; however, certain products have longer payment terms, including Keytruda (pembrolizumab), which has payment terms of 90 days. Payment terms for vaccine sales in the U.S. typically range from 30 days to 60 days. Outside of the U.S., payment terms are typically 30 days to 90 days, although certain markets have longer payment terms.
See Note 18 for disaggregated revenue disclosures.
Depreciation Depreciation — Depreciation is provided over the estimated useful lives of the assets, principally using the straight-line method. For tax purposes, accelerated tax methods are used. The estimated useful lives primarily range from 25 to 45 years for Buildings, and from 3 to 15 years for Machinery, equipment and office furnishings.
Advertising and Promotion Costs Advertising and Promotion Costs — Advertising and promotion costs are expensed as incurred.
Software Capitalization
Software Capitalization — The Company capitalizes certain costs incurred in connection with obtaining or developing internal-use software including external direct costs of material and services, and payroll costs for employees directly involved with the software development. These costs are included in Property, plant and equipment. In addition, the Company capitalizes certain costs incurred to implement a cloud computing arrangement
that is considered a service agreement, which are included in Other Assets. Capitalized software costs are being amortized over periods ranging from 2 to 10 years, with the longer lives generally associated with enterprise-wide projects implemented over multiple years. Costs incurred during the preliminary project stage and post-implementation stage, as well as maintenance and training costs, are expensed as incurred.
Goodwill
Goodwill — Goodwill represents the excess of the consideration transferred over the fair value of net assets acquired in a business combination. Goodwill is assigned to reporting units and evaluated for impairment at least annually, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company concludes it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed. If the carrying value of a reporting unit is greater than its fair value, a goodwill impairment charge will be recorded for the difference (up to the carrying value of goodwill).
Acquired Intangibles
Acquired Intangibles — Intangibles acquired in a business combination include product rights, trade names and patents, licenses and other, which are initially recorded at fair value, assigned an estimated useful life, and amortized primarily on a straight-line basis over their estimated useful lives ranging from 2 to 24 years. The Company periodically evaluates whether current facts or circumstances indicate that the carrying values of its acquired intangibles may not be recoverable. If such circumstances are determined to exist, an estimate of the undiscounted future cash flows of these assets, or appropriate asset groupings, is compared to the carrying value to determine whether an impairment exists. If the asset is determined to be impaired, the loss is measured based on the difference between the carrying value of the intangible asset and its fair value, which is determined based on the net present value of estimated future cash flows.
Acquired In-Process Research and Development
Acquired In-Process Research and Development — IPR&D that the Company acquires in conjunction with a business combination represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each IPR&D project, Merck will make a determination as to the then-useful life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization. The Company evaluates IPR&D for impairment at least annually, or more frequently if impairment indicators exist, by performing a quantitative test that compares the fair value of the IPR&D intangible asset with its carrying value. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results.
Contingent Consideration for Business Combinations Contingent Consideration for Business Combinations — Certain of the Company’s acquisitions involve the potential for future payment of consideration that is contingent upon the achievement of performance milestones, including product development milestones and royalty payments on future product sales. If the transaction is accounted for as a business combination, the fair value of contingent consideration liabilities is determined at the acquisition date using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period until the contingency is resolved, the contingent consideration liability is remeasured at current fair value with changes (either expense or income) recorded in earnings. Significant events that increase or decrease the probability of achieving development and regulatory milestones or that increase or decrease projected cash flows will result in corresponding increases or decreases in the fair values of the related contingent consideration obligations.
Research and Development Research and Development — Research and development is expensed as incurred. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Research and development expenses include restructuring costs and IPR&D impairment charges. In addition, research and development expenses include expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration associated with IPR&D assets. Research and development expenses also include upfront and milestone payments related to asset acquisitions and licensing transactions involving clinical development programs that have not yet received regulatory approval.
Collaborative Arrangements
Collaborative Arrangements — Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. When Merck is the principal on sales transactions with third parties, the Company recognizes sales, cost of sales and selling, general and administrative expenses on a gross basis. Profit sharing amounts it pays to its collaborative partners are recorded within Cost of sales. When the collaborative partner is the principal on sales transactions with third parties, the Company records profit sharing amounts received from its collaborative partners as alliance revenue
(within Sales). Alliance revenue is recorded net of cost of sales and includes an adjustment to share commercialization costs between the partners in accordance with the collaboration agreement. The adjustment is determined by comparing the commercialization costs Merck has incurred directly and reported within Selling, general and administrative expenses with the costs the collaborative partner has incurred. Research and development costs Merck incurs related to collaborations are recorded within Research and development expenses. Cost reimbursements to the collaborative partner or payments received from the collaborative partner to share these costs pursuant to the terms of the collaboration agreements are recorded as increases or decreases to Research and development expenses.
In addition, the terms of the collaboration agreements may require the Company to make payments based upon the achievement of certain developmental, regulatory approval or commercial milestones. Upfront and milestone payments payable by Merck to collaborative partners prior to regulatory approval are expensed as incurred and included in Research and development expenses. Payments due to collaborative partners upon or subsequent to regulatory approval are capitalized and amortized to Cost of sales over the estimated useful life of the corresponding intangible asset, provided that future cash flows support the amounts capitalized. Sales-based milestones payable by Merck to collaborative partners are accrued and capitalized, subject to cumulative amortization catch-up, when determined by the Company to be probable of being achieved based on future sales forecasts. The amortization catch-up is calculated either from the time of the first regulatory approval for products that were unapproved at the time the collaboration was formed or, for new indications of approved products, from the time of the formation of the collaboration. The related intangible asset that is recognized is amortized to Cost of sales over its remaining useful life, subject to impairment testing.
Share-Based Compensation
Share-Based Compensation — The Company expenses all share-based payments to employees over the requisite service period based on the grant-date fair value of the awards.
Restructuring Costs
Restructuring Costs — The Company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. In accordance with existing benefit arrangements, future employee termination costs to be incurred in conjunction with involuntary separations are accrued when such separations are probable and estimable. When accruing these costs, the Company will recognize the amount within a range of costs that is the best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company recognizes the minimum amount within the range. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period.
Contingencies and Legal Defense Costs
Contingencies and Legal Defense Costs — The Company records accruals for contingencies and legal defense costs expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated.
Taxes on Income
Taxes on Income — Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. The Company evaluates tax positions to determine whether the benefits of tax positions are more likely than not of being sustained upon audit based on the technical merits of the tax position. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the amount of the benefit that is greater than 50% likely of being realized upon ultimate settlement in the financial statements. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit in the financial statements. The Company recognizes interest and penalties associated with uncertain tax positions as a component of Taxes on Income. The Company accounts for the tax effects of the tax on global intangible low-taxed income (GILTI) of certain foreign subsidiaries in the income tax provision in the period the tax arises. The Company’s policy for releasing disproportionate income tax effects from AOCL is to utilize the item-by-item approach.
Reclassifications Reclassifications — Certain reclassifications have been made to prior year amounts to conform to the current year presentation.
Use of Estimates
Use of Estimates — The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the U.S. (GAAP) and, accordingly, include certain amounts that are based on management’s best estimates and judgments. Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities in a business combination (primarily IPR&D, other intangible assets and contingent consideration), as well as subsequent fair value measurements. Additionally, estimates are used in determining such items as provisions for sales discounts, rebates and returns, depreciable and amortizable lives, recoverability of inventories, including those produced in preparation for product launches, amounts recorded for contingencies, environmental liabilities, accruals for contingent sales-
based milestone payments and other reserves, pension and other postretirement benefit plan assumptions, share-based compensation assumptions, restructuring costs, impairments of long-lived assets (including intangible assets and goodwill) and investments, and taxes on income. Because of the uncertainty inherent in such estimates, actual results may differ from these estimates.
Recently Adopted Accounting Standards and Recently Issued Accounting Standards Not Yet Adopted
Recently Adopted Accounting Standards — In August 2023, the Financial Accounting Standards Board (FASB) issued amended guidance that requires a newly formed joint venture to recognize and initially measure its assets and liabilities at fair value upon formation. The amended guidance includes exceptions to fair value measurement that are consistent with the accounting for business combinations guidance. The Company adopted the guidance effective July 1, 2024 on a prospective basis. There was no impact to the Company’s consolidated financial statements upon adoption.
In November 2023, the FASB issued guidance intended to improve reportable segment disclosure requirements, primarily through expanded disclosures for significant segment expenses. The Company adopted the guidance effective for the 2024 annual period. The guidance resulted in incremental disclosures to the Company’s segment reporting disclosures. See Note 18 for further details.
Recently Issued Accounting Standards Not Yet Adopted — In December 2023, the FASB issued guidance intended to improve the transparency of income tax disclosures by requiring consistent categories and disaggregation of information in the effective income tax rate reconciliation and income taxes paid disclosures by jurisdiction. The guidance also includes other amendments to improve the effectiveness of income tax disclosures by removing certain previously required disclosures. The guidance is effective for 2025 annual reporting. The guidance will result in incremental disclosures within the footnotes to the Company’s financial statements.
In November 2024, the FASB issued guidance intended to improve financial reporting by requiring entities to disclose additional information about specific expense categories at interim and annual reporting periods. The guidance is effective for 2027 annual reporting and 2028 interim reporting. Early adoption is permitted. The guidance, which can be applied on a prospective or retrospective basis, will result in incremental disclosures within the footnotes to the Company’s financial statements.
XML 75 R34.htm IDEA: XBRL DOCUMENT v3.25.0.1
Acquisitions, Divestitures, Research Collaborations and Licensing Agreements (Tables)
12 Months Ended
Dec. 31, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]  
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed
The estimated fair values of assets acquired and liabilities assumed from the Elanco aqua business are as follows:
July 9, 2024
Inventories
$65 
Property, plant and equipment
66
Product rights - Clynav (useful life 15 years) (1)
340
Other product rights (useful lives 15 years) (1)
291
Other assets and liabilities, net23 
Total identifiable net assets785 
Goodwill (2)
518
Consideration transferred$1,303 
(1)    The estimated fair values of Clynav and other product rights were determined using an income approach, specifically the multi-period excess earnings method. The future probability-weighted net cash flows were discounted to present value utilizing a discount rate of 8.5%. Actual cash flows are likely to be different than those assumed.
(2)    The goodwill recognized is largely attributable to anticipated synergies expected to arise after the acquisition and was allocated to the Animal Health segment. The goodwill is expected to be deductible for tax purposes.
XML 76 R35.htm IDEA: XBRL DOCUMENT v3.25.0.1
Collaborative Arrangements (Tables)
12 Months Ended
Dec. 31, 2024
Collaborative Arrangements [Abstract]  
Collaborative Arrangements
Summarized financial information related to this collaboration is as follows:
Years Ended December 31202420232022
Alliance revenue - Lynparza$1,311 $1,199 $1,116 
Alliance revenue - Koselugo170 97 54 
Total alliance revenue$1,481 $1,296 $1,170 
Cost of sales (1)
378 311 492 
Selling, general and administrative165 192 185 
Research and development77 79 106 
December 3120242023
Receivables from AstraZeneca included in Other current assets
$424 $341 
Payables to AstraZeneca included in Accrued and other current liabilities (2)
713 256 
Payables to AstraZeneca included in Other Noncurrent Liabilities (2)
 600 
(1)    Represents amortization of capitalized milestone payments. Amounts in 2024 and 2022 include $48 million and $250 million, respectively, of cumulative amortization catch-up expense as noted above.
(2)    Includes accrued milestone payments.
Summarized financial information related to this collaboration is as follows:
Years Ended December 31202420232022
Alliance revenue - Lenvima$1,010 $960 $876 
Cost of sales (1)
241 381 212 
Selling, general and administrative159 189 158 
Research and development21 66 136 
December 3120242023
Receivables from Eisai included in Other current assets
$257 $226 
Payables to Eisai included in Accrued and other current liabilities (2)
 125 
(1)     Represents amortization of capitalized milestone payments. Amount in 2023 includes $154 million of cumulative amortization catch-up expense as noted above.
(2)     Represents an accrued milestone payment.
Summarized financial information related to this collaboration is as follows:
Years Ended December 31202420232022
Alliance revenue - Adempas/Verquvo$415 $367 $341 
Net sales of Adempas recorded by Merck287 255 238 
Net sales of Verquvo recorded by Merck37 36 22 
Total sales$739 $658 $601 
Cost of sales (1)
244 224 210 
Selling, general and administrative111 131 153 
Research and development102 90 75 
December 3120242023
Receivables from Bayer included in Other current assets
$160 $156 
Payables to Bayer included in Accrued and other current liabilities
82 80 
(1)    Includes amortization of intangible assets, cost of products sold by Merck, as well as Bayer’s share of profits from sales in Merck’s marketing territories.
Summarized financial information related to this collaboration is as follows:
Years Ended December 31202420232022
Net sales of Lagevrio recorded by Merck
$964 $1,428 $5,684 
Cost of sales (1)
554 852 3,038 
Selling, general and administrative
57 97 147 
Research and development
13 60 88 
December 3120242023
Payables to Ridgeback included in Accrued and other current liabilities (2)
$68 $113 
(1)    Includes cost of products sold by Merck, Ridgeback’s share of profits, royalty expense, amortization of capitalized milestone payments and inventory reserves.
(2)    Includes accrued royalties.
Summarized financial information related to this collaboration is as follows:
Years Ended December 3120242023
Selling, general and administrative
$26 $
Research and development (1)
351 5,549 
December 3120242023
Receivables from Daiichi Sankyo included in Other current assets
$8 $— 
Payables to Daiichi Sankyo included in Accrued and other current liabilities (2)
817 800 
Payables to Daiichi Sankyo included in Other Noncurrent Liabilities (2)
 750 
(1)    Expenses in 2023 include the $5.5 billion charge for the upfront and continuing option payments noted above.
(2)    Includes accrued continuation payment.
Summarized financial information related to this collaboration is as follows:
Years Ended December 31202420232022
Selling, general and administrative
$16 $$— 
Research and development (1)
358 218 288 
December 3120242023
Payables to Moderna included in Accrued and other current liabilities
$57 $63 
(1)    Expenses in 2022 include the $250 million option exercise payment noted above.
XML 77 R36.htm IDEA: XBRL DOCUMENT v3.25.0.1
Restructuring (Tables)
12 Months Ended
Dec. 31, 2024
Restructuring and Related Activities [Abstract]  
Charges Related to Restructuring Program Activities by Type of Cost
The following table summarizes the charges related to the restructuring programs by type of cost:
Accelerated
Depreciation
Separation
Costs
Other Exit Costs
Total
Year Ended December 31, 2024
2024 Restructuring Program
Cost of sales$254 $ $241 $495 
Selling, general and administrative  83 83 
Research and development  1 1 
Restructuring costs 122 187 309 
$254 $122 $512 $888 
Year Ended December 31, 2023
2024 Restructuring Program
Cost of sales$— $— $62 $62 
Restructuring costs— 115 13 128 
— 115 75 190 
2019 Restructuring Program
Cost of sales131 — 18 149 
Selling, general and administrative— 113 122 
Research and development— — 
Restructuring costs— 339 132 471 
 140 339 264 743 
$140 $454 $339 $933 
Year Ended December 31, 2022    
2019 Restructuring Program
Cost of sales$72 $— $133 $205 
Selling, general and administrative19 — 75 94 
Research and development29 — 30 
Restructuring costs— 212 125 337 
 $120 $212 $334 $666 
Charges and Spending Relating to Restructuring Activities by Program
The following table summarizes the charges and spending relating to restructuring program activities:
Accelerated
Depreciation
Separation
Costs
Other Exit Costs
Total
Restructuring reserves January 1, 2023
$— $479 $34 $513 
Expenses140 454 339 933 
(Payments) receipts, net— (252)(158)(410)
Non-cash activity(140)— (184)(324)
Restructuring reserves December 31, 2023
— 681 31 712 
Expenses254 122 512 888 
(Payments) receipts, net (239)(206)(445)
Non-cash activity(254) (337)(591)
Restructuring reserves December 31, 2024
$ $564 $ $564 
XML 78 R37.htm IDEA: XBRL DOCUMENT v3.25.0.1
Financial Instruments (Tables)
12 Months Ended
Dec. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Effect of Net Investment Hedges
The effects of the Company’s net investment hedges on OCI and the Consolidated Statement of Income are shown below:
Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income (1)
Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing
Years Ended December 31202420232022202420232022
Net Investment Hedging Relationships
Foreign exchange contracts$(30)$— $(48)$(4)$$(1)
Euro-denominated notes(192)105 (162) — — 
(1)    No amounts were reclassified from AOCL into income related to the sale of a subsidiary.
Summary of Interest Rate Derivatives
At December 31, 2024, the Company was a party to six pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of the fixed-rate notes as detailed in the table below.
Par Value of DebtNumber of Interest Rate Swaps HeldTotal Swap Notional Amount
4.50% notes due 2033
$1,500 $1,500 
Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position
The table below presents the location of amounts recorded in the Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges as of December 31:
Carrying Amount of Hedged Liabilities
Cumulative Amount of Fair Value Hedging Adjustment Increase Included in the Carrying Amount
2024202320242023
Balance Sheet Caption
Long-Term Debt $1,509 $1,056 $17 $56 
Fair Value of Derivatives on a Gross Basis Segregated Between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments
Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments as of December 31:
  20242023
  Fair Value of
Derivative
U.S. Dollar
Notional
Fair Value of
Derivative
U.S. Dollar
Notional
 AssetLiabilityAssetLiability
Derivatives Designated as Hedging InstrumentsBalance Sheet Caption      
Interest rate swap contracts
Other Assets
$17 $ $1,500 $57 $— $1,000 
Foreign exchange contractsOther current assets323  8,662 106 — 6,138 
Foreign exchange contractsOther Assets66  2,125 26 — 1,929 
Foreign exchange contractsAccrued and other current liabilities 1 162 — 76 3,680 
Foreign exchange contractsOther Noncurrent Liabilities 1 16 — 
  $406 $2 $12,465 $189 $77 $12,754 
Derivatives Not Designated as Hedging InstrumentsBalance Sheet Caption      
Foreign exchange contractsOther current assets$323 $ $12,544 $153 $— $9,693 
Foreign exchange contractsAccrued and other current liabilities 343 13,551 — 162 8,104 
  $323 $343 $26,095 $153 $162 $17,797 
  $729 $345 $38,560 $342 $239 $30,551 
Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis The following table provides information on the Company’s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes as of December 31:
20242023
AssetLiabilityAssetLiability
Gross amounts recognized in the consolidated balance sheet$729 $345 $342 $239 
Gross amounts subject to offset in master netting arrangements not offset in the consolidated balance sheet(299)(299)(215)(215)
Cash collateral received
(165) (3)— 
Net amounts$265 $46 $124 $24 
Location and Pretax Gain or Loss Amounts for Derivatives
The table below provides information regarding the location and amount of pretax gains and losses of derivatives designated in fair value or cash flow hedging relationships:
Years Ended December 31202420232022202420232022202420232022
Financial Statement Caption in which Effects of Fair Value or Cash Flow Hedges are RecordedSales
Other (income) expense, net (1)
Other comprehensive income (loss)
$64,168 $60,115 $59,283 $(24)$466 $1,501 $216 $(393)$(339)
(Gain) loss on fair value hedging relationships:
Interest rate swap contracts
Hedged items — — (39)56 (13) — — 
Derivatives designated as hedging instruments — — 39 (57) — — 
Impact of cash flow hedging relationships:
Foreign exchange contracts
Amount of gain recognized in OCI on derivatives
 — —  — — 508 114 684 
Increase in Sales as a result of AOCL reclassifications
167 249 773  — — (167)(249)(773)
Interest rate contracts
Amount of gain recognized in Other (income) expense, net on derivatives
 — — (1)(1)(2) — — 
Amount of (loss) gain recognized in OCI on derivatives
 — —  — — (1)13 (2)
(1)    Interest expense is a component of Other (income) expense, net.
Income Statement Effects of Derivatives Not Designated as Hedging Instruments
The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:
Amount of Derivative Pretax Loss (Gain) Recognized in Income
Years Ended December 31202420232022
Derivatives Not Designated as Hedging InstrumentsIncome Statement Caption
Foreign exchange contracts (1)
Other (income) expense, net$251 $(6)$(49)
Foreign exchange contracts (2)
Sales(28)(37)
(1)    These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates.
(2)     These derivative contracts serve as economic hedges of forecasted transactions.
Information on Investments in Debt and Equity Securities
Information on investments in debt and equity securities at December 31 is as follows:
 
 20242023
 Amortized
Cost
Gross UnrealizedFair
Value
Amortized
Cost
Gross UnrealizedFair
Value
GainsLossesGainsLosses
Commercial paper$348 $ $ $348 $252 $— $— $252 
U.S. government and agency securities188   188 72— — 72 
Corporate notes and bonds    13 — — 13 
Total debt securities$536 $ $ $536 $337 $— $— $337 
Publicly traded equity securities (1)
920 764 
Total debt and publicly traded equity securities$1,456 $1,101 
(1)    Unrealized net losses of $30 million were recorded in Other (income) expense, net in 2024 on equity securities still held at December 31, 2024. Unrealized net gains of $411 million were recorded in Other (income) expense, net in 2023 on equity securities still held at December 31, 2023.
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
Financial assets and liabilities measured at fair value on a recurring basis at December 31 are summarized below:
 Fair Value Measurements UsingFair Value Measurements Using
Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
  20242023
Assets
Investments
Commercial paper$ $348 $ $348 $— $252 $— $252 
U.S. government and agency securities 99  99 — — — — 
Publicly traded equity securities463   463 252 — — 252 
 463 447  910 252 252 — 504 
Other assets (1)
U.S. government and agency securities89   89 72 — — 72 
Corporate notes and bonds    13 — — 13 
Publicly traded equity securities (2)
457   457 512 — — 512 
546   546 597 — — 597 
Derivative assets (3)
Forward exchange contracts 499  499 — 202 — 202 
Purchased currency options 213  213 — 83 — 83 
Interest rate swaps 17  17 — 57 — 57 
  729  729 — 342 — 342 
Total assets$1,009 $1,176 $ $2,185 $849 $594 $— $1,443 
Liabilities
Other liabilities
Contingent consideration$ $ $193 $193 $— $— $354 $354 
Derivative liabilities (3)
Forward exchange contracts 338  338 — 239 — 239 
Written currency options 7  7 — — — — 
 345  345 — 239 — 239 
Total liabilities$ $345 $193 $538 $— $239 $354 $593 
(1)    Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.
(2)    Balance at December 31, 2024 includes securities with a fair value of $81 million, which are subject to a contractual sale restriction that expires in March 2025. Balance at December 31, 2023 includes securities with a fair value of $177 million, which were subject to a contractual sale restriction that expired in July 2024.
(3)    The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company’s own credit risk, the effects of which were not significant.
Summarized Information about the Changes in Liabilities for Contingent Consideration
Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:
20242023
Fair value January 1$354 $456 
Changes in estimated fair value (1)
(10)15 
Payments(151)(117)
Fair value December 31 (2)
$193 $354 
(1)    Recorded in Cost of sales, Research and development expenses, and Other (income) expense, net. Includes cumulative translation adjustments.
(2)    Balance at December 31, 2024 includes $148 million of current liabilities, of which $123 million relates to the termination of the Sanofi Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate to present value the cash flows.
XML 79 R38.htm IDEA: XBRL DOCUMENT v3.25.0.1
Inventories (Tables)
12 Months Ended
Dec. 31, 2024
Inventory Disclosure [Abstract]  
Inventories
Inventories at December 31 consisted of:
20242023
Finished goods$2,022 $1,954 
Raw materials and work in process8,831 8,037 
Supplies289 277 

11,142 10,268 
Decrease to LIFO cost(840)(562)
 $10,302 $9,706 
Recognized as:
Inventories$6,109 $6,358 
Other Assets4,193 3,348 
Inventories
Inventories at December 31 consisted of:
20242023
Finished goods$2,022 $1,954 
Raw materials and work in process8,831 8,037 
Supplies289 277 

11,142 10,268 
Decrease to LIFO cost(840)(562)
 $10,302 $9,706 
Recognized as:
Inventories$6,109 $6,358 
Other Assets4,193 3,348 
XML 80 R39.htm IDEA: XBRL DOCUMENT v3.25.0.1
Goodwill and Other Intangibles (Tables)
12 Months Ended
Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill Activity by Segment
The following table summarizes goodwill activity by segment:
PharmaceuticalAnimal HealthTotal
Balance January 1, 2023
$17,936 $3,268 $21,204 
Other (1)
(14)(7)
Balance December 31, 2023 (2)
17,922 3,275 21,197 
Acquisitions
 518 518 
Other (1)
(19)(28)(47)
Balance December 31, 2024 (2)
$17,903 $3,765 $21,668 
(1)    Includes cumulative translation adjustments on goodwill balances.
(2)    Accumulated goodwill impairment losses were $531 million at both December 31, 2024 and 2023.
Other Intangibles
Other acquired intangibles at December 31 consisted of:
 20242023
Gross
Carrying
Amount
Accumulated
Amortization
NetGross
Carrying
Amount
Accumulated
Amortization
Net
Product rights
$29,988 $19,066 $10,922 $23,643 $17,765 $5,878 
IPR&D430  430 6,816 — 6,816 
Trade names2,881 954 1,927 2,881 776 2,105 
Licenses and other8,863 5,772 3,091 8,263 5,051 3,212 
 $42,162 $25,792 $16,370 $41,603 $23,592 $18,011 
XML 81 R40.htm IDEA: XBRL DOCUMENT v3.25.0.1
Loans Payable, Long-Term Debt and Leases (Tables)
12 Months Ended
Dec. 31, 2024
Debt Disclosure [Abstract]  
Schedule of Long-term Debt Instruments
Long-term debt at December 31 consisted of:
20242023
2.15% notes due 2031
$1,989 $1,988 
2.75% notes due 2051
1,980 1,980 
3.70% notes due 2045
1,980 1,979 
3.40% notes due 2029
1,742 1,740 
4.50% notes due 2033
1,509 1,547 
1.70% notes due 2027
1,497 1,495 
2.90% notes due 2061
1,484 1,484 
5.00% notes due 2053
1,482 1,481 
4.00% notes due 2049
1,474 1,473 
4.15% notes due 2043
1,240 1,240 
1.45% notes due 2030
1,240 1,238 
2.45% notes due 2050
1,216 1,214 
1.875% euro-denominated notes due 2026
1,041 1,103 
0.75% notes due 2026
998 996 
1.90% notes due 2028
996 995 
5.15% notes due 2063
987 987 
3.90% notes due 2039
987 986 
2.35% notes due 2040
986 985 
3.25% euro-denominated notes due 2032
880 — 
3.50% euro-denominated notes due 2037
877 — 
3.70% euro-denominated notes due 2044
876 — 
3.75% euro-denominated notes due 2054
873 — 
4.30% notes due 2030
746 745 
4.90% notes due 2044
740 740 
6.50% notes due 2033
702 707 
1.375% euro-denominated notes due 2036
517 548 
2.50% euro-denominated notes due 2034
517 548 
4.05% notes due 2028
498 497 
3.60% notes due 2042
492 492 
6.55% notes due 2037
404 406 
5.75% notes due 2036
339 339 
5.95% debentures due 2028
307 307 
5.85% notes due 2039
271 271 
6.40% debentures due 2028
251 250 
6.30% debentures due 2026
135 135 
2.75% notes due 2025
 2,498 
Other209 289 
$34,462 $33,683 
Supplemental Balance Sheet Information
Supplemental balance sheet information related to operating leases is as follows:
December 3120242023
Assets
Other Assets (1)
$1,370 $1,437 
Liabilities
Accrued and other current liabilities282 285 
Other Noncurrent Liabilities877 928 
$1,159 $1,213 
Weighted-average remaining lease term (years)6.07.0
Weighted-average discount rate3.2 %3.3 %
(1)    Includes prepaid leases that have no related lease liability.
Schedule of Maturities of Operating Lease Liabilities
Maturities of operating leases liabilities are as follows:
2025$329 
2026292 
2027235 
2028146 
2029116 
Thereafter403 
Total lease payments1,521 
Less: Imputed interest362 
$1,159 
XML 82 R41.htm IDEA: XBRL DOCUMENT v3.25.0.1
Equity (Tables)
12 Months Ended
Dec. 31, 2024
Equity [Abstract]  
Summary of Common Stock and Treasury Stock Transactions
A summary of common stock and treasury stock transactions (shares in millions) is as follows:
 202420232022
  Common
Stock
Treasury
Stock
Common
Stock
Treasury
Stock
Common
Stock
Treasury
Stock
Balance January 13,577 1,045 3,577 1,039 3,577 1,049 
Purchases of treasury stock 11 — 13 — — 
Issuances (1)
 (7)— (7)— (10)
Balance December 313,577 1,049 3,577 1,045 3,577 1,039 
(1)    Issuances primarily reflect activity under share-based compensation plans.
XML 83 R42.htm IDEA: XBRL DOCUMENT v3.25.0.1
Share-Based Compensation Plans (Tables)
12 Months Ended
Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Assumptions Used to Determine Weighted-Average Fair Value of Options Granted The weighted average fair value of options granted in 2024, 2023 and 2022 was $25.60, $21.69 and $15.45 per option, respectively, and were determined using the following assumptions:
Years Ended December 31202420232022
Expected dividend yield3.0 %3.1 %3.1 %
Risk-free interest rate4.7 %3.4 %3.0 %
Expected volatility20.5 %22.4 %22.5 %
Expected life (years)5.85.85.9
Summarized Information Relative to Stock Option Plan Activity
Summarized information relative to stock option plan activity (options in thousands) is as follows:
Number
of Options
Weighted
Average
Exercise
Price
Weighted
Average
Remaining
Contractual
Term (Years)
Aggregate
Intrinsic
Value
Outstanding January 1, 2024
13,527 $77.54 
Granted1,753 129.22 
Exercised(2,581)68.90 
Forfeited(199)111.48   
Outstanding December 31, 2024
12,500 $86.04 5.9$249 
Vested and expected to vest December 31, 202412,201 $85.10 5.9$249 
Exercisable December 31, 20249,084 $74.00 4.9$241 
Additional Information Pertaining to Stock Option Plans
Additional information pertaining to stock option plans is provided in the table below:
Years Ended December 31202420232022
Total intrinsic value of stock options exercised$144 $95 $225 
Fair value of stock options vested32 30 30 
Cash received from the exercise of stock options177 125 384 
Summary of Nonvested RSU and PSU Activity
A summary of nonvested RSU and PSU activity (shares in thousands) is as follows:
 RSUsPSUs
  Number
of Shares
Weighted
Average
Grant Date
Fair Value
Number
of Shares
Weighted
Average
Grant Date
Fair Value
Nonvested January 1, 2024
12,542 $100.10 1,966 $90.80 
Granted6,356 128.79 968 121.91 
Vested(6,091)92.97 (1,109)73.50 
Forfeited(575)113.18 (59)121.12 
Nonvested December 31, 202412,232 $117.94 1,766 $117.57 
Expected to vest December 31, 202410,976 $117.25 1,669 $116.26 
XML 84 R43.htm IDEA: XBRL DOCUMENT v3.25.0.1
Pension and Other Postretirement Benefit Plans (Tables)
12 Months Ended
Dec. 31, 2024
Retirement Benefits [Abstract]  
Components of Net Periodic Benefit Cost
The net periodic benefit cost (credit) for pension and other postretirement benefit plans consisted of the following components:
Pension Benefits
U.S.InternationalOther Postretirement Benefits
Years Ended December 31202420232022202420232022202420232022
Service cost$373 $326 $372 $243 $196 $283 $30 $32 $48 
Interest cost537 526 457 294 299 145 56 63 46 
Expected return on plan assets(826)(735)(753)(554)(517)(383)(80)(64)(86)
Amortization of unrecognized prior service (credit) cost
 (1)(32)(13)(14)(43)(49)(57)
Net loss (gain) amortization43 — 128 5 (3)96 (51)(42)(43)
Termination benefits5 1 — 4 — — 
Curtailments 12  (1)—  (1)(1)
Settlements 28 239 (1)(5) — — 
Net periodic benefit cost (credit)$132 $155 $425 $(25)$(29)$129 $(84)$(61)$(93)
Obligation and Funded Status
Summarized information about the changes in plan assets and benefit obligations, the funded status and the amounts recorded at December 31 is as follows:

Pension BenefitsOther
Postretirement
Benefits
U.S.International
202420232024202320242023
Fair value of plan assets January 1$9,804 $9,094 $9,562 $8,473 $1,045 $947 
Actual return on plan assets266 1,077 637 832 35 115 
Company contributions262 307 198 249 46 74 
Effects of exchange rate changes — (522)283  — 
Benefits paid(615)(497)(250)(256)(89)(95)
Settlements (177)(14)(53) (2)
Other — 36 34 3 
Fair value of plan assets December 31$9,717 $9,804 $9,647 $9,562 $1,040 $1,045 
Benefit obligation January 1$10,446 $9,854 $9,042 $7,755 $1,104 $1,157 
Service cost373 326 243 196 30 32 
Interest cost537 526 294 299 56 63 
Actuarial (gains) losses (1)
(595)403 (549)766 32 (58)
Benefits paid(615)(497)(250)(256)(89)(95)
Effects of exchange rate changes — (473)288 (4)
Plan amendments — (56)14  — 
Curtailments  (1) — 
Termination benefits5 1 — 4 — 
Settlements (177)(14)(53) (2)
Other — 36 34 3 
Benefit obligation December 31$10,151 $10,446 $8,274 $9,042 $1,136 $1,104 
Funded status December 31$(434)$(642)$1,373 $520 $(96)$(59)
Recognized as:
Other Assets$26 $— $1,785 $1,019 $51 $107 
Accrued and other current liabilities(55)(49)(18)(19)(7)(8)
Other Noncurrent Liabilities(405)(593)(394)(480)(140)(158)
(1)    Actuarial (gains) losses primarily reflect changes in discount rates.
Funded Status of Selected Pension Plans
Information related to the funded status of selected pension plans at December 31 is as follows:
U.S.International
2024202320242023
Pension plans with a projected benefit obligation in excess of plan assets
Projected benefit obligation
$9,517 $10,446 $1,847 $2,961 
Fair value of plan assets9,057 9,804 1,435 2,462 
Pension plans with an accumulated benefit obligation in excess of plan assets
Accumulated benefit obligation$442 $9,700 $1,768 $1,791 
Fair value of plan assets 9,186 1,385 1,336 
Funded Status of Selected Pension Plans
Information related to the funded status of selected pension plans at December 31 is as follows:
U.S.International
2024202320242023
Pension plans with a projected benefit obligation in excess of plan assets
Projected benefit obligation
$9,517 $10,446 $1,847 $2,961 
Fair value of plan assets9,057 9,804 1,435 2,462 
Pension plans with an accumulated benefit obligation in excess of plan assets
Accumulated benefit obligation$442 $9,700 $1,768 $1,791 
Fair value of plan assets 9,186 1,385 1,336 
Schedule of Allocation of Plan Assets
The fair values of the Company’s pension plan assets at December 31 by asset category are as follows:
 Fair Value Measurements UsingFair Value Measurements Using
Level 1Level 2Level 3
NAV (1)
TotalLevel 1Level 2Level 3
NAV (1)
Total
20242023
U.S. Pension Plans
Cash and cash equivalents$43 $ $ $121 $164 $34 $— $— $124 $158 
Investment funds
Developed markets equities170   2,385 2,555 224 — — 2,573 2,797 
Emerging markets equities   1,265 1,265 — — — 740 740 
Real estate   174 174 — — — 113 113 
Equity securities
Developed markets2,171    2,171 2,071 — — — 2,071 
Fixed income securities
Government and agency obligations 2,101   2,101 — 2,307 — — 2,307 
Corporate obligations 1,293   1,293 — 1,485 — — 1,485 
Mortgage and asset-backed securities 21   21 — 21 — — 21 
Other investments (liabilities)
Derivatives(29)   (29)109 — — — 109 
Other  2  2 — — — 
Plan assets at fair value$2,355 $3,415 $2 $3,945 $9,717 $2,438 $3,813 $$3,550 $9,804 
International Pension Plans
Cash and cash equivalents$112 $ $ $11 $123 $98 $— $— $20 $118 
Investment funds
Developed markets equities599 3,537  96 4,232 507 3,257 — 106 3,870 
Government and agency obligations262 2,974  149 3,385 234 3,123 — 166 3,523 
Corporate obligations23 8  149 180 23 — 166 197 
Emerging markets equities54   91 145 44 — — 66 110 
Other fixed income obligations8 7  4 19 — 20 
Real estate   12 12 — — — 10 10 
Equity securities
Developed markets287    287 278 — — — 278 
Fixed income securities
Government and agency obligations 368   368 — 423 — — 423 
Corporate obligations 141   141 — 160 — — 160 
Mortgage and asset-backed securities 54   54 — 61 — — 61 
Other investments
Insurance contracts (2)
 1 698 2 701 — 785 788 
Other     — — — 
Plan assets at fair value$1,345 $7,090 $698 $514 $9,647 $1,197 $7,041 $785 $539 $9,562 
(1)    Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December 31, 2024 and 2023.
(2)    The plans’ Level 3 investments in insurance contracts are generally valued using a crediting rate that approximates market returns and invest in underlying securities whose market values are unobservable and determined using pricing models, discounted cash flow methodologies, or similar techniques.
The fair values of the Company’s other postretirement benefit plan assets at December 31 by asset category are as follows:
 Fair Value Measurements UsingFair Value Measurements Using
Level 1Level 2Level 3
NAV (1)
TotalLevel 1Level 2Level 3
NAV (1)
Total
20242023
Cash and cash equivalents$ $ $ $5 $5 $— $— $— $13 $13 
Investment funds
Developed markets equities3   46 49 24 — — 277 301 
Emerging markets equities   24 24 — — — 80 80 
Real estate   3 3 — — — 12 12 
Equity securities
Developed markets41   41 223 — — — 223 
Fixed income securities
Corporate obligations 598  598 — 157 — — 157 
Government and agency obligations 266  266 — 245 — — 245 
Mortgage and asset-backed securities 54   54 — — — 
Other Investments (liabilities)
Derivatives     12 — — — 12 
Plan assets at fair value$44 $918 $ $78 $1,040 $259 $404 $— $382 $1,045 
(1)    Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December 31, 2024 and 2023.
Summary of Changes in Fair Value of Company's Level 3 Pension Plan Assets
The table below provides a summary of the changes in fair value, including transfers in and/or out, of all financial assets measured at fair value using significant unobservable inputs (Level 3) for the Company’s pension plan assets:
 20242023
Insurance
Contracts
OtherTotalInsurance
Contracts
OtherTotal
U.S. Pension Plans
Balance January 1$ $3 $3 $— $$
Actual return on plan assets:
Relating to assets still held at December 31 (2)(2)— (2)(2)
Relating to assets sold during the year 2 2 — 
Purchases and sales, net (1)(1)— (1)(1)
Balance December 31$ $2 $2 $— $$
International Pension Plans
Balance January 1$785 $ $785 $761 $— $761 
Actual return on plan assets:
Relating to assets still held at December 31(26) (26)77 — 77 
Purchases and sales, net(61) (61)(53)— (53)
Balance December 31$698 $ $698 $785 $— $785 
Summary of Expected Benefit Payments
Expected benefit payments are as follows:
U.S. Pension BenefitsInternational Pension
Benefits
Other
Postretirement
Benefits
2025$771 $291 $86 
2026775 275 87 
2027789 286 89 
2028799 300 91 
2029822 314 96 
2030 — 2034
4,386 1,792 515 
Components of Other Comprehensive Income (Loss) The following amounts were reflected as components of OCI:
 Pension PlansOther Postretirement
Benefit Plans
U.S.International
Years Ended December 31202420232022202420232022202420232022
Net gain (loss) arising during the period
$35 $(69)$(42)$634 $(438)$116 $(78)$110 $— 
Prior service credit (cost) arising during the period
 — — 56 (16)(4) — — 
 $35 $(69)$(42)$690 $(454)$112 $(78)$110 $— 
Net loss (gain) amortization included in benefit cost$43 $— $128 $5 $(3)$96 $(51)$(42)$(43)
Prior service (credit) cost amortization included in benefit cost
 (1)(32)(13)(14)(43)(49)(57)
Settlements and curtailments 36 251 (1)(6) (1)(1)
 $43 $35 $347 $(9)$(7)$83 $(94)$(92)$(101)
Summary of Weighted Average Assumptions Used in Determining Pension Plan and U.S. Pension and Other Postretirement Benefit Plan Information
The Company reassesses its benefit plan assumptions on a regular basis. The weighted average assumptions used in determining U.S. pension and other postretirement benefit plan and international pension plan information are as follows:
 U.S. Pension and Other
Postretirement Benefit Plans
International Pension Plans
December 31202420232022202420232022
Net periodic benefit cost      
Discount rate5.30 %5.50 %3.00 %3.40 %3.90 %1.50 %
Expected rate of return on plan assets7.75 %7.00 %6.70 %5.20 %5.00 %3.70 %
Salary growth rate4.60 %4.60 %4.60 %3.20 %3.20 %2.90 %
Interest crediting rate5.30 %5.30 %5.00 %3.40 %3.30 %3.00 %
Benefit obligation      
Discount rate5.70 %5.30 %5.50 %3.70 %3.40 %3.90 %
Salary growth rate4.80 %4.60 %4.60 %3.10 %3.20 %3.20 %
Interest crediting rate5.40 %5.30 %5.30 %3.50 %3.40 %3.30 %
Summary of Health Care Cost Trend Rate Assumptions for Other Postretirement Benefit Plans
The health care cost trend rate assumptions for other postretirement benefit plans are as follows:
December 3120242023
Health care cost trend rate assumed for next year7.90 %7.80 %
Rate to which the cost trend rate is assumed to decline4.50 %4.50 %
Year that the trend rate reaches the ultimate trend rate20402038
XML 85 R44.htm IDEA: XBRL DOCUMENT v3.25.0.1
Other (Income) Expense, Net (Tables)
12 Months Ended
Dec. 31, 2024
Other Income and Expenses [Abstract]  
Other (Income) Expense, Net
Other (income) expense, net, consisted of:
Years Ended December 31202420232022
Interest income$(415)$(365)$(157)
Interest expense1,271 1,146 962 
Exchange losses227 370 237 
(Income) loss from investments in equity securities, net (1)
(14)(340)1,419 
Net periodic defined benefit plan (credit) cost other than service cost(633)(498)(279)
Other, net(460)153 (681)
 $(24)$466 $1,501 
(1)    Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag.
XML 86 R45.htm IDEA: XBRL DOCUMENT v3.25.0.1
Taxes on Income (Tables)
12 Months Ended
Dec. 31, 2024
Income Tax Disclosure [Abstract]  
Reconciliation Between Effective Tax Rate and U.S. Statutory Rate
A reconciliation between the effective tax rate and the U.S. statutory rate is as follows:
 202420232022
AmountTax RateAmountTax RateAmountTax Rate
U.S. statutory rate applied to income before taxes
$4,186 21.0 %$397 21.0 %$3,453 21.0 %
Differential arising from:
Foreign earnings(1,301)(6.5)(941)(49.8)(1,821)(11.1)
Tax settlements and statute lapses
(557)(2.8)— — (10)(0.1)
R&D tax credit(202)(1.0)(214)(11.3)(117)(0.7)
Inventory donations
(71)(0.4)(65)(3.5)(52)(0.3)
State taxes(39)(0.2)(117)(6.2)(110)(0.7)
Charges for certain research and development asset acquisitions
554 2.8 253 13.4 — — 
Valuation allowances54 0.3 70 3.7 108 0.7 
Restructuring52 0.3 41 2.2 11 0.1 
GILTI and the foreign-derived intangible income deduction29 0.1 (80)(4.3)462 2.8 
Acquisition-related costs, including amortization
18 0.1 42 2.2 (3)— 
Acquisition of Prometheus
  2,139 113.3 — — 
Other80 0.4 (13)(0.7)(3)— 
 $2,803 14.1 %$1,512 80.0 %$1,918 11.7 %
Where applicable, the impact of changes in uncertain tax positions is reflected in the reconciling items above.
Income Before Taxes
Income before taxes consisted of:
Years Ended December 31202420232022
Domestic$(1,849)$(15,622)$1,011 
Foreign21,785 17,511 15,433 
 $19,936 $1,889 $16,444 
Taxes on Income
Taxes on income consisted of:
Years Ended December 31202420232022
Current provision
Federal$944 $928 $2,265 
Foreign3,123 2,435 1,164 
State(15)48 57 
 4,052 3,411 3,486 
Deferred provision
Federal(1,475)(1,559)(1,510)
Foreign212 (233)71 
State14 (107)(129)
 (1,249)(1,899)(1,568)
 $2,803 $1,512 $1,918 
Deferred Income Taxes
Deferred income taxes at December 31 consisted of:
 20242023
AssetsLiabilitiesAssetsLiabilities
Product intangibles and licenses$71 $978 $— $1,308 
R&D capitalization3,062  2,099 — 
Inventory related84 413 86 370 
Accelerated depreciation 645 — 626 
Undistributed foreign earnings
275 371 76 118 
Equity investments 90 — 73 
Pensions and other postretirement benefits224 400 323 249 
Compensation related400  357 — 
Unrecognized tax benefits152  147 — 
Net operating losses and other tax credit carryforwards910  868 — 
Other802 159 755 214 
Subtotal5,980 3,056 4,711 2,958 
Valuation allowance(710) (656) 
Total deferred taxes$5,270 $3,056 $4,055 $2,958 
Net deferred income taxes$2,214 $1,097 
Recognized as:
Other Assets$3,601 $1,968 
Deferred Income Taxes $1,387  $871 
Income Taxes Paid
Income taxes paid in 2024, 2023 and 2022 consisted of:
Years Ended December 31202420232022
Domestic (1)
$974 $2,258 $1,891 
Foreign2,954 2,080 1,348 
 $3,928 $4,338 $3,239 
(1)    Includes TCJA transition tax payments.
Unrecognized Tax Benefits
A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:
202420232022
Balance January 1$2,384 $1,835 $1,529 
Additions related to current year positions421 553 344 
Additions related to prior year positions35 91 48 
Reductions for tax positions of prior years
(33)(20)(40)
Settlements
(18)(23)(6)
Lapse of statute of limitations (1)
(528)(52)(40)
Balance December 31$2,261 $2,384 $1,835 
(1)    Amount in 2024 reflects a reduction of $451 million resulting from the expiration of the statute of limitations related to the 2019 and 2020 federal tax return years.
XML 87 R46.htm IDEA: XBRL DOCUMENT v3.25.0.1
Earnings per Share (Tables)
12 Months Ended
Dec. 31, 2024
Earnings Per Share [Abstract]  
Calculations of Earnings Per Share
The calculations of earnings per share (shares in millions) are as follows:
Years Ended December 31202420232022
Net Income Attributable to Merck & Co., Inc.$17,117 $365 $14,519 
Average common shares outstanding2,532 2,537 2,532 
Common shares issuable (1)
9 10 10 
Average common shares outstanding assuming dilution2,541 2,547 2,542 
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders
$6.76 $0.14 $5.73 
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders
$6.74 $0.14 $5.71 
(1)     Issuable primarily under share-based compensation plans.
XML 88 R47.htm IDEA: XBRL DOCUMENT v3.25.0.1
Other Comprehensive Income (Loss) (Tables)
12 Months Ended
Dec. 31, 2024
Equity [Abstract]  
Changes in AOCI by Component
Changes in each component of other comprehensive income (loss) are as follows:
DerivativesEmployee
Benefit
Plans
 Foreign Currency
Translation
Adjustment
Accumulated Other
Comprehensive Loss
Balance at January 1, 2022, net of taxes
$144 $(2,743)$(1,830)$(4,429)
Other comprehensive income (loss) before reclassification adjustments, pretax684 70 (584)170 
Tax(143)12 (19)(150)
Other comprehensive income (loss) before reclassification adjustments, net of taxes541 82 (603)20 
Reclassification adjustments, pretax(775)
(1)
329 
(2)
— (446)
Tax163 (76)— 87 
Reclassification adjustments, net of taxes(612)253 — (359)
Other comprehensive income (loss), net of taxes(71)335 (603)(339)
Balance at December 31, 2022, net of taxes73 (2,408)(2,433)(4,768)
Other comprehensive income (loss) before reclassification adjustments, pretax114 (413)17 (282)
Tax(24)86 63 125 
Other comprehensive income (loss) before reclassification adjustments, net of taxes90 (327)80 (157)
Reclassification adjustments, pretax(237)
(1)
(64)
(2)
(292)
Tax50 — 56 
Reclassification adjustments, net of taxes(187)(58)(236)
Other comprehensive income (loss), net of taxes(97)(385)89 (393)
Balance at December 31, 2023, net of taxes(24)(2,793)
(3)
(2,344)(5,161)
Other comprehensive income (loss) before reclassification adjustments, pretax508 647 (559)596 
Tax(109)(138)23 (224)
Other comprehensive income (loss) before reclassification adjustments, net of taxes399 509 (536)372 
Reclassification adjustments, pretax(168)
(1)
(60)
(2)
20 (208)
Tax35 17  52 
Reclassification adjustments, net of taxes(133)(43)20 (156)
Other comprehensive income (loss), net of taxes266 466 (516)216 
Balance at December 31, 2024, net of taxes$242 $(2,327)
(3)
$(2,860)$(4,945)
(1)    Primarily relates to foreign currency cash flow hedges that were reclassified from AOCL to Sales (see Note 6).
(2)    Includes net amortization of prior service cost, actuarial gains and losses, settlements and curtailments included in net periodic benefit cost (see Note 13).
(3)    Includes pension plan net loss of $3.0 billion and $3.5 billion at December 31, 2024 and 2023, respectively, and other postretirement benefit plan net gain of $400 million and $500 million at December 31, 2024 and 2023, respectively, as well as pension plan prior service credit of $174 million and $141 million at December 31, 2024 and 2023, respectively, and other postretirement benefit plan prior service credit of $61 million and $95 million at December 31, 2024 and 2023, respectively.
XML 89 R48.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment Reporting (Tables)
12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Sales of Company's Products
Sales of the Company’s products were as follows:
Years Ended December 31202420232022
U.S.Int’lTotalU.S.Int’lTotalU.S.Int’lTotal
Pharmaceutical:
Oncology
Keytruda$17,872 $11,610 $29,482 $15,114 $9,897 $25,011 $12,686 $8,251 $20,937 
Alliance revenue - Lynparza (1)
626 685 1,311 607 592 1,199 584 532 1,116 
Alliance revenue - Lenvima (1)
705 305 1,010 657 303 960 579 297 876 
Welireg466 43 509 209 10 218 123 — 123 
Alliance revenue - Reblozyl (2)
303 68 371 168 43 212 123 43 166 
Vaccines
Gardasil/Gardasil 9
2,425 6,158 8,583 2,083 6,803 8,886 2,065 4,832 6,897 
ProQuad/M-M-R II/Varivax1,919 566 2,485 1,837 531 2,368 1,724 518 2,241 
Vaxneuvance461 347 808 561 103 665 163 170 
RotaTeq472 239 711 493 276 769 508 275 783 
Pneumovax 23
56 207 263 127 285 412 346 256 602 
Hospital Acute Care
Bridion1,401 363 1,764 1,156 686 1,842 922 762 1,685 
Prevymis371 414 785 264 341 605 188 240 428 
Dificid303 37 340 274 28 302 241 22 263 
Zerbaxa146 106 252 119 100 218 89 79 169 
Noxafil7 170 177 32 181 213 51 187 238 
Cardiovascular
Winrevair
408 11 419 — — — — — — 
Alliance revenue - Adempas/Verquvo (3)
388 27 415 350 16 367 329 12 341 
Adempas 287 287 — 255 255 — 238 238 
Virology
Lagevrio176 787 964 10 1,418 1,428 1,523 4,161 5,684 
Isentress/Isentress HD185 209 394 215 268 483 274 359 633 
Delstrigo
56 193 249 49 152 201 39 111 151 
Pifeltro
113 50 163 101 41 142 87 30 118 
Neuroscience
Belsomra72 150 222 81 150 231 79 179 258 
Immunology
Simponi 543 543 — 710 710 — 706 706 
Remicade 114 114 — 187 187 — 207 207 
Diabetes
Januvia469 865 1,334 1,151 1,039 2,189 1,248 1,565 2,813 
Janumet161 774 935 223 954 1,177 355 1,344 1,700 
Other pharmaceutical (4)
729 1,782 2,510 658 1,675 2,333 663 1,803 2,462 
Total Pharmaceutical segment sales30,290 27,110 57,400 26,539 27,044 53,583 24,989 27,016 52,005 
Animal Health:
Livestock732 2,729 3,462 700 2,637 3,337 710 2,590 3,300 
Companion Animal1,129 1,287 2,415 1,104 1,184 2,288 1,112 1,138 2,250 
Total Animal Health segment sales1,861 4,016 5,877 1,804 3,821 5,625 1,822 3,728 5,550 
Total segment sales32,151 31,126 63,277 28,343 30,865 59,208 26,811 30,744 57,555 
Other (5)
126 765 891 137 770 907 395 1,333 1,728 
 $32,277 $31,891 $64,168 $28,480 $31,635 $60,115 $27,206 $32,077 $59,283 
U.S. plus international may not equal total due to rounding.
(1)    Alliance revenue for Lynparza and Lenvima represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 4).
(2)    Alliance revenue for Reblozyl represents royalties and, for 2022, also includes a payment received related to the achievement of a regulatory approval milestone (see Note 4).
(3)    Alliance revenue for Adempas/Verquvo represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 4).
(4)    Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.
(5)    Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities which increased sales by $195 million, $244 million and $810 million in 2024, 2023 and 2022, respectively, as well as revenue from third-party manufacturing arrangements (including sales to Organon). Other for 2024, 2023 and 2022 also includes $106 million, $118 million and $165 million, respectively, related to upfront and milestone payments received by Merck for out-licensing arrangements.
Consolidated Revenues by Geographic Area
Consolidated sales by geographic area where derived are as follows:
Years Ended December 31202420232022
United States$32,277 $28,480 $27,206 
Europe, Middle East and Africa14,041 13,254 14,493 
China5,494 6,802 5,191 
Latin America3,459 3,086 2,582 
Japan3,280 3,164 3,629 
Asia Pacific (other than China and Japan)3,058 3,225 3,614 
Other2,559 2,104 2,568 
 $64,168 $60,115 $59,283 
Reconciliation of Segment Profits to Income Before Taxes
A reconciliation of segment profits to Income Before Taxes is as follows:
Years Ended December 31202420232022
Pharma-ceutical
Animal Health
Total
Pharma-ceutical
Animal Health
Total
Pharma-ceutical
Animal Health
Total
Segment sales
$57,400 $5,877 $63,277 $53,583 $5,625 $59,208 $52,005 $5,550 $57,555 
Less segment costs: (1)
Cost of sales
6,828 2,469 8,849 2,498 9,678 2,259 
Selling, general and administrative
6,128 1,084 5,903 1,038 5,474 999 
Research and development (2)
 385 — 353 — 329 
Other segment items (3)
(89)1 (49)(1)— 
Total segment profits44,533 1,938 46,471 38,880 1,737 40,617 36,852 1,963 38,815 
Other profits492 474 1,160 
Unallocated:
Interest income415 365 157 
Interest expense(1,271)(1,146)(962)
Amortization(2,395)(2,044)(2,085)
Depreciation(1,843)(1,625)(1,642)
Research and development(17,350)(30,008)(13,011)
Restructuring costs(309)(599)(337)
Charge for Zetia antitrust litigation settlements (573)— 
Other unallocated, net(4,274)(3,572)(5,651)
$19,936 $1,889 $16,444 
(1)    The significant expense categories and amounts align with the segment level information that is regularly provided to the chief operating decision maker.
(2)    Human health-related research and development expenses incurred by Merck Research Laboratories are not allocated to segment profits as noted below.
(3)    Includes equity (income) loss from affiliates and other miscellaneous non-operating expenses.
Equity Loss from Affiliates and Depreciation Included in Segment Profits
Equity income from affiliates and depreciation included in segment profits is as follows:
PharmaceuticalAnimal HealthTotal
Year Ended December 31, 2024
Equity income from affiliates$144 $ $144 
Depreciation5 256 261 
Year Ended December 31, 2023
Equity income from affiliates$111 $— $111 
Depreciation198 203 
Year Ended December 31, 2022
Equity income from affiliates
$39 $— $39 
Depreciation177 182 
Property, Plant and Equipment, Net by Geographic Area
Property, plant and equipment, net, by geographic area where located is as follows:
December 31202420232022
United States$14,724 $13,915 $12,891 
Europe, Middle East and Africa7,548 7,562 6,993 
Asia Pacific (other than China and Japan)982 1,022 966 
China202 193 207 
Japan143 133 135 
Latin America133 222 225 
Other47 
 $23,779 $23,051 $21,422 
XML 90 R49.htm IDEA: XBRL DOCUMENT v3.25.0.1
Nature of Operations (Details)
12 Months Ended
Dec. 31, 2024
segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Number of operating segments 2
XML 91 R50.htm IDEA: XBRL DOCUMENT v3.25.0.1
Summary of Accounting Policies (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Intangible Assets Excluding Goodwill [Line Items]      
Customer discounts $ 13,300 $ 12,500 $ 12,300
Accrual for chargebacks reflected as direct reduction to accounts receivable 293 188  
Accrual for rebates included in accrued and other current liabilities $ 2,200 2,300  
Product return period and expiration 12 months    
Depreciation $ 2,104 1,828 1,824
Advertising and promotion costs $ 2,400 $ 2,300 $ 2,200
Minimum      
Intangible Assets Excluding Goodwill [Line Items]      
Product return period 3 months    
Estimated useful life of intangible assets 2 years    
Minimum | Capitalized Software      
Intangible Assets Excluding Goodwill [Line Items]      
Estimated useful life of intangible assets 2 years    
Minimum | Buildings      
Intangible Assets Excluding Goodwill [Line Items]      
Estimated useful life of property, plant and equipment 25 years    
Minimum | Machinery, equipment and office furnishings      
Intangible Assets Excluding Goodwill [Line Items]      
Estimated useful life of property, plant and equipment 3 years    
Minimum | United States      
Intangible Assets Excluding Goodwill [Line Items]      
Payment terms, vaccine sales 30 days    
Minimum | United States | Pharmaceutical      
Intangible Assets Excluding Goodwill [Line Items]      
Payment terms 36 days    
Minimum | United States | Animal Health      
Intangible Assets Excluding Goodwill [Line Items]      
Payment terms 30 days    
Minimum | Outside of the United States      
Intangible Assets Excluding Goodwill [Line Items]      
Payment terms 30 days    
Maximum      
Intangible Assets Excluding Goodwill [Line Items]      
Product return period 6 months    
Estimated useful life of intangible assets 24 years    
Maximum | Capitalized Software      
Intangible Assets Excluding Goodwill [Line Items]      
Estimated useful life of intangible assets 10 years    
Maximum | Buildings      
Intangible Assets Excluding Goodwill [Line Items]      
Estimated useful life of property, plant and equipment 45 years    
Maximum | Machinery, equipment and office furnishings      
Intangible Assets Excluding Goodwill [Line Items]      
Estimated useful life of property, plant and equipment 15 years    
Maximum | United States      
Intangible Assets Excluding Goodwill [Line Items]      
Payment terms 90 days    
Payment terms, vaccine sales 60 days    
Maximum | Outside of the United States      
Intangible Assets Excluding Goodwill [Line Items]      
Payment terms 90 days    
XML 92 R51.htm IDEA: XBRL DOCUMENT v3.25.0.1
Acquisitions, Divestitures, Research Collaborations and Licensing Agreements - Narrative (Details)
$ in Millions
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 02, 2021
Dec. 31, 2024
USD ($)
jurisdiction
Sep. 30, 2024
USD ($)
Jul. 31, 2024
USD ($)
candidate
aqua_facility
Mar. 31, 2024
USD ($)
Jun. 30, 2023
USD ($)
Jan. 31, 2023
USD ($)
Oct. 31, 2022
USD ($)
Aug. 31, 2022
USD ($)
Jul. 31, 2022
USD ($)
May 31, 2022
USD ($)
Mar. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
jurisdiction
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
jurisdiction
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Apr. 30, 2024
candidate
Oct. 31, 2023
USD ($)
antibodyDrugConjugate
candidate
Feb. 28, 2023
USD ($)
candidate
Business Acquisition [Line Items]                                        
Research and development                             $ 17,938 $ 30,531 $ 13,548      
Sales                             64,168 60,115 59,283      
Cost of sales                             15,193 16,126 17,411      
Other current assets   $ 8,706                     $ 8,706   8,706 8,368        
Accrued and other current liabilities   15,694                     15,694   15,694 15,766        
Forecast | Subsequent Event                                        
Business Acquisition [Line Items]                                        
Contingent consideration                       $ 440                
Royalty Pharma                                        
Business Acquisition [Line Items]                                        
Compensation earned on arragement               $ 50                        
Related Party                                        
Business Acquisition [Line Items]                                        
Other current assets   330                     330   330 632        
Accrued and other current liabilities   $ 113                     $ 113   113 598        
Manufacturing and supply agreements | Related Party                                        
Business Acquisition [Line Items]                                        
Sales                             392 394 383      
Cost of sales                             $ 390 422 404      
Minimum | Manufacturing and supply agreements | Related Party                                        
Business Acquisition [Line Items]                                        
Period of continuing involvement after disposal 4 years                                      
Maximum | Manufacturing and supply agreements | Related Party                                        
Business Acquisition [Line Items]                                        
Period of continuing involvement after disposal 10 years                                      
Discontinued Operations, Disposed of by Means Other than Sale, Spinoff | Organon & Co.                                        
Business Acquisition [Line Items]                                        
Number of jurisdictions under interim operating agreement | jurisdiction   1                     1   1          
Orion                                        
Business Acquisition [Line Items]                                        
Eligible future contingent development-related payments (up to)       $ 30                                
Aggregate, regulatory milestones payments, maximum       625                                
Sales milestone payments       $ 975                                
Orion | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement                                        
Business Acquisition [Line Items]                                        
Upfront payment made to collaborative partner                   $ 290                    
Daiichi Sankyo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement                                        
Business Acquisition [Line Items]                                        
Research and development                             $ 351 5,549        
Number of antibody drug conjugates obtained right and obligations | antibodyDrugConjugate                                     3  
Accrued and other current liabilities   $ 817                     $ 817   817 800        
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement                                        
Business Acquisition [Line Items]                                        
Eligible future contingent development-related payments (up to)                                     $ 540  
Aggregate, regulatory milestones payments, maximum                                     1,500  
Sales milestone payments                     $ 780               $ 3,100  
Number of antibody drug conjugates | candidate                                       7
Upfront payment made to collaborative partner                                       $ 175
Number of antibody drug conjugates terminated | candidate                                   1 2  
Number of exercised license option antibody drug conjugates | candidate       1                                
Number of licensed antibody drug conjugates | candidate       3                                
Number of unexercised license option antibody drug conjugates | candidate       1                                
Payment resulting from the license option exercise       $ 38                                
Stock investment in counterparty             $ 100                          
Option payment made to collaborative partner                     30                  
Milestone payment to be made to a collaborative partner                               25        
Contingent developmental milestone payments                             90          
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | First Commercial Sale Milestones                                        
Business Acquisition [Line Items]                                        
Sales milestone payments                     $ 290                  
Orna Therapeutics | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement                                        
Business Acquisition [Line Items]                                        
Eligible future contingent development-related payments (up to)                 $ 440                      
Aggregate, regulatory milestones payments, maximum                 675                      
Sales milestone payments                 2,400                      
Preferred stock investment in counterparty                                 $ 100      
Upfront payment made to collaborative partner                 $ 150                      
Elanco Animal Health Incorporated Aqua Business                                        
Business Acquisition [Line Items]                                        
Cash paid for acquisition of business       $ 1,300                                
Aqua manufacturing facilities | aqua_facility       2                                
LM-299, LaNova Medicines Ltd                                        
Business Acquisition [Line Items]                                        
Consideration transferred, asset acquisition   588                                    
Maximum aggregate sales-based milestone payments   1,400                     1,400   1,400          
Future contingent developmental milestone payments (up to)   140                     140   140          
Future regulatory milestone payments (up to)   860                     860   860          
LM-299, LaNova Medicines Ltd | Forecast                                        
Business Acquisition [Line Items]                                        
Contingent consideration dependent upon technology transfer                           $ 300            
CN201, Curon Biopharmaceutical                                        
Business Acquisition [Line Items]                                        
Consideration transferred, asset acquisition     $ 700                                  
Future contingent developmental milestone payments (up to)     300                                  
Future regulatory milestone payments (up to)     300                                  
Research and development                             750          
CN201, Curon Biopharmaceutical | Third-Party                                        
Business Acquisition [Line Items]                                        
Aggregate contingent developmental, regulatory, and sales-based-related payments     $ 128                                  
Eyebiotech Limited                                        
Business Acquisition [Line Items]                                        
Consideration transferred, asset acquisition       $ 1,200                                
Maximum aggregate sales-based milestone payments       500                                
Future contingent developmental milestone payments (up to)       200                                
Future regulatory milestone payments (up to)       1,000                                
Research and development                             1,350          
Transaction costs       207                                
Developmental milestone payment triggered and paid                         100              
Net assets acquired       $ 21                                
Harpoon Therapeutics, Inc.                                        
Business Acquisition [Line Items]                                        
Consideration transferred, asset acquisition         $ 765                              
Research and development                             656          
Transaction costs         56                              
Net assets acquired         $ 165                              
Prometheus Biosciences, Inc.                                        
Business Acquisition [Line Items]                                        
Consideration transferred, asset acquisition           $ 11,000                            
Research and development                               10,200        
Net assets acquired           877                            
Consideration transferred, to settle share-based equity awards           1,200                            
Consideration transferred, to settle equity awards, unvested           700                            
Cash recorded for asset acquisition           368                            
Investments recorded for asset acquisition           296                            
Deferred tax assets recorded for asset acquisition           218                            
Other net liabilities recorded for asset acquisition           $ 5                            
Imago BioSciences, Inc.                                        
Business Acquisition [Line Items]                                        
Consideration transferred, asset acquisition             1,350                          
Research and development                               $ 1,200        
Transaction costs             60                          
Net assets acquired             $ 219                          
HS-10535 Hansoh Pharma                                        
Business Acquisition [Line Items]                                        
Consideration transferred, asset acquisition   112                                    
Maximum aggregate sales-based milestone payments   1,470                     1,470   1,470          
Future contingent developmental milestone payments (up to)   115                     115   115          
Future regulatory milestone payments (up to)   $ 315                     $ 315   $ 315          
XML 93 R52.htm IDEA: XBRL DOCUMENT v3.25.0.1
Acquisitions, Divestitures, Research Collaborations and Licensing Agreements - Estimated Fair Value of Assets Acquired and Liabilities Assumed (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Jul. 09, 2024
Dec. 31, 2023
Dec. 31, 2022
Business Acquisition [Line Items]        
Goodwill $ 21,668   $ 21,197 $ 21,204
Elanco Animal Health Incorporated Aqua Business        
Business Acquisition [Line Items]        
Inventories   $ 65    
Property, plant and equipment   66    
Other assets and liabilities, net   23    
Total identifiable net assets   785    
Goodwill   518    
Consideration transferred   $ 1,303    
Discount rate   8.50%    
Elanco Animal Health Incorporated Aqua Business | Product Rights - Clynay        
Business Acquisition [Line Items]        
Product rights and other   $ 340    
Estimated useful life of intangible assets   15 years    
Elanco Animal Health Incorporated Aqua Business | Other Product Rights        
Business Acquisition [Line Items]        
Product rights and other   $ 291    
Estimated useful life of intangible assets   15 years    
XML 94 R53.htm IDEA: XBRL DOCUMENT v3.25.0.1
Collaborative Arrangements - AstraZeneca PLC - Narrative (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Amortization expense for intangible assets $ 2,400 $ 2,000 $ 2,100
Licenses and other      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Intangible assets 3,091 3,212  
Koselugo | Licenses and other      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Intangible assets 49    
Lynparza | Licenses and other      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Intangible assets 1,200    
AstraZeneca      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Amortization expense for intangible assets 48   250
AstraZeneca | Koselugo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Probable contingent payments 100    
Liabilities 100    
AstraZeneca | Lynparza | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Milestone payments sales-based     400
Probable contingent payments     600
Liabilities     600
Sales milestone payments 2,000    
Regulatory milestone payments $ 245 $ 105 $ 250
XML 95 R54.htm IDEA: XBRL DOCUMENT v3.25.0.1
Collaborative Arrangements - AstraZeneca PLC (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Collaborative Arrangement, Revenue Not from Contract with Customer, Statement of Income or Comprehensive Income [Extensible Enumeration] Sales Sales Sales
Cost of sales $ 15,193 $ 16,126 $ 17,411
Selling, general and administrative 10,816 10,504 10,042
Research and development 17,938 30,531 13,548
Other current assets 38,782 32,168  
Accrued and other current liabilities 15,694 15,766  
AstraZeneca | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenue from collaborative arrangement 1,481 1,296 1,170
Cost of sales 378 311 492
Selling, general and administrative 165 192 185
Research and development 77 79 106
Other current assets 424 341  
Accrued and other current liabilities 713 256  
Other Noncurrent Liabilities 0 600  
AstraZeneca | Alliance revenue - Lynparza | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenue from collaborative arrangement 1,311 1,199 1,116
AstraZeneca | Alliance revenue - Koselugo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenue from collaborative arrangement $ 170 $ 97 $ 54
XML 96 R55.htm IDEA: XBRL DOCUMENT v3.25.0.1
Collaborative Arrangements - Eisai Co., Ltd. - Narrative (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Amortization expense for intangible assets $ 2,400 $ 2,000 $ 2,100
Licenses and other      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Intangible assets 3,091 3,212  
Alliance revenue - Lenvima | Licenses and other      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Intangible assets 442    
Eisai      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Amortization expense for intangible assets   154  
Eisai | Alliance revenue - Lenvima | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Milestone payments sales-based 125 125 600
Probable contingent payments   250  
Liabilities   $ 250  
Sales milestone payments $ 2,300    
Regulatory milestone payments     50
Bayer AG | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Milestone payments sales-based     $ 400
XML 97 R56.htm IDEA: XBRL DOCUMENT v3.25.0.1
Collaborative Arrangements - Eisai Co., Ltd. (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Cost of sales $ 15,193 $ 16,126 $ 17,411
Selling, general and administrative 10,816 10,504 10,042
Research and development 17,938 30,531 13,548
Other current assets 38,782 32,168  
Accrued and other current liabilities 15,694 15,766  
Amortization expense for intangible assets 2,400 2,000 2,100
Eisai      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Amortization expense for intangible assets   154  
Eisai | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenue from collaborative arrangement 1,010 960 876
Cost of sales 241 381 212
Selling, general and administrative 159 189 158
Research and development 21 66 $ 136
Other current assets 257 226  
Accrued and other current liabilities $ 0 $ 125  
XML 98 R57.htm IDEA: XBRL DOCUMENT v3.25.0.1
Collaborative Arrangements - Bayer AG (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Sales $ 64,168 $ 60,115 $ 59,283
Cost of sales 15,193 16,126 17,411
Selling, general and administrative 10,816 10,504 10,042
Research and development 17,938 30,531 13,548
Other current assets 38,782 32,168  
Accrued and other current liabilities 15,694 15,766  
Bayer AG | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Milestone payments sales-based     400
Revenue from collaborative arrangement 415 367 341
Sales 739 658 601
Cost of sales 244 224 210
Selling, general and administrative 111 131 153
Research and development 102 90 75
Other current assets 160 156  
Accrued and other current liabilities 82 80  
Licenses and other      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Intangible assets 3,091 3,212  
Adempas | Bayer AG | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Sales 287 255 238
Adempas | Licenses and other      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Intangible assets 372    
Verquvo | Bayer AG | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Sales 37 $ 36 $ 22
Verquvo | Licenses and other      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Intangible assets $ 42    
XML 99 R58.htm IDEA: XBRL DOCUMENT v3.25.0.1
Collaborative Arrangements - Ridgeback Biotherapeutics LP (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Sales $ 64,168 $ 60,115 $ 59,283
Cost of sales 15,193 16,126 17,411
Selling, general and administrative 10,816 10,504 10,042
Research and development 17,938 30,531 13,548
Accrued and other current liabilities 15,694 15,766  
Ridgeback Biotherapeutics LP | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Cost of sales 554 852 3,038
Selling, general and administrative 57 97 147
Research and development 13 60 88
Accrued and other current liabilities 68 113  
Ridgeback Biotherapeutics LP | Lagevrio | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Sales $ 964 $ 1,428 $ 5,684
XML 100 R59.htm IDEA: XBRL DOCUMENT v3.25.0.1
Collaborative Arrangements - Daiicho Sankyo - Narrative (Details)
$ in Millions
1 Months Ended 12 Months Ended
Aug. 31, 2024
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Oct. 31, 2023
USD ($)
antibodyDrugConjugate
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Research and development   $ 17,938 $ 30,531 $ 13,548  
Daiichi Sankyo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Number of antibody drug conjugates obtained right and obligations | antibodyDrugConjugate         3
Aggregate upfront payments due upon execution in collaborative arrangement         $ 4,000
Refundable upfront payments         1,000
Maximum aggregate contingent milestone payments, per product         $ 5,500
Research and development   $ 351 5,549    
Royalty percentage         5.00%
Upfront cash payment $ 170        
Daiichi Sankyo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Ifinatamab Deruxtecan          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Refundable upfront payments         $ 500
Daiichi Sankyo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Patritumab Deruxtecan          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Refundable upfront payments         500
Aggregate upfront payments due upon lapse of time         750
Daiichi Sankyo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Patritumab Deruxtecan and Ralduotatug Deruxtecan          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Aggregate upfront payments due upon lapse of time     $ 1,500    
Daiichi Sankyo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Raludotatug Deruxtecan          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Aggregate upfront payments due upon lapse of time         $ 750
Liable contracted portion amount of research and development expenses to incur costs for, percentage         75.00%
Liable contracted portion amount of research and development expenses to incur costs for         $ 2,000
XML 101 R60.htm IDEA: XBRL DOCUMENT v3.25.0.1
Collaborative Arrangements - Daiicho Sankyo (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Selling, general and administrative $ 10,816 $ 10,504 $ 10,042
Research and development 17,938 30,531 13,548
Other current assets 38,782 32,168  
Accrued and other current liabilities 15,694 15,766  
Daiichi Sankyo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Selling, general and administrative 26 3  
Research and development 351 5,549  
Other current assets 8 0  
Accrued and other current liabilities 817 800  
Other Noncurrent Liabilities 0 750  
Bayer AG | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Selling, general and administrative 111 131 153
Research and development 102 90 $ 75
Other current assets 160 156  
Accrued and other current liabilities $ 82 $ 80  
XML 102 R61.htm IDEA: XBRL DOCUMENT v3.25.0.1
Collaborative Arrangements - Moderna, Inc. - Narrative (Details) - Moderna - Collaborative Arrangement, Transaction with Party to Collaborative Arrangement - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Contractual payment $ 250  
Capitalization of shared costs   $ 198
XML 103 R62.htm IDEA: XBRL DOCUMENT v3.25.0.1
Collaborative Arrangements - Moderna, Inc. (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Selling, general and administrative $ 10,816 $ 10,504 $ 10,042
Research and development 17,938 30,531 13,548
Accrued and other current liabilities 15,694 15,766  
Moderna | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Selling, general and administrative 16 5 0
Research and development 358 218 $ 288
Accrued and other current liabilities $ 57 $ 63  
XML 104 R63.htm IDEA: XBRL DOCUMENT v3.25.0.1
Collaborative Arrangements - Bristol Meyers Squibb Company - Narrative (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Bristol Myers Squibb | Licensing Agreements      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Royalty rate, deduction, percentage 50.00%    
Bristol Myers Squibb | Licensing Agreements | Regulatory Milestones      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Proceeds from collaborators     $ 20
Bristol Myers Squibb | Licensing Agreements | Alliance Revenue-Reblozyl      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Sales milestone payments $ 80    
Bristol Myers Squibb | Minimum | Licensing Agreements      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Royalty rate, percentage 20.00%    
Bristol Myers Squibb | Maximum | Licensing Agreements      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Royalty rate, percentage 24.00%    
Bristol Myers Squibb Company | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenue from collaborative arrangement $ 371 $ 212 $ 166
XML 105 R64.htm IDEA: XBRL DOCUMENT v3.25.0.1
Restructuring - Narrative (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Restructuring Cost and Reserve [Line Items]      
Total pretax restructuring costs $ 888 $ 933  
2024 Restructuring Program      
Restructuring Cost and Reserve [Line Items]      
Expected restructuring and related cost $ 4,000    
Estimate of cumulative pre tax costs that will be noncash 60.00%    
Total pretax restructuring costs $ 888 190  
Cumulative costs since inception $ 1,100    
2019 Restructuring Program      
Restructuring Cost and Reserve [Line Items]      
Total pretax restructuring costs   $ 743 $ 666
XML 106 R65.htm IDEA: XBRL DOCUMENT v3.25.0.1
Restructuring - Charges Activities by Type of Cost (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Restructuring Cost and Reserve [Line Items]      
Total pretax restructuring costs $ 888 $ 933  
Restructuring Program, 2024 and 2019      
Restructuring Cost and Reserve [Line Items]      
Total pretax restructuring costs   933  
2024 Restructuring Program      
Restructuring Cost and Reserve [Line Items]      
Total pretax restructuring costs $ 888 190  
2019 Restructuring Program      
Restructuring Cost and Reserve [Line Items]      
Total pretax restructuring costs   $ 743 $ 666
Cost of sales | 2024 Restructuring Program      
Restructuring Cost and Reserve [Line Items]      
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration] Cost of sales Cost of sales  
Total pretax restructuring costs $ 495 $ 62  
Cost of sales | 2019 Restructuring Program      
Restructuring Cost and Reserve [Line Items]      
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]   Cost of sales Cost of sales
Total pretax restructuring costs   $ 149 $ 205
Selling, general and administrative | 2024 Restructuring Program      
Restructuring Cost and Reserve [Line Items]      
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration] Selling, general and administrative    
Total pretax restructuring costs $ 83    
Selling, general and administrative | 2019 Restructuring Program      
Restructuring Cost and Reserve [Line Items]      
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]   Selling, general and administrative Selling, general and administrative
Total pretax restructuring costs   $ 122 $ 94
Research and development | 2024 Restructuring Program      
Restructuring Cost and Reserve [Line Items]      
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration] Research and development    
Total pretax restructuring costs $ 1    
Research and development | 2019 Restructuring Program      
Restructuring Cost and Reserve [Line Items]      
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]   Research and development Research and development
Total pretax restructuring costs   $ 1 $ 30
Restructuring costs | 2024 Restructuring Program      
Restructuring Cost and Reserve [Line Items]      
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration] Restructuring costs Restructuring costs  
Total pretax restructuring costs $ 309 $ 128  
Restructuring costs | 2019 Restructuring Program      
Restructuring Cost and Reserve [Line Items]      
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]   Restructuring costs Restructuring costs
Total pretax restructuring costs   $ 471 $ 337
Accelerated Depreciation      
Restructuring Cost and Reserve [Line Items]      
Total pretax restructuring costs 254 140  
Accelerated Depreciation | Restructuring Program, 2024 and 2019      
Restructuring Cost and Reserve [Line Items]      
Total pretax restructuring costs   140  
Accelerated Depreciation | 2024 Restructuring Program      
Restructuring Cost and Reserve [Line Items]      
Total pretax restructuring costs $ 254 0  
Accelerated Depreciation | 2019 Restructuring Program      
Restructuring Cost and Reserve [Line Items]      
Total pretax restructuring costs   $ 140 $ 120
Accelerated Depreciation | Cost of sales | 2024 Restructuring Program      
Restructuring Cost and Reserve [Line Items]      
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration] Cost of sales Cost of sales  
Total pretax restructuring costs $ 254 $ 0  
Accelerated Depreciation | Cost of sales | 2019 Restructuring Program      
Restructuring Cost and Reserve [Line Items]      
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]   Cost of sales Cost of sales
Total pretax restructuring costs   $ 131 $ 72
Accelerated Depreciation | Selling, general and administrative | 2024 Restructuring Program      
Restructuring Cost and Reserve [Line Items]      
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration] Selling, general and administrative    
Total pretax restructuring costs $ 0    
Accelerated Depreciation | Selling, general and administrative | 2019 Restructuring Program      
Restructuring Cost and Reserve [Line Items]      
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]   Selling, general and administrative Selling, general and administrative
Total pretax restructuring costs   $ 9 $ 19
Accelerated Depreciation | Research and development | 2024 Restructuring Program      
Restructuring Cost and Reserve [Line Items]      
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration] Research and development    
Total pretax restructuring costs $ 0    
Accelerated Depreciation | Research and development | 2019 Restructuring Program      
Restructuring Cost and Reserve [Line Items]      
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]   Research and development Research and development
Total pretax restructuring costs   $ 0 $ 29
Accelerated Depreciation | Restructuring costs | 2024 Restructuring Program      
Restructuring Cost and Reserve [Line Items]      
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration] Restructuring costs Restructuring costs  
Total pretax restructuring costs $ 0 $ 0  
Accelerated Depreciation | Restructuring costs | 2019 Restructuring Program      
Restructuring Cost and Reserve [Line Items]      
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]   Restructuring costs Restructuring costs
Total pretax restructuring costs   $ 0 $ 0
Separation Costs      
Restructuring Cost and Reserve [Line Items]      
Total pretax restructuring costs 122 454  
Separation Costs | Restructuring Program, 2024 and 2019      
Restructuring Cost and Reserve [Line Items]      
Total pretax restructuring costs   454  
Separation Costs | 2024 Restructuring Program      
Restructuring Cost and Reserve [Line Items]      
Total pretax restructuring costs $ 122 115  
Separation Costs | 2019 Restructuring Program      
Restructuring Cost and Reserve [Line Items]      
Total pretax restructuring costs   $ 339 $ 212
Separation Costs | Cost of sales | 2024 Restructuring Program      
Restructuring Cost and Reserve [Line Items]      
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration] Cost of sales Cost of sales  
Total pretax restructuring costs $ 0 $ 0  
Separation Costs | Cost of sales | 2019 Restructuring Program      
Restructuring Cost and Reserve [Line Items]      
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]   Cost of sales Cost of sales
Total pretax restructuring costs   $ 0 $ 0
Separation Costs | Selling, general and administrative | 2024 Restructuring Program      
Restructuring Cost and Reserve [Line Items]      
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration] Selling, general and administrative    
Total pretax restructuring costs $ 0    
Separation Costs | Selling, general and administrative | 2019 Restructuring Program      
Restructuring Cost and Reserve [Line Items]      
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]   Selling, general and administrative Selling, general and administrative
Total pretax restructuring costs   $ 0 $ 0
Separation Costs | Research and development | 2024 Restructuring Program      
Restructuring Cost and Reserve [Line Items]      
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration] Research and development    
Total pretax restructuring costs $ 0    
Separation Costs | Research and development | 2019 Restructuring Program      
Restructuring Cost and Reserve [Line Items]      
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]   Research and development Research and development
Total pretax restructuring costs   $ 0 $ 0
Separation Costs | Restructuring costs | 2024 Restructuring Program      
Restructuring Cost and Reserve [Line Items]      
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration] Restructuring costs Restructuring costs  
Total pretax restructuring costs $ 122 $ 115  
Separation Costs | Restructuring costs | 2019 Restructuring Program      
Restructuring Cost and Reserve [Line Items]      
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]   Restructuring costs Restructuring costs
Total pretax restructuring costs   $ 339 $ 212
Other Exit Costs      
Restructuring Cost and Reserve [Line Items]      
Total pretax restructuring costs 512 339  
Other Exit Costs | Restructuring Program, 2024 and 2019      
Restructuring Cost and Reserve [Line Items]      
Total pretax restructuring costs   339  
Other Exit Costs | 2024 Restructuring Program      
Restructuring Cost and Reserve [Line Items]      
Total pretax restructuring costs $ 512 75  
Other Exit Costs | 2019 Restructuring Program      
Restructuring Cost and Reserve [Line Items]      
Total pretax restructuring costs   $ 264 $ 334
Other Exit Costs | Cost of sales | 2024 Restructuring Program      
Restructuring Cost and Reserve [Line Items]      
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration] Cost of sales Cost of sales  
Total pretax restructuring costs $ 241 $ 62  
Other Exit Costs | Cost of sales | 2019 Restructuring Program      
Restructuring Cost and Reserve [Line Items]      
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]   Cost of sales Cost of sales
Total pretax restructuring costs   $ 18 $ 133
Other Exit Costs | Selling, general and administrative | 2024 Restructuring Program      
Restructuring Cost and Reserve [Line Items]      
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration] Selling, general and administrative    
Total pretax restructuring costs $ 83    
Other Exit Costs | Selling, general and administrative | 2019 Restructuring Program      
Restructuring Cost and Reserve [Line Items]      
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]   Selling, general and administrative Selling, general and administrative
Total pretax restructuring costs   $ 113 $ 75
Other Exit Costs | Research and development | 2024 Restructuring Program      
Restructuring Cost and Reserve [Line Items]      
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration] Research and development    
Total pretax restructuring costs $ 1    
Other Exit Costs | Research and development | 2019 Restructuring Program      
Restructuring Cost and Reserve [Line Items]      
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]   Research and development Research and development
Total pretax restructuring costs   $ 1 $ 1
Other Exit Costs | Restructuring costs | 2024 Restructuring Program      
Restructuring Cost and Reserve [Line Items]      
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration] Restructuring costs Restructuring costs  
Total pretax restructuring costs $ 187 $ 13  
Other Exit Costs | Restructuring costs | 2019 Restructuring Program      
Restructuring Cost and Reserve [Line Items]      
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]   Restructuring costs Restructuring costs
Total pretax restructuring costs   $ 132 $ 125
XML 107 R66.htm IDEA: XBRL DOCUMENT v3.25.0.1
Restructuring - Activities by Program (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Restructuring Reserve [Roll Forward]    
Restructuring reserve, beginning balance $ 712 $ 513
Expenses 888 933
(Payments) receipts, net (445) (410)
Non-cash activity (591) (324)
Restructuring reserve, ending balance 564 712
Separation Costs    
Restructuring Reserve [Roll Forward]    
Restructuring reserve, beginning balance 681 479
Expenses 122 454
(Payments) receipts, net (239) (252)
Non-cash activity 0 0
Restructuring reserve, ending balance 564 681
Accelerated Depreciation    
Restructuring Reserve [Roll Forward]    
Restructuring reserve, beginning balance 0 0
Expenses 254 140
(Payments) receipts, net 0 0
Non-cash activity (254) (140)
Restructuring reserve, ending balance 0 0
Other Exit Costs    
Restructuring Reserve [Roll Forward]    
Restructuring reserve, beginning balance 31 34
Expenses 512 339
(Payments) receipts, net (206) (158)
Non-cash activity (337) (184)
Restructuring reserve, ending balance $ 0 $ 31
XML 108 R67.htm IDEA: XBRL DOCUMENT v3.25.0.1
Financial Instruments - Narrative (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Jan. 31, 2025
Derivative [Line Items]        
Total Swap Notional Amount $ 38,560 $ 30,551    
Pretax net unrealized losses on derivatives maturing within the next 12 months estimated to be reclassified from AOCI to sales (262)      
Equity investments without readily determinable fair values 863 832    
Unrealized gains recognized on investments in equity securities without readily determinable fair value 19 10    
Unrealized losses recognized on investments in equity securities without readily determinable fair values 51 61    
Cumulative upward price adjustment 309      
Cumulative downward price adjustment 107      
(Income) loss from investments in equity securities, net (14) (340) $ 1,419  
Payments of contingent consideration 151 117    
Fair value of loans payable and long-term debt, including current portion 32,600 32,000    
Debt, carrying amount 37,100 35,100    
Factored accounts receivable 2,100 3,000    
Cash collateral received from counterparties $ 165 3    
5.00% notes due 2053        
Derivative [Line Items]        
Stated interest rate 5.00%      
Senior Notes | Subsequent Event | 5.00% notes due 2053        
Derivative [Line Items]        
Stated interest rate       5.00%
Interest rate swap contracts | 5.00% notes due 2053 | Subsequent Event        
Derivative [Line Items]        
Total Swap Notional Amount       $ 250
Lyfnua        
Derivative [Line Items]        
Payments of contingent consideration $ 25      
Sanofi Pasteur        
Derivative [Line Items]        
Payments of contingent consideration 126      
Equity Funds        
Derivative [Line Items]        
Equity securities held through ownership interests in investment funds 267 417 598  
(Income) loss from investments in equity securities, net 29 106 $ 1,000  
Accounts Receivable Factoring Collections        
Derivative [Line Items]        
Funds collected from factoring of receivable, held in restricted cash $ 55 44    
Customer Concentration Risk | Accounts Receivable | McKesson Corporation        
Derivative [Line Items]        
Percentage of accounts receivable represented by customers with largest balances 21.00%      
Customer Concentration Risk | Accounts Receivable | Cencora, Inc.        
Derivative [Line Items]        
Percentage of accounts receivable represented by customers with largest balances 21.00%      
Customer Concentration Risk | Accounts Receivable | Cardinal Health, Inc.        
Derivative [Line Items]        
Percentage of accounts receivable represented by customers with largest balances 13.00%      
Level 2        
Derivative [Line Items]        
Cash equivalents $ 12,300 6,000    
Derivatives Designated as Hedging Instruments        
Derivative [Line Items]        
Total Swap Notional Amount 12,465 12,754    
Derivatives Not Designated as Hedging Instruments        
Derivative [Line Items]        
Total Swap Notional Amount $ 26,095 $ 17,797    
Maximum | Derivatives Designated as Hedging Instruments        
Derivative [Line Items]        
Term of derivative contract 2 years      
Maximum | Derivatives Not Designated as Hedging Instruments        
Derivative [Line Items]        
Maximum planning cycle of hedges (less than) 6 months      
XML 109 R68.htm IDEA: XBRL DOCUMENT v3.25.0.1
Financial Instruments - Effect of Net Investment Hedges (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Foreign exchange contracts      
Derivative Instruments and Hedging Activities Disclosures [Line Items]      
Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income $ (30) $ 0 $ (48)
Foreign exchange contracts | Other (income) expense, net      
Derivative Instruments and Hedging Activities Disclosures [Line Items]      
Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing (4) 1 (1)
Euro-denominated notes      
Derivative Instruments and Hedging Activities Disclosures [Line Items]      
Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income (192) 105 (162)
Euro-denominated notes | Other (income) expense, net      
Derivative Instruments and Hedging Activities Disclosures [Line Items]      
Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing $ 0 $ 0 $ 0
XML 110 R69.htm IDEA: XBRL DOCUMENT v3.25.0.1
Financial Instruments - Summary of Interest Rate Swaps Held (Details)
Jan. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
interest_rate_swap
May 31, 2024
EUR (€)
Dec. 31, 2023
USD ($)
May 31, 2023
Derivative [Line Items]          
Total Swap Notional Amount   $ 38,560,000,000   $ 30,551,000,000  
4.50% notes due 2033          
Derivative [Line Items]          
Stated interest rate   4.50%      
Senior Notes          
Derivative [Line Items]          
Par Value of Debt | €     € 3,400,000,000    
Senior Notes | 4.50% notes due 2033          
Derivative [Line Items]          
Stated interest rate         4.50%
Interest rate swap contracts | 4.50% notes due 2033          
Derivative [Line Items]          
Par Value of Debt   $ 1,500,000,000      
Number of Interest Rate Swaps Held | interest_rate_swap   6      
Total Swap Notional Amount   $ 1,500,000,000      
Interest rate swap contracts | 5.00% notes due 2053 | Subsequent Event          
Derivative [Line Items]          
Total Swap Notional Amount $ 250,000,000        
XML 111 R70.htm IDEA: XBRL DOCUMENT v3.25.0.1
Financial Instruments - Amounts Recorded on Balance Sheet Related to Fair Value Hedges (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]    
Hedged Liability, Statement of Financial Position [Extensible Enumeration] Long-Term Debt Long-Term Debt
Carrying Amount of Hedged Liabilities $ 1,509 $ 1,056
Cumulative Amount of Fair Value Hedging Adjustment Increase Included in the Carrying Amount $ 17 $ 56
XML 112 R71.htm IDEA: XBRL DOCUMENT v3.25.0.1
Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Derivatives, Fair Value [Line Items]    
Fair value of derivative, asset $ 729 $ 342
Fair value of derivative, liability 345 239
U.S dollar notional amount 38,560 30,551
Derivatives Designated as Hedging Instruments    
Derivatives, Fair Value [Line Items]    
Fair value of derivative, asset 406 189
Fair value of derivative, liability 2 77
U.S dollar notional amount 12,465 12,754
Derivatives Not Designated as Hedging Instruments    
Derivatives, Fair Value [Line Items]    
Fair value of derivative, asset 323 153
Fair value of derivative, liability 343 162
U.S dollar notional amount $ 26,095 $ 17,797
Interest rate swap contracts | Derivatives Designated as Hedging Instruments    
Derivatives, Fair Value [Line Items]    
Derivative Asset, Statement of Financial Position [Extensible Enumeration] Other Assets Other Assets
Fair value of derivative, asset $ 17 $ 57
Derivative asset, notional amount $ 1,500 $ 1,000
Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Other current assets    
Derivatives, Fair Value [Line Items]    
Derivative Asset, Statement of Financial Position [Extensible Enumeration] Other current assets Other current assets
Fair value of derivative, asset $ 323 $ 106
Derivative asset, notional amount $ 8,662 $ 6,138
Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Other Assets    
Derivatives, Fair Value [Line Items]    
Derivative Asset, Statement of Financial Position [Extensible Enumeration] Other Assets Other Assets
Fair value of derivative, asset $ 66 $ 26
Derivative asset, notional amount $ 2,125 $ 1,929
Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Accrued and other current liabilities    
Derivatives, Fair Value [Line Items]    
Derivative Liability, Statement of Financial Position [Extensible Enumeration] Accrued and other current liabilities Accrued and other current liabilities
Fair value of derivative, liability $ 1 $ 76
Derivative liability, notional amount $ 162 $ 3,680
Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Other Noncurrent Liabilities    
Derivatives, Fair Value [Line Items]    
Derivative Liability, Statement of Financial Position [Extensible Enumeration] Other Noncurrent Liabilities Other Noncurrent Liabilities
Fair value of derivative, liability $ 1 $ 1
Derivative liability, notional amount $ 16 $ 7
Foreign exchange contracts | Derivatives Not Designated as Hedging Instruments    
Derivatives, Fair Value [Line Items]    
Derivative Asset, Statement of Financial Position [Extensible Enumeration] Other current assets Other current assets
Fair value of derivative, asset $ 323 $ 153
Derivative asset, notional amount $ 12,544 $ 9,693
Derivative Liability, Statement of Financial Position [Extensible Enumeration] Accrued and other current liabilities Accrued and other current liabilities
Fair value of derivative, liability $ 343 $ 162
Derivative liability, notional amount $ 13,551 $ 8,104
XML 113 R72.htm IDEA: XBRL DOCUMENT v3.25.0.1
Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]    
Gross amounts recognized in the consolidated balance sheet, asset $ 729 $ 342
Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, asset (299) (215)
Cash collateral received/posted, asset (165) (3)
Net amounts, asset 265 124
Gross amounts recognized in the consolidated balance sheet, liability 345 239
Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, liability (299) (215)
Cash collateral received/posted, liability 0 0
Net amounts, liability $ 46 $ 24
XML 114 R73.htm IDEA: XBRL DOCUMENT v3.25.0.1
Financial Instruments - Location and Pretax (Gains) or Loss Amounts for Derivatives (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Derivative Instruments, Gain (Loss) [Line Items]      
Sales $ 64,168 $ 60,115 $ 59,283
Other (income) expense, net (24) 466 1,501
Other comprehensive income (loss) $ 216 $ (393) $ (339)
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Other (income) expense, net Other (income) expense, net Other (income) expense, net
Foreign exchange contracts      
Derivative Instruments, Gain (Loss) [Line Items]      
Amount of gain recognized in OCI on derivatives $ 508 $ 114 $ 684
Increase in Sales as a result of AOCL reclassifications (167) (249) (773)
Interest rate swap contracts      
Derivative Instruments, Gain (Loss) [Line Items]      
Amount of gain recognized in OCI on derivatives (1) 13 (2)
Amount of gain recognized in Other (income) expense, net on derivatives (1) (1) (2)
Other (income) expense, net | Interest rate swap contracts      
Derivative Instruments, Gain (Loss) [Line Items]      
Hedged items (39) 56 (13)
Derivatives designated as hedging instruments 39 (57) 4
Reclassification out of Accumulated Other Comprehensive Income | Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest | Foreign exchange contracts      
Derivative Instruments, Gain (Loss) [Line Items]      
Sales $ 167 $ 249 $ 773
XML 115 R74.htm IDEA: XBRL DOCUMENT v3.25.0.1
Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Currency Swap | Other (income) expense, net      
Derivative [Line Items]      
Amount of Derivative Pretax Loss (Gain) Recognized in Income $ 251 $ (6) $ (49)
Foreign Exchange Future | Sales      
Derivative [Line Items]      
Amount of Derivative Pretax Loss (Gain) Recognized in Income $ (28) $ 5 $ (37)
XML 116 R75.htm IDEA: XBRL DOCUMENT v3.25.0.1
Financial Instruments - Information on Debt and Equity Securities (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Debt Securities, Available-for-sale [Line Items]    
Debt securities, amortized cost $ 536 $ 337
Debt securities, gross unrealized gains 0 0
Debt securities, gross unrealized losses 0 0
Debt securities, fair value 536 337
Equity securities 920 764
Total debt and publicly traded equity securities, fair value 1,456 1,101
Unrealized net gains (losses) (30) 411
Commercial paper    
Debt Securities, Available-for-sale [Line Items]    
Debt securities, amortized cost 348 252
Debt securities, gross unrealized gains 0 0
Debt securities, gross unrealized losses 0 0
Debt securities, fair value 348 252
U.S. government and agency securities    
Debt Securities, Available-for-sale [Line Items]    
Debt securities, amortized cost 188 72
Debt securities, gross unrealized gains 0 0
Debt securities, gross unrealized losses 0 0
Debt securities, fair value 188 72
Corporate notes and bonds    
Debt Securities, Available-for-sale [Line Items]    
Debt securities, amortized cost 0 13
Debt securities, gross unrealized gains 0 0
Debt securities, gross unrealized losses 0 0
Debt securities, fair value $ 0 $ 13
XML 117 R76.htm IDEA: XBRL DOCUMENT v3.25.0.1
Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Assets      
Investments $ 536 $ 337  
Equity securities 920 764  
Other Assets 16,044 11,996  
Fair value of derivative, asset 729 342  
Liabilities      
Contingent consideration 193 354 $ 456
Fair value of derivative, liability 345 239  
Commercial paper      
Assets      
Investments 348 252  
U.S. government and agency securities      
Assets      
Investments 188 72  
Corporate notes and bonds      
Assets      
Investments 0 13  
Fair Value, Measurements, Recurring      
Assets      
Investments 910 504  
Other Assets 546 597  
Fair value of derivative, asset 729 342  
Total assets 2,185 1,443  
Liabilities      
Contingent consideration 193 354  
Fair value of derivative, liability 345 239  
Total liabilities 538 593  
Fair Value, Measurements, Recurring | Foreign exchange contracts      
Assets      
Fair value of derivative, asset 499 202  
Liabilities      
Fair value of derivative, liability 338 239  
Fair Value, Measurements, Recurring | Currency Options      
Assets      
Fair value of derivative, asset 213 83  
Liabilities      
Fair value of derivative, liability 7 0  
Fair Value, Measurements, Recurring | Interest rate swap contracts      
Assets      
Fair value of derivative, asset 17 57  
Fair Value, Measurements, Recurring | Commercial paper      
Assets      
Investments 348 252  
Fair Value, Measurements, Recurring | Publicly traded equity securities      
Assets      
Equity securities 463 252  
Publicly traded equity securities 457 512  
Fair Value, Measurements, Recurring | U.S. government and agency securities      
Assets      
Available-for-sale debt securities included in Short-term investments 99 0  
Debt securities, available-for-sale, noncurrent 89 72  
Fair Value, Measurements, Recurring | Corporate notes and bonds      
Assets      
Debt securities, available-for-sale, noncurrent 0 13  
Fair Value, Measurements, Recurring | Level 1      
Assets      
Investments 463 252  
Other Assets 546 597  
Fair value of derivative, asset 0 0  
Total assets 1,009 849  
Liabilities      
Contingent consideration 0 0  
Fair value of derivative, liability 0 0  
Total liabilities 0 0  
Fair Value, Measurements, Recurring | Level 1 | Foreign exchange contracts      
Assets      
Fair value of derivative, asset 0 0  
Liabilities      
Fair value of derivative, liability 0 0  
Fair Value, Measurements, Recurring | Level 1 | Currency Options      
Assets      
Fair value of derivative, asset 0 0  
Liabilities      
Fair value of derivative, liability 0 0  
Fair Value, Measurements, Recurring | Level 1 | Interest rate swap contracts      
Assets      
Fair value of derivative, asset 0 0  
Fair Value, Measurements, Recurring | Level 1 | Commercial paper      
Assets      
Investments 0 0  
Fair Value, Measurements, Recurring | Level 1 | Publicly traded equity securities      
Assets      
Equity securities 463 252  
Publicly traded equity securities 457 512  
Liabilities      
Securities, fair value, which are subject to a contractual sale restriction 81 177  
Fair Value, Measurements, Recurring | Level 1 | U.S. government and agency securities      
Assets      
Available-for-sale debt securities included in Short-term investments 0 0  
Debt securities, available-for-sale, noncurrent 89 72  
Fair Value, Measurements, Recurring | Level 1 | Corporate notes and bonds      
Assets      
Debt securities, available-for-sale, noncurrent 0 13  
Fair Value, Measurements, Recurring | Level 2      
Assets      
Investments 447 252  
Other Assets 0 0  
Fair value of derivative, asset 729 342  
Total assets 1,176 594  
Liabilities      
Contingent consideration 0 0  
Fair value of derivative, liability 345 239  
Total liabilities 345 239  
Fair Value, Measurements, Recurring | Level 2 | Foreign exchange contracts      
Assets      
Fair value of derivative, asset 499 202  
Liabilities      
Fair value of derivative, liability 338 239  
Fair Value, Measurements, Recurring | Level 2 | Currency Options      
Assets      
Fair value of derivative, asset 213 83  
Liabilities      
Fair value of derivative, liability 7 0  
Fair Value, Measurements, Recurring | Level 2 | Interest rate swap contracts      
Assets      
Fair value of derivative, asset 17 57  
Fair Value, Measurements, Recurring | Level 2 | Commercial paper      
Assets      
Investments 348 252  
Fair Value, Measurements, Recurring | Level 2 | Publicly traded equity securities      
Assets      
Equity securities 0 0  
Publicly traded equity securities 0 0  
Fair Value, Measurements, Recurring | Level 2 | U.S. government and agency securities      
Assets      
Available-for-sale debt securities included in Short-term investments 99 0  
Debt securities, available-for-sale, noncurrent 0 0  
Fair Value, Measurements, Recurring | Level 2 | Corporate notes and bonds      
Assets      
Debt securities, available-for-sale, noncurrent 0 0  
Fair Value, Measurements, Recurring | Level 3      
Assets      
Investments 0 0  
Other Assets 0 0  
Fair value of derivative, asset 0 0  
Total assets 0 0  
Liabilities      
Contingent consideration 193 354  
Fair value of derivative, liability 0 0  
Total liabilities 193 354  
Fair Value, Measurements, Recurring | Level 3 | Foreign exchange contracts      
Assets      
Fair value of derivative, asset 0 0  
Liabilities      
Fair value of derivative, liability 0 0  
Fair Value, Measurements, Recurring | Level 3 | Currency Options      
Assets      
Fair value of derivative, asset 0 0  
Liabilities      
Fair value of derivative, liability 0 0  
Fair Value, Measurements, Recurring | Level 3 | Interest rate swap contracts      
Assets      
Fair value of derivative, asset 0 0  
Fair Value, Measurements, Recurring | Level 3 | Commercial paper      
Assets      
Investments 0 0  
Fair Value, Measurements, Recurring | Level 3 | Publicly traded equity securities      
Assets      
Equity securities 0 0  
Publicly traded equity securities 0 0  
Fair Value, Measurements, Recurring | Level 3 | U.S. government and agency securities      
Assets      
Available-for-sale debt securities included in Short-term investments 0 0  
Debt securities, available-for-sale, noncurrent 0 0  
Fair Value, Measurements, Recurring | Level 3 | Corporate notes and bonds      
Assets      
Debt securities, available-for-sale, noncurrent $ 0 $ 0  
XML 118 R77.htm IDEA: XBRL DOCUMENT v3.25.0.1
Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)
$ in Millions
12 Months Ended
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Contingent consideration, beginning balance $ 354 $ 456
Changes in estimated fair value (10) 15
Payments (151) (117)
Contingent consideration, ending balance 193 $ 354
Contingent consideration, liability, current 148  
Sanofi Pasteur    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Payments (126)  
Contingent consideration, liability, current $ 123  
Contingent consideration, measurement input, discount rate 0.115  
XML 119 R78.htm IDEA: XBRL DOCUMENT v3.25.0.1
Inventories - Inventories (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Inventory Disclosure [Abstract]    
Finished goods $ 2,022 $ 1,954
Raw materials and work in process 8,831 8,037
Supplies 289 277
Total 11,142 10,268
Decrease to LIFO cost (840) (562)
Total current and noncurrent inventories 10,302 9,706
Recognized as:    
Inventories 6,109 6,358
Other Assets $ 4,193 $ 3,348
XML 120 R79.htm IDEA: XBRL DOCUMENT v3.25.0.1
Inventories - Narrative (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Inventory [Line Items]    
LIFO inventory amount $ 3,400 $ 3,100
Inventory classified in Other assets 4,193 3,348
Inventory Not Expected to be Sold Within One Year    
Inventory [Line Items]    
Inventory classified in Other assets 3,800 2,600
Inventories Produced in Preparation for Product Launches    
Inventory [Line Items]    
Inventory classified in Other assets $ 412 $ 790
XML 121 R80.htm IDEA: XBRL DOCUMENT v3.25.0.1
Goodwill and Other Intangibles - Goodwill Activity by Segment (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Goodwill [Roll Forward]    
Goodwill, beginning balance $ 21,197 $ 21,204
Acquisitions 518  
Other (47) (7)
Goodwill, ending balance 21,668 21,197
Accumulated goodwill impairment losses 531 531
Pharmaceutical    
Goodwill [Roll Forward]    
Goodwill, beginning balance 17,922 17,936
Acquisitions 0  
Other (19) (14)
Goodwill, ending balance 17,903 17,922
Animal Health    
Goodwill [Roll Forward]    
Goodwill, beginning balance 3,275 3,268
Acquisitions 518  
Other (28) 7
Goodwill, ending balance $ 3,765 $ 3,275
XML 122 R81.htm IDEA: XBRL DOCUMENT v3.25.0.1
Goodwill and Other Intangibles - Other Intangibles (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Intangible Assets Excluding Goodwill [Line Items]    
Intangible assets, gross carrying amount $ 42,162 $ 41,603
Accumulated amortization 25,792 23,592
Intangible assets, net 16,370 18,011
IPR&D    
Intangible Assets Excluding Goodwill [Line Items]    
Indefinite-lived intangible assets 430 6,816
Product rights    
Intangible Assets Excluding Goodwill [Line Items]    
Finite-lived intangible assets, gross carrying amount 29,988 23,643
Accumulated amortization 19,066 17,765
Finite-lived intangible assets, net 10,922 5,878
Trade names    
Intangible Assets Excluding Goodwill [Line Items]    
Finite-lived intangible assets, gross carrying amount 2,881 2,881
Accumulated amortization 954 776
Finite-lived intangible assets, net 1,927 2,105
Licenses and other    
Intangible Assets Excluding Goodwill [Line Items]    
Finite-lived intangible assets, gross carrying amount 8,863 8,263
Accumulated amortization 5,772 5,051
Finite-lived intangible assets, net $ 3,091 $ 3,212
XML 123 R82.htm IDEA: XBRL DOCUMENT v3.25.0.1
Goodwill and Other Intangibles - Narrative (Details) - USD ($)
$ in Millions
1 Months Ended 3 Months Ended 12 Months Ended
Dec. 31, 2022
Sep. 30, 2022
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Intangible Assets Excluding Goodwill [Line Items]          
Other intangibles, net     $ 16,370 $ 18,011  
Intangible asset impairment charges     39 $ 792 $ 1,749
Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]       Research and development Research and development
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]         Research and development
Amortization expense for intangible assets     2,400 $ 2,000 $ 2,100
Estimated aggregate amortization expense, 2025     2,400    
Estimated aggregate amortization expense, 2026     2,300    
Estimated aggregate amortization expense, 2027     2,100    
Estimated aggregate amortization expense, 2028     1,800    
Estimated aggregate amortization expense, 2029     1,500    
IPR&D          
Intangible Assets Excluding Goodwill [Line Items]          
IPR&D intangible asset     430 6,816  
Animal Health          
Intangible Assets Excluding Goodwill [Line Items]          
Other intangibles, net     4,300    
gefapixant | IPR&D          
Intangible Assets Excluding Goodwill [Line Items]          
IPR&D impairment charges       779  
Lyfnua          
Intangible Assets Excluding Goodwill [Line Items]          
Finite-lived intangible assets, net     21    
nemtabrutinib | IPR&D          
Intangible Assets Excluding Goodwill [Line Items]          
IPR&D intangible asset     418    
IPR&D impairment charges $ 780 $ 807     1,600
Product rights          
Intangible Assets Excluding Goodwill [Line Items]          
Finite-lived intangible assets, net     10,922 5,878  
Product rights | Reblozyl          
Intangible Assets Excluding Goodwill [Line Items]          
Finite-lived intangible assets, net     2,800    
Product rights | Zerbaxa          
Intangible Assets Excluding Goodwill [Line Items]          
Finite-lived intangible assets, net     260    
Product rights | Animal Health          
Intangible Assets Excluding Goodwill [Line Items]          
Finite-lived intangible assets, net     1,700    
Product rights | Winrevair          
Intangible Assets Excluding Goodwill [Line Items]          
Finite-lived intangible assets, net     5,900    
Trade names          
Intangible Assets Excluding Goodwill [Line Items]          
Finite-lived intangible assets, net     1,927 2,105  
Trade names | Animal Health          
Intangible Assets Excluding Goodwill [Line Items]          
Finite-lived intangible assets, net     1,900    
Licenses and other          
Intangible Assets Excluding Goodwill [Line Items]          
Finite-lived intangible assets, net     3,091 $ 3,212  
Licenses and other | Lynparza          
Intangible Assets Excluding Goodwill [Line Items]          
Finite-lived intangible assets, net     1,200    
Licenses and other | Lenvima          
Intangible Assets Excluding Goodwill [Line Items]          
Finite-lived intangible assets, net     442    
Licenses and other | Adempas          
Intangible Assets Excluding Goodwill [Line Items]          
Finite-lived intangible assets, net     $ 372    
Licenses and other | derazantinib          
Intangible Assets Excluding Goodwill [Line Items]          
Intangible asset impairment charge related to finite-lived intangible asset         $ 80
XML 124 R83.htm IDEA: XBRL DOCUMENT v3.25.0.1
Loans Payable, Long-Term Debt and Leases - Narrative (Details)
$ in Millions
12 Months Ended
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
May 31, 2024
EUR (€)
Debt Instrument [Line Items]        
Long-term debt, current maturities $ 2,500 $ 1,300    
Loans payable and current portion of long-term debt 2,649 $ 1,372    
Long-term debt, maturities, repayments of principal in 2025 2,600      
Long-term debt, maturities, repayments of principal in 2026 2,200      
Long-term debt, maturities, repayments of principal in 2027 1,500      
Long-term debt, maturities, repayments of principal in 2028 2,100      
Long-term debt, maturities, repayments of principal in 2029 1,700      
Long-term debt, interest payments in 2025 1,200      
Long-term debt, interest payments in 2026 1,200      
Long-term debt, interest payments in 2027 1,100      
Long-term debt, interest payments in 2028 1,100      
Long-term debt, interest payments in 2029 1,000      
Available borrowing capacity under credit facility $ 6,000      
Operating lease, weighted average remaining lease term 6 years 7 years    
Operating lease, cost $ 348 $ 339 $ 334  
Operating lease, payments 357 347 335  
Right-of-use asset obtained in exchange for operating lease liability 47 $ 122 $ 57  
Lessee, operating lease, lease not yet commenced, amount $ 183      
Buildings        
Debt Instrument [Line Items]        
Operating lease, weighted average remaining lease term 6 years      
Lessee, operating lease, renewal term 5 years      
Vehicles        
Debt Instrument [Line Items]        
Operating lease, weighted average remaining lease term 4 years      
Senior Notes        
Debt Instrument [Line Items]        
Face amount of debt | €       € 3,400,000,000
Other Variable Rate Debt        
Debt Instrument [Line Items]        
Effective interest rate 5.02% 4.82%    
6.30% debentures due 2026        
Debt Instrument [Line Items]        
Stated interest rate 6.30%      
3.25% Notes due 2032 | Senior Notes        
Debt Instrument [Line Items]        
Stated interest rate       3.25%
Face amount of debt | €       € 850,000,000
3.50% Notes due 2037 | Senior Notes        
Debt Instrument [Line Items]        
Stated interest rate       3.50%
Face amount of debt | €       € 850,000,000
3.70% Notes due 2044 | Senior Notes        
Debt Instrument [Line Items]        
Stated interest rate       3.70%
Face amount of debt | €       € 850,000,000
3.75% Notes due 2054 | Senior Notes        
Debt Instrument [Line Items]        
Stated interest rate       3.75%
Face amount of debt | €       € 850,000,000
Notes Subject To Repayment At Option Of Holder        
Debt Instrument [Line Items]        
Loans payable and current portion of long-term debt $ 149 $ 69    
Commercial paper        
Debt Instrument [Line Items]        
Weighted-average interest rate of commercial paper 5.18% 5.14%    
XML 125 R84.htm IDEA: XBRL DOCUMENT v3.25.0.1
Loans Payable, Long-Term Debt and Leases - Long-Term Debt (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Debt Instrument [Line Items]    
Long-Term Debt $ 34,462 $ 33,683
2.15% notes due 2031    
Debt Instrument [Line Items]    
Stated interest rate 2.15%  
Long-Term Debt $ 1,989 1,988
2.75% notes due 2051    
Debt Instrument [Line Items]    
Stated interest rate 2.75%  
Long-Term Debt $ 1,980 1,980
3.70% notes due 2045    
Debt Instrument [Line Items]    
Stated interest rate 3.70%  
Long-Term Debt $ 1,980 1,979
3.40% notes due 2029    
Debt Instrument [Line Items]    
Stated interest rate 3.40%  
Long-Term Debt $ 1,742 1,740
4.50% notes due 2033    
Debt Instrument [Line Items]    
Stated interest rate 4.50%  
Long-Term Debt $ 1,509 1,547
1.70% notes due 2027    
Debt Instrument [Line Items]    
Stated interest rate 1.70%  
Long-Term Debt $ 1,497 1,495
2.90% notes due 2061    
Debt Instrument [Line Items]    
Stated interest rate 2.90%  
Long-Term Debt $ 1,484 1,484
5.00% notes due 2053    
Debt Instrument [Line Items]    
Stated interest rate 5.00%  
Long-Term Debt $ 1,482 1,481
4.00% notes due 2049    
Debt Instrument [Line Items]    
Stated interest rate 4.00%  
Long-Term Debt $ 1,474 1,473
4.15% notes due 2043    
Debt Instrument [Line Items]    
Stated interest rate 4.15%  
Long-Term Debt $ 1,240 1,240
1.45% notes due 2030    
Debt Instrument [Line Items]    
Stated interest rate 1.45%  
Long-Term Debt $ 1,240 1,238
2.45% notes due 2050    
Debt Instrument [Line Items]    
Stated interest rate 2.45%  
Long-Term Debt $ 1,216 1,214
1.875% euro-denominated notes due 2026    
Debt Instrument [Line Items]    
Stated interest rate 1.875%  
Long-Term Debt $ 1,041 1,103
0.75% notes due 2026    
Debt Instrument [Line Items]    
Stated interest rate 0.75%  
Long-Term Debt $ 998 996
1.90% notes due 2028    
Debt Instrument [Line Items]    
Stated interest rate 1.90%  
Long-Term Debt $ 996 995
5.15% notes due 2063    
Debt Instrument [Line Items]    
Stated interest rate 5.15%  
Long-Term Debt $ 987 987
3.90% notes due 2039    
Debt Instrument [Line Items]    
Stated interest rate 3.90%  
Long-Term Debt $ 987 986
2.35% notes due 2040    
Debt Instrument [Line Items]    
Stated interest rate 2.35%  
Long-Term Debt $ 986 985
3.25% euro-denominated notes due 2032    
Debt Instrument [Line Items]    
Stated interest rate 3.25%  
Long-Term Debt $ 880 0
3.50% euro-denominated notes due 2037    
Debt Instrument [Line Items]    
Stated interest rate 3.50%  
Long-Term Debt $ 877 0
3.70% euro-denominated notes due 2044    
Debt Instrument [Line Items]    
Stated interest rate 3.70%  
Long-Term Debt $ 876 0
3.75% euro-denominated notes due 2054    
Debt Instrument [Line Items]    
Stated interest rate 3.75%  
Long-Term Debt $ 873 0
4.30% notes due 2030    
Debt Instrument [Line Items]    
Stated interest rate 4.30%  
Long-Term Debt $ 746 745
4.90% notes due 2044    
Debt Instrument [Line Items]    
Stated interest rate 4.90%  
Long-Term Debt $ 740 740
6.50% notes due 2033    
Debt Instrument [Line Items]    
Stated interest rate 6.50%  
Long-Term Debt $ 702 707
1.375% euro-denominated notes due 2036    
Debt Instrument [Line Items]    
Stated interest rate 1.375%  
Long-Term Debt $ 517 548
2.50% euro-denominated notes due 2034    
Debt Instrument [Line Items]    
Stated interest rate 2.50%  
Long-Term Debt $ 517 548
4.05% notes due 2028    
Debt Instrument [Line Items]    
Stated interest rate 4.05%  
Long-Term Debt $ 498 497
3.60% notes due 2042    
Debt Instrument [Line Items]    
Stated interest rate 3.60%  
Long-Term Debt $ 492 492
6.55% notes due 2037    
Debt Instrument [Line Items]    
Stated interest rate 6.55%  
Long-Term Debt $ 404 406
5.75% notes due 2036    
Debt Instrument [Line Items]    
Stated interest rate 5.75%  
Long-Term Debt $ 339 339
5.95% debentures due 2028    
Debt Instrument [Line Items]    
Stated interest rate 5.95%  
Long-Term Debt $ 307 307
5.85% notes due 2039    
Debt Instrument [Line Items]    
Stated interest rate 5.85%  
Long-Term Debt $ 271 271
6.40% debentures due 2028    
Debt Instrument [Line Items]    
Stated interest rate 6.40%  
Long-Term Debt $ 251 250
6.30% debentures due 2026    
Debt Instrument [Line Items]    
Stated interest rate 6.30%  
Long-Term Debt $ 135 135
2.75% notes due 2025    
Debt Instrument [Line Items]    
Stated interest rate 2.75%  
Long-Term Debt $ 0 2,498
Other    
Debt Instrument [Line Items]    
Long-Term Debt $ 209 $ 289
XML 126 R85.htm IDEA: XBRL DOCUMENT v3.25.0.1
Loans Payable, Long-Term Debt and Leases - Balance Sheet Information (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Debt Disclosure [Abstract]    
Other Assets $ 1,370 $ 1,437
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Other Assets Other Assets
Accrued and other current liabilities $ 282 $ 285
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Accrued and other current liabilities Accrued and other current liabilities
Other Noncurrent Liabilities $ 877 $ 928
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Other Noncurrent Liabilities Other Noncurrent Liabilities
Total operating lease liability $ 1,159 $ 1,213
Weighted-average remaining lease term (years) 6 years 7 years
Weighted-average discount rate 3.20% 3.30%
XML 127 R86.htm IDEA: XBRL DOCUMENT v3.25.0.1
Loans Payable, Long-Term Debt and Leases - Maturity Schedule (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Debt Disclosure [Abstract]    
2025 $ 329  
2026 292  
2027 235  
2028 146  
2029 116  
Thereafter 403  
Total lease payments 1,521  
Less: Imputed interest 362  
Total operating lease liability $ 1,159 $ 1,213
XML 128 R87.htm IDEA: XBRL DOCUMENT v3.25.0.1
Contingencies and Environmental Liabilities (Details)
$ in Millions
1 Months Ended 2 Months Ended 5 Months Ended 12 Months Ended
Dec. 19, 2022
Jul. 31, 2023
motion
Jun. 30, 2023
May 31, 2023
patent
Oct. 31, 2024
patent
Dec. 31, 2024
USD ($)
case
Plaintiff
Dec. 31, 2023
USD ($)
Loss Contingencies [Line Items]              
Environmental Loss Contingency Statement Of Financial Position Extensible Enumeration Not Disclosed Flag           liabilities  
Accrued liabilities for environmental matters | $           $ 41 $ 42
Term for paying off environmental liabilities           15 years  
Aggregate possible expenditure on environmental matters in excess of amounts accrued | $           $ 46  
Legal Defense Costs              
Loss Contingencies [Line Items]              
Legal defense costs reserve | $           $ 225 $ 210
Commercial and Other Litigation | Pending Litigation              
Loss Contingencies [Line Items]              
Loss contingency, pending claims           2  
Loss contingency, number of plaintiffs | Plaintiff           2  
The Johns Hopkins University              
Loss Contingencies [Line Items]              
Number of patents allegedly infringed | patent       9      
Number of patents allegedly infringed under review | patent         9    
Qui Tam | United States | Settled Litigation              
Loss Contingencies [Line Items]              
Loss contingency, motion for summary judgements granted | motion   2          
Gardasil/Gardasil 9 | United States | Pending Litigation              
Loss Contingencies [Line Items]              
Loss contingency, pending claims           225  
Gardasil/Gardasil 9 | Outside of the United States | Pending Litigation              
Loss Contingencies [Line Items]              
Loss contingency, pending claims           15  
RotaTeq | United States | Pending Litigation              
Loss Contingencies [Line Items]              
Loss contingency, number of plaintiffs           35  
Bridion | Patents              
Loss Contingencies [Line Items]              
Loss contingency, claims settled (in cases)           5  
Bridion | Patents | Pending Litigation              
Loss Contingencies [Line Items]              
Loss contingency, pending claims           2  
Loss contingency, trial period 1 day            
Bridion | Patents | Settled Litigation              
Loss Contingencies [Line Items]              
Patent extension, term     5 years        
Januvia/Janumet              
Loss Contingencies [Line Items]              
Loss contingency, claims settled (in cases)           26  
Dr. Scholl's | United States | Pending Litigation              
Loss Contingencies [Line Items]              
Loss contingency, pending claims           415  
XML 129 R88.htm IDEA: XBRL DOCUMENT v3.25.0.1
Equity - Narrative (Details) - shares
Dec. 31, 2024
Dec. 31, 2023
Equity [Abstract]    
Common stock, authorized (in shares) 6,500,000,000 6,500,000,000
Preferred stock, authorized (in shares) 20,000,000  
XML 130 R89.htm IDEA: XBRL DOCUMENT v3.25.0.1
Equity - Shareholders' Equity (Details) - shares
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Movement in Common Stock and Treasury Stock [Roll Forward]      
Balance January 1, common stock (in shares) 3,577,103,522    
Balance January 1, treasury stock (in shares) 1,045,470,249    
Balance December 31, common stock (in shares) 3,577,103,522 3,577,103,522  
Balance December 31, treasury stock (in shares) 1,049,466,187 1,045,470,249  
Common Stock      
Movement in Common Stock and Treasury Stock [Roll Forward]      
Balance January 1, common stock (in shares) 3,577,000,000 3,577,000,000 3,577,000,000
Purchases of treasury stock (in shares) 0 0 0
Issuances (in shares) 0 0 0
Balance December 31, common stock (in shares) 3,577,000,000 3,577,000,000 3,577,000,000
Treasury Stock      
Movement in Common Stock and Treasury Stock [Roll Forward]      
Balance January 1, treasury stock (in shares) 1,045,000,000 1,039,000,000 1,049,000,000
Purchases of treasury stock (in shares) 11,000,000 13,000,000 0
Issuances (in shares) (7,000,000) (7,000,000) (10,000,000)
Balance December 31, treasury stock (in shares) 1,049,000,000 1,045,000,000 1,039,000,000
XML 131 R90.htm IDEA: XBRL DOCUMENT v3.25.0.1
Share-Based Compensation Plans - Narrative (Details) - USD ($)
$ / shares in Units, $ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Shares collectively authorized for future grants under share-based compensation plans (in shares) 75,000,000    
Pretax share-based compensation cost recorded, related to continuing operations $ 761 $ 645 $ 541
Income tax benefits related to share-based compensation $ 117 $ 96 $ 78
Weighted average exercise price of options granted (in dollars per share) $ 129.22 $ 117.89 $ 87.10
Total pre tax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards $ 1,100    
Weighted average period in years of recognition for nonvested stock options, RSU and PSU awards 1 year 10 months 24 days    
Employee Stock Option      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Quantity of stock options that vest per year 33.33%    
Period over which share-based payment awards vest 3 years    
PSUs      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Period over which share-based payment awards vest 3 years    
RSUs      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Quantity of stock options that vest per year 33.33%    
Period over which share-based payment awards vest 3 years    
Minimum | Employee Stock Option      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Contractual term of options 7 years    
Maximum | Employee Stock Option      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Contractual term of options 10 years    
XML 132 R91.htm IDEA: XBRL DOCUMENT v3.25.0.1
Share-Based Compensation Plans - Assumptions Used to Determine Weighted-Average Fair Value of Options Granted (Details) - $ / shares
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]      
Weighted average fair value of options granted (in dollars per share) $ 25.60 $ 21.69 $ 15.45
Expected dividend yield 3.00% 3.10% 3.10%
Risk-free interest rate 4.70% 3.40% 3.00%
Expected volatility 20.50% 22.40% 22.50%
Expected life (years) 5 years 9 months 18 days 5 years 9 months 18 days 5 years 10 months 24 days
XML 133 R92.htm IDEA: XBRL DOCUMENT v3.25.0.1
Share-Based Compensation Plans - Summary of Information Relative to Stock Option Plan Activity (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Number of Options      
Number of Options, Outstanding, January 1 (in shares) 13,527    
Number of Options, Granted (in shares) 1,753    
Number of Options, Exercised (in shares) (2,581)    
Number of Options, Forfeited (in shares) (199)    
Number of Options, Outstanding, December 31 (in shares) 12,500 13,527  
Number of Options, Vested and expected to vest (in shares) 12,201    
Number of Options, Exercisable (in shares) 9,084    
Weighted Average Exercise Price      
Weighted Average Exercise Price, Options Outstanding, January 1 (in dollars per share) $ 77.54    
Weighted Average Exercise Price, Granted (in dollars per share) 129.22 $ 117.89 $ 87.10
Weighted Average Exercise Price, Exercised (in dollars per share) 68.90    
Weighted Average Exercise Price, Forfeited (in dollars per share) 111.48    
Weighted Average Exercise Price, Options Outstanding, December 31 (in dollars per share) 86.04 $ 77.54  
Weighted Average Exercise Price, Vested and expected to vest (in dollars per share) 85.10    
Weighted Average Exercise Price, Exercisable (in dollars per share) $ 74.00    
Weighted Average Remaining Contractual Term, Outstanding 5 years 10 months 24 days    
Weighted Average Remaining Contractual Term, Vested and expected to vest 5 years 10 months 24 days    
Weighted Average Remaining Contractual Term, Exercisable 4 years 10 months 24 days    
Aggregate Intrinsic Value, Outstanding $ 249    
Aggregate Intrinsic Value, Vested and expected to vest 249    
Aggregate Intrinsic Value, Exercisable $ 241    
XML 134 R93.htm IDEA: XBRL DOCUMENT v3.25.0.1
Share-Based Compensation Plans - Additional Information Pertaining to Stock Option Plans (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]      
Total intrinsic value of stock options exercised $ 144 $ 95 $ 225
Fair value of stock options vested 32 30 30
Cash received from the exercise of stock options $ 177 $ 125 $ 384
XML 135 R94.htm IDEA: XBRL DOCUMENT v3.25.0.1
Share-Based Compensation Plans - Summary of Nonvested RSU and PSU Activity (Details)
shares in Thousands
12 Months Ended
Dec. 31, 2024
$ / shares
shares
RSUs  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]  
Number of Shares, Nonvested January 1 (in shares) | shares 12,542
Number of Shares, Granted (in shares) | shares 6,356
Number of Shares, Vested (in shares) | shares (6,091)
Number of Shares, Forfeited (in shares) | shares (575)
Number of Shares, Nonvested December 31 (in shares) | shares 12,232
Number of Shares, Expected to Vest (in shares) | shares 10,976
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]  
Weighted Average Grant Date Fair Value, Nonvested January 1 (in dollars per share) | $ / shares $ 100.10
Weighted Average Grant Date Fair Value, Granted (in dollars per share) | $ / shares 128.79
Weighted Average Grant Date Fair Value, Vested (in dollars per share) | $ / shares 92.97
Weighted Average Grant Date Fair Value, Forfeited (in dollars per share) | $ / shares 113.18
Weighted Average Grant Date Fair Value, Nonvested December 31 (in dollars per share) | $ / shares 117.94
Weighted Average Grant Date Fair Value, Expected to vest (in dollars per share) | $ / shares $ 117.25
PSUs  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]  
Number of Shares, Nonvested January 1 (in shares) | shares 1,966
Number of Shares, Granted (in shares) | shares 968
Number of Shares, Vested (in shares) | shares (1,109)
Number of Shares, Forfeited (in shares) | shares (59)
Number of Shares, Nonvested December 31 (in shares) | shares 1,766
Number of Shares, Expected to Vest (in shares) | shares 1,669
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]  
Weighted Average Grant Date Fair Value, Nonvested January 1 (in dollars per share) | $ / shares $ 90.80
Weighted Average Grant Date Fair Value, Granted (in dollars per share) | $ / shares 121.91
Weighted Average Grant Date Fair Value, Vested (in dollars per share) | $ / shares 73.50
Weighted Average Grant Date Fair Value, Forfeited (in dollars per share) | $ / shares 121.12
Weighted Average Grant Date Fair Value, Nonvested December 31 (in dollars per share) | $ / shares 117.57
Weighted Average Grant Date Fair Value, Expected to vest (in dollars per share) | $ / shares $ 116.26
XML 136 R95.htm IDEA: XBRL DOCUMENT v3.25.0.1
Pension and Other Postretirement Benefit Plans - Narrative (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Defined Benefit Plan Disclosure [Line Items]        
Employer contributions to defined contribution savings plans   $ 215 $ 199 $ 175
Pension Benefits        
Defined Benefit Plan Disclosure [Line Items]        
Accumulated benefit obligation   $ 18,100 $ 19,100  
Percentage of Company's pension investments categorized as level 3 assets   4.00% 4.00%  
Pension Benefits | Level 3        
Defined Benefit Plan Disclosure [Line Items]        
Fair value of plan assets   $ 700 $ 788  
Other Postretirement Benefits        
Defined Benefit Plan Disclosure [Line Items]        
Fair value of plan assets   1,040 1,045 $ 947
Expected contributions to the pension plans and other postretirement benefit plans during next fiscal year   70    
Other Postretirement Benefits | Level 3        
Defined Benefit Plan Disclosure [Line Items]        
Fair value of plan assets   $ 0 $ 0  
United States        
Defined Benefit Plan Disclosure [Line Items]        
Expected annual standard deviation in returns of the target portfolio which reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests   12.00%    
Expected rate of return on plan assets   7.75% 7.00% 6.70%
United States | Forecast | Subsequent Event        
Defined Benefit Plan Disclosure [Line Items]        
Expected rate of return on plan assets 7.70%      
United States | U.S. equities | Minimum        
Defined Benefit Plan Disclosure [Line Items]        
Target allocation   25.00%    
United States | U.S. equities | Maximum        
Defined Benefit Plan Disclosure [Line Items]        
Target allocation   40.00%    
United States | International equities | Minimum        
Defined Benefit Plan Disclosure [Line Items]        
Target allocation   15.00%    
United States | International equities | Maximum        
Defined Benefit Plan Disclosure [Line Items]        
Target allocation   30.00%    
United States | Fixed Income Investments | Minimum        
Defined Benefit Plan Disclosure [Line Items]        
Target allocation   40.00%    
United States | Fixed Income Investments | Maximum        
Defined Benefit Plan Disclosure [Line Items]        
Target allocation   50.00%    
United States | Cash And Other Investments | Maximum        
Defined Benefit Plan Disclosure [Line Items]        
Target allocation   8.00%    
United States | Pension Benefits        
Defined Benefit Plan Disclosure [Line Items]        
Accumulated benefit obligation   $ 10,000 $ 10,300  
Fair value of plan assets   9,717 9,804 $ 9,094
Expected contributions to the pension plans and other postretirement benefit plans during next fiscal year   270    
United States | Pension Benefits | Level 3        
Defined Benefit Plan Disclosure [Line Items]        
Fair value of plan assets   2 3 4
International | Pension Benefits        
Defined Benefit Plan Disclosure [Line Items]        
Fair value of plan assets   9,647 $ 9,562 $ 8,473
Expected contributions to the pension plans and other postretirement benefit plans during next fiscal year   $ 180    
Expected rate of return on plan assets   5.20% 5.00% 3.70%
International | Pension Benefits | Level 3        
Defined Benefit Plan Disclosure [Line Items]        
Fair value of plan assets   $ 698 $ 785 $ 761
XML 137 R96.htm IDEA: XBRL DOCUMENT v3.25.0.1
Pension and Other Postretirement Benefit Plans - Components of Net Periodic Benefit Cost (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Other Postretirement Benefits      
Defined Benefit Plan Disclosure [Line Items]      
Service cost $ 30 $ 32 $ 48
Interest cost 56 63 46
Expected return on plan assets (80) (64) (86)
Amortization of unrecognized prior service (credit) cost (43) (49) (57)
Net loss (gain) amortization (51) (42) (43)
Termination benefits 4 0 0
Curtailments 0 (1) (1)
Settlements 0 0 0
Net periodic benefit cost (credit) (84) (61) (93)
United States | Pension Benefits      
Defined Benefit Plan Disclosure [Line Items]      
Service cost 373 326 372
Interest cost 537 526 457
Expected return on plan assets (826) (735) (753)
Amortization of unrecognized prior service (credit) cost 0 (1) (32)
Net loss (gain) amortization 43 0 128
Termination benefits 5 3 2
Curtailments 0 8 12
Settlements 0 28 239
Net periodic benefit cost (credit) 132 155 425
International | Pension Benefits      
Defined Benefit Plan Disclosure [Line Items]      
Service cost 243 196 283
Interest cost 294 299 145
Expected return on plan assets (554) (517) (383)
Amortization of unrecognized prior service (credit) cost (13) 2 (14)
Net loss (gain) amortization 5 (3) 96
Termination benefits 1 0 1
Curtailments 0 (1) 0
Settlements (1) (5) 1
Net periodic benefit cost (credit) $ (25) $ (29) $ 129
XML 138 R97.htm IDEA: XBRL DOCUMENT v3.25.0.1
Pension and Other Postretirement Benefit Plans - Obligation and Funded Status (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Other Postretirement Benefits      
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]      
Fair value of plan assets January 1 $ 1,045 $ 947  
Actual return on plan assets 35 115  
Company contributions 46 74  
Effects of exchange rate changes 0 0  
Benefits paid (89) (95)  
Settlements 0 (2)  
Other 3 6  
Fair value of plan assets December 31 1,040 1,045 $ 947
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]      
Benefit obligation January 1 1,104 1,157  
Service cost 30 32 48
Interest cost 56 63 46
Actuarial (gains) losses 32 (58)  
Benefits paid (89) (95)  
Effects of exchange rate changes (4) 1  
Plan amendments 0 0  
Curtailments 0 0  
Termination benefits 4 0 0
Settlements 0 (2)  
Other 3 6  
Benefit obligation December 31 1,136 1,104 1,157
Funded status December 31 (96) (59)  
Recognized as:      
Other Assets 51 107  
Accrued and other current liabilities (7) (8)  
Other Noncurrent Liabilities (140) (158)  
United States | Pension Benefits      
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]      
Fair value of plan assets January 1 9,804 9,094  
Actual return on plan assets 266 1,077  
Company contributions 262 307  
Effects of exchange rate changes 0 0  
Benefits paid (615) (497)  
Settlements 0 (177)  
Other 0 0  
Fair value of plan assets December 31 9,717 9,804 9,094
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]      
Benefit obligation January 1 10,446 9,854  
Service cost 373 326 372
Interest cost 537 526 457
Actuarial (gains) losses (595) 403  
Benefits paid (615) (497)  
Effects of exchange rate changes 0 0  
Plan amendments 0 0  
Curtailments 0 8  
Termination benefits 5 3 2
Settlements 0 (177)  
Other 0 0  
Benefit obligation December 31 10,151 10,446 9,854
Funded status December 31 (434) (642)  
Recognized as:      
Other Assets 26 0  
Accrued and other current liabilities (55) (49)  
Other Noncurrent Liabilities (405) (593)  
International | Pension Benefits      
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]      
Fair value of plan assets January 1 9,562 8,473  
Actual return on plan assets 637 832  
Company contributions 198 249  
Effects of exchange rate changes (522) 283  
Benefits paid (250) (256)  
Settlements (14) (53)  
Other 36 34  
Fair value of plan assets December 31 9,647 9,562 8,473
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]      
Benefit obligation January 1 9,042 7,755  
Service cost 243 196 283
Interest cost 294 299 145
Actuarial (gains) losses (549) 766  
Benefits paid (250) (256)  
Effects of exchange rate changes (473) 288  
Plan amendments (56) 14  
Curtailments 0 (1)  
Termination benefits 1 0 1
Settlements (14) (53)  
Other 36 34  
Benefit obligation December 31 8,274 9,042 $ 7,755
Funded status December 31 1,373 520  
Recognized as:      
Other Assets 1,785 1,019  
Accrued and other current liabilities (18) (19)  
Other Noncurrent Liabilities $ (394) $ (480)  
XML 139 R98.htm IDEA: XBRL DOCUMENT v3.25.0.1
Pension and Other Postretirement Benefit Plans - Accumulated and Projected Benefit Obligation in Excess of Plan Assets (Details) - Pension Benefits - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
United States    
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]    
Pension plans with a projected benefit obligation in excess of plan assets, projected benefit obligation $ 9,517 $ 10,446
Pension plans with a projected benefit obligation in excess of plan assets, fair value of plan assets 9,057 9,804
Pension plans with an accumulated benefit obligation in excess of plan assets, accumulated benefit obligation 442 9,700
Pension plans with an accumulated benefit obligation in excess of plan assets, fair value of plan assets 0 9,186
International    
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]    
Pension plans with a projected benefit obligation in excess of plan assets, projected benefit obligation 1,847 2,961
Pension plans with a projected benefit obligation in excess of plan assets, fair value of plan assets 1,435 2,462
Pension plans with an accumulated benefit obligation in excess of plan assets, accumulated benefit obligation 1,768 1,791
Pension plans with an accumulated benefit obligation in excess of plan assets, fair value of plan assets $ 1,385 $ 1,336
XML 140 R99.htm IDEA: XBRL DOCUMENT v3.25.0.1
Pension and Other Postretirement Benefit Plans - Fair Values of Pension Plan Assets (Details) - Pension Benefits - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Level 3      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets $ 700 $ 788  
United States      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 9,717 9,804 $ 9,094
United States | Cash and cash equivalents      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 164 158  
United States | Developed markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 2,555 2,797  
United States | Emerging markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 1,265 740  
United States | Real estate      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 174 113  
United States | Developed markets      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 2,171 2,071  
United States | Government and agency obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 2,101 2,307  
United States | Corporate obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 1,293 1,485  
United States | Mortgage and asset-backed securities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 21 21  
United States | Derivatives      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets (29) 109  
United States | Other      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 2 3  
United States | Level 1      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 2,355 2,438  
United States | Level 1 | Cash and cash equivalents      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 43 34  
United States | Level 1 | Developed markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 170 224  
United States | Level 1 | Emerging markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Level 1 | Real estate      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Level 1 | Developed markets      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 2,171 2,071  
United States | Level 1 | Government and agency obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Level 1 | Corporate obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Level 1 | Mortgage and asset-backed securities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Level 1 | Derivatives      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets (29) 109  
United States | Level 1 | Other      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Level 2      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 3,415 3,813  
United States | Level 2 | Cash and cash equivalents      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Level 2 | Developed markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Level 2 | Emerging markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Level 2 | Real estate      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Level 2 | Developed markets      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Level 2 | Government and agency obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 2,101 2,307  
United States | Level 2 | Corporate obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 1,293 1,485  
United States | Level 2 | Mortgage and asset-backed securities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 21 21  
United States | Level 2 | Derivatives      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Level 2 | Other      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Level 3      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 2 3 4
United States | Level 3 | Cash and cash equivalents      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Level 3 | Developed markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Level 3 | Emerging markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Level 3 | Real estate      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Level 3 | Developed markets      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Level 3 | Government and agency obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Level 3 | Corporate obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Level 3 | Mortgage and asset-backed securities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Level 3 | Derivatives      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Level 3 | Insurance contracts      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0 0
United States | Level 3 | Other      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 2 3 4
United States | NAV      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 3,945 3,550  
United States | NAV | Cash and cash equivalents      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 121 124  
United States | NAV | Developed markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 2,385 2,573  
United States | NAV | Emerging markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 1,265 740  
United States | NAV | Real estate      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 174 113  
United States | NAV | Developed markets      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | NAV | Government and agency obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | NAV | Corporate obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | NAV | Mortgage and asset-backed securities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | NAV | Derivatives      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | NAV | Other      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 9,647 9,562 8,473
International | Cash and cash equivalents      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 123 118  
International | Developed markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 4,232 3,870  
International | Emerging markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 145 110  
International | Real estate      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 12 10  
International | Government and agency obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 3,385 3,523  
International | Corporate obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 180 197  
International | Other fixed income obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 19 20  
International | Developed markets      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 287 278  
International | Government and agency obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 368 423  
International | Corporate obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 141 160  
International | Mortgage and asset-backed securities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 54 61  
International | Insurance contracts      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 701 788  
International | Other      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 4  
International | Level 1      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 1,345 1,197  
International | Level 1 | Cash and cash equivalents      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 112 98  
International | Level 1 | Developed markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 599 507  
International | Level 1 | Emerging markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 54 44  
International | Level 1 | Real estate      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International | Level 1 | Government and agency obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 262 234  
International | Level 1 | Corporate obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 23 23  
International | Level 1 | Other fixed income obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 8 9  
International | Level 1 | Developed markets      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 287 278  
International | Level 1 | Government and agency obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International | Level 1 | Corporate obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International | Level 1 | Mortgage and asset-backed securities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International | Level 1 | Insurance contracts      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International | Level 1 | Other      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 4  
International | Level 2      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 7,090 7,041  
International | Level 2 | Cash and cash equivalents      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International | Level 2 | Developed markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 3,537 3,257  
International | Level 2 | Emerging markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International | Level 2 | Real estate      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International | Level 2 | Government and agency obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 2,974 3,123  
International | Level 2 | Corporate obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 8 8  
International | Level 2 | Other fixed income obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 7 8  
International | Level 2 | Developed markets      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International | Level 2 | Government and agency obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 368 423  
International | Level 2 | Corporate obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 141 160  
International | Level 2 | Mortgage and asset-backed securities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 54 61  
International | Level 2 | Insurance contracts      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 1 1  
International | Level 2 | Other      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International | Level 3      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 698 785 761
International | Level 3 | Cash and cash equivalents      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International | Level 3 | Developed markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International | Level 3 | Emerging markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International | Level 3 | Real estate      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International | Level 3 | Government and agency obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International | Level 3 | Corporate obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International | Level 3 | Other fixed income obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International | Level 3 | Developed markets      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International | Level 3 | Government and agency obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International | Level 3 | Corporate obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International | Level 3 | Mortgage and asset-backed securities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International | Level 3 | Insurance contracts      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 698 785 761
International | Level 3 | Other      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0 $ 0
International | NAV      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 514 539  
International | NAV | Cash and cash equivalents      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 11 20  
International | NAV | Developed markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 96 106  
International | NAV | Emerging markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 91 66  
International | NAV | Real estate      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 12 10  
International | NAV | Government and agency obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 149 166  
International | NAV | Corporate obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 149 166  
International | NAV | Other fixed income obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 4 3  
International | NAV | Developed markets      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International | NAV | Government and agency obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International | NAV | Corporate obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International | NAV | Mortgage and asset-backed securities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International | NAV | Insurance contracts      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 2 2  
International | NAV | Other      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets $ 0 $ 0  
XML 141 R100.htm IDEA: XBRL DOCUMENT v3.25.0.1
Pension and Other Postretirement Benefit Plans - Summary of Changes in Fair Value of Company's Level 3 Pension Plan Assets (Details) - Pension Benefits - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Level 3    
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]    
Fair value of plan assets January 1 $ 788  
Actual return on plan assets:    
Fair value of plan assets December 31 700 $ 788
United States    
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]    
Fair value of plan assets January 1 9,804 9,094
Actual return on plan assets:    
Fair value of plan assets December 31 9,717 9,804
United States | Other    
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]    
Fair value of plan assets January 1 3  
Actual return on plan assets:    
Fair value of plan assets December 31 2 3
United States | Level 3    
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]    
Fair value of plan assets January 1 3 4
Actual return on plan assets:    
Relating to assets still held at December 31 (2) (2)
Relating to assets sold during the year 2 2
Purchases and sales, net (1) (1)
Fair value of plan assets December 31 2 3
United States | Level 3 | Insurance Contracts    
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]    
Fair value of plan assets January 1 0 0
Actual return on plan assets:    
Relating to assets still held at December 31 0 0
Relating to assets sold during the year 0 0
Purchases and sales, net 0 0
Fair value of plan assets December 31 0 0
United States | Level 3 | Other    
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]    
Fair value of plan assets January 1 3 4
Actual return on plan assets:    
Relating to assets still held at December 31 (2) (2)
Relating to assets sold during the year 2 2
Purchases and sales, net (1) (1)
Fair value of plan assets December 31 2 3
International    
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]    
Fair value of plan assets January 1 9,562 8,473
Actual return on plan assets:    
Fair value of plan assets December 31 9,647 9,562
International | Insurance Contracts    
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]    
Fair value of plan assets January 1 788  
Actual return on plan assets:    
Fair value of plan assets December 31 701 788
International | Other    
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]    
Fair value of plan assets January 1 4  
Actual return on plan assets:    
Fair value of plan assets December 31 0 4
International | Level 3    
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]    
Fair value of plan assets January 1 785 761
Actual return on plan assets:    
Relating to assets still held at December 31 (26) 77
Purchases and sales, net (61) (53)
Fair value of plan assets December 31 698 785
International | Level 3 | Insurance Contracts    
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]    
Fair value of plan assets January 1 785 761
Actual return on plan assets:    
Relating to assets still held at December 31 (26) 77
Purchases and sales, net (61) (53)
Fair value of plan assets December 31 698 785
International | Level 3 | Other    
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]    
Fair value of plan assets January 1 0 0
Actual return on plan assets:    
Relating to assets still held at December 31 0 0
Purchases and sales, net 0 0
Fair value of plan assets December 31 $ 0 $ 0
XML 142 R101.htm IDEA: XBRL DOCUMENT v3.25.0.1
Pension and Other Postretirement Benefit Plans - Fair Values of Other Postretirement Benefit Plan Assets (Details) - Other Postretirement Benefits - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value $ 1,040 $ 1,045 $ 947
Cash and cash equivalents      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 5 13  
Developed markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 49 301  
Emerging markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 24 80  
Real estate      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 3 12  
Developed markets      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 41 223  
Corporate obligations      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 598 157  
Government and agency obligations      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 266 245  
Mortgage and asset-backed securities      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 54 2  
Derivatives      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 12  
Level 1      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 44 259  
Level 1 | Cash and cash equivalents      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
Level 1 | Developed markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 3 24  
Level 1 | Emerging markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
Level 1 | Real estate      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
Level 1 | Developed markets      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 41 223  
Level 1 | Corporate obligations      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
Level 1 | Government and agency obligations      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
Level 1 | Mortgage and asset-backed securities      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
Level 1 | Derivatives      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 12  
Level 2      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 918 404  
Level 2 | Cash and cash equivalents      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
Level 2 | Developed markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
Level 2 | Emerging markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
Level 2 | Real estate      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
Level 2 | Developed markets      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
Level 2 | Corporate obligations      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 598 157  
Level 2 | Government and agency obligations      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 266 245  
Level 2 | Mortgage and asset-backed securities      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 54 2  
Level 2 | Derivatives      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
Level 3      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
Level 3 | Cash and cash equivalents      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
Level 3 | Developed markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
Level 3 | Emerging markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
Level 3 | Real estate      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
Level 3 | Developed markets      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
Level 3 | Corporate obligations      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
Level 3 | Government and agency obligations      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
Level 3 | Mortgage and asset-backed securities      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
Level 3 | Derivatives      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
NAV      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 78 382  
NAV | Cash and cash equivalents      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 5 13  
NAV | Developed markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 46 277  
NAV | Emerging markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 24 80  
NAV | Real estate      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 3 12  
NAV | Developed markets      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0  
NAV | Corporate obligations      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0  
NAV | Government and agency obligations      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0  
NAV | Mortgage and asset-backed securities      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
NAV | Derivatives      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value $ 0 $ 0  
XML 143 R102.htm IDEA: XBRL DOCUMENT v3.25.0.1
Pension and Other Postretirement Benefit Plans - Summary of Expected Benefit Payments (Details)
$ in Millions
Dec. 31, 2024
USD ($)
Other Postretirement Benefits  
Defined Benefit Plan Disclosure [Line Items]  
2025 $ 86
2026 87
2027 89
2028 91
2029 96
2030 — 2034 515
United States | Pension Benefits  
Defined Benefit Plan Disclosure [Line Items]  
2025 771
2026 775
2027 789
2028 799
2029 822
2030 — 2034 4,386
International | Pension Benefits  
Defined Benefit Plan Disclosure [Line Items]  
2025 291
2026 275
2027 286
2028 300
2029 314
2030 — 2034 $ 1,792
XML 144 R103.htm IDEA: XBRL DOCUMENT v3.25.0.1
Pension and Other Postretirement Benefit Plans - Components of Other Comprehensive Income (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Other Postretirement Benefits      
Defined Benefit Plan Disclosure [Line Items]      
Net gain (loss) arising during the period $ (78) $ 110 $ 0
Prior service credit (cost) arising during the period 0 0 0
Total (78) 110 0
Net loss (gain) amortization included in benefit cost (51) (42) (43)
Prior service (credit) cost amortization included in benefit cost (43) (49) (57)
Settlements and curtailments 0 (1) (1)
Total (94) (92) (101)
United States | Pension Benefits      
Defined Benefit Plan Disclosure [Line Items]      
Net gain (loss) arising during the period 35 (69) (42)
Prior service credit (cost) arising during the period 0 0 0
Total 35 (69) (42)
Net loss (gain) amortization included in benefit cost 43 0 128
Prior service (credit) cost amortization included in benefit cost 0 (1) (32)
Settlements and curtailments 0 36 251
Total 43 35 347
International | Pension Benefits      
Defined Benefit Plan Disclosure [Line Items]      
Net gain (loss) arising during the period 634 (438) 116
Prior service credit (cost) arising during the period 56 (16) (4)
Total 690 (454) 112
Net loss (gain) amortization included in benefit cost 5 (3) 96
Prior service (credit) cost amortization included in benefit cost (13) 2 (14)
Settlements and curtailments (1) (6) 1
Total $ (9) $ (7) $ 83
XML 145 R104.htm IDEA: XBRL DOCUMENT v3.25.0.1
Pension and Other Postretirement Benefit Plans - Summary of Weighted Average Assumptions Used in Determining Pension Plan and U.S. Pension and Other Postretirement Benefit Plan Information (Details)
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
United States      
Net periodic benefit cost      
Discount rate 5.30% 5.50% 3.00%
Expected rate of return on plan assets 7.75% 7.00% 6.70%
Salary growth rate 4.60% 4.60% 4.60%
Interest crediting rate 5.30% 5.30% 5.00%
Benefit obligation      
Discount rate 5.70% 5.30% 5.50%
Salary growth rate 4.80% 4.60% 4.60%
Interest crediting rate 5.40% 5.30% 5.30%
International | Pension Benefits      
Net periodic benefit cost      
Discount rate 3.40% 3.90% 1.50%
Expected rate of return on plan assets 5.20% 5.00% 3.70%
Salary growth rate 3.20% 3.20% 2.90%
Interest crediting rate 3.40% 3.30% 3.00%
Benefit obligation      
Discount rate 3.70% 3.40% 3.90%
Salary growth rate 3.10% 3.20% 3.20%
Interest crediting rate 3.50% 3.40% 3.30%
XML 146 R105.htm IDEA: XBRL DOCUMENT v3.25.0.1
Pension and Other Postretirement Benefit Plans - Summary of Health Care Cost Trend Rate Assumptions for Other Postretirement Benefit Plans (Details) - Other Postretirement Benefits
Dec. 31, 2024
Dec. 31, 2023
Defined Benefit Plan Disclosure [Line Items]    
Health care cost trend rate assumed for next year 7.90% 7.80%
Rate to which the cost trend rate is assumed to decline 4.50% 4.50%
XML 147 R106.htm IDEA: XBRL DOCUMENT v3.25.0.1
Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Other Income and Expenses [Abstract]      
Interest income $ (415) $ (365) $ (157)
Interest expense 1,271 1,146 962
Exchange losses 227 370 237
(Income) loss from investments in equity securities, net (14) (340) 1,419
Net periodic defined benefit plan (credit) cost other than service cost (633) (498) (279)
Other, net (460) 153 (681)
Other (income) expense, net $ (24) $ 466 $ 1,501
XML 148 R107.htm IDEA: XBRL DOCUMENT v3.25.0.1
Other (Income) Expense, Net - Narrative (Details) - USD ($)
$ in Millions
1 Months Ended 12 Months Ended
Aug. 31, 2024
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Component of Other Income / Expense of Nonoperating [Line Items]        
Interest paid   $ 1,300.0 $ 1,100.0 $ 937.0
Zetia antitrust litigation        
Component of Other Income / Expense of Nonoperating [Line Items]        
Loss related to settlement litigation     $ 572.5  
Daiichi Sankyo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement        
Component of Other Income / Expense of Nonoperating [Line Items]        
Upfront cash payment $ 170.0      
XML 149 R108.htm IDEA: XBRL DOCUMENT v3.25.0.1
Taxes on Income - Reconciliation Between Effective Tax Rate and US Statutory Rate (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Amount      
U.S. statutory rate applied to income before taxes $ 4,186 $ 397 $ 3,453
Differential arising from:      
Foreign earnings (1,301) (941) (1,821)
Tax settlements and statute lapses (557) 0 (10)
R&D tax credit (202) (214) (117)
Inventory donations (71) (65) (52)
State taxes (39) (117) (110)
Charges for certain research and development asset acquisitions 554 253 0
Valuation allowances 54 70 108
Restructuring 52 41 11
GILTI and the foreign-derived intangible income deduction 29 (80) 462
Acquisition-related costs, including amortization 18 42 (3)
Acquisition of Prometheus 0 2,139 0
Other 80 (13) (3)
Taxes on income $ 2,803 $ 1,512 $ 1,918
Tax Rate      
U.S. statutory rate applied to income before taxes 21.00% 21.00% 21.00%
Differential arising from:      
Foreign earnings (6.50%) (49.80%) (11.10%)
Tax settlements and statute lapses (2.80%) 0.00% (0.10%)
R&D tax credit (1.00%) (11.30%) (0.70%)
Inventory donations (0.40%) (3.50%) (0.30%)
State taxes (0.20%) (6.20%) (0.70%)
Charges for certain research and development asset acquisitions 2.80% 13.40% 0.00%
Valuation allowances 0.30% 3.70% 0.70%
Restructuring 0.30% 2.20% 0.10%
GILTI and the foreign-derived intangible income deduction 0.10% (4.30%) 2.80%
Acquisition-related costs, including amortization 0.10% 2.20% 0.00%
Acquisition of Prometheus 0.00% 113.30% 0.00%
Other 0.40% (0.70%) 0.00%
Total, Tax Rate 14.10% 80.00% 11.70%
XML 150 R109.htm IDEA: XBRL DOCUMENT v3.25.0.1
Taxes on Income - Narrative (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Tax Contingency [Line Items]        
Transition tax for accumulated foreign earnings, liability $ 518      
Transition tax liability, current 1,200      
Transition tax asset, credit, noncurrent 702      
Deferred tax assets on NOL carryforwards relating to foreign jurisdictions 324      
Deferred tax assets relating to various U.S. tax credit carryforwards and NOL carryforwards 586      
Tax benefits relating to stock option exercises 26 $ 12 $ 45  
Unrecognized tax benefits 2,261 2,384 1,835 $ 1,529
Favorable net impact to income tax provision if unrecognized tax benefits were recognized 2,200      
Reasonably possible amount that liability for unrecognized tax benefits could decline up to in next 12 months (up to) 22      
Interest and penalties associated with uncertain tax positions, expense (benefit) 51 131 $ 54  
Liabilities for accrued interest and penalties 437 $ 388    
Tax Year 2019 and 2020        
Income Tax Contingency [Line Items]        
Reduction in reserves resulting from lapse of statute of limitations 519      
Foreign Jurisdiction        
Income Tax Contingency [Line Items]        
Valuation allowance on foreign NOL carryforwards 264      
Federal        
Income Tax Contingency [Line Items]        
Valuation allowance on foreign NOL carryforwards $ 446      
XML 151 R110.htm IDEA: XBRL DOCUMENT v3.25.0.1
Taxes on Income - Income Before Taxes (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Income Tax Disclosure [Abstract]      
Domestic $ (1,849) $ (15,622) $ 1,011
Foreign 21,785 17,511 15,433
Income Before Taxes $ 19,936 $ 1,889 $ 16,444
XML 152 R111.htm IDEA: XBRL DOCUMENT v3.25.0.1
Taxes on Income - Taxes on Income (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Current provision      
Federal $ 944 $ 928 $ 2,265
Foreign 3,123 2,435 1,164
State (15) 48 57
Total current provision 4,052 3,411 3,486
Deferred provision      
Federal (1,475) (1,559) (1,510)
Foreign 212 (233) 71
State 14 (107) (129)
Total deferred provision (1,249) (1,899) (1,568)
Taxes on income $ 2,803 $ 1,512 $ 1,918
XML 153 R112.htm IDEA: XBRL DOCUMENT v3.25.0.1
Taxes on Income - Deferred Income Taxes (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Income Tax [Line Items]    
Product intangibles and licenses, Assets $ 71  
Product intangibles and licenses, Liabilities 978 $ 1,308
R&D capitalization, Assets 3,062 2,099
Inventory related, Assets 84 86
Inventory related, Liabilities 413 370
Accelerated depreciation, Liabilities 645 626
Undistributed foreign earnings, Assets 275 76
Undistributed foreign earnings, Liabilities 371 118
Equity method investments, Liabilities 90 73
Pensions and other postretirement benefits, Assets 224 323
Pensions and other postretirement benefits, Liabilities 400 249
Compensation related, Assets 400 357
Unrecognized tax benefits, Assets 152 147
Net operating losses and other tax credit carryforwards, Assets 910 868
Other, Assets 802 755
Other, Liabilities 159 214
Subtotal, Assets 5,980 4,711
Subtotal, Liabilities 3,056 2,958
Valuation allowance, Assets (710) (656)
Total deferred taxes 5,270 4,055
Deferred income taxes, Assets 2,214 1,097
Deferred Income Taxes 1,387 871
Other Assets    
Income Tax [Line Items]    
Total deferred taxes $ 3,601 $ 1,968
XML 154 R113.htm IDEA: XBRL DOCUMENT v3.25.0.1
Taxes on Income - Income Tax Authority (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Income Tax Contingency [Line Items]      
Income taxes paid $ 3,928 $ 4,338 $ 3,239
Federal      
Income Tax Contingency [Line Items]      
Income taxes paid 974 2,258 1,891
Foreign Jurisdiction      
Income Tax Contingency [Line Items]      
Income taxes paid $ 2,954 $ 2,080 $ 1,348
XML 155 R114.htm IDEA: XBRL DOCUMENT v3.25.0.1
Taxes on Income - Unrecognized Tax Benefits (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Reconciliation of Unrecognized Tax Benefits [Roll Forward]      
Balance January 1 $ 2,384 $ 1,835 $ 1,529
Additions related to current year positions 421 553 344
Additions related to prior year positions 35 91 48
Reductions for tax positions of prior years (33) (20) (40)
Settlements (18) (23) (6)
Lapse of statute of limitations (528) (52) (40)
Balance December 31 2,261 $ 2,384 $ 1,835
Tax Year 2019 and 2020      
Reconciliation of Unrecognized Tax Benefits [Roll Forward]      
Lapse of statute of limitations $ (451)    
XML 156 R115.htm IDEA: XBRL DOCUMENT v3.25.0.1
Earnings Per Share - Calculations of Earnings Per Share (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Earnings Per Share [Abstract]      
Net income attributable to Merck & Co., Inc., basic $ 17,117 $ 365 $ 14,519
Net income attributable to Merck & Co., Inc., diluted $ 17,117 $ 365 $ 14,519
Average common shares outstanding (in shares) 2,532 2,537 2,532
Common shares issuable (in shares) 9 10 10
Average common shares outstanding assuming dilution (in shares) 2,541 2,547 2,542
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) $ 6.76 $ 0.14 $ 5.73
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) $ 6.74 $ 0.14 $ 5.71
XML 157 R116.htm IDEA: XBRL DOCUMENT v3.25.0.1
Earnings Per Share - Narrative (Details) - shares
shares in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Earnings Per Share [Abstract]      
Antidilutive shares (in shares) 6 5 2
XML 158 R117.htm IDEA: XBRL DOCUMENT v3.25.0.1
Other Comprehensive Income (Loss) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Roll Forward]      
Beginning balance $ 37,635 $ 46,058 $ 38,257
Other comprehensive income (loss), net of taxes 216 (393) (339)
Ending balance 46,372 37,635 46,058
Derivatives      
Accumulated Other Comprehensive Income (Loss) [Roll Forward]      
Beginning balance (24) 73 144
Other comprehensive income (loss) before reclassification adjustments, pretax 508 114 684
Tax (109) (24) (143)
Other comprehensive income (loss) before reclassification adjustments, net of taxes 399 90 541
Reclassification adjustments, pretax (168) (237) (775)
Tax 35 50 163
Reclassification adjustments, net of taxes (133) (187) (612)
Other comprehensive income (loss), net of taxes 266 (97) (71)
Ending balance 242 (24) 73
Employee Benefit Plans      
Accumulated Other Comprehensive Income (Loss) [Roll Forward]      
Beginning balance (2,793) (2,408) (2,743)
Other comprehensive income (loss) before reclassification adjustments, pretax 647 (413) 70
Tax (138) 86 12
Other comprehensive income (loss) before reclassification adjustments, net of taxes 509 (327) 82
Reclassification adjustments, pretax (60) (64) 329
Tax 17 6 (76)
Reclassification adjustments, net of taxes (43) (58) 253
Other comprehensive income (loss), net of taxes 466 (385) 335
Ending balance (2,327) (2,793) (2,408)
Pension Plan Net Loss      
Accumulated Other Comprehensive Income (Loss) [Roll Forward]      
Pension and other postretirement benefit plans, net loss (gain) and prior service (credit) included in AOCI 3,000 3,500  
Other Postretirement Benefit Plan Net Gain      
Accumulated Other Comprehensive Income (Loss) [Roll Forward]      
Pension and other postretirement benefit plans, net loss (gain) and prior service (credit) included in AOCI (400) (500)  
Pension Plan Prior Service Credit      
Accumulated Other Comprehensive Income (Loss) [Roll Forward]      
Pension and other postretirement benefit plans, net loss (gain) and prior service (credit) included in AOCI (174) (141)  
Other Postretirement Benefit Plan Prior Service Credit      
Accumulated Other Comprehensive Income (Loss) [Roll Forward]      
Pension and other postretirement benefit plans, net loss (gain) and prior service (credit) included in AOCI (61) (95)  
Foreign Currency Translation Adjustment      
Accumulated Other Comprehensive Income (Loss) [Roll Forward]      
Beginning balance (2,344) (2,433) (1,830)
Other comprehensive income (loss) before reclassification adjustments, pretax (559) 17 (584)
Tax 23 63 (19)
Other comprehensive income (loss) before reclassification adjustments, net of taxes (536) 80 (603)
Reclassification adjustments, pretax 20 9 0
Tax 0 0 0
Reclassification adjustments, net of taxes 20 9 0
Other comprehensive income (loss), net of taxes (516) 89 (603)
Ending balance (2,860) (2,344) (2,433)
Accumulated Other Comprehensive Loss      
Accumulated Other Comprehensive Income (Loss) [Roll Forward]      
Beginning balance (5,161) (4,768) (4,429)
Other comprehensive income (loss) before reclassification adjustments, pretax 596 (282) 170
Tax (224) 125 (150)
Other comprehensive income (loss) before reclassification adjustments, net of taxes 372 (157) 20
Reclassification adjustments, pretax (208) (292) (446)
Tax 52 56 87
Reclassification adjustments, net of taxes (156) (236) (359)
Other comprehensive income (loss), net of taxes 216 (393) (339)
Ending balance $ (4,945) $ (5,161) $ (4,768)
XML 159 R118.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment Reporting - Narrative (Details)
12 Months Ended
Dec. 31, 2024
segment
Segment Reporting [Abstract]  
Number of operating segments 2
XML 160 R119.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment Reporting - Sales of Company's Products (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Segment Reporting Information [Line Items]      
Sales $ 64,168 $ 60,115 $ 59,283
Increase (decrease) in revenue hedging activities 195 244 810
Revenue related to the sale of the marketing rights 106 118 165
Operating Segments      
Segment Reporting Information [Line Items]      
Sales 63,277 59,208 57,555
Operating Segments | Pharmaceutical      
Segment Reporting Information [Line Items]      
Sales 57,400 53,583 52,005
Operating Segments | Pharmaceutical | Keytruda      
Segment Reporting Information [Line Items]      
Sales 29,482 25,011 20,937
Operating Segments | Pharmaceutical | Alliance revenue - Lynparza      
Segment Reporting Information [Line Items]      
Sales 1,311 1,199 1,116
Operating Segments | Pharmaceutical | Alliance revenue - Lenvima      
Segment Reporting Information [Line Items]      
Sales 1,010 960 876
Operating Segments | Pharmaceutical | Welireg      
Segment Reporting Information [Line Items]      
Sales 509 218 123
Operating Segments | Pharmaceutical | Alliance revenue - Reblozyl      
Segment Reporting Information [Line Items]      
Sales 371 212 166
Operating Segments | Pharmaceutical | Gardasil/Gardasil 9      
Segment Reporting Information [Line Items]      
Sales 8,583 8,886 6,897
Operating Segments | Pharmaceutical | ProQuad/M-M-R II/Varivax      
Segment Reporting Information [Line Items]      
Sales 2,485 2,368 2,241
Operating Segments | Pharmaceutical | Vaxneuvance      
Segment Reporting Information [Line Items]      
Sales 808 665 170
Operating Segments | Pharmaceutical | RotaTeq      
Segment Reporting Information [Line Items]      
Sales 711 769 783
Operating Segments | Pharmaceutical | Pneumovax 23      
Segment Reporting Information [Line Items]      
Sales 263 412 602
Operating Segments | Pharmaceutical | Bridion      
Segment Reporting Information [Line Items]      
Sales 1,764 1,842 1,685
Operating Segments | Pharmaceutical | Prevymis      
Segment Reporting Information [Line Items]      
Sales 785 605 428
Operating Segments | Pharmaceutical | Dificid      
Segment Reporting Information [Line Items]      
Sales 340 302 263
Operating Segments | Pharmaceutical | Zerbaxa      
Segment Reporting Information [Line Items]      
Sales 252 218 169
Operating Segments | Pharmaceutical | Noxafil      
Segment Reporting Information [Line Items]      
Sales 177 213 238
Operating Segments | Pharmaceutical | Winrevair      
Segment Reporting Information [Line Items]      
Sales 419 0 0
Operating Segments | Pharmaceutical | Alliance revenue - Adempas/Verquvo      
Segment Reporting Information [Line Items]      
Sales 415 367 341
Operating Segments | Pharmaceutical | Adempas      
Segment Reporting Information [Line Items]      
Sales 287 255 238
Operating Segments | Pharmaceutical | Lagevrio      
Segment Reporting Information [Line Items]      
Sales 964 1,428 5,684
Operating Segments | Pharmaceutical | Isentress/Isentress HD      
Segment Reporting Information [Line Items]      
Sales 394 483 633
Operating Segments | Pharmaceutical | Delstrigo      
Segment Reporting Information [Line Items]      
Sales 249 201 151
Operating Segments | Pharmaceutical | Pifeltro      
Segment Reporting Information [Line Items]      
Sales 163 142 118
Operating Segments | Pharmaceutical | Belsomra      
Segment Reporting Information [Line Items]      
Sales 222 231 258
Operating Segments | Pharmaceutical | Simponi      
Segment Reporting Information [Line Items]      
Sales 543 710 706
Operating Segments | Pharmaceutical | Remicade      
Segment Reporting Information [Line Items]      
Sales 114 187 207
Operating Segments | Pharmaceutical | Januvia      
Segment Reporting Information [Line Items]      
Sales 1,334 2,189 2,813
Operating Segments | Pharmaceutical | Janumet      
Segment Reporting Information [Line Items]      
Sales 935 1,177 1,700
Operating Segments | Pharmaceutical | Other pharmaceutical      
Segment Reporting Information [Line Items]      
Sales 2,510 2,333 2,462
Operating Segments | Animal Health      
Segment Reporting Information [Line Items]      
Sales 5,877 5,625 5,550
Operating Segments | Animal Health | Livestock      
Segment Reporting Information [Line Items]      
Sales 3,462 3,337 3,300
Operating Segments | Animal Health | Companion Animal      
Segment Reporting Information [Line Items]      
Sales 2,415 2,288 2,250
Other      
Segment Reporting Information [Line Items]      
Sales 891 907 1,728
United States      
Segment Reporting Information [Line Items]      
Sales 32,277 28,480 27,206
United States | Operating Segments      
Segment Reporting Information [Line Items]      
Sales 32,151 28,343 26,811
United States | Operating Segments | Pharmaceutical      
Segment Reporting Information [Line Items]      
Sales 30,290 26,539 24,989
United States | Operating Segments | Pharmaceutical | Keytruda      
Segment Reporting Information [Line Items]      
Sales 17,872 15,114 12,686
United States | Operating Segments | Pharmaceutical | Alliance revenue - Lynparza      
Segment Reporting Information [Line Items]      
Sales 626 607 584
United States | Operating Segments | Pharmaceutical | Alliance revenue - Lenvima      
Segment Reporting Information [Line Items]      
Sales 705 657 579
United States | Operating Segments | Pharmaceutical | Welireg      
Segment Reporting Information [Line Items]      
Sales 466 209 123
United States | Operating Segments | Pharmaceutical | Alliance revenue - Reblozyl      
Segment Reporting Information [Line Items]      
Sales 303 168 123
United States | Operating Segments | Pharmaceutical | Gardasil/Gardasil 9      
Segment Reporting Information [Line Items]      
Sales 2,425 2,083 2,065
United States | Operating Segments | Pharmaceutical | ProQuad/M-M-R II/Varivax      
Segment Reporting Information [Line Items]      
Sales 1,919 1,837 1,724
United States | Operating Segments | Pharmaceutical | Vaxneuvance      
Segment Reporting Information [Line Items]      
Sales 461 561 163
United States | Operating Segments | Pharmaceutical | RotaTeq      
Segment Reporting Information [Line Items]      
Sales 472 493 508
United States | Operating Segments | Pharmaceutical | Pneumovax 23      
Segment Reporting Information [Line Items]      
Sales 56 127 346
United States | Operating Segments | Pharmaceutical | Bridion      
Segment Reporting Information [Line Items]      
Sales 1,401 1,156 922
United States | Operating Segments | Pharmaceutical | Prevymis      
Segment Reporting Information [Line Items]      
Sales 371 264 188
United States | Operating Segments | Pharmaceutical | Dificid      
Segment Reporting Information [Line Items]      
Sales 303 274 241
United States | Operating Segments | Pharmaceutical | Zerbaxa      
Segment Reporting Information [Line Items]      
Sales 146 119 89
United States | Operating Segments | Pharmaceutical | Noxafil      
Segment Reporting Information [Line Items]      
Sales 7 32 51
United States | Operating Segments | Pharmaceutical | Winrevair      
Segment Reporting Information [Line Items]      
Sales 408 0 0
United States | Operating Segments | Pharmaceutical | Alliance revenue - Adempas/Verquvo      
Segment Reporting Information [Line Items]      
Sales 388 350 329
United States | Operating Segments | Pharmaceutical | Adempas      
Segment Reporting Information [Line Items]      
Sales 0 0 0
United States | Operating Segments | Pharmaceutical | Lagevrio      
Segment Reporting Information [Line Items]      
Sales 176 10 1,523
United States | Operating Segments | Pharmaceutical | Isentress/Isentress HD      
Segment Reporting Information [Line Items]      
Sales 185 215 274
United States | Operating Segments | Pharmaceutical | Delstrigo      
Segment Reporting Information [Line Items]      
Sales 56 49 39
United States | Operating Segments | Pharmaceutical | Pifeltro      
Segment Reporting Information [Line Items]      
Sales 113 101 87
United States | Operating Segments | Pharmaceutical | Belsomra      
Segment Reporting Information [Line Items]      
Sales 72 81 79
United States | Operating Segments | Pharmaceutical | Simponi      
Segment Reporting Information [Line Items]      
Sales 0 0 0
United States | Operating Segments | Pharmaceutical | Remicade      
Segment Reporting Information [Line Items]      
Sales 0 0 0
United States | Operating Segments | Pharmaceutical | Januvia      
Segment Reporting Information [Line Items]      
Sales 469 1,151 1,248
United States | Operating Segments | Pharmaceutical | Janumet      
Segment Reporting Information [Line Items]      
Sales 161 223 355
United States | Operating Segments | Pharmaceutical | Other pharmaceutical      
Segment Reporting Information [Line Items]      
Sales 729 658 663
United States | Operating Segments | Animal Health      
Segment Reporting Information [Line Items]      
Sales 1,861 1,804 1,822
United States | Operating Segments | Animal Health | Livestock      
Segment Reporting Information [Line Items]      
Sales 732 700 710
United States | Operating Segments | Animal Health | Companion Animal      
Segment Reporting Information [Line Items]      
Sales 1,129 1,104 1,112
United States | Other      
Segment Reporting Information [Line Items]      
Sales 126 137 395
Int’l      
Segment Reporting Information [Line Items]      
Sales 31,891 31,635 32,077
Int’l | Operating Segments      
Segment Reporting Information [Line Items]      
Sales 31,126 30,865 30,744
Int’l | Operating Segments | Pharmaceutical      
Segment Reporting Information [Line Items]      
Sales 27,110 27,044 27,016
Int’l | Operating Segments | Pharmaceutical | Keytruda      
Segment Reporting Information [Line Items]      
Sales 11,610 9,897 8,251
Int’l | Operating Segments | Pharmaceutical | Alliance revenue - Lynparza      
Segment Reporting Information [Line Items]      
Sales 685 592 532
Int’l | Operating Segments | Pharmaceutical | Alliance revenue - Lenvima      
Segment Reporting Information [Line Items]      
Sales 305 303 297
Int’l | Operating Segments | Pharmaceutical | Welireg      
Segment Reporting Information [Line Items]      
Sales 43 10 0
Int’l | Operating Segments | Pharmaceutical | Alliance revenue - Reblozyl      
Segment Reporting Information [Line Items]      
Sales 68 43 43
Int’l | Operating Segments | Pharmaceutical | Gardasil/Gardasil 9      
Segment Reporting Information [Line Items]      
Sales 6,158 6,803 4,832
Int’l | Operating Segments | Pharmaceutical | ProQuad/M-M-R II/Varivax      
Segment Reporting Information [Line Items]      
Sales 566 531 518
Int’l | Operating Segments | Pharmaceutical | Vaxneuvance      
Segment Reporting Information [Line Items]      
Sales 347 103 7
Int’l | Operating Segments | Pharmaceutical | RotaTeq      
Segment Reporting Information [Line Items]      
Sales 239 276 275
Int’l | Operating Segments | Pharmaceutical | Pneumovax 23      
Segment Reporting Information [Line Items]      
Sales 207 285 256
Int’l | Operating Segments | Pharmaceutical | Bridion      
Segment Reporting Information [Line Items]      
Sales 363 686 762
Int’l | Operating Segments | Pharmaceutical | Prevymis      
Segment Reporting Information [Line Items]      
Sales 414 341 240
Int’l | Operating Segments | Pharmaceutical | Dificid      
Segment Reporting Information [Line Items]      
Sales 37 28 22
Int’l | Operating Segments | Pharmaceutical | Zerbaxa      
Segment Reporting Information [Line Items]      
Sales 106 100 79
Int’l | Operating Segments | Pharmaceutical | Noxafil      
Segment Reporting Information [Line Items]      
Sales 170 181 187
Int’l | Operating Segments | Pharmaceutical | Winrevair      
Segment Reporting Information [Line Items]      
Sales 11 0 0
Int’l | Operating Segments | Pharmaceutical | Alliance revenue - Adempas/Verquvo      
Segment Reporting Information [Line Items]      
Sales 27 16 12
Int’l | Operating Segments | Pharmaceutical | Adempas      
Segment Reporting Information [Line Items]      
Sales 287 255 238
Int’l | Operating Segments | Pharmaceutical | Lagevrio      
Segment Reporting Information [Line Items]      
Sales 787 1,418 4,161
Int’l | Operating Segments | Pharmaceutical | Isentress/Isentress HD      
Segment Reporting Information [Line Items]      
Sales 209 268 359
Int’l | Operating Segments | Pharmaceutical | Delstrigo      
Segment Reporting Information [Line Items]      
Sales 193 152 111
Int’l | Operating Segments | Pharmaceutical | Pifeltro      
Segment Reporting Information [Line Items]      
Sales 50 41 30
Int’l | Operating Segments | Pharmaceutical | Belsomra      
Segment Reporting Information [Line Items]      
Sales 150 150 179
Int’l | Operating Segments | Pharmaceutical | Simponi      
Segment Reporting Information [Line Items]      
Sales 543 710 706
Int’l | Operating Segments | Pharmaceutical | Remicade      
Segment Reporting Information [Line Items]      
Sales 114 187 207
Int’l | Operating Segments | Pharmaceutical | Januvia      
Segment Reporting Information [Line Items]      
Sales 865 1,039 1,565
Int’l | Operating Segments | Pharmaceutical | Janumet      
Segment Reporting Information [Line Items]      
Sales 774 954 1,344
Int’l | Operating Segments | Pharmaceutical | Other pharmaceutical      
Segment Reporting Information [Line Items]      
Sales 1,782 1,675 1,803
Int’l | Operating Segments | Animal Health      
Segment Reporting Information [Line Items]      
Sales 4,016 3,821 3,728
Int’l | Operating Segments | Animal Health | Livestock      
Segment Reporting Information [Line Items]      
Sales 2,729 2,637 2,590
Int’l | Operating Segments | Animal Health | Companion Animal      
Segment Reporting Information [Line Items]      
Sales 1,287 1,184 1,138
Int’l | Other      
Segment Reporting Information [Line Items]      
Sales $ 765 $ 770 $ 1,333
XML 161 R120.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment Reporting - Consolidated Revenues by Geographic Area (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Revenues from External Customers and Long-Lived Assets [Line Items]      
Sales $ 64,168 $ 60,115 $ 59,283
United States      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Sales 32,277 28,480 27,206
Europe, Middle East and Africa      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Sales 14,041 13,254 14,493
China      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Sales 5,494 6,802 5,191
Latin America      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Sales 3,459 3,086 2,582
Japan      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Sales 3,280 3,164 3,629
Asia Pacific (other than China and Japan)      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Sales 3,058 3,225 3,614
Other      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Sales $ 2,559 $ 2,104 $ 2,568
XML 162 R121.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment Reporting - Reconciliation of Segment Profits to Income Before Taxes (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Segment Reporting Information [Line Items]      
Sales $ 64,168 $ 60,115 $ 59,283
Cost of sales 15,193 16,126 17,411
Selling, general and administrative 10,816 10,504 10,042
Research and development 17,938 30,531 13,548
Other segment items (24) 466 1,501
Income Before Taxes 19,936 1,889 16,444
Interest income 415 365 157
Interest expense (1,271) (1,146) (962)
Amortization (2,395) (2,044) (2,085)
Depreciation (2,104) (1,828) (1,824)
Research and development (17,938) (30,531) (13,548)
Restructuring costs (309) (599) (337)
Total segment profits      
Segment Reporting Information [Line Items]      
Sales 63,277 59,208 57,555
Income Before Taxes 46,471 40,617 38,815
Depreciation (261) (203) (182)
Total segment profits | Pharmaceutical      
Segment Reporting Information [Line Items]      
Sales 57,400 53,583 52,005
Cost of sales 6,828 8,849 9,678
Selling, general and administrative 6,128 5,903 5,474
Research and development 0 0 0
Other segment items (89) (49) 1
Income Before Taxes 44,533 38,880 36,852
Depreciation (5) (5) (5)
Research and development 0 0 0
Total segment profits | Animal Health      
Segment Reporting Information [Line Items]      
Sales 5,877 5,625 5,550
Cost of sales 2,469 2,498 2,259
Selling, general and administrative 1,084 1,038 999
Research and development 385 353 329
Other segment items 1 (1) 0
Income Before Taxes 1,938 1,737 1,963
Depreciation (256) (198) (177)
Research and development (385) (353) (329)
Other profits      
Segment Reporting Information [Line Items]      
Sales 891 907 1,728
Research and development 17,350 30,008 13,011
Income Before Taxes 492 474 1,160
Interest income 415 365 157
Interest expense (1,271) (1,146) (962)
Amortization (2,395) (2,044) (2,085)
Depreciation (1,843) (1,625) (1,642)
Research and development (17,350) (30,008) (13,011)
Restructuring costs (309) (599) (337)
Charge for Zetia antitrust litigation settlements 0 (573) 0
Other unallocated, net $ (4,274) $ (3,572) $ (5,651)
XML 163 R122.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment Reporting - Equity Income from Affiliates and Depreciation Included in Segment Profits (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Segment Reporting Information [Line Items]      
Depreciation $ 2,104 $ 1,828 $ 1,824
Operating Segments      
Segment Reporting Information [Line Items]      
Equity income from affiliates 144 111 39
Depreciation 261 203 182
Operating Segments | Pharmaceutical      
Segment Reporting Information [Line Items]      
Equity income from affiliates 144 111 39
Depreciation 5 5 5
Operating Segments | Animal Health      
Segment Reporting Information [Line Items]      
Equity income from affiliates 0 0 0
Depreciation $ 256 $ 198 $ 177
XML 164 R123.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment Reporting - Property, Plant and Equipment, Net by Geographic Area (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Revenues from External Customers and Long-Lived Assets [Line Items]      
Property, plant and equipment, net $ 23,779 $ 23,051 $ 21,422
United States      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Property, plant and equipment, net 14,724 13,915 12,891
Europe, Middle East and Africa      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Property, plant and equipment, net 7,548 7,562 6,993
Asia Pacific (other than China and Japan)      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Property, plant and equipment, net 982 1,022 966
China      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Property, plant and equipment, net 202 193 207
Japan      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Property, plant and equipment, net 143 133 135
Latin America      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Property, plant and equipment, net 133 222 225
Other      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Property, plant and equipment, net $ 47 $ 4 $ 5
EXCEL 165 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( %V"65H'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !=@EE:W@D)G^\ K @ $0 &1O8U!R;W!S+V-O&ULS9)1 M2\,P$,>_BN2]O39EHJ'+BV-/"H(#Q;>0W+9@DX;DI-VW-ZU;A^@'\#%W__SN M=W"M#D+W$9]C'S"2Q70SNLXGH<.:'8F" $CZB$ZE,B=\;N[[Z!3E9SQ 4/I# M'1!X5=V"0U)&D8()6(2%R&1KM- 1%?7QC#=ZP8?/V,TPHP$[=.@I05W6P.0T M,9S&KH4K8((11I>^"V@6XES]$SMW@)V38[)+:AB&GQY=YW<+Z M1,IKS+^2%70*N&:7R:_-PV:W99)7?%54O."K':]%?2>:^_?)]8??5=CUQN[M M/S:^",H6?MV%_ )02P,$% @ 78)96IE&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" !=@EE:2^ZGM<,* !+7@ & 'AL+W=O;;5U)X2H?,MCX'LL/K>Y[)%DGSXQ_+Q:4"O*RS/+B=+008O5Y/"[B M!5U&Q2%;T5S^9L[X,A+R(7\<%RM.HZ0J6F9CQ[*"\3)*\]'92?7<+3\[86N1 MI3F]Y:18+Y<1?SVG&7L^'=FC[1-WZ>-"E$^,STY6T2.]I^*WU2V7C\8[2I(N M:5ZD+">=_T\T'JC8P9EE1_9\\UZ_UW1&)UX5@RTVQW()EFM?_1B^;(/8*CJR& M F=3X+PIL+V& G=3X'8M\#8%7I5,_5&J'&:1B,Y..'LFO'RUI)4_5&%6U?+C MIWGY=[\77/XVE77B+&1/E)-;^2RW#DRO;OV:=Q=YF[%;Y.LK( M'5TQ+DQ!P1S!UZ9X0["J;U!(,"VH8!=4T"VH6\I3EI0S%Y$3JG%,M9"V[Q(XZSE<\DKU3-?,W[Y,P:QYEA7&G!,OZIH4$T](ZWJ5U#'["BURD MXE4.KXR2F_7R@7)32C##/@C\B7%0@75]8T*":3'9EFKBK"Y!W=''M!!R9 ER M$RV-NV +Z)KR^'N]83]$R]5/)&2'GV2?$A^:$H1A?2/$HND9[C7"=I<,ITDB MZ<6G[0^DZLM^S2&%2[RB1:'J4CHK2Z15E M6#YBG'QES[DQ1AAW%RV>HU=C:F!A[]20:'IJR@ILL%/^O]3NA5Q&R]AN.7N2 M \@\ F'FS<_&V%#[?RR:'ILR !ONX=_&=LL*(9N1_Z0K.7DEYM!@HC6Q I,F MAG!=[]R&$ -;F8$-M_353CGE-&J."08<6T?&D%"= (NFAZ2LP(:;^2^L;&QO M%RR'.I 6R,2S#CS+LHQIHV"XN'=Z0\B"K6S![J0+?] L._B>RUZ#W-.HD+MN0JZ*8MT0'\S\1DT' M0$.XJG=N0]B#H^S!Z60/O[-,[I\1KX6+&P_\MI!NF/'@+*HF8-'TL)0F.)TT M87OHHY;W-'^LIKFU.328V##$X*K>J0UA!(XR J>3$5SE@O+Z5$]YD"C:QFA, M#28VI89J!%@T/35E!$XG(ZAV1Q+*5?21<9,'G;=POD3\D9)I'%,)DIBD1AKS M0U4#+)J>GU(#IY,:W"^C+"/GZT+^NC#OH3"G\4@;7-<[K2&$P%%"X,#]_":M MBR7EC^6$]B])$ O9K2U746X>=C"P.3941<"BZ;$I17#@[OXJO+PCTW62"MGB M3H6@4C^KENTRBQZ-J<&\IE,M<%GOT(8P!4>9@@/W\KOCX)=I'N5Q*B6KTH3J MN0O.*UN02T-]<<"?993&LZ(M;],\ E&M 8NFAZFLP>ED#?<+V?B"N^O?/)\ MU_4.:PA)<)0D.)TD0<:TE"/K7K#XNU34123?B_RZ%G+GS1,Y^QGSPVSZPPW- MKVCEY3E/9X[O!)8;.)YU,G[2,AM"$%PE"&XG0;A=/V1I+.\@&ZZ$\&S.GLKDU'[=MH=YR M]O*Z-R7.Y80H%G1[&O^:TLHYV+P>N@N6)=+8B&#D@1(Y#R3D.GHESJ2^Y.73 MYA=SV?4EY#F5JWH)NZ?QFJ=W@SA#'K_A8

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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 167 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 169 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.0.1 html 1368 686 1 false 254 0 false 15 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.merck.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Document - Audit Information Sheet http://www.merck.com/role/AuditInformation Audit Information Cover 2 false false R3.htm 9952151 - Statement - Consolidated Statement of Income Sheet http://www.merck.com/role/ConsolidatedStatementofIncome Consolidated Statement of Income Statements 3 false false R4.htm 9952152 - Statement - Consolidated Statement of Comprehensive Income (Loss) Sheet http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncomeLoss Consolidated Statement of Comprehensive Income (Loss) Statements 4 false false R5.htm 9952153 - Statement - Consolidated Balance Sheet Sheet http://www.merck.com/role/ConsolidatedBalanceSheet Consolidated Balance Sheet Statements 5 false false R6.htm 9952154 - Statement - Consolidated Balance Sheet (Parenthetical) Sheet http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical Consolidated Balance Sheet (Parenthetical) Statements 6 false false R7.htm 9952155 - Statement - Consolidated Statement of Equity Sheet http://www.merck.com/role/ConsolidatedStatementofEquity Consolidated Statement of Equity Statements 7 false false R8.htm 9952156 - Statement - Consolidated Statement of Equity (Parenthetical) Sheet http://www.merck.com/role/ConsolidatedStatementofEquityParenthetical Consolidated Statement of Equity (Parenthetical) Statements 8 false false R9.htm 9952157 - Statement - Consolidated Statement of Cash Flows Sheet http://www.merck.com/role/ConsolidatedStatementofCashFlows Consolidated Statement of Cash Flows Statements 9 false false R10.htm 9952158 - Statement - Consolidated Statement of Cash Flows (Parenthetical) Sheet http://www.merck.com/role/ConsolidatedStatementofCashFlowsParenthetical Consolidated Statement of Cash Flows (Parenthetical) Statements 10 false false R11.htm 9952159 - Disclosure - Nature of Operations Sheet http://www.merck.com/role/NatureofOperations Nature of Operations Notes 11 false false R12.htm 9952160 - Disclosure - Summary of Accounting Policies Sheet http://www.merck.com/role/SummaryofAccountingPolicies Summary of Accounting Policies Notes 12 false false R13.htm 9952161 - Disclosure - Acquisitions, Divestitures, Research Collaborations and Licensing Agreements Sheet http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreements Acquisitions, Divestitures, Research Collaborations and Licensing Agreements Notes 13 false false R14.htm 9952162 - Disclosure - Collaborative Arrangements Sheet http://www.merck.com/role/CollaborativeArrangements Collaborative Arrangements Notes 14 false false R15.htm 9952163 - Disclosure - Restructuring Sheet http://www.merck.com/role/Restructuring Restructuring Notes 15 false false R16.htm 9952164 - Disclosure - Financial Instruments Sheet http://www.merck.com/role/FinancialInstruments Financial Instruments Notes 16 false false R17.htm 9952165 - Disclosure - Inventories Sheet http://www.merck.com/role/Inventories Inventories Notes 17 false false R18.htm 9952166 - Disclosure - Goodwill and Other Intangibles Sheet http://www.merck.com/role/GoodwillandOtherIntangibles Goodwill and Other Intangibles Notes 18 false false R19.htm 9952167 - Disclosure - Loans Payable, Long-Term Debt and Leases Sheet http://www.merck.com/role/LoansPayableLongTermDebtandLeases Loans Payable, Long-Term Debt and Leases Notes 19 false false R20.htm 9952168 - Disclosure - Contingencies and Environmental Liabilities Sheet http://www.merck.com/role/ContingenciesandEnvironmentalLiabilities Contingencies and Environmental Liabilities Notes 20 false false R21.htm 9952169 - Disclosure - Equity Sheet http://www.merck.com/role/Equity Equity Notes 21 false false R22.htm 9952170 - Disclosure - Share-Based Compensation Plans Sheet http://www.merck.com/role/ShareBasedCompensationPlans Share-Based Compensation Plans Notes 22 false false R23.htm 9952171 - Disclosure - Pension and Other Postretirement Benefit Plans Sheet http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans Pension and Other Postretirement Benefit Plans Notes 23 false false R24.htm 9952172 - Disclosure - Other (Income) Expense, Net Sheet http://www.merck.com/role/OtherIncomeExpenseNet Other (Income) Expense, Net Notes 24 false false R25.htm 9952173 - Disclosure - Taxes on Income Sheet http://www.merck.com/role/TaxesonIncome Taxes on Income Notes 25 false false R26.htm 9952174 - Disclosure - Earnings per Share Sheet http://www.merck.com/role/EarningsperShare Earnings per Share Notes 26 false false R27.htm 9952175 - Disclosure - Other Comprehensive Income (Loss) Sheet http://www.merck.com/role/OtherComprehensiveIncomeLoss Other Comprehensive Income (Loss) Notes 27 false false R28.htm 9952176 - Disclosure - Segment Reporting Sheet http://www.merck.com/role/SegmentReporting Segment Reporting Notes 28 false false R29.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 29 false false R30.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 30 false false R31.htm 995447 - Disclosure - Insider Trading Policies and Procedures Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc Insider Trading Policies and Procedures Notes 31 false false R32.htm 995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure Sheet http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure Cybersecurity Risk Management and Strategy Disclosure Notes 32 false false R33.htm 9955511 - Disclosure - Summary of Accounting Policies (Policies) Sheet http://www.merck.com/role/SummaryofAccountingPoliciesPolicies Summary of Accounting Policies (Policies) Policies http://www.merck.com/role/SummaryofAccountingPolicies 33 false false R34.htm 9955512 - Disclosure - Acquisitions, Divestitures, Research Collaborations and Licensing Agreements (Tables) Sheet http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsTables Acquisitions, Divestitures, Research Collaborations and Licensing Agreements (Tables) Tables http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreements 34 false false R35.htm 9955513 - Disclosure - Collaborative Arrangements (Tables) Sheet http://www.merck.com/role/CollaborativeArrangementsTables Collaborative Arrangements (Tables) Tables http://www.merck.com/role/CollaborativeArrangements 35 false false R36.htm 9955514 - Disclosure - Restructuring (Tables) Sheet http://www.merck.com/role/RestructuringTables Restructuring (Tables) Tables http://www.merck.com/role/Restructuring 36 false false R37.htm 9955515 - Disclosure - Financial Instruments (Tables) Sheet http://www.merck.com/role/FinancialInstrumentsTables Financial Instruments (Tables) Tables http://www.merck.com/role/FinancialInstruments 37 false false R38.htm 9955516 - Disclosure - Inventories (Tables) Sheet http://www.merck.com/role/InventoriesTables Inventories (Tables) Tables http://www.merck.com/role/Inventories 38 false false R39.htm 9955517 - Disclosure - Goodwill and Other Intangibles (Tables) Sheet http://www.merck.com/role/GoodwillandOtherIntangiblesTables Goodwill and Other Intangibles (Tables) Tables http://www.merck.com/role/GoodwillandOtherIntangibles 39 false false R40.htm 9955518 - Disclosure - Loans Payable, Long-Term Debt and Leases (Tables) Sheet http://www.merck.com/role/LoansPayableLongTermDebtandLeasesTables Loans Payable, Long-Term Debt and Leases (Tables) Tables http://www.merck.com/role/LoansPayableLongTermDebtandLeases 40 false false R41.htm 9955519 - Disclosure - Equity (Tables) Sheet http://www.merck.com/role/EquityTables Equity (Tables) Tables http://www.merck.com/role/Equity 41 false false R42.htm 9955520 - Disclosure - Share-Based Compensation Plans (Tables) Sheet http://www.merck.com/role/ShareBasedCompensationPlansTables Share-Based Compensation Plans (Tables) Tables http://www.merck.com/role/ShareBasedCompensationPlans 42 false false R43.htm 9955521 - Disclosure - Pension and Other Postretirement Benefit Plans (Tables) Sheet http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables Pension and Other Postretirement Benefit Plans (Tables) Tables http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans 43 false false R44.htm 9955522 - Disclosure - Other (Income) Expense, Net (Tables) Sheet http://www.merck.com/role/OtherIncomeExpenseNetTables Other (Income) Expense, Net (Tables) Tables http://www.merck.com/role/OtherIncomeExpenseNet 44 false false R45.htm 9955523 - Disclosure - Taxes on Income (Tables) Sheet http://www.merck.com/role/TaxesonIncomeTables Taxes on Income (Tables) Tables http://www.merck.com/role/TaxesonIncome 45 false false R46.htm 9955524 - Disclosure - Earnings per Share (Tables) Sheet http://www.merck.com/role/EarningsperShareTables Earnings per Share (Tables) Tables http://www.merck.com/role/EarningsperShare 46 false false R47.htm 9955525 - Disclosure - Other Comprehensive Income (Loss) (Tables) Sheet http://www.merck.com/role/OtherComprehensiveIncomeLossTables Other Comprehensive Income (Loss) (Tables) Tables http://www.merck.com/role/OtherComprehensiveIncomeLoss 47 false false R48.htm 9955526 - Disclosure - Segment Reporting (Tables) Sheet http://www.merck.com/role/SegmentReportingTables Segment Reporting (Tables) Tables http://www.merck.com/role/SegmentReporting 48 false false R49.htm 9955527 - Disclosure - Nature of Operations (Details) Sheet http://www.merck.com/role/NatureofOperationsDetails Nature of Operations (Details) Details http://www.merck.com/role/NatureofOperations 49 false false R50.htm 9955528 - Disclosure - Summary of Accounting Policies (Details) Sheet http://www.merck.com/role/SummaryofAccountingPoliciesDetails Summary of Accounting Policies (Details) Details http://www.merck.com/role/SummaryofAccountingPoliciesPolicies 50 false false R51.htm 9955529 - Disclosure - Acquisitions, Divestitures, Research Collaborations and Licensing Agreements - Narrative (Details) Sheet http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails Acquisitions, Divestitures, Research Collaborations and Licensing Agreements - Narrative (Details) Details http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsTables 51 false false R52.htm 9955530 - Disclosure - Acquisitions, Divestitures, Research Collaborations and Licensing Agreements - Estimated Fair Value of Assets Acquired and Liabilities Assumed (Details) Sheet http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails Acquisitions, Divestitures, Research Collaborations and Licensing Agreements - Estimated Fair Value of Assets Acquired and Liabilities Assumed (Details) Details 52 false false R53.htm 9955531 - Disclosure - Collaborative Arrangements - AstraZeneca PLC - Narrative (Details) Sheet http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails Collaborative Arrangements - AstraZeneca PLC - Narrative (Details) Details 53 false false R54.htm 9955532 - Disclosure - Collaborative Arrangements - AstraZeneca PLC (Details) Sheet http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCDetails Collaborative Arrangements - AstraZeneca PLC (Details) Details 54 false false R55.htm 9955533 - Disclosure - Collaborative Arrangements - Eisai Co., Ltd. - Narrative (Details) Sheet http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails Collaborative Arrangements - Eisai Co., Ltd. - Narrative (Details) Details 55 false false R56.htm 9955534 - Disclosure - Collaborative Arrangements - Eisai Co., Ltd. (Details) Sheet http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdDetails Collaborative Arrangements - Eisai Co., Ltd. (Details) Details 56 false false R57.htm 9955535 - Disclosure - Collaborative Arrangements - Bayer AG (Details) Sheet http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails Collaborative Arrangements - Bayer AG (Details) Details 57 false false R58.htm 9955536 - Disclosure - Collaborative Arrangements - Ridgeback Biotherapeutics LP (Details) Sheet http://www.merck.com/role/CollaborativeArrangementsRidgebackBiotherapeuticsLPDetails Collaborative Arrangements - Ridgeback Biotherapeutics LP (Details) Details 58 false false R59.htm 9955537 - Disclosure - Collaborative Arrangements - Daiicho Sankyo - Narrative (Details) Sheet http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails Collaborative Arrangements - Daiicho Sankyo - Narrative (Details) Details 59 false false R60.htm 9955538 - Disclosure - Collaborative Arrangements - Daiicho Sankyo (Details) Sheet http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoDetails Collaborative Arrangements - Daiicho Sankyo (Details) Details 60 false false R61.htm 9955539 - Disclosure - Collaborative Arrangements - Moderna, Inc. - Narrative (Details) Sheet http://www.merck.com/role/CollaborativeArrangementsModernaIncNarrativeDetails Collaborative Arrangements - Moderna, Inc. - Narrative (Details) Details 61 false false R62.htm 9955540 - Disclosure - Collaborative Arrangements - Moderna, Inc. (Details) Sheet http://www.merck.com/role/CollaborativeArrangementsModernaIncDetails Collaborative Arrangements - Moderna, Inc. (Details) Details 62 false false R63.htm 9955541 - Disclosure - Collaborative Arrangements - Bristol Meyers Squibb Company - Narrative (Details) Sheet http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails Collaborative Arrangements - Bristol Meyers Squibb Company - Narrative (Details) Details 63 false false R64.htm 9955542 - Disclosure - Restructuring - Narrative (Details) Sheet http://www.merck.com/role/RestructuringNarrativeDetails Restructuring - Narrative (Details) Details 64 false false R65.htm 9955543 - Disclosure - Restructuring - Charges Activities by Type of Cost (Details) Sheet http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails Restructuring - Charges Activities by Type of Cost (Details) Details 65 false false R66.htm 9955544 - Disclosure - Restructuring - Activities by Program (Details) Sheet http://www.merck.com/role/RestructuringActivitiesbyProgramDetails Restructuring - Activities by Program (Details) Details 66 false false R67.htm 9955545 - Disclosure - Financial Instruments - Narrative (Details) Sheet http://www.merck.com/role/FinancialInstrumentsNarrativeDetails Financial Instruments - Narrative (Details) Details 67 false false R68.htm 9955546 - Disclosure - Financial Instruments - Effect of Net Investment Hedges (Details) Sheet http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails Financial Instruments - Effect of Net Investment Hedges (Details) Details 68 false false R69.htm 9955547 - Disclosure - Financial Instruments - Summary of Interest Rate Swaps Held (Details) Sheet http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails Financial Instruments - Summary of Interest Rate Swaps Held (Details) Details 69 false false R70.htm 9955548 - Disclosure - Financial Instruments - Amounts Recorded on Balance Sheet Related to Fair Value Hedges (Details) Sheet http://www.merck.com/role/FinancialInstrumentsAmountsRecordedonBalanceSheetRelatedtoFairValueHedgesDetails Financial Instruments - Amounts Recorded on Balance Sheet Related to Fair Value Hedges (Details) Details 70 false false R71.htm 9955549 - Disclosure - Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details) Sheet http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details) Details 71 false false R72.htm 9955550 - Disclosure - Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details) Sheet http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details) Details 72 false false R73.htm 9955551 - Disclosure - Financial Instruments - Location and Pretax (Gains) or Loss Amounts for Derivatives (Details) Sheet http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails Financial Instruments - Location and Pretax (Gains) or Loss Amounts for Derivatives (Details) Details 73 false false R74.htm 9955552 - Disclosure - Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details) Sheet http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details) Details 74 false false R75.htm 9955553 - Disclosure - Financial Instruments - Information on Debt and Equity Securities (Details) Sheet http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails Financial Instruments - Information on Debt and Equity Securities (Details) Details 75 false false R76.htm 9955554 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Sheet http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Details 76 false false R77.htm 9955555 - Disclosure - Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details) Sheet http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details) Details 77 false false R78.htm 9955556 - Disclosure - Inventories - Inventories (Details) Sheet http://www.merck.com/role/InventoriesInventoriesDetails Inventories - Inventories (Details) Details 78 false false R79.htm 9955557 - Disclosure - Inventories - Narrative (Details) Sheet http://www.merck.com/role/InventoriesNarrativeDetails Inventories - Narrative (Details) Details 79 false false R80.htm 9955558 - Disclosure - Goodwill and Other Intangibles - Goodwill Activity by Segment (Details) Sheet http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails Goodwill and Other Intangibles - Goodwill Activity by Segment (Details) Details 80 false false R81.htm 9955559 - Disclosure - Goodwill and Other Intangibles - Other Intangibles (Details) Sheet http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails Goodwill and Other Intangibles - Other Intangibles (Details) Details 81 false false R82.htm 9955560 - Disclosure - Goodwill and Other Intangibles - Narrative (Details) Sheet http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails Goodwill and Other Intangibles - Narrative (Details) Details 82 false false R83.htm 9955561 - Disclosure - Loans Payable, Long-Term Debt and Leases - Narrative (Details) Sheet http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails Loans Payable, Long-Term Debt and Leases - Narrative (Details) Details 83 false false R84.htm 9955562 - Disclosure - Loans Payable, Long-Term Debt and Leases - Long-Term Debt (Details) Sheet http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails Loans Payable, Long-Term Debt and Leases - Long-Term Debt (Details) Details 84 false false R85.htm 9955563 - Disclosure - Loans Payable, Long-Term Debt and Leases - Balance Sheet Information (Details) Sheet http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails Loans Payable, Long-Term Debt and Leases - Balance Sheet Information (Details) Details 85 false false R86.htm 9955564 - Disclosure - Loans Payable, Long-Term Debt and Leases - Maturity Schedule (Details) Sheet http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails Loans Payable, Long-Term Debt and Leases - Maturity Schedule (Details) Details 86 false false R87.htm 9955565 - Disclosure - Contingencies and Environmental Liabilities (Details) Sheet http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails Contingencies and Environmental Liabilities (Details) Details http://www.merck.com/role/ContingenciesandEnvironmentalLiabilities 87 false false R88.htm 9955566 - Disclosure - Equity - Narrative (Details) Sheet http://www.merck.com/role/EquityNarrativeDetails Equity - Narrative (Details) Details 88 false false R89.htm 9955567 - Disclosure - Equity - Shareholders' Equity (Details) Sheet http://www.merck.com/role/EquityShareholdersEquityDetails Equity - Shareholders' Equity (Details) Details 89 false false R90.htm 9955568 - Disclosure - Share-Based Compensation Plans - Narrative (Details) Sheet http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails Share-Based Compensation Plans - Narrative (Details) Details 90 false false R91.htm 9955569 - Disclosure - Share-Based Compensation Plans - Assumptions Used to Determine Weighted-Average Fair Value of Options Granted (Details) Sheet http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails Share-Based Compensation Plans - Assumptions Used to Determine Weighted-Average Fair Value of Options Granted (Details) Details 91 false false R92.htm 9955570 - Disclosure - Share-Based Compensation Plans - Summary of Information Relative to Stock Option Plan Activity (Details) Sheet http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails Share-Based Compensation Plans - Summary of Information Relative to Stock Option Plan Activity (Details) Details 92 false false R93.htm 9955571 - Disclosure - Share-Based Compensation Plans - Additional Information Pertaining to Stock Option Plans (Details) Sheet http://www.merck.com/role/ShareBasedCompensationPlansAdditionalInformationPertainingtoStockOptionPlansDetails Share-Based Compensation Plans - Additional Information Pertaining to Stock Option Plans (Details) Details 93 false false R94.htm 9955572 - Disclosure - Share-Based Compensation Plans - Summary of Nonvested RSU and PSU Activity (Details) Sheet http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails Share-Based Compensation Plans - Summary of Nonvested RSU and PSU Activity (Details) Details 94 false false R95.htm 9955573 - Disclosure - Pension and Other Postretirement Benefit Plans - Narrative (Details) Sheet http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails Pension and Other Postretirement Benefit Plans - Narrative (Details) Details 95 false false R96.htm 9955574 - Disclosure - Pension and Other Postretirement Benefit Plans - Components of Net Periodic Benefit Cost (Details) Sheet http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails Pension and Other Postretirement Benefit Plans - Components of Net Periodic Benefit Cost (Details) Details 96 false false R97.htm 9955575 - Disclosure - Pension and Other Postretirement Benefit Plans - Obligation and Funded Status (Details) Sheet http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails Pension and Other Postretirement Benefit Plans - Obligation and Funded Status (Details) Details 97 false false R98.htm 9955576 - Disclosure - Pension and Other Postretirement Benefit Plans - Accumulated and Projected Benefit Obligation in Excess of Plan Assets (Details) Sheet http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails Pension and Other Postretirement Benefit Plans - Accumulated and Projected Benefit Obligation in Excess of Plan Assets (Details) Details 98 false false R99.htm 9955577 - Disclosure - Pension and Other Postretirement Benefit Plans - Fair Values of Pension Plan Assets (Details) Sheet http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails Pension and Other Postretirement Benefit Plans - Fair Values of Pension Plan Assets (Details) Details 99 false false R100.htm 9955578 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Changes in Fair Value of Company's Level 3 Pension Plan Assets (Details) Sheet http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails Pension and Other Postretirement Benefit Plans - Summary of Changes in Fair Value of Company's Level 3 Pension Plan Assets (Details) Details 100 false false R101.htm 9955579 - Disclosure - Pension and Other Postretirement Benefit Plans - Fair Values of Other Postretirement Benefit Plan Assets (Details) Sheet http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails Pension and Other Postretirement Benefit Plans - Fair Values of Other Postretirement Benefit Plan Assets (Details) Details 101 false false R102.htm 9955580 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Expected Benefit Payments (Details) Sheet http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails Pension and Other Postretirement Benefit Plans - Summary of Expected Benefit Payments (Details) Details 102 false false R103.htm 9955581 - Disclosure - Pension and Other Postretirement Benefit Plans - Components of Other Comprehensive Income (Details) Sheet http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails Pension and Other Postretirement Benefit Plans - Components of Other Comprehensive Income (Details) Details 103 false false R104.htm 9955582 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Weighted Average Assumptions Used in Determining Pension Plan and U.S. Pension and Other Postretirement Benefit Plan Information (Details) Sheet http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails Pension and Other Postretirement Benefit Plans - Summary of Weighted Average Assumptions Used in Determining Pension Plan and U.S. Pension and Other Postretirement Benefit Plan Information (Details) Details 104 false false R105.htm 9955583 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Health Care Cost Trend Rate Assumptions for Other Postretirement Benefit Plans (Details) Sheet http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails Pension and Other Postretirement Benefit Plans - Summary of Health Care Cost Trend Rate Assumptions for Other Postretirement Benefit Plans (Details) Details 105 false false R106.htm 9955584 - Disclosure - Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details) Sheet http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details) Details http://www.merck.com/role/OtherIncomeExpenseNetTables 106 false false R107.htm 9955585 - Disclosure - Other (Income) Expense, Net - Narrative (Details) Sheet http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails Other (Income) Expense, Net - Narrative (Details) Details http://www.merck.com/role/OtherIncomeExpenseNetTables 107 false false R108.htm 9955586 - Disclosure - Taxes on Income - Reconciliation Between Effective Tax Rate and US Statutory Rate (Details) Sheet http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails Taxes on Income - Reconciliation Between Effective Tax Rate and US Statutory Rate (Details) Details 108 false false R109.htm 9955587 - Disclosure - Taxes on Income - Narrative (Details) Sheet http://www.merck.com/role/TaxesonIncomeNarrativeDetails Taxes on Income - Narrative (Details) Details 109 false false R110.htm 9955588 - Disclosure - Taxes on Income - Income Before Taxes (Details) Sheet http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails Taxes on Income - Income Before Taxes (Details) Details 110 false false R111.htm 9955589 - Disclosure - Taxes on Income - Taxes on Income (Details) Sheet http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails Taxes on Income - Taxes on Income (Details) Details 111 false false R112.htm 9955590 - Disclosure - Taxes on Income - Deferred Income Taxes (Details) Sheet http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails Taxes on Income - Deferred Income Taxes (Details) Details 112 false false R113.htm 9955591 - Disclosure - Taxes on Income - Income Tax Authority (Details) Sheet http://www.merck.com/role/TaxesonIncomeIncomeTaxAuthorityDetails Taxes on Income - Income Tax Authority (Details) Details 113 false false R114.htm 9955592 - Disclosure - Taxes on Income - Unrecognized Tax Benefits (Details) Sheet http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails Taxes on Income - Unrecognized Tax Benefits (Details) Details 114 false false R115.htm 9955593 - Disclosure - Earnings Per Share - Calculations of Earnings Per Share (Details) Sheet http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails Earnings Per Share - Calculations of Earnings Per Share (Details) Details 115 false false R116.htm 9955594 - Disclosure - Earnings Per Share - Narrative (Details) Sheet http://www.merck.com/role/EarningsPerShareNarrativeDetails Earnings Per Share - Narrative (Details) Details 116 false false R117.htm 9955595 - Disclosure - Other Comprehensive Income (Loss) (Details) Sheet http://www.merck.com/role/OtherComprehensiveIncomeLossDetails Other Comprehensive Income (Loss) (Details) Details http://www.merck.com/role/OtherComprehensiveIncomeLossTables 117 false false R118.htm 9955596 - Disclosure - Segment Reporting - Narrative (Details) Sheet http://www.merck.com/role/SegmentReportingNarrativeDetails Segment Reporting - Narrative (Details) Details 118 false false R119.htm 9955597 - Disclosure - Segment Reporting - Sales of Company's Products (Details) Sheet http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails Segment Reporting - Sales of Company's Products (Details) Details 119 false false R120.htm 9955598 - Disclosure - Segment Reporting - Consolidated Revenues by Geographic Area (Details) Sheet http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails Segment Reporting - Consolidated Revenues by Geographic Area (Details) Details 120 false false R121.htm 9955599 - Disclosure - Segment Reporting - Reconciliation of Segment Profits to Income Before Taxes (Details) Sheet http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails Segment Reporting - Reconciliation of Segment Profits to Income Before Taxes (Details) Details 121 false false R122.htm 9955600 - Disclosure - Segment Reporting - Equity Income from Affiliates and Depreciation Included in Segment Profits (Details) Sheet http://www.merck.com/role/SegmentReportingEquityIncomefromAffiliatesandDepreciationIncludedinSegmentProfitsDetails Segment Reporting - Equity Income from Affiliates and Depreciation Included in Segment Profits (Details) Details 122 false false R123.htm 9955601 - Disclosure - Segment Reporting - Property, Plant and Equipment, Net by Geographic Area (Details) Sheet http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails Segment Reporting - Property, Plant and Equipment, Net by Geographic Area (Details) Details 123 false false All Reports Book All Reports mrk-20241231.htm mrk-20241231.xsd mrk-20241231_cal.xml mrk-20241231_def.xml mrk-20241231_lab.xml mrk-20241231_pre.xml mrk-20241231_g1.jpg mrk-20241231_g2.jpg mrk-20241231_g3.jpg mrk-20241231_g4.jpg mrk-20241231_g5.jpg mrk-20241231_g6.jpg mrk-20241231_g7.gif mrk-20241231_g8.jpg mrk-20241231_g9.jpg http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/cyd/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 172 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "mrk-20241231.htm": { "nsprefix": "mrk", "nsuri": "http://www.merck.com/20241231", "dts": { "inline": { "local": [ "mrk-20241231.htm" ] }, "schema": { "local": [ "mrk-20241231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "mrk-20241231_cal.xml" ] }, "definitionLink": { "local": [ "mrk-20241231_def.xml" ] }, "labelLink": { "local": [ "mrk-20241231_lab.xml" ] }, "presentationLink": { "local": [ "mrk-20241231_pre.xml" ] } }, "keyStandard": 578, "keyCustom": 108, "axisStandard": 50, "axisCustom": 0, "memberStandard": 88, "memberCustom": 160, "hidden": { "total": 94, "http://xbrl.sec.gov/dei/2024": 4, "http://fasb.org/us-gaap/2024": 89, "http://www.merck.com/20241231": 1 }, "contextCount": 1368, "entityCount": 1, "segmentCount": 254, "elementCount": 1260, "unitCount": 15, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 3085, "http://xbrl.sec.gov/dei/2024": 59, "http://xbrl.sec.gov/cyd/2024": 15, "http://xbrl.sec.gov/ecd/2024": 5 }, "report": { "R1": { "role": "http://www.merck.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.merck.com/role/AuditInformation", "longName": "0000002 - Document - Audit Information", "shortName": "Audit Information", "isDefault": "false", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "2", "firstAnchor": { "contextRef": "c-1", "name": "dei:AuditorName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:AuditorName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.merck.com/role/ConsolidatedStatementofIncome", "longName": "9952151 - Statement - Consolidated Statement of Income", "shortName": "Consolidated Statement of Income", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "mrk:CostsExpensesAndOther", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "unique": true } }, "R4": { "role": "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncomeLoss", "longName": "9952152 - Statement - Consolidated Statement of Comprehensive Income (Loss)", "shortName": "Consolidated Statement of Comprehensive Income (Loss)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "unique": true } }, "R5": { "role": "http://www.merck.com/role/ConsolidatedBalanceSheet", "longName": "9952153 - Statement - Consolidated Balance Sheet", "shortName": "Consolidated Balance Sheet", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical", "longName": "9952154 - Statement - Consolidated Balance Sheet (Parenthetical)", "shortName": "Consolidated Balance Sheet (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.merck.com/role/ConsolidatedStatementofEquity", "longName": "9952155 - Statement - Consolidated Statement of Equity", "shortName": "Consolidated Statement of Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-22", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-16", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "unique": true } }, "R8": { "role": "http://www.merck.com/role/ConsolidatedStatementofEquityParenthetical", "longName": "9952156 - Statement - Consolidated Statement of Equity (Parenthetical)", "shortName": "Consolidated Statement of Equity (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.merck.com/role/ConsolidatedStatementofCashFlows", "longName": "9952157 - Statement - Consolidated Statement of Cash Flows", "shortName": "Consolidated Statement of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "unique": true } }, "R10": { "role": "http://www.merck.com/role/ConsolidatedStatementofCashFlowsParenthetical", "longName": "9952158 - Statement - Consolidated Statement of Cash Flows (Parenthetical)", "shortName": "Consolidated Statement of Cash Flows (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "10", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:RestrictedCashAndCashEquivalents", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:RestrictedCashAndCashEquivalents", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.merck.com/role/NatureofOperations", "longName": "9952159 - Disclosure - Nature of Operations", "shortName": "Nature of Operations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.merck.com/role/SummaryofAccountingPolicies", "longName": "9952160 - Disclosure - Summary of Accounting Policies", "shortName": "Summary of Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreements", "longName": "9952161 - Disclosure - Acquisitions, Divestitures, Research Collaborations and Licensing Agreements", "shortName": "Acquisitions, Divestitures, Research Collaborations and Licensing Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "mrk:AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "mrk:AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.merck.com/role/CollaborativeArrangements", "longName": "9952162 - Disclosure - Collaborative Arrangements", "shortName": "Collaborative Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.merck.com/role/Restructuring", "longName": "9952163 - Disclosure - Restructuring", "shortName": "Restructuring", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.merck.com/role/FinancialInstruments", "longName": "9952164 - Disclosure - Financial Instruments", "shortName": "Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.merck.com/role/Inventories", "longName": "9952165 - Disclosure - Inventories", "shortName": "Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.merck.com/role/GoodwillandOtherIntangibles", "longName": "9952166 - Disclosure - Goodwill and Other Intangibles", "shortName": "Goodwill and Other Intangibles", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.merck.com/role/LoansPayableLongTermDebtandLeases", "longName": "9952167 - Disclosure - Loans Payable, Long-Term Debt and Leases", "shortName": "Loans Payable, Long-Term Debt and Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilities", "longName": "9952168 - Disclosure - Contingencies and Environmental Liabilities", "shortName": "Contingencies and Environmental Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.merck.com/role/Equity", "longName": "9952169 - Disclosure - Equity", "shortName": "Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.merck.com/role/ShareBasedCompensationPlans", "longName": "9952170 - Disclosure - Share-Based Compensation Plans", "shortName": "Share-Based Compensation Plans", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans", "longName": "9952171 - Disclosure - Pension and Other Postretirement Benefit Plans", "shortName": "Pension and Other Postretirement Benefit Plans", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.merck.com/role/OtherIncomeExpenseNet", "longName": "9952172 - Disclosure - Other (Income) Expense, Net", "shortName": "Other (Income) Expense, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.merck.com/role/TaxesonIncome", "longName": "9952173 - Disclosure - Taxes on Income", "shortName": "Taxes on Income", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.merck.com/role/EarningsperShare", "longName": "9952174 - Disclosure - Earnings per Share", "shortName": "Earnings per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.merck.com/role/OtherComprehensiveIncomeLoss", "longName": "9952175 - Disclosure - Other Comprehensive Income (Loss)", "shortName": "Other Comprehensive Income (Loss)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.merck.com/role/SegmentReporting", "longName": "9952176 - Disclosure - Segment Reporting", "shortName": "Segment Reporting", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R29": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true }, "uniqueAnchor": null }, "R30": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "30", "firstAnchor": { "contextRef": "c-1368", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1368", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R31": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "longName": "995447 - Disclosure - Insider Trading Policies and Procedures", "shortName": "Insider Trading Policies and Procedures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R32": { "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure", "shortName": "Cybersecurity Risk Management and Strategy Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies", "longName": "9955511 - Disclosure - Summary of Accounting Policies (Policies)", "shortName": "Summary of Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsTables", "longName": "9955512 - Disclosure - Acquisitions, Divestitures, Research Collaborations and Licensing Agreements (Tables)", "shortName": "Acquisitions, Divestitures, Research Collaborations and Licensing Agreements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.merck.com/role/CollaborativeArrangementsTables", "longName": "9955513 - Disclosure - Collaborative Arrangements (Tables)", "shortName": "Collaborative Arrangements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.merck.com/role/RestructuringTables", "longName": "9955514 - Disclosure - Restructuring (Tables)", "shortName": "Restructuring (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.merck.com/role/FinancialInstrumentsTables", "longName": "9955515 - Disclosure - Financial Instruments (Tables)", "shortName": "Financial Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.merck.com/role/InventoriesTables", "longName": "9955516 - Disclosure - Inventories (Tables)", "shortName": "Inventories (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.merck.com/role/GoodwillandOtherIntangiblesTables", "longName": "9955517 - Disclosure - Goodwill and Other Intangibles (Tables)", "shortName": "Goodwill and Other Intangibles (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesTables", "longName": "9955518 - Disclosure - Loans Payable, Long-Term Debt and Leases (Tables)", "shortName": "Loans Payable, Long-Term Debt and Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.merck.com/role/EquityTables", "longName": "9955519 - Disclosure - Equity (Tables)", "shortName": "Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.merck.com/role/ShareBasedCompensationPlansTables", "longName": "9955520 - Disclosure - Share-Based Compensation Plans (Tables)", "shortName": "Share-Based Compensation Plans (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables", "longName": "9955521 - Disclosure - Pension and Other Postretirement Benefit Plans (Tables)", "shortName": "Pension and Other Postretirement Benefit Plans (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.merck.com/role/OtherIncomeExpenseNetTables", "longName": "9955522 - Disclosure - Other (Income) Expense, Net (Tables)", "shortName": "Other (Income) Expense, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "44", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.merck.com/role/TaxesonIncomeTables", "longName": "9955523 - Disclosure - Taxes on Income (Tables)", "shortName": "Taxes on Income (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "45", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.merck.com/role/EarningsperShareTables", "longName": "9955524 - Disclosure - Earnings per Share (Tables)", "shortName": "Earnings per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "46", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.merck.com/role/OtherComprehensiveIncomeLossTables", "longName": "9955525 - Disclosure - Other Comprehensive Income (Loss) (Tables)", "shortName": "Other Comprehensive Income (Loss) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "47", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.merck.com/role/SegmentReportingTables", "longName": "9955526 - Disclosure - Segment Reporting (Tables)", "shortName": "Segment Reporting (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "48", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.merck.com/role/NatureofOperationsDetails", "longName": "9955527 - Disclosure - Nature of Operations (Details)", "shortName": "Nature of Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true }, "uniqueAnchor": null }, "R50": { "role": "http://www.merck.com/role/SummaryofAccountingPoliciesDetails", "longName": "9955528 - Disclosure - Summary of Accounting Policies (Details)", "shortName": "Summary of Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-1", "name": "mrk:SalesDiscounts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "mrk:SalesDiscounts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails", "longName": "9955529 - Disclosure - Acquisitions, Divestitures, Research Collaborations and Licensing Agreements - Narrative (Details)", "shortName": "Acquisitions, Divestitures, Research Collaborations and Licensing Agreements - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-73", "name": "us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "unique": true } }, "R52": { "role": "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "longName": "9955530 - Disclosure - Acquisitions, Divestitures, Research Collaborations and Licensing Agreements - Estimated Fair Value of Assets Acquired and Liabilities Assumed (Details)", "shortName": "Acquisitions, Divestitures, Research Collaborations and Licensing Agreements - Estimated Fair Value of Assets Acquired and Liabilities Assumed (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-84", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "unique": true } }, "R53": { "role": "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails", "longName": "9955531 - Disclosure - Collaborative Arrangements - AstraZeneca PLC - Narrative (Details)", "shortName": "Collaborative Arrangements - AstraZeneca PLC - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-132", "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "unique": true } }, "R54": { "role": "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCDetails", "longName": "9955532 - Disclosure - Collaborative Arrangements - AstraZeneca PLC (Details)", "shortName": "Collaborative Arrangements - AstraZeneca PLC (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-139", "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "unique": true } }, "R55": { "role": "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails", "longName": "9955533 - Disclosure - Collaborative Arrangements - Eisai Co., Ltd. - Narrative (Details)", "shortName": "Collaborative Arrangements - Eisai Co., Ltd. - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-144", "name": "mrk:MilestonePaymentsSalesBased", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "unique": true } }, "R56": { "role": "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdDetails", "longName": "9955534 - Disclosure - Collaborative Arrangements - Eisai Co., Ltd. (Details)", "shortName": "Collaborative Arrangements - Eisai Co., Ltd. (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-151", "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "unique": true } }, "R57": { "role": "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "longName": "9955535 - Disclosure - Collaborative Arrangements - Bayer AG (Details)", "shortName": "Collaborative Arrangements - Bayer AG (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-159", "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "unique": true } }, "R58": { "role": "http://www.merck.com/role/CollaborativeArrangementsRidgebackBiotherapeuticsLPDetails", "longName": "9955536 - Disclosure - Collaborative Arrangements - Ridgeback Biotherapeutics LP (Details)", "shortName": "Collaborative Arrangements - Ridgeback Biotherapeutics LP (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-172", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "unique": true } }, "R59": { "role": "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails", "longName": "9955537 - Disclosure - Collaborative Arrangements - Daiicho Sankyo - Narrative (Details)", "shortName": "Collaborative Arrangements - Daiicho Sankyo - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-94", "name": "mrk:CollaborativeArrangementRightsAndObligationsAggregateUpfrontPaymentsDueUponExecution", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "unique": true } }, "R60": { "role": "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoDetails", "longName": "9955538 - Disclosure - Collaborative Arrangements - Daiicho Sankyo (Details)", "shortName": "Collaborative Arrangements - Daiicho Sankyo (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-183", "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "unique": true } }, "R61": { "role": "http://www.merck.com/role/CollaborativeArrangementsModernaIncNarrativeDetails", "longName": "9955539 - Disclosure - Collaborative Arrangements - Moderna, Inc. - Narrative (Details)", "shortName": "Collaborative Arrangements - Moderna, Inc. - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-186", "name": "mrk:CollaborativeArrangementRightsAndObligationsContractualPayment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-186", "name": "mrk:CollaborativeArrangementRightsAndObligationsContractualPayment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.merck.com/role/CollaborativeArrangementsModernaIncDetails", "longName": "9955540 - Disclosure - Collaborative Arrangements - Moderna, Inc. (Details)", "shortName": "Collaborative Arrangements - Moderna, Inc. (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-188", "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "unique": true } }, "R63": { "role": "http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails", "longName": "9955541 - Disclosure - Collaborative Arrangements - Bristol Meyers Squibb Company - Narrative (Details)", "shortName": "Collaborative Arrangements - Bristol Meyers Squibb Company - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-193", "name": "mrk:RoyaltyRateDeductionPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-193", "name": "mrk:RoyaltyRateDeductionPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.merck.com/role/RestructuringNarrativeDetails", "longName": "9955542 - Disclosure - Restructuring - Narrative (Details)", "shortName": "Restructuring - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedCostIncurredCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-199", "name": "us-gaap:RestructuringAndRelatedCostExpectedCost1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "unique": true } }, "R65": { "role": "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails", "longName": "9955543 - Disclosure - Restructuring - Charges Activities by Type of Cost (Details)", "shortName": "Restructuring - Charges Activities by Type of Cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedCostIncurredCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-256", "name": "us-gaap:RestructuringAndRelatedCostIncurredCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "unique": true } }, "R66": { "role": "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "longName": "9955544 - Disclosure - Restructuring - Activities by Program (Details)", "shortName": "Restructuring - Activities by Program (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-15", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-34", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "unique": true } }, "R67": { "role": "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "longName": "9955545 - Disclosure - Financial Instruments - Narrative (Details)", "shortName": "Financial Instruments - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "unique": true } }, "R68": { "role": "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "longName": "9955546 - Disclosure - Financial Instruments - Effect of Net Investment Hedges (Details)", "shortName": "Financial Instruments - Effect of Net Investment Hedges (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-293", "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-293", "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails", "longName": "9955547 - Disclosure - Financial Instruments - Summary of Interest Rate Swaps Held (Details)", "shortName": "Financial Instruments - Summary of Interest Rate Swaps Held (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-306", "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "unique": true } }, "R70": { "role": "http://www.merck.com/role/FinancialInstrumentsAmountsRecordedonBalanceSheetRelatedtoFairValueHedgesDetails", "longName": "9955548 - Disclosure - Financial Instruments - Amounts Recorded on Balance Sheet Related to Fair Value Hedges (Details)", "shortName": "Financial Instruments - Amounts Recorded on Balance Sheet Related to Fair Value Hedges (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:HedgedLiabilityFairValueHedge", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:HedgedLiabilityFairValueHedge", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "longName": "9955549 - Disclosure - Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details)", "shortName": "Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:DerivativeAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-319", "name": "us-gaap:DerivativeAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "unique": true } }, "R72": { "role": "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails", "longName": "9955550 - Disclosure - Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details)", "shortName": "Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R73": { "role": "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails", "longName": "9955551 - Disclosure - Financial Instruments - Location and Pretax (Gains) or Loss Amounts for Derivatives (Details)", "shortName": "Financial Instruments - Location and Pretax (Gains) or Loss Amounts for Derivatives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-293", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "unique": true } }, "R74": { "role": "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "longName": "9955552 - Disclosure - Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details)", "shortName": "Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-334", "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-334", "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R75": { "role": "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails", "longName": "9955553 - Disclosure - Financial Instruments - Information on Debt and Equity Securities (Details)", "shortName": "Financial Instruments - Information on Debt and Equity Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R76": { "role": "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "longName": "9955554 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "shortName": "Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-379", "name": "us-gaap:Investments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "unique": true } }, "R77": { "role": "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails", "longName": "9955555 - Disclosure - Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)", "shortName": "Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c-15", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "unique": true } }, "R78": { "role": "http://www.merck.com/role/InventoriesInventoriesDetails", "longName": "9955556 - Disclosure - Inventories - Inventories (Details)", "shortName": "Inventories - Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:InventoryFinishedGoods", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:InventoryFinishedGoods", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R79": { "role": "http://www.merck.com/role/InventoriesNarrativeDetails", "longName": "9955557 - Disclosure - Inventories - Narrative (Details)", "shortName": "Inventories - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:LIFOInventoryAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:LIFOInventoryAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R80": { "role": "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails", "longName": "9955558 - Disclosure - Goodwill and Other Intangibles - Goodwill Activity by Segment (Details)", "shortName": "Goodwill and Other Intangibles - Goodwill Activity by Segment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "c-15", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAcquiredDuringPeriod", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "unique": true } }, "R81": { "role": "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails", "longName": "9955559 - Disclosure - Goodwill and Other Intangibles - Other Intangibles (Details)", "shortName": "Goodwill and Other Intangibles - Other Intangibles (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R82": { "role": "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "longName": "9955560 - Disclosure - Goodwill and Other Intangibles - Narrative (Details)", "shortName": "Goodwill and Other Intangibles - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "unique": true } }, "R83": { "role": "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails", "longName": "9955561 - Disclosure - Loans Payable, Long-Term Debt and Leases - Narrative (Details)", "shortName": "Loans Payable, Long-Term Debt and Leases - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:LongTermDebtCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:LongTermDebtCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R84": { "role": "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails", "longName": "9955562 - Disclosure - Loans Payable, Long-Term Debt and Leases - Long-Term Debt (Details)", "shortName": "Loans Payable, Long-Term Debt and Leases - Long-Term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:LongTermDebtNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-465", "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "unique": true } }, "R85": { "role": "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails", "longName": "9955563 - Disclosure - Loans Payable, Long-Term Debt and Leases - Balance Sheet Information (Details)", "shortName": "Loans Payable, Long-Term Debt and Leases - Balance Sheet Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "mrk:LeaseAssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "mrk:LeaseAssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R86": { "role": "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails", "longName": "9955564 - Disclosure - Loans Payable, Long-Term Debt and Leases - Maturity Schedule (Details)", "shortName": "Loans Payable, Long-Term Debt and Leases - Maturity Schedule (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R87": { "role": "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails", "longName": "9955565 - Disclosure - Contingencies and Environmental Liabilities (Details)", "shortName": "Contingencies and Environmental Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "c-1", "name": "mrk:EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "mrk:EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R88": { "role": "http://www.merck.com/role/EquityNarrativeDetails", "longName": "9955566 - Disclosure - Equity - Narrative (Details)", "shortName": "Equity - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "unique": true } }, "R89": { "role": "http://www.merck.com/role/EquityShareholdersEquityDetails", "longName": "9955567 - Disclosure - Equity - Shareholders' Equity (Details)", "shortName": "Equity - Shareholders' Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "c-15", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:CommonStockSharesIssued", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-16", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "unique": true } }, "R90": { "role": "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails", "longName": "9955568 - Disclosure - Share-Based Compensation Plans - Narrative (Details)", "shortName": "Share-Based Compensation Plans - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R91": { "role": "http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails", "longName": "9955569 - Disclosure - Share-Based Compensation Plans - Assumptions Used to Determine Weighted-Average Fair Value of Options Granted (Details)", "shortName": "Share-Based Compensation Plans - Assumptions Used to Determine Weighted-Average Fair Value of Options Granted (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R92": { "role": "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails", "longName": "9955570 - Disclosure - Share-Based Compensation Plans - Summary of Information Relative to Stock Option Plan Activity (Details)", "shortName": "Share-Based Compensation Plans - Summary of Information Relative to Stock Option Plan Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "92", "firstAnchor": { "contextRef": "c-15", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "unique": true } }, "R93": { "role": "http://www.merck.com/role/ShareBasedCompensationPlansAdditionalInformationPertainingtoStockOptionPlansDetails", "longName": "9955571 - Disclosure - Share-Based Compensation Plans - Additional Information Pertaining to Stock Option Plans (Details)", "shortName": "Share-Based Compensation Plans - Additional Information Pertaining to Stock Option Plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "93", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R94": { "role": "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails", "longName": "9955572 - Disclosure - Share-Based Compensation Plans - Summary of Nonvested RSU and PSU Activity (Details)", "shortName": "Share-Based Compensation Plans - Summary of Nonvested RSU and PSU Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "94", "firstAnchor": { "contextRef": "c-572", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-572", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R95": { "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "longName": "9955573 - Disclosure - Pension and Other Postretirement Benefit Plans - Narrative (Details)", "shortName": "Pension and Other Postretirement Benefit Plans - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "95", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DefinedContributionPlanCostRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DefinedContributionPlanCostRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R96": { "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails", "longName": "9955574 - Disclosure - Pension and Other Postretirement Benefit Plans - Components of Net Periodic Benefit Cost (Details)", "shortName": "Pension and Other Postretirement Benefit Plans - Components of Net Periodic Benefit Cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "96", "firstAnchor": { "contextRef": "c-582", "name": "us-gaap:DefinedBenefitPlanServiceCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-582", "name": "us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "unique": true } }, "R97": { "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails", "longName": "9955575 - Disclosure - Pension and Other Postretirement Benefit Plans - Obligation and Funded Status (Details)", "shortName": "Pension and Other Postretirement Benefit Plans - Obligation and Funded Status (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "97", "firstAnchor": { "contextRef": "c-589", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-582", "name": "us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "unique": true } }, "R98": { "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails", "longName": "9955576 - Disclosure - Pension and Other Postretirement Benefit Plans - Accumulated and Projected Benefit Obligation in Excess of Plan Assets (Details)", "shortName": "Pension and Other Postretirement Benefit Plans - Accumulated and Projected Benefit Obligation in Excess of Plan Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "98", "firstAnchor": { "contextRef": "c-591", "name": "us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "us-gaap:ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-591", "name": "us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "us-gaap:ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R99": { "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails", "longName": "9955577 - Disclosure - Pension and Other Postretirement Benefit Plans - Fair Values of Pension Plan Assets (Details)", "shortName": "Pension and Other Postretirement Benefit Plans - Fair Values of Pension Plan Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "99", "firstAnchor": { "contextRef": "c-596", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-602", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "unique": true } }, "R100": { "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails", "longName": "9955578 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Changes in Fair Value of Company's Level 3 Pension Plan Assets (Details)", "shortName": "Pension and Other Postretirement Benefit Plans - Summary of Changes in Fair Value of Company's Level 3 Pension Plan Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "100", "firstAnchor": { "contextRef": "c-597", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-850", "name": "us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "unique": true } }, "R101": { "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails", "longName": "9955579 - Disclosure - Pension and Other Postretirement Benefit Plans - Fair Values of Other Postretirement Benefit Plan Assets (Details)", "shortName": "Pension and Other Postretirement Benefit Plans - Fair Values of Other Postretirement Benefit Plan Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "101", "firstAnchor": { "contextRef": "c-593", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-868", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "unique": true } }, "R102": { "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails", "longName": "9955580 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Expected Benefit Payments (Details)", "shortName": "Pension and Other Postretirement Benefit Plans - Summary of Expected Benefit Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "102", "firstAnchor": { "contextRef": "c-593", "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-593", "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R103": { "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails", "longName": "9955581 - Disclosure - Pension and Other Postretirement Benefit Plans - Components of Other Comprehensive Income (Details)", "shortName": "Pension and Other Postretirement Benefit Plans - Components of Other Comprehensive Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "103", "firstAnchor": { "contextRef": "c-582", "name": "us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-582", "name": "us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R104": { "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails", "longName": "9955582 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Weighted Average Assumptions Used in Determining Pension Plan and U.S. Pension and Other Postretirement Benefit Plan Information (Details)", "shortName": "Pension and Other Postretirement Benefit Plans - Summary of Weighted Average Assumptions Used in Determining Pension Plan and U.S. Pension and Other Postretirement Benefit Plan Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "104", "firstAnchor": { "contextRef": "c-970", "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-970", "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R105": { "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails", "longName": "9955583 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Health Care Cost Trend Rate Assumptions for Other Postretirement Benefit Plans (Details)", "shortName": "Pension and Other Postretirement Benefit Plans - Summary of Health Care Cost Trend Rate Assumptions for Other Postretirement Benefit Plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "105", "firstAnchor": { "contextRef": "c-593", "name": "us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-593", "name": "us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R106": { "role": "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails", "longName": "9955584 - Disclosure - Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details)", "shortName": "Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "106", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentIncomeInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "unique": true } }, "R107": { "role": "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails", "longName": "9955585 - Disclosure - Other (Income) Expense, Net - Narrative (Details)", "shortName": "Other (Income) Expense, Net - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "107", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InterestPaidNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InterestPaidNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R108": { "role": "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails", "longName": "9955586 - Disclosure - Taxes on Income - Reconciliation Between Effective Tax Rate and US Statutory Rate (Details)", "shortName": "Taxes on Income - Reconciliation Between Effective Tax Rate and US Statutory Rate (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "108", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R109": { "role": "http://www.merck.com/role/TaxesonIncomeNarrativeDetails", "longName": "9955587 - Disclosure - Taxes on Income - Narrative (Details)", "shortName": "Taxes on Income - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "109", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R110": { "role": "http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails", "longName": "9955588 - Disclosure - Taxes on Income - Income Before Taxes (Details)", "shortName": "Taxes on Income - Income Before Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "110", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R111": { "role": "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails", "longName": "9955589 - Disclosure - Taxes on Income - Taxes on Income (Details)", "shortName": "Taxes on Income - Taxes on Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "111", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R112": { "role": "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails", "longName": "9955590 - Disclosure - Taxes on Income - Deferred Income Taxes (Details)", "shortName": "Taxes on Income - Deferred Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "112", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R113": { "role": "http://www.merck.com/role/TaxesonIncomeIncomeTaxAuthorityDetails", "longName": "9955591 - Disclosure - Taxes on Income - Income Tax Authority (Details)", "shortName": "Taxes on Income - Income Tax Authority (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "113", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxesPaid", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "mrk:ScheduleOfIncomeTaxesPaidTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxesPaid", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "mrk:ScheduleOfIncomeTaxesPaidTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R114": { "role": "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails", "longName": "9955592 - Disclosure - Taxes on Income - Unrecognized Tax Benefits (Details)", "shortName": "Taxes on Income - Unrecognized Tax Benefits (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "114", "firstAnchor": { "contextRef": "c-15", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "unique": true } }, "R115": { "role": "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails", "longName": "9955593 - Disclosure - Earnings Per Share - Calculations of Earnings Per Share (Details)", "shortName": "Earnings Per Share - Calculations of Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "115", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted", "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted", "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R116": { "role": "http://www.merck.com/role/EarningsPerShareNarrativeDetails", "longName": "9955594 - Disclosure - Earnings Per Share - Narrative (Details)", "shortName": "Earnings Per Share - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "116", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true, "unique": true } }, "R117": { "role": "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails", "longName": "9955595 - Disclosure - Other Comprehensive Income (Loss) (Details)", "shortName": "Other Comprehensive Income (Loss) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "117", "firstAnchor": { "contextRef": "c-15", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-988", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "unique": true } }, "R118": { "role": "http://www.merck.com/role/SegmentReportingNarrativeDetails", "longName": "9955596 - Disclosure - Segment Reporting - Narrative (Details)", "shortName": "Segment Reporting - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "118", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true }, "uniqueAnchor": null }, "R119": { "role": "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails", "longName": "9955597 - Disclosure - Segment Reporting - Sales of Company's Products (Details)", "shortName": "Segment Reporting - Sales of Company's Products (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "119", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "mrk:IncreaseDecreaseInHedgeRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "unique": true } }, "R120": { "role": "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails", "longName": "9955598 - Disclosure - Segment Reporting - Consolidated Revenues by Geographic Area (Details)", "shortName": "Segment Reporting - Consolidated Revenues by Geographic Area (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "120", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1329", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "unique": true } }, "R121": { "role": "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails", "longName": "9955599 - Disclosure - Segment Reporting - Reconciliation of Segment Profits to Income Before Taxes (Details)", "shortName": "Segment Reporting - Reconciliation of Segment Profits to Income Before Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "121", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1307", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "unique": true } }, "R122": { "role": "http://www.merck.com/role/SegmentReportingEquityIncomefromAffiliatesandDepreciationIncludedinSegmentProfitsDetails", "longName": "9955600 - Disclosure - Segment Reporting - Equity Income from Affiliates and Depreciation Included in Segment Profits (Details)", "shortName": "Segment Reporting - Equity Income from Affiliates and Depreciation Included in Segment Profits (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "122", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1307", "name": "us-gaap:IncomeLossFromEquityMethodInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "unique": true } }, "R123": { "role": "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails", "longName": "9955601 - Disclosure - Segment Reporting - Property, Plant and Equipment, Net by Geographic Area (Details)", "shortName": "Segment Reporting - Property, Plant and Equipment, Net by Geographic Area (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "123", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:PropertyPlantAndEquipmentNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-34", "name": "us-gaap:PropertyPlantAndEquipmentNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mrk-20241231.htm", "unique": true } } }, "tag": { "mrk_A075NotesDue2026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "A075NotesDue2026Member", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "0.75% notes due 2026", "label": "0.75% Notes due 2026 [Member]", "documentation": "0.75% Notes due 2026" } } }, "auth_ref": [] }, "mrk_A1.375Notesdue2036Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "A1.375Notesdue2036Member", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "1.375% Notes due 2036", "label": "1.375% Notes due 2036 [Member]", "documentation": "1.375% Notes due 2036 [Member]" } } }, "auth_ref": [] }, "mrk_A1.375eurodenominatednotesdue2036Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "A1.375eurodenominatednotesdue2036Member", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "1.375% euro-denominated notes due 2036", "label": "1.375% euro-denominated notes due 2036 [Member]", "documentation": "1.375% euro-denominated notes due 2036 [Member]" } } }, "auth_ref": [] }, "mrk_A1.875EuroNotesDue2026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "A1.875EuroNotesDue2026Member", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "1.875% euro-denominated notes due 2026", "label": "1.875% Euro Notes Due 2026 [Member]", "documentation": "1.875% Euro Notes Due 2026 [Member]" } } }, "auth_ref": [] }, "mrk_A1.875Notesdue2026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "A1.875Notesdue2026Member", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "1.875% Notes due 2026", "label": "1.875% Notes due 2026 [Member]", "documentation": "1.875% Notes due 2026 [Member]" } } }, "auth_ref": [] }, "mrk_A145NotesDue2030Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "A145NotesDue2030Member", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "1.45% notes due 2030", "label": "1.45% Notes Due 2030 [Member]", "documentation": "1.45% Notes Due 2030" } } }, "auth_ref": [] }, "mrk_A170NotesDue2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "A170NotesDue2027Member", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "1.70% notes due 2027", "label": "1.70% notes due 2027 [Member]", "documentation": "1.70% notes due 2027" } } }, "auth_ref": [] }, "mrk_A190NotesDue2028Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "A190NotesDue2028Member", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "1.90% notes due 2028", "label": "1.90% notes due 2028 [Member]", "documentation": "1.90% notes due 2028" } } }, "auth_ref": [] }, "mrk_A2.500Notesdue2034Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "A2.500Notesdue2034Member", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "2.500% Notes due 2034", "label": "2.500% Notes due 2034 [Member]", "documentation": "2.500% Notes due 2034 [Member]" } } }, "auth_ref": [] }, "mrk_A2.75NotesDue2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "A2.75NotesDue2025Member", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2.75% notes due 2025", "label": "2.75% Notes Due 2025 [Member]", "documentation": "2.75% Notes Due 2025 [Member]" } } }, "auth_ref": [] }, "mrk_A215NotesDue2031Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "A215NotesDue2031Member", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2.15% notes due 2031", "label": "2.15% notes due 2031 [Member]", "documentation": "2.15% notes due 2031" } } }, "auth_ref": [] }, "mrk_A235NotesDue2040Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "A235NotesDue2040Member", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2.35% notes due 2040", "label": "2.35% Notes Due 2040 [Member]", "documentation": "2.35% Notes Due 2040" } } }, "auth_ref": [] }, "mrk_A245NotesDue2050Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "A245NotesDue2050Member", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2.45% notes due 2050", "label": "2.45% Notes Due 2050 [Member]", "documentation": "2.45% Notes Due 2050" } } }, "auth_ref": [] }, "mrk_A25EuroDenominatedNotesDue2034Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "A25EuroDenominatedNotesDue2034Member", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2.50% euro-denominated notes due 2034", "label": "2.5% euro-denominated Notes Due 2034 [Member]", "documentation": "2.5% euro-denominated Notes Due 2034 [Member]" } } }, "auth_ref": [] }, "mrk_A275NotesDue2051Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "A275NotesDue2051Member", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2.75% notes due 2051", "label": "2.75% notes due 2051 [Member]", "documentation": "2.75% notes due 2051" } } }, "auth_ref": [] }, "mrk_A290NotesDue2061Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "A290NotesDue2061Member", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2.90% notes due 2061", "label": "2.90% notes due 2061 [Member]", "documentation": "2.90% notes due 2061" } } }, "auth_ref": [] }, "mrk_A3.250NotesDue2032Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "A3.250NotesDue2032Member", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "3.250% Notes due 2032", "label": "3.250% Notes Due 2032 [Member]", "documentation": "3.250% Notes Due 2032" } } }, "auth_ref": [] }, "mrk_A3.25EuroNotesDue2032Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "A3.25EuroNotesDue2032Member", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.25% euro-denominated notes due 2032", "label": "3.25% Euro Notes Due 2032 [Member]", "documentation": "3.25% Euro Notes Due 2032" } } }, "auth_ref": [] }, "mrk_A3.25NotesDue2032Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "A3.25NotesDue2032Member", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.25% Notes due 2032", "label": "3.25% Notes due 2032 [Member]", "documentation": "3.25% Notes due 2032" } } }, "auth_ref": [] }, "mrk_A3.40NotesDue2029Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "A3.40NotesDue2029Member", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.40% notes due 2029", "label": "3.40% Notes Due 2029 [Member]", "documentation": "3.40% Notes Due 2029" } } }, "auth_ref": [] }, "mrk_A3.500NotesDue2037Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "A3.500NotesDue2037Member", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "3.500% Notes due 2037", "label": "3.500% Notes Due 2037 [Member]", "documentation": "3.500% Notes Due 2037" } } }, "auth_ref": [] }, "mrk_A3.50EuroNotesDue2037Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "A3.50EuroNotesDue2037Member", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.50% euro-denominated notes due 2037", "label": "3.50% Euro Notes Due 2037 [Member]", "documentation": "3.50% Euro Notes Due 2037" } } }, "auth_ref": [] }, "mrk_A3.50NotesDue2037Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "A3.50NotesDue2037Member", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.50% Notes due 2037", "label": "3.50% Notes due 2037 [Member]", "documentation": "3.50% Notes due 2037" } } }, "auth_ref": [] }, "mrk_A3.700NotesDue2044Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "A3.700NotesDue2044Member", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "3.700% Notes due 2044", "label": "3.700% Notes Due 2044 [Member]", "documentation": "3.700% Notes Due 2044" } } }, "auth_ref": [] }, "mrk_A3.70EuroNotesDue2044Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "A3.70EuroNotesDue2044Member", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.70% euro-denominated notes due 2044", "label": "3.70% Euro Notes Due 2044 [Member]", "documentation": "3.70% Euro Notes Due 2044" } } }, "auth_ref": [] }, "mrk_A3.70NotesDue2044Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "A3.70NotesDue2044Member", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.70% Notes due 2044", "label": "3.70% Notes due 2044 [Member]", "documentation": "3.70% Notes due 2044" } } }, "auth_ref": [] }, "mrk_A3.70NotesDue2045Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "A3.70NotesDue2045Member", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.70% notes due 2045", "label": "3.70% Notes Due 2045 [Member]", "documentation": "3.70% Notes Due 2045 [Member]" } } }, "auth_ref": [] }, "mrk_A3.750NotesDue2054Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "A3.750NotesDue2054Member", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "3.750% Notes due 2054", "label": "3.750% Notes Due 2054 [Member]", "documentation": "3.750% Notes Due 2054" } } }, "auth_ref": [] }, "mrk_A3.75EuroNotesDue2054Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "A3.75EuroNotesDue2054Member", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.75% euro-denominated notes due 2054", "label": "3.75% Euro Notes Due 2054 [Member]", "documentation": "3.75% Euro Notes Due 2054" } } }, "auth_ref": [] }, "mrk_A3.75NotesDue2054Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "A3.75NotesDue2054Member", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.75% Notes due 2054", "label": "3.75% Notes due 2054 [Member]", "documentation": "3.75% Notes due 2054" } } }, "auth_ref": [] }, "mrk_A3.90NotesDue2039Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "A3.90NotesDue2039Member", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.90% notes due 2039", "label": "3.90% Notes Due 2039 [Member]", "documentation": "3.90% Notes Due 2039" } } }, "auth_ref": [] }, "mrk_A360NotesDue2042Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "A360NotesDue2042Member", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.60% notes due 2042", "label": "3.60% Notes Due 2042 [Member]", "documentation": "3.60% Notes Due 2042" } } }, "auth_ref": [] }, "mrk_A4.00NotesDue2049Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "A4.00NotesDue2049Member", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "4.00% notes due 2049", "label": "4.00% Notes Due 2049 [Member]", "documentation": "4.00% Notes Due 2049" } } }, "auth_ref": [] }, "mrk_A405NotesDue2028Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "A405NotesDue2028Member", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "4.05% notes due 2028", "label": "4.05% Notes Due 2028 [Member]", "documentation": "4.05% Notes Due 2028" } } }, "auth_ref": [] }, "mrk_A415NotesDue2043Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "A415NotesDue2043Member", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "4.15% notes due 2043", "label": "4.15% Notes Due 2043 [Member]", "documentation": "4.15% Notes Due 2043 [Member]" } } }, "auth_ref": [] }, "mrk_A430NotesDue2030Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "A430NotesDue2030Member", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "4.30% notes due 2030", "label": "4.30% Notes Due 2030 [Member]", "documentation": "4.30% Notes Due 2030" } } }, "auth_ref": [] }, "mrk_A450NotesDue2033Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "A450NotesDue2033Member", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails", "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "4.50% notes due 2033", "label": "4.50% notes due 2033 [Member]", "documentation": "4.50% notes due 2033" } } }, "auth_ref": [] }, "mrk_A490NotesDue2044Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "A490NotesDue2044Member", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "4.90% notes due 2044", "label": "4.90% notes due 2044 [Member]", "documentation": "4.90% notes due 2044" } } }, "auth_ref": [] }, "mrk_A500NotesDue2053Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "A500NotesDue2053Member", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails", "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "5.00% notes due 2053", "label": "5.00% Notes Due 2053 [Member]", "documentation": "5.00% Notes Due 2053" } } }, "auth_ref": [] }, "mrk_A515NotesDue2063Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "A515NotesDue2063Member", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "5.15% notes due 2063", "label": "5.15% Notes Due 2063 [Member]", "documentation": "5.15% Notes Due 2063" } } }, "auth_ref": [] }, "mrk_A575NotesDue2036Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "A575NotesDue2036Member", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "5.75% notes due 2036", "label": "5.75% Notes Due 2036 [Member]", "documentation": "5.75% Notes Due 2036" } } }, "auth_ref": [] }, "mrk_A585NotesDue2039Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "A585NotesDue2039Member", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "5.85% notes due 2039", "label": "5.85% Notes Due 2039 [Member]", "documentation": "5.85% Notes Due 2039" } } }, "auth_ref": [] }, "mrk_A595DebenturesDue2028Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "A595DebenturesDue2028Member", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "5.95% debentures due 2028", "label": "5.95% Debentures Due 2028 [Member]", "documentation": "5.95% Debentures Due 2028" } } }, "auth_ref": [] }, "mrk_A63DebenturesDue2026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "A63DebenturesDue2026Member", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails", "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "6.30% debentures due 2026", "label": "6.3% Debentures Due 2026 [Member]", "documentation": "Six point three percentage debentures due on two thousand and twenty six." } } }, "auth_ref": [] }, "mrk_A640DebenturesDue2028Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "A640DebenturesDue2028Member", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "6.40% debentures due 2028", "label": "6.40% Debentures Due 2028 [Member]", "documentation": "6.40% Debentures Due 2028" } } }, "auth_ref": [] }, "mrk_A650NotesDue2033Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "A650NotesDue2033Member", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "6.50% notes due 2033", "label": "6.50% Notes Due 2033 [Member]", "documentation": "6.50% Notes Due 2033" } } }, "auth_ref": [] }, "mrk_A655NotesDue2037Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "A655NotesDue2037Member", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "6.55% notes due 2037", "label": "6.55% Notes Due 2037 [Member]", "documentation": "6.55% Notes Due 2037" } } }, "auth_ref": [] }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AOCIAttributableToParentNetOfTaxRollForward", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Roll Forward]", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "mrk_AcceleratedDepreciationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "AcceleratedDepreciationMember", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accelerated Depreciation", "label": "Accelerated Depreciation [Member]", "documentation": "Accelerated Depreciation [Member]" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity of Counterparty, Type [Axis]", "label": "Legal Entity of Counterparty, Type [Axis]", "documentation": "Information by legal entity of counterparty. A counterparty is the other party that participates in a financial transaction." } } }, "auth_ref": [ "r123", "r129" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Trade accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r108", "r1190" ] }, "mrk_AccountsReceivableFactoringCollectionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "AccountsReceivableFactoringCollectionsMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable Factoring Collections", "label": "Accounts Receivable Factoring Collections [Member]", "documentation": "Accounts Receivable Factoring Collections" } } }, "auth_ref": [] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable", "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r1094" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable (net of allowance for doubtful accounts of $89 in 2024 and $88 in 2023)", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r1404" ] }, "us-gaap_AccountsReceivableSale": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableSale", "crdr": "credit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Factored accounts receivable", "label": "Accounts Receivable, Sale", "documentation": "Amount of decrease from sale of accounts receivable." } } }, "auth_ref": [ "r426" ] }, "mrk_AccrualForChargebacks": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "AccrualForChargebacks", "crdr": "credit", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrual for chargebacks reflected as direct reduction to accounts receivable", "label": "Accrual For Chargebacks", "documentation": "Accrual for chargebacks reflected as a direction reduction to accounts receivable." } } }, "auth_ref": [] }, "us-gaap_AccrualForEnvironmentalLossContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccrualForEnvironmentalLossContingencies", "crdr": "credit", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued liabilities for environmental matters", "label": "Accrual for Environmental Loss Contingencies", "documentation": "Total costs accrued as of the balance sheet date for environmental loss contingencies." } } }, "auth_ref": [ "r497", "r1143", "r1342", "r1343", "r1442", "r1445" ] }, "mrk_AccrualForRebates": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "AccrualForRebates", "crdr": "credit", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrual for rebates included in accrued and other current liabilities", "label": "Accrual For Rebates", "documentation": "Accrual for rebates recorded as current liability." } } }, "auth_ref": [] }, "us-gaap_AccruedIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedIncomeTaxesCurrent", "crdr": "credit", "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes payable", "label": "Accrued Income Taxes, Current", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations." } } }, "auth_ref": [ "r111", "r202" ] }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Benefit Plans", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent." } } }, "auth_ref": [ "r4", "r5", "r15", "r32", "r137", "r1371", "r1372", "r1373" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Less: accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r53", "r247", "r926" ] }, "us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest", "label": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]", "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, including portion attributable to noncontrolling interest." } } }, "auth_ref": [ "r271", "r280", "r757", "r933", "r1372", "r1373" ] }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r271", "r281", "r282", "r757", "r1121", "r1371" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax", "crdr": "debit", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pension and other postretirement benefit plans, net loss (gain) and prior service (credit) included in AOCI", "label": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax", "documentation": "Amount, after tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit)." } } }, "auth_ref": [ "r4", "r5", "r32", "r137", "r1457" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r280", "r281", "r805", "r807", "r808", "r809", "r810", "r811" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r31", "r32", "r138", "r259", "r921", "r968", "r969" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r280", "r281", "r805", "r807", "r808", "r809", "r810", "r811" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofEquity", "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Accumulated Other Comprehensive Loss", "terseLabel": "Accumulated Other Comprehensive Loss", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r2", "r15", "r32", "r771", "r774", "r830", "r964", "r965", "r1371", "r1372", "r1373", "r1390", "r1391", "r1392", "r1394" ] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Translation Adjustment", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent." } } }, "auth_ref": [ "r3", "r15", "r32", "r135", "r136", "r281", "r282", "r807", "r808", "r809", "r810", "r811", "r1371" ] }, "mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.merck.com/20241231", "localname": "AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreements" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisitions, Divestitures, Research Collaborations and Licensing Agreements", "label": "Acquisitions Research Collaborations And License Agreements [Text Block]", "documentation": "Information related to acquisitions, research collaborations and license agreements." } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r1278" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Other paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r124" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Other Paid-In Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r985", "r1390", "r1391", "r1392", "r1394", "r1493", "r1566" ] }, "mrk_AdempasMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "AdempasMember", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adempas", "label": "Adempas [Member]", "documentation": "Adempas" } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r1291" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r1291" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r1291" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r1291" ] }, "us-gaap_AdjustmentForAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentForAmortization", "crdr": "debit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization", "negatedTerseLabel": "Amortization", "label": "Amortization", "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives." } } }, "auth_ref": [ "r11" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdvertisingCostsPolicyTextBlock", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Advertising and Promotion Costs", "label": "Advertising Cost [Policy Text Block]", "documentation": "Disclosure of accounting policy for advertising cost." } } }, "auth_ref": [ "r221" ] }, "us-gaap_AdvertisingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdvertisingExpense", "crdr": "debit", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Advertising and promotion costs", "label": "Advertising Expense", "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line." } } }, "auth_ref": [ "r692", "r1170" ] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r1336" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r1249", "r1260", "r1270", "r1303" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r1252", "r1263", "r1273", "r1306" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r1337" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r1291" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r1298" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r1253", "r1264", "r1274", "r1298", "r1307", "r1311", "r1319" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r1317" ] }, "mrk_AllianceRevenueAdempasVerquvoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "AllianceRevenueAdempasVerquvoMember", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Alliance revenue - Adempas/Verquvo", "label": "Alliance revenue - Adempas/Verquvo [Member]", "documentation": "Alliance revenue - Adempas/Verquvo" } } }, "auth_ref": [] }, "mrk_AllianceRevenueKoselugoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "AllianceRevenueKoselugoMember", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Alliance revenue - Koselugo", "label": "Alliance revenue - Koselugo [Member]", "documentation": "Alliance revenue - Koselugo" } } }, "auth_ref": [] }, "mrk_AllianceRevenueReblozylMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "AllianceRevenueReblozylMember", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Alliance Revenue-Reblozyl", "label": "Alliance Revenue-Reblozyl [Member]", "documentation": "Alliance Revenue-Reblozyl" } } }, "auth_ref": [] }, "mrk_AlliancerevenueLynparzaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "AlliancerevenueLynparzaMember", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Alliance revenue - Lynparza", "label": "Alliance revenue - Lynparza [Member]", "documentation": "Alliance revenue - Lynparza [Member]" } } }, "auth_ref": [] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for doubtful accounts", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r260", "r385", "r424" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization expense for intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r11", "r453", "r461", "r1142" ] }, "mrk_AnimalHealthMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "AnimalHealthMember", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Animal Health", "label": "Animal Health [Member]", "documentation": "Animal Health [Member]" } } }, "auth_ref": [] }, "mrk_AnimalHealthsegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "AnimalHealthsegmentMember", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails", "http://www.merck.com/role/SegmentReportingEquityIncomefromAffiliatesandDepreciationIncludedinSegmentProfitsDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails", "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Animal Health", "label": "Animal Health segment [Member]", "documentation": "Animal Health segment [Member]" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.merck.com/role/EarningsPerShareNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive shares (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r342" ] }, "mrk_AquaManufacturingFacilities": { "xbrltype": "integerItemType", "nsuri": "http://www.merck.com/20241231", "localname": "AquaManufacturingFacilities", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aqua manufacturing facilities", "label": "Aqua Manufacturing Facilities", "documentation": "Aqua Manufacturing Facilities" } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCDetails", "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsModernaIncDetails", "http://www.merck.com/role/CollaborativeArrangementsModernaIncNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsRidgebackBiotherapeuticsLPDetails", "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r751" ] }, "srt_AsiaPacificMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "AsiaPacificMember", "presentation": [ "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asia Pacific (other than China and Japan)", "label": "Asia Pacific [Member]" } } }, "auth_ref": [ "r1567", "r1569", "r1570", "r1571" ] }, "mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet", "crdr": "debit", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net assets acquired", "label": "Asset Acquisition, Assets Acquired And Liabilities Assumed, Net", "documentation": "Asset Acquisition, Assets Acquired And Liabilities Assumed, Net" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionAxis", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Axis]", "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } } }, "auth_ref": [ "r454", "r455", "r456", "r457", "r459", "r1483" ] }, "mrk_AssetAcquisitionCashAndEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "AssetAcquisitionCashAndEquivalents", "crdr": "debit", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash recorded for asset acquisition", "label": "Asset Acquisition, Cash and Equivalents", "documentation": "Asset Acquisition, Cash and Equivalents" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionConsiderationTransferred", "crdr": "credit", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consideration transferred, asset acquisition", "label": "Asset Acquisition, Consideration Transferred", "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer." } } }, "auth_ref": [ "r1173", "r1484", "r1485", "r1486" ] }, "us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionConsiderationTransferredContingentConsideration", "crdr": "credit", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration", "label": "Asset Acquisition, Consideration Transferred, Contingent Consideration", "documentation": "Amount of contingent consideration recognized as part of consideration transferred in asset acquisition." } } }, "auth_ref": [ "r1484", "r1485", "r1486" ] }, "mrk_AssetAcquisitionConsiderationTransferredEquityInterestSettledUnvested": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "AssetAcquisitionConsiderationTransferredEquityInterestSettledUnvested", "crdr": "credit", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consideration transferred, to settle equity awards, unvested", "label": "Asset Acquisition, Consideration Transferred, Equity Interest Settled, Unvested", "documentation": "Asset Acquisition, Consideration Transferred, Equity Interest Settled, Unvested" } } }, "auth_ref": [] }, "mrk_AssetAcquisitionConsiderationTransferredShareBasedEquityInterestSettled": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "AssetAcquisitionConsiderationTransferredShareBasedEquityInterestSettled", "crdr": "credit", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consideration transferred, to settle share-based equity awards", "label": "Asset Acquisition, Consideration Transferred, Share-Based Equity Interest Settled", "documentation": "Asset Acquisition, Consideration Transferred, Share-Based Equity Interest Settled" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionConsiderationTransferredTransactionCost", "crdr": "credit", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transaction costs", "label": "Asset Acquisition, Consideration Transferred, Transaction Cost", "documentation": "Amount of transaction cost incurred as part of consideration transferred in asset acquisition." } } }, "auth_ref": [ "r1173", "r1484", "r1485", "r1486" ] }, "mrk_AssetAcquisitionContingentConsiderationReceivedUponTransferOfTechnology": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "AssetAcquisitionContingentConsiderationReceivedUponTransferOfTechnology", "crdr": "credit", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration dependent upon technology transfer", "label": "Asset Acquisition, Contingent Consideration Received Upon Transfer Of Technology", "documentation": "Asset Acquisition, Contingent Consideration Received Upon Transfer Of Technology" } } }, "auth_ref": [] }, "mrk_AssetAcquisitionDeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "AssetAcquisitionDeferredTaxAssets", "crdr": "debit", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets recorded for asset acquisition", "label": "Asset Acquisition, Deferred Tax Assets", "documentation": "Asset Acquisition, Deferred Tax Assets" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionDomain", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Domain]", "label": "Asset Acquisition [Domain]", "documentation": "Asset acquisition." } } }, "auth_ref": [ "r454", "r455", "r456", "r457", "r459", "r1483" ] }, "mrk_AssetAcquisitionInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "AssetAcquisitionInvestments", "crdr": "debit", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investments recorded for asset acquisition", "label": "Asset Acquisition, Investments", "documentation": "Asset Acquisition, Investments" } } }, "auth_ref": [] }, "mrk_AssetAcquisitionMaximumAggregateContingentDevelopmentRegulatoryAndSalesBasedRelatedPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "AssetAcquisitionMaximumAggregateContingentDevelopmentRegulatoryAndSalesBasedRelatedPayments", "crdr": "credit", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate contingent developmental, regulatory, and sales-based-related payments", "label": "Asset Acquisition, Maximum Aggregate Contingent Development, Regulatory, and Sales-Based-Related Payments", "documentation": "Asset Acquisition, Maximum Aggregate Contingent Development, Regulatory, and Sales-Based-Related Payments" } } }, "auth_ref": [] }, "mrk_AssetAcquisitionMaximumAggregateContingentDevelopmentRelatedPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "AssetAcquisitionMaximumAggregateContingentDevelopmentRelatedPayments", "crdr": "credit", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Future contingent developmental milestone payments (up to)", "label": "Asset Acquisition, Maximum Aggregate Contingent Development-Related Payments", "documentation": "Asset Acquisition, Maximum Aggregate Contingent Development-Related Payments" } } }, "auth_ref": [] }, "mrk_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments", "crdr": "credit", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Future regulatory milestone payments (up to)", "label": "Asset Acquisition, Maximum Aggregate Regulatory Milestone Payments", "documentation": "Asset Acquisition, Maximum Aggregate Regulatory Milestone Payments" } } }, "auth_ref": [] }, "mrk_AssetAcquisitionMaximumAggregateSalesBasedMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "AssetAcquisitionMaximumAggregateSalesBasedMilestonePayments", "crdr": "credit", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum aggregate sales-based milestone payments", "label": "Asset Acquisition, Maximum Aggregate Sales-Based Milestone Payments", "documentation": "Asset Acquisition, Maximum Aggregate Sales-Based Milestone Payments" } } }, "auth_ref": [] }, "mrk_AssetAcquisitionMilestonePaymentTriggeredAndPaidDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "AssetAcquisitionMilestonePaymentTriggeredAndPaidDevelopment", "crdr": "credit", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Developmental milestone payment triggered and paid", "label": "Asset Acquisition, Milestone Payment Triggered and Paid, Development", "documentation": "Asset Acquisition, Milestone Payment Triggered and Paid, Development" } } }, "auth_ref": [] }, "mrk_AssetAcquisitionNetLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "AssetAcquisitionNetLiabilitiesOther", "crdr": "credit", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other net liabilities recorded for asset acquisition", "label": "Asset Acquisition, Net Liabilities, Other", "documentation": "Asset Acquisition, Net Liabilities, Other" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total Assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r200", "r213", "r251", "r299", "r346", "r354", "r372", "r376", "r421", "r503", "r504", "r506", "r507", "r508", "r509", "r510", "r512", "r513", "r753", "r758", "r798", "r916", "r1028", "r1134", "r1135", "r1190", "r1227", "r1450", "r1451", "r1519" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCDetails", "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdDetails", "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "terseLabel": "Other current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r241", "r264", "r299", "r421", "r503", "r504", "r506", "r507", "r508", "r509", "r510", "r512", "r513", "r753", "r758", "r798", "r1190", "r1450", "r1451", "r1519" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Current Assets", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r782", "r783", "r1177" ] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosureAbstract", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "mrk_AstraZenecaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "AstraZenecaMember", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCDetails", "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AstraZeneca", "label": "AstraZeneca [Member]", "documentation": "AstraZeneca [Member]" } } }, "auth_ref": [] }, "mrk_AuditInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.merck.com/20241231", "localname": "AuditInformationAbstract", "lang": { "en-us": { "role": { "label": "Audit Information [Abstract]", "documentation": "Audit Information [Abstract]" } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorFirmId", "presentation": [ "http://www.merck.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Firm ID", "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r1232", "r1233", "r1256" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLocation", "presentation": [ "http://www.merck.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Location", "label": "Auditor Location" } } }, "auth_ref": [ "r1232", "r1233", "r1256" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorName", "presentation": [ "http://www.merck.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Name", "label": "Auditor Name" } } }, "auth_ref": [ "r1232", "r1233", "r1256" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt securities, gross unrealized gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r391" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Debt securities, gross unrealized losses", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r392" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Debt securities, amortized cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r388", "r431", "r915" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 2.0 }, "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "parentTag": "us-gaap_Investments", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Debt securities, fair value", "terseLabel": "Investments", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r389", "r431", "r782", "r907", "r1177", "r1181", "r1405", "r1497", "r1498", "r1499" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "crdr": "debit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Available-for-sale debt securities included in Short-term investments", "label": "Debt Securities, Available-for-Sale, Current", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current." } } }, "auth_ref": [ "r386", "r431" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "crdr": "debit", "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt securities, available-for-sale, noncurrent", "label": "Debt Securities, Available-for-Sale, Noncurrent", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent." } } }, "auth_ref": [ "r245", "r386", "r431" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r1314" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r1315" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r1310" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r1310" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r1310" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r1310" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r1310" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r1310" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails", "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r653", "r654", "r655", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r677", "r678", "r679", "r680", "r681" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r1313" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r1312" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r1311" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r1311" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position Location, Balance [Axis]", "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r477", "r1532", "r1533" ] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position Location, Balance [Domain]", "label": "Statement of Financial Position Location, Balance [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r88", "r91", "r477", "r1532", "r1533" ] }, "mrk_BayerAGMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "BayerAGMember", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bayer AG", "label": "Bayer AG [Member]", "documentation": "Bayer AG [Member]" } } }, "auth_ref": [] }, "mrk_BelsomraMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "BelsomraMember", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Belsomra", "label": "Belsomra [Member]", "documentation": "Belsomra [Member]" } } }, "auth_ref": [] }, "mrk_BridionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "BridionMember", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bridion", "label": "Bridion [Member]", "documentation": "Bridion [Member]." } } }, "auth_ref": [] }, "mrk_BristolMyersSquibbCompanyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "BristolMyersSquibbCompanyMember", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bristol Myers Squibb Company", "label": "Bristol Myers Squibb Company [Member]", "documentation": "Bristol Myers Squibb Company" } } }, "auth_ref": [] }, "mrk_BristolMyersSquibbMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "BristolMyersSquibbMember", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bristol Myers Squibb", "label": "Bristol Myers Squibb [Member]", "documentation": "Bristol Myers Squibb" } } }, "auth_ref": [] }, "us-gaap_BuildingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BuildingMember", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails", "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Buildings", "label": "Building [Member]", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities." } } }, "auth_ref": [ "r162" ] }, "us-gaap_BuildingsAndImprovementsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BuildingsAndImprovementsGross", "crdr": "debit", "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Buildings", "label": "Buildings and Improvements, Gross", "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing." } } }, "auth_ref": [ "r162" ] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r454", "r455", "r456", "r457", "r459", "r745", "r1162", "r1165" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r71", "r72", "r454", "r455", "r456", "r457", "r459", "r745", "r1162", "r1165" ] }, "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionContingentConsiderationLineItems", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Contingent Consideration [Line Items]", "label": "Business Acquisition, Contingent Consideration [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r745" ] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Changes in estimated fair value", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": [ "r748", "r1380" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration", "periodStartLabel": "Contingent consideration, beginning balance", "periodEndLabel": "Contingent consideration, ending balance", "label": "Business Combination, Contingent Consideration, Liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [ "r77", "r190", "r747", "r784", "r785", "r786" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "crdr": "credit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration, liability, current", "label": "Business Combination, Contingent Consideration, Liability, Current", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r77", "r190" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration, measurement input, discount rate", "label": "Business Combination, Contingent Consideration, Liability, Measurement Input", "documentation": "Value of input used to measure contingent consideration liability from business combination." } } }, "auth_ref": [ "r784", "r785", "r786" ] }, "mrk_BusinessCombinationDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://www.merck.com/20241231", "localname": "BusinessCombinationDiscountRate", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount rate", "label": "Business Combination, Discount Rate", "documentation": "Business Combination, Discount Rate" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "crdr": "debit", "calculation": { "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product rights and other", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date." } } }, "auth_ref": [ "r73", "r74" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "crdr": "debit", "calculation": { "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "documentation": "The amount of inventory recognized as of the acquisition date." } } }, "auth_ref": [ "r73", "r74" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "crdr": "debit", "calculation": { "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total identifiable net assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": [ "r73", "r74" ] }, "mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet", "crdr": "debit", "calculation": { "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets and liabilities, net", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other, Net", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other, Net" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date." } } }, "auth_ref": [ "r73", "r74" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "crdr": "debit", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consideration transferred", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": [ "r74" ] }, "us-gaap_BusinessCombinationsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationsPolicy", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisitions", "label": "Business Combinations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy." } } }, "auth_ref": [ "r184", "r185", "r186", "r187" ] }, "country_CN": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "CN", "presentation": [ "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "China", "label": "CHINA" } } }, "auth_ref": [] }, "mrk_CardinalHealthIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "CardinalHealthIncMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cardinal Health, Inc.", "label": "Cardinal Health, Inc. [Member]", "documentation": "Cardinal Health, Inc." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r36", "r244", "r1113" ] }, "us-gaap_CashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsMember", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents [Member]", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Equivalents", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r37" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes $68, $79 and $71 of restricted cash at January 1, 2024, 2023 and 2022, respectively, included in Other current assets)", "periodEndLabel": "Cash, Cash Equivalents and Restricted Cash at End of Year (includes $76, $68 and $79 of restricted cash at December 31, 2024, 2023 and 2022, respectively, included in Other current assets)", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r36", "r152", "r295" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r152" ] }, "us-gaap_CashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents", "label": "Cash Equivalents, at Carrying Value", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r1362", "r1530" ] }, "mrk_CencoraInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "CencoraInc.Member", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cencora, Inc.", "label": "Cencora, Inc. [Member]", "documentation": "Cencora, Inc." } } }, "auth_ref": [] }, "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "crdr": "credit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Derivatives designated as hedging instruments", "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments", "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement." } } }, "auth_ref": [ "r197" ] }, "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1", "crdr": "credit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Hedged items", "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge", "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement." } } }, "auth_ref": [ "r197" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r1289" ] }, "us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Obligation and Funded Status", "label": "Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block]", "documentation": "Tabular disclosure of the change in the benefit obligation, fair value of plan assets, and funded status of pension plans or other employee benefit plans." } } }, "auth_ref": [ "r25" ] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, "auth_ref": [ "r1286" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r1284" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r235", "r256", "r257", "r258", "r299", "r331", "r332", "r339", "r341", "r348", "r349", "r421", "r503", "r506", "r507", "r508", "r512", "r513", "r542", "r543", "r546", "r549", "r556", "r798", "r977", "r978", "r979", "r980", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r1015", "r1037", "r1056", "r1086", "r1087", "r1088", "r1089", "r1090", "r1341", "r1384", "r1395" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.merck.com/role/EquityShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r256", "r257", "r258", "r348", "r542", "r543", "r544", "r546", "r549", "r554", "r556", "r977", "r978", "r979", "r980", "r1154", "r1341", "r1384" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r1290" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r1290" ] }, "us-gaap_CollaborativeArrangementAccountingPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementAccountingPolicy", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangements", "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for collaborative arrangements." } } }, "auth_ref": [ "r225" ] }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementDisclosureTextBlock", "presentation": [ "http://www.merck.com/role/CollaborativeArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangements", "label": "Collaborative Arrangement Disclosure [Text Block]", "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants." } } }, "auth_ref": [ "r220", "r223", "r234" ] }, "mrk_CollaborativeArrangementNumberOfAntibodyDrugConjugates": { "xbrltype": "integerItemType", "nsuri": "http://www.merck.com/20241231", "localname": "CollaborativeArrangementNumberOfAntibodyDrugConjugates", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of antibody drug conjugates", "label": "Collaborative Arrangement, Number Of Antibody Drug Conjugates", "documentation": "Collaborative Arrangement, Number Of Antibody Drug Conjugates" } } }, "auth_ref": [] }, "mrk_CollaborativeArrangementPreferredStockInvestmentInCounterparty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "CollaborativeArrangementPreferredStockInvestmentInCounterparty", "crdr": "credit", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock investment in counterparty", "label": "Collaborative Arrangement, Preferred Stock Investment In Counterparty", "documentation": "Collaborative Arrangement, Preferred Stock Investment In Counterparty" } } }, "auth_ref": [] }, "mrk_CollaborativeArrangementRightsAndObligationsAggregateUpfrontPaymentsDueUponExecution": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "CollaborativeArrangementRightsAndObligationsAggregateUpfrontPaymentsDueUponExecution", "crdr": "credit", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate upfront payments due upon execution in collaborative arrangement", "label": "Collaborative Arrangement, Rights And Obligations, Aggregate Upfront Payments Due Upon Execution", "documentation": "Collaborative Arrangement, Rights And Obligations, Aggregate Upfront Payments Due Upon Execution" } } }, "auth_ref": [] }, "mrk_CollaborativeArrangementRightsAndObligationsAggregateUpfrontPaymentsDueUponLapseOfTime": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "CollaborativeArrangementRightsAndObligationsAggregateUpfrontPaymentsDueUponLapseOfTime", "crdr": "credit", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate upfront payments due upon lapse of time", "label": "Collaborative Arrangement, Rights And Obligations, Aggregate Upfront Payments Due Upon Lapse Of Time", "documentation": "Collaborative Arrangement, Rights And Obligations, Aggregate Upfront Payments Due Upon Lapse Of Time" } } }, "auth_ref": [] }, "mrk_CollaborativeArrangementRightsAndObligationsContractualPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "CollaborativeArrangementRightsAndObligationsContractualPayment", "crdr": "credit", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsModernaIncNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contractual payment", "label": "Collaborative Arrangement, Rights And Obligations, Contractual Payment", "documentation": "Collaborative Arrangement, Rights And Obligations, Contractual Payment" } } }, "auth_ref": [] }, "mrk_CollaborativeArrangementRightsAndObligationsLiableContractedPortionAmountOfResearchAndDevelopmentExpensesToIncurCostsFor": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "CollaborativeArrangementRightsAndObligationsLiableContractedPortionAmountOfResearchAndDevelopmentExpensesToIncurCostsFor", "crdr": "credit", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liable contracted portion amount of research and development expenses to incur costs for", "label": "Collaborative Arrangement, Rights And Obligations, Liable Contracted Portion Amount Of Research And Development Expenses To Incur Costs For", "documentation": "Collaborative Arrangement, Rights And Obligations, Liable Contracted Portion Amount Of Research And Development Expenses To Incur Costs For" } } }, "auth_ref": [] }, "mrk_CollaborativeArrangementRightsAndObligationsLiableContractedPortionAmountOfResearchAndDevelopmentExpensesToIncurCostsForPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.merck.com/20241231", "localname": "CollaborativeArrangementRightsAndObligationsLiableContractedPortionAmountOfResearchAndDevelopmentExpensesToIncurCostsForPercentage", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liable contracted portion amount of research and development expenses to incur costs for, percentage", "label": "Collaborative Arrangement, Rights And Obligations, Liable Contracted Portion Amount Of Research And Development Expenses To Incur Costs For, Percentage", "documentation": "Collaborative Arrangement, Rights And Obligations, Liable Contracted Portion Amount Of Research And Development Expenses To Incur Costs For, Percentage" } } }, "auth_ref": [] }, "mrk_CollaborativeArrangementRightsAndObligationsLicenseOptionExercisedNumberOfAntibodyDrugConjugates": { "xbrltype": "integerItemType", "nsuri": "http://www.merck.com/20241231", "localname": "CollaborativeArrangementRightsAndObligationsLicenseOptionExercisedNumberOfAntibodyDrugConjugates", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of exercised license option antibody drug conjugates", "label": "Collaborative Arrangement, Rights And Obligations, License Option Exercised, Number Of Antibody Drug Conjugates", "documentation": "Collaborative Arrangement, Rights And Obligations, License Option Exercised, Number Of Antibody Drug Conjugates" } } }, "auth_ref": [] }, "mrk_CollaborativeArrangementRightsAndObligationsLicenseOptionUnexercisedNumberOfAntibodyDrugConjugates": { "xbrltype": "integerItemType", "nsuri": "http://www.merck.com/20241231", "localname": "CollaborativeArrangementRightsAndObligationsLicenseOptionUnexercisedNumberOfAntibodyDrugConjugates", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of unexercised license option antibody drug conjugates", "label": "Collaborative Arrangement, Rights And Obligations, License Option Unexercised, Number Of Antibody Drug Conjugates", "documentation": "Collaborative Arrangement, Rights And Obligations, License Option Unexercised, Number Of Antibody Drug Conjugates" } } }, "auth_ref": [] }, "mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments", "crdr": "credit", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Eligible future contingent development-related payments (up to)", "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Contingent Development-Related Payments", "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Contingent Development-Related Payments" } } }, "auth_ref": [] }, "mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentMilestonePaymentsPerProduct": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentMilestonePaymentsPerProduct", "crdr": "credit", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum aggregate contingent milestone payments, per product", "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Contingent Milestone Payments, Per Product", "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Contingent Milestone Payments, Per Product" } } }, "auth_ref": [] }, "mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments", "crdr": "credit", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate, regulatory milestones payments, maximum", "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments", "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments" } } }, "auth_ref": [] }, "mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments", "crdr": "credit", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales milestone payments", "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Sales-Based Milestone Payments", "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Sales-Based Milestone Payments" } } }, "auth_ref": [] }, "mrk_CollaborativeArrangementRightsAndObligationsMilestonePaymentsDevelopmentalRelated": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "CollaborativeArrangementRightsAndObligationsMilestonePaymentsDevelopmentalRelated", "crdr": "credit", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent developmental milestone payments", "label": "Collaborative Arrangement, Rights and Obligations, Milestone Payments, Developmental-Related", "documentation": "Collaborative Arrangement, Rights and Obligations, Milestone Payments, Developmental-Related" } } }, "auth_ref": [] }, "mrk_CollaborativeArrangementRightsAndObligationsMilestonePaymentsRegulatory": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "CollaborativeArrangementRightsAndObligationsMilestonePaymentsRegulatory", "crdr": "credit", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Regulatory milestone payments", "label": "Collaborative Arrangement, Rights and Obligations, Milestone Payments, Regulatory", "documentation": "Collaborative Arrangement, Rights and Obligations, Milestone Payments, Regulatory" } } }, "auth_ref": [] }, "mrk_CollaborativeArrangementRightsAndObligationsNumberOfAntibodyDrugConjugates": { "xbrltype": "integerItemType", "nsuri": "http://www.merck.com/20241231", "localname": "CollaborativeArrangementRightsAndObligationsNumberOfAntibodyDrugConjugates", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of antibody drug conjugates obtained right and obligations", "label": "Collaborative Arrangement, Rights And Obligations, Number of Antibody Drug Conjugates", "documentation": "Collaborative Arrangement, Rights And Obligations, Number of Antibody Drug Conjugates" } } }, "auth_ref": [] }, "mrk_CollaborativeArrangementRightsAndObligationsNumberOfLicensedAntibodyDrugConjugates": { "xbrltype": "integerItemType", "nsuri": "http://www.merck.com/20241231", "localname": "CollaborativeArrangementRightsAndObligationsNumberOfLicensedAntibodyDrugConjugates", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of licensed antibody drug conjugates", "label": "Collaborative Arrangement, Rights And Obligations, Number Of Licensed Antibody Drug Conjugates", "documentation": "Collaborative Arrangement, Rights And Obligations, Number Of Licensed Antibody Drug Conjugates" } } }, "auth_ref": [] }, "mrk_CollaborativeArrangementRightsAndObligationsPaymentResultingFromExerciseOfLicenseOption": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "CollaborativeArrangementRightsAndObligationsPaymentResultingFromExerciseOfLicenseOption", "crdr": "credit", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payment resulting from the license option exercise", "label": "Collaborative Arrangement, Rights And Obligations, Payment Resulting From Exercise Of License Option", "documentation": "Collaborative Arrangement, Rights And Obligations, Payment Resulting From Exercise Of License Option" } } }, "auth_ref": [] }, "mrk_CollaborativeArrangementRightsAndObligationsProbableContingentPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "CollaborativeArrangementRightsAndObligationsProbableContingentPayments", "crdr": "credit", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Probable contingent payments", "label": "Collaborative Arrangement, Rights and Obligations, Probable Contingent Payments", "documentation": "Collaborative Arrangement, Rights and Obligations, Probable Contingent Payments" } } }, "auth_ref": [] }, "mrk_CollaborativeArrangementRightsAndObligationsRefundableUpfrontPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "CollaborativeArrangementRightsAndObligationsRefundableUpfrontPayments", "crdr": "credit", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Refundable upfront payments", "label": "Collaborative Arrangement, Rights And Obligations, Refundable Upfront Payments", "documentation": "Collaborative Arrangement, Rights And Obligations, Refundable Upfront Payments" } } }, "auth_ref": [] }, "mrk_CollaborativeArrangementRightsAndObligationsRoyaltyPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.merck.com/20241231", "localname": "CollaborativeArrangementRightsAndObligationsRoyaltyPercentage", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty percentage", "label": "Collaborative Arrangement, Rights And Obligations, Royalty Percentage", "documentation": "Collaborative Arrangement, Rights And Obligations, Royalty Percentage" } } }, "auth_ref": [] }, "mrk_CollaborativeArrangementRightsAndObligationsUpfrontPaymentDueUponExecution": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "CollaborativeArrangementRightsAndObligationsUpfrontPaymentDueUponExecution", "crdr": "credit", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Upfront payment made to collaborative partner", "label": "Collaborative Arrangement, Rights And Obligations, Upfront Payment Due Upon Execution", "documentation": "Collaborative Arrangement, Rights And Obligations, Upfront Payment Due Upon Execution" } } }, "auth_ref": [] }, "mrk_CollaborativeArrangementStockInvestmentInCounterparty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "CollaborativeArrangementStockInvestmentInCounterparty", "crdr": "credit", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock investment in counterparty", "label": "Collaborative Arrangement, Stock Investment In Counterparty", "documentation": "Collaborative Arrangement, Stock Investment In Counterparty" } } }, "auth_ref": [] }, "mrk_CollaborativeArrangementTerminatedNumberOfAntibodyDrugConjugates": { "xbrltype": "integerItemType", "nsuri": "http://www.merck.com/20241231", "localname": "CollaborativeArrangementTerminatedNumberOfAntibodyDrugConjugates", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of antibody drug conjugates terminated", "label": "Collaborative Arrangement, Terminated, Number Of Antibody Drug Conjugates", "documentation": "Collaborative Arrangement, Terminated, Number Of Antibody Drug Conjugates" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement, Revenue Not from Contract with Customer, Statement of Income or Comprehensive Income [Extensible Enumeration]", "label": "Collaborative Arrangement, Revenue Not from Contract with Customer, Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606." } } }, "auth_ref": [ "r751" ] }, "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCDetails", "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsModernaIncDetails", "http://www.merck.com/role/CollaborativeArrangementsModernaIncNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsRidgebackBiotherapeuticsLPDetails", "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement", "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]", "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement." } } }, "auth_ref": [ "r1487" ] }, "mrk_CollaborativeArrangementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.merck.com/20241231", "localname": "CollaborativeArrangementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangements [Abstract]", "label": "Collaborative Arrangements [Abstract]", "documentation": "Collaborative Arrangements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCDetails", "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsModernaIncDetails", "http://www.merck.com/role/CollaborativeArrangementsModernaIncNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsRidgebackBiotherapeuticsLPDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r751" ] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialPaperMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails", "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial paper", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": [ "r169", "r502", "r1216", "r1217", "r1218", "r1221" ] }, "mrk_CommercialandOtherLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "CommercialandOtherLitigationMember", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial and Other Litigation", "label": "Commercial and Other Litigation [Member]", "documentation": "Commercial and Other Litigation [Member]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Contingencies and Environmental Liabilities", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r167", "r490", "r492", "r1095", "r1437", "r1444" ] }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesPolicyTextBlock", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Contingencies and Legal Defense Costs", "label": "Commitments and Contingencies, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies." } } }, "auth_ref": [ "r56", "r1096" ] }, "us-gaap_CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockDividendsPerShareDeclared", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofEquityParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, dividends declared (in dollars per share)", "label": "Common Stock, Dividends, Per Share, Declared", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r174" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofEquity", "http://www.merck.com/role/CoverPage", "http://www.merck.com/role/EquityShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Common Stock ($0.50\u00a0par value)", "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r1212", "r1213", "r1214", "r1216", "r1217", "r1218", "r1221", "r1390", "r1391", "r1394", "r1493", "r1564", "r1566" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r122" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical", "http://www.merck.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r122", "r1015" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical", "http://www.merck.com/role/EquityShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "periodStartLabel": "Balance January\u00a01, common stock (in shares)", "periodEndLabel": "Balance December\u00a031, common stock (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r122" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2024 and 2023", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r122", "r920", "r1190" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r1295" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r1294" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r1296" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r1293" ] }, "mrk_CompanionAnimalsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "CompanionAnimalsMember", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Companion Animal", "label": "Companion Animals [Member]", "documentation": "Companion Animals [Member]" } } }, "auth_ref": [] }, "mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.merck.com/20241231", "localname": "CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of Company's pension investments categorized as level 3 assets", "label": "Company Pension Investments Which Are Categorized As Level Three Assets Percentage", "documentation": "Company pension investments which are categorized as level three assets percentage." } } }, "auth_ref": [] }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Retirement Benefits [Abstract]", "label": "Retirement Benefits [Abstract]" } } }, "auth_ref": [] }, "mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.merck.com/20241231", "localname": "ComponentofOtherIncomeExpenseofNonoperatingLineItems", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Component of Other Income / Expense of Nonoperating [Line Items]", "label": "Component of Other Income / Expense of Nonoperating [Line Items]", "documentation": "[Line Items] for Component of Other Income / Expense of Nonoperating [Table]" } } }, "auth_ref": [] }, "mrk_ComponentofOtherIncomeExpenseofNonoperatingTable": { "xbrltype": "stringItemType", "nsuri": "http://www.merck.com/20241231", "localname": "ComponentofOtherIncomeExpenseofNonoperatingTable", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Component of Other Income / Expense of Nonoperating [Table]", "label": "Component of Other Income / Expense of Nonoperating [Table]", "documentation": "Component of Other Income / Expense of Nonoperating [Table]" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncomeLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive Income (Loss) Attributable to Merck\u00a0& Co., Inc.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r33", "r276", "r278", "r285", "r909", "r935", "r936" ] }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNoteTextBlock", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss)", "label": "Comprehensive Income (Loss) Note [Text Block]", "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income." } } }, "auth_ref": [ "r134", "r284", "r908", "r933" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r39", "r40", "r102", "r103", "r383", "r1094" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r39", "r40", "r102", "r103", "r383", "r971", "r1094" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r39", "r40", "r102", "r103", "r383", "r1094", "r1350" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of accounts receivable represented by customers with largest balances", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r39", "r40", "r102", "r103", "r383" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r39", "r40", "r102", "r103", "r383", "r1094" ] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsAxis", "presentation": [ "http://www.merck.com/role/SegmentReportingEquityIncomefromAffiliatesandDepreciationIncludedinSegmentProfitsDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Axis]", "label": "Consolidation Items [Axis]" } } }, "auth_ref": [ "r211", "r306", "r346", "r356", "r370", "r371", "r372", "r373", "r374", "r376", "r377", "r378", "r503", "r504", "r505", "r506", "r508", "r509", "r510", "r511", "r512", "r1134", "r1135", "r1450", "r1451" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsDomain", "presentation": [ "http://www.merck.com/role/SegmentReportingEquityIncomefromAffiliatesandDepreciationIncludedinSegmentProfitsDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Domain]", "label": "Consolidation Items [Domain]" } } }, "auth_ref": [ "r211", "r306", "r346", "r356", "r370", "r371", "r372", "r373", "r374", "r376", "r377", "r378", "r503", "r504", "r505", "r506", "r508", "r509", "r510", "r511", "r512", "r1134", "r1135", "r1450", "r1451" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Principles of Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r80", "r1122" ] }, "us-gaap_ConstructionInProgressGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConstructionInProgressGross", "crdr": "debit", "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Construction in progress", "label": "Construction in Progress, Gross", "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [ "r162" ] }, "us-gaap_ContingentConsiderationByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContingentConsiderationByTypeAxis", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration by Type [Axis]", "label": "Contingent Consideration by Type [Axis]", "documentation": "Information by type of contingent consideration." } } }, "auth_ref": [] }, "mrk_ContingentConsiderationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.merck.com/20241231", "localname": "ContingentConsiderationPolicyTextBlock", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration for Business Combinations", "label": "Contingent Consideration [Policy Text Block]", "documentation": "Discussion of the accounting policy for contingent consideration." } } }, "auth_ref": [] }, "us-gaap_ContingentConsiderationTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContingentConsiderationTypeDomain", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration Type [Domain]", "label": "Contingent Consideration Type [Domain]", "documentation": "Description of contingent payment arrangement." } } }, "auth_ref": [] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateDebtSecuritiesMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate notes and bonds", "verboseLabel": "Corporate obligations", "label": "Corporate Debt Securities [Member]", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": [ "r1158", "r1160", "r1177", "r1191", "r1209", "r1561" ] }, "us-gaap_CorporateNonSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateNonSegmentMember", "presentation": [ "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "verboseLabel": "Other profits", "label": "Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]", "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment." } } }, "auth_ref": [ "r22", "r371", "r372", "r373", "r374", "r377", "r1400" ] }, "mrk_CorporateObligationsFixedIncomeSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "CorporateObligationsFixedIncomeSecuritiesMember", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate obligations", "label": "Corporate Obligations Fixed Income Securities [Member]", "documentation": "Corporate obligations fixed income securities." } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofIncome": { "parentTag": "mrk_CostsExpensesAndOther", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCDetails", "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdDetails", "http://www.merck.com/role/CollaborativeArrangementsRidgebackBiotherapeuticsLPDetails", "http://www.merck.com/role/ConsolidatedStatementofIncome", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of sales", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r142", "r143", "r873" ] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesMember", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of sales", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpensesAbstract", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Costs, Expenses and Other", "label": "Costs and Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Costs", "label": "Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations." } } }, "auth_ref": [ "r28", "r163", "r164" ] }, "mrk_CostsExpensesAndOther": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "CostsExpensesAndOther", "crdr": "debit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofIncome": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Total costs, expenses and other", "label": "Costs Expenses And Other", "documentation": "Total of cost of sales, operating expenses and nonoperating income or expense." } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCDetails", "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsModernaIncDetails", "http://www.merck.com/role/CollaborativeArrangementsModernaIncNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsRidgebackBiotherapeuticsLPDetails", "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r304", "r305", "r518", "r544", "r834", "r852", "r913", "r1117", "r1120" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CurrencySwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrencySwapMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency Swap", "label": "Currency Swap [Member]", "documentation": "Swap involving the exchange of principal and interest in one currency for another currency." } } }, "auth_ref": [] }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentFederalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal", "label": "Current Federal Tax Expense (Benefit)", "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1352", "r1387", "r1482" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentForeignTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign", "label": "Current Foreign Tax Expense (Benefit)", "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r1352", "r1387" ] }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total current provision", "label": "Current Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations." } } }, "auth_ref": [ "r731", "r1387" ] }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current provision", "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentStateAndLocalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State", "label": "Current State and Local Tax Expense (Benefit)", "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1352", "r1387", "r1482" ] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r158", "r383" ] }, "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r1241", "r1330" ] }, "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]" } } }, "auth_ref": [ "r1241", "r1330" ] }, "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]" } } }, "auth_ref": [ "r1243", "r1332" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]" } } }, "auth_ref": [ "r1243", "r1332" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]" } } }, "auth_ref": [ "r1245", "r1334" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r1243", "r1332" ] }, "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]" } } }, "auth_ref": [ "r1236", "r1325" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesIntegratedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Flag]" } } }, "auth_ref": [ "r1237", "r1326" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Text Block]" } } }, "auth_ref": [ "r1237", "r1326" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]" } } }, "auth_ref": [ "r1235", "r1324" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]" } } }, "auth_ref": [ "r1235", "r1324" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]" } } }, "auth_ref": [ "r1235", "r1324" ] }, "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Third Party Engaged [Flag]" } } }, "auth_ref": [ "r1238", "r1327" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]" } } }, "auth_ref": [ "r1240", "r1329" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]" } } }, "auth_ref": [ "r1240", "r1329" ] }, "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r1241", "r1330" ] }, "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r1244", "r1333" ] }, "cyd_CybersecurityRiskRoleOfManagementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskRoleOfManagementTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Role of Management [Text Block]" } } }, "auth_ref": [ "r1242", "r1331" ] }, "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]" } } }, "auth_ref": [ "r1239", "r1328" ] }, "mrk_DaiichiSankyoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "DaiichiSankyoMember", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails", "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Daiichi Sankyo", "label": "Daiichi Sankyo [Member]", "documentation": "Daiichi Sankyo" } } }, "auth_ref": [] }, "us-gaap_DebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtCurrent", "crdr": "credit", "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet", "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loans payable and current portion of long-term debt", "label": "Debt, Current", "documentation": "Amount of debt and lease obligation, classified as current." } } }, "auth_ref": [ "r254" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeases" ], "lang": { "en-us": { "role": { "terseLabel": "Loans Payable, Long-Term Debt and Leases", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r168", "r297", "r472", "r473", "r474", "r475", "r476", "r501", "r502", "r514", "r520", "r521", "r522", "r523", "r524", "r525", "r530", "r537", "r538", "r540", "r813" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails", "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails", "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r29", "r110", "r111", "r201", "r204", "r306", "r515", "r516", "r517", "r518", "r519", "r521", "r526", "r527", "r528", "r529", "r531", "r532", "r533", "r534", "r535", "r536", "r1149", "r1150", "r1151", "r1152", "r1153", "r1188", "r1385", "r1438", "r1439", "r1440", "r1513", "r1514" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails", "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Par Value of Debt", "terseLabel": "Face amount of debt", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r515", "r813", "r814", "r1150", "r1151", "r1188" ] }, "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFairValue", "crdr": "credit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of loans payable and long-term debt, including current portion", "label": "Debt Instrument, Fair Value Disclosure", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } } }, "auth_ref": [ "r528", "r797", "r1150", "r1151", "r1496", "r1497", "r1498", "r1499", "r1506" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails", "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails", "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stated interest rate", "verboseLabel": "Stated interest rate", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r113", "r516" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails", "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r306", "r515", "r516", "r517", "r518", "r519", "r521", "r526", "r527", "r528", "r529", "r531", "r532", "r533", "r534", "r535", "r536", "r539", "r1149", "r1150", "r1151", "r1152", "r1153", "r1188", "r1385", "r1513", "r1514" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails", "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails", "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r29", "r306", "r515", "r516", "r517", "r518", "r519", "r521", "r526", "r527", "r528", "r529", "r531", "r532", "r533", "r534", "r535", "r536", "r1149", "r1150", "r1151", "r1152", "r1153", "r1188", "r1385", "r1438", "r1439", "r1440", "r1513", "r1514" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails", "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": [ "r29", "r60", "r63", "r104", "r172", "r173", "r306", "r515", "r516", "r517", "r518", "r519", "r521", "r526", "r527", "r528", "r529", "r531", "r532", "r533", "r534", "r535", "r536", "r539", "r1149", "r1150", "r1151", "r1152", "r1153", "r1188", "r1385", "r1513", "r1514" ] }, "us-gaap_DebtLongtermAndShorttermCombinedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtLongtermAndShorttermCombinedAmount", "crdr": "credit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt, carrying amount", "label": "Debt, Long-Term and Short-Term, Combined Amount", "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Available-for-sale Securities [Table]", "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398" ] }, "mrk_DebtSecuritiesandEquitySecuritiesFVNI": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "DebtSecuritiesandEquitySecuritiesFVNI", "crdr": "debit", "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total debt and publicly traded equity securities, fair value", "label": "Debt Securities and Equity Securities, FV-NI", "documentation": "Debt Securities and Equity Securities, FV-NI" } } }, "auth_ref": [] }, "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible", "crdr": "debit", "presentation": [ "http://www.merck.com/role/TaxesonIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reasonably possible amount that liability for unrecognized tax benefits could decline up to in next 12 months (up to)", "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible", "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit." } } }, "auth_ref": [ "r214" ] }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFederalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal", "label": "Deferred Federal Income Tax Expense (Benefit)", "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1387", "r1481", "r1482" ] }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredForeignIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign", "label": "Deferred Foreign Income Tax Expense (Benefit)", "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r1387", "r1481" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 }, "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows", "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "totalLabel": "Total deferred provision", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r11", "r230", "r1387" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred provision", "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilities", "crdr": "credit", "calculation": { "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Subtotal, Liabilities", "label": "Deferred Tax Liabilities, Gross", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences." } } }, "auth_ref": [ "r118", "r119", "r203", "r724" ] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet", "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred Income Taxes", "terseLabel": "Deferred Income Taxes", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r701", "r702", "r917" ] }, "mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable": { "xbrltype": "stringItemType", "nsuri": "http://www.merck.com/20241231", "localname": "DeferredIncomeTaxesAssetsAndLiabilitiesNetTable", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Income Taxes Assets And Liabilities Net [Table]", "label": "Deferred Income Taxes Assets And Liabilities Net [Table]", "documentation": "Deferred Income Taxes Assets And Liabilities Net [Table]" } } }, "auth_ref": [] }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State", "label": "Deferred State and Local Income Tax Expense (Benefit)", "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1387", "r1481", "r1482" ] }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "crdr": "debit", "calculation": { "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product intangibles and licenses, Assets", "label": "Deferred Tax Assets, Goodwill and Intangible Assets", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill." } } }, "auth_ref": [ "r1479" ] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Subtotal, Assets", "label": "Deferred Tax Assets, Gross", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r725" ] }, "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment", "crdr": "debit", "calculation": { "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "R&D capitalization, Assets", "label": "Deferred Tax Asset, In-Process Research and Development", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both." } } }, "auth_ref": [ "r1479" ] }, "us-gaap_DeferredTaxAssetsInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsInventory", "crdr": "debit", "calculation": { "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory related, Assets", "label": "Deferred Tax Assets, Inventory", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory." } } }, "auth_ref": [ "r1479" ] }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsLiabilitiesNet", "crdr": "debit", "calculation": { "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred income taxes, Assets", "label": "Deferred Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting." } } }, "auth_ref": [ "r1474" ] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total deferred taxes", "label": "Deferred Tax Assets, Net of Valuation Allowance", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r1474" ] }, "mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards", "crdr": "debit", "calculation": { "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net operating losses and other tax credit carryforwards, Assets", "label": "Deferred Tax Assets Operating Loss Carryforwards And Other Tax Credit Carryforwards", "documentation": "Deferred tax assets operating loss carryforwards and other tax credit carryforwards." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign", "crdr": "debit", "presentation": [ "http://www.merck.com/role/TaxesonIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets on NOL carryforwards relating to foreign jurisdictions", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards." } } }, "auth_ref": [ "r1479" ] }, "us-gaap_DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOther", "crdr": "debit", "calculation": { "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other, Assets", "label": "Deferred Tax Assets, Other", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other." } } }, "auth_ref": [ "r1479" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits", "crdr": "debit", "calculation": { "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pensions and other postretirement benefits, Assets", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from employee benefits, classified as other." } } }, "auth_ref": [ "r1479" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation", "crdr": "debit", "calculation": { "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation related, Assets", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation." } } }, "auth_ref": [ "r1479" ] }, "mrk_DeferredTaxAssetsUndistributedForeignEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "DeferredTaxAssetsUndistributedForeignEarnings", "crdr": "debit", "calculation": { "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Undistributed foreign earnings, Assets", "label": "Deferred Tax Assets, Undistributed Foreign Earnings", "documentation": "Deferred Tax Assets, Undistributed Foreign Earnings" } } }, "auth_ref": [] }, "mrk_DeferredTaxAssetsUnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "DeferredTaxAssetsUnrecognizedTaxBenefits", "crdr": "debit", "calculation": { "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax benefits, Assets", "label": "Deferred Tax Assets Unrecognized Tax Benefits", "documentation": "Deferred tax assets unrecognized tax benefits." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Valuation allowance, Assets", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r726" ] }, "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts", "crdr": "credit", "calculation": { "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory related, Liabilities", "label": "Deferred Tax Liabilities, Inventory", "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from inventory." } } }, "auth_ref": [ "r1479" ] }, "mrk_DeferredTaxLiabilitiesEquityMethodInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "DeferredTaxLiabilitiesEquityMethodInvestment", "crdr": "credit", "calculation": { "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity method investments, Liabilities", "label": "Deferred Tax Liabilities, Equity Method Investment", "documentation": "Deferred Tax Liabilities, Equity Method Investment" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets", "crdr": "credit", "calculation": { "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product intangibles and licenses, Liabilities", "label": "Deferred Tax Liabilities, Intangible Assets", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill." } } }, "auth_ref": [ "r1479" ] }, "us-gaap_DeferredTaxLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesOther", "crdr": "credit", "calculation": { "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other, Liabilities", "label": "Deferred Tax Liabilities, Other", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other." } } }, "auth_ref": [ "r1479" ] }, "mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans", "crdr": "credit", "calculation": { "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pensions and other postretirement benefits, Liabilities", "label": "Deferred Tax Liabilities Pensions And Other Postretirement Benefit Plans", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from pensions and other postretirement benefits." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accelerated depreciation, Liabilities", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment." } } }, "auth_ref": [ "r1479" ] }, "us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesUndistributedForeignEarnings", "crdr": "credit", "calculation": { "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Undistributed foreign earnings, Liabilities", "label": "Deferred Tax Liabilities, Undistributed Foreign Earnings", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences." } } }, "auth_ref": [ "r1479" ] }, "mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic", "crdr": "debit", "presentation": [ "http://www.merck.com/role/TaxesonIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets relating to various U.S. tax credit carryforwards and NOL carryforwards", "label": "Deferred tax assets credit loss carryforwards and NOL carryforwards domestic", "documentation": "Deferred tax assets credit loss carryforwards and NOL carryforwards domestic" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAccumulatedBenefitObligation", "crdr": "credit", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated benefit obligation", "label": "Defined Benefit Plan, Accumulated Benefit Obligation", "documentation": "Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level." } } }, "auth_ref": [ "r601" ] }, "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanActualReturnOnPlanAssets", "crdr": "debit", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Actual return on plan assets", "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)", "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses." } } }, "auth_ref": [ "r583", "r1160" ] }, "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanActualReturnOnPlanAssetsAbstract", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Actual return on plan assets:", "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod", "crdr": "debit", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Relating to assets sold during the year", "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Actual Return (Loss) on Plan Assets Sold", "documentation": "Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan from actual return (loss) on assets sold." } } }, "auth_ref": [ "r597", "r1160" ] }, "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld", "crdr": "debit", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Relating to assets still held at December 31", "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Actual Return (Loss) on Plan Assets Still Held", "documentation": "Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan from actual return (loss) on assets still held." } } }, "auth_ref": [ "r597", "r1160" ] }, "us-gaap_DefinedBenefitPlanActuarialGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanActuarialGainLoss", "crdr": "credit", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Actuarial (gains) losses", "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)", "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan." } } }, "auth_ref": [ "r576" ] }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "crdr": "credit", "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Net loss (gain) amortization", "label": "Defined Benefit Plan, Amortization of Gain (Loss)", "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan." } } }, "auth_ref": [ "r570", "r608", "r634", "r1160", "r1161" ] }, "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit", "crdr": "debit", "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of unrecognized prior service (credit) cost", "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)", "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan." } } }, "auth_ref": [ "r570", "r609", "r635", "r1160", "r1161" ] }, "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recognized as:", "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent", "crdr": "debit", "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails": { "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Assets", "label": "Assets for Plan Benefits, Defined Benefit Plan", "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans." } } }, "auth_ref": [ "r199", "r567", "r568", "r591", "r1027", "r1160", "r1529" ] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount rate", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate", "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan." } } }, "auth_ref": [ "r615" ] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Salary growth rate", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase", "documentation": "Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan." } } }, "auth_ref": [ "r616" ] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest crediting rate", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Weighted-Average Interest Crediting Rate", "documentation": "Weighted-average interest crediting rate used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, cash balance and other defined benefit plans with promised interest crediting rate." } } }, "auth_ref": [ "r618" ] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount rate", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate", "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan." } } }, "auth_ref": [ "r615" ] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Expected rate of return on plan assets", "terseLabel": "Expected rate of return on plan assets", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets", "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan." } } }, "auth_ref": [ "r617", "r639" ] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Salary growth rate", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase", "documentation": "Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan." } } }, "auth_ref": [ "r616" ] }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest crediting rate", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Weighted-Average Interest Crediting Rate", "documentation": "Weighted-average interest crediting rate used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, cash balance and other defined benefit plans with promised interest crediting rate." } } }, "auth_ref": [ "r618" ] }, "us-gaap_DefinedBenefitPlanBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanBenefitObligation", "crdr": "credit", "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails_1": { "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Benefit obligation January\u00a01", "periodEndLabel": "Benefit obligation December\u00a031", "label": "Defined Benefit Plan, Benefit Obligation", "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan." } } }, "auth_ref": [ "r571" ] }, "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid", "crdr": "credit", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Benefits paid", "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid", "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services." } } }, "auth_ref": [ "r578", "r642" ] }, "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]", "label": "Defined Benefit Plan, Plan Assets, Category [Axis]", "documentation": "Information by defined benefit plan asset investment." } } }, "auth_ref": [ "r592", "r593", "r595", "r596", "r597", "r598", "r599", "r600", "r620", "r1158", "r1159", "r1160" ] }, "us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanCashAndCashEquivalentsMember", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Defined Benefit Plan, Cash and Cash Equivalents [Member]", "documentation": "Cash and cash equivalent in which defined benefit plan asset is invested." } } }, "auth_ref": [ "r1158" ] }, "mrk_DefinedBenefitPlanCashandOtherInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "DefinedBenefitPlanCashandOtherInvestmentsMember", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash And Other Investments", "label": "Defined Benefit Plan, Cash and Other Investments [Member]", "documentation": "Defined Benefit Plan, Cash and Other Investments [Member]" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]", "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]", "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanContributionsByEmployer", "crdr": "debit", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Company contributions", "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer", "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets." } } }, "auth_ref": [ "r585", "r595", "r638", "r1158", "r1159", "r1160", "r1161" ] }, "us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod", "crdr": "debit", "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Termination benefits", "label": "Defined Benefit Plan, Cost of Providing Special and Contractual Termination Benefits", "documentation": "Amount of cost of providing special or contractual termination benefits payable from defined benefit plan." } } }, "auth_ref": [ "r623" ] }, "us-gaap_DefinedBenefitPlanCurtailments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanCurtailments", "crdr": "debit", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Curtailments", "label": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Curtailment", "documentation": "Amount of (increase) decrease in benefit obligation of defined benefit plan from event reducing expected years of future service of present employees or eliminating accrual of benefits for some or all future services of present employees." } } }, "auth_ref": [ "r573" ] }, "us-gaap_DefinedBenefitPlanDerivativeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanDerivativeMember", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives", "label": "Defined Benefit Plan, Derivative [Member]", "documentation": "Financial instrument or other contract with one or more underlyings, notional amount or payment provision or both; can be settled net by means outside contract or delivery of asset; and with minimal or no initial net investment, in which defined benefit plan asset is invested." } } }, "auth_ref": [ "r1158" ] }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanDisclosureLineItems", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan Disclosure [Line Items]", "label": "Defined Benefit Plan Disclosure [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanEquitySecuritiesNonUsMember", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "International equities", "label": "Defined Benefit Plan, Equity Securities, Non-US [Member]", "documentation": "Security representing ownership in corporation or other legal entity, not domiciled in United States of America (US), for which ownership is represented by share of stock; in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant." } } }, "auth_ref": [ "r1158", "r1159", "r1160" ] }, "us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanEquitySecuritiesUsMember", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S.\u00a0equities", "label": "Defined Benefit Plan, Equity Securities, US [Member]", "documentation": "Security representing ownership in corporation or other legal entity, domiciled in United States of America (US), for which ownership is represented by share of stock; in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant." } } }, "auth_ref": [ "r1158", "r1159", "r1160" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter", "crdr": "credit", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2030\u00a0\u2014\u00a02034", "label": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years", "documentation": "Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year." } } }, "auth_ref": [ "r602" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "crdr": "credit", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year One", "documentation": "Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year." } } }, "auth_ref": [ "r602" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive", "crdr": "credit", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five", "documentation": "Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year." } } }, "auth_ref": [ "r602" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour", "crdr": "credit", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four", "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year." } } }, "auth_ref": [ "r602" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree", "crdr": "credit", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three", "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year." } } }, "auth_ref": [ "r602" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo", "crdr": "credit", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two", "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year." } } }, "auth_ref": [ "r602" ] }, "us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear", "crdr": "debit", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected contributions to the pension plans and other postretirement benefit plans during next fiscal year", "label": "Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year", "documentation": "Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year." } } }, "auth_ref": [ "r603", "r1161" ] }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "crdr": "credit", "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Expected return on plan assets", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan." } } }, "auth_ref": [ "r570", "r607", "r633", "r1160", "r1161" ] }, "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanFairValueOfPlanAssets", "crdr": "debit", "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails_1": { "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of plan assets", "periodStartLabel": "Fair value of plan assets January\u00a01", "periodEndLabel": "Fair value of plan assets December\u00a031", "verboseLabel": "Plan assets at fair value", "label": "Defined Benefit Plan, Plan Assets, Amount", "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee." } } }, "auth_ref": [ "r582", "r593", "r595", "r596", "r1158", "r1159", "r1160" ] }, "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation", "crdr": "credit", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effects of exchange rate changes", "label": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan." } } }, "auth_ref": [ "r577" ] }, "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanFundedStatusOfPlan", "crdr": "debit", "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Funded status December\u00a031", "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan", "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status." } } }, "auth_ref": [ "r567", "r591", "r1160" ] }, "us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Health care cost trend rate assumed for next year", "label": "Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year", "documentation": "Assumed rate, for next fiscal year, based on annual change in cost of health care cost benefits used to measure expected cost of benefits covered by defined benefit postretirement plan. Factors include, but are not limited to, estimate of health care inflation, change in health care utilization or delivery pattern, technological advances, and change in health status of participant. Excludes factors for change in composition of plan population by age and dependency status." } } }, "auth_ref": [ "r619" ] }, "us-gaap_DefinedBenefitPlanInterestCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanInterestCost", "crdr": "debit", "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest cost", "label": "Defined Benefit Plan, Interest Cost", "documentation": "Amount of cost recognized for passage of time related to defined benefit plan." } } }, "auth_ref": [ "r570", "r574", "r606", "r632", "r1160", "r1161" ] }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "crdr": "debit", "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net periodic benefit cost (credit)", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan." } } }, "auth_ref": [ "r604", "r630", "r1160", "r1161" ] }, "us-gaap_DefinedBenefitPlanOtherChanges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanOtherChanges", "crdr": "credit", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Other Change", "documentation": "Amount of increase (decrease) in benefit obligation of defined benefit plan from change, classified as other." } } }, "auth_ref": [] }, "mrk_DefinedBenefitPlanOtherChangesPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "DefinedBenefitPlanOtherChangesPlanAssets", "crdr": "debit", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Defined Benefit Plan Other Changes Plan Assets", "documentation": "Changes in plan assets, not otherwise separately disclosed in the financial statements." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets", "crdr": "debit", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pension plans with a projected benefit obligation in excess of plan assets, fair value of plan assets", "label": "Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets", "documentation": "Amount of plan asset for defined benefit pension plan with projected benefit obligation in excess of plan assets." } } }, "auth_ref": [ "r627", "r1160" ] }, "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation", "crdr": "credit", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pension plans with an accumulated benefit obligation in excess of plan assets, accumulated benefit obligation", "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation", "documentation": "Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets." } } }, "auth_ref": [ "r627", "r628", "r1160" ] }, "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets", "crdr": "debit", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pension plans with an accumulated benefit obligation in excess of plan assets, fair value of plan assets", "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets", "documentation": "Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets." } } }, "auth_ref": [ "r627", "r628", "r1160" ] }, "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation", "crdr": "credit", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pension plans with a projected benefit obligation in excess of plan assets, projected benefit obligation", "label": "Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation", "documentation": "Amount of projected benefit obligation for defined benefit pension plan with accumulated benefit obligation in excess of plan assets." } } }, "auth_ref": [ "r1458" ] }, "us-gaap_DefinedBenefitPlanPlanAmendments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPlanAmendments", "crdr": "credit", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan amendments", "label": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment", "documentation": "Amount of increase (decrease) in benefit obligation of defined benefit plan from change in terms of existing plan or initiation of new plan." } } }, "auth_ref": [ "r579" ] }, "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid", "crdr": "credit", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Benefits paid", "label": "Defined Benefit Plan, Plan Assets, Benefits Paid", "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services." } } }, "auth_ref": [ "r587", "r1460" ] }, "us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effects of exchange rate changes", "label": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan." } } }, "auth_ref": [ "r584" ] }, "us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPlanAssetsTargetAllocationPercentage", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Target allocation", "label": "Defined Benefit Plan, Plan Assets, Target Allocation, Percentage", "documentation": "Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan." } } }, "auth_ref": [ "r592", "r1160" ] }, "us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanPurchasesSalesAndSettlements", "crdr": "debit", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchases and sales, net", "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement", "documentation": "Amount, measured using unobservable input, of increase (decrease) in plan asset of defined benefit plan from purchase, sale and settlement of trade associated with underlying investment." } } }, "auth_ref": [ "r598", "r1160" ] }, "us-gaap_DefinedBenefitPlanRealEstateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanRealEstateMember", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real estate", "label": "Employee Benefit Plan, Real Estate [Member]", "documentation": "Property composed of building, land, and land improvement; in which employee benefit plan asset is invested." } } }, "auth_ref": [ "r1158", "r1160" ] }, "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments", "crdr": "credit", "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Curtailments", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment", "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from event reducing expected years of future service of present employees or eliminating accrual of defined benefits for some or all future services of present employees." } } }, "auth_ref": [ "r569", "r611", "r637" ] }, "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1", "crdr": "credit", "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Settlements", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement", "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement." } } }, "auth_ref": [ "r569", "r611", "r637" ] }, "us-gaap_DefinedBenefitPlanServiceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanServiceCost", "crdr": "debit", "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Service cost", "label": "Defined Benefit Plan, Service Cost", "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan." } } }, "auth_ref": [ "r572", "r605", "r631", "r1160", "r1161" ] }, "us-gaap_DefinedBenefitPlanSettlementsBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanSettlementsBenefitObligation", "crdr": "debit", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Settlements", "label": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement", "documentation": "Amount of (increase) decrease to benefit obligation of defined benefit plan from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Includes, but is not limited to, lump-sum cash payment to participant in exchange for right to receive specified benefits, purchase of nonparticipating annuity contract and change from remeasurement." } } }, "auth_ref": [ "r573" ] }, "us-gaap_DefinedBenefitPlanSettlementsPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanSettlementsPlanAssets", "crdr": "credit", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Settlements", "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement", "documentation": "Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract." } } }, "auth_ref": [ "r590" ] }, "us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanUltimateHealthCareCostTrendRate1", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rate to which the cost trend rate is assumed to decline", "label": "Defined Benefit Plan, Ultimate Health Care Cost Trend Rate", "documentation": "Ultimate trend rate for health care cost for defined benefit postretirement plan." } } }, "auth_ref": [ "r619" ] }, "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Benefit obligation", "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net periodic benefit cost", "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]", "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]", "documentation": "Disclosure of information about defined benefit pension plans or other postretirement defined benefit plans. The arrangements are generally based on terms and conditions stipulated by the entity, and which contain a promise by the employer to pay certain amounts or awards at designated future dates, including a period after retirement, upon compliance with stipulated requirements. Excludes disclosures pertaining to defined contribution plans." } } }, "auth_ref": [ "r14", "r66", "r67", "r68", "r69" ] }, "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]", "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanCostRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanCostRecognized", "crdr": "debit", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employer contributions to defined contribution savings plans", "label": "Defined Contribution Plan, Cost", "documentation": "Amount of cost for defined contribution plan." } } }, "auth_ref": [ "r643" ] }, "mrk_DelstrigoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "DelstrigoMember", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Delstrigo", "label": "Delstrigo [Member]", "documentation": "Delstrigo" } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows", "http://www.merck.com/role/SegmentReportingEquityIncomefromAffiliatesandDepreciationIncludedinSegmentProfitsDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails", "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "negatedLabel": "Depreciation", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r11", "r52" ] }, "us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortizationPolicyTextBlock", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation, Depletion, and Amortization [Policy Text Block]", "documentation": "Disclosure of accounting policy for depreciation, depletion, and amortization of property and equipment costs, including methods used and estimated useful lives and how impairment of such assets is assessed and recognized." } } }, "auth_ref": [ "r1123" ] }, "mrk_DerazantinibMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "DerazantinibMember", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "derazantinib", "label": "derazantinib [Member]", "documentation": "derazantinib" } } }, "auth_ref": [] }, "us-gaap_DerivativeAssetAfterOffsetSubjectToMasterNettingArrangement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssetAfterOffsetSubjectToMasterNettingArrangement", "crdr": "debit", "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net amounts, asset", "label": "Derivative Asset, Subject to Master Netting Arrangement, after Offset", "documentation": "Fair value, after effect of master netting arrangement, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset. Includes derivative subject to master netting arrangement not elected or qualified to offset. Excludes derivative not subject to master netting arrangement or similar agreement." } } }, "auth_ref": [ "r266", "r1120" ] }, "us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssetNotOffsetPolicyElectionDeduction", "crdr": "credit", "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "parentTag": "us-gaap_DerivativeAssetAfterOffsetSubjectToMasterNettingArrangement", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, asset", "label": "Derivative Asset, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset", "documentation": "Fair value of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset, subject to master netting arrangement or similar agreement and not elected or qualified to offset, deducted from derivative asset." } } }, "auth_ref": [ "r21", "r26", "r229" ] }, "us-gaap_DerivativeAssetNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssetNotionalAmount", "calculation": { "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails": { "parentTag": "us-gaap_DerivativeNotionalAmount", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative asset, notional amount", "label": "Derivative Asset, Notional Amount", "documentation": "Nominal or face amount used to calculate payments on the derivative asset." } } }, "auth_ref": [ "r1071", "r1075", "r1078", "r1081", "r1488", "r1489", "r1490" ] }, "us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]", "label": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes derivative asset." } } }, "auth_ref": [ "r760" ] }, "us-gaap_DerivativeAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssets", "crdr": "debit", "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair value of derivative, asset", "label": "Derivative Asset", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r266", "r268", "r782", "r783", "r792", "r797", "r997", "r998", "r999", "r1000", "r1001", "r1003", "r1004", "r1005", "r1006", "r1007", "r1021", "r1022", "r1071", "r1076", "r1079", "r1080", "r1082", "r1083", "r1120", "r1177", "r1181", "r1214", "r1497", "r1498", "r1499", "r1565" ] }, "us-gaap_DerivativeAverageRemainingMaturity1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAverageRemainingMaturity1", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum planning cycle of hedges (less than)", "label": "Derivative, Average Remaining Maturity", "documentation": "Average remaining period until maturity of the derivative contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DerivativeCollateralObligationToReturnCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeCollateralObligationToReturnCash", "crdr": "credit", "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "parentTag": "us-gaap_DerivativeAssetAfterOffsetSubjectToMasterNettingArrangement", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash collateral received from counterparties", "negatedLabel": "Cash collateral received/posted, asset", "label": "Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Cash Not Offset", "documentation": "Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets." } } }, "auth_ref": [ "r26", "r98", "r267", "r1118" ] }, "us-gaap_DerivativeCollateralRightToReclaimCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeCollateralRightToReclaimCash", "crdr": "debit", "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "parentTag": "us-gaap_DerivativeLiabilityAfterOffsetSubjectToMasterNettingArrangement", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Cash collateral received/posted, liability", "label": "Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Cash Not Offset", "documentation": "Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities." } } }, "auth_ref": [ "r26", "r98", "r267", "r1118" ] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r1005", "r1007", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1029", "r1030", "r1031", "r1032", "r1043", "r1044", "r1045", "r1046", "r1049", "r1050", "r1051", "r1052", "r1071", "r1073", "r1079", "r1082", "r1212", "r1214", "r1500", "r1501", "r1502", "r1503", "r1504", "r1505", "r1507", "r1508" ] }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeAsset", "crdr": "debit", "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "parentTag": "us-gaap_DerivativeAssetAfterOffsetSubjectToMasterNettingArrangement", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross amounts recognized in the consolidated balance sheet, asset", "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement." } } }, "auth_ref": [ "r24", "r133", "r194", "r195", "r265", "r1120" ] }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeLiability", "crdr": "credit", "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "parentTag": "us-gaap_DerivativeLiabilityAfterOffsetSubjectToMasterNettingArrangement", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross amounts recognized in the consolidated balance sheet, liability", "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement." } } }, "auth_ref": [ "r24", "r133", "r194", "r195", "r265", "r1120" ] }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeGainLossOnDerivativeNet", "crdr": "credit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of gain recognized in Other (income) expense, net on derivatives", "label": "Derivative, Gain (Loss) on Derivative, Net", "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement." } } }, "auth_ref": [ "r1491" ] }, "us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "label": "Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from derivative." } } }, "auth_ref": [ "r1491" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r89", "r92", "r95", "r196", "r1005", "r1007", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1029", "r1030", "r1031", "r1032", "r1043", "r1044", "r1045", "r1046", "r1049", "r1050", "r1051", "r1052", "r1071", "r1073", "r1079", "r1082", "r1120", "r1212", "r1214", "r1500", "r1501", "r1502", "r1503", "r1504", "r1505", "r1507", "r1508" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]", "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]", "label": "Derivative Instruments and Hedging Activities Disclosures [Table]", "documentation": "Disclosure of information about derivatives and hedging activities." } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Table]", "label": "Derivative Instruments, Gain (Loss) [Table]", "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r17", "r89", "r92", "r95", "r99", "r100", "r765" ] }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossLineItems", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r765" ] }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "crdr": "credit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Amount of Derivative Pretax Loss (Gain) Recognized in Income", "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments." } } }, "auth_ref": [ "r94", "r1351" ] }, "us-gaap_DerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilities", "crdr": "credit", "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair value of derivative, liability", "label": "Derivative Liability", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r266", "r268", "r782", "r783", "r792", "r797", "r997", "r998", "r999", "r1000", "r1003", "r1004", "r1005", "r1006", "r1007", "r1029", "r1031", "r1032", "r1073", "r1074", "r1076", "r1079", "r1080", "r1082", "r1083", "r1120", "r1497", "r1498", "r1499", "r1565" ] }, "us-gaap_DerivativeLiabilityAfterOffsetSubjectToMasterNettingArrangement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilityAfterOffsetSubjectToMasterNettingArrangement", "crdr": "credit", "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net amounts, liability", "label": "Derivative Liability, Subject to Master Netting Arrangement, after Offset", "documentation": "Fair value, after effect of master netting arrangement, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset. Includes derivative subject to master netting arrangement not elected or qualified to offset. Excludes derivative not subject to master netting arrangement or similar agreement." } } }, "auth_ref": [ "r266", "r1120" ] }, "us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilityNotOffsetPolicyElectionDeduction", "crdr": "debit", "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "parentTag": "us-gaap_DerivativeLiabilityAfterOffsetSubjectToMasterNettingArrangement", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, liability", "label": "Derivative Liability, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset", "documentation": "Fair value of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset, subject to master netting arrangement or similar agreement and not elected or qualified to offset, deducted from derivative liability." } } }, "auth_ref": [ "r21", "r26", "r229" ] }, "us-gaap_DerivativeLiabilityNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilityNotionalAmount", "calculation": { "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails": { "parentTag": "us-gaap_DerivativeNotionalAmount", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative liability, notional amount", "label": "Derivative Liability, Notional Amount", "documentation": "Nominal or face amount used to calculate payments on the derivative liability." } } }, "auth_ref": [ "r1072", "r1075", "r1077", "r1081", "r1488", "r1489", "r1490" ] }, "us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]", "label": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes derivative liability." } } }, "auth_ref": [ "r760" ] }, "us-gaap_DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLineItems", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Line Items]", "label": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r776" ] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeNotionalAmount", "calculation": { "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total Swap Notional Amount", "totalLabel": "U.S dollar notional amount", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r1489", "r1490" ] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeTable", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Table]", "label": "Derivative [Table]", "documentation": "Disclosure of information about derivative instrument or group of derivative instruments, including, but not limited to, type of derivative instrument, risk being hedged, notional amount, hedge designation, related hedged item, inception date, and maturity date." } } }, "auth_ref": [ "r17", "r83", "r84", "r86", "r87", "r90", "r92", "r96", "r97", "r100", "r776" ] }, "us-gaap_DerivativeTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeTermOfContract", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term of derivative contract", "label": "Derivative, Term of Contract", "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DerivativesFairValueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativesFairValueLineItems", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives, Fair Value [Line Items]", "label": "Derivatives, Fair Value [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives Designated as Hedging Instruments", "label": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r17" ] }, "mrk_DevelopedMarketsEquitiesInvestmentFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "DevelopedMarketsEquitiesInvestmentFundsMember", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Developed markets equities", "label": "Developed Markets Equities Investment Funds [Member]", "documentation": "Developed markets equities investment funds." } } }, "auth_ref": [] }, "mrk_DevelopedMarketsEquitySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "DevelopedMarketsEquitySecuritiesMember", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Developed markets", "label": "Developed Markets Equity Securities [Member]", "documentation": "Developed markets equity securities." } } }, "auth_ref": [] }, "us-gaap_DevelopedTechnologyRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DevelopedTechnologyRightsMember", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product rights", "label": "Developed Technology Rights [Member]", "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property." } } }, "auth_ref": [ "r189", "r1425", "r1426", "r1427", "r1428", "r1430", "r1431", "r1433", "r1434" ] }, "mrk_DificidMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "DificidMember", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dificid", "label": "Dificid [Member]", "documentation": "Dificid [Member]" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlans" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation Plans", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r649", "r652", "r683", "r684", "r686", "r1169" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Period of continuing involvement after disposal", "label": "Discontinued Operation, Period of Continuing Involvement after Disposal", "documentation": "Period of expected continuing involvement with a discontinued operation after the disposal date, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r106" ] }, "us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discontinued Operations, Disposed of by Means Other than Sale, Spinoff", "label": "Discontinued Operations, Disposed of by Means Other than Sale, Spinoff [Member]", "documentation": "Component or group of components representing strategic shift that has or will have major effect on operation and financial result, disposed of in spinoff." } } }, "auth_ref": [ "r105" ] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationAxis", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Axis]", "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": [ "r239" ] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationDomain", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Domain]", "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "mrk_DisposalGroupIncludingDiscontinuedOperationUnderInterimOperatingAgreementNumberOfJurisdiction": { "xbrltype": "integerItemType", "nsuri": "http://www.merck.com/20241231", "localname": "DisposalGroupIncludingDiscontinuedOperationUnderInterimOperatingAgreementNumberOfJurisdiction", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of jurisdictions under interim operating agreement", "label": "Disposal Group, Including Discontinued Operation, Under Interim Operating Agreement, Number Of Jurisdiction", "documentation": "Disposal Group, Including Discontinued Operation, Under Interim Operating Agreement, Number Of Jurisdiction" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Domain]", "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": [ "r1162", "r1165" ] }, "us-gaap_DividendsCommonStockCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsCommonStockCash", "crdr": "debit", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofEquity" ], "lang": { "en-us": { "role": { "negatedLabel": "Cash dividends declared on common stock", "label": "Dividends, Common Stock, Cash", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash." } } }, "auth_ref": [ "r174" ] }, "us-gaap_DividendsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsPayableCurrent", "crdr": "credit", "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends payable", "label": "Dividends Payable, Current", "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r111" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Annual Report", "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r1232", "r1233", "r1256" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Financial Statement Error Correction [Flag]", "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r1232", "r1233", "r1256", "r1299" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Line Items]", "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Table]", "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r1277" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Documents Incorporated by Reference", "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r1230" ] }, "us-gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DomesticCountryMember", "presentation": [ "http://www.merck.com/role/TaxesonIncomeIncomeTaxAuthorityDetails", "http://www.merck.com/role/TaxesonIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal", "label": "Domestic Tax Jurisdiction [Member]", "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction." } } }, "auth_ref": [ "r705" ] }, "us-gaap_DomesticPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DomesticPlanMember", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Domestic Plan", "label": "Domestic Plan [Member]", "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [ "r1461", "r1462", "r1463" ] }, "mrk_Dr.SchollsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "Dr.SchollsMember", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dr. Scholl's", "label": "Dr. Scholl's [Member]", "documentation": "Dr. Scholl's" } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } }, "auth_ref": [ "r1288" ] }, "us-gaap_EMEAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EMEAMember", "presentation": [ "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Europe, Middle East and Africa", "label": "EMEA [Member]", "documentation": "Regions of Europe, Middle East and Africa." } } }, "auth_ref": [ "r1567", "r1569", "r1570", "r1571" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofIncome", "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic Earnings per Common Share Attributable to Merck\u00a0& Co., Inc. Common Shareholders (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r286", "r317", "r318", "r319", "r320", "r321", "r322", "r328", "r331", "r339", "r340", "r341", "r345", "r743", "r750", "r779", "r780", "r910", "r937", "r1127" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofIncome", "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r286", "r317", "r318", "r319", "r320", "r321", "r322", "r331", "r339", "r340", "r341", "r345", "r743", "r750", "r779", "r780", "r910", "r937", "r1127" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.merck.com/role/EarningsperShare" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r327", "r342", "r343", "r344" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r804" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total, Tax Rate", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r705", "r1172" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract", "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax\u00a0Rate", "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]" } } }, "auth_ref": [] }, "mrk_EffectiveIncomeTaxRateReconciliationAcquisitionRelatedCostsAndAmortizationAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "EffectiveIncomeTaxRateReconciliationAcquisitionRelatedCostsAndAmortizationAmount", "crdr": "debit", "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition-related costs, including amortization", "label": "Effective Income Tax Rate Reconciliation, Acquisition-Related Costs And Amortization, Amount", "documentation": "Effective Income Tax Rate Reconciliation, Acquisition-Related Costs And Amortization, Amount" } } }, "auth_ref": [] }, "mrk_EffectiveIncomeTaxRateReconciliationAcquisitionRelatedCostsAndAmortizationPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.merck.com/20241231", "localname": "EffectiveIncomeTaxRateReconciliationAcquisitionRelatedCostsAndAmortizationPercent", "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition-related costs, including amortization", "label": "Effective Income Tax Rate Reconciliation, Acquisition-Related Costs And Amortization, Percent", "documentation": "Effective Income Tax Rate Reconciliation, Acquisition-Related Costs And Amortization, Percent" } } }, "auth_ref": [] }, "mrk_EffectiveIncomeTaxRateReconciliationAssetAcquisitionThreePercent": { "xbrltype": "percentItemType", "nsuri": "http://www.merck.com/20241231", "localname": "EffectiveIncomeTaxRateReconciliationAssetAcquisitionThreePercent", "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition of Prometheus", "label": "Effective Income Tax Rate Reconciliation, Asset Acquisition Three, Percent", "documentation": "Effective Income Tax Rate Reconciliation, Asset Acquisition Three, Percent" } } }, "auth_ref": [] }, "mrk_EffectiveIncomeTaxRateReconciliationAssetAcquisitionTwoPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.merck.com/20241231", "localname": "EffectiveIncomeTaxRateReconciliationAssetAcquisitionTwoPercent", "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Charges for certain research and development asset acquisitions", "label": "Effective Income Tax Rate Reconciliation, Asset Acquisition Two, Percent", "documentation": "Effective Income Tax Rate Reconciliation, Asset Acquisition Two, Percent" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. statutory rate applied to income before taxes", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r301", "r705", "r734", "r1172" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation allowances", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r710", "r1172", "r1388", "r1469" ] }, "mrk_EffectiveIncomeTaxRateReconciliationDeductionInventoryDonationsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "EffectiveIncomeTaxRateReconciliationDeductionInventoryDonationsAmount", "crdr": "credit", "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Inventory donations", "label": "Effective Income Tax Rate Reconciliation, Deduction, Inventory Donations, Amount", "documentation": "Effective Income Tax Rate Reconciliation, Deduction, Inventory Donations, Amount" } } }, "auth_ref": [] }, "mrk_EffectiveIncomeTaxRateReconciliationDeductionInventoryDonationsPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.merck.com/20241231", "localname": "EffectiveIncomeTaxRateReconciliationDeductionInventoryDonationsPercent", "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Inventory donations", "label": "Effective Income Tax Rate Reconciliation, Deduction, Inventory Donations, Percent", "documentation": "Effective Income Tax Rate Reconciliation, Deduction, Inventory Donations, Percent" } } }, "auth_ref": [] }, "mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.merck.com/20241231", "localname": "EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract", "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Differential arising from:", "label": "Effective Income Tax Rate Reconciliation, Differential Arising From, Amount [Abstract]", "documentation": "Effective Income Tax Rate Reconciliation, Differential Arising From, Amount [Abstract]" } } }, "auth_ref": [] }, "mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.merck.com/20241231", "localname": "EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract", "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Differential arising from:", "label": "Effective Income Tax Rate Reconciliation, Differential Arising From, Percent [Abstract]", "documentation": "Effective Income Tax Rate Reconciliation, Differential Arising From, Percent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign earnings", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile." } } }, "auth_ref": [ "r706", "r709", "r1172", "r1388", "r1469" ] }, "mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount", "crdr": "debit", "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "GILTI and the foreign-derived intangible income deduction", "label": "Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income Foreign Derived Intangible Income Deduction, Amount", "documentation": "Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income Foreign Derived Intangible Income Deduction, Amount" } } }, "auth_ref": [] }, "mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.merck.com/20241231", "localname": "EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent", "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "GILTI and the foreign-derived intangible income deduction", "label": "Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income Foreign Derived Intangible Income Deduction, Percent", "documentation": "Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income Foreign Derived Intangible Income Deduction, Percent" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges", "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Restructuring Charges, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to restructuring charges." } } }, "auth_ref": [ "r1388", "r1469", "r1471" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r1172", "r1388", "r1469", "r1470" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State taxes", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)." } } }, "auth_ref": [ "r708", "r1172", "r1388", "r1469" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "R&D tax credit", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit." } } }, "auth_ref": [ "r1172", "r1388", "r1469", "r1471" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlements", "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax settlements and statute lapses", "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements." } } }, "auth_ref": [ "r1388", "r1469", "r1470" ] }, "mrk_EisaiMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "EisaiMember", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Eisai", "label": "Eisai [Member]", "documentation": "Eisai [Member]" } } }, "auth_ref": [] }, "mrk_ElancoAnimalHealthIncorporatedAquaBusinessMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "ElancoAnimalHealthIncorporatedAquaBusinessMember", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Elanco Animal Health Incorporated Aqua Business", "label": "Elanco Animal Health Incorporated Aqua Business [Member]", "documentation": "Elanco Animal Health Incorporated Aqua Business" } } }, "auth_ref": [] }, "mrk_EmergingMarketsEquitiesInvestmentFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "EmergingMarketsEquitiesInvestmentFundsMember", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Emerging markets equities", "label": "Emerging Markets Equities Investment Funds [Member]", "documentation": "Emerging markets equities investment funds." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total pre tax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r685" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average period in years of recognition for nonvested stock options, RSU and PSU awards", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r685" ] }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "crdr": "credit", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax benefits related to share-based compensation", "label": "Share-Based Payment Arrangement, Expense, Tax Benefit", "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement." } } }, "auth_ref": [ "r682" ] }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions", "crdr": "credit", "presentation": [ "http://www.merck.com/role/TaxesonIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax benefits relating to stock option exercises", "label": "Share-Based Payment Arrangement, Exercise of Option, Tax Benefit", "documentation": "Amount of tax benefit from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r228" ] }, "us-gaap_EmployeeSeveranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeSeveranceMember", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Separation Costs", "label": "Employee Severance [Member]", "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Option", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1229" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1229" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r1229" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r1339" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Public Float", "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1229" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r1229" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r1229" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1229" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Voluntary Filers", "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Well-known Seasoned Issuer", "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r1340" ] }, "us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EnvironmentalExitCostsReasonablyPossibleAdditionalLoss", "crdr": "debit", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate possible expenditure on environmental matters in excess of amounts accrued", "label": "Environmental Exit Costs, Reasonably Possible Additional Loss", "documentation": "Estimate of reasonably possible loss exposure in excess of amount accrued for remediation, site restoration, postclosure, monitoring commitments, or other exit costs associated with the sale, disposal or abandonment of a particular property resulting from unanticipated contamination of the assets." } } }, "auth_ref": [ "r494", "r498", "r499", "r1143" ] }, "mrk_EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag": { "xbrltype": "stringItemType", "nsuri": "http://www.merck.com/20241231", "localname": "EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Environmental Loss Contingency Statement Of Financial Position Extensible Enumeration Not Disclosed Flag", "label": "Environmental Loss Contingency Statement Of Financial Position Extensible Enumeration Not Disclosed Flag", "documentation": "Environmental Loss Contingency Statement Of Financial Position Extensible Enumeration Not Disclosed Flag" } } }, "auth_ref": [] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r1282" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": [ "r1335" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]" } } }, "auth_ref": [ "r1335" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r1335" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofEquity", "http://www.merck.com/role/EquityShareholdersEquityDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails", "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r16", "r236", "r280", "r281", "r282", "r312", "r313", "r314", "r316", "r321", "r323", "r325", "r347", "r422", "r423", "r469", "r557", "r732", "r733", "r740", "r741", "r742", "r744", "r749", "r750", "r770", "r771", "r772", "r773", "r774", "r775", "r778", "r805", "r807", "r808", "r809", "r810", "r811", "r815", "r818", "r830", "r933", "r964", "r965", "r966", "r985", "r1056" ] }, "us-gaap_EquityFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityFundsMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Funds", "label": "Equity Funds [Member]", "documentation": "An investment that pools funds from many investors to invest in a combination of underlying investments, primarily equity investments." } } }, "auth_ref": [ "r1454" ] }, "us-gaap_EquitySecuritiesFVNINoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFVNINoncurrent", "crdr": "debit", "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "parentTag": "us-gaap_OtherAssetsNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity securities held through ownership interests in investment funds", "verboseLabel": "Publicly traded equity securities", "label": "Equity Securities, FV-NI, Noncurrent", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent." } } }, "auth_ref": [ "r796" ] }, "us-gaap_EquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNi", "crdr": "debit", "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails": { "parentTag": "mrk_DebtSecuritiesandEquitySecuritiesFVNI", "weight": 1.0, "order": 2.0 }, "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "parentTag": "us-gaap_Investments", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity securities", "label": "Equity Securities, FV-NI, Current", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current." } } }, "auth_ref": [ "r252", "r796", "r1115" ] }, "us-gaap_EquitySecuritiesFvNiGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiGainLoss", "crdr": "credit", "calculation": { "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 4.0 }, "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "(Income) loss from investments in equity securities, net", "negatedLabel": "(Income) loss from investments in equity securities, net", "label": "Equity Securities, FV-NI, Gain (Loss)", "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r940", "r1410" ] }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "crdr": "credit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized net gains (losses)", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r939", "r1410" ] }, "us-gaap_EquitySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Publicly traded equity securities", "label": "Equity Securities [Member]", "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants." } } }, "auth_ref": [ "r51", "r1191", "r1222", "r1223", "r1224", "r1568" ] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "crdr": "debit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity investments without readily determinable fair values", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "documentation": "Amount of investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r417" ] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount", "crdr": "debit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized losses recognized on investments in equity securities without readily determinable fair values", "label": "Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount", "documentation": "Amount of loss from downward price adjustment on investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r418" ] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount", "crdr": "debit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative downward price adjustment", "label": "Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount", "documentation": "Amount of cumulative loss from downward price adjustment on investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r418" ] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount", "crdr": "credit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gains recognized on investments in equity securities without readily determinable fair value", "label": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount", "documentation": "Amount of gain from upward price adjustment on investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r419" ] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount", "crdr": "credit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative upward price adjustment", "label": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount", "documentation": "Amount of cumulative gain from upward price adjustment on investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r419" ] }, "us-gaap_EquitySecurityFvNiContractualSaleRestriction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecurityFvNiContractualSaleRestriction", "crdr": "debit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Securities, fair value, which are subject to a contractual sale restriction", "label": "Equity Security, FV-NI, Contractual Sale Restriction", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI) subject to contractual sale restriction. Excludes investment in equity security by investment company for which discount for contractual sale restriction is applied." } } }, "auth_ref": [ "r795" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r1292" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r1249", "r1260", "r1270", "r1303" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r1246", "r1257", "r1267", "r1300" ] }, "mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash": { "xbrltype": "percentItemType", "nsuri": "http://www.merck.com/20241231", "localname": "EstimateOfCumulativePreTaxCostsThatWillBeNoncash", "presentation": [ "http://www.merck.com/role/RestructuringNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimate of cumulative pre tax costs that will be noncash", "label": "Estimate Of Cumulative Pre Tax Costs That Will Be Noncash", "documentation": "Estimate of cumulative pre tax costs that will be noncash." } } }, "auth_ref": [] }, "mrk_EurodominatedNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "EurodominatedNotesMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Euro-denominated notes", "label": "Euro-dominated Notes [Member]", "documentation": "Euro-dominated Notes [Member]" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r1298" ] }, "mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests": { "xbrltype": "percentItemType", "nsuri": "http://www.merck.com/20241231", "localname": "ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected annual standard deviation in returns of the target portfolio which reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests", "label": "Expected Annual Standard Deviation In Returns Of Target Portfolio Which Reflects Both Equity Allocation And Diversification Benefits Among Asset Classes In Which Portfolio Invests", "documentation": "Expected annual standard deviation in returns of the target portfolio which reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests." } } }, "auth_ref": [] }, "mrk_EyebiotechLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "EyebiotechLimitedMember", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Eyebiotech Limited", "label": "Eyebiotech Limited [Member]", "documentation": "Eyebiotech Limited" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Assets and Liabilities Measured at Fair Value on Recurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r782", "r783", "r792", "r1177" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r782", "r783", "r792", "r1177" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r528", "r595", "r596", "r597", "r598", "r599", "r600", "r781", "r783", "r784", "r785", "r786", "r791", "r792", "r794", "r839", "r840", "r841", "r1150", "r1151", "r1158", "r1159", "r1160", "r1177", "r1181" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r782", "r783", "r784", "r786", "r1177", "r1498", "r1509" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r528", "r595", "r600", "r783", "r792", "r839", "r1158", "r1159", "r1160", "r1177" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r528", "r595", "r600", "r783", "r784", "r792", "r840", "r1150", "r1151", "r1158", "r1159", "r1160", "r1177" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r528", "r595", "r596", "r597", "r598", "r599", "r600", "r783", "r784", "r785", "r786", "r792", "r841", "r1150", "r1151", "r1158", "r1159", "r1160", "r1177", "r1181" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summarized Information about the Changes in Liabilities for Contingent Consideration", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": [ "r787", "r790", "r793" ] }, "us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasuredAtNetAssetValuePerShareMember", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "NAV", "label": "Fair Value Measured at Net Asset Value Per Share [Member]", "documentation": "Fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r595", "r781", "r794", "r1177" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [ "r782", "r783", "r784", "r786", "r1177", "r1498", "r1509" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "crdr": "debit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments of contingent consideration", "negatedTerseLabel": "Payments", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r789", "r793" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r528", "r595", "r596", "r597", "r598", "r599", "r600", "r781", "r783", "r784", "r785", "r786", "r791", "r792", "r794", "r839", "r840", "r841", "r1150", "r1151", "r1158", "r1159", "r1160", "r1177", "r1181" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Measurements, Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r1177", "r1495", "r1496", "r1497", "r1498", "r1499", "r1509" ] }, "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "documentation": "Disclosure of information about location and fair value of derivative instrument and nonderivative instrument designated as hedging instrument." } } }, "auth_ref": [ "r88", "r90", "r99" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r425", "r427", "r428", "r429", "r430", "r432", "r433", "r434", "r539", "r554", "r776", "r795", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r934", "r1140", "r1177", "r1179", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186", "r1187", "r1191", "r1354", "r1355", "r1356", "r1357", "r1358", "r1359", "r1360", "r1406", "r1407", "r1408", "r1409", "r1494", "r1497", "r1498", "r1499", "r1506", "r1509" ] }, "us-gaap_FinancialInstrumentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentsDisclosureTextBlock", "presentation": [ "http://www.merck.com/role/FinancialInstruments" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments", "label": "Financial Instruments Disclosure [Text Block]", "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated useful life of intangible assets", "label": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r249", "r438", "r460", "r1142" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated aggregate amortization expense, 2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r462", "r1108", "r1142" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated aggregate amortization expense, 2029", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r462", "r1108", "r1142" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated aggregate amortization expense, 2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r462", "r1108", "r1142" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated aggregate amortization expense, 2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r462", "r1108", "r1142" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated aggregate amortization expense, 2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r462", "r1108", "r1142" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails", "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r452", "r454", "r455", "r456", "r459", "r460", "r464", "r465", "r874", "r875", "r1108" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails": { "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-lived intangible assets, gross carrying amount", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r438", "r460", "r875", "r1142" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails", "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets Excluding Goodwill [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r452", "r460", "r464", "r465", "r467", "r874", "r1108", "r1142" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails", "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r452", "r454", "r455", "r456", "r459", "r460", "r464", "r465", "r1108" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails_1": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "verboseLabel": "Finite-lived intangible assets, net", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r874", "r1431" ] }, "mrk_FirstCommercialSaleMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "FirstCommercialSaleMilestonesMember", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "First Commercial Sale Milestones", "label": "First Commercial Sale Milestones [Member]", "documentation": "First Commercial Sale Milestones" } } }, "auth_ref": [] }, "us-gaap_FixedIncomeInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FixedIncomeInvestmentsMember", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed Income Investments", "label": "Fixed Income Investments [Member]", "documentation": "Investments that regularly generate a fixed amount of interest income. Examples include, but are not limited to, bonds, certificates of deposit, notes and debt securities." } } }, "auth_ref": [ "r1216", "r1217", "r1218", "r1221" ] }, "mrk_FixedIncomeObligationsInvestmentFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "FixedIncomeObligationsInvestmentFundsMember", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other fixed income obligations", "label": "Fixed Income Obligations Investment Funds [Member]", "documentation": "Fixed income obligations investment funds." } } }, "auth_ref": [] }, "us-gaap_ForeignCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCountryMember", "presentation": [ "http://www.merck.com/role/TaxesonIncomeIncomeTaxAuthorityDetails", "http://www.merck.com/role/TaxesonIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Jurisdiction", "label": "Foreign Tax Jurisdiction [Member]", "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile." } } }, "auth_ref": [ "r705", "r706" ] }, "us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months", "crdr": "credit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Pretax net unrealized losses on derivatives maturing within the next 12 months estimated to be reclassified from AOCI to sales", "label": "Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months", "documentation": "The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months." } } }, "auth_ref": [ "r101" ] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": { "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Exchange losses", "label": "Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r800", "r801", "r802", "r803", "r1053" ] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Translation", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r799" ] }, "us-gaap_ForeignExchangeContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignExchangeContractMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange contracts", "label": "Foreign Exchange Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates." } } }, "auth_ref": [ "r1120", "r1158", "r1176", "r1177" ] }, "us-gaap_ForeignExchangeFutureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignExchangeFutureMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Exchange Future", "label": "Foreign Exchange Future [Member]", "documentation": "A standardized contract, traded on a futures exchange, to buy or sell a certain currency, at a specified future date, at a fixed exercise rate (expressed as an exchange)." } } }, "auth_ref": [] }, "us-gaap_ForeignExchangeOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignExchangeOptionMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency Options", "label": "Foreign Exchange Option [Member]", "documentation": "An option that allows the holder to buy (if call) or sell (if put) an underlying currency at a fixed exercise rate, expressed as an exchange, during a specified period (an American option) or at a specified date (a European option)." } } }, "auth_ref": [] }, "us-gaap_ForeignPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignPlanMember", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "International", "label": "Foreign Plan [Member]", "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [ "r1461", "r1462", "r1463" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r1253", "r1264", "r1274", "r1307" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r1253", "r1264", "r1274", "r1307" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r1253", "r1264", "r1274", "r1307" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r1253", "r1264", "r1274", "r1307" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r1253", "r1264", "r1274", "r1307" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": [ "r1287" ] }, "us-gaap_GainLossRelatedToLitigationSettlement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossRelatedToLitigationSettlement", "crdr": "credit", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss related to settlement litigation", "terseLabel": "Charge for Zetia antitrust litigation settlements", "label": "Gain (Loss) from Litigation Settlement", "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process." } } }, "auth_ref": [ "r1134", "r1445" ] }, "mrk_GardasilGardasil9Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "GardasilGardasil9Member", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gardasil/Gardasil 9", "label": "Gardasil/Gardasil 9 [Member]", "documentation": "Gardasil/Gardasil 9 [Member]." } } }, "auth_ref": [] }, "mrk_GefapixantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "GefapixantMember", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "gefapixant", "label": "Gefapixant [Member]", "documentation": "Gefapixant" } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.merck.com/role/ConsolidatedBalanceSheet", "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "periodStartLabel": "Goodwill, beginning balance", "periodEndLabel": "Goodwill, ending balance", "label": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r248", "r440", "r906", "r1135", "r1141", "r1178", "r1190", "r1414", "r1421" ] }, "us-gaap_GoodwillAcquiredDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAcquiredDuringPeriod", "crdr": "debit", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisitions", "label": "Goodwill, Acquired During Period", "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination." } } }, "auth_ref": [ "r443", "r1141" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangibles" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Other Intangibles", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r1412", "r1424" ] }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined." } } }, "auth_ref": [ "r439", "r451", "r1141" ] }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "crdr": "credit", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated goodwill impairment losses", "label": "Goodwill, Impaired, Accumulated Impairment Loss", "documentation": "Amount of accumulated impairment loss for asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r442", "r449", "r1141" ] }, "us-gaap_GoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillLineItems", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Line Items]", "label": "Goodwill [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r1141" ] }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillRollForward", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Roll Forward]", "label": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillTranslationAndPurchaseAccountingAdjustments", "crdr": "debit", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Goodwill, Translation and Measurement Period Adjustments", "documentation": "Amount of increase (decrease) from foreign currency translation and measurement period adjustments of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r0", "r1413" ] }, "mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government and agency obligations", "label": "Government And Agency Obligations Fixed Income Securities [Member]", "documentation": "Government and agency obligations fixed income securities." } } }, "auth_ref": [] }, "mrk_GovernmentAndAgencyObligationsInvestmentFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "GovernmentAndAgencyObligationsInvestmentFundsMember", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government and agency obligations", "label": "Government And Agency Obligations Investment Funds [Member]", "documentation": "Government and agency obligations investment funds." } } }, "auth_ref": [] }, "mrk_HarpoonTherapeuticsInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "HarpoonTherapeuticsInc.Member", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Harpoon Therapeutics, Inc.", "label": "Harpoon Therapeutics, Inc. [Member]", "documentation": "Harpoon Therapeutics, Inc." } } }, "auth_ref": [] }, "us-gaap_HedgedLiabilityFairValueHedge": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgedLiabilityFairValueHedge", "crdr": "credit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsAmountsRecordedonBalanceSheetRelatedtoFairValueHedgesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying Amount of Hedged Liabilities", "label": "Hedged Liability, Fair Value Hedge", "documentation": "Amount of liability hedged in fair value hedging relationship." } } }, "auth_ref": [ "r766" ] }, "us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease", "crdr": "credit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsAmountsRecordedonBalanceSheetRelatedtoFairValueHedgesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative Amount of Fair Value Hedging Adjustment Increase Included in the Carrying Amount", "label": "Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)", "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk." } } }, "auth_ref": [ "r767" ] }, "us-gaap_HedgedLiabilityStatementOfFinancialPositionExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgedLiabilityStatementOfFinancialPositionExtensibleEnumeration", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsAmountsRecordedonBalanceSheetRelatedtoFairValueHedgesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedged Liability, Statement of Financial Position [Extensible Enumeration]", "label": "Hedged Liability, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes hedged liability." } } }, "auth_ref": [ "r768" ] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationAxis", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Axis]", "label": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": [ "r17", "r765" ] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationDomain", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Domain]", "label": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": [ "r17" ] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "ICFR Auditor Attestation Flag", "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r1232", "r1233", "r1256" ] }, "mrk_IfinatamabDeruxtecanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "IfinatamabDeruxtecanMember", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ifinatamab Deruxtecan", "label": "Ifinatamab Deruxtecan [Member]", "documentation": "Ifinatamab Deruxtecan" } } }, "auth_ref": [] }, "mrk_ImagoBioSciencesIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "ImagoBioSciencesIncMember", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Imago BioSciences, Inc.", "label": "Imago BioSciences, Inc. [Member]", "documentation": "Imago BioSciences, Inc." } } }, "auth_ref": [] }, "us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]", "label": "Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes impairment of finite-lived intangible asset." } } }, "auth_ref": [ "r1108", "r1436" ] }, "us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]", "label": "Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes impairment of indefinite-lived intangible asset excluding goodwill." } } }, "auth_ref": [ "r1436" ] }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows", "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible asset impairment charges", "label": "Impairment of Intangible Assets (Excluding Goodwill)", "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value." } } }, "auth_ref": [ "r11", "r453", "r466" ] }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfIntangibleAssetsFinitelived", "crdr": "debit", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible asset impairment charge related to finite-lived intangible asset", "label": "Impairment of Intangible Assets, Finite-Lived", "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value." } } }, "auth_ref": [ "r453", "r1381", "r1435" ] }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "crdr": "debit", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "IPR&D impairment charges", "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)", "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value." } } }, "auth_ref": [ "r453", "r1381", "r1432", "r1435" ] }, "us-gaap_InProcessResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InProcessResearchAndDevelopmentMember", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "IPR&D", "label": "In Process Research and Development [Member]", "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process." } } }, "auth_ref": [ "r1425", "r1426", "r1427", "r1428", "r1429", "r1430", "r1431", "r1432", "r1433", "r1434" ] }, "us-gaap_InProcessResearchAndDevelopmentPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InProcessResearchAndDevelopmentPolicy", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired In-Process Research and Development", "label": "In Process Research and Development, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "crdr": "credit", "calculation": { "http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Domestic", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations." } } }, "auth_ref": [ "r300", "r704" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofIncome": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 }, "http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofIncome", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails", "http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Income Before Taxes", "terseLabel": "Income Before Taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r140", "r208", "r212", "r911", "r929", "r1129", "r1134", "r1397", "r1399", "r1401", "r1402", "r1403" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "crdr": "credit", "calculation": { "http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile." } } }, "auth_ref": [ "r300", "r704" ] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "presentation": [ "http://www.merck.com/role/SegmentReportingEquityIncomefromAffiliatesandDepreciationIncludedinSegmentProfitsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Equity income from affiliates", "label": "Income (Loss) from Equity Method Investments", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": [ "r11", "r141", "r207", "r346", "r361", "r376", "r420", "r928" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Axis]", "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [ "r1162", "r1165" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of Income Location, Balance [Axis]", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r470", "r477", "r482", "r788", "r790", "r793", "r961", "r963", "r1040", "r1108", "r1180", "r1534" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of Income Location, Balance [Domain]", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r477", "r482", "r788", "r790", "r793", "r961", "r963", "r1040", "r1108", "r1180", "r1534" ] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://www.merck.com/role/TaxesonIncomeIncomeTaxAuthorityDetails", "http://www.merck.com/role/TaxesonIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Jurisdiction [Axis]", "label": "Income Tax Jurisdiction [Axis]", "documentation": "Information by income tax jurisdiction." } } }, "auth_ref": [ "r294", "r705", "r706", "r715", "r729", "r1172", "r1478" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://www.merck.com/role/TaxesonIncomeIncomeTaxAuthorityDetails", "http://www.merck.com/role/TaxesonIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Jurisdiction [Domain]", "label": "Income Tax Jurisdiction [Domain]", "documentation": "Income tax jurisdiction." } } }, "auth_ref": [ "r294", "r705", "r706", "r715", "r729", "r1172", "r1478" ] }, "us-gaap_IncomeTaxContingencyLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxContingencyLineItems", "presentation": [ "http://www.merck.com/role/TaxesonIncomeIncomeTaxAuthorityDetails", "http://www.merck.com/role/TaxesonIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Contingency [Line Items]", "label": "Income Tax Contingency [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxContingencyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxContingencyTable", "presentation": [ "http://www.merck.com/role/TaxesonIncomeIncomeTaxAuthorityDetails", "http://www.merck.com/role/TaxesonIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Contingency [Table]", "label": "Income Tax Contingency [Table]", "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months." } } }, "auth_ref": [ "r1472" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.merck.com/role/TaxesonIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Taxes on Income", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r301", "r697", "r705", "r711", "r712", "r713", "r722", "r728", "r735", "r737", "r738", "r739", "r982", "r1172" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofIncome": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 2.0 }, "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofIncome", "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails", "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Taxes on Income", "totalLabel": "Taxes on income", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r216", "r231", "r324", "r325", "r346", "r362", "r376", "r703", "r705", "r736", "r941", "r1172" ] }, "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract", "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount", "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]" } } }, "auth_ref": [] }, "mrk_IncomeTaxLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.merck.com/20241231", "localname": "IncomeTaxLineItems", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax [Line Items]", "label": "Income Tax [Line Items]", "documentation": "Income Tax [Line Items]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Taxes on Income", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r279", "r699", "r700", "r722", "r723", "r727", "r730", "r976" ] }, "mrk_IncomeTaxRateReconciliationAssetAcquisitionThreeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "IncomeTaxRateReconciliationAssetAcquisitionThreeAmount", "crdr": "debit", "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition of Prometheus", "label": "Income Tax Rate Reconciliation, Asset Acquisition Three, Amount", "documentation": "Income Tax Rate Reconciliation, Asset Acquisition Three, Amount" } } }, "auth_ref": [] }, "mrk_IncomeTaxRateReconciliationAssetAcquisitionTwoAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "IncomeTaxRateReconciliationAssetAcquisitionTwoAmount", "crdr": "debit", "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Charges for certain research and development asset acquisitions", "label": "Income Tax Rate Reconciliation, Asset Acquisition Two, Amount", "documentation": "Income Tax Rate Reconciliation, Asset Acquisition Two, Amount" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "crdr": "debit", "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation allowances", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r710", "r1172", "r1469" ] }, "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "crdr": "debit", "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign earnings", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)." } } }, "auth_ref": [ "r706", "r709", "r1172", "r1469" ] }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "crdr": "debit", "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. statutory rate applied to income before taxes", "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r705", "r1172" ] }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges", "crdr": "debit", "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Restructuring Charges, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible restructuring charges." } } }, "auth_ref": [ "r1469", "r1471" ] }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationOtherAdjustments", "crdr": "debit", "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r1172", "r1469", "r1470" ] }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "crdr": "debit", "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State taxes", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)." } } }, "auth_ref": [ "r708", "r1172", "r1469" ] }, "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationTaxCreditsResearch", "crdr": "credit", "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "R&D tax credit", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit." } } }, "auth_ref": [ "r1172", "r1469", "r1471" ] }, "us-gaap_IncomeTaxReconciliationTaxSettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationTaxSettlements", "crdr": "debit", "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax settlements and statute lapses", "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements." } } }, "auth_ref": [ "r1469", "r1470" ] }, "us-gaap_IncomeTaxesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaid", "crdr": "credit", "presentation": [ "http://www.merck.com/role/TaxesonIncomeIncomeTaxAuthorityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes paid", "label": "Income Taxes Paid", "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": [ "r38", "r155", "r1382", "r1476", "r1477" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableTrade", "crdr": "debit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Trade accounts payable", "label": "Increase (Decrease) in Accounts Payable, Trade", "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "crdr": "debit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes payable", "label": "Increase (Decrease) in Income Taxes Payable", "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued and other current liabilities", "label": "Increase (Decrease) in Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r10" ] }, "mrk_IncreaseDecreaseInHedgeRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "IncreaseDecreaseInHedgeRevenue", "crdr": "debit", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in revenue hedging activities", "label": "Increase (Decrease) In Hedge Revenue", "documentation": "Increase (Decrease) In Hedge Revenue" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 15.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Net changes in assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "crdr": "credit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Other", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Noncurrent liabilities", "label": "Increase (Decrease) in Other Operating Liabilities", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets [Axis]", "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r452", "r457", "r463", "r1142" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails": { "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0, "order": 1.0 }, "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails_1": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Indefinite-lived intangible assets", "terseLabel": "IPR&D intangible asset", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r438", "r463", "r1142" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": [ "r452", "r457", "r463", "r1142" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r1253", "r1264", "r1274", "r1298", "r1307", "r1311", "r1319" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r1317" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r1234", "r1323" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r1234", "r1323" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r1234", "r1323" ] }, "mrk_InsuranceContractsOtherInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "InsuranceContractsOtherInvestmentsMember", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Insurance contracts", "verboseLabel": "Insurance Contracts", "label": "Insurance Contracts Other Investments [Member]", "documentation": "Insurance contracts other investments." } } }, "auth_ref": [] }, "mrk_IntangibleAssetsExcludingGoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.merck.com/20241231", "localname": "IntangibleAssetsExcludingGoodwillLineItems", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets Excluding Goodwill [Line Items]", "label": "Intangible Assets Excluding Goodwill [Line Items]", "documentation": "Intangible Assets Excluding Goodwill [Line Items]" } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsFiniteLivedPolicy", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired Intangibles", "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets." } } }, "auth_ref": [ "r870", "r871", "r872", "r874", "r1124", "r1424" ] }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsGrossExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Intangible assets, gross carrying amount", "label": "Intangible Assets, Gross (Excluding Goodwill)", "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill." } } }, "auth_ref": [ "r248" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 }, "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet", "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Intangibles, Net", "totalLabel": "Intangible assets, net", "verboseLabel": "Other intangibles, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r452", "r1431", "r1432" ] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "negatedLabel": "Interest expense", "label": "Interest Expense, Nonoperating", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": [ "r358", "r1375" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest paid", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r288", "r292", "r293" ] }, "us-gaap_InterestRateContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestRateContractMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate swap contracts", "label": "Interest Rate Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate." } } }, "auth_ref": [ "r1110", "r1120", "r1158", "r1177" ] }, "us-gaap_InterestRateSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestRateSwapMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate swap contracts", "verboseLabel": "Interest rate swap contracts", "label": "Interest Rate Swap [Member]", "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period." } } }, "auth_ref": [ "r1110", "r1219", "r1220" ] }, "us-gaap_InternalUseSoftwarePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InternalUseSoftwarePolicy", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Software Capitalization", "label": "Internal Use Software, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs incurred when both (1) the software is acquired, internally developed, or modified solely to meet the entity's internal needs, and (2) during the software's development or modification, no substantive plan exists or is being developed to market the software externally." } } }, "auth_ref": [ "r468" ] }, "mrk_InternationalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "InternationalMember", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Int\u2019l", "label": "International [Member]", "documentation": "International [Member]" } } }, "auth_ref": [] }, "mrk_InventoriesProducedinPreparationforProductLaunchesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "InventoriesProducedinPreparationforProductLaunchesMember", "presentation": [ "http://www.merck.com/role/InventoriesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories Produced in Preparation for Product Launches", "label": "Inventories Produced in Preparation for Product Launches [Member]", "documentation": "Inventories Produced in Preparation for Product Launches [Member]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Inventory Disclosure [Abstract]", "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://www.merck.com/role/Inventories" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r435" ] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoods", "crdr": "debit", "calculation": { "http://www.merck.com/role/InventoriesInventoriesDetails": { "parentTag": "us-gaap_InventoryGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/InventoriesInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Gross", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": [ "r1366" ] }, "us-gaap_InventoryGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryGross", "crdr": "debit", "calculation": { "http://www.merck.com/role/InventoriesInventoriesDetails": { "parentTag": "mrk_InventoryNetAndInventoryNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/InventoriesInventoriesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Inventory, Gross", "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r1370" ] }, "us-gaap_InventoryLIFOReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryLIFOReserve", "crdr": "credit", "calculation": { "http://www.merck.com/role/InventoriesInventoriesDetails": { "parentTag": "mrk_InventoryNetAndInventoryNoncurrent", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/InventoriesInventoriesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Decrease to LIFO cost", "label": "Inventory, LIFO Reserve", "documentation": "Amount by which inventory stated at last-in first-out (LIFO) is less than (in excess of) inventory stated at other inventory cost methods." } } }, "auth_ref": [ "r1369" ] }, "us-gaap_InventoryLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryLineItems", "presentation": [ "http://www.merck.com/role/InventoriesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory [Line Items]", "label": "Inventory [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.merck.com/role/InventoriesInventoriesDetails_1": { "parentTag": "mrk_InventoryNetAndInventoryNoncurrent", "weight": 1.0, "order": 1.0 }, "http://www.merck.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet", "http://www.merck.com/role/InventoriesInventoriesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Inventories (excludes inventories of $4,193 in 2024 and $3,348 in 2023 classified in Other assets - see Note\u00a07)", "terseLabel": "Inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r262", "r1114", "r1190" ] }, "mrk_InventoryNetAndInventoryNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "InventoryNetAndInventoryNoncurrent", "crdr": "debit", "calculation": { "http://www.merck.com/role/InventoriesInventoriesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.merck.com/role/InventoriesInventoriesDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.merck.com/role/InventoriesInventoriesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total current and noncurrent inventories", "label": "Inventory Net And Inventory Noncurrent", "documentation": "Total of current and noncurrent inventories." } } }, "auth_ref": [] }, "us-gaap_InventoryNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNoncurrent", "crdr": "debit", "calculation": { "http://www.merck.com/role/InventoriesInventoriesDetails_1": { "parentTag": "mrk_InventoryNetAndInventoryNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical", "http://www.merck.com/role/InventoriesInventoriesDetails", "http://www.merck.com/role/InventoriesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory classified in Other assets", "verboseLabel": "Other Assets", "label": "Inventory, Noncurrent", "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle." } } }, "auth_ref": [ "r1364" ] }, "mrk_InventoryNotExpectedtobeSoldWithinOneYearMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "InventoryNotExpectedtobeSoldWithinOneYearMember", "presentation": [ "http://www.merck.com/role/InventoriesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory Not Expected to be Sold Within One Year", "label": "Inventory Not Expected to be Sold Within One Year [Member]", "documentation": "Inventory Not Expected to be Sold Within One Year [Member]" } } }, "auth_ref": [] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory, Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r218", "r243", "r261", "r435", "r436", "r437", "r869", "r1125" ] }, "mrk_InventoryTable": { "xbrltype": "stringItemType", "nsuri": "http://www.merck.com/20241231", "localname": "InventoryTable", "presentation": [ "http://www.merck.com/role/InventoriesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory [Table]", "label": "Inventory [Table]", "documentation": "Inventory [Table]" } } }, "auth_ref": [] }, "mrk_InventoryWorkInProcessAndRawMaterialsExcludingSupplies": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "InventoryWorkInProcessAndRawMaterialsExcludingSupplies", "crdr": "debit", "calculation": { "http://www.merck.com/role/InventoriesInventoriesDetails": { "parentTag": "us-gaap_InventoryGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/InventoriesInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials and work in process", "label": "Inventory, Work in Process and Raw Materials, Excluding Supplies", "documentation": "Inventory, Work in Process and Raw Materials, Excluding Supplies" } } }, "auth_ref": [] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest income", "terseLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r346", "r357", "r376", "r1134", "r1374" ] }, "us-gaap_InvestmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentPolicyTextBlock", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Investments", "label": "Investment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment in financial asset." } } }, "auth_ref": [ "r938", "r972", "r973", "r974", "r975", "r1064", "r1065" ] }, "us-gaap_Investments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Investments", "crdr": "debit", "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Investments", "label": "Investments", "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments." } } }, "auth_ref": [ "r913", "r914", "r1208", "r1211" ] }, "mrk_IsentressIsentressHDMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "IsentressIsentressHDMember", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Isentress/Isentress HD", "label": "Isentress/Isentress HD [Member]", "documentation": "Isentress/Isentress HD [Member]." } } }, "auth_ref": [] }, "country_JP": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "JP", "presentation": [ "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Japan", "label": "JAPAN" } } }, "auth_ref": [] }, "mrk_JanumetMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "JanumetMember", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Janumet", "label": "Janumet [Member]", "documentation": "Janumet [Member]." } } }, "auth_ref": [] }, "mrk_JanuviaJanumetMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "JanuviaJanumetMember", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Januvia/Janumet", "label": "Januvia/Janumet [Member]", "documentation": "Januvia/Janumet" } } }, "auth_ref": [] }, "mrk_JanuviaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "JanuviaMember", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Januvia", "label": "Januvia [Member]", "documentation": "Januvia [Member] ." } } }, "auth_ref": [] }, "mrk_KeytrudaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "KeytrudaMember", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Keytruda", "label": "Keytruda [Member]", "documentation": "Keytruda [Member]" } } }, "auth_ref": [] }, "mrk_KoselugoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "KoselugoMember", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Koselugo", "label": "Koselugo [Member]", "documentation": "Koselugo" } } }, "auth_ref": [] }, "us-gaap_LIFOInventoryAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LIFOInventoryAmount", "crdr": "debit", "presentation": [ "http://www.merck.com/role/InventoriesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "LIFO inventory amount", "label": "LIFO Inventory Amount", "documentation": "The amount of LIFO (last in first out) inventory present at the reporting date when inventory is also valued using different valuation methods." } } }, "auth_ref": [ "r1116" ] }, "mrk_LagevrioMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "LagevrioMember", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsRidgebackBiotherapeuticsLPDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lagevrio", "label": "Lagevrio [Member]", "documentation": "Lagevrio" } } }, "auth_ref": [] }, "us-gaap_Land": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Land", "crdr": "debit", "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Land", "label": "Land", "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale." } } }, "auth_ref": [ "r1363" ] }, "srt_LatinAmericaMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LatinAmericaMember", "presentation": [ "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Latin America", "label": "Latin America [Member]" } } }, "auth_ref": [ "r1567", "r1569", "r1570", "r1571" ] }, "mrk_LeaseAssetsAndLiabilitiesLesseeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.merck.com/20241231", "localname": "LeaseAssetsAndLiabilitiesLesseeTableTextBlock", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental Balance Sheet Information", "label": "Lease Assets and Liabilities, Lessee [Table Text Block]", "documentation": "Lease Assets and Liabilities, Lessee [Table Text Block]" } } }, "auth_ref": [] }, "mrk_LegalDefenseCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "LegalDefenseCostsMember", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Defense Costs", "label": "Legal Defense Costs [Member]", "documentation": "Legal Defense Costs [Member]" } } }, "auth_ref": [] }, "us-gaap_LegalEntityTypeOfCounterpartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LegalEntityTypeOfCounterpartyDomain", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity Type of Counterparty [Domain]", "label": "Legal Entity Type of Counterparty [Domain]", "documentation": "Nature of the other party participating in a financial transaction." } } }, "auth_ref": [] }, "mrk_LenvimaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "LenvimaMember", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Alliance revenue - Lenvima", "verboseLabel": "Lenvima", "label": "Lenvima [Member]", "documentation": "Lenvima [Member]" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Maturities of Operating Lease Liabilities", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r1517" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r828" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r828" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r828" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r828" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r828" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r828" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r828" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less: Imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r828" ] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, operating lease, renewal term", "label": "Lessee, Operating Lease, Renewal Term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1515" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeases" ], "lang": { "en-us": { "role": { "terseLabel": "Loans Payable, Long-Term Debt and Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r817" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r29", "r110", "r111", "r112", "r115", "r116", "r117", "r120", "r299", "r421", "r503", "r504", "r506", "r507", "r508", "r509", "r510", "r512", "r513", "r754", "r758", "r759", "r798", "r1014", "r1128", "r1227", "r1450", "r1519", "r1520" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total Liabilities and Equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r128", "r206", "r924", "r1190", "r1386", "r1411", "r1510" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and Equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r112", "r242", "r299", "r421", "r503", "r504", "r506", "r507", "r508", "r509", "r510", "r512", "r513", "r754", "r758", "r759", "r798", "r1190", "r1450", "r1519", "r1520" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Current Liabilities", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities, Fair Value Disclosure", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r783", "r1495" ] }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosureAbstract", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities", "label": "Liabilities, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Noncurrent Liabilities", "label": "Liabilities, Noncurrent", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r29", "r115", "r116", "r117", "r120", "r299", "r421", "r503", "r504", "r506", "r507", "r508", "r509", "r510", "r512", "r513", "r754", "r758", "r759", "r798", "r1450", "r1519", "r1520" ] }, "mrk_LicensesAndOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "LicensesAndOtherMember", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Licenses and other", "label": "Licenses and Other [Member]", "documentation": "Licenses and Other" } } }, "auth_ref": [] }, "us-gaap_LicensingAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LicensingAgreementsMember", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Licensing Agreements", "label": "Licensing Agreements [Member]", "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory)." } } }, "auth_ref": [ "r76", "r695", "r1425", "r1426", "r1427", "r1428", "r1429", "r1430", "r1431", "r1432", "r1433", "r1434", "r1467" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Available borrowing capacity under credit facility", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r109", "r114" ] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseAxis", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails", "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Axis]", "label": "Litigation Case [Axis]" } } }, "auth_ref": [] }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseTypeDomain", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails", "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Domain]", "label": "Litigation Case [Domain]" } } }, "auth_ref": [] }, "us-gaap_LitigationReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationReserve", "crdr": "credit", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal defense costs reserve", "label": "Estimated Litigation Liability", "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs." } } }, "auth_ref": [ "r117", "r1445" ] }, "us-gaap_LitigationStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationStatusAxis", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Status [Axis]", "label": "Litigation Status [Axis]", "documentation": "Information by status of pending, threatened, or settled litigation." } } }, "auth_ref": [ "r1438", "r1439", "r1440", "r1445" ] }, "us-gaap_LitigationStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationStatusDomain", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Status [Domain]", "label": "Litigation Status [Domain]", "documentation": "Status of pending, threatened, or settled litigation." } } }, "auth_ref": [ "r1438", "r1439", "r1440", "r1445" ] }, "mrk_LivestockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "LivestockMember", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Livestock", "label": "Livestock [Member]", "documentation": "Livestock [Member]" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtCurrent", "crdr": "credit", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, current maturities", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r253" ] }, "mrk_LongTermDebtInterestPayableYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "LongTermDebtInterestPayableYearFive", "crdr": "credit", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, interest payments in 2029", "label": "Long-term Debt, Interest Payable, Year Five", "documentation": "Long-term Debt, Interest Payable, Year Five" } } }, "auth_ref": [] }, "mrk_LongTermDebtInterestPayableYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "LongTermDebtInterestPayableYearFour", "crdr": "credit", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, interest payments in 2028", "label": "Long-term Debt, Interest Payable, Year Four", "documentation": "Long-term Debt, Interest Payable, Year Four" } } }, "auth_ref": [] }, "mrk_LongTermDebtInterestPayableYearOne": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "LongTermDebtInterestPayableYearOne", "crdr": "credit", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, interest payments in 2025", "label": "Long-term Debt, Interest Payable, Year One", "documentation": "Long-term Debt, Interest Payable, Year One" } } }, "auth_ref": [] }, "mrk_LongTermDebtInterestPayableYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "LongTermDebtInterestPayableYearThree", "crdr": "credit", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, interest payments in 2027", "label": "Long-term Debt, Interest Payable, Year Three", "documentation": "Long-term Debt, Interest Payable, Year Three" } } }, "auth_ref": [] }, "mrk_LongTermDebtInterestPayableYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "LongTermDebtInterestPayableYearTwo", "crdr": "credit", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, interest payments in 2026", "label": "Long-term Debt, Interest Payable, Year Two", "documentation": "Long-term Debt, Interest Payable, Year Two" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, maturities, repayments of principal in 2025", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r13", "r306", "r532" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "crdr": "credit", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, maturities, repayments of principal in 2029", "label": "Long-Term Debt, Maturity, Year Five", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r13", "r306", "r532" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, maturities, repayments of principal in 2028", "label": "Long-Term Debt, Maturity, Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r13", "r306", "r532" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, maturities, repayments of principal in 2027", "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r13", "r306", "r532" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, maturities, repayments of principal in 2026", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r13", "r306", "r532" ] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet", "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Debt", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r255" ] }, "us-gaap_LongTermDebtPercentageBearingVariableInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtPercentageBearingVariableInterestRate", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective interest rate", "label": "Long-Term Debt, Percentage Bearing Variable Interest, Percentage Rate", "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time." } } }, "auth_ref": [ "r113" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails", "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r29", "r1438", "r1439", "r1440" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails", "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r29", "r57", "r1438", "r1439", "r1440" ] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesLineItems", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r493", "r495", "r496", "r500", "r691", "r1148", "r1446", "r1447" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesTable", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Table]", "label": "Loss Contingencies [Table]", "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation." } } }, "auth_ref": [ "r493", "r495", "r496", "r500", "r691", "r1148", "r1446", "r1447" ] }, "us-gaap_LossContingencyClaimsSettledNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyClaimsSettledNumber", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss contingency, claims settled (in cases)", "label": "Loss Contingency, Claims Settled, Number", "documentation": "Number of claims settled." } } }, "auth_ref": [ "r1446", "r1447" ] }, "mrk_LossContingencyMotionForSummaryJudgementsGrantedNumber": { "xbrltype": "integerItemType", "nsuri": "http://www.merck.com/20241231", "localname": "LossContingencyMotionForSummaryJudgementsGrantedNumber", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss contingency, motion for summary judgements granted", "label": "Loss Contingency, Motion For Summary Judgements Granted, Number", "documentation": "Loss Contingency, Motion For Summary Judgements Granted, Number" } } }, "auth_ref": [] }, "us-gaap_LossContingencyNumberOfPlaintiffs": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyNumberOfPlaintiffs", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss contingency, number of plaintiffs", "label": "Loss Contingency, Number of Plaintiffs", "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency." } } }, "auth_ref": [ "r1446", "r1447" ] }, "us-gaap_LossContingencyPatentsAllegedlyInfringedNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyPatentsAllegedlyInfringedNumber", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of patents allegedly infringed", "label": "Loss Contingency, Patents Allegedly Infringed, Number", "documentation": "Number of another entity's patents that the entity has allegedly infringed." } } }, "auth_ref": [ "r1446", "r1447" ] }, "mrk_LossContingencyPatentsAllegedlyInfringedUnderReviewNumber": { "xbrltype": "integerItemType", "nsuri": "http://www.merck.com/20241231", "localname": "LossContingencyPatentsAllegedlyInfringedUnderReviewNumber", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of patents allegedly infringed under review", "label": "Loss Contingency, Patents Allegedly Infringed Under Review, Number", "documentation": "Loss Contingency, Patents Allegedly Infringed Under Review, Number" } } }, "auth_ref": [] }, "us-gaap_LossContingencyPendingClaimsNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyPendingClaimsNumber", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss contingency, pending claims", "label": "Loss Contingency, Pending Claims, Number", "documentation": "Number of pending claims pertaining to a loss contingency." } } }, "auth_ref": [ "r1446", "r1447" ] }, "mrk_LossContingencyTrialPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.merck.com/20241231", "localname": "LossContingencyTrialPeriod", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss contingency, trial period", "label": "Loss Contingency, Trial Period", "documentation": "Loss Contingency, Trial Period" } } }, "auth_ref": [] }, "mrk_LyfnuaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "LyfnuaMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lyfnua", "label": "Lyfnua [Member]", "documentation": "Lyfnua" } } }, "auth_ref": [] }, "mrk_LynparzaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "LynparzaMember", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lynparza", "label": "Lynparza [Member]", "documentation": "Lynparza [Member]" } } }, "auth_ref": [] }, "mrk_MK1045CN201CuronBiopharmaceuticalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "MK1045CN201CuronBiopharmaceuticalMember", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CN201, Curon Biopharmaceutical", "label": "MK-1045/CN201, Curon Biopharmaceutical [Member]", "documentation": "MK-1045/CN201, Curon Biopharmaceutical" } } }, "auth_ref": [] }, "mrk_MK2010LM299LaNovaMedicinesLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "MK2010LM299LaNovaMedicinesLtdMember", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "LM-299, LaNova Medicines Ltd", "label": "MK-2010 (LM-299), LaNova Medicines Ltd [Member]", "documentation": "MK-2010 (LM-299), LaNova Medicines Ltd" } } }, "auth_ref": [] }, "mrk_MK4082HS10535HansohPharmaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "MK4082HS10535HansohPharmaMember", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "HS-10535 Hansoh Pharma", "label": "MK-4082 (HS-10535) Hansoh Pharma [Member]", "documentation": "MK-4082 (HS-10535) Hansoh Pharma" } } }, "auth_ref": [] }, "us-gaap_MachineryAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MachineryAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Machinery, equipment and office furnishings", "label": "Machinery and Equipment, Gross", "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [ "r162" ] }, "us-gaap_MachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MachineryAndEquipmentMember", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Machinery, equipment and office furnishings", "label": "Machinery and Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]" } } }, "auth_ref": [ "r383", "r1157", "r1201", "r1206", "r1453", "r1531", "r1535", "r1536", "r1538", "r1539", "r1540", "r1541", "r1542", "r1543", "r1544", "r1545", "r1546", "r1547", "r1548", "r1549", "r1550", "r1551", "r1552", "r1553", "r1554", "r1555", "r1556", "r1557", "r1558", "r1559", "r1560", "r1562", "r1563" ] }, "mrk_ManufacturingAndSupplyAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "ManufacturingAndSupplyAgreementsMember", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Manufacturing and supply agreements", "label": "Manufacturing and supply agreements [Member]", "documentation": "Manufacturing and supply agreements" } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesCurrent", "crdr": "debit", "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "label": "Marketable Securities, Current", "documentation": "Amount of investment in marketable security, classified as current." } } }, "auth_ref": [ "r1365" ] }, "us-gaap_MarketableSecuritiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesNoncurrent", "crdr": "debit", "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Investments", "label": "Marketable Securities, Noncurrent", "documentation": "Amount of investment in marketable security, classified as noncurrent." } } }, "auth_ref": [ "r1365" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails", "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r495", "r496", "r498", "r499", "r646", "r691", "r786", "r868", "r960", "r962", "r970", "r1006", "r1007", "r1062", "r1066", "r1068", "r1069", "r1084", "r1106", "r1107", "r1139", "r1154", "r1168", "r1181", "r1182", "r1186", "r1187", "r1202", "r1452", "r1521", "r1522", "r1523", "r1524", "r1525", "r1526" ] }, "mrk_McKessonCorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "McKessonCorporationMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "McKesson Corporation", "label": "McKesson Corporation [Member]", "documentation": "McKesson Corporation" } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r1290" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r1290" ] }, "mrk_MilestonePaymentMadeToCollaborativePartner": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "MilestonePaymentMadeToCollaborativePartner", "crdr": "credit", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone payment to be made to a collaborative partner", "label": "Milestone Payment Made to Collaborative Partner", "documentation": "Milestone Payment Made to Collaborative Partner" } } }, "auth_ref": [] }, "mrk_MilestonePaymentsSalesBased": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "MilestonePaymentsSalesBased", "crdr": "credit", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone payments sales-based", "label": "Milestone Payments Sales-Based", "documentation": "Milestone Payments Sales-Based" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails", "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r495", "r496", "r498", "r499", "r646", "r691", "r786", "r868", "r960", "r962", "r970", "r1006", "r1007", "r1062", "r1066", "r1068", "r1069", "r1084", "r1106", "r1107", "r1139", "r1154", "r1168", "r1181", "r1182", "r1186", "r1202", "r1452", "r1521", "r1522", "r1523", "r1524", "r1525", "r1526" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interests", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r127", "r205", "r299", "r421", "r503", "r506", "r507", "r508", "r512", "r513", "r798", "r923", "r1017" ] }, "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "crdr": "debit", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofEquity" ], "lang": { "en-us": { "role": { "negatedLabel": "Distributions attributable to noncontrolling interests", "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders", "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders." } } }, "auth_ref": [ "r174" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r1310" ] }, "mrk_ModernaIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "ModernaIncMember", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsModernaIncDetails", "http://www.merck.com/role/CollaborativeArrangementsModernaIncNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Moderna", "label": "Moderna, Inc. [Member]", "documentation": "Moderna, Inc." } } }, "auth_ref": [] }, "mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Mortgage and asset-backed securities", "label": "Mortgage And Asset Backed Securities Fixed Income Securities [Member]", "documentation": "Mortgage and asset backed securities fixed income securities." } } }, "auth_ref": [] }, "mrk_MovementinCommonStockandTreasuryStockRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.merck.com/20241231", "localname": "MovementinCommonStockandTreasuryStockRollForward", "presentation": [ "http://www.merck.com/role/EquityShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Movement in Common Stock and Treasury Stock [Roll Forward]", "label": "Movement in Common Stock and Treasury Stock [Roll Forward]", "documentation": "Movement in Common Stock and Treasury Stock [Roll Forward]" } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r1318" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]" } } }, "auth_ref": [ "r383", "r1157", "r1201", "r1206", "r1453", "r1531", "r1535", "r1536", "r1538", "r1539", "r1540", "r1541", "r1542", "r1543", "r1544", "r1545", "r1546", "r1547", "r1548", "r1549", "r1550", "r1551", "r1552", "r1553", "r1554", "r1555", "r1556", "r1557", "r1558", "r1559", "r1560", "r1562", "r1563" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r1291" ] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NatureOfOperations", "presentation": [ "http://www.merck.com/role/NatureofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Nature of Operations", "label": "Nature of Operations [Text Block]", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": [ "r219", "r232" ] }, "mrk_NemtabrutinibMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "NemtabrutinibMember", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "nemtabrutinib", "label": "Nemtabrutinib [Member]", "documentation": "Nemtabrutinib" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net Cash Used in Financing Activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r291" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flows from Financing Activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net Cash Used in Investing Activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r291" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flows from Investing Activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net Cash Provided by Operating Activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r152", "r153", "r156" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flows from Operating Activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncomeLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.merck.com/role/ConsolidatedStatementofIncome": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncomeLoss", "http://www.merck.com/role/ConsolidatedStatementofEquity", "http://www.merck.com/role/ConsolidatedStatementofIncome", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net Income Attributable to Merck & Co., Inc.", "terseLabel": "Net Income Attributable to Merck & Co., Inc.", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r144", "r156", "r209", "r240", "r274", "r277", "r282", "r299", "r315", "r317", "r318", "r319", "r320", "r321", "r324", "r325", "r337", "r421", "r503", "r504", "r506", "r507", "r508", "r509", "r510", "r512", "r513", "r743", "r750", "r780", "r798", "r932", "r1036", "r1054", "r1055", "r1225", "r1450" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofIncome": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofEquity", "http://www.merck.com/role/ConsolidatedStatementofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Less: Net Income Attributable to Noncontrolling Interests", "verboseLabel": "Net income attributable to noncontrolling interests", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r82", "r193", "r274", "r277", "r321", "r324", "r325", "r931", "r1373" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "presentation": [ "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net income attributable to Merck & Co., Inc., basic", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r287", "r317", "r318", "r319", "r320", "r328", "r329", "r338", "r341", "r750" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "presentation": [ "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net income attributable to Merck & Co., Inc., diluted", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r287", "r330", "r333", "r334", "r335", "r336", "r338", "r341" ] }, "us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent", "crdr": "debit", "calculation": { "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net periodic defined benefit plan (credit) cost other than service cost", "label": "Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component", "documentation": "Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits." } } }, "auth_ref": [ "r570" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recently Adopted Accounting Standards and Recently Issued Accounting Standards Not Yet Adopted", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r1290" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r1253", "r1264", "r1274", "r1298", "r1307" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r1281" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r1280" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r1298" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r1318" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r1318" ] }, "us-gaap_NonUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonUsMember", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails", "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outside of the United States", "label": "Non-US [Member]", "documentation": "Countries excluding the United States of America (US)." } } }, "auth_ref": [ "r1567", "r1569", "r1570", "r1571" ] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestMember", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Non- controlling Interests", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r78", "r557", "r1390", "r1391", "r1392", "r1394", "r1566" ] }, "us-gaap_NondesignatedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NondesignatedMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives Not Designated as Hedging Instruments", "verboseLabel": "Derivatives Not Designated as Hedging Instruments", "label": "Not Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r17" ] }, "mrk_NotesSubjectToRepaymentAtOptionOfHolderMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "NotesSubjectToRepaymentAtOptionOfHolderMember", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notes Subject To Repayment At Option Of Holder", "label": "Notes Subject To Repayment At Option Of Holder [Member]", "documentation": "Notes Subject To Repayment At Option Of Holder [Member]" } } }, "auth_ref": [] }, "mrk_NoxafilMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "NoxafilMember", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noxafil", "label": "Noxafil [Member]", "documentation": "Noxafil [Member]." } } }, "auth_ref": [] }, "us-gaap_NumberOfInterestRateDerivativesHeld": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfInterestRateDerivativesHeld", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Interest Rate Swaps Held", "label": "Number of Interest Rate Derivatives Held", "documentation": "Number of interest rate derivative instruments held by the entity at the reporting date." } } }, "auth_ref": [ "r85", "r86" ] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.merck.com/role/NatureofOperationsDetails", "http://www.merck.com/role/SegmentReportingNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r1135", "r1398" ] }, "mrk_OffsettingAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.merck.com/20241231", "localname": "OffsettingAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis", "label": "Offsetting Assets And Liabilities [Table Text Block]", "documentation": "Tabular disclosure of derivative positions subject to master netting arrangements as if they were presented on a net basis." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, cost", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r823", "r1189" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 }, "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails", "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating lease liability", "verboseLabel": "Total operating lease liability", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r820" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued and other current liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r820" ] }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes current operating lease liability." } } }, "auth_ref": [ "r821" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Noncurrent Liabilities", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r820" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability." } } }, "auth_ref": [ "r821" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, payments", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r822", "r824" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other Assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r819" ] }, "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset." } } }, "auth_ref": [ "r821" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average discount rate", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r827", "r1189" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails", "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, weighted average remaining lease term", "verboseLabel": "Weighted-average remaining lease term (years)", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r826", "r1189" ] }, "us-gaap_OperatingLossCarryforwardsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwardsValuationAllowance", "crdr": "credit", "presentation": [ "http://www.merck.com/role/TaxesonIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation allowance on foreign NOL carryforwards", "label": "Operating Loss Carryforwards, Valuation Allowance", "documentation": "The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r1475" ] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingSegmentsMember", "presentation": [ "http://www.merck.com/role/SegmentReportingEquityIncomefromAffiliatesandDepreciationIncludedinSegmentProfitsDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Segments", "verboseLabel": "Total segment profits", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r370", "r371", "r372", "r373", "r374", "r377", "r1134", "r1135" ] }, "mrk_OptionPaymentMadeToCollaborativePartner": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "OptionPaymentMadeToCollaborativePartner", "crdr": "credit", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Option payment made to collaborative partner", "label": "Option Payment Made to Collaborative Partner", "documentation": "Option Payment Made to Collaborative Partner" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "mrk_OrganonCoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "OrganonCoMember", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Organon & Co.", "label": "Organon & Co. [Member]", "documentation": "Organon & Co." } } }, "auth_ref": [] }, "mrk_OrionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "OrionMember", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Orion", "label": "Orion [Member]", "documentation": "Orion" } } }, "auth_ref": [] }, "mrk_OrnaTherapeuticsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "OrnaTherapeuticsMember", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Orna Therapeutics", "label": "Orna Therapeutics [Member]", "documentation": "Orna Therapeutics" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r263", "r1190" ] }, "us-gaap_OtherAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsMember", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Assets", "label": "Other Assets [Member]", "documentation": "Primary financial statement caption encompassing other assets." } } }, "auth_ref": [ "r88", "r99" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 2.0 }, "http://www.merck.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet", "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Assets", "totalLabel": "Other Assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r250" ] }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax", "crdr": "debit", "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Prior service credit (cost) arising during the period", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax", "documentation": "Amount, before tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit)." } } }, "auth_ref": [ "r4", "r138", "r612" ] }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "debit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncomeLoss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "negatedLabel": "Benefit plan net gain (loss) and prior service credit (cost), net of amortization", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent", "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent." } } }, "auth_ref": [ "r4", "r5", "r15", "r137", "r138", "r192" ] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncomeLoss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative translation adjustment", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity." } } }, "auth_ref": [ "r9", "r15", "r192" ] }, "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax", "crdr": "credit", "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prior service (credit) cost amortization included in benefit cost", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax", "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan." } } }, "auth_ref": [ "r8", "r138", "r273", "r612" ] }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax", "crdr": "credit", "calculation": { "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss) before reclassification adjustments, pretax", "label": "Other Comprehensive Income (Loss), before Reclassifications, before Tax", "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r32", "r281", "r805", "r808", "r811", "r933", "r1371" ] }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "crdr": "credit", "calculation": { "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive income (loss) before reclassification adjustments, net of taxes", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r27", "r32", "r281", "r805", "r808", "r811", "r933", "r1371" ] }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsTax", "crdr": "debit", "calculation": { "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Tax", "label": "Other Comprehensive Income (Loss) before Reclassifications, Tax", "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r6", "r280", "r933" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "crdr": "credit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncomeLoss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Net unrealized income (loss) on derivatives, net of reclassifications", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent", "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r270" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of gain recognized in OCI on derivatives", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r269", "r270", "r761", "r762", "r769" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "crdr": "debit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in Sales as a result of AOCL reclassifications", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r270", "r272" ] }, "mrk_OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax", "crdr": "credit", "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Settlements and curtailments", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement And Curtailment Gain (Loss), Reclassification Adjustment From AOCI, Before Tax", "documentation": "Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement And Curtailment Gain (Loss), Reclassification Adjustment From AOCI, Before Tax" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge." } } }, "auth_ref": [ "r763" ] }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax", "crdr": "debit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax", "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge." } } }, "auth_ref": [ "r764" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofEquity", "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss), net of taxes", "totalLabel": "Other comprehensive income (loss), net of taxes", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r16", "r27", "r275", "r278", "r284", "r321", "r805", "r806", "r811", "r908", "r933", "r1371", "r1372" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss) Net of Taxes:", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncomeLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncomeLoss", "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive income (loss), net of taxes", "terseLabel": "Other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r9", "r15", "r192", "r275", "r278", "r321" ] }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax", "crdr": "debit", "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax", "documentation": "Amount, before tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income of defined benefit plan, that has not been recognized in net periodic benefit cost (credit)." } } }, "auth_ref": [ "r4", "r5", "r137", "r138" ] }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax", "crdr": "credit", "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net gain (loss) arising during the period", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax", "documentation": "Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit." } } }, "auth_ref": [ "r137", "r138", "r175" ] }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax", "crdr": "credit", "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, before Tax", "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for net period benefit cost (credit) of defined benefit plan." } } }, "auth_ref": [ "r8", "r138", "r273", "r1456" ] }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax", "crdr": "debit", "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net loss (gain) amortization included in benefit cost", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax", "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan." } } }, "auth_ref": [ "r8", "r138", "r273", "r612" ] }, "mrk_OtherCountriesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "OtherCountriesMember", "presentation": [ "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Countries [Member]", "documentation": "Other Countries [Member]" } } }, "auth_ref": [] }, "us-gaap_OtherCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentAssetsMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other Current Assets [Member]", "documentation": "Primary financial statement caption encompassing other current assets." } } }, "auth_ref": [ "r88", "r99" ] }, "us-gaap_OtherCurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentLiabilitiesMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued and other current liabilities", "label": "Other Current Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other current liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncomeAndExpensesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Other Income and Expenses [Abstract]", "label": "Other Income and Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNet" ], "lang": { "en-us": { "role": { "terseLabel": "Other (Income) Expense, Net", "label": "Other Income and Other Expense Disclosure [Text Block]", "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions." } } }, "auth_ref": [ "r1353", "r1465" ] }, "us-gaap_OtherInventorySupplies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherInventorySupplies", "crdr": "debit", "calculation": { "http://www.merck.com/role/InventoriesInventoriesDetails": { "parentTag": "us-gaap_InventoryGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.merck.com/role/InventoriesInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplies", "label": "Other Inventory, Supplies, Gross", "documentation": "Amount before valuation and LIFO reserves of other supplies used within the manufacturing or production process expected to be consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r1367" ] }, "us-gaap_OtherInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherInvestmentsMember", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "verboseLabel": "Other", "label": "Other Investments [Member]", "documentation": "Primary financial statement caption encompassing other investments." } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCDetails", "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdDetails", "http://www.merck.com/role/CollaborativeArrangementsModernaIncDetails", "http://www.merck.com/role/CollaborativeArrangementsRidgebackBiotherapeuticsLPDetails", "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued and other current liabilities", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r111", "r1190" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Other Noncurrent Liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r116" ] }, "mrk_OtherLongTermDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "OtherLongTermDebtMember", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Long Term Debt [Member]", "documentation": "Other long term debt." } } }, "auth_ref": [] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 16.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Other", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r156" ] }, "us-gaap_OtherNoncurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncurrentAssetsMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Assets", "label": "Other Noncurrent Assets [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent assets." } } }, "auth_ref": [] }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncurrentLiabilitiesMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Noncurrent Liabilities", "label": "Other Noncurrent Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofIncome": { "parentTag": "mrk_CostsExpensesAndOther", "weight": -1.0, "order": 5.0 }, "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofIncome", "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails", "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Other (income) expense, net", "negatedTotalLabel": "Other (income) expense, net", "negatedTerseLabel": "Other segment items", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r146" ] }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpenseMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other (income) expense, net", "label": "Other Nonoperating Income (Expense) [Member]", "documentation": "Primary financial statement caption encompassing other nonoperating income (expense)." } } }, "auth_ref": [] }, "mrk_OtherNonoperatingIncomeExpenseOther": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "OtherNonoperatingIncomeExpenseOther", "crdr": "credit", "calculation": { "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Other, net", "label": "Other Nonoperating Income Expense, Other", "documentation": "Other nonoperating income and expense items not separately disclosed." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r1290" ] }, "mrk_OtherPharmaceuticalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "OtherPharmaceuticalMember", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other pharmaceutical", "label": "Other Pharmaceutical [Member]", "documentation": "Other pharmaceutical." } } }, "auth_ref": [] }, "mrk_OtherPostretirementBenefitPlanNetLossMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "OtherPostretirementBenefitPlanNetLossMember", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Postretirement Benefit Plan Net Gain", "label": "Other Postretirement Benefit Plan Net Loss [Member]", "documentation": "Other Postretirement Benefit Plan Net Loss [Member]" } } }, "auth_ref": [] }, "mrk_OtherPostretirementBenefitPlanPriorServiceCostMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "OtherPostretirementBenefitPlanPriorServiceCostMember", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Postretirement Benefit Plan Prior Service Credit", "label": "Other Postretirement Benefit Plan Prior Service Cost [Member]", "documentation": "Other Postretirement Benefit Plan Prior Service Cost [Member]" } } }, "auth_ref": [] }, "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Postretirement Benefits", "label": "Other Postretirement Benefits Plan [Member]", "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits." } } }, "auth_ref": [ "r567", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r595", "r596", "r597", "r598", "r599", "r600", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r615", "r617", "r618", "r620", "r623", "r626", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r643", "r644", "r645", "r1160", "r1161", "r1162", "r1163", "r1164" ] }, "mrk_OtherProductRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "OtherProductRightsMember", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Product Rights", "label": "Other Product Rights [Member]", "documentation": "Other Product Rights" } } }, "auth_ref": [] }, "us-gaap_OtherRestructuringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherRestructuringMember", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Exit Costs", "label": "Other Restructuring [Member]", "documentation": "Restructuring and related activities classified as other." } } }, "auth_ref": [ "r1144", "r1145", "r1146", "r1147" ] }, "mrk_OtherVariableRateDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "OtherVariableRateDebtMember", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Variable Rate Debt", "label": "Other Variable Rate Debt [Member]", "documentation": "Other Variable Rate Debt [Member]" } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r1251", "r1262", "r1272", "r1305" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r1254", "r1265", "r1275", "r1308" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r1254", "r1265", "r1275", "r1308" ] }, "mrk_PatentExtensionTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.merck.com/20241231", "localname": "PatentExtensionTerm", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Patent extension, term", "label": "Patent Extension, Term", "documentation": "Patent Extension, Term" } } }, "auth_ref": [] }, "us-gaap_PatentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PatentsMember", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Patents", "label": "Patents [Member]", "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law." } } }, "auth_ref": [ "r189", "r1425", "r1426", "r1427", "r1428", "r1430", "r1431", "r1433", "r1434" ] }, "mrk_PatritumabDeruxtecanAndRalduotatugDeruxtecanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "PatritumabDeruxtecanAndRalduotatugDeruxtecanMember", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Patritumab Deruxtecan and Ralduotatug Deruxtecan", "label": "Patritumab Deruxtecan and Ralduotatug Deruxtecan [Member]", "documentation": "Patritumab Deruxtecan and Ralduotatug Deruxtecan" } } }, "auth_ref": [] }, "mrk_PatritumabDeruxtecanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "PatritumabDeruxtecanMember", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Patritumab Deruxtecan", "label": "Patritumab Deruxtecan [Member]", "documentation": "Patritumab Deruxtecan" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r1279" ] }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Other", "label": "Payments for (Proceeds from) Other Investing Activities", "documentation": "Amount of cash (inflow) outflow from investing activities classified as other." } } }, "auth_ref": [ "r1348", "r1376" ] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of treasury stock", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r150" ] }, "us-gaap_PaymentsForRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRestructuring", "crdr": "credit", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "(Payments) receipts, net", "label": "Payments for Restructuring", "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r481", "r1379" ] }, "us-gaap_PaymentsOfDividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDividendsCommonStock", "crdr": "credit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Dividends paid to stockholders", "label": "Payments of Ordinary Dividends, Common Stock", "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity." } } }, "auth_ref": [ "r150" ] }, "mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "PaymentsToAcquireBusinessFiveNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquisition of Eyebiotech Limited, net of cash acquired", "label": "Payments to Acquire Business Five, Net of Cash Acquired", "documentation": "Payments to Acquire Business Five, Net of Cash Acquired" } } }, "auth_ref": [] }, "mrk_PaymentsToAcquireBusinessFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "PaymentsToAcquireBusinessFour", "crdr": "credit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquisition of Elanco Animal Health Incorporated aqua business", "label": "Payments to Acquire Business Four", "documentation": "Payments to Acquire Business Four" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessThreeNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquisition of Prometheus Biosciences, Inc., net of cash acquired", "label": "Payments to Acquire Business Three, Net of Cash Acquired", "documentation": "The cash outflow associated with a third acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r1376" ] }, "us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessTwoNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquisition of Imago BioSciences Inc., net of cash acquired", "label": "Payments to Acquire Business Two, Net of Cash Acquired", "documentation": "The cash outflow associated with a second acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r1376" ] }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for acquisition of business", "label": "Payments to Acquire Businesses, Gross", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": [ "r35", "r746" ] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Acquisition of Harpoon Therapeutics, Inc., net of cash acquired", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r35" ] }, "mrk_PaymentsToAcquireGlobalRights": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "PaymentsToAcquireGlobalRights", "crdr": "credit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquisition of MK-1045 from Curon Pharmaceutical", "label": "Payments to Acquire Global Rights", "documentation": "Payments to Acquire Global Rights" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireInvestments", "crdr": "credit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of securities and other investments", "label": "Payments to Acquire Investments", "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period." } } }, "auth_ref": [ "r148" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Capital expenditures", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r149" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r1289" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r1289" ] }, "us-gaap_PendingLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PendingLitigationMember", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pending Litigation", "label": "Pending Litigation [Member]", "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process." } } }, "auth_ref": [ "r1445" ] }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans" ], "lang": { "en-us": { "role": { "terseLabel": "Pension and Other Postretirement Benefit Plans", "label": "Retirement Benefits [Text Block]", "documentation": "The entire disclosure for retirement benefits." } } }, "auth_ref": [ "r566", "r592", "r594", "r600", "r619", "r621", "r622", "r623", "r624", "r625", "r640", "r641", "r643", "r1160" ] }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities", "crdr": "credit", "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails": { "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Accrued and other current liabilities", "label": "Liability, Defined Benefit Plan, Current", "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current." } } }, "auth_ref": [ "r111", "r567", "r568", "r591", "r1160" ] }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails": { "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Other Noncurrent Liabilities", "label": "Liability, Defined Benefit Plan, Noncurrent", "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent." } } }, "auth_ref": [ "r116", "r567", "r568", "r591", "r1160" ] }, "mrk_PensionPlanNetLossMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "PensionPlanNetLossMember", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Plan Net Loss", "label": "Pension Plan Net Loss [Member]", "documentation": "Pension Plan Net Loss [Member]" } } }, "auth_ref": [] }, "mrk_PensionPlanPriorServiceCostMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "PensionPlanPriorServiceCostMember", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Plan Prior Service Credit", "label": "Pension Plan Prior Service Cost [Member]", "documentation": "Pension Plan Prior Service Cost [Member]" } } }, "auth_ref": [] }, "us-gaap_PensionPlansDefinedBenefitMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionPlansDefinedBenefitMember", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits", "label": "Pension Plan [Member]", "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits." } } }, "auth_ref": [ "r567", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r615", "r617", "r618", "r620", "r623", "r626", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r643", "r644", "r648", "r1160", "r1161", "r1165", "r1166", "r1167" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r1281" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r1298" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r1291" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r1280" ] }, "us-gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PerformanceSharesMember", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails", "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PSUs", "label": "Performance Shares [Member]", "documentation": "Share-based payment arrangement awarded for meeting performance target." } } }, "auth_ref": [] }, "mrk_PharmaceuticalsegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "PharmaceuticalsegmentMember", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails", "http://www.merck.com/role/SegmentReportingEquityIncomefromAffiliatesandDepreciationIncludedinSegmentProfitsDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails", "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Pharmaceutical", "label": "Pharmaceutical segment [Member]", "documentation": "Pharmaceutical segment." } } }, "auth_ref": [] }, "mrk_PifeltroMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "PifeltroMember", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pifeltro", "label": "Pifeltro [Member]", "documentation": "Pifeltro" } } }, "auth_ref": [] }, "us-gaap_PlanAssetCategoriesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanAssetCategoriesDomain", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Domain]", "label": "Defined Benefit Plan, Plan Assets, Category [Domain]", "documentation": "Defined benefit plan asset investment." } } }, "auth_ref": [ "r592", "r593", "r595", "r596", "r597", "r598", "r599", "r600", "r620", "r1158", "r1159", "r1160" ] }, "mrk_Pneumovax23Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "Pneumovax23Member", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pneumovax 23", "label": "Pneumovax 23 [Member]", "documentation": "Pneumovax 23[Member]." } } }, "auth_ref": [] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]" } } }, "auth_ref": [ "r1282" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r1338" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r1281" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.merck.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r121", "r1015" ] }, "us-gaap_PrepaidExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssets", "crdr": "debit", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsModernaIncNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capitalization of shared costs", "label": "Prepaid Expense and Other Assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets." } } }, "auth_ref": [] }, "mrk_PrevymisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "PrevymisMember", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prevymis", "label": "Prevymis [Member]", "documentation": "Prevymis" } } }, "auth_ref": [] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassifications", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r1361" ] }, "mrk_ProQuadMMRIIVarivaxMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "ProQuadMMRIIVarivaxMember", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ProQuad/M-M-R II/Varivax", "label": "ProQuad MMR II Varivax [Member]", "documentation": "ProQuad/M-M-R II/Varivax [Member]." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromCollaborators": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromCollaborators", "crdr": "debit", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from collaborators", "label": "Proceeds from Collaborators", "documentation": "Cash received from collaborators during the current period." } } }, "auth_ref": [ "r154" ] }, "us-gaap_ProceedsFromIssuanceOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfDebt", "crdr": "debit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of debt", "label": "Proceeds from Issuance of Debt", "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt." } } }, "auth_ref": [ "r1378" ] }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "crdr": "debit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Proceeds from (Payments for) Other Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities classified as other." } } }, "auth_ref": [ "r1349", "r1377" ] }, "us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleAndMaturityOfOtherInvestments", "crdr": "debit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sales of securities and other investments", "label": "Proceeds from Sale and Maturity of Other Investments", "documentation": "The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy." } } }, "auth_ref": [ "r34" ] }, "us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfEquitySecuritiesFvNi", "crdr": "debit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of Seagen Inc. common stock", "label": "Proceeds from Sale of Equity Securities, FV-NI", "documentation": "Amount of cash inflow from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity." } } }, "auth_ref": [ "r215", "r289" ] }, "us-gaap_ProceedsFromSaleOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue related to the sale of the marketing rights", "label": "Proceeds from Sale of Intangible Assets", "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": [ "r147" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows", "http://www.merck.com/role/ShareBasedCompensationPlansAdditionalInformationPertainingtoStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of stock options", "verboseLabel": "Cash received from the exercise of stock options", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r7", "r20" ] }, "mrk_ProceedsFromUpfrontPaymentCash": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "ProceedsFromUpfrontPaymentCash", "crdr": "credit", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails", "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Upfront cash payment", "label": "Proceeds from Upfront Payment, Cash", "documentation": "Proceeds from Upfront Payment, Cash" } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCDetails", "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsRidgebackBiotherapeuticsLPDetails", "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r379", "r873", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r1111", "r1155", "r1200", "r1202", "r1203", "r1207", "r1210", "r1448", "r1449", "r1453", "r1531", "r1535", "r1536", "r1537", "r1538", "r1539", "r1540", "r1541", "r1542", "r1543", "r1544", "r1545", "r1546", "r1547", "r1548", "r1549", "r1550", "r1551", "r1552", "r1553", "r1554", "r1555", "r1556", "r1557", "r1558", "r1559", "r1560", "r1562", "r1563" ] }, "mrk_ProductRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "ProductRightsMember", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product Rights - Clynay", "label": "Product Rights [Member]", "documentation": "Product Rights" } } }, "auth_ref": [] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCDetails", "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsRidgebackBiotherapeuticsLPDetails", "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r379", "r873", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r1111", "r1155", "r1200", "r1202", "r1203", "r1207", "r1210", "r1448", "r1449", "r1453", "r1531", "r1535", "r1536", "r1537", "r1538", "r1539", "r1540", "r1541", "r1542", "r1543", "r1544", "r1545", "r1546", "r1547", "r1548", "r1549", "r1550", "r1551", "r1552", "r1553", "r1554", "r1555", "r1556", "r1557", "r1558", "r1559", "r1560", "r1562", "r1563" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofIncome": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 }, "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows", "http://www.merck.com/role/ConsolidatedStatementofIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Net Income", "terseLabel": "Net income", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r240", "r274", "r277", "r290", "r299", "r315", "r321", "r324", "r325", "r421", "r503", "r504", "r506", "r507", "r508", "r509", "r510", "r512", "r513", "r743", "r750", "r752", "r755", "r756", "r780", "r798", "r911", "r930", "r984", "r1036", "r1054", "r1055", "r1174", "r1175", "r1226", "r1373", "r1450" ] }, "mrk_PrometheusBiosciencesIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "PrometheusBiosciencesIncMember", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prometheus Biosciences, Inc.", "label": "Prometheus Biosciences, Inc. [Member]", "documentation": "Prometheus Biosciences, Inc." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails", "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r12", "r829" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Property, plant and equipment (at cost)", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r162", "r246", "r927" ] }, "us-gaap_PropertyPlantAndEquipmentGrossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGrossAbstract", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment (at cost)", "label": "Property, Plant and Equipment, Gross [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet", "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Property, plant and equipment, net", "verboseLabel": "Property, plant and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r12", "r829", "r912", "r927", "r1190" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails", "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r162", "r829" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated useful life of property, plant and equipment", "label": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "us-gaap_PublicUtilitiesInventoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PublicUtilitiesInventoryAxis", "presentation": [ "http://www.merck.com/role/InventoriesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory [Axis]", "label": "Inventory [Axis]", "documentation": "Information by type of inventory held." } } }, "auth_ref": [ "r1368" ] }, "us-gaap_PublicUtilitiesInventoryTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PublicUtilitiesInventoryTypeDomain", "presentation": [ "http://www.merck.com/role/InventoriesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory [Domain]", "label": "Inventory [Domain]", "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale." } } }, "auth_ref": [ "r1368" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r1279" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r1279" ] }, "mrk_QuiTamMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "QuiTamMember", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Qui Tam", "label": "Qui Tam [Member]", "documentation": "Qui Tam" } } }, "auth_ref": [] }, "mrk_RaludotatugDeruxtecanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "RaludotatugDeruxtecanMember", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raludotatug Deruxtecan", "label": "Raludotatug Deruxtecan [Member]", "documentation": "Raludotatug Deruxtecan" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails", "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r495", "r496", "r498", "r499", "r592", "r646", "r678", "r679", "r680", "r691", "r786", "r842", "r851", "r868", "r960", "r962", "r970", "r1006", "r1007", "r1062", "r1066", "r1068", "r1069", "r1084", "r1106", "r1107", "r1139", "r1154", "r1168", "r1181", "r1182", "r1186", "r1187", "r1202", "r1214", "r1441", "r1452", "r1498", "r1522", "r1523", "r1524", "r1525", "r1526" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails", "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r495", "r496", "r498", "r499", "r592", "r646", "r678", "r679", "r680", "r691", "r786", "r842", "r851", "r868", "r960", "r962", "r970", "r1006", "r1007", "r1062", "r1066", "r1068", "r1069", "r1084", "r1106", "r1107", "r1139", "r1154", "r1168", "r1181", "r1182", "r1186", "r1187", "r1202", "r1214", "r1441", "r1452", "r1498", "r1522", "r1523", "r1524", "r1525", "r1526" ] }, "mrk_ReblozylMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "ReblozylMember", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reblozyl", "verboseLabel": "Alliance revenue - Reblozyl", "label": "Reblozyl [Member]", "documentation": "Reblozyl" } } }, "auth_ref": [] }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax", "crdr": "debit", "calculation": { "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Reclassification adjustments, pretax", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax", "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r32", "r281", "r805", "r810", "r811", "r933", "r1371" ] }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "crdr": "debit", "calculation": { "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Reclassification adjustments, net of taxes", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r27", "r32", "r281", "r805", "r810", "r811", "r933", "r1371" ] }, "us-gaap_ReclassificationFromAociCurrentPeriodTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationFromAociCurrentPeriodTax", "crdr": "credit", "calculation": { "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax", "label": "Reclassification from AOCI, Current Period, Tax", "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r6", "r273", "r280", "r933" ] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r282" ] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "documentation": "Item reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r282" ] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r282" ] }, "mrk_RecognizedAsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.merck.com/20241231", "localname": "RecognizedAsAbstract", "presentation": [ "http://www.merck.com/role/InventoriesInventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recognized as:", "label": "Recognized As [Abstract]", "documentation": "Recognized as." } } }, "auth_ref": [] }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "presentation": [ "http://www.merck.com/role/SegmentReportingTables" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Segment Profits to Income Before Taxes", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment." } } }, "auth_ref": [ "r47", "r48" ] }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "presentation": [ "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Unrecognized Tax Benefits [Roll Forward]", "label": "Unrecognized Tax Benefits [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r1246", "r1257", "r1267", "r1300" ] }, "mrk_RegulatoryMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "RegulatoryMilestonesMember", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Regulatory Milestones", "label": "Regulatory Milestones [Member]", "documentation": "Regulatory Milestones [Member]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Domain]", "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r384", "r620", "r831", "r832", "r918", "r925", "r1009", "r1010", "r1011", "r1012", "r1013", "r1033", "r1035", "r1061" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyMember", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r302", "r303", "r831", "r832", "r833", "r834", "r918", "r925", "r1009", "r1010", "r1011", "r1012", "r1013", "r1033", "r1035", "r1061" ] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Axis]", "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r831", "r832", "r1518" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Domain]", "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Axis]", "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r384", "r620", "r831", "r832", "r918", "r925", "r1009", "r1010", "r1011", "r1012", "r1013", "r1033", "r1035", "r1061", "r1518" ] }, "mrk_RemicadeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "RemicadeMember", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remicade", "label": "Remicade [Member]", "documentation": "Remicade [Member]." } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments on debt", "label": "Repayments of Long-Term Debt", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r151", "r980" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCDetails", "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsModernaIncDetails", "http://www.merck.com/role/CollaborativeArrangementsModernaIncNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsRidgebackBiotherapeuticsLPDetails", "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r304", "r305", "r518", "r544", "r834", "r852", "r913", "r1119", "r1120" ] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]", "documentation": "Information by form of arrangement related to research and development." } } }, "auth_ref": [ "r695", "r1467" ] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned", "crdr": "credit", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation earned on arragement", "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned", "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others." } } }, "auth_ref": [ "r696" ] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]", "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others." } } }, "auth_ref": [ "r695", "r1467" ] }, "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff", "crdr": "debit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Charges for certain research and development asset acquisitions", "label": "Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation, Writeoff", "documentation": "Amount of writeoff for research and development asset acquired in transaction other than business combination or from joint venture formation or both." } } }, "auth_ref": [ "r458", "r1108", "r1466" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofIncome": { "parentTag": "mrk_CostsExpensesAndOther", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCDetails", "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdDetails", "http://www.merck.com/role/CollaborativeArrangementsModernaIncDetails", "http://www.merck.com/role/CollaborativeArrangementsRidgebackBiotherapeuticsLPDetails", "http://www.merck.com/role/ConsolidatedStatementofIncome", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "negatedLabel": "Research and development", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r694", "r1108", "r1134", "r1527" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development", "label": "Research and Development Expense, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r693" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r1247", "r1258", "r1268", "r1301" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r1248", "r1259", "r1269", "r1302" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r1255", "r1266", "r1276", "r1309" ] }, "us-gaap_RestrictedCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalents", "crdr": "debit", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Cash, cash equivalents, and restricted cash", "label": "Restricted Cash and Cash Equivalents", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r36", "r198", "r244", "r295", "r919" ] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Cash and Cash Equivalents [Axis]", "label": "Restricted Cash and Cash Equivalents [Axis]", "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage." } } }, "auth_ref": [ "r107" ] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Domain]", "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r244" ] }, "us-gaap_RestrictedCashCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashCurrent", "crdr": "debit", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Funds collected from factoring of receivable, held in restricted cash", "label": "Restricted Cash, Current", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r1362", "r1383" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails", "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "RSUs", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Restructuring and Related Activities [Abstract]", "label": "Restructuring and Related Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": [ "http://www.merck.com/role/Restructuring" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring", "label": "Restructuring and Related Activities Disclosure [Text Block]", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": [ "r478", "r479", "r481", "r484", "r489" ] }, "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostCostIncurredToDate1", "crdr": "debit", "presentation": [ "http://www.merck.com/role/RestructuringNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative costs since inception", "label": "Restructuring and Related Cost, Cost Incurred to Date", "documentation": "Amount of costs incurred to date for the specified restructuring cost." } } }, "auth_ref": [ "r480", "r483", "r486", "r488" ] }, "us-gaap_RestructuringAndRelatedCostExpectedCost1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostExpectedCost1", "crdr": "debit", "presentation": [ "http://www.merck.com/role/RestructuringNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected restructuring and related cost", "label": "Restructuring and Related Cost, Expected Cost", "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost." } } }, "auth_ref": [ "r480", "r483", "r486", "r488" ] }, "us-gaap_RestructuringAndRelatedCostIncurredCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostIncurredCost", "crdr": "debit", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails", "http://www.merck.com/role/RestructuringNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Total pretax restructuring costs", "terseLabel": "Expenses", "label": "Restructuring and Related Cost, Incurred Cost", "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost." } } }, "auth_ref": [ "r480", "r483", "r486", "r488" ] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCharges", "crdr": "debit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofIncome": { "parentTag": "mrk_CostsExpensesAndOther", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofIncome", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring costs", "negatedLabel": "Restructuring costs", "label": "Restructuring Charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r11", "r485", "r486", "r1443" ] }, "us-gaap_RestructuringChargesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringChargesMember", "presentation": [ "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring costs", "label": "Restructuring Charges [Member]", "documentation": "Primary financial statement caption in which the reported facts about restructuring charges have been included." } } }, "auth_ref": [ "r163", "r166" ] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveAxis", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Type [Axis]", "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": [ "r480", "r481", "r486", "r487" ] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveLineItems", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails", "http://www.merck.com/role/RestructuringNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Cost and Reserve [Line Items]", "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r480", "r481", "r482", "r483", "r486", "r487", "r488" ] }, "us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "presentation": [ "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]", "label": "Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes restructuring charges." } } }, "auth_ref": [ "r1344", "r1345" ] }, "us-gaap_RestructuringPlanAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanAxis", "presentation": [ "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails", "http://www.merck.com/role/RestructuringNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Axis]", "label": "Restructuring Plan [Axis]", "documentation": "Information by individual restructuring plan." } } }, "auth_ref": [] }, "us-gaap_RestructuringPlanDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanDomain", "presentation": [ "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails", "http://www.merck.com/role/RestructuringNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Domain]", "label": "Restructuring Plan [Domain]", "documentation": "Identification of the individual restructuring plans." } } }, "auth_ref": [] }, "mrk_RestructuringProgram2019Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "RestructuringProgram2019Member", "presentation": [ "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails", "http://www.merck.com/role/RestructuringNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2019 Restructuring Program", "label": "Restructuring Program, 2019 [Member]", "documentation": "Restructuring Program, 2019" } } }, "auth_ref": [] }, "mrk_RestructuringProgram2024And2019Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "RestructuringProgram2024And2019Member", "presentation": [ "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Program, 2024 and 2019", "label": "Restructuring Program, 2024 and 2019 [Member]", "documentation": "Restructuring Program, 2024 and 2019" } } }, "auth_ref": [] }, "mrk_RestructuringProgram2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "RestructuringProgram2024Member", "presentation": [ "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails", "http://www.merck.com/role/RestructuringNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024 Restructuring Program", "label": "Restructuring Program, 2024 [Member]", "documentation": "Restructuring Program, 2024" } } }, "auth_ref": [] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserve", "crdr": "credit", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Restructuring reserve, beginning balance", "periodEndLabel": "Restructuring reserve, ending balance", "label": "Restructuring Reserve", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": [ "r481", "r487" ] }, "mrk_RestructuringReserveIncreaseDecreaseNoncashActivity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "RestructuringReserveIncreaseDecreaseNoncashActivity", "crdr": "credit", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash activity", "label": "Restructuring Reserve, Increase (Decrease) Noncash Activity", "documentation": "Noncash activity affecting the restructuring reserve, including accelerated depreciation." } } }, "auth_ref": [] }, "us-gaap_RestructuringReserveRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveRollForward", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Reserve [Roll Forward]", "label": "Restructuring Reserve [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r125", "r174", "r922", "r967", "r969", "r981", "r1016", "r1190" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Retained Earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r236", "r312", "r313", "r314", "r316", "r321", "r323", "r325", "r422", "r423", "r469", "r732", "r733", "r740", "r741", "r742", "r744", "r749", "r750", "r770", "r772", "r773", "r775", "r778", "r815", "r818", "r964", "r966", "r985", "r1566" ] }, "us-gaap_RetirementPlanSponsorLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanSponsorLocationAxis", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Sponsor Location [Axis]", "label": "Retirement Plan Sponsor Location [Axis]", "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [ "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r615", "r616", "r617", "r618", "r620", "r623", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r1461", "r1462", "r1463" ] }, "us-gaap_RetirementPlanSponsorLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanSponsorLocationDomain", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Sponsor Location [Domain]", "label": "Retirement Plan Sponsor Location [Domain]", "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": [ "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r615", "r616", "r617", "r618", "r620", "r623", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r1461", "r1462", "r1463" ] }, "us-gaap_RetirementPlanTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanTypeAxis", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Type [Axis]", "label": "Retirement Plan Type [Axis]", "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } }, "auth_ref": [ "r567", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r615", "r617", "r618", "r620", "r623", "r626", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r643", "r644", "r645", "r648", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167" ] }, "us-gaap_RetirementPlanTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanTypeDomain", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Type [Domain]", "label": "Retirement Plan Type [Domain]", "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } }, "auth_ref": [ "r567", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r615", "r617", "r618", "r620", "r623", "r626", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r643", "r644", "r645", "r648", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167" ] }, "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer", "crdr": "credit", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCDetails", "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from collaborative arrangement", "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer", "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606." } } }, "auth_ref": [ "r217", "r1487" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r233", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r1109" ] }, "mrk_RevenuePerformanceObligationPaymentTerms": { "xbrltype": "durationItemType", "nsuri": "http://www.merck.com/20241231", "localname": "RevenuePerformanceObligationPaymentTerms", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payment terms", "label": "Revenue, Performance Obligation, Payment Terms", "documentation": "Revenue, Performance Obligation, Payment Terms" } } }, "auth_ref": [] }, "mrk_RevenuePerformanceObligationVaccineSalesPaymentTerms": { "xbrltype": "durationItemType", "nsuri": "http://www.merck.com/20241231", "localname": "RevenuePerformanceObligationVaccineSalesPaymentTerms", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payment terms, vaccine sales", "label": "Revenue, Performance Obligation, Vaccine Sales, Payment Terms", "documentation": "Revenue, Performance Obligation, Vaccine Sales, Payment Terms" } } }, "auth_ref": [] }, "mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate": { "xbrltype": "durationItemType", "nsuri": "http://www.merck.com/20241231", "localname": "RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product return period and expiration", "label": "Revenue Recognition, Goods, Goods Return Period After to Expiration Date", "documentation": "Revenue Recognition, Goods, Goods Return Period After to Expiration Date" } } }, "auth_ref": [] }, "mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate": { "xbrltype": "durationItemType", "nsuri": "http://www.merck.com/20241231", "localname": "RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product return period", "label": "Revenue Recognition, Goods, Goods Return Period Prior to Expiration Date", "documentation": "Revenue Recognition, Goods, Goods Return Period Prior to Expiration Date" } } }, "auth_ref": [] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofIncome": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/CollaborativeArrangementsRidgebackBiotherapeuticsLPDetails", "http://www.merck.com/role/ConsolidatedStatementofIncome", "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails", "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r210", "r211", "r283", "r299", "r346", "r355", "r356", "r370", "r376", "r379", "r381", "r383", "r421", "r503", "r504", "r506", "r507", "r508", "r509", "r510", "r512", "r513", "r798", "r911", "r1134", "r1450" ] }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "presentation": [ "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]", "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "mrk_RidgebackBiotherapeuticsLPMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "RidgebackBiotherapeuticsLPMember", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsRidgebackBiotherapeuticsLPDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ridgeback Biotherapeutics LP", "label": "Ridgeback Biotherapeutics LP [Member]", "documentation": "Ridgeback Biotherapeutics LP" } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use asset obtained in exchange for operating lease liability", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r825", "r1189" ] }, "mrk_RotateqMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "RotateqMember", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "RotaTeq", "label": "Rotateq [Member]", "documentation": "RotaTeq [Member]" } } }, "auth_ref": [] }, "mrk_RoyaltyPharmaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "RoyaltyPharmaMember", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty Pharma", "label": "Royalty Pharma [Member]", "documentation": "Royalty Pharma" } } }, "auth_ref": [] }, "mrk_RoyaltyRateDeductionPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.merck.com/20241231", "localname": "RoyaltyRateDeductionPercentage", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty rate, deduction, percentage", "label": "Royalty Rate, Deduction, Percentage", "documentation": "Royalty Rate, Deduction, Percentage" } } }, "auth_ref": [] }, "mrk_RoyaltyRatePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.merck.com/20241231", "localname": "RoyaltyRatePercentage", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty rate, percentage", "label": "Royalty Rate, Percentage", "documentation": "Royalty Rate, Percentage" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r1318" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r1318" ] }, "mrk_SalesDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "SalesDiscounts", "crdr": "debit", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer discounts", "label": "Sales Discounts", "documentation": "Sales Discounts" } } }, "auth_ref": [] }, "us-gaap_SalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales", "label": "Sales [Member]", "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business." } } }, "auth_ref": [ "r23" ] }, "mrk_SanofiPasteurMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "SanofiPasteurMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sanofi Pasteur", "label": "Sanofi Pasteur [Member]", "documentation": "Sanofi Pasteur [Member]" } } }, "auth_ref": [] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioForecastMember", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forecast", "label": "Forecast [Member]" } } }, "auth_ref": [ "r647", "r1393" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Domain]", "label": "Scenario [Domain]" } } }, "auth_ref": [ "r326", "r647", "r1346", "r1393" ] }, "us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Funded Status of Selected Pension Plans", "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Table Text Block]", "documentation": "Tabular disclosure of benefit obligation and plan assets of defined benefit plan with accumulated benefit obligation in excess of plan assets." } } }, "auth_ref": [ "r1160", "r1458", "r1459" ] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossTables" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in AOCI by Component", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r32", "r1511", "r1512" ] }, "us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAllocationOfPlanAssetsTableTextBlock", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Allocation of Plan Assets", "label": "Schedule of Allocation of Plan Assets [Table Text Block]", "documentation": "Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall." } } }, "auth_ref": [ "r176" ] }, "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAssumptionsUsedTableTextBlock", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Weighted Average Assumptions Used in Determining Pension Plan and U.S. Pension and Other Postretirement Benefit Plan Information", "label": "Defined Benefit Plan, Assumptions [Table Text Block]", "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate." } } }, "auth_ref": [ "r614" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale [Line Items]", "label": "Debt Securities, Available-for-Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Information on Investments in Debt and Equity Securities", "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Funded Status of Selected Pension Plans", "label": "Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block]", "documentation": "Tabular disclosure of benefit obligation and plan assets for defined benefit pension plan with projected benefit obligation in excess of plan assets." } } }, "auth_ref": [ "r1160", "r1458" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]", "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]", "documentation": "Disclosure of information about contingent consideration arrangement in business combination." } } }, "auth_ref": [ "r191" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability." } } }, "auth_ref": [ "r71", "r72", "r745" ] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCDetails", "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsModernaIncDetails", "http://www.merck.com/role/CollaborativeArrangementsModernaIncNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsRidgebackBiotherapeuticsLPDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r751" ] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangements", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]", "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r1487" ] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://www.merck.com/role/TaxesonIncomeTables" ], "lang": { "en-us": { "role": { "terseLabel": "Taxes on Income", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r1480" ] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r29", "r60", "r63", "r104", "r172", "r173", "r1150", "r1152", "r1389", "r1513" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://www.merck.com/role/TaxesonIncomeTables" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Income Taxes", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r1474" ] }, "us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Components of Other Comprehensive Income (Loss)", "label": "Schedule of Defined Benefit Plan Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the changes in plan assets and benefit obligations recognized in other comprehensive income (loss) during the period." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan [Table]", "label": "Defined Benefit Plan [Table]", "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r14", "r66", "r67", "r68", "r69" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Location and Pretax Gain or Loss Amounts for Derivatives", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r89", "r92", "r765" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value of Derivatives on a Gross Basis Segregated Between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position." } } }, "auth_ref": [ "r90" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.merck.com/role/EarningsperShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Calculations of Earnings Per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r1396" ] }, "us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Changes in Fair Value of Company's Level 3 Pension Plan Assets", "label": "Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets [Table Text Block]", "documentation": "Tabular disclosure of the effect of fair value measurements using significant unobservable inputs (Level 3) on changes in plan assets of pension plans and/or other employee benefit plans for the period." } } }, "auth_ref": [ "r1455" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://www.merck.com/role/TaxesonIncomeTables" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation Between Effective Tax Rate and U.S. Statutory Rate", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r707", "r1172", "r1469" ] }, "us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock", "presentation": [ "http://www.merck.com/role/SegmentReportingTables" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Net by Geographic Area", "label": "Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]", "documentation": "Tabular disclosure of the names of foreign countries in which material long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets are located, and amount of such long-lived assets located in that country or foreign geographic area." } } }, "auth_ref": [ "r160" ] }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "presentation": [ "http://www.merck.com/role/SegmentReportingTables" ], "lang": { "en-us": { "role": { "terseLabel": "Sales of Company's Products", "label": "Revenue from External Customers by Products and Services [Table Text Block]", "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information." } } }, "auth_ref": [ "r49" ] }, "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Expected Benefit Payments", "label": "Schedule of Expected Benefit Payments [Table Text Block]", "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter." } } }, "auth_ref": [ "r177" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r1495", "r1496" ] }, "us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position", "label": "Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]", "documentation": "Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position." } } }, "auth_ref": [ "r93" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails", "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Asset, Finite-Lived [Table]", "label": "Intangible Asset, Finite-Lived [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": [ "r452", "r460", "r464", "r465", "r467", "r874", "r1108", "r1142" ] }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTable", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Table]", "label": "Goodwill [Table]", "documentation": "Disclosure of information about goodwill, including, but not limited to, change from acquisition, sale, impairment, and other reason." } } }, "auth_ref": [ "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r1141" ] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill Activity by Segment", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r1141", "r1413", "r1414", "r1415", "r1416", "r1417", "r1418", "r1419", "r1420", "r1421", "r1422", "r1423" ] }, "us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfHealthCareCostTrendRatesTableTextBlock", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Health Care Cost Trend Rate Assumptions for Other Postretirement Benefit Plans", "label": "Schedule of Health Care Cost Trend Rates [Table Text Block]", "documentation": "Tabular disclosure of the assumed health care cost trend rates for the next year used to measure the expected cost of benefits covered by the plans, including the ultimate trend rate(s) and when that rate is expected to be achieved." } } }, "auth_ref": [ "r179" ] }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "presentation": [ "http://www.merck.com/role/TaxesonIncomeTables" ], "lang": { "en-us": { "role": { "terseLabel": "Income Before Taxes", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions." } } }, "auth_ref": [ "r1387" ] }, "mrk_ScheduleOfIncomeTaxesPaidTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.merck.com/20241231", "localname": "ScheduleOfIncomeTaxesPaidTableTextBlock", "presentation": [ "http://www.merck.com/role/TaxesonIncomeTables" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes Paid", "label": "Schedule of Income Taxes Paid [Table Text Block]", "documentation": "Schedule of Income Taxes Paid" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Other Intangibles", "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class." } } }, "auth_ref": [ "r1412", "r1424" ] }, "us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInterestRateDerivativesTableTextBlock", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Interest Rate Derivatives", "label": "Schedule of Interest Rate Derivatives [Table Text Block]", "documentation": "Tabular disclosure of interest rate derivatives, including, but not limited to, the fair value of the derivatives, statement of financial position location, and statement of financial performance location of these instruments." } } }, "auth_ref": [ "r92" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.merck.com/role/InventoriesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r30", "r130", "r131", "r132" ] }, "us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryNoncurrentTableTextBlock", "presentation": [ "http://www.merck.com/role/InventoriesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Schedule of Inventory, Noncurrent [Table Text Block]", "documentation": "Tabular disclosure of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle including inventoried costs relating to long-term contracts or programs." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Components of Net Periodic Benefit Cost", "label": "Schedule of Net Benefit Costs [Table Text Block]", "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments." } } }, "auth_ref": [ "r178" ] }, "us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of Net Investment Hedges", "label": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period." } } }, "auth_ref": [ "r1492" ] }, "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Effects of Derivatives Not Designated as Hedging Instruments", "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]", "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument." } } }, "auth_ref": [ "r94", "r1351" ] }, "mrk_ScheduleOfOtherIntangiblesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.merck.com/20241231", "localname": "ScheduleOfOtherIntangiblesTable", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Other Intangibles [Table]", "label": "Schedule Of Other Intangibles [Table]", "documentation": "Schedule Of Other Intangibles [Table]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Other (Income) Expense, Net", "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree." } } }, "auth_ref": [ "r188" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails", "http://www.merck.com/role/RestructuringNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Cost [Table]", "label": "Restructuring Cost [Table]", "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve." } } }, "auth_ref": [ "r480", "r481", "r482", "r483", "r486", "r487", "r488" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "presentation": [ "http://www.merck.com/role/RestructuringTables" ], "lang": { "en-us": { "role": { "terseLabel": "Charges Related to Restructuring Program Activities by Type of Cost", "label": "Restructuring and Related Costs [Table Text Block]", "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets." } } }, "auth_ref": [ "r54", "r163", "r164" ] }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "presentation": [ "http://www.merck.com/role/RestructuringTables" ], "lang": { "en-us": { "role": { "terseLabel": "Charges and Spending Relating to Restructuring Activities by Program", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period." } } }, "auth_ref": [ "r55", "r165" ] }, "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "presentation": [ "http://www.merck.com/role/SegmentReportingTables" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidated Revenues by Geographic Area", "label": "Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]", "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries." } } }, "auth_ref": [ "r139", "r159" ] }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "presentation": [ "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "documentation": "Disclosure of information about revenue from external customer and long-lived asset by geographical area. Long-lived asset excludes financial instrument, customer relationship with financial institution, mortgage and other servicing right, deferred policy acquisition cost, and deferred tax asset." } } }, "auth_ref": [ "r50", "r139" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.merck.com/role/SegmentReportingEquityIncomefromAffiliatesandDepreciationIncludedinSegmentProfitsDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": [ "r44", "r45", "r46" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://www.merck.com/role/SegmentReportingTables" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Loss from Affiliates and Depreciation Included in Segment Profits", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r44", "r45", "r46" ] }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Nonvested RSU and PSU Activity", "label": "Share-Based Payment Arrangement, Activity [Table Text Block]", "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value." } } }, "auth_ref": [ "r18", "r19", "r181" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails", "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r650", "r651", "r653", "r654", "r655", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r677", "r678", "r679", "r680", "r681" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summarized Information Relative to Stock Option Plan Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r18", "r19", "r180" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Assumptions Used to Determine Weighted-Average Fair Value of Options Granted", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r183" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.merck.com/role/EquityShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock, Class of Stock [Table]", "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": [ "r58", "r59", "r60", "r61", "r62", "r63", "r170", "r172", "r173", "r174", "r256", "r257", "r258", "r348", "r542", "r543", "r544", "r546", "r549", "r554", "r556", "r977", "r978", "r979", "r980", "r1154", "r1341", "r1384" ] }, "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityTableTextBlock", "presentation": [ "http://www.merck.com/role/EquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Common Stock and Treasury Stock Transactions", "label": "Schedule of Stockholders Equity [Table Text Block]", "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented." } } }, "auth_ref": [ "r16" ] }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "presentation": [ "http://www.merck.com/role/TaxesonIncomeTables" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized Tax Benefits", "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "documentation": "Tabular disclosure of the change in unrecognized tax benefits." } } }, "auth_ref": [ "r716", "r1171" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1228" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r1231" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails", "http://www.merck.com/role/SegmentReportingEquityIncomefromAffiliatesandDepreciationIncludedinSegmentProfitsDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails", "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r210", "r211", "r212", "r213", "r346", "r351", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r376", "r377", "r378", "r383", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r467", "r483", "r488", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r1131", "r1134", "r1135", "r1141", "r1205", "r1531", "r1535", "r1536", "r1537", "r1538", "r1539", "r1540", "r1541", "r1542", "r1543", "r1544", "r1545", "r1546", "r1547", "r1548", "r1549", "r1550", "r1551", "r1552", "r1553", "r1554", "r1555", "r1556", "r1557", "r1558", "r1559", "r1560", "r1562", "r1563" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails", "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails", "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": [ "r381", "r382", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r999", "r1002", "r1004", "r1063", "r1067", "r1070", "r1085", "r1093", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1112", "r1156", "r1192", "r1193", "r1194", "r1195", "r1196", "r1197", "r1198", "r1199", "r1204", "r1214", "r1453", "r1531", "r1535", "r1536", "r1538", "r1539", "r1540", "r1541", "r1542", "r1543", "r1544", "r1545", "r1546", "r1547", "r1548", "r1549", "r1550", "r1551", "r1552", "r1553", "r1554", "r1555", "r1556", "r1557", "r1558", "r1559", "r1560", "r1562", "r1563" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.merck.com/role/SegmentReporting" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r213", "r346", "r350", "r351", "r352", "r353", "r354", "r366", "r368", "r369", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r383", "r1130", "r1132", "r1133", "r1134", "r1136", "r1137", "r1138" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.merck.com/role/SegmentReportingEquityIncomefromAffiliatesandDepreciationIncludedinSegmentProfitsDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "mrk_SegmentReportingUnallocatedOtherExpensesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "SegmentReportingUnallocatedOtherExpensesNet", "crdr": "debit", "presentation": [ "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Other unallocated, net", "label": "Segment Reporting Unallocated Other Expenses Net", "documentation": "Other net expenses not allocated to segments." } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofIncome": { "parentTag": "mrk_CostsExpensesAndOther", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCDetails", "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdDetails", "http://www.merck.com/role/CollaborativeArrangementsModernaIncDetails", "http://www.merck.com/role/CollaborativeArrangementsRidgebackBiotherapeuticsLPDetails", "http://www.merck.com/role/ConsolidatedStatementofIncome", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r145" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [ "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeniorNotesMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails", "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes", "label": "Senior Notes [Member]", "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors." } } }, "auth_ref": [] }, "us-gaap_SettledLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SettledLitigationMember", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Settled Litigation", "label": "Settled Litigation [Member]", "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval." } } }, "auth_ref": [ "r1445" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows", "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Share-based compensation", "terseLabel": "Pretax share-based compensation cost recorded, related to continuing operations", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r10" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Period over which share-based payment awards vest", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period", "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1169" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contractual term of options", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r1169" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of Shares, Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r670" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant Date Fair Value, Forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r670" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Shares, Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r668" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant Date Fair Value, Granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r668" ] }, "mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber": { "xbrltype": "sharesItemType", "nsuri": "http://www.merck.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Shares, Expected to Vest (in shares)", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Expected to Vest, Number", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Expected to Vest, Number" } } }, "auth_ref": [] }, "mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.merck.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant Date Fair Value, Expected to vest (in dollars per share)", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Expected to Vest, Weighted Average Grant Date Fair Value", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Expected to Vest, Weighted Average Grant Date Fair Value" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of Shares, Nonvested January 1 (in shares)", "periodEndLabel": "Number of Shares, Nonvested December 31 (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r665", "r666" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted Average Grant Date Fair Value, Nonvested January 1 (in dollars per share)", "periodEndLabel": "Weighted Average Grant Date Fair Value, Nonvested December 31 (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r665", "r666" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of Shares, Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r669" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant Date Fair Value, Vested (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r669" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected dividend yield", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r679" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r678" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r680" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails", "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r650", "r651", "r653", "r654", "r655", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r677", "r678", "r679", "r680", "r681" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares collectively authorized for future grants under share-based compensation plans (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r70" ] }, "mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.merck.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Information Pertaining to Stock Option Plans", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures [Table Text Block]", "documentation": "Additional information pertaining to stock option plans." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Options, Exercisable (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r659" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price, Exercisable (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r659" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansAdditionalInformationPertainingtoStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total intrinsic value of stock options exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": [ "r672" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of Options, Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r663" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Options, Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r661" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average fair value of options granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r671" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value, Outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r70" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of Options, Outstanding, January 1 (in shares)", "periodEndLabel": "Number of Options, Outstanding, December 31 (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r657", "r658" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of\u00a0Options", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted Average Exercise Price, Options Outstanding, January 1 (in dollars per share)", "periodEndLabel": "Weighted Average Exercise Price, Options Outstanding, December 31 (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r657", "r658" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r673" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Options, Vested and expected to vest (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r673" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price, Vested and expected to vest (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r673" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails", "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r653", "r654", "r655", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r677", "r678", "r679", "r680", "r681" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price, Exercised (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r662" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price, Forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r663" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails", "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price of options granted (in dollars per share)", "verboseLabel": "Weighted Average Exercise Price, Granted (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r661" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r649", "r656", "r675", "r676", "r677", "r678", "r681", "r687", "r688", "r689", "r690" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Quantity of stock options that vest per year", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": [ "r1464" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected life (years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r677" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value, Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r70" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Term, Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r70" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Term, Outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r182" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Term, Vested and expected to vest", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r673" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "crdr": "credit", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansAdditionalInformationPertainingtoStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of stock options vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value", "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock." } } }, "auth_ref": [ "r672" ] }, "us-gaap_ShortTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeAxis", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term Debt, Type [Axis]", "label": "Short-Term Debt, Type [Axis]", "documentation": "Information by type of short-term debt arrangement." } } }, "auth_ref": [ "r110", "r1438", "r1439", "r1440" ] }, "us-gaap_ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeDomain", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term Debt, Type [Domain]", "label": "Short-Term Debt, Type [Domain]", "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "auth_ref": [ "r108", "r1438", "r1439", "r1440" ] }, "us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtWeightedAverageInterestRateOverTime", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average interest rate of commercial paper", "label": "Short-Term Debt, Weighted Average Interest Rate, over Time", "documentation": "Weighted average interest rate of short-term debt outstanding calculated over time." } } }, "auth_ref": [] }, "mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "SichuanKelunBiotechBiopharmaceuticalCoLtdMember", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.", "label": "Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. [Member]", "documentation": "Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r157", "r296" ] }, "us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems", "presentation": [ "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]", "label": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r214" ] }, "us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable", "presentation": [ "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Unrecognized Tax Benefit, Reasonably Possible [Table]", "label": "Change in Unrecognized Tax Benefit, Reasonably Possible [Table]", "documentation": "Disclosure of information about unrecognized tax benefit for which significant change is reasonably possible within 12 months. Includes, but is not limited to, nature of uncertainty, nature of event that could cause significant change within 12 months, and estimate of range of reasonably possible change or statement of fact that estimate of range cannot be made." } } }, "auth_ref": [ "r214" ] }, "mrk_SimponiMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "SimponiMember", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Simponi", "label": "Simponi [Member]", "documentation": "Simponi [Member]." } } }, "auth_ref": [] }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capitalized Software", "label": "Software and Software Development Costs [Member]", "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use." } } }, "auth_ref": [] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails", "http://www.merck.com/role/SegmentReportingEquityIncomefromAffiliatesandDepreciationIncludedinSegmentProfitsDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails", "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r210", "r211", "r212", "r213", "r238", "r346", "r351", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r376", "r377", "r378", "r383", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r467", "r471", "r483", "r488", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r1131", "r1134", "r1135", "r1141", "r1205", "r1531", "r1535", "r1536", "r1537", "r1538", "r1539", "r1540", "r1541", "r1542", "r1543", "r1544", "r1545", "r1546", "r1547", "r1548", "r1549", "r1550", "r1551", "r1552", "r1553", "r1554", "r1555", "r1556", "r1557", "r1558", "r1559", "r1560", "r1562", "r1563" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r235", "r256", "r257", "r258", "r299", "r331", "r332", "r339", "r341", "r348", "r349", "r421", "r503", "r506", "r507", "r508", "r512", "r513", "r542", "r543", "r546", "r549", "r556", "r798", "r977", "r978", "r979", "r980", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r1015", "r1037", "r1056", "r1086", "r1087", "r1088", "r1089", "r1090", "r1341", "r1384", "r1395" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofEquity", "http://www.merck.com/role/EquityShareholdersEquityDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails", "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r16", "r122", "r126", "r127", "r236", "r280", "r281", "r282", "r312", "r313", "r314", "r316", "r321", "r323", "r325", "r347", "r422", "r423", "r469", "r557", "r732", "r733", "r740", "r741", "r742", "r744", "r749", "r750", "r770", "r771", "r772", "r773", "r774", "r775", "r778", "r805", "r807", "r808", "r809", "r810", "r811", "r815", "r818", "r830", "r933", "r964", "r965", "r966", "r985", "r1056" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails", "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails", "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": [ "r381", "r382", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r999", "r1002", "r1004", "r1063", "r1067", "r1070", "r1085", "r1093", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1112", "r1156", "r1192", "r1193", "r1194", "r1195", "r1196", "r1197", "r1198", "r1199", "r1204", "r1214", "r1453", "r1531", "r1535", "r1536", "r1538", "r1539", "r1540", "r1541", "r1542", "r1543", "r1544", "r1545", "r1546", "r1547", "r1548", "r1549", "r1550", "r1551", "r1552", "r1553", "r1554", "r1555", "r1556", "r1557", "r1558", "r1559", "r1560", "r1562", "r1563" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r312", "r313", "r314", "r347", "r818", "r873", "r972", "r996", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1015", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1029", "r1030", "r1031", "r1032", "r1033", "r1035", "r1038", "r1039", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1049", "r1050", "r1051", "r1052", "r1056", "r1215" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Axis]", "label": "Scenario [Axis]" } } }, "auth_ref": [ "r326", "r647", "r1346", "r1347", "r1393" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r312", "r313", "r314", "r347", "r384", "r818", "r873", "r972", "r996", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1015", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1029", "r1030", "r1031", "r1032", "r1033", "r1035", "r1038", "r1039", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1049", "r1050", "r1051", "r1052", "r1056", "r1215" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r1250", "r1261", "r1271", "r1304" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://www.merck.com/role/EquityShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Issuances (in shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r16", "r121", "r122", "r174" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of Options, Exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r16", "r121", "r122", "r174", "r662" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total Merck\u00a0& Co., Inc. stockholders\u2019 equity", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r122", "r126", "r127", "r161", "r1017", "r1034", "r1057", "r1058", "r1190", "r1227", "r1386", "r1411", "r1510", "r1566" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Merck\u00a0& Co., Inc. Stockholders\u2019 Equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityBeforeTreasuryStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityBeforeTreasuryStock", "crdr": "credit", "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Stockholders' equity before deduction for treasury stock", "label": "Stockholders' Equity before Treasury Stock", "documentation": "Total amount of stockholders' equity (deficit) items including stock value, paid in capital, retained earnings and including equity attributable to noncontrolling interests and before deducting the carrying value of treasury stock." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet", "http://www.merck.com/role/ConsolidatedStatementofEquity", "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r78", "r79", "r81", "r236", "r237", "r281", "r312", "r313", "r314", "r316", "r321", "r323", "r422", "r423", "r469", "r557", "r732", "r733", "r740", "r741", "r742", "r744", "r749", "r750", "r770", "r771", "r772", "r773", "r774", "r775", "r778", "r805", "r807", "r811", "r816", "r830", "r965", "r966", "r983", "r1017", "r1034", "r1057", "r1058", "r1091", "r1226", "r1386", "r1411", "r1510", "r1566" ] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.merck.com/role/Equity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r171", "r298", "r541", "r543", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r555", "r557", "r777", "r1059", "r1060", "r1092" ] }, "us-gaap_StockholdersEquityOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityOther", "crdr": "debit", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofEquity" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Share-based compensation plans and other", "label": "Stockholders' Equity, Other", "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r812", "r835" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r812", "r835" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r812", "r835" ] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r1297" ] }, "us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability", "crdr": "credit", "presentation": [ "http://www.merck.com/role/TaxesonIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transition tax for accumulated foreign earnings, liability", "label": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability", "documentation": "Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act." } } }, "auth_ref": [ "r1468" ] }, "us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent", "crdr": "credit", "presentation": [ "http://www.merck.com/role/TaxesonIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transition tax liability, current", "label": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability, Current", "documentation": "Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act, classified as current." } } }, "auth_ref": [ "r1468" ] }, "mrk_TaxCutsAndJobsActTransitionTaxCreditForAccumulatedForeignEarningsAssetsOtherNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "TaxCutsAndJobsActTransitionTaxCreditForAccumulatedForeignEarningsAssetsOtherNoncurrent", "crdr": "debit", "presentation": [ "http://www.merck.com/role/TaxesonIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transition tax asset, credit, noncurrent", "label": "Tax Cuts and Jobs Act, Transition Tax Credit for Accumulated Foreign Earnings, Assets, Other, Noncurrent", "documentation": "Tax Cuts and Jobs Act, Transition Tax Credit for Accumulated Foreign Earnings, Assets, Other, Noncurrent" } } }, "auth_ref": [] }, "us-gaap_TaxPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxPeriodAxis", "presentation": [ "http://www.merck.com/role/TaxesonIncomeNarrativeDetails", "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Period [Axis]", "label": "Tax Period [Axis]", "documentation": "Information by period subject to enacted tax law." } } }, "auth_ref": [ "r1473" ] }, "us-gaap_TaxPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxPeriodDomain", "presentation": [ "http://www.merck.com/role/TaxesonIncomeNarrativeDetails", "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Period [Domain]", "label": "Tax Period [Domain]", "documentation": "Identified tax period." } } }, "auth_ref": [ "r1473" ] }, "mrk_TaxYear2019And2020Member": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "TaxYear2019And2020Member", "presentation": [ "http://www.merck.com/role/TaxesonIncomeNarrativeDetails", "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Year 2019 and 2020", "label": "Tax Year 2019 and 2020 [Member]", "documentation": "Tax Year 2019 and 2020" } } }, "auth_ref": [] }, "mrk_TermForPayingOffEnvironmentalLiabilities": { "xbrltype": "durationItemType", "nsuri": "http://www.merck.com/20241231", "localname": "TermForPayingOffEnvironmentalLiabilities", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term for paying off environmental liabilities", "label": "Term For Paying Off Environmental Liabilities", "documentation": "Term for paying off environmental liabilities." } } }, "auth_ref": [] }, "mrk_TheJohnsHopkinsUniversityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "TheJohnsHopkinsUniversityMember", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "The Johns Hopkins University", "label": "The Johns Hopkins University [Member]", "documentation": "The Johns Hopkins University" } } }, "auth_ref": [] }, "mrk_ThirdPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "ThirdPartyMember", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Third-Party", "label": "Third-Party [Member]", "documentation": "Third-Party" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r1289" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r1296" ] }, "us-gaap_TradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeNamesMember", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade names", "label": "Trade Names [Member]", "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": [ "r75", "r1425", "r1426", "r1427", "r1428", "r1429", "r1430", "r1431", "r1432", "r1433", "r1434" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r1317" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r1319" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.merck.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r539", "r554", "r776", "r795", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r934", "r1177", "r1179", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186", "r1187", "r1191", "r1354", "r1355", "r1356", "r1357", "r1358", "r1359", "r1360", "r1406", "r1407", "r1408", "r1409", "r1494", "r1497", "r1498", "r1499", "r1506", "r1509" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r1320" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r1321" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date" } } }, "auth_ref": [ "r1321" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r1319" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r1319" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r1322" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r1320" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofEquity", "http://www.merck.com/role/EquityShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r64" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonShares", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical", "http://www.merck.com/role/EquityShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock, shares (in shares)", "periodStartLabel": "Balance January\u00a01, treasury stock (in shares)", "periodEndLabel": "Balance December\u00a031, treasury stock (in shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r64" ] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonValue", "crdr": "debit", "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Less treasury stock, at cost: 1,049,466,187 shares in 2024 and 1,045,470,249 shares in 2023", "label": "Treasury Stock, Common, Value", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r64", "r65", "r126" ] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockSharesAcquired", "presentation": [ "http://www.merck.com/role/EquityShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchases of treasury stock (in shares)", "label": "Treasury Stock, Shares, Acquired", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": [ "r16", "r122", "r174" ] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofEquity" ], "lang": { "en-us": { "role": { "negatedLabel": "Treasury stock shares purchased", "label": "Treasury Stock, Value, Acquired, Cost Method", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": [ "r16", "r64", "r174" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCDetails", "http://www.merck.com/role/CollaborativeArrangementsAstraZenecaPLCNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails", "http://www.merck.com/role/CollaborativeArrangementsBristolMeyersSquibbCompanyNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoDetails", "http://www.merck.com/role/CollaborativeArrangementsDaiichoSankyoNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdDetails", "http://www.merck.com/role/CollaborativeArrangementsEisaiCoLtdNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsModernaIncDetails", "http://www.merck.com/role/CollaborativeArrangementsModernaIncNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsRidgebackBiotherapeuticsLPDetails", "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r751" ] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfRestructuringDomain", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Type of Restructuring [Domain]", "label": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": [ "r480", "r481", "r486", "r487" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails", "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails", "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "United States", "label": "UNITED STATES" } } }, "auth_ref": [] }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USGovernmentAgenciesDebtSecuritiesMember", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. government and agency securities", "label": "US Government Agencies Debt Securities [Member]", "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)." } } }, "auth_ref": [ "r1126", "r1158", "r1528" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r1316" ] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://www.merck.com/role/TaxesonIncomeNarrativeDetails", "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax benefits", "periodStartLabel": "Balance January\u00a01", "periodEndLabel": "Balance December\u00a031", "label": "Unrecognized Tax Benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r698", "r716", "r1171" ] }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "crdr": "debit", "presentation": [ "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Reductions for tax positions of prior years", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": [ "r717", "r1171" ] }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities", "crdr": "debit", "presentation": [ "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Settlements", "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities", "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities." } } }, "auth_ref": [ "r719", "r1171" ] }, "mrk_UnrecognizedTaxBenefitsIncludingAccruedInterestReductionResultingFromLapseOfApplicableStatuteOfLimitations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "UnrecognizedTaxBenefitsIncludingAccruedInterestReductionResultingFromLapseOfApplicableStatuteOfLimitations", "crdr": "debit", "presentation": [ "http://www.merck.com/role/TaxesonIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reduction in reserves resulting from lapse of statute of limitations", "label": "Unrecognized Tax Benefits, Including Accrued Interest, Reduction Resulting from Lapse of Applicable Statute of Limitations", "documentation": "Unrecognized Tax Benefits, Including Accrued Interest, Reduction Resulting from Lapse of Applicable Statute of Limitations" } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "crdr": "credit", "presentation": [ "http://www.merck.com/role/TaxesonIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities for accrued interest and penalties", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": [ "r714", "r1171" ] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "crdr": "debit", "presentation": [ "http://www.merck.com/role/TaxesonIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest and penalties associated with uncertain tax positions, expense (benefit)", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense", "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": [ "r714", "r1171" ] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions related to current year positions", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return." } } }, "auth_ref": [ "r718", "r1171" ] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions related to prior year positions", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns." } } }, "auth_ref": [ "r717", "r1171" ] }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "crdr": "debit", "presentation": [ "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Lapse of statute of limitations", "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations", "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations." } } }, "auth_ref": [ "r720" ] }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "crdr": "credit", "presentation": [ "http://www.merck.com/role/TaxesonIncomeNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Favorable net impact to income tax provision if unrecognized tax benefits were recognized", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate." } } }, "auth_ref": [ "r721", "r1171" ] }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount", "crdr": "credit", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, operating lease, lease not yet commenced, amount", "label": "Unrecorded Unconditional Purchase Obligation", "documentation": "Amount of unrecorded obligation to transfer funds in future for fixed or minimum amount or quantity of product and service at fixed or minimum price. Includes, but is not limited to, lease not yet commenced and take-or-pay and throughput contracts." } } }, "auth_ref": [ "r491", "r1516" ] }, "mrk_UpfrontPaymentMadeToCollaborativePartner": { "xbrltype": "monetaryItemType", "nsuri": "http://www.merck.com/20241231", "localname": "UpfrontPaymentMadeToCollaborativePartner", "crdr": "credit", "presentation": [ "http://www.merck.com/role/AcquisitionsDivestituresResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Upfront payment made to collaborative partner", "label": "Upfront Payment Made to Collaborative Partner", "documentation": "Upfront Payment Made to Collaborative Partner" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r41", "r42", "r43", "r222", "r224", "r226", "r227" ] }, "us-gaap_ValuationAllowancesAndReservesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowancesAndReservesDomain", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "documentation": "Valuation and qualifying accounts and reserves." } } }, "auth_ref": [ "r307", "r308", "r309", "r310", "r311" ] }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowancesAndReservesTypeAxis", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "documentation": "Information by valuation and qualifying accounts and reserves." } } }, "auth_ref": [ "r307", "r308", "r309", "r310", "r311" ] }, "mrk_VaxneuvanceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "VaxneuvanceMember", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vaxneuvance", "label": "Vaxneuvance [Member]", "documentation": "Vaxneuvance" } } }, "auth_ref": [] }, "us-gaap_VehiclesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VehiclesMember", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vehicles", "label": "Vehicles [Member]", "documentation": "Equipment used primarily for road transportation." } } }, "auth_ref": [] }, "mrk_VerquvoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "VerquvoMember", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsBayerAGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Verquvo", "label": "Verquvo [Member]", "documentation": "Verquvo" } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]" } } }, "auth_ref": [ "r1285" ] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "calculation": { "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares issuable (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation." } } }, "auth_ref": [ "r1396" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Average common shares outstanding assuming dilution (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r330", "r341" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average common shares outstanding (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r328", "r341" ] }, "mrk_WeliregMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "WeliregMember", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Welireg", "label": "Welireg [Member]", "documentation": "Welireg" } } }, "auth_ref": [] }, "mrk_WinrevairMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "WinrevairMember", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Winrevair", "label": "Winrevair [Member]", "documentation": "Winrevair" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r1283" ] }, "mrk_ZerbaxaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "ZerbaxaMember", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Zerbaxa", "label": "Zerbaxa [Member]", "documentation": "Zerbaxa [Member]" } } }, "auth_ref": [] }, "mrk_ZetiaantitrustlitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.merck.com/20241231", "localname": "ZetiaantitrustlitigationMember", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Zetia antitrust litigation", "label": "Zetia antitrust litigation [Member]", "documentation": "Zetia antitrust litigation [Member]" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "16", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-16" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(j)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(1)(i)", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-4" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(c)(2)", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4D" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Subparagraph": "(a)(b)(c)", "Paragraph": "1", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-13" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "SubTopic": "10", "Topic": "420", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "320", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "460", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1B" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-7" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/220/tableOfContent" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(d)(5)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(f)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(h)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r179": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(l)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r180": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r181": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r182": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r183": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r184": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r185": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r186": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r187": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r188": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r189": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r190": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1" }, "r191": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r192": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r193": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r194": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r195": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r196": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r197": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "25", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1" }, "r198": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r199": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r200": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r201": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r202": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r203": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r204": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r205": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r206": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r207": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r208": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r209": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r210": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r211": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r212": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r213": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r214": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "10", "Topic": "321", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479567/321-10-45-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479428/808-10-45-3" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "35", "Topic": "720", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(1)(ii)", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/808/tableOfContent" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-17A" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-19" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column C)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column C)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-40/tableOfContent" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/420/tableOfContent" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/715/tableOfContent" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-2" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3A" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3A" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(10)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(9)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(p)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-8" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-4" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480606/715-80-35-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-9" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.1.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4EE", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4EE", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4EE", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480627/815-20-45-3" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/830/tableOfContent" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r820": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r821": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2" }, "r822": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r824": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r825": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r826": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r827": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r828": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r829": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r830": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r831": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r832": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r833": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r834": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r835": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r836": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r837": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r838": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r839": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r840": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r841": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r842": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r843": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r844": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r845": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r846": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r847": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r848": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r849": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r850": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r851": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r852": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r853": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r854": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r855": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r856": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r857": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r858": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r859": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r860": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r861": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r862": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r863": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r864": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r865": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r866": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r867": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r868": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r869": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1" }, "r870": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1" }, "r871": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1" }, "r872": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4" }, "r873": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r874": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r875": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r876": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r877": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r878": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r879": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r880": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r881": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r882": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r883": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r884": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r885": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r886": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r887": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r888": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r889": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r890": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r891": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r892": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r893": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r894": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r895": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r896": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r897": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r898": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r899": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r900": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r901": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r902": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r903": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r904": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r905": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r906": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r907": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r908": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r909": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r910": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r911": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r912": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r913": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r914": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(h))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r915": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r916": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r917": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r918": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r919": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r920": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r921": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r922": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r923": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r924": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r925": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r926": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r927": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r928": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r929": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r930": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r931": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r932": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r933": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r934": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r935": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r936": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r937": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r938": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r939": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r940": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r941": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r942": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r943": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r944": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r945": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r946": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r947": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r948": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r949": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r950": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r951": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r952": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r953": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r954": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r955": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r956": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r957": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r958": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r959": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r960": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r961": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r962": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r963": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r964": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r965": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r966": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r967": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r968": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r969": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r970": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r971": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r972": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r973": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r974": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r975": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r976": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r977": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r978": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r979": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r980": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r981": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r982": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r983": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r984": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r985": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r986": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r987": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r988": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r989": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r990": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r991": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r992": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r993": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r994": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r995": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r996": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r997": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r998": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r999": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r1000": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r1001": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-12" }, "r1002": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r1003": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1004": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1005": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1006": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1007": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1008": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1009": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1010": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1011": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1012": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1013": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1014": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1015": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1016": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1017": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1018": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1019": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1020": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1021": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1022": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1023": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1024": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1025": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1026": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1027": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1028": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1029": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1030": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1031": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1032": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1033": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r1034": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r1035": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r1036": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r1037": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r1038": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1039": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1040": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1041": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1042": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1043": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1044": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1045": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1046": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1047": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1048": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1049": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1050": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1051": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1052": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1053": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1054": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1055": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1056": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1057": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1058": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1059": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r1060": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r1061": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r1062": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1063": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1064": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "12", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12" }, "r1065": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19" }, "r1066": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1067": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1068": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1069": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1070": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1071": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r1072": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r1073": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r1074": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r1075": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A" }, "r1076": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A" }, "r1077": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r1078": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r1079": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r1080": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r1081": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r1082": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r1083": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r1084": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1085": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1086": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r1087": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r1088": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r1089": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r1090": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r1091": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3" }, "r1092": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r1093": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r1094": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r1095": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r1096": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "450", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477850/954-450-50-1" }, "r1097": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1098": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1099": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r1107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r1108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r1109": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r1110": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r1111": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r1112": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r1113": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r1114": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r1115": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r1116": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r1117": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r1118": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-20" }, "r1119": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r1120": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r1121": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r1122": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r1123": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r1124": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r1125": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r1126": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1127": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r1128": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1129": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r1130": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1131": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1132": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1133": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1134": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r1135": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r1136": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1137": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1138": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1139": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r1140": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r1141": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r1142": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r1143": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481899/410-30-55-16" }, "r1144": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r1145": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r1146": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r1147": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r1148": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r1149": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1150": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r1151": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r1152": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r1153": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r1154": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r1155": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1156": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1157": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1158": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1159": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1160": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r1161": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-18" }, "r1162": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r1163": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r1164": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r1165": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r1166": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r1167": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r1168": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r1169": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1170": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483385/720-35-55-1" }, "r1171": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217" }, "r1172": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r1173": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479908/805-50-55-1" }, "r1174": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r1175": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r1176": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r1177": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r1178": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r1179": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r1180": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r1181": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r1182": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1183": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1184": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1185": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1186": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1187": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1188": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r1189": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r1190": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r1191": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r1192": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r1193": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r1194": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r1195": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r1196": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r1197": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r1198": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r1199": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r1200": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r1201": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r1202": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r1203": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1204": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1205": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1206": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1207": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r1208": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-14" }, "r1209": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17" }, "r1210": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r1211": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-9" }, "r1212": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r1213": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1214": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r1215": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r1216": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1217": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1218": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1219": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r1220": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r1221": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1222": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r1223": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r1224": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r1225": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r1226": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r1227": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r1228": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1229": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r1230": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r1231": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r1232": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r1233": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r1234": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r1235": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K" }, "r1236": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1" }, "r1237": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r1238": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r1239": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r1240": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "2" }, "r1241": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "1" }, "r1242": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2" }, "r1243": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r1244": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r1245": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r1246": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r1247": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r1248": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r1249": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r1250": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r1251": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r1252": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r1253": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r1254": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r1255": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r1256": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r1257": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r1258": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r1259": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r1260": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r1261": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r1262": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r1263": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r1264": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r1265": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r1266": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r1267": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r1268": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r1269": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r1270": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r1271": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r1272": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r1273": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r1274": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r1275": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r1276": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r1277": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r1278": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r1279": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r1280": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r1281": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r1282": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r1283": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r1284": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r1285": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r1286": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r1287": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r1288": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r1289": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r1290": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r1291": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r1292": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r1293": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r1294": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r1295": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r1296": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r1297": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r1298": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r1299": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r1300": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r1301": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r1302": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r1303": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r1304": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r1305": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r1306": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r1307": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r1308": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r1309": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r1310": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r1311": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r1312": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r1313": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r1314": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r1315": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r1316": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r1317": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r1318": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r1319": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r1320": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r1321": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r1322": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r1323": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r1324": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106" }, "r1325": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1" }, "r1326": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r1327": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r1328": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r1329": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "2" }, "r1330": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "1" }, "r1331": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2" }, "r1332": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r1333": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r1334": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r1335": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r1336": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r1337": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r1338": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r1339": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r1340": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r1341": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r1342": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1343": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1344": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r1345": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r1346": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r1347": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r1348": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r1349": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r1350": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r1351": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CC", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC" }, "r1352": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1353": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "610", "Publisher": "FASB", "URI": "https://asc.fasb.org/610/tableOfContent" }, "r1354": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r1355": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r1356": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r1357": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r1358": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r1359": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r1360": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r1361": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1" }, "r1362": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1363": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1364": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1365": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1366": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1367": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1368": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1369": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1370": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1371": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r1372": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r1373": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r1374": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1375": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1376": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r1377": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r1378": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r1379": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r1380": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1381": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1382": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r1383": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r1384": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1385": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1386": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1387": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1388": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1389": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r1390": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r1391": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r1392": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r1393": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r1394": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r1395": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r1396": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r1397": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r1398": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r1399": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r1400": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1401": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1402": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1403": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1404": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r1405": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r1406": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r1407": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1408": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1409": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1410": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-4" }, "r1411": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1412": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r1413": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1414": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1415": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1416": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1417": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1418": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1419": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1420": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1421": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1422": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r1423": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r1424": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r1425": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r1426": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1427": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1428": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1429": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1430": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1431": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1432": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1433": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1434": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1435": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r1436": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r1437": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r1438": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1439": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1440": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1441": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1442": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-7" }, "r1443": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3" }, "r1444": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r1445": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r1446": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r1447": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1448": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1449": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r1450": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1451": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1452": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1453": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1454": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1455": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1456": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1457": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1458": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r1459": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r1460": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-4" }, "r1461": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480606/715-80-35-1" }, "r1462": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r1463": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-9" }, "r1464": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1465": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/720/tableOfContent" }, "r1466": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r1467": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r1468": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r1469": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1470": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1471": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r1472": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r1473": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r1474": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r1475": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r1476": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r1477": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r1478": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r1479": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6" }, "r1480": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1481": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1482": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r1483": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3" }, "r1484": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1" }, "r1485": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1" }, "r1486": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2" }, "r1487": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r1488": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r1489": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r1490": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r1491": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r1492": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC" }, "r1493": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1494": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r1495": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1496": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1497": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1498": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1499": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1500": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1501": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1502": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1503": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1504": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1505": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1506": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1507": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1508": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1509": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1510": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1511": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r1512": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r1513": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1514": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1515": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1516": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1517": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r1518": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r1519": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1520": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1521": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1522": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1523": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1524": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1525": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1526": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1527": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r1528": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r1529": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1530": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1531": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1532": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1533": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1534": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1535": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1536": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1537": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1538": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1539": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1540": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1541": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1542": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1543": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1544": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1545": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1546": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1547": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1548": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1549": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1550": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1551": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1552": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1553": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1554": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1555": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1556": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1557": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1558": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1559": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1560": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1561": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1" }, "r1562": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1563": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1564": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1565": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1566": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1567": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1568": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1569": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1570": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1571": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" } } } ZIP 173 0001628280-25-007732-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-25-007732-xbrl.zip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

#&H"533IWE!F&9W@,PZH#H7IV:&"RH MO3X&W"B,?4]09S/OUS+U1")]W9*!TT;*(%8K5KSY:%]HB=0Q(0S]JT:I5X\I M8FH"536]! (=721-.YH6*+%HDO6$,14%F/I:Z?7Z0UU*+4[':F_WN?1%_)IQ M75M-7393=_78^';ENA]B=O%-N*E24 L)^=1&L8B,$]4/\VL].QY^<*I+R;LMW1&'6#: M.NE\WB1BU.$J3,R%;W#-]SD^B:30FI9@:ZV.J;-3O/K MPCY@"RV7K:ANNI^6/87OZ7++SAV+6>W93&V[(P0* 'T:F*DW()HNZ&HBSS>% MB(4 +B9,PXB\HEJC&H\ 0)$?4A">/K!HF-V&L0->8,X[LXP085ES.-F 0IW. MYP:I)XA3B3&Q&:?4L>*]., Y:4V;O8$IC*BE"5-1#OR93]W*&M0@3R)3K>L1 M:LDB5(W-VCAU =LTT]?TN7L'0^C 15Y2]^[./ P8936!>WY1QU2@@0%H M:]FI<<("X$+=N'<_K(A'Z./K].>-&OE2]_$=(!:J[FRM!7RF0-6?41/):YM! M@597WOY@;Q?%X+C$RW#;4U#/TF0:23^Y):Y9C=FS3#= TO6OV)DW\T,_3A2 MI'%V6*1F_/:0I?,H9#=2]\+%8QD#@,3GNNDYY(E CLU:NL,/>-Q= (AP,SD MP%G/>K (U6K2ZXD@;)'U8.&J#I\G@E 7AX?$QB3'6&"JP^M\(>+\QNYHS7=1 M]90"P&0RJJAY=E6N% RRRPSVN6U%]VV;Z;4">E[ 5.>JHC'F@+ AC[MHB8P M"H#+(J75GO)UZ@]UWMN==3 4%HF0N-E&@# DR>'4VM!F N,.CFEAL<* NQ M==&(KP( 4U$[@#H9 W)I'>3^^6V/X7CZ'VI7^.,_19-\F;NF: ?8;-W]GAJ5 M9N5/ 5#:KKE;F/+ASZ/97(3Q76T!=K#8CN^OANUB(]K:JF878O0 76,'N#1H M;_1\P5&+:J9/4WSMQ_'U_;[+76Q#$9?>]@)J%JM\^+>^%&X2;:WX MNX-=Z6[V+ !6Y!+U '?X\]B5JOD+ +C<685H%] \P!F^BY6TS1F^ U@Z_?M[ MOW< "X#J_-U!@AW Y(E 7/&$6)'&7%DW?K+-W;L+ V,?1$B*>*[T'N+55M-9 M%0";K?&E7>B"D*C+E]("8_K/89C"]63IUF-[R73$Z>MD^U7+QQ'21+-3MK+2_@XCH(TV7R) M2<#E@7\5GKA"5X=OGDY_)GT>; 2B4:6 SCH&JW].9?$( M\(0'-_PV7G^/F1\6M^Z-6H.A&K[\RMF+O?EI+-_4#;NA-H%3KDW0&[2<>>-Z M>T\L2_K=>ML2I)]\_/IZ>Y?N5'AI0.L\<6ITTKO*8^Q@OLZ(3]#[%YS9 2BD M48\'58W; 2BTIV?]X0D R^KA220M]R\9MP-[_[6&NHD3E* 62?GM6$:OI^X3'S7G_.$ M/.JP%TI'T5]WVR';;^M_GGB3?_ Y-FI5=[%*;=-VJ]\G\BEJ__190)S_ALE[ M^K/%+NGD3C]!BYH59YC<5C9JT[5,)W:+S\:2.$% ZX?'^]N^=# M>-J++#;ZA&S,;4BM-)^2_H1*"UL]OK[#7ASTU/JH,D[,AV1.KEZ@S._9AC_\UB,:DQPS(O6"-JKD! WBI*RSHRBB4(4=]2^@!KK(=I G=H5\\=7:0=0EM<0E! M+J3'4C':U?2#7CO[*4Y1$T3'T,@ \DD$44)=HA'3^_]E*B2?"W4:NJ2'(2Q M[T*7V-)_[D8UJ&"H,X_5[N\6I.7PDT@2L[IAH9FK"R.[LFK3CEFB[LA,Z3@M M/LQ#+.H.;-]"*#P0-)G&D $I0@,$@FUCX+8K2(^?7]OXP;:%2';Q6'OE4AP+ ME\_L'GL/Q+@E!]T#K86F3)Q.#)&\T!@U\@(L$''>QG"1YX\V2(H$AD]W]^4A M\0+=+^5'5Y 8"V7E4@O>?BW4?_,P)3\*]H)%ZA!'*#N8@95.N]-N%D^IR\UU MJN&40:P$3<:1S;W "L$#J3&,$9& L M$$C!(0]TX=JNU!$M2'E!"5QAJC_TZG+5P0P "[VR4Y-2#( +1H2I&I0#@(:> M90OIL8 (KF'NO1!!-$RIH8Z:/43!VX$7N6G4+.MD4DUTKH;-^L,LF%;)?^[; M1*2UN%G'%+H]"Q,1!/[?< <@0$A7U]2()'4!.]@.;/1I.)A5:NA33R&H-\U2 M3VD$!X*I6I>:1*TD[$,Q6O+L+8@T$LCL+4QJ5IZ]A><7 L"&.EJ(DF0!MLO@ M%N>UB8_UN!2&%(.Q&O:"30P1_ +=FBTJP&E;F#86>?0+,=T(\&S']%Q !,,P M;7, 5CBD;041#4,]J5SBBIB89Q0"H1!R+?G$?7(Z_?N73-U%AU2% 4'=;UZK*^#$KJOOMR() MU^>9-_-#/TXD3[8&]'9P0$$HQHV!\X3ZH<*.N,$+J':(P=2!V/AQF3H0*D[5 M$IWR@+)[*VS09BS/O8A>S>1#="MEZI8ZJ!7=Q&TNSVRES-$>M M40U%LY.Q.5,S21-4WWU@?[W[\N'B\G)G$W)+ MSQ8-; X 13J]E0V:W)1%U:L4^U!494QNTWU^C9@0N[&U%;G7AQ91D%T1M1= O?BX/(X-;L) M,HF=G-VT%POMK7#%;"PD<<^(FJ0U '"T7;KE"1Z_"T/E"5I-/"G]=MF3TAET M6L.J*\4TXGOQYJ>$CP-1W&@<275>'ZEW"O@\%B?%7TX]/YX'_/;$#\USF8M. M\V''49)$LQ/]$M=")K[+@R,>J#/_Q/AILJ]/;WPOF9[TCEO#KGZ9GQ*I_O6* M@;-OE:%#/1#%!R,V^F[$-I\*9+6_W_ONE OB,!*F4G$F8Q$*G@;) M^MF^69BL?,H#6,E(F/YYM<@&O- MAPKF(HQ-9);IUA0_*Z F*QGR2XA^--I(C5I4[.'ZW-0*4!3[^G8G4@11D&W;DE\5O[4S^A[_WKA M3T83MS>9C#N>F/0ZO# MSJ3C=9XNG&;8%.\O/KQ5_W[9LG,\_F,\2JF&':"CJ;5'3A-#Q:F$?!VGUQIV M*I;*XN.&2VP';_G^XO/Y?XCG_VZ/ H XO'K9'6XK7K0+H.[/H-P!,.0 I= ? 7%Y\.OM\]N7= MQP^$\, >R#]??+CXY=V72VIM!5)T/OU^]J&)KM+.&FI5M)7C>FWE&$M;.=B: MO_-\=U3#.=L:E][!KH$)S?:DY5W L@_:[6<1)WP[2^C9GCOD>PZF>KLU$+T+ M6+X_06H'*-U=#GH'ZPI3V]U:#GHG @1I3^OH_.LFJIQ3B8\/6M5$@^/>2BWH M3(G[;QHG_N1V/?>@W^H2N2([!;/_;)MJWQOJ?Y[T(;;F%3PJ"%77MQ[_O9#N MUUU!4/\(U!!<3KF\3O_C::SH0IG49GU'/?E\&4%8!4'A]R.)Y%,:1C'62;[X]9]KD^;8LSN.1_N=IUXC= MHS8_P&"D__E'[U%_MG9F3V,"<"GF/"N(LJ#<,9UQS@YXGJ:_.X?W/JDW.PR9 M-"[9! #+KF,DC;,_ ;#978RD>3$^ %AV%R/9I_UEQS&1AY;7 T!J=R&2?9*? MM0@)#3 U7 < 8 ZVUV[8Q3Y<#:G=A8YO@]L?ZGR>&HC]J5,>L M+KHXJ(LN'C>)+O9TWBX9;2R/+E+&FP&(@_7Y-O-4QBE7(R<1.]-95H%@0SK# MN7V'XV('B#C:SZZ=.7=4)WOBC:M-[$/)BT:S/!#%#B+)M 7MI<$MXVDRC:2Z M%YX!#;"FI)A+$:N-CR<^K0!=TP(AB-6T[^_EN@.0IO3&\S[ I%>4O*;><(Z) M*:H;]VEB$:(F?V^0&?UWZL5%S-[=(#';@E.[@.7[.W/N "6N@P3$OO#[5U/? M 3!;FSH\XU5E>C=L[^T%X=M$P(K^S,+*S*F'Z0XC= ?2M!\[-?4QOQ?"M)U0 MN@N##'/;]KL]K== M2?T?T:3PL25+WB]M%.4'6IQB=C[UQ81=T*+PC1:%HO+8Q\G$=\4V+?P94/QH M54C8^'CAL=>=:3P1B"O-6C)[RW)+49N-,6X7@8YB^UEGL%H.*6VXEII"N2AU M:-=9=?B/UZ8A!*F'L=Y#! #.HD&6I9):HLX>$76L>DF[VV\HS "P:)OL:,]C MCK2ZY4BN=:#%AJI'N ME,N$V@GT':[K?DTWG^-N,T9Q7[.1J3W7U/X)/V3+#97I[<-0-'.Y,/Z<9;." M]9;%*XZAN_H3[V"!U?4G!EA@=WG=GZWK8Z?5T/<)F*U)_[MP&-*^OLU7L]52 M8!VEF-(!XBC%!,?4@C,>#^M] ?&^8 J*#077NUN*@*\%IT9F*#GPL*C,^%>[ ME.J<+4(FG-2K"PN-89*H?TG==/M2TP/!W5+74@ &GJN.ZC_FQH51%!L) DZ MDH2YP]#OO'?GB0# 5 002.N7;4@K!H"'7HH@-QT8%\U*0'(GCU##KH-4/5<* M>]XWQZA=DV/4,P6A&C26H,@M0W6[3I/3>LX5'G5.N],?$ M5; !,A11;764[2.1O/:Z"W9 *V:;4L#]\_.NY:-?UXW_1)L8O'S_O M+'6(&H9-!__R:&,K^S@;JS-/*05Z>8YOF1\SHSSYPF,+78&ZK!_F;D_>B .S M7(M/G0VP%_4R_="-Y#R2Y"U+'$PI(J^Z2MU^NAZ6210$T/CKKM5J>W23_*%O"#7J;3Z%4O#E3 JT_XP&<*V?[@Y.2(+<] MV%L_=J4PF%)W)_[G@'K6( /U&91 ^()*:@&@)9]Y,S_TXT0)#VE?(5B 9IQX M]5#7N4KGQ+Y$4,&XD9K1;:&IRW68SV5TS8-%,U\NE9K_0VS[1YABO^FP<9OJ1J'?19QE$I7C9VWFC -@*=^S.P>70?L=&L=QN=;H[*H M,[BM:LTN3C#BA##,DM;D;1PQLX1)HP[-"&8 *,6I2YQCCGD21(D]"S;5L?#\ M:]]+J5U6F)OQS92Z)S.FU'"7OOPW)"[4J& >WK8XPZ;36AES,;7QMA>:C56+ MZWT'?Z?^-0_H,U-V(+2?1<@=IJ:YD7U MFN@\BDW,>\47J=,*&8V3J?%C[SA\TOBY#O+X 5LXRZFW"997JIF+,#:A9),B M^K,(Q40W-D&H88/;K22'[^>(2T^'/=[Z4KA))./U&(A>-!K,8M%D?6.DB.?J MUSIQ-R?O,V=0^/[CUXT-S#,_XPVJ9R0F5>Y#O45N%AP>_10 &D,E M(DX:0<2%?MOIE4QY2)@TY\J0A]<(MO=E$/=KB[.T%\59EI58.E256$RCH0\[ M+82"5_9R0[.^=U\^7%QN*P'YU-@ ."VV]#'\^,O.VG;58[,7.PG A@NIYR'8 M9*B']-3&:&IQ<7D:DV8L;G&*D&\SY.6-]F([/L.HHKD7+6Q?Q7:M50;+J4^R2$U'&+[$]10V);AWNE3]]I#1.S%&V]KUO). M3$[(;9F<#+<'RO&V]?:+&,N4R]O=%HS9DT--NWJ(*VTT";)V5VLR9;6)!YW6 ML!)E7;2V2/@X$,6-QI%4TG"DWBG@\UB<%'\Y]?QX'O#;$S\TSV4N.LV''4=) M$LU.]$M<"YGX+@_RIAI&UK*O3V]\+YF>]-2XP]'_Z'&E^M#5J^[^=MM=]W]LPZ'K=&@T^BV/QIT9?�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�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

, A2C$J,S6+!M29'=;36(HP''($>C!S;\:W# SP24 ! MM*%#DJK"JW-OF-B9Q)G"K?;P=V=H>N/O=3S. <%&!"BQS\G(#L#>\Q<+Z$!" MGW;<0XE& FU4JEQF?K>>"V\\E*)V2[THUV=^@]W7XFGN:X2T2\?20)H>%9+4D53P^?4 M+P.106BDR27/:R\ZRBV&B.>!A8F\'X-@3O$6*,>051W7S=Y)#\. \A&8\!D,.?( M/"? 037;^!XU9*&(X^8Q'[E'-CX79=L7P1^UDT/"\O>B5_ 3_4UE$W0#XV;S MAD)[PIO1(JTLUTXI;Y4L(V)5J,3:07J/5E )9-L:[&9#):5.7! M@2INYL00!_/W#*VR4KP8B>=>Y\I#PC]5M^1\#,<#&NO:6QO#1Y!,%JI;H5[B M]#@DI$#'J!#ST L%U.75+415T=$*; ,%EY'JD:G80H,UJH9(*4;CU@Q%1UFL M6?0<5M# MQT3%@KI?L#92<#\+9%KHB<'@%) +-2=UJ@9A:5OL@"Q";KP7'2.+U\3U$;<^ M[WW<:[U1PG2 N<@+$W *%-&'+.TQ.4E:H3&Q+,)P<1H$ZG?.810= $4KT+LO"B0=4 M(0%RQQ^4/IB3"P98U5'!%W$+E@1@8Y$! "P(N3XZ6&G*W)S>RWR0S4M$B[Z3 MF5$&\*<0:*V^@H1$D\R=B=D(/U:/39FPC&,,2.F:N@C'F[?8P9M_^4W'#7&J MYZ"$B')U##H8ZPT!5H+9.KZ2BU@T;M#9!2T_3UM:7V1JBD@S- M>4K\W;1V87B:UMXJ: M3!X734F%Q&S8XQ!D#G0I]/H66/*"8"),#B4'V+@@CEAD*&R8QX*0M1WVT[ R M#Y++GY(\ P7\@>VHT<@LBPFH8"@L:N3^G(#3<=96TJ 6=LHFP*!)\%>5FL+[ M66A:AS4=>&PJ4%O$> 11&Y4$C(Y*54TT^3"Z=RX0J03BH40/X^KPD$%'UE17 MM9?W*BDFM57]6&DC_*$@:1C-X\=C$#U_ >RLA>+!1W< "@^B2[#K4%8[L&ZJ M8?J>_=SY*/!VV)(@= 1 )J]07M"T ?&7 I#)'R!&8Z#S./W.&L=2@-15.*UMW<8TX1*$I*@_ M5H$Z"92)C( F+ZM$3=@$"W '$&H$!OQ?_ERM8,RD1,TKYJ4&NL9V))D&E 0- M$=0>C>Y=G3#*#G1J]-1:"J9>XJ%#%VQA61$ QV0>"4A2>F.S2AT /"-OPM+ M?TQ \JJZQ^><0D ?L=:MVE#+-Q03@+6Z"D(2ASKAZ&.. M12_(5_6WF(URMGKA+< \&FNZP"?^>,AJV,IV<;T= V^WBZ;JK)*D*](9IG_WIM$@!;W8L/L!2Y*BU7.((F5U"TIR\/.ZY@_UHY^CX:)>?/LK0O :<_ ; 7WD M-%7!.PX/X+=+?K'KPU9O\J'PW0_.8O9K'$8[;SX<[0+;=>9B.NL%7@VXB# V MA2O>?[#_/'HE($>X1"_ Z"T:/B=BG-P!,'XCIN<2GAP$0$Q"3DKT,X=2-Y&E M.7(W)F6#!O9*=2N&JO TN2.HP*6PJ2*YY7^8IYA0&4(5-,-CR&2"W+CW374K")C MQ- ,C49\&+@A UX7+;7)!K!?]N]8FK3JMM7'/1:TG[;^R7>>& MLU$EW.@+C:X@&QA]H8>@ <(1OV!%.5P=$JDRR&9.V>H0M^Q':M*I_9H4=BJJ M"?IW,?Y7"HIV%>NH&BL>HH3*,% 8ZE;85B0WI+8GSMC85+0->8AU-C$.M[(3 MA,W7>B1I50ILLJX*(\#%. C@]Q^%5>_LNF$,A14<"I5Q?*P=LG41:'N%\$L; M:>-?SL2Y6HOH*JN@)C[8.X4&<0*7/L- 8(IV4NDVBTR[J>"?8V>3H741^(6! M(8(*78^M'@FXP0D+I^+J)1=E'_$2 5C9_!7O;@Y(OX=AW[28V<9YI7@UK8>1 MO(I(%];MC#NPA.3]N !/*X$)>':U&8M%G$(&3$ F@,'RQ8"(#,-_<,O4# "H M'S=O%9?6(BZ 28N?Z#+^.A\P@F]X64[EB,?!8Z"Y-/E034$51'EI7\+:3#.TT[!81FIKD-P4VA![F/S"DQ\!2VFL=4DYYSN LFT@609]KG(A'CT^FP M;VF6[Z"-,8$R9QEN'XF?XW7$*A/6ZCH^?1]_3=FYX!)GNJ8XYQJY4-XL0/+3 M"T^Q'*-@[6(^108QE4X3*@-,*71%=5&D0I?!@>+J(Z3L^MJBWB#0-B*;2 MKD6U5-TL(0X;V\+53]0#%T$&D;&2"/A-SCG5R MP,G:@&2=RY"B-P7A;V*I=(%$!J"O53Z Q>\1,P_(GVO/2-8V)2[2-GDQ P&M MCFA$+3[*)1;'9 %/HC=MA@WYRS_>!K%PB?MMJ+WXAB)CAST?6640:%>L=?K1P;-H M1_Z]"SH$6I"*16UWS5/+$=0\(6#HOF)?XUV^'++J#' M<5C.N.VQ '99M=O+271,72"E^3]E$9NL$YI']8X\I$Z%">ZN!.6H=(KN LD7 M[50:OL \P2=6PKYR.C %IGPH^F,S ?N.@A=PP2]4K7I6WKX#^_W?_W;P:/_9 MP?Z>7>B8XI%A%"=( 87EWXH2"]_:=08Z+J+6TJ^*M4 JQ)D!W(S^$/J MZ*:*NQ=+[DH74F ^Y[KT7D6T"@!/3<(N'7RKN"?'-)*Q!H:\%YU8G<&64:A< MI3.Z".J!A>E9XAAP^3F41M/4%2PMN>62=&.M#_*@J#.6LNB.#@I%G)MA2=6Q MA(.E1(BB)U0QY;RGE91AMDOSN=4#]G*R!4=['$&@Y)BB_$I@*J(,)-*(797H M8*W9H9_.:)O#)A5EJVH?A",(>%2KH/$GMI19P6[JTHC<]7%F?^QNY_Z-P=V6 MIL\J[,%BY^*R! ,+LJ#)%\5J*^?:UEBLG9,7VB,GEBG%BS3#IB$K:Q\@CELP M.=X(>\HTQBD4W:H!!04;+OQDA9(R!Y^VA$XY@ *N62 M$I:2L#WY3R(ECJ'(V_<\%M-Y3&K>P;T>M(Y;++!DA?2:<*]B>L9TQ)C;:;<+LY9 M44$9I ^K??*@I$ ):_CL.C/[RD,H3%;'' 2%"C636F3 MDJME%W!RNLGRTJ5&HZ?ZXL0W6X9,J7Z6XZ!6D1:%Y?U-Z,\&,L$*"?&%\XN MC5"4&C, NI7R\IJP,P+&QSG%U9F9"5B2UCM+.]^+/J)?@5/@$+Y+7VN3:J3T M$YD A8M\_P%^OY3[MDWGEB](0-:I)**L!VK+045Y\S"TM7GT7"O27(W-D/0B M0G\U(GG$!:(FUD[#Y&"LC3?/Y>FY_#J.]CPOP)X/*9)*[SD S;EGTDL%@R'! MH= MMYO4P+'_C1K02: <6XQRF+P^*_KD[Y_@Y OX^!50K4E\?V%0FZPN*DIB(862 M;?3G,.\Q*(?)HDY&ZQC2_>"KG3<[HOOI/&T9J3<69R&E'P&UEJQC6>4VJ,.0 M HQH:I1PB; (G,LA0,4P5/4BQ=8@;#"-Q),$*0$)R2)X:U.39J!S%=ON/]P* M@.6C)-E()Z%:FX*UGAAXGJ_E90.'!LTM M^IQO;DWVRRL48XMMBYE\>>6D=1L,T<[+S[MM"<)R/\S?FQ/\K/]11!U9U)(. M2XLJC259T+4B:K ^6KO2UY>?(U77.IO4UF'A4@!OFW'M5.9V_UNCPGUW"6Y>HO+KF"3O'C8FD-%KHI>U,ZO,5)2;<,8-KNT!71Y<+,FC:/M)NGD+RR&K M484W528-LRNN_,$7BVO G2U%7X3K<#+0HOPGG%XMP7'>:5AN@(&@!L0QI4QL MJ*Y.FB30R@G/A/@8:,9.$:(41JW[%K+<.0%=3$WM.L>Y.[;9,=8XX@P0*2ZQ M:AWEY>Y%[Q'C,(] ?Y6R=-LUH:2+$KQH39NB'$L74Z/J*VQE%>82JIQ:5565 M350Y&VO";4/&.96-MCK.V)Q@,B7FR8!2ET"MXT%82 @;>]](HDEQEA//#SMJ MS+ER@P:"G735>?VR)]V8*-XI4J)EX/?:RC\9R@-5 L,NF3S9*:A+5IUMS5N. M2E*GYQ)WNEB$MKTH+HNJZG.'7-&&1?=-BS/"WX!7D_+%1F5;1 E0Q"LSLQ45 M%KG%IPH7UMG IMKK[8*@Q:@+WHV.Y< MVK(P%F>VNHH1&NIN>W6\_-QKV9:M7TG&_Q2]==B6$K.K\?[#([$3)[BW:#$7 MM-L@1"#-H6OKN7Z%14X)=NB84-T-D=QSWNJ!I&H7;T?B_ESV>.:$FJQ5?8L_T0+,E0B*+7DF$2MH"#WI.$00!3#H!B;9I:-OK@QI#T M,L*,$;YD";RM].O2;-A!27;MIZ;+4:DPZ(XG)SS9)B=LDQ/6/#GA:IZ6'T$E MPE0I&B(.6A21G]/:9-2G!%/GB0_[C@UC.(ET3#B&()UT MBWQ^'/O&*&R?V+\AZ?>?_%&/O"SQ/0,IYGOO\/#)(0GG#[OL-F:YARG($O$2 M=:=R">?65\Z=@N&%;"=+;1(IR__$1OO1L2T#"]Z_\\_CHUU_+5:>8!%?4P76 ME"Q&K2ZY+MQX43HOD&'5RN5FQF1!4#8#]0R"A4!!2:U;0XOGG7?A^\&V*](" M'WH/I"1K5 I?9*,V)NRA6L&CM5/V6,4045D%+GRG.GQPT"8E*R5H2.?D$LNYU^^O 96]V+ M-E1.,"(Y_\*EBSUY9DNY\93^'#:S YW6A%4\+JT]U*P=;C_:;$: M2V/I)D5/.[T@;5FD>Y-P@" ;H7.,B_1H:G],\5KSE?I*%=RPAJ,2%.);:.N@ M$@I$4H5M.-E*M'OK\Q$V%1T^!>WDL6(*S^K3CJ5E0KS4VIF/F_JX]_GF#67A MM*8"L!FR[$W"<=L($CISJ6S/J?CSG/G(=^H0$XYJ=2]H((Q(@&CG$[8"=HJ1 M*7LJ5LI*+FG%_D;=%A3BI<$8[2(#' /KZ/H+4FNHZGC N]]0].H '2Y1X8S% MQ.,$-?Q'7DO?%\G,UM-3;3,JF!3/N*!ERT(3WNH)3I@[%RQG%\)>_FA*4R7< M&J;38&2.'_@0)=[[3-=!CB#K?LZASVX2YC/D"L1 2$XY>Z0@^.I6DL#L$B8[ MGJLC]EYZ[!4F<8,1)X-1:D:MMW#Q2Q\SWL/V-5@G3MAD!0K M!5HI"/-17.:P/=L#UF7DN=9XXBGZ1O/F:I/9?;$K%XG1=5VPM]3>,J4^D#-T MH7O8*T!MI]R&TLVGRWNEJ-7]8G=SM]1^H%O9=59_OJ*O[AQ^Z5UVI$[:9L?6 M3\>J:]G*)*!$1 I=T0P)O%<,E]H>EJ6;9V*(D MXME^6)V2*MQ34">&%,+>[-)%01F#O0+G_--#Q%27&B!$*,B35 Y'U)J BZO#(U=SE&U;QI+'RSN=$+Y MJ;95N,T2L+U*R-9O14!=GFIP$T+5^AO<(.6!^SWUI(M#^/Y XQCH<)W@*$V> MTC2,FOIF5@08CC#&H( "CBDVJ7- VJ6=[ ,4H!W'8_AGRMRXB..&ZBN.X)Q\C*VDFU,1H5 0U,&[&<"!2P\ZN0^J%YKH[G\?7[)%ZMH\T'P/W8[7U MN=E^+I U-WW- UP-*BW0!JTTH1L /L(%/=09C*>A^9Y=-M?O34Z9]WEM[Y#V M,,9-MG@L@Y['ODA1D*MYHH3(,'V[;##)F;.0J.,S>IW@F*DN;2J*RR\.(1>" M2NQ%F0/!JI!/D'3MFLAYB5V\V6'J-BCVQX;"P-\6"3!]YCGSR0HL>. [;WEE/U(>6JDBYW&^Q7F;G MW8<7;W?%>V3=FQ6W(?.Q<27L/@]ZG+0JNSC,6;/W!8L([*E]BV2?J4TY9^+" M.(MP ]3>A/%6NG&E6IH \&OPAUKL1L6U,DGTZ/Z_S6DB%FQSF8]X3QSHXZ@$ MKTXLH[=@%$V'-TFUC"^?(.]9PN6;1+$6;SHCE,C%*UUW7786 +O)M)W<">@$ MB[(7_\OSTUTBXL/]@Z=SBE%(H?@5_-HW;)*U@3,C[Y..<(7C13P),W!U23NF MJ9[?JS?.?Y.O_K>,JCI&2P> AX49+[F%MSCU):7@I/,:[V6@8#!!74"6DK1! M1E'RY#0 &YYHK)(>V\!TSSV'?5[9P%;(KHSGX?Z_+:ZDP,6H7152ILY,WVFO M#!;:FU1=3G67?%U98A=R63&5I#LTV[_?K/G'?P[*>_^XXY'[I]O(_39R_U-% M[F^Y1B+3)>76GW"ZY4]DN+B"-VW/Z$:LF78O6BO-E6^OD(2M_3CUC$1$9RG? M?Y3>QNG/,0^T83?N?,(N3T4ER4;5/)VZ&_;'V00*%B?2YUBGJ F)*,)F K,P MKLQ]@]D:1_>:JMCYB968;@Y( WL%W96'N/+WZ$(TU+EQTK3'][6J-9>:-A*A ML/K-\DEJM+6N0E8M\E?:6='=RL?V?#7N[C!CDP[S.UW6>/=: M-]5?_ES/BCR8%G@.I'HNKN)\O6:.5(*H"SK7SIE/$0SO#3N4H!$N0*YT2'\6 M:7W]'%IOUJ^()0T4U.JY?JG4VA=-6@!/,%1/9P.XD8),Z;#+*EG+H&P.4[1! MPS$W3&6]H'(WQB:H\(D=9H^^-CMXN#M+?=CP@.?.H"G,:0=\KK$)1CTV-D80 M$C]J_CEU#[=ELJY'?2^8F1,X&US'@5G05CLPF9P/H^N%""[(>4SGPR \QBL* MNPGCL!*9P%RAOD[A-S>-Z#S\\ UO7>=O*L/UL4E@0YA-XCFL]= PEMINJ6&P MK(MD5-IO"_,O1:/G*&C?)VO.[28GAGCLB8FC-Z)20RVSD#NYV*VA MQZV %O:58*'U$\1(W[?:8P0N5U.YFO76Z >IEI3@-5;VB+N&>0ZU_[!E?""& MN6&BM=1[ O!>%]J^J0']'GBF3OG)UI#W;MN'CBKAJX:<^L(G:&V1T<+.-R)= M*G2Y:)Q?T4BBOAV*#B^E FV<9(OX1),'"LMNY\?%#RP,LB"2$L Q.JI]L ;? MXO?*>F2&S>UM.BMZ85U'F="?S%NSZ8^!=T^Y.Y"$,K)?@T[-F&EH<\JXZ9?X M+GW#;.^43,0KZ9R7\LZ6I\<-<9'$3/*(NX593[/G\WDIKBNWE?\,.>L<"H;/ M!8 D+PP\8V@2>CJ3"228_TG^&9YEP; MRLURL"5;'!5$?/0\7U O-+,J681[T2Q^!#F'-3OG M>C7,W4:OFP3NIGW4)4]1(0O'5@G;*)8=W8%"NQ(5;C*>53C[A,+-]@?H/)W3 MGU-"9H]$PI*)L0](;RZIX)".L1>]*_(^>><-X8^,AST'6LNPCBFF@).,Y%K1 M+L%4ND =07SBL'FW*AV;^]D4\@8'G5826\<=):4Z4W9V][(\=,YTX6WHG#(< M;4;2W-OGBN)-*X"_8$I#RQ;V238VKN74(4Y28]\#UP/&UL%>^[3Z($W<5K=Y M!O2,'@&I2ORW)V4=,O32=QB?YXSTWFW]9>FAL& M.C>K':,%G5PG-(#$>NH@0ZJ:/!Y3RK<^\PT46.8&>!08=GO1SD?ME($/<)FJ ME-Z@+[P^T>I +.V)I$MH,"\PQ-1N='+WDF;5K7DT%UM:1\ZE=&+5E@TUN:C\ M7L;VMIV%A'J]N1%=)D/=%9@PJ_C2EH%^(Y9M[R59.\_JHQ XH\&H83 Q3O"CV)J:*ZTK%.)[8O7!ZTTT,A MBJI?[)J>56UWBAW=VQJ_Q$XL2BFDR+H?VLGPPP20\%"FJX?C%HBE4VN#_I\< MG62;!H/^.) &DYY% 4*O9VL:>3MW0^IHG +"/A('=@J;D8QB'RO/6_?]%#I3 MQ ,G:7#NC4UY;V.M&YWN; I[(W1V4W.SF5):&'#WP*H.E2L[][TN$C4CG3#5 ME(1FI2N/;@Y_VG+_ME#C_ZNH[4"_%#=?8+Y0MEP27(?@)4Y S[ -(46%:^G+ M!P*<=#I4*2FG OLOA2.G>;3]R(IO+P^\+NP6P38U7!HA_""<."_X0_4H@:>S M77$^:$JX;7Y5D^-@#)M'2-!IDP<7ABL[S,R.UJX8 &A"%\ MD9K2M":#S^V-4_65=)@*W,EC+DB@/DDM27OL>9XT$G%MH3M\S_NQ>9Y3KS4; MNVWFU+F!SLSUK&P@:"9XSN$?SMA.L;N,&V).8JZ@TS MM5Y\UZL_T,OM"&3MFHO9_D[D!F],BOWV8"72E%L=Q@Q[JYJ<2T]#Z3Z8A0*> M]0Y^^ZG@UQ%%&,D]8$=V1NZP"S@T#^/3] ? MP,A+\E%JFGT9)85W9\SU2(M\7#>DQWL!XJ3_@N MME1$,V$P+#/*?A-+QEX6VE49Q;W9FT,J#7GAQ/7FLJI;Y&>1!VTU@_=#\KRC MLG#91U+DRL?&R%=K:G24Y<%11,.;5^O"V9$GHFN^;W".!*BMB$O](,+N?H-%;,Z*AMN, !6+09T^JYVAZ[';M;EKPH+ ):2L-W&>CSJ=K:1 MOS@^SJASH>02UT0OU/N67L.3&0^P/C^/QP4@(!!=9?AVTEDV&:.>C#G?"!GX M8B]J]V.SHQJ(03L >&TN//G;D!J-5X(+)CD[[]<+,L/'_ZR5GD&-%%.)!X+9I M15A"<.3!$$\LV8T [MZ+QYI4K'(

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ͅ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

    #3K3FI06HG;&-3!B@>65O-8Z'+R%)-, MW>&EG8\O>=)D:;P4=]+")&I8=?)VRF07KS..OZ7DBU+GA9 CS"PK8?*"HBXQ M098'NI[JM!+7D%OH,.N+?6J:DY)W-TP'2G0B=DSB[_*=2>C*VA0""8* OX.V MN*'[3TDV:6-6T%UPJYHKUK3V)-IAU2!\QV:OO1ISL'!Q"' 4GV#B_\6F# =V M3"C'&*:N^K!O-_:IB$3Q3&MG/KO\N+*T@XB"79.Z#AFFL*]P(900!7/- M^J2[T!+MQC4N^61+?HT:)\EV!_#\[.4B%G+3=XCP%O6T2>M<7X7+N;SL==I; MJC8^^>&2'=?%IWX]R!%/+D[P^6+U)#-4 +@+6E<$#J(>PES710J'=8M="VXAN6DNH/HZD)B.$H M(VWA>8G=+O1"$>W(43I(O'L_%^/!'F(>FV=I'"J7>30G<1WR 1P&82U!!**. M>ZX=61J@@QX.5"M\T?\,O?KQ52*/.$D==_Z)'T?@6+[+%@.-S9H:V=4X'L7/ MWB)YNCM>A]AD>VO [!ACB$$ Q&LZ:KVNG&%@J%4--T-]9A@O_]CFKEIA/F#< MK_U;C,(/L6Q#OC$._X8I ;^$GS;=C8 I9(GB[F!W\ES!,C^;5.TF?$\XI-Q_ M;O+>X"KN\NWO\[2J:NE)%W9^'Y?; _+97]#%->;#JB.J[Z-LRX.UV*(RN]^] M5(^T1G>A2$JZ^X&(("*97P>O=W.ID\C4,!)P/Z6K2^J#U%R)&^G \>: [@>W M4(D8S>S6C[YVM@.O*M*> +CX)C/M,1V$+T65H"@*(2L;DZ$YJVIT$!OI N!( MY-)7'K4L/%Z9NZDJM,-ZCD7E$S+O('P28,<0YRTJ8"X>Z OXM D@Q2Q=H,LU M+ P;"M06V]!X7'O[3>T=F\=;E(96$3T1.3DYF5;1Z1BK]Z;^:4@N2*$B "L: M(_ZVJ57Z0[UXKP*R+LR3D/FB^,3H5Y_LNV$-9T_&!IC5^EJ Z_D/>=%!=JP' M:D.6O2D"FN23P+N54U$43:*W41^;"A:4-K<\C%6QM?DA%O**VNRN? MD,NZ-XV9DPX2VR(VTMH.U=!!F0)A-)0&)T6V!WZ4(D.@@UX]$T 4SM?R]>)[ M+Z2M%EP+X!&K.B:K?U='?6DW$##&KP#IIL*>T$&% 6C$0LMDA:-NHFN2YU0[ M(Q(,D/ OT_\_K?C?1ROR:6*PZSWP8[!+.)@1VC(W.7P_U"TQ% 7Q9KEA];J5 M3YF)H:(NMXWB#P#.* @^G7LOJ)+616/'F)7J"LU%/+[_I(WOL,\%N47>"X5L MS0\LY_PBS]6W&9].W[7U6%_;CB:-?Z'UH, PFZG1>X]JB?;9&JG=CW]*=O]\ M]UIXB=]5C*_KO$ HE/)#V\ #)L_ 1%;N*Y@GT5\6RV2\9EGC6> MY(>A[J3\/'@M8!1?\E*.NT6B"'?'0Y9$)261K\;^DZN[Y:[8O.OIU !UDXV2>[1#R_O9U)0#+*S[0)%$\M.%: M/L)'.3Y)&'CBR_"-#=K7Q44S4<1WT5*%W2KK.&'%EVH_KZ'W^=6CWQRUF5NS M$()3B$PM*K<#TRU*9G/SK*]F#EW&^/G.N LZJK=?!$>"X("IK2\$%PR3$'76 MXJ2A;(N+U;A1"N13/+3*A3/;LB.S=C?6ENFEQO>II/X]C"5DN9N@>IN:B'"@ M@YA(3#>'!^"JO^/W'NUD8Z'C?GLF^K%>3_OD_! M7[O^23D[#/_:8A@]AZ4=!7;DX$5(:296!K_&# VMY2-Q3TP51_-T^/43VG1\ MWS9>/W17I*O-*H ZR_033'@"I9SHHIT0:S338"')4K!3TKSFJSBI3S -Y.=: M3>1)2N%W675C22R#GP*<%V>V%7$4U]9N_=']?/9@W8[N?XAG'2&!74^ MY][V2%*/+=\;_"I'2D[VO>G(3L?>N5AD!F"9Z:"AJD9(H79=%SN)H<$8X]"] M*>#.Z\706?V.TM-U;DTT2I?SAP,#"*2Z)XZ6\]?7=SWVSVY;]0^WO9I!4P01 MQ(.)&Q/>0;9NL,HP*5F&9&R 0D$^=210K9GBGL;X6N: MA/ZDO!\^+.OZE]3U16_6?CR ]5BUK_8Q6'IRR89%%Y#6!7$,L"@$A_)>BO MG&%%A9FB@M^:5,Y=\OV/HO1S+X]?Y$WC?>O@K8G^;N2]X?B MV,#/P%M='%(7#<&"/E(L)WL5^)##%WJ1I)WR^H<,@B),EV5_R?. JD=\6UN; MH*VM[T>U=AHT9)6_3'CT>Q9F<:&I-5R8'$_:TD_J0&JUV+8N\(M(B@2U8-D& MV:BRZ04_^7!4*C"+P^W+]:E6#,'O,Q:XOJ^M;>D:JD6T(=S[:8M*R2CYC!HQ3 MBVM+&::N(C/].0>A,/=1$]E)E.9"?IF12HI>X2J$)J\N XYOD/C?"O=A,O2' MXB<98";4C]5,D_9>T7K/&[>5UF-P'=&C?/4[+#._0"FPC+HLK^G^B>Q4551-2?0LSP0Y@@RU!]*N\6I16W.40' M,0;10>\'._$55+TZ83'-A[G)4]M]#!,OZ:!=2=A&>V:.6W0Z^-O*C?S4E#T1?80C MK/"B6C#C,R6/ M[&@KZH\Y/<2.*B1S>\%R>KE8+R&[A@&X%G7LMW!MB9UT&K?R%/'0;:2KH2R^ M#.I P(6/TSAJ'.56(D^7VW'<>1Y6$H#;[ ;6&D/-PTP4 M86S0ATEQZTLKUJ=[;&D-N%;7[VZNL?>^C:_H\H79TD%6?VMOFR&>F@\_![O1 M V>C*. H9GD_)?,B)VHT_&]N&U(XK@6-"&<>K5M](A&Q#.%'X&?7AK_YC$Q! M@^#'%N(MEF$\;M2"G-.<)>A5GAWQ1G+W"*4N"G?-'R*YE$_]5"OOC"F&8MFY M2$L6KL.HL))+6^?BW>U".IX:G^DBI*YH"<5>SM.H,7>?"=..O6O9LW_N6/@W M,37%X ?'!^D@\G.L\'D2+MLLVWS^QACX![\6'12?Q66^:+=Y[JCH_:C#Y6\\ MN78-)[K8H3Y538K\MQ-<%/9G8F@[.;D=ZXAI%V&\9K#8<5EX%I.%&'39MBF@ M1B'L( P,N]"^/JLY92H? ZIZ]25J!](JN2>'VL M39;].A$7]H/\NQ!T%'C[CL(:5?FGR=8E:#N8\,_M0^9\?@+VAD2?39E GG,!2[8=_;52*M'QKBN@UR3 MF6F*S^#QC-C;1UKN"3<4B']BO_%KJ2% R;0,)[5I)\HPE*=(TB-$^/BFD88H M8D(76!]6HG,^HRVDH^LO_C8MEDE.780F )[-3TO[PGP :-*/Y MO^UU:0D0?%3MA7XU8"\8!T@FV2[F<2DYSO%Q2I+NOOY/=G@XWSY_\JFHXL(@ MB$W_LL1"V"Z4=O@#'21>3M*F@^Z3T52I"O17B;8LHEQ?)D'Z,D#^=?_Y-&\# M/'QU^SO)@BPR+_D%=HU8&C)1(E$K8?9Y0_JQ-E6V-$*^QVOF3D"R._3MODZ0 ME+'-8-[E-8H$P;J'7"\,_O!,SN?EQ(L!:<[,U2LSKO>0DP?3YZ]>?RIQ\UF& M9,2B482W1BG@69H1]8[%F"&&*[6DYX2QO2XC4I9/L$#VNZ8?/F:'R6O]YM.! MZ]>?\JPIM_0AZB,=3*N(W&C/+\X\)CQEN%[UYLZF=;XSR=H/.E:Q^\W(Q*+U MM/ZCM,H^SWG#SY]RD!H9VDI>OTMO^E4OR1)TT*%*6F=7AH_J)$]S^(A_;K8> M.'@SZS#H?6K3CJCW^>\#4^IRG)Y8,%*#F]"2,H7@7*B4BG%23/FZN&-@9F;> MH*3C(1]U7+G/V]X>]#R1]AGS #'T&;M]F1I+X22L8MN]"*L?WX[="@S/QG;$ MRR(=$J;OLU^^O&))2C!77'UFD^8++5@$_)GOW">$+(9@,OZZDZA-8S8CAA@X ML;SL@OJ?0@QQWXCS >_@:0H;KL\P?!3G\>/PBZ2BIEMCMBY[G;/I%N06I[%; MF^"Q3;"F9;]?M[&Q6H)J%6!$[OU;)IK),(IPV>V%!+&=Q@R9^-#^!;:B6N<5 M0TK$"W^8'.'":*1..J*$ML%^I#R,'00_ 'GU"ZX.PU7M+Z^:2*/U-FX7QI)? M\@[[]H$1&C_?TKYMY63?_/%H(,)-'EZ\/YM#^/U_ [4?^#\_1\0D9/]\&>+: MR;1]B)JXA1!T;I"HT::I;>HIH%R=\\?P M#@)[.()K"T"7"$Z%+AY2VIT/1D2FUX_'MK<7#3NBL)^$N.[9&&DS?P75@4Q4 MM;@6A!U__PW].?>;M%$#/)$D<GR%&\[3LSU.BC'4FFSK4!)/)\[= MA%\37#?+-Q)@OJMC%27C.@1^ 'R&:@CA%H9DEBP5,H6)+!X= Q.H]?I'AK^C MI%+\!6S0%Z^S/+EXZO"2N-C)YJX5SX<^#'5^D(9Q1B<- 0(-Y98Q[R>4XV6L M^$9J<&4B\LK7@&4FZ\RLV9*ECBR#[R:_=E*^O]\5X/)?38OYO_5"UT-(%VHK M/<=)YYB:[-MWO7)M'@6\$/ RM3BT,%@ZJ8$)@F^;;$P ^Z]3$;U$8SY"-$CW M>AM<>(?[4IUI]V4*B(& ]C@%Q<2L4PU(V"@N_M8OC35&I.N(61\N@%":(J3_ MD2KHX^96[3:>@@0=4;DKDS>F(\.*'[%I,CX]K#9M,@@M[*)PCT_N+--!V_Z0 M)AX#BA:!HFQXJ$#"OU)A:M4JHM:'#HI+U5R6F$J4X!_T\S21U/+H:_.HAIN9 MC-P_W_:Q.AG9_P@76*:!5W']E<;9+GE./\9,?XZ,F5N>C#Z'?_,O$VC?:)>C9U:KU@+!)=)- M;D-CR[IX%+]/8&,VIL/EN44I^4+N(N%C"QU$.*,P.2G+6^/8-J:_1P?);=^* M:5G6D\^:+;Z'V[BJO1'>C=$^@=#I,YE"UKN1E/4GD8'<$@@^DG7(A^<&I\D/:ART<#DPG0=EYIXS&=2B)V=+$^PB M".QC=[6OL$]9\GJZ+*1I@,;:._--D2982A8A/_"25D'M/&08^:QAA8-I M(B:3S%VHM_7E2,,_)#RO&8V+C;IF?3^:7J)=>?G^YSKWZ MY;2GK;6%UO/WL(/,_/4NXUDDW#'W%H^/8\IMZ)A=D57LJ@4=--*YG_J?OWOR M'S(?(]*DDQHU5#3Y4$WMC-LRYOBX^0NVFS,G/S#]H.U KD@0%3&V&/QHI&XG M]0W%QJ'H$#NOGN+RUKB=O0S237H++:)JT@CKWLL,C+WD$ZJ]FZ*P"_E!W@L3 M1T=!VH^IY5-GD[I'Q$?-4-\$SET_&<%1SU3"M2U&X6'?5H8. M"6S/X\!ZQ61($,R'_77QB[0==_D<>"]H65&_.@CL=>DT.FJI+R(O#WG>P-W+ M1NN$T?&_Y?!H N!N&(Z#$+Y@G&L,)Z(RG]IVP\^,V'?([)[NRXU-1Z)'-TYM MQ%,_FX:HF<2R:AM:Q(Y@]8'4+Y VLGY$6-LL_DCD]H[_G20_;O(P@9]KR@C MGZY*?IH/ E^ *O&F*'2MK$T)/>A96M$ $Y8QA*CY# MQU]R$V'3H]L/WG2?5 MW$]NY@FJJW99AWCZQ04GZ<<[IH9MLJO]-C1"!0'OZ$4'/63?KR(N=:.(\6>@ MDR;&@][DI1_];!M_-T;"L3K"3D9TB.E4BKXYE8)^A\!'( J9*#)KRV(3D1I[ MN.4Q<>(#)(>+3>^CMYTJ65'4.[9OY(W4V?F\UE"SQT(=ZPL *>_AW9[C_OFD!XJSG M'WBSI4]>B#6/USZ4=T]*^4/7@MC!/[)FY56F=0> DN?Y3/P7,E>8-@%U801L MSCM+&( P\_UQM'A+7#_7.H;"H40S<"<@:?4[T#TK#^@]DQC#28=L?;QU@-:) M>W'_8)]NIB^T9K@,,;ZQ:SBFOG*G<46XMTE8KGO-?$.G]_$#7]N:!!&O]3:1 MM(KS LPY1Y098L+(ES#XN37DMR8P$^4DXQ/-GA)AR+I?K=O^C"1$FRZ<#3%8 M#Z:]V-K$4 3WX6(O0(A]23GCO&I"F<7PH\22(=K@2R[JV-NL6M-22/ YFKU0 MW.6I%]]*(G8M=Q]&IG6D='*;_#H\6V-_>#8!L3\\&TD'B1G\.M;:?W^L-9X. MHC&7@&FWT=_YS]=$J'*N9/ZD"O\7;A+?OK@L/.S?U2WD36-SIJ8H/)<3J@TA ME.G".&:'%W@>38GP45=&T$)^_AX]U;I33!3N\.UX4J^K0FD*4=>TY]'LU+,H=(G3?G+A3;&*:^'; MV9_M\Z\S-7)N?FF_R/AX./_FZC1_+EZ]Q**XYQ)UFNX=;-7J"*E):7IL8']+&0X-I8)+QS\8TG\=]%BT= M3 D>I\ZD)U]1EM4YY6#;>\$](,!JU-?3V:-M+NLF2O015Q?,$I=.0#>@.!?? MK&T\&SV[N* (B1N)YK$)IG%BK?M_X/Y@V5^O.F[_2V_5?]>?D_8:@Q];"TG; MGPAT"W)DC)=2 3/(2%:%:0E4'U/L MD^'_V9C_NG"]SH4>[9&5YG/SV MV]4*2(O-T3I&I8EKD.H61F^@RT/ 5_U_L%VJ--X;#8?DY@KQL? ME&C@&6.J+<4])&9\=>'_7AA:JCO2(F!]7.7K2+[C%?= @>-* C8^ORPOOP'VVY/Q0;15\G:@T+]R\:R7B>P$Z7!Z-8X)]:E8Y(PN5>D&S65^LRJ..6MS@ M=_IL^^.\^ 7L(#-SA"7J@O>Y;JC+_EPRPA5D!(2OY^C:"?_ B>](139/R&:D MYKL=BX=J8*/8*8W^'8P*.2#@#L5O^M->W@UBWN 3GWH"T3Q)T?;QZ;L'I M(,OJL"ZW@0L)F'4A^#P)/($+H?'.AWXFN5WMID RM2-+*UT_>N4# .,%>T^I M2VLVJ@_1&&9=20>]W8LRPWLQ']$%OWXW[IC!M5-K3PS5W(G MT:%P< ]!\V'/LP7T#AM>/I)-HTJ_M^2Y=R.2I#0R@7FY.E5519QK<@D?)(;* MD[/]U76^/[^VUL?0&*7E3]1ZQ;?1Q49[81?G>U"<\'@_ MTPX DN%#4IJ8EL&Z3"+#/:Z_;RM#;CERU0F>.Z;/6W=)S5NLC&N1GZF!5:SQ M*E5XK?FX)WC!^DQ?'L!0<68C=%"NE197\_G^,SD?-,J.OL/G+_:=NZX1RB=+ M.O_=,8'?U53BE\S'V<\R45=$O^V%3<,,R!=)SYM#Q9*R*=>*WQ*N#OFLF9>( MNT?]8G60AIWTN7SK.P+*($[<@1PMKDJ]MEM5*D M*N92=R2/GF>Q'WMQJ)\'3EW/AR<*@O\)8;$^PAY,$W,9=II.7?2S-*E8>''+ MC1VCO-8;A;@IGE?I&W46S(),P#YATXSP1@>'P_6P=)".(\6.% -@91+,AE > M#65?2F8E7CNO<6-@5ERK(3L^=7?_D6U+=&9%BZ>-^R[XD-Q@C3ND9$1'3"N5A>)"0<5_7X=_TX MA)Z%Q*M(["F3QLG'*&>I:0]0-$[V Z3G]RK+R3OMKMLNR\ G;;*P6_JN]*!6 MG)H"P8_F,IE$/>\*UI"K[EZ];28_Z@OO==:W,YLR$'6&#.NPU_B]DVOC[/%& M3F+0;W=KW?$#'D&W?2Y=+X;5#/EWZ5?JH6+Z3$K@/2B"/C0<51BNIQ1>+0*K MO*87D#U(!WUV6E;E/._0WJ5\G/&QBDD8#GT[W;[BTRJRC?A>\#9;=DK8YXDS M/3J9.X!_.?_]SC]$! ?=2$JWC_!LFQ&+@WBOT\[;F6#;FLPMH@]L\8'?;Z&Q MB53 / 7Z; W+Y5' ML1>?I8..PC-'WQEHP9RH_\GL[7]BE+4'N.M)$K8)0[!YBG%&#WG<'Y*OD M/";1P7E[M&0..=&!>G??PVN!AS<4H\Q6IH26=D?12[.38ZKMOJ<2Y>/.W4M+ MRYOQ5#NFN@9 9)]P;'P+T]8';B$GSV+&R@!3"5M_X, WLFB[AM',P49YQ M:_V]FNC.Q9BQJB=%9#'A\V GL&JW%M> ^V_3-L"?P/LC$$D2+*C"3 IG]I1V MXU#)H9"FMXW;*,;CMS?C-G-KOEW]XG2(O( (B("0A2$B'00D"8M) I21"$" E*C M%!$ID2XUTIN(]%Y"E9Y00B"%;_&\W]YGN_6\NYWS[?U>U_=CP8]DKXAU70XSB1<&E*Q[ ]MWR*/ 5MMAM8"P:=CK9G18::9A)=3]([6_"T:_BHW-(DEG7"EI MTS@P-6@5NUDQ5_,>(YS5T&F"_EP-W)8M\7^%#.(J]A2-E80D/B498'S$&TW$ MLGV0#7$1=KYT#Z^E:HC1.$V8VNIC;0PO<5#&_O>D$44[-M1*I!7R**(.61Q7 M/LGJ[]7PZ,4%SVH-R]M;9IPB;2F(3^<^6XNGY]^0AC_"9DB2)/0I)^(FB#1J MTARM)9"+=L9'W;H&OU4+DIMH3P!L:J640>!5YC-OA5B': ^W5.7G-7M=)-;. MSQ57%4>]365,O]C*G'TZZM5Z[F&!H)8S%:*]\ZB$3E.T4%68?5KXX,]W1A(>P\JDCGZX4WT M9?J!3F\=> M&+K/T)8#I3%Z W>@\2C*B:Q:?9]NC2E(V'##;ZIFYO;XCQCZ$=- &5Z!QSH0 MV:>''H#>HTVA:-,RA4H^U)4(?G,+ -I#+WW[E7[[A!XVTP"V(YKH3GKR;B5A M#U2LHO!^Q/FIK=:$TQF<%EM')R^_8_JGU.9UCY]K4V%]D&61S-)0\E$X3X'M MG5.=GX>%6#X_;'P@#U XS>V3_G !@3V8>=] *4\7?UG^B;_6SJ0DLIHS&; ZQA%$9>I*2-0_$IT M*T'R,T''*YV=*\#P2.%@P1J6)[U3AYWEO;<<,99CONG&A>^;9SG.VB(%!DZN MF][58>FJ,FQHY.-[5"@U&:A\;.$ZIF>-I.A*8\S: S%Y3#'#7?$NJ>TX),?H M"N%\E?BZ0^+SU L7AY4#?9?/,J#'WX-?RRU><;SV?7V>D]/VKTMZ&3;I@-'Q M >+U"ACT/0J+V@&"\78"@1-'_:"UWBZ\()>G:"E8/A\7Q7A[5F7F]6ARRV7R M*A;PB_I#&?XG,ZC_@XB"Y[H$.]N.Q1 8*N_C=RF%.LH=. MSYH[:*>T3J 3O%7/.TE8"*>V8%JP),6!S\TW2&OXM89*J8J:(/FD2O3KD;O< M;&5@)WX*57R@]>P#O^./ZQL^ZVF)/A\I9$"GRW-DQ>Q6C1M'=68RJ^Q&P?+[-]&(P)HWU*> HH_: M QU%/@ARRH>)^RA\=C\*&+3MCS%RN]YD"15NR,3][(>*PC^!"]#($/T^4 MQ[<4X"V"V16ZFP2K^E8+Y-.1$]O1DY;N,@6_O5$)YIB=EG&\I3I([EZAV2TD M"^(0-LF981ARHN2*7&[\MM5NY84!B!+2:HTDP/E,Q8TOOX3@?0O)M+ 2>HH_ M=4$^_=RNCF0'[Z7- R,%@TZ;.40?:E0-+ZVMXK<%VD%\?E):G%Z,!?V&JTN% M74?*AJ"[3."(]CT&C@5V:/M4P58.-F!AY"WU='W5B5?6!?H,.I?V0"HE,3N; MF^&Z^[T+IM4^_G=H^$&!!$'6_5R5"U/AQY9[?H'B,\CA=MKA6CR*&!.Y=+-K M&8F#^20^^%33]=:X)*'3U]DGHKSUK$JIT$P!)O]]WON![&MW>\<2YFS++S!( MIR]?W(R]NI-7S;^P\RZ!0J,-0O"Z:^'8@OJ.@%P'R,CXR1:JY3B-? MN28.S+ E'Q2:E(%^+:%JZM-[WU1Q/]/*&V[<%3)[ST<@JR_F6K96>:7I!.C)"SA9M M^]I DT/K[Z)"^(DP! "W^-\E6JT]A M_!3>[48$.W33&-!GNWANDA/Y&/Q\]QV5\G3\;.:7%K=7<3X-ZT<4<3.6-%6G M^LXLQXLH[UUPL<_I8(^OXM"%4\[P65':L]1&0.6THGO_KE']JX0-L!X[RG%. MFD$ZWH/6N+D'ZD+!OJ0@]=#XJ[ =+51M)YFS![ RJNY3->Q>E@CA $!Q0QE' M.78Z]T ,_+1F"+X28J,,?N:GATG 4"Z^KAZ"5;3N-9_WJ:PNN2U2^0<]]&,J(^KN;GJ1+F;\1+Y MUZ<[>, ML1R+$Z7SR[7O$4U[H!+)%S5\B_P>[X+@=4U3QK751LW.(R ,2FASKW1#Y4]Y#GS>[#%JDWG=K(F MEV6@2K:V']4% SFAW#:&TF!EUJ("SG2^QQOQ':M?U$!AL]MH #R?? M91\)X M(Z#M #"!"4:%8BB%2')-X6ZCVAP6FCU(>?+??0V5:[0* M_A__+;+9+S,)]U'Q$)K&M40TPZ/J82L8TE4LCJ,LCFT%7$!%K9C-1]_=,9L9 M0CS*3V65M4@)$L6\^D5 MX?Z9%C>R^ATU9;Q\%$&YU@\3"E?/&EFLX"]W.ANQE;Q4H?S:VC _8HM^_1)? M>:Y#[\/8C@]&1A&H&=OP71X:DQWYD",P0GWLL),A/J4YQ1M7K?WH+:Y#LYF" MN -@EN:L).X=7K<6%A#4=&>N6K%5SM,W6D]9*BU<[(>&5:)_;M+S#MAT\< C M;[B2?!D:\Z#U2'S*]YHCI_@^P/39^]<\WEO4F3G)56DX2FE\O.3 CDE\*NZ! M&MD##?;0#I/Q&D0Q)ST-#?P$16:>.X:BJTJ9MZCYAI_<(.B5^;[+( M1$Y3 MCO_!!CAA<*.9J;SNPXL#"YM0CFO=J?->2A=#:C793;3^8!VXN>@'-ZU)@;FCTA<=L6RXI(([IV*4L M+X\6/^6#?TG%!NN>IQP+:JIOQN*O0YY"D[9+\F,O)([.9)>4)TZ 7VG@FRU* M*%T#:PH4GDL$ [@EF=')@B=:;\""C:#:H,._O%SV*5SL)=E6 T+=(!V!&VY? M\+2$U2"> V9\/O7Q_XQ,Q?VLRM2H3HH)R>PMW)GDG$?2;AB&F[Y[,L6C(^&: M9SVIR_."]UC;QT6N>]F@0 "M).R?"BWKY-,^ PBWM& RP.QK18^[JZRJ3H]] MGP3?:VU)7EZI[ MH!!7,'/%73;IOI%BCW/!2\%N/+S! BM7LL0'K$YM[L3VSV_K%DG?.E]T[#R@%CG] GB<$HLIQU)23E:5:-+X2LP#R9]-$; M>R"UO'?"[,+ZXW$LP:I?_-G.WAU8T/3U>/Z\2/6JCHXY(&R&-_\),?B/N:#S M^YI3%=]7I4D^[V/4T*5= V/U>:Q^NGDT9(Z3!;DV0ZKQ!-S7A3I.VI^<50=2F/> _VVF9_+JF\7]I32F3C-6SY= M>-V$PW&4QR)G'!:NO8$%G+<)[DX'1"5ZX^-?Q#N1!5?"N4QKA_]JS:3>.OMYH& MOX@C5HQ77>EPP!7^'J?DN\A:NZ 21$YNJIK_TC*RAL7K@TG"DH#[9(EAU7ZO M1T0>I5RN?NY,+"902B*IU9<0@PVML4N\QVKI MK:%3\_L%)XS&T^#!>$/TG8(-B@&>Z !QR]4$KSU0X)7PME>;M@-=5=-J(><^ M8AL_E9?[O1]QIMNEF'JE?WBW:5F/!;+Z-;R/4'LS7Q,L3/;V(,W$UTQQ)-=W5WXF/Z/.UI,%%,%QOI'(1RK (9=',1 M=DR-?5C/%R=:?WCC9J:>K9G61:\FQ,4 MNAW),$5OGIC[XVQ\/&JHC'B?FAR"F>P^GOKF8_D/2M2A@7K8P;OP:Z0(W![H MB*F+@H5 ;][FX.6E&@<3.>IMZ&9?AH/)[I$8)RN'4_5.=DSJ+$Y=QRX;TWT' M<9 T]IGL25&+T;$1;%K_#;6H,];7:@05(X<3R#@X<.BQJE$6"ZD6V7.5T*'_)VOU%>SLC M-E5C=:ZR310C$J!OYOQ?J8[_\T(KO^J6"TN6VP7,^"'L/E3TJ:2U4N=IR9[# M7\L^=XA2[*GC@+"TJ_[-Q'S,K"010-(QE?N10:N0O#U09A%TR^$7;7KR@:G, M &!3 7AP\=1?@DTUU%]GH5'E!S;._JI/3SXOM"%R6;)N'V\:O=]IIC&%D@\L M ,X)[RWF' !DG4;O"[ MBP97<6;%U7R,$"!$9%;Y.DP:E"I3CKR3.GF);?LWA0.\J;FJ9FHF[E-B8QZ" MA'Q@6--/_U)S+V/ML"@+(>KK&AD?9#/B>!7Y2#6N_:V'RXQ+I$$@ACV(E.XI M\4*QK6"A'YOE.EA)+,-/K)23E;_#CL*ER>>W9-6UJ@I2M&O[\UBAU:1FJ]NF7"B7>,DQHS[>!H+*F3*- ] M$1IYRS+6QK*6_J@Z[S'#@62_'U(=-_8/9H[")5Q#D7@C5J0A#>/80"[ A.SS7AY)(EVP[JYAI_P>"([C=J%<"KB@M,;L]J"<..2) M/$7QQ1B^P-#[QJ8[_)&5]>?,:4P/FB3//)U&TB"F$IH?NPBO3Q+>A<43VYI# MRPM?XBYO277*\#Y"#4+GY/RPRS)DC7:R&&( QD83D(C6=L6-68A)!IZHT+TD MP]'&XFW/KSZ!\0N/FGNNV1,O$0/Y8'I.G/F[ERZ72]YLI+__TSOWHWC<6UY( M<_%/!B7WELSRO_\?Y/*__..W9X'?!FQ5K1RD8.L0H'@GJR$GRZ['T2Z6/%$, M-[RBB0 MSX3-[(&X].G,1+(>C ?#TY.BV/]98O\W+U"]-2T;Z4J M\2XA]CJ'24OK-:"'XI5L)DNQR8KAC^ M.Z6 ^*?_P"BUJ,9$L28P+.\08.H$ M3+ K6H_ $++:O_[5ZSO70^-0@J"8C8V*=!%=+6:AA\A.+:A2)7O2.H;!J.)# MD=P7!I:'\QX'=&;"SF!27,9($MPZ=.Y*"CPY.U88#'(R$H(WJ$0-GB"^C/!Z MG@W!W24U3A<26!0ESDM=#=^ZW#IVS.H32%?KJ]3M"U(8_01S%U< G!0-TE#? MWWNN:$U >R8KBU-Y]]O;!M7Z%"%R9V1JH$&^6;,W1;NM3&H69PL9]WDN2BS# M= R3ESEPMD]4.>ALSG.RU%Y9 CE-P)D18Y@IHOW?NJYC>TKT0%]/1S>+Z6UD_F M+^K-I?.;H..7(57HC_'+;#CPH!&NO$?6F-9-.)3Q?KBI3.6>?H V$N;4A1\ MXU$38Y.[[D4)>V!?J4#NF3,03Y!^KX"K:65.K9@;.GN;')91>0TN#YM^^.3( MHZ!6H8):1; ZM,76-R:?F@()W8#D4"[AUU/U=*P*LE6NQV/.!'!N8Q,HOZMG?TV7QZ L=1"VNR!'.'&)./,/5 :9$LW/O7#.QW>C?JX2K=PP*A/4*>7*^-S"+7I< MLH)JT@%N3^'8!9GH0-$M9Y1>:= TIYCC%M]EU%UH.;JC3K255)/!)'+CJ6!@A5Z/A":L=4 M;_ZCCOOW-(?9V],FWNX%=XC_79_DH-Z./Y>?AAU,:3(^@ M!5G %P2$T>#E(A4Z59EC?!&(U]!H6MT$B&&YD2Q,$JS%G&H.>+?0?B']26O5 MZX2LUK5G?*_ FN!K6Q]($EY(9PLC,YC^[\B'#RWTJ?'1.+R[273$+$W,OYN< M5+8?#YM1>_/_#1O> V"]K^R!VF3W'9X:].[%I9V87[+>0>LB"R_HYX)"IDQ%*=\_$E:10A\_Z/%.D:PWS;1"\\,,[SPQ M_3BH3/81^T&:T?<\&"])W(CD/&UN55_1ES.X=(IU>3A@JY+Z7>39%_?3N])1 M)!-CO]"X7P6$E12''3B,[R1$@NB$$FDIV,EX2*$TK1%6H!U$X7'[30.CQT L MK;I<+__V(5U;UD [SVF&BKIW6'; ?@5#"CDI7%$(0?,$$XE;N9YV.%CN(U.)H#D70$TX'[E/ ME6JCNC0Y1A_^0-3S"[:%=;M?-,]L#O_NA?.VL]S_\>&?^1;,?VZ>:10YB13> MSY6;C_R10O@7+C@%]XO6./U>-8<U5[?8#2SN+/[-LD^D&+)4@9(R >!( M7CE7ZOE$;,ZUGYD#]FMZ3" +1@P M"Z78!,F?F0,>3M4(>5LB3@+3<4]1-RY)X>]I,%7M1[\W'1D?G+A"W);?:!(* M]QF[5J&4RGU'AY[_L)QM.(@&[(%)# 1_(P=+$EE;$7-S?CDL](%6:0_XF*?<-.?VGQ_:S\AP\MO/SLC"5#45C_4&A"S:*SC MP)9]#3RP 9\+.U#E]-YEP)/KE#ZCN;ZPQ6[K ;O"UD6\J$3RQLE;H#/S6S>P M41@0:>,VR7S:6:0A%=Q[0;;:5:,BDMBT>FCD;%771YM[ 6$+WS95H)NU ,KY M2JV619)$)9<[WI$ *$I$"/40!WU0>B_0FSQ]!G$W?=1'IX!Z(=;\GY!@IV(E>[5$FSM^3((?B M"9=+\HV>]!:>6&%2'0P0WRG$+/5 NYU+5H07F]:Y5A^LW?<1"6XRN3W(82/X M+5![&M:&6O'",VT0S:CO*&YX&L%Z#.=LX:3(KQZ2.O'H.V U2E\6NV[ZK=2U M:Y]XSL%W"W4)6+?<'[@5(6DHDL#$B@^VA&U9,&W!>\#"^UD-#P=^[DTNPOL) MIWST+NYMG?6Z!2-K0#;L*QOEF#9Q'#981NSJ1IM4F^D?)(U>",XO1I7R/%PA M/W_72=?VZD7! D_[$JQKR[=D8;UE_[6% <;FV6W M.L*YG3-VS:D'^VA$5X+<,@_UZB&_( MVD8(7D^?I >7GP"K\-S##E=(,+,]S[N'FJLJN2OA/4@7'V8I)'+IA=CD[QXD MK$6*4KA;^=RM=SCQ@S_P[.WGP1;O@? N6 I[#@U8-B:1SS!N1Z;A_B Z71S/ MLXFYZJ++=Y8+$1MUTBV7U$PF0<<\=G-@+1/U$V&GFNO0?/8T8?P69=>B_,U8 M@4P'\4/+MRV^,S9GM>FZH#UW:]<":YZ<;ABK8\G.V('2$HM"["]U?'21#1]'IWL]WE#&):MK MWEU S?^BQ.V7UX&NWWO:"IIR5V?.?7@1)P)X)<[8R9> ,C^,M5X+99S6Y[B3 M37HV]=SF/&_.AOVCO)"3T]TFDRW^1X\&=)O-0DBG,9035+7SI!':R?GG$BJ= MK"3;>=L@5VEX8O#NT>LDB)^B8K/5:5[:RA/J8TS"UX)M)#1K8P\DN0%)JSH] M&4DC( +VIYAX(,=BZR#+SB&/>]C7:2GW$.TUM#U1O MP>=;ZJVGAUB-QTK&=,%G;5P&E@/V^WLV@(?^[FJI?T^*TI^6"<$!^)NMR()R MD@[YV@*2HSA)"Z5!BN",>?_JLF"0T9/?DJ>?S-4=:_(]S]LL4C97C;P)PQN! MAXZ 1SR(<@3OP)-<9F922 =[Z19(K^/1W[Y-[H&.[($2A56C;3%SA]:_.BNM MF_F'60=.,5QL9P\WGK[W\%90BP!>':/!IF8_4C _=;I=?%L0V+EOYG]$C)B' M@*"ZT=I.((9AI0J!%,;9EF&]L<&J?G.?]6(2TA=RB4=7=+UW#^2GF3$6.]A= M60AQQ$X^Q@+.MPQD63++)^AFV>TJ'8)Z3P/G[_G\RE<^%8:E3K<)PZP>UI<$ M-!K_\W]]?_YTDT_\M*(@!S6UL' MP^N!219H5IYI[2!/8DP3/UO)",9TI#F^K[AW_NOGI;.?6KC)O>[]1[G<:Q$XK9XC([!]-J)@!!&T?6RB41^:AOV,(H,E9G MX#*$WDZW=\MWFS/,DXM+A8@&[8W)-HRPUTU--0(80VE#J':\Z*=*J1_Z^^S* MT!A#R0&.$WA]U/#]^L9C 6E+=Y75<=$,,13K: M J*C("FL24?TJVI[-7K6UL]S4:P)I\EN8OM':!L6CL5[="[GCW.2RB;7GN\& MY(](LILA[RVNGZ&DK8,L&*Q0U4(\KSRZ!\J0PQ_P$R31[64TVTH6F8?4\_F^ MK%))7]:([!T>NK9> >H,+[J".S2NN?!J7R;W>MNF/:FI8O)W]$;%>!H1!79\DZDCKWP,5.9+ M#=!Q;Q2-9Z39Z6(LUC=[H7ZFK'P^SOISN$9KBY:(-'2#8!%!%D7TU A346JJ M).04P]/Y]2V](P&== 7KKF\L2\U\+R]&9@2-\DK5WM3RRMYH:GKEZ'YM?LM9 MTQ>['$\V\C$CMI'8WI+(=0H6CY)RM)_E#3U)NO'IILJ(P^6%,R=05Y@^MGT4 MZ19O][/O-%!>#/P':GS^*+?YC/ZY[0SUT"_ZTQBB/J,NE#75A8OFL?PYW/4+ M"N@=&5CN!-ZQF8+: W%CE\&9R._M'YJP^*$2MBE!HFFX*$9V\T^C/.S%IS8! M[9DOK@SYGZ;0-?*GJV:VW:WI. M<-/82$&3#(WF_K4(L8( Y09^GBI_\1:>-UXJTN@I+4/NVP_;VK0/E2=NHF1_ M.&-:0)'.PBCL^XY%(!S18^*W43S SSI0ZC N4G"]+,FI\HRGQ7J=CM>JNF?+ M$3UXIZ:8IIRM8FN6)])\G(L@CYZ&L2[L-L7XNKY?\,NK\G[D;;+*+_[:^F;+ M8GU@;L;1 %8+3',G20%"8S(F^IX@(@BQZSLN-N5XK]&U[=NSLSVMVSLS*%5* M8VN;*#4( _4O;U'W75> ++^98&\X!ZH,#\O??!R MH4^.N@CT6Q)89E0KRY-[,Y996":BD9%=9)2#9DM+,+1,<,/75^E M'@UM<]N2XHJ8W/X^H%65.( ? Q2$&;_BW_)^H9F(%G21%H9\E_:-'XR71U6< M[!.>\/F0;:;V?3W0-'>NG!LCAQG6)YT.77Z I4/:O2,%YYJN$!0: M%/OM%?+Y>ZXS2+W? ^5G;6=$?KB_6E+_^GX-1K/#M7!+K?V)XOT[Z>[*..2E7R$:?'1=J> M#%B^0%?#]**F+]1@+B1BUB')5;8XS1L9'E^DNTTB=+W)TCO+E.[%SB3[M/!= M0?S?#+BGA<,%G8[IH'0&0TC>>[ZBW^SFG MR()1="ED13]CP;MT121810UJ,I"<;S"IQ>/<6=7YM,FCN)*M$H;]_OSXN0_! MQEP@%I#X/(0DS+ELS+9L1)8;V;4NCLJ# MD<& Q5WY&A'9)G^_\;6Z8MC\!J2@2AZGOWP]V]_&L<]9; ]) MWM_=B2S#_BU[Z@16!S@QUIBCYHN$-]--UJP=H85ZSVKT,D( MYNDHLYCO>%H1S'=7R[?160M>>#'OB#VZHYK=P")J[@Z>TP&.:H\O^YV)@??JU:\%^^I\G@M7X\"Y!;$.; MKBP.WQSB[!';\*;:JM@J7NQD5^][(E9"\8)7Q8_GA+RH&,(ONOTA_ MR6&NO.1F)MC\/2U\5?'*#XDG/U<,[,C\G/PRW>BIA*\LVD\'>+'RJYJ!_+J? MTE_$FA]"8I1^YJO99Q0*@NV!9FA5YGL@:]K&'NB&DC/BX<"O_'FE"3K9=$+Z MMA_@!$AL_4V5@7V%'>&AW5B;RJ)&GBJCQ77 ^C)_.FBO &82PU&H,AXNFM_S M0UKX+H3&R+H'$CN_'^*QHD?NT@ULCL"^Q/]\TO[)#79<^2.6&9A1^8TW?SJ( M[L ZH88\ZI&ET,]L1^%JA.N7>K;>'PZ9O2D[[%6WP?'%EZ8XPL!WN"V5*YQF MB76 #4TTH OCF_9 1WT8&N.P-OU5JN[W7N;#*U\)R'IHZ=^>N9*?U55>VX)9 M8JJA!RS;&K)6%HO[6,, >,G^.&4VA2G(X[Q4S7"N,MU\AVG)LV6\Q<\V=([. M"[4\MKVLK<6/$2\:G&\PFH.:H3OWPQ)/YO]2J$\X[$8T1;U7]W90Z2\S*93X MV''B5;2(4:R-9J&QM>8'7KZ-!A\!3N\2'#A/ MZ4T*'K-(0^%>T7UB<8ZZ>T_L"C+YU%;G()+XF0!>5B!K?;> X)>*0QHI$=<: M:@:WS$0$OY8AMQ\?U&%P^B#/:-I6HN:SDV20W2HIN/LFK1S\&,L+5R;K4/CQ M^S3](O#$D"=3NIJ5):^.E7O4:TV3K+597E0;QX8Z+N5\4?U32@K=#@ 1@YY" M[KN2;+'#.U5NZ4,[:NRDK#E'C?:[VL[98F GU(BOS6N[[(3/./%)4]I;R&0& MNB B?F6,+$2*^5SH>]')#%+LR9RM>#+QA?H+H61>P=DTC\ KUTCS')0&$KK> M-#20HOO>?K1>1G3'::N/K)+T2/6P_F!'U<;GMU*>SM=X$7Z$5Q)/\^X=BG!B8]ZY8\NB#J+=]5-W:9 MD4GDA1]^*59QYPXR'?QT#W1219G0B>N/F>ID7.Q/G _U:CG8$;M2Y*)S$Z_. M9_PJ,#>73ORWP_3'8*WG WP!]0GHWD ,*8;&.$*@6U:H(S> 64JR@QR'SRE* MFQ9,KYA4AAF_9K'181;@NG\8>L.OU[?Z^ZJG05[[:C5JX;?PF1H&N"<>O7(: MWZQ+" WTRE'UKQ^N\I^L*',))47U4EK/I')S'3*4NIQ?6K7Q[6]'Q#%1^WII M G^[$U#K'S6#^Z.WQ:;9PJX]5<=U*+E5C(6U*+BOGQ]X^5#CJCK]:6Y+@^UK6_- U)Q&+?^A-.7&3]@W"C,6Y MD=0:6J;I;9#O''QH;O?IX] M6Y8HSQ(M>$1#'*3.=QBSH$%C5 7L)!-@(P.#:%_Z*QI[X_IIBOC5#DA#OP'N MT:CSCHN!OZ;4P5>>)D<2E*61B4K;*)*(PDIK'N(SK+@_9EH/TEG190.Q'-AL M>,!ZK;%E_ V_2H. $K_4]P,[NG01CG#"AGRZ4;2%]A:CIB5%EH1*H]PC(=-] MLNK]GBJ]"YIBOKJ6ZY(&D>A2"C%:9%,4F P\+'!4TP6:Z/=/56O^AUP,8,+& M)"*(?!4N, #GF')R+5XXM540>/U #<,2[WM];6VFQ8!;7KS0C5:R :)C_#0U M!B'O9'&8('2[JGOF"^>Y3,O>\R/"RF$;?>;(,]SZYS21.E[K\Q0.<1KCEA/Y M(9QGH_C]R@H%B7OE6VP65T?-TY>T$T1Z$=9CML$,CV%JI<8HXHD9=!T@_A.4 MSG;*C4GT2BZX_V,.-2VZA]PUUCR0"U^M&*6<3,M;&N:8#]ZJ[% P+$EMOMDS MY^^4Y/LRX^75ISF"8C-2 H%LF;0D&EDX@RW9 M ZT8X] ,%3K42!N%W2_/T&.WZT/BH[9U*05!0YFFM%!/JAJKC6YUQHC3N71IU% MHQ M=%FR/U>9 M$2<'VWS-@$R]^.E JT\ZQU8P2V4\O37_8=4E4[G,:VG9?%US\]SFO.T'H70P MW/M$A#GZPR.G/Y)]5M%X0\FA)!HW!#"B=L$K>;3.M+O7Y?2X#CPE\^YX&A,C MRAK1MR-\S!%/;J0ELT\708(]6%COGCSW[GA%\5L1SL44+ Z898[B?XN[L%?W M4SG0>/TF0M:S*5+75/M)6DN7K36^L:IU?=P\^W0^WB]#^URRA_!5@>;.+P"6 MUL,.BAA3RVOD&FW.W!TB26IX?AK88N<:X7<_/^V2ZOE: .EYZ 'O/1J)I%OG MY_J8(IGU/5$NMB8I8T&>,'QG^'.E5=DS]G-G4)=!')/S7+2KY,,NV^LPO/Z( MRME)[Q?Y1KZIOTWP(C.ZB]\_MM8ZS\@5__/T?3$"9)$ MUK+;'HC%CNSN$Z/;LZ*)#8;?0N).?[LBN3H5Z.V,/U+?EF!]N;Q%G1OB VTK MH0)27EN++JA'=",+[HY+=.=V-#^K.=FRVV!V0EKOWF?FEN;"M(QF6G7+HM/. M)N9:Q W[5&=[]_U39)YZ?>":7I*I4-^[4OK03/3Q\.-XSYNHRAX&V M^^W'#-EOV'K72/+*Q"O[["E3T/ :6<>X96<5&1[[4R>D*7F^TH?*8_6WTY]$ MJ1ZN<)G".HBW0.YAA]Q[B++4Z"I./'&BW2GO9(-:IK1G>P6@CT7O7# MM]J.6[OKBYV)4-5K-VO::8O.\9Z@AP5Z(9[+7%>K0(]I7@-;282U2==0 MB ,L:%P +_E< GH3\,Z?G3?M7Q2LE]32.0K(>AC.W.R/TI)G5$#G6[L>HS6 MBRVJ\>2&<.LDO9BO'ZMOC?!GV\[L*(@MMTEIW1B &KJ_JV91O6'3MJU"T52# M?BE5 =8I/RCY+P=+/0X,=G]W7(?@XM6DV()KI&K6*733.24GO4^H"7;)"1\P M7O?3E#^IL,RE-0I@R2WH.@,,"\:KHTEB*(I<62V2!%63[+T^<:R*V?%#S UR MYH#L;)W03*KI[?6"%GV1B^5"E5:H8[HKZ45LT&69S>/[!?)_T&WLQR*.J _ M_TCA*<68K1G+N+!"C<]3ND,JY3*:+:G 658)%K9=Y$D&\=U<[TZDIN9"GB&/ MR,)>@-FVT,P^,?JAM[[!U1W.1FSEIL\FBACFJJK/"[PX>ED@\$">6._#V"^+ M1O,1J!E$^/9^,X)EP7Q@EA"D@ZINW:G 47-[!1L,7/F#XHX7C_!]3B&02B\Y M6I++\J5\8"_++3==S8J:'5(_,VU,"Q>OS-L8L2"I5=E M17CGE>,P*^Y\UN)[2 VV5@#\Z%:]Y(U;A65KV&5&P.73)ED"?P_BVY!U"N^1 M5J2*\6,7WN)2KFB:+3T(F$.]215 SJ9Y'O0^=Z(4FZ"$Q2'9%Q&,!-;4O'1' MSN$;.5EM(B5512EO4H?5N[IZ0TSXW\P59&OJ6[SK75+T P\XGB>; MPA6I>2I"%0/UG9SV-.&BX5.W5V9'O!Q2>RX/Q@D3O<"Q#[\FIY>/,47%-:?M M=Y][\_.AJ0]F10^8&AM)F7QJZ!K67_!LGYY#BN\!WJ )%U*:AQ7X%32KT4>R0HJ)HX&F?4;*E?KU7YO!8W1 MBU"G%7"P1.0)Q#E2TK3V"Y+O4CFJK3UN-63BT6^P^)ML),7T9AB_(;D>>=AY#<%',C'O4OO0S;;2/M-I M['7669TO70+09M_L.':J?7WETWW/-S84ZKLI)YR-TY)8OWA)0FHUQ-J M?2\M-_+2#4-ONTT>0)/-(MMDB[%D+CE)*JO3ZBY)@\;:!B@0!P('5T@5!9\1_]1YL9-;U2J*J0*M-4]_["X?\C(:;]Y)$LZBR"M\[IK& M,"[0O!M0!T9D&GG%$KSR5(ZOFQ+:E8YW:UV:J7B2( U!5VR)W9J/Z+R0IZ9S M&U :W[[\H+QT]T!!WLC)3"0^%VZ/_0UN\]YY7V]>N%YSLCR%9L8\/[LB[2&.:5]_&#]=,'K%D_FUPG MW!<;F=!VX<^C-@5$:+)#3_?_NVFH_I4+ 0?4B!5R,OX\8>1Z)2D36$M]$T(< M^M"*G5[P9:718]G419":TZN;AY1:PD$[L1H(E<+8!\<"%06(F$7I/XK,\V'X MJUW3L;TU8A2)'K=\U@%38I 3F/*TLJ2C K7CW%ME1;634(.'[DIDR M0&U"#A*4ZT/-VQ7;TM?6#)DQOIK>-)L!K[RU'05-EDPS^GN1AU7?8]Y!DJ_\ M[QSMTAI>THF;I'0"G0:^/Q:PT6R ?;E/U-;;N@@83XJU,HT+52'#;;(+M M+:F+>Z#X:)T=\47:M65J$DD;/Z!/DL-7UH^?Z(:ZI. ZE%B5)F:'[]R_G(0B MZ[U NSNEI853=@V=Q]!CK[*;DCD4Q85RXZU+ =\BZA?J\Y_+T-II!I0%&ZTS M9PK\M.88*=;ND OEDH]G@'HOO*D?7OQ@8CGC_2W_400L:HLJB!A TZ=3TY&V M^KP^8M-WA >*$])*1GW,,OEM*L';ME='\)BYU=N)C*:7.**^Q=I8!F9XT4,' MK+UVOBNY+F-K]T#7:5 "6F0WWXWW 6>EJ0)R*B*&O,4,C0) M!/GFIWLJK;.J8V&[HDSI3&_8KJ2%DX9T6LMU'R'-+3_V?MQ,O_+TEB5[ MM*YUW#Y$B+GW/PH_G>[=' EPTOM45!4HGJ/[:9C[;:R&]CFIT[%/)@,9Z?G? M#*QO S9=@!I] 7(?-G*BB9]N2(2H5]TY4JR3#)Y8V*"MT\5LA_]VWZH'K@_K M-4;8 4JC#5G023D/&1K1)I5D#*_U(_BOG9>[@O5SEO8&'5?>,7HER'?206>A M68O_46QE,BG,0XN*JM^/6=!U_C$L\C2-=8;ZLG.%D?Q >_J\UD@'?JWN4[R) M>_NKF)L![;9H8YOH>]K^;H,#GP&A1M:R(ZW!)&O]08WZ1]M$K!T!\N(S@;^H MW$W(50D3P[BJ\HG>\=:FATAVKMN)V2>E_+P]:J7 .G3\^3S[_T4,OT!*M*Q? M$T=5?*PLBN(T0\-\;;M-+<<8%@'_OWV(UTHS_/9KUYC7+ MJQFIC,]1YWM765W28UY0F^-.>;=S.:O-+Y3]]8==>Z!C6G"+/5!: 'Z"M@.\ MD>FMG1A-_B:^H!']\EWGGS_>_&E\".LN[8+0>_^W![^TME]FSW""\VY39]+Z(JM4DF,^ 6[95\]_5\G*#QFA@!M;:X><3/I& M&\<69<17L.9"\(4JG+SQB;Q/+@=HJ=B:'7+5D6*R"WXI>8Z[(R!*\Y;UU.JS M5[=B$RA!8Z;M5EY",MI",E<:A2)ZU,T M_!'>%EU63Q,J/T;Z,'R89JZV@S^^1I?ADX''NEB:JJ:&BF&""-UXO9 _#Y:&\NF:Z$N<7._#5W\4LTO!A+T=!>SMHR* MM6I1&>#4!"&-(06H%3L<=L2.Z/T-(4"R(8XL1NUXQSW 9?9<^'9 KAB](LA_ MY-#LN<^6P7XIR$M8O!8;24P(^Q&Z&6C"/JDPZD;$ M#9^=:.#M1NU75Q_86*.P)Q$/?4-.OH44I6P'>[$)-S>8(I8FCBPV(IR5\)*@ MU'?<4L[?;\2L& M%#BD[EK0,GI V/?9R&,=D[K2F>_U_;-PC%5J-;_-ES)(:L6Y\>HW$S[0NU4] M1##_:/J'+/7B6)YF5>,N[H>GVO[''BXY$R ZH;()\ASYZQJ(D_;P2S M228=&-YMF+@3B*P\7[HM.)9F0%G""XI\2SMT^3&U2&ZX)7[LEH]W MHX70MRO';SD,)_=7>B1/MUM2YRB=>??QU0F%C=[:6P6:R/-*"A1VLVEBX*)S MC3S=J:0A*^--IG4.KN8L#O=M&I,#6+Y[(@Q1$#!A=2NOECY\O*>A:A^JH-W:-ZI]MU M!.-L5UI5^B0D'^DV/M+>Q!"\:(B M 96CR$\5GX&@8'A/9'#QJ\01'+H^P,DT:35S.\PENHD#,GZTSMH.=I^0ZN^) M:=P5OXI[4R83)^QJM009UJ8Q.Y,U$=UH^[)R0L/XL:Y5!;;E->:W/8),?MD) M.I]L!%_(9EB5B4!$SG2$>JXWSD0-%BF?B-91B=:_),?'47P_KDDZ MQO]/35%I(R7: MKU>-O-\K&CV@L&SM$?3 7>VP]2A=2?*)9 Q?NIS9G9?S,_@M A8. X0YT1-9?A-_? P5GXU@A[7APY.K@A ;3 M?54>(WCE.P9F]D&[ZP__Z]QO8P!,($_:A2(=D$&I?QS[Q9$O$\ZFFXXV-\U\ M-_P=4G]&$6JRW)95XG M2RC?S@2M\@ I[ G-H0T#;HE"&.#_L0U+6I "IC2E M]=ZUSM^V^.",NE7D#D]Z1;3A$A1QRLF^9&1A8)'F#=6.Z[GQ W06[__C[CU0 M ^SC_ K/&\IE_#+J=,_,NI$AE)T[,L>1>.YU7'I;C&EO]]K::=(Y"I#S6!/ M(7A70-65T;@KIP9)NM/G==OPDI$70HG6&V6KF\YZ'W,Z\8V0PV.Q#<[K08+@ ML<7UQ9Z'L2C#V!L^H\ HOWS[/Q%#^G==%"H@#6G(6K[S"$@[DD"'"Z@N39FV M^S(<^9*IT2F??_WTI/9#_YC@E^N/2N]@!> :N!6-.M.5N?@/M\<6*N+0,F9C MIF._?^MP/9,LK21U\/8Q0.5B%G^KL:)B]_/::$S43YL.%FK"N)8:HJ '=7AD&B7O2:7.K_ MT]Z9QT/9[_]_BE()"4F6J1!9*_LZJ=N6&R%+MDD4DH3L8Z82;L*$<%LR25)9 MQJYLDSU1]EW,&/N2&;Z M7/.YWLOU>;]?GY*([O1O5:(.)2VN?,)N)R&,OFJ*=_\/VN)%.^F8V-LT]=WK_XAIR)L3I2<2S_]?63 M>-5JQ?XTN!MCW-D_V,L# J@@!NV:AJOO;+M)!QVD M@W#"U-642T1EJM-6CO M3N31%7!(2RYYIO\T'^(G(+05=TY/.8_E';P9)@48XSH?BK 6$3H?K8=H<5WL MM7 Y4M%6KI_'T_]KIM%9&5.Q1$E@^(?KU3;>?E]I+5A2N3#$,[0\*Y YWJ2MFW%L/S*S*["#).15PY M6T63:JF0?,XU+4&JI&9L0(>E20G$R,;::P:#CD?[7"JB78TQMRLAFCP/A@S9 M];#^$]%K:=08AD?*0#@CECFX&B:$%$,LUQ17ZT2(W+I33B#)>AO>)P7\84KF0X&"[*:<2P''E2[\WM[D4, MSS?6Y/'K3EF]GL,)0BXN00D"+IUZ%[F7TZA'T1K:?6'?VSIY)_K1[@FH8VQ_'BV1JIKP[A8+ZY?$7S( MUM YU$-RZV947Q[7Y:"/HJR']AV_[[&5RO!C<;3&8Q-+N\@_+XQS]!V97+SX M[A2Y<20]3DGZB'-1 DCD^K6782P'7SXH?XI:./"G/6T+$/7:BG00( E9:@]Z M4<^7+Z+2I;(@;^FH*'9I=T6V1=)B<>PMV*)QYPP\ MNG82<7!!A)UX*BM[82#@F/^;''M#]R /==[D$;>AO.S34^>*CB/-KGCT:';] MQL^,K J(;0#3G00NW0]D<)&?)55#25L5!OBC%+39S#%.BFE8IDNCWS":L[' M[.*'1"L5$S8G]Q83\)&X<&>$A0]K5/C9I"W%U3W/6L MQ[[D**D.]3S3WV]/>R^)1B&P::C*""0CXF.AII9-\-M2,SN;K%2+B$=^C?T< MOO!Z[(H+2DIGK<4$;E'V[-.'T#V.+HDF'>MXL?XNAI6)^-.[]GN(>G<$-O8, M;=#6<[9I)8)4/$HQ*;XO2-4R,*"8'I8#S8:_MP1)"[&!I!'L7 U:SOHUA&\% M?KD+1RJ550;,R_B/#'(K6NCL! =%>VP.Z>P4X@\^@_'\'V4<.;>)2DY4 ![% M(IL91G0FO3Q[(=MQ?"G.MD]^1=]W:^M% M!4T4ICI8=PC 6Q &H];3E[DDCG>)A-TE\I MAOP.P%U>%,$D.DBRIX?Q'%_KPZPKH:L7<5R BC3-+">'#AJJ?X.8\X &#*;8 MX5W?F&)U=OK-(K&F/XKHX6&([V+_-_I8?<:I3HS3(OXLN_.#EB=*Z@_VO72& M K='(HG<9-F=6OT?EL2QM6 (MF#@U#JT$K6T,$@#ET;5B0?*BE5W31VU[KNN MV7Z]-?<+Z#2J^F3<%8U$RMS?? ]"A5E/,D:E\[_%O,,M\%':ZH$JIC84E4F/ M>'"T+!::8MHG!I$=8/LI(^/LG/A4P@V0'VZ!&N%S_32U#&[/<%PCWG]Y:W<7 MZ['>U3\>UT_=BZAGQV!SG$E? "XZ:)]7] 988Q+ZX+A-H:,5=:;TVIEXA^U2 M-/>G((V*]Y":#S388A?F!F+$N6FBA*L5R<7( YZU)N:YJ0AVF)@FAK##2D8_ ML=E,7;BR*G_N?N^#\=(,VE\K)EP!74C7 C:.#?A'A>;]6]BQXS.#Z MS;T> I&'&6<:BL+>+'G'/]'1#G-T'!%Y$=#_1\L,_%<10K= 'CKR4I_7[/?# MH07<_+6/=WNIA80\_=)2OZL[XIB*@.J]$Q&!)S$2B#NFP GKQ]J'E&9_J>-M M"\";4FIGWRA;VUQ=9MXLQ1OXS.1 D>;# M?EZ@Y_1)53L"$A1I:DG!S#OBJ2@J:E(9Z6)+^E6W=M7YU=K#TEWS)RO8 M+M1ZK.))!8Q#16&V5!2\^S5PYRM<%/ _9V/\LJ'QF-XPAI>Z4W"4? OZF>\M=#QN<=KO*^I8M[GCU<^Y#FU> MW@>?F++S)JCQYF5S/@_[*-K5Y[< 3EO._DN_*3NGKD@3'919)UM^]46HVS5Q M!@5BBEAW$%EKY_3[:#$$^0-)!QU%JQ_! MIR6V&6Y/>M9TXA]MA_K/>Q_4$5B\*4OL1:Q$X\3AV^8C)ACE]&KPN4D1Q0) K8CBW\XG+A719B:T#I94B$:9J%=+;J*[,J]B; MZ+TH\=+Z\\I<(079R34\2K(ESBY;X\6[*.RXT:^WI@W(/WW2K+83A[0J?GX4 M<]<[,;D%)!%-]:0R(DQL-)R=FG:CE"@1E];9ZJCX^/!/"1>?R?\,A_3K32S: M"TT:LF7M>WFS[@/@0:AL1.REB'L]!ZPO]FI"LD?6A'-BJQJ/:NYNVK5V]D.[ M4.)8VC@ZM<65SR.D:-,90'7#1'$F#DE*42WP[9)OM4,8R0VX5_].\UO@[$+6 M/YO:_;'""?^!-Z+,]4,MF)0*\$^B0< #FWEMJ=ZH#BT]3%3ARRHZ;8$;YD*:<''9W^*5[-_,JF1' MT,U@0"V=I+*S4\1D9R1N CA0[RKQG .$&P0\CA??6N>*[8M/(W'-HP%=SJ(N5X?HJOG+[O5$L^%Z&C MO-\<5OR^W42SIWC[,Q;#-C_!!1-^.7=,*]_?UB32E1-UXTX8.ROW\3A%D4]O MV7"V5WXHZO4#\;(--6@[>$?CVW01'TE]RA%"!YFH\/6'?\UX5Q"/7S?3#1#Z MC7[&#]3+**F#&ZED+43;;@*$^I@$WC86]IZL$@YT&-XIL&GQ_UZ]S-K)'K', MOO-?6L$D^0DZ:%[Q*?X=N.T9KYGC>_P_$A")K/QX,0@A#R48T4%;!JAZ*%E( M<84J4DZ],,@I?>__KM/\H*01O=#S75[AP!A'6_2PB!=CSKDW_>5\"P7_J*(1 M/6/T@]3"7A4=)3P$#=_1D^[&W_KJ A*QL>Y,GD(-T33'MS 38*YAH#*\W4]Y49&(505B\J$GF\C][CX MFLZ=UH_M(U@^?:*SP(%0AA"L((#$LTT*SP0I^7V/IW-5^H\2']LE:V0V2MPO2>@$_VSX/NBIIS?$2X%=Y!NT!CJ(&^$$B9+'38BX=7H(=;2:],NNG4+EZ7%-1/SL M._3TMOK4';-X:-]7'X@0?#< (24"?J$XB!" ,"6>>O!:3KR\^N?EVX=$E(^Z M3=D3YBZ>GN*VZ\G'9P\U%/!I6SIG]S37)*<-P)RZZF0WC)A@T)^ M\V+_DRI:CQX_C*M]QGDNQY"01DO&8/,1!%,C\$YRW>GWTK;9@RNN1J..#FKD M[\'YFSZH&YXHLY *UPK;-Q96RD<9 B(;-\=Y!E?*"DQZ)AO->^7$RJHKGATP M\E*\;8GWTXRP8CT4S.V8="R#N*8YTK8/N7*ES2\!4]C*I!X1;.K,YF6A-6+83ZBJ6#="[5]YW+>#/% M/8YYHDYE_"(,@=FIU.M![]R=;_$?'_?\*1/3)^K2&';FR6XNN#-?Z9)TWE MSFOMZ9"RC)H"73?[T.X;OYW#R!R(&W/S^]U'[\$R@^H%Y#R#G"7E DC9W]I7 M["C?D+-0/(+",XM762+<3&P&<]7H>#E[)6R2GE"KVJX@N-,.SSW?:#P4FM>R MN!V#/@-4DX_ ) "B3&E@*6XS?"/D?6D=,=]*NH4.JB N)])!(NCK<7!2'KB: M@MI"/9W)W-M<*5/)LYI&!XUFTT$?45_X^,C61'G:OOV$BRWGC.0BO2=7]GT< M/MOL^OIQWKWM@@:->#K(<]F$!J:R?[[_Z#APW!E>BLEA/3BPEDD5@>HP4RI?6(\('8(B)#9XX M3&0=?S+.3UC':VEC[X/9LLSQ@Q>]%!.*%8R.?GHSFI$!,B"7TL#A9(9O[1I] MB\!&,Q[ZV,'P=(NDX+=7^,]5+%J&U+4N9Q[!GQD^96?-E6'LM' I^Y826"PC MZ/K3A*1GZ<82Y;U+H=ZZ,(8QXFJ@9M!!+@7Q#KR@LH MX&0-'83WFP[5YZ8@O[G.8Q:3+S(>QS(,094.2MUHYEN%4"#L)%\Z**N2$??6 M\\W208+9WUU:]X:0_BKD?>3V]!/&KSWE*9R0F=_]Z??^]X<[T=Z[0-8%&1:; M!;FUTW4JRC!1!(PK9%O0SY3"[8@@5D%P +041>6HRJ7M0T. KV"S)H0H^5=$ MX54NZMX>.N@#GN8ZR&O]D?%=4N2'.VD17RT8P8LUBG('"<#YEQC7?O'.3E>N M="=-1;_/&_R1-@-F#I@Y8.: _\T&S+>&I/"UZM.^,D9V#V8:^6FMIEHP)/9] MBV;>1_%.7*DVL&*/_GY0A6RD[!V],I@XM9@& M)Q7HU?72\/U'CB\V[TW+-C MZ[U9;E>=*G;YEQNI5HJ=F\_N"W_VC&RP#K?YXE1?OVFN&+,U%-OPK!;O1\4J6O=%,6Z^'37G61\X J>C*@/3R<'"K96Z MW1"$"UXC/%8IGBU(7*UL@+/?EW*>@\&TQ:#61:@]<K"PP!]&L< D/6:U].K)7-/3W>109E'7AM/+JNB64Q<\%DAOYG: M$!P=1!&,PH7P" ;F3=[$O+TG+Y+TJM$)>?F87CK$(7M^I"C3,QPY0BX,L3%E M!Y*K>P].5G\R@X8%4+C:WO824AZ6H\"+9^>K.!/?+-H^FO 9:.C_=A/QXK@, M0HK:N]-MQ.I"S:0)& JUUB<$1B_(<"N7(V2[(#8/;$PGD]9=']"$ @-PR?%4 M%*Z639>P<;]%MJQ=LN#$T?E5O>?PI$9K[5>8R"/4>W20PM+J!$MQKSN>R/UP MF7>*$0!9QU ]XK!.]!M9@\DBMRM/FT\K&[6A@_0?[;B/(3%G'6K-'DDNC5 MO!D@.DWB4PVFTW>=DM)0$R9_R^?5HK%?9AX=M*L'$@Q_9?JP9O\+F#)AZ9A^ MY+U0A0L]!7HG2XO*C0)%MT^"V$PO#;R(7AWULH(_WJ?';?:PY$^J2'O^2_': M]T+V:(-""5(R(2Z+R$+R 1X\GS]"!WGTEV,X%I2/7 YZ#'ZF65&B?^S.=3Z? MCKTV]Q7:=K_5B%I"2"A:#S*>=!QTI)$694JS'X'00>+==! G'S4?,O>4#IK^ MS)C@JP[!\![A[FFR&LGU(^_O.T.D1[@KY'_B^._EA("<[P^',TQ(O9HV-Q") M55G2( S6TV1ZZ:"2><55C6:UD3F%T5XVPJ!(;CWXDF79=.YQ&;S/^2H>B2 M\U:KY,]-@;^I=&!8R#N=PW?:21W4IYJNA-653W%X^V+G7%.)KV5UR,WDG@2U M$?$K7^,N)0LO#DJ^>O:L2\GO)D+\&+@!S!T8-DE%WU]>;T<"E[YM^'4EFCJ1 MZP-OKL*R8U;%L(,;TF1)6F71#L(DC=QA380^L#@"*1NB@!@7E1&HN1Y;TT\&ICL,&/*C$-@YE M?-BL4?RFQ_*M\5I'#S'?KIQV_X8_[4/\W:C^UK[$E/W4XIUWJ-"RP6;HR,ID M;K0B. +EU55CB.> 7NDM1.!.]KP@ZY9MEAKQ+(4D^8W%Y!YD.8B]'UB8H9AP M9U;YE&R.\]I,]#8=1!.2)ML@ND_30>WI^G30%,- -V#*(ZF'493W90B:46&G M.^<VR4-6:L0$\]7$Z$-8#[W8!C$K:ZO+*3:SJUR MSYI8H(.E3].NY.,N3_8HO0.W:?%M, RVJC6IB YZP?#5*XIA;%GDOR/%+:.KJGM]WAC[C!!'F\?_?'S_#,+??O]3%3BSM MO(B]3LV!'X0/3[!3KDY"(^B@X3HP825*!KW!C@8,%-_7=;+ZY&DLQ4T_*]JE M:BE&XB.WV0>FGNJ/&U.T?;S3,-#Q-QH&0ND@=RAP$KRLP_!7,41:[4O86;)C M8@&0:(8I0=$.:YV"J.^_\S)!9610)T7J ^Z^J.9]CSQVL?3W[=&/W6T N=]E M2C ,4S+U;V5*OORP0B8<0S"! J+(Y1,$0=(DX('G.@)3HWTBK$1N/*K"5-,F M>F971?=]J/CX[>IH@JKE*;, M#?,4MDX 681.>T"!R&]+0$4I;I75AC1N)MA,V'[2=LO1DPJ:N[)Q4/6:#NM# MCFN#WSHI_-*T_6P%\*$4=6@3,CQ8MWRSR<@A#8[.#7W!#EG.NWQ6:-PE/WZK MBX#1X.A^HO!KO]U:RG?W9]W)5M:A],LS 0D7Y.^[HSM?+M)5NV-K]^^9"]DC M%ZNX_HFC7_4J:3SC-ZNL*7V7UK/:HYNV'^MN20C(O5RB KD-AH^^89[EJDDHK!N$H.VKP+UQ8- MU#I90CP(\B3;'/\%??G>J*3%.Z[JD^\^F+_?7L6PT4%.$\ IS'(N^2"MNPK< MQ,5)D7:O:Z#IY5R#663G!^9ZXPLQ(95\I'+7SFT(5Z-=LKF MD\R-CWTDK?&>.V_ FLU[T[B]:_FF?=Q^H<$];LV7B$,KV:=5R:.)O]F>P[H- M4YE+X<;@^)='*FW+OV6.'R)V?$@BBB /O^RM.Z/=S[__KKI+A5C#?3&SYM ; MNE=<>JM.F9E;N:XYD^\BZ@7K%.!-A^UOJ>^4(.T/",.+H7]1E!R?W'@$Y91>LAO4G)2K M:GY+F]@K<"[HYDCA& 5?X&?1?"^^W8)]0&(M4C=TC6R%J*]&"=6Q:#5OAN&+ M@)SGSR,V_SECF)LB&%?F9;MYXK. M&Z]M:\N;V+JS[PJ8]EE?N9E3W"[Y22.US$S7[,3?7))U"[1KL*V,\QL-E?^I M9X/#V:+:\\G5H5&MIC65%R]V=X3>1Y?303>Y )56_&;K0&4-<6^J$Z'SXJ]L M"HNKB%001 MC1P?19Q;C.8QL3I*KG#SYX-\3FC#MS5^^1Q94Y-;Q]#S< M?%!27>KM?5ZN\V?M>YOE2^XU'J!U,Q)QRN%>TKD!R+6)8:Y+!$Y,WOS(0#'? M%&D4";VLO8+0]2#PT]DB&ZZ@#YLG7:,.D.AG %XL #&H@X(AEF6.+9%?3 MLJ9YV<9SMS/OP5G>?!D3VEB$"G\7KR2IQU\V+/W\QL3$\R7L@6XHXON@'OQ7 M:4(_V2#@I_^9I.-'W1G)?V5$T%T3P'%^"L_*Y.:2T20=%%4)Y:D1I8/V=8B< M*.V=[!TEFW_:7.;@&>,_6IEVX1TG)D2@4V"FI,!#?>DICRS,L M]2B\P1+, [B:$M$1&QQ@J]+*OGNU5N-&1NUVC[CX.LZ=MM:SJ+,'T[NNW2OI=D7E MR:K0F4,&*3S9*4AQ=F=.7A4!*B :$1L*U%OX:I \+EB MX<5Y\.^XZA3&54,8_YF*I_Z"\,!PT<8@I8A(VHG H&3QONQ5/_:3Y)<]*Y=W M*54CJEJE# 3CXXM8#FR\I80S7+4RK153GDOA(9/"W& ZA$_3=<> #SF%M8<# M$PU3EC@Y3];]9/>BHWLJPI*U[/;0P4\/,8YYG6_X!-R+YRP2O0?OOHB65O@= MTL3_3\$R#05D_9\)KU!X/%I[SEX;\)E//,7%^DQO6(W4B&KE S2@7?H4/@\= MK\.(>DW::;NW*V?GW?UBTX&(R=-1K14=LQ4*(QA4\'9'. V'AG2#V^M4>CW4 ML[774W",$&QG^\O:1N*3?^55HV_M[.PQW!9*#J"<,D@)D8_*GQ*E)CU1 '_8 MC3A M-W6H.T7?,Y(U0T9@0 _X.05LQ4PR \-\=I.5V,$X\/J ?G>)GTW*:BI M$'L5X[[/166#MD^@L'@R59?7>C9W\^X_VG7 Y.]T9? 3LTD^!*YE_BS$36"E MGB9,O)'VQF;0HC@.A^VT$"SZ*H@H>P0.7I9\SO5E8H2%QI$/"!//SE01;N9, M(B)5>EQ>6FV"1ZP.F/KR3K77+YTR:Q/Y%1C$FU($98EY]5PRXYQ$_K :;[?W MPP*IZ]7#D.6,YTT*=) #I@43(%F0_4O:@K.,)OCB5BC ,+:LU=2L.G8!DUI" M9$O[0;;#ID[7_#3N+2?*OHD';7Z-)E ]+M81QK/%,[-<_9P"]C<]L6_J-HCL MR@/IXZ5P0]2%!(,%>IL8!H>7M(NN]I;HH?Q89D:UFP[ MVE0,HW\#PRU0UTU ZB._?/ J6> ?>->BO9*DOCP_*C#;UT^]I64&MDSQW7KS M I,]P3"42ZC_,)3.?S:4;730GRSE (1AW@>R9N3?=GZDW7V-GG^\LV"I1.NP M/?A9#,Q&41$]R_HXZHZ<-=)=S(FF-.?(20VC[8=!_$+Y DD]JR,.+9PKCHB$U\+[NC #LX9";F%?& MT@;E7?G.Y<7EE:7ER$<1^YJ\<[O/@RRC(Z-#N5\T%.935':V?MS[@6)-M+NH M$EOCB:6#V$;:-B=+#/T\WK5634HRDCSCT%@"/XVC%MA#*,=6$2T U*3X>J"K ML=[Z\/ 1X0'I4&3,6OG4W6"AF+#M/;HWI-9"C44OL&>U4L!4%(R=K#T'':YC M(R C81+.,8K!#H_\Q[VJDT#5WOU1$@/5!R3SC7]8WL'DAW!I40M@(O#CM';( M844E9$>B):$EV_,0BT2'A_MN[F^"K*'26^7H!:E T:H'^/@C!E/FA3$JTBSU MK %[,:F(Q[0]B;B 9C1OX$V'<==(OY#:LZMG?%D[!>B@+H_Y0'BPB4@,+8 X MN&^+\&O.B#="S@JC[,M()T(%*+1_I0H2'RF%RH3)O\9T@0H MC5V:4$:1VQ&L#AQL?]Q>1N0?WFB':]-!SPYO%=!!B(%;U#ET.PI0'<4R_,[C M "+G/CNO%8I&B)RJ\!W9%#KH$A+G6&%DG M5)X1C\];PR.G/_.:05T08O](]>S?!3Z*J-^C?43E/AWDY+;QQEE:):8\K];P M:H3@)Z3G6ZY7<\*1Y-D*::+RER^>>JO2(8'C[K/>0M[/Q[XT84$:"8'H>7V2 M!V (_N U3*ZOXXB1@ZEDC]I\:N\Q-#\CC@!XT].):"[M@G9=BV]TD"@)S>K3 M:JU4$.MQZ6XEM58E%_O2?]U,%Y9*U?RC-=V8,/G/X%M;H? )8C7@71-%LW%E M'F[:W6_=!U"CZCYOO_DJO5FK>$Y;:RG1@RSFA.ZY*#==+\#VD"NX)TG?Y)9' M]OOFU&ON^+M)9_S@Q^*]X;$V-/LYM-O.ZB;\BRQ9FC8(/T?(N+RE_G- !-GP MPY;Q4SJH-ER_\,/X5AFIU5YXNR?>]-$(5[.#\H3?YB,A][12R:VT%G?(O=D1M5$0HK=1 MI'^+!]J;TH2*K+)N1D5N#T8HM3L%9"^2S(<KK;+:=QX"\D\HY4WD6EG>Y#^!M\*EK_&O=\L'\JL/#6 MG%NZ.-SOAT<\=I!_%I10QICG:Z-/Q%M/17".\_TI[_-YFC':+( M]=->C7ZS,XQ-<+)UE=>,2RWP[**1QZ;>8';N_;EN/Y M>,M5+4>&53FQ!N56X$);YD\WH"H"*H12(P!,R&VLX^IV7EW'< Q==/**C_ ^ M=M\!,^*<+/'^ND<.(R9H&WY]-,?7Z&P(]A6FF&]PR8BLZ^A>4=0QSCG8/@$$ M3YA?*&4]9V6_U1OX).'M)@0!? :UGXI@F!(O@TL>8$_?T?"CADTGNILZ? M@OF6*!Z<'391:T;H3K#4<<[10:6;#?)<@'PC84O=-/)V3X_(F9[X]H\3R]7) M_EK#4>A8##:2#BJZ"G 0LNI.!:9UMA.]8@M2EK@O8;137V6<(P[/G+#?/AYS M-^ ^4L=1+4EQ#;SBX;^&B2O1@+'GS1-!T&;6OKSQ"AXCIX-!,^6Q%O&.&M\ M-_Y:"80)DW]76%H1=Y!#9#UJ!1QTRY&[+\:_*@&1,S<2)F>""GS^"*XFZ6,Y M6%7<>IR;L@VS )P*84> J/Q ZZ8JV(CC^RS[\H*O96%/G;K"NI,>',Q7O7%- MYW@8M-<39D$'[0G9T>I#+WMB30%C3?#-QT3!QN2I?6;GU3?>KEZ3H 6C3YT+ M7HV,,*\;L/@U1"!$"L5. 6^!GP Y']!*C720^S5G\K;'E;HQ:U.BW+.!M#FX M6+>YPTB[DY\83ZN8PH49-='X2V6W.?<=7]VG>:W/;Z-U]?5_R<*.@ GZ2$ B M$3X .6+=3),L7M,6 ?1PCF[3T*^+*LX'DQLU%3U6RYY%)T'Q'XE>0\XD&2)X MN9Y8.-AHJ][F\7(DZ=W AGGJXY\KVMHVXPF6/$!Z8KB5$YD.(OCBV")INV'G MNBFBN)!]ZU^Y+E8>(76A94)*W],D;HJG(F4Z#!<=Y3Q_#3E*EH29$J S\%J< MU^Z:WL.E,K<1WL9SJ-&$^5F^P>K-D-%7EB/O6$!W0?\=0FQ,F/P/P#9#!U&. M<-'VZTHTK;V&60&NK_("H_@*-76R[20^Y^UJ=[B0G8\-76_9,]^3)PKJ>E-[O/04H=THQX J;CL_.GT:>[-R@Q^Q]7HE:]^7SU" M:(;_J5E9;UW[]9\R)]GP=F@)'12-\<#$' L(HTC<['5P.!.2EVM!"CTW=DAD M\N;2X\QG-D^>'SDNB"HQ70K'RX^J3,9H"Q!BD:G3RXF7^TYM>=Y[QWZM71H> M:)9\?1\(B]_T)2E2'VL*D[DI^9F+!R-VLJO!=9RC MF9UJ"]BUJI>4R1#CKB3C,IT(EIJ^F)+)& M(I, "8VK!&/8&M32)%]*/Y-SCG:CX]R8U>[J1N?C.-5O:;3":J7L.5XS7;?? M*2YG6<"O6T,4*?!RRAUQ@$XX&IQ\.#)R*ME]C,!GJ2/36L2BR'G6HRE-9N,7A3)%"++YU5[EY%^B](^O\95D!/5L8Y=-)X\O6VT_)H$8 MH>%A!P\NY\G.V"CQ9\^EE2K#LU)X?E9'EG_$>)M2UBY6DSM>\J'[T)R KRDA M(MPU9UY9.?AF>FY3D9VM;4-1H]>Q&*F3DKNN<-X_:!V&_.+,Y1.!QNC2$/'D M -9 0^@1?.R7Q'"M/N6GF.8!Z?9)N%T&8@E/5@J$D,R!&QXXR)YY]U?S%720 M9L_9">]099#[*]CN5>6]IJ"='[8@7;[5U<3$F>39]4PPUZ5PR>XLOJ/-5\7R M$Y9V[-VI^G\#)\J$R3_+'D]GO5+BD21OI]>VHU";<;VN,;NQGTJ:U<\T2DOO M%C# /CSCL39(&F0\I@<"?2>EQP/#<'S3F$<;D1W(K*_)Z@[M?M1>D.,8RC15 M'73(97#N&5]W9+-EEMRM.ZV1J+OC#AEF)(%P);E.=WG]*@KJ2N=,-CYE:1'O M-8QN7G6#JQ+&W>W9'@$F%J$7Q5 M[W^N+8,D#1LCEDNVKI+TIPKX%B?*H$LGB%"2U;NG0'M]54XR2N!#OVSOLFU( MW/TMXC2_VE%KJ?'^*:7E"R]OOG_^#?GQ[*\R>D?RLJ/"'B4O&.9NGGD1+15W M^<=I=GFV6V6F:/^)XMZE;^B5.W8NRB2B8LFG\>BW^R6&#K#QCI9(=4-=X)\A MA(LK,1BAD?&UIB/^#"]S3ZVHQ=.%!]9.^_SB&:XVYVQHL.MZ&,F<\;5<@(E0 M4^"=\!$(Y11<[%'DL5=549 $?,T9YW8DVY.[7R 8QYL2REE&/VVA;M!FOL_L0B(*EX(/]%R]Y6.C$@83]*VX6'"K MF$^A)>BK%QN7LOZ).IO.S<6-4I+R3D4H19$:K=B4V)AF=\M1+$$K19WVXHC= ML,^9!H78HJRV+6<64<''W&F;;Z5GB*G/;FUKB0[#:SOG3/@(LZ?;9*VX24F8 M3#LTH2 ;P.QL%1#4.O%'2\8P8?*OA"-9//-4G*YU;+V5EICLD4X'[1EU._9RJA0*A-)!I3EM"\V'@F2:UE)BX^"Y$ ,S6XL"]3L$ MSV AM0CKL%8+DLTGLS%;VT\,D">JP0V@/!MM-:0*J/]BN-)+I MH)+%$;F"%P[W5KV6IBH2:5MW.5P&-_:_F;>J^AJ37)D\L)G<$Z-IH2<6VUJ5 MR1&$BD$X8<+@D""Q_KHC .>"NT*=TPN[9@57M8Y?LJH3!]]\#KCXBR@)MZDP M69RY9\ $L+>%FS^&1GNM0C*"I3<['1DF1@/^1>2D?U#=L9%ZT3LG"OSLR'=? M;AY(#,<7B;+T\G7<@A(N<@U/;HO;4#0*ATLRDB/MWHG7UOD[;1V8BPN-#,D% M$*FX/H*I%K+1/)$.JLS9_D!1>(&Y"\$U8DKI("H+Q8)Q$U/HH -CO700-@I< M&OJ4/$4PWAC!"XH/HANH<,.GM#+$'1P9\AZ1>HA@#0GYDK#Q%&.@0(B+IH5I MJM!!K&AJ)D72>@G#KJDF-XZZO8;6<$:I34"0\. UQQPLZKX("^"V,"Y(,'T$ MT_[HDVOP8)7,G96D5U MRC5UE]C-QOO9CT Z_U.*>*T4$/B@L7HM>D MG:4M:6+IE#K\>@PJW"<&;<\IV_UO4#K+A D3)DR8 M,&'"A D3)DR8,&'"A D3)DR8,&'"A D3)DR8,&'"A D3)DR8,&'"A D3)DR8 M,&'"A D3)DR8,&'"A D3)DR8,&'"A,G_SW#1A_\74$L#!!0 ( &""65JM M4% P&]D 'P_ 0 3 ;7)K+3(P,C0Q,C,Q7VHF0!%24FJ"$@;0[?O__W?WO?M^SS[V[]^[N?:[C\P8SYSTSY[SU]YXY&>XH MEP)(.MC:VP(\&WB ,_ _@+L(;+0Z%W36!_ !X(.'2P*L@0T\/X^?GQM^'GR\ M/S_Y^?AX^03X!03^($%A(9@$!02$1(6$17X>\/_$1$7$?G[Y>9&_==W S\O+ M+R(H("CROWUPFP IH0T[^"B\/.K !BD>7BD>;AN @,?(_\?P>("_'SP;>/GX M!03A88C"#)62\/!Y>>%!\\,CAELCX7: 3XI?>LM.*P&9HUZ"ZE=DC6[LCZ:YZ^S5:&$1>85-BDI;M;2W;=5\__PO7@D.NAV+"PF-NQL;%WTI(3$N_<_=>QOT'F7GY!86/ MBYX\??:JO**RJOIU36U+:UM[1^>;KN[^@<&AX9'1L7'JU/2GSU]FOGZ;I2]_ M_['"6(76UG_.BP?@Y?F?QU_.2PJ>UX:?.A#\.2^>#:$_&:3X^+?L%)"V.BKH M=45&W>B&D.R!V[EES<(:NX[1Y,Y>[1.1US2F;J7_G-H?,_M?FUCTOVMF_S2Q M?Y[7."#&RP,KCU<*0 +0*@/!CN<"EU"0;NE"%YU,M6O!D^K:U(2XP$V--J58 M9F/)E/CADX4)*WMS3^:?]%&^/OTM57=> KI)XH@\X +VU[E =UP-%^A\P@5B MG(B?MQ,JR>QZ\-MR.)OS2*()\9>,MYR(E*>$'QE!K"(4MZB2,BR 7X(J! RE("0AI) MRXK9?]+]!I6T(R&*&X^1+ =EWQ.VXP$$;'/F_@1:^:$,DVMGAT,I:J(YZ MZW-*=Y=*)ONESYG+5OS09D9QK$XE3JCZZPO??15/L5<=AT:_?7WARE$H;4:L MZ^'DN$!+'(D+).7_Z4R)97$BQVYU%[*$"LY\POT(<;X[C5?!6%.+;IH@$!AF MFTNF;4J!N\7[PJ=H!^EMZD?3WJ(^"1X[R*MYX]12 M(?'".W[!.?26#9T7M; M7*KDY1;JT/P#V>P#I +HU1R2="_#;T\&%UJE5FF"45EV_ MI:*_0D3%A$F"?8C_"8KGQQMK!78W!;7U,.LO9"D?>Q+HG'RM?S9?6 M$VR^AR.TVS\&W+O#>ELD=QDU?O AC'!7[.LGU$^R M#T&;/+J,5_K\\&@&TV:K2!E$F>RM;:1'(KIFK_]PU>4"HB,4/%L>*<(%J-:! M7*"][\^G1KK9KG(L_*+O<&20*!= :JSF/\NK04.GB7S@US+(E0N(* =Q#&HQ MVM&S?+65#S03?Q-7N?U2I]O6BB^$+_1)MDX%9T_E['-_D<%G+&E4WTV5 M=F7Y8;AI.SZ1+&')SS(:X1BQW.G.5?%4O.BW7;/AC-+0UYW^ 2(*:0=DY2]N M0^I$MU$ ^PW$#4C_+"<[BB%+WI?QF M$%V N*:;TSI/IT]3 D40EP+$ZUB1; M;L)T4#6FP\UAF-$>. IL-66Y5"!EJY\ M2(YH'M_OY.%Z5Q7%DZ;K=^-K"R7Y(>6+7T0F%VAV@E5JQT[-8G !]+C"8:1@ M_\R;(&4NX'LZ; .J*DFUT35]!NSLDN("Q7.]AP,ZD%.:AI"Z*QM!C.<"-,(0 M<4V::* /?K:K(S"5!#E%V]&1F ".Z#0 =/ MR@OQS,Q__#X995D6PQ&YP13XR.D\KG%PX:)A2[N>LAKD/!,'5]L\HAWU@GC MRU*1HR=171=XN8# %&9F&M5LH;38VJJF_IJV,GPW ,QMS-KWA*Z:N9OI+^>N MI9=\>;]VS&2M/!>(2452XEQ/;RRC72^FPS:$KJM[E3B,V*C=W'#6/V1[XK,P MJ8)AG;1=.T5X]FBFACV2^("*02AS)#A]X$;C)=@I>#A:?CF&M,;GR>/7ZZAL M6[-B?T:9RY&O!\6>B[QZ:/1RNTM_2+IA5\^_>O!=H* M=-@BO<%F$:0WZB:Y7((E0Z 2DG\@Q<9/0:0I=(PQ%U# 'J#?_7@V$.4Q&+)' MFF%]Y>I:FK,U\MZCAUZFWM=V24KD$GVXP/@2PY==T:A4U+XTAIX^'#L-2AA_ M$0[ZX5'2,7Z&9T>O#(^F])F8SV^>C9ZY$BV.8N[!#1( +A!0NL$3Z\1^R-'P MP.0?>#6\6)%4&>FZJ/&>!U()Q_9KBJG0G,)"FY&0%K)I::R70:/W M+KRC6;L/F>\T; L2)7UK-(3 ?!L^)?G<2-D.JV?UNFK4D.K/W7**:>>W9)XW M@?!,;=B._5?0HZXKDES[Y&U:SV_U@X_* MGIQQU7ISY^C' _E[&K@9]LCT8137LA!_(I.'PC'9E\6T7 MW(MN_JC3S7IJ3#J6>S/C6+NR=<#OQT5WY2-VFTM,:BTYE\(>1+F/H*%ZQV88 M&R%!%;0@]@AG]PCKVN>YR3U0]=-32276'2/EI5F,;P:FN[]ZO#V?N./MLUDW50NXM^">^-&B,><0/ M(=&(F(!S(+91D?XX_YQYQP=U>D/)G>\=/!.?RN-=KW1(+GS<%7U8MHUNO+VY MJ\>&A&Z^$.QU]=2(XJU8D6"T<:8#9[9N:;O[]K"JM-GW,U-H? 4B%KUQA9S0 MN)W0,X!%%IRZ8/KN(4)GT[@M[\?8)M4N6:PQG1%#=Z5.QM)-6P;6,H-N&2=% MVK:7IW]V4GKSB!DUJE$F0-3B I>0D/[&(N8AK- (T3>;EV*Q=+-P:'%+TO%! M@Q6Z>9+8L>=XB3N;#Q0^D$.]6PW=L#>?H0+[PH=9L!S9E"+("!OA\$Y"59[J M4WX5[PX,H"4/?NC1/?C[FJV@GG/V'2PYU(\W<0V_0M3E]#&P7*#N,U1BF,AT M'R&]81,Y6V=2P2&)%Y$>['*2QUB$ ]C\B8@T16Y=^U%MLE""'UG7[>:(X :5 M!-L0\8P< RC7, ZK\&02OS-8&!L4$&$N]?ONM;X ".:75H1)(YI;7UEK5:9Y^DWGOS*O>)E MI_F9BMWOXW?V*%_N7 K_Y#JT R7^=ONU0*,NE42EO5(W7(X9"6D\,8%F:*Z, M+G8L\AP:,D0LD*XP [&G:/A8]9$BFA(46.\J=.7JAZ_/?:5\E)5_>[GX;?5> MQ9Y,?T(>^A6>):?!$5YB7L$D@H*X;F(E_F8]NH1$4GY@K.M8%0VU[*QUKGI] M\G/PJ92WSPY\.I><^ GTPT/ZO2SI'L9AJ*L$UTNL,%R(R(=\.RQ5,:YN'Q8K M FW=] ]]L+NR25^\/'="MJQ:#',I[$WI#="O%X\N,V3)[N*(D)B:$I!F24[6 M%$J990[%K<^THQ"0VRM]O-KAG;&#V>N[]+#BSXF5LP MPSA=Z)!KF1_0R[O?3";H..['NT2,(M).$:"MI@L6]%!K2)RFP6CMJ[>96I(^5=F8D$?RJ[T3%*+> MT2\GKO_J48L&XD&\0Q;C%JR=CW"4TB.>6TK.')EG,@]P1FJ1<5AOZDAL2/;& M.=M!G[3!=WRA4M$?2/M4^QQA!<7-/$S\P@6\2R%=099,.:,&HC]FR4$\M)GV MZZ>WU5?5U)35#N.D)OV/J+?*'%RKR>0_868%^&K2]HVTG59CPP9QKG3T&D?T M,S.(C!NRE!VI/%A_,(=V72S]"T\0A=F .< &7[^YD:^O= M-H7UC2Y\?5=)H;[)% KO#R0#SF71;; >8/^\B$*06-O9#XD72X4P\6TCN>_B MH@>S MN^B#+(61>N=IO VH-_";@:%;E/&LM/L%$^8; @X(+ZR$< MO/Z/-NK9&*;M)(]Y,N9$S"^KW^4REF MC."ABEX NX7VOGK#QS&__OD'2Z7#PCRH"N,/]^R%-(53]Z8:-<+%&O]U>BA+ M*HM11).X!9[M)3DR6B$?"JCTM=_#ONA"1N;*'24N<#-H?^(7Q86W-\WUWKQQ M^"28>DA-'(C+OO)A-K%^J\K CA.1!UJ/5-R2WK]6F#,F M)6CA%J4:X=I#I'FB4N&QX3;Y$^"D.Z[;CMBDW([C^=!H\DWIW6KJ=/S"0O&W M,G=KC0O*@4?6OIQLSI#:\M'C\^G]+XH8B;#&5L%F&:(?\29''9*B$#?,$959 M=E.J&V<'#D*>^:Q-0UL;AGTP]_6N)"49"W\_LQ:U>.C2$8<;^Q%%DRIT1'R] M%Y6)D(<<3[\:,BXYW&]68GI\X$5:1,1KS2/T'ME;#F^2"W;X:$I:"31:0ZU< M0) ?MC1E#A_6[C6$HBLSYFG= =V)]7;1MPTAI$.L^QW&HE_;I+M ML+PT7SC4Z"I_X4R(X.I9%ZOHJ)$YN_E*ICSN';*,V&1ARK@("=,(=GTL0Z^B MK85#KT[:HD]LV5V_BJ\V->KJ"L7>TXNXLE\5W8Q/10C"(HG?%]J^%,4%9()1 M"I"W2W(CX04&/)HZ.WY1Q2C^P'Z?O2[6<<>$S@BIOP)]T>/I%,2"+]7)M1-1 MWMD6$"3C[XY(,/@A[K+\$]V1CU:19DBWC;9L-7UQD/\P1HMH23R/YL6$R?.\$ M(*.SK:4E<1\2VJW-.;0TK<#.UDXF9A<"D>W3^)^C: W"GQ9BW\<&T95(*/I, M&\9$N%Z&.J;_V-_DM[*HWN WLW'&RU/'.B,,KG2@Y*80%8(L!5&.L"M3CW5F MF,.#C62_- [:B"&VIMO)5^:=^CJ>7'IA2?I05(4+G";?I+0B&N9.*\(6!Z/9 MNTG(,TBF D<3_!9]@2X!([YW[!@XR*(@ ^V%>2Y016Y?$L(%&L^>*Q)6EANR1EJH).FJ^?API4?+E"B MFSE=&2#-WE'5K,W2$+HV[9CM.S72AN"%SGOHJB);E26= L)"/G64K_7,=,3H M\1XZHO+V!.?#!QX;V2-_HVO?L27D>':.:KO$Q-G0&H0%H9N>;E4,DNU^>\5 M^+_L@O_[VH@!)M2*'C05&H<3P^X:L=2!.J9[!H+U]SG6/914[6F/CVP+7)B+- MW7"<;$L7CTMAFF#WT"U*5HKO#F&=KA5-Z)65\25%7'US<(]9(1SH7]CB(?6E MA:!\3'BK&SNS40/*&>X8$KW0J%@S:'!OVV :?_MKW\UBV:^><8&1X^@<+M!F M!4^F%#WZL6?LZO)W<&!B 3>\"K;G?@$O'(?Q(^+\,)&P4O1T?:_--2*MNE$& M[#M"6^)LI/P=K#70LCB)\?$@+500+JS0N?^T]# P$Q\]QM MO5"%VINT.-T9_<*"J^^]/RI:SX\[_+[12FYIQSOQMNU7@G2ZE)^<"[X8)_B[ ME:H-S@D;,LS1^XE!D)277$ 127E$4 6]D"I8?\B?[FOU80NMJ T?KR06_KZ( MQM;3YU-P.>:QTZ4ZSFWWFWX!&R^5;9= M4H26&$>AWI^KO[ ,\N#[VM3+,*_@WI KMI+C.<8LY <3#X041MUBFU_UY-97 MKY.Z_59T(^[SHO7+SE^FF5V\[K2PO%D-3O?\P^QR [>,[H9F!1AMHI4HFVT3G/6= M[V0ZXWH15;XMCH:IQ'+!]DC##DLYX@-JO/. 8F>&D3?6J%/]^>\.-<>\;SLW M^6B>289*__W(/!ML%K64R/K"R*:6(6:W\Y4A^6%@4LL$IX4,#5S M$[M=O@$9-=(:./7:.NE>O(WWGJ1MH^-;XT-1]14\ZUN9VV#V8T@*[ C5"K>* M:*'SQ5"CX#85%>;-Q^["PQL#[XIQ<)H:'S7 M],B\(SQ5,7BJ59PN7HZPKN]C*+V#"TA8;FFLH1_OY C0VJIC BC@WJ5V3OFSY1K[>EZL;G.WGR9B>D+PMJ4H)5 M/@B^14H3*54(F@,ZABQ928Q%R("7T+Q?.>JTR6++K!??3$/3PJI<+]>DGD0+ M[3\7XJ-A+ADP9B[%=,&]XP)21-_77" (V4A=,V\;E2A)/+O:7O-B:MFJ?(]1X\N&I)Y/Y MNHV2W6X'S_*LHN?+84&BXXQY;&GX.X/,[?/T5_\ M!I:ZQ*[E*=\\VN57';576V7$F>F!FT26KA?R:9TMF=>3 MIB6BDFKGAH;[7W4I=44&\;.Q: MG'J4Y20["WD!'!MAM$ ^$AW(L?AI^?CI('&4F17[:>YI89?M=S9\Z"Z2$'MD ME*Z2^)QW>X=0+XA^B"Y_?[L 1C:TJ_'MY!L(L>#7QG@Q+)J=54&^E;F(+VK3 MJ-JW\+B4G7G)Q:0EOTOF;?\.H*[J2]?>TK[Q?UYE^7>2+EV0(Q'&!=+=( 07 M\.$]R@7ZI=#50Q"<_05A[^YZSI+@ J]N/.$"WX0>22#_O$>OM D!&9,XQQXP M/;D J9-#T"XES_['Q]5B$@1I(>=%7\Q6[YLL9>IC3D\M+E-G:G,<0R4"&U_!5A?.!?J*H.-<@.?3W]):O!O8; %^'6!MYP)1RR ]9&G0U9?!@>.Q ME3.2MA=\T,DI_83\(?S3_UM9>$(1?!$7L-G\Q9F(,*0/0C3VMDA9ZO:C41HJ M1J\W,V-NH]/1M!-P_5S]MX<)1#R+1_QO#Q-(CV_PG?M=5\SZ8] M7KU+)CZ8Z2:.))1!%;=KLK2DP6K.O\# !S[UK^X33,3TZ+39_J==%57: MRV%V0AL%3M+7>P19TN4IU\QL;MC\VTKZ63^(TBC\#3[O9J90_D)F*5] MO>6"+G?=CCVN2/;6>EY79Q)FV5!EU:K"<_N3XM5\ESL!SN'=QQ)#(_.#%^0& M&N=I""@D@R4SPDE!MA @"6T8:-BQ]O5PA.>X@"V!BF()IG.!I%)<7F,$$[3@ M H^>$2 5XMMUY JX!?[F )?WB$\8B;_HSWZ%[(QI^H,FZIH@]ZB2SURRNMC M&LNKC//L.Z@%!=@68 P4G36?7!;&T>K2P*3GG=V.Y0.CB]X%,9GXK@785/>]6 M".%:G6K9#T&_I=V3[[<5D&BGYU.ZHU2PG#RB[=='$MUH2-]WP307;+8'*60D M7$=*<0%?PYMP='8^3[=-*&I^!"4UC\B'%[RR*O'O/S@7\-W,KG)YTY7EZMS2 M6F) [V@\A<"2%63L;V0_L+3 A&F]'#;>TT%X^EPDR-ALY5:8PO#SL%0_@MB. M_6<4E77>%GW<]DCB+0AIXXJ85CBX$BP;Z41"ZD4LV;S64S%3KE$_=.' TS5- M>F?I&]^^3^ZMOEQJ.7];E'Y;GV#"_?2:&]6A/?7WOQ#/&D*ZI[@ S7%I;*:5 M^-*4)1=/0;;A!3!$ZN$L1-P/"26_TT(-P\82"M]<\KO+7K^JJ4SI"BHO\.ON MWG%$VKG'!C&[(,M#LV/),!G)[#HN$ 2[2$8;N;)RY*:Y/ZV4<;J/I9:)B&+) M3$=*ZUK8=63FWG^S/M"L;CQ,R]NE?C=D(]\>_8038026$\M MM:+Q2)XMBTJ/ZUWP(B4GP/GS\YY>8V= XSI,JJZGWC]D!(,Y-M MG1>%-$)2TCE:[$<@Y0$7J+Q4 X-!=W;!19;-%"*>UFE0SC1A'7\]\#ES,E!U M[-.^K1,M+]X4Q5^\P7OWLZ9-B\4KPD#XMD<;$O]&$E)#("6+^+*Q^NG'N7W5 M\^^H3Q=?S(2]\$T3_%O$?#>8YF0%A\(N=C3RZXBY(1SSEGX^3ZSM.X72[\GB MB"%IEY.\MUDC5[TQ@GVL-3)@[M0D7+B8/*_9 M&T0C#3BN#G?"T86^0Y',0#"TRT%7AEK/^+6>.;6!#&BRG_F=^3&[8?)240K8 M^@H\@U\WZ86!,@6NC^C!?SH3LECA^H$+G/],_OX% <'%K\:RQ+\470N1.H9\ M:<=6FH'K:IHJ%X!JD7\ZL^J^C?.NASCS]J<"K3BU5_!LL3($M.^G]JP*O]U3 MTGH0F._O4LQ?4B L7B&\ZITBJ_.$ ?"@,[G R][Y)>H2C):NPCZ E&&=@Q1] MBOU-KV( */0HW33N6$38K;[/;BD5Z1W.+P_$CV(V\WYP_18I-Y[F\&;MJ<.Q M],")Q\#@U/VZ?IU=>RJ,N'=4_K&0I2Q0#-E MR?AR1(N8?ACF=&^S1.+Z"SQ=V%Q*(:X2P8>UK!G:\N#YC]]D/@]CBWMW[96R%?Z,!UR[]RDLD"@PA.AE*: 8'^BKG81HA-R*)V)*&J-N*'[! M4@B*O/;,>I?;UUO:/8^' ,4[8C)OO#IT&;:) '2-@F8IS# .LA_A=D(!%/Q- M2SYLV,LA\^//K1Z/GH:5+[Q8HI=[ST6DU/SM)YM-VO?,>4[!B:NZ.6=''Y$" M!Y/JSB03O,@%ETR74L%6\GSVX2\=!Q>6L V*PR@M6YYSXQ]W]U_&F*QOL0%P M'K"B[2W%6,=^0@L2AP:^3O M 67N;3LNY9]OW1=U*.*_S82A[7+@SI;P\&D^KT1C&PSY[+$Y1:*;<^7 M5AU!N_&F'=TO]VR6RK$Y#0<<0YRA/[H"R9(JXH@XTU&,:9KI_!@,#Q*)Y>0% M00%")%V^A_H^F\$.:,YD/PQ$D&QRK%$!V]+<5.]$B15=0>N89'0C+_5"VU#S M<,[E5X5,Z;R4SGDXEO UT D=B!10FF48D>L.%7($V\^,BP^UYU:F2^)W,52-MW%ONG8A'O;MQ]QFU 9--],SZ>4MH+05K"I5P;:-[7J 5?LQUO" MP>0LZ]@E_7G-RE=5B;[^1R^KN]JJ>;4\]#59667)K7*$ZR06N 3]B(_UO;! M^#B<*=;R?@!1H![T,APK#7[G@LC6YWQX?:[Z(5Z_XWJQ;#I?!W]D "SP4W.9 MKAT2D.$J2\IRM0FG3WN12YMAQ-$.EP7JM^-O!3\-_E%.CTNC]@>[2096U1Z8 M5;76^U>06YD4B90L02Q%AROC0NP!&18QJRSD*>] RG*@]/L/DEUKAQ M4'_%8]"SQ"#CRL5269I#ZS:W.^(4@9 -MFQ56/Q[X0A-%@#]T211CHCI-!K2 M(RXXTY#ND'>!$V5/O3#-D$I.G)(*V#V^^37ST'K*#XTL?Y_?&T?Q;_G;'GT^ MME>33AQ#,%[%ZLI]I^"/13QY)]!B.+76JF<.V5@,VG\[TP7XW1]9V2),R,RA3Z_GTNY,6X)//2G=0N,G;@OLJY5[\V88-_%.C'/8'>5 M0\Z%++B6O8ER\K2YM.)9J]@0L!"S>I1 ;J]T3KAJ>?&E=<)3Z5O M=-.QIVXVRW9IF?6UGMW=7;,K8_Y/[UXTV=:?7F2_-]C%@Y"HIC6\F2YQ:VF% MY*DV=D^;V ^_>+N[K<'$P1]CAQ(_G[CG9KB\&;:ZJUY$U*)VLC1Q/?+ M>PL'EHX'F^H\%T[H##DC\O!:3#LN&FR-(<[.$9?;N<#B+)+:3%X)(:^=Y0*K M(: )V+9S>LE_P?)IR1*]G\P%>,N6P3'%NTM=4">K-P\GC>N$CPV4W-$ZU?:'YIP]U][W5SS.],% Z_-W4)^AG0C:,7"\FB,,,OU9SC0B2_8XE=B& M5L&*T'%5F;W-I8FG!6EG+\CG*%4$:WDJK>EKN*+T&T^$DG7#(AI#(KO6C]J$ M?]-\GL) ;C$!;S4*P_[0#C8[PR@:-:[ D&9GL'QROQ($6#:A)5@'B#V%Y._* MM7YZ@D]L+*@=N*N:^N 2?VQ^^,3YZ2$5*_?)EX?W+F+ M0^P[)#&3SQ$FTCRF).;AHH'?!0IBN@: +T96N9QWX_ MS#5EC+E/.(,A/-57WUJB>6E)&CNY'I'&!JI&%:Q0D9!#9VR(QBF)H0^#T LHI M:^I>RA0^!;>5KG##1%R]IT5I]\,%XV%7Z=,V2@WSJ4>]#R;?(T*QS;B0V#:>,^;AK5S ,Z'6\%5JXU^82@^_ZA7OAW M$U$2I*P2UDP(\ 081TP0["URS$CT+20MHI>5V=L$9^5M2GC.[XG =QB<_FEI MB,7S%[_S_ ^/Z?\W^K^L XE]/S<$!(!C^0PC*!BGAQLD*OV0X/TJ0/%H!5], MWN(,[.2_>:3#Z'M7A?R84KF7?0>/R3O<&P+M*'X49/RH'GS,OHWT1XE#DYZJ MSI6.XKM#4Y?[-E'/P19I?\\(L_&XOSEO9L\?#S^6(3LZ/ >8[4I[PX(:?4'EEYZJ##8LD]>P78]&GL:'W2,ZZ8,SA#X^S+3V2DL*:[K_P M.-]Y*N[&W?V6%>Q'<(0M 6E.O6..4W=7FY'CVHQF&GBSWNUQJUCUNGQQ\!1& MVF_X9!+_ 8&O$R>O]=U8.AW#-.&,(LJU%V)IX]^G)>;?T?-MZ/C8'PN'/2V9 M'OV^6I.B]_-2W=3/7WZMJU)6-L^;R") $G0$XUX68YG]BF.!V<41:I@R'!=8 M\H3>U)X*)R<$561+MXS8]07B6B_H%0S=S5ETDU04NVR7$B=]\AX0@J =68*V M&S;C\6A:$-B!5L5U("06<0IS&3CM"II$*DOB6KY-X:R:TM"E$%%'3]OAV4W[ M^7.&KA[[1NY#GEVX2J\@W*HF*O9A O> L M3YMH].&-YL4!<4?Y!](LG1/M]$DF/QIP6+#9EW@6'466@.44A]L%!]_IIEI< M"J(9Q>\QA]YH(FXYM*6VS["B(_%$;?0)GOQ,*^4$3<%K:R].IK6-C(*O$.WZ MOM,9\]DTXC3Z5C0,TC&MU,F$$O)%S_SW=2_C0IM4!;Y)R/)\O7/4S7(??>-3 M*DJ(#.%_HY5,UH3Z\Z2):[7?<0H>0ZC+3R/1#L!P7KTA1ZEUVI>]B0NDPF6O M#@DN65Y44S(6>$T[B/P(17_RQDI1R8SOXTX!^A^/55S]C712_H#M-5(E$&XA MAX=QB$$I%S@0N\3^40&V.!9S@0^Y$5P@4A^X>/0D?+VT62[P8]MI+D!VM&-I MUA+9(@K$U?X/ NV_^O[J^ZOOK[Z_^O[J^ZOO?_>^+A4E+JM';O?/_98SJ//) MN,"KX?4CT;]^EEU*FF59P2AX$OPTC!/D F/[!\$?-X\($KA \V/R\IW>\27. M)/+'F@6."[A2)%A*@5Q@^R'V"RZP,,T%4.DC2RN [%&;?R*<"]RQ&4$[2DX! M12RU,(8,/LA,HJU4!!/1X>XWV&B =8-"*'79QX_W!_N&>7LB#RTWG:C/ZOK= MN/!&K-IN!&:Z@@M$'P*;]Q,IF3@10C.!AD*,XADGH!Y*L:?5"Z>JW"EBG,+N M(YX3=@%;VT;"8W\D._:J-]G=7^NY:".2>P*'ATO5[,:?.XB'H0S&$2B%KD'1 M9LEU4L\W4+B K%^.(2R#6)]2C"@UI^R)W^3N#R=YSPVG>90,&[S?=#!MG\X] MYZTG]Y6^6W=ER4@P\MG5("43485O+T%3U8HH*"5./Q>0UJ"/M'"!^,SUDJI\ MWX#"CYW7SF0<;--OF!BU]_;!\AMI[ 18Q(H31P0_H1;*N #_40)'Q)7)"VNG MV0(\WSLV,W66TT>6-YY#BD%U39E+K0N.J)AF?E(_4Y_-6.)VP>ZN:7 MJ[YQ._X[\GBC$-:@GR/(DJ?%-P=N_/SX%2T^]@=;^OUYS\<'2_3S;VQ*'3O9 MW![R]YU_IQ5@H+O*!=*TB\'1U>>PFNU+@TM%88G ]M(E,T2;LRS>.#+!1R<@(A"V:/[^7_1/Q-N,RS_)>1R )*7"\P_NH!A9>X@*:*#A) ME2VYP6ZC)&_7?\RN_B>T;V],+YKAUC!+5*25%J8",\ZOPWN M,L:4 4/AZ)_A'-5HC#TS3#Q3.HYL(@LTRK*VT(=FHNN13^;($JYM"CFFP\^= MQ>?3'FBE7)R/J=6QE_35::/>VA+"D0>; X.,):"MOAT2)$-&'A3H]1CKP":8 MVSS#[)IRC:D(>.QAAI<9/V43L,'#;#&XNB9SBB06*DO>S,^J?RGXU49N+8@. M_O&#;0JG!5FN=1=&>#O9CSD[L:;TD9LEA[.?LIPAT5R6V;Z+'*7^2Y\3-)5P M18SX>U^^D-\[M82,+>_MB1)F[Z45)1HCE"&T$[THME*V?L D0B@H>.YUXSS- M(?K@QPBCE\@4 /W'RS?^Y DCM7_Z\$__1[:;_;U)]#Z.9G1O<.Q;#B!SA MZ'M6!$8$!C(BI<=1:YC&=%T1[]>",U[L-N_QFK+[]9:\PL=E/,FWA(IC)*QFI1QL%]U\N3?V_%<=KI\$![/-[W_BKW%=$/2 M (/%AMV"DDWF1W4@4C,+/WY'GS;(IB*%OUXG^P_5.STE2IT<):7ZW$T5P#@+ MZNTOS8:Y"C7C*5RA4&$[UN[7_X&X98I#I-M"-K2X[NEWU="UW$/V MH.5A\P6'D+-;+PM\6"Q2OGG$#VRV05*2UDL7OC,],-J,^@'D)1"!-1GFJ/GI M%T&6O2WC(<]O?TL_N%RQ>MNX9KMYL;K&'D62V!G$'1?B/%P4\36RGQ)]R7AW MP78N< NDN9:F$&6" U47E5:;.'I,4P;NL6;5/3F9BVN-=K=]3H&RCOO50N ( MUKNEGW@6E: F-,CQ#&@%*\#D'V2I%O*<>H/'DXF[G4=(GON8KC,9"RD%%TYO M@QT'!)L/<;2@Z_V.1#$29ZSVZH1)[6)J4-ELU=%);Y7=:GZ.B,,HN?4D.L@1 MYIF^SP7\$*JX#\B7Q 7F=.\89V:J?NX:W7H_;?%&T6SM]5*,@C>9U(FY.7IZ M7WKCE,;KZG?-[R-=*4$L&4'&84B9*4(&FRTN8K5#2S$2G@-!)?4>AK<,Q48X MFW-6M189L]0#Y:?>O'M]L,Y!SBGKP#9 Q92E<+Q]4JX:'NE.+(YN,5P8I)4= M2>N@ZKVPCE$IO>J=^O'IUU![O8A(>[EY\.7&F!+(E2$!:5-!&6O-\'M9-'SK M]=J;5Y.->M4R+J7QYE!OO,-F%X#-_)5+DE]Q,C]M C9A:+M@NV$"&<"*/AV? M@$(I[XF%_B_MKJGFQU54#%9N4O=(L1W7?\)G6'DY4>%2'_Y#N[.-4"+ "_ T MR0*5Z=/%R$UDR);32^64^1?-'=MOFQT1>-&JZ89U:*R1[?-OIW??W31:;O#3J?J2:9E2W: M:Z8OH:,QY1VO==:P5Q\V/B.8-=BINNJ$VS+->ES/+_3XUGQW&_8Z?.*NTK&& MU>H5]LGU)8[0&M/Q EF\<1>*IL8%/%-)#O1BB9=9=R=4W-.VC^%1)KL0=7H' MB,;-;(3D M_LU,U\70^4CF@6^$"BXPSWR$=:_P&V9\(X? MOWC(NBX*?H 1[5DZD2TP3Z1MX@(IB'_\#_^ LH_U^A94(*L:IH?H6FQ,($M5L: MK"LT04NG7(K".M&#IN0S'HU1[H]S/NF^M7-.W9EQESBV M'U6)(; TB7!!LZ"_C+%K=4'PU>N;.J%.)X2(XS"]P5539E=MK=QVS%ZV>E%$ MM9N7H"E0A^O-(Z=Z8*]7P]2\\:]WGBXN?W)J225&B;@XU?R^O_CU1E,E.K&R M7*_U4-W&07#FLT>+95D\?>OW(ZB"9(M*=V)+:O;G/&8U&/^T!VP]A>M#5"#6 M%>8#F9:]:G=-A>FB4SH-<=FPR_4N':%[?#3MWJ;I(;,*- M(3:9E":L/SPF[-6WJ#+Z]1Z>"QR:IV[>J6JZLQ4PJOQQ!A#CL=E#6S$_=.>[ M#EZ2"]QS/W[ZSD@MZ^':^**HR.,EM^\X=.C:1TB7(^+-U.4,D55-R!M_OGZH M<0/)AL9L&LH_RTEP<=,?J-._>*Y+#9HG? M>C9[^%C=#RZ@04_GJ%HQ<5R@CP^>8Y$#%_CT;'W@YTM0+#GCR%P9 MR'%K?$PET^ORI3BBUY[RQF0O=$\BE2"M=33QZ6?O]X!6XTQ>L2:M7/W-KGT8 MEG[X1UKXZ2/EM>5..@&V%>&YU.6+NY5>/15VF'L'_G[41F[=;>[70O]_)SK# M^@W*I\U0M>,+Z.BV)>5OF?+9:E:U@TOR6[WQM76IG@UR5U%>I^4,%\KIJ.F' M)06<-@(05&]S\>T1S/<.H?5+"8A >MR&@$=FSV*]O@9T=_JZ74L1)1R PK$+G] M1%&OC0:HOL,8IB IN6BQ CK?SPV4ODCA.82\.0K1/6PIF11RMV;>M]'KLVUV M]0N:V53YA6,%4MM7QJ,VH*X-KKY ^+?M MS6B6BRN:=,EV_28[L2>\^OC[;=W0LSH#FYEB9A4:GTM!T/*(@8;C2+8&(PD: M0K22)9Q6Z^5HPZ<\W\1#!B:"78(J1ITUF]2&9LE\1!]R%+F\\D8%9$^;;#V4 M8]/^_O&;\_6O%[$]"<*W7X5U+.2;\WBRY89BWKQB;?6YE1:BPP7,R<:-3M_D M/O/+??)'B3M(?PGOJ1N"8=3:R6UYB0RGEO^*_"FM'2Q/.$#:9)YH$TLVE4'&>;'VYCJI=*)KV_,.-M>7*.:,7Q M-]T-)SLKK7C*.KXIELK8WVCXSJ2Z$HU6M7VTC7@M C(>:Z-B&1P>V>8CI5U]![=H*J12 M_;:-7^>C=JRY/YW$$47!^-(*DJ G?F?H0F6T#$KG_+B)H=3<<:P7K9-A,UPY M]6#JX$)@2:X!QZ\J;<_G[SP48>N;AIL"D4EDQ7I[N/=56(@O62J0-=.N33U2+T9JEO/A5G\%X,NRPQ MF+DM+TKD7].?'B-'%/XYM$59]/]7;[G_OT+;-=/V>/O[7'[VZ-[Y/<#&@DS M7;>E41-LMK(4@0+:#&G?J1:/G])WM=?'PAY_(]!IYM[$+I,6SNQ6P3BS^Z4A M+T".7/7"--,!83HUTA:!BN%LRBJ-8TGMJ1WV2>8"8B,SGV*)XS>E1DLPH*RQR-5EBUW3^(5K M< +M%=&WW,JRKDPZGK%A9/]+@;DCK\\SGU71?3JF]HLU&3:$$5CZAJ1RQAWV M2'-IG#Q9V'R7Z03=#K]90:G^"9BJ:H$[F35^UFI^Z!N2EWA.8NP[(]S["78? M!%XR\;]ZJ=[F:5G=X"7%QN\F;35>=4]%*U&%X3Z^*V)S.T>4/<:LU[:;@O;. M_HY< $@Q97\Q]+U5S+*_^J*/[4/\>)N*V/C'(KY L*%D41LR.3RUF(YLC^&; M:]Q;PSSVV[6'UA?!$&G>[NA-+_:H-PQORXO>&BTT)"6KHVZPX<8'GM'C3TI= M>>^=,>J^M,G]@L(DJ7K2:4[["^G\X-?^O!+^H+G2RWF)NJ\__%>_1D5WQA#2 MP2^,/8/!A3GQG)/==%$,3@FAB*D[,F*\M!&CT/+XFO2%\'>L*67,1.<6 ;,OS*[ MX>UWI^T'A[*C.Y)'CYR.\'^6FW+1MK?'@BI MRCEG-/$Q/.RRK1B^5U'TQL?$N;:IEZ/[#*K4+TAZU!BGK00=F-ES'&^D&5 MD\+=H)T6^C6D:2M7" ALCQ4\N33Y7QK=L>DY5TJ%P@\2U_WN:,RPF(] M#0_FN)[ZOOP9K\L)OL8^&X*,45YK4%@CIE4_. ##F>41CO[I'BIQM(ARO71Z M[9ZU;([NX-&*"8&Q>+X'GWD>Z[X_>B#-\IN)"ECFVTY.738H8EYD@0W#\Q,Q MIE%8V:7'7Y\@9QZFOL[\&BZOTSHXTL>0E]_G?,?]T@,?\BYSX'^R] M=U23P;LN&D5%5$2D23,J($BU@*! 8@,$! 0I4J/204!$(4!(5*27"(@(B)$F M38A2I4:ZTJMT4A"0GE#"!RG?<]==ZY1]USI_LF"8F6_>]WF? M9^9]9] >'T 5A@F!<:(]&L# M&&?B"(/^KA:PQ=NX_=[$?K&J[=/*LVXIYE)>""U-.6((*8H10!*89ZV:J;"] V&Y1B,=0;,4+Z4?>IV@59 MK;0U^I.+R'?G)@.O/+14TOZTDC=JO?+$B^O:SR'8B#5S2. M:HAX1=A3)\+NA?$-:GB3E4*WG9(I2IQG\6(!V8D=@O/Q!58_S44W7:168+U#VT MQ$=>%$42U#&D"GCI+/,5W-'KL!MT?+#&;)HPM/A["=MBPL.ZH+*&LL;UD[^$ MEE]%'#=_M:*:93'/3+ARX7OBZT:]3&(._N8*SVL<7\TE&H[\,8QF43]TTBFU M:*YW8LSA5>\R5-DC-OI?Z^1EF4O@.DN@^W&K0JS$FGNY&(PY%?]^!V)4.E:$ MX;H&71\>^ILH)H7KI]B$QEZ%\YFG+*ED)OC#L3)E_K[I9?G6O<4+LJ/TZ@\5,"D\^)(RYVNU.L/2%,< M<9W(]UVGV[X^MQ6"!40AKU_Y%9!+3/1O:^^8_2@;H]H>6-=N 7BLJ74#\JU+ M5W8@AQI):14_,$?F155PHLZ,F^TH91&'QQH=V_[X\-9'!3+X;NB('#T2'(,C M#BNBU,)]EDM18?'/^7DZ;UV_O_.I,7D;VH>'21J<6IH%TE,K+2OAF%)HT\)* M^ Z$3^/^:"?S^ZO#Z6Y?SXREGU&^G10^)+:T\$XR7ECV$%>H^,D*Z_NT>TF4NZ;BF&T5 MS2Z!ZEYOE59EY"X8?-4M8&FI)-?1J_2(%L3Q5"CV:.4?D76C5[AOJHL;5"43 MV*Y2?XVPH$EB9VR BJ;- SL0DQ3#E5E==B$6(W_6?3?E&63JH"7*[^:'P?

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�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end XML 174 mrk-20241231_htm.xml IDEA: XBRL DOCUMENT 0000310158 2024-01-01 2024-12-31 0000310158 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0000310158 mrk:A1.875Notesdue2026Member 2024-01-01 2024-12-31 0000310158 mrk:A3.250NotesDue2032Member 2024-01-01 2024-12-31 0000310158 mrk:A2.500Notesdue2034Member 2024-01-01 2024-12-31 0000310158 mrk:A1.375Notesdue2036Member 2024-01-01 2024-12-31 0000310158 mrk:A3.500NotesDue2037Member 2024-01-01 2024-12-31 0000310158 mrk:A3.700NotesDue2044Member 2024-01-01 2024-12-31 0000310158 mrk:A3.750NotesDue2054Member 2024-01-01 2024-12-31 0000310158 2025-01-31 0000310158 2024-06-28 0000310158 2023-01-01 2023-12-31 0000310158 2022-01-01 2022-12-31 0000310158 2024-12-31 0000310158 2023-12-31 0000310158 us-gaap:CommonStockMember 2021-12-31 0000310158 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000310158 us-gaap:RetainedEarningsMember 2021-12-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000310158 us-gaap:TreasuryStockCommonMember 2021-12-31 0000310158 us-gaap:NoncontrollingInterestMember 2021-12-31 0000310158 2021-12-31 0000310158 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0000310158 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-12-31 0000310158 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0000310158 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-12-31 0000310158 us-gaap:CommonStockMember 2022-12-31 0000310158 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000310158 us-gaap:RetainedEarningsMember 2022-12-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000310158 us-gaap:TreasuryStockCommonMember 2022-12-31 0000310158 us-gaap:NoncontrollingInterestMember 2022-12-31 0000310158 2022-12-31 0000310158 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-12-31 0000310158 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-12-31 0000310158 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-12-31 0000310158 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0000310158 us-gaap:CommonStockMember 2023-12-31 0000310158 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000310158 us-gaap:RetainedEarningsMember 2023-12-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000310158 us-gaap:TreasuryStockCommonMember 2023-12-31 0000310158 us-gaap:NoncontrollingInterestMember 2023-12-31 0000310158 us-gaap:RetainedEarningsMember 2024-01-01 2024-12-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-12-31 0000310158 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-12-31 0000310158 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-12-31 0000310158 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-12-31 0000310158 us-gaap:CommonStockMember 2024-12-31 0000310158 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000310158 us-gaap:RetainedEarningsMember 2024-12-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0000310158 us-gaap:TreasuryStockCommonMember 2024-12-31 0000310158 us-gaap:NoncontrollingInterestMember 2024-12-31 0000310158 srt:MinimumMember 2024-01-01 2024-12-31 0000310158 srt:MaximumMember 2024-01-01 2024-12-31 0000310158 srt:MinimumMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 srt:MinimumMember country:US mrk:AnimalHealthsegmentMember 2024-01-01 2024-12-31 0000310158 srt:MaximumMember country:US 2024-01-01 2024-12-31 0000310158 srt:MinimumMember country:US 2024-01-01 2024-12-31 0000310158 srt:MinimumMember us-gaap:NonUsMember 2024-01-01 2024-12-31 0000310158 srt:MaximumMember us-gaap:NonUsMember 2024-01-01 2024-12-31 0000310158 srt:MinimumMember us-gaap:BuildingMember 2024-12-31 0000310158 srt:MaximumMember us-gaap:BuildingMember 2024-12-31 0000310158 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2024-12-31 0000310158 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2024-12-31 0000310158 srt:MinimumMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2024-12-31 0000310158 srt:MaximumMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2024-12-31 0000310158 srt:MinimumMember 2024-12-31 0000310158 srt:MaximumMember 2024-12-31 0000310158 srt:ScenarioForecastMember us-gaap:SubsequentEventMember 2025-01-01 2025-03-31 0000310158 mrk:MK2010LM299LaNovaMedicinesLtdMember 2024-12-01 2024-12-31 0000310158 srt:ScenarioForecastMember mrk:MK2010LM299LaNovaMedicinesLtdMember 2025-01-01 2025-12-31 0000310158 mrk:MK2010LM299LaNovaMedicinesLtdMember 2024-12-31 0000310158 mrk:MK4082HS10535HansohPharmaMember 2024-12-01 2024-12-31 0000310158 mrk:MK4082HS10535HansohPharmaMember 2024-12-31 0000310158 mrk:MK1045CN201CuronBiopharmaceuticalMember 2024-09-01 2024-09-30 0000310158 mrk:MK1045CN201CuronBiopharmaceuticalMember 2024-09-30 0000310158 mrk:MK1045CN201CuronBiopharmaceuticalMember 2024-01-01 2024-12-31 0000310158 mrk:ThirdPartyMember mrk:MK1045CN201CuronBiopharmaceuticalMember 2024-09-30 0000310158 mrk:ElancoAnimalHealthIncorporatedAquaBusinessMember 2024-07-01 2024-07-31 0000310158 mrk:ElancoAnimalHealthIncorporatedAquaBusinessMember 2024-07-09 0000310158 mrk:ElancoAnimalHealthIncorporatedAquaBusinessMember mrk:ProductRightsMember 2024-07-09 0000310158 mrk:ElancoAnimalHealthIncorporatedAquaBusinessMember mrk:OtherProductRightsMember 2024-07-09 0000310158 mrk:EyebiotechLimitedMember 2024-07-01 2024-07-31 0000310158 mrk:EyebiotechLimitedMember 2024-07-31 0000310158 mrk:EyebiotechLimitedMember 2024-07-01 2024-12-31 0000310158 mrk:EyebiotechLimitedMember 2024-01-01 2024-12-31 0000310158 mrk:OrionMember 2024-07-31 0000310158 mrk:HarpoonTherapeuticsInc.Member 2024-03-01 2024-03-31 0000310158 mrk:HarpoonTherapeuticsInc.Member 2024-01-01 2024-12-31 0000310158 mrk:DaiichiSankyoMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-10-31 0000310158 mrk:PrometheusBiosciencesIncMember 2023-06-01 2023-06-30 0000310158 mrk:PrometheusBiosciencesIncMember 2023-01-01 2023-12-31 0000310158 mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-02-28 0000310158 mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-10-31 0000310158 mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-04-30 0000310158 mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-07-31 0000310158 mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-01-31 0000310158 mrk:ImagoBioSciencesIncMember 2023-01-01 2023-01-31 0000310158 mrk:ImagoBioSciencesIncMember 2023-01-01 2023-12-31 0000310158 mrk:RoyaltyPharmaMember 2022-10-01 2022-10-31 0000310158 mrk:OrnaTherapeuticsMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-08-01 2022-08-31 0000310158 mrk:OrnaTherapeuticsMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-08-31 0000310158 mrk:OrnaTherapeuticsMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-12-31 0000310158 mrk:OrionMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-07-01 2022-07-31 0000310158 mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-05-01 2022-05-31 0000310158 mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-01-01 2023-12-31 0000310158 mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-01-01 2024-12-31 0000310158 mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember mrk:FirstCommercialSaleMilestonesMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-05-31 0000310158 mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-05-31 0000310158 us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember mrk:OrganonCoMember 2024-12-31 0000310158 srt:MinimumMember mrk:ManufacturingAndSupplyAgreementsMember us-gaap:RelatedPartyMember 2021-06-02 2021-06-02 0000310158 srt:MaximumMember mrk:ManufacturingAndSupplyAgreementsMember us-gaap:RelatedPartyMember 2021-06-02 2021-06-02 0000310158 mrk:ManufacturingAndSupplyAgreementsMember us-gaap:RelatedPartyMember 2024-01-01 2024-12-31 0000310158 mrk:ManufacturingAndSupplyAgreementsMember us-gaap:RelatedPartyMember 2023-01-01 2023-12-31 0000310158 mrk:ManufacturingAndSupplyAgreementsMember us-gaap:RelatedPartyMember 2022-01-01 2022-12-31 0000310158 us-gaap:RelatedPartyMember 2024-12-31 0000310158 us-gaap:RelatedPartyMember 2023-12-31 0000310158 mrk:AstraZenecaMember mrk:KoselugoMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-01-01 2024-12-31 0000310158 mrk:AstraZenecaMember mrk:KoselugoMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-12-31 0000310158 mrk:AstraZenecaMember 2024-01-01 2024-12-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-01-01 2022-12-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-12-31 0000310158 mrk:AstraZenecaMember 2022-01-01 2022-12-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-12-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-01-01 2024-12-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-01-01 2023-12-31 0000310158 mrk:LynparzaMember mrk:LicensesAndOtherMember 2024-12-31 0000310158 mrk:KoselugoMember mrk:LicensesAndOtherMember 2024-12-31 0000310158 mrk:AstraZenecaMember mrk:AlliancerevenueLynparzaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-01-01 2024-12-31 0000310158 mrk:AstraZenecaMember mrk:AlliancerevenueLynparzaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-01-01 2023-12-31 0000310158 mrk:AstraZenecaMember mrk:AlliancerevenueLynparzaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-01-01 2022-12-31 0000310158 mrk:AstraZenecaMember mrk:AllianceRevenueKoselugoMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-01-01 2024-12-31 0000310158 mrk:AstraZenecaMember mrk:AllianceRevenueKoselugoMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-01-01 2023-12-31 0000310158 mrk:AstraZenecaMember mrk:AllianceRevenueKoselugoMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-01-01 2022-12-31 0000310158 mrk:AstraZenecaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-01-01 2024-12-31 0000310158 mrk:AstraZenecaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-01-01 2023-12-31 0000310158 mrk:AstraZenecaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-01-01 2022-12-31 0000310158 mrk:AstraZenecaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-12-31 0000310158 mrk:AstraZenecaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-12-31 0000310158 mrk:EisaiMember mrk:LenvimaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-01-01 2024-12-31 0000310158 mrk:EisaiMember mrk:LenvimaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-01-01 2023-12-31 0000310158 mrk:EisaiMember mrk:LenvimaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-01-01 2022-12-31 0000310158 mrk:EisaiMember mrk:LenvimaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-12-31 0000310158 mrk:EisaiMember 2023-01-01 2023-12-31 0000310158 mrk:EisaiMember mrk:LenvimaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-12-31 0000310158 mrk:LenvimaMember mrk:LicensesAndOtherMember 2024-12-31 0000310158 mrk:EisaiMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-01-01 2024-12-31 0000310158 mrk:EisaiMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-01-01 2023-12-31 0000310158 mrk:EisaiMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-01-01 2022-12-31 0000310158 mrk:EisaiMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-12-31 0000310158 mrk:EisaiMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-12-31 0000310158 mrk:BayerAGMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-01-01 2022-12-31 0000310158 mrk:AdempasMember mrk:LicensesAndOtherMember 2024-12-31 0000310158 mrk:VerquvoMember mrk:LicensesAndOtherMember 2024-12-31 0000310158 mrk:BayerAGMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-01-01 2024-12-31 0000310158 mrk:BayerAGMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-01-01 2023-12-31 0000310158 mrk:BayerAGMember mrk:AdempasMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-01-01 2024-12-31 0000310158 mrk:BayerAGMember mrk:AdempasMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-01-01 2023-12-31 0000310158 mrk:BayerAGMember mrk:AdempasMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-01-01 2022-12-31 0000310158 mrk:BayerAGMember mrk:VerquvoMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-01-01 2024-12-31 0000310158 mrk:BayerAGMember mrk:VerquvoMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-01-01 2023-12-31 0000310158 mrk:BayerAGMember mrk:VerquvoMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-01-01 2022-12-31 0000310158 mrk:BayerAGMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-12-31 0000310158 mrk:BayerAGMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-12-31 0000310158 mrk:RidgebackBiotherapeuticsLPMember mrk:LagevrioMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-01-01 2024-12-31 0000310158 mrk:RidgebackBiotherapeuticsLPMember mrk:LagevrioMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-01-01 2023-12-31 0000310158 mrk:RidgebackBiotherapeuticsLPMember mrk:LagevrioMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-01-01 2022-12-31 0000310158 mrk:RidgebackBiotherapeuticsLPMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-01-01 2024-12-31 0000310158 mrk:RidgebackBiotherapeuticsLPMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-01-01 2023-12-31 0000310158 mrk:RidgebackBiotherapeuticsLPMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-01-01 2022-12-31 0000310158 mrk:RidgebackBiotherapeuticsLPMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-12-31 0000310158 mrk:RidgebackBiotherapeuticsLPMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-12-31 0000310158 mrk:DaiichiSankyoMember mrk:PatritumabDeruxtecanMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-10-31 0000310158 mrk:DaiichiSankyoMember mrk:IfinatamabDeruxtecanMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-10-31 0000310158 mrk:DaiichiSankyoMember mrk:RaludotatugDeruxtecanMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-10-31 0000310158 mrk:DaiichiSankyoMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-01-01 2023-12-31 0000310158 mrk:DaiichiSankyoMember mrk:PatritumabDeruxtecanAndRalduotatugDeruxtecanMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-12-31 0000310158 mrk:DaiichiSankyoMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-08-01 2024-08-31 0000310158 mrk:DaiichiSankyoMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-01-01 2024-12-31 0000310158 mrk:DaiichiSankyoMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-12-31 0000310158 mrk:DaiichiSankyoMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-12-31 0000310158 mrk:ModernaIncMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-01-01 2022-12-31 0000310158 mrk:ModernaIncMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-12-31 0000310158 mrk:ModernaIncMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-01-01 2024-12-31 0000310158 mrk:ModernaIncMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-01-01 2023-12-31 0000310158 mrk:ModernaIncMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-12-31 0000310158 mrk:BristolMyersSquibbMember srt:MinimumMember us-gaap:LicensingAgreementsMember 2024-01-01 2024-12-31 0000310158 mrk:BristolMyersSquibbMember srt:MaximumMember us-gaap:LicensingAgreementsMember 2024-01-01 2024-12-31 0000310158 mrk:BristolMyersSquibbMember us-gaap:LicensingAgreementsMember 2024-01-01 2024-12-31 0000310158 mrk:BristolMyersSquibbMember mrk:AllianceRevenueReblozylMember us-gaap:LicensingAgreementsMember 2024-12-31 0000310158 mrk:BristolMyersSquibbMember mrk:RegulatoryMilestonesMember us-gaap:LicensingAgreementsMember 2022-01-01 2022-12-31 0000310158 mrk:BristolMyersSquibbCompanyMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2024-01-01 2024-12-31 0000310158 mrk:BristolMyersSquibbCompanyMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-01-01 2023-12-31 0000310158 mrk:BristolMyersSquibbCompanyMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-01-01 2022-12-31 0000310158 mrk:RestructuringProgram2024Member 2024-12-31 0000310158 mrk:RestructuringProgram2024Member 2024-01-01 2024-12-31 0000310158 mrk:RestructuringProgram2024Member 2023-01-01 2023-12-31 0000310158 mrk:RestructuringProgram2019Member 2023-01-01 2023-12-31 0000310158 mrk:RestructuringProgram2019Member 2022-01-01 2022-12-31 0000310158 us-gaap:CostOfSalesMember mrk:RestructuringProgram2024Member 2024-01-01 2024-12-31 0000310158 us-gaap:CostOfSalesMember us-gaap:EmployeeSeveranceMember mrk:RestructuringProgram2024Member 2024-01-01 2024-12-31 0000310158 us-gaap:CostOfSalesMember mrk:AcceleratedDepreciationMember mrk:RestructuringProgram2024Member 2024-01-01 2024-12-31 0000310158 us-gaap:CostOfSalesMember us-gaap:OtherRestructuringMember mrk:RestructuringProgram2024Member 2024-01-01 2024-12-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember mrk:RestructuringProgram2024Member 2024-01-01 2024-12-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:EmployeeSeveranceMember mrk:RestructuringProgram2024Member 2024-01-01 2024-12-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OtherRestructuringMember mrk:RestructuringProgram2024Member 2024-01-01 2024-12-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember mrk:AcceleratedDepreciationMember mrk:RestructuringProgram2024Member 2024-01-01 2024-12-31 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:OtherRestructuringMember mrk:RestructuringProgram2024Member 2024-01-01 2024-12-31 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember mrk:AcceleratedDepreciationMember mrk:RestructuringProgram2024Member 2024-01-01 2024-12-31 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember mrk:RestructuringProgram2024Member 2024-01-01 2024-12-31 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:EmployeeSeveranceMember mrk:RestructuringProgram2024Member 2024-01-01 2024-12-31 0000310158 us-gaap:RestructuringChargesMember mrk:AcceleratedDepreciationMember mrk:RestructuringProgram2024Member 2024-01-01 2024-12-31 0000310158 us-gaap:RestructuringChargesMember us-gaap:OtherRestructuringMember mrk:RestructuringProgram2024Member 2024-01-01 2024-12-31 0000310158 us-gaap:RestructuringChargesMember mrk:RestructuringProgram2024Member 2024-01-01 2024-12-31 0000310158 us-gaap:RestructuringChargesMember us-gaap:EmployeeSeveranceMember mrk:RestructuringProgram2024Member 2024-01-01 2024-12-31 0000310158 mrk:AcceleratedDepreciationMember mrk:RestructuringProgram2024Member 2024-01-01 2024-12-31 0000310158 us-gaap:EmployeeSeveranceMember mrk:RestructuringProgram2024Member 2024-01-01 2024-12-31 0000310158 us-gaap:OtherRestructuringMember mrk:RestructuringProgram2024Member 2024-01-01 2024-12-31 0000310158 us-gaap:CostOfSalesMember mrk:RestructuringProgram2024Member 2023-01-01 2023-12-31 0000310158 us-gaap:CostOfSalesMember us-gaap:OtherRestructuringMember mrk:RestructuringProgram2024Member 2023-01-01 2023-12-31 0000310158 us-gaap:CostOfSalesMember mrk:AcceleratedDepreciationMember mrk:RestructuringProgram2024Member 2023-01-01 2023-12-31 0000310158 us-gaap:CostOfSalesMember us-gaap:EmployeeSeveranceMember mrk:RestructuringProgram2024Member 2023-01-01 2023-12-31 0000310158 us-gaap:RestructuringChargesMember mrk:AcceleratedDepreciationMember mrk:RestructuringProgram2024Member 2023-01-01 2023-12-31 0000310158 us-gaap:RestructuringChargesMember mrk:RestructuringProgram2024Member 2023-01-01 2023-12-31 0000310158 us-gaap:RestructuringChargesMember us-gaap:OtherRestructuringMember mrk:RestructuringProgram2024Member 2023-01-01 2023-12-31 0000310158 us-gaap:RestructuringChargesMember us-gaap:EmployeeSeveranceMember mrk:RestructuringProgram2024Member 2023-01-01 2023-12-31 0000310158 mrk:AcceleratedDepreciationMember mrk:RestructuringProgram2024Member 2023-01-01 2023-12-31 0000310158 us-gaap:EmployeeSeveranceMember mrk:RestructuringProgram2024Member 2023-01-01 2023-12-31 0000310158 us-gaap:OtherRestructuringMember mrk:RestructuringProgram2024Member 2023-01-01 2023-12-31 0000310158 us-gaap:CostOfSalesMember mrk:AcceleratedDepreciationMember mrk:RestructuringProgram2019Member 2023-01-01 2023-12-31 0000310158 us-gaap:CostOfSalesMember mrk:RestructuringProgram2019Member 2023-01-01 2023-12-31 0000310158 us-gaap:CostOfSalesMember us-gaap:OtherRestructuringMember mrk:RestructuringProgram2019Member 2023-01-01 2023-12-31 0000310158 us-gaap:CostOfSalesMember us-gaap:EmployeeSeveranceMember mrk:RestructuringProgram2019Member 2023-01-01 2023-12-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember mrk:AcceleratedDepreciationMember mrk:RestructuringProgram2019Member 2023-01-01 2023-12-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember mrk:RestructuringProgram2019Member 2023-01-01 2023-12-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:EmployeeSeveranceMember mrk:RestructuringProgram2019Member 2023-01-01 2023-12-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OtherRestructuringMember mrk:RestructuringProgram2019Member 2023-01-01 2023-12-31 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember mrk:AcceleratedDepreciationMember mrk:RestructuringProgram2019Member 2023-01-01 2023-12-31 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:EmployeeSeveranceMember mrk:RestructuringProgram2019Member 2023-01-01 2023-12-31 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:OtherRestructuringMember mrk:RestructuringProgram2019Member 2023-01-01 2023-12-31 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember mrk:RestructuringProgram2019Member 2023-01-01 2023-12-31 0000310158 us-gaap:RestructuringChargesMember us-gaap:EmployeeSeveranceMember mrk:RestructuringProgram2019Member 2023-01-01 2023-12-31 0000310158 us-gaap:RestructuringChargesMember mrk:AcceleratedDepreciationMember mrk:RestructuringProgram2019Member 2023-01-01 2023-12-31 0000310158 us-gaap:RestructuringChargesMember mrk:RestructuringProgram2019Member 2023-01-01 2023-12-31 0000310158 us-gaap:RestructuringChargesMember us-gaap:OtherRestructuringMember mrk:RestructuringProgram2019Member 2023-01-01 2023-12-31 0000310158 mrk:AcceleratedDepreciationMember mrk:RestructuringProgram2019Member 2023-01-01 2023-12-31 0000310158 us-gaap:EmployeeSeveranceMember mrk:RestructuringProgram2019Member 2023-01-01 2023-12-31 0000310158 us-gaap:OtherRestructuringMember mrk:RestructuringProgram2019Member 2023-01-01 2023-12-31 0000310158 mrk:AcceleratedDepreciationMember mrk:RestructuringProgram2024And2019Member 2023-01-01 2023-12-31 0000310158 us-gaap:EmployeeSeveranceMember mrk:RestructuringProgram2024And2019Member 2023-01-01 2023-12-31 0000310158 us-gaap:OtherRestructuringMember mrk:RestructuringProgram2024And2019Member 2023-01-01 2023-12-31 0000310158 mrk:RestructuringProgram2024And2019Member 2023-01-01 2023-12-31 0000310158 us-gaap:CostOfSalesMember us-gaap:EmployeeSeveranceMember mrk:RestructuringProgram2019Member 2022-01-01 2022-12-31 0000310158 us-gaap:CostOfSalesMember us-gaap:OtherRestructuringMember mrk:RestructuringProgram2019Member 2022-01-01 2022-12-31 0000310158 us-gaap:CostOfSalesMember mrk:AcceleratedDepreciationMember mrk:RestructuringProgram2019Member 2022-01-01 2022-12-31 0000310158 us-gaap:CostOfSalesMember mrk:RestructuringProgram2019Member 2022-01-01 2022-12-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember mrk:RestructuringProgram2019Member 2022-01-01 2022-12-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OtherRestructuringMember mrk:RestructuringProgram2019Member 2022-01-01 2022-12-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:EmployeeSeveranceMember mrk:RestructuringProgram2019Member 2022-01-01 2022-12-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember mrk:AcceleratedDepreciationMember mrk:RestructuringProgram2019Member 2022-01-01 2022-12-31 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember mrk:RestructuringProgram2019Member 2022-01-01 2022-12-31 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:EmployeeSeveranceMember mrk:RestructuringProgram2019Member 2022-01-01 2022-12-31 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:OtherRestructuringMember mrk:RestructuringProgram2019Member 2022-01-01 2022-12-31 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember mrk:AcceleratedDepreciationMember mrk:RestructuringProgram2019Member 2022-01-01 2022-12-31 0000310158 us-gaap:RestructuringChargesMember mrk:RestructuringProgram2019Member 2022-01-01 2022-12-31 0000310158 us-gaap:RestructuringChargesMember us-gaap:OtherRestructuringMember mrk:RestructuringProgram2019Member 2022-01-01 2022-12-31 0000310158 us-gaap:RestructuringChargesMember us-gaap:EmployeeSeveranceMember mrk:RestructuringProgram2019Member 2022-01-01 2022-12-31 0000310158 us-gaap:RestructuringChargesMember mrk:AcceleratedDepreciationMember mrk:RestructuringProgram2019Member 2022-01-01 2022-12-31 0000310158 mrk:AcceleratedDepreciationMember mrk:RestructuringProgram2019Member 2022-01-01 2022-12-31 0000310158 us-gaap:EmployeeSeveranceMember mrk:RestructuringProgram2019Member 2022-01-01 2022-12-31 0000310158 us-gaap:OtherRestructuringMember mrk:RestructuringProgram2019Member 2022-01-01 2022-12-31 0000310158 mrk:AcceleratedDepreciationMember 2022-12-31 0000310158 us-gaap:EmployeeSeveranceMember 2022-12-31 0000310158 us-gaap:OtherRestructuringMember 2022-12-31 0000310158 mrk:AcceleratedDepreciationMember 2023-01-01 2023-12-31 0000310158 us-gaap:EmployeeSeveranceMember 2023-01-01 2023-12-31 0000310158 us-gaap:OtherRestructuringMember 2023-01-01 2023-12-31 0000310158 mrk:AcceleratedDepreciationMember 2023-12-31 0000310158 us-gaap:EmployeeSeveranceMember 2023-12-31 0000310158 us-gaap:OtherRestructuringMember 2023-12-31 0000310158 mrk:AcceleratedDepreciationMember 2024-01-01 2024-12-31 0000310158 us-gaap:EmployeeSeveranceMember 2024-01-01 2024-12-31 0000310158 us-gaap:OtherRestructuringMember 2024-01-01 2024-12-31 0000310158 mrk:AcceleratedDepreciationMember 2024-12-31 0000310158 us-gaap:EmployeeSeveranceMember 2024-12-31 0000310158 us-gaap:OtherRestructuringMember 2024-12-31 0000310158 srt:MaximumMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-01-01 2024-12-31 0000310158 srt:MaximumMember us-gaap:NondesignatedMember 2024-01-01 2024-12-31 0000310158 us-gaap:ForeignExchangeContractMember 2024-01-01 2024-12-31 0000310158 us-gaap:ForeignExchangeContractMember 2023-01-01 2023-12-31 0000310158 us-gaap:ForeignExchangeContractMember 2022-01-01 2022-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:OtherNonoperatingIncomeExpenseMember 2024-01-01 2024-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:OtherNonoperatingIncomeExpenseMember 2023-01-01 2023-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:OtherNonoperatingIncomeExpenseMember 2022-01-01 2022-12-31 0000310158 mrk:EurodominatedNotesMember 2024-01-01 2024-12-31 0000310158 mrk:EurodominatedNotesMember 2023-01-01 2023-12-31 0000310158 mrk:EurodominatedNotesMember 2022-01-01 2022-12-31 0000310158 mrk:EurodominatedNotesMember us-gaap:OtherNonoperatingIncomeExpenseMember 2024-01-01 2024-12-31 0000310158 mrk:EurodominatedNotesMember us-gaap:OtherNonoperatingIncomeExpenseMember 2023-01-01 2023-12-31 0000310158 mrk:EurodominatedNotesMember us-gaap:OtherNonoperatingIncomeExpenseMember 2022-01-01 2022-12-31 0000310158 us-gaap:InterestRateSwapMember mrk:A450NotesDue2033Member 2024-12-31 0000310158 mrk:A450NotesDue2033Member us-gaap:SeniorNotesMember 2023-05-31 0000310158 us-gaap:InterestRateSwapMember mrk:A500NotesDue2053Member us-gaap:SubsequentEventMember 2025-01-31 0000310158 mrk:A500NotesDue2053Member us-gaap:SeniorNotesMember us-gaap:SubsequentEventMember 2025-01-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-12-31 0000310158 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-12-31 0000310158 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000310158 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000310158 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-12-31 0000310158 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000310158 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-12-31 0000310158 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000310158 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-12-31 0000310158 us-gaap:DesignatedAsHedgingInstrumentMember 2024-12-31 0000310158 us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2023-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2024-12-31 0000310158 us-gaap:NondesignatedMember 2024-12-31 0000310158 us-gaap:NondesignatedMember 2023-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2024-01-01 2024-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2023-01-01 2023-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2022-01-01 2022-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2024-01-01 2024-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2023-01-01 2023-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2022-01-01 2022-12-31 0000310158 us-gaap:InterestRateContractMember 2024-01-01 2024-12-31 0000310158 us-gaap:InterestRateContractMember 2023-01-01 2023-12-31 0000310158 us-gaap:InterestRateContractMember 2022-01-01 2022-12-31 0000310158 us-gaap:CurrencySwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2024-01-01 2024-12-31 0000310158 us-gaap:CurrencySwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2023-01-01 2023-12-31 0000310158 us-gaap:CurrencySwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2022-01-01 2022-12-31 0000310158 us-gaap:ForeignExchangeFutureMember us-gaap:SalesMember 2024-01-01 2024-12-31 0000310158 us-gaap:ForeignExchangeFutureMember us-gaap:SalesMember 2023-01-01 2023-12-31 0000310158 us-gaap:ForeignExchangeFutureMember us-gaap:SalesMember 2022-01-01 2022-12-31 0000310158 us-gaap:CommercialPaperMember 2024-12-31 0000310158 us-gaap:CommercialPaperMember 2023-12-31 0000310158 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-12-31 0000310158 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0000310158 us-gaap:CorporateDebtSecuritiesMember 2024-12-31 0000310158 us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000310158 us-gaap:EquityFundsMember 2024-12-31 0000310158 us-gaap:EquityFundsMember 2023-12-31 0000310158 us-gaap:EquityFundsMember 2022-12-31 0000310158 us-gaap:EquityFundsMember 2024-01-01 2024-12-31 0000310158 us-gaap:EquityFundsMember 2023-01-01 2023-12-31 0000310158 us-gaap:EquityFundsMember 2022-01-01 2022-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2024-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2024-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2024-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2024-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2024-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2024-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2024-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2024-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2023-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2023-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2023-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2023-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000310158 us-gaap:FairValueInputsLevel2Member 2024-12-31 0000310158 us-gaap:FairValueInputsLevel2Member 2023-12-31 0000310158 mrk:SanofiPasteurMember 2024-12-31 0000310158 mrk:SanofiPasteurMember 2024-01-01 2024-12-31 0000310158 mrk:LyfnuaMember 2024-01-01 2024-12-31 0000310158 mrk:McKessonCorporationMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0000310158 mrk:CencoraInc.Member us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0000310158 mrk:CardinalHealthIncMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0000310158 mrk:AccountsReceivableFactoringCollectionsMember 2024-12-31 0000310158 mrk:AccountsReceivableFactoringCollectionsMember 2023-12-31 0000310158 mrk:InventoryNotExpectedtobeSoldWithinOneYearMember 2024-12-31 0000310158 mrk:InventoryNotExpectedtobeSoldWithinOneYearMember 2023-12-31 0000310158 mrk:InventoriesProducedinPreparationforProductLaunchesMember 2024-12-31 0000310158 mrk:InventoriesProducedinPreparationforProductLaunchesMember 2023-12-31 0000310158 mrk:PharmaceuticalsegmentMember 2022-12-31 0000310158 mrk:AnimalHealthsegmentMember 2022-12-31 0000310158 mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 mrk:AnimalHealthsegmentMember 2023-01-01 2023-12-31 0000310158 mrk:PharmaceuticalsegmentMember 2023-12-31 0000310158 mrk:AnimalHealthsegmentMember 2023-12-31 0000310158 mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 mrk:AnimalHealthsegmentMember 2024-01-01 2024-12-31 0000310158 mrk:PharmaceuticalsegmentMember 2024-12-31 0000310158 mrk:AnimalHealthsegmentMember 2024-12-31 0000310158 us-gaap:DevelopedTechnologyRightsMember 2024-12-31 0000310158 us-gaap:DevelopedTechnologyRightsMember 2023-12-31 0000310158 us-gaap:InProcessResearchAndDevelopmentMember 2024-12-31 0000310158 us-gaap:InProcessResearchAndDevelopmentMember 2023-12-31 0000310158 us-gaap:TradeNamesMember 2024-12-31 0000310158 us-gaap:TradeNamesMember 2023-12-31 0000310158 mrk:LicensesAndOtherMember 2024-12-31 0000310158 mrk:LicensesAndOtherMember 2023-12-31 0000310158 mrk:WinrevairMember us-gaap:DevelopedTechnologyRightsMember 2024-12-31 0000310158 mrk:ReblozylMember us-gaap:DevelopedTechnologyRightsMember 2024-12-31 0000310158 mrk:ZerbaxaMember us-gaap:DevelopedTechnologyRightsMember 2024-12-31 0000310158 mrk:AnimalHealthMember 2024-12-31 0000310158 mrk:AnimalHealthMember us-gaap:DevelopedTechnologyRightsMember 2024-12-31 0000310158 mrk:AnimalHealthMember us-gaap:TradeNamesMember 2024-12-31 0000310158 mrk:NemtabrutinibMember us-gaap:InProcessResearchAndDevelopmentMember 2024-12-31 0000310158 mrk:GefapixantMember us-gaap:InProcessResearchAndDevelopmentMember 2023-01-01 2023-12-31 0000310158 mrk:LyfnuaMember 2024-12-31 0000310158 mrk:NemtabrutinibMember us-gaap:InProcessResearchAndDevelopmentMember 2022-01-01 2022-12-31 0000310158 mrk:NemtabrutinibMember us-gaap:InProcessResearchAndDevelopmentMember 2022-07-01 2022-09-30 0000310158 mrk:NemtabrutinibMember us-gaap:InProcessResearchAndDevelopmentMember 2022-12-01 2022-12-31 0000310158 mrk:DerazantinibMember mrk:LicensesAndOtherMember 2022-01-01 2022-12-31 0000310158 mrk:NotesSubjectToRepaymentAtOptionOfHolderMember 2024-12-31 0000310158 mrk:NotesSubjectToRepaymentAtOptionOfHolderMember 2023-12-31 0000310158 us-gaap:CommercialPaperMember 2024-01-01 2024-12-31 0000310158 us-gaap:CommercialPaperMember 2023-01-01 2023-12-31 0000310158 mrk:A215NotesDue2031Member 2024-12-31 0000310158 mrk:A215NotesDue2031Member 2023-12-31 0000310158 mrk:A275NotesDue2051Member 2024-12-31 0000310158 mrk:A275NotesDue2051Member 2023-12-31 0000310158 mrk:A3.70NotesDue2045Member 2024-12-31 0000310158 mrk:A3.70NotesDue2045Member 2023-12-31 0000310158 mrk:A3.40NotesDue2029Member 2024-12-31 0000310158 mrk:A3.40NotesDue2029Member 2023-12-31 0000310158 mrk:A450NotesDue2033Member 2024-12-31 0000310158 mrk:A450NotesDue2033Member 2023-12-31 0000310158 mrk:A170NotesDue2027Member 2024-12-31 0000310158 mrk:A170NotesDue2027Member 2023-12-31 0000310158 mrk:A290NotesDue2061Member 2024-12-31 0000310158 mrk:A290NotesDue2061Member 2023-12-31 0000310158 mrk:A500NotesDue2053Member 2024-12-31 0000310158 mrk:A500NotesDue2053Member 2023-12-31 0000310158 mrk:A4.00NotesDue2049Member 2024-12-31 0000310158 mrk:A4.00NotesDue2049Member 2023-12-31 0000310158 mrk:A415NotesDue2043Member 2024-12-31 0000310158 mrk:A415NotesDue2043Member 2023-12-31 0000310158 mrk:A145NotesDue2030Member 2024-12-31 0000310158 mrk:A145NotesDue2030Member 2023-12-31 0000310158 mrk:A245NotesDue2050Member 2024-12-31 0000310158 mrk:A245NotesDue2050Member 2023-12-31 0000310158 mrk:A1.875EuroNotesDue2026Member 2024-12-31 0000310158 mrk:A1.875EuroNotesDue2026Member 2023-12-31 0000310158 mrk:A075NotesDue2026Member 2024-12-31 0000310158 mrk:A075NotesDue2026Member 2023-12-31 0000310158 mrk:A190NotesDue2028Member 2024-12-31 0000310158 mrk:A190NotesDue2028Member 2023-12-31 0000310158 mrk:A515NotesDue2063Member 2024-12-31 0000310158 mrk:A515NotesDue2063Member 2023-12-31 0000310158 mrk:A3.90NotesDue2039Member 2024-12-31 0000310158 mrk:A3.90NotesDue2039Member 2023-12-31 0000310158 mrk:A235NotesDue2040Member 2024-12-31 0000310158 mrk:A235NotesDue2040Member 2023-12-31 0000310158 mrk:A3.25EuroNotesDue2032Member 2024-12-31 0000310158 mrk:A3.25EuroNotesDue2032Member 2023-12-31 0000310158 mrk:A3.50EuroNotesDue2037Member 2024-12-31 0000310158 mrk:A3.50EuroNotesDue2037Member 2023-12-31 0000310158 mrk:A3.70EuroNotesDue2044Member 2024-12-31 0000310158 mrk:A3.70EuroNotesDue2044Member 2023-12-31 0000310158 mrk:A3.75EuroNotesDue2054Member 2024-12-31 0000310158 mrk:A3.75EuroNotesDue2054Member 2023-12-31 0000310158 mrk:A430NotesDue2030Member 2024-12-31 0000310158 mrk:A430NotesDue2030Member 2023-12-31 0000310158 mrk:A490NotesDue2044Member 2024-12-31 0000310158 mrk:A490NotesDue2044Member 2023-12-31 0000310158 mrk:A650NotesDue2033Member 2024-12-31 0000310158 mrk:A650NotesDue2033Member 2023-12-31 0000310158 mrk:A1.375eurodenominatednotesdue2036Member 2024-12-31 0000310158 mrk:A1.375eurodenominatednotesdue2036Member 2023-12-31 0000310158 mrk:A25EuroDenominatedNotesDue2034Member 2024-12-31 0000310158 mrk:A25EuroDenominatedNotesDue2034Member 2023-12-31 0000310158 mrk:A405NotesDue2028Member 2024-12-31 0000310158 mrk:A405NotesDue2028Member 2023-12-31 0000310158 mrk:A360NotesDue2042Member 2024-12-31 0000310158 mrk:A360NotesDue2042Member 2023-12-31 0000310158 mrk:A655NotesDue2037Member 2024-12-31 0000310158 mrk:A655NotesDue2037Member 2023-12-31 0000310158 mrk:A575NotesDue2036Member 2024-12-31 0000310158 mrk:A575NotesDue2036Member 2023-12-31 0000310158 mrk:A595DebenturesDue2028Member 2024-12-31 0000310158 mrk:A595DebenturesDue2028Member 2023-12-31 0000310158 mrk:A585NotesDue2039Member 2024-12-31 0000310158 mrk:A585NotesDue2039Member 2023-12-31 0000310158 mrk:A640DebenturesDue2028Member 2024-12-31 0000310158 mrk:A640DebenturesDue2028Member 2023-12-31 0000310158 mrk:A63DebenturesDue2026Member 2024-12-31 0000310158 mrk:A63DebenturesDue2026Member 2023-12-31 0000310158 mrk:A2.75NotesDue2025Member 2024-12-31 0000310158 mrk:A2.75NotesDue2025Member 2023-12-31 0000310158 mrk:OtherLongTermDebtMember 2024-12-31 0000310158 mrk:OtherLongTermDebtMember 2023-12-31 0000310158 mrk:OtherVariableRateDebtMember 2024-12-31 0000310158 mrk:OtherVariableRateDebtMember 2023-12-31 0000310158 us-gaap:SeniorNotesMember 2024-05-31 0000310158 mrk:A3.25NotesDue2032Member us-gaap:SeniorNotesMember 2024-05-31 0000310158 mrk:A3.50NotesDue2037Member us-gaap:SeniorNotesMember 2024-05-31 0000310158 mrk:A3.70NotesDue2044Member us-gaap:SeniorNotesMember 2024-05-31 0000310158 mrk:A3.75NotesDue2054Member us-gaap:SeniorNotesMember 2024-05-31 0000310158 us-gaap:BuildingMember 2024-12-31 0000310158 us-gaap:VehiclesMember 2024-12-31 0000310158 mrk:Dr.SchollsMember country:US us-gaap:PendingLitigationMember 2024-12-31 0000310158 mrk:GardasilGardasil9Member country:US us-gaap:PendingLitigationMember 2024-12-31 0000310158 mrk:GardasilGardasil9Member us-gaap:NonUsMember us-gaap:PendingLitigationMember 2024-12-31 0000310158 mrk:RotateqMember country:US us-gaap:PendingLitigationMember 2024-01-01 2024-12-31 0000310158 mrk:CommercialandOtherLitigationMember us-gaap:PendingLitigationMember 2024-01-01 2024-12-31 0000310158 mrk:QuiTamMember country:US us-gaap:SettledLitigationMember 2023-07-01 2023-07-31 0000310158 mrk:CommercialandOtherLitigationMember us-gaap:PendingLitigationMember 2024-12-31 0000310158 us-gaap:PatentsMember mrk:BridionMember us-gaap:PendingLitigationMember 2022-12-19 2022-12-19 0000310158 us-gaap:PatentsMember mrk:BridionMember us-gaap:SettledLitigationMember 2023-06-01 2023-06-30 0000310158 us-gaap:PatentsMember mrk:BridionMember 2024-01-01 2024-12-31 0000310158 us-gaap:PatentsMember mrk:BridionMember us-gaap:PendingLitigationMember 2024-12-31 0000310158 mrk:JanuviaJanumetMember 2024-01-01 2024-12-31 0000310158 mrk:TheJohnsHopkinsUniversityMember 2023-04-01 2023-05-31 0000310158 mrk:TheJohnsHopkinsUniversityMember 2024-06-01 2024-10-31 0000310158 mrk:LegalDefenseCostsMember 2024-12-31 0000310158 mrk:LegalDefenseCostsMember 2023-12-31 0000310158 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0000310158 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0000310158 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0000310158 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-12-31 0000310158 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2024-01-01 2024-12-31 0000310158 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2024-01-01 2024-12-31 0000310158 us-gaap:PerformanceSharesMember 2024-01-01 2024-12-31 0000310158 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-12-31 0000310158 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0000310158 us-gaap:PerformanceSharesMember 2023-12-31 0000310158 us-gaap:RestrictedStockUnitsRSUMember 2024-12-31 0000310158 us-gaap:PerformanceSharesMember 2024-12-31 0000310158 country:US us-gaap:PensionPlansDefinedBenefitMember 2024-01-01 2024-12-31 0000310158 country:US us-gaap:PensionPlansDefinedBenefitMember 2023-01-01 2023-12-31 0000310158 country:US us-gaap:PensionPlansDefinedBenefitMember 2022-01-01 2022-12-31 0000310158 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-01-01 2024-12-31 0000310158 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-01-01 2023-12-31 0000310158 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-01-01 2022-12-31 0000310158 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-01-01 2024-12-31 0000310158 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-01-01 2023-12-31 0000310158 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-01-01 2022-12-31 0000310158 country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:DefinedBenefitPlanDerivativeMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:DefinedBenefitPlanDerivativeMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:OtherInvestmentsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:OtherInvestmentsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:GovernmentAndAgencyObligationsInvestmentFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:GovernmentAndAgencyObligationsInvestmentFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:GovernmentAndAgencyObligationsInvestmentFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:GovernmentAndAgencyObligationsInvestmentFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:GovernmentAndAgencyObligationsInvestmentFundsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:GovernmentAndAgencyObligationsInvestmentFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:GovernmentAndAgencyObligationsInvestmentFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:GovernmentAndAgencyObligationsInvestmentFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:GovernmentAndAgencyObligationsInvestmentFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:GovernmentAndAgencyObligationsInvestmentFundsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:CorporateDebtSecuritiesMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:CorporateDebtSecuritiesMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:FixedIncomeObligationsInvestmentFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:FixedIncomeObligationsInvestmentFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:FixedIncomeObligationsInvestmentFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:FixedIncomeObligationsInvestmentFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:FixedIncomeObligationsInvestmentFundsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:FixedIncomeObligationsInvestmentFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:FixedIncomeObligationsInvestmentFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:FixedIncomeObligationsInvestmentFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:FixedIncomeObligationsInvestmentFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:FixedIncomeObligationsInvestmentFundsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:InsuranceContractsOtherInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:InsuranceContractsOtherInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:InsuranceContractsOtherInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:InsuranceContractsOtherInvestmentsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:InsuranceContractsOtherInvestmentsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:InsuranceContractsOtherInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:InsuranceContractsOtherInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:InsuranceContractsOtherInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:InsuranceContractsOtherInvestmentsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:InsuranceContractsOtherInvestmentsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:InsuranceContractsOtherInvestmentsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:InsuranceContractsOtherInvestmentsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:InsuranceContractsOtherInvestmentsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-01-01 2024-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-01-01 2024-12-31 0000310158 us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-01-01 2024-12-31 0000310158 mrk:InsuranceContractsOtherInvestmentsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-01-01 2023-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-01-01 2023-12-31 0000310158 us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2023-01-01 2023-12-31 0000310158 mrk:InsuranceContractsOtherInvestmentsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:InsuranceContractsOtherInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:InsuranceContractsOtherInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-01-01 2024-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-01-01 2024-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2024-01-01 2024-12-31 0000310158 mrk:InsuranceContractsOtherInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-01-01 2023-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-01-01 2023-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2023-01-01 2023-12-31 0000310158 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:CashAndCashEquivalentsMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:CashAndCashEquivalentsMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel1Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel3Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel1Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel3Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:CorporateDebtSecuritiesMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:CorporateDebtSecuritiesMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueInputsLevel1Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueInputsLevel3Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueInputsLevel1Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueInputsLevel3Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2024-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2023-12-31 0000310158 srt:MinimumMember us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember country:US 2024-12-31 0000310158 srt:MaximumMember us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember country:US 2024-12-31 0000310158 srt:MinimumMember us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember country:US 2024-12-31 0000310158 srt:MaximumMember us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember country:US 2024-12-31 0000310158 srt:MinimumMember us-gaap:FixedIncomeInvestmentsMember country:US 2024-12-31 0000310158 srt:MaximumMember us-gaap:FixedIncomeInvestmentsMember country:US 2024-12-31 0000310158 srt:MaximumMember mrk:DefinedBenefitPlanCashandOtherInvestmentsMember country:US 2024-12-31 0000310158 country:US 2024-12-31 0000310158 country:US 2024-01-01 2024-12-31 0000310158 country:US 2023-01-01 2023-12-31 0000310158 country:US 2022-01-01 2022-12-31 0000310158 country:US 2023-12-31 0000310158 country:US 2022-12-31 0000310158 srt:ScenarioForecastMember country:US us-gaap:SubsequentEventMember 2025-01-01 2025-12-31 0000310158 mrk:ZetiaantitrustlitigationMember 2023-01-01 2023-12-31 0000310158 us-gaap:OtherAssetsMember 2024-12-31 0000310158 us-gaap:OtherAssetsMember 2023-12-31 0000310158 us-gaap:ForeignCountryMember 2024-12-31 0000310158 us-gaap:DomesticCountryMember 2024-12-31 0000310158 us-gaap:DomesticCountryMember 2024-01-01 2024-12-31 0000310158 us-gaap:DomesticCountryMember 2023-01-01 2023-12-31 0000310158 us-gaap:DomesticCountryMember 2022-01-01 2022-12-31 0000310158 us-gaap:ForeignCountryMember 2024-01-01 2024-12-31 0000310158 us-gaap:ForeignCountryMember 2023-01-01 2023-12-31 0000310158 us-gaap:ForeignCountryMember 2022-01-01 2022-12-31 0000310158 mrk:TaxYear2019And2020Member 2024-01-01 2024-12-31 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-12-31 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-12-31 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2021-12-31 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-01-01 2022-12-31 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-12-31 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-12-31 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-01 2023-12-31 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-12-31 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-12-31 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2023-12-31 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-01-01 2024-12-31 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-12-31 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-12-31 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2024-12-31 0000310158 mrk:PensionPlanNetLossMember 2024-12-31 0000310158 mrk:PensionPlanNetLossMember 2023-12-31 0000310158 mrk:OtherPostretirementBenefitPlanNetLossMember 2024-12-31 0000310158 mrk:OtherPostretirementBenefitPlanNetLossMember 2023-12-31 0000310158 mrk:PensionPlanPriorServiceCostMember 2024-12-31 0000310158 mrk:PensionPlanPriorServiceCostMember 2023-12-31 0000310158 mrk:OtherPostretirementBenefitPlanPriorServiceCostMember 2024-12-31 0000310158 mrk:OtherPostretirementBenefitPlanPriorServiceCostMember 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:WeliregMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:WeliregMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:WeliregMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:WeliregMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:WeliregMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:WeliregMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:WeliregMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:WeliregMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:WeliregMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ReblozylMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ReblozylMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ReblozylMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ReblozylMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ReblozylMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ReblozylMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ReblozylMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ReblozylMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ReblozylMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaxneuvanceMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaxneuvanceMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaxneuvanceMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaxneuvanceMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaxneuvanceMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaxneuvanceMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaxneuvanceMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaxneuvanceMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaxneuvanceMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:DificidMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:DificidMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:DificidMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:DificidMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:DificidMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:DificidMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:DificidMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:DificidMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:DificidMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:WinrevairMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:WinrevairMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:WinrevairMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:WinrevairMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:WinrevairMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:WinrevairMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:WinrevairMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:WinrevairMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:WinrevairMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasVerquvoMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasVerquvoMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasVerquvoMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasVerquvoMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasVerquvoMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasVerquvoMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasVerquvoMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasVerquvoMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasVerquvoMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LagevrioMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LagevrioMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LagevrioMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LagevrioMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LagevrioMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LagevrioMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LagevrioMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LagevrioMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LagevrioMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:DelstrigoMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:DelstrigoMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:DelstrigoMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:DelstrigoMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:DelstrigoMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:DelstrigoMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:DelstrigoMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:DelstrigoMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:DelstrigoMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PifeltroMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PifeltroMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PifeltroMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PifeltroMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PifeltroMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PifeltroMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PifeltroMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PifeltroMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PifeltroMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PharmaceuticalsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PharmaceuticalsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember country:US mrk:AnimalHealthsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:AnimalHealthsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember country:US mrk:AnimalHealthsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:AnimalHealthsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember country:US mrk:AnimalHealthsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:AnimalHealthsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember country:US mrk:AnimalHealthsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:AnimalHealthsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember country:US mrk:AnimalHealthsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:AnimalHealthsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember country:US mrk:AnimalHealthsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:AnimalHealthsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:AnimalHealthsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AnimalHealthsegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:AnimalHealthsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AnimalHealthsegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:AnimalHealthsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AnimalHealthsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember country:US 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember 2024-01-01 2024-12-31 0000310158 us-gaap:OperatingSegmentsMember country:US 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember 2023-01-01 2023-12-31 0000310158 us-gaap:OperatingSegmentsMember country:US 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember 2022-01-01 2022-12-31 0000310158 us-gaap:CorporateNonSegmentMember country:US 2024-01-01 2024-12-31 0000310158 us-gaap:CorporateNonSegmentMember mrk:InternationalMember 2024-01-01 2024-12-31 0000310158 us-gaap:CorporateNonSegmentMember 2024-01-01 2024-12-31 0000310158 us-gaap:CorporateNonSegmentMember country:US 2023-01-01 2023-12-31 0000310158 us-gaap:CorporateNonSegmentMember mrk:InternationalMember 2023-01-01 2023-12-31 0000310158 us-gaap:CorporateNonSegmentMember 2023-01-01 2023-12-31 0000310158 us-gaap:CorporateNonSegmentMember country:US 2022-01-01 2022-12-31 0000310158 us-gaap:CorporateNonSegmentMember mrk:InternationalMember 2022-01-01 2022-12-31 0000310158 us-gaap:CorporateNonSegmentMember 2022-01-01 2022-12-31 0000310158 country:US 2024-01-01 2024-12-31 0000310158 mrk:InternationalMember 2024-01-01 2024-12-31 0000310158 country:US 2023-01-01 2023-12-31 0000310158 mrk:InternationalMember 2023-01-01 2023-12-31 0000310158 country:US 2022-01-01 2022-12-31 0000310158 mrk:InternationalMember 2022-01-01 2022-12-31 0000310158 us-gaap:EMEAMember 2024-01-01 2024-12-31 0000310158 us-gaap:EMEAMember 2023-01-01 2023-12-31 0000310158 us-gaap:EMEAMember 2022-01-01 2022-12-31 0000310158 country:CN 2024-01-01 2024-12-31 0000310158 country:CN 2023-01-01 2023-12-31 0000310158 country:CN 2022-01-01 2022-12-31 0000310158 srt:LatinAmericaMember 2024-01-01 2024-12-31 0000310158 srt:LatinAmericaMember 2023-01-01 2023-12-31 0000310158 srt:LatinAmericaMember 2022-01-01 2022-12-31 0000310158 country:JP 2024-01-01 2024-12-31 0000310158 country:JP 2023-01-01 2023-12-31 0000310158 country:JP 2022-01-01 2022-12-31 0000310158 srt:AsiaPacificMember 2024-01-01 2024-12-31 0000310158 srt:AsiaPacificMember 2023-01-01 2023-12-31 0000310158 srt:AsiaPacificMember 2022-01-01 2022-12-31 0000310158 mrk:OtherCountriesMember 2024-01-01 2024-12-31 0000310158 mrk:OtherCountriesMember 2023-01-01 2023-12-31 0000310158 mrk:OtherCountriesMember 2022-01-01 2022-12-31 0000310158 country:US 2024-12-31 0000310158 country:US 2023-12-31 0000310158 country:US 2022-12-31 0000310158 us-gaap:EMEAMember 2024-12-31 0000310158 us-gaap:EMEAMember 2023-12-31 0000310158 us-gaap:EMEAMember 2022-12-31 0000310158 srt:AsiaPacificMember 2024-12-31 0000310158 srt:AsiaPacificMember 2023-12-31 0000310158 srt:AsiaPacificMember 2022-12-31 0000310158 country:CN 2024-12-31 0000310158 country:CN 2023-12-31 0000310158 country:CN 2022-12-31 0000310158 country:JP 2024-12-31 0000310158 country:JP 2023-12-31 0000310158 country:JP 2022-12-31 0000310158 srt:LatinAmericaMember 2024-12-31 0000310158 srt:LatinAmericaMember 2023-12-31 0000310158 srt:LatinAmericaMember 2022-12-31 0000310158 mrk:OtherCountriesMember 2024-12-31 0000310158 mrk:OtherCountriesMember 2023-12-31 0000310158 mrk:OtherCountriesMember 2022-12-31 0000310158 2024-10-01 2024-12-31 shares iso4217:USD iso4217:USD shares mrk:segment mrk:aqua_facility pure mrk:antibodyDrugConjugate mrk:candidate mrk:jurisdiction mrk:interest_rate_swap iso4217:EUR mrk:case mrk:Plaintiff mrk:motion mrk:patent false 2024 FY 0000310158 P3M http://fasb.org/us-gaap/2024#Revenues http://fasb.org/us-gaap/2024#Revenues http://fasb.org/us-gaap/2024#Revenues http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense http://fasb.org/us-gaap/2024#RestructuringCharges http://fasb.org/us-gaap/2024#RestructuringCharges http://fasb.org/us-gaap/2024#RestructuringCharges http://fasb.org/us-gaap/2024#RestructuringCharges http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#RestructuringCharges http://fasb.org/us-gaap/2024#RestructuringCharges http://fasb.org/us-gaap/2024#RestructuringCharges http://fasb.org/us-gaap/2024#RestructuringCharges http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense http://fasb.org/us-gaap/2024#RestructuringCharges http://fasb.org/us-gaap/2024#RestructuringCharges http://fasb.org/us-gaap/2024#RestructuringCharges http://fasb.org/us-gaap/2024#RestructuringCharges http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense http://fasb.org/us-gaap/2024#RestructuringCharges http://fasb.org/us-gaap/2024#RestructuringCharges http://fasb.org/us-gaap/2024#RestructuringCharges http://fasb.org/us-gaap/2024#RestructuringCharges http://fasb.org/us-gaap/2024#LongTermDebtNoncurrent http://fasb.org/us-gaap/2024#LongTermDebtNoncurrent http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#OtherAssetsCurrent http://fasb.org/us-gaap/2024#OtherAssetsCurrent http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2024#OtherAssetsCurrent http://fasb.org/us-gaap/2024#OtherAssetsCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent 0.3333 0.3333 10-K true 2024-12-31 --12-31 false 1-6571 Merck & Co., Inc. 126 East Lincoln Avenue Rahway NJ 07065 908 740-4000 NJ 22-1918501 Common Stock ($0.50 par value) MRK NYSE 1.875% Notes due 2026 MRK/26 NYSE 3.250% Notes due 2032 MRK/32 NYSE 2.500% Notes due 2034 MRK/34 NYSE 1.375% Notes due 2036 MRK 36A NYSE 3.500% Notes due 2037 MRK/37 NYSE 3.700% Notes due 2044 MRK/44 NYSE 3.750% Notes due 2054 MRK/54 NYSE Yes No Yes Yes Large Accelerated Filer false false true false false 2526036240 313799000000 <div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Proxy Statement for the Annual Meeting of Shareholders to be held May 27, 2025, to be filed with the </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Securities and Exchange Commission within 120 days after the close of the fiscal year covered by this report</span></div> <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company’s cybersecurity measures are primarily focused on ensuring the security and protection of its IT systems and data. The Company’s information security program is managed by a dedicated Chief Information Security Officer (CISO), whose group is responsible for leading enterprise-wide cybersecurity risk management, strategy, policy, standards, architecture, and processes. The CISO has worked in the cybersecurity and national security fields for more than 30 years. He has a Master of Science in Telecommunications and Computers. He has served as a board member of the Health Information Sharing and Analysis Center for 10 years. Oversight of the information security program has been integrated into the Company’s overall enterprise risk management program.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The CISO provides periodic reports to the Audit Committee (Audit Committee) of the Board of Directors (Board), the full Board, as well as to the Company’s Chief Executive Officer and other members of senior management, as appropriate. These reports include updates on the Company’s cybersecurity risks and threats, the status of projects intended to strengthen its information security systems, assessments of the information security program (including remediation, mitigation, and management of identified vulnerabilities), and the emerging threat landscape. The information security program is regularly evaluated by internal and external consultants and auditors with the results of those reviews reported to senior management and the Audit Committee, which is comprised entirely of independent directors and has oversight responsibility for these risks. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company’s information security group monitors the Company’s information systems to prevent, detect, mitigate, and remediate cybersecurity incidents. The Company uses tools and techniques to continually assess and monitor, manage and mitigate cybersecurity threats to its IT systems in a manner consistent with industry practice. The Company engages with key vendors, industry participants, and intelligence and law enforcement communities as part of its continuing efforts to obtain current threat intelligence, collaborate on security enhancements, and evaluate and improve the effectiveness of its information security program. As part of this program, the Company conducts periodic tabletop and red-teaming exercises to assess its cybersecurity incident response processes and defenses. The Company also maintains vendor management diligence and oversight processes to identify and monitor potential risks from cybersecurity threats attendant to its use of third-party service providers. Additionally, the Company monitors cybersecurity threat intelligence received from key third-party service providers associated with the Company.</span></div> <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company’s cybersecurity measures are primarily focused on ensuring the security and protection of its IT systems and data. The Company’s information security program is managed by a dedicated Chief Information Security Officer (CISO), whose group is responsible for leading enterprise-wide cybersecurity risk management, strategy, policy, standards, architecture, and processes. The CISO has worked in the cybersecurity and national security fields for more than 30 years. He has a Master of Science in Telecommunications and Computers. He has served as a board member of the Health Information Sharing and Analysis Center for 10 years. Oversight of the information security program has been integrated into the Company’s overall enterprise risk management program.</span></div> <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company’s cybersecurity measures are primarily focused on ensuring the security and protection of its IT systems and data. The Company’s information security program is managed by a dedicated Chief Information Security Officer (CISO), whose group is responsible for leading enterprise-wide cybersecurity risk management, strategy, policy, standards, architecture, and processes. The CISO has worked in the cybersecurity and national security fields for more than 30 years. He has a Master of Science in Telecommunications and Computers. He has served as a board member of the Health Information Sharing and Analysis Center for 10 years. Oversight of the information security program has been integrated into the Company’s overall enterprise risk management program.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the event of a cybersecurity incident, the Company has a process in place whereby members of the information security group will alert the CISO and the CISO will alert the appropriate levels of management, including an incident assessment team, as well as the legal and finance departments so that the materiality of any such event can be assessed in furtherance of fulfilling any reporting requirements. If warranted, senior management will notify the Audit Committee or the full Board, as appropriate.</span></div> The Company’s information security program is managed by a dedicated Chief Information Security Officer (CISO), whose group is responsible for leading enterprise-wide cybersecurity risk management, strategy, policy, standards, architecture, and processes. true The CISO has worked in the cybersecurity and national security fields for more than 30 years. He has a Master of Science in Telecommunications and Computers. He has served as a board member of the Health Information Sharing and Analysis Center for 10 years. true <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The CISO provides periodic reports to the Audit Committee (Audit Committee) of the Board of Directors (Board), the full Board, as well as to the Company’s Chief Executive Officer and other members of senior management, as appropriate. These reports include updates on the Company’s cybersecurity risks and threats, the status of projects intended to strengthen its information security systems, assessments of the information security program (including remediation, mitigation, and management of identified vulnerabilities), and the emerging threat landscape. The information security program is regularly evaluated by internal and external consultants and auditors with the results of those reviews reported to senior management and the Audit Committee, which is comprised entirely of independent directors and has oversight responsibility for these risks. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the event of a cybersecurity incident, the Company has a process in place whereby members of the information security group will alert the CISO and the CISO will alert the appropriate levels of management, including an incident assessment team, as well as the legal and finance departments so that the materiality of any such event can be assessed in furtherance of fulfilling any reporting requirements. If warranted, senior management will notify the Audit Committee or the full Board, as appropriate.</span></div> The CISO provides periodic reports to the Audit Committee (Audit Committee) of the Board of Directors (Board), the full Board, as well as to the Company’s Chief Executive Officer and other members of senior management, as appropriate. These reports include updates on the Company’s cybersecurity risks and threats, the status of projects intended to strengthen its information security systems, assessments of the information security program (including remediation, mitigation, and management of identified vulnerabilities), and the emerging threat landscape. The information security program is regularly evaluated by internal and external consultants and auditors with the results of those reviews reported to senior management and the Audit Committee, which is comprised entirely of independent directors and has oversight responsibility for these risks.<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the event of a cybersecurity incident, the Company has a process in place whereby members of the information security group will alert the CISO and the CISO will alert the appropriate levels of management, including an incident assessment team, as well as the legal and finance departments so that the materiality of any such event can be assessed in furtherance of fulfilling any reporting requirements. If warranted, senior management will notify the Audit Committee or the full Board, as appropriate.</span></div> The CISO provides periodic reports to the Audit Committee (Audit Committee) of the Board of Directors (Board), the full Board, as well as to the Company’s Chief Executive Officer and other members of senior management, as appropriate. These reports include updates on the Company’s cybersecurity risks and threats, the status of projects intended to strengthen its information security systems, assessments of the information security program (including remediation, mitigation, and management of identified vulnerabilities), and the emerging threat landscape. The information security program is regularly evaluated by internal and external consultants and auditors with the results of those reviews reported to senior management and the Audit Committee, which is comprised entirely of independent directors and has oversight responsibility for these risks.<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the event of a cybersecurity incident, the Company has a process in place whereby members of the information security group will alert the CISO and the CISO will alert the appropriate levels of management, including an incident assessment team, as well as the legal and finance departments so that the materiality of any such event can be assessed in furtherance of fulfilling any reporting requirements. If warranted, senior management will notify the Audit Committee or the full Board, as appropriate.</span></div> true The information security program is regularly evaluated by internal and external consultants and auditors with the results of those reviews reported to senior management and the Audit Committee, which is comprised entirely of independent directors and has oversight responsibility for these risks. true true false 64168000000 60115000000 59283000000 15193000000 16126000000 17411000000 10816000000 10504000000 10042000000 17938000000 30531000000 13548000000 309000000 599000000 337000000 24000000 -466000000 -1501000000 44232000000 58226000000 42839000000 19936000000 1889000000 16444000000 2803000000 1512000000 1918000000 17133000000 377000000 14526000000 16000000 12000000 7000000 17117000000 365000000 14519000000 6.76 0.14 5.73 6.74 0.14 5.71 17117000000 365000000 14519000000 266000000 -97000000 -71000000 -466000000 385000000 -335000000 -516000000 89000000 -603000000 216000000 -393000000 -339000000 17333000000 -28000000 14180000000 13242000000 6841000000 447000000 252000000 89000000 88000000 10278000000 10349000000 4193000000 3348000000 6109000000 6358000000 8706000000 8368000000 38782000000 32168000000 463000000 252000000 307000000 326000000 16360000000 14966000000 18283000000 17763000000 7984000000 8262000000 42934000000 41317000000 19155000000 18266000000 23779000000 23051000000 21668000000 21197000000 16370000000 18011000000 16044000000 11996000000 117106000000 106675000000 2649000000 1372000000 4079000000 3922000000 15694000000 15766000000 3914000000 2649000000 2084000000 1985000000 28420000000 25694000000 34462000000 33683000000 1387000000 871000000 6465000000 8792000000 0.50 0.50 6500000000 6500000000 3577103522 3577103522 1788000000 1788000000 44704000000 44509000000 63069000000 53895000000 -4945000000 -5161000000 104616000000 95031000000 1049466187 1045470249 58303000000 57450000000 46313000000 37581000000 59000000 54000000 46372000000 37635000000 117106000000 106675000000 1788000000 44238000000 53696000000 -4429000000 -57109000000 73000000 38257000000 14519000000 14519000000 -339000000 -339000000 2.80 7134000000 7134000000 7000000 7000000 13000000 13000000 -141000000 -620000000 -761000000 1788000000 44379000000 61081000000 -4768000000 -56489000000 67000000 46058000000 365000000 365000000 -393000000 -393000000 2.96 7551000000 7551000000 1346000000 1346000000 12000000 12000000 25000000 25000000 -130000000 -385000000 -515000000 1788000000 44509000000 53895000000 -5161000000 -57450000000 54000000 37635000000 17117000000 17117000000 216000000 216000000 3.12 7943000000 7943000000 1306000000 1306000000 16000000 16000000 12000000 12000000 -195000000 -453000000 -1000000 -649000000 1788000000 44704000000 63069000000 -4945000000 -58303000000 59000000 46372000000 17133000000 377000000 14526000000 2395000000 2044000000 2085000000 2104000000 1828000000 1824000000 39000000 792000000 1749000000 14000000 340000000 -1419000000 3456000000 11409000000 0 -1249000000 -1899000000 -1568000000 761000000 645000000 541000000 -510000000 -355000000 -1301000000 244000000 1148000000 644000000 835000000 816000000 161000000 182000000 -380000000 -289000000 -2328000000 1783000000 -50000000 1023000000 214000000 380000000 -49000000 456000000 -545000000 1416000000 2314000000 1473000000 21468000000 13006000000 19095000000 3372000000 3863000000 4388000000 519000000 955000000 1204000000 0 1145000000 0 377000000 1658000000 721000000 1344000000 0 0 1303000000 0 0 746000000 0 0 700000000 0 0 0 10705000000 0 0 1327000000 0 127000000 36000000 89000000 -7734000000 -14083000000 -4960000000 1290000000 1755000000 2251000000 3599000000 5939000000 0 1306000000 1346000000 0 7840000000 7445000000 7012000000 177000000 125000000 384000000 -372000000 -328000000 -240000000 -7032000000 -4810000000 -9119000000 -293000000 23000000 -410000000 6409000000 -5864000000 4606000000 68000000 79000000 71000000 6909000000 12773000000 8167000000 76000000 68000000 79000000 13318000000 6909000000 12773000000 Nature of Operations<div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck &amp; Co., Inc. (Merck or the Company) is a global health care company that delivers innovative health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company’s operations are principally managed on a product basis and include two operating segments, Pharmaceutical and Animal Health, both of which are reportable segments. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors, animal producers, farmers and pet owners.</span></div> 2 Summary of Accounting Policies<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. Intercompany balances and transactions are eliminated. Controlling interest is determined by majority ownership interest and the absence of substantive third-party participating rights or, in the case of variable interest entities, by majority exposure to expected losses, residual returns or both. For those consolidated subsidiaries where Merck ownership is less than 100%, the outside shareholders’ interests are shown as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling interests</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in equity. Investments in affiliates over which the Company has significant influence but not a controlling interest, such as interests in entities owned equally by the Company and a third party that are under shared control, are carried on the equity method basis.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In a business combination, the acquisition method of accounting requires that the assets acquired and liabilities assumed be recorded as of the date of the acquisition at their respective fair values with limited exceptions. Assets acquired and liabilities assumed in a business combination that arise from contingencies are generally recognized at fair value. If fair value cannot be determined, the asset or liability is recognized if probable and reasonably estimable; if these criteria are not met, no asset or liability is recognized. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Accordingly, the Company may be required to value assets at fair value measures that do not reflect the Company’s intended use of those assets. Any excess of the purchase price (consideration transferred) over the estimated fair values of net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Company’s consolidated financial statements after the date of the acquisition. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If the Company determines the assets acquired do not meet the definition of a business under the acquisition method of accounting, the transaction will be accounted for as an acquisition of assets rather than a business combination and, therefore, no goodwill will be recorded. In an asset acquisition, acquired in-process research and development (IPR&amp;D) with no alternative future use is charged to expense and contingent consideration is not recognized at the acquisition date.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Translation —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The net assets of international subsidiaries where the local currencies have been determined to be the functional currencies are translated into U.S. dollars using current exchange rates and results of operations are translated at average exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries at changing rates are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Comprehensive Income (OCI)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and remain in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">) until either the sale or complete or substantially complete liquidation of the subsidiary. For those subsidiaries that operate in highly inflationary economies and for those subsidiaries where the U.S. dollar has been determined to be the functional currency, non-monetary foreign currency </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">assets and liabilities are translated using historical rates, while monetary assets and liabilities are translated at current rates, with the U.S. dollar effects of rate changes included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cash Equivalents —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash equivalents are comprised of certain highly liquid investments with original maturities of less than three months.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Inventories —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventories are valued at the lower of cost or net realizable value. The cost of a substantial majority of U.S. human health inventories is determined using the last-in, first-out (LIFO) method for both financial reporting and tax purposes. The cost of all other inventories is determined using the first-in, first-out (FIFO) method. Inventories consist of currently marketed products, as well as certain inventories produced in preparation for product launches that are considered by the Company to be probable of obtaining regulatory approval. In evaluating the recoverability of inventories produced in preparation for product launches, the Company considers the likelihood that revenue will be obtained from the future sale of the related inventory together with the status of the product during the research and regulatory approval process.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Investments —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Investments in marketable debt securities classified as available-for-sale are reported at fair value. Fair values of the Company’s investments in marketable debt securities are determined using quoted market prices in active markets for identical assets or quoted prices for similar assets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Changes in fair value that are not impairment related are reported net of taxes in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company considers available evidence in evaluating potential impairments of its investments in marketable debt securities, including the extent to which fair value is less than cost, whether an allowance for credit loss is required, as well as adverse factors that could affect the value of the securities. An impairment has occurred if the Company does not expect to recover the entire amortized cost basis of the marketable debt security. If the Company does not intend to sell the impaired debt security, and it is not more likely than not it will be required to sell the debt security before the recovery of its amortized cost basis, the amount of the impairment recognized in earnings, recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, is limited to the portion attributed to credit loss. The remaining portion of the impairment related to other factors is recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Realized gains and losses for debt securities are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Investments in publicly traded equity securities are reported at fair value as determined using quoted market prices in active markets for identical assets or quoted prices for similar assets or other inputs that are observable or can be corroborated by observable market data. Changes in fair value are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period. Gains and losses from ownership interests in investment funds, which are accounted for as equity method investments, are reported on a one quarter lag. Investments in equity securities without readily determinable fair values are recorded at cost, plus or minus subsequent observable price changes in orderly transactions for identical or similar investments, minus impairments. Such adjustments are recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Realized gains and losses for equity securities are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recognition of revenue requires evidence of a contract, probable collection of sales proceeds and completion of substantially all performance obligations. Merck acts as the principal in substantially all of its customer arrangements and therefore records revenue on a gross basis. The majority of the Company’s contracts related to the Pharmaceutical and Animal Health segments have a single performance obligation - the promise to transfer goods. Shipping is considered immaterial in the context of the overall customer arrangement and damages or loss of goods in transit are rare. Therefore, shipping is not deemed a separately recognized performance obligation.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The vast majority of revenues from sales of products are recognized at a point in time when control of the goods is transferred to the customer, which the Company has determined is when title and risks and rewards of ownership transfer to the customer and the Company is entitled to payment. The Company recognizes revenue from the sales of vaccines to the U.S. federal government for placement into vaccine stockpiles in accordance with Securities and Exchange Commission (SEC) Interpretation,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> Commission Guidance Regarding Accounting for Sales of Vaccines and BioTerror Countermeasures to the Federal Government for Placement into the Pediatric Vaccine Stockpile or the Strategic National Stockpile</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. This interpretation allows companies to recognize revenue for sales of vaccines into U.S. government stockpiles even though these sales might not meet the criteria for revenue recognition under other accounting guidance. For certain services in the Animal Health segment, revenue is recognized over time, generally ratably over the contract term as services are provided. These service revenues are not material.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The nature of the Company’s business gives rise to several types of variable consideration including discounts and returns, which are estimated at the time of sale generally using the expected value method, although the most likely amount method is used for prompt pay discounts. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the U.S., sales discounts are issued to customers at the point-of-sale, through an intermediary wholesaler (known as chargebacks), or in the form of rebates. Additionally, sales are generally made with a limited right of return under certain conditions. Revenues are recorded net of provisions for sales discounts and returns, which are established at the time of sale. In addition, if collection of accounts receivable is expected to be in excess of one year, sales are recorded net of time value of money discounts, which have not been material. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The U.S. provision for aggregate customer discounts covering chargebacks and rebates was $13.3 billion in 2024, $12.5 billion in 2023 and $12.3 billion in 2022. Chargebacks are discounts that occur when a contracted customer purchases through an intermediary wholesaler. The wholesaler then charges the Company back for the difference between the price initially paid by the wholesaler and the contract price agreed to between Merck and the customer. The provision for chargebacks is based on expected sell-through levels by the Company’s wholesale customers to contracted customers, as well as estimated wholesaler inventory levels. Rebates are amounts owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part D) benefit providers after the final dispensing of the product to a benefit plan participant. The provision for rebates is based on expected patient usage, as well as inventory levels in the distribution channel to determine the contractual obligation to the benefit providers. The Company uses historical customer segment utilization mix, sales forecasts, changes to product mix and price, inventory levels in the distribution channel, government pricing calculations and prior payment history in order to estimate the expected provision. Amounts accrued for aggregate customer discounts are evaluated on a quarterly basis through comparison of information provided by the wholesalers, health maintenance organizations, pharmacy benefit managers, federal and state agencies, and other customers to the amounts accrued. The accrued balances relative to the provisions for chargebacks and rebates included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accounts receivable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> were $293 million and $2.2 billion, respectively, at December 31, 2024 and were $188 million and $2.3 billion, respectively, at December 31, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outside of the U.S., variable consideration in the form of discounts and rebates are a combination of commercially-driven discounts in highly competitive product classes, discounts required to gain or maintain reimbursement, or legislatively mandated rebates. In certain European countries, legislatively mandated rebates are calculated based on an estimate of the government’s total unbudgeted spending and the Company’s specific payback obligation. Rebates may also be required based on specific product sales thresholds. The Company applies an estimated factor against its actual invoiced sales to represent the expected level of future discount or rebate obligations associated with the sale.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company maintains a returns policy that allows its U.S. pharmaceutical customers to return product within a specified period prior to and subsequent to the expiration date (generally, <span style="-sec-ix-hidden:f-436">three</span> to six months before and 12 months after product expiration). The estimate of the provision for returns is based upon historical experience with actual returns. Additionally, the Company considers factors such as levels of inventory in the distribution channel, product dating and expiration period, whether products have been discontinued, entrance in the market of generic or other competition, changes in formularies or launch of over-the-counter products, among others. Outside of the U.S., returns are only allowed in certain countries on a limited basis.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck’s payment terms for U.S. pharmaceutical customers are typically 36 days from receipt of invoice and for U.S. animal health customers are typically 30 days from receipt of invoice; however, certain products have longer payment terms, including </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">pembrolizumab</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, which has payment terms of 90 days. Payment terms for vaccine sales in the U.S. typically range from 30 days to 60 days. Outside of the U.S., payment terms are typically 30 days to 90 days, although certain markets have longer payment terms.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Note 18 for disaggregated revenue disclosures.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Depreciation —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation is provided over the estimated useful lives of the assets, principally using the straight-line method. For tax purposes, accelerated tax methods are used. The estimated useful lives primarily range from 25 to 45 years for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Buildings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, and from 3 to 15 years for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Machinery, equipment and office furnishings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Depreciation expense was $2.1 billion in 2024, $1.8 billion in 2023 and $1.8 billion in 2022.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Advertising and Promotion Costs —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Advertising and promotion costs are expensed as incurred. The Company recorded advertising and promotion expenses of $2.4 billion in 2024, $2.3 billion in 2023 and $2.2 billion in 2022.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Software Capitalization —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company capitalizes certain costs incurred in connection with obtaining or developing internal-use software including external direct costs of material and services, and payroll costs for employees directly involved with the software development. These costs are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Property, plant and equipment</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. In addition, the Company capitalizes certain costs incurred to implement a cloud computing arrangement </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">that is considered a service agreement, which are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Capitalized software costs are being amortized over periods ranging from 2 to 10 years, with the longer lives generally associated with enterprise-wide projects implemented over multiple years. Costs incurred during the preliminary project stage and post-implementation stage, as well as maintenance and training costs, are expensed as incurred.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Goodwill —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill represents the excess of the consideration transferred over the fair value of net assets acquired in a business combination. Goodwill is assigned to reporting units and evaluated for impairment at least annually, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company concludes it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed. If the carrying value of a reporting unit is greater than its fair value, a goodwill impairment charge will be recorded for the difference (up to the carrying value of goodwill).</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Acquired Intangibles —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Intangibles acquired in a business combination include product rights, trade names and patents, licenses and other, which are initially recorded at fair value, assigned an estimated useful life, and amortized primarily on a straight-line basis over their estimated useful lives ranging from 2 to 24 years. The Company periodically evaluates whether current facts or circumstances indicate that the carrying values of its acquired intangibles may not be recoverable. If such circumstances are determined to exist, an estimate of the undiscounted future cash flows of these assets, or appropriate asset groupings, is compared to the carrying value to determine whether an impairment exists. If the asset is determined to be impaired, the loss is measured based on the difference between the carrying value of the intangible asset and its fair value, which is determined based on the net present value of estimated future cash flows.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Acquired In-Process Research and Development —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">IPR&amp;D that the Company acquires in conjunction with a business combination represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each IPR&amp;D project, Merck will make a determination as to the then-useful life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization. The Company evaluates IPR&amp;D for impairment at least annually, or more frequently if impairment indicators exist, by performing a quantitative test that compares the fair value of the IPR&amp;D intangible asset with its carrying value. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration for Business Combinations —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain of the Company’s acquisitions involve the potential for future payment of consideration that is contingent upon the achievement of performance milestones, including product development milestones and royalty payments on future product sales. If the transaction is accounted for as a business combination, the fair value of contingent consideration liabilities is determined at the acquisition date using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period until the contingency is resolved, the contingent consideration liability is remeasured at current fair value with changes (either expense or income) recorded in earnings. Significant events that increase or decrease the probability of achieving development and regulatory milestones or that increase or decrease projected cash flows will result in corresponding increases or decreases in the fair values of the related contingent consideration obligations. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and Development —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development is expensed as incurred. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Research and development expenses include restructuring costs and IPR&amp;D impairment charges. In addition, research and development expenses include expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration associated with IPR&amp;D assets. Research and development expenses also include upfront and milestone payments related to asset acquisitions and licensing transactions involving clinical development programs that have not yet received regulatory approval. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. When Merck is the principal on sales transactions with third parties, the Company recognizes sales, cost of sales and selling, general and administrative expenses on a gross basis. Profit sharing amounts it pays to its collaborative partners are recorded within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. When the collaborative partner is the principal on sales transactions with third parties, the Company records profit sharing amounts received from its collaborative partners as alliance revenue </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">). Alliance revenue is recorded net of cost of sales and includes an adjustment to share commercialization costs between the partners in accordance with the collaboration agreement. The adjustment is determined by comparing the commercialization costs Merck has incurred directly and reported within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses with the costs the collaborative partner has incurred. Research and development costs Merck incurs related to collaborations are recorded within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses. Cost reimbursements to the collaborative partner or payments received from the collaborative partner to share these costs pursuant to the terms of the collaboration agreements are recorded as increases or decreases to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, the terms of the collaboration agreements may require the Company to make payments based upon the achievement of certain developmental, regulatory approval or commercial milestones. Upfront and milestone payments payable by Merck to collaborative partners prior to regulatory approval are expensed as incurred and included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses. Payments due to collaborative partners upon or subsequent to regulatory approval are capitalized and amortized to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> over the estimated useful life of the corresponding intangible asset, provided that future cash flows support the amounts capitalized. Sales-based milestones payable by Merck to collaborative partners are accrued and capitalized, subject to cumulative amortization catch-up, when determined by the Company to be probable of being achieved based on future sales forecasts. The amortization catch-up is calculated either from the time of the first regulatory approval for products that were unapproved at the time the collaboration was formed or, for new indications of approved products, from the time of the formation of the collaboration. The related intangible asset that is recognized is amortized to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> over its remaining useful life, subject to impairment testing.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Compensation —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company expenses all share-based payments to employees over the requisite service period based on the grant-date fair value of the awards.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Costs —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. In accordance with existing benefit arrangements, future employee termination costs to be incurred in conjunction with involuntary separations are accrued when such separations are probable and estimable. When accruing these costs, the Company will recognize the amount within a range of costs that is the best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company recognizes the minimum amount within the range. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Contingencies and Legal Defense Costs —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company records accruals for contingencies and legal defense costs expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Taxes on Income —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. The Company evaluates tax positions to determine whether the benefits of tax positions are more likely than not of being sustained upon audit based on the technical merits of the tax position. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the amount of the benefit that is greater than 50% likely of being realized upon ultimate settlement in the financial statements. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit in the financial statements. The Company recognizes interest and penalties associated with uncertain tax positions as a component of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Taxes on Income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company accounts for the tax effects of the tax on global intangible low-taxed income (GILTI) of certain foreign subsidiaries in the income tax provision in the period the tax arises. The Company’s policy for releasing disproportionate income tax effects from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is to utilize the item-by-item approach.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Reclassifications —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior year amounts to conform to the current year presentation. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the U.S. (GAAP) and, accordingly, include certain amounts that are based on management’s best estimates and judgments. Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities in a business combination (primarily IPR&amp;D, other intangible assets and contingent consideration), as well as subsequent fair value measurements. Additionally, estimates are used in determining such items as provisions for sales discounts, rebates and returns, depreciable and amortizable lives, recoverability of inventories, including those produced in preparation for product launches, amounts recorded for contingencies, environmental liabilities, accruals for contingent sales-</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">based milestone payments and other reserves, pension and other postretirement benefit plan assumptions, share-based compensation assumptions, restructuring costs, impairments of long-lived assets (including intangible assets and goodwill) and investments, and taxes on income. Because of the uncertainty inherent in such estimates, actual results may differ from these estimates.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standards —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In August 2023, the Financial Accounting Standards Board (FASB) issued amended guidance that requires a newly formed joint venture to recognize and initially measure its assets and liabilities at fair value upon formation. The amended guidance includes exceptions to fair value measurement that are consistent with the accounting for business combinations guidance. The Company adopted the guidance effective July 1, 2024 on a prospective basis. There was no impact to the Company’s consolidated financial statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In November 2023, the FASB issued guidance intended to improve reportable segment disclosure requirements, primarily through expanded disclosures for significant segment expenses. The Company adopted the guidance effective for the 2024 annual period. The guidance resulted in incremental disclosures to the Company’s segment reporting disclosures. See Note 18 for further details.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Standards Not Yet Adopted —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In December 2023, the FASB issued guidance intended to improve the transparency of income tax disclosures by requiring consistent categories and disaggregation of information in the effective income tax rate reconciliation and income taxes paid disclosures by jurisdiction. The guidance also includes other amendments to improve the effectiveness of income tax disclosures by removing certain previously required disclosures. The guidance is effective for 2025 annual reporting. The guidance will result in incremental disclosures within the footnotes to the Company’s financial statements. </span></div>In November 2024, the FASB issued guidance intended to improve financial reporting by requiring entities to disclose additional information about specific expense categories at interim and annual reporting periods. The guidance is effective for 2027 annual reporting and 2028 interim reporting. Early adoption is permitted. The guidance, which can be applied on a prospective or retrospective basis, will result in incremental disclosures within the footnotes to the Company’s financial statements. <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. Intercompany balances and transactions are eliminated. Controlling interest is determined by majority ownership interest and the absence of substantive third-party participating rights or, in the case of variable interest entities, by majority exposure to expected losses, residual returns or both. For those consolidated subsidiaries where Merck ownership is less than 100%, the outside shareholders’ interests are shown as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling interests</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in equity. Investments in affiliates over which the Company has significant influence but not a controlling interest, such as interests in entities owned equally by the Company and a third party that are under shared control, are carried on the equity method basis.</span></div> <div style="margin-top:8pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In a business combination, the acquisition method of accounting requires that the assets acquired and liabilities assumed be recorded as of the date of the acquisition at their respective fair values with limited exceptions. Assets acquired and liabilities assumed in a business combination that arise from contingencies are generally recognized at fair value. If fair value cannot be determined, the asset or liability is recognized if probable and reasonably estimable; if these criteria are not met, no asset or liability is recognized. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Accordingly, the Company may be required to value assets at fair value measures that do not reflect the Company’s intended use of those assets. Any excess of the purchase price (consideration transferred) over the estimated fair values of net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Company’s consolidated financial statements after the date of the acquisition. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If the Company determines the assets acquired do not meet the definition of a business under the acquisition method of accounting, the transaction will be accounted for as an acquisition of assets rather than a business combination and, therefore, no goodwill will be recorded. In an asset acquisition, acquired in-process research and development (IPR&amp;D) with no alternative future use is charged to expense and contingent consideration is not recognized at the acquisition date.</span></div> <div style="margin-top:8pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Translation —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The net assets of international subsidiaries where the local currencies have been determined to be the functional currencies are translated into U.S. dollars using current exchange rates and results of operations are translated at average exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries at changing rates are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Comprehensive Income (OCI)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and remain in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">) until either the sale or complete or substantially complete liquidation of the subsidiary. For those subsidiaries that operate in highly inflationary economies and for those subsidiaries where the U.S. dollar has been determined to be the functional currency, non-monetary foreign currency </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">assets and liabilities are translated using historical rates, while monetary assets and liabilities are translated at current rates, with the U.S. dollar effects of rate changes included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div> <div style="margin-top:8pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cash Equivalents —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash equivalents are comprised of certain highly liquid investments with original maturities of less than three months.</span></div> <div style="margin-top:8pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Inventories —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventories are valued at the lower of cost or net realizable value. The cost of a substantial majority of U.S. human health inventories is determined using the last-in, first-out (LIFO) method for both financial reporting and tax purposes. The cost of all other inventories is determined using the first-in, first-out (FIFO) method. Inventories consist of currently marketed products, as well as certain inventories produced in preparation for product launches that are considered by the Company to be probable of obtaining regulatory approval. In evaluating the recoverability of inventories produced in preparation for product launches, the Company considers the likelihood that revenue will be obtained from the future sale of the related inventory together with the status of the product during the research and regulatory approval process.</span></div> <div style="margin-top:8pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Investments —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Investments in marketable debt securities classified as available-for-sale are reported at fair value. Fair values of the Company’s investments in marketable debt securities are determined using quoted market prices in active markets for identical assets or quoted prices for similar assets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Changes in fair value that are not impairment related are reported net of taxes in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company considers available evidence in evaluating potential impairments of its investments in marketable debt securities, including the extent to which fair value is less than cost, whether an allowance for credit loss is required, as well as adverse factors that could affect the value of the securities. An impairment has occurred if the Company does not expect to recover the entire amortized cost basis of the marketable debt security. If the Company does not intend to sell the impaired debt security, and it is not more likely than not it will be required to sell the debt security before the recovery of its amortized cost basis, the amount of the impairment recognized in earnings, recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, is limited to the portion attributed to credit loss. The remaining portion of the impairment related to other factors is recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Realized gains and losses for debt securities are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Investments in publicly traded equity securities are reported at fair value as determined using quoted market prices in active markets for identical assets or quoted prices for similar assets or other inputs that are observable or can be corroborated by observable market data. Changes in fair value are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period. Gains and losses from ownership interests in investment funds, which are accounted for as equity method investments, are reported on a one quarter lag. Investments in equity securities without readily determinable fair values are recorded at cost, plus or minus subsequent observable price changes in orderly transactions for identical or similar investments, minus impairments. Such adjustments are recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Realized gains and losses for equity securities are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div> <div style="margin-top:8pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recognition of revenue requires evidence of a contract, probable collection of sales proceeds and completion of substantially all performance obligations. Merck acts as the principal in substantially all of its customer arrangements and therefore records revenue on a gross basis. The majority of the Company’s contracts related to the Pharmaceutical and Animal Health segments have a single performance obligation - the promise to transfer goods. Shipping is considered immaterial in the context of the overall customer arrangement and damages or loss of goods in transit are rare. Therefore, shipping is not deemed a separately recognized performance obligation.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The vast majority of revenues from sales of products are recognized at a point in time when control of the goods is transferred to the customer, which the Company has determined is when title and risks and rewards of ownership transfer to the customer and the Company is entitled to payment. The Company recognizes revenue from the sales of vaccines to the U.S. federal government for placement into vaccine stockpiles in accordance with Securities and Exchange Commission (SEC) Interpretation,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> Commission Guidance Regarding Accounting for Sales of Vaccines and BioTerror Countermeasures to the Federal Government for Placement into the Pediatric Vaccine Stockpile or the Strategic National Stockpile</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. This interpretation allows companies to recognize revenue for sales of vaccines into U.S. government stockpiles even though these sales might not meet the criteria for revenue recognition under other accounting guidance. For certain services in the Animal Health segment, revenue is recognized over time, generally ratably over the contract term as services are provided. These service revenues are not material.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The nature of the Company’s business gives rise to several types of variable consideration including discounts and returns, which are estimated at the time of sale generally using the expected value method, although the most likely amount method is used for prompt pay discounts. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the U.S., sales discounts are issued to customers at the point-of-sale, through an intermediary wholesaler (known as chargebacks), or in the form of rebates. Additionally, sales are generally made with a limited right of return under certain conditions. Revenues are recorded net of provisions for sales discounts and returns, which are established at the time of sale. In addition, if collection of accounts receivable is expected to be in excess of one year, sales are recorded net of time value of money discounts, which have not been material. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The U.S. provision for aggregate customer discounts covering chargebacks and rebates was $13.3 billion in 2024, $12.5 billion in 2023 and $12.3 billion in 2022. Chargebacks are discounts that occur when a contracted customer purchases through an intermediary wholesaler. The wholesaler then charges the Company back for the difference between the price initially paid by the wholesaler and the contract price agreed to between Merck and the customer. The provision for chargebacks is based on expected sell-through levels by the Company’s wholesale customers to contracted customers, as well as estimated wholesaler inventory levels. Rebates are amounts owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part D) benefit providers after the final dispensing of the product to a benefit plan participant. The provision for rebates is based on expected patient usage, as well as inventory levels in the distribution channel to determine the contractual obligation to the benefit providers. The Company uses historical customer segment utilization mix, sales forecasts, changes to product mix and price, inventory levels in the distribution channel, government pricing calculations and prior payment history in order to estimate the expected provision. Amounts accrued for aggregate customer discounts are evaluated on a quarterly basis through comparison of information provided by the wholesalers, health maintenance organizations, pharmacy benefit managers, federal and state agencies, and other customers to the amounts accrued. The accrued balances relative to the provisions for chargebacks and rebates included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accounts receivable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> were $293 million and $2.2 billion, respectively, at December 31, 2024 and were $188 million and $2.3 billion, respectively, at December 31, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outside of the U.S., variable consideration in the form of discounts and rebates are a combination of commercially-driven discounts in highly competitive product classes, discounts required to gain or maintain reimbursement, or legislatively mandated rebates. In certain European countries, legislatively mandated rebates are calculated based on an estimate of the government’s total unbudgeted spending and the Company’s specific payback obligation. Rebates may also be required based on specific product sales thresholds. The Company applies an estimated factor against its actual invoiced sales to represent the expected level of future discount or rebate obligations associated with the sale.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company maintains a returns policy that allows its U.S. pharmaceutical customers to return product within a specified period prior to and subsequent to the expiration date (generally, <span style="-sec-ix-hidden:f-436">three</span> to six months before and 12 months after product expiration). The estimate of the provision for returns is based upon historical experience with actual returns. Additionally, the Company considers factors such as levels of inventory in the distribution channel, product dating and expiration period, whether products have been discontinued, entrance in the market of generic or other competition, changes in formularies or launch of over-the-counter products, among others. Outside of the U.S., returns are only allowed in certain countries on a limited basis.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck’s payment terms for U.S. pharmaceutical customers are typically 36 days from receipt of invoice and for U.S. animal health customers are typically 30 days from receipt of invoice; however, certain products have longer payment terms, including </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">pembrolizumab</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, which has payment terms of 90 days. Payment terms for vaccine sales in the U.S. typically range from 30 days to 60 days. Outside of the U.S., payment terms are typically 30 days to 90 days, although certain markets have longer payment terms.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Note 18 for disaggregated revenue disclosures.</span></div> 13300000000 12500000000 12300000000 293000000 2200000000 188000000 2300000000 P6M P12M P36D P30D P90D P30D P60D P30D P90D <span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Depreciation —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation is provided over the estimated useful lives of the assets, principally using the straight-line method. For tax purposes, accelerated tax methods are used. The estimated useful lives primarily range from 25 to 45 years for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Buildings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, and from 3 to 15 years for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Machinery, equipment and office furnishings</span>. P25Y P45Y P3Y P15Y 2100000000 1800000000 1800000000 <span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Advertising and Promotion Costs —</span> Advertising and promotion costs are expensed as incurred. 2400000000 2300000000 2200000000 <div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Software Capitalization —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company capitalizes certain costs incurred in connection with obtaining or developing internal-use software including external direct costs of material and services, and payroll costs for employees directly involved with the software development. These costs are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Property, plant and equipment</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. In addition, the Company capitalizes certain costs incurred to implement a cloud computing arrangement </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">that is considered a service agreement, which are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Capitalized software costs are being amortized over periods ranging from 2 to 10 years, with the longer lives generally associated with enterprise-wide projects implemented over multiple years. Costs incurred during the preliminary project stage and post-implementation stage, as well as maintenance and training costs, are expensed as incurred.</span></div> P2Y P10Y <div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Goodwill —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill represents the excess of the consideration transferred over the fair value of net assets acquired in a business combination. Goodwill is assigned to reporting units and evaluated for impairment at least annually, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company concludes it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed. If the carrying value of a reporting unit is greater than its fair value, a goodwill impairment charge will be recorded for the difference (up to the carrying value of goodwill).</span></div> <div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Acquired Intangibles —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Intangibles acquired in a business combination include product rights, trade names and patents, licenses and other, which are initially recorded at fair value, assigned an estimated useful life, and amortized primarily on a straight-line basis over their estimated useful lives ranging from 2 to 24 years. The Company periodically evaluates whether current facts or circumstances indicate that the carrying values of its acquired intangibles may not be recoverable. If such circumstances are determined to exist, an estimate of the undiscounted future cash flows of these assets, or appropriate asset groupings, is compared to the carrying value to determine whether an impairment exists. If the asset is determined to be impaired, the loss is measured based on the difference between the carrying value of the intangible asset and its fair value, which is determined based on the net present value of estimated future cash flows.</span></div> P2Y P24Y <div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Acquired In-Process Research and Development —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">IPR&amp;D that the Company acquires in conjunction with a business combination represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each IPR&amp;D project, Merck will make a determination as to the then-useful life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization. The Company evaluates IPR&amp;D for impairment at least annually, or more frequently if impairment indicators exist, by performing a quantitative test that compares the fair value of the IPR&amp;D intangible asset with its carrying value. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results.</span></div> <span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration for Business Combinations —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span>Certain of the Company’s acquisitions involve the potential for future payment of consideration that is contingent upon the achievement of performance milestones, including product development milestones and royalty payments on future product sales. If the transaction is accounted for as a business combination, the fair value of contingent consideration liabilities is determined at the acquisition date using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period until the contingency is resolved, the contingent consideration liability is remeasured at current fair value with changes (either expense or income) recorded in earnings. Significant events that increase or decrease the probability of achieving development and regulatory milestones or that increase or decrease projected cash flows will result in corresponding increases or decreases in the fair values of the related contingent consideration obligations. <span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and Development —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span>Research and development is expensed as incurred. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Research and development expenses include restructuring costs and IPR&amp;D impairment charges. In addition, research and development expenses include expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration associated with IPR&amp;D assets. Research and development expenses also include upfront and milestone payments related to asset acquisitions and licensing transactions involving clinical development programs that have not yet received regulatory approval. <div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. When Merck is the principal on sales transactions with third parties, the Company recognizes sales, cost of sales and selling, general and administrative expenses on a gross basis. Profit sharing amounts it pays to its collaborative partners are recorded within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. When the collaborative partner is the principal on sales transactions with third parties, the Company records profit sharing amounts received from its collaborative partners as alliance revenue </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">). Alliance revenue is recorded net of cost of sales and includes an adjustment to share commercialization costs between the partners in accordance with the collaboration agreement. The adjustment is determined by comparing the commercialization costs Merck has incurred directly and reported within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses with the costs the collaborative partner has incurred. Research and development costs Merck incurs related to collaborations are recorded within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses. Cost reimbursements to the collaborative partner or payments received from the collaborative partner to share these costs pursuant to the terms of the collaboration agreements are recorded as increases or decreases to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, the terms of the collaboration agreements may require the Company to make payments based upon the achievement of certain developmental, regulatory approval or commercial milestones. Upfront and milestone payments payable by Merck to collaborative partners prior to regulatory approval are expensed as incurred and included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses. Payments due to collaborative partners upon or subsequent to regulatory approval are capitalized and amortized to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> over the estimated useful life of the corresponding intangible asset, provided that future cash flows support the amounts capitalized. Sales-based milestones payable by Merck to collaborative partners are accrued and capitalized, subject to cumulative amortization catch-up, when determined by the Company to be probable of being achieved based on future sales forecasts. The amortization catch-up is calculated either from the time of the first regulatory approval for products that were unapproved at the time the collaboration was formed or, for new indications of approved products, from the time of the formation of the collaboration. The related intangible asset that is recognized is amortized to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> over its remaining useful life, subject to impairment testing.</span></div> <div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Compensation —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company expenses all share-based payments to employees over the requisite service period based on the grant-date fair value of the awards.</span></div> <div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Costs —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. In accordance with existing benefit arrangements, future employee termination costs to be incurred in conjunction with involuntary separations are accrued when such separations are probable and estimable. When accruing these costs, the Company will recognize the amount within a range of costs that is the best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company recognizes the minimum amount within the range. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period.</span></div> <div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Contingencies and Legal Defense Costs —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company records accruals for contingencies and legal defense costs expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated.</span></div> <div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Taxes on Income —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. The Company evaluates tax positions to determine whether the benefits of tax positions are more likely than not of being sustained upon audit based on the technical merits of the tax position. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the amount of the benefit that is greater than 50% likely of being realized upon ultimate settlement in the financial statements. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit in the financial statements. The Company recognizes interest and penalties associated with uncertain tax positions as a component of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Taxes on Income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company accounts for the tax effects of the tax on global intangible low-taxed income (GILTI) of certain foreign subsidiaries in the income tax provision in the period the tax arises. The Company’s policy for releasing disproportionate income tax effects from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is to utilize the item-by-item approach.</span></div> <span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Reclassifications —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span>Certain reclassifications have been made to prior year amounts to conform to the current year presentation. <div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the U.S. (GAAP) and, accordingly, include certain amounts that are based on management’s best estimates and judgments. Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities in a business combination (primarily IPR&amp;D, other intangible assets and contingent consideration), as well as subsequent fair value measurements. Additionally, estimates are used in determining such items as provisions for sales discounts, rebates and returns, depreciable and amortizable lives, recoverability of inventories, including those produced in preparation for product launches, amounts recorded for contingencies, environmental liabilities, accruals for contingent sales-</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">based milestone payments and other reserves, pension and other postretirement benefit plan assumptions, share-based compensation assumptions, restructuring costs, impairments of long-lived assets (including intangible assets and goodwill) and investments, and taxes on income. Because of the uncertainty inherent in such estimates, actual results may differ from these estimates.</span></div> <div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standards —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In August 2023, the Financial Accounting Standards Board (FASB) issued amended guidance that requires a newly formed joint venture to recognize and initially measure its assets and liabilities at fair value upon formation. The amended guidance includes exceptions to fair value measurement that are consistent with the accounting for business combinations guidance. The Company adopted the guidance effective July 1, 2024 on a prospective basis. There was no impact to the Company’s consolidated financial statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In November 2023, the FASB issued guidance intended to improve reportable segment disclosure requirements, primarily through expanded disclosures for significant segment expenses. The Company adopted the guidance effective for the 2024 annual period. The guidance resulted in incremental disclosures to the Company’s segment reporting disclosures. See Note 18 for further details.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Standards Not Yet Adopted —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In December 2023, the FASB issued guidance intended to improve the transparency of income tax disclosures by requiring consistent categories and disaggregation of information in the effective income tax rate reconciliation and income taxes paid disclosures by jurisdiction. The guidance also includes other amendments to improve the effectiveness of income tax disclosures by removing certain previously required disclosures. The guidance is effective for 2025 annual reporting. The guidance will result in incremental disclosures within the footnotes to the Company’s financial statements. </span></div>In November 2024, the FASB issued guidance intended to improve financial reporting by requiring entities to disclose additional information about specific expense categories at interim and annual reporting periods. The guidance is effective for 2027 annual reporting and 2028 interim reporting. Early adoption is permitted. The guidance, which can be applied on a prospective or retrospective basis, will result in incremental disclosures within the footnotes to the Company’s financial statements. Acquisitions, Divestitures, Research Collaborations and Licensing Agreements<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company continues to pursue acquisitions and the establishment of external alliances such as research collaborations and licensing agreements to complement its internal research capabilities. These arrangements often include upfront payments; expense reimbursements or payments to the third party; milestone, royalty or profit share arrangements contingent upon the occurrence of certain future events linked to the success of the asset in development; and can also include option and continuation payments. The Company also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial results of the acquired entity are not significant when compared with the Company’s financial results.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Recent Transactions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In January 2025, Merck and WuXi Vaccines, a wholly owned subsidiary of WuXi Biologics, entered into a definitive agreement pursuant to which Merck will acquire WuXi Vaccines’ facility in Dundalk, Ireland for a payment of approximately $440 million at closing. The transaction is expected to close in the first quarter of 2025, subject to the satisfaction of customary closing conditions. There are no future contingent payments associated with the acquisition.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024 Transactions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In December 2024, Merck closed an exclusive global license to develop, manufacture and commercialize MK-2010 (LM-299), a novel investigational PD-1/vascular endothelial growth factor (VEGF) bispecific antibody from LaNova Medicines Ltd (LaNova). Merck recorded a charge of $588 million to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">expenses in 2024 for the upfront payment, which was made in January 2025. LaNova is also eligible to receive $300 million upon technology transfer, which is anticipated to be completed in 2025, as well as future contingent developmental milestone payments of up to $140 million, regulatory milestone payments of up to $860 million and sales-based milestone payments of up to $1.4 billion.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Also in December 2024, Merck closed an exclusive global license to develop, manufacture and commercialize MK-4082 (HS-10535), an investigational preclinical oral small molecule GLP-1 receptor agonist from Hansoh Pharma (Hansoh). Merck recorded a charge of $112 million to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">expenses in 2024 for the upfront payment, which was made in February 2025. Hansoh is also eligible to receive future contingent </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">development-related milestone payments of up to $115 million, regulatory milestone payments of up to $315 million and sales-based milestone payments of up to $1.47 billion, as well as tiered royalties ranging from a high-single-digit rate to a low-double-digit rate on future net sales of MK-4082 (HS-10535), if approved. Under the agreement, Hansoh may co-promote or solely commercialize MK-4082 (HS-10535) in Chinese mainland, Hong Kong and Macau, subject to certain conditions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In September 2024, Merck acquired MK-1045 (formally CN201), a novel investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases, from Curon Biopharmaceutical (Curon) for an upfront payment of $700 million. In addition, Curon is eligible to receive future contingent developmental milestone payments of up to $300 million and regulatory milestone payments of up to $300 million. The transaction was accounted for as an asset acquisition. Merck recorded a charge of $750 million (reflecting the upfront payment and other related costs) to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in 2024 related to the execution of the transaction. In connection with the agreement, Merck is also obligated to pay a third party future contingent developmental, regulatory and sales-based milestone payments of up to $128 million in the aggregate, as well as tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales of MK-1045, if approved.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In July 2024, Merck acquired the aqua business of Elanco Animal Health Incorporated (Elanco aqua business) for total consideration of $1.3 billion. The Elanco aqua business consists of an innovative portfolio of medicines and vaccines, nutritionals and supplements for aquatic species; two related aqua manufacturing facilities in Canada and Vietnam; as well as a research facility in Chile. The acquisition broadens Animal Health’s aqua portfolio with products, such as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Clynav</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, a new generation DNA-based vaccine that protects Atlantic salmon against pancreas disease, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Imvixa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, an anti-parasitic sea lice treatment. This acquisition also brings a portfolio of water treatment products for warm water production, complementing Animal Health’s warm water vaccine portfolio. In addition to these products, the DNA-based vaccine technology that is a part of the business has the potential to accelerate the development of novel vaccines to address the unmet needs of the aqua industry. There are no contingent payments associated with the acquisition, which was accounted for as a business combination.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The estimated fair values of assets acquired and liabilities assumed from the Elanco aqua business are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 9, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product rights - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Clynav </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(useful life 15 years) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">340</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other product rights (useful lives 15 years) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">291</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">785 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">518</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consideration transferred</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,303 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The estimated fair values of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Clynav</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> and other product rights were determined using an income approach, specifically the multi-period excess earnings method. The future probability-weighted net cash flows were discounted to present value utilizing a discount rate of 8.5%. Actual cash flows are likely to be different than those assumed. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The goodwill recognized is largely attributable to anticipated synergies expected to arise after the acquisition and was allocated to the Animal Health segment. The goodwill is expected to be deductible for tax purposes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Also in July 2024, Merck acquired Eyebiotech Limited (EyeBio), a privately held ophthalmology-focused biotechnology company, for $1.2 billion (including payments to settle share-based equity awards) and also incurred $207 million of transaction costs. The acquisition agreement also provides for former EyeBio shareholders to receive future contingent developmental milestone payments of up to $200 million (of which $100 million was triggered and paid in 2024 as noted below), regulatory milestone payments of up to $1.0 billion and sales-based milestone payments of up to $500 million. EyeBio’s development work focused on candidates for the prevention and treatment of vision loss associated with retinal vascular leakage, a known risk factor for retinal diseases. EyeBio’s lead candidate, MK-3000 (formerly EYE103), is an investigational, potentially first-in-class tetravalent, tri-specific antibody that acts as an agonist of the Wingless-related integration site signaling pathway, which is in clinical development for the treatment of diabetic macular edema and neovascular age-related macular degeneration. The transaction was accounted for as an asset acquisition since MK-3000 accounted for substantially all of the fair value of the gross assets acquired (excluding cash and deferred income taxes). Merck recorded net assets of $21 million, as well as a charge of $1.35 billion to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in 2024 related to the acquisition. Additionally, a $100 million developmental milestone was triggered and paid in 2024 upon initiation of a Phase 2/3 clinical trial </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">evaluating MK-3000 for the treatment of diabetic macular edema, which was also recorded as a charge to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additionally in July 2024, Merck and Orion Corporation (Orion) announced the mutual exercise of an option to convert the companies’ ongoing co-development and co-commercialization agreement for opevesostat (MK-5684/ODM-208), an investigational cytochrome P450 11A1 (CYP11A1) inhibitor in Phase 3 clinical development, and other candidates targeting CYP11A1, into an exclusive global license for Merck. With the exercise of the option, Merck assumed full responsibility for all past and future development and commercialization expenses associated with the candidates covered by the original agreement entered into in 2022 as discussed below. In addition, Orion became eligible to receive developmental milestone payments of up to $30 million, regulatory milestone payments of up to $625 million and sales-based milestone payments of up to $975 million, as well as annually tiered royalties ranging from a low double-digit rate up to a rate in the low twenties on net sales for any commercialized licensed product. Orion retained responsibility for the manufacture of clinical and commercial supply for Merck. No payment was associated with the exercise of the option, which became effective in September 2024. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Also in July 2024, Merck notified Kelun-Biotech (a holding subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.) it was terminating the license and collaboration agreement entered into in July 2022 in which Merck gained exclusive worldwide rights for the development, manufacture and commercialization of an investigational antibody drug conjugate (ADC) MK-1200 (SKB315) for the treatment of solid tumors. As a result of this termination, which became effective in September 2024, all rights to SKB315 have reverted to Kelun-Biotech.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In March 2024, Merck acquired Harpoon Therapeutics, Inc. (Harpoon), a clinical-stage immunotherapy company developing a novel class of T-cell engagers designed to harness the power of the body’s immune system to treat patients suffering from cancer and other diseases for $765 million and also incurred $56 million of transaction costs. Harpoon’s lead candidate, MK-6070 (formerly HPN328), is a T-cell engager targeting delta-like ligand 3 (DLL3), an inhibitory canonical Notch ligand that is expressed at high levels in small-cell lung cancer and neuroendocrine tumors. The transaction was accounted for as an asset acquisition since MK-6070 represented substantially all of the fair value of the gross assets acquired (excluding cash and deferred income taxes). Merck recorded net assets of $165 million, as well as a charge of $656 million to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in 2024 related to the transaction. There are no future contingent payments associated with the acquisition. In August 2024, Merck and Daiichi Sankyo expanded their existing global co-development and co-commercialization agreement to include MK-6070. See Note 4 for more information on Merck’s collaboration with Daiichi Sankyo.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023 Transactions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In October 2023, Merck and Daiichi Sankyo entered into a global development and commercialization agreement for three of Daiichi Sankyo’s deruxtecan (DXd) ADC candidates: patritumab deruxtecan (HER3-DXd) (MK-1022), ifinatamab deruxtecan (I-DXd) (MK-2400) and raludotatug deruxtecan (R-DXd) (MK-5909). See Note 4 for additional information related to this collaboration.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In June 2023, Merck acquired Prometheus Biosciences, Inc. (Prometheus), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases. Total consideration paid of $11.0 billion included $1.2 billion of costs to settle share-based equity awards (including $700 million to settle unvested equity awards). Prometheus’ lead candidate, tulisokibart (MK-7240, formerly PRA023), is a humanized monoclonal antibody directed to tumor necrosis factor-like ligand 1A, a target associated with both intestinal inflammation and fibrosis. Tulisokibart is being developed for the treatment of immune-mediated diseases including ulcerative colitis, Crohn’s disease, and other autoimmune conditions. Phase 3 clinical trials evaluating tulisokibart for Crohn’s disease and ulcerative colitis are underway. The transaction was accounted for as an asset acquisition since tulisokibart accounted for substantially all of the fair value of the gross assets acquired (excluding cash and deferred income taxes). Merck recorded net assets of $877 million, including cash of $368 million, investments of $296 million, deferred tax assets of $218 million and other net liabilities of $5 million, as well as a charge of $10.2 billion to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in 2023 related to the transaction. There are no future contingent payments associated with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In February 2023, Merck and Kelun-Biotech closed a license and collaboration agreement expanding their relationship in which Merck gained exclusive rights for the research, development, manufacture and commercialization of up to seven investigational preclinical ADCs for the treatment of cancer. Kelun-Biotech retained the right to research, develop, manufacture and commercialize certain licensed and option ADCs for Chinese mainland, Hong Kong and Macau. Merck made an upfront payment of $175 million, which was recorded as a charge to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in 2023. In October 2023, Merck notified Kelun-Biotech it was terminating two of the seven candidates under the agreement. Subsequently, in April 2024, Merck notified Kelun-Biotech it was terminating one additional candidate under the agreement. In July 2024, Merck notified Kelun-Biotech that it was </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">exercising an existing license option for one of the candidates under the agreement, granting Merck a license for the development, manufacture and commercialization worldwide excluding China. There are now three candidates licensed under the original agreement and one candidate for which the license option remains unexercised. Merck paid Kelun-Biotech $38 million in connection with the July option exercise, following which Kelun-Biotech remains eligible to receive future contingent payments aggregating up to $540 million in development-related payments, $1.5 billion in regulatory milestones, and $3.1 billion in sales-based milestones, if Kelun-Biotech does not retain Chinese mainland, Hong Kong and Macau rights for the remaining option ADC and all remaining candidates achieve regulatory approval. In addition, Kelun-Biotech is eligible to receive tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales for any commercialized ADC product. Also, in connection with the agreement, Merck invested $100 million in Kelun-Biotech shares in January 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In January 2023, Merck acquired Imago BioSciences, Inc. (Imago), a clinical-stage biopharmaceutical company developing new medicines for the treatment of myeloproliferative neoplasms and other bone marrow diseases, for $1.35 billion (including payments to settle share-based equity awards) and also incurred approximately $60 million of transaction costs. Imago’s lead candidate, bomedemstat (MK-3543, formerly IMG-7289), which is in Phase 3 clinical development, is an investigational orally available lysine-specific demethylase 1 inhibitor currently being evaluated in multiple clinical trials for the treatment of essential thrombocythemia, myelofibrosis, and polycythemia vera, in addition to other indications. The transaction was accounted for as an asset acquisition since bomedemstat represented substantially all of the fair value of the gross assets acquired (excluding cash and deferred income taxes). Merck recorded net assets of $219 million, as well as a charge of $1.2 billion to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in 2023 related to the transaction. There are no future contingent payments associated with the acquisition.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022 Transactions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In October 2022, Merck and Royalty Pharma plc (Royalty Pharma) entered into a funding arrangement under which Royalty Pharma paid Merck $50 million to co-fund Merck’s development costs for a Phase 2b trial of MK-8189, an investigational oral phosphodiesterase 10A (PDE10A) inhibitor, which was being evaluated for the treatment of schizophrenia. As Royalty Pharma was sharing the risk of technical and regulatory success with Merck, the development funding was recognized by Merck as an obligation to perform contractual services. Accordingly, the payment received was recognized by Merck as a reduction to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses ratably over the estimated Phase 2b research period. In 2024, it was determined the Phase 2b clinical trial for MK-8189 as a monotherapy for acute schizophrenia did not meet its primary efficacy endpoint; therefore, further development in schizophrenia, bipolar, and dementia indications has stopped, and the funding arrangement was terminated.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In September 2022, Merck exercised its option to jointly develop and commercialize V940 (mRNA-4157), an investigational individualized neoantigen therapy, pursuant to the terms of an existing collaboration and license agreement with Moderna, Inc. (Moderna). See Note 4 for additional information related to this collaboration.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In August 2022, Merck and Orna Therapeutics (Orna), a biotechnology company pioneering a new investigational class of engineered circular RNA (oRNA) therapies, entered into a collaboration agreement to discover, develop, and commercialize multiple programs, including vaccines and therapeutics in the areas of infectious disease and oncology. Under the terms of the agreement, Merck made an upfront payment to Orna of $150 million, which was recorded as a charge to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in 2022. In addition, Orna is eligible to receive future contingent payments aggregating up to $440 million in development-related payments, $675 million in regulatory milestones, and $2.4 billion in sales-based milestones associated with the progress of the multiple vaccine and therapeutic programs, as well as royalties ranging from a high-single-digit rate to a low-double-digit rate on any approved products derived from the collaboration. Merck also invested $100 million in Orna’s Series B preferred shares in 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In July 2022, Merck and Orion Corporation (Orion) announced a global co-development and co-commercialization agreement for Orion’s investigational candidate opevesostat (MK-5684/ODM-208) and other drugs targeting cytochrome P450 11A1 (CYP11A1), an enzyme important in steroid production. Merck made an upfront payment to Orion of $290 million, which was recorded as a charge to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in 2022. Orion is responsible for the manufacture of clinical and commercial supply of opevesostat. In addition, the contract provided both parties with an option to convert the initial co-development and co-commercialization agreement into a global exclusive license to Merck, which was mutually exercised in July 2024 (as noted above).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In May 2022, in connection with an existing arrangement, Merck exercised its option to obtain an exclusive license outside of Chinese mainland, Hong Kong, Macau and Taiwan for the development, manufacture and commercialization of Kelun-Biotech’s trophoblast antigen 2 (TROP2)-targeting ADC programs, including its lead compound, sacituzumab tirumotecan (MK-2870/SKB-264), which is currently in Phase 3 clinical development. Under the terms of the agreement, Merck and Kelun-Biotech are collaborating on certain early clinical development plans, </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">including evaluating the potential of sacituzumab tirumotecan as a monotherapy and in combination with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">for advanced solid tumors. Upon option exercise, Merck made a payment of $30 million, which was recorded as a charge to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in 2022. Additionally, Merck made an additional payment of $25 million upon technology transfer in 2023. Merck has also made all contingent developmental milestone payments under the agreement, which aggregated $90 million, nearly all of which were paid in 2024 and were recorded to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses. In addition, Kelun-Biotech is eligible to receive future contingent milestone payments (which include all program compounds) aggregating up to $290 million in first commercial sale milestones, and $780 million in sales-based milestones. The agreement also provides for Merck to pay tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Spin-Off of Organon &amp; Co.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with the 2021 spin-off of Organon &amp; Co. (Organon), Merck and Organon entered into a series of interim operating agreements pursuant to which in various jurisdictions where Merck held licenses, permits and other rights in connection with marketing, import and/or distribution of Organon products prior to the separation, Merck continued to market, import and distribute such products on behalf of Organon until such time as the relevant licenses and permits transferred to Organon, with Organon receiving all of the economic benefits and burdens of such activities. As of December 31, 2024, only one jurisdiction remains under an interim operating agreement. Additionally, Merck and Organon entered into a number of manufacturing and supply agreements (MSAs) with terms ranging from four years to ten years. The amounts included in the consolidated statement of income for the above MSAs include sales of $392 million, $394 million and $383 million in 2024, 2023 and 2022, respectively, and related cost of sales of $390 million, $422 million and $404 million in 2024, 2023 and 2022, respectively. The amounts due from Organon under all spin-off related agreements were $330 million and $632 million at December 31, 2024 and 2023, respectively, and are reflected in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The amounts due to Organon under these agreements were $113 million and $598 million at December 31, 2024 and 2023, respectively, and are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div> 440000000 588000000 300000000 140000000 860000000 1400000000 112000000 115000000 315000000 1470000000 700000000 300000000 300000000 750000000 128000000 1300000000 2 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The estimated fair values of assets acquired and liabilities assumed from the Elanco aqua business are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 9, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product rights - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Clynav </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(useful life 15 years) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">340</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other product rights (useful lives 15 years) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">291</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">785 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">518</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consideration transferred</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,303 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The estimated fair values of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Clynav</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> and other product rights were determined using an income approach, specifically the multi-period excess earnings method. The future probability-weighted net cash flows were discounted to present value utilizing a discount rate of 8.5%. Actual cash flows are likely to be different than those assumed. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The goodwill recognized is largely attributable to anticipated synergies expected to arise after the acquisition and was allocated to the Animal Health segment. The goodwill is expected to be deductible for tax purposes.</span></div> 65000000 66000000 P15Y 340000000 P15Y 291000000 23000000 785000000 518000000 1303000000 0.085 1200000000 207000000 200000000 100000000 1000000000 500000000 21000000 1350000000 100000000 30000000 625000000 975000000 765000000 56000000 165000000 656000000 3 11000000000.0 1200000000 700000000 877000000 368000000 296000000 218000000 5000000 10200000000 7 175000000 2 7 1 1 3 1 38000000 540000000 1500000000 3100000000 100000000 1350000000 60000000 219000000 1200000000 50000000 150000000 440000000 675000000 2400000000 100000000 290000000 30000000 25000000 90000000 290000000 780000000 1 P4Y P10Y 392000000 394000000 383000000 390000000 422000000 404000000 330000000 632000000 113000000 598000000 Collaborative Arrangements<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merck’s more significant collaborative arrangements are discussed below.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AstraZeneca PLC</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca’s Lynparza (olaparib) for multiple cancer types. Independently, Merck and AstraZeneca are developing and commercializing Lynparza in combinations with their respective PD-1 and PD-L1 medicines, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and Imfinzi. The companies are also jointly developing and commercializing AstraZeneca’s Koselugo (selumetinib) for multiple indications. Under the terms of the agreement, AstraZeneca and Merck share the development and commercialization costs for Lynparza and Koselugo monotherapy and non-PD-1/PD-L1 combination therapy opportunities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Profits from Lynparza and Koselugo product sales generated through monotherapies or combination therapies are shared equally. AstraZeneca is the principal on Lynparza and Koselugo sales transactions. Merck records its share of Lynparza and Koselugo product sales, net of cost of sales and commercialization costs, as alliance revenue, and its share of development costs associated with the collaboration as part of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses. Reimbursements received from AstraZeneca for research and development expenses are recognized as reductions to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As part of the agreement, Merck made an upfront payment to AstraZeneca and also made payments over a multi-year period for certain license options. In addition, the agreement provides for contingent payments from Merck to AstraZeneca related to the successful achievement of sales-based and regulatory milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> In 2024, sales of Koselugo triggered a $100 million sales-based milestone payment from Merck to AstraZeneca. Accordingly, Merck recorded a $100 million liability (which remained accrued at December 31, 2024 and was subsequently paid in January 2025) and a corresponding increase to the intangible asset related to Koselugo. Merck also recognized $48 million of cumulative amortization catch-up expense related to the recognition of this milestone in 2024. Merck made a sales-based milestone payment to AstraZeneca of $400 million in 2022 (which had been previously accrued for). Additionally, in 2022, Merck determined it was probable that sales of Lynparza in the future would trigger a $600 million sales-based milestone payment from Merck to AstraZeneca. Accordingly, Merck recorded a $600 million liability (which remained accrued at December 31, 2024 and was </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">subsequently paid in January 2025) and a corresponding increase to the intangible asset related to Lynparza. Merck also recognized $250 million of cumulative amortization catch-up expense related to the recognition of this milestone in 2022. Potential future sales-based milestone payments of $2.0 billion have not yet been accrued as they are not deemed by the Company to be probable at this time.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lynparza received regulatory approvals triggering capitalized milestone payments from Merck to AstraZeneca of $245 million, $105 million and $250 million in 2024, 2023 and 2022, respectively (each of which had been previously accrued for). In 2024, the partners agreed that no future regulatory milestone payments from Merck to AstraZeneca are likely under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The intangible asset balances related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) and Koselugo (which reflects the 2024 capitalized sales-based milestone payment) were $1.2 billion and $49 million, respectively, at December 31, 2024 and are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The assets are being amortized over their estimated useful lives (through 2028 for Lynparza and through 2029 for Koselugo) as supported by projected future cash flows, subject to impairment testing.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,311</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,199 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,116 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Koselugo</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">170</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-595"><span style="-sec-ix-hidden:f-596"><span style="-sec-ix-hidden:f-597">Total alliance revenue</span></span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,481</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,296 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,170 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">378</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">311 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">492 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">165</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">77</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables from AstraZeneca included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">424</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">713</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">256 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other Noncurrent Liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments. Amounts in 2024 and 2022 include $48 million and $250 million, respectively, of cumulative amortization catch-up expense as noted above.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone payments.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Eisai Co., Ltd.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Under the agreement, Merck and Eisai are developing and commercializing Lenvima jointly, both as monotherapy and in combination with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions) and Merck and Eisai share applicable profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue. Expenses incurred during co-development are shared by the two companies in accordance with the collaboration agreement and reflected in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">expenses. Certain expenses incurred solely by Merck or Eisai are not shareable under the collaboration agreement, including costs incurred in excess of agreed upon caps and costs related to certain combination studies of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and Lenvima.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the agreement, Merck made an upfront payment to Eisai and also made payments over a multi-year period for certain option rights. In addition, the agreement provides for contingent payments from Merck to Eisai related to the successful achievement of sales-based and regulatory milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck made sales-based milestone payments to Eisai aggregating $125 million, $125 million and $600 million in 2024, 2023 and 2022, respectively. In 2023, Merck determined it was probable that sales of Lenvima in the future would trigger $250 million of sales-based milestone payments from Merck to Eisai. Accordingly, Merck recorded $250 million of liabilities (of which $125 million was subsequently paid in each of 2024 and 2023 as noted above) and corresponding increases to the intangible asset related to Lenvima. Merck also recognized $154 million of cumulative amortization catch-up expense related to the recognition of these milestones in 2023. Potential future sales-based milestone payments of $2.3 billion have not yet been accrued as they are not deemed by the Company to be probable at this time.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2022, Lenvima received regulatory approvals triggering capitalized milestone payments of $50 million from Merck to Eisai. There are no regulatory milestone payments remaining under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was $442 million at December 31, 2024 and is included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The amount is being amortized over its estimated useful life through 2026 as supported by projected future cash flows, subject to impairment testing.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,010</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">960 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">876 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">241</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">212 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">159</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables from Eisai included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">257</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to Eisai included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)     </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments. Amount in 2023 includes $154 million of cumulative amortization catch-up expense as noted above.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)     </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents an accrued milestone payment.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Bayer AG</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Bayer’s Adempas (riociguat) and Verquvo (vericiguat). The two companies have implemented a joint development and commercialization strategy. Under the agreement, Bayer commercializes Adempas in the Americas, while Merck commercializes in the rest of the world. For Verquvo, Merck commercializes in the U.S. and Bayer commercializes in the rest of the world. Both companies share in development costs and profits on sales. Merck records sales of Adempas and Verquvo in its marketing territories, as well as alliance revenue. Alliance revenue represents Merck’s share of profits from sales of Adempas and Verquvo in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs. Cost of sales includes Bayer’s share of profits from sales in Merck’s marketing territories. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, the agreement provided for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones. In 2022, Merck made the final $400 million sales-based milestone payment under this collaboration to Bayer. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The intangible asset balances related to Adempas (which includes the acquired intangible asset balance, as well as capitalized sales-based milestone payments attributed to Adempas) and Verquvo (which reflects the portion of the final sales-based milestone payment that was attributed to Verquvo) were $372 million and $42 million, respectively, at December 31, 2024 and are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The assets are being amortized over their estimated useful lives (through 2027 for Adempas and through 2031 for Verquvo) as supported by projected future cash flows, subject to impairment testing.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Adempas/Verquvo</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">415</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">367 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net sales of Adempas recorded by Merck</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">287</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net sales of Verquvo recorded by Merck</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">37</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">739</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">658 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">601 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">244</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">111</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">153 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">102</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables from Bayer included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">160</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to Bayer included in</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> Accrued and other current liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">82</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes amortization of intangible assets, cost of products sold by Merck, as well as Bayer’s share of profits from sales in Merck’s marketing territories. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Ridgeback Biotherapeutics LP</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2020, Merck and Ridgeback Biotherapeutics LP (Ridgeback), a closely held biotechnology company, entered into a collaboration agreement to develop </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(molnupiravir), an investigational orally available antiviral candidate for the treatment of patients with COVID-19. Merck gained exclusive worldwide rights to develop and commercialize </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and related molecules. Following initial authorizations in certain markets in 2021, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> has since received multiple additional authorizations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the terms of the agreement, Ridgeback received an upfront payment and is eligible to receive future contingent payments dependent upon the achievement of certain developmental and regulatory approval milestones. The agreement also provides for Merck to reimburse Ridgeback for a portion of certain third-party contingent milestone payments and royalties on net sales, which is part of the profit-sharing calculation. Merck is the principal on sales transactions, recognizing sales and related costs, with profit-sharing amounts recorded within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Profits from the collaboration are split equally between the partners. Reimbursements from Ridgeback for its share of research and development costs (deducted from Ridgeback’s share of profits) are reflected as decreases to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses. </span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> recorded by Merck</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">964</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,428 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,684 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">554</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">852 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,038 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">57</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Payables to Ridgeback included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">68</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes cost of products sold by Merck, Ridgeback’s share of profits, royalty expense, amortization of capitalized milestone payments and inventory reserves.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued royalties. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Daiichi Sankyo</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In October 2023, Merck and Daiichi Sankyo entered into a global development and commercialization agreement for three of Daiichi Sankyo’s DXd ADC candidates: patritumab deruxtecan (HER3-DXd) (MK-1022), ifinatamab deruxtecan (I-DXd) (MK-2400) and raludotatug deruxtecan (R-DXd) (MK-5909). All three potentially first-in-class DXd ADCs are in various stages of clinical development for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments. The companies will jointly develop and potentially commercialize these ADC candidates worldwide, except in Japan where Daiichi Sankyo will maintain exclusive rights. Daiichi Sankyo will be solely responsible for manufacturing and supply.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the terms of the agreement, Merck made payments to Daiichi Sankyo totaling $4.0 billion in 2023. These payments included $1.0 billion ($500 million each for patritumab deruxtecan and ifinatamab deruxtecan) which may be refundable on a pro-rated basis in the event of early termination of development with respect to either program. In addition, the agreement provided for a continuation payment of $750 million related to patritumab deruxtecan, which Merck paid in October 2024, and a continuation payment of $750 million related to raludotatug deruxtecan due from Merck in October 2025. If Merck does not make the remaining continuation payment for raludotatug deruxtecan, the rights for that program will revert to Daiichi Sankyo and the non-refundable upfront payments already paid will be retained by Daiichi Sankyo. The agreement also provides for contingent payments from Merck to Daiichi Sankyo of up to an additional $5.5 billion for each DXd ADC upon the successful achievement of certain sales-based milestones.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In conjunction with this transaction, Merck recorded an aggregate pretax charge of $5.5 billion to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in 2023 for the $4.0 billion of upfront payments and the $1.5 billion of continuation payments. Merck determined it was appropriate to expense the $1.0 billion refundable portion of the consideration in 2023 because of the significant number of clinical studies that were underway and planned in the near future, as well as certain studies in advanced stages, making it highly likely that the programs would continue to progress and incur substantial expenses, and therefore the likelihood of the programs terminating before the end of the refundable period was deemed remote. Merck also determined that it was appropriate to expense the continuation payments upon execution of the agreement because such payments do not result in the Company gaining any additional intellectual property rights. In addition, the significant number of ongoing and planned clinical studies and the short-term nature of the option period makes the likelihood of Merck not making these payments remote.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck and Daiichi Sankyo equally share research and development costs, except for raludotatug deruxtecan, where Merck is responsible for 75% of the first $2.0 billion of research and development expenses. Merck includes its share of development costs associated with the collaboration as part of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses. Following regulatory approval, Daiichi Sankyo will generally record sales worldwide (Daiichi Sankyo will be the principal on sales transactions) and the companies will equally share expenses as well as profits worldwide except for Japan where Daiichi Sankyo retains exclusive rights and Merck will receive a 5% sales-based royalty. Merck will record its share of product sales, net of cost of sales and commercialization costs, as alliance revenue. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In August 2024, Merck and Daiichi Sankyo expanded their agreement to include MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, which Merck obtained through its acquisition of Harpoon (see Note 3). The companies are planning to evaluate MK-6070 in combination with ifinatamab deruxtecan in certain patients with SCLC, as well as other potential combinations. Merck received an upfront cash payment of $170 million from Daiichi Sankyo (recorded within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">) and has also satisfied a contingent quid obligation from the original collaboration agreement. The companies will jointly develop and commercialize MK-6070 worldwide and share research and development and commercialization expenses. Research and development expenses related to MK-6070 in combination with ifinatamab deruxtecan will be shared in a manner consistent with the original agreement for ifinatamab deruxtecan. Merck will be solely responsible for manufacturing and supply of MK-6070. If approved, Merck will generally record sales for MK-6070 worldwide (Merck will be the principal on sales transactions) and the companies will equally share expenses as well as profits worldwide, except for Japan where Merck retains exclusive rights and Daiichi Sankyo will receive a 5% sales-based royalty.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">26</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">351</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,549 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Receivables from Daiichi Sankyo included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Other current assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> </span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Payables to Daiichi Sankyo included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Accrued and other current liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">817</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Payables to Daiichi Sankyo included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Other Noncurrent Liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Expenses in 2023 include the $5.5 billion charge for the upfront and continuing option payments noted above.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued continuation payment.</span></div><div style="margin-top:9pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Moderna, Inc.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2022, Merck exercised its option to jointly develop and commercialize V940 (mRNA-4157), an investigational individualized neoantigen therapy, pursuant to the terms of an existing collaboration and license agreement with Moderna, Inc. (Moderna), which resulted in a $250 million payment that was charged to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in 2022. V940 (mRNA-4157) is currently being evaluated in combination with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in multiple Phase 3 clinical trials. Merck and Moderna share costs and will share any profits equally under this worldwide collaboration. Merck records its share of development costs associated with the collaboration as part of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses. Any reimbursements received from Moderna for research and development expenses are recognized as reductions to</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> Research and development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">costs. Merck has also capitalized certain of the shared costs, mainly related to facility costs, which aggregated $198 million at December 31, 2024 and will be amortized over the assets’ estimated useful lives. </span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative </span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">358</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Payables to Moderna included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Accrued and other current liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">57</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">    Expenses in 2022 include the $250 million option exercise payment noted above.</span></div><div style="margin-top:9pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Bristol-Myers Squibb Company</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reblozyl (luspatercept-aamt) is a first-in-class erythroid maturation recombinant fusion protein that is being commercialized through a global collaboration with Bristol-Myers Squibb Company (BMS). Reblozyl is approved in the U.S., Europe, and certain other markets for the treatment of anemia in certain rare blood disorders and is also being evaluated for additional indications for hematology therapies. BMS is the principal on sales transactions for Reblozyl; however, Merck co-promotes Reblozyl (and may co-promote any future products approved under this collaboration) in North America, which is reimbursed by BMS. Merck receives tiered royalties ranging from 20% to 24% based on sales levels. This royalty will be reduced by 50% upon the earlier of patent expiry or generic entry on an indication-by-indication basis in each market. Additionally, Merck is eligible to receive future contingent sales-based milestone payments of up to $80 million. Alliance revenue related to this collaboration (recorded within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">) consists of royalties and, for 2022, also includes the receipt of a regulatory approval milestone payment of $20 million. Merck recorded alliance revenue related to this collaboration of $371 million in 2024, $212 million in 2023 and $166 million in 2022.</span></div> 100000000 100000000 48000000 400000000 600000000 600000000 250000000 2000000000.0 245000000 105000000 250000000 1200000000 49000000 <div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,311</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,199 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,116 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Koselugo</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">170</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-595"><span style="-sec-ix-hidden:f-596"><span style="-sec-ix-hidden:f-597">Total alliance revenue</span></span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,481</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,296 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,170 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">378</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">311 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">492 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">165</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">77</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables from AstraZeneca included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">424</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">713</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">256 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other Noncurrent Liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments. Amounts in 2024 and 2022 include $48 million and $250 million, respectively, of cumulative amortization catch-up expense as noted above.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone payments.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,010</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">960 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">876 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">241</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">212 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">159</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables from Eisai included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">257</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to Eisai included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)     </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments. Amount in 2023 includes $154 million of cumulative amortization catch-up expense as noted above.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)     </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents an accrued milestone payment.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Adempas/Verquvo</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">415</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">367 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net sales of Adempas recorded by Merck</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">287</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net sales of Verquvo recorded by Merck</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">37</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">739</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">658 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">601 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">244</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">111</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">153 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">102</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables from Bayer included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">160</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to Bayer included in</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> Accrued and other current liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">82</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes amortization of intangible assets, cost of products sold by Merck, as well as Bayer’s share of profits from sales in Merck’s marketing territories. </span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> recorded by Merck</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">964</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,428 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,684 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">554</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">852 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,038 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">57</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Payables to Ridgeback included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">68</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes cost of products sold by Merck, Ridgeback’s share of profits, royalty expense, amortization of capitalized milestone payments and inventory reserves.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued royalties. </span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">26</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">351</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,549 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Receivables from Daiichi Sankyo included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Other current assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> </span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Payables to Daiichi Sankyo included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Accrued and other current liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">817</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Payables to Daiichi Sankyo included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Other Noncurrent Liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Expenses in 2023 include the $5.5 billion charge for the upfront and continuing option payments noted above.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued continuation payment.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative </span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">358</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Payables to Moderna included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Accrued and other current liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">57</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">    Expenses in 2022 include the $250 million option exercise payment noted above.</span></div> 1311000000 1199000000 1116000000 170000000 97000000 54000000 1481000000 1296000000 1170000000 378000000 311000000 492000000 165000000 192000000 185000000 77000000 79000000 106000000 424000000 341000000 713000000 256000000 0 600000000 48000000 250000000 125000000 125000000 600000000 250000000 250000000 125000000 125000000 154000000 2300000000 50000000 442000000 1010000000 960000000 876000000 241000000 381000000 212000000 159000000 189000000 158000000 21000000 66000000 136000000 257000000 226000000 0 125000000 154000000 400000000 372000000 42000000 415000000 367000000 341000000 287000000 255000000 238000000 37000000 36000000 22000000 739000000 658000000 601000000 244000000 224000000 210000000 111000000 131000000 153000000 102000000 90000000 75000000 160000000 156000000 82000000 80000000 964000000 1428000000 5684000000 554000000 852000000 3038000000 57000000 97000000 147000000 13000000 60000000 88000000 68000000 113000000 3 3 4000000000 1000000000 500000000 500000000 750000000 750000000 5500000000 5500000000 4000000000 1500000000 1000000000 0.75 2000000000 0.05 170000000 0.05 26000000 3000000 351000000 5549000000 8000000 0 817000000 800000000 0 750000000 5500000000 250000000 198000000 16000000 5000000 0 358000000 218000000 288000000 57000000 63000000 250000000 0.20 0.24 0.50 80000000 20000000 371000000 212000000 166000000 Restructuring<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In January 2024, the Company approved a new restructuring program (2024 Restructuring Program) intended to continue the optimization of the Company’s Human Health global manufacturing network as the future pipeline shifts to new modalities and also optimize the Animal Health global manufacturing network to improve supply reliability and increase efficiency. The actions contemplated under the 2024 Restructuring Program are expected to be substantially completed by the end of 2031, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $4.0 billion. Approximately 60% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested. The remainder of the costs will result in cash outlays, relating primarily to facility shut-down costs. The Company recorded total pretax costs of $888 million and $190 million in 2024 and 2023, respectively, related to the 2024 Restructuring Program, bringing total cumulative pretax costs incurred through December 31, 2024 to $1.1 billion. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2019, Merck approved a global restructuring program (2019 Restructuring Program) as part of a worldwide initiative focused on optimizing the Company’s manufacturing and supply network, as well as reducing its global real estate footprint. The Company recorded total pretax costs of $743 million in 2023 and $666 million in 2022 related to the 2019 Restructuring Program. The actions under the 2019 Restructuring Program were substantially complete at the end of 2023 and, as of January 1, 2024, any remaining activities are being accounted for as part of the 2024 Restructuring Program.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For segment reporting, restructuring charges are unallocated expenses.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the charges related to the restructuring programs by type of cost:</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:45.202%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.766%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Exit Costs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Year Ended December 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024 Restructuring Program</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-745"><span style="-sec-ix-hidden:f-746"><span style="-sec-ix-hidden:f-747"><span style="-sec-ix-hidden:f-748">Cost of sales</span></span></span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">254</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">241</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">495</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-753"><span style="-sec-ix-hidden:f-754"><span style="-sec-ix-hidden:f-755"><span style="-sec-ix-hidden:f-756">Selling, general and administrative</span></span></span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">83</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">83</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-761"><span style="-sec-ix-hidden:f-762"><span style="-sec-ix-hidden:f-763"><span style="-sec-ix-hidden:f-764">Research and development</span></span></span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-769"><span style="-sec-ix-hidden:f-770"><span style="-sec-ix-hidden:f-771"><span style="-sec-ix-hidden:f-772">Restructuring costs</span></span></span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">122</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">187</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">309</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">254</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">122</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">512</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">888</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Restructuring Program</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-781"><span style="-sec-ix-hidden:f-782"><span style="-sec-ix-hidden:f-783"><span style="-sec-ix-hidden:f-784">Cost of sales</span></span></span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-789"><span style="-sec-ix-hidden:f-790"><span style="-sec-ix-hidden:f-791"><span style="-sec-ix-hidden:f-792">Restructuring costs</span></span></span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019 Restructuring Program</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-801"><span style="-sec-ix-hidden:f-802"><span style="-sec-ix-hidden:f-803"><span style="-sec-ix-hidden:f-804">Cost of sales</span></span></span></span></span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-809"><span style="-sec-ix-hidden:f-810"><span style="-sec-ix-hidden:f-811"><span style="-sec-ix-hidden:f-812">Selling, general and administrative</span></span></span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-817"><span style="-sec-ix-hidden:f-818"><span style="-sec-ix-hidden:f-819"><span style="-sec-ix-hidden:f-820">Research and development</span></span></span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-825"><span style="-sec-ix-hidden:f-826"><span style="-sec-ix-hidden:f-827"><span style="-sec-ix-hidden:f-828">Restructuring costs</span></span></span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">339 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">471 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">339 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">743 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">454 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">339 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">933 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019 Restructuring Program</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-841"><span style="-sec-ix-hidden:f-842"><span style="-sec-ix-hidden:f-843"><span style="-sec-ix-hidden:f-844">Cost of sales</span></span></span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-849"><span style="-sec-ix-hidden:f-850"><span style="-sec-ix-hidden:f-851"><span style="-sec-ix-hidden:f-852">Selling, general and administrative</span></span></span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-857"><span style="-sec-ix-hidden:f-858"><span style="-sec-ix-hidden:f-859"><span style="-sec-ix-hidden:f-860">Research and development</span></span></span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-865"><span style="-sec-ix-hidden:f-866"><span style="-sec-ix-hidden:f-867"><span style="-sec-ix-hidden:f-868">Restructuring costs</span></span></span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">212 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">337 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">212 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">666 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accelerated depreciation costs primarily relate to manufacturing, research and administrative facilities and equipment to be sold or closed as part of the programs. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. All the sites will continue to operate up through the respective closure dates and, since future undiscounted cash flows are sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of the site assets. Anticipated site closure dates, particularly related to manufacturing locations, have been and may continue to be adjusted to reflect changes resulting from regulatory or other factors.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Separation costs are associated with actual headcount reductions, as well as involuntary headcount reductions which were probable and could be reasonably estimated. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other exit costs in 2024, 2023 and 2022 include asset impairment, facility shut-down and other related costs, as well as pretax gains and losses resulting from the sales of facilities and related assets. Additionally, other activity includes certain employee-related costs associated with pension and other postretirement benefit plans (see Note 13) and share-based compensation. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the charges and spending relating to restructuring program activities:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"></td><td style="width:45.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Exit Costs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring reserves January 1, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">479 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">513 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">454 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">339 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">933 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Payments) receipts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(252)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(410)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(140)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(184)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(324)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring reserves December 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">681 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">712 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">254</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">122</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">512</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">888</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Payments) receipts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(239)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(206)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(445)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-cash activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(254)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(337)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(591)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restructuring reserves December 31, 2024 </span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">564</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">564</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 4000000000 0.60 888000000 190000000 1100000000 743000000 666000000 <div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the charges related to the restructuring programs by type of cost:</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:45.202%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.766%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Exit Costs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Year Ended December 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024 Restructuring Program</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-745"><span style="-sec-ix-hidden:f-746"><span style="-sec-ix-hidden:f-747"><span style="-sec-ix-hidden:f-748">Cost of sales</span></span></span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">254</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">241</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">495</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-753"><span style="-sec-ix-hidden:f-754"><span style="-sec-ix-hidden:f-755"><span style="-sec-ix-hidden:f-756">Selling, general and administrative</span></span></span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">83</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">83</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-761"><span style="-sec-ix-hidden:f-762"><span style="-sec-ix-hidden:f-763"><span style="-sec-ix-hidden:f-764">Research and development</span></span></span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-769"><span style="-sec-ix-hidden:f-770"><span style="-sec-ix-hidden:f-771"><span style="-sec-ix-hidden:f-772">Restructuring costs</span></span></span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">122</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">187</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">309</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">254</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">122</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">512</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">888</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Restructuring Program</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-781"><span style="-sec-ix-hidden:f-782"><span style="-sec-ix-hidden:f-783"><span style="-sec-ix-hidden:f-784">Cost of sales</span></span></span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-789"><span style="-sec-ix-hidden:f-790"><span style="-sec-ix-hidden:f-791"><span style="-sec-ix-hidden:f-792">Restructuring costs</span></span></span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019 Restructuring Program</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-801"><span style="-sec-ix-hidden:f-802"><span style="-sec-ix-hidden:f-803"><span style="-sec-ix-hidden:f-804">Cost of sales</span></span></span></span></span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-809"><span style="-sec-ix-hidden:f-810"><span style="-sec-ix-hidden:f-811"><span style="-sec-ix-hidden:f-812">Selling, general and administrative</span></span></span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-817"><span style="-sec-ix-hidden:f-818"><span style="-sec-ix-hidden:f-819"><span style="-sec-ix-hidden:f-820">Research and development</span></span></span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-825"><span style="-sec-ix-hidden:f-826"><span style="-sec-ix-hidden:f-827"><span style="-sec-ix-hidden:f-828">Restructuring costs</span></span></span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">339 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">471 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">339 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">743 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">454 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">339 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">933 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2019 Restructuring Program</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-841"><span style="-sec-ix-hidden:f-842"><span style="-sec-ix-hidden:f-843"><span style="-sec-ix-hidden:f-844">Cost of sales</span></span></span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-849"><span style="-sec-ix-hidden:f-850"><span style="-sec-ix-hidden:f-851"><span style="-sec-ix-hidden:f-852">Selling, general and administrative</span></span></span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-857"><span style="-sec-ix-hidden:f-858"><span style="-sec-ix-hidden:f-859"><span style="-sec-ix-hidden:f-860">Research and development</span></span></span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-865"><span style="-sec-ix-hidden:f-866"><span style="-sec-ix-hidden:f-867"><span style="-sec-ix-hidden:f-868">Restructuring costs</span></span></span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">212 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">337 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">212 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">666 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 254000000 0 241000000 495000000 0 0 83000000 83000000 0 0 1000000 1000000 0 122000000 187000000 309000000 254000000 122000000 512000000 888000000 0 0 62000000 62000000 0 115000000 13000000 128000000 0 115000000 75000000 190000000 131000000 0 18000000 149000000 9000000 0 113000000 122000000 0 0 1000000 1000000 0 339000000 132000000 471000000 140000000 339000000 264000000 743000000 140000000 454000000 339000000 933000000 72000000 0 133000000 205000000 19000000 0 75000000 94000000 29000000 0 1000000 30000000 0 212000000 125000000 337000000 120000000 212000000 334000000 666000000 <div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the charges and spending relating to restructuring program activities:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"></td><td style="width:45.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Exit Costs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring reserves January 1, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">479 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">513 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">454 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">339 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">933 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Payments) receipts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(252)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(410)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(140)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(184)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(324)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring reserves December 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">681 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">712 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">254</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">122</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">512</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">888</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Payments) receipts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(239)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(206)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(445)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-cash activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(254)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(337)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(591)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restructuring reserves December 31, 2024 </span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">564</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">564</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0 479000000 34000000 513000000 140000000 454000000 339000000 933000000 0 252000000 158000000 410000000 -140000000 0 -184000000 -324000000 0 681000000 31000000 712000000 254000000 122000000 512000000 888000000 0 239000000 206000000 445000000 -254000000 0 -337000000 -591000000 0 564000000 0 564000000 Financial Instruments<div style="margin-top:5pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Derivative Instruments and Hedging Activities</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A significant portion of the Company’s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives of and accounting related to the Company’s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.</span></div><div><span><br/></span></div><div><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Risk Management</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has established revenue hedging, balance sheet risk management and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S. dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than two years into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and foreign exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts, and purchased collar options. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and reclassified into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> when the hedged anticipated revenue is recognized. The amount reclassified into earnings as a result of the discontinuation of cash flow hedges because it was no longer deemed probable the forecasted hedged transactions would occur was not material for the years ended December 31, 2024, 2023 or 2022. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> each period. The cash flows from both designated and non-designated contracts are reported as operating activities in the Consolidated Statement of Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of foreign exchange on monetary assets and liabilities. Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company also uses a balance sheet risk management program to mitigate the exposure of such assets and liabilities from the effects of volatility in foreign exchange. Merck principally utilizes forward exchange contracts to </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">offset the effects of foreign exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the foreign exchange rate and the cost of the hedging instrument (primarily the euro, Swiss franc, Japanese yen, and Chinese renminbi). The forward contracts are not designated as hedges and are marked to market through </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than six months. The cash flows from these contracts are reported as operating activities in the Consolidated Statement of Cash Flows.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in foreign exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, and remain in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded components). Changes in fair value of the excluded components are recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company recognizes in earnings the initial value of the excluded components on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Consolidated Statement of Cash Flows.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign exchange risk is also managed through the use of foreign currency debt. Certain of the Company’s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The effects of the Company’s net investment hedges on </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and the Consolidated Statement of Income are shown below:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.476%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.476%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.476%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.323%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> for Amounts Excluded from Effectiveness Testing</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Relationships</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro-denominated notes</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(192)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(162)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">No amounts were reclassified from AOCL into income related to the sale of a subsidiary.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk Management</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal at risk. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At December 31, 2024, the Company was a party to six pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of the fixed-rate notes as detailed in the table below.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.739%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.448%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Par Value of Debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of Interest Rate Swaps Held</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Swap Notional Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.50% notes due 2033</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The interest rate swap contracts are designated hedges of the fair value changes in the notes attributable to changes in the benchmark Secured Overnight Financing Rate (SOFR) swap rate. The fair value changes in the notes attributable to changes in the SOFR swap rate are recorded in interest expense along with the offsetting fair value changes in the swap contracts. In January 2025, the Company entered into an additional interest rate swap contract with a notional amount of $250 million related to its 5.00% notes due 2053. The cash flows from these contracts are reported as operating activities in the Consolidated Statement of Cash Flows. </span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below presents the location of amounts recorded in the Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges as of December 31:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"></td><td style="width:45.253%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.703%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.703%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.703%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.708%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Increase Included in the Carrying Amount</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Caption</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-939"><span style="-sec-ix-hidden:f-940">Long-Term Debt</span></span> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,509</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,056 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments as of December 31:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.893%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.519%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2023</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair Value of<br/>Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">U.S. Dollar<br/>Notional</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value of<br/>Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">U.S. Dollar<br/>Notional</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-946"><span style="-sec-ix-hidden:f-947">Other Assets</span></span></span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,500</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-952"><span style="-sec-ix-hidden:f-953">Other current assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">323</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">8,662</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">6,138 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-958"><span style="-sec-ix-hidden:f-959">Other Assets</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">66</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,125</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,929 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-964"><span style="-sec-ix-hidden:f-965">Accrued and other current liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">162</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">3,680 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-970"><span style="-sec-ix-hidden:f-971">Other Noncurrent Liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">406</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">12,465</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">189 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">12,754 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-982"><span style="-sec-ix-hidden:f-983">Other current assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">323</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">12,544</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">153 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">9,693 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-988"><span style="-sec-ix-hidden:f-989">Accrued and other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">343</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">13,551</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">8,104 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">323</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">343</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">26,095</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">153 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">17,797 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">729</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">345</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">38,560</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">30,551 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As noted above, the Company records its derivatives on a gross basis in the Consolidated Balance Sheet. The Company has master netting agreements with several of its financial institution counterparties (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Concentrations of Credit Risk</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> below). The following table provides information on the Company’s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes as of December 31:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:59.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts recognized in the consolidated balance sheet</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">729</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">345</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts subject to offset in master netting arrangements not offset in the consolidated balance sheet</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(299)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(299)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(215)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(215)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash collateral received</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(165)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net amounts</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">265</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below provides information regarding the location and amount of pretax gains and losses of derivatives designated in fair value or cash flow hedging relationships:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Financial Statement Caption in which Effects of Fair Value or Cash Flow Hedges are Recorded</span></td><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other (income) expense, net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">64,168</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">60,115 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">59,283 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(24)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">466 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,501 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">216</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(393)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(339)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(Gain) loss on fair value hedging relationships:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Hedged items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">39</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Impact of cash flow hedging relationships:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of gain recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">508</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">684 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Increase in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> as a result of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> reclassifications</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">167</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">249 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">773 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(167)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(249)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(773)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="-sec-ix-hidden:f-1048"><span style="-sec-ix-hidden:f-1049"><span style="-sec-ix-hidden:f-1050"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of gain recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></span></span></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of (loss) gain recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Interest expense is a component of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.797%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.797%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.800%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of Derivative Pretax Loss (Gain) Recognized in Income</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Income Statement Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">251</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(28)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">     These derivative contracts serve as economic hedges of forecasted transactions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At December 31, 2024, the Company estimates $262 million of pretax net unrealized gains on derivatives maturing within the next 12 months that hedge foreign currency denominated sales over that same period will be reclassified from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The amount ultimately reclassified to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual foreign exchange rates at maturity.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Investments in Debt and Equity Securities</span></div><div style="margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Information on investments in debt and equity securities at December 31 is as follows:</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:27.332%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.828%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">348</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">348</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">188</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">188</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">536</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">536</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">337 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">337 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Publicly traded equity securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">920</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">764 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total debt and publicly traded equity securities</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,456</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,101 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Unrealized net losses of $30 million were recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> in 2024 on equity securities still held at December 31, 2024. Unrealized net gains of $411 million were recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> in 2023 on equity securities still held at December 31, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At December 31, 2024 and 2023, the Company also had $863 million and $832 million, respectively, of equity investments without readily determinable fair values included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company records unrealized gains on these equity investments based on favorable observable price changes from transactions involving similar investments of the same investee and records unrealized losses based on unfavorable observable price changes, which are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. During 2024, the Company recorded unrealized gains of $19 million and unrealized losses of $51 million related to certain of these equity investments still held at December 31, 2024. During 2023, the Company recorded unrealized gains of $10 million and unrealized losses of $61 million related to certain of these equity investments still held at December 31, 2023. Cumulative unrealized gains and cumulative unrealized losses based on observable price changes for investments in equity investments without readily determinable fair values still held at December 31, 2024 were $309 million and $107 million, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At December 31, 2024, 2023 and 2022, the Company also had $267 million, $417 million and $598 million, respectively, recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for equity securities held through ownership interests in investment funds. Losses recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> relating to these investment funds were $29 million, $106 million and $1.0 billion for the years ended December 31, 2024, 2023 and 2022, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest: </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> — Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> — Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> — Unobservable inputs that are supported by little or no market activity. Level 3 assets or liabilities are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as assets or liabilities for which the determination of fair value requires significant judgment or estimation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.</span></div><div><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis at December 31 are summarized below:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.597%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">  </span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">348</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">348</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">99</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">99</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">463</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">463</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">463</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">447</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">910</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">504 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">89</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">89</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Publicly traded equity securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">457</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">457</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">512 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">512 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">546</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">546</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">597 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">597 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Derivative assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">499</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">499</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchased currency options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">213</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">213</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">729</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">729</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,009</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,176</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,185</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">849 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">594 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,443 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">193</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">193</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">354 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">354 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Derivative liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">338</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">338</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Written currency options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">345</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">345</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">345</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">193</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">538</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">354 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">593 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Balance at December 31, 2024 includes securities with a fair value of $81 million, which are subject to a contractual sale restriction that expires in March 2025. Balance at December 31, 2023 includes securities with a fair value of $177 million, which were subject to a contractual sale restriction that expired in July 2024. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company’s own credit risk, the effects of which were not significant.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December 31, 2024 and 2023, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> included $12.3 billion and $6.0 billion of cash equivalents, respectively (which would be considered Level 2 in the fair value hierarchy). </span></div><div style="margin-top:6pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:</span></div><div style="margin-bottom:1pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.393%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">354</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">456 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in estimated fair value </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(151)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value December 31</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (2)</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">193</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">354 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cost of sales,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> expenses, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes cumulative translation adjustments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Balance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">at December 31, 2024 includes $148 million of current liabilities, of which $123 million relates to the termination of the Sanofi Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate to present value the cash flows. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The payments of contingent consideration in 2024 include $126 million related to the Sanofi Pasteur MSD liabilities described above and $25 million related to the first commercial sale of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lyfnua</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (gefapixant) in the European Union (EU). The payments of contingent consideration in 2023 relate to the Sanofi Pasteur MSD liabilities. </span></div><div style="margin-top:6pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Fair Value Measurements</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Some of the Company’s financial instruments, such as cash and cash equivalents, receivables and payables, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The estimated fair value of loans payable and long-term debt (including current portion) at December 31, 2024, was $32.6 billion compared with a carrying value of $37.1 billion and at December 31, 2023, was $32.0 billion compared with a carrying value of $35.1 billion. Fair value was estimated using recent observable market prices and would be considered Level 2 in the fair value hierarchy.</span></div><div style="margin-top:6pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government issuers of securities and financial institutions with which it conducts business. Credit exposure limits are established to limit a concentration with any single issuer or institution. Cash and investments are placed in instruments that meet high credit quality standards, as specified in the Company’s investment policy guidelines. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The majority of the Company’s accounts receivable arise from product sales in the U.S., Europe and China and are primarily due from drug wholesalers, distributors and retailers, hospitals and government agencies. The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company also continues to monitor global economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets and its business. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company’s customers with the largest accounts receivable balances are: McKesson Corporation, Cencora, Inc. and Cardinal Health, Inc., which represented approximately 21%, 21% and 13%, respectively, of total accounts receivable at December 31, 2024. Vaccines distributed by Chongqing Zhifei Biological Products Co., Ltd. (Zhifei) represent a substantial portion of total sales in China; however, nearly all of the accounts receivable for Zhifei were factored as of December 31, 2024, as part of the Company’s factoring program discussed below. The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business. Bad debts have been minimal. The Company does not normally require collateral or other security to support credit sales.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $2.1 billion and $3.0 billion of accounts receivable as of December 31, 2024 and 2023, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions, generally within thirty days after receipt. At December 31, 2024 and 2023, the Company had collected $55 million and $44 million, respectively, on behalf of the financial institutions, which is reflected as restricted cash in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, and the related obligation to remit the cash is recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The net cash flows related to these collections are reported as financing activities in the Consolidated Statement of Cash Flows. The cost of factoring such accounts receivable was </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">de minimis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements. The master agreements with several of the Company’s financial institution counterparties also include credit support annexes. These annexes contain provisions that require collateral to be exchanged depending on the value of the derivative assets and liabilities, the Company’s credit rating, and the credit rating of the counterparty. Cash collateral received by the Company from various counterparties was $165 million and $3 million at December 31, 2024 and 2023, respectively. The obligation to return such collateral is recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span>. P2Y P6M <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The effects of the Company’s net investment hedges on </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and the Consolidated Statement of Income are shown below:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.476%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.476%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.476%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.323%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> for Amounts Excluded from Effectiveness Testing</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Relationships</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro-denominated notes</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(192)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(162)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">No amounts were reclassified from AOCL into income related to the sale of a subsidiary.</span></div> 30000000 0 48000000 4000000 -1000000 1000000 192000000 -105000000 162000000 0 0 0 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At December 31, 2024, the Company was a party to six pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of the fixed-rate notes as detailed in the table below.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.739%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.448%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Par Value of Debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of Interest Rate Swaps Held</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Swap Notional Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.50% notes due 2033</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,500 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 6 0.0450 1500000000 6 1500000000 250000000 0.0500 <div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below presents the location of amounts recorded in the Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges as of December 31:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"></td><td style="width:45.253%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.703%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.703%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.703%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.708%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Increase Included in the Carrying Amount</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Caption</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-939"><span style="-sec-ix-hidden:f-940">Long-Term Debt</span></span> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,509</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,056 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1509000000 1056000000 17000000 56000000 <div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments as of December 31:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.893%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.519%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2023</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair Value of<br/>Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">U.S. Dollar<br/>Notional</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value of<br/>Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">U.S. Dollar<br/>Notional</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-946"><span style="-sec-ix-hidden:f-947">Other Assets</span></span></span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,500</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-952"><span style="-sec-ix-hidden:f-953">Other current assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">323</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">8,662</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">6,138 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-958"><span style="-sec-ix-hidden:f-959">Other Assets</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">66</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,125</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,929 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-964"><span style="-sec-ix-hidden:f-965">Accrued and other current liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">162</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">3,680 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-970"><span style="-sec-ix-hidden:f-971">Other Noncurrent Liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">406</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">12,465</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">189 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">12,754 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-982"><span style="-sec-ix-hidden:f-983">Other current assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">323</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">12,544</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">153 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">9,693 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-988"><span style="-sec-ix-hidden:f-989">Accrued and other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">343</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">13,551</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">8,104 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">323</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">343</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">26,095</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">153 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">17,797 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">729</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">345</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">38,560</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">30,551 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 17000000 1500000000 57000000 1000000000 323000000 8662000000 106000000 6138000000 66000000 2125000000 26000000 1929000000 1000000 162000000 76000000 3680000000 1000000 16000000 1000000 7000000 406000000 2000000 12465000000 189000000 77000000 12754000000 323000000 12544000000 153000000 9693000000 343000000 13551000000 162000000 8104000000 323000000 343000000 26095000000 153000000 162000000 17797000000 729000000 345000000 38560000000 342000000 239000000 30551000000 The following table provides information on the Company’s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes as of December 31:<div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:59.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts recognized in the consolidated balance sheet</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">729</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">345</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts subject to offset in master netting arrangements not offset in the consolidated balance sheet</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(299)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(299)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(215)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(215)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash collateral received</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(165)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net amounts</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">265</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 729000000 345000000 342000000 239000000 299000000 299000000 215000000 215000000 165000000 0 3000000 0 265000000 46000000 124000000 24000000 <div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below provides information regarding the location and amount of pretax gains and losses of derivatives designated in fair value or cash flow hedging relationships:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Financial Statement Caption in which Effects of Fair Value or Cash Flow Hedges are Recorded</span></td><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other (income) expense, net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">64,168</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">60,115 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">59,283 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(24)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">466 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,501 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">216</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(393)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(339)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(Gain) loss on fair value hedging relationships:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Hedged items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">39</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Impact of cash flow hedging relationships:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of gain recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">508</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">684 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Increase in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> as a result of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> reclassifications</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">167</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">249 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">773 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(167)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(249)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(773)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="-sec-ix-hidden:f-1048"><span style="-sec-ix-hidden:f-1049"><span style="-sec-ix-hidden:f-1050"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of gain recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></span></span></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of (loss) gain recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Interest expense is a component of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net.</span></div> 64168000000 60115000000 59283000000 24000000 -466000000 -1501000000 216000000 -393000000 -339000000 39000000 -56000000 13000000 -39000000 57000000 -4000000 508000000 114000000 684000000 167000000 249000000 773000000 -167000000 -249000000 -773000000 -1000000 -1000000 -2000000 -1000000 13000000 -2000000 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.797%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.797%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.800%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of Derivative Pretax Loss (Gain) Recognized in Income</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Income Statement Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">251</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(28)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">     These derivative contracts serve as economic hedges of forecasted transactions.</span></div> -251000000 6000000 49000000 28000000 -5000000 37000000 262000000 <div style="margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Information on investments in debt and equity securities at December 31 is as follows:</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:27.332%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.828%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">348</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">348</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">188</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">188</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">536</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">536</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">337 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">337 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Publicly traded equity securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">920</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">764 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total debt and publicly traded equity securities</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,456</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,101 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Unrealized net losses of $30 million were recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> in 2024 on equity securities still held at December 31, 2024. Unrealized net gains of $411 million were recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> in 2023 on equity securities still held at December 31, 2023.</span></div> 348000000 0 0 348000000 252000000 0 0 252000000 188000000 0 0 188000000 72000000 0 0 72000000 0 0 0 0 13000000 0 0 13000000 536000000 0 0 536000000 337000000 0 0 337000000 920000000 764000000 1456000000 1101000000 -30000000 411000000 863000000 832000000 19000000 51000000 10000000 61000000 309000000 107000000 267000000 417000000 598000000 -29000000 -106000000 -1000000000 <div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis at December 31 are summarized below:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.597%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">  </span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">348</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">348</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">99</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">99</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">463</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">463</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">463</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">447</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">910</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">504 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">89</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">89</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Publicly traded equity securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">457</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">457</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">512 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">512 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">546</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">546</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">597 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">597 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Derivative assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">499</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">499</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchased currency options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">213</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">213</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">729</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">729</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,009</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,176</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,185</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">849 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">594 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,443 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">193</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">193</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">354 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">354 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Derivative liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">338</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">338</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Written currency options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">345</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">345</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">345</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">193</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">538</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">354 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">593 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Balance at December 31, 2024 includes securities with a fair value of $81 million, which are subject to a contractual sale restriction that expires in March 2025. Balance at December 31, 2023 includes securities with a fair value of $177 million, which were subject to a contractual sale restriction that expired in July 2024. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company’s own credit risk, the effects of which were not significant.</span></div> 0 348000000 0 348000000 0 252000000 0 252000000 0 99000000 0 99000000 0 0 0 0 463000000 0 0 463000000 252000000 0 0 252000000 463000000 447000000 0 910000000 252000000 252000000 0 504000000 89000000 0 0 89000000 72000000 0 0 72000000 0 0 0 0 13000000 0 0 13000000 457000000 0 0 457000000 512000000 0 0 512000000 546000000 0 0 546000000 597000000 0 0 597000000 0 499000000 0 499000000 0 202000000 0 202000000 0 213000000 0 213000000 0 83000000 0 83000000 0 17000000 0 17000000 0 57000000 0 57000000 0 729000000 0 729000000 0 342000000 0 342000000 1009000000 1176000000 0 2185000000 849000000 594000000 0 1443000000 0 0 193000000 193000000 0 0 354000000 354000000 0 338000000 0 338000000 0 239000000 0 239000000 0 7000000 0 7000000 0 0 0 0 0 345000000 0 345000000 0 239000000 0 239000000 0 345000000 193000000 538000000 0 239000000 354000000 593000000 81000000 177000000 12300000000 6000000000 <div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:</span></div><div style="margin-bottom:1pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.393%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">354</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">456 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in estimated fair value </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(151)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value December 31</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (2)</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">193</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">354 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cost of sales,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> expenses, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes cumulative translation adjustments.</span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Balance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"> </span>at December 31, 2024 includes $148 million of current liabilities, of which $123 million relates to the termination of the Sanofi Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate to present value the cash flows. 354000000 456000000 -10000000 15000000 151000000 117000000 193000000 354000000 148000000 123000000 0.115 126000000 25000000 32600000000 37100000000 32000000000.0 35100000000 0.21 0.21 0.13 2100000000 3000000000.0 55000000 44000000 165000000 3000000 Inventories<div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventories at December 31 consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,022</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,954 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,831</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,037 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">289</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">277 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11,142</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,268 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decrease to LIFO cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(840)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(562)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10,302</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,706 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,109</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,358 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,193</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,348 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventories valued under the LIFO method comprised approximately $3.4 billion and $3.1 billion at December 31, 2024 and 2023, respectively, after reflecting the decrease to LIFO cost. Amounts recognized as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> are comprised almost entirely of raw materials and work in process inventories. At December 31, 2024 and 2023, these amounts included $3.8 billion and $2.6 billion, respectively, of inventories not expected to be sold within one year. In addition, these amounts included $412 million and $790 million at December 31, 2024 and 2023, respectively, of inventories produced in preparation for product launches.</span></div> <div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventories at December 31 consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,022</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,954 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,831</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,037 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">289</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">277 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11,142</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,268 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decrease to LIFO cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(840)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(562)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10,302</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,706 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,109</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,358 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,193</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,348 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventories at December 31 consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,022</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,954 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,831</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,037 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">289</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">277 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11,142</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,268 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decrease to LIFO cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(840)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(562)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10,302</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,706 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,109</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,358 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,193</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,348 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2022000000 1954000000 8831000000 8037000000 289000000 277000000 11142000000 10268000000 840000000 562000000 10302000000 9706000000 6109000000 6358000000 4193000000 3348000000 3400000000 3100000000 3800000000 2600000000 412000000 790000000 Goodwill and Other Intangibles<div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes goodwill activity by segment:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.485%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Animal Health</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,936 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,268 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,204 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance December 31, 2023 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,922 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,275 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,197 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Acquisitions</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">518</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">518</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance December 31, 2024 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">17,903</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,765</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21,668</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes cumulative translation adjustments on goodwill balances.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Accumulated goodwill impairment losses were $531 million at both December 31, 2024 and 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other acquired intangibles at December 31 consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:25.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.222%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product rights</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">29,988</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">19,066</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10,922</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,643 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,765 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,878 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">430</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">430</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,816 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,816 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,881</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">954</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,927</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,881 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">776 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,105 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Licenses and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,863</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,772</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,091</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,263 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,051 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,212 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">42,162</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">25,792</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,370</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,603 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,592 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,011 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Some of the more significant acquired intangibles included in product rights, on a net basis, related to human health marketed products at December 31, 2024 were </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Winrevair</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, $5.9 billion; Reblozyl, $2.8 billion; and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, $260 million. Additionally, the Company had $4.3 billion of net acquired intangibles related to animal health at December 31, 2024, of which $1.7 billion related to product rights and $1.9 billion was attributable to trade names, primarily related to Allflex. At December 31, 2024, IPR&amp;D primarily relates to MK-1026 (nemtabrutinib), obtained through the acquisition of ArQule, Inc. (ArQule), which had a balance of $418 million. Some of the more significant net intangible assets included in licenses and other above at December 31, 2024 include Lynparza, $1.2 billion, related to a collaboration with AstraZeneca; Lenvima, $442 million, related to a collaboration with Eisai; and Adempas, $372 million, related to a collaboration with Bayer. See Note 4 for additional information related to the intangible assets associated with these collaborations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">IPR&amp;D that the Company acquires through business combinations represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. Amounts capitalized as IPR&amp;D are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each IPR&amp;D project, the Company will make a separate determination as to the then-useful life of the asset and begin amortization. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2023, the Company recorded a $779 million IPR&amp;D impairment charge within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-1381">Research and development</span></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses related to MK-7264, gefapixant, a non-narcotic, oral selective P2X3 receptor antagonist, that was in development for the treatment of refractory or unexplained chronic cough in adults. In December 2023, the FDA issued a Complete Response Letter (CRL) regarding the resubmission of Merck’s New Drug Application (NDA) for gefapixant. In the CRL, the FDA concluded that Merck’s application did not meet substantial evidence of effectiveness for treating refractory chronic cough and unexplained chronic cough. The CRL was not related to the safety of gefapixant. The marketing application for gefapixant was based on results from the COUGH-1 and COUGH-2 clinical trials. In January 2022, the FDA issued a CRL regarding Merck’s original NDA for gefapixant. In that CRL, the FDA requested additional information related to the cough counting system that was used to assess efficacy. Receipt of the second CRL from the FDA constituted a triggering event that required the evaluation of the gefapixant intangible asset for impairment. The Company estimated the current fair value of gefapixant utilizing an income approach, which calculates the present value of projected future cash flows. The market participant assumptions used to derive the forecasted cash flows were updated to reflect revised market launch plans, resulting in a reduction in the estimated fair value. The revised estimated fair value of gefapixant when compared with its related carrying value resulted in the impairment charge noted above. The remaining intangible asset balance related to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lyfnua</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (gefapixant) at December 31, 2024 of $21 million is included in product rights in the table above and is being amortized over its expected useful life as supported by projected future cash flows in the markets where it is approved including Japan and the EU.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2022, the Company recorded $1.7 billion of intangible asset impairment charges within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-1384"><span style="-sec-ix-hidden:f-1385">Research and development</span></span></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses, of which $1.6 billion represents IPR&amp;D impairment charges related to nemtabrutinib (MK-1026), an oral, reversible, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor currently being evaluated for the treatment of hematological malignancies that was obtained through the 2020 acquisition of ArQule. Following discussions with regulatory authorities in the third quarter of 2022, the development period for nemtabrutinib was extended, which constituted a triggering event that required the evaluation of the nemtabrutinib intangible asset for impairment. The Company estimated the current fair value of nemtabrutinib utilizing an income approach which calculates the present value of projected future cash flows. The market participant assumptions used to derive the forecasted cash flows were updated to reflect a delay in the anticipated launch date for nemtabrutinib, which resulted in lower cumulative revenue forecasts and a reduction in the estimated fair value. The revised estimated fair value of nemtabrutinib when compared with its related carrying value resulted in a $807 million impairment charge recorded in the third quarter of 2022. In December 2022, regulatory authorities provided additional feedback with respect to clinical study design that led to a further reassessment of the development plan for nemtabrutinib, which was expected to result in changes to the clinical study design, and corresponding delays in the anticipated approval and launch timelines, which constituted a triggering event. Utilizing an income approach, the forecasted cash flows were updated to reflect a decline in forecasted revenue coupled with an increase in development cost forecasts, which reduced projected cash flows lowering the estimated fair value of nemtabrutinib. The revised estimated fair value of nemtabrutinib when compared with its then-related carrying value resulted in a $780 million impairment charge. The remaining IPR&amp;D intangible asset related to nemtabrutinib is $418 million. If the assumptions used to estimate the fair value of nemtabrutinib prove to be incorrect and the development of nemtabrutinib does not progress as anticipated thereby adversely affecting projected future cash flows, the Company may record an additional impairment charge in the future and such charge could be material. The Company also recorded an $80 million intangible asset impairment charge in 2022 related to derazantinib resulting from the termination of the out-licensing agreement and the decision by Merck not to pursue development of derazantinib. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The IPR&amp;D projects that remain in development are subject to the inherent risks and uncertainties in drug development and it is possible that the Company will not be able to successfully develop and complete the IPR&amp;D programs and profitably commercialize the underlying product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company may recognize additional non-cash impairment charges in the future related to marketed products or pipeline programs and such charges could be material.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Aggregate amortization expense primarily recorded within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> was $2.4 billion in 2024, $2.0 billion in 2023 and $2.1 billion in 2022. The estimated aggregate amortization expense for each of the next five years is as follows: 2025, $2.4 billion; 2026, $2.3 billion; 2027, $2.1 billion; 2028, $1.8 billion; 2029, $1.5 billion.</span></div> <div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes goodwill activity by segment:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.485%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Animal Health</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,936 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,268 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,204 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance December 31, 2023 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,922 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,275 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,197 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Acquisitions</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">518</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">518</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance December 31, 2024 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">17,903</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,765</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21,668</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes cumulative translation adjustments on goodwill balances.</span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span>Accumulated goodwill impairment losses were $531 million at both December 31, 2024 and 2023. 17936000000 3268000000 21204000000 -14000000 7000000 -7000000 17922000000 3275000000 21197000000 0 518000000 518000000 -19000000 -28000000 -47000000 17903000000 3765000000 21668000000 531000000 531000000 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other acquired intangibles at December 31 consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:25.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.222%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product rights</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">29,988</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">19,066</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10,922</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,643 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,765 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,878 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">430</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">430</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,816 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,816 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,881</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">954</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,927</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,881 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">776 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,105 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Licenses and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,863</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,772</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,091</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,263 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,051 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,212 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">42,162</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">25,792</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,370</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,603 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,592 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,011 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 29988000000 19066000000 10922000000 23643000000 17765000000 5878000000 430000000 430000000 6816000000 6816000000 2881000000 954000000 1927000000 2881000000 776000000 2105000000 8863000000 5772000000 3091000000 8263000000 5051000000 3212000000 42162000000 25792000000 16370000000 41603000000 23592000000 18011000000 5900000000 2800000000 260000000 4300000000 1700000000 1900000000 418000000 1200000000 442000000 372000000 779000000 21000000 1700000000 1600000000 807000000 780000000 418000000 80000000 2400000000 2000000000.0 2100000000 2400000000 2300000000 2100000000 1800000000 1500000000 Loans Payable, Long-Term Debt and Leases<div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Loans Payable</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loans payable at December 31, 2024 included $2.5 billion of notes due in 2025 and $149 million of long-dated notes that are subject to repayment at the option of the holders. Loans payable at December 31, 2023 included $1.3 billion of notes due in 2024 and $69 million of long-dated notes that are subject to repayment at the option of the holders. The weighted-average interest rate of commercial paper borrowings was 5.18% and 5.14% for the years ended December 31, 2024 and 2023, respectively. There were no commercial paper borrowings outstanding at December 31, 2024 or 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Long-Term Debt</span></div><div style="margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-term debt at December 31 consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.15% notes due 2031</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,989</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,988 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.75% notes due 2051</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,980</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,980 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.70% notes due 2045</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,980</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,979 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.40% notes due 2029</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,742</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,740 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.50% notes due 2033</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,509</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,547 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.70% notes due 2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,497</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,495 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.90% notes due 2061</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,484</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,484 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.00% notes due 2053</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,482</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,481 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.00% notes due 2049</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,474</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,473 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.15% notes due 2043</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,240</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,240 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.45% notes due 2030</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,240</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,238 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.45% notes due 2050</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,216</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,214 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.875% euro-denominated notes due 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,041</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.75% notes due 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">998</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">996 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.90% notes due 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">996</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">995 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.15% notes due 2063</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">987</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">987 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.90% notes due 2039</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">987</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">986 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.35% notes due 2040</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">986</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">985 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.25% euro-denominated notes due 2032</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">880</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.50% euro-denominated notes due 2037</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">877</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.70% euro-denominated notes due 2044</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">876</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.75% euro-denominated notes due 2054</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">873</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.30% notes due 2030</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">746</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">745 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.90% notes due 2044</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">740</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">740 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6.50% notes due 2033</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">702</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">707 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.375% euro-denominated notes due 2036</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">517</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">548 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.50% euro-denominated notes due 2034</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">517</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">548 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.05% notes due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">498</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">497 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.60% notes due 2042</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">492</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">492 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6.55% notes due 2037</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">404</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">406 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.75% notes due 2036</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">339</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">339 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.95% debentures due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">307</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">307 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.85% notes due 2039</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">271</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6.40% debentures due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">251</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6.30% debentures due 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">135</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.75% notes due 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,498 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">209</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">34,462</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">33,683 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other (as presented in the table above) includes borrowings at variable rates that resulted in effective interest rates of 5.02% and 4.82% for 2024 and 2023, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">With the exception of the 6.30% debentures due 2026, the notes listed in the table above are redeemable in whole or in part, at Merck’s option at any time, at varying redemption prices. Effective as of November 3, 2009, the Company executed a full and unconditional guarantee of the then existing debt of its subsidiary Merck Sharp &amp; Dohme LLC. (MSD) and MSD executed a full and unconditional guarantee of the then existing debt of the Company </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(excluding commercial paper), including for payments of principal and interest. These guarantees do not extend to debt issued subsequent to that date.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In May 2024, MSD Netherlands Capital B.V., a wholly owned finance subsidiary of Merck, completed a registered public offering of €3.4 billion in aggregate principal amount of euro-dominated senior notes comprised of €850 million of 3.25% senior notes due 2032, €850 million of 3.50% senior notes due 2037, €850 million of 3.70% senior notes due 2044 and €850 million of 3.75% senior notes due 2054 (collectively, the Euronotes). The Company has fully and unconditionally guaranteed all of MSD Netherlands Capital B.V.’s obligations under the Euronotes and no other subsidiary of the Company will guarantee these obligations. MSD Netherlands Capital B.V. is a “finance subsidiary” as defined in Rule 13-01(a)(4)(vi) of Regulation S-X of the Exchange Act, with no assets or operations other than those related to the issuance, administration and repayment of the Euronotes. The financial condition, results of operations and cash flows of MSD Netherlands Capital B.V. are consolidated in the financial statements of the Company. The net cash proceeds from the offering were used for general corporate purposes. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain of the Company’s borrowings require that Merck comply with covenants and, at December 31, 2024, the Company was in compliance with these covenants.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The aggregate maturities of long-term debt for each of the next five years are as follows: 2025, $2.6 billion; 2026, $2.2 billion; 2027, $1.5 billion; 2028, $2.1 billion; 2029, $1.7 billion. Interest payments related to these debt obligations are as follows: 2025, $1.2 billion; 2026, $1.2 billion; 2027, $1.1 billion; 2028, $1.1 billion; 2029, $1.0 billion.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has a $6.0 billion credit facility that matures in May 2028. The facility provides backup liquidity for the Company’s commercial paper borrowing facility and is to be used for general corporate purposes. The Company has not drawn funding from this facility.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has operating leases primarily for manufacturing facilities, research and development facilities, corporate offices, employee housing, vehicles and certain equipment. The Company determines if an arrangement is a lease at inception. When evaluating contracts for embedded leases, the Company exercises judgment to determine if there is an explicit or implicit identified asset in the contract and if Merck controls the use of that asset. Embedded leases, primarily associated with contract manufacturing organizations, are immaterial. The lease term includes options to extend or terminate the lease when it is reasonably certain that Merck will exercise that option. Real estate leases for facilities have an average remaining lease term of approximately six years, which include options to extend the leases for up to five years where applicable. Vehicle leases are generally in effect for four years. The Company elected to exclude short-term leases (leases with an initial term of 12 months or less) from the lease assets and liabilities on the balance sheet.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Lease expense for operating lease payments is recognized on a straight-line basis over the term of the lease. Operating lease assets and liabilities are recognized based on the present value of lease payments over the lease term. Since the Company’s leases do not have a readily determinable implicit discount rate, the Company uses its incremental borrowing rate to calculate the present value of lease payments by asset class. On a quarterly basis, an updated incremental borrowing rate is determined based on the average remaining lease term of each asset class and the Company’s pretax cost of debt for that same term. The updated rates for each asset class are applied prospectively to new leases. The Company does not separate lease components (e.g., payments for rent, real estate taxes and insurance costs) from non-lease components (e.g. common-area maintenance costs) in the event that the agreement contains both. Merck includes both the lease and non-lease components for purposes of calculating the right-of-use asset and related lease liability (if the non-lease components are fixed). For vehicle leases and employee housing, the Company applies a portfolio approach to account for the operating lease assets and liabilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain of the Company’s lease agreements contain variable lease payments that are adjusted periodically for inflation or for actual operating expense true-ups compared with estimated amounts; however, these amounts are immaterial. Sublease income was immaterial and there were no sale and leaseback transactions in 2024. Merck’s lease agreements do not contain any material residual value guarantees or material restrictive covenants. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease cost was $348 million in 2024, $339 million in 2023 and $334 million in 2022. Cash paid for amounts included in the measurement of operating lease liabilities was $357 million in 2024, $347 million in 2023 and $335 million in 2022. Operating lease assets obtained in exchange for lease obligations were $47 million in 2024, $122 million in 2023 and $57 million in 2022. </span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating leases is as follows:</span></div><div style="margin-bottom:1pt;margin-top:6pt;padding-left:9pt;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="-sec-ix-hidden:f-1556"><span style="-sec-ix-hidden:f-1557"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></span></span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,370</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,437 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1560"><span style="-sec-ix-hidden:f-1561">Accrued and other current liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">282</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1564"><span style="-sec-ix-hidden:f-1565">Other Noncurrent Liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">877</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">928 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,159</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,213 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.0</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes prepaid leases that have no related lease liability.</span></div><div style="margin-bottom:3pt;margin-top:9pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Maturities of operating leases liabilities are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:89.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">292 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">403 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,521 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">362 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,159 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At December 31, 2024, the Company had entered into additional real estate operating leases that had not yet commenced; the obligations associated with these leases total $183 million.</span></div> Loans Payable, Long-Term Debt and Leases<div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Loans Payable</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loans payable at December 31, 2024 included $2.5 billion of notes due in 2025 and $149 million of long-dated notes that are subject to repayment at the option of the holders. Loans payable at December 31, 2023 included $1.3 billion of notes due in 2024 and $69 million of long-dated notes that are subject to repayment at the option of the holders. The weighted-average interest rate of commercial paper borrowings was 5.18% and 5.14% for the years ended December 31, 2024 and 2023, respectively. There were no commercial paper borrowings outstanding at December 31, 2024 or 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Long-Term Debt</span></div><div style="margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-term debt at December 31 consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.15% notes due 2031</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,989</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,988 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.75% notes due 2051</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,980</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,980 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.70% notes due 2045</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,980</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,979 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.40% notes due 2029</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,742</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,740 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.50% notes due 2033</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,509</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,547 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.70% notes due 2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,497</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,495 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.90% notes due 2061</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,484</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,484 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.00% notes due 2053</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,482</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,481 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.00% notes due 2049</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,474</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,473 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.15% notes due 2043</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,240</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,240 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.45% notes due 2030</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,240</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,238 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.45% notes due 2050</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,216</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,214 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.875% euro-denominated notes due 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,041</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.75% notes due 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">998</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">996 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.90% notes due 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">996</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">995 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.15% notes due 2063</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">987</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">987 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.90% notes due 2039</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">987</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">986 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.35% notes due 2040</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">986</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">985 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.25% euro-denominated notes due 2032</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">880</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.50% euro-denominated notes due 2037</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">877</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.70% euro-denominated notes due 2044</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">876</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.75% euro-denominated notes due 2054</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">873</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.30% notes due 2030</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">746</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">745 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.90% notes due 2044</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">740</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">740 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6.50% notes due 2033</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">702</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">707 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.375% euro-denominated notes due 2036</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">517</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">548 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.50% euro-denominated notes due 2034</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">517</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">548 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.05% notes due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">498</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">497 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.60% notes due 2042</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">492</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">492 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6.55% notes due 2037</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">404</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">406 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.75% notes due 2036</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">339</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">339 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.95% debentures due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">307</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">307 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.85% notes due 2039</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">271</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6.40% debentures due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">251</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6.30% debentures due 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">135</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.75% notes due 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,498 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">209</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">34,462</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">33,683 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other (as presented in the table above) includes borrowings at variable rates that resulted in effective interest rates of 5.02% and 4.82% for 2024 and 2023, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">With the exception of the 6.30% debentures due 2026, the notes listed in the table above are redeemable in whole or in part, at Merck’s option at any time, at varying redemption prices. Effective as of November 3, 2009, the Company executed a full and unconditional guarantee of the then existing debt of its subsidiary Merck Sharp &amp; Dohme LLC. (MSD) and MSD executed a full and unconditional guarantee of the then existing debt of the Company </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(excluding commercial paper), including for payments of principal and interest. These guarantees do not extend to debt issued subsequent to that date.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In May 2024, MSD Netherlands Capital B.V., a wholly owned finance subsidiary of Merck, completed a registered public offering of €3.4 billion in aggregate principal amount of euro-dominated senior notes comprised of €850 million of 3.25% senior notes due 2032, €850 million of 3.50% senior notes due 2037, €850 million of 3.70% senior notes due 2044 and €850 million of 3.75% senior notes due 2054 (collectively, the Euronotes). The Company has fully and unconditionally guaranteed all of MSD Netherlands Capital B.V.’s obligations under the Euronotes and no other subsidiary of the Company will guarantee these obligations. MSD Netherlands Capital B.V. is a “finance subsidiary” as defined in Rule 13-01(a)(4)(vi) of Regulation S-X of the Exchange Act, with no assets or operations other than those related to the issuance, administration and repayment of the Euronotes. The financial condition, results of operations and cash flows of MSD Netherlands Capital B.V. are consolidated in the financial statements of the Company. The net cash proceeds from the offering were used for general corporate purposes. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain of the Company’s borrowings require that Merck comply with covenants and, at December 31, 2024, the Company was in compliance with these covenants.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The aggregate maturities of long-term debt for each of the next five years are as follows: 2025, $2.6 billion; 2026, $2.2 billion; 2027, $1.5 billion; 2028, $2.1 billion; 2029, $1.7 billion. Interest payments related to these debt obligations are as follows: 2025, $1.2 billion; 2026, $1.2 billion; 2027, $1.1 billion; 2028, $1.1 billion; 2029, $1.0 billion.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has a $6.0 billion credit facility that matures in May 2028. The facility provides backup liquidity for the Company’s commercial paper borrowing facility and is to be used for general corporate purposes. The Company has not drawn funding from this facility.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has operating leases primarily for manufacturing facilities, research and development facilities, corporate offices, employee housing, vehicles and certain equipment. The Company determines if an arrangement is a lease at inception. When evaluating contracts for embedded leases, the Company exercises judgment to determine if there is an explicit or implicit identified asset in the contract and if Merck controls the use of that asset. Embedded leases, primarily associated with contract manufacturing organizations, are immaterial. The lease term includes options to extend or terminate the lease when it is reasonably certain that Merck will exercise that option. Real estate leases for facilities have an average remaining lease term of approximately six years, which include options to extend the leases for up to five years where applicable. Vehicle leases are generally in effect for four years. The Company elected to exclude short-term leases (leases with an initial term of 12 months or less) from the lease assets and liabilities on the balance sheet.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Lease expense for operating lease payments is recognized on a straight-line basis over the term of the lease. Operating lease assets and liabilities are recognized based on the present value of lease payments over the lease term. Since the Company’s leases do not have a readily determinable implicit discount rate, the Company uses its incremental borrowing rate to calculate the present value of lease payments by asset class. On a quarterly basis, an updated incremental borrowing rate is determined based on the average remaining lease term of each asset class and the Company’s pretax cost of debt for that same term. The updated rates for each asset class are applied prospectively to new leases. The Company does not separate lease components (e.g., payments for rent, real estate taxes and insurance costs) from non-lease components (e.g. common-area maintenance costs) in the event that the agreement contains both. Merck includes both the lease and non-lease components for purposes of calculating the right-of-use asset and related lease liability (if the non-lease components are fixed). For vehicle leases and employee housing, the Company applies a portfolio approach to account for the operating lease assets and liabilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain of the Company’s lease agreements contain variable lease payments that are adjusted periodically for inflation or for actual operating expense true-ups compared with estimated amounts; however, these amounts are immaterial. Sublease income was immaterial and there were no sale and leaseback transactions in 2024. Merck’s lease agreements do not contain any material residual value guarantees or material restrictive covenants. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease cost was $348 million in 2024, $339 million in 2023 and $334 million in 2022. Cash paid for amounts included in the measurement of operating lease liabilities was $357 million in 2024, $347 million in 2023 and $335 million in 2022. Operating lease assets obtained in exchange for lease obligations were $47 million in 2024, $122 million in 2023 and $57 million in 2022. </span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating leases is as follows:</span></div><div style="margin-bottom:1pt;margin-top:6pt;padding-left:9pt;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="-sec-ix-hidden:f-1556"><span style="-sec-ix-hidden:f-1557"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></span></span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,370</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,437 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1560"><span style="-sec-ix-hidden:f-1561">Accrued and other current liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">282</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1564"><span style="-sec-ix-hidden:f-1565">Other Noncurrent Liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">877</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">928 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,159</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,213 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.0</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes prepaid leases that have no related lease liability.</span></div><div style="margin-bottom:3pt;margin-top:9pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Maturities of operating leases liabilities are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:89.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">292 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">403 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,521 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">362 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,159 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At December 31, 2024, the Company had entered into additional real estate operating leases that had not yet commenced; the obligations associated with these leases total $183 million.</span></div> 2500000000 149000000 1300000000 69000000 0.0518 0.0514 <div style="margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-term debt at December 31 consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.15% notes due 2031</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,989</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,988 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.75% notes due 2051</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,980</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,980 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.70% notes due 2045</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,980</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,979 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.40% notes due 2029</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,742</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,740 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.50% notes due 2033</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,509</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,547 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.70% notes due 2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,497</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,495 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.90% notes due 2061</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,484</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,484 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.00% notes due 2053</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,482</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,481 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.00% notes due 2049</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,474</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,473 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.15% notes due 2043</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,240</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,240 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.45% notes due 2030</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,240</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,238 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.45% notes due 2050</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,216</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,214 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.875% euro-denominated notes due 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,041</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.75% notes due 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">998</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">996 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.90% notes due 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">996</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">995 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.15% notes due 2063</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">987</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">987 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.90% notes due 2039</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">987</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">986 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.35% notes due 2040</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">986</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">985 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.25% euro-denominated notes due 2032</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">880</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.50% euro-denominated notes due 2037</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">877</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.70% euro-denominated notes due 2044</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">876</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.75% euro-denominated notes due 2054</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">873</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.30% notes due 2030</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">746</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">745 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.90% notes due 2044</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">740</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">740 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6.50% notes due 2033</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">702</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">707 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.375% euro-denominated notes due 2036</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">517</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">548 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.50% euro-denominated notes due 2034</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">517</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">548 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.05% notes due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">498</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">497 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.60% notes due 2042</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">492</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">492 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6.55% notes due 2037</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">404</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">406 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.75% notes due 2036</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">339</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">339 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.95% debentures due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">307</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">307 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.85% notes due 2039</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">271</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6.40% debentures due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">251</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6.30% debentures due 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">135</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.75% notes due 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,498 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">209</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">34,462</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">33,683 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0.0215 1989000000 1988000000 0.0275 1980000000 1980000000 0.0370 1980000000 1979000000 0.0340 1742000000 1740000000 0.0450 1509000000 1547000000 0.0170 1497000000 1495000000 0.0290 1484000000 1484000000 0.0500 1482000000 1481000000 0.0400 1474000000 1473000000 0.0415 1240000000 1240000000 0.0145 1240000000 1238000000 0.0245 1216000000 1214000000 0.01875 1041000000 1103000000 0.0075 998000000 996000000 0.0190 996000000 995000000 0.0515 987000000 987000000 0.0390 987000000 986000000 0.0235 986000000 985000000 0.0325 880000000 0 0.0350 877000000 0 0.0370 876000000 0 0.0375 873000000 0 0.0430 746000000 745000000 0.0490 740000000 740000000 0.0650 702000000 707000000 0.01375 517000000 548000000 0.0250 517000000 548000000 0.0405 498000000 497000000 0.0360 492000000 492000000 0.0655 404000000 406000000 0.0575 339000000 339000000 0.0595 307000000 307000000 0.0585 271000000 271000000 0.0640 251000000 250000000 0.0630 135000000 135000000 0.0275 0 2498000000 209000000 289000000 34462000000 33683000000 0.0502 0.0482 0.0630 3400000000 850000000 0.0325 850000000 0.0350 850000000 0.0370 850000000 0.0375 2600000000 2200000000 1500000000 2100000000 1700000000 1200000000 1200000000 1100000000 1100000000 1000000000.0 6000000000.0 P6Y P5Y P4Y 348000000 339000000 334000000 357000000 347000000 335000000 47000000 122000000 57000000 <div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating leases is as follows:</span></div><div style="margin-bottom:1pt;margin-top:6pt;padding-left:9pt;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="-sec-ix-hidden:f-1556"><span style="-sec-ix-hidden:f-1557"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></span></span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,370</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,437 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1560"><span style="-sec-ix-hidden:f-1561">Accrued and other current liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">282</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1564"><span style="-sec-ix-hidden:f-1565">Other Noncurrent Liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">877</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">928 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,159</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,213 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.0</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes prepaid leases that have no related lease liability.</span></div> 1370000000 1437000000 282000000 285000000 877000000 928000000 1159000000 1213000000 P6Y P7Y 0.032 0.033 <div style="margin-bottom:3pt;margin-top:9pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Maturities of operating leases liabilities are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:89.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">292 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">403 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,521 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">362 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,159 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 329000000 292000000 235000000 146000000 116000000 403000000 1521000000 362000000 1159000000 183000000 Contingencies and Environmental Liabilities <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, commercial litigation, and securities litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of the Company, it is unlikely that the resolution of these matters will be material to the Company’s financial condition, results of operations or cash flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Given the nature of the litigation discussed below and the complexities involved in these matters, the Company is unable to reasonably estimate a possible loss or range of possible loss for such matters until the Company knows, among other factors, (i) what claims, if any, will survive dispositive motion practice, (ii) the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii) how the discovery process will affect the litigation, (iv) the settlement posture of the other parties to the litigation and (v) any other factors that may have a material effect on the litigation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. Generally, for product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company’s decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Product Liability Litigation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Dr Scholl’s Foot Powder</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, Merck is a defendant in product liability lawsuits in the U.S. arising from consumers’ alleged exposure to talc in Dr. Scholl’s foot powder, which Merck acquired through its merger with Schering-Plough Corporation and sold as part of the divestiture of Merck’s consumer care business to Bayer in 2014. In these actions, plaintiffs allege that they were exposed to asbestos-contaminated talc and developed mesothelioma as a result. As of December 31, 2024, approximately 415 cases were pending against Merck in various state courts.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil 9</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, Merck is a defendant in product liability lawsuits in the U.S. involving </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 9 (Human Papillomavirus 9-valent Vaccine, Recombinant). As of December 31, 2024, approximately 225 cases were filed and pending against Merck in either federal or state court. In these actions, plaintiffs allege, among other things, that they suffered various personal injuries after vaccination with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 9, with postural orthostatic tachycardia syndrome (POTS) as a predominate alleged injury. In August 2022, the U.S. Judicial Panel on Multidistrict Litigation ordered that </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 9 product liability cases pending in federal courts nationwide be transferred to Judge Robert J. Conrad in the Western District of North Carolina for coordinated pre-trial proceedings. In February 2024, the multidistrict litigation was reassigned to Judge Kenneth D. Bell. As previously disclosed, there are fewer than 15 product liability cases pending outside the U.S.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On January 28, 2025, a trial commenced in California state court. Plaintiff claims that she suffers from POTS and fibromyalgia as a result of her </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> vaccinations. On February 14, 2025, after four weeks of trial and an opportunity to litigate plaintiff’s claims before a jury, plaintiff’s counsel approached Merck and proposed that the jury be discharged and the case adjourned. Merck agreed, subject to an explicit stipulation that Merck would provide no financial or other consideration in exchange for the agreement to adjourn. The case has thus been adjourned until a new trial date of September 15, 2025. Merck is vigorously defending this case and believes that evidence presented in court will show that </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> had no role in causing any of plaintiff’s conditions.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Governmental Proceedings</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Civil Investigative Demands</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, in June 2024, Merck received a Civil Investigative Demand (CID) from the U.S. Department of Justice, pursuant to a False Claims Act investigation, seeking documents and materials related to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Steglatro</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and certain related drugs. The CID states that it is investigating Merck’s price reporting under the Medicaid Drug Rebate Program as well as compliance with anti-kickback requirements in connection with patient assistance programs. The Company is cooperating with the investigation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, in June 2020, Merck received a CID from the U.S. Department of Justice. The CID requests answers to interrogatories, as well as various documents, regarding temperature excursions at a third-party storage facility containing certain Merck products. Merck is cooperating with the government’s investigation and intends to produce information and/or documents as necessary in response to the CID.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Inflation Reduction Act</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, in June 2023, Merck filed a complaint in the U.S. District Court for the District of Columbia against the U.S. government regarding the Inflation Reduction Act’s “Drug Price Negotiation Program” for Medicare (the Program). This litigation seeks relief from the Program by challenging its constitutionality as violative of the First and Fifth Amendments to the U.S. Constitution.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Matters</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, in April 2019, Merck received a set of investigative interrogatories from the California Attorney General’s Office pursuant to its investigation of conduct and agreements that allegedly affected or delayed competition to Lantus in the insulin market. The interrogatories seek information concerning Merck’s development of an insulin glargine product, and its subsequent termination, as well as Merck’s patent litigation against Sanofi S.A. concerning Lantus and the resolution of that litigation. Merck is cooperating with the California Attorney General’s investigation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, from time to time, the Company’s subsidiaries in China receive inquiries regarding their operations from various Chinese governmental agencies. Some of these inquiries may be related to matters involving other multinational pharmaceutical companies, as well as Chinese entities doing business with such companies. The Company’s policy is to cooperate with these authorities and to provide responses as appropriate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, from time to time, the Company receives inquiries and is the subject of preliminary investigation activities from competition and other governmental authorities in markets outside the U.S. These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings. Should those proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In February 2025, a putative class action was filed against Merck and certain of its officers in the U.S. District Court for the District of New Jersey purportedly on behalf of all purchasers of Merck common stock between February 2022 and February 2025. Plaintiff alleges that Merck violated federal securities laws by making materially false and misleading statements and material omissions regarding demand for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil 9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in China. Plaintiff seeks unspecified monetary damages, pre-judgment and post-judgment interest, and fees and costs.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commercial and Other Litigation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Zetia</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Antitrust Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, Merck, MSD, Schering Corporation, Schering-Plough Corporation, and MSP Singapore Company LLC (collectively, the Merck Defendants) were defendants in a number of lawsuits filed in 2018 on behalf of direct and indirect purchasers of Zetia (ezetimibe) alleging violations of federal and state antitrust laws, as well as other state statutory and common law causes of action. The cases were consolidated in a federal multidistrict litigation (Zetia MDL) before Judge Rebecca Beach Smith in the Eastern District of Virginia. In April 2023, the Merck Defendants reached settlements with the direct purchaser and retailer plaintiffs and a settlement with the indirect purchaser class that the court approved in October 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, in 2020 and 2021, United Healthcare Services, Inc. (United Healthcare), Humana Inc. (Humana), Centene Corporation and others (Centene), and Kaiser Foundation Health Plan, Inc. (Kaiser) (collectively, the Insurer Plaintiffs), each filed a lawsuit in a jurisdiction outside of the Eastern District of Virginia against the Merck Defendants and others, making similar allegations as those made in the Zetia MDL, as well as additional allegations about Vytorin. These cases were transferred to the Eastern District of Virginia to proceed with the Zetia MDL.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In December 2023, the U.S. Judicial Panel on Multidistrict Litigation remanded the four Insurer Plaintiff cases to the transferor courts in the Northern District of California (Kaiser), the District of Minnesota (United Healthcare), and the District of New Jersey (Humana and Centene). The Merck Defendants filed motions to dismiss in each of the Insurer Plaintiff cases. On December 30, 2024, the court granted in part and denied in part the motions to dismiss in the Humana and Centene cases, and on January 29, 2025, Humana and Centene filed amended complaints.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">RotaTeq Antitrust Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, in March 2023, the Mayor and City Council of Baltimore filed a putative class action against MSD in the Eastern District of Pennsylvania on behalf of all third-party payors in 35 states that indirectly purchased, paid, and/or provided reimbursement for some or all of the purchase price of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">RotaTeq</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (Rotavirus Vaccine, Live Oral, Pentavalent), other than for resale, from March 3, 2019 to the present. Plaintiff alleges that MSD violated federal and state antitrust laws and state consumer protection laws. Plaintiff alleges that MSD has implemented an anticompetitive vaccine bundling scheme whereby MSD leverages its alleged monopoly power in certain pediatric vaccine markets to maintain its alleged monopoly power in the U.S. market for rotavirus vaccines in order to charge supracompetitive prices for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">RotaTeq</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Plaintiff seeks permanent injunctive relief and unspecified monetary damages on purchases of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">RotaTeq</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, trebled, and fees and costs. In May 2023, MSD moved to dismiss the complaint. In November 2023, the court granted in part and denied in part the motion to dismiss, dismissing plaintiff’s Idaho and Utah consumer law claims and allowing all other claims to proceed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bravecto Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, in January 2020, the Company was served with a complaint in the U.S. District Court for the District of New Jersey. Following motion practice, the plaintiffs filed a third amended complaint in August 2024, seeking to certify a nationwide class action of purchasers or users of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bravecto </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(fluralaner) products in the U.S. or its territories between May 1, 2014 and July 1, 2021. Plaintiffs contend </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bravecto </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">causes neurological events in dogs and cats and alleges violations of the New Jersey Consumer Fraud Act, Breach of Warranty, Product Liability, and related theories. The Company moved to dismiss or, alternatively, to strike the class allegations from the third amended complaint, and that motion is pending. A similar case was filed in Quebec, Canada in May 2019. The </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Superior Court certified a class of dog owners in Quebec who gave </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bravecto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Chew to their dogs between February 16, 2017 and November 2, 2018 whose dogs experienced one of the conditions in the post-marketing adverse reactions section of the labeling approved on November 2, 2018. The Company and plaintiffs each appealed the class certification decision. The Court of Appeal of Quebec amended the class period to start July 2, 2014, allowed the second plaintiff to serve as a class representative, and modified the list of conditions in the class definition. The Company sought leave to appeal to the Supreme Court of Canada, which was denied. The case is proceeding in the Superior Court.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">340B Program Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, Merck filed a complaint in the U.S. District Court for the District of Columbia to challenge the letter Merck received from the U.S. Health Resources and Services Administration (HRSA) in May 2022 regarding Merck’s 340B Program integrity initiative. On September 17, 2024, the court entered a consent judgment granting Merck the relief it had sought in the litigation, including declarations that HRSA’s May 2022 letter was unlawful and that the version of Merck’s 340B Program integrity initiative at issue in the litigation did not violate Section 340B on its face. </span></div><div style="margin-top:6pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Qui Tam Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, in June 2012, the U.S. District Court for the Eastern District of Pennsylvania unsealed a complaint that had been filed against the Company under the federal False Claims Act by two former employees alleging, among other things, that the Company defrauded the U.S. government by falsifying data in connection with a clinical study conducted on the mumps component of the Company’s </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">M-M-R</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> II vaccine. The complaint alleges the fraud took place between 1999 and 2001. The U.S. government had the right to participate in and take over the prosecution of this lawsuit but notified the court that it declined to exercise that right. The two former employees pursued the lawsuit without the involvement of the U.S. government. In July 2023, the court denied relators’ motion for summary judgment, granted two of the Company’s motions for summary judgment, and denied the Company’s remaining motions for summary judgment as moot. The court entered judgment in favor of the Company and dismissed relators’ amended complaint in full with prejudice. Relators appealed that decision, and in August 2024, the Third Circuit affirmed the district court’s decision.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, as previously disclosed, two putative class action lawsuits on behalf of direct purchasers of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">M‑M‑R</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> II vaccine, which charge that the Company misrepresented the efficacy of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">M-M-R</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> II vaccine in violation of federal antitrust laws and various state consumer protection laws, are pending in the Eastern District of Pennsylvania. The court granted the Company’s motion for summary judgment as to plaintiffs’ state law claims and denied the motion as to plaintiffs’ antitrust claim. The Company appealed, and on October 7, 2024, the Third Circuit reversed-in-part the district court’s order and remanded the case with instructions to enter summary judgment for the Company. On November 20, 2024, plaintiffs-appellees filed a petition for rehearing and rehearing en banc, and on February 10, 2025, the court denied the petition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Merck KGaA Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, in January 2016, to protect its long-established brand rights in the U.S., the Company filed a lawsuit against Merck KGaA, Darmstadt, Germany (KGaA), historically operating as the EMD Group in the U.S., alleging it improperly uses the name “Merck” in the U.S. KGaA has filed suit against the Company in a number of jurisdictions outside of the U.S. alleging, among other things, unfair competition, trademark infringement and/or corporate name infringement. In certain of those jurisdictions, KGaA also alleges breach of the parties’ coexistence agreement. The litigation is ongoing in the U.S. with no trial date set, and also ongoing in jurisdictions outside of the U.S.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Patent Litigation</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">From time to time, generic manufacturers of pharmaceutical products file abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration (FDA) seeking to market generic forms of the Company’s products prior to the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file patent infringement lawsuits against such generic companies. Similar lawsuits defending the Company’s patent rights may exist in other countries. The Company intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened periods of exclusivity for these products and, with respect to products acquired through acquisitions accounted for as business combinations, potentially significant intangible asset impairment charges.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion </span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, between January and November 2020, the Company received multiple Paragraph IV Certification Letters under the Hatch-Waxman Act notifying the Company that generic drug companies had filed applications to the FDA seeking pre-patent expiry approval to sell generic versions of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (sugammadex) </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Injection. In March, April and December 2020, the Company filed patent infringement lawsuits in the U.S. District Courts for the District of New Jersey and the Northern District of West Virginia against those generic companies. All actions in the District of New Jersey were consolidated. The West Virginia case was jointly dismissed with prejudice in August 2022 in favor of proceeding in New Jersey. The remaining defendants in the New Jersey action have stipulated to infringement of the asserted claims and withdrew all remaining claims and defenses other than a defense seeking to shorten the patent term extension (PTE) of the sugammadex patent to December 2022. The U.S. District Court for the District of New Jersey held a one-day trial in December 2022 on this remaining PTE calculation defense. The court ordered a post-trial briefing on this defense and held closing arguments in February 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, in June 2023, the U.S. District Court for the District of New Jersey ruled in Merck’s favor. The court held that Merck’s calculation of PTE for the sugammadex patent covering the compound is not invalid and that the U.S. Patent &amp; Trademark Office correctly granted a full five-year extension. This ruling affirms and validates Merck’s U.S. patent protection for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> through at least January 2026. Also in June 2023, the U.S. District Court for the District of New Jersey issued a final judgment prohibiting the FDA from approving any of the pending or tentatively approved generic applications until January 27, 2026, except for any subsequent agreements between defendants and Merck or further order by the court.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In July 2023, defendants filed a notice of appeal with the U.S. Court of Appeals for the Federal Circuit. The appeal is currently pending. Oral argument took place on February 4, 2025.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">While the New Jersey action was pending, the Company settled with five generic companies providing that these generic companies can bring their generic versions of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to the market in January 2026 (which may be delayed by any applicable pediatric exclusivity) or earlier under certain circumstances. The Company agreed to stay the lawsuit filed against two generic companies, which in exchange agreed to be bound by a judgment on the merits of the consolidated action in the District of New Jersey. One of the generic companies in the consolidated action requested dismissal of the action against it and the Company did not oppose this request, which was subsequently granted by the court. The Company does not expect this company to bring its generic version of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">to the market before January 2026 or later, depending on any applicable pediatric exclusivity.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In February 2024, the Company received another Paragraph IV Certification Letter under the Hatch-Waxman Act notifying the Company that Hikma Pharmaceuticals USA Inc. (Hikma) had filed an application to the FDA seeking pre-patent expiry approval to sell a generic version of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Injection. In March 2024, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Hikma, postponing FDA approval of the Hikma generic drug for 30 months or until expiration of the sugammadex patent (January 27, 2026) and any potentially applicable pediatric exclusivity or an adverse court decision, if any, whichever may occur earlier. Expiration of the patent, and any potentially applicable pediatric exclusivity, will occur earlier than expiry of the 30-month stay. On April 16, 2024, the district court stayed the case during the pendency of the Federal Circuit appeal noted above.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia, Janumet, Janumet XR </span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, the FDA granted pediatric exclusivity with respect to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(sitagliptin), </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(sitagliptin/metformin HCl), and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (sitagliptin and metformin HCl extended-release), which provides a further six months of exclusivity in the U.S. beyond the expiration of all patents listed in the FDA’s Orange Book. Adding this exclusivity to the term of the key patent protection extended exclusivity on these products to January 2023. However, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> contain sitagliptin phosphate monohydrate and the Company has another patent covering certain phosphate salt and polymorphic forms of sitagliptin that expires in May 2027, including pediatric exclusivity (salt/polymorph patent).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, beginning in 2019, a number of generic drug companies filed ANDAs seeking approval of generic forms of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> along with paragraph IV certifications challenging the validity of the salt/polymorph patent. The Company responded by filing infringement suits which have all been settled. The Company has settled with a total 26 generic companies providing that these generic companies can bring their generic versions of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to the market in the U.S. in May 2026 or earlier under certain circumstances, and their generic versions of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to the market in July 2026 or earlier under certain circumstances.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In March 2021, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc., and Cadila Healthcare Ltd. (collectively, Zydus). In that lawsuit, the Company alleged infringement of the salt/polymorph patent based on the filing of Zydus’s NDA seeking approval of a form of sitagliptin that is a different from than that used in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. In December 2022, the parties reached settlement that included dismissal of the case without prejudice enabling Zydus to seek final approval of a non-automatically substitutable product.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In January 2023, the Company received a Paragraph IV Certification Letter under the Hatch-Waxman Act notifying the Company that Zydus filed an ANDA seeking approval of sitagliptin/metformin HCl tablets and certifying that no valid or enforceable claim of any of the patents listed in FDA’s Orange Book for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> will be infringed by the proposed Zydus product. In March 2023, the parties reached settlement enabling Zydus to seek final approval of a non-automatically substitutable product containing a different form of sitagliptin than that used in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. In November 2023, the Company received a Paragraph IV Certification Letter under the Hatch-Waxman Act notifying the Company that Zydus filed an ANDA seeking approval of sitagliptin/metformin HCl Extended Release tablets. In January 2024, the parties reached settlement enabling Zydus to seek final approval of a non-automatically substitutable version containing a different form of sitagliptin than that used in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As a result of these settlement agreements related to the later expiring salt/polymorph patent directed to the specific sitagliptin salt form of the products, the Company expects that </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> will not lose market exclusivity in the U.S. until May 2026 and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> will not lose market exclusivity in the U.S. until July 2026, although Zydus has received FDA approval for a non-automatically substitutable form of sitagliptin that differs from the form in the Company’s sitagliptin products. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In March 2024, the Company received another Paragraph IV Certification Letter under the Hatch-Waxman Act from Azurity Pharmaceuticals, Inc. (Azurity) asserting that a different sitagliptin product subject to its ANDA does not infringe the salt/polymorph patent. In May 2024, Merck filed a civil action in the U.S. District Court of Delaware alleging infringement. The case was dismissed without prejudice in July 2024. Following the dismissal, the Company granted Azurity a covenant not to assert the salt/polymorph patent against the Azurity product that is the subject of such ANDA.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Supplementary Protection Certificates (SPCs) for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expired in April 2023 for the majority of European countries. Prior to expiration, generic companies sought revocation of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> SPCs in a number of European countries. In February 2022, a Finnish court referred certain questions to the Court of Justice of the European Union that could impact the validity of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> SPCs in Europe. A decision was rendered on December 19, 2024. The decision provides guidance on points of law and does not directly apply these to the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> SPCs. Thus, additional proceedings in certain countries where generic companies were prevented from launching products during the SPC period may be necessary to determine whether the SPCs are valid and if not, whether damages are appropriate. Those countries include Belgium, Czech Republic, Ireland, Finland, France, Slovakia and Switzerland. If the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> SPCs are ultimately upheld, the Company has reserved its rights related to the pursuit of damages for those countries where a generic launched prior to expiry of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">SPC.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In October 2023, the Company filed a patent infringement lawsuit against Sawai Pharmaceuticals Co., Ltd. and Medisa Shinyaku Co., Ltd (collectively, Defendants) in the Tokyo District Court seeking an injunction to stop the manufacture, sale and offer for sale of the Defendants’ sitagliptin dihydrogen phosphate product, while the Company’s patents and patent term extensions are in force. The lawsuit is in response to the Defendants’ application for marketing authorization to sell a generic sitagliptin dihydrogen phosphate product, in the anhydrate form, which was approved in August 2023. Merck asserts that the Defendants’ activity infringes a patent term extension associated with Merck’s patent directed to the sitagliptin compound patent.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> As previously disclosed,</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">in November 2022, the Company filed a complaint against The Johns Hopkins University (JHU) in the U.S. District Court of Maryland. This action concerns patents emerging from a joint research collaboration between Merck and JHU regarding the use of pembrolizumab, which Merck sells under the trade name </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Merck and JHU partnered to design and conduct a clinical study administering </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to cancer patients having tumors that had the genetic biomarker known as microsatellite instability-high (MSI-H). After the conclusion of the study, JHU secured U.S. patents citing the joint research study. Merck alleges that JHU has breached the collaboration agreement by filing and obtaining these patents without informing or involving Merck and then licensing the patents to others. Merck therefore brought this action for breach of contract, declaratory judgment of noninfringement, and promissory estoppel. JHU answered the complaint in April and May 2023, denying Merck’s claims, and counterclaiming for willful infringement of nine issued U.S. patents, including a demand for damages. Between November 30, 2023 and March 13, 2024, the Company filed </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> review petitions with the United States Patent &amp; Trademark Office Patent Trial and Appeal Board (PTAB), challenging the validity of all nine patents asserted in the case. Between June 2024 and October 2024, the PTAB instituted a review of all nine asserted patents. In July 2024, the district court granted Merck’s motion to stay the case in its entirety pending the outcome of the PTAB proceeding instituted in June 2024.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lynparza</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> As previously disclosed, in December 2022, AstraZeneca Pharmaceuticals LP received a Paragraph IV Certification Letter under the Hatch-Waxman Act notifying AstraZeneca that Natco Pharma Limited (Natco) has filed an application to the FDA seeking pre-patent expiry approval to sell generic versions of Lynparza (olaparib) tablet. In February 2023, AstraZeneca and the Company filed a patent infringement lawsuit in the U.S. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">District Court for the District of New Jersey against Natco. This lawsuit, which asserts one or more patents covering olaparib, automatically stays FDA approval of the generic application until June 2025 or until an adverse court decision, if any, whichever may occur earlier. In May, June, July, and November 2024, AstraZeneca and the Company filed additional patent infringement lawsuits in the U.S. District Court for the District of New Jersey against Natco asserting additional patents covering olaparib.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In December 2023, AstraZeneca Pharmaceuticals LP received a second Paragraph IV Certification Letter under the Hatch-Waxman Act notifying AstraZeneca that Sandoz Inc. has filed an application to the FDA seeking pre-patent expiry approval to sell generic versions of Lynparza (olaparib) tablet. In February 2024, AstraZeneca and the Company filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Sandoz. This lawsuit, which asserts one or more patents covering olaparib, automatically stays FDA approval of the generic application until June 2026 or until an adverse court decision, if any, whichever may occur earlier. In May, July, and November 2024, AstraZeneca and the Company filed additional patent infringement lawsuits in the U.S. District Court for the District of New Jersey against Sandoz asserting additional patents covering olaparib.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In May 2024, AstraZeneca Pharmaceuticals LP received a third Paragraph IV Certification Letter under the Hatch-Waxman Act notifying AstraZeneca that Cipla USA, Inc. and Cipla Limited (collectively, Cipla) filed an application to the FDA seeking pre-patent expiry approval to sell generic versions of Lynparza (olaparib) tablet. In June 2024, AstraZeneca and the Company filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Cipla. This lawsuit, which asserts one or more patents covering olaparib, automatically stays FDA approval of the generic application until November 2026 or until an adverse court decision, if any, whichever may occur earlier. In June, July, and November 2024, AstraZeneca and the Company filed additional patent infringement lawsuits in the U.S. District Court for the District of New Jersey against Cipla asserting additional patents covering olaparib.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In November 2024, AstraZeneca Pharmaceuticals LP received another Paragraph IV Certification Letter under the Hatch-Waxman Act notifying AstraZeneca that Zydus Pharmaceuticals (USA) Inc. filed an application to the FDA seeking pre-patent expiry approval to sell generic versions of Lynparza (olaparib) tablet. In November 2024, AstraZeneca and the Company filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Zydus. This lawsuit, which asserts one or more patents covering olaparib, automatically stays FDA approval of the generic application until May 2027 or until an adverse court decision, if any, whichever may occur earlier. In November 2024, AstraZeneca and the Company filed an additional patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Zydus asserting an additional patent covering olaparib.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There are various other pending legal proceedings involving the Company, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company’s financial condition, results of operations or cash flows either individually or in the aggregate.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Legal Defense Reserves</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company’s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of December 31, 2024 and 2023 of approximately $225 million and $210 million, respectively, represents the Company’s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Environmental Matters</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The Company and its subsidiaries are parties to a number of proceedings brought under the Comprehensive Environmental Response, Compensation and Liability Act, commonly known as Superfund, and other federal and state equivalents. These proceedings seek to require the operators of hazardous waste disposal facilities, transporters of waste to the sites and generators of hazardous waste disposed of at the sites to clean up the sites or </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">to reimburse the government for cleanup costs. The Company has been made a party to these proceedings as an alleged generator of waste disposed of at the sites. In each case, the government alleges that the defendants are jointly and severally liable for the cleanup costs. Although joint and several liability is alleged, these proceedings are frequently resolved so that the allocation of cleanup costs among the parties more nearly reflects the relative contributions of the parties to the site situation. The Company’s potential liability varies greatly from site to site. For some sites the potential liability is </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">de minimis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and for others the final costs of cleanup have not yet been determined. While it is not feasible to predict the outcome of many of these proceedings brought by federal or state agencies or private litigants, in the opinion of the Company, such proceedings should not ultimately result in any liability which would have a material adverse effect on the financial condition, results of operations or liquidity of the Company. The Company has taken an active role in identifying and accruing for these costs and such amounts do not include any reduction for anticipated recoveries of cleanup costs from former site owners or operators or other recalcitrant potentially responsible parties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In management’s opinion, the liabilities for all environmental matters that are probable and reasonably estimable have been accrued and totaled $41 million and $42 million at December 31, 2024 and 2023, respectively. These liabilities are undiscounted, do not consider potential recoveries from other parties and will be paid out over the periods of remediation for the applicable sites, which are expected to occur primarily over the next 15 years. Although it is not possible to predict with certainty the outcome of these matters, or the ultimate costs of remediation, management does not believe that any reasonably possible expenditures that may be incurred in excess of the liabilities accrued should exceed approximately $46 million in the aggregate. Management also does not believe that these expenditures should result in a material adverse effect on the Company’s financial condition, results of operations or liquidity for any year.</span></div> 415 225 15 35 2 2 2 2 P1D P5Y 5 2 26 9 9 225000000 210000000 liabilities 41000000 42000000 P15Y 46000000 Equity<div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Merck certificate of incorporation authorizes 6,500,000,000 shares of common stock and 20,000,000 shares of preferred stock.</span></div><div style="margin-top:5pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Capital Stock</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of common stock and treasury stock transactions (shares in millions) is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.624%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury<br/>Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,577</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,045</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,039 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,049 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of treasury stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance December 31</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,577</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,049</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,045 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,039 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Issuances primarily reflect activity under share-based compensation plans.</span></div> 6500000000 20000000 <div style="margin-bottom:3pt;margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of common stock and treasury stock transactions (shares in millions) is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.624%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury<br/>Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,577</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,045</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,039 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,049 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of treasury stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance December 31</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,577</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,049</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,045 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,039 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Issuances primarily reflect activity under share-based compensation plans.</span></div> 3577000000 1045000000 3577000000 1039000000 3577000000 1049000000 0 11000000 0 13000000 0 0 0 7000000 0 7000000 0 10000000 3577000000 1049000000 3577000000 1045000000 3577000000 1039000000 Share-Based Compensation Plans<div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has share-based compensation plans under which the Company grants restricted stock units (RSUs) and performance share units (PSUs) to certain management level employees. In addition, employees and non-employee directors may be granted options to purchase shares of Company common stock at the fair market value at the time of grant. These plans were approved by the Company’s shareholders.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At December 31, 2024, 75 million shares collectively were authorized for future grants under the Company’s share-based compensation plans. These awards are settled with treasury shares.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employee stock options are granted to purchase shares of Company stock at the fair market value at the time of grant. These awards generally vest one-third each year over a three-year period, with a contractual term of 7-10 years. RSUs are stock awards that are granted to employees and entitle the holder to shares of common stock as the awards vest. The fair value of the stock option and RSU awards is determined and fixed on the grant date based on the Company’s stock price. PSUs are stock awards where the ultimate number of shares issued will be contingent on the Company’s performance against a pre-set objective or set of objectives. The fair value of each PSU is determined on the date of grant based on the Company’s stock price. For RSUs and PSUs, dividends declared during the vesting period are payable to the employees only upon vesting. Over the PSU performance period, the number of shares of stock that are expected to be issued will be adjusted based on the probability of achievement of a performance target and final compensation expense will be recognized based on the ultimate number of shares issued. RSU and PSU distributions will be in shares of Company stock after the end of the vesting or performance </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">period, subject to the terms applicable to such awards. PSU awards generally vest after three years. RSU awards generally vest one-third each year over a three-year period.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total pretax share-based compensation cost recorded in 2024, 2023 and 2022 was $761 million, $645 million and $541 million, respectively. Income tax benefits for share-based compensation expense recognized in 2024, 2023 and 2022 were $117 million, $96 million and $78 million, respectively.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option pricing model for determining the fair value of option grants. In applying this model, the Company uses both historical data and current market data to estimate the fair value of its options. The Black-Scholes model requires several assumptions including expected dividend yield, risk-free interest rate, volatility, and term of the options. The expected dividend yield is based on historical patterns of dividend payments. The risk-free interest rate is based on the rate at grant date of zero-coupon U.S. Treasury Notes with a term equal to the expected term of the option. Expected volatility is estimated using a blend of historical and implied volatility. The historical component is based on historical monthly price changes. The implied volatility is obtained from market data on the Company’s traded options. The expected life represents the amount of time that options granted are expected to be outstanding, based on historical and forecasted exercise behavior.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The weighted average exercise price of options granted in 2024, 2023 and 2022 was $129.22, $117.89 and $87.10 per option, respectively. The weighted average fair value of options granted in 2024, 2023 and 2022 was $25.60, $21.69 and $15.45 per option, respectively, and were determined using the following assumptions:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">20.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.8</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.8</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.9</span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized information relative to stock option plan activity (options in thousands) is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:52.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.975%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.296%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number<br/>of Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding January 1, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,527 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.54 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,753</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">129.22</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2,581)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">68.90</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(199)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">111.48</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Outstanding December 31, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,500</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">86.04</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.9</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">249</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Vested and expected to vest December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,201</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">85.10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.9</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">249</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercisable December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9,084</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">74.00</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4.9</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">241</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additional information pertaining to stock option plans is provided in the table below:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intrinsic value of stock options exercised</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">144</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of stock options vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">32</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash received from the exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">177</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">384 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of nonvested RSU and PSU activity (shares in thousands) is as follows:</span></div><div style="margin-bottom:1pt;margin-top:6pt;padding-left:9pt;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:52.351%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.461%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PSUs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number<br/>of Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number<br/>of Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nonvested January 1, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,542 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.10 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,966 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90.80 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,356</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">128.79</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">968</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">121.91</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(6,091)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">92.97</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,109)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">73.50</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(575)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">113.18</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">121.12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nonvested December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,232</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">117.94</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,766</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">117.57</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected to vest December 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10,976</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">117.25</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,669</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">116.26</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At December 31, 2024, there was $1.1 billion of total pretax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards which will be recognized over a weighted average period of 1.9 years. For segment reporting, share-based compensation costs are unallocated expenses.</span></div> 75000000 P3Y P7Y P10Y P3Y P3Y 761000000 645000000 541000000 117000000 96000000 78000000 129.22 117.89 87.10 The weighted average fair value of options granted in 2024, 2023 and 2022 was $25.60, $21.69 and $15.45 per option, respectively, and were determined using the following assumptions:<div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">20.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.8</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.8</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.9</span></td></tr></table></div> 25.60 21.69 15.45 0.030 0.031 0.031 0.047 0.034 0.030 0.205 0.224 0.225 P5Y9M18D P5Y9M18D P5Y10M24D <div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized information relative to stock option plan activity (options in thousands) is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:52.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.975%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.296%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number<br/>of Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding January 1, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,527 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.54 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,753</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">129.22</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2,581)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">68.90</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(199)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">111.48</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Outstanding December 31, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,500</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">86.04</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.9</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">249</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Vested and expected to vest December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,201</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">85.10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.9</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">249</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercisable December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9,084</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">74.00</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4.9</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">241</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 13527000 77.54 1753000 129.22 2581000 68.90 199000 111.48 12500000 86.04 P5Y10M24D 249000000 12201000 85.10 P5Y10M24D 249000000 9084000 74.00 P4Y10M24D 241000000 <div style="margin-bottom:3pt;margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additional information pertaining to stock option plans is provided in the table below:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intrinsic value of stock options exercised</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">144</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of stock options vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">32</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash received from the exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">177</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">384 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 144000000 95000000 225000000 32000000 30000000 30000000 177000000 125000000 384000000 <div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of nonvested RSU and PSU activity (shares in thousands) is as follows:</span></div><div style="margin-bottom:1pt;margin-top:6pt;padding-left:9pt;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:52.351%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.461%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PSUs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number<br/>of Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number<br/>of Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nonvested January 1, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,542 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.10 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,966 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90.80 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,356</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">128.79</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">968</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">121.91</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(6,091)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">92.97</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,109)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">73.50</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(575)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">113.18</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">121.12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nonvested December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,232</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">117.94</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,766</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">117.57</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected to vest December 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10,976</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">117.25</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,669</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">116.26</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 12542000 100.10 1966000 90.80 6356000 128.79 968000 121.91 6091000 92.97 1109000 73.50 575000 113.18 59000 121.12 12232000 117.94 1766000 117.57 10976000 117.25 1669000 116.26 1100000000 P1Y10M24D Pension and Other Postretirement Benefit Plans<div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has defined benefit pension plans covering eligible employees in the U.S. and in certain of its international subsidiaries. In addition, the Company provides medical benefits, principally to its eligible U.S. retirees and their dependents, through its other postretirement benefit plans. The Company uses December 31 as the year-end measurement date for all of its pension plans and other postretirement benefit plans.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net Periodic Benefit Cost</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The net periodic benefit cost (credit) for pension and other postretirement benefit plans consisted of the following components:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:27.035%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.973%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.134%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.134%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.973%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.134%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.134%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.134%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.469%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Postretirement Benefits</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">373</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">372 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">243</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">283 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">30</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">537</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">526 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">457 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">294</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">299 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">56</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(826)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(735)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(753)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(554)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(517)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(383)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(80)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service (credit) cost</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss (gain) amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">43</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net periodic benefit cost (credit)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">132</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">425 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(25)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(84)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> In connection with restructuring actions (see Note 5), termination charges were recorded in 2024, 2023 and 2022 on pension and other postretirement benefit plans related to expanded eligibility for certain employees exiting Merck. Also, in connection with these restructuring activities, curtailments and settlements were recorded on certain pension plans. Lump sum payments to U.S. pension plan participants also contributed to the settlements recorded during 2023 and 2022.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The components of net periodic benefit cost (credit) other than the service cost component are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (see Note 14), with the exception of certain amounts for termination benefits, curtailments and settlements, which are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Restructuring costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> if the event giving rise to the termination benefits, curtailment or settlement is related to restructuring actions.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Obligations and Funded Status</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized information about the changes in plan assets and benefit obligations, the funded status and the amounts recorded at December 31 is as follows:</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:43.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.453%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other<br/>Postretirement<br/>Benefits</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,804</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,094 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,562</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,473 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,045</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">947 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">266</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,077 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">637</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">832 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Company contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">262</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">198</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">249 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effects of exchange rate changes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(522)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">283 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(615)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(497)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(256)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(89)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(177)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">36</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets December 31</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,717</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,804 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,647</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,562 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,040</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,045 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit obligation January 1</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,446</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,854 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,042</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,755 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,104</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,157 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">373</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">243</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">30</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">537</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">526 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">294</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">299 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">56</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actuarial (gains) losses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(595)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">403 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(549)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">766 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">32</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(615)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(497)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(256)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(89)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effects of exchange rate changes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(473)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan amendments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(56)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(177)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">36</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit obligation December 31</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,151</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,446 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,274</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,042 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,136</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,104 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Funded status December 31</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(434)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(642)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,373</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">520 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(96)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">26</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,785</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,019 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">51</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(405)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(593)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(394)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(480)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(140)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Actuarial (gains) losses primarily reflect changes in discount rates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At December 31, 2024 and 2023, the accumulated benefit obligation was $18.1 billion and $19.1 billion, respectively, for all pension plans, of which $10.0 billion and $10.3 billion, respectively, related to U.S. pension plans.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Information related to the funded status of selected pension plans at December 31 is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.075%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension plans with a projected benefit obligation in excess of plan assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Projected benefit obligation</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,517</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,446 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,847</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,961 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,057</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,804 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,435</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,462 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension plans with an accumulated benefit obligation in excess of plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">442</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,768</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,791 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,186 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,385</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,336 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Plan Assets</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Entities are required to use a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest:</span></div><div style="margin-top:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> — Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> — Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> — Unobservable inputs that are supported by little or no market activity. The Level 3 assets are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as instruments for which the determination of fair value requires significant judgment or estimation. At December 31, 2024 and 2023, $700 million and $788 million, respectively, or approximately 4% of the Company’s pension investments were categorized as Level 3 assets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If the inputs used to measure the financial assets fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.</span></div><div style="margin-bottom:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair values of the Company’s pension plan assets at December 31 by asset category are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.111%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.791%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.791%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.111%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.111%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.111%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">NAV </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">NAV </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. Pension Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">43</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">121</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">164</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investment funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets equities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">170</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,385</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,555</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,573 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,797 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging markets equities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,265</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,265</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">740 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">740 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">174</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">174</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,171</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,171</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,071 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,071 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,101</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,101</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,307 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,307 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,293</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,293</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,485 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,485 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">21</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">21</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other investments (liabilities)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan assets at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,355</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,415</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,945</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,717</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,438 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,813 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,550 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,804 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">International Pension Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">112</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">123</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">118 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investment funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets equities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">599</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,537</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">96</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,232</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">507 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,870 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">262</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,974</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">149</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,385</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,123 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,523 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">149</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">180</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging markets equities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">54</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">91</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">145</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other fixed income obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">287</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">287</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">278 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">278 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">368</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">368</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">423 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">423 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">141</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">141</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">54</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">54</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Insurance contracts </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">698</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">701</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">785 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">788 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,345</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,090</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">698</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">514</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,647</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,197 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,041 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">785 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">539 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,562 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December 31, 2024 and 2023.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The plans’ Level 3 investments in insurance contracts are generally valued using a crediting rate that approximates market returns and invest in underlying securities whose market values are unobservable and determined using pricing models, discounted cash flow methodologies, or similar techniques.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below provides a summary of the changes in fair value, including transfers in and/or out, of all financial assets measured at fair value using significant unobservable inputs (Level 3) for the Company’s pension plan assets:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.611%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.237%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance<br/>Contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Insurance<br/>Contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Pension Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance January 1</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual return on plan assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relating to assets still held at December 31</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relating to assets sold during the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases and sales, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance December 31</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">International Pension Plans</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">785</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">785</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">761 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">761 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual return on plan assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relating to assets still held at December 31</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases and sales, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance December 31</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">698</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">698</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">785 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">785 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair values of the Company’s other postretirement benefit plan assets at December 31 by asset category are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">NAV </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">NAV </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investment funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets equities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">49</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">277 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">301 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging markets equities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">223 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">223 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">598</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">598</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">266</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">266</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">245 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">245 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">54</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">54</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other Investments (liabilities)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan assets at fair value</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">44</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">918</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">78</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,040</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">259 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">404 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">382 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,045 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December 31, 2024 and 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has established investment guidelines for its U.S. pension and other postretirement plans to create an asset allocation that is expected to deliver a rate of return sufficient to meet the long-term obligation of each plan, given an acceptable level of risk. The target investment portfolio of the Company’s U.S. pension and other postretirement benefit plans is allocated 25% to 40% in U.S. equities, 15% to 30% in international equities, 40% to 50% in fixed-income investments, and up to 8% in cash and other investments. The portfolio’s equity weighting is consistent with the long-term nature of the plans’ benefit obligations. The expected annual standard deviation of returns of the target portfolio, which approximates 12%, reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests. For international pension plans, the targeted investment portfolio varies based on the duration of pension liabilities and local government rules and regulations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Although a significant percentage of plan assets are invested in U.S. equities, concentration risk is mitigated through the use of strategies that are diversified within management guidelines.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Expected Contributions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contributions during 2025 are expected to be approximately $270 million for U.S. pension plans, approximately $180 million for international pension plans and approximately $70 million for other postretirement benefit plans.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Expected Benefit Payments</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected benefit payments are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International Pension<br/>Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other<br/>Postretirement<br/>Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">771 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">291 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">775 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">789 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">286 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">799 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">822 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2030 — 2034</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,386 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,792 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">515 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected benefit payments are based on the same assumptions used to measure the benefit obligations and include estimated future employee service.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amounts Recognized in Other Comprehensive Income (Loss)</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net gain/loss amounts reflect differences between expected and actual returns on plan assets as well as the effects of changes in actuarial assumptions. Net gain/loss amounts in excess of certain thresholds are amortized into net periodic benefit cost over the average remaining service life of employees. The following amounts were reflected as components of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"></td><td style="width:28.690%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.990%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Postretirement<br/>Benefit Plans</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net gain (loss) arising during the period</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">634</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(438)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(78)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prior service credit (cost) arising during the period</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">56</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">690</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(454)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(78)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss (gain) amortization included in benefit cost</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">43</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(51)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prior service (credit) cost amortization included in benefit cost</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements and curtailments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">43</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">347 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(94)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Actuarial Assumptions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company reassesses its benefit plan assumptions on a regular basis. The weighted average assumptions used in determining U.S. pension and other postretirement benefit plan and international pension plan information are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:33.144%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.189%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.189%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.189%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.189%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.189%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.196%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Pension and Other<br/>Postretirement Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International Pension Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net periodic benefit cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.30</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.50 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.00 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.40</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.90 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.50 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected rate of return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7.75</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.00 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.20</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Salary growth rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4.60</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.20</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.30</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.40</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.00 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Benefit obligation</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.70</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.30 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.50 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.70</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.40 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.90 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Salary growth rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4.80</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.40</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.30 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.30 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.50</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.40 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.30 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For both the pension and other postretirement benefit plans, the discount rate is evaluated on measurement dates and modified to reflect the prevailing market rate of a portfolio of high-quality fixed-income debt instruments that would provide the future cash flows needed to pay the benefits included in the benefit obligation as they come due. The expected rate of return for both the pension and other postretirement benefit plans represents the average rate of return to be earned on plan assets over the period the benefits included in the benefit obligation are to be paid and is determined on a plan basis. The expected rate of return for each plan is developed considering long-term historical returns data, current market conditions, and actual returns on the plan assets. Using this reference information, the long-term return expectations for each asset category and a weighted-average expected return for each plan’s target portfolio is developed according to the allocation among those investment categories. The expected portfolio performance reflects the contribution of active management as appropriate. For 2025, the expected rate of return for the Company’s U.S. pension and other postretirement benefit plans will be 7.70%, as compared to 7.75% in 2024. </span></div><div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The health care cost trend rate assumptions for other postretirement benefit plans are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Health care cost trend rate assumed for next year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7.90</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.80 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate to which the cost trend rate is assumed to decline</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4.50</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year that the trend rate reaches the ultimate trend rate</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2040</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2038</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Savings Plans</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company also maintains defined contribution savings plans in the U.S. The Company matches a percentage of each employee’s contributions consistent with the provisions of the plan for which the employee is eligible. Total employer contributions to these plans in 2024, 2023 and 2022 were $215 million, $199 million and $175 million, respectively.</span></div> <div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The net periodic benefit cost (credit) for pension and other postretirement benefit plans consisted of the following components:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:27.035%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.973%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.134%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.134%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.973%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.134%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.134%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.134%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.469%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Postretirement Benefits</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">373</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">372 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">243</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">283 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">30</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">537</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">526 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">457 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">294</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">299 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">56</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(826)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(735)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(753)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(554)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(517)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(383)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(80)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service (credit) cost</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss (gain) amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">43</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net periodic benefit cost (credit)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">132</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">425 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(25)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(84)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 373000000 326000000 372000000 243000000 196000000 283000000 30000000 32000000 48000000 537000000 526000000 457000000 294000000 299000000 145000000 56000000 63000000 46000000 826000000 735000000 753000000 554000000 517000000 383000000 80000000 64000000 86000000 0 -1000000 -32000000 -13000000 2000000 -14000000 -43000000 -49000000 -57000000 -43000000 0 -128000000 -5000000 3000000 -96000000 51000000 42000000 43000000 5000000 3000000 2000000 1000000 0 1000000 4000000 0 0 0 -8000000 -12000000 0 1000000 0 0 1000000 1000000 0 -28000000 -239000000 1000000 5000000 -1000000 0 0 0 132000000 155000000 425000000 -25000000 -29000000 129000000 -84000000 -61000000 -93000000 <div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized information about the changes in plan assets and benefit obligations, the funded status and the amounts recorded at December 31 is as follows:</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:43.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.453%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other<br/>Postretirement<br/>Benefits</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,804</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,094 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,562</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,473 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,045</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">947 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">266</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,077 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">637</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">832 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Company contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">262</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">198</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">249 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effects of exchange rate changes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(522)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">283 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(615)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(497)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(256)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(89)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(177)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">36</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets December 31</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,717</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,804 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,647</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,562 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,040</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,045 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit obligation January 1</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,446</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,854 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,042</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,755 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,104</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,157 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">373</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">243</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">30</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">537</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">526 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">294</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">299 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">56</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actuarial (gains) losses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(595)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">403 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(549)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">766 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">32</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(615)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(497)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(256)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(89)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effects of exchange rate changes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(473)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan amendments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(56)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(177)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">36</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit obligation December 31</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,151</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,446 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,274</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,042 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,136</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,104 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Funded status December 31</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(434)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(642)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,373</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">520 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(96)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">26</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,785</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,019 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">51</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(405)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(593)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(394)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(480)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(140)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Actuarial (gains) losses primarily reflect changes in discount rates.</span></div> 9804000000 9094000000 9562000000 8473000000 1045000000 947000000 266000000 1077000000 637000000 832000000 35000000 115000000 262000000 307000000 198000000 249000000 46000000 74000000 0 0 -522000000 283000000 0 0 615000000 497000000 250000000 256000000 89000000 95000000 0 177000000 14000000 53000000 0 2000000 0 0 36000000 34000000 3000000 6000000 9717000000 9804000000 9647000000 9562000000 1040000000 1045000000 10446000000 9854000000 9042000000 7755000000 1104000000 1157000000 373000000 326000000 243000000 196000000 30000000 32000000 537000000 526000000 294000000 299000000 56000000 63000000 595000000 -403000000 549000000 -766000000 -32000000 58000000 615000000 497000000 250000000 256000000 89000000 95000000 0 0 -473000000 288000000 -4000000 1000000 0 0 -56000000 14000000 0 0 0 -8000000 0 1000000 0 0 5000000 3000000 1000000 0 4000000 0 0 177000000 14000000 53000000 0 2000000 0 0 36000000 34000000 3000000 6000000 10151000000 10446000000 8274000000 9042000000 1136000000 1104000000 -434000000 -642000000 1373000000 520000000 -96000000 -59000000 26000000 0 1785000000 1019000000 51000000 107000000 55000000 49000000 18000000 19000000 7000000 8000000 405000000 593000000 394000000 480000000 140000000 158000000 18100000000 19100000000 10000000000.0 10300000000 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Information related to the funded status of selected pension plans at December 31 is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.075%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension plans with a projected benefit obligation in excess of plan assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Projected benefit obligation</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,517</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,446 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,847</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,961 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,057</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,804 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,435</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,462 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension plans with an accumulated benefit obligation in excess of plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">442</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,768</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,791 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,186 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,385</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,336 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Information related to the funded status of selected pension plans at December 31 is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.075%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension plans with a projected benefit obligation in excess of plan assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Projected benefit obligation</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,517</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,446 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,847</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,961 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,057</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,804 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,435</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,462 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension plans with an accumulated benefit obligation in excess of plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">442</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,768</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,791 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,186 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,385</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,336 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 9517000000 10446000000 1847000000 2961000000 9057000000 9804000000 1435000000 2462000000 442000000 9700000000 1768000000 1791000000 0 9186000000 1385000000 1336000000 700000000 788000000 0.04 0.04 <div style="margin-bottom:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair values of the Company’s pension plan assets at December 31 by asset category are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.111%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.791%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.791%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.111%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.111%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.111%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">NAV </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">NAV </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. Pension Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">43</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">121</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">164</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investment funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets equities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">170</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,385</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,555</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,573 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,797 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging markets equities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,265</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,265</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">740 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">740 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">174</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">174</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,171</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,171</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,071 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,071 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,101</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,101</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,307 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,307 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,293</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,293</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,485 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,485 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">21</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">21</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other investments (liabilities)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan assets at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,355</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,415</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,945</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,717</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,438 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,813 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,550 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,804 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">International Pension Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">112</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">123</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">118 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investment funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets equities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">599</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,537</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">96</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,232</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">507 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,870 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">262</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,974</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">149</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,385</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,123 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,523 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">149</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">180</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging markets equities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">54</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">91</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">145</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other fixed income obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">287</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">287</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">278 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">278 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">368</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">368</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">423 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">423 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">141</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">141</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">54</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">54</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Insurance contracts </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">698</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">701</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">785 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">788 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,345</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,090</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">698</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">514</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,647</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,197 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,041 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">785 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">539 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,562 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December 31, 2024 and 2023.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The plans’ Level 3 investments in insurance contracts are generally valued using a crediting rate that approximates market returns and invest in underlying securities whose market values are unobservable and determined using pricing models, discounted cash flow methodologies, or similar techniques.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair values of the Company’s other postretirement benefit plan assets at December 31 by asset category are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">NAV </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">NAV </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investment funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets equities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">49</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">277 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">301 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging markets equities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">223 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">223 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">598</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">598</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">266</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">266</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">245 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">245 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">54</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">54</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other Investments (liabilities)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan assets at fair value</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">44</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">918</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">78</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,040</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">259 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">404 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">382 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,045 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December 31, 2024 and 2023.</span></div> 43000000 0 0 121000000 164000000 34000000 0 0 124000000 158000000 170000000 0 0 2385000000 2555000000 224000000 0 0 2573000000 2797000000 0 0 0 1265000000 1265000000 0 0 0 740000000 740000000 0 0 0 174000000 174000000 0 0 0 113000000 113000000 2171000000 0 0 0 2171000000 2071000000 0 0 0 2071000000 0 2101000000 0 0 2101000000 0 2307000000 0 0 2307000000 0 1293000000 0 0 1293000000 0 1485000000 0 0 1485000000 0 21000000 0 0 21000000 0 21000000 0 0 21000000 -29000000 0 0 0 -29000000 109000000 0 0 0 109000000 0 0 2000000 0 2000000 0 0 3000000 0 3000000 2355000000 3415000000 2000000 3945000000 9717000000 2438000000 3813000000 3000000 3550000000 9804000000 112000000 0 0 11000000 123000000 98000000 0 0 20000000 118000000 599000000 3537000000 0 96000000 4232000000 507000000 3257000000 0 106000000 3870000000 262000000 2974000000 0 149000000 3385000000 234000000 3123000000 0 166000000 3523000000 23000000 8000000 0 149000000 180000000 23000000 8000000 0 166000000 197000000 54000000 0 0 91000000 145000000 44000000 0 0 66000000 110000000 8000000 7000000 0 4000000 19000000 9000000 8000000 0 3000000 20000000 0 0 0 12000000 12000000 0 0 0 10000000 10000000 287000000 0 0 0 287000000 278000000 0 0 0 278000000 0 368000000 0 0 368000000 0 423000000 0 0 423000000 0 141000000 0 0 141000000 0 160000000 0 0 160000000 0 54000000 0 0 54000000 0 61000000 0 0 61000000 0 1000000 698000000 2000000 701000000 0 1000000 785000000 2000000 788000000 0 0 0 0 0 4000000 0 0 0 4000000 1345000000 7090000000 698000000 514000000 9647000000 1197000000 7041000000 785000000 539000000 9562000000 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below provides a summary of the changes in fair value, including transfers in and/or out, of all financial assets measured at fair value using significant unobservable inputs (Level 3) for the Company’s pension plan assets:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.611%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.237%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance<br/>Contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Insurance<br/>Contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Pension Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance January 1</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual return on plan assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relating to assets still held at December 31</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relating to assets sold during the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases and sales, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance December 31</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">International Pension Plans</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">785</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">785</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">761 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">761 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual return on plan assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relating to assets still held at December 31</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases and sales, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance December 31</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">698</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">698</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">785 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">785 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0 3000000 3000000 0 4000000 4000000 0 -2000000 -2000000 0 -2000000 -2000000 0 2000000 2000000 0 2000000 2000000 0 -1000000 -1000000 0 -1000000 -1000000 0 2000000 2000000 0 3000000 3000000 785000000 0 785000000 761000000 0 761000000 -26000000 0 -26000000 77000000 0 77000000 -61000000 0 -61000000 -53000000 0 -53000000 698000000 0 698000000 785000000 0 785000000 0 0 0 5000000 5000000 0 0 0 13000000 13000000 3000000 0 0 46000000 49000000 24000000 0 0 277000000 301000000 0 0 0 24000000 24000000 0 0 0 80000000 80000000 0 0 0 3000000 3000000 0 0 0 12000000 12000000 41000000 0 0 41000000 223000000 0 0 0 223000000 0 598000000 0 598000000 0 157000000 0 0 157000000 0 266000000 0 266000000 0 245000000 0 0 245000000 0 54000000 0 0 54000000 0 2000000 0 0 2000000 0 0 0 0 0 12000000 0 0 0 12000000 44000000 918000000 0 78000000 1040000000 259000000 404000000 0 382000000 1045000000 0.25 0.40 0.15 0.30 0.40 0.50 0.08 0.12 270000000 180000000 70000000 <div style="margin-bottom:3pt;margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected benefit payments are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International Pension<br/>Benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other<br/>Postretirement<br/>Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">771 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">291 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">775 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">789 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">286 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">799 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">822 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2030 — 2034</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,386 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,792 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">515 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 771000000 291000000 86000000 775000000 275000000 87000000 789000000 286000000 89000000 799000000 300000000 91000000 822000000 314000000 96000000 4386000000 1792000000 515000000 The following amounts were reflected as components of <span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">:</span><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"></td><td style="width:28.690%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.985%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.990%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Postretirement<br/>Benefit Plans</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net gain (loss) arising during the period</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">634</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(438)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(78)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prior service credit (cost) arising during the period</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">56</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">690</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(454)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(78)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss (gain) amortization included in benefit cost</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">43</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(51)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prior service (credit) cost amortization included in benefit cost</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements and curtailments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">43</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">347 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(94)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 35000000 -69000000 -42000000 634000000 -438000000 116000000 -78000000 110000000 0 0 0 0 -56000000 16000000 4000000 0 0 0 -35000000 69000000 42000000 -690000000 454000000 -112000000 78000000 -110000000 0 -43000000 0 -128000000 -5000000 3000000 -96000000 51000000 42000000 43000000 0 -1000000 -32000000 -13000000 2000000 -14000000 -43000000 -49000000 -57000000 0 36000000 251000000 -1000000 -6000000 1000000 0 -1000000 -1000000 43000000 35000000 347000000 -9000000 -7000000 83000000 -94000000 -92000000 -101000000 <div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company reassesses its benefit plan assumptions on a regular basis. The weighted average assumptions used in determining U.S. pension and other postretirement benefit plan and international pension plan information are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:33.144%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.189%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.189%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.189%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.189%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.189%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.196%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Pension and Other<br/>Postretirement Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International Pension Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net periodic benefit cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.30</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.50 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.00 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.40</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.90 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.50 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected rate of return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7.75</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.00 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.20</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Salary growth rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4.60</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.20</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.30</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.40</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.00 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Benefit obligation</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.70</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.30 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.50 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.70</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.40 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.90 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Salary growth rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4.80</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.40</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.30 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.30 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.50</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.40 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.30 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 0.0530 0.0550 0.0300 0.0340 0.0390 0.0150 0.0775 0.0700 0.0670 0.0520 0.0500 0.0370 0.0460 0.0460 0.0460 0.0320 0.0320 0.0290 0.0530 0.0530 0.0500 0.0340 0.0330 0.0300 0.0570 0.0530 0.0550 0.0370 0.0340 0.0390 0.0480 0.0460 0.0460 0.0310 0.0320 0.0320 0.0540 0.0530 0.0530 0.0350 0.0340 0.0330 0.0770 0.0775 <div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The health care cost trend rate assumptions for other postretirement benefit plans are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Health care cost trend rate assumed for next year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7.90</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.80 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate to which the cost trend rate is assumed to decline</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4.50</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year that the trend rate reaches the ultimate trend rate</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2040</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2038</span></td></tr></table></div> 0.0790 0.0780 0.0450 0.0450 215000000 199000000 175000000 Other (Income) Expense, Net<div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other (income) expense, net, consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(415)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(365)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(157)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,271</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,146 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">962 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exchange losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">227</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">370 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Income) loss from investments in equity securities, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(340)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,419 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net periodic defined benefit plan (credit) cost other than service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(633)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(498)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(279)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(460)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">153 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(681)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(24)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">466 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,501 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other, net (as reflected in the table above) in 2024 includes $170 million of income related to the expansion of a collaboration agreement with Daiichi Sankyo (see Note 4). Other, net, in 2023 includes a $572.5 million charge related to settlements with certain plaintiffs in the Zetia antitrust litigation (see Note 10).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest paid was $1.3 billion in 2024, $1.1 billion in 2023 and $937 million in 2022.</span></div> <div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other (income) expense, net, consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(415)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(365)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(157)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,271</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,146 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">962 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exchange losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">227</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">370 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Income) loss from investments in equity securities, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(340)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,419 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net periodic defined benefit plan (credit) cost other than service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(633)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(498)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(279)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(460)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">153 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(681)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(24)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">466 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,501 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span>Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. 415000000 365000000 157000000 1271000000 1146000000 962000000 -227000000 -370000000 -237000000 14000000 340000000 -1419000000 -633000000 -498000000 -279000000 460000000 -153000000 681000000 24000000 -466000000 -1501000000 170000000 -572500000 1300000000 1100000000 937000000 Taxes on Income<div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A reconciliation between the effective tax rate and the U.S. statutory rate is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"></td><td style="width:35.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.078%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.078%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.078%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.371%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Tax Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. statutory rate applied to income before taxes</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,186</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">397 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,453 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Differential arising from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,301)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(6.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(941)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(49.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,821)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax settlements and statute lapses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(557)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">R&amp;D tax credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(214)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory donations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(71)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Charges for certain research and development asset acquisitions </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">554</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">54</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">52</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GILTI and the foreign-derived intangible income deduction</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">462 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition-related costs, including amortization</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of Prometheus</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">80</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,803</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,512 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80.0 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,918 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.7 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Where applicable, the impact of changes in uncertain tax positions is reflected in the reconciling items above. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company’s remaining transition tax liability under the Tax Cuts and Jobs Act (TCJA) of 2017, which has been reduced by payments and the expected utilization of foreign tax credits, was a net liability of $518 million at December 31, 2024, which is comprised of a $1.2 billion tax liability included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income taxes payable,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> offset by $702 million of foreign tax credits included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">that Merck expects to be applied upon the completion of the IRS’s examination of the Company’s tax returns for the 2017 and 2018 federal tax years. As a result of the transition tax under the TCJA, the Company is no longer indefinitely reinvested with respect to its undistributed earnings from foreign subsidiaries and has provided a deferred tax liability for foreign withholding taxes that would apply. The </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Company remains indefinitely reinvested with respect to its financial statement basis in excess of tax basis of its foreign subsidiaries. A determination of the net deferred tax liability with respect to this basis difference is not practicable. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The foreign earnings tax rate differentials in the tax rate reconciliation above primarily reflect the impacts of operations in jurisdictions with different effective tax rates than the U.S., particularly Ireland, the Netherlands and Switzerland, as well as Singapore and Puerto Rico which operate under tax incentive grants (which begin to expire in 2025), thereby yielding a favorable impact on the effective tax rate compared with the U.S. statutory rate of 21%. The Company has an additional Cantonal tax holiday in Switzerland that provides for a tax rate reduction and is effective through 2032. The Company’s income that is subject to tax incentive grants and the Cantonal tax holiday in Switzerland is subject to the global minimum tax provision of the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Organization for Economic Cooperation and Development (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">OECD) Pillar 2, effective in 2024.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income before taxes consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,849)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,622)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,011 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21,785</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,511 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,433 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">19,936</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,889 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,444 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Taxes on income consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Current provision</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">944</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">928 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,123</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,435 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,164 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,052</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,411 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,486 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Deferred provision</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,475)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,559)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,510)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">212</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(233)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(107)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,249)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,899)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,568)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,803</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,512 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,918 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred income taxes at December 31 consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.921%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product intangibles and licenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">71</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">978</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,308 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">R&amp;D capitalization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,062</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,099 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">84</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">413</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">370 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">645</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">626 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Undistributed foreign earnings</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">275</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">371</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">90</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pensions and other postretirement benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">224</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">400</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">323 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">249 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compensation related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">400</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">357 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrecognized tax benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">152</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating losses and other tax credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">910</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">868 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">802</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">159</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">755 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,980</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,056</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,711 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,958 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(710)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(656)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred taxes</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,270</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,056</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,055 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,958 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,214</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,097 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,601</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,968 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred Income Taxes</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,387</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">871 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has net operating loss (NOL) carryforwards in several jurisdictions. As of December 31, 2024, $324 million of deferred tax assets on NOL carryforwards relate to foreign jurisdictions. Valuation allowances of $264 million have been established on these foreign NOL carryforwards and other foreign deferred tax assets. In addition, the Company has $586 million of deferred tax assets relating to various U.S. tax credit carryforwards and NOL carryforwards. Valuation allowances of $446 million have been established on these U.S. tax credit carryforwards and NOL carryforwards. </span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income taxes paid in 2024, 2023 and 2022 consisted of:</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">974</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,258 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,891 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,954</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,080 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,348 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,928</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,338 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,239 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes TCJA transition tax payments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tax benefits relating to stock option exercises were $26 million in 2024, $12 million in 2023 and $45 million in 2022. </span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,384</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,835 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,529 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions related to current year positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">421</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">553 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">344 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions related to prior year positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(528)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance December 31</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,261</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,384 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,835 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Amount in 2024 reflects a reduction of $451 million resulting from the expiration of the statute of limitations related to the 2019 and 2020 federal tax return years. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If the Company were to recognize the unrecognized tax benefits of $2.3 billion at December 31, 2024, the income tax provision would reflect a favorable net impact of $2.2 billion.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is under examination by numerous tax authorities in various jurisdictions globally. The Company believes that it is reasonably possible that the total amount of unrecognized tax benefits as of December 31, 2024 could decrease by up to approximately $22 million in the next 12 months as a result of various audit closures, settlements or the expiration of the statute of limitations. The ultimate finalization of the Company’s examinations with relevant taxing authorities can include formal administrative and legal proceedings, which could have a significant impact on the timing of the reversal of unrecognized tax benefits. The Company believes that its reserves for uncertain tax positions are adequate to cover existing risks or exposures. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest and penalties associated with uncertain tax positions amounted to an expense of $51 million in 2024, $131 million in 2023 and $54 million in 2022. These amounts reflect the beneficial impacts of various tax settlements. Liabilities for accrued interest and penalties were $437 million and $388 million as of December 31, 2024 and 2023, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2024, the Company recorded a benefit of $519 million due to a reduction in reserves for unrecognized income tax benefits resulting from the expiration in 2024 of the statute of limitations for assessments related to the 2019 and 2020 federal tax return years. The Internal Revenue Service (IRS) is currently conducting examinations of the Company’s tax returns for the years 2017 and 2018, including the one-time transition tax enacted under the TCJA. If the IRS disagrees with the Company’s transition tax position, it may result in a significant tax liability. The IRS is also currently conducting examinations of the Company’s tax returns for the years 2021 and 2022. In addition, various state and foreign tax examinations are in progress and for these jurisdictions, the Company’s income tax returns are open for examination for the period 2009 through 2024.</span></div> <div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A reconciliation between the effective tax rate and the U.S. statutory rate is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"></td><td style="width:35.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.078%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.078%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.078%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.371%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Tax Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. statutory rate applied to income before taxes</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,186</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">397 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,453 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Differential arising from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,301)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(6.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(941)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(49.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,821)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax settlements and statute lapses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(557)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">R&amp;D tax credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(214)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory donations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(71)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Charges for certain research and development asset acquisitions </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">554</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">54</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">52</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GILTI and the foreign-derived intangible income deduction</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">462 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition-related costs, including amortization</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of Prometheus</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">80</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,803</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,512 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80.0 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,918 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.7 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div>Where applicable, the impact of changes in uncertain tax positions is reflected in the reconciling items above. 4186000000 0.210 397000000 0.210 3453000000 0.210 -1301000000 -0.065 -941000000 -0.498 -1821000000 -0.111 -557000000 -0.028 0 0 -10000000 -0.001 202000000 0.010 214000000 0.113 117000000 0.007 71000000 0.004 65000000 0.035 52000000 0.003 -39000000 -0.002 -117000000 -0.062 -110000000 -0.007 554000000 0.028 253000000 0.134 0 0 54000000 0.003 70000000 0.037 108000000 0.007 52000000 0.003 41000000 0.022 11000000 0.001 29000000 0.001 -80000000 -0.043 462000000 0.028 18000000 0.001 42000000 0.022 -3000000 0 0 0 2139000000 1.133 0 0 80000000 0.004 -13000000 -0.007 -3000000 0 2803000000 0.141 1512000000 0.800 1918000000 0.117 518000000 1200000000 702000000 <div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income before taxes consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,849)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,622)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,011 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21,785</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,511 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,433 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">19,936</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,889 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,444 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -1849000000 -15622000000 1011000000 21785000000 17511000000 15433000000 19936000000 1889000000 16444000000 <div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Taxes on income consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Current provision</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">944</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">928 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,123</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,435 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,164 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,052</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,411 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,486 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Deferred provision</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,475)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,559)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,510)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">212</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(233)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(107)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,249)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,899)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,568)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,803</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,512 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,918 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 944000000 928000000 2265000000 3123000000 2435000000 1164000000 -15000000 48000000 57000000 4052000000 3411000000 3486000000 -1475000000 -1559000000 -1510000000 212000000 -233000000 71000000 14000000 -107000000 -129000000 -1249000000 -1899000000 -1568000000 2803000000 1512000000 1918000000 <div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred income taxes at December 31 consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.921%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product intangibles and licenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">71</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">978</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,308 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">R&amp;D capitalization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,062</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,099 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">84</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">413</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">370 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">645</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">626 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Undistributed foreign earnings</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">275</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">371</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">90</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pensions and other postretirement benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">224</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">400</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">323 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">249 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compensation related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">400</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">357 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrecognized tax benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">152</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating losses and other tax credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">910</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">868 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">802</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">159</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">755 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,980</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,056</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,711 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,958 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(710)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(656)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred taxes</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,270</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,056</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,055 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,958 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,214</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,097 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,601</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,968 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred Income Taxes</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,387</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">871 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 71000000 978000000 1308000000 3062000000 2099000000 84000000 413000000 86000000 370000000 645000000 626000000 275000000 371000000 76000000 118000000 90000000 73000000 224000000 400000000 323000000 249000000 400000000 357000000 152000000 147000000 910000000 868000000 802000000 159000000 755000000 214000000 5980000000 3056000000 4711000000 2958000000 710000000 656000000 5270000000 3056000000 4055000000 2958000000 2214000000 1097000000 3601000000 1968000000 1387000000 871000000 324000000 264000000 586000000 446000000 <div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income taxes paid in 2024, 2023 and 2022 consisted of:</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">974</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,258 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,891 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,954</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,080 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,348 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,928</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,338 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,239 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes TCJA transition tax payments.</span></div> 974000000 2258000000 1891000000 2954000000 2080000000 1348000000 3928000000 4338000000 3239000000 26000000 12000000 45000000 <div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,384</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,835 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,529 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions related to current year positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">421</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">553 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">344 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions related to prior year positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(528)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance December 31</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,261</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,384 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,835 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span>Amount in 2024 reflects a reduction of $451 million resulting from the expiration of the statute of limitations related to the 2019 and 2020 federal tax return years. 2384000000 1835000000 1529000000 421000000 553000000 344000000 35000000 91000000 48000000 33000000 20000000 40000000 18000000 23000000 6000000 528000000 52000000 40000000 2261000000 2384000000 1835000000 451000000 2300000000 2200000000 22000000 51000000 131000000 54000000 437000000 388000000 519000000 Earnings per Share<div style="margin-bottom:6pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The calculations of earnings per share (shares in millions) are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income Attributable to Merck &amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">17,117</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">365 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,519 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,532</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,537 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,532 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common shares issuable </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average common shares outstanding assuming dilution</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,541</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,547 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,542 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic Earnings per Common Share Attributable to Merck &amp; Co., Inc. Common Shareholders</span></div></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6.76</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.14 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.73 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6.74</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.14 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.71 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Issuable primarily under share-based compensation plans.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2024, 2023 and 2022, 6 million, 5 million and 2 million, respectively, of common shares issuable under share-based compensation plans were excluded from the computation of earnings per common share assuming dilution because the effect would have been antidilutive.</span></div> <div style="margin-bottom:6pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The calculations of earnings per share (shares in millions) are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income Attributable to Merck &amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">17,117</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">365 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,519 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,532</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,537 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,532 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common shares issuable </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average common shares outstanding assuming dilution</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,541</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,547 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,542 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic Earnings per Common Share Attributable to Merck &amp; Co., Inc. Common Shareholders</span></div></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6.76</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.14 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.73 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6.74</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.14 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.71 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Issuable primarily under share-based compensation plans.</span></div> 17117000000 17117000000 365000000 365000000 14519000000 14519000000 2532000000 2537000000 2532000000 9000000 10000000 10000000 2541000000 2547000000 2542000000 6.76 0.14 5.73 6.74 0.14 5.71 6000000 5000000 2000000 Other Comprehensive Income (Loss)<div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Changes in each component of other comprehensive income (loss) are as follows:</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.996%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Employee<br/>Benefit<br/>Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> Foreign Currency<br/>Translation<br/>Adjustment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance at January 1, 2022, net of taxes</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">144 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(2,743)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1,830)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(4,429)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">684 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(584)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(143)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">541 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(603)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(775)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(446)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(612)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">253 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(359)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">335 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(603)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(339)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance at December 31, 2022, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(2,408)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(2,433)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(4,768)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(413)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(282)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">125 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(327)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(157)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(237)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(292)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(187)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(236)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(385)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(393)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance at December 31, 2023, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(2,793)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(2,344)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(5,161)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">508</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">647</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(559)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">596</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(109)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(138)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(224)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">399</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">509</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(536)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">372</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(168)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(208)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">52</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(133)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(43)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(156)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">266</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">466</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(516)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">216</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance at December 31, 2024, net of taxes</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">242</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(2,327)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(3)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(2,860)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(4,945)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Primarily relates to foreign currency cash flow hedges that were reclassified from</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> (see Note 6).</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes net amortization of prior service cost, actuarial gains and losses, settlements and curtailments included in net periodic benefit cost (see Note 13).</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes pension plan net loss of $3.0 billion and $3.5 billion at December 31, 2024 and 2023, respectively, and other postretirement benefit plan net gain of $400 million and $500 million at December 31, 2024 and 2023, respectively, as well as pension plan prior service credit of $174 million and $141 million at December 31, 2024 and 2023, respectively, and other postretirement benefit plan prior service credit of $61 million and $95 million at December 31, 2024 and 2023, respectively.</span></div> <div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Changes in each component of other comprehensive income (loss) are as follows:</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.996%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Employee<br/>Benefit<br/>Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> Foreign Currency<br/>Translation<br/>Adjustment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance at January 1, 2022, net of taxes</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">144 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(2,743)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1,830)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(4,429)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">684 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(584)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(143)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">541 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(603)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(775)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(446)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(612)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">253 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(359)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">335 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(603)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(339)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance at December 31, 2022, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(2,408)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(2,433)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(4,768)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(413)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(282)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">125 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(327)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(157)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(237)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(292)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(187)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(236)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(385)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(393)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance at December 31, 2023, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(2,793)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(2,344)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(5,161)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">508</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">647</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(559)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">596</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(109)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(138)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(224)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">399</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">509</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(536)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">372</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(168)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(208)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">35</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">52</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(133)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(43)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(156)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">266</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">466</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(516)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">216</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance at December 31, 2024, net of taxes</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">242</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(2,327)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(3)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(2,860)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(4,945)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Primarily relates to foreign currency cash flow hedges that were reclassified from</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> (see Note 6).</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes net amortization of prior service cost, actuarial gains and losses, settlements and curtailments included in net periodic benefit cost (see Note 13).</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes pension plan net loss of $3.0 billion and $3.5 billion at December 31, 2024 and 2023, respectively, and other postretirement benefit plan net gain of $400 million and $500 million at December 31, 2024 and 2023, respectively, as well as pension plan prior service credit of $174 million and $141 million at December 31, 2024 and 2023, respectively, and other postretirement benefit plan prior service credit of $61 million and $95 million at December 31, 2024 and 2023, respectively.</span></div> 144000000 -2743000000 -1830000000 -4429000000 684000000 70000000 -584000000 170000000 143000000 -12000000 19000000 150000000 541000000 82000000 -603000000 20000000 775000000 -329000000 0 446000000 163000000 -76000000 0 87000000 612000000 -253000000 0 359000000 -71000000 335000000 -603000000 -339000000 73000000 -2408000000 -2433000000 -4768000000 114000000 -413000000 17000000 -282000000 24000000 -86000000 -63000000 -125000000 90000000 -327000000 80000000 -157000000 237000000 64000000 -9000000 292000000 50000000 6000000 0 56000000 187000000 58000000 -9000000 236000000 -97000000 -385000000 89000000 -393000000 -24000000 -2793000000 -2344000000 -5161000000 508000000 647000000 -559000000 596000000 109000000 138000000 -23000000 224000000 399000000 509000000 -536000000 372000000 168000000 60000000 -20000000 208000000 35000000 17000000 0 52000000 133000000 43000000 -20000000 156000000 266000000 466000000 -516000000 216000000 242000000 -2327000000 -2860000000 -4945000000 3000000000.0 3500000000 -400000000 -500000000 -174000000 -141000000 -61000000 -95000000 Segment Reporting<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company’s operations are principally managed on a product basis and include two operating segments, Pharmaceutical and Animal Health, both of which are reportable segments. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. A large component of pediatric and adolescent vaccine sales are made to the U.S. Centers for Disease Control and Prevention Vaccines for Children program, which is funded by the U.S. government. Additionally, the Company sells vaccines to the Federal government for placement into vaccine stockpiles. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors, animal producers, farmers and pet owners.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales of the Company’s products were as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pharmaceutical:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">17,872</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,610</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">29,482</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,114 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,897 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25,011 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,686 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,251 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20,937 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">626</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">685</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,311</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">607 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">592 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">584 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">532 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">705</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">305</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,010</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">657 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">303 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">960 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">579 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">876 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Welireg</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">466</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">43</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">509</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue - Reblozyl </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">303</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">68</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">371</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">168 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">212 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vaccines</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,425</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,158</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,583</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,083 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,803 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,886 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,065 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,832 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,897 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">ProQuad/M-M-R II/Varivax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,919</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">566</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,485</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,837 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">531 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,368 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,724 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">518 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,241 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Vaxneuvance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">461</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">347</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">808</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">561 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">665 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">RotaTeq</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">472</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">239</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">711</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">493 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">769 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">508 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">783 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Pneumovax </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">56</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">207</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">263</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">285 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">346 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">256 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">602 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hospital Acute Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Bridion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,401</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">363</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,764</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,156 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">686 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,842 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">922 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">762 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,685 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">371</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">414</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">785</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">341 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">605 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">240 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">428 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Dificid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">303</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">37</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">340</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">274 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">302 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">241 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">263 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Zerbaxa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">146</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">106</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">252</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">119 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Noxafil</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">170</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">177</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">213 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">187 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Winrevair</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">408</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">419</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue - Adempas/Verquvo </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">388</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">27</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">415</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">367 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">329 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">341 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adempas</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">287</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">287</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Virology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">176</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">787</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">964</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,418 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,428 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,523 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,161 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,684 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Isentress/Isentress HD</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">185</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">209</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">394</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">215 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">268 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">483 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">274 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">359 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">633 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Delstrigo</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">56</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">193</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">249</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">201 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Pifeltro</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">113</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">50</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">163</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">118 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Belsomra</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">72</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">150</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">222</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">150 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">231 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">179 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">258 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Simponi</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">543</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">543</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">710 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">710 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">706 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">706 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Remicade</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">114</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">114</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">187 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">187 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Januvia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">469</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">865</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,334</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,151 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,039 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,189 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,248 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,565 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,813 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Janumet</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">161</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">774</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">935</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">954 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,177 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">355 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,344 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other pharmaceutical </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">729</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,782</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,510</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">658 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,675 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,333 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">663 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,803 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,462 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Pharmaceutical segment sales</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">30,290</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">27,110</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">57,400</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26,539 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27,044 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">53,583 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24,989 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27,016 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52,005 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Animal Health:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Livestock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">732</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,729</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,462</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,637 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,337 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">710 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,590 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Companion Animal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,129</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,287</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,415</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,104 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,184 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,112 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,138 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Animal Health segment sales</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,861</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,016</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,877</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,804 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,821 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,625 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,822 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,728 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,550 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">32,151</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">31,126</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">63,277</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28,343 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30,865 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59,208 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26,811 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30,744 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57,555 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">126</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">765</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">891</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">770 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">907 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">395 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,333 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,728 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">32,277</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">31,891</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">64,168</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28,480 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31,635 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60,115 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27,206 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32,077 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59,283 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">U.S. plus international may not equal total due to rounding.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">    Alliance revenue for Lynparza and Lenvima represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 4).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">    Alliance revenue for Reblozyl represents royalties and, for 2022, also includes a payment received related to the achievement of a regulatory approval milestone (see Note 4).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">    Alliance revenue for Adempas/Verquvo represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 4).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">    Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(5)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities which increased sales by $195 million, $244 million and $810 million in 2024, 2023 and 2022, respectively, as well as revenue from third-party manufacturing arrangements (including sales to Organon). Other for 2024, 2023 and 2022 also includes $106 million, $118 million and $165 million, respectively, related to upfront and milestone payments received by Merck for out-licensing arrangements. </span></div><div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Consolidated sales by geographic area where derived are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">32,277</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,480 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,206 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,041</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,254 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,493 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,494</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,802 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,191 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,459</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,086 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,582 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,280</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,164 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,629 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia Pacific (other than China and Japan)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,058</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,225 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,614 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,559</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,104 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,568 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">64,168</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,115 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,283 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A reconciliation of segment profits to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income Before Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.143%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.271%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.271%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.271%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.271%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.271%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.271%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.271%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.271%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pharma-ceutical</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Animal Health</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pharma-ceutical</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Animal Health</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pharma-ceutical</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Animal Health</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Segment sales</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">57,400</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,877</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">63,277</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">53,583 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,625 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59,208 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52,005 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,550 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57,555 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Less segment costs:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,828</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,469</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,849 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,498 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,678 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,259 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling, general and administrative</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,128</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,084</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,903 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,038 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,474 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">999 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">385</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">353 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">329 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other segment items</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(89)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total segment profits</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">44,533</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,938</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">46,471</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">38,880 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,737 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40,617 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36,852 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,963 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">38,815 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other profits</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">492</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">474 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,160 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unallocated:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">415</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">365 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,271)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,146)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(962)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,395)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,044)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,085)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,843)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,625)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,642)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(17,350)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(30,008)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(13,011)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(309)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(599)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(337)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Charge for Zetia antitrust litigation settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(573)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other unallocated, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(4,274)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,572)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,651)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,936</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,889 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,444 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">The significant expense categories and amounts align with the segment level information that is regularly provided to the chief operating decision maker.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">Human health-related research and development expenses incurred by Merck Research Laboratories are not allocated to segment profits as noted below. </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">Includes equity (income) loss from affiliates and other miscellaneous non-operating expenses. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as selling, general and administrative expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as selling, general and administrative expenses and research and development costs directly incurred by the segment. The chief operating decision maker (Merck’s Chief Executive Officer) uses segment profit to allocate resources predominately during the planning and forecasting process. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred by Merck Research Laboratories, the Company’s research and development division that focuses on human health-related activities, or general and administrative expenses not directly incurred by the segments, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. In addition, costs related to restructuring activities, as well as the amortization of intangible assets and amortization of purchase accounting adjustments are not allocated to segments. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other profits are primarily comprised of miscellaneous corporate profits, as well as operating profits (losses) related to third-party manufacturing arrangements.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other unallocated, net, includes expenses from corporate and manufacturing cost centers, intangible asset impairment charges, gains or losses on sales of businesses, expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration, and other miscellaneous income or expense items.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity income from affiliates and depreciation included in segment profits is as follows:</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.643%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.643%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.646%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Animal Health</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Year Ended December 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Equity income from affiliates</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">144</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">144</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">256</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">261</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity income from affiliates</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">198 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">203 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity income from affiliates</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Property, plant and equipment, net, by geographic area where located is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.357%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,724</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,915 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,891 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,548</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,562 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,993 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia Pacific (other than China and Japan)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">982</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,022 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">966 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">202</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">143</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">133</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">47</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">23,779</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,051 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,422 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company does not disaggregate assets on a products and services basis for internal management reporting and, therefore, such information is not presented.</span></div> 2 <div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales of the Company’s products were as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pharmaceutical:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">17,872</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,610</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">29,482</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,114 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,897 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25,011 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,686 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,251 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20,937 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">626</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">685</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,311</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">607 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">592 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">584 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">532 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">705</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">305</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,010</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">657 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">303 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">960 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">579 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">876 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Welireg</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">466</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">43</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">509</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue - Reblozyl </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">303</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">68</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">371</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">168 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">212 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vaccines</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,425</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,158</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,583</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,083 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,803 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,886 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,065 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,832 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,897 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">ProQuad/M-M-R II/Varivax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,919</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">566</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,485</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,837 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">531 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,368 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,724 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">518 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,241 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Vaxneuvance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">461</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">347</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">808</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">561 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">665 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">RotaTeq</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">472</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">239</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">711</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">493 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">769 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">508 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">783 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Pneumovax </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">56</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">207</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">263</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">285 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">346 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">256 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">602 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hospital Acute Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Bridion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,401</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">363</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,764</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,156 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">686 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,842 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">922 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">762 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,685 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">371</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">414</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">785</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">341 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">605 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">240 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">428 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Dificid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">303</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">37</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">340</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">274 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">302 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">241 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">263 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Zerbaxa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">146</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">106</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">252</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">119 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Noxafil</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">170</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">177</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">213 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">187 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Winrevair</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">408</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">419</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue - Adempas/Verquvo </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">388</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">27</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">415</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">367 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">329 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">341 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adempas</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">287</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">287</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Virology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">176</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">787</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">964</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,418 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,428 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,523 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,161 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,684 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Isentress/Isentress HD</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">185</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">209</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">394</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">215 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">268 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">483 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">274 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">359 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">633 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Delstrigo</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">56</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">193</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">249</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">201 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Pifeltro</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">113</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">50</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">163</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">118 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Belsomra</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">72</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">150</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">222</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">150 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">231 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">179 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">258 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Simponi</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">543</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">543</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">710 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">710 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">706 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">706 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Remicade</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">114</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">114</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">187 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">187 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Januvia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">469</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">865</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,334</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,151 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,039 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,189 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,248 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,565 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,813 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Janumet</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">161</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">774</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">935</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">954 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,177 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">355 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,344 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other pharmaceutical </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">729</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,782</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,510</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">658 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,675 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,333 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">663 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,803 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,462 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Pharmaceutical segment sales</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">30,290</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">27,110</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">57,400</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26,539 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27,044 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">53,583 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24,989 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27,016 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52,005 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Animal Health:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Livestock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">732</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,729</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,462</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,637 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,337 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">710 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,590 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Companion Animal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,129</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,287</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,415</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,104 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,184 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,112 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,138 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Animal Health segment sales</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,861</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,016</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,877</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,804 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,821 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,625 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,822 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,728 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,550 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">32,151</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">31,126</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">63,277</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28,343 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30,865 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59,208 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26,811 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30,744 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57,555 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">126</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">765</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">891</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">770 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">907 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">395 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,333 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,728 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">32,277</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">31,891</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">64,168</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28,480 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31,635 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60,115 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27,206 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32,077 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59,283 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">U.S. plus international may not equal total due to rounding.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">    Alliance revenue for Lynparza and Lenvima represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 4).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">    Alliance revenue for Reblozyl represents royalties and, for 2022, also includes a payment received related to the achievement of a regulatory approval milestone (see Note 4).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">    Alliance revenue for Adempas/Verquvo represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 4).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">    Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.</span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(5)    </span>Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities which increased sales by $195 million, $244 million and $810 million in 2024, 2023 and 2022, respectively, as well as revenue from third-party manufacturing arrangements (including sales to Organon). Other for 2024, 2023 and 2022 also includes $106 million, $118 million and $165 million, respectively, related to upfront and milestone payments received by Merck for out-licensing arrangements. 17872000000 11610000000 29482000000 15114000000 9897000000 25011000000 12686000000 8251000000 20937000000 626000000 685000000 1311000000 607000000 592000000 1199000000 584000000 532000000 1116000000 705000000 305000000 1010000000 657000000 303000000 960000000 579000000 297000000 876000000 466000000 43000000 509000000 209000000 10000000 218000000 123000000 0 123000000 303000000 68000000 371000000 168000000 43000000 212000000 123000000 43000000 166000000 2425000000 6158000000 8583000000 2083000000 6803000000 8886000000 2065000000 4832000000 6897000000 1919000000 566000000 2485000000 1837000000 531000000 2368000000 1724000000 518000000 2241000000 461000000 347000000 808000000 561000000 103000000 665000000 163000000 7000000 170000000 472000000 239000000 711000000 493000000 276000000 769000000 508000000 275000000 783000000 56000000 207000000 263000000 127000000 285000000 412000000 346000000 256000000 602000000 1401000000 363000000 1764000000 1156000000 686000000 1842000000 922000000 762000000 1685000000 371000000 414000000 785000000 264000000 341000000 605000000 188000000 240000000 428000000 303000000 37000000 340000000 274000000 28000000 302000000 241000000 22000000 263000000 146000000 106000000 252000000 119000000 100000000 218000000 89000000 79000000 169000000 7000000 170000000 177000000 32000000 181000000 213000000 51000000 187000000 238000000 408000000 11000000 419000000 0 0 0 0 0 0 388000000 27000000 415000000 350000000 16000000 367000000 329000000 12000000 341000000 0 287000000 287000000 0 255000000 255000000 0 238000000 238000000 176000000 787000000 964000000 10000000 1418000000 1428000000 1523000000 4161000000 5684000000 185000000 209000000 394000000 215000000 268000000 483000000 274000000 359000000 633000000 56000000 193000000 249000000 49000000 152000000 201000000 39000000 111000000 151000000 113000000 50000000 163000000 101000000 41000000 142000000 87000000 30000000 118000000 72000000 150000000 222000000 81000000 150000000 231000000 79000000 179000000 258000000 0 543000000 543000000 0 710000000 710000000 0 706000000 706000000 0 114000000 114000000 0 187000000 187000000 0 207000000 207000000 469000000 865000000 1334000000 1151000000 1039000000 2189000000 1248000000 1565000000 2813000000 161000000 774000000 935000000 223000000 954000000 1177000000 355000000 1344000000 1700000000 729000000 1782000000 2510000000 658000000 1675000000 2333000000 663000000 1803000000 2462000000 30290000000 27110000000 57400000000 26539000000 27044000000 53583000000 24989000000 27016000000 52005000000 732000000 2729000000 3462000000 700000000 2637000000 3337000000 710000000 2590000000 3300000000 1129000000 1287000000 2415000000 1104000000 1184000000 2288000000 1112000000 1138000000 2250000000 1861000000 4016000000 5877000000 1804000000 3821000000 5625000000 1822000000 3728000000 5550000000 32151000000 31126000000 63277000000 28343000000 30865000000 59208000000 26811000000 30744000000 57555000000 126000000 765000000 891000000 137000000 770000000 907000000 395000000 1333000000 1728000000 32277000000 31891000000 64168000000 28480000000 31635000000 60115000000 27206000000 32077000000 59283000000 195000000 244000000 810000000 106000000 118000000 165000000 <div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Consolidated sales by geographic area where derived are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">32,277</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,480 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,206 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,041</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,254 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,493 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,494</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,802 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,191 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,459</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,086 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,582 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,280</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,164 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,629 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia Pacific (other than China and Japan)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,058</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,225 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,614 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,559</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,104 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,568 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">64,168</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,115 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,283 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 32277000000 28480000000 27206000000 14041000000 13254000000 14493000000 5494000000 6802000000 5191000000 3459000000 3086000000 2582000000 3280000000 3164000000 3629000000 3058000000 3225000000 3614000000 2559000000 2104000000 2568000000 64168000000 60115000000 59283000000 <div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A reconciliation of segment profits to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income Before Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.143%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.271%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.271%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.271%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.271%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.271%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.271%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.271%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.271%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pharma-ceutical</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Animal Health</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pharma-ceutical</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Animal Health</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pharma-ceutical</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Animal Health</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Segment sales</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">57,400</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,877</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">63,277</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">53,583 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,625 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59,208 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52,005 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,550 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57,555 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Less segment costs:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,828</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,469</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,849 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,498 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,678 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,259 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling, general and administrative</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,128</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,084</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,903 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,038 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,474 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">999 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">385</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">353 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">329 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other segment items</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(89)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total segment profits</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">44,533</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,938</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">46,471</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">38,880 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,737 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40,617 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36,852 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,963 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">38,815 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other profits</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">492</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">474 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,160 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unallocated:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">415</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">365 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,271)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,146)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(962)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,395)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,044)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,085)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,843)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,625)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,642)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(17,350)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(30,008)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(13,011)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(309)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(599)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(337)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Charge for Zetia antitrust litigation settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(573)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other unallocated, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(4,274)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,572)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,651)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,936</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,889 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,444 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">The significant expense categories and amounts align with the segment level information that is regularly provided to the chief operating decision maker.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">Human health-related research and development expenses incurred by Merck Research Laboratories are not allocated to segment profits as noted below. </span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">    </span>Includes equity (income) loss from affiliates and other miscellaneous non-operating expenses. 57400000000 5877000000 63277000000 53583000000 5625000000 59208000000 52005000000 5550000000 57555000000 6828000000 2469000000 8849000000 2498000000 9678000000 2259000000 6128000000 1084000000 5903000000 1038000000 5474000000 999000000 0 385000000 0 353000000 0 329000000 89000000 -1000000 49000000 1000000 -1000000 0 44533000000 1938000000 46471000000 38880000000 1737000000 40617000000 36852000000 1963000000 38815000000 492000000 474000000 1160000000 415000000 365000000 157000000 1271000000 1146000000 962000000 2395000000 2044000000 2085000000 1843000000 1625000000 1642000000 17350000000 30008000000 13011000000 309000000 599000000 337000000 0 -573000000 0 4274000000 3572000000 5651000000 19936000000 1889000000 16444000000 <div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity income from affiliates and depreciation included in segment profits is as follows:</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.643%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.643%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.646%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Animal Health</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Year Ended December 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Equity income from affiliates</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">144</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">144</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">256</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">261</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity income from affiliates</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">198 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">203 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity income from affiliates</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 144000000 0 144000000 5000000 256000000 261000000 111000000 0 111000000 5000000 198000000 203000000 39000000 0 39000000 5000000 177000000 182000000 <div style="margin-bottom:3pt;margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Property, plant and equipment, net, by geographic area where located is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.874%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.357%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,724</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,915 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,891 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,548</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,562 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,993 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia Pacific (other than China and Japan)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">982</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,022 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">966 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">202</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">143</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">133</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">47</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">23,779</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,051 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,422 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 14724000000 13915000000 12891000000 7548000000 7562000000 6993000000 982000000 1022000000 966000000 202000000 193000000 207000000 143000000 133000000 135000000 133000000 222000000 225000000 47000000 4000000 5000000 23779000000 23051000000 21422000000 PricewaterhouseCoopers LLP Florham Park, New Jersey false false false false true 238

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

/V_;%O%O#I+\WUD.8VCO-(43(52+DPB+TE4=)==SZ=?G M,F.(,.#ZSGCM+%S5.Z0AS,=3YN/!YK,=8ZHY;KJPJ@5T\^W^PI067-;[4N,A MSHUXRH6\ENN=#H\F_C_)#1-2*9(U+>4C,(:%V?F'J+09%DW/4'F$Y^ O&AZF M(H2HM!D63<]3"8<'.T*/1:.%U'5TAS"G=WZ#?+]B[PL6L"^T+Q,M +E,C!MR M0I4.+)J>DY(.#S:%'BL%#&I<*5!E XNFIZ5DPX-EPSUT?$O?EUS'&!:J7J#2 M9E@T/4.E%]X >N&AZ@4J;89%T_-4>N&AZ44+J>OH#F%.[_R&$ I/"87W7J%H M 90K14-.J$Z!1=._D:>$ M4_C**?SW.D4+H%HIS#FA.@463<]I[\O;6$[1 FI<*7"_OSV$4_C**7S8*>Q# M]ZV?N\:C3S"G]\R&ZA18-#U#Y13^ $[AHSH%*FV&1=/S5$[AHSE%"ZGKZ YA M3N_\AG *7SF%_UZG: '(E8*XP=08%*I48-'TNUDY** $LJ6D"-*P6J5 M]+3V;@O5=J)B\G9?\HR'GV!.[YD-]QY10TA%H*0B&$ J E2I0*7-L&AZGDHJ M C2I:"%U'=TAS.F=WQ!2$2BI"-XK%2V 8M#G%Y.U)/]^X4L"2]3M$"*%>*AIQ0G0*+IN>DG&*" MY10MH,:5 M4IL&AU6N.]NV^7WYVO[F)>D+B\VU%](^[=L[L[I4^K^X./U7UG.[J)9X4#F )F^\$&KN MY5J7,]]7:0ZR@**V0P_K2: M7G>D#3R=']77+G>3RY8JN)?%3Y;I?.[=>22#':T*_2SKK]#F,[%ZJ2R4^Y*Z M\0T_>22ME):\#38$G(EFI&_M/9P&W%X("-N T'$W!SG*%=4TCE#6!*VW4;,3 MEZJ+-G!,V)_RHM'L,A.GXT65,4T>1/-[S3U%OC:R=M-/6XEE(Q%>D!B&Y%$* MG2OR1620_2_@&YX.*CQ"+<->Q16D S(:WI P",<]>J,NR9'3&UV;)/FUV"J- MYDG\/I=OHS8^KV;+9*9*FL+<,W6@ %_!BS]^&$Z#SSVLXXYUW*?>L$HD3Y3# M.;;^Z 19"C75@+FL[%LUU8N*;#9)#]JD0YMT#7NN._4$L#!!0 ( %V"65KA[\T"\@0 !,3 8 >&PO M=V]R:W-H965T&ULK5C;;N,V$/T50ETL-D#6$G57UC80VRFZ M0+,-XMWVH>@#+=&V$$ET23I._[XDI<@R1:D!FI=8ES-'+,EM$1?,UFUF.] @7 M..62 HF?9[S$12&9A!]_-Z16^TUIV+U^9?]9B1=B-HCA)2G^R#.^GUFQ!3*\ M1<>"/Y+3+[@1%$B^E!1,_06G!NM8(#TR3LK&6'A0YE7]BUZ:0'0,8#A@X#8& MKF[@#QAXC8'W5@._,?!59&HI*@XKQ-%\2LD)4(D6;/)"!5-9"_EY)?.^YE2\ MS84=GR])Q4B19XCC#*RY^!%)Y8!LP=B>PBB'X;1'^,?;Y&!3;6 M9FT6*C/9"Y_GH0_#>&H_=^-@0#D0!I>H51\5)&[LM:@+SX/6\V T_4O".+L& M=R^BHS/, *HR\!O?8VI2$[QG\M^3;/5.9!%H1&% A=$.M" RHR(?07 11JR :+U^Q_^75[AKL<(4I*E05H$ST_5RV M KE%FG1%?5^<&&H>+TVHP/$U72:4X[MF77&K*Q[5]2ARC6BZ5WHR_"S&C8/L M<28QL2&PB:>OU#[*=:U!A8TX:MJX3GUVM MQ;FC@IKIH(%%B,^!M_1B[FS-2P784T23V\!)E@C#O"C2!1BX_*!3>I<*SI,&'-V%Y[]BQF[ 60>X MY9SFFR-'FP(#3L W(IY7G!*U&PD4QV*W-K>YYEN7Q:*K-6!ZV>ICAKK<>1Z MXP/!B,1[3-,G\!&5AR]@22;7$CH_H@/AZ[-(B<&&W)T6&*9/;!,A$ M+2!:.?11S@3J@X@!%4RB@2D;GB<1.#Z*C$2)L6,I MZWV5%T=U*/&FHOF_(8M-(>OMK7V4*61]E B9OKG:G=."$M.=.G5A8O,\5KS^ MY[M]VI[LW*KS#.WY0I[XJ%.(,TU]7'2/Z"ZO&"CP5E ZDT@L:UJ?P-0WG!S4 MF<2&<$Y*=;G'2(1. L3[+2'\]49^H#T'F_\+4$L#!!0 ( %V"65J53S&Z MS , ,8, 8 >&PO=V]R:W-H965T&ULK5??C^(V$/Y7 MK/1TVI46\I, >X"T0*N>U+U;W?;:AZH/)AG 7<=.;0/;^^MK)R$'BDYA-^$Y1PN!)(+G+,BS^FP/EAZGC.\>-+V2S M56;#G4URO(%G4%_S)Z%7;HV2D@R8))PA >NI\^#?+WW/.!06?Q XR)-[9*BL M.'\QBX_IU/',B8!"H@P$UI<]+(!2@Z3/\6\%ZM0QC>/I_1']EX*\)K/"$A:< M_DE2M9TZ(P>EL,8[JK[PPZ]0$1H8O(136?RB0V7K.2C92<6SREF?(".LO.+7 M2H@3!S^^X!!4#D'3(;K@$%8.X5L=HLHA*I0IJ10Z++'"LXG@!R2,M48S-X68 MA;>F3YC)^[,2^BG1?FJVX$QR2E*L($7/2E]T4A7B:[3@F:ZDK4GQ'M!'EO , MT,UO7,I;U$-?GY?HYMTM>H<(0X^$4IU$.7&5/I(!=I,J_+P,'UP([P?HD3.U ME>AGED)Z#N!J+C6AX$AH'G0B+B'IH]"_0X$71)8#+=[N'EK5>YCB!J:.!)8@].+/W/_FQ]\&F MW#7!EE<".U,UJE6-NM!GGW0_K>1[4$J0U4[A%06D.'H$D;R@]SC+/VB]^W?& MKF]3MHP0%Q%,<]W/_*'O#R?N_E2RME48#\YMEA:D:."/:ZLSBH.:XJ"S<#ZK M+8C.=]B(H(OJ=_P*\M[&<'#-VKDFV/)*8&?"QK6P\0]K9\?T)Y:2;[IEDDI3 M6FBJ/V0I"++'YF,F[Q K-1:04"PE69,$JTN-L@P[."F#((X;Y=2VZ8T;);>T MV Q]>S$-:\[#3LYS8+ F"N44LX+31@\41\Z8I2@7A.MA0DM-$D")@%1;WR1< MJMM:!)QQHLH_59FW[9(=[0 M^:O YZT_#!NT%A:S7C!J<+=A1?[(:[!W3P:\#,2F&)2ESM^.J7(TJG?K8?RA M&$$;^W,SI!>#XW>8W&YSP< "PA 8 M >&PO=V]R:W-H965T&ULM5IK;]LZ$OTKA&_0[06<6"3U M3!,#;;*/ FDW:'IW/S,2'0N51%^*2IK]]3N45,L6'\D"V0^M;?F0.C.>F3-# MY>))R!_MEG.%?M95TUXNMDKMSE>K-M_RFK5G8L<;^&8C9,T4?)0/JW8G.2OZ M176U(D$0KVI6-HOU17_M5JXO1*>JLN&W$K5=73/Y_(E7XNER@1>_+GPK'[9* M7UBM+W;L@=]Q]B!_ZP^?B\JO1.P.//<=/%_IYZX>'[7[O_K3<> MC+EG+;\2U;_+0FTO%^D"%7S#NDI]$T__X*-!D=XO%U7;_X^>1FRP0'G7*E&/ MBX%!73;#*_LY.N)@ 0X="\BX@+QV 1T7T-[0@5EOUC53;'TAQ1.2&@V[Z3>] M;_K58$W9Z)_Q3DGXMH1U:GTEFE949<$4+] G5K$FY^BN#Z!3],?=-7I_\CLZ M066#OI15!8YO+U8*[JM7K_+Q'I^&>Q#'/:YY?H8H7B(2D-"R_.KUR^GQ\A58 MNS>9[$TF_7[497(G)6\4^MBV7%G-&=:']O4ZL<[;'IAJ[C?2F?_XQI3 M$I*+U>.A.28J3D.\!QW1#/_QDF:CI_I[S8K(\,"') DG=EI0]$PLUL:[RV-O99^ M!O\W2LB2M^@]_YE770'ORH.KVIYPB3-Z;!)=TG!O%S!46PBV*VIYB]&$2> M),[,)([IC)>)<28Q#B:M"[R5_U9"^R/5\Q+=@M"I/G#_"D5QIZFB]TRA7+3* M&H_CSF^D"6^UV[$?#C0?>W^?&S#<:B0VHR&8EU<;B,2.GV;29.S5P?6GKJR* MLGFPMQ?$+'4QC8,Y,PLLS&(7MTE$L5]%O[!\"Y$IV0U=,Q3CG10/$%1VJJ9V)ED: MSIF:J)3$KNR<-!;[17;*SMT^._DKL]/4PI!DU"!N@6&*$P?S23.Q7S1OP)WG M6O&[NJOZ3KK@D+AYR;33K81-Z<(9CJ(Y80L,7.V*Z$GCL%_DO*Y>(NALK*1- M.2,T2>:J;(4%D:-'Q)/N8;_P_5V(X@F&$"LU4\= QN)YRV2%X8;_@ M#4W#YT:QYJ&$YK!=HJ\.'YK"!J4L,4J9!98&V.%#,BD@\2K+2-0S^006>D$X M3R0;#&>9(R[))$S$+TQ#;^.A9VH/Q@DV^BX;+HCC)'(0/!@=7S<[WI3LOJQ* M!0VQE>?;3I#_CQ&23/)'_/)W(UC3HAU[[L>>?IHA@FN MX/?6R">FOI$XG!=\->NA#N$A9K"%H?QO&VTH-(D??HSMMDV,Z[WU?0AV;/RDK]2OK$,$[5A:GP#5GNQ)JF)6E]>PV MF)=6*RP*'-6?3M)*_=+ZC2L&EV#.83"M.T9U:NIC3(-XKOX66$33S%'_Z22C MU"^C'P\FR%'^10U!N]6/S1XY-%GVL9V:@GD:9J%1%BRP",>N(C8)*_4+ZV'R M_Z6?(]4SNN<;(3ET@\5X]*!/QY7DK.WD\Y M5E,LRAJ$,9YW^!9<%@749FNIZ]Q=UZTGN]BPQJ+X292Z'B)-BA_Z%5_+ MJ&B4%!5\\Z#'<0[N=SQ(,N4\FJ>Y#>/HF\))\@==R/Z0W$&7F$\-;1.Y#6>;R%<'C[+UWQ%\8?*AA/&S MXAM8&)PE8+$<'LT/'Y38]4^W[X52HN[?;CD,>U(#X/N-$.K7!_W ?/\'$NO_ M E!+ P04 " !=@EE::: LD1(# # " & 'AL+W=O0[@0XBM533>E$-E76[F'9A$D.L M.G%F.]#NU^_8H1$?@5)I7!#;.>?U,5*>'-G(L"*^B*A2TK07!FG IF>XX3V06FI94,S=A$)$->*T9+,A%( MUD6!Q"!+G*E!^QD6.$%F1+U6$T$].Q6):,%*27E)1)D/K*N MW:MQ7]L;@Q^4K.1&&^E(9IP_ZRCB?4>BEGTORC56,; MQ19*:ZEXL78&@H*6S1,_K_.PX> &!QR\M8-WJH._=O!-H V9">L6*YP,!5\A MH:U!33=,;HPW1$-+O8I3)> M!3^5C'DI.:,95B1#-YCA,B5H:NKG?((%*55. M%$TQNT"?T./T%IV?7: S1$MT3QF#A9!#6P&'5K/3]9PWS9S>@3EO2=I#OGN) M/,<+.MS'I[O[V^XV1-^FP&M3X!D]_X#>5$'P4)@*\3GZ0DM( <4,3;BDIM)^ M7<^D$E!OO[M";;2#;FV]!Z]DA5,RLF"322*6Q$H^?G CYW-7X/]);"L-?IL& M_YAZJ7G-8)^EO"Y5YS(W@I$1U,?%,ND/AO9R,Z(.DWYK MLL49M)S!4H5(%@A'3#!GLD@3OP=W#WC7P_ M. Q+PHH(]C*Z=,EJK! 2\QJ@LX!.N.,82%1!>@RA_UVT87>Z,<; M5$XOW"$_;K,%'K7@T3O <:UR+NA?R+8F-[2R$[=1#3=0HM!9_W:H3S+=@H]; M^/@=\ TMHE+6;_/'>U!^&,>NXX>>M\-_DND6?[_E[Q_E_PYWLJRARK .] MO\?C.L$@B"*W'^^@=YJ&00QG\F 'W=ZX7_3=?H_%@I82,3('9Z<7@XIH[LNF MHWAEKIP95W"!F68.GQA$: -X/^=PN"=#8N@18NR!9MP_#/B@2$PO1Q97HI/WWHV3%LDB: ML9>#?JDO.><]O+PBJ:?6Z5-9/=1+2AGZGF=%?39:,K;Z.)G4\9+F47U2KFC! M_W)75GG$^,?J?E*O*AHE;5*>38AA.),\2HO1^6G[W55U?EJN6986]*I"]3K/ MH^K'!+UGSQ>3\=!7=TQO*OJZN*OYILE5)TIP6=5H6J*)W M9Z-/^&-(IDU"&_%72I_JG?>HZ=E]G>:L.79:#I"";V+UAF[+I]"VG7( M;O3B,JO;?]'3)M:>C5"\KEF9=\F\!7E:;%ZC[]U ["1@Q+<+L$5^["OPK1+:.TRV4Q' M.Y>+B$7GIU7YA*HFFJLU;UI#M-E\"M.B\>X-J_A?4Y['SN=E49=9FD2,)NB& M\1=N3(;*.^1]6Z?L!QJCKS<+].[->_0&I07ZG&89]UQ].F&\>J,QB;M*%YM* M9$^E/TL698JTN3YM7N8Y]_@-*^,'1?9"G_T'6](*745I,KXLT#Q:I>I&>'J9 M:\KX,L!'R(NJ(BWN5=WW]1*?XGB=K[-VG#>MXCWCR\VR60<>*?J]K%6JP0N# MRM>K>EW]V#L^H3[_2UF,45P6K"KYO!;WZ+)@M*(U$]HRX;;:>HMLO45:<6N/ M^ 6]3XMFN/CJDD5%3%'$T(+&)\C$'Q Q"%:Y:*/IM)K-ROMX;DZ)[9Y.'G=- M(T=A=SH=!BWD(,LBIA#ER5&VZB[2M.-8]D&(>I)A_ MR%@$D!5#(+&!>9RM>1RM>>91O41)^I@FM$AJ?DL39U'%SU_\/!EOCI7UGF/3 MA2,/E(M-2W"-MORQKH$4\PYJOP]9,H 4"X'$!K9QM[9Q7]RSNC4F$O:LHBQV M3\NI^K2\L9 K38%XB-4VXUC[0(IYD&(^I%@ *1;JIFA@G>G6.E.M=19IO3%, MT58_UC-R06P)!3W(@CZD M6""WWB&&<*<.5'!@!6ST<,[0FL$K$@T^(4H(9TB]LAS#%J#'7!&F "@J,K;<;2)0.DOJ)I_T'@$H#5#*+6A MBWJTB_5L]Q5X!K2+]6QW M^Y^7K4U0W=SYU&BUKN)E<_NC](T"8&+34]"I*8M,0 MF0XHP@55"Q0=,*>VN$D!E1QZHL>X6,]Q]>C.5%I!!I*FZYB2&13458'NY"C+ MLL5?(GF*,-N7%>=&4=527X6DAZ7$^(GHCFC)[+'H M#E1M :KF@:KYH&H!J%H(I38T:,^6B18-@J"[KL3PXL=8^GDD*"H&5?,.ZX(/ M6C0 50NAU(9&VOE=K9X! ^ [(A-4@L7;:'TSCG81* (&5?,/&8X M&0(I3;T M4(^ B1X!OP+>$07J=&>6R'[U#3C:/:#L][ N^*!% U"U$$IMZ)\>_A(]_/T? M\(XHB"F_\9!6'5#H"ZKF@:KYH&K!8<,;0A4=^J:'OD0/?8'@'9%)I;Q]@5)@ M4#4/5,T'50M U4+]3 U=U"-@HD? B>XI+=%36CV1LY3SNU$% M%&%C:V;9XCV+(LR>FH8TX'*9)RX?+JJ MS;/BFP^L7+5/'M^6C)5Y^W9)HX1630#_^UU9LN&PO=V]R:W-H965T&ULK57?;]HP$/Y7K&S:6JDCY$=IUT&D IVVATJH:-O#M <3'\2J8Z>V@?:_ MW]D)&72AZD-?8M_YON]\9_O+<*OTO2D +'DLA32CH+"VN@I#DQ=04M-3%4A< M62I=4HNF7H6FTD"9!Y4BC/O]05A2+H-LZ'TSG0W5V@HN8::)692:%B.@NOH:IJZ>!_PD\/6 M[,V)JV2AU+TSOK-1T'<; @&Y=0P4APU,0 A'A-MX:#B#-J4#[L]W[%]][5C+ M@AJ8*/&+,UN,@LN ,%C2M;!W:OL-FGK.'5^NA/%?LJUC!W% \K6QJFS N(.2 MRWJDCTT?]@#1X @@;@#QGG3 IZ^'QR]4D[3'D7B^Y C?P0G,KQ.0JY,17,8!:@1!O0&@NS#NVC0_]+5 MN;,G+$C7&N'Z>$<8WG(%D!O4A%WB/&3GADC ET#"D M EU?[].N!M>)+GPB)ZF;+.E%>/*;_<;]'Q3W/@\.@Z9=09=M3%UGN/>P2] K M+Y"&Y&HM;?U$6F^KP==>>I[YQZC-M93^HZF%_9;J%9>&"%@B9;]W<1X078ME M;5A5>?E8*(MBY*<%_E] NP!<7RIE=X9+T/ZQLK]02P,$% @ 78)96B2C M"J"_"0 -2X !@ !X;"]W;W)K&BD)27_OH>4+(H H>( MW*I?;"TOCO >; \ GCZ5U8]ZH51#GO.LJ,]&BZ99?AR/ZW2AJ@&_N MRRJ7#;RM'L;ULE)RWA;*LS$+@FB<2UV,SD_;SVZJ\]-RU62Z4#<5J5=Y+JN7 M2Y653V5/!NO(TRU[DJ:ET6I%+W9Z,+ M^C$1L2G0*OZNU5.]\YH8*W=E^<.\N9Z?C0)3(Y6IM#$A)/Q[5#.59282U./G M)NAH^YNFX.[KU^B?6O-@YD[6:E9F_]#S9G$VFHS(7-W+5=9\*Y\^JXVAT,1+ MRZQN_Y*GC388D715-V6^*0PUR'6Q_B^?-XG8*4"C@0)L4X#9!<1 ;XIP/R47-RV\ _:-2&E/=D)NL%^03]HB8GY/MM0MX=O2='1!?DB\XR:+/Z=-Q M#4R<<;KYMD'PNDQ M80$32(5F^Q?G2/%D_^+,XX9O6X.W\?A0:W0YOZ_*G'Q=JDHVNG@@%V9\Z$8K M-.OKJ */:J:.C_52INIL!'-#K:I'-3K_\Y]H%/P%R]@A@R4'"M;+IMAF4_BB MG_\.TZ8NTC)76,[69:.VK)D='\]I3#ET@L?=9+@J'L=]38)$$B&+MJI>Y<-M MY4-O5[B8_PM&OQF,-6E*F&+3LDAUIDBQ=64^-^]2TVN65?FH84R1NQ=2;KN- MW':;CU@.PD/VFT,&2PX4K)?Z:)OZR-MO+O*R:O2_I5F8L*RM2X<[[UC[VU3Q2D)-6#M8_=WZ2!5;&9*Z(3-K%JCXH$7OO) MMO83;^VOBT86#_H..KJL:]/5\Z745;LHI0M9/> 3X,2I"I]:EEQ)/&66(U=# M8S'%'4VWCJ9>1^^NV\'ZGF1EO9G6=?&H7L-[A)_J+X7:O MJ@KFW=23:C>D(JH[<<512*TW;BB4- !+QU,42]=G']M%JI"*\[=GZ.!77%7 MQ$.GXJZ(\F"HYAVX4.%=_ VYP&Q7F,$$8Z@=*G4[@C(M[W0VO*)3+Q*]=4D_ M:+3D4-'Z2>V BGJAX?PB353Z4<(:@V8P=$<6LU?N&::"*<=>(C%9 M) ;62-H!"O43RC4L($535@/; >IRQ.&'JWR$&\R.&6=S:@XZ;G2WKOB<=S"4% MZ$&1/600&:S+@=- B&P:3(=:J",/]K9SG.L6^/=P=]"#G(-&2PX5K9_2#HF8 M_S!G)I>ZD1E1S\"D<]VLJH$4"F0EX+&]8*"R261/JIA,\,D 9K..19B?16Y6 ML"4"R*[-26NW\=M90G;VB*A-!"Q"ZLQ2B&KJ0"RFHBP8H!3640KS4PJ,[U2I M^68,U!+V].#V5LD'5<"02#^8'49>%J1NRO0'ZM*%#QO3$0EPF&/1%ZAOKT,8 MYD<8U]Y_WYHNF#C'C#-$1*/0)DY$%;,!7&,=XK!?(VNOK(/^#=>$4ZAW %L1&;CG%?2-]KQ#O/SCFTTDP! MY*+0.H)Q8VA" JVZ]7TO?;L1/W MLY/E]\M?3V@@PO40GJTJ^/1F(:LF!"58] GZ1OLZ(K[ MZ]ZY-?,?]%B> MKW/Y4!J[MQN[;W7K'NHX;ET)#&IFWPQY(_7-=B#$_2 T2/\<815J5VF&J;C- MQ9AH:)_,.^CA?NC9@O_WNCTOW1N+.0(H<T8RS^"\:2+^MK$AC9B$0^(@#[IA#9&)BWW,EF&Q*ARZ#Q<[#-WY. MN;J_5VD+7%?/Z[LL\@UV3&2VN=>"&=VX/U[GX IP[!&VT,7FGNL;@$&E4[/# M,M^C:4 @A4V=!WABB,%T?^LL_E:S( M.UVDV6H.'>4HFAR3HWC:ECV*J9%478AT$^(W6:PD+$";9P'7C_2U9<>F MR%*U3YEF+\=D$[T==U][=S;KR];W:-[=4Z1HZN8=.9%B<>QT.E. MF(2?F-Z6]RMS0N5F/(Z.3=HW&9\.9!QZM,KO('7\_YGSM=W>TW6<4_O 'Y&Y M39-@P7I-LT[Z>.=YVEQ5#^USR35I[RK7CZ9N/]T^^WS1/O%K?7Y)/R;K)YB[ M,.L'JK_("GI\33)U#R&##S'T@VK]C/+Z35,NVZ=V[\JF*?/VY4)) !$C@._O MR[)Y?6-^8/ND^/E_ %!+ P04 " !=@EE:B0ZY;F4" #L!@ &0 'AL M+W=OX]S'>VD>M49@"'O MN2CTV,N,*4>4ZB2#G.FN+*' E954.3,X5&NJ2P4L=:1,_7Q $+NQI[O[2>>^3HS=H+&4_5'%SO&LF0:)E+\XJG)QMZ=1U)8L8TPSW+W'>IX;JU> M(H5V7[*KL,.A1Y*--C*OR7B"G!=5R][K/!P0_/X)0E 3@G,)84T(SR7T:T+_ M7,)M37"ATRIVE[@I,RR.E-P19=&H9CLN^XZ-^>*%O2<+HW"5(\_$$UEH*7C* M#*1D8;#!2V"(7)$)TQEYQ'NDR?6<*9S-P/"$B1ORA;PLIN3ZZH9<$5Z0)RX$ MFJXC:O!$5IX/U>[!B=VGD'1)Z'=(T OZ+?3)^?2PA3X]GQZTT&?GT_UC M.D47&BN"QHK Z84G]$YE__?]4AN%?]2?M@17FOUV35ME1KID"8P]+",:U!:\ M^/,G?]#[UI;N2XI-+RDVNY#8D3%A8TSX/_78>M$AB74$WC9\RP2:I#N$%2F6 M2O2&)_;OL8 VARKQ@1.W97L;#P<1W1[F_5_(X.X8,FU1^7H,F;5 _ 9214X/ M*H5]!YZ86O-"$P$K)/6Z0ZPNJJJMU<#(TA6/I318BEPWP^<(E 7@^DI*LQ_8 M>M0\&PO=V]R:W-H M965T%<;:Q[]+64@3TUVOA% M5H?07DPF7M2RX?[4MM+@2VE=PP->737QK9.\B$J-GLRGTW>3ABN3+:_BV;U; M7MDN:&7DO6.^:QKNMC=2V\TBFV7#P3=5U8$.)LNKEE?R089?VWN'M\EHI5"- M-%Y9PYPL%]GU[.+FG.2CP&]*;OS>,Z-(5M8^TLN78I%-"9#44@2RP/&WEK=2 M:S($&'_W-K/1)2GN/P_6/\78$WEK]>^J"/4B^Y"Q0I:\T^&;W7R6?3QO MR9ZPVL=?MNEEIQD3G0^VZ96!H%$F_?.G/@^O49CW"O.(.SF**#_RP)=7SFZ8 M(VE8HX<8:M0&.&6(E(?@\%5!+RQ_YJ%SDMF2?6VEXY0I?S4)L$S?)Z*W M17MGW['WU57!0H@R# M9W]=>&0GO&DOD;?3G'TQH.:'=&P="[7$>=-RL_V1*<\XJ[1=(7&U MY#K43'"8%$D PCR@:30ZT7FFC+%K3FTY"(.5+KD-M;-=53.%O%/"A%-M)*>1 MA1( [G/H"]T5RE1LI:RVE1*$QO%6T=>V5WPA+UU\*-:KO46G6- H1@ M6>&Z"LFU6GJNJ08)MY.!*WK+66U]JP+7!-VB2$W$1-$(U9?24 /[]0UG:T58 M<;L1;W[X2O=BD#1+T%=[,PCV>[Q;MD*.2A5ZPSTF2\D%F3ZHD%KB&3_/Z=LG M9H^(%NW"@U,B9[R@L$4,B%JBP,TU=LDKDSPVU4%6VWKKT92J M"[8/:R^I!#"HP?-!'XS%#'U!&F0*(6G;X@EPNA)3&+-J8,0]RD"C!Y@FVC8L29C#6 MKOB(,D!7DP"^E]:&X84&ULW3UIC]O(E7^%< YT ^JV MW?8DD\P!V)XCWIW#L&<2+!;[@2)+4MD\%!;9;O?LL?7G7#^_"P;FQ>-\V7?CJP6$6X;H_N@Z^V?5#6X[P MSV'_,!P'5];T4ML\O'GTZ$\/V])W#[[^DCY[-7S]93^-C>_AA7J7WKNN#[KAC<[JL' MSQ[_]?E3?)X>^+MW=\'\7>!)MGW_#O_QLO[JP2,$R#6N&G&%$OYSZUZXIL&% M (Q_RIH/XI;XHOU;5_^.S@YGV9;!O>B;?_AZ/'SUX/,'1>UVY=2,K_N[OSDY MSV>X7M4W@?Z_N.-GG\".U13&OI67X=^M[_B_Y7O!@WGA\T0O%M5[LZ7^ A !%#>/;I[>L]Z3>.(GM-Z3E?46CEG\Y[-M& ?@D/]: M.C&O]W1Y/92:OX9C6;FO'H!8!#?7SS1?'+P155_,;5QF2=Z(U\=\O^O98=J>B[.JB;!K\V,.W8=H& M7_MR0$A\5]P=?'4H2MQL'/JF04A]-SHXS%CX4* B&N%_KKXN7N+GE:R[+1L M"!;!#8#872A),< '@RM8*.W_>!'P-I=YX9P M\,?T,&V!9]P&!WOB6? <8]FA#H*O_%!?'^J:&QXE9_OQ%/ *C/AQ@L:(,Q4]]MT15(KO[YP2G0Y+> MPD?*346YV_G& ZAPE%LW"'=8=CK PL'O.[_S%: ?7MHU$Q%E.XU%UX\KO+2! MLR.CA1D<@G1"0(U@ :^>D )G/,QD+IC,@)V13CN!6AP8*[5NO*%OJG( --=% MSX3G$Q>M [+4:'E\N ;QA$^#9[Y5V7L)>(#3!.!,H /P^Q8Y&1[9B*#%=W0U MX*'[J44Q5^Y(YX13?R0X?@T1BGX/ M_+T;^I80#T<'/J#W ?OPMQN(EG@BX)??<*/1 C,MS/_!'IUR#Z @Z08-@E] M*%L*Y FEQ*SK=\5QZ+ 7E")J#6(.:_)S TU M<$!SVF22VY8G/KRP&IR3L:&Z#J3L3W(8K2<1J 1$$I=('*&;3J(%PM% ! +UG_$56)@\@&&^&"!3M MSURRA5U4@O=]7]_YIKDN?C$HKGK2U5TM?P%24"$.4S62I5$Y9Y4F*A"-*MB? M+O#*0/\) ;TF5P&"BD$LG@O@0(=,7^ Z48QQ(4$IB_@27C_L>I2[4?"SHIY( MO"TK1*D.BSI1J-UBY$3+HFRQHD/UF@[ &O]C-#&SHF5NI 7RHSRCTAA((,UJ MN S#!V@]T';EJC($0M).@-5^<*1(E.YQ0V6*:[(N*OUFRXWAH>X*M!FQ+;J4 MY8!V$YBE=K<0]!U)["Y>OGK]Q[(]?O'-)>MYU%X-(!AA0CLP$2NA6 !+ L\/ M>Y8^X2'A/M':8Y$+ KS"DF$0VWY^=W45;*B>0D9?A2@"+OP MPJ_7;ZZ!XYJF'("A @H.OS$F)3Z0&\3F),J4")JZN69=-(B@,D #SY9@"34[ M%FZW ^D+9U945T-PQC.4L>W*4 6OTTXD^ SN8%P($.Z?B7M1!,%KQ-@?$/@2 MW,(6E-_/+UY>ROG0R\?'08]/[<0'ZNG5*GL5'=_BHGCV\XL?BLL"I:PIG!<) M >!*,, ]O]2XD?Z.CCHY _&;Q@,G2= CRB,>[63]Y^S A#&F 7KNQ0'\^^9$ M3BCS$D1=\4&(R2QAT;C^%O4XH[-U5VP.E<.N="(-^'97-^ SKOYQBR%/""OK,J@?YD=5'@3<$S*98V-(:9CG MPA._7*KJV!!?0EA7AD/Q+5 1+"*9!)5V^L*9+\@;1S[R:+Q@Q\H-&%,J^9@7 M8,<4BQ#,@ U@;< 'F-]ID#AA9\*C\3 X0M!X"!S+=(A"9WWY]!F"0=8[JK.F MOX,#(D#H0@&GX,G >6S\;^1+BI_*P3@^@8;(,+0)6G>,WX#D;IS M C\5\ENH>$'F=] T8"[R3H!CRV+ (Y \@XN*DP7S16G#JR7P>(:HP%4V5O< ME'VC/>JV'F7I"(\ >.Z1S4KNH/U&3BZM,UNI? SCWA15H]G\:_\XU_@". M A]K .O>@0^L'@.#C1X*F89#M.FL9'<"JAHU!A#/OW=$\BCUZ+1-R0,6$&L0 MJ'A>XV0LX*@0;R3/%E@),QD$Y@#"?>VV8Q%PZ<"A-ZH:M,S*HS':33,W&\Q;\CL.F 8C.0'$PX\W ]$7N!Q M\Y! ",:SY'TR"\N< CR$QXM^>03!6 Y0X5'IVR@L H8^H <<^X%\3F6VC$RH M,7&3\CVO TY%P5KHG.TCR4'B$(45V7 C?4= (2O6M&W0S.5'DW# M8AJF A$2&E>4 BC)X!) O+=Z/1%N#%@MOM$;Z2L.\R1YD8*IWK&/SCE)#B&K M%+,"%H%*98MVXC?'@28GO73?%?R=SN,VW8J#;=PJX''Q&886HS>[Q(8TB1\U MC@ H1-^=&-.TVFB"HY0=B$MG*\)3Z%M9]7Q2OE@ZI.2-6@SR], 9)Z?4$3!@ M.:!YH'SNW'->=GXVQ#B26 MV?++2AP%Y/^%UEU3G)^&V5^[89UN:/.MPHM@UR H%;I:G#"?63+Q:U%,HX>@ MOB)$31Z=N.\7-SNONM#I$@P8_M0RX[,^QA#=EV\H1)(_7;2(U^+ M"_J:()7H.] MGW6^A3__QB%D<'L&BU)?$'QBCMVMX**X4A>_Q9R2K2E@0A(9$ 3\2&6Y8&,H MWV*">_",L)%KSR/X37H@BH>:9A%EG)LLVQ)%!CW,GO/MM"6MAT!X5E\#_!_A M3).EP4"$;D'M'):>X*0<6KF\@K1\<*;"+832&2F$:*+AF.7Z78Q-Y]*'&A:L MLJ>J9C'ZUJ$SV&E547$AYPJV7*#T5/QL5BJG1E7[P*N/?M2JE0_O-.%X5R+7 M8?0:]7*DY6RO6!W7C6!E*JLV#->Q/"&9LR.HA4;4O&)3_N='/3[_*"O\H.2%(./5X+75^D.Q1L]=B$EN#'OE)D][I&22-E\)X/"1''T$*0-X%]?&);(EJ:'[."):2W(9,AA;X,J9% MI_U!\\JT1HO]$GD=)A9+<:>D]I,UX'H,.UFF"KX7NG N5U,_:&G5Q%@-4%>) M];E2,5)]7O*/V#,=M ()4=RT+KJ!H MQ^]A67@$7)=WG72W<$UK6U;OPN4&Q4PX"LT#*_\M5U^>U;5GD=0[P.$D&X7-D8Z,>+AN@US=Q.R8L0NX7H-9[A9Y7*P"8^');I MS$5$.=8&4P.Y/ MGUP_*;:^:5B4J*]Q Q_?7'\V^_@)O8S?S%^XH9 N[4&!EH+!12=,Q+#%3NXM MYAP4;&TM"!_!QHP.P]8C^1D$0Z"5$_\GLE$$!Y@M<4?UH?EP,RS#GU+%T\><0*CP?IU MF"7LHPZ-D!HU@3KC'-5Y42%I1'/6E _G35%*M[% RBH.>\Y<+4!/1ZQH2\O! M;4(2-O<1AB05">XML&NC<8\I5@$V;Y&/(?H:>\8V)TOTDXL?@0\JI U^Q_\ M8%Y!"%Q\KZER C)->U-T"/ESG&@0JNKL9XR%.3= B3M39^7.' M=4+),B72*'?B,Q2P.9;MN!G$OU=%AE%&!8$!,(V&]>@3"^+@0:84BL+FD\ZW ML:X5OD^*JFRJJ=$& 5Z86KQ.G-$E^$\QL4 -&<*_N;&.Y +[)=P*6GV8--ER MG]HD"\))=4VV2*(%.RLI!ZPB2*F,?WCBR('M*9(50C;@)GQ9 PA$#S44P6FX58/SQM)W8)5 2N9&-#!W M*$YB,S+%U]03W*N$6/N[9DALCN39@O6DP%SVLC!RG=U6X^^PK^#W-W]Y KS% M%H9LSLWUC9JG71(\$C,LWL%.[A16U+Y]>XJ4>?_[Y?*DGG[#4D^OB9VD= M%J7!GMJJ*YHY47-/Q>C0K 6*2N@MD*LB$W15@S+$-HKX>BKV(\NYD;6LBB%5 M!I'^Z05;$\!D%V7NI!<=OO3M=AJ"XVB!M;(/3'IRZ#IN78M.(#A,ZKM].PW] MT5&]!W8:B._N?UW:B5FTH\D@>B3QC=D!50K1LHW]".P^==NIWE-Q'-5X'\42[DIMSX(_ M3CGY7C4Y6MJNMMEC431P8B\R1 V1%S&\V$B;"KE5D<1J$M! LFZZ'U3J\CD= M\5/@T"=_@EU.DM@B/74WJ8F"RV2;E#+/D@MO[$31!]QP612N-*H;0Z46^F9I4!( M<7!)GJ6:6GML^I.CK(U47E$C-K>9B=+=38NV)A@3 :V3^0I]D %;)3!<8_Y, MW#I+\(R?AD,0"(^E-&9\<*[ZB:MK$_<,FM(-FVUJZKR:*--$ MUXD#T"]0C*3C;QWM'KLU2$&Q<0TD^92O)]DGF7[$,FWZ5T63LM9(Z;NYT^ X MC^Z#N[I#W0[<_Y9Z72-6=/=V:D8!579P&@;[/HV89+,C3)?$TXVMPCY-_K.(%*5?P@NEUQ LE,NZQ.MR3C M8+H7UB9:UN8>#%B>/#>_EW[IU',P=5YBAQ204O4\-;L S:NI"'/;F)_B6:: M!C0$[&.AS.WL.[[#Y FUQ+CW'HO[$*52URJ!'Z2S!'AQE'$([<>R.0GM].)& MI<4FI3C!E^.IG!TQ[R.CVC)(V4GX?4)E,&NJ M*0'(7_B]TWG ' FF YFQ($ M=X2'<:6P2A,JPCVZR+T;@XXH1QV0P;W3VKAM'(0QU.,@_&PT9BG->3$=8[GS M#!Q=^U+F.)%;7X+X@2;9-ED/>/KLPVRM&BZ&!#Q#O.&.IZ(K6RD@'LN1&ST@ M\&";&C,#N<+4O*QM2M$:;-;1XORK%(0J/YD!VU-Z *18_5%.+'1=LUXH&G8BY; 0ID^=1J+(>!R;5CBWL*/0,8[; MJ'N,83"V0P/J*6-%XUO[H9^.W#GHI5!K>P%RAEU4/676\$G@ABB O$G>KB^E M&VF[W(A9Y(Y4*6";), ]18-S<:(FQ(A\G5"C1LY:*Z8Q*VI+8GWPKDSM:Y%N4^YDI MS?H6DVVCUBD>88I]\]'!(,QLYB6[;,HOUL= ;U98WQM==>CZIM]3P+\#&GH> M/) ,9YN2NI5QL$@C+#7A@<1Q&<-=-31O/*=IP%'\[5OI&C;LAZ: 53N.==EV M+%AX"QOVG.Q.Q0AE;RVD3(368&V?(<9Q=C0 MQ_T/,?6+U;$KHP_7N-6V!>272Q"\G,>)=UZ0X[XRR\,2$M6!>F:F>LH[C=3_ MW>& ]QXM"JMHTY.D#)D49\+$_Y8C)*:<[']N]\G82T\Z*:LS5I>S)R#/- *) M4.9DI&G^V6*97Y(IG>B79/HOM=;;CLBSV6:^440&5U]D/BZG"42X7R3A-L-I M$C.M='*4]D(("?2D54%'$W /46&:TZ'T=^9KI[A* :4*(ZGUZN!!F^F+MJ.M MQ>:_R&88XLF-T8'J2,_/]J6SH]I.3%"J["*/-_T8JV:%H'Q;FH>^Y "-G ME]4A8EL5R8W%RC"QY)VFSC3DVQM+2PVVOO3$-,=RX0I&5;Z5**MH&J\=1 MG#>JOK9FQ$O45W$Q(X\6+N6(F)<;+V/B'EOVKKBA%^-%36X/?!KIO\LLX6SK MJSNZYRJ##_N$Y^GE.:[(R)!FG3=XB_K.X*[D'HM >8O-_%#+=)-WHE=A!DL- M!Y ZT,KJAHQL2B MSBDC'+,Y-B,K%&&LK;_$*X5$V:AXV)D8L.36<_U&EPEVG9B)GET70?PB[;^K MR,\:FS_H ;U>NQY NGW.,PD_]=W@L).?RYIX:4CEDMI Z>?^5IL;8YQIO$9\ M[:-^6;VB@"8X4AMZA(>[7HFGZ8%3&KN.02CB,S[' *79_WB3BKV;(3ZM.IGN MKJK=]3J28BY4]4FZA"-F9>@E8PWG46R8I>I6L7&VV9F,V-YP,X&0*[GSRU)4 M45EU2Z7N-1:;I\O2Z?3>E ]CC.J.>I+I"#&DB%V4M<13YEAGMU[H-'LE?2W9 MF 6;7R(%1+;D'EM@0%SW0]D*=T:_^D0CW,HA2Q._+W "GH9\T"=Z9IO_5;#8 M-T6^I&2BDVLCJNS-;&R @)#B2Q:*$(YO2_9[Y#XRB@7I)!N=)V;LZ124%-;R M85YRNC((L,NGHU:9?QQBXY:?ST"@<\YE6HM=R:KJE5I^/JUL.L3I[4T<*Y<. MP8[;N^B>%?&[.2JIP?ABPPS#F"H.9Z,3$.EA:PA>WI6<0LJ(':7$MG[DO$-1 MRK8O,@@%*VSL%M;XG\04=NL?EX^3+GZBH:Y[3H1R!6+Y.\V*D7C%,U,72M33+<,;VUR5%H@/\ M\1ZQ/#&F.1^;O0H?Y&9/RECO!,B*/O=F:7&6$[CHZCG1#\D-,KK>>F$\]X8U MNO!OU#=8+HF]#E'02%F"KYX&I23+D"7\P0_OQBO*X9SG$DN:921C::*KO/_E MO(LE+ 0T%(_-B_UX.2;W3QW[@"HEA9UZ6>9"XC=+LV?R*X^C?>= MBO=+KXMOI08\=U\EPZ&#A4GKI69([LL2SS)$3A^I;1^O3M;JFKQ!G(/O"!!X M.6&V9'R 1 3=3*PAFU9X]%,!-IDJE&SQ2GB"'Z-;UT[MVC;:VH%\!+KZBK6) M(940-^1<$JGJ\X;DP?&MPR(2DG$SR]D&?W&U!%NRS6ST^&R(4;5Q)G0F\5WI MS.P/-([RC=M1,N'#4D7\ .%[GB.(R_%T2RW+,;G/YL;6>[5*SN';Q"/Q+?<* M1$;E+ETCA#$#E'DGAA7E?HZSBWWI@O%?Z/(A@$%N-DR]D3J=30_,<*[M!H)J M;%LTE^*-0'O0^\/)%%!3/)3N8A,O"K?%%5(V-LW5=#R^A%\WY9TD[-/-D.7@LIU,*V@"5V\J^70 [I7P_#(?5<:JBK(VE,\>_4$WCOO%NU9H.^S[:GE: M:QP;'><67^7\MMM[S[EZP]$GG#7>L93T,/5>Y%<$Z:'OA70N](+"["Y]\ 7* M1J_ZSLPIF"6);68<%7CB ^"7&&@N=+-Y AVB42F;BY=\!._O&] *C?6GP N_ M0I&-DG7Q_.\IC&WG)G0/>GVU=SK*46?1XIX'DY M+,W*A#:V@3!A^!;2N)F>CWQ+NB/5D_CR:!I; '"EVJOMZ0K_RWXIN.+H'.GM M>.JVS@N6P]D3*2-. \Q4:L) $)MX8N#"(Y0TSQ/OC> B#CTFQ2GQ;W_E6[2_ M%=4:/O'G*-@9<=P%P]:!"M&C9$'-[0#']!L8II&SPCOJ7;R5FEKY+[Y_]NS5 M)5^R7-IKQC7]K!P13ZR"&=49SYYE,SF9V\(J^>U4[T6&$@*T@5TF?_.+)4R& M+]:VSBRB27;;HJZTA5E_.6M_".8.ZOF-K^N]:Q>I-2RF]3?Q JQ9'\B]=T!? M9JVK)I)?KD"MEKN/O-WSC '.G"I 1'?K!^Z<*1M+QLV*+R:E^JMB MEF!(H5J:0)2?G,'Y#?EAI_0=-B4#IF1*.1\/IE]X. I3VG"PLH%D]M1"<6PS MOZ81&[2EZTA8[,)R_!+_Q29.\:3LG6&=>F[DDLR=,F]&G ]$9]K\ M8LBS:0]6GJ8EV+1_%S7DXJO/>_A/ME* M3&TT)\UWO*6;BI"7Y>=IK.]0F[Y3$5-NLURY0SJ3:_)28BY$4T SV&))(?VR M" *Q4J#,;^X-="%G3+K/U.J29@OF/IG,SQ#R4!9"06,[C#'7OTUP?IVII0(4 M"''\L91T@]? ,S\=9UJJF-G^]-]%8 \/H2+4 6?\!/J')G(-;P#5E>@&H?); M%ISOP825A!.DSW3./8V$99<0;$Q7L$YW0^!6THIFC$SN2$QM%[INRO)^ G[5 MNY.99>Q;B['J+_85%CS6JY3X%WUH(5O!N0*80JML*FX^2+>;!E)_8&I*WUA1 M?LD(7Q1'6*'X#S=&<3>2'2>J_P7ZQ58K](DP&B;[$QU&>_JM5B98O48IP>[I MO5Q@WM5V3M"?3^UKOT DD U-RY'C7^#9QL>?KC"/4 [;UW.PWH+*#[6ODC*( M9[9] "%F:P -,:=H,1'!ZF1(Y3Y4M#V7_N.PJ;OU_12:4\K$9'R0P87]+QF3 M NT^4P:-C#1[:=;JL\:F)K>TZ_L1HK9UWET.T99^Q^ZA^<'XZ>%_GCC,_[-PO0X__+CC^6PQ^'HQNW@U4?7?_[L 3<>Z#_&_DB_8+CM MQ[%OZ<^#@Q!BP ?@>SR6_@,WB#]I^?5_ U!+ P04 " !=@EE:CK%P"[L; M #)6P &0 'AL+W=O<<>*J\;&Q-SZF[&QVMUZ]'R 2DA"3!,-C9.6O?U\W !*4.)?M MI%*U&X\D FCT^76CP>\WIOA4KI6JQ.&7 MI2E26>%CL3HN\T+)F >ER?%L,CD[3J7.#IY^S]]=%T^_-W65Z$Q=%Z*LTU06 MVVK6NZ(OCI]_GJP*\:XZJG5]%OM2XU<:@_9;YG-3:IRA(\2!_5 MHJP**.#_];'($G#23P 9Y7=E+B/UPP&LKE3%C3IX^O>_3<\F3^[8WDFSO9.[ M9O_#Q?_GK2Y^7BL24BZSK8B@5#JK52DJ(_*Z*&L%^V\7XUDJ#,""6?GX!@^&<, M*I1.%]BI'U8TSQ =M-=JK8L8WQ;5]@E<28*]FTP-16&V,JFV/*0P2UV)TD3J'2M.$)HKJHE!@$G$N4D6%(""6-6N_NN%Q$/DG%7L2P,J(C F/ MTT?)9H0Q,9Y.3$Y+/6%^1A(..RE-LW&36R=.OUGA6M/RFQQWY,]#"W5#/IP9 MCX#S254@!#N,ZZBR4LMUKD@GB3SU6:;T)U:.=2PK"'ZSUI!0*K6YVL-L1!O__M8C8]?U+NKS&&94?$@9^A7:6,K V]SL0_)61:;,EQGP[%6U5$ MGUA(_Z[_H\4O,HIH9V N5H;]05TW&18NZT6I8TT#03P_^TR;Q*QTA(=IYT0> M[ [Q3#X- MQ>M")40VR\6K)]$F<\C\LX;8%*@_/#F9D!$FK-40>V)(@:P:5RUK2(YDXE%E MK8B>4[0@,7NI"VC,;V ;MDEK6-Z!)[]B0&-T4)1RZ:8C0V5401QSBY)%Q=8Q M\OIL^R1Q;\N!\3=.!?II(-$C/"LT@6(I5^]E'E/,82-G<+: M2Y+/*C$+*(VU+#90YR/(8K*:MD.467^0II@'.J9_5^+M3Z/99#H1@S=O1[/+ MRR/2F,Q@*)C&\67%=H.YKU^,ILJE5Z8>"O@C%/Q1KXS-Q)[B36KAWA3Q5B>OST:NST6*C)% M3+L4$;SKBEWFX>G%1:,$V&(3\VA;@4_T3IX"B.4K:1=Q?"<>#)T&;R2YO)@5 M);2KL2<66L5.!_M=Z47"# :)BEA_.)^TJFF=O8K6&1G5UJKF4A5^)9H(W(AT M+IV&+I2+>NQT,J>3(&BCR*#*'J4*M@KN-Z&I53;PJLYI\L-I:S:(7&H%V4%& MV[L'79P%M@;6EA(/CPC,Q_>L-CZ!W'G@6%S9>/3GZ/#)Y&(F!J\^CJ:3T_DI M:7&VI\#P[1'"%_MRH)%$E"E0"X(44IX:,OWQS?5HRF+-28_ERF1P_E9I7T&, M9BVNH8L(+0/[\1YMG0*N_]':^@^U* )U=63>I:YWJM.(O'%UKYBGIX]7JGD[ MZ-%*=>ZUJF,8P( 4K"P> QX4A+_(/[/$)$+W:CTBAYVH40Q&5'B@8EY(@>1Z M%)MZT?W)-' L ]!B"HF0/OW2+D+=J'@L_H5LS(JLB9-#+PL"+)$9X='4T!+( M\*%PR?9>'2;Q/E^3AP20 L1)&"R],MC@3\9B)_%61K+N1#"/A\(8A4#R$3J] M;X4-<,'JT\G)J1@P4"*X\/P=PL(=T3!YA#2N@MBR,(!GDS-2)1W3''#)0 =V'"7 SH_;6D; M%&K)I1UH3H]O8=HIH!?"NX#(E%5Y]#C/Y<4"8H]TGQHZG>IP#FK6HPR%)N0*11,NC'%*JXV_E MC\A:=YP0Y01ULNTW<"8:R+=)>6B>EW ID1%7&5!V(EXI4+W&-%"EG+)U#!NX M1SI#K0U6AFP#W$8^H6QN;Z/>>-YB %+LOBGLN-*RF4,UO(SD3*--__!3VH!$ MDMA-D]5D=55HZXGL3V6=N\)!:>WE-TIX(\%>22'OKS:FT4XFI844+"&;FVBK MR\]E)F/)$_^B597)]$DH9]G6(\*5YLLWDC6!_K#8"ZNUY_N+=E5-BQQ[(6G+"#!@*;EQ5"2-.4I^4 MG-0*X:$DP\\B..;2^U];DGN=WNC/4C!^HF$CV):DC6"\DHS-6G].>R7C##;+ MAKH@EA*;.K+<2,JZVF#0E!9(7AOX>O>$^Y[]=EL/XNI5+P.#H9X#S;J=,."\ M$L)IRU^RBQX.!@">F*EY,ZY&04,:/5Z3V:]IQ8J(!'5DSA%BG++&C=]"CXGQ M-IYZ7>;GX[B@R=@O9RE,/5,J;LL+I"$ZBY&'%MN=C/,+4LT01NX'F=!$FPJN M56J*_RE/NY2ZL'4=:\!<>VF=C:WP-74Z^KU.:1BYP>HVE\ U--*&!,ZP_,XZ MLTM;F888J3YF"IKN4)R=4ITG!]39#D5.^LUK*JQOV7QV1@^0C$5!YPRE&'D3 M&M2E6M:49BR5 ";=PI#AT@;3(S%'LO2>8V#>'=R. 0C:&32[G+I!G@W=W0_9 M=\_FXF=VF'"6D-@2OR?6J[M1YQ>GXD=C8BZC#&9'XG1Z(9YWO*O/)8G%AV(Z MG$_F3,&=LG&[;L/[SM8VI$PQDL^"RGFQJ%U=CBJ))E4VOLAH/10>X#$\)"FF M=4(.0A7:Q)3&D1#!EXR-'UJ\-K%5'!?#,-'"LF4[VO#Q#]8C%D2RA"<.H6F=E92K41_(M1M,^Y8 M+\%(FA7V32&=JD1.35!\&J5 :;'Y H2 EB82E8(0HNZD@Y/AHE] MN86#7I&VAM4H66A:9UGY;"'TG) 0FR34/PI!5#<\EVKE76] X$[5BW:HV(D2 M:1RMY6>JW.789]FFYK?CA9=;M= 40=;BC4ZUQ0);!5C..4%>Z!M;F%NK!)J5 MK\%'A!=RF:.EB6KRIFX"YT@C6^D<,CE "3./$L3 %JU)IF$-'F91@7HNKCO_ M3 9.]56X_!CF1RSS5>_:FL5L&4IX-/!EQS9(?#0<*FM2ZRNK@'AZG* M_0)?$+$IV9E-VT)8)T$(RX#C^6EC9U^337?R_BL':HD'I/0=CW&;_[G'DW#Q MFD]\FG1.4LD3,6MV/&\5"%/@OXHX+1F8>SD]0ILZ*-0>/_H21L"_A["KRXO^ ML(:A[PO:TG.7V[*[Y:\HC&30KLAER6G-Z$%]IMI'IZ=G%R_/[%V]%L M/[?:_J#*HAKO=#D <$5*\AYKQ\8!@ Q M\-(5"8$E[*8YN\O:QIKZTJ%@CQ'2,3X+MJ 6*<:*XT0KFLZIJ+65F;") M,T);Z2/O3LG1ZMM"11+"Z2L[/JK(^/AZ^]GL"^OME^>G_4XMRVJ+_>\I7]H,KH]&3U89B)B4K65#ELE7>G2*Y[QMI^Q+&CLT([I+3EQ[U8:,. MSH_H2->;0%=U;!5I&ZKP.]-42-E3]>C2;5U-GHF4/D RD(AA++N^?Y'[%B#>/DQ]UA55- ?V[&0SIK'<,OV-W8 MI$\V-6%OPI8K0=/.'<;@:9[1A[ ?8&4%TOH)H,$$V4JL?.KIA=/Q0W>=]+51 M:=\3-C J+FH^H?^UIOJL&%R]>'[$%5-"VH.//SV;3T^/^B-5:1)$PZI.34%1 MQ17ZD.5:T>J 8X\1\) ]F-LTN&9I$&MY0VU(%$QLC.\(F;W)6PY\O0G:*XE M!FY0-4CF+.-R2,7;,9U.\F^V<1N,\?SLZY?VTD 3\_NR?\<<^Z"_6>3\Q#VO[I^-Y]= M.-B_PX\@1,8JJ>2(R@R"SBE VEP,7KQY,_>AV\7B+:UFK/]Y9RH(V#WN2XV( M7%0.)"A4\2$F:(1(&!?RD;6E ,JR"IF5J;HPU)81%5S#=&K\#3 X\Z-0;6_4 M7PB!3\]NB58A!#\+M.)K$'CG^.J;=?[ T*_J50V LXM97T@-%Z/%1YE]VE+/ M':PUMC@5?%:?D1X2"QT">SSHK-J&02?F,7R7(K54PO8A< M?V$"'_S&!C0%U M(P5OL4LW]S;-]WJ;WB,U=RYR?M>FNSUI;J_WX[\NM*[6^$2ZT)T]*%L4]6?X M71C"X,5_XB.!L!&@Q._(6Q4:-B47G6=?O?PP'_& 9_*S6;<&T Q0NX^^[I] M<'8RF=CZ50%CB0T0?[WJ//RA??CTI5;:)*^VM?8.DM]HD4A1,RR&AOT,P=B:D<]>-70D%'6:1:YU#$H6@BW?6'*^B%CW1K:+LM>JS+$& MGCF"L\=06W7KA,+I%>F,#99['G&!.,_EK-*6Z*#/B4R=0G/2IQ<\,V01[@!+ M+90-O:PJ+IX]6+2BY76=1"S:&_+A=' #M7]>F'6+$SK'I!:8R+HR#MR$[39[ MB3;72\JP8-(1!-'9W(;Z@*+?)' CX < M\S\-_/#G:S0MU@,OR _M+6& MDHX6[NP"19"_)1I87#W>84939F "B5Y;T-FA]+Y^5=^CUU0S6-ULA;$AZ4&M M?]YJN!WTEJZX:5C/:8NN7UQO]9HZO@W$W5*UZ"LZ;(SW'U9805VNWN^I! :" M0T+8P]]4]08A5WFADX?43'I6I_I7@**:M?N7[FNONF4MF\C9!5UUR!VJ-Y#= M6Y.3.E=_L\:9WLV&(9RMM!TQSFH[Q=WY8%\/"D^-&H4CI:>^^MA9[16?7VX;S3GM?74LB"NTX3V:BG9M75+Q,,Z1EO7ZSH#&52XX]+@ZDKW\E9S?.:'#PDYG@9XLK?< M6UH0RN\)7<)=K<6&V5O.UE_]C!7L^^?Z7&VH\9SN8),$OP8Z IP MOE9<\VK[,+E[428[M?,=T^T7PI_2;7E+'9KVVI2@J7P[O$WU]KM9/7SOG-CI M;&?3G"&4.Q=2K,\-O]C+X5ZGT-F MNJ6'"T.-50ZP9LKDB2S3,@!4"W($J2SHYFW0^FV;0H*3TF_8%;)SE2RXW=)? M(F16W5H@7 "TQBIM3NGFIR?S((=Z_?9'I%47=),J/'V_^_2MMZ& +ZD0[KZ1 M.N$FHV1+O7)M[P#(0,*W36CJ:7#:9^^9(D:Z_,AE'O:"$;=MY9AM-S_IE2H5 M(EUC(YTS+DRTQ3.IED,K<)^:69>4FV3K'Q!(XR7;1=B :95 @YN1;*_0?54" M$PKD+UJEG$TO'](H\%=.&?B,YXX:WBS,(3ZX.]+NOE2>1&+0_>YHM["WK&WF M$%RC=J#"FM'NE 0$[(*'IYTR261&--=.E3)DH*W&V!NGKKUAX9H:;'?]Q?3B MLO>\G:^-Y6M3XO^Q)C]>L.U-KL3@^L5+_!L]<.^\^?$"!_AS.&[6K) M!U [FZ:9R//Y SON<2(5ILI;\;[I, U.BZVS?$\ M-T#8RQ>.Q[DJR.&Q)M&+&JAC@MZU !Q')V<160&%WJU=SJ^&38ZH>E ME2IC_C3-7BVOJ1,K%"2B7,QH*Z67QO -]T+S?6*UI';::$N7:7-Z%\83+F0J M3$3PM"[L\5>P:4)YX=R(1AH^5Q9#QQ]NE9>A?^46=4#!/%?QL'F10Y^UA?F1 MNU#2.M[?U$+$W^BX M=E@+((*<.-R5*_-2SW=P"9W-"&3[NR1-CK53I6A>.Q'>9K>&86)ZS81'2N[C M-RRYM\<[LVY+4B8[![C4DH2%":0]H)Y.F&S_6IX[ME6$A14[V$@7MO$*;!<# M@_\>.4YR>_J.'[ZMMD/7<5UQ/BAT[(NX@1? 7,A3TS(LUS6W'IP>MCOW%ZOX M2@K5;#,^3S=UMQIJ$'6)(^&=RT;XO7C[MM((]L/\Y\A[.ODC2B2SO9:@3#[\ M$N)=*>7)HU+*L[8"=%]*.6MO<-^>4O:"!19W\+*21@_\I9H=D0?Z$0"B;WN9 ME]]MXB[(M<<_T!L.0LUUE!V#=09J4XA;DC4298,M/BJ^E_*,:HL.';;I6Z,' M3:?,8[L2Y99;]#&85. MZ6*6='$,9FMT'%SWNJ^8R1;KLK;#V>4?9;)V#5VVO61)6UA[7",9G@BXNN,- MK.99_.2O'<3V+(RNFI%&L7'=VGUJ.W6_1"VZ9^EM"3YX]8(#B\$;![@O%IL* MHG]0$A6#YAX"3.E&';D&)J_R/>61,%8'..0^E&$6]H4_60_AIJ[HD)8O/MU> MU!JZBA9QZF>I-S+[BEZT3MFF,;.J $0#9K9MJQ:]S,3@YP_OKV='H]9X7"%I M+U#2EFWA 9$??@#D(^_25?T[MR!4NJCI=0+<*D#]!!?GD^.//ST;SYU-AP>DG3N5E!O=LOL] M%$[TL;(UMQ>MMOVDME51Q](AN1O)OK7;\O=05IMZ#"0]S%7SSX'SIAK]-'+BOCKJXR3ZVD[R4%HEQ_H ?=$KQ MUSFEX$V#^^\P ZMO9,'IQJ]UH4NDSS9[WG#]S!D,W75TH0;RRBE7KL+:MCLB MZ8EU]H5ZFF*/14$TZMAPK"B=]8@U9S4%4T[R93=!\_O#SA7]W(5F)7 M"9=HYU?V70+-O'PY82V3#M=K3);8!RN=\GUL>]:3P#=G5;-Y6^QU^P_O)3-& MX[F&=N-^9FMS+(>V$ L#STR*7&"A,K7TO%S4!;\O@;P^O_Z ^JK=&Q^O^.OF ME5+^S:5#;(?P%@PW%%]PDAASE^Q=:M'O=N]0MJQF&NCHH_,NB>9]%-M0YP9O M/U[!45C-YPC;L<*EJ0M[K9QE#;C 'YREIU0,]_U*%GDY^,@!S%XY!L143S67>YD\G)HY;K5GJ]$L>>AI/;V\^#IJ0_6ZBJ*B]JTI'<+#;JAQWSMUCX/7*R/8K?@ETE06 MPQ;MFY:;;YOW5%_9US.WC]N77+\%>"+[3=020R?C\],#ZV3]A\KD_+)FI$V5 M2?G/-6"S*N@!_+XT0 #N RW0O+W[Z?\#4$L#!!0 ( %V"65JHG1CB_!< M (Q8 9 >&PO=V]R:W-H965T M98JL(BD^12J)727;R<03.W'92?95^Z%)M,B.08#!0S+]Z_?/+\7!X=;F5.GGR[%O^V]OLV;=I6<0Z46\SD9?; MK'RV;<[N5;O5?'K[FV&3Y=^ETAO59+K-!&9 MNGWZY&;T]?,IK><%OVEUGP>_"SK),DT_T(=7T=,G0R)(Q6I5T X2/^[4"Q7' MM!'(^,/N^<3?DBX,?W>[?\]GQUF6,E5]D^%;CNN(93A/+99I)8HZXR3*9 MK!687N3?7A;8GU9=KNQ>S\U>XR-[C<;B39H4FUQ\ET0JJF]P"<(\=6-'W?/Q MR1U?JM5 3$8],1Z.IR?VF_C33GB_R:-/*_[K9ID7&93DO]L.;K:=MF]+AO-U MOI,K]?0)+"-7V9UZ\NRO?QE=#;\Y0?34$ST]M?LC1?1G]Q)O5+;Z(#8R%_BH M,A4)G12I6-6ND.$5Q4868I>E=SI2^*#$BW2[D\D>*EQLQ!UL7"=KD9%=8'$* M8[F#$]CUZ)JH7&&W)((N9Q]48?_$Z]8*>V5F$XV_U"G8R:Q(5)8/Q/,4"^BC M5CEH)0KR!H4R4];NS<*5!GWT=]Q8?=RE.4X)PG*]3O2M7N$[D)M_, LR=2^S M* ?9\( 1]A,IWP0$;;=@EI8Q?-EJI?)_ 2SZ2B1SN$2B.@E>=.!N"&5_4^5J)44;U^_$*\26,IHWK/" MI%,TEW2"/W3KHI9B':=+.A56%&JM5S@Q2$K7^_HY!.M%W\J3;X./%5OT)Q7> MUY_W]3Z!&#Y)T4ECB=_TLBL05\06+E3O8G!+)BN(OMCO% 3\*O&LC_?'SL1\ M,820MAE:*D+H;_ZV4!)\M]0)GR(W*@8IZ0S"SG?*:,K;E_T1[X-?7H_$5D70 MFT3E/?&CVA=9&4G^]M7V5B>?]$#\8E0"FD5R9Y6+\U3\GFJB^R'BVOCT(Q0S M+M>IZ-#/K2IT6G8&#!>N&7I;I=F M19FPQ0S$VRR])8._S=+MD9M8-R%R&8/7:YR'-!5&O,G2-4/9' 'V(M,9Q^FEN<$$I/P&GC$)JL!_>]4TFI>GQ%[>:AC(TT99ZGV(XX MZ&RA8>G8F3PG7?X.[E5FJPUO'.X%3PJ41A)\I_1V66:Y]5E@@8)%14:B(8-) MC;*']F,Q$1OA(#]A%TD[$J/8>.&#CE+$IR.1>N(;YF!$M)41!2%1[D @+MO) M/5^.K9OVPB;-Z^TB:-<=;$X:B^SO08C8J4RG$1\.;JP )!:Q7M%9H.I6.>"B M911I^M2K4^5"J3&R%0B"?U 56=8P#.D-$C,5&SM(>4\;EF[+&"%IH\$9OH%3 MIC[AV,@&N76)2]-L#W2)KXHT,:Z7(5?/*A\N],I:(*"O.6A(<3$:#NFZF%0E MW-KOY7EZE':(:466@L-67MX8S^$]H.-+'>MB+SKW&PW)9XHR#UJX6F4E_2P$ M4*/:+B$ ML&6QVO3+G3.&IH3MCH7=IMC 955,UT9\@YJ>/R"@AD9ATXMIP'FSY=CQ?2,) MA*@$2JON=%KF8*@3 =2W"ZE:+2?OVG.7._E&B@(5"TX7+!HH_U(21QE5>K4+ M8S>=^[8L2GB%^[2,(Z>*I"177T 1K_Y?*:+CW%%%',^&7TH3QPCN:8'3$F:V M(CPI)9;]Q7@P%$M+X4:", 1WL<JD&E93YB!7Y1[L@Q@WU.WT@2*P")@I%N*_7'/36?:SISG.^1?_.? M6.@UP6CGB/'_A+\V9E3A52A01\'+T\[GVJ9W[XQR;$9E(E%D##!)G9S:(L0Y M!R5QQ/H#T5=Z>.J#G8'-!_J+[(- 3-ZFR,[28 1Q26$RE,$Y<&*2&Q"KM\S.,E<$"F(0D8N.0\VX]^(0 MV0??7O.WCF%=P1Z,P;LQ-!C([S@:Z9=1FI7,-^(6.2JHA:^C+TF4&K:H,Q-N MB*AD/1#ON1S()".A@O3)1^C$U!M-Z2_P-SIO %1-*!;DQ72SK\5_ (?9^E/( M7\->MB&.8C<-M"SZU=DOQ*@W&8WXY^CZVOP<7;5=XU5H-!^*Z[F83<4O*33F M (WS)M.%V71\?64VQ44O:B"_,^J*R7PAZ/;3Z[%XK[!/LN[93"S\7\6HR&5T>8\H[]'GG&_!"L'VKCJD14HDS1J-^% MF&*C"S&9CL1;N3?;--Q!N,F-\]R@,JUMZ,(J)6F=<5?,1Q#8[.JL70UI/Z6) MV^QU8S/.K\??"(KCQ.EWBJMU7%T)(QX%PY/N'4AAFY9TG77/WC$[@FHPK^G4 MFZ[@,<$7NHX81[Q;PL '?*Y7SB$Z)]]&\721T;<+C/TAPP2WR J\C)46[T4L/->5A]Z ;5G>J(I@0 ((-TE/FXLZ467_TX5;-H(_,S52G $I?L:V.W\%NE M05@-_:E*-A;9%?=I4'?3# A!/6]_K)KA1H3 MS@%AAH_0QTJW"),RY0@$]M:EPZFDB[="@,S9-&Z.Q:>VE+K_.S\FMG+4?2ZQ' X#\BO:8F M5Z6%5C,F?S;!GGR9!/N5*_\X5?M'5OV8Z:$5( MB=IP-,3/ZROZ?S&_:DG:QLA\)DCOD%^]2VG"FD+SF>. W$ M<[G'L6_^9A,F6S-S3J_1/P^R'Z@ L';<:$N%JLH8U6_?X=^Z) <[$A&H P', MDCS.NL1=2?_%:K^**0/JY'][T44>$AGGD0?HD7?T3>6;2(%F2 NP:Z6Q46%" MX&\J^Z.\2T4'!J_M%\8YU $VQP=8;,R^D)-!3H?.:!W;I'%_!%D:'M3&!RIR M+2:YV1)U$OX#+A6,,#Z^<8U="\'ZGA]+9""^!TRT!^V=O/;7P?L!GZ*5J.,W MX&&4BEDF><+REIXK-G?IEVM6-/,OC\P<%T)!85>ZUF@)R1DJF%$.K)5)LN[A M@-J3K0,_EU5F4!]-\=G?+FS*/T177>..4&AB(FU?3WP?FU .&G[8.XHZ%:=. M I(;$SEM))^3B41G9B)&K?Y4)G+8GQW7LC*&[@B9<;UQ=[H;YF#.02!UM#ZB M4.\]3 /UF,FH/TIM/67K3C7-/;OP#@4I !:799V$AF=KJ>\36*D@M>7; PU2 MRID(AM5O:>_B6@"3^;B>QE60[?]X"V#.*AQ:=O4E<,=MY4+_-1L ]N273FTN MQ'0THZKVU=S6MHGI!R[09["^^C->S(&P9F(\6=0O<3L?7C*9XS8 9+9]8*ZX M$/,)M1^N !+Q_W#4"CQQ*CH9(.I9P',T J+$O]GD./ <#BCFLW.!I_%J M9P#/$6/H4:.B?WCY>A5+EZ_M5Y]&):H3Z[O^&^I7 [,2>VHO=@H.@^6J]4F M<>.;C%=[3N*UW*M[H 916>;QDFYTYF\TYFIS^ODCJQX+!*=1JY+!U_?L/$P%2',)19;%!A+[9 =%J8!J M:Y1&KJ[N J_M-Z?1Z5P;GV*+&WY:4_IAF,;6Y\QN5CK@-VZIP-K47\7:J'N1 MNN7>)[>@DVJXF0O))E37((@[>. @K&MI*=W40,HO-:#$!;):W=:#HLR-#09' MI04R#-..#H2 +.K3T,(^/%$;-" :T[V,S4!VP@C3=B\L1*D/"!J[[I.=F])3 MO.(,TT]NMS9C#ILP/5\(I&TJ(.M4S_9#6-4;]Y2VL>A#!"W"J>N>OS$KV])- MH/K?#F[2=7B #8I[*NJ%$Q\' YN\6UT&M5;0T9%-D]IT(A[/= .??J.C'K1K M1SQ='T:20@8UV#.:,O\4]%"+ZMX!'(9U*AI-3>]_3#%\UKM:3%NB^&PV%8O9 M6$QZ0V"&<^+X;$[S!J/I_$04GP SB,7BR$'" %R)_,]5?X!.Z'@CW+(6C1\* MM0]K2,]:\-Z)O/?(>I)MRP+DL:.RC^?D1SKGWET,Q$NIX2*T>"^3#_N48O// MJR(E-H8]%MJ]L;+]F8J'JR25JS01$I_H>/7=/:->_GLD;EZ^J.(JM!=!%$BC MW,HE;I>5'P$ $"@Z/WSW;M+'^J[HO/FQ#W W1O369"V%;*Y]52T<(XLTB11T ML(P 3(MR75O\KEH\NQY>=[G 8"G?N78$?,^MSO*BKY,^E:P\Z;G-<^A)(9I2 M$WD!2V*3:JV>M>(&'V&A61I&7FZI!G:D/7])_JRE0V^4V^^;-Y_IN$?^UGR> MP]1Q@D/6(8?IT]0%5*&6'O=Q=X69^L1=$(\H>VQH$M^7&A*V[>S0CVN0MBU? M*M>--HVMG,$ /SHBD_(6$VJS;;=ILA=&^"WDB(?19@RB1B1DJ&1 M<^F;!T>0[&M?UZ-4D+4*#A4,--U3[V="762UL=D\,4)I5B'LN\[D]OR"D;00 MIC1W<5B.NEKSH*T5Q+!61C@\8\3DVJ"!OYKV_#SQXVYWQ/0C9,Q!8:M^LQG. M?^MZT*GBZCLD\4'9XJEKL;72PD^&M-[4,-+B?>,,S/.'Q'*C_)3,9T6+9IIJ MAN*'D@)E:&!H*IG2D\VVD^SL*5.%R3\0N.K[/HQQ'ZX(-BB%+,H=_5TF8=9P M,1O,O(W0QFP9+@AX['Z\DNC@\XF*(FC]O4Q6E5\T#=P*V!X.Q2=^HH% ,?CT M4:P0P=?*-&8#FL]!<[[GXUQ]S8\P9YKRLG*%"YF%"]M4RU?9#^.W6"MKO18%1T)WE^ST38'ADC9[N%V,"< MX.KLH#;?V69"9%6Y'0*Q[&3F\%C [=<[K LPAP*@C%M5F,0,I\K(=%W:HT MQK;41[4J0WE7-N]D#-/;!'EUREX/C ) <2)S7<.U=8#T>V#CB/.0(2(*,C;B M#(X)W'MT&JI=F])DG;KX[C3F0,.0;:'&?^"3 ^S+SFFHGL2RCR7?G+1(T MW+;>G4M=]0C?D$H+5+;)J4']I[-+CYE.10@#HWRNWH1 \]E75<4?F+3^B,FI M!+=*.%W$LYG#%W["LBI5M51?>JV(T&:1C C);]N\LRJA=8[@R#,J'5VO2@VT M7)=L]41GY:=<$;6B(Y#O"5!LHG%^ (>#P5>+!4SQ2PH(/8QZ-J$<-!839VK" M_,?,N\*,;\IUB4T,+#MN&Q_!@HB]%S5P:K59-V6.Q.MJ.!^VUF(C%1>R3P8+ MJUW3#9"M(5!45H=K6_]%+D?1_M! M9KN44'N.E.\G&+N8=-N>B&=/Q!X"!X.FEN1^+?6M*5E[>AK48>L%X_ZC*TLJQI?"DWG1N61LOW9>6L]5W5RJ"R1 MD\/3/KE=\\-'P1\">T&6\7A-\+FN&0DGD$,);L(S&_#X>>'3M!KGZD66UKUK MCN'QZ30'1G,>SH.,KZP6^X=\\O.B$ZXX[; \K!? M_M(EW7/JK1=B3 ]MG6B:\K-;LY&8]6;3ZW,;IPT&G=%!I3JK&[8+2[@G=CJ_ MCKL8S<5B.#QWX[.?N*+B O'GNV:BYP(99UIANFBS2)<(.O=LO [#=+(Z!U,= MX'SXT:@VC ^#3V'^B>S1^H/A&F!_^+A<&7A@;UDS>7O/E%[DCTE:P$Y52)K56_C4I/;$KL[R4)O37JG22/*[F.8IF3 Q M[MT3E<]C?U@_;,=^[+K@;U(6YU-K8_D'DS!&2M%CDOOQX( M9+%6@[A11:=Q M(.&!1ZJH(>LJP&\W- \YJ;*= EE>G(?IASVK=7_5/!X[)ON05+)O/AT5#DF% MS[<=OMFI_0&J?WQ6<)/LJR9JV[M7W,&_S'M7JE>),)*C@R>F*AY_"I7\GV_MIGO4^1W MGK]YWQU4I]"Y1Y#AC')/?%=2AF1L78=G*OXF,OZ+7AA9F[*AP;]R"S-Z\/W-Z@C=QY_]& M;-)[JNI78]M]<(/J2GD@:B*7>CW5M^S([>"+;S][3AX;>^T28WZ"D]BXB?-@ M5,1[6.X$X$"-1)(>=N+.;S5T0B_P(^:Q$QX/OR*C&D^_$@;Q^N/'9*7<=J3; MV(9WU7Z@ER7R/6?8P=?ZJ4FE3=&/U-PX<)WMZ>E3]AAZ1;UH^D-B@(>34W^Y M[U>?JAX8]Q2,]C3?W^-+:N?-%SW\[)EI?JY;!=JS9M1%E/LW.&,GIV:9:@6 0CT8G1UU7Q#TZ#ME:.7P1MBH==K?@\NW;],"O.R6/]7X5ZU>V/>,%LM M-^_I?0/(1PE?K&YQZ7 PGSTQ*9_[4*0[?M_L,BV*=,N_;I2$O=$"?'^;PCSM M![J!?P'QL_\!4$L#!!0 ( %V"65I,J[/AO0@ !(8 9 >&PO=V]R M:W-H965T-@S#?J ERN8JB3J2BN/]]7M>DI*MQ/:EP'"%8O'CY?,^[R=U-UNEOYN- M$)8]E45E;@<;:^NWHY%)-Z+DYEK5HL),KG3)+5[U>F1J+7CF-I7%*!Z/9Z.2 MRVIP=^/&'O3=C6IL(2OQH)EIRI+KW7M1J.WM(!JT U_E>F-I8'1W4_.U^";L MW^H'C;=1)R63I:B,5!73(K\=W$=OWT]HO5OP=RFVYN W(TU62GVGE\_9[6!, M@$0A4DL2./X\B@^B*$@08/P>9 ZZ(VGCX>]6^J].=^BRXD9\4,4_9&8WMX/% M@&4BYTUAOZKM)Q'TF9*\5!7&/=G6KYU@<=H8J\JP&0A*6?F__"GP<+!A,3ZQ M(0X;8H?;'^10_L(MO[O1:LLTK88T^N%4=;L!3E9DE&]68U9BG[W[*HS536H; M+:OUSG]@>Q>R+JNS&L(]5)K*^@!&P=(#B%M#[^*S$7T1Z MS9)HR.)Q/#DC+^D43)R\Y#4*,EYE[*LHN!49NR>'D%8*P_YUO\(J>,B_CU'@ M#Y@2IN!P@+(_2C&-S]_%,T&[\[ W_2P9^L4^"%W;# MUH5:\0+.7S4Y;\^IA*6P9]PX 7F#<<%J60NB@IF-S*VALPE^J3)>>(N3(_#" MJ!:&QW1?R1)'O.9 B)2E(P<)K:Z+'<@I)%])'+!SXF65(DT:P42>RU2**MU= ML]]P"G<)R3@Z1%E[;VQ DG8@3K/).'033S4RFB=T18?#=3EXY04PI""P$#2[ MVCEAX)[(C<<44EL)K6@T;W! P74RNQPR\%%#ZFMWWYF;C/[6V/X5IBYTDM%+5FY2; MS9"(QCKG@)"C9>&@6<=LBGRO'91,0$PJ._^""64POD>9%LI@G=(LPZ$&>[QY MM*!B1M9HD>UQ( "0[L$0(RB,JAS?F5.0PI$[N&%CWV1J6WE9_IR65J!4VD>( MA;OUE >"B\5B@!2L4N /.&.>];0[:B M5QKQ.$[9H_,.N]&J66\8,K8H5Z"KS=ITV$5T'>V-_IE01LLA^R)T^OTPJX08 M.YE8HN6IQ(*(K[FV1!>E]DJ)SDO+"QAYTK%%"R<-5&N=/N2)[IASAQ&6(Z M1/N03MNB=:"_T+U):9T$&QU^/( 37.-89>$&E?TQ,\\GR3.K)M[.IGG,,DD7[49XU+FKM:D IDW+?H,_9)Z9N >CXE M_14R-/OX)"U8L&2\[J#1VP:81/2GEG2$B^1$B]A3L?\UB_SB+,9JR M* &L16]HCE'DWS/QTP<0)=%^_X)%D^6K#+ \.#1QW/S?R$^2)5#%;#+'RLG8 MO<>S":,$=.%&X"?.)#1SP99)NYN&#SN&>'**$CX_'KG#+:DP(K+">G M*8D/Z(.3G:4##_ [A;)SYX6D?NR\,$F(!$J_]Z?Z"B]J7_1]BJ ,T2LI+BWM MH3[3ZZ SH5GQ>R.]&J'#4X7K4D*_\BQ%MGGG^H] :N%N *%URV2>(\]7*>5A MNQ6B\L.'^T*2##"H?JTK)$6 >0Q51(M'29A09O.F8(7,18N+&R/LT-V8,5\K M+Y\J2BIKC]$QA4$C\:-M\UYV9?3;%9V.ETR:VJ_*A\'V1V"#J PU2X-K@F#! M<=< ' *&]>B$8TD]U$UP"W MU- *[B\S=(EPO$//KBL*PD(KYM2BFPDI;7S- M-)+8#S<65&9IVDKH>LL<)D?=!43V(B*8J\1$[I!M..$G%R1; MEGS7XY;N$]E_&A.D:)'3%QTJRI4ORM21D\14S19, M= MS+C4%!W#8]<.VN7): WB9/<4"AWI&MV:3T0PJWG)L/,'E\[[ERK:T0KO7"7+ M))%!3>0P A=X*Y5 /=@H2T.97075CLAWO0POC!0'3X)[G5",K +[6_FJY0 M0G+0AYLU-+DT0K"_*/AIE%SYWA[]G'CC,Q-UMI#GG.*'FD$G"%M=<'77/^>@ MQZXR^][W1QO"?NT*'W',LUX[Z975R9SJMJM>4W0/'T.SZVH[57:JZU35+Q_X MCA@S5Y0HA*S)(W#EZ41=QM/XBEU&TP6>DVA\!2+]+7QOQDM(O=KOB!83K$UB M/$\@?]G-M9MG"U3KB,U1?3O,U!Q2^T.-(;6%K\"<+*_HZC@CS)/I4H 9 MI1]KI\OHU9C[O?5T]O+]V+>_T<%WVE+ C>AK-'T'0N;PGVR[T>Z#][W_SKM? M[K^6?X$74IP6(L?6\?5\.F#:?X'V+U;5[JOO2EFK2O>3LI30M #S=$MM7^B M[G\#W/T/4$L#!!0 ( %V"65K1QLQ#VQX "5J 9 >&PO=V]R:W-H M965TR';,/MW0>L5JL[*RLKWYE5_'*GBC_*K915 M]&V7Y>6O3[95M7_V]&D9;^5.E$.UESG\LE;%3E3PM=@\+?>%% F]M,N>3D:C MQ=.=2/,GSW^A>Q^*Y[^HNLK27'XHHK+>[41Q>"DS=??KD_$3<^-CNME6>./I M\U_V8B-O9/5Y_Z& ;T\ME"3=R;Q,51X5=80S M62GU!WZY3GY],D*$9";C"B$(^+B55S++$!"@\57#?&*'Q!?]:P/]#]?Q-FHL\3D467>=E5=1 [ZK\Y6D%H/&!I[$&\Y+!3'K C"?1 M.Y57VS)ZG2U$IP1OV@NO M2&\%LH _TTCD2?2;3#9IOHE>((>D52K+Z%5:QIDJZT)&__5B!8\#]_QW%UEX MT%GWH"A1S\J]B.6O3T!D2EGR49L>@/WSMO@-,]#AZ M?=K*Z$KM]B(_ '?F(,YE5,&]%&[%5:36$>@/D) \DM_BK<@W,BI$):.=NI4. M<)I7$LA4-7\#Z4WA0XHBAW'+012+VN1%M&MR&H8%88292DUQ"P5 MJS1C'*MMH>K--@*%!O!!)<",=U+D_*3Y%;&N2XEP;D61JKJ,UI9 J:/$ +[$ M69T@(1)'*^^)8?0B*F'*Z3J-15Y%>U60(@+(E2/77_^RG(PO?BY!P]W*'&> MV)BI CQ+.;%>PU2 ,G 7B/%MKTH)>*N("1H\&U 9,,'U4:LODG0@$PE&$7&L MZKS"*10R@R<)7!=R!FY<%X7,XT-4I.4?>J5QLM&^4)M"[ 9 _.@.="Q^XIJ% M2]I\2S@.$B!J"4A=7>*L5F@MAM$;/>R5&?8C GCG /A\MX4A822QRE+0AXDA M:+1E=AV ]LY@'67$UJZ%"Q DA_MI#A2JZ)9^TTRN1.K =05DC,1&X%I'MPH( MARQV("ZO*]09+7(U&-9?,D4-3S6F;!!'?@'4"YG4,'U\$%F; M)>/PF&'A75&!G:VS!-D1Z8#0/@]OAE&BLDR8J3A2>#,G,8&1UH7:M4F4R%R! M@2,N+$4F0<+V10J>0IH=:!19%VH0_5W 8H,JC0XR)UI>;5/Z#E#@]54*I%' M6-L4: 'OP=0MF08^;X.A!39%2LE(^,*);(O8 >:(RU%$ 7Z1G.]% 72T&BS6 M P [5T6ZJBM51,!.2&N:6'3J@:<[9TQ8E &0:T"6)5'%,&@$:K @I/; OJ@5 MHO@09SB9PQXT2P;DR15HRP*G*_*HNE- '%&0\+$X\UH, W&AZ6?B@,!SID/) M8U7@=9%Z R^OQ/$0A$>@)O;\:;. B.^A;521<)<( $SH+2VPZ>H*6%A MRY2 GT4@#KY=/@5>*?W?X6F6T[Q469H0-5YJW7V#NGL(0F\U516@BIC>CZ,$ M_1"!&Y J%%F#+].N5]# .Z]M]5&]H[0E;H 'J M!+*S6L7XRPFT!_E:1Z5BC02"+ VO!$^2!?2&*9V>"$>S6E8+,L.MA[="^UC6,%S, JD%10[N@&PKL$@[6L MQ(@'_.58[E8PF(E9Z.\420Z?$U[):JL"&4(:IL"*2'H5$\T>+D\ TZ&>Z5 [?B(HM^D\G/O5I.G4*GSE+3O M#:+DN7Y=\GY3P0 MDNM4=H9%P-L[!<,@@.Y 9HBA]K$' @\%D!#.*BBMNX36FW4>ZTC(/8(Z:P,T MROVY\$)"N(1F*,$YEWM5::\052A[@ZQ6&IXV67VR5HW)>_ZF!\WR"]Q^3_B> M@M%3.WE&CD1>@G."ZQ NG3P?*G2;@%#9H4P;;A.'\SL!BKRJ$^O$F4'9WH2QD-&R;1>JZ2,9 M&Q+Z2=%IE_]_6N :PP&$P,.B,!LZT+]-T@'I4KE:E%!P7.-_B#W;%Z:JR M68+C?/DB1JT*L\D.@R# :W@M+:2V,MN'3-EXQ?HX'.TY>>QF55%Q ,)6KS-3 M8.4^C/0&^%WN*^?"5UH9XS>4UG.#?I("8R(,K4W1PKE;EM!^*B2II0%<;D'8 MST%][]@SM[/S?%4VDB[> A@STI6=F7Z#=5J MM2V[C5JW+_2OLEM.5QT7_I[@M)&E\!;3IK9*FY]P6;1[D@G=(M(I'GJ%VGB( M-B8,_,<\T1:ODJO&(566,W^DJ5?:UQC+X/GS&.XO$#=#'0D.'"RJ#CV*7A1#&LS M\5.M?:6^S!]H.K]GTZ@%G]1W3 FY;XH6L",R6%P"Y*9R:Z M(P>UPBA8\U=/1KF4>0H,78-EBLE*H 4]]YU#T,N85T%UNI+@- 32/K!FT/(7 MW>V(.QZA#4+;V"G8.DIN*@IM-*RG"&M7QU6M]9WV/%M31$H%DH03XM3]=RL7 MYA_/'^NB?D4#_?7)-K0=B"B;S+.27^+'K!T3,\\:& (.!;=/HW MH--9]!:3*!]#<2610+P*N<4Z*M5R".SI^.SQD+K='0RR&%09O3;B30+U.E!+ MG[3P_ <%S:^;03/%S!PR8[S<_/H[C'3MJ&E*4!]-XFV;[LNV?#EA/HE.IZ,S M^*#UF?R,-V;+,_K OV.\ J*\[A:1T_'EY"P:C^9PM8 K Z7YB2!^5SK%@940 MUJ$NT4&$(6-$T2I3M%E]8;.$<9AO8JY-*>4C,O^Q2LA.'$ASA,67\D[L/8H M)QK[Y&DVX,N5*@IU1RK4SXA41D-9'\0&3#01?RCC9Q*;V\(#OH30JXB)I-C">Q_ODZ_R69UL[$:H9_E M&>A0R1*DL*V@=11/\P%O@5ZL+?:YH2J1B?H6Z( MMK])H,@G50$E\ 8PL\X/:&TQ&\Y'/^FQ42%/1M,IBL]@/AI%"WOU:7L/]S5\ MR\8L>T,F/>G^L(:R#Z#&MVCRHQMM^-X#6^3H7D2ZV(VJ [$ZO7G_YN,9(X=H M-C/?WS4^PG0@6]ZLI8M6HV#]%>!C$R1>8:(?D9"47V7)W;P$G(MCR+D@72*IAG M@'A1'*BOPM+Y-\Y,O_5"^BLWEGON#<)G,;?-&9*'AE_Z_;0[!HC!C97 M7X63OA(<7+\%CCW_A$$[Z106^TOZ',U)#5S '[CZP!3OU$Y4ECY2O=&AP:9 MAX0)6\I-(3=$]Y6L[B05()HY]9X:24U<+>60S&T^7],#6F"_?B9#"> MS*.)NS$>7$XNCT&"8*2H=0U#!9CZ630++@+?SWZ[6$33P6+Y@-G_KG(#]FT/ M6.\+$G@V0AF:(($G@]EBCA=+%*^+"[YW,9\%' %F^KNYXK&K=T+K%W#!9#"? MS?!B'OYP.5A<3O_W%F ZFT;CZ6 ^'SMZP8HL!^/1S**%#P'M%H/1Y=RBA(\A M3P\N+I&"%Y-+>A(?F"X'\\6(ON(SDRG]-*)17I!;B?BM5+-]A$U%V4C:=.BL M!Y2S?=<7VYAV6,,KT,EF\P=*3R?QR":7Y.9FMEDEZ$]+JYJ6E5J[9('N*579 M2TDXQ!)I;]-15^ 7I!5'$Z24;<(\RW000 I[7ZC;-"'[RYW 9#CSSLC72]&X M*AE$,E^H7TAIN]^<8U$@;UCMFI(K>. 0:F^M"%$7@P^B[0!\)XVFJTXEL\F,F6EGOT5F!GW+Y MK=NF.YMPGW[_&W&,[X>X\%NGPQW[A 6N!C];-@Y!>@N@20.0CRT"&D+WY#TX MG$XN+\_LW_'<_+UJD%J'1 G&T7,71Y].W36&^@9I%&2/S*(L9H/Q8HD7H\%XC LWOQQ,EJB!3R>49YDM3)"(&9?)>$&9FSD)14Y#*FZYS!WV/>C7:@TZ!9&5_U@;'!6?U=#SM3^V\ZN:''O^P#PJ( MY>G\XBR:]3YQ;5NF[^6L8X;5LCAU7[7S^"H/.+P/F[[/^6@9C<>S:+&0E MP_V9/2B8\I/:WK8#G96F=+16"F%66N>R'ZA?'^\N:_AMA7M$[IRF[&8VT'ES MRC4O./<,;'T,&JPP2]3I9 DJ"C35!:_YI_YN3-&0V#VQW\U/5#\G=8KY[1^U&)Q.(#4PNR[D$N%CMJG4HM]QZH'-W M)D,HOU7@J>AN TXK<)7V_HYW4_'$[BH!G*<[5*E3>]5;2+#]F$%[):A>FF!V M"-^S3V.1@/LT*./]O^I<^AG3P/"7T)+RQ$HFM'&G.&PH$UN>R/N"B,LT; M5-TP:7IB&THKX3"OO];H'E,FEYGM.HQ TO#%Q+PH^<72O2@"KB M6>I IPQ< M]1W6ZW&V[$%_=FQ ;M5]O_^-:/26Z1-\ >[;R8+!&]_O>QE]U!EG,@=C\%41F+?.J!U1CU@!^)K;# M]KT6"J"A:(-*EC0XE_79L(F/5E& SFP\_A%\IM^#S[1;ZQ*Y\>=0_5+#PU8D MTQWN%1J']O11:(\>@/;B7X0VR)97]FGA M1RFMSM^;W-#/DJIH&M(?D;1[5H&5$FC-D!> R!?=HM_GT9&RTAIFTJ=A)@L/ M*NC&BW#0^>6R3]^TU:96&$BNMH*D^=I=QG>Y+#!.MR76,DI];P6;[Q/P5;5K M\% 5S2D #,-,(K4)4E-WML%7.]%RITRJ$')?;6QR"$Z M%>AFTNX_ &GWDKG^#@"PP]X3D=R*O )?"7=XZ_Y 0P@[E(.+[6QZ.T<6MJF9 M.J2&0?EV'$JW-E(VV5&$-D.$]D9O6O 37:DL1!%O#UHQ[\0W, M_RM+O"?1D M.#CEG#78=#/8+S@-^W2.1MEC'H\/@#LS\D M^AJ@A>,: ]XYZ@"_,U@]ABT[>RM$265D+-I:JE;DC%,\Y3VDV0W82?"X0=LR ME=5KT,'46*\=B*.$<*[[YPYNL6CJF@>C Q JQC>W.R1TJ\;!P>T<5K,75M[O MZ*^V'%RVMS$DM_(B>?%SIQ)@Q %O!JRI'N1RI#L)X!*5J8TAM%F*2L;;//V* MX+E\YNU$Z!"-X R#;N21X'I3PM;A:[M)/'DHT$S@IAQ_T"]ULN%VE<(D(J@W M]GJMDVN=4L;]7Z8,T+_]7H M$Z.$C*QPG'K\UT9-L0Q2)QT9AF9&H?][,]?P\ R#>>?RLNNR[_/^&'ZV:*<4 M\!YBUKR/]_"WV>S"(0%^.][WGY^/9MK#,AO4,;9_T#27[3G!K?^;-,H#$AZ3 MLV@VOV@3#.[-QVTD\=Y\MFC?AWOSRS8^\Q-IZUS76V?UK%D[;(X.= M4=P0-[X(\UR3P7B)I='E[)(*I+-&1]5L-@VT(/.JK\JN:"?\!OG4[,]DS=V= M+AM?3NW?SG3:?*;_>JL;G-#PL"6>3I>=U]B+X%__$_BUDGG_ E]T7-WWB;P!)?>_)C9I4Z4KU^XKQ7/@HEUM:FB M[7_^$5(F]-B+@S&7>D,NIG=P$[G<[3-UD#*RYYMD(M?U$]-.U!EL:[Q*7U7H MUMZP\_)D.78AHTL)>8TCPJXZIO5IFX*96$K.@J B)#D\0(5W&,10/_+P&(K3 M1Z XOKAHXDCA[G3:V;D\N%;<(T08O M.I@F:,;2KI(/R^T("INI<.N/!VS0W KNT:"QRW:([6MA0U(K)TN-(;8E"DT* M3#ODYI/Q9#BUN0)*'BR\Y('I4_#>#7,#T:E&T03V1F7)Q#HX[6-<; B,.Q>= MNKL*U-V-\\G\4C5XMG75M7LZY*6F0Q_W:5408Q6G%(,14ZXP*L$M3;':K31K ME/WE)"\%8EKTQU:18(W!VYEIRI+^F7:Z\V!T%HWGT0?6#^BTS.GV^.+,'\%W M6U$S&&6&HR&\(($RY_HT8 WT$0_N&"0O>=3@+GTR6J$.(H-?]V9) M >IX/)S_A#$)4E/7A-?8Y&A/D%!)'9N W/1&WN(QA2!II-#MJCGD^-5A7L']%GA7F$ZQ5>4V+3K(2\L>C*TOPD1^^<<(9Z^ M_GSVZ+E.-2(/F]50"W1?O'J#+3 ]6UQ[#L8TR;&XS[B8G7&8=&'+!].C+P/M M+*TS9ANSHROH-<5C2(.ZZW@_NYONJ_#-^+VN FXU3IP0N_F[=*\:"44 MGA"J\=.-#_F&WZ=Z\JESXHQ6TOO]SSJ5VH#V#9Y,)\.%-:)T8F!A[(MH3(]+ MS!?#<6"%NQPI!WOT*-AS!WOH6Y,[/E)3$X8%%Y<.'=16*E(G01&W[[3UPWL: MU-]S$C[?*)NJ"8L^.Y6GE2K0,C?A^ Y9TZ#'-E1'Y+TL0%J6-9Y]@T;2ZR/! MLP&[>NZUT\K,F))TLK8V'L/03,=NGS' MF5'T[,RA;9U:P:M'[5660GRWJ8$'\& 'K;AWX@L7 7KTBCZ7MO34!""?EI)+ MY]H(:ONHL< $SD#K3WL2D+!'&+BF.%0&!"8IZ@TFGP$( "HXKVP.[#0-_[2U M%G_;JG*?0NA8-GF$LD1IZR0QPXEAUG8O"_)3R>/)S4Z".] 76W8I]98./OD; M6:]4.ME:45%@C_/#$A2? Z*Q+/Z+,"UWR,BI/DO2J3MJ)71'/C6EBNJ>N3EIN42*<1<80S7^I/<:AU"V;.;( M9@H[Q-&!/'WJ8!]'/+NG-A/%!G-!79REC0O)Q[/H7?QO %CE-G]'SMT5K#%\ M&:!_.V3VHFY8P.TW"5[*9Y0PT!S_-, _!&,\_:FCQ:7B1%*7 M#'1V-/P#'D5J./;EZLS5%C3E5URH_]RF:YE&+U.JCF!-[(/Q(Z\4(/VV2L 9 MYZ?.'/+Z_ %=50K.KR84K?R1J/T,(G*'&Y,P%!#$HEEF2T\=LT&O6&-&CNP: MUEX5>NMO1]@Z\(_5['1'"(!_[G'K0.E>$;U?$$$\K&('X#@9+5SH"W@[Q$&\ M\7R#NN#BJ^/5EX*/(_%/7*%ZK-K21JR\1G$.@M26:' MDCM8U]]>UKD:EGC-W68]IBYUYT<0M$(G-DJJG+5'"-&PBWTR:?@U)],PN] I M"/,QGR:UV?@CFBJ8]@WM&& MND+WXSO!-,, M3S]PHE)AGP$$$RA,-C#JHL_ G.>ACS8F,J2X92\1!^#9-6Y4HS'VU:-Z#;$) M2,\&^6T^#SMA9K/>=D.LP6]%MG:G;W0CKB=;>H&+*/V4+S&*;>QI[*=U9T8; MRBIP S?L[]'I*;NT<@%P&O8*/6P'+?,K)A6\0#Q'Q[W[,LE)\PD)[HWEII3%#@!3QCA<-J?::BH]KBK"-#1>[*7U57>3,IAZFWR.% M7?_ERU/OO^X!+;NA_Z!(SY'_%Q][U_X?2"_XO_YQC_-_H/0.?%QL!\WD&EX= M#2_F3W@WM/E2J3W]1T K58%*I\NM%+#H^ #\OE:J,E]P /L_0SW_'U!+ P04 M " !=@EE:*6ML5(P# 7" &0 'AL+W=OVQYYGG&=LSS+9*?STRPZHE2\06FXDJ!Q/0^6R?0Z=_O] MAF\V_=XL#:#LC%7- MWID8-%SV7_:\S\.)0Q&_X9#N'5+/NP_D6=XPRQ8SK;:@W6Y"^;IW3M]P3E+XK*2M#?PJ*ZS. 2)B M\#\=4#W1J:F927. WH$!O43!HN??TI&\2\7Z.9'NODE]/=.XS\[P^F8 M6:"T8K-"3:F%4M&+,A8K4.NIS[/[R>"62T[WJ(*-4I6!*TC#.$WIFX2380X/ M;$OWSJ+F3!"FK/QS RZAU:I$8Z ("X(OPC@;PV/7ML(%3XL)I.,Q)$F8Y"DD M<9B."L>'*HA!L I^O[O]0J2,A0]%'G^$#\-1^M&%C<,L=O$GX3@>P0.6:B/Y M/T20F>F9P"L8A4D\\=]L6, 76Y/4I3%H#>1A,LD@"[.\.'-Z8J(CK(XNK@9R MZ'DT:&M5$9VFU=RX6"W)>^9.N=C!53;(8<6%\ 6%7):BHP+@TE&*PG12;%N4&]\2S)T>*2@K]M' MZ['K+?MB_[*];YF?F=YP:4#@FESCP7@8@.[;4#^QJO6E?Z4L-1(_K*ESHW8; M:'VME#U,7(#C?X'%OU!+ P04 " !=@EE:PJ47) <- #N(P &0 'AL M+W=O[HQ5Y)2O$E>]L$6YX)&7TZ?[@;Y MXCXWMW:CE!,/:9+9ET<;YXKG9VJ Q/5KE)I<.E69_9PB@9\Z(T M.0N'P^E9*G5V=/6"[[TW5R_RTB4Z4^^-L&6:2K.]5DE^__)H=%3?N-'KC:,; M9U#>5T1D'Y MQ1D\U5CGKK[+\_A>)XF062Q^=AMEQ)O,R6RMEXFR+\X<]J WSZ)*WK67%SXB M;Q2*=WGF-E9\D\4J[@LX@W*-AF&MX77XI,37*AJ(\2@0X3">+#1HE5GB"!=;863I*[?!;KSWB\ M;E93BFFW%X MP'_A'/]-GMAGPOMXI8=C5GHV/?=*3Z$]B7J314D9PVE1F9:))$H2P%AFZ3.Q M5/P[DIX\9P4N&]]R>,R5K,1D/FSC2YVDP'TV;._[J@Y&Q$IE,85 8S.8NPEEU M/9M-\6DT/!=O=80"1);#/3D[9A[,IV-L/)L1F(87(]P)^<[P?$3P&I&J$ZR? MLLYX\X(^C*;!>#:D1T #PP/FG/M'\V X&HE?\E3!DP+;B#1'Z*Q>9WJ%M$%( M#\9#>S3135'T'!D0>J3(X&$4+8UKH[S372XV92HSL?$IB"R^5?2@$K ;Y0H? MC*5?=6;4'5 F N!J<"&6'E>7XD8MD_SS-L']<#!O[Y/??E-F*1\DK0FGPQJ+ M [&(8TX]F23;@*U^E0/#V59L9"R.)X-Q+8>\0J8<=$+',.G)I;+LD!T!B;K? MZ&@CCD>#6;-!1TC?D6P!7FUL%?>27.2,7I:>"K'&M9@*($ 3-2;;KM1%DJP2 M]0"K#VK50GAWM:75[WY\-AJ&4W&2J12;&I!III>GL&;IT'G1%AN3E^L-NU&V MM$;F+LP_RD0%Q#V@#W^%I=X+Y&I9TPN]?3P!]S4Q>A*3%)(V$D+Z"MH%9;*? M/W*9@_,.8JQ:*=YNLT*:SS(@QX>UXWL0EB"?)($LXWGS7B/@"RK7OZE,1?)2 MO%79'3P)&9-)6!OTQS*^T59JC]M%K !'!/1X//L?)%S+K3+PG%+BI]PI,4'M MA-D-V&&F;Z9W<$!:[NY5.6,;1"R+"T0 M RJ.\G2I,R\"BG"?0G6'5J\HR>]D4K(BB+G7$1&"V 1\(>AM:8 @Y,OOBGB# M 16(:G^G/7(Z8 R -L0^RY%<2F*^@$P5;;(\R=?<'*P4N KA1@^!1$GSDM2) M9*'1):#5 %)MQU1I".H1O85'[&1"'WIR)(=3SQ(4UWC?I0%ZER5IS :U11.I MYJB_@3B=B,I.3B$"+0"19_Q>E0VUV0/QL0L5T3@!^X@W9@NG3%H%B$RK,()_V;/2*MHJT:LF/=DZ!NY2K9%[$OGJ M]&=>#H1D7)O[^QH5Y89258KCV>RB:1-:=3O^B=#(K16C$-)OZO#3AK&ZPWA7 M\&OJH? IWX$VZ&L63D%S:\Q+A7X >014G?+L608A.5I#4)D! JIY#2AY'_YK M3 JJPE$ $,5UGJ';"#S$[SG6O9T) >P@@,O5H<*01RU\CK82C\L,ZB6>,2/D M0Z8CA(NR@AP68Y2S[*J&FUJ???MZ(;2U)7OK59T%< .BCXQ\JYRC=O'5S=M3 M;+J6)N9F><.94BY3K*T0\4Z9Z)9[DMFE11-T+UZ;GUXI0- M:CW&BG'T;MZV*J$'J^B6W=*7+3LB8QUSYJ4TZD,AB[1P&BY7=SI6%?FKUXUFY4I@8L'?74EKD&Q/:NFM& MWR-WWS\;L8K^E%S*A/I>*N^Z[:)&BLB!K>J,[G7CLLBV[I"61"@X5_1#AIMY4LK,TAM.X+3T]5 @T/:@" M#(C,5R)%T#"YI++CVQD$-BJKMHE)FFM:*ZZB7ZH7I:,A/Y)V(U88;6T7=0(< M#%+2!;?>P$%:^#)9>SN&C^Z4+Y5HBR"%9+;"?+]<%G$=2:0/,1O^WFF24>V3 MR#*C&HKVBWMT C!92'2$2VI$R=':9W[KL-9)7NU:[*$W=MQXC_K!-4J:NJG0 MKJ7K2!JS)17\6J^2[^:X0]DK"$AJ@@ZU=;4N=!KHK=A!0]UG=B#^=KM"\HF3 M5L/3P]TA]:9A.\KJI\:?6EO?H%^,*?+'GV[W(V"^NU?VI:-J9BIJF\(F6H%?J>P.*.*D&%XP;,N,*3R"'QRTI M'G '$.5 &DF[QJH\:YC5;4U.G:JX!;^BPIYG2@ %B/IRUY+Q7)1H>>RH!]GKO,'@LCXA/==QO MHE9*Q4L9W=8):(MJRFMZ/NO*>(N0T43K$R*I)_E5:?A\ IS!G51WUNNE)"K8 MX_'T>5D5$L8)^8B,AA^RM6JFN(,J!1Q@.,KP6,%U@O%E#P',%Q7I3^TKM-'4 M3:?[]LM( ^NS9S0T,K5@JQ@DP&KFF?^F&;F]IG"L_^T'&VM"40D>H'213 MXBET5S*FUD"AI$L_B,(!3U!\OU-*9=TM$:ZZL]4>&57)5 DD&VQ)N>*? J() M':((\@L-B?U"AZ$Q[YR<9,1\;3S_L"NCS8G9NN%#^9&?R2'DK78(:.:T[D%0 M14EYZ9[YTU7.7;A5\29M0"+-!PYP*T^L' ZWBX-QMK=@'4U\.;N'5G9NH,@ M:.ZF*YW%=8[5_%DF136CEMS>VNJ8(%*&6JRZ%8KIX*,GAYIT;IF+W'*3N'^B MR:=E9,V26GM_ -\>OR7;6F!%IM5)C=NU:6UDZM7"Q4K3J+"EUU-X2_-Y(Z\I MT6*99%M!D6>,"(LT,9_M(Z-&X#JCQ1T$QV '%_AQ7M/Y!;S0/12LV__>5PX5K*O)X16Q,.!A)7W30L7M.!Q,FOG M0WG"7_H,=^Z._3M0'5 ;JC[:8:BR/5[;Z M?MKRUY#G04_-2[HWY7OCWKU9T-./[\WY2X=Y[]X%WSNO[PT.?8-_UOD-!A"T MYE^:6']LXW^.T=QM?LRR\+_A:%_WOX1YASAJ4'2B5E@Z',S.C_Q86U^XO.!? M="QSY_*4/VZ4!$SI!3Q?Y1C)JPO:H/F)S]5_ 5!+ P04 " !=@EE:/(Z@ MZY0. F20 &0 'AL+W=O4+,M. M4F!;8!_T(-N2R,-S_<[A!7ZYU^8WNU&J$O?;HK2O+C95M?OFYL:F&[65=JQW MJL2;E39;6>'6K&_LSBB9<:=M<1-.)M.;K? Y7V\J>G#S^N5.KM475?UC]Z/!W4U+)_Y%FU>74QOQ"96LFZJ#[K_=^5EX<9 M3'5A^5/L7=L8(Z:UK?36=\;]-B_=M[SW>NATF$\>Z1#Z#B'S[09B+M_+2KY^ M:?1>&&H-:O2#1>7>8"XOR2A?*H.W.?I5KS]J65KQHWR0RT*-Q$==KJ]_4F8K MWJME)629B8\*0MN7-Q5&HSXWJ:?\UE$.'Z$,GZ$6M[!'3BQZE!Q'?YS8MM*V-$O]ZL[25@9_\ M^YRTCE9\GA;%SC=V)U/UZ@+!896Y4Q>OO_Y;,)W[ MC2XR9>SX>7:C#KO!.'J*W=BQ._WKN/T)-WN&$Y5=RSME@(X8O%)PK$H8C$)= M4KW=*I/FLH!@.XBRU 9NE9=K*_;2BF0-,.X[&]]6=)NQ[QWU MQ9!(!)84K%??.$)LMW <)%]UC!1.T/B%"$:+^<)_S]%HUFN4!/QJXC^C\6QR MW"!.#@UF"S2(>PW"!5[-XI _)R(>)[T&4817R82:)?%,!"=#A'@XBA?N,P&3 MBUZ#*3$9SV/_F8PGO09)Q*]"_@S 0[]!3*/',Z8PB]"@KZR8*(3QI/D+>8*>X7,B1*&8 MPSF^_ML\#,);]"#K/]UC)N:S6:?'[+D><8P>TVZ/Y[A*J$?4]HC'45\#$S&+ MI[@2O.RK!^.1)],U/>?-LTF(BSPY>I:3:"J28":2F%SF>=W$;6OX<-\9\'!! M%YETVN>^[\Y$/(EQ@9D3'P.'$1R"KF2\P$N@#K 9A4!GX CBTI6, MY_WN"Q'. KZFC WGNH> F3 A=49G6\"]HX2O4X1"7FSL&(Y( 3\ O0DZ,3!# M6Q2/XFE(/Z+1=![Y]Y> ?JY 2E(R4A9A?N7RWE+?J:LFT]DN: -L[Z3)N1DE M&)_ 0 ?5K:.C5BN7#HY3D:5;5ASM1]JHZRX*.J M&O%KIZ'"98)3Z3CE&I4I3%WH(5KLD5<5)1W\WDE3C4C83\A>O[%Z9[>VR<.4 ML: L1O2VKLG.Y*E"BO[0*D.R K['V"Y349*;+!RS[_1V1Q35 MO4IK8EB*55T4K)6Z1$;+[W9HCK[^&XL+C]]>7_%0^''G\="5ZY+6 ^N1*_[ M%<'5R/L9O21W\*4/:PM:+--\)QT;C3MQD6'5@1'87I/!P42%>H5**.8BM[:& M)*0(]7M-]13>L+]2!386WY7BDWQ@!QRQ\-\K"HT"@UGQ3N[R"B._'?\\AI79 M/8H'H?'CRTZ(GYS:,VY.XUL[S([WR5VH?YHK_.\(5U=8@);-+C@HN8#-,&M MKEPIW'C;!J%&OOMPZKQXUGH-S /_)K,]8?E#Z,-XL FH6)!$_7W, @^%@E2*W?=7*O 8CE1CD$',_%2%@ETTTC30E$AF+OFMDDZ9ZB$[$, M4_'T+!G1Q'_: ."MS^%X%AX] ]9@QIT#$]O!:@NB(W&G M-GE:>.!/?0Q3@#*]8WDS11$"/(:A5N@ ]S*$L3PR0SJ+02&+?._*7)2^7%;= MR:)VH@*S>-'1NBA#8&>T-.,T<%)'PH"DF%_K;+WUE4_+!G%1\3H-#4ZU&P @ MA7-1\;OUO^$T996O!L%I,"]])4 ![@5^N,H@V1UI,=\]"=W"%P[W.2#US8_-X!*#(RW&[3B'=&NE8@ M-S0B'N\Z"+QGNX,\K$PSG['XV7ERTXL4ZP,9([?S.2>(KHVC<^S@O'?B -55 M^JA*-MI4+C-XPI?^FXTLJ=*%2J"O1N0@%%NW#X"1$%GVZI!7?7RX*H0<#PEK MV>A4.\=@WWHM(9UA%4J]#"ZC6M M@]-V#MH@(SK$;#AN.1N+'WJT'V'5S3K;H6B;*&OX]Y-Q01'/\=/CLAW^X"EC M\84 XRR,>VW[F9'S._+LC&*N@0(W]VU"/LMMRM,, K]C1*F)%LTJ,9YAX(+E M#HF!T1+63V614E&I_I!$RP'0(7V>-%<(> O^I2"55JKL=O>) MF5\L[&[V%( M%) NXQ' HQ?5MM5F[%&UL]CD5WQ\(/&\Z@PKO%;@RPO>YO"N1_:E[H;#5Z^N MZR8<_;S#U7Z.7A.;#^(R]Q7KN;'(4JO\7F68:7Z+<>]ZD FZIQ5"-WR$U-UH>J\W#R[.3!=VXT;QO5'];P>A'9[D;)[->: ME\[ 2*XSY(K"%U=YN?*S1DX(AO;+:[C5@>4&8D2_'_?.3'/^E7CI^X2P:T<83F/9]$[:=[2BQ#>P9-4F;OJO-%JNX'IXW2+ MD6L'JYV)=)R0!ZODS@3 MOS@9E%@)PO \*R>,A^13",TVIW1+"/)T/L_ACI6T4\:3R0<5T9VY8G_;?8DM:&D/S(*.$\Q)5X MTM_KLFG4)44[2HMPSL,$B=OP#(-(_-+?/CZ;)"^YYKL2-!^=X3KI=50YT!JC M^ J?$3Y)QN\:;-_1JD_>3 (;3@<*+]?GG5G[;3OD>X<)LH MX2)TVZDA[:30QDL03_T6;3!U>]=R!9%%/(G$3YI\HH>0P2@) Q27%N2_V^YJ M5Y;X%8:(MUF.6F['#< M[-9EC^Y*1F]VY1"V(<02O@CF41,8XR<.H23M(93D+SN$\N=0'@ZA#(=0AD,H MPR&4X1#*< AE.(0R'$(9#J$,AU"&0RC#(93A$,IP"&4XA#(<0AD.H0R'4(9# M*,,AE.$0RG (93B$,AQ"&0ZA#(=0AD,HPR&4X1#*< AE.(0R'$(9#J'\_QU" MN>G\=\U6F37_0P_!.BSN_L:F?=K^"= ;]]\WA^;N'X0^2;.FU%^H%;K2ANZ% MR]3-3:5W_$\X* ,JO>6?&Q2MRE #O%]I734W-$#[UTBO_PM02P,$% @ M78)96MMF"GI8* 088 !D !X;"]W;W)K&UL MU5WK?W/KZNEE8VV;OEV75_/A@T;:K/Q\= M-?G"+DUSZ%>VHF]FOEZ:EGZMYT?-JK:FX)>6Y='I\?'CHZ5QU8.G3_BSR_KI M$]^UI:OL99TUW7)IZO4S6_K;'Q^5G\^. 8 -G2 MYBU6,/3/C3VW98F%"(Q_Z)H/XI9X,?TYK/Z<<2=?:;TP=9WC6M7^K+!,'25?*O>:]T2%[X M[GC'"Z?ZPBG#+1LQE!>F-4^?U/XVJ_$TK88?&%5^FX!S%9ARU=;TK:/WVJ?G MOFI=-;=5[FR3F:K(?JIN7.TK(GQKRNRU,U-7NI:^?7+4TH9X[2C7Q9_)XJ<[ M%C\YS=[0^HN&%BUL,5S@B""-X)X&<)^=WKGBAL]C.@_ MY/4>[D1_N70M^J:K;?8_9].FK4F&_G<;&6231]LW@5[]N5F9 MW/[X@!2GL?6-??#T3_]U\OCXASM0>!11>'37ZO\L![_8XMF[A27Z+5>F6F>N MR5QUX\L;6] /V8VIG>^:+"^-6\HZI9W3^ZO:Y]86M$63^5EFLLJT('?N2>T+ M6]/K%92OS%J?.6+2M&L(Q*:9T+)YV>%-+%)T>9N5"LP:7[:DZ*3YG6RRLC4^ MSHG=MLX=?0B@YP:68<+P-#;O:D%D\%63W=)*^#>G-/:EFOZSK3\ M (F/+[NV?Z6Q$8A;1W!.^7=;.R%9LNB?_NN[TY-O?VBRF:M,Q30@*@LJ$RQ, M=HR9 &(Q]O1;G>6F660SLMT$]%_(@ KI_'X;9W9IG5 DL1EY9O&X0E24P:W-B2M M@&OX#7DO\COY(A*K([DN![M=5X0C,7SIB8V>OJFS&>F[!U1[;C^[!0]$@(D_ M)*O@$].<#,0-40:XTZX.;B9;>B;'"B;#Y19+T!K8S[YO218"Z>*"48+P:>,^ M,!* :^7Q/+.K-!#\E:EIR:XT-='B=D$<*Z-X-'8MBTMY!JT M3L5!B,=@$E JA8F,0";V:!5@-R"TR/G2K+.%N0%[HRA; <97H[4.!U:GMKFO M"Z)#GM>D^,+V?&#"F%ZB783M5*0+NYK>?-#N9&@L'JS(*, (!3$FZ2#)(:6H MH&E;9+)@B$BB(PR@ORG^(%=.ZY!J.5^XW)3T#NU"#"6"B__)%R*[=6IA7"6! M%^@V)?268/.-<24@)XVT%2DK+39A7#]R(%@5^$08KT[0DTT",2$S"577+*;&4ME%K7UMLK0L%.C7) Y'* MTZYE^5U3,!K>@JDLW(TK.H:K_!(6?LN]Q%1D;LMX % PD>7%XD&+T@JU*13I37]NVM^T#XP+T& J5 M(7679)@;@)^IFR&PK' ZP""T79IB""NKBKTQ90?99P]=N^9:7#R^2^0H.C$& M HZ&<=KJP1-$*9.X16S=J.JS0YR2W,^<^"M94JG!F[A$1P )NW&@,V&8*I\L M#[59 J Q#&0M#K-+_?!U!.QU;\ME M1R%-HR!DI"1V3L0F"9; %>;7E#F6N*@/QP#/ /"* 29GMG#$<0'/Y/_H7,U< MJWTW7S!K::,Y8<9R3PN1RE?S@\N2OS_W-2EL;^ I3BG$/M31V9$>0^2#K^"= M(B@!%3*N]'6(\P#_,[.FCPF!T^.31R%T8A.K\KTB.T+J-YLUBG^4-7*0%$0* M-42=33,E&'QS (TUXA$+(1' +NP-Q2TK^H@L+9Q3Z?S2L*G6&.D0G"7H*16Q M;.E".D)2MB(>OF?[1BQ_=/(-HBX-^E/3P>DG[E2W<].)E@G@8@MX!;AA!-VW$OFAJ%CNT!.,TD$L>DHAH%& M!7Z3RVS4Q_]!J0?@A/Y4F(O!KE=> #MY2_OKO9%E$F,"B_"'TT&@[%F7,^Z.<4K(.WII!>35^1# M.&^X-)4MX6O>D#XXDL.V=FPDHVFD,,S6P>9O$^4MD0KS*S"(6!)X(1J1"45N M*0J!2Z9HY$B@:T&@0ATT'+HF:2H3)OG=DH!$T7+(GA8?SD@0Q+IWIJ&_3VB MEA30OUH*(FC[B\/L&667A[LU&\)DV??.["W+%2D-&9:/T8^\)@*VGGF_5-DK M4PG@W['6?(.H4'#DO)B\(5/LW)2.R%%!=E(=N P2'^(V9FZ#5(!%NQ&7!"EC M79NY*?V^-N7<#0PHJ \5B=*0"'S#@$82GSR*D+)JS @24FE[+8Z?8>=HAB1N MA7BQJT *HK,RP?9ZVCL:@7YJ"4DD&9#ZR;;G*-1O2,[9M)!"$774-\*0U%Y= M2HAJL PD$\Q;F'J>9 U@#7( @KY"1*O+S&L+%C?=] _.M#SP(%=5DI8185NW MHB2/Y8@WD;=N?5?R]C=@+X4R?3I/(BS&)T3K\C*LVWM-+B#FG,=@;\[=L*M M)H$=PXHHJ5UTF@5%R#5K-EEE;Y7Z!6A,O+BRJU9L\LDWPK/#WBO=N+FO5;39 M/4F>2]\(92JN%CARO2I4%L@A.N-Z6=6&T)OD4%-N25X3XT(PHU:4D3Y;?MAT M'"9QDCG;RMX0().S3:LVETE-ZIPRCY*TGN,6*#6EI1>6'!=EF3MUEG9_U556 M#810@5)3ZU#R,'>LF>V=O[S8%S6*BGMA$4(MM6;PBNPRUQ-67=UT1AF8/:=, MDX)RD>RS',X_+H^LO2&= 34*GW=]M3.DUS!2I=%\YZJU<_JE]MF$+<8-M!?\I!(Q8,J_-1AQ]^#:Y==3P^3F\%50W9*UK0@H4!2F MF2 74>,]FL-Q(9/<@E3$"$Y^&6 .Z'N'_4YDX7B;+!#E[L'NGLQ S#;,O^86 M-A=U45*0FJ WE)-3&#$H6H9@(S(>I;XY(@.HH%TR9AV'R)3C:J:':@BI9UT< M !8*76AA)%>4]JNO0>PLJ5L0"T%-W5*3*/]6\O5ETB@2 XJRQ $O*!JA*.O: M03F$'CDB:FT<>Y+SN*:DT,1./+/6521M&W.P"/],,/I\<_ ML-I^=?*.:A _=/(#PR2:1JS?P_+ZP#Y$S:4U<+8=;"&E23@.BLI2\KBN:U M\!:I_\ML!I*G5EFRK%2H4?(BKX.XC:.6X(35;&H@CLH@ESNE?EN0O5W;@F7- MMJ[5@M!KVJ6+:1SJ&13':O%'S,48'_!QH$ $"VEOM6F=-0D.1LA4<7WR##7Q MV09%E]X),*4HIH%M NY::1XW4$8NP' =/*T+JRY':8PJ@8AZ!J MW HQ[: N?+?]N0]+[VOB14Y0,8//[VTN?*\K* M444N32WQ#M2C%R2@QZPAK BW2<<9UP#T!>$%_?".H6I M<<3,&T?_--RX6$KVHL:I[*,*BO:")US!^J,KYE&142GL/V$M(1T3/9Y9-6G< M_T+4%0GBS+\7@6"!G<35)OS+6 MQD7LI>'PW5 <"U(N#=]X+/FXO7^Z%DIL56.[5Y;K)GUI _OUK"-:O^_V0VZZV_.02.SDA]68-S M9%3;6(6B*1?<^B&#I@_>QF37MBI9I!)S!TEAOM)@/PPJ).G[QB)B_)(F):P6 M1P\ZJ?)+WJ*^S&#?G?$CV>?-Z8>32?9KY4#O%]:4[8(SKBLXJ!Q:^K+*#[.] MC2?V)QGW1XP^(+_0I^>HAE5VH]W&\M%D>_K]ONC+7XT#:L\]N0IY5K: *:G" MYO+0_C85>HDV*2T0+4]#"S._0P:L.B/"A#9&0TFE!.4:IFBZ=Y=,#++@#5GH MT9L$\QM\.FN6:A27+'TC3>H@B5%X!\J4S%<,5I@2S-EO:^1+50BK$NT9]1P^ MBI6$I/#ZO>!%@%@/8B.K5X5/[;34[#VLY$1<']]@FN*@( 3Y(>CNC[G(BCMI$;U](2KESR$3=\MD* ;S9QD:V% M"CYIPGP?6AM;7E'M0D5$,W]&A!!X2U1^9__QB:X7]3E#ABXUN6;MQ7*>HT)# M01HECB4(^(Q8YY:^[YON"!!C6'AU<9?AO[15U:S+&P,9V@CMTC+C"B Q)1]^ M,ZPGJ[4NU]%>%YB#<\4D!,6:^\$/N.6T(\%B@\]S?YP)L[$(\A%6T3HT?1KH MNH]K. MV!V'$BDWHM!=\4'R19R=(#*T6N?&(W=NA":/PU3F4CHLIN(-8F)*2$MG#M,8 M55&RX<6A (NIIMI2-(QE2BNC-PVG J&93"&)IR0>XXNW,KP1T-GIH+PNS\+S8KZU9]&+(P6@_ MZTV,]+?^G#BF,"GAL3/>R!9S"<;-TV[3C7I^.(Q:.^/0!AX'= M19DIR3CJK NI1Z3@WJS$3 B)+,5UH2$]HQ>/O?30W1IGAU8U1OHGF!%CH7EM$W0P"$T6:1&Q?G-"B/B,$L]\+[J@M1[&\= M*P43"ZN>9OZVT.B,KDOWVV1PC MUI%UYPNT]+W6G)E5&T65D\I!+&V9\\U]@H\SS]:3 G@"=#7N:K#4B&'.;*1R^S+#?T-L6G&C,+ MI91VN9YBT*G7L%0G,XQG_!Y^4CH&7O?KR("WR RL*BN/ (8I-1@0?9Y0\REL M_ Z,ELS*R'*UU9"!I5$D:>D+X;+,P\HL[29M98'"SB@7V1R5;U!@:5'2O.&: MMY DQ"DD6*@R]IB+!(81T5L>[(7W2&9&9*)>:YP!B*&$'F8/'QT_BZW#>Q>- MOF"_52(!;E>*/I<69>%QBW#8D]>D^2WE.&1XU4V''#X[2XKJ*)B\>'MUMM\K MZ^EI4NL;ML &U$!!;E[+[+/CMNV-Y80E&:WY=C-CL5S'$^)4D)0LEOC8Z<== MM6G&,0LE[!B742%PXU,5Z<0XJ0(9)S5U;,2 7T0AXJATA&AT%?G_65?V=@_+ M0[55E3^1"AF/=#>=W8241*7@(P,:-:/JS9_SHE[BR)G!!,7?.I>]NZ?4]3W_ MDW0 @?33KP1R9&4LP$P9/=H:MR); 5'/P-GOY,D3S:FDB^?ITA@C#D4'K_37,:6ZC MZSKY_OOOM1!W?"(KC-$"!U@S<'R7XU$^7N70GN:J%F387,N!&4WB/!H#O5]R M32R#Z0F6WCZ+DH:I*"B3TTE0^QX%]D9GU7E[@7 K*WFP(-A\W0P$1\5*"II\ MI&Z94'2$*2<(XHY&R8$F API^?XH@08K32YH[I8>+.]N)-['5LZVX,&QI<+0((Q]__$/Y--3-$!9IA;Y@5(G , M8Q0]BX:AR==Q^9&R\[&(D!0,>R4;%9#Q\8GME9 )SU GT^7W,=RI6$6!WRGI M.R441B5&H$&^!-Q1HIPHA*ZYZ_6>$/SZ*.9508Q%Q]"Z&,0/0_&K+Q8&K M#F(]8(<82E%%LJND^BP)C/2!Z+TNCT52ULE-V@0'JG!SM).4, *P/?8'P(P, MO^U3[#A$(16XA36UC/T6R6_D"J:FRB,]^I3F.%1A-\PAFWI=/(P3_?4OYNS3 MRQ/(FZ30 8GDD*0D=WQ@20:F%,"CT36M&6)X@4&B/BQLC+LNP\X\H)MD%Z9> MTL(%V=B_<-EJG>WAF_U)1IX*N;Z7&1_J7VW&NX?NY?H\BSE M+#V]SID^GJK(4H;APQC88<8P#=&9<(N8VPZ 3Q$<=633AE(S[BC):;@[0YRN MFAE7I[,V*+H9=-QKGH6#=,11ER-NB4A?3?%*'V&CFZ?#(TAX!R!.!%$*DWP, M4*9UVIG04]%!C7//1R]YUCV. XHR)T&N@YF>^\1R,>ZL:I5/)_$;JZZ504A> M^C@E+V4>+Y'NYYM#47/,R+D\(['J< @8719V$J/QL%AS K\S,YU"2[@.@\H. MSZA2,EUJOMUD>V<_7YRA0Q_Z9 S2<^_E$(6\,,JSGE]0FI54SK06'$!$"-7L MBDTB?"O.3C7MM>]7KHX^AR(">X-93IE4;+B,4G"PG=JL=T/-UK%&T>2A]F)$ MA^FASPSD+SKDH!8\)A>02<;EKK1<%%](CU1LP32%AT%@B>/:N%1B<:)]LS*6 M#%]O'-]($&V"]T?P&\YPP-7>F)+;,XK- %?,# >$,HQE+5?MD(GWX0\32*'@ M?KR> U@/,MF6#U#I@?T*YS_CP6(]"-^U?*Q>$9&[':00A0M#,,&EYY:(9,GQ M M%: P2]#I#[M]7$BR@J,;5@4WBO*QML*C)BN"X=+49//,:I&]_(VG\OH"W&L; MKND(R>\+T^:+@]_->YP:1=++:=9Z)/82?0:MP1&51-*0ZJD'36V/"A>9DVA- M,#NEBL,RM]:"HU3(&HP1A#VTK*'U=R'=7M/-S1)S"._WR6G\874:YZ6V82\T%KO+8,W')NY"5WYKVQ\G)K>-9\#C;;%)9WR1Q*#\N&/7 MC3$DL3K#_6(E_ ]R7ZU(G:9IP^1KF%:=#E*]83$R[>.\XT)8R"^'\V"CYH-F M2WP=23B0)^G[@!]J2J!4?--%$M(#X**F%='[ZG<=!/U\]423MI--O) B<7!J M;C2.:,.HO=PHP[6UOEN3R!1\PM\W"N49%,\ZQPMY%T]]I<.?'QG92H[X?%Y[,*L[[=H,JYLLCRF"#&X_==J?1TSH@CR4 M2!5VW.0DWW<1;!_7TCJ91T$ZH[:<=P[2+DXZ+9X_,>#(""GR3GP#'8S>CTN#%! M2IVT>!_#RC3^R_"*J\F,GL,06$Q(":Z%F[HV4!8^@5L!8OZ3\Z22'>I9:]HK MM&C*==^;"H9RX&WD"&U$3#+RQ[B");G/6 ML2W7!%TCU?X*@Z3Z5XR'J@P[5 F+M!DT#,9'7;#>OSS7VHQ6$D36=0F0WTVWI3-# MPFO1DFW>36+'H&R43=[E^366T"AV.*3P.-N34%E'] MKT@X3-GN (->B4*=GY9*+^A))H^5>7=&"B@&Q1A]DRFAR;EE63T\8F-UU\2Y MK]'DFFMC%!1[(-I/PG4"7)MG_\4+IMW/7CT3:SG4MY0+A;=BFN5B*5DV#R&K M5_$"N4;"M5NVPBQV*E\>66&+JWSD1BCUF/>1KEU76VQ$[Z:2,.6CP?MGQNXO MW/729)>#<@(YCZNS, F-[_?36+Y*#>QG1O/F+L)OB>"W4"@6)'?'Z__$^9@@ MLHS^A&.CE>>8"IA&?%3.A8B#- CK/SS&=!KN8\74$#NB84J]/=C8&WNK?;UT M8SW(-#\F8CR#6<4ACU!L#5V2>*4BE S%:+:3/B?_$8?;3!K@"X^2S(-+[ M&P=[2/RM4JM>1O,A 3!&%8+.=GT\)XT<6 36YKZ]L?(P\: MG"=I"21JZC$(H%$T0$ZL]SRT6BSR@VH<"S MZ&\L2?<+$_5(PI25USC+MA'D!O2&ZA#NE(K5'R5YG[&\\+?0A/XBCI[X&Q36 M.QFRE- K2MA7"Q2&,4.[6!>UC!$/?1[J\L&LC_.+.+4;5R)W&LZ3E>NEKU>+ MM-B:[BY7N8#XXK!U5N3;P=V]6P5Q#YL4RQQ%<-E[>1 M<2-TCJK\; \O85!P\M6#@@M*&V[YBE$-"?Z^ M+KHF^]W79<'#PA=OSL\G^NDXCMK[%;-IB*2$1.>F<*5)CZ:];DE(1D?!>*U] MO07/1,B'J/;7R&T6QK;*-M^F'\>"5)QQ@!*[14/\XOWCR*J+O(6?8M64;L@V,XIZ]56ESZ M"C2$-1QZVFLM00Q1JWQU8+K6XZ(.Z=8BX>!K4"2:$8\A27WB,7;%[%\M6A=4 M8B!^MHM;.R.%C!'2.H;.OD<34WFQDJR)+^;8)@2?'R2Z@Y!^?(L3Z]>&@CY=F78(O- >]=AD?\HR?DI M!%5O)68,HC36BD?_GVP*Z>,781.Y)PYYTIL3Q>TFP"?EP>12%RGT@#T<@/'9 MK:U&6$:^^I?T(%,^ )%CO@"[J@>'K$.QD>J&C@EO\_&L;JB#E')0EWWNK@A> M$M3H^4?A[FSI5Y@<)-==C/\KUG:Y(.)^<$>$G%;2- M&X+2R#U>I'9'R>'+%F48QK,/'4]?CP*'<%9TU*F,;T$CO>,2$2IK M>RR*!>-[5QC1>^-$PZ#IN/0ER=Q MXJ/T8)C6 20>&#(KI-Z!PH:3+-QKS$3@JZE!TSL"IG1B*BP3*!PB'RGAQ N) M>$@"Y#[$60P][ G#>-EGI[V@$$/VKB[/F_V!DY043F98X\4-,39=FC]\K7G, M3QW&PTR5#I5N4*&6>A#-,L;O[NB@S&!UOC"9+'+5( 2# %H]>5=RLTA8?F0ER2GF*5OZO $UPC'\_G AS+ M:D!3%'.(F3"I+PD+(U ('&CG-IEEC4KO/OGT#+>_V._6N(V<]-Q3,LIII_0R MR7Z:[(JD9&VNN_CM."=-[_51H__.7Z_]V.K'F+**9[>E2]"T?J4&+,XR3F!X MI4#FX,<=^+M"H<2FY_;M%X6;TJ\C7W,[3-ZD@-M'>QH]*_X M9)P#Z7QH*!^P7H[O.MT$-&V2\!^]Z(]=RC5P'V(#9=02N3^*R@A3A5(CPIVT M;Y;>I],/[CR,5V*S!TQNX=F"AMS)MHZ2UO3"-YJ&H=5\+E.G7-W:>O_D1OR; M(!L'*T(4\E>[;NNN,!\ON+MA?G6Z76F2XTRJ(N#L*[\@CK_P*Q+D:#7J(Z/FX4;#J5Z'=?EP^D@0;CY&3$_SW.TW3+^Y:EP%@R" MCS^C,,7?_B MJ?F/@_%AC*7+:]_ ;)>.#XAAAI^/FQ\LR$!G>V^N7AZ\0*6: M+ZS7'C5G)4F+#:!.&$&^8H[02Z9C&HIHXP3*B"_\9B12>J,'%N._6Q7R6]DZ M96-_Z7M?/F93%_\.C_8C%(P0]LJUC#KITM\2VG.JQ1\Y(N,"O0LM+ET#?[H( M3CC>"(U?I'4]K27D:Q,YA6'J!^:11..*A4D\A>K3XR,>?KY*/8X4-Q,W)&U#&>BO28E#-7($7LX;H_]3 #/!A1C; G$VX4][]> M5\2Z#_=S.:,R]AD.2_R=C%F^.5'Q^O(K5/G2#=DJ_4S/>MT[>TU: @3W^-/] MY#S0%YGAV-;HB=3;\Z6AG]QT7\N$&XGBPR&]QDW2_Y_Q#J9,N((]=%G$B8;8 MB"_4P-\LJWOEB>W:@.4D&Y6K2$Z;K:,B6X848[E,A/";?EKDGQW?D"K.A)>> ML.I--HX-/+H7'Y($]?/FXS^)(TFY:V/G+=3?=K??_751+P;Y6BIY113U'Z2> M]^^E@??C_%?60"'/OYD*/OX:*O@?H'PJJY^A?7VQ^/Z*)__T'.4>3W,]3S M#ISNU-$O.WR\H:,?&YKY%ROCITO"5U9(IM>_B4*&Z<(OJHN?3O'JGNHWHOZ3 MH_;IDR/7T/]R^J_VM_3_9F%M>V%:\_0)_^G=2$,A_-+Z%9;,IKXE1O"/ M"TM9?XT'Z'O\H>#P"S:X]?4U@_?T_P!02P,$% @ 78)96MX?^]KQ @ MT 8 !D !X;"]W;W)K&ULC55M;]HP$/XK5BI5 MK<3("U!:"DA .ZV3*J&VVSY,^V"2"['JV*GME':_?F<; IV [0/)^7S/Y^@+K?GJ6+Y5RJ-1N,L09\:W+S4S[\/0()?UA.D: M-_6XY N3LB]%*;0Y%9DD'TD"+&(II)D4\DT.X2OTW36 M<7R=HYV1GY.%-@H/_]>^)CU%=S^%O1 #7=$41@%.O ;U"L'X]"2^B*Z/%-AM M"NP>8S_RZ?\'1YX*(/>@TF>2@C(L9RDU0&1.F$BEJJ2B?NQK4TC%?H,F%ZU> M%+4B_R.ZH-B3!:2R+#$29PW)J,CP!/9$X1?(02G(?&";S&C%#.7DT>$FFWN] ME]&@8.@:-[T+#T1HZNZE)F?K'$S@@'-N?>>$:4(UR25'U= #-Q/VT;&/A,P\ M_].&]5_K*>54I$"^4E';$F/2:?7Z?1*WHFYO:W>N=OQ79%ZKM, ;[]K_JX/3 MD\LD3JY)'&_-3F-NWG=:US8Q-AF?-]ZS_@$[CLZ;4O$Z0+D A5?B0U&'"K<) MMNDJQ? L&'^WPFD5T,N?G9L:[ZORY_K)ZEEF3PLU7OMYJ3"];N\;[W!'94I0 M2Z>E&M&U,%YP&F\CUQ.O4MMPK_7W5"T9'CV''*%1N]\+B/+ZZ1=&5DZS%M*@ M CJSP+\<4#8 ]W,IS69A$S1_8N,_4$L#!!0 ( %V"65KVNW9DD@D '(9 M 9 >&PO=V]R:W-H965TWU@+;!IMOB<+@?:(FVUAZ)?.R=W?#SQ[-W8UN;)&7ZM&(NEFMI-D^J$)O;GM1 MKWWP,5\L+3VXOKNIY$(]*?NI>C2XN]Y9R?*5*NM.6&:R5N]T\6N>V>5M;](3F9K+IK ?]>;ORL>3D+U4%S7_%!LW=CCHB;2I MK5[YR?!@E9?NMWSQ.'0F3,(S$V(_(6:_W4+LY;?2RKL;HS?"T&A8HPL.E6?# MN;RD37FR!F]SS+-W3TMIU-4#XLK$.[W"7M>2X7HL9%G?7%NL02.O4V_OP=F+ MS]B+8O&#+NVR%N_+3&6'!J[AW,[#N/7P(7[5XKOV!OL(AZP MO<$71/PHMR"8%??&R'*A^/I?][/:&K#EWZ>B=[:'IVU3!KVM*YFJVQY2I%9F MK7IW7W\5C<)O7O%\N/-\^)KU_V&O_HH]\?-2\6-9;L52UJ+FX3,>GG:'5SR\ MP7X;L5GFZ5+8SM0%H+4U$ABHYJG%9) Z?<;X'(\O/SY]JM\(66:B4H9%IDR5 M6ZL=\LA#K!:I,A8Z _Z7TN]6H=:J$&I5%7JK5!V([Y'I69:38_W]H:5K632J?6$A8S29EP@(6-ATJ&T4XI159?0::\^V7>B^_FH21^-O//)+ M70!@1'AO!7)"K6: N\V+OA@GD(>BH/WPWD(:6/L T-:OT]BE-OD?6 E(BWEC M&Z/:#7+[=W;YLQO?QB,WTF0 &A9K96V!P9O<@@NH%75CMMZM0+QOM\"!U^(M MS7X/7L?^+X#NG5RH4AE9 )94!+LW2II!/;#" E+1JDK?@)^ MYCKKNZ@DD"A9)AI9"*O,BM8:7T4A3T>81&R'AG/7K6R7<.^S4 ]9"E;G0(]C M<'M.8_8H'#*OYG'>. 7#D3I4'!R80D.Z8/,Z\*^=E]3X:_61(/:3*J9KXBDV7#3(:;/L:\KALF M3U%07A+..<2YM.?6[0J'7$ @L*42?J@K$%'HV6\N"P0HSP_F^V?U*;B8!/#_ M,US\ZHQ#RZO_ A T$9X3P)?0Z4.#UGFFRHR620L$GXFL,0B6K=%NTK7C'6-9 MR:V<$3HIA4(37YRL4J83(58Z0U-"SK?RT>;TH=#X::X N]8%]-BZ MP1 ?MM,_Z*;8@9E&!<( M"_@4D&2)#F*M#&&DLS70WY.!:;VR7'L J'L*["+ M]# P%XE1OS M'#6/.D%AX$Y?K'6!O229Z+/_;1TE/P^\.F.:%'HG QU *FEAJN1$WLVH7+/O M+9[QZ< BN<$/(86=(@BC?RBCKU+-BOLI>(+)MLOY45M5MST"QP/PJ$7PDKU3 MTZ-0T1FU+_>XD#_M]F78?<)9"LB'DZ%.S(1?CH*0'\QWP7:&40I!(A#+&>Q6 M='R#F'#9$NC!4'L]9L?FR8B>45-./:71JP/JG2F+:)NR?:/]V087^9Q2FH]/ MU)9R>[/2C2L=W-1Q:6K;QK:/.E&J=&-K"UB 6?]DJ%QS-/1#<@E3+\JD.11E MII9RG6OC7-OPR9Z6(/(OU'Z<@VB7R'MG7E/(*)X&<=QG/0HF4Z<^DW& SK&B MPE79,QITY,"9KA\&8QPSY)\TZ ME4MQ&"1X%<<\#K^2[D!FWB77US!D%(1#ANE"Q,.I^$5Q+O%) MII..W)J<-!.'$9E)* 'V9KRSW"@=3YOVP\F0HAT&<&+H9T7BWI_\D=O=G:K< M=P,FZXF]X@,0G-)5NXVX$-&0 MXI@F%$"V0'<1B$-*_=[)>4O.C\G4KOJ[">'4Z,A"-QP \$0-@ M=]]^AJ5AI2Z]\6Z3O&=PVTF_1F ^VO"A[W,J']WO5CMB,4@UC F5,"0Z1/WI M:$3PA,$DW)%ZU!\D(XR=!..IF(XFN(R":=0R[W+4#Z<@]S0.IF-0NA^%(/5X M$"0'5$_&"5$=LC+!#=$>5J*XX]UIM@[8/TCW=$CIQ?[1;3+>*\DK? _[TW$[ M!5L1]4>C*=^.@GATYM..Y4.S*QY0P9EO6ZD<=KOWINQTPF6#[P\7O!AT#4=VTLU^57SQSN"T*# M?"YT*EV-YE#JX-3WU.O.=_"5PK&2OO;3AS!T#^Z3^.[I[@\*]^X[^GZX^VO$ M#SB5(HE%H>:8&@;CI(>6D;_PNQNK*_ZJCE[6NS\!4$L#!!0 ( %V"65K\O>G$918 #U* 9 >&PO=V]R:W-H M965TYFA=? M,C-75U?W@:8@B1.*U/#%CO?7W],-@ 0E2K9ON'=[*H[M^<>6?FQN=\ MO6GIQM7;U[MT+;_(]K?=38U?5SV59;Z599-7I:CEZLW9M??J74CO\PN_Y_*^ ML;X+&LEM57VE'Y^6;\Y<8D@6,FN)0HK+G7POBX((@8T_-O1O&9R+K MFK;:ZL;@8)N7ZII^TW*P&B3ND0:^;N SWZHCYO)O:9N^?5U7]Z*FMT&-OO!0 MN368RTN:E"]MC: @'3"X[0^WPPUD;\Y_4MA "-^:^I$2MZX30]6D6OFEV: MR3=G6":-K._DV=N__L6;NS^L6%2[L:AZ(=#@9R-9=0W(0I/E]A;M D] =L3V@TSKE^@![*9-I^DL MTU8*V%\!5HTPQH(E!I_"PL^P\C>8@@JRZ&?R/9HP8*(9EH^46!;&(T#B,8N$OT,]B(;PP$M%+/+\5%'$3T&07XC**0/KT8GT%"=Q(7'W.ZF^#EZVU5M_D_ M6&0D\:ZL95:MR_P?Z 4JCPEL]!C[665>__J7Q/?\'\2%1Y1]?'B@[N-"I$/J M*5Q0U^B9]*BH&C"XQ@*]%*G=*01D:'E^(B)0NQ20%Y@F&KZF]JNLX<]4$[,H M\3+F07@# 1'VW\WU?4=FH:#);_J;"?H:#6&_%0\+_P$SVD*.&X-+/UBH5R!I M[Z"QN?[\^ J!;K N>%%$&N'3YX4?7?)EP<_]!?U(0KXW]_BR@$1@Q+!82HU7 M[O-V(TB5ZBZ#;M!Z2?D)I-Y(*7ZN8!6B2]@A2Y#9)JW7,"WW4$)!$U_3:H - M)35WE)[3NF5=)V5[WEJN99&2ML)0[-),35X#U&EG(F?NRV M.X*@8I<^J)88#-L:^T4\A4*3=^"^P#%QV];Y;:?'3Y;,[K_O>JD8'XE:&?_! MW-'"?(*U53/2;M)2=V?9IIZ82#%P>+*BTU.MK.0%;E5;>4D3A8%)ASL<- >K MVNG%CIGI&0'V39QMFS];$SZ/YI;' M2O/(.]H M/&M,.)[4.91!"_K1W@6;-=.WR$>J.KF(9N*76VANJE84\?ZQ8WW^TJ9MUX@O M'*6PU-ZD+#BE[.O932 M=N3 ,)JTT6YSRE.J"9_PER/?=O#M8PI TCRSOU]]*EF9;_7 M8"Z"$$YN?D+\]MR3P&,O'DW$/(RMB: )'>@>J/9]%PG#.>*6J2G-20J ML1.SP_(X!Y,X#7@,V%% A_6BSJ$:C!>:2P8/ MF"WE<4FZH1O@&P&,&'H"NA=1D")23T2?"/'?\/3@$E>CB=Z4"?T MYST9DYP")$?QSP _AGZ^M_)-J,E8ZZ H7C32F,3Q8UMCH"'!O->8CR/+-J8% MN*>Q#H$_:J%@=>2[#'WF_##")'X>H&H*2Z=&<:U6!> V=6?&0F3B1*FLZQ&B MTNR2&HB:_4.0I(Y6<="^*#*3U$OJ@;R30Q(COYZHT#7^T&X9N MQ&I+D#A8,#IF#.Z%_!DE"FD>U7J@<'(M"#MKN:+TE.U+EGF3D3M@O867NA[Y M I7U,+@B4%XES;)NVREW=^AZQ#V^3<67",G.6+#Y 6!^^#?[5>/728Z%_E\RB4&0? M)SWF$UWCS8@D8Z.4$@A_J!XG1$LP%\BI:?9-^,VI5FR[V:;WB\MS$C;JOK.8 M>R=< Q8?S+)R!9X3PH/Z3@@W,,5Z^9AB'.7^^G0[A#5L >"97.5YXGFBKHM3 MS)NENW"\A+! @.6+3U@1-KMZG7\H6[7.%'#\LT,HPOK0 0^F8C60W^2R3NML M\Z"UJ68'-*29V\W'4:H<'R'K[:E8H1^I ZAR&V_N5 1%:48MA1_3N(LR@ :,2?([:HWP;B+])Z MNE>'?BNRN@]05X&.-4,4:Z;D.P$]ZKJZK6JEL _V2VJLE$)+5;_=+8P)AJS2 M?FQB8.@HP##YJ9."&'#D;Q/:TK/9=+M=56MV0*%5_):584C'M0\J,C2T30S! M.E5!*^_YDW5&W5Y*%0N!0-I!,Z;JMEM ^I_"%+FXU8056@@2"WK(IJ M;:1KY-_*;%/F?Q)YULDFA_]=02'@@2;6@T.S>2\+4A?[YP,T-9V0S&@W';:"Y%/V\&O,''*')'UC]K&X129OFP MWE;D9TGT6)_;BM]**7;2]@2B;#)$1=3?;74GE;AZ3WB@L'CMHK I^8$;RP,IM^VQV([\S M5S\-7#7B-];ZTT^-&3*VRTS3S]>_,S+[M6HQ 4][:X 'C"*,HU7;'^]IA9'> M\5(CQ89DF)%SP7GB :U:N-5GH#HG,!V$1U_B*"RBC++1049#!*[!9[7#=!M# M3AVSR_1B]P#T^^QG?2="?.?[AZ$+G@"-^_#=L?BPE?6:K/TT.,0?^//O<"_O^!&'L ' 1"5QP>BL5WO/AX+E<] M]1WWY#OT]&/^C;- E$^S>_P7VLXJ>69(!]*U++,'.^EC]^4>]C*^BWE"[#(Q M>[C[OJIW[-XFJ4/ZB\/\QO@NP&)R.$/J[D_P5&MPKT9!R_+E;9I])=P]#+9G M:&( M;E \SS]F+-B@^-35(CGR#L?:GO<\>Q(M%L1\,.CE8BY"QP]\$4$M \>/8DOV MXAUK(7NA=05FRK*43@TG/X9I82<"'>F%P(>)"-"7N+NW:3D MXTD#%QW:' 0SM%D7'CXA:IZK-6UEFP>;K40,PH%56XB%Q1$%GD^SB+Z]M76H M\/3O2=8P.;0NPP98+/PX.?X^Y\T/ M?2+=>Y;5F] .Z];\D(/YE-7[5 *I /Y)E>M.*55)V;J>+3&G;+>(77L'E+)< MN =@.VW9CEV/.]'PI)5#2,X6+7;E:@-7"MVF+:0[5]GD A6,)W9LN%*W0X6.)F ,@M1SMJ3ZV5G'T" M3MY1.-/R#@W0.YR7"6R.=34!KO>R(>FIT&;&>D'<HMH"9?D>ZA6- M $L1[%"@RQR8D#$5:H.1=]EH6:FP=8B-&A.EJIV<1A?D4)_4'>7DZN*!FEM+ M186JNJ$5L8ZB2"+TOQ?"JOE5,WA+]89#^4]JR@[-I%DIUV&.'+V1RFD62+19 MR9I? =]7E)/H6LZ"4LQV$,G9^FQ-NQKC(W&UN-!3JTILGAA5O;*BD\&V*"NA MHI?INQ.1S+NTX-?LS:(!/!@@,]P)^?^I#;]7\&Y%RDJ&M:!EA- >HMO(XF"3 MT]Z]L&VB^3U%K"KZ[793/&6A/'_T_:;#LDP;7VKT3TPW/%JW\G\H!W$J/IA"_<.W2/\__1:'+%[P MK"!A K0A2%B(J5P#5"H N'E^GH$$)[N/2,K@3!F\GMXF"F@>]\1,1\&-+[V4)^> ME"5X*@8^%3GY)U%PR'#72_:LDE5PX4>$=D-WG,(+$E.4$?T_!OXG,?!^=3FM M;>AQLY%+2YYBW0'B42&[WM(RQ<./%C>JW5)P"3Q,R\\P1OBNRM3X3.)H]6[E3$Z#R]T0];[X:;%NO96L/GK:9X+#RZIA[?)HHQG6>M'^N1( !^]$+ M&DWHOB %87+&7#NP./PP4 _')?K#6]06;T7J+4Z8O-1VT%H7#K/7[>C5A-_, MC+NK]F-I)8Y^\/UHI;+>]WP:ASQ,/E2@8YA]P>,P)6"7-F>T]$;AUD0=G^JW M5X:T+ F*T9;B,JTIMKD;UH6)GC1I/7<]SWV!I!UX>?X+QY2%-.*V,O69:EB6 M7IKBP25I8L.AQ;B4",M;XV*-;2VO3MIP)-S(Y>6H*=/2LU&\K^WX]J'L>_AD+BB,G;%NA6[NUEGOOQL!-* M5O"PT,;9;T)94KO)B5E7+G_;(/RD?!:U\@ M.!UM*4C!$H3SCBG\\!?TF\<3YDAG9KCXVVRPS[<*[?J*<7(*"Y+WJ3Z/8?EH#JQ-E<#A\;W#:7XYPWT1 M1N%EO\,VR>_)$T_VZ8N1ZAQ4 ="!*!6'TZ&H<\''R/A@5,\2'XZZ.7%0ZVE= MC])8CQSGLJN+.;DP5!=@@LEZI@^^:C1\_L?8WN]!81#-XLQ>X M1'0)9JZZA.JRH(NGG@U'%L>QSYY1CV=PJR]P84KS6:S(^^JBR?/-+VE!.=!U M7=W3B3>B&L[F]&1\"51C??$54\/Q@_&61C^>8-2A'D]@#7*J%'Y/-/&(5&3Q M/I;0Y$B2J9%XAP,Z/I)PU+WF/3H<$"'W/F)X7L3GZ%C"'C<%O12U,Z*HRH,C MR;J2%IK%B)GU)QS$KE;R^_!/P@ \0VJ'A4MZVHR)# ME3>INF)I-G9T!2>CG7ZOJ($SER9ID3[8V*D9&\ :/;T M?O4_ESI(Z.1+,P88XQX4WH=W+]5$V,NL!R?:0SY[K+74]/F(#9NQQMZB8Z/* M/5H6]90L^J2&(F12IQR$+]7Q_R'XWB NKVJN/S;@D$IUG?[$AM8=M%:G^W62 MX!!0FN"]K\54:7C.9T$O%3RU[;"SEP?00U!#T^BZ'\_^1@&QT/N5EV;>Y-YI M[I$X^A3%?AY@+*O^&E<**^75(3QNM5N!MJD'E_NP,74 [>. D@SZ[ MP-N@5LC)B].4B/=Q*U8#!WX[^.A6JOP 152./CAZ7!.^5S;JGG:OH*%P*>X+ MQX#F5!\+($?SPAQQ5@+8R+3 @LQ(N=G7@7:I6;1]_]/"U@.'/>U]__Y8IQ27 M40VX_-:JK8U8N8C/O!-?6]0J$#1?NY34AMA; (O1L<,FHF_\,'GH"GVH7AJ^&,?(QUJ=&N= M2+3^JH=-";TS-^E>TH97BXFB>J49GPR=2N>Q.V@4"AP2>7M5Z7TXG ]_Z6.F MM]CTLWJO+[4&&SD,9^H@/4=UYSY"_K[T_-Q;+,:5Z5X<35>FSZ;^+,R5]2=] M:+.,_W 1C1WN6?UUG_YN_[>1KM6?!!I>5W]8Z:>4]MH:4<@5FKI8+F>B5G^L M2/UHJQW_@2!XL;;:\E>L(-AJ>@'/5U75FA_40?\7H][^-U!+ P04 " != M@EE:U#ZAZ2L$ !Z"0 &0 'AL+W=O;2>9;2!I.JP?V@4-VF$;]H&6SA(1BE1(*D[VZW>D M9-DI$J/=!_'U[KGG[DB>ECNE[TV%:.&I%M*L@LK:YC(,35YAS&JOJ7ID8U%QV M/7OJXW"DNE5CO03IK0W,"[ZK6)') H3$;*"7[.E=)R<1;S"?0AI/((F2[ 1>.KB;>KSTI+N=M\!DL7?8P-]7 M&V,U'9)_7O.[0\U>1W47Y](T+,=50#?#H'[$8/WS3_$\^N4$YVS@G)U"_]$4 M_6\PZ/=XOX?[/8EV KFBBV@L%J"VE_ G,MUG&2A'6&](,XU]FER3NB:A0%ND M@%CH,.$,1ED\&[L^G7=]/%N,#W*]38@GR2*F-L[F<#%/B&=>,5DB"&5DB@B1=')QQ>[#5JB9SCX1&;X9H2TM9W-G<):2V'GLXY!DKLOFRT MZ-$5_%^BXPYN*X=I26^O\8M]=+XK!H#<4U<[YV'!-;V3XAF4H'0'S@\U-DI; M+LL^/Q/855S@&R:_D[PWR_)![]-W%M-AK;D0KA*1/_U]T"B8P["J<_:I85VY M(Q%&YT@( M2LJU^E1O3$=Y0XN&&S13*=#7SH:NGR!1F#U@KL\N6MY:@MA=E= HGWV[-WN^_T')&T;?<:BI7 M(.APE1WC ZD]NZ#;7K_82*:O M/;#A43VLD7QS5=^ 3W)7&H?5X* M!/G('A=VO]'U!+ P04 " !=@EE: M- ><_N8- "6) &0 'AL+W=OM"G/HB"8G&UD41V]><7W/M9O7NG&ED6E/M;"-)N- MK!_>JE+?O3X*C_R-ZV*UMG3C[,VKK5RI&V4_;S_6N#KKJ"R*C:I,H2M1J^7K MH_/PQ=N$UO."7PIU9WJ_!4DRU_H+75PM7A\%Q) J56Z)@L37K;I094F$P,;O M+_%@N[?GV4'8F%6LJFM-?Z[I^JE2KDN M#7^*.[U MOA,UK08U^L&B\FXP5U1DE!M;XVF!??;-)WFOC(!ZKJI<;]2K,PNB].@L;PF\ M=02B)PB$D?A)5W9MQ+MJH19# F?@IF,I\BR]C9ZE>*GRL8C#D8B"*'F&7MR) M&#.]^ EZ3C(!2<5E8?)2FZ96XM_GI?8Y*_1$"<(WIR7>5%64@.A;FR=TI5PJZ5 M4,NEXL@0%@JJI55"5@M^]'E\,Q;&2MM873^X9X41THBE+A'-Y@6;B#YB^HC$ M^48WE6557]/J/[L^=(+<;LM"@0,M"L?_7 %\F#^(=2R249A-1!2. _$M+N/9 MM'3-)UB?42[ MO_L&FZ.7W?=)&.!10)2NOY.;[JT5AL2>(Z*0Q+8K"Q)T:\]>4]^'S MJKK%R:2PA:[8HCAR&O)CVC$A"6*6(XWX+@C<6%*NT^%)/./;44=WTOX._!D7 M:UFO%%FZ%KFJ+>!=D*O+.E^SR MU"T3?D@[@$5 ( /;W!CIV_*0I_&*,T; *S8AJ(>#P589#AA'(@QQ%8I_7+W_=-4Y[M)9]_N%JN'8"_B1E=6JF)?*NQ20JG%I(9HQ@9., M1$](4\DD8M;/=_)\7ZL2ZEN(7!MK1D2E;!;$C=SHVA9_.$G"C&DE$;-V$N^L MWZ,E]%)\A!,J<-J81WJ)1F$\@U@Q9-Q_]@%;:I$%."6!M6)OK/Y)QZ"0!5!Z M DXH),)1"HS.@C9"PM$,;,*IIKC\%?3:B,LEU#-B]14;8)LE/O,U] :[P/A- MY=V W'6KO:$!",BCE&19T4R@@QLHJ+!J@R"9ZULU%I_P\$*#?/7 _$Y?TFZJ M'6@IX+AJ=41G *WFH&$?<#8LR90I^"Z:-NI^U',#S2)J/EW\>'Y*#$=!.!V) MNW4!+UT#J.8$XD"1?8?[]N:4XQ"(%<.66@-F8S-@1^9 M6"J8&G!-*Q^ -F8,-J$H8 _J+$]WSU-Z_@%'&/6/)IU76I0:?EQ#=!1L<#:K M2F0;50!(#1G_KK!K.H*DY\0#'8!H =PIY@VMZ!(%Y8].OZ:9FV)1(+HE*VX,!6]T!>PYH%D^XV+GC? 3%A#XAE5;UO:PJ+)^3=Y\FN M<88[:='FZ%PY2UFHCRIUAB,G^7(_5W>%RJ*7X(T'G^[I7M'#$ 3J!9J/@G7& MJ-5#/)8;[4[=YE00_ TYQRR*W-U@.;I##Y1.;+RJ*YY&B%5DA[PI98T3KRB+ M5 OGGS\3_M=T[3SG!L3_<#=&5&+=H5&A[QN(++=4_]"JCPU 6(OK(M9@1/:-[A,[+85+]1A>U[I9K2%T'!U.16UQP =@*]S^-^^QA_3J M<\C7,+U'#KM6I9YC#\*HV#0;EU5)*-.+J0_U2E8^*Y&D[^#2>E/D8+US5.;C MLE>.G8@/[RXN3\5') 19HQ[H*<$9/1G[E#*HK4$<,6DY.;T0_R+X=5U=/Z7M MU_R7(&/@Y*@MJ%).4%K2KW0TB:)3+C@"%&F^X(["T31+!;)TBKM8E<0Q+9J- M9O&$5V?9C+XGHR1)1-?*M*;Y6QQ>-#7'ZTZ]/[19YEC,< @^HXP+IVB2=IS& MHY (@$&P.PHG25M"0S34B)E(I^A$ E2CZ#D@"C[1E5QZ 'Q\%I233%-N)])T MYKZIWMYI!B5C%*.4FX;M42%5>0$5>&'D=D2)^\YF+85)=MJ5?+[6\T5>QTS1 M+Q^&!1G>::XN#]RV(4X([< N%+,5;K\)V88%Z4E6&VS5( P5/2<&[&I6Z MK:QK@'*Y+:SLRJ]X%* $WQ7$P6S67>UZ'U^29PEZ@5A ^3'ZAO,\5R4C(K4H MZ,[S%OX]@4F2[GY'$_%YD.8?Y9IHFH)N**83U,R9>(1*@Y2%W2V:,2MCMV/92T@)/ M/H;K^=^?*TIS*X!$FW4[LF&ZTV&8['8@\?@D!Z0OM3&JSV6O&R M1I*:A3L.LDGVJ"E!+Y;.Q#1-X[21)3A!-G4WQG\(_]M%8]TK(X^?G#^],]I0*. M#9";\&%0:G#5BR1PH)4XCN$OO5I_4'-))P&>X+"]LYPK4?KQ7KYWY,&6G/J; M:+([<2UOE6NK$ $H$ JS)NS@ZL#LBK7'Q^]&!;RI-7C%&'^ M)[*SF%Q-:W&+4D^CR>:"Y$G/)LX>\?N,.I)D\K7J^%L'[W5[Q<)G[9 M\PM? =2?6,9J]&"ZBWO4?=H2 N"ICL:4< %.Y5WRC@.H[V; M3C?'@/CA_6C\> C:EEA<%?/X@;:JRD]U:$Z))MH)LY;;S<=UD,7>5NR4 O<&[8D42C2-!8QJI:#^]#>H$K< MVX7#8%18[]H7QVWW/1CD0-C=;IH1TG@IXJD8/FYZ$\^3D*:B$3T'4+^GF2?M M]D-0_"R+#1)Z.YD,>0Z9^6DD4?/:Z;NIJ[\>ZXGVMW/CUO*^=7-S 5_O.XFP<='B5QO]HA1*_0=",#W];V6SA*1KNAWG&TFSD-^['"M&UD?Y2# MOK!J-JHF'&68;>Q:UZ[\@T$\Q X[9=?<[,\NYJHLD.W:$4=AW?!0&C1/<_3' M\$7#0UI^S+T\%P%?$XWR<+H$1))2%BJG[DEAT,H+[5L&-7=.R4S&KP8:.=;7^MT3E7DLL04SVSZ \E#X[2> MF8P?LI3J%NTH*8>!K&>L7%9^""CX;2XTNZ#VD]Z#<7/(E;M:X0&4DRM%6&C\ M\-)IDO.=% ;IH5@6.1TU'!" ?3JXY;BFXL: X'/&>]Y)C&A?L3G0>FH.+6E" MLE"_-VV-D^M;=F1(1_S .;^P26 .9RS*LQ81:BS+C9);EJPGU!&:N@8_T7CR M1'9+AQ*RXMEIY9#PN =#O6P5[]]MTU6:/$Y7G[A\<$>8P:S*:8VG>;VQE7=( M.WP[-1YT:SPKR?.Z<>]$#@GOLFT23W<#;6(QSGH3[B="K07(>.1'?7 I0H"K MJH=7D&^&\A24.=S=7USRN\'7.(')J%88;'!^R#. M_\)HW67RP8"]_^Z*ENA*?8^0?312AT.XUR*#T7J7XL"N0-\L5[529C?X>\34 M7A'8QLZ(L'\C'SR@P@Y#2!F,CUO5X40JN4JC_S]*0FGE"^N]+L3'%@_/>5'_ M_T:))OT)APGU,[.7 &UFH8GS8-8; M@<7\;Z>YV?[HY=_\UV2UW_]CY2=8K>A51 MJB6V!N-I>@2&ULI59M;]LX#/XKA&\8-L#G]R1;EP1(V@WKAQZ*=7?#X7 ?%)N. MAYUA6C@H1:-7GB5,>U%&.J\ MPIKI0+;8$*>4JF:&CFH;ZE8A*YQ2+<(DBJ9AS7CC+>?NVZU:SF5G!&_P5H'N MZIJIQS4*N5]XL3=^^,2WE;$?PN6\95N\0_-G>ZOH%!Y0"EYCH[EL0&&Y\%;Q MQ3JS\D[@+XY[?42#C60CY;T]7!<++[(.H<#<6 1&VPXO40@+1&[\-V!Z!Y-6 M\9@>T3^XV"F6#=-X*<477IAJX;WQH,"2=<)\DON/.,0SL7BY%-JML.]ET\B# MO--&UH,R>5#SIM_9PY"'(X4W/U)(!H7$^=T;,<.6JT MR3G>V$NY,XJXG/3,\CU3#6^V&EI4<%XQDA]@Q G0!K[D$1)=@8O/429.KST9U'>CE'"/ZN- M-HJ*XM]3 ?=PV6DX^U N=,MR7'CT$C2J'7K+E[_%T^C=&6>S@[/9.?1G7LFO M8L#G"B%G(N\$L^]!@RP!C\6T$WOE-@V\H7(3PDJ^!LM@&DHIZ!'K"_B;%(?; M!KHKK#>DG\;NNNR2VB6!/ZBI7#>YK!%6QBB^Z0S;" 0CX095?@\O6=V^@TL9 M^%8N@!<0S_PXGA&13B?VF/F3^"VL=JBH10!!U?24!Q>IQVC#FH(B@,2?I(E; M9P-]^426:]TYVZ_BU_ 6XLC^?@[+2*VV1,%%Y]H(@6>Q6YVA+($UTSR')QD? M;/>)?U[HQRJ5% 52@E_ -)A-:8N".*-M$LS2R)Z=CE[GI, M9*LXM7$N'J&C.AC*YW?;(0N;4)H:VA4:M((U.B!3KCS\OCXHOZY&?)B.=>;# M9"1[]C<&74N+KG^+1]\6;G[ZR1